<SEC-DOCUMENT>0001628280-24-022215.txt : 20240509
<SEC-HEADER>0001628280-24-022215.hdr.sgml : 20240509
<ACCEPTANCE-DATETIME>20240509160929
ACCESSION NUMBER:		0001628280-24-022215
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		93
CONFORMED PERIOD OF REPORT:	20240331
FILED AS OF DATE:		20240509
DATE AS OF CHANGE:		20240509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		24930622

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>arwr-20240331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:ac9daf9b-fe65-44cf-acd3-206171097241,g:5004fc8e-4246-4d68-a802-ef4d83a3dac9,d:ee955c12611347149f2269c0ac74c071-->
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:srt="http://fasb.org/srt/2023" xmlns:arwr="http://www.arrowheadresearch.com/20240331" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arwr-20240331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-26">0000879407</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-27">09-30</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-28">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-29">Q2</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-30">false</ix:nonNumeric><ix:nonNumeric contextRef="c-261" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-890">11</ix:nonNumeric><ix:nonNumeric contextRef="c-263" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-891">262</ix:nonNumeric><ix:nonNumeric contextRef="c-265" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-892">11</ix:nonNumeric><ix:nonNumeric contextRef="c-267" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-893">11</ix:nonNumeric><ix:nonNumeric contextRef="c-269" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-894">11</ix:nonNumeric><ix:nonNumeric contextRef="c-271" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-895">11</ix:nonNumeric><ix:nonNumeric contextRef="c-273" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-896">11</ix:nonNumeric><ix:nonNumeric contextRef="c-275" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-897">15</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arwr-20240331.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="obligation"><xbrli:measure>arwr:obligation</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="bundle"><xbrli:measure>arwr:bundle</xbrli:measure></xbrli:unit><xbrli:unit id="agreement"><xbrli:measure>arwr:agreement</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="option"><xbrli:measure>arwr:option</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-02</xbrli:startDate><xbrli:endDate>2024-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:UnderwritingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputerAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputerAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-02</xbrli:startDate><xbrli:endDate>2022-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2023-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch12PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch12PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="iee955c12611347149f2269c0ac74c071_1"></div><div style="min-height:22.5pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.796%"><tr><td style="width:1.0%"/><td style="width:3.009%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.791%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">March 31, 2024</ix:nonNumeric></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.810%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-4">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-38042</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">ARROWHEAD PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:48.596%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.598%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">46-0408024</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-10">Suite 700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Pasadena</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-12">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">91105</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-14">626</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-15">304-3400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Address and telephone number of principal executive offices) </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Former name, former address, and former fiscal year, if changed since last report: N/A</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:37.233%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.78pt;text-align:center;text-indent:-0.8pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-16">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:1.38pt;padding-right:1.38pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-17">ARWR</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 2.38pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-18">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-19">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:44.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" id="f-21">Large Accelerated Filer</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non-Accelerated Filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%">o</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Smaller Reporting Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-22">o</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Emerging Growth Company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-23">o</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-24">x</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the registrant&#8217;s common stock outstanding as of May&#160;1, 2024 was <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-25">124,200,230</ix:nonFraction>. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.220%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:4pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="height:22.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"/><td style="width:91.680%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Page(s)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_10">PART I &#8212; FINANCIAL INFORMATION</a></span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_13">ITEM 1. FINANCIAL STATEMENTS </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_13">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_16">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_16">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_19">Consolidated Statements of Operations and Comprehensive </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_19">(</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_19">Loss</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">) Income</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_19">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline">Consolidated Statements of Stockholders&#8217; Equity</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_22">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_25">Consolidated Statements of Cash Flows</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_25">4</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:24pt;text-indent:-13.5pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_28">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_28">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_67">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_67">21</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_85">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_85">27</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_88">ITEM 4. CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_88">27</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_91">PART II &#8212; OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_91">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_94">ITEM 1. LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_94">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_97">ITEM 1A. RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_97">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_100">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_100">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_103">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_103">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_106">ITEM 4. MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_106">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_109">ITEM 5. OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_109">29</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_112">ITEM 6. EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_112">30</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#iee955c12611347149f2269c0ac74c071_115">SIGNATURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#iee955c12611347149f2269c0ac74c071_115">31</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_10"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I. FINANCIAL INFORMATION </span></div><div id="iee955c12611347149f2269c0ac74c071_13"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS </span></div><div id="iee955c12611347149f2269c0ac74c071_16"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.166%"><tr><td style="width:1.0%"/><td style="width:67.336%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.386%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.389%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.389%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(unaudited)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">ASSETS</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-31">127,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-32">110,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Available-for-sale securities, at fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-33">395,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-34">292,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-35">11,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-36">8,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-37">7,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-38">7,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-39">541,650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-40">419,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-41">359,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-42">290,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-43">9,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-44">10,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-45">44,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-46">45,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-47">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-48">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-49">955,150</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-50">765,552</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-51">8,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-52">35,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-53">37,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-54">39,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-55">13,741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-56">17,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-57">5,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-58">10,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="f-59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-60">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-61">573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-62">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-63">65,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-64">105,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-65">113,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-66">104,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-67">280,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-68">268,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-69">394,570</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-70">372,934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-3" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-71"/></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-4" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-72"/></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Noncontrolling interest and stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-73"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-74">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Authorized <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-75"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-76">290,000</ix:nonFraction></ix:nonFraction> shares; issued and outstanding <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-77"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-78">124,133</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-79"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-80">107,312</ix:nonFraction></ix:nonFraction> shares</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-81">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-82">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-83">1,768,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-84">1,300,395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-85">1,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-86">3,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-87">1,284,194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-88">1,026,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total Arrowhead Pharmaceuticals, Inc. stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-89">483,794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-90">271,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-91">11,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-92">15,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total noncontrolling interest and stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-93">495,405</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-94">287,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Total Liabilities, Noncontrolling Interest and Stockholders&#8217; Equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-95">955,150</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-96">765,552</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements. </span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive (Loss) Income</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(In thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited) </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:51.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.416%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-97">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-98">146,267</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-99">3,551</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-100">208,813</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-101">101,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-102">74,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-103">217,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-104">158,576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-105">25,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-106">23,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-107">48,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-108">44,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-109">126,191</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-110">98,102</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-111">266,287</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-112">202,782</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating (loss) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-113">126,191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-114">48,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-115">262,736</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-116">6,031</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-117">6,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-118">4,560</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-119">9,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-120">7,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-121">7,244</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-122">5,057</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-123">12,611</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-124">7,906</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-125">189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-126">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-127">610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-128">515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total other expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-129">805</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-130">489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-131">2,949</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="f-132">149</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(Loss) income before income tax (benefit) expense and noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-133">126,996</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-134">47,676</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-135">265,685</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-136">5,882</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Income tax (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-137">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-138">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-139">3,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-140">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net (loss) income including noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-141">126,996</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-142">47,676</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-143">262,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-144">5,865</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss attributable to noncontrolling interest, net of tax</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-145">1,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-146">999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-147">4,208</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-148">1,485</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-149">125,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-150">48,675</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-151">258,164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-152">7,350</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-153">1.02</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-154">0.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-155">2.24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-156">0.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-157">1.02</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-158">0.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-159">2.24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-160">0.07</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Weighted-average shares used in calculating</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-161">123,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-162">106,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-163">115,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-164">106,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-165">123,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-166">108,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-167">115,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-168">107,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other comprehensive (loss) income, net of tax:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Change in unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-169">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-171">2,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-172">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-173">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-174">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-175">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-176">196</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Comprehensive (loss) income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-177">126,836</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-178">47,602</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-179">260,245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-180">5,669</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:10pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.305%"><tr><td style="width:1.0%"/><td style="width:35.123%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.270%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.711%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.872%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.157%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Common</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Stock</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Other </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Comprehensive </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Loss</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Non-<br/>controlling Interest</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at September 30, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-181">107,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-182">200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-183">1,300,395</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-184">3,222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-185">1,026,030</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-186">15,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-187">287,162</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-188">19,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-189">19,694</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-190">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-191">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-192">267</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-193">154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-194">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-195">58</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Change in unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-196">1,909</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-197">1,909</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net loss </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-198">132,864</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-199">2,512</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-200">135,376</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at December 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-201">107,500</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-202">200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-203">1,320,356</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-204">1,255</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-205">1,158,894</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-206">13,307</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-207">173,714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-208">17,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-209">17,750</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-210">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-211">1,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-212">1,512</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-213">723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-214">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-215">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-216">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Common stock issued, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-217">15,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-218">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-219">429,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-220">429,265</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-221">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-222">56</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Change in unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-223">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="f-224">216</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-225">125,300</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-226">1,696</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-227">126,996</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at March 31, 2024</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-30" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-228">124,133</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-229">217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-230">1,768,866</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-231">1,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-232">1,284,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-233">11,611</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-234">495,405</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:10pt;text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.861%"><tr><td style="width:1.0%"/><td style="width:35.200%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.940%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.913%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.112%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Common</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Stock</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Amount ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Additional</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Paid-In</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Capital</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Other </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Comprehensive </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Loss</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Accumulated</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Deficit</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Non-<br/>controlling Interest</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Totals</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-235">105,960</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-236">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-237">1,219,213</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-238">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-239">820,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-240">19,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-241">418,339</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-242">19,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-243">19,390</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-244">82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-245">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-246">576</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-247">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-248">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-249">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-250">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-251">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-252">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-253">41,325</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-254">486</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-255">41,811</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-47" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-256">106,140</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-257">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-258">1,239,178</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-259">258</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-260">862,080</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-261">19,333</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-262">396,372</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-263">20,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-264">20,612</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Exercise of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-265">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-266">520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-267">520</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-268">665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.22pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-269">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-270">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Net income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-271">48,675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-272">999</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-273">47,676</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-58" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-274">106,869</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-275">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-276">1,260,310</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-277">332</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-278">813,405</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-279">18,334</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-280">465,106</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.778%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 8.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net (loss) income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-281">262,372</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-282">5,865</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Adjustments to reconcile net loss to net cash flow from operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-283">37,444</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-284">40,002</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-285">8,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-286">5,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Amortization (accretion) of note premiums/discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="f-287">896</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="f-288">82</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Realized gain on investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" scale="3" id="f-289">80</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RealizedInvestmentGainsLosses" format="ixt:fixed-zero" scale="3" id="f-290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Non-cash interest expense on liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-291">12,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-292">7,906</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-293">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-294">68,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-295">2,643</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-296">20,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-297">8,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-298">6,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-299">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-300">27,279</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="f-301">866</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-302">99,135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating lease, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-303">4,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-304">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 38.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-305">210,217</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-306">107,187</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-307">102,731</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-308">66,225</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-309">309,982</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-310">192,528</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-311">208,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-312">141,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 38.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-313">204,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-314">116,759</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-315">1,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-316">1,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the issuance of common stock, net of offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-317">429,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 8.5pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Proceeds from the sale of future royalties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:ProceedsFromSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-319">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="arwr:ProceedsFromSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-320">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 38.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-321">431,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-322">251,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-323">16,729</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-324">27,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Effect of exchange rate on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-325">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-326">196</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">BEGINNING OF PERIOD</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-327">110,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-328">108,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">END OF PERIOD</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-329">127,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-330">134,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:1.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Supplementary disclosure of cash flows:</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Income taxes paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-331">3,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Supplemental disclosure of noncash investing activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Capital expenditures included in accrued expenses</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-333">7,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="f-334">12,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these unaudited consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="iee955c12611347149f2269c0ac74c071_31"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-335" continuedAt="f-335-1" escape="true">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-335-1" continuedAt="f-335-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Recent Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><ix:nonNumeric contextRef="c-1" name="arwr:ScheduleOfCurrentProductsTableTextBlock" id="f-336" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.172%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.508%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">plozasiran (ARO-APOC3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">zodasiran (ARO-ANG3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">olpasiran</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-RAGE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK-4532990</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">fazirsiran</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-PNPLA3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-CFB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Muscle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-DUX4</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-DM1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Central Nervous System (CNS)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thus far in fiscal 2024, the Company has continued to develop and advance its pipeline and partnered candidates. Several key recent developments include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.7pt">Completed enrollment in Amgen&#8217;s Phase 3 OCEAN(a) - outcome trial of olpasiran, triggering a $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" format="ixt:num-dot-decimal" scale="6" id="f-337">50.0</ix:nonFraction>&#160;million milestone payment to the Company, which was paid in the third quarter of fiscal 2024;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Presented final data from the double-blind treatment period of the Company&#8217;s Phase 2 SHASTA-2 study of investigational plozasiran in patients with severe Hypertriglyceridemia. Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Announced an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for qualifying patients with familial chylomicronemia syndrome (FCS); </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initiated a Phase 1/2a clinical trial of ARO-DM1, being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, being developed as a potential treatment for complement mediated renal disease; </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-335-2" continuedAt="f-335-3"><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Entered into an Amended and Restated License Agreement with GSK, pursuant to which GSK received a worldwide, exclusive license to develop and commercialize JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen Pharmaceuticals, Inc. See Note 2.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company&#8217;s financial position at March&#160;31, 2024 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company&#8217;s Annual Report on Form 10-K for the year ended September&#160;30, 2023 for more complete descriptions and discussions. Operating results and cash flows for the six months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending September&#160;30, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary sources of financing have been through the sale of its equity securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded. Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-338">127.7</ix:nonFraction> million in cash, cash equivalents and restricted cash ($<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-339">2.2</ix:nonFraction> million in restricted cash) and $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-340">395.4</ix:nonFraction>&#160;million in available-for-sale securities to fund operations. During the six months ended March&#160;31, 2024, the Company&#8217;s cash, cash equivalents and restricted cash and investments balance increased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arwr:IncreaseDecreaseInCashAndInvestments" format="ixt:num-dot-decimal" scale="6" id="f-341">119.5</ix:nonFraction> million which was primarily due to the net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-342">429.3</ix:nonFraction>&#160;million from the underwritten offering in January 2024 discussed below, offset by ongoing expenses related to the Company&#8217;s research and development programs, general and administrative expenses and capital expenditures. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2024, the Company entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued <ix:nonFraction unitRef="shares" contextRef="c-65" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-343">15,790,000</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-66" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-344">28.50</ix:nonFraction> per share. The aggregate purchase price paid by investors was $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="arwr:SaleOfStockAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="6" id="f-345">450.0</ix:nonFraction>&#160;million and the Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-346">429.3</ix:nonFraction>&#160;million after deducting advisory fees and offering expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-8" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="9" id="f-347">2.8</ix:nonFraction> billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the significant accounting policies disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded an income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="f-348">3.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-349">0</ix:nonFraction> for the six months ended March&#160;31, 2024 and 2023, respectively. The income tax benefit is primarily due to the discrete change in the Company&#8217;s uncertain tax positions related to the statute of limitation expiration.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-350" escape="true"><ix:continuation id="f-335-3"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to improve its income tax disclosure requirements. Under the ASU, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This ASU will become effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU.</span></div></ix:continuation></ix:nonNumeric><div id="iee955c12611347149f2269c0ac74c071_34"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-351" continuedAt="f-351-1" escape="true">COLLABORATION AND LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="f-351-1" continuedAt="f-351-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-352" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.982%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.982%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.982%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.403%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.988%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-353">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-354">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-355">2,685</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-356">29,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Horizon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-358">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-360">21,667</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-361">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-362">116,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-363">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-364">132,468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-365">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-366">111</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-367">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-368">355</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-370">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-371">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-372">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-373">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-374">146,267</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-375">3,551</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-376">208,813</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-377" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"/><td style="width:59.575%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.947%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.414%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.950%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Receivables included in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:fixed-zero" scale="3" id="f-378">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:fixed-zero" scale="3" id="f-379">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities included in deferred revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="f-381">866</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;). Under the GSK License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. GSK dosed the first patient in a Phase 2b trial in March 2023 and paid a $<ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="f-382">30.0</ix:nonFraction>&#160;million milestone payment to the Company in the third quarter of fiscal 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible for an additional payment of $<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" format="ixt:num-dot-decimal" scale="6" id="f-383">100.0</ix:nonFraction> million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="arwr:CommercialMilestonePaymentsAtFirstCommercialSale" format="ixt:num-dot-decimal" scale="6" id="f-384">190.0</ix:nonFraction> million at first commercial sale, and up to $<ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="arwr:SalesRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-385">590.0</ix:nonFraction> million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK-HBV Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2023, the Company entered into an Amended and Restated License Agreement with GSK (the &#8220;GSK-HBV Agreement&#8221;) pursuant to which GSK received a worldwide, exclusive license to develop and commercialize JNJ-3989 (formerly ARO-HBV), the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. JNJ-3989 had previously been licensed to Janssen in October 2018. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the GSK-HBV Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-386">2.7</ix:nonFraction>&#160;million in December 2023, upon signing the amended GSK-HBV Agreement. The Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="arwr:DevelopmentAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="f-387">832.5</ix:nonFraction>&#160;million in development and sales milestone payments under the GSK-HBV Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="usd" contextRef="c-92" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-388"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="f-389">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of March&#160;31, 2024. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-351-2" continuedAt="f-351-3"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, Horizon and the Company entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Horizon License Agreement, the Company identified <ix:nonFraction unitRef="obligation" contextRef="c-93" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-390">one</ix:nonFraction> distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#8220;Horizon R&amp;D Services&#8221;). The Company received a $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-391">40.0</ix:nonFraction>&#160;million upfront payment in July 2021. Revenue was recognized on a straight-line basis over the timeframe for completing the Horizon R&amp;D Services, concluding in the first quarter of 2023. Further, the Company received an additional $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="f-392">15.0</ix:nonFraction>&#160;million upon Horizon&#8217;s initiation of a Phase 1 clinical trial in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2023, Amgen completed its acquisition of Horizon and subsequently notified the Company of Amgen&#8217;s intent to terminate the HZN-457 license. Horizon exercised its right to terminate the Horizon License Agreement for convenience, which took effect on December 21, 2023. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop the Company&#8217;s fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit sharing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-96" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="f-393">20</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-97" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="f-394">25</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on net sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Takeda License Agreement, the Company identified <ix:nonFraction unitRef="obligation" contextRef="c-98" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-395">one</ix:nonFraction> distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent <ix:nonFraction unitRef="bundle" contextRef="c-98" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="f-396">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="obligation" contextRef="c-98" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-397">one</ix:nonFraction> performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Takeda License Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-398">300.0</ix:nonFraction>&#160;million as an upfront payment in January 2021 and an additional $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="f-399">40.0</ix:nonFraction>&#160;million upon Takeda&#8217;s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="f-400">527.5</ix:nonFraction>&#160;million in additional potential development, regulatory and commercial milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-401">300.0</ix:nonFraction>&#160;million initial transaction price to its <ix:nonFraction unitRef="obligation" contextRef="c-98" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-402">one</ix:nonFraction> distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;D Services. Revenue was recognized using the input method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Phase 2 study visits for patients in the SEQUOIA and AROAAT2002 studies concluded by December 31, 2023, and the Company has substantially completed its performance obligation under the Takeda license agreement. As such, all revenue has been fully recognized as of December 31, 2023. There were no further deferred revenue and contract liabilities as of March 31, 2024</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-403">13.8</ix:nonFraction>&#160;million as accrued expenses as of March&#160;31, 2024 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company and the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. ARO-PNPLA3 is in Phase 1 clinical trials, which are </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-351-3" continuedAt="f-351-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">now being developed by the Company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on December 11, 2023, the Company entered into the GSK-HBV Agreement, as discussed above, pursuant to which GSK received an exclusive license for JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen in October 2018.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Amgen and the Company entered into <ix:nonFraction unitRef="agreement" contextRef="c-102" decimals="INF" name="arwr:NumberOfAgreements" format="ixt-sec:numwordsen" scale="0" id="f-404">two</ix:nonFraction> collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi olpasiran (previously referred to as AMG- 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Olpasiran Agreement, the Company has received $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-405">35.0</ix:nonFraction>&#160;million in upfront payments and $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-406">21.5</ix:nonFraction>&#160;million in the form of an equity investment by Amgen in the Company&#8217;s common stock. Further, the Company received additional an $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-407">55.0</ix:nonFraction>&#160;million in milestone payments; $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-408">10.0</ix:nonFraction>&#160;million upon Amgen&#8217;s initiation of a Phase 1 study in September 2018,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-409">20.0</ix:nonFraction>&#160;million upon its initiation of a Phase 2 clinical study in July 2020, and $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-410">25.0</ix:nonFraction>&#160;million upon its first subject enrollment in a Phase 3 trial in December 2022. The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were <ix:nonFraction unitRef="usd" contextRef="c-104" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="f-411"><ix:nonFraction unitRef="usd" contextRef="c-104" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-412">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of March&#160;31, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) and the Company entered into the Royalty Pharma Agreement. In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="f-413">535.0</ix:nonFraction>&#160;million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 11.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company and Visirna, its subsidiary, entered into a License Agreement (the &#8220;Visirna License Agreement&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#8217;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan). </span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-351-4">The Company also performs manufacturing and development work pursuant to a Clinical Supply Agreement between the parties contemplated by the Visirna License Agreement. The Company received $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-414">0.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-415">0.9</ix:nonFraction>&#160;million as consideration for this manufacturing and development work for the six months ended March&#160;31, 2024 and 2023, respectively. There were <ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="f-416"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-417">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of March&#160;31, 2024.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="c-1" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="f-418" continuedAt="f-418-1" escape="true">BALANCE SHEET ACCOUNTS</ix:nonNumeric></span></div><ix:continuation id="f-418-1"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-419" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property, plant and equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Land</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-420">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-421">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-422">75,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:fixed-zero" scale="3" id="f-423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-424">62,926</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-425">56,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-426">4,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-427">1,540</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Computers and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-428">923</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-429">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-430">104,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-431">103,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-432">158,243</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-433">166,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-434">409,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-435">332,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-436">49,971</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-437">41,951</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-438">359,252</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-439">290,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property, plant and equipment for the three months ended March&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-440">4.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-441">2.2</ix:nonFraction>&#160;million, respectively. Depreciation and amortization expense for property and equipment for the six months ended March&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-442">7.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-443">4.5</ix:nonFraction>&#160;million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal 2024, the Company completed the build out of one of its laboratory and office facilities in Verona, Wisconsin, which resulted in the reclassification of $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" sign="-" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-444"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentTransfersAndChanges" format="ixt:num-dot-decimal" scale="6" id="f-445">75.3</ix:nonFraction></ix:nonFraction>&#160;million from construction in progress to building as of March&#160;31, 2024. Further, the Company commenced depreciation on the newly completed facility over a <ix:nonNumeric contextRef="c-128" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-446">39-year</ix:nonNumeric> period.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-447" escape="true"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued R&amp;D expenses</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-448">14,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-449">16,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued R&amp;D expenses; co-development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-450">13,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-451">5,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued capital expenditures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:AccruedCapitalExpenditureCurrent" format="ixt:num-dot-decimal" scale="3" id="f-452">7,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:AccruedCapitalExpenditureCurrent" format="ixt:num-dot-decimal" scale="3" id="f-453">14,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-454">1,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-455">3,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total accrued expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-456">37,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-457">39,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_40"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-458" continuedAt="f-458-1" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" id="f-459" escape="true"><ix:continuation id="f-458-1" continuedAt="f-458-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.278%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.269%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-460">396,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" scale="3" id="f-461">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" scale="3" id="f-462">850</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-463">395,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-464">396,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" scale="3" id="f-465">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" scale="3" id="f-466">850</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-467">395,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"><tr><td style="width:1.0%"/><td style="width:45.323%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.284%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.185%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-468">295,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" scale="3" id="f-469">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-470">2,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-471">292,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-472">295,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" scale="3" id="f-473">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-474">2,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-475">292,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-458-2">The Company has determined that the available-for-sale securities that were in an unrealized loss position did not have any credit loss impairment as of March&#160;31, 2024 and 2023.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-476" continuedAt="f-476-1" escape="true">INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="f-476-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-477" continuedAt="f-477-1" escape="true">The following table presents the components of intangible assets: </ix:nonNumeric></span></div><ix:continuation id="f-477-1"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.361%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-478">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-479">14,097</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-480">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-481">7,631</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-131" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-482">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-483">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-484">1,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-485">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-486">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-132" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-487">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-488">24,857</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-489">15,445</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-490">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-491">9,412</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-492">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-493">13,321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-494">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-495">8,407</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-134" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-496">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-497">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-498">1,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-499">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-500">1,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-135" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-501">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-502">24,857</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-503">14,595</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-504">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-505">10,262</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the six months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-506"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-507">0.4</ix:nonFraction></ix:nonFraction> million for each of the three months ended March&#160;31, 2024 and 2023, and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-508"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-509">0.9</ix:nonFraction></ix:nonFraction> million for each of six months ended March&#160;31, 2024 and 2023. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-510" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future amortization expense related to intangible assets as of March&#160;31, 2024:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"/><td style="width:71.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.543%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.099%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="3" id="f-511">850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-512">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-513">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-514">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-515">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="f-516">1,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-517">9,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_46"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-518" continuedAt="f-518-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:continuation id="f-518-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-519" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:30.310%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.047%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.049%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-520">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-521">290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-522">124,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-523">124,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-524">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-525">5,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-526">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-527">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-528">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-529">290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-530">107,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-531">107,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-532">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-533">5,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-534">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-535">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and September&#160;30, 2023, respectively, <ix:nonFraction unitRef="shares" contextRef="c-137" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-536">11,723,683</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-138" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-537">12,709,837</ix:nonFraction> shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, 2021 Incentive Plan, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2024, the Company entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued <ix:nonFraction unitRef="shares" contextRef="c-65" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-538">15,790,000</ix:nonFraction> shares of common stock at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-66" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-539">28.50</ix:nonFraction> per share. The aggregate purchase price paid by investors was $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="arwr:SaleOfStockAggregatePurchasePrice" format="ixt:num-dot-decimal" scale="6" id="f-540">450.0</ix:nonFraction>&#160;million and the Company received net proceeds of $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="f-541">429.3</ix:nonFraction>&#160;million after deducting advisory fees and offering expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into an open market sale agreement (the &#8220;Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="INF" name="arwr:CommonStockCapitalSharesValueReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-542">250,000,000</ix:nonFraction> in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to <ix:nonFraction unitRef="number" contextRef="c-140" decimals="3" name="arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" scale="-2" id="f-543">3.0</ix:nonFraction>% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of March&#160;31, 2024, <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="f-544">no</ix:nonFraction> shares have been issued under the Open Market Sale Agreement.</span></div></ix:continuation><div id="iee955c12611347149f2269c0ac74c071_49"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-545" continuedAt="f-545-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-545-1" continuedAt="f-545-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were <ix:nonFraction unitRef="usd" contextRef="c-3" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-546">no</ix:nonFraction> contingent liabilities recorded as of March&#160;31, 2024. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately <ix:nonFraction unitRef="sqft" contextRef="c-142" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="f-547">160,000</ix:nonFraction> square foot drug manufacturing facility and an approximately <ix:nonFraction unitRef="sqft" contextRef="c-143" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="f-548">140,000</ix:nonFraction> square foot laboratory and office facility which will support the Company&#8217;s manufacturing process development and analytical activities. During the first quarter of fiscal 2024, the Company completed the build out of one of its laboratory and office facilities.</span></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-545-2">As of March&#160;31, 2024, the Company has incurred $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="arwr:CommitmentsCapitalExpendituresIncurredToDate" format="ixt:num-dot-decimal" scale="6" id="f-549">247.0</ix:nonFraction> million and intends to spend an additional $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="arwr:AmountIntendsToInvestForBuildoutOfFacilities" format="ixt:num-dot-decimal" scale="6" id="f-550">37.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="arwr:AmountIntendsToInvestForBuildoutOfFacilities" format="ixt:num-dot-decimal" scale="6" id="f-551">51.0</ix:nonFraction> million to complete the build out of the facilities.</ix:continuation> </span></div><div id="iee955c12611347149f2269c0ac74c071_52"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-552" continuedAt="f-552-1" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="f-552-1" continuedAt="f-552-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases <ix:nonFraction unitRef="sqft" contextRef="c-147" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-553">49,000</ix:nonFraction> square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for <ix:nonFraction unitRef="option" contextRef="c-148" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="f-554">one</ix:nonFraction> additional <ix:nonNumeric contextRef="c-148" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-555">five-year</ix:nonNumeric> term. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases <ix:nonFraction unitRef="sqft" contextRef="c-149" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-556">144,000</ix:nonFraction> square feet of office and research and development laboratory space located at 10102 Hoyt Park, San Diego, California, which lease expires on April&#160;30, 2038. Pursuant to the lease, within </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-552-2" continuedAt="f-552-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">twelve months of the expiration of the initial <ix:nonNumeric contextRef="c-149" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-557">15</ix:nonNumeric>-year term, the Company has the option to extend the lease for up to <ix:nonFraction unitRef="option" contextRef="c-150" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="f-558">one</ix:nonFraction> additional <ix:nonNumeric contextRef="c-149" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-559">ten-year</ix:nonNumeric> term, with certain annual increases in base rent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease agreement grants the Company the right to receive an Additional Tenant Improvement Allowance (&#8220;ATIA&#8221;) funded by the lessor, with a maximum amount of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="arwr:MaximumAdditionalTenantImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="f-560">7.2</ix:nonFraction> million, subject to a <ix:nonFraction unitRef="number" contextRef="c-149" decimals="2" name="arwr:AdditionalTenantImprovementAllowanceInterestPerAnnum" scale="-2" id="f-561">7</ix:nonFraction>% interest per annum over the base term. Further, on September&#160;25, 2023, the Company executed the first amendment to the lease, which grants a second ATIA with a maximum amount of $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="arwr:MaximumAdditionalTenantImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="f-562">23.6</ix:nonFraction> million, bearing interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-151" decimals="2" name="arwr:AdditionalTenantImprovementAllowanceInterestPerAnnum" scale="-2" id="f-563">9</ix:nonFraction>% per annum over the base term. The Company received $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="arwr:AdditionalTenantImprovementAllowanceLiability" format="ixt:num-dot-decimal" scale="6" id="f-564">30.8</ix:nonFraction>&#160;million</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATIA from the lessor during the first quarter of fiscal 2024. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increased lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously subleased additional research and development space in San Diego, California, which subleases ended during the fiscal year of 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases space for office and laboratory facilities, which expires on September&#160;30, 2031. The lease contains options to renew for <ix:nonFraction unitRef="option" contextRef="c-153" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="f-565">two</ix:nonFraction> terms of <ix:nonNumeric contextRef="c-153" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-566">five years</ix:nonNumeric>. After accounting for additional rental square feet added pursuant to amendments to the lease agreement in 2019 and 2020, the Company currently leases a total of <ix:nonFraction unitRef="sqft" contextRef="c-153" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-567">115,000</ix:nonFraction>  square feet.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-568" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.144%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-569">44,626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-570">45,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-571">5,285</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-572">10,563</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-573">113,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-574">104,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:17.839%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.298%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-575">2,572</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-576">2,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-577">5,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-578">4,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-579">491</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-580">500</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="f-581">967</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-582">1,033</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-583">836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-584">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-585">1,615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-586">370</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="f-587">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="f-588">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="f-589">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="f-590">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-591">3,899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-592">3,003</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-593">8,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-594">5,815</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Variable lease cost is primarily related to operating expenses associated with the Company&#8217;s operating leases.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:fixed-zero" scale="6" id="f-595">no</ix:nonFraction> short-term lease cost during the first half of fiscal 2024. There was $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-596">0.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-597">0.7</ix:nonFraction>&#160;million short-term lease cost during the three and six months ended March&#160;31, 2023, respectively. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-598" continuedAt="f-598-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of March&#160;31, 2024:</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:83.996%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.804%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024 (remainder of fiscal year)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="f-599">6,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-600">15,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-601">15,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-602">14,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-603">13,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2029 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-604">128,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-605">194,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-606">75,868</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-607">118,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-598-1"><ix:continuation id="f-552-3"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:39.284%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.162%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.166%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash received for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-608">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-609">8,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-610">3,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-611">17,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchanged for amended operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-612">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="f-614">64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-615">22,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-616">2,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-617">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-618">4,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-619">2,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-620">13.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-63" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-621">6.6</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-3" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-622">8.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-63" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-623">8.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-624" continuedAt="f-624-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-624-1" continuedAt="f-624-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#8220;2004 Plan&#8221;) and the 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), <ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="f-625">0</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-626"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-627">2,967,887</ix:nonFraction></ix:nonFraction> shares, respectively, of the Company&#8217;s common stock are reserved for grants of stock options and restricted stock awards to employees and directors as of March&#160;31, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2021, the Company&#8217;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), which authorized <ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-628">8,000,000</ix:nonFraction> shares (subject to certain adjustments) available for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of March&#160;31, 2024, the total number of shares available for issuance was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-629">4,553,827</ix:nonFraction> shares, which includes <ix:nonFraction unitRef="shares" contextRef="c-165" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-630">158,678</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-166" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-631">134,389</ix:nonFraction> shares that were forfeited under the 2013 and 2021 Plans, respectively, and <ix:nonFraction unitRef="shares" contextRef="c-166" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-632">3,689,089</ix:nonFraction> shares have been granted under the 2021 Plan.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there were <ix:nonFraction unitRef="shares" contextRef="c-167" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-633">688,165</ix:nonFraction> shares reserved for options and <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-634">637,563</ix:nonFraction> shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="f-635" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.381%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.708%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.711%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:fixed-zero" scale="0" id="f-636">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-637">1,358,377</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-638">32,151</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-639">688,165</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-640">2,078,693</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-641">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-642">1,609,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-173" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-643">2,844,090</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-644">637,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-174" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-645">5,091,163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-162" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:fixed-zero" scale="0" id="f-646">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-647"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-648">2,967,887</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-649">2,876,241</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-650">1,325,728</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-651">7,169,856</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-652" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expenses included in operating expenses:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:31.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.370%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-653">7,097</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-654">8,745</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-655">15,413</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-656">17,147</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-657">9,491</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-658">11,868</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-659">18,860</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-660">22,855</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-661">16,588</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-662">20,613</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-663">34,273</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-664">40,002</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-665" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the six months ended March&#160;31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.268%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-666">2,263,477</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-667">22.68</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-668">&#8212;</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-669">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cancelled or expired</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-670">30,437</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-671">61.11</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-672">154,347</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-673">11.53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-674">2,078,693</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-675">23.04</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-676">4.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-677">26,788,979</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at March&#160;31, 2024</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-678">2,054,866</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-3" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-679">22.72</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-680">3.9</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="f-681">26,788,746</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the three months ended March&#160;31, 2024 </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-624-2"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-682">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-683">1.4</ix:nonFraction> million, respectively. The total intrinsic value of the options exercised during the six months ended March&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-684">3.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-685">3.6</ix:nonFraction>&#160;million, respectively</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options outstanding for the three months ended March&#160;31, 2024 and 2023, was $<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-686">0.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-687">2.2</ix:nonFraction> million, respectively. Stock-based compensation expense related to stock options outstanding for the six months ended March&#160;31, 2024 and 2023, was $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-688">2.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-689">4.6</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-690">0.8</ix:nonFraction>&#160;million will be recognized in the Company&#8217;s results of operations over a weighted average period of <ix:nonNumeric contextRef="c-177" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:durmonth" id="f-691">4</ix:nonNumeric> months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-692"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="f-693">No</ix:nonFraction></ix:nonFraction> options were granted during the six months ended March&#160;31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Visirna ESOP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On October 1, 2023, Visirna, a subsidiary of the Company, granted <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-694">7,500,000</ix:nonFraction> stock options to its employees from the Employee Stock Option Plan (the &#8220;Visirna ESOP&#8221;), which authorizes <ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-695">20,000,000</ix:nonFraction> shares for issuance. The Visirna ESOP is independently managed by Visirna, including the valuation process. For the three and six months ended March&#160;31, 2024, stock-based compensation expense related to the Visirna ESOP was $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-696">1.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-697">3.2</ix:nonFraction> million, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-698" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-184" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-699">4,241,640</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-184" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-700">58.43</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-185" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-701">1,838,025</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-702">30.75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-185" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-703">876,352</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-704">53.60</ix:nonFraction>&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="shares" contextRef="c-185" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-705">112,150</ix:nonFraction>)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-185" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-706">44.16</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-174" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-707">5,091,163</ix:nonFraction></span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-174" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-708">49.58</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-709">16.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-710">18.4</ix:nonFraction> million of expense related to RSUs, respectively. For the six months ended March&#160;31, 2024 and 2023, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-711">32.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-712">35.4</ix:nonFraction>&#160;million of expense related to RSUs, respectively. As of March&#160;31, 2024, there was $<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-713">112.0</ix:nonFraction>&#160;million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-185" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-714">1.7</ix:nonNumeric> years.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-715" continuedAt="f-715-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="f-715-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The Company&#8217;s valuation techniques and inputs used to measure fair value and the definition of the three levels (Level 1, Level 2, and Level 3) of the fair value hierarchy are disclosed in Note 10 - Fair Value Measurements of Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules&#8221; of its Annual Report on Form 10-K for the year ended September 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At March&#160;31, 2024 and September&#160;30, 2023, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-716" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.466%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.449%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-717">4,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-720">4,963</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-721">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-722">48,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-723">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-724">48,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-726">3,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-727">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-728">3,949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-729">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-730">120,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-731">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-732">120,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-733">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-734">217,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-735">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-736">217,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-737">4,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-738">390,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-740">395,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-741">77,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-742">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-743">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-744">77,080</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-745">4,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-746">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-747">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-748">4,993</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-749">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-750">4,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-751">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-752">4,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-753">82,073</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-754">4,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-755">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-756">87,070</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-757">87,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-758">395,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-759">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-760">482,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:33.194%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-761">31,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-762">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-763">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-764">31,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-766">7,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-768">7,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-770">22,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-772">22,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-774">231,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-776">231,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total available-for-sale securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-777">31,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-778">261,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-780">292,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="f-781">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-782">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-783">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="f-784">347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="f-785">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-787">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="f-788">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-789">31,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-790">261,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-791">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-792">293,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:12pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_61"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="c-1" name="arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" id="f-793" continuedAt="f-793-1" escape="true">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</ix:nonNumeric></span></div><ix:continuation id="f-793-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-794">410.0</ix:nonFraction>&#160;million in cash to the Company in consideration for the Company&#8217;s future royalty interest in olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in September 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $<ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-795">250.0</ix:nonFraction> million upfront and agreed to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="f-796">160.0</ix:nonFraction>&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" format="ixt:num-dot-decimal" scale="6" id="f-797">50.0</ix:nonFraction>&#160;million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="arwr:MilestonePaymentReceivableUponFDAApproval" format="ixt:num-dot-decimal" scale="6" id="f-798">50.0</ix:nonFraction>&#160;million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" format="ixt:num-dot-decimal" scale="6" id="f-799">60.0</ix:nonFraction>&#160;million upon Royalty Pharma&#8217;s receipt of at least $<ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="arwr:RoyaltyPaymentThreshold" format="ixt:num-dot-decimal" scale="6" id="f-800">70.0</ix:nonFraction>&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $<ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-5" name="arwr:LiabilitySaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="f-801">250.0</ix:nonFraction>&#160;million from Royalty Pharma was recorded as a liability related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay this upfront funding received under the  Royalty Pharma Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the obligations at their carrying value using the effective interest method. In order to amortize the sale of future royalties, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods. The Company periodically assesses the amount and the timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success and sales price, among others. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. As of March&#160;31, 2024, the estimated effective interest rate was <ix:nonFraction unitRef="number" contextRef="c-252" decimals="3" name="arwr:LiabilitySaleOfFutureRoyaltiesInterestRate" scale="-2" id="f-802">9.3</ix:nonFraction>%. </span></div><ix:nonNumeric contextRef="c-1" name="arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" id="f-803" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity with respect to the liability related to the sale of future royalties.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:79.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.688%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying value as of September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-804">268,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash interest expense recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-805">12,612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying value as of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-806">280,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="iee955c12611347149f2269c0ac74c071_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-807" continuedAt="f-807-1" escape="true">NET LOSS PER SHARE</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-808" continuedAt="f-808-1" escape="true"><ix:continuation id="f-807-1" continuedAt="f-807-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net loss per share for the three and six months ended March&#160;31, 2024 and 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                            </span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-807-2"><ix:continuation id="f-808-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:43.057%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.253%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.260%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-809">125,300</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-810">48,675</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-811">258,164</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-812">7,350</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-813">123,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-814">106,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-815">115,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-816">106,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-817">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="f-818">1,386</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-819">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:num-dot-decimal" scale="3" id="f-820">1,499</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-821">123,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-822">108,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-823">115,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-824">107,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net (loss) gain per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-825">1.02</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-826">0.46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-827">2.24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-828">0.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net (loss) gain per share</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-829">1.02</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-830">0.45</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-831">2.24</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-832">0.07</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-833" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.006%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-253" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-834">595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-254" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-835">767</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-255" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-836">657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-256" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-837">779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-257" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-838">3,411</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-258" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-839">3,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-259" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-840">3,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-260" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-841">3,290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-842">4,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-843">4,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-844">4,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-845">4,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_67"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Quarterly Report on Form 10-Q except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;goal,&#8221; &#8220;endeavor,&#8221; &#8220;strive,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;forecast&#8221; or &#8220;continue&#8221; or the negative of these words or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, our research and development programs, and our &#8220;20 in 25&#8221; pipeline goal; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding the amount and timing of future milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately, and many of which are beyond our control. As such, our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated or indicated in any forward-looking statements. Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and cash flows may differ materially. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in &#8220;Item 1. Business&#8221; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 1A. Risk Factors&#8221; of Part I and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of Part II of our most recent Annual Report on Form 10-K. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;). In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Statements made herein are as of the date of the filing of this Quarterly Report on Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Except as may be required by law, we disclaim any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</span></div><div id="iee955c12611347149f2269c0ac74c071_70"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNAi  interference mechanism to induce rapid, deep and durable knockdown of target genes. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has focused its resources on therapeutics that exclusively utilize its high levels of pharmacologic activity in multiple animal models spanning several therapeutic areas. The Company believes that TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> enabled therapeutics offer several potential advantages over prior generation and competing technologies, including: simplified manufacturing and reduced costs; multiple routes of administration including subcutaneous injection and inhaled administration; the ability to target multiple tissue types including liver, lung, CNS, muscle and adipose tissue; and the potential for improved safety and reduced risk of intracellular buildup, because there are fewer metabolites from smaller, simpler molecules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s clinical pipeline includes:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Hypertriglyceridemia - plozasiran (formerly ARO-APOC3);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Dyslipidemia - zodasiran (formerly ARO-ANG3);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Cardiovascular disease - olpasiran (formerly AMG 890 or ARO-LPA, out-licensed to Amgen);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Muco-obstructive or inflammatory pulmonary conditions - ARO-MUC5AC and ARO-RAGE;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Idiopathic pulmonary fibrosis - ARO-MMP7;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Non-alcoholic steatohepatitis (NASH) - GSK-4532990 (formerly ARO-HSD, out-licensed to GSK);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Alpha-1 antitrypsin deficiency (AATD) - fazirsiran (formerly ARO-AAT, a collaboration with Takeda);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Chronic hepatitis B virus - JNJ-3989 (formerly ARO-HBV, out-licensed to GSK);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Complement mediated diseases - ARO-C3;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Non-alcoholic steatohepatitis (NASH) - ARO-PNPLA3 (formerly JNJ-75220795 or ARO-JNJ1);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Facioscapulohumeral muscular dystrophy - ARO-DUX4;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Dystrophia myotonica protein kinase (DMPK) - ARO-DM1; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Hepatic expression of complement factor B (CFB) - ARO-CFB.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to develop other clinical candidates for future clinical trials. Clinical candidates are tested internally and through Good Laboratory Practice (GLP) toxicology studies at outside laboratories. Drug materials for such studies and clinical trials are either manufactured internally or contracted to third-party manufacturers. The Company engages third-party contract research organizations (CROs) to manage clinical trials and works cooperatively with such organizations on all aspects of clinical trial management, including plan design, patient recruiting, and follow up. These outside costs, including toxicology/efficacy testing and manufacturing costs, as well as the preparation for and administration of clinical trials, are referred to as &#8220;candidate costs.&#8221; As clinical candidates progress through clinical development, candidate costs will increase. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The First Half of Fiscal 2024 Business Highlights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key recent developments through fiscal 2024 included the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.7pt">Completed enrollment in Amgen&#8217;s Phase 3 OCEAN(a) - outcome trial of olpasiran, triggering a $50.0&#160;million milestone payment to the Company, which was paid in the third quarter of fiscal 2024;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Presented final data from the double-blind treatment period of the Company&#8217;s Phase 2 SHASTA-2 study of investigational plozasiran in patients with severe Hypertriglyceridemic. Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Announced an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for qualifying patients with familial chylomicronemia syndrome (FCS); </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initiated a Phase 1/2a clinical trial of ARO-DM1, being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, being developed as a potential treatment for complement mediated renal disease; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued 15,790,000 shares of common stock at a price of $28.50 per share. The aggregate purchase price paid by investors was $450.0 million and the Company received net proceeds of $429.3 million after deducting advisory fees and offering expenses; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Entered into an Amended and Restated License Agreement with GSK, pursuant to which GSK received a worldwide, exclusive license to develop and commercialize JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen Pharmaceuticals, Inc. See Note 2 - Collaboration and License Agreements to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to the Company was $125.3 million for the three months ended March&#160;31, 2024 as compared to net income attributable to the Company of $48.7 million for the three months ended March&#160;31, 2023. Net loss attributable to the Company was $258.2 million for the six months ended March&#160;31, 2024 as compared to net income attributable to the Company of $7.4 million for the six months ended March&#160;31, 2023. Net loss per share &#8211; diluted was $1.02 for the three months ended March&#160;31, 2024 as compared to net income per share &#8211; diluted of $0.45 for the three months ended March&#160;31, 2023. Net loss per share &#8211; diluted was $2.24 for the six months ended March&#160;31, 2024 as compared to net income per share &#8211; diluted of $0.07 for the six months ended March&#160;31, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in net loss attributable to the Company for the three and six months ended March&#160;31, 2024 were mainly due to a decrease in revenue from the Company&#8217;s license and collaboration agreements, in conjunction with increased </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development expenses, which have continued to increase as the Company&#8217;s pipeline of candidates has expanded and progressed through clinical trial phases. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $127.7 million of cash, cash equivalents and restricted cash, $395.4 million in available-for-sale securities, and $955.2 million of total assets as of March&#160;31, 2024, as compared to $110.9 million of cash, cash equivalents and restricted cash, $292.7 million in available-for-sale securities and $765.6 million of total assets as of September&#160;30, 2023. Based upon the Company&#8217;s current cash and investment resources and operating plan, the Company expects to have sufficient liquidity to fund operations for at least the next twelve months. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes to the Company&#8217;s critical accounting estimates disclosed in the most recent Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2023.</span></div><div id="iee955c12611347149f2269c0ac74c071_73"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following data summarizes the Company&#8217;s results of operations for the following periods indicated: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.273%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.153%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.962%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">146,267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">208,813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating (loss) income</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(126,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(262,736)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,031&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(125,300)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(258,164)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net (loss) income per share-diluted</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.02)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div id="iee955c12611347149f2269c0ac74c071_76"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue for the three months ended March&#160;31, 2024 decreased by $146.3 million or 100.0% from the same period of 2023. Total revenue for the six months ended March&#160;31, 2024 decreased by $205.3 million, or 98.3% from the same period of 2023. The changes were primarily driven by decreased revenue recognition associated with the Company&#8217;s license and collaboration agreements during the first half of fiscal 2024. The revenue for the six months ended March&#160;31, 2024 was mainly driven by the revenue recognition associated with Takeda and GSK, as discussed below.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated each agreement in accordance with FASB Topic 808&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Topic 606-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Note 2 &#8212; Collaboration and License Agreements to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements&#8221; for more information on revenue recognized under the collaboration and license agreements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Takeda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In October 2020, Takeda and the Company entered into the Takeda License Agreement. The Company has allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;D Services. Revenue was recognized using the input method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Phase 2 study visits for patients in the SEQUOIA and AROAAT2002 studies concluded by December 31, 2023, and the Company has substantially completed its performance obligation under the Takeda license agreement. As such, all revenue has been fully recognized as of December 31, 2023.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended March 31, 2023, the Company recorded $132.5&#160;million revenue, including $40.0 million milestone payment by dosing the first patient in the Phase 3 REDWOOD clinical study of fazirsiran.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GSK</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On December 11, 2023, GSK and the Company entered into the GSK HBV Agreement. Under the GSK-HBV Agreement, GSK received a worldwide, exclusive license to develop and commercialize JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen in October 2018. Under the terms of the GSK-HBV Agreement, the Company received $2.7&#160;million in December 2023, upon signing the GSK-HBV Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended March 31, 2023, the Company recorded a $30.0 million milestone payment by dosing the first patient in a Phase 2b trial under GSK License Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Horizon/Amgen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: During the six months ended March 31, 2023, the Company recorded $6.7 million revenue of the total $40.0 million upfront payment received in July 2021, which was recognized on a straight-line basis over the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">timeframe for completing the Horizon R&amp;D Services, concluding in the first quarter of 2023. Horizon enrolled the first subject in December 2022 in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HZN-457, triggering a $15.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. Further, Amgen enrolled the first subject in its Phase 3 trial of olpasiran, which triggered a $25.0 million milestone payment to the Company which was paid in the second quarter of fiscal 2023. On October 6, 2023, Amgen, Inc. completed its acquisition of Horizon and subsequently notified the Company of Amgen&#8217;s intent to terminate the HZN-457 license. Horizon exercised its right to terminate the Horizon License Agreement for convenience, which took effect on December 21, 2023. </span></div><div id="iee955c12611347149f2269c0ac74c071_79"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The analysis below details the operating expenses and discusses the expenditures of the Company within the major expense categories. For purposes of comparison, the amounts for the three and six months ended March&#160;31, 2024 and 2023 are shown in the tables below. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development (R&amp;D) Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses are related to the Company&#8217;s research and development discovery efforts and related candidate costs, which are comprised primarily of outsourced costs related to the manufacturing of clinical supplies, toxicity/efficacy studies and clinical trial expenses. Internal costs primarily relate to discovery operations at the Company&#8217;s research facilities in California and Wisconsin, including facility costs and laboratory-related expenses. The Company does not separately track R&amp;D expenses by individual research and development project, or by individual drug candidate. The Company operates in a cross-functional manner across projects and does not separately allocate facilities-related costs, candidate costs, discovery costs, compensation expenses, depreciation and amortization expenses, and other expenses related to research and development activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of research and development expenses for the periods indicated:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.663%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.291%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended <br/>March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended <br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Candidate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">33,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,319&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,786&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,921&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89,535&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">63,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,664&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,487&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,745&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,258)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,835&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101,122&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">74,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,241&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">35&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:27.663%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.654%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.288%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.396%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.291%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended <br/>March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended <br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">% of</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Expense</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Category </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Candidate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">68,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">54,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,884&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">79&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,423&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,674&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">193,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">89&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">136,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">56,290&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,494&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,147&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(653)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Depreciation/amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,951&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">217,613&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">158,576&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">59,037&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">37&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Candidate costs increased $7.3 million, or 28%, for the three months ended March&#160;31, 2024 and $10.3 million, or 15%, for the six months ended March&#160;31, 2024 compared to the same period of 2023. This increase was primarily due to the additional progression of the Company&#8217;s pipeline of candidates into and through clinical trials, which resulted in higher </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing, outsourced clinical trial, and toxicity study costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D discovery costs increased $7.4 million, or 42%, for the three months ended March&#160;31, 2024 and $23.9 million, or 79%, for the six months ended March&#160;31, 2024 compared to the same period of 2023. This increase was primarily driven by the growth of the Company&#8217;s discovery efforts and continued advancement into novel therapeutic areas and tissue types, particularly due to an increase in labor along with rising costs associated with CNS studies and lab supplies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries and stock compensation expense consist of salary, bonuses, payroll taxes, related benefits and stock compensation for the Company&#8217;s R&amp;D personnel. The increase in salaries for the three and six months ended March&#160;31, 2024 was primarily due to an increase in R&amp;D headcount that has occurred as the Company has expanded its pipeline of candidates, in addition to annual salary increases. Stock compensation expense was based upon the valuation of stock options and restricted stock units granted to employees and directors. The decrease in stock compensation expense for the three and six months ended March&#160;31, 2024 was primarily due to the cancelled awards upon the departure of employees. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities-related expense includes lease costs for the Company&#8217;s research and development facilities in San Diego, California and Madison, Wisconsin. Facilities-related costs increased $2.5 million, or 72%, for the three months ended March&#160;31, 2024 and $5.7 million, or 84%, for the six months ended March&#160;31, 2024 compared to the same period of 2023. This increase was mainly due to the ATIAs on the lease in San Diego, California. See Note 8 &#8212; Leases of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense, a non-cash expense, increased $1.8 million, or 81% for the three months ended March&#160;31, 2024 and $3.4 million, or 75%, for the six months ended March&#160;31, 2024, compared to the same period of 2023. The increase was primarily attributed to higher leasehold improvements, due to completion of the development of the San Diego facility. Additionally, as of December 31, 2023, the Company completed the build out of one of its laboratory and office facilities in Verona, Wisconsin, and commenced depreciation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates these R&amp;D expenses to continue to increase as its pipeline of candidates grows and progresses to later phase clinical trials, in addition to inflationary pressure on goods and services and the labor market. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General &amp; Administrative Expenses </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of the Company&#8217;s general and administrative expenses for the periods indicated: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.279%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended <br/>March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended <br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Salaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,005&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,083&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">42&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Professional, outside services, and other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,355&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Total general &amp; administrative expense, excluding non-cash expenses</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,381&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">57&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">47&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,433&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,263&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,868&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">51&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,605)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(14)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">425&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">405&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Total general &amp; administrative expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">23,221&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,848&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:28.959%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.036%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.275%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.279%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended <br/>March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended <br/>March 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Increase (Decrease)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Salaries</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">27&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Professional, outside services, and other </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Facilities related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,040&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Total general &amp; administrative expense, excluding non-cash expenses</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">26,887&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">55&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,543&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6,344&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Stock compensation</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,950&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">43&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,855&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1,905)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Total general &amp; administrative expenses</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,206&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">100&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,468&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries expense increased $2.1 million, or 42%, for the three months ended March&#160;31, 2024 and $4.1 million, or 45%, for the six months ended March&#160;31, 2024 compared to the same period of 2023. The increase was driven by the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">combination of annual salary increases and increased headcount required to support the Company&#8217;s growth. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional, outside services, and other expense includes legal, consulting, patent expenses, business insurance expenses, other outside services, travel, and communication and technology expenses. This expense increased $1.4 million, or 28%, for the three months ended March&#160;31, 2024 and $2.2 million, or 24%, for the six months ended March&#160;31, 2024 compared to the same period of 2023. The increase was mainly due to legal services associated with new patent applications and intellectual property matters, as well as other professional services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities related expense primarily includes rental costs and other facilities-related costs for the Company&#8217;s corporate headquarters in Pasadena, California. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense, a non-cash expense, was based upon the valuation of stock options and restricted stock units granted to employees. This expense decreased $1.6 million, or 14%, for the three months ended March&#160;31, 2024 and  $1.9 million, or 8%, for the six months ended March&#160;31, 2024 compared to the same period of 2023. The decrease was mainly due to the decreased compensation costs related to performance awards. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense, a noncash expense, was primarily related to amortization of leasehold improvements for the Company&#8217;s corporate headquarters.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates these general and administrative expenses to continue to increase as its pipeline of candidates grows and progresses to later phase clinical trials, in addition to inflationary pressure on goods and services and the labor market. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Income (Expense)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) is primarily related to interest income and expense. Other expense increased $0.3 million and $2.8 million for the three and six months ended March&#160;31, 2024, respectively, compared to the same periods of 2023. The increase was primarily due to the non-cash interest expense on the liability related to the sale of future royalties, partially offset by higher yields on investments due to increased interest rates. </span></div><div id="iee955c12611347149f2269c0ac74c071_82"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically financed its operations through the sale of its equity securities, revenue from its licensing and collaboration agreements, and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure as the Company&#8217;s pipeline continues to expand and matures into later stage clinical trials. Additionally, the Company expanded its facilities in Verona, Wisconsin and leased additional facilities in San Diego, California. Each of these expansions is designed to increase the Company&#8217;s internal manufacturing and discovery capabilities and requires significant capital investment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and restricted cash increased to $127.7 million at March&#160;31, 2024 compared to $110.9 million at September&#160;30, 2023. Cash invested in available-for-sale securities was $395.4 million at March&#160;31, 2024 compared to $292.7 million at September&#160;30, 2023.</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into the Open Market Sale Agreement, pursuant to which the Company may, from time to time, sell up to $250.0 million in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering. As of March&#160;31, 2024, no shares have been issued under the Open Market Sale Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2024, the Company entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued 15,790,000 shares of common stock at an offering price of $28.50 per share. The aggregate purchase price paid by investors was $450.0 million and the Company received net proceeds of $429.3 million after deducting advisory fees and offering expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes its current financial resources are sufficient to fund its operations through at least the next twelve months.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of cash flows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.083%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash Flow from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(210,217)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(107,187)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(204,098)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(116,759)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">431,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">251,096&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net increase in cash, cash equivalents and restricted cash</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">16,729&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">27,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">127,704&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">134,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended March&#160;31, 2024, cash flow used in operating activities was $210.2 million, which was primarily due to the ongoing expenses related to the Company&#8217;s research and development programs and general and administrative expenses. Cash used in investing activities amounted to $204.1 million, which was primarily attributable to capital expenditures of $102.7 million and investment purchases of $310.0 million, offset by proceeds from sales and maturities of investments of $208.6 million. Cash provided by financing activities of $431.0 million was primarily related to cash received from the issuance of common stock as well as stock option exercises (See Note 6 &#8212; Stockholders&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended March 31, 2023, cash flows used by operating activities was $107.2 million, which was primarily due to the ongoing expenses related to the Company&#8217;s research and development programs and general and administrative expenses, partially offset by the receipt of $40.0 million from Amgen and Horizon. Cash used in investing activities was $116.8 million, which was primarily related to capital expenditures, $66.2 million of construction in progress and investment purchases of $192.5 million, offset by proceeds from sales and maturities of investments of $142.0 million. Cash provided by financing activities of $251.1 million was primarily related to the $250.0&#160;million payment from Royalty Pharma as well as cash received from stock option exercises. See Note 11 &#8211; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contractual Obligations</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the Company&#8217;s contractual obligations from that described in Item 7 of its Annual Report on Form 10-K for the year ended September 2023.</span></div><div id="iee955c12611347149f2269c0ac74c071_85"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> exposure to market risk from that described in Item 7A of its Annual Report on Form 10-K for the year ended September 30, 2023.</span></div><div id="iee955c12611347149f2269c0ac74c071_88"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains disclosure controls and procedures designed to ensure that information required to be disclosed in its reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to its management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule 13a-15(b) of the Exchange Act, the Company carried out an evaluation, under the supervision and with the participation of its management, including its Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company&#8217;s disclosure controls and procedures as of the end of the quarter covered by this Quarterly Report on Form 10-Q. Based on the foregoing, the Company&#8217;s Chief Executive Officer and Chief Financial Officer concluded that the Company&#8217;s disclosure controls and procedures were effective at the reasonable </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">assurance level.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in the Company&#8217;s internal control over financial reporting during the Company&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company regularly evaluates its controls and procedures and makes improvements in the design and effectiveness of established controls and procedures and the remediation of any deficiencies which may be identified during this process.</span></div><div style="margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_91"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II&#8212;OTHER INFORMATION</span></div><div id="iee955c12611347149f2269c0ac74c071_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be involved in routine legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of its business. Litigation can be expensive and disruptive to normal business operations. Moreover, the results of legal proceedings, particularly complex legal proceedings, cannot be predicted with any certainty. There have been no material developments in the legal proceedings that the Company disclosed in Part I, Item 3 of its Annual Report on Form 10-K for the year ended September&#160;30, 2023.</span></div><div id="iee955c12611347149f2269c0ac74c071_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s business, results of operations and financial conditions are subject to various risks. These risks are described elsewhere in this Quarterly Report on Form 10-Q and in the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s other filings with the SEC, including the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Annual Report on Form 10-K for the year ended September&#160;30, 2023. There have been no material changes from the risk factors identified in the Company</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s Annual Report on Form 10-K for the year ended September&#160;30, 2023.</span></div><div id="iee955c12611347149f2269c0ac74c071_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="iee955c12611347149f2269c0ac74c071_103"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="iee955c12611347149f2269c0ac74c071_106"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.&#160;&#160;&#160;&#160;MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable. </span></div><div id="iee955c12611347149f2269c0ac74c071_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(c) <ix:nonNumeric contextRef="c-5" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-846"><ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-847"><ix:nonNumeric contextRef="c-5" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-848">Trading Plans</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-849" continuedAt="f-849-1" escape="true"><div style="margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended March&#160;31, 2024, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.354%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.358%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Adoption Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Plan Start Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Plan End Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Vesting and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Subject to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Sell-To-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cover </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Other<br/>Shares<br/>Being Sold<br/>(Subject to<br/>Certain<br/>Conditions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-261" name="ecd:TrdArrIndName" id="f-850">James Hamilton</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-261" name="ecd:TrdArrIndTitle" id="f-851">Chief Discovery and Translational Medicine</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-261" name="ecd:TrdArrAdoptionDate" id="f-852"><ix:nonNumeric contextRef="c-261" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-853">3/26/2024</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/6/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/17/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-262" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-854">60,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-263" name="ecd:TrdArrIndName" id="f-855">Ken Myszkowski</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-263" name="ecd:TrdArrIndTitle" id="f-856">Chief Financial Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-263" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-857"><ix:nonNumeric contextRef="c-263" name="ecd:TrdArrAdoptionDate" id="f-858">3/12/2024</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">6/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2/28/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-264" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-859">115,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-265" name="ecd:TrdArrIndName" id="f-860">Ken Myszkowski</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-265" name="ecd:TrdArrIndTitle" id="f-861">Chief Financial Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-265" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-862"><ix:nonNumeric contextRef="c-265" name="ecd:TrdArrAdoptionDate" id="f-863">3/28/2024</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/6/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/17/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-266" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-864">15,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-267" name="ecd:TrdArrIndName" id="f-865">Ken Myszkowski</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-267" name="ecd:TrdArrIndTitle" id="f-866">Chief Financial Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-267" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-867"><ix:nonNumeric contextRef="c-267" name="ecd:TrdArrAdoptionDate" id="f-868">3/28/2024</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/6/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/17/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-268" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-869">15,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-269" name="ecd:TrdArrIndName" id="f-870">Ken Myszkowski</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-269" name="ecd:TrdArrIndTitle" id="f-871">Chief Financial Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-269" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-872"><ix:nonNumeric contextRef="c-269" name="ecd:TrdArrAdoptionDate" id="f-873">3/28/2024</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/6/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/17/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-270" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-874">15,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-271" name="ecd:TrdArrIndName" id="f-875">Ken Myszkowski</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-271" name="ecd:TrdArrIndTitle" id="f-876">Chief Financial Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-271" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-877"><ix:nonNumeric contextRef="c-271" name="ecd:TrdArrAdoptionDate" id="f-878">3/28/2024</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/6/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/17/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-272" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-879">18,750</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-273" name="ecd:TrdArrIndName" id="f-880">Patrick O'Brien</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-273" name="ecd:TrdArrIndTitle" id="f-881">Chief Operating Officer and General Counsel</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-273" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-882"><ix:nonNumeric contextRef="c-273" name="ecd:TrdArrAdoptionDate" id="f-883">3/21/2024</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/6/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/17/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-274" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-884">67,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-275" name="ecd:TrdArrIndName" id="f-885">William Waddill</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-275" name="ecd:TrdArrIndTitle" id="f-886">Board Member</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-275" name="ecd:TrdArrAdoptionDate" id="f-887"><ix:nonNumeric contextRef="c-275" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-888">3/27/2024</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">12/16/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-276" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-889">7,495</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><ix:continuation id="f-849-1" continuedAt="f-849-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="f-849-2"> This column indicates the total number of shares vesting in connection with equity awards, not the number of shares to be sold. The actual number of shares to be sold will be a smaller number based on whatever is required to satisfy payment of applicable withholding taxes under sell-to-cover arrangements.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.173%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Document Description</span></td></tr><tr style="height:9pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex33.htm">Amended and Restated Certificate of Incorporation (incorporated by reference from Exhibit 3.3 of the Company&#8217;s Form 8-K filed on April 6, 2016)</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023014856/arrowheadpharmaceuticals.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">. </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex33.htm">(incorporated by reference from Exhibit 3.2 of the Company&#8217;s Form 10-Q filed on May 2, 2023)</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023001757/arrowheadpharmaceuticals.htm">Second Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc., as amended January 24, 2023(incorporated by reference from Exhibit 3.3 of the Company&#8217;s Form 10-Q filed on May 2, 2023)</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="exhibit101-arrowheadindu.htm">Arrowhead Pharmaceuticals, Inc. Inducement Plan</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-2024331xex311.htm">Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-2024331xex312.htm">Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-2024331xex321.htm">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32.2**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline" href="arwr-2024331xex322.htm">Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Instance Document </span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The cover page from this Quarterly Report on Form 10-Q, formatted in Inline XBRL (included as Exhibit 101)</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_________________</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:31pt">Filed herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26pt">Furnished herewith.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8224;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">          </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Certain portions of this exhibit were redacted by means of marking such portions with asterisks because the identified portions are (i) not material and (ii) treated as private or confidential by the Company.</span></div><div style="text-indent:-18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="iee955c12611347149f2269c0ac74c071_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: May&#160;9, 2024</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:50.720%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARROWHEAD PHARMACEUTICALS, INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Kenneth A. Myszkowski</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Kenneth A. Myszkowski<br/>Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Principal Financial Officer and Duly Authorized Officer)</span></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exhibit101-arrowheadindu.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit101-arrowheadindu</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exhibit101-arrowheadindu001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-arrowheadindu001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">1  ARROWHEAD PHARMACEUTICALS, INC.  INDUCEMENT PLAN  1. DEFINED TERMS  Exhibit A, which is incorporated by reference, defines the terms used in the Plan and sets forth certain operational  rules related to those terms.  2. PURPOSE  The Plan has been established to advance the interests of the Company by providing for the grant to Participants of  Stock-based and other incentive Awards.  Each Award granted under the Plan is intended to qualify as an  employment inducement award pursuant to Nasdaq Listing Rule 5635(c)(4), and shall be interpreted and  administered accordingly.  3. ADMINISTRATION  The Administrator has discretionary authority, subject only to the express provisions of the Plan, to interpret the Plan;  determine eligibility for and grant Awards; determine, modify or waive the terms and conditions of any Award;  prescribe forms, rules and procedures relating to the Plan; determine whether Awards should be settled in cash  and/or shares of Stock; and otherwise do all things necessary or appropriate to carry out the purposes of the Plan.   Determinations of the Administrator made under the Plan will be conclusive and will bind all parties.  4. LIMITS ON AWARDS UNDER THE PLAN  (a) Number of Shares.  The maximum number of shares of Stock that may be delivered in satisfaction of Awards  under the Plan is 832,950.  For purposes of this Section 4(a), the aggregate number of shares of Stock available for  issuance under this Plan at any time shall not be reduced by (i) shares subject to Awards that have been retained or  withheld by the Company in payment or satisfaction of the exercise price or tax withholding obligation of an Award,  (ii) shares of Stock underlying the portion of any Award that expires, terminates or is forfeited or is settled in cash  prior to the issuance of Stock thereunder, or (iii) shares subject to Awards that otherwise do not result in the issuance  of shares in connection with payment or settlement thereof.  To the extent consistent with applicable legal  requirements (including applicable stock exchange requirements), Stock issued under awards of an acquired  company that are converted, replaced or adjusted in connection with the acquisition shall not reduce the number of  shares of Stock available for Awards under the Plan. In addition, shares that have been delivered (either actually or  by attestation) to the Company in payment or satisfaction of the exercise price or tax withholding obligation of an  Award shall be available for issuance under this Plan.  (b) Type of Shares.  Stock delivered by the Company under the Plan may be authorized but unissued Stock or  previously issued Stock acquired by the Company.  No fractional shares of Stock will be delivered under the Plan.  5. ELIGIBILITY AND PARTICIPATION  The Administrator will select Participants from among only individuals who, at the time of grant (i) has not previously  been an Employee or director, or (ii) is commencing employment following a bona fide period of non-employment by  the Company or any subsidiary; provided that in each case, the grant of the Award is made as a material inducement  to his or her commencement as an Employee of the Company or a subsidiary.    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-arrowheadindu002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-arrowheadindu002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">2  6. RULES APPLICABLE TO AWARDS  (a) All Awards.  (1) Award Provisions.  The Administrator will determine the terms of all Awards, subject to the limitations provided  herein.  By accepting (or, under such rules as the Administrator may prescribe, being deemed to have accepted) an  Award, the Participant will be deemed to have agreed to the terms of the Award and the Plan.  Notwithstanding any  provision of this Plan to the contrary, awards of an acquired company that are converted, replaced or adjusted in  connection with the acquisition may contain terms and conditions that are inconsistent with the terms and conditions  specified herein, as determined by the Administrator.  (2) Term of Plan.  No Awards may be made after ten years from the Date of Adoption, but previously granted Awards  may continue beyond that date in accordance with their terms.  (3) Transferability.  Except as the Administrator otherwise expressly provides in accordance with the third sentence of  this Section 6(a)(3), no Award may be transferred other than by will or by the laws of descent and distribution.  During  a Participant&#8217;s lifetime, except as the Administrator otherwise expressly provides in accordance with the third  sentence of this Section 6(a)(3), SARs and Stock Options may be exercised only by the Participant.  The  Administrator may permit the gratuitous transfer (i.e., transfer not for value) of Awards to any transferee eligible to be  covered by the provisions of Form S-8 (under the Securities Act of 1933, as amended), subject to such limitations as  the Administrator may impose.  (4) Vesting, etc.  Subject to Section 6(a)(5), the Administrator will determine the time or times at which an Award will  vest or become exercisable and the terms on which a Stock Option or SAR will remain exercisable.  Without limiting  the foregoing, the Administrator may at any time accelerate the vesting or exercisability of an Award, regardless of  any adverse or potentially adverse tax or other consequences resulting from such acceleration.  Unless the  Administrator expressly provides otherwise, however, the following rules will apply if a Participant&#8217;s Employment  ceases:  (A) Immediately upon the cessation of the Participant&#8217;s Employment and except as provided in (B), (C), and  (D) below, each Stock Option and SAR that is then held by the Participant or by the Participant&#8217;s permitted  transferees, if any, will cease to be exercisable and will terminate and all other Awards that are then held by the  Participant or by the Participant&#8217;s permitted transferees, if any, to the extent not already vested will be forfeited.  (B) Subject to (C), (D) and (E) below, all Stock Options and SARs held by the Participant or the Participant&#8217;s  permitted transferees, if any, immediately prior to the cessation of the Participant&#8217;s Employment, to the extent then  exercisable, will remain exercisable for the lesser of (i) a period of three months and (ii) the period ending on the  latest date on which such Stock Option or SAR could have been exercised without regard to this Section 6(a)(4), and  will thereupon immediately terminate.  (C) All Stock Options and SARs held by a Participant or the Participant&#8217;s permitted transferees, if any, immediately  prior to the cessation of the Participant&#8217;s Employment due to his or her death, to the extent then exercisable, will  remain exercisable for the lesser of (i) a period of twelve months and (ii) the period ending on the latest date on which  such Stock Option or SAR could have been exercised without regard to this Section 6(a)(4), and will thereupon  immediately terminate.  (D) All Stock Options and SARs held by a Participant or the Participant&#8217;s permitted transferees, if any, immediately  prior to the cessation of the Participant&#8217;s Employment due to his or her &#8220;permanent and total disability&#8221; (within the  meaning of Section 22(e)(3) of the Code), to the extent then exercisable, will remain exercisable for the lesser of (i) a  period of six months and (ii) the period ending on the latest date on which such Stock Option or SAR could have been  exercised without regard to this Section 6(a)(4), and will thereupon immediately terminate.  (E) All Awards (whether or not exercisable) held by a Participant or the Participant&#8217;s permitted transferees, if any,  immediately prior to the cessation of the Participant&#8217;s Employment will immediately terminate upon such cessation of  Employment if the termination is for Cause or occurs in circumstances that in the sole determination of the  Administrator would have constituted grounds for the Participant&#8217;s Employment to be terminated for Cause.  (5) Additional Restrictions.  The Administrator may cancel, rescind, withhold or otherwise limit or restrict any Award at  any time if the Participant is not in compliance with all applicable provisions of the Award agreement and the Plan, or  if the Participant breaches any agreement with the Company or its Affiliates with respect to non-competition, non- </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-arrowheadindu003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-arrowheadindu003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">3  solicitation or confidentiality.  Without limiting the generality of the foregoing, the Administrator may recover Awards  made under the Plan and payments under or gain in respect of any Award in accordance with all applicable Company  clawback or recoupment policy, as such policy may be amended and in effect from time to time, or as otherwise  required by law or applicable stock exchange listing standards, including, without limitation, the Arrowhead  Pharmaceuticals, Inc. Compensation Recoupment (Clawback) Policy.  (6) Taxes.  The grant of an Award and the delivery, vesting and retention of Stock, cash or other property under an  Award are conditioned upon full satisfaction by the Participant of all tax withholding requirements with respect to the  Award.  The Administrator will prescribe such rules for the withholding of taxes as it deems necessary or appropriate.   The Administrator may, but need not, hold back shares of Stock from an Award or permit a Participant to tender  previously owned shares of Stock in satisfaction of tax withholding requirements (only up to the amount permitted that  will not cause an adverse accounting consequence or cost).  (7) Dividend Equivalents, Etc.  The Administrator may provide for the payment of amounts (on terms and subject to  conditions established by the Administrator) in lieu of cash dividends or other cash distributions with respect to Stock  subject to an Award whether or not the holder of such Award is otherwise entitled to share in the actual dividend or  distribution in respect of such Award.  Any entitlement to dividend equivalents or similar entitlements will be  established and administered either consistent with an exemption from, or in compliance with, the requirements of  Section 409A.  Dividends or dividend equivalent amounts payable in respect of Awards that are subject to restrictions  will be subject to the same vesting and forfeiture restrictions as apply to the Awards to which they relate.  (8) Rights Limited.  Nothing in the Plan or in any Award will be construed as giving any person the right to continued  employment or service with the Company or its Affiliates, or any rights as a stockholder except as to shares of Stock  actually issued under the Plan; nor will anything in the Plan or in any Award affect the right of the Company or its  Affiliates to discharge or discipline a Participant at any time.  The loss of existing or potential profit in Awards will not  constitute an element of damages in the event of termination of Employment for any reason, even if the termination is  in violation of an obligation of the Company or any Affiliate to the Participant.  (9) Coordination with Other Plans.  Awards under the Plan may be granted in tandem with, or in satisfaction of or  substitution for, other Awards under the Plan or awards made under other compensatory plans or programs of the  Company or its Affiliates.    (10) Section 409A.  Each Award will contain such terms as the Administrator determines, and will be construed and  administered, such that the Award either qualifies for an exemption from the requirements of Section 409A or  satisfies such requirements.  (b) Stock Options and SARs.  Only Stock Options that are not intended to qualify as an &#8220;incentive stock option&#8221; within  the meaning of Section 422 of the Code may be granted under the Plan.  (1) Time And Manner Of Exercise.  Unless the Administrator expressly provides otherwise, no Stock Option or SAR  will be deemed to have been exercised until the Administrator receives a notice of exercise (in form acceptable to the  Administrator), which may be an electronic notice, signed (including electronic signature in form acceptable to the  Administrator) by the appropriate person and accompanied by any payment required under the Award.  A Stock  Option or SAR exercised by any person other than the Participant will not be deemed to have been exercised until  the Administrator has received such evidence as it may require that the person exercising the Award has the right to  do so.  (2) Exercise Price.  The exercise price (or the base value from which appreciation is to be measured) of each Award  requiring exercise will be no less than 100% of the Fair Market Value of the Stock subject to the Award, determined  as of the date of grant, or such higher amount as the Administrator may determine in connection with the grant.   Except in connection with a corporate transaction involving the Company (which term shall include, without limitation,  any stock dividend, stock split, extraordinary cash dividend, recapitalization, reorganization, merger,  consolidation, split-up, spin-off, combination, or exchange of shares) or as otherwise contemplated by Section 7 of  the Plan, the Company may not, without obtaining stockholder approval, (A) amend the terms of outstanding Stock  Options or SARs to reduce the exercise price or base value of such Stock Options or SARs, (B) cancel outstanding  Stock Options or SARs in exchange for Stock Options or SARs with an exercise price or base value that is less than  the exercise price or base value of the original Stock Options or SARs, or (C) cancel outstanding Stock Options or  SARs that have an exercise price or base value greater than the Fair Market Value of a share of Stock on the date of  such cancellation in exchange for cash or other consideration.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-arrowheadindu004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-arrowheadindu004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">4  (3) Payment Of Exercise Price.  Where the exercise of an Award is to be accompanied by payment, payment of the  exercise price will be by cash or check acceptable to the Administrator or by such other legally permissible means, if  any, as may be acceptable to the Administrator.  (4) Maximum Term.  Stock Options and SARs will have a maximum term not to exceed ten (10) years from the date  of grant; provided, however, that, if a Participant still holding an outstanding but unexercised Stock Option or SAR ten  (10) years from the date of grant (or, in the case of a Stock Option or SAR with a maximum term of less than ten  (10) years, such maximum term) is prohibited by applicable law or a written policy of the Company applicable to  similarly situated employees from engaging in any open-market sales of Stock, and if at such time the Stock is  publicly traded (as determined by the Administrator), the maximum term of such Award will instead be deemed to  expire on the thirtieth (30th) day following the date the Participant is no longer prohibited from engaging in such open  market sales.  7. EFFECT OF CERTAIN TRANSACTIONS  (a) Mergers, etc.  Except as otherwise provided in an Award agreement, the following provisions will apply in the  event of a Covered Transaction:  (1) Assumption or Substitution.  If the Covered Transaction is one in which there is an acquiring or surviving entity,  the Administrator may (but, for the avoidance of doubt, need not) provide (i) for the assumption or continuation of  some or all outstanding Awards or any portion thereof or (ii) for the grant of new awards in substitution therefor by the  acquiror or survivor or an affiliate of the acquiror or survivor.  (2) Cash-Out of Awards.  Subject to Section 7(a)(6) below, the Administrator may (but, for the avoidance of doubt,  need not) provide for payment (a &#8220;cash-out&#8221;), with respect to some or all Awards or any portion thereof, equal in the  case of each affected Award or portion thereof to the excess, if any, of (A) the Fair Market Value of one share of  Stock (as determined by the Administrator in its reasonable discretion) times the number of shares of Stock subject to  the Award or such portion, over (B) the aggregate exercise or purchase price, if any, under the Award or such portion  (in the case of an SAR, the aggregate base value above which appreciation is measured), in each case on such  payment terms (which need not be the same as the terms of payment to holders of Stock) and other terms, and  subject to such conditions, as the Administrator determines, it being understood that if the exercise or purchase price  (or base value) of an Award is equal to or greater than the Fair Market Value of one share of Stock (as determined in  accordance with this Section 7(a)(2)), the Award may be cancelled with no payment due hereunder.  (3) Acceleration of Certain Awards.  Subject to Section 7(a)(6) below, the Administrator may (but, for the avoidance of  doubt, need not) provide that any Award requiring exercise will become exercisable, in full or in part and/or that the  delivery of any shares of Stock remaining deliverable under any outstanding Award of Stock Units (including  Restricted Stock Units and Performance Awards to the extent consisting of Stock Units) will be accelerated in full or  in part, in each case on a basis that gives the holder of the Award a reasonable opportunity, as determined by the  Administrator, following exercise of the Award or the delivery of the shares, as the case may be, to participate as a  stockholder in the Covered Transaction.  (4) Change in Control.  Notwithstanding anything herein to the contrary, unless otherwise expressly provided for in  the Award agreement or another contract, including an employment or severance agreement or severance plan, or  under the terms of a transaction constituting a Change in Control, in the event of a Change in Control, each  outstanding Award will fully vest (which, in the case of Performance Awards shall be to their maximal value) and  become exercisable immediately prior to the consummation of such Change in Control, and the Administrator shall  notify the Participant in writing or electronically that the Award will be fully vested and exercisable for a period of at  least fifteen (15) days from the date of such notice, (which notice may be delivered prior to the consummation of the  Change in Control) and the Award will terminate upon the expiration of such period if not otherwise assumed or  substituted pursuant to Section 7(a)(1) above or cashed-out pursuant to Section 7(a)(2) above.  (5) Termination of Awards Upon Consummation of Covered Transaction.  Except as the Administrator may otherwise  determine in any case and except for the 15-day exercise period set forth above in Section 7(a)(4), each Award will  automatically terminate (and in the case of outstanding shares of Restricted Stock, will automatically be forfeited)  upon consummation of the Covered Transaction, other than Awards assumed pursuant to Section 7(a)(1) above.  (6) Additional Limitations.  Any share of Stock and any cash or other property delivered pursuant to Section 7(a)(2) or  Section 7(a)(3) above with respect to an Award may, in the discretion of the Administrator, contain such restrictions, if  any, as the Administrator deems appropriate to reflect any performance or other vesting conditions to which the  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-arrowheadindu005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-arrowheadindu005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">5  Award was subject and that did not lapse (and were not satisfied) in connection with the Covered Transaction.  For  purposes of the immediately preceding sentence, a cash-out under Section 7(a)(2) above or acceleration under  Section 7(a)(3) above will not, in and of itself, be treated as the lapsing (or satisfaction) of a performance or other  vesting condition.  In the case of Restricted Stock that does not vest and is not forfeited in connection with the  Covered Transaction, the Administrator may require that any amounts delivered, exchanged or otherwise paid in  respect of such Stock in connection with the Covered Transaction be placed in escrow or otherwise made subject to  such restrictions as the Administrator deems appropriate to carry out the intent of the Plan.  (b) Changes in and Distributions With Respect to Stock.  (1) Basic Adjustment Provisions.  In the event of a stock dividend, stock split or combination of shares (including a  reverse stock split), recapitalization, reclassification or other distribution of the Company&#8217;s equity securities without  the receipt of consideration by the Company, or other change in the Company&#8217;s capital structure that constitutes an  equity restructuring within the meaning of FASB ASC 718, the Administrator will make appropriate adjustments to the  maximum number of shares specified in Section 4(a) that may be delivered under the Plan and will also make  appropriate adjustments to the number and kind of shares of stock or securities subject to Awards then outstanding  or subsequently granted, any exercise or purchase prices (or base values) relating to Awards and any other provision  of Awards affected by such change.  (2) Certain Other Adjustments.  The Administrator may also make adjustments of the type described in  Section 7(b)(1) above to take into account distributions to stockholders other than those provided for in Section 7(a)  and 7(b)(1), or any other event, if the Administrator determines that adjustments are appropriate to avoid distortion in  the operation of the Plan, having due regard for the requirements of Section 409A, where applicable.  (3) Continuing Application of Plan Terms.  References in the Plan to shares of Stock will be construed to include any  stock or securities resulting from an adjustment pursuant to this Section 7.  8. LEGAL CONDITIONS ON DELIVERY OF STOCK  The Company will not be obligated to deliver any shares of Stock pursuant to the Plan or to remove any restriction  from shares of Stock previously delivered under the Plan until:  (i) the Company is satisfied that all legal matters in  connection with the issuance and delivery of such shares have been addressed and resolved; (ii) if the outstanding  Stock is at the time of delivery listed on any stock exchange or national market system, the shares to be delivered  have been listed or authorized to be listed on such exchange or system upon official notice of issuance; and (iii) all  conditions of the Award have been satisfied or waived.  The Company may require, as a condition to exercise of the  Award, such representations or agreements as counsel for the Company may consider appropriate to avoid violation  of the Securities Act of 1933, as amended, or any applicable state or non-U.S. securities law.  Any Stock required to  be issued to Participants under the Plan will be evidenced in such manner as the Administrator may deem  appropriate, including book-entry registration or delivery of stock certificates.  In the event that the Administrator  determines that Stock certificates will be issued to Participants under the Plan, the Administrator may require that  certificates evidencing Stock issued under the Plan bear an appropriate legend reflecting any restriction on transfer  applicable to such Stock, and the Company may hold the certificates pending lapse of the applicable restrictions.  9. AMENDMENT AND TERMINATION  10. OTHER COMPENSATION ARRANGEMENTS  The Administrator may at any time or times amend the Plan or any outstanding Award for any purpose which may at  the time be permitted by law, and may at any time terminate the Plan as to any future grants of Awards; provided,  that except as otherwise expressly provided in the Plan the Administrator may not, without the Participant&#8217;s consent,  alter the terms of an Award so as to affect materially and adversely the Participant&#8217;s rights under the Award, unless  the Administrator expressly reserved the right to do so at the time the Award was granted or unless the Administrator  determines in its sole discretion and prior to the date of any Covered Transaction that such amendment or alteration  either (i) is required or advisable in order for the Company, the Plan or the Award to satisfy any law or regulation or to  meet the requirements of or avoid adverse financial accounting consequences under any accounting standard, or  (ii) is not reasonably likely to significantly diminish the benefits provided under such Award, or that any such  diminishment has been adequately compensated.    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-arrowheadindu006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-arrowheadindu006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">6  The existence of the Plan or the grant of any Award will not in any way affect the Company&#8217;s right to Award a person  bonuses or other compensation in addition to Awards under the Plan.  11. MISCELLANEOUS  (a) Waiver of Jury Trial.  By accepting an Award under the Plan, each Participant waives any right to a trial by jury in  any action, proceeding or counterclaim concerning any rights under the Plan and any Award, or under any  amendment, waiver, consent, instrument, document or other agreement delivered or which in the future may be  delivered in connection therewith, and agrees that any such action, proceedings or counterclaim will be tried before a  court and not before a jury.  By accepting an Award under the Plan, each Participant certifies that no officer,  representative, or attorney of the Company has represented, expressly or otherwise, that the Company would not, in  the event of any action, proceeding or counterclaim, seek to enforce the foregoing waivers.  Notwithstanding anything  to the contrary in the Plan, nothing herein is to be construed as limiting the ability of the Company and a Participant to  agree to submit disputes arising under the terms of the Plan or any Award made hereunder to binding arbitration or  as limiting the ability of the Company to require any eligible individual to agree to submit such disputes to binding  arbitration as a condition of receiving an Award hereunder.  (b) Limitation of Liability.  Notwithstanding anything to the contrary in the Plan, neither the Company, nor any Affiliate,  nor the Administrator, nor any person acting on behalf of the Company, any Affiliate, or the Administrator, will be  liable to any Participant or to the estate or beneficiary of any Participant or to any other holder of an Award by reason  of any acceleration of income, or any additional tax (including any interest and penalties), asserted by reason of the  failure of an Award to satisfy the requirements of Section 409A or by reason of Section 4999 of the Code, or  otherwise asserted with respect to the Award.  12. ESTABLISHMENT OF SUB-PLANS  The Administrator may from time to time establish one or more sub-plans under the Plan for purposes of satisfying  applicable blue sky, securities or tax laws of various jurisdictions.  The Administrator will establish such sub-plans by  adopting supplements to the Plan setting forth (i) such limitations on the Administrator&#8217;s discretion under the Plan as  it deems necessary or desirable and (ii) such additional terms and conditions not otherwise inconsistent with the Plan  as it deems necessary or desirable.  All supplements so established will be deemed to be part of the Plan, but each  supplement will apply only to Participants within the affected jurisdiction (as determined by the Administrator).  13. GOVERNING LAW  The laws of the State of Delaware will govern all questions concerning the construction, validity and interpretation of  this Plan, without regard to that state&#8217;s conflict of laws rules.     </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-arrowheadindu007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-arrowheadindu007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">7  EXHIBIT A  Definition of Terms  The following terms, when used in the Plan, will have the meanings and be subject to the provisions set forth below:  &#8220;Administrator&#8221;:  The Compensation Committee, except that the Compensation Committee may delegate (i) to one or  more of its members (or one or more other members of the Board (including the full Board)) such of its duties, powers  and responsibilities as it may determine; (ii) to one or more officers of the Company the power to grant Awards to the  extent permitted by Section 157(c) of the Delaware General Corporation Law; and (iii) to such Employees or other  persons as it determines such ministerial tasks as it deems appropriate; provided, however, that all Awards granted  under the Plan must be approved by the Compensation Committee.  In the event of any delegation described in the  preceding sentence, the term &#8220;Administrator&#8221; will include the person or persons so delegated to the extent of such  delegation.  &#8220;Affiliate&#8221;:  Any corporation or other entity that stands in a relationship to the Company that would result in the  Company and such corporation or other entity being treated as one employer under Section 414(b) and  Section 414(c) of the Code.  &#8220;Award&#8221;:  Any or a combination of the following:  (i)  Stock Options.  (ii)  SARs.  (iii)  Restricted Stock.  (iv)  Unrestricted Stock.  (v)  Stock Units, including Restricted Stock Units.  (vi)  Performance Awards.  (vii)  Cash Awards.  (viii)  Awards (other than Awards described in (i) through (vii) above) that are convertible into or otherwise based on  Stock.  &#8220;Board&#8221;:  The Board of Directors of the Company.  &#8220;Cash Award&#8221;:  An Award denominated in cash.  &#8220;Cause&#8221;:  In the case of any Participant who is party to an employment or severance-benefit agreement that contains  a definition of &#8220;Cause,&#8221; the definition set forth in such agreement will apply with respect to such Participant under the  Plan for so long as such agreement is in effect.  In the case of any other Participant, &#8220;Cause&#8221; will mean, as  determined by the Administrator in its reasonable judgment, (i) a substantial failure of the Participant to perform the  Participant&#8217;s duties and responsibilities to the Company or subsidiaries or substantial negligence in the performance  of such duties and responsibilities; (ii) the commission by the Participant of a felony or a crime involving moral  turpitude; (iii) the commission by the Participant of theft, fraud, embezzlement, material breach of trust or any material  act of dishonesty involving the Company or any of its subsidiaries; (iv) a significant violation by the Participant of the  code of conduct of the Company or its subsidiaries of any material policy of the Company or its subsidiaries, or of any  statutory or common law duty of loyalty to the Company or its subsidiaries; (v) material breach of any of the terms of  the Plan or any Award made under the Plan, or of the terms of any other agreement between the Company or  subsidiaries and the Participant; or (vi) other conduct by the Participant that could be expected to be harmful to the  business, interests or reputation of the Company.  &#8220;Change in Control&#8221;:  The first to occur of (i) a &#8220;person,&#8221; as such term is used in Sections 13(d) and 14(d) of the  Exchange Act (other than the Company or one of its subsidiaries or an employee benefit plan of the Company or any  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-arrowheadindu008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-arrowheadindu008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">8  of its subsidiaries, including any trustee of such plan acting as trustee) becoming the &#8220;beneficial owner&#8221; (as defined in  Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent  (50%) or more of the combined voting power of the Company&#8217;s then outstanding securities entitled to vote generally  in the election of directors; (ii) a consummation of (x) a merger or consolidation of the Company with any other  corporation, other than a merger or consolidation that would result in the voting securities of the Company  outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted  into voting securities of the surviving entity) more than fifty percent (50%) of the total voting power represented by the  voting securities of the Company or such surviving entity outstanding immediately after such merger or consolidation,  or (y) the sale or disposition by the Company of all or substantially all the Company&#8217;s assets; or (iii) a change in the  composition of the Board, as a result of which fewer than a majority of the directors are Incumbent Directors.   &#8220;Incumbent Directors&#8221; shall mean directors who either (A) are directors of the Company as of the Date of Adoption, or  (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the  Incumbent Directors at the time of such election or nomination (but shall not include an individual whose election or  nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the  Company).  For the avoidance of doubt, a transaction will not constitute a Change in Control if:  (i) its sole purpose is  to change the jurisdiction of the Company&#8217;s incorporation, or (ii) its sole purpose is to create a holding company that  will be owned in substantially the same proportions by the persons who held the Company&#8217;s securities immediately  before such transaction.  &#8220;Code&#8221;:  The U.S. Internal Revenue Code of 1986 as from time to time amended and in effect, or any successor  statute as from time to time in effect.  &#8220;Compensation Committee&#8221;:  The Compensation Committee of the Board.  &#8220;Company&#8221;:  Arrowhead Pharmaceuticals, Inc.  &#8220;Covered Transaction&#8221;:  Any of (i) a consolidation, merger, or similar transaction or series of related transactions,  including a sale or other disposition of stock, in which the Company is not the surviving corporation or which results in  the acquisition of all or substantially all of the Company&#8217;s then outstanding common stock by a single person or entity  or by a group of persons and/or entities acting in concert; (ii) a sale or transfer of all or substantially all the Company&#8217;s  assets; or (iii) a dissolution or liquidation of the Company.  Where a Covered Transaction involves a tender offer that  is reasonably expected to be followed by a merger described in clause (i) (as determined by the Administrator), the  Covered Transaction will be deemed to have occurred upon consummation of the tender offer.  &#8220;Date of Adoption&#8221;:  The date the Plan was adopted by the Board.  &#8220;Employee&#8221;:  Any person who is employed by the Company or an Affiliate.  &#8220;Employment&#8221;:  A Participant&#8217;s employment or other service relationship with the Company and its Affiliates.   Employment will be deemed to continue, unless the Administrator expressly provides otherwise, so long as the  Participant is employed by, or otherwise is providing services as a director, consultant, or advisor to the Company or  an Affiliate.  If a Participant&#8217;s employment or other service relationship is with an Affiliate and that entity ceases to be  an Affiliate, the Participant&#8217;s Employment will be deemed to have terminated when the entity ceases to be an Affiliate  unless the Participant transfers Employment to the Company or its remaining Affiliates.  Notwithstanding the  foregoing and the definition of &#8220;Affiliate&#8221; above, in construing the provisions of any Award relating to the payment of  &#8220;nonqualified deferred compensation&#8221; (subject to Section 409A) upon a termination or cessation of Employment,  references to termination or cessation of employment, separation from service, retirement or similar or correlative  terms will be construed to require a &#8220;separation from service&#8221; (as that term is defined in Section 1.409A-1(h) of the  Treasury Regulations, after giving effect to the presumptions contained therein) from the Company and from all other  corporations and trades or businesses, if any, that would be treated as a single &#8220;service recipient&#8221; with the Company  under Section 1.409A-1(h)(3) of the Treasury Regulations.  The Company may, but need not, elect in writing, subject  to the applicable limitations under Section 409A, any of the special elective rules prescribed in Section 1.409A-1(h) of  the Treasury Regulations for purposes of determining whether a &#8220;separation from service&#8221; has occurred.  Any such  written election will be deemed a part of the Plan.  &#8220;Exchange Act&#8221;:  The Securities Exchange Act of 1934, as amended.  &#8220;Fair Market Value&#8221;:  As of any date, the value of the Stock determined as follows:  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit101-arrowheadindu009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit101-arrowheadindu009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">9  (i) If the Stock is listed on any established stock exchange or traded on any established market, the Fair Market  Value of a share of Stock as of any date of determination will be, unless otherwise determined by the Board, the  closing sales price for such stock as quoted on such exchange or market (or the exchange or market with the  greatest volume of trading in the Stock) on the date of determination, as reported in a source the Board deems  reliable.  (ii) Unless otherwise provided by the Board, if there is no closing sales price for the Stock on the date of  determination, then the Fair Market Value will be the closing selling price on the last preceding date for which  such quotation exists.  (iii) In the absence of such markets for the Stock, the Fair Market Value will be determined by the Board in good faith  and in a manner that complies with Sections 409A of the Code.  &#8220;Participant&#8221;:  A person who is granted an Award under the Plan.  &#8220;Performance Award&#8221;:  An Award subject to Performance Criteria.  &#8220;Performance Criteria&#8221;:  Specified criteria, other than the mere continuation of Employment or the mere passage of  time, the satisfaction of which is a condition for the grant, exercisability, vesting or full enjoyment of an Award.  Such  criteria shall be determined by the Administrator and may include any measure of performance (measured either  absolutely or by reference to an index or indices and determined either on a consolidated basis or, as the context  permits, on a divisional, subsidiary, line of business, project or geographical basis or in combinations thereof) as  deemed appropriate by the Administrator.  A Performance Criterion and any targets with respect thereto determined  by the Administrator need not be based upon an increase, a positive or improved result or avoidance of loss.  &#8220;Plan&#8221;:  The Arrowhead Pharmaceuticals, Inc. Inducement Plan, as from time to time amended and in effect.  &#8220;Restricted Stock&#8221;:  Stock subject to restrictions requiring that it be redelivered or offered for sale to the Company if  specified conditions are not satisfied.  &#8220;Restricted Stock Unit&#8221;:  A Stock Unit that is, or as to which the delivery of Stock or cash in lieu of Stock is, subject to  the satisfaction of specified performance or other vesting conditions.  &#8220;SAR&#8221;:  A right entitling the holder upon exercise to receive an amount (payable in cash and/or in shares of Stock of  equivalent value) equal to the excess of the Fair Market Value of the shares of Stock subject to the right over the  base value from which appreciation under the SAR is to be measured.  &#8220;Section 409A&#8221;:  Section 409A of the Code.  &#8220;Stock&#8221;:  Common stock of the Company, par value $0.001 per share.  &#8220;Stock Option&#8221;:  An option entitling the holder to acquire shares of Stock upon payment of the exercise price.  &#8220;Stock Unit&#8221;:  An unfunded and unsecured promise, denominated in shares of Stock, to deliver Stock or cash  measured by the value of Stock in the future.  &#8220;Unrestricted Stock&#8221;:  Stock not subject to any restrictions under the terms of the Award.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>arwr-2024331xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arwr-2024331xex311</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arwr-2024331xex311001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arwr-2024331xex311001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>arwr-2024331xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arwr-2024331xex312</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arwr-2024331xex312001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arwr-2024331xex312001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>arwr-2024331xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arwr-2024331xex321</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arwr-2024331xex321001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arwr-2024331xex321001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>arwr-2024331xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arwr-2024331xex322</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arwr-2024331xex322001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arwr-2024331xex322001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>arwr-20240331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:ac9daf9b-fe65-44cf-acd3-206171097241,g:5004fc8e-4246-4d68-a802-ef4d83a3dac9-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arwr="http://www.arrowheadresearch.com/20240331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20240331">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20240331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20240331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20240331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20240331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.arrowheadresearch.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLossIncome" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome">
        <link:definition>0000004 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000005 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies">
        <link:definition>0000007 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements">
        <link:definition>0000008 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccounts" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccounts">
        <link:definition>0000009 - Disclosure - Balance Sheet Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.arrowheadresearch.com/role/Investments">
        <link:definition>0000010 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets">
        <link:definition>0000011 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity">
        <link:definition>0000012 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies">
        <link:definition>0000013 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.arrowheadresearch.com/role/Leases">
        <link:definition>0000014 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation">
        <link:definition>0000015 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements">
        <link:definition>0000016 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyalties" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties">
        <link:definition>0000017 - Disclosure - Liability Related to the Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.arrowheadresearch.com/role/NetLossPerShare">
        <link:definition>0000018 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesTables" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Organization and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTables" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables">
        <link:definition>9954473 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsTables" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables">
        <link:definition>9954474 - Disclosure - Balance Sheet Accounts (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables">
        <link:definition>9954475 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables">
        <link:definition>9954476 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables">
        <link:definition>9954477 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.arrowheadresearch.com/role/LeasesTables">
        <link:definition>9954478 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables">
        <link:definition>9954479 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables">
        <link:definition>9954480 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesTables" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables">
        <link:definition>9954481 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareTables">
        <link:definition>9954482 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesNarrativeDetail" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail">
        <link:definition>9954483 - Disclosure - Organization and Significant Accounting Policies - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsRevenueDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails">
        <link:definition>9954484 - Disclosure - Collaboration and License Agreements - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails">
        <link:definition>9954485 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails">
        <link:definition>9954486 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails">
        <link:definition>9954487 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails">
        <link:definition>9954488 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAmgenIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails">
        <link:definition>9954489 - Disclosure - Collaboration and License Agreements - Amgen, Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails">
        <link:definition>9954490 - Disclosure - Collaboration and License Agreements - Visirna Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsSummaryofPropertyandEquipmentDetail" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail">
        <link:definition>9954491 - Disclosure - Balance Sheet Accounts - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetAccountsAccruedExpensesDetails" roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails">
        <link:definition>9954492 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails">
        <link:definition>9954493 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>9954494 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsExpectedFutureAmortizationDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails">
        <link:definition>9954495 - Disclosure - Intangible Assets - Expected Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails">
        <link:definition>9954496 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetail" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail">
        <link:definition>9954497 - Disclosure - Commitments and Contingencies - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails">
        <link:definition>9954498 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseAssetsandLiabilitiesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails">
        <link:definition>9954499 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails">
        <link:definition>9954500 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1">
        <link:definition>9954500 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails">
        <link:definition>9954501 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9954502 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails">
        <link:definition>9954503 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationExpensesIncludedinOperatingExpensesDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails">
        <link:definition>9954504 - Disclosure - Stock-Based Compensation - Expenses Included in Operating Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails">
        <link:definition>9954505 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRSUsActivityDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails">
        <link:definition>9954506 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9954507 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails">
        <link:definition>9954508 - Disclosure - Liability Related to the Sale of Future Royalties - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails">
        <link:definition>9954509 - Disclosure - Liability Related to the Sale of Future Royalties - Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareBasicandDilutedNetLossPerShareDetails" roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails">
        <link:definition>9954510 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAntidulitiveDetails" roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails">
        <link:definition>9954511 - Disclosure - Net Loss Per Share - Antidulitive (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" abstract="true" name="TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_JamesHamiltonMember" abstract="true" name="JamesHamiltonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FacilitiesMember" abstract="true" name="FacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_CommitmentsCapitalExpendituresIncurredToDate" abstract="false" name="CommitmentsCapitalExpendituresIncurredToDate" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_RoyaltiesLiabilityNoncurrent" abstract="false" name="RoyaltiesLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" abstract="false" name="LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" abstract="false" name="HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="arwr_InitialTransactionPrice" abstract="false" name="InitialTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" abstract="false" name="MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_GSKHBVAgreementMember" abstract="true" name="GSKHBVAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LaboratoryAndOfficeFacilityMember" abstract="true" name="LaboratoryAndOfficeFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_OlpasiranAgreementMember" abstract="true" name="OlpasiranAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_RoyaltyPaymentThreshold" abstract="false" name="RoyaltyPaymentThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_InducementAwardsMember" abstract="true" name="InducementAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" abstract="false" name="OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ResearchFacilityInMadisonMember" abstract="true" name="ResearchFacilityInMadisonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_KenMyszkowskiMarch28Plan1Member" abstract="true" name="KenMyszkowskiMarch28Plan1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ComputerAndSoftwareMember" abstract="true" name="ComputerAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CommercialNotesMember" abstract="true" name="CommercialNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_FiniteLivedIntangibleAssetsImpairment" abstract="false" name="FiniteLivedIntangibleAssetsImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_VisirnaTherapeuticsIncMember" abstract="true" name="VisirnaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_AccruedCapitalExpenditureCurrent" abstract="false" name="AccruedCapitalExpenditureCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_KenMyszkowskiMarch28Plan4Member" abstract="true" name="KenMyszkowskiMarch28Plan4Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MaximumAdditionalTenantImprovementAllowance" abstract="false" name="MaximumAdditionalTenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" abstract="false" name="PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="arwr_TwoThousandsThirteenIncentivePlanMember" abstract="true" name="TwoThousandsThirteenIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_SalesRelatedMilestonePayments" abstract="false" name="SalesRelatedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_JanssenPharmaceuticalsIncorporationMember" abstract="true" name="JanssenPharmaceuticalsIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_ResearchFacilityInSanDiegoMember" abstract="true" name="ResearchFacilityInSanDiegoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" abstract="false" name="MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_PatrickOBrienMember" abstract="true" name="PatrickOBrienMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesValueReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" abstract="false" name="FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_HorizonLicenseAgreementMember" abstract="true" name="HorizonLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_IncreaseDecreaseInCashAndInvestments" abstract="false" name="IncreaseDecreaseInCashAndInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" abstract="false" name="CommercialMilestonePaymentsAtFirstCommercialSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_KenMyszkowskiMember" abstract="true" name="KenMyszkowskiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_AtTheMarketAgreementMember" abstract="true" name="AtTheMarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" abstract="false" name="MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CorporateHeadquartersInPasadenaMember" abstract="true" name="CorporateHeadquartersInPasadenaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_NumberOfOptionsToRenew" abstract="false" name="NumberOfOptionsToRenew" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" abstract="false" name="AdditionalTenantImprovementAllowanceInterestPerAnnum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_CashReceivedAsDueUnderCollaborationAgreement" abstract="false" name="CashReceivedAsDueUnderCollaborationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" abstract="false" name="LiabilitySaleOfFutureRoyaltiesInterestRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_ScheduleOfCurrentProductsTableTextBlock" abstract="false" name="ScheduleOfCurrentProductsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="arwr_AdditionalTenantImprovementAllowanceLiability" abstract="false" name="AdditionalTenantImprovementAllowanceLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponFDAApproval" abstract="false" name="MilestonePaymentReceivableUponFDAApproval" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_GSKLicenseAgreementMember" abstract="true" name="GSKLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivable" abstract="false" name="MilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_HorizonTherapeuticsIrelandDACMember" abstract="true" name="HorizonTherapeuticsIrelandDACMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="DevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DevelopmentAndSalesMilestonesPayments" abstract="false" name="DevelopmentAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfAgreements" abstract="false" name="NumberOfAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_AmgenIncorporatedMember" abstract="true" name="AmgenIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_LicenseAndCoFundingAgreementMember" abstract="true" name="LicenseAndCoFundingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" abstract="false" name="ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" abstract="false" name="PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" abstract="true" name="GlaxosmithklineIntellectualPropertyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_VisirnaLicenseAgreementMember" abstract="true" name="VisirnaLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_SaleOfStockAggregatePurchasePrice" abstract="false" name="SaleOfStockAggregatePurchasePrice" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ResearchEquipmentMember" abstract="true" name="ResearchEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_WilliamWaddillMember" abstract="true" name="WilliamWaddillMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LiabilitySaleOfFutureRoyalties" abstract="false" name="LiabilitySaleOfFutureRoyalties" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" abstract="true" name="TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_NumberOfDistinctBundle" abstract="false" name="NumberOfDistinctBundle" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_AmountIntendsToInvestForBuildoutOfFacilities" abstract="false" name="AmountIntendsToInvestForBuildoutOfFacilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfDistinctPerformanceObligations" abstract="false" name="NumberOfDistinctPerformanceObligations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_MilestonePaymentEarned" abstract="false" name="MilestonePaymentEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_KenMyszkowskiMarch28Plan2Member" abstract="true" name="KenMyszkowskiMarch28Plan2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentReceived" abstract="false" name="MilestonePaymentReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ColoradoOwnerLLCMember" abstract="true" name="ColoradoOwnerLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="arwr_KenMyszkowskiMarch12PlanMember" abstract="true" name="KenMyszkowskiMarch12PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_KenMyszkowskiMarch28Plan3Member" abstract="true" name="KenMyszkowskiMarch28Plan3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ProceedsFromSaleOfFutureRoyalties" abstract="false" name="ProceedsFromSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_VisirnaESOPMember" abstract="true" name="VisirnaESOPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LiabilitySaleOfFutureRoyaltiesRollForward" abstract="true" name="LiabilitySaleOfFutureRoyaltiesRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_TwoThousandTwentyOneIncentivePlanMember" abstract="true" name="TwoThousandTwentyOneIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_TwoThousandsFourEquityIncentivePlanMember" abstract="true" name="TwoThousandsFourEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_RoyaltyPharmaAgreementMember" abstract="true" name="RoyaltyPharmaAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_DrugManufacturingFacilityMember" abstract="true" name="DrugManufacturingFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_UnderwritingAgreementMember" abstract="true" name="UnderwritingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>arwr-20240331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:ac9daf9b-fe65-44cf-acd3-206171097241,g:5004fc8e-4246-4d68-a802-ef4d83a3dac9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20240331.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5b29896b-6242-4467-b47f-409e15eda3bf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bea82a32-ed87-47bd-9019-a90535ed66bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5b29896b-6242-4467-b47f-409e15eda3bf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_bea82a32-ed87-47bd-9019-a90535ed66bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_aca1ca45-19d2-490f-bed3-da95ff016c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5b29896b-6242-4467-b47f-409e15eda3bf" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_aca1ca45-19d2-490f-bed3-da95ff016c3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d4625475-b308-4651-95fe-c1d02e8e3f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5b29896b-6242-4467-b47f-409e15eda3bf" xlink:to="loc_us-gaap_CommonStockValue_d4625475-b308-4651-95fe-c1d02e8e3f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d726dbfb-a7a7-49c0-af3f-dbaec02cc137" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_5b29896b-6242-4467-b47f-409e15eda3bf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d726dbfb-a7a7-49c0-af3f-dbaec02cc137" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eeee7bab-d97d-4748-89d0-67fcfa9c93ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_12a499b9-548a-431f-92ec-699b485d8fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eeee7bab-d97d-4748-89d0-67fcfa9c93ce" xlink:to="loc_us-gaap_StockholdersEquity_12a499b9-548a-431f-92ec-699b485d8fc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_e8944a47-c6d5-43d4-939d-007609e97dc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_eeee7bab-d97d-4748-89d0-67fcfa9c93ce" xlink:to="loc_us-gaap_MinorityInterest_e8944a47-c6d5-43d4-939d-007609e97dc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_47859a6c-04e5-4a2a-8751-1d56f7bb58db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_4bece676-dec5-43d6-b7d1-5a929c8d8b53" xlink:href="arwr-20240331.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_47859a6c-04e5-4a2a-8751-1d56f7bb58db" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_4bece676-dec5-43d6-b7d1-5a929c8d8b53" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d07612a-5447-4752-950e-59992c44179f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_47859a6c-04e5-4a2a-8751-1d56f7bb58db" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_6d07612a-5447-4752-950e-59992c44179f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_35f34fb4-0626-4adb-a6ec-7e8fecad4546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d0457ba2-f588-485d-aee9-7edb8c8aa981" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35f34fb4-0626-4adb-a6ec-7e8fecad4546" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d0457ba2-f588-485d-aee9-7edb8c8aa981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_8237fede-e772-4dab-83b4-1270f021ae2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35f34fb4-0626-4adb-a6ec-7e8fecad4546" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_8237fede-e772-4dab-83b4-1270f021ae2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7bec1660-86a5-4b6b-9fb8-ed7ac28bbe30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35f34fb4-0626-4adb-a6ec-7e8fecad4546" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_7bec1660-86a5-4b6b-9fb8-ed7ac28bbe30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_509afcf5-d17a-4d9f-97d0-0780498dfedc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35f34fb4-0626-4adb-a6ec-7e8fecad4546" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_509afcf5-d17a-4d9f-97d0-0780498dfedc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_dd88786c-9f79-47f6-a09a-831448f004e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35f34fb4-0626-4adb-a6ec-7e8fecad4546" xlink:to="loc_us-gaap_AccountsPayableCurrent_dd88786c-9f79-47f6-a09a-831448f004e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_11e485bb-4f49-4677-baa5-89e2de5aea60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_35f34fb4-0626-4adb-a6ec-7e8fecad4546" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_11e485bb-4f49-4677-baa5-89e2de5aea60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_1d3d2bd4-5f04-4106-93b5-b204ee969005" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d8756edc-9924-48ca-a829-db2e7d0fc65e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1d3d2bd4-5f04-4106-93b5-b204ee969005" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d8756edc-9924-48ca-a829-db2e7d0fc65e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8185bf5b-4144-49d7-a729-a5cd8aacf7a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1d3d2bd4-5f04-4106-93b5-b204ee969005" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8185bf5b-4144-49d7-a729-a5cd8aacf7a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5cc9c338-226f-41f9-8f36-99590cc4521f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1d3d2bd4-5f04-4106-93b5-b204ee969005" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5cc9c338-226f-41f9-8f36-99590cc4521f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_7a446687-8944-4462-b3ad-0e42f5c8a27d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_1d3d2bd4-5f04-4106-93b5-b204ee969005" xlink:to="loc_us-gaap_OtherAssetsCurrent_7a446687-8944-4462-b3ad-0e42f5c8a27d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_55f8c350-9011-4c0e-aba3-c8065c5767d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_440afc2d-50e6-4279-8c0c-140b29f249f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_55f8c350-9011-4c0e-aba3-c8065c5767d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_440afc2d-50e6-4279-8c0c-140b29f249f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e83b76bd-6729-4a1f-b105-620f7b9019d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_55f8c350-9011-4c0e-aba3-c8065c5767d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e83b76bd-6729-4a1f-b105-620f7b9019d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_5ca7102b-05d3-4c31-967c-9318f865da32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_55f8c350-9011-4c0e-aba3-c8065c5767d3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_5ca7102b-05d3-4c31-967c-9318f865da32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e5f01684-df9a-4aac-a6da-c83b02bbc154" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_55f8c350-9011-4c0e-aba3-c8065c5767d3" xlink:to="loc_us-gaap_AssetsCurrent_e5f01684-df9a-4aac-a6da-c83b02bbc154" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_10a67a60-dccc-4f81-a084-4affb6fbf67f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_55f8c350-9011-4c0e-aba3-c8065c5767d3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_10a67a60-dccc-4f81-a084-4affb6fbf67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dab0c7ef-7897-437d-b02b-5b38a4c0897d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e67b81bb-3a1c-4b71-b42f-6eb9a0edbea4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dab0c7ef-7897-437d-b02b-5b38a4c0897d" xlink:to="loc_us-gaap_LiabilitiesCurrent_e67b81bb-3a1c-4b71-b42f-6eb9a0edbea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_acb12951-860e-4e4e-a5e4-339eb6470f13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dab0c7ef-7897-437d-b02b-5b38a4c0897d" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_acb12951-860e-4e4e-a5e4-339eb6470f13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fb99c501-aa82-4620-8a0f-5104c698c5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dab0c7ef-7897-437d-b02b-5b38a4c0897d" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fb99c501-aa82-4620-8a0f-5104c698c5ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_afc7e551-9362-486a-b202-4d22da454ae4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dab0c7ef-7897-437d-b02b-5b38a4c0897d" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_afc7e551-9362-486a-b202-4d22da454ae4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="simple" xlink:href="arwr-20240331.xsd#ConsolidatedStatementsofOperationsandComprehensiveLossIncome"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_94202aee-d53a-4023-8def-c5c76a03b86e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bf9d45ec-afc7-4c1e-b2d7-1cf1cbba3e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_94202aee-d53a-4023-8def-c5c76a03b86e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bf9d45ec-afc7-4c1e-b2d7-1cf1cbba3e4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f4a641be-cb19-424c-907e-3b8e08c36eb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_94202aee-d53a-4023-8def-c5c76a03b86e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f4a641be-cb19-424c-907e-3b8e08c36eb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_209879d4-60d3-44f3-bc72-3b84183d4d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3abe49ac-e314-4b30-ac43-83ee65ee5f63" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_209879d4-60d3-44f3-bc72-3b84183d4d1d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_3abe49ac-e314-4b30-ac43-83ee65ee5f63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8f48e9e5-6627-475a-8171-2f392a7965ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_209879d4-60d3-44f3-bc72-3b84183d4d1d" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8f48e9e5-6627-475a-8171-2f392a7965ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5e1a7b81-3277-427c-8f40-8f5f734d4ff4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2c60ccb7-b0f8-425d-bc80-31e64f210d96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5e1a7b81-3277-427c-8f40-8f5f734d4ff4" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2c60ccb7-b0f8-425d-bc80-31e64f210d96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_a6ffbddf-ddd5-4fd8-901b-244e00a8ce62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5e1a7b81-3277-427c-8f40-8f5f734d4ff4" xlink:to="loc_us-gaap_InterestExpense_a6ffbddf-ddd5-4fd8-901b-244e00a8ce62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_346ef344-511c-42c1-a15f-070fbb4686d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5e1a7b81-3277-427c-8f40-8f5f734d4ff4" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_346ef344-511c-42c1-a15f-070fbb4686d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3f45bea6-854b-4be9-a2bc-fdc41b5b3bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5ddf4002-4540-4670-a125-3bb87bef8d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3f45bea6-854b-4be9-a2bc-fdc41b5b3bb7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5ddf4002-4540-4670-a125-3bb87bef8d7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a830c6fa-0068-4533-acde-61e2a188935f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3f45bea6-854b-4be9-a2bc-fdc41b5b3bb7" xlink:to="loc_us-gaap_OperatingIncomeLoss_a830c6fa-0068-4533-acde-61e2a188935f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_39e7a40f-408e-45d1-b96c-aeec367f20c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee3139ba-7e7a-4b6b-bcb4-dd9503dfcd77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_39e7a40f-408e-45d1-b96c-aeec367f20c5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ee3139ba-7e7a-4b6b-bcb4-dd9503dfcd77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_651d4bae-5335-4c95-8fb1-b6666d439802" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_39e7a40f-408e-45d1-b96c-aeec367f20c5" xlink:to="loc_us-gaap_OperatingExpenses_651d4bae-5335-4c95-8fb1-b6666d439802" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9dcb6477-8b90-4b13-a4fe-d2e9391c233d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ed4e799c-3296-4f7e-97b4-b99d31cb1b75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9dcb6477-8b90-4b13-a4fe-d2e9391c233d" xlink:to="loc_us-gaap_ProfitLoss_ed4e799c-3296-4f7e-97b4-b99d31cb1b75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fffe68bf-61ff-4cd6-9840-0e378a003bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9dcb6477-8b90-4b13-a4fe-d2e9391c233d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_fffe68bf-61ff-4cd6-9840-0e378a003bdd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_62133a68-7563-40ee-9fb2-c975ba433536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_9dcb6477-8b90-4b13-a4fe-d2e9391c233d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_62133a68-7563-40ee-9fb2-c975ba433536" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fccf7b9c-3ed0-48ed-81d1-154d5ebb52b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c8231e56-3cb4-482b-9d19-5c73cd5acbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fccf7b9c-3ed0-48ed-81d1-154d5ebb52b6" xlink:to="loc_us-gaap_ProfitLoss_c8231e56-3cb4-482b-9d19-5c73cd5acbb8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d6616bb5-2914-46b2-bd16-67d1cd5b19af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fccf7b9c-3ed0-48ed-81d1-154d5ebb52b6" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_d6616bb5-2914-46b2-bd16-67d1cd5b19af" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20240331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2e5e7ce-6188-44e2-a65d-b7d92aa0faa3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_03b70e15-10d5-4426-820b-395b68efb813" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2e5e7ce-6188-44e2-a65d-b7d92aa0faa3" xlink:to="loc_us-gaap_ShareBasedCompensation_03b70e15-10d5-4426-820b-395b68efb813" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6d7e9e90-ab1e-4ec9-aaea-1bcd161e831c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2e5e7ce-6188-44e2-a65d-b7d92aa0faa3" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6d7e9e90-ab1e-4ec9-aaea-1bcd161e831c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_45095898-7154-4d57-b68f-6d3c197d814c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2e5e7ce-6188-44e2-a65d-b7d92aa0faa3" xlink:to="loc_us-gaap_DepreciationAndAmortization_45095898-7154-4d57-b68f-6d3c197d814c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7550a0e2-d00c-4703-b96a-24c44ae52985" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2e5e7ce-6188-44e2-a65d-b7d92aa0faa3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_7550a0e2-d00c-4703-b96a-24c44ae52985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_3f407cc7-2bea-4f10-9f48-15de05658a80" xlink:href="arwr-20240331.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2e5e7ce-6188-44e2-a65d-b7d92aa0faa3" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_3f407cc7-2bea-4f10-9f48-15de05658a80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_e2979abb-d906-4c7d-bba8-2790b6054be4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2e5e7ce-6188-44e2-a65d-b7d92aa0faa3" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_e2979abb-d906-4c7d-bba8-2790b6054be4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_61165e7c-dc55-45c0-a51a-d912b8c6b558" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2e5e7ce-6188-44e2-a65d-b7d92aa0faa3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_61165e7c-dc55-45c0-a51a-d912b8c6b558" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f1899f85-7e9f-4093-9616-788ca3f0ed56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2e5e7ce-6188-44e2-a65d-b7d92aa0faa3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_f1899f85-7e9f-4093-9616-788ca3f0ed56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_40d214e9-1b25-487e-a2f8-41c8631377fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2e5e7ce-6188-44e2-a65d-b7d92aa0faa3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_40d214e9-1b25-487e-a2f8-41c8631377fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d5d123d2-25b8-49ab-bdfc-bf023b7eb61e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2e5e7ce-6188-44e2-a65d-b7d92aa0faa3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_d5d123d2-25b8-49ab-bdfc-bf023b7eb61e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_885076d2-0761-49f9-86ef-09ed0c7acad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2e5e7ce-6188-44e2-a65d-b7d92aa0faa3" xlink:to="loc_us-gaap_ProfitLoss_885076d2-0761-49f9-86ef-09ed0c7acad5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_debce226-f590-44a7-96de-d18c0618fb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f2e5e7ce-6188-44e2-a65d-b7d92aa0faa3" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_debce226-f590-44a7-96de-d18c0618fb7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_88865464-3b22-402c-85aa-597b83d57d2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e5f757f6-16c0-4371-8250-791dd1523a82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_88865464-3b22-402c-85aa-597b83d57d2c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e5f757f6-16c0-4371-8250-791dd1523a82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_fa08d73e-5d7c-4dfc-a40d-74ccbdb20ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_88865464-3b22-402c-85aa-597b83d57d2c" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_fa08d73e-5d7c-4dfc-a40d-74ccbdb20ad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_db170582-d105-4d71-a29b-a00487006d05" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_88865464-3b22-402c-85aa-597b83d57d2c" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_db170582-d105-4d71-a29b-a00487006d05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_97c0d58c-e7f2-45ab-a35a-bc319a4d7e57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ddec29e8-0d11-4e06-8c59-2aceb948dfab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_97c0d58c-e7f2-45ab-a35a-bc319a4d7e57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ddec29e8-0d11-4e06-8c59-2aceb948dfab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6c7a4b68-fc59-4db3-a7a1-cb1f5867506e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_97c0d58c-e7f2-45ab-a35a-bc319a4d7e57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_6c7a4b68-fc59-4db3-a7a1-cb1f5867506e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79ae29d2-356f-4a17-bde4-4c2e69d98368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_97c0d58c-e7f2-45ab-a35a-bc319a4d7e57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_79ae29d2-356f-4a17-bde4-4c2e69d98368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_78bc06f3-9642-48dd-8ecf-c6591cb9d48b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_7906c9f4-62b4-4684-bf3e-2eb1a7dfce27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_78bc06f3-9642-48dd-8ecf-c6591cb9d48b" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_7906c9f4-62b4-4684-bf3e-2eb1a7dfce27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromSaleOfFutureRoyalties_06c3176e-3cd2-4dab-90d1-6fd9251cf47b" xlink:href="arwr-20240331.xsd#arwr_ProceedsFromSaleOfFutureRoyalties"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_78bc06f3-9642-48dd-8ecf-c6591cb9d48b" xlink:to="loc_arwr_ProceedsFromSaleOfFutureRoyalties_06c3176e-3cd2-4dab-90d1-6fd9251cf47b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_eaa20bd9-9f7a-4309-9f94-48b4ee973f48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_78bc06f3-9642-48dd-8ecf-c6591cb9d48b" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_eaa20bd9-9f7a-4309-9f94-48b4ee973f48" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="arwr-20240331.xsd#BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_345777df-2ac8-4d55-b9b1-9e713e1449f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b8493bc3-5ea5-474a-ae2a-87b3440951fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_345777df-2ac8-4d55-b9b1-9e713e1449f9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b8493bc3-5ea5-474a-ae2a-87b3440951fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90aa955c-55f5-4a28-bfc4-bf28e3bd3172" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_345777df-2ac8-4d55-b9b1-9e713e1449f9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_90aa955c-55f5-4a28-bfc4-bf28e3bd3172" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#BalanceSheetAccountsAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e7d4e280-ba06-4e83-847b-28ea57a06536" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedCapitalExpenditureCurrent_240d24c9-4c45-4492-b208-7138445abc5b" xlink:href="arwr-20240331.xsd#arwr_AccruedCapitalExpenditureCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e7d4e280-ba06-4e83-847b-28ea57a06536" xlink:to="loc_arwr_AccruedCapitalExpenditureCurrent_240d24c9-4c45-4492-b208-7138445abc5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent_b67d354f-ba89-4867-a03f-20b924dea0e7" xlink:href="arwr-20240331.xsd#arwr_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e7d4e280-ba06-4e83-847b-28ea57a06536" xlink:to="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent_b67d354f-ba89-4867-a03f-20b924dea0e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9f275d02-7653-4e11-bc2b-d1ab314d51a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e7d4e280-ba06-4e83-847b-28ea57a06536" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_9f275d02-7653-4e11-bc2b-d1ab314d51a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_926549b9-ab15-4db4-90ac-1f5958dd9110" xlink:href="arwr-20240331.xsd#arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_e7d4e280-ba06-4e83-847b-28ea57a06536" xlink:to="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_926549b9-ab15-4db4-90ac-1f5958dd9110" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_e40184b3-d23f-49f4-a834-2413568bddde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_75c68534-7715-44c9-a457-0439929ab7ac" xlink:href="arwr-20240331.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_e40184b3-d23f-49f4-a834-2413568bddde" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_75c68534-7715-44c9-a457-0439929ab7ac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_38e5057e-d5a3-42aa-9646-1aa3c248ee41" xlink:href="arwr-20240331.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_e40184b3-d23f-49f4-a834-2413568bddde" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_38e5057e-d5a3-42aa-9646-1aa3c248ee41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4fd8b5c4-9302-4b4d-8819-ee92fed2926b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_e40184b3-d23f-49f4-a834-2413568bddde" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_4fd8b5c4-9302-4b4d-8819-ee92fed2926b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_991bc051-317c-4d0f-b91c-f7b6172b9c5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_faff7cf8-df55-42c5-bba1-b8846c23d528" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_991bc051-317c-4d0f-b91c-f7b6172b9c5d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_faff7cf8-df55-42c5-bba1-b8846c23d528" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_59d7329a-f919-4fea-a372-f96c90ad856f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_991bc051-317c-4d0f-b91c-f7b6172b9c5d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_59d7329a-f919-4fea-a372-f96c90ad856f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_6cc9fd6a-4334-4d17-8719-6579a5054a19" xlink:href="arwr-20240331.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_991bc051-317c-4d0f-b91c-f7b6172b9c5d" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_6cc9fd6a-4334-4d17-8719-6579a5054a19" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#IntangibleAssetsExpectedFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef5a225d-c9f7-4bba-9cc9-6fc0582ac400" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_9f95a6b9-cb32-4083-b8e9-aaa2c11cc300" xlink:href="arwr-20240331.xsd#arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef5a225d-c9f7-4bba-9cc9-6fc0582ac400" xlink:to="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_9f95a6b9-cb32-4083-b8e9-aaa2c11cc300" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_877a0f2d-4ba5-4264-ab89-3f098338bd3f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef5a225d-c9f7-4bba-9cc9-6fc0582ac400" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_877a0f2d-4ba5-4264-ab89-3f098338bd3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a3b5fb39-279d-4f07-8b4f-f4d4683b1322" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef5a225d-c9f7-4bba-9cc9-6fc0582ac400" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_a3b5fb39-279d-4f07-8b4f-f4d4683b1322" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8543cb92-a1fa-4540-bb06-36e69ade09cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef5a225d-c9f7-4bba-9cc9-6fc0582ac400" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_8543cb92-a1fa-4540-bb06-36e69ade09cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2738656e-d275-42f1-9ec2-50914c064120" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef5a225d-c9f7-4bba-9cc9-6fc0582ac400" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_2738656e-d275-42f1-9ec2-50914c064120" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2e365073-0a71-4c14-8e79-a43f3944e7fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_ef5a225d-c9f7-4bba-9cc9-6fc0582ac400" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2e365073-0a71-4c14-8e79-a43f3944e7fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_f80c83b4-5ae6-4e55-b22d-6ec607dcd47d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_b0fd84f3-e130-487d-838a-1aa9a4259202" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f80c83b4-5ae6-4e55-b22d-6ec607dcd47d" xlink:to="loc_us-gaap_VariableLeaseCost_b0fd84f3-e130-487d-838a-1aa9a4259202" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_e23c3d69-2e01-4b0c-a2dd-cdd16965f67e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_f80c83b4-5ae6-4e55-b22d-6ec607dcd47d" xlink:to="loc_us-gaap_OperatingLeaseCost_e23c3d69-2e01-4b0c-a2dd-cdd16965f67e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f3d50a62-5776-4519-b557-7c0c070187e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8f7ec198-7cd3-4943-a41d-a2f4d3ceab31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f3d50a62-5776-4519-b557-7c0c070187e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_8f7ec198-7cd3-4943-a41d-a2f4d3ceab31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_28fc8119-e6de-46c6-aade-7d09a22ebcef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f3d50a62-5776-4519-b557-7c0c070187e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_28fc8119-e6de-46c6-aade-7d09a22ebcef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b2a4b15a-79bd-4858-a2bf-586db85c6d77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f3d50a62-5776-4519-b557-7c0c070187e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_b2a4b15a-79bd-4858-a2bf-586db85c6d77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0d52def8-7883-4343-ae18-5cfdea753b75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f3d50a62-5776-4519-b557-7c0c070187e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0d52def8-7883-4343-ae18-5cfdea753b75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_dc8a123d-c1f4-446f-8211-bce203193571" xlink:href="arwr-20240331.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f3d50a62-5776-4519-b557-7c0c070187e6" xlink:to="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_dc8a123d-c1f4-446f-8211-bce203193571" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e7c2a39b-0349-4d8b-83cc-8ae9d5aebde4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f3d50a62-5776-4519-b557-7c0c070187e6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e7c2a39b-0349-4d8b-83cc-8ae9d5aebde4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="simple" xlink:href="arwr-20240331.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ba503281-064a-4fdf-b761-a22082b1daf5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0d3e2b64-9da0-43b3-a869-1c9a0902ecb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ba503281-064a-4fdf-b761-a22082b1daf5" xlink:to="loc_us-gaap_OperatingLeaseLiability_0d3e2b64-9da0-43b3-a869-1c9a0902ecb0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4ebfcff6-f116-4d8b-b2f0-3c51ab11fa30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ba503281-064a-4fdf-b761-a22082b1daf5" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_4ebfcff6-f116-4d8b-b2f0-3c51ab11fa30" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_37825ff5-b4f6-4111-ace7-197d1a80db32" xlink:href="arwr-20240331.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4a180f4-bc41-4a97-9f88-be45b7514727" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_37825ff5-b4f6-4111-ace7-197d1a80db32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c4a180f4-bc41-4a97-9f88-be45b7514727" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_08153d86-9618-4768-a9a6-7a42f5980d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_37825ff5-b4f6-4111-ace7-197d1a80db32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_08153d86-9618-4768-a9a6-7a42f5980d6c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d6c9f2be-a67c-4f01-a48d-d255f41b1a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b05f8477-e2ad-4efa-978a-50efe3701265" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d6c9f2be-a67c-4f01-a48d-d255f41b1a9e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b05f8477-e2ad-4efa-978a-50efe3701265" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9f5f3668-07b0-40e4-b87a-99e39a1d62d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d6c9f2be-a67c-4f01-a48d-d255f41b1a9e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9f5f3668-07b0-40e4-b87a-99e39a1d62d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#NetLossPerShareBasicandDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8a27d0b6-46bf-4fae-8b9c-3e86eaceb488" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6aa0e07c-726b-4af8-99ed-e9e19cc6d92a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8a27d0b6-46bf-4fae-8b9c-3e86eaceb488" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6aa0e07c-726b-4af8-99ed-e9e19cc6d92a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d72c7089-cac1-400c-948f-645280822984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8a27d0b6-46bf-4fae-8b9c-3e86eaceb488" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d72c7089-cac1-400c-948f-645280822984" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>arwr-20240331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:ac9daf9b-fe65-44cf-acd3-206171097241,g:5004fc8e-4246-4d68-a802-ef4d83a3dac9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20240331.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_391ddd79-4f28-4335-8ac6-0c04eba4553a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_94e325a6-188c-41b3-bbaf-6cb0d94ab70f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_391ddd79-4f28-4335-8ac6-0c04eba4553a" xlink:to="loc_us-gaap_StatementTable_94e325a6-188c-41b3-bbaf-6cb0d94ab70f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_04bcd26d-7d7e-48ac-9c77-0160d2da545f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_94e325a6-188c-41b3-bbaf-6cb0d94ab70f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_04bcd26d-7d7e-48ac-9c77-0160d2da545f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_04bcd26d-7d7e-48ac-9c77-0160d2da545f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04bcd26d-7d7e-48ac-9c77-0160d2da545f" xlink:to="loc_us-gaap_EquityComponentDomain_04bcd26d-7d7e-48ac-9c77-0160d2da545f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04bcd26d-7d7e-48ac-9c77-0160d2da545f" xlink:to="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9bf0785e-90d0-46c1-8507-7c95e6c83f60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:to="loc_us-gaap_CommonStockMember_9bf0785e-90d0-46c1-8507-7c95e6c83f60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_da3bbbc4-4a04-484d-92bf-96121ab932a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_da3bbbc4-4a04-484d-92bf-96121ab932a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f623831e-edfa-421c-810b-696044ba6ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f623831e-edfa-421c-810b-696044ba6ecc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8ac5bb4c-4e00-4e3d-81e5-3fdb091cf9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:to="loc_us-gaap_RetainedEarningsMember_8ac5bb4c-4e00-4e3d-81e5-3fdb091cf9f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f428e9cd-b29c-45a1-946d-f31888921134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f428e9cd-b29c-45a1-946d-f31888921134" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_391ddd79-4f28-4335-8ac6-0c04eba4553a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_214f8657-926c-41d0-b3d5-d5fdd2bb1edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_214f8657-926c-41d0-b3d5-d5fdd2bb1edf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cd0bced3-352f-4642-940a-658025c74dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_SharesOutstanding_cd0bced3-352f-4642-940a-658025c74dd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f0513a27-d293-42cb-a624-b8f02726ab88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f0513a27-d293-42cb-a624-b8f02726ab88" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_07ec84f2-c006-469d-89ae-3c97a90a83ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_07ec84f2-c006-469d-89ae-3c97a90a83ff" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_792a6061-f984-4d5c-8949-fce5553f4a64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_792a6061-f984-4d5c-8949-fce5553f4a64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_5fa69201-c7f7-46b8-be3c-1b13790d4ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_5fa69201-c7f7-46b8-be3c-1b13790d4ebd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_bd6b836f-00de-4e81-8f5a-cb1378f1eb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_bd6b836f-00de-4e81-8f5a-cb1378f1eb5a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0198efd7-7451-4928-b2a6-8648a755b0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0198efd7-7451-4928-b2a6-8648a755b0ef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_329b8050-66c4-4efe-bdec-3baaa964f010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_329b8050-66c4-4efe-bdec-3baaa964f010" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2fe589fa-aed2-4a45-a064-a82d9aea8b72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2fe589fa-aed2-4a45-a064-a82d9aea8b72" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1770867a-2bc4-4170-804c-139b6eaca26c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1770867a-2bc4-4170-804c-139b6eaca26c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8857220b-f45f-4c57-aa8e-21c1d15a5644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_ProfitLoss_8857220b-f45f-4c57-aa8e-21c1d15a5644" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5ec130ca-d2e9-4a6f-827f-dec2c27bf135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dc268a0b-84e8-459e-8c4a-fa35b7051e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail" xlink:type="simple" xlink:href="arwr-20240331.xsd#OrganizationandSignificantAccountingPoliciesNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:href="arwr-20240331.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_bbc0146b-cd6f-4102-8cbf-c745a13a6d8e" xlink:href="arwr-20240331.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_bbc0146b-cd6f-4102-8cbf-c745a13a6d8e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dcd8250c-bfc1-4040-843c-c1b25e7edf41" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_bbc0146b-cd6f-4102-8cbf-c745a13a6d8e" xlink:to="loc_srt_CounterpartyNameAxis_dcd8250c-bfc1-4040-843c-c1b25e7edf41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dcd8250c-bfc1-4040-843c-c1b25e7edf41_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_dcd8250c-bfc1-4040-843c-c1b25e7edf41" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_dcd8250c-bfc1-4040-843c-c1b25e7edf41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9d05d78-0761-4f45-9df9-b53084df78be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_dcd8250c-bfc1-4040-843c-c1b25e7edf41" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9d05d78-0761-4f45-9df9-b53084df78be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_9b211632-4fba-4c1b-90a3-b5f8a03aac92" xlink:href="arwr-20240331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9d05d78-0761-4f45-9df9-b53084df78be" xlink:to="loc_arwr_AmgenIncorporatedMember_9b211632-4fba-4c1b-90a3-b5f8a03aac92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2e1a652d-6e60-48a9-8ef0-ebe0ad579c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_bbc0146b-cd6f-4102-8cbf-c745a13a6d8e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2e1a652d-6e60-48a9-8ef0-ebe0ad579c6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e1a652d-6e60-48a9-8ef0-ebe0ad579c6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2e1a652d-6e60-48a9-8ef0-ebe0ad579c6d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2e1a652d-6e60-48a9-8ef0-ebe0ad579c6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e9319c79-82f3-4c40-96cb-295ff0e5f65c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2e1a652d-6e60-48a9-8ef0-ebe0ad579c6d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e9319c79-82f3-4c40-96cb-295ff0e5f65c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_4f290e29-e59b-4268-8c12-13bcae009270" xlink:href="arwr-20240331.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e9319c79-82f3-4c40-96cb-295ff0e5f65c" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_4f290e29-e59b-4268-8c12-13bcae009270" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4503b3b4-6c90-492c-a06d-d4b2d53f6ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_bbc0146b-cd6f-4102-8cbf-c745a13a6d8e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4503b3b4-6c90-492c-a06d-d4b2d53f6ce6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4503b3b4-6c90-492c-a06d-d4b2d53f6ce6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4503b3b4-6c90-492c-a06d-d4b2d53f6ce6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4503b3b4-6c90-492c-a06d-d4b2d53f6ce6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_728c56df-6949-462b-bb36-44e139c354cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4503b3b4-6c90-492c-a06d-d4b2d53f6ce6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_728c56df-6949-462b-bb36-44e139c354cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UnderwritingAgreementMember_4b5e5520-00f2-424f-8480-310ef11deec2" xlink:href="arwr-20240331.xsd#arwr_UnderwritingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_728c56df-6949-462b-bb36-44e139c354cc" xlink:to="loc_arwr_UnderwritingAgreementMember_4b5e5520-00f2-424f-8480-310ef11deec2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_322bba83-db47-4c6c-bb63-c54590979968" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_322bba83-db47-4c6c-bb63-c54590979968" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d98bcca7-cc67-49db-9bbd-cdecfd2e2641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d98bcca7-cc67-49db-9bbd-cdecfd2e2641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_a8bf70ce-2eb5-4969-97fc-5c020b55d90d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_a8bf70ce-2eb5-4969-97fc-5c020b55d90d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d28106ae-1c19-4900-a3e9-02d6554cf366" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d28106ae-1c19-4900-a3e9-02d6554cf366" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_b612db3d-2932-4853-a988-fc480a510583" xlink:href="arwr-20240331.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_b612db3d-2932-4853-a988-fc480a510583" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a716b691-b215-4b4a-a80c-0fa2ad3a1151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a716b691-b215-4b4a-a80c-0fa2ad3a1151" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_454f8f7e-6ab4-49df-a877-7990cac90089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_454f8f7e-6ab4-49df-a877-7990cac90089" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_13be3a54-7ef2-47a0-ad6a-3b693d0d8e77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_13be3a54-7ef2-47a0-ad6a-3b693d0d8e77" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockAggregatePurchasePrice_6bd0a9d0-95ff-4878-9df9-10f58a3d224d" xlink:href="arwr-20240331.xsd#arwr_SaleOfStockAggregatePurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_arwr_SaleOfStockAggregatePurchasePrice_6bd0a9d0-95ff-4878-9df9-10f58a3d224d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_dd59fc80-b502-4ced-afc1-a1a653aefd73" xlink:href="arwr-20240331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_dd59fc80-b502-4ced-afc1-a1a653aefd73" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e9293e76-de3b-4cef-ad9a-32cfe0381916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e9293e76-de3b-4cef-ad9a-32cfe0381916" xlink:type="arc" order="10"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c6171171-7797-417a-ae73-f44db1c69b71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0c4633c5-c2b7-42e7-8967-7bcb7cb7abdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c6171171-7797-417a-ae73-f44db1c69b71" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0c4633c5-c2b7-42e7-8967-7bcb7cb7abdd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dcc17c03-845f-44c3-aec8-ee678b4febb9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0c4633c5-c2b7-42e7-8967-7bcb7cb7abdd" xlink:to="loc_srt_MajorCustomersAxis_dcc17c03-845f-44c3-aec8-ee678b4febb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_dcc17c03-845f-44c3-aec8-ee678b4febb9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_dcc17c03-845f-44c3-aec8-ee678b4febb9" xlink:to="loc_srt_NameOfMajorCustomerDomain_dcc17c03-845f-44c3-aec8-ee678b4febb9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_dcc17c03-845f-44c3-aec8-ee678b4febb9" xlink:to="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_6ab73c56-aa42-47a2-a6da-57490b9916c9" xlink:href="arwr-20240331.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_6ab73c56-aa42-47a2-a6da-57490b9916c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_62807b0d-ed7f-4977-9eda-2cb1e6662b67" xlink:href="arwr-20240331.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_62807b0d-ed7f-4977-9eda-2cb1e6662b67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_aa1d3484-8440-491f-8a3f-d9ec2f548c06" xlink:href="arwr-20240331.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_aa1d3484-8440-491f-8a3f-d9ec2f548c06" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_2b6e3298-1fd9-4be9-b657-b27d28f1cb1e" xlink:href="arwr-20240331.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_2b6e3298-1fd9-4be9-b657-b27d28f1cb1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_076f3ace-339f-4d63-bdac-15d837d9b1a3" xlink:href="arwr-20240331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:to="loc_arwr_AmgenIncorporatedMember_076f3ace-339f-4d63-bdac-15d837d9b1a3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fad2de4e-81a3-49ef-a488-3680e86bea32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c6171171-7797-417a-ae73-f44db1c69b71" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fad2de4e-81a3-49ef-a488-3680e86bea32" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220859c4-8118-47aa-ab90-b39e6dc377a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220859c4-8118-47aa-ab90-b39e6dc377a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a08b6bec-3550-48cb-b9d9-23a28f491f43" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220859c4-8118-47aa-ab90-b39e6dc377a4" xlink:to="loc_srt_CounterpartyNameAxis_a08b6bec-3550-48cb-b9d9-23a28f491f43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a08b6bec-3550-48cb-b9d9-23a28f491f43_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a08b6bec-3550-48cb-b9d9-23a28f491f43" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a08b6bec-3550-48cb-b9d9-23a28f491f43_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_767ef64b-f40c-4cd0-b78a-79a3a72906f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a08b6bec-3550-48cb-b9d9-23a28f491f43" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_767ef64b-f40c-4cd0-b78a-79a3a72906f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_9f59ab20-ee9f-455b-8014-e971792f2c96" xlink:href="arwr-20240331.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_767ef64b-f40c-4cd0-b78a-79a3a72906f8" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_9f59ab20-ee9f-455b-8014-e971792f2c96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_43c1c6f4-85bb-4ffa-a811-22c28b3c7225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220859c4-8118-47aa-ab90-b39e6dc377a4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_43c1c6f4-85bb-4ffa-a811-22c28b3c7225" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_43c1c6f4-85bb-4ffa-a811-22c28b3c7225_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_43c1c6f4-85bb-4ffa-a811-22c28b3c7225" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_43c1c6f4-85bb-4ffa-a811-22c28b3c7225_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4bd9f7c5-9661-43b8-a594-2c83208d9d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_43c1c6f4-85bb-4ffa-a811-22c28b3c7225" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4bd9f7c5-9661-43b8-a594-2c83208d9d27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKLicenseAgreementMember_1990f605-1855-433e-8329-7333242cae1e" xlink:href="arwr-20240331.xsd#arwr_GSKLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4bd9f7c5-9661-43b8-a594-2c83208d9d27" xlink:to="loc_arwr_GSKLicenseAgreementMember_1990f605-1855-433e-8329-7333242cae1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHBVAgreementMember_04a88e34-f96a-4f56-adbf-be125573aa91" xlink:href="arwr-20240331.xsd#arwr_GSKHBVAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4bd9f7c5-9661-43b8-a594-2c83208d9d27" xlink:to="loc_arwr_GSKHBVAgreementMember_04a88e34-f96a-4f56-adbf-be125573aa91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2179b52-3820-4017-ad2b-66ef5e337aea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220859c4-8118-47aa-ab90-b39e6dc377a4" xlink:to="loc_srt_RangeAxis_d2179b52-3820-4017-ad2b-66ef5e337aea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d2179b52-3820-4017-ad2b-66ef5e337aea_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d2179b52-3820-4017-ad2b-66ef5e337aea" xlink:to="loc_srt_RangeMember_d2179b52-3820-4017-ad2b-66ef5e337aea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_688b7754-b480-410e-b6cd-82e8a215d8ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d2179b52-3820-4017-ad2b-66ef5e337aea" xlink:to="loc_srt_RangeMember_688b7754-b480-410e-b6cd-82e8a215d8ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee89ebad-ddbc-4121-a301-09264e8da4cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_688b7754-b480-410e-b6cd-82e8a215d8ae" xlink:to="loc_srt_MaximumMember_ee89ebad-ddbc-4121-a301-09264e8da4cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_a1cb8562-8057-42df-80ef-0f82fd1b8aeb" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_arwr_MilestonePaymentReceivable_a1cb8562-8057-42df-80ef-0f82fd1b8aeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_1b20c40b-6bee-422e-a9e6-6d02cafe40e1" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_1b20c40b-6bee-422e-a9e6-6d02cafe40e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_acd19659-277b-43cc-992b-94695dbb3d37" xlink:href="arwr-20240331.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_acd19659-277b-43cc-992b-94695dbb3d37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_b412b19b-071f-45b0-b764-80612698ede2" xlink:href="arwr-20240331.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_arwr_SalesRelatedMilestonePayments_b412b19b-071f-45b0-b764-80612698ede2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_67b732b8-a8b5-46c7-a15f-c888693fbb33" xlink:href="arwr-20240331.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_arwr_InitialTransactionPrice_67b732b8-a8b5-46c7-a15f-c888693fbb33" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentAndSalesMilestonesPayments_50a6b05b-472a-4397-9a5e-ae0c75d478e7" xlink:href="arwr-20240331.xsd#arwr_DevelopmentAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_arwr_DevelopmentAndSalesMilestonesPayments_50a6b05b-472a-4397-9a5e-ae0c75d478e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_547c783e-76a4-4782-b32b-8cc6785c6105" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_547c783e-76a4-4782-b32b-8cc6785c6105" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5b65c64a-0419-4aff-8a40-e758f5c6a827" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5b65c64a-0419-4aff-8a40-e758f5c6a827" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8e85c5-d129-4740-9113-0af1b26c488e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65fbb230-5195-4aac-928c-4d9899771f38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8e85c5-d129-4740-9113-0af1b26c488e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65fbb230-5195-4aac-928c-4d9899771f38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_75b5c88d-ef57-4ca4-9dea-39e29558b098" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65fbb230-5195-4aac-928c-4d9899771f38" xlink:to="loc_srt_CounterpartyNameAxis_75b5c88d-ef57-4ca4-9dea-39e29558b098" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_75b5c88d-ef57-4ca4-9dea-39e29558b098_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_75b5c88d-ef57-4ca4-9dea-39e29558b098" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_75b5c88d-ef57-4ca4-9dea-39e29558b098_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32173e14-3e65-435d-918d-ed2ebcd2f7da" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_75b5c88d-ef57-4ca4-9dea-39e29558b098" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32173e14-3e65-435d-918d-ed2ebcd2f7da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_b67ad5c5-02ec-4ee3-bea0-ef2a91011286" xlink:href="arwr-20240331.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32173e14-3e65-435d-918d-ed2ebcd2f7da" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_b67ad5c5-02ec-4ee3-bea0-ef2a91011286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f4aabef-6dc7-4c60-a9fe-12242fc90d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65fbb230-5195-4aac-928c-4d9899771f38" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f4aabef-6dc7-4c60-a9fe-12242fc90d0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f4aabef-6dc7-4c60-a9fe-12242fc90d0c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f4aabef-6dc7-4c60-a9fe-12242fc90d0c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4f4aabef-6dc7-4c60-a9fe-12242fc90d0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb73cf11-d71c-411e-9c63-e8199eb8cde5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f4aabef-6dc7-4c60-a9fe-12242fc90d0c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb73cf11-d71c-411e-9c63-e8199eb8cde5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonLicenseAgreementMember_aeb4df95-7a04-4ee5-bb5c-1672eeeb8812" xlink:href="arwr-20240331.xsd#arwr_HorizonLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb73cf11-d71c-411e-9c63-e8199eb8cde5" xlink:to="loc_arwr_HorizonLicenseAgreementMember_aeb4df95-7a04-4ee5-bb5c-1672eeeb8812" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_d299243e-0996-427e-a7fd-750f7df09e34" xlink:href="arwr-20240331.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8e85c5-d129-4740-9113-0af1b26c488e" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_d299243e-0996-427e-a7fd-750f7df09e34" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_e3f92a73-1863-4267-b515-8fbbb0d28abe" xlink:href="arwr-20240331.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8e85c5-d129-4740-9113-0af1b26c488e" xlink:to="loc_arwr_InitialTransactionPrice_e3f92a73-1863-4267-b515-8fbbb0d28abe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_23dfe1d1-44ac-4590-b53f-b4666ee9b557" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8e85c5-d129-4740-9113-0af1b26c488e" xlink:to="loc_arwr_MilestonePaymentEarned_23dfe1d1-44ac-4590-b53f-b4666ee9b557" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13fa7617-9d6c-4de4-9e37-ea6e0aa394c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13fa7617-9d6c-4de4-9e37-ea6e0aa394c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d2af20d3-32b0-47dc-8f9d-896eb6e6751b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13fa7617-9d6c-4de4-9e37-ea6e0aa394c9" xlink:to="loc_srt_CounterpartyNameAxis_d2af20d3-32b0-47dc-8f9d-896eb6e6751b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2af20d3-32b0-47dc-8f9d-896eb6e6751b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d2af20d3-32b0-47dc-8f9d-896eb6e6751b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d2af20d3-32b0-47dc-8f9d-896eb6e6751b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07f5e04a-9a07-4894-a6af-6caec70c0510" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d2af20d3-32b0-47dc-8f9d-896eb6e6751b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07f5e04a-9a07-4894-a6af-6caec70c0510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_30d36630-4606-49a3-bbb3-e140ed92b677" xlink:href="arwr-20240331.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07f5e04a-9a07-4894-a6af-6caec70c0510" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_30d36630-4606-49a3-bbb3-e140ed92b677" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1f10001d-3e4a-4a6c-9aac-d5ec42e49820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13fa7617-9d6c-4de4-9e37-ea6e0aa394c9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1f10001d-3e4a-4a6c-9aac-d5ec42e49820" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f10001d-3e4a-4a6c-9aac-d5ec42e49820_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1f10001d-3e4a-4a6c-9aac-d5ec42e49820" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f10001d-3e4a-4a6c-9aac-d5ec42e49820_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93a17622-658b-443d-8dc4-69351d2b5934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1f10001d-3e4a-4a6c-9aac-d5ec42e49820" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93a17622-658b-443d-8dc4-69351d2b5934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_2e33963e-f862-4516-8e9f-683a9d8fa49b" xlink:href="arwr-20240331.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93a17622-658b-443d-8dc4-69351d2b5934" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_2e33963e-f862-4516-8e9f-683a9d8fa49b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_31dc0928-9158-478d-ab33-9bed541b2730" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13fa7617-9d6c-4de4-9e37-ea6e0aa394c9" xlink:to="loc_srt_RangeAxis_31dc0928-9158-478d-ab33-9bed541b2730" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_31dc0928-9158-478d-ab33-9bed541b2730_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_31dc0928-9158-478d-ab33-9bed541b2730" xlink:to="loc_srt_RangeMember_31dc0928-9158-478d-ab33-9bed541b2730_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1826c02-0d06-4f87-a2ff-59ddc3fba31d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_31dc0928-9158-478d-ab33-9bed541b2730" xlink:to="loc_srt_RangeMember_d1826c02-0d06-4f87-a2ff-59ddc3fba31d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3b86169f-265a-4d27-bb66-9f5fd1cc003e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d1826c02-0d06-4f87-a2ff-59ddc3fba31d" xlink:to="loc_srt_MinimumMember_3b86169f-265a-4d27-bb66-9f5fd1cc003e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9cd716bf-051b-43be-b619-03284a98cb99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d1826c02-0d06-4f87-a2ff-59ddc3fba31d" xlink:to="loc_srt_MaximumMember_9cd716bf-051b-43be-b619-03284a98cb99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_836aa0ca-3a19-41fb-8945-a767aa682b57" xlink:href="arwr-20240331.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_836aa0ca-3a19-41fb-8945-a767aa682b57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_bcfb06ce-2f1e-42cd-b2f8-00776c64a49d" xlink:href="arwr-20240331.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_bcfb06ce-2f1e-42cd-b2f8-00776c64a49d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_25191209-647f-425d-a3e7-03762647b05e" xlink:href="arwr-20240331.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_arwr_NumberOfDistinctBundle_25191209-647f-425d-a3e7-03762647b05e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_7e74d0ee-cee6-4708-95f7-2aa89a6b08d2" xlink:href="arwr-20240331.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_arwr_InitialTransactionPrice_7e74d0ee-cee6-4708-95f7-2aa89a6b08d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_7b6ad4a2-b271-417a-b15c-d472266a7e62" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_arwr_MilestonePaymentEarned_7b6ad4a2-b271-417a-b15c-d472266a7e62" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_716a09bd-b00d-4b1e-ad01-f4158f97614a" xlink:href="arwr-20240331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_716a09bd-b00d-4b1e-ad01-f4158f97614a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b6c50b07-9423-4a14-b101-92723ace39ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b6c50b07-9423-4a14-b101-92723ace39ab" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7a20e8-8567-4942-a7af-00bf910e1cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7a20e8-8567-4942-a7af-00bf910e1cb0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_659e285c-8b1a-4bd8-941a-69f6bbf8ffd8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7a20e8-8567-4942-a7af-00bf910e1cb0" xlink:to="loc_srt_CounterpartyNameAxis_659e285c-8b1a-4bd8-941a-69f6bbf8ffd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_659e285c-8b1a-4bd8-941a-69f6bbf8ffd8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_659e285c-8b1a-4bd8-941a-69f6bbf8ffd8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_659e285c-8b1a-4bd8-941a-69f6bbf8ffd8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f28939a-8433-4478-9933-4b2b41a7c955" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_659e285c-8b1a-4bd8-941a-69f6bbf8ffd8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f28939a-8433-4478-9933-4b2b41a7c955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_28e3a9e9-6646-4176-b285-e25bb4ededd9" xlink:href="arwr-20240331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f28939a-8433-4478-9933-4b2b41a7c955" xlink:to="loc_arwr_AmgenIncorporatedMember_28e3a9e9-6646-4176-b285-e25bb4ededd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4a3622bb-b31d-4431-9d89-a27b1d5addb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7a20e8-8567-4942-a7af-00bf910e1cb0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4a3622bb-b31d-4431-9d89-a27b1d5addb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a3622bb-b31d-4431-9d89-a27b1d5addb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4a3622bb-b31d-4431-9d89-a27b1d5addb4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4a3622bb-b31d-4431-9d89-a27b1d5addb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7615f5a0-6657-4128-bd82-655682a3aa53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4a3622bb-b31d-4431-9d89-a27b1d5addb4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7615f5a0-6657-4128-bd82-655682a3aa53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_324f4894-65d7-4988-883d-f26233ff7159" xlink:href="arwr-20240331.xsd#arwr_OlpasiranAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7615f5a0-6657-4128-bd82-655682a3aa53" xlink:to="loc_arwr_OlpasiranAgreementMember_324f4894-65d7-4988-883d-f26233ff7159" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e83c98a1-06fd-4082-bfc2-2d15c558deb0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7a20e8-8567-4942-a7af-00bf910e1cb0" xlink:to="loc_srt_RangeAxis_e83c98a1-06fd-4082-bfc2-2d15c558deb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e83c98a1-06fd-4082-bfc2-2d15c558deb0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e83c98a1-06fd-4082-bfc2-2d15c558deb0" xlink:to="loc_srt_RangeMember_e83c98a1-06fd-4082-bfc2-2d15c558deb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4aad494b-69c1-4949-8e00-8952100e3878" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e83c98a1-06fd-4082-bfc2-2d15c558deb0" xlink:to="loc_srt_RangeMember_4aad494b-69c1-4949-8e00-8952100e3878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c35364ee-92c3-4c56-8ab0-9cf93aa552ca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4aad494b-69c1-4949-8e00-8952100e3878" xlink:to="loc_srt_MaximumMember_c35364ee-92c3-4c56-8ab0-9cf93aa552ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_effb56d3-188f-4156-ae78-72cc53464b63" xlink:href="arwr-20240331.xsd#arwr_NumberOfAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_arwr_NumberOfAgreements_effb56d3-188f-4156-ae78-72cc53464b63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_b78cac2c-d706-4527-8229-9518b2bf7fc5" xlink:href="arwr-20240331.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_b78cac2c-d706-4527-8229-9518b2bf7fc5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c9419768-9d91-4767-837a-c080b060b1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c9419768-9d91-4767-837a-c080b060b1fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived_47335863-c862-4e42-a3ee-adbbacd77431" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_arwr_MilestonePaymentReceived_47335863-c862-4e42-a3ee-adbbacd77431" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_53788916-ef80-494f-a49d-4d576e4c8dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_53788916-ef80-494f-a49d-4d576e4c8dd4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_071a19da-ab92-4b8e-a388-41d331369df1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_071a19da-ab92-4b8e-a388-41d331369df1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_8d5dbf3f-a040-4a49-8bee-3b4b4a5b4568" xlink:href="arwr-20240331.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_8d5dbf3f-a040-4a49-8bee-3b4b4a5b4568" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6580e33-cc5e-4d69-80f5-b3f39f570e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b037a215-c963-42b6-aa3e-cb6e0acb4440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6580e33-cc5e-4d69-80f5-b3f39f570e8a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b037a215-c963-42b6-aa3e-cb6e0acb4440" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_06d18c43-464c-4b2c-91cd-08303ccf44ed" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b037a215-c963-42b6-aa3e-cb6e0acb4440" xlink:to="loc_srt_CounterpartyNameAxis_06d18c43-464c-4b2c-91cd-08303ccf44ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06d18c43-464c-4b2c-91cd-08303ccf44ed_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_06d18c43-464c-4b2c-91cd-08303ccf44ed" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_06d18c43-464c-4b2c-91cd-08303ccf44ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5433a09f-030f-4df4-991a-658b10e21aac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_06d18c43-464c-4b2c-91cd-08303ccf44ed" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5433a09f-030f-4df4-991a-658b10e21aac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_8a7d1660-f52d-4b6a-ad62-adf3c2c3a743" xlink:href="arwr-20240331.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5433a09f-030f-4df4-991a-658b10e21aac" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_8a7d1660-f52d-4b6a-ad62-adf3c2c3a743" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_aa09a91e-20ca-481a-b701-9bb4726bd204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b037a215-c963-42b6-aa3e-cb6e0acb4440" xlink:to="loc_us-gaap_TypeOfArrangementAxis_aa09a91e-20ca-481a-b701-9bb4726bd204" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aa09a91e-20ca-481a-b701-9bb4726bd204_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_aa09a91e-20ca-481a-b701-9bb4726bd204" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_aa09a91e-20ca-481a-b701-9bb4726bd204_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b10c535-be43-430a-8b0b-d2cdddc9d25b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_aa09a91e-20ca-481a-b701-9bb4726bd204" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b10c535-be43-430a-8b0b-d2cdddc9d25b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaLicenseAgreementMember_1007759e-a716-48b2-a194-e6b6dac21e78" xlink:href="arwr-20240331.xsd#arwr_VisirnaLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b10c535-be43-430a-8b0b-d2cdddc9d25b" xlink:to="loc_arwr_VisirnaLicenseAgreementMember_1007759e-a716-48b2-a194-e6b6dac21e78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_32efa31a-96b9-489f-959a-783eca1a1d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6580e33-cc5e-4d69-80f5-b3f39f570e8a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_32efa31a-96b9-489f-959a-783eca1a1d9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_af2ede14-dd85-4f2b-96be-304519a1358e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6580e33-cc5e-4d69-80f5-b3f39f570e8a" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_af2ede14-dd85-4f2b-96be-304519a1358e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_52138194-d2e1-45bc-9217-0e27670475cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6580e33-cc5e-4d69-80f5-b3f39f570e8a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_52138194-d2e1-45bc-9217-0e27670475cc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="arwr-20240331.xsd#BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_da306ed4-6bb1-422a-af97-7e421fbeafef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_da306ed4-6bb1-422a-af97-7e421fbeafef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_266b30a4-8f06-4fd5-839f-1e7af631fd12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_da306ed4-6bb1-422a-af97-7e421fbeafef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_266b30a4-8f06-4fd5-839f-1e7af631fd12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_266b30a4-8f06-4fd5-839f-1e7af631fd12_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_266b30a4-8f06-4fd5-839f-1e7af631fd12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_266b30a4-8f06-4fd5-839f-1e7af631fd12_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_266b30a4-8f06-4fd5-839f-1e7af631fd12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_f04a153a-da82-49a0-90a9-589634f7dae9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_us-gaap_LandMember_f04a153a-da82-49a0-90a9-589634f7dae9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_5955bc11-a324-4fbb-9734-df5b8a6bd300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_us-gaap_BuildingMember_5955bc11-a324-4fbb-9734-df5b8a6bd300" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember_ca7e4ba9-eadd-42f2-a888-4c70170c99dc" xlink:href="arwr-20240331.xsd#arwr_ResearchEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_arwr_ResearchEquipmentMember_ca7e4ba9-eadd-42f2-a888-4c70170c99dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_582df5d6-da32-4da8-9ea7-49385fc234cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_582df5d6-da32-4da8-9ea7-49385fc234cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputerAndSoftwareMember_e773447e-6449-4f37-b17b-6527445fcfb8" xlink:href="arwr-20240331.xsd#arwr_ComputerAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_arwr_ComputerAndSoftwareMember_e773447e-6449-4f37-b17b-6527445fcfb8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_87e33f43-842c-4723-a6c1-9a2dffde0aab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_87e33f43-842c-4723-a6c1-9a2dffde0aab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b74e1a34-21cc-4671-b1a4-938343e96a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_us-gaap_ConstructionInProgressMember_b74e1a34-21cc-4671-b1a4-938343e96a1f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_90734f57-aef3-40c3-b1d9-c0ae62320a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_90734f57-aef3-40c3-b1d9-c0ae62320a81" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_671a7386-5f0c-4708-ba52-c36db4c9cb26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_671a7386-5f0c-4708-ba52-c36db4c9cb26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8031abd7-9c83-4a9e-b8fe-82a724b7f8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8031abd7-9c83-4a9e-b8fe-82a724b7f8fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e6c62372-7360-47bf-a374-1c64b378242c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e6c62372-7360-47bf-a374-1c64b378242c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_6c66e71c-b660-4bb4-b93a-433206e71c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_6c66e71c-b660-4bb4-b93a-433206e71c9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_de3b833c-f2bc-4265-9c71-afa52caae58e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_de3b833c-f2bc-4265-9c71-afa52caae58e" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_7c751e76-0a0f-4b0a-ab98-f4ba877dba76" xlink:href="arwr-20240331.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_f8652386-b7ba-4503-b540-844d9768d430" xlink:href="arwr-20240331.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_7c751e76-0a0f-4b0a-ab98-f4ba877dba76" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_f8652386-b7ba-4503-b540-844d9768d430" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fe26efe6-8bea-47e4-8036-55b1f08f0e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_f8652386-b7ba-4503-b540-844d9768d430" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fe26efe6-8bea-47e4-8036-55b1f08f0e92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fe26efe6-8bea-47e4-8036-55b1f08f0e92_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fe26efe6-8bea-47e4-8036-55b1f08f0e92" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fe26efe6-8bea-47e4-8036-55b1f08f0e92_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74bc47a3-d754-4d94-b465-246ea11045c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fe26efe6-8bea-47e4-8036-55b1f08f0e92" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74bc47a3-d754-4d94-b465-246ea11045c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_5f24676c-901b-49cd-a2f0-c83e59c2589f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74bc47a3-d754-4d94-b465-246ea11045c6" xlink:to="loc_us-gaap_DebtSecuritiesMember_5f24676c-901b-49cd-a2f0-c83e59c2589f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_8a6c5fbf-63ec-4368-873b-dd57c0ed3599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_7c751e76-0a0f-4b0a-ab98-f4ba877dba76" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_8a6c5fbf-63ec-4368-873b-dd57c0ed3599" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_7f8766c5-7635-4c92-9b6d-782e5858604a" xlink:href="arwr-20240331.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_7c751e76-0a0f-4b0a-ab98-f4ba877dba76" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_7f8766c5-7635-4c92-9b6d-782e5858604a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_885add97-f397-446f-907a-2b57688c0ac6" xlink:href="arwr-20240331.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_7c751e76-0a0f-4b0a-ab98-f4ba877dba76" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_885add97-f397-446f-907a-2b57688c0ac6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8bd0694f-7dd8-4d56-a1f2-cdcf6b49b390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_7c751e76-0a0f-4b0a-ab98-f4ba877dba76" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8bd0694f-7dd8-4d56-a1f2-cdcf6b49b390" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_39fdcda7-f518-4050-bc36-9f21c0f83d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_39fdcda7-f518-4050-bc36-9f21c0f83d8a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_d94fd28e-d4f9-46dd-82aa-cba9b9e1c93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_39fdcda7-f518-4050-bc36-9f21c0f83d8a" xlink:to="loc_us-gaap_AssetAcquisitionAxis_d94fd28e-d4f9-46dd-82aa-cba9b9e1c93d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_d94fd28e-d4f9-46dd-82aa-cba9b9e1c93d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_d94fd28e-d4f9-46dd-82aa-cba9b9e1c93d" xlink:to="loc_us-gaap_AssetAcquisitionDomain_d94fd28e-d4f9-46dd-82aa-cba9b9e1c93d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_45419ae9-47da-401e-a4c7-e792a3e89579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_d94fd28e-d4f9-46dd-82aa-cba9b9e1c93d" xlink:to="loc_us-gaap_AssetAcquisitionDomain_45419ae9-47da-401e-a4c7-e792a3e89579" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_76786e66-fcb4-4738-925e-9ee745f9a7cb" xlink:href="arwr-20240331.xsd#arwr_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_45419ae9-47da-401e-a4c7-e792a3e89579" xlink:to="loc_arwr_NovartisMember_76786e66-fcb4-4738-925e-9ee745f9a7cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70fbc6bc-c340-4f9d-b0d4-b213311eb78f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_39fdcda7-f518-4050-bc36-9f21c0f83d8a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70fbc6bc-c340-4f9d-b0d4-b213311eb78f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70fbc6bc-c340-4f9d-b0d4-b213311eb78f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70fbc6bc-c340-4f9d-b0d4-b213311eb78f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_70fbc6bc-c340-4f9d-b0d4-b213311eb78f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_842a3b51-9912-4703-8f2a-f0e2157cfb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70fbc6bc-c340-4f9d-b0d4-b213311eb78f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_842a3b51-9912-4703-8f2a-f0e2157cfb1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_337462ec-0e7b-4a43-8a58-34e1f6d63467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_842a3b51-9912-4703-8f2a-f0e2157cfb1b" xlink:to="loc_us-gaap_PatentsMember_337462ec-0e7b-4a43-8a58-34e1f6d63467" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_0ae9e160-b32e-49bf-a220-76b1f816a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_842a3b51-9912-4703-8f2a-f0e2157cfb1b" xlink:to="loc_us-gaap_LicensingAgreementsMember_0ae9e160-b32e-49bf-a220-76b1f816a3ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e93bd0fd-bc45-488b-aa31-5499a4e9afaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e93bd0fd-bc45-488b-aa31-5499a4e9afaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_57724b52-03a1-415d-b7cf-089720b70010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_57724b52-03a1-415d-b7cf-089720b70010" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_f06f24d4-c3dc-4b5f-af9a-76bae05e4c8e" xlink:href="arwr-20240331.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_f06f24d4-c3dc-4b5f-af9a-76bae05e4c8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b4e69499-0c09-47ae-9ca7-ac68c651299d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b4e69499-0c09-47ae-9ca7-ac68c651299d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_12be652f-93b2-4804-bf7c-799535f6b020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_12be652f-93b2-4804-bf7c-799535f6b020" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0951dd47-3407-4f12-89d9-600127f7f8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0951dd47-3407-4f12-89d9-600127f7f8d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_05f2a763-5a0d-4e31-8b6e-923f21dfb2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0951dd47-3407-4f12-89d9-600127f7f8d5" xlink:to="loc_us-gaap_PlanNameAxis_05f2a763-5a0d-4e31-8b6e-923f21dfb2ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_05f2a763-5a0d-4e31-8b6e-923f21dfb2ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_05f2a763-5a0d-4e31-8b6e-923f21dfb2ce" xlink:to="loc_us-gaap_PlanNameDomain_05f2a763-5a0d-4e31-8b6e-923f21dfb2ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0b284140-2796-4076-b92e-6dc6fea50a09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_05f2a763-5a0d-4e31-8b6e-923f21dfb2ce" xlink:to="loc_us-gaap_PlanNameDomain_0b284140-2796-4076-b92e-6dc6fea50a09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_7e544e0d-53c8-4cde-a6f3-97c7039c0efa" xlink:href="arwr-20240331.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0b284140-2796-4076-b92e-6dc6fea50a09" xlink:to="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_7e544e0d-53c8-4cde-a6f3-97c7039c0efa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6948a7a0-e9ac-4b40-9ed1-f22f45daa931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0951dd47-3407-4f12-89d9-600127f7f8d5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6948a7a0-e9ac-4b40-9ed1-f22f45daa931" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6948a7a0-e9ac-4b40-9ed1-f22f45daa931_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6948a7a0-e9ac-4b40-9ed1-f22f45daa931" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6948a7a0-e9ac-4b40-9ed1-f22f45daa931_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c04f6122-5006-4336-8627-bb3be1e0299b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6948a7a0-e9ac-4b40-9ed1-f22f45daa931" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c04f6122-5006-4336-8627-bb3be1e0299b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UnderwritingAgreementMember_0090696b-d986-4fb9-942f-89a90fca54df" xlink:href="arwr-20240331.xsd#arwr_UnderwritingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c04f6122-5006-4336-8627-bb3be1e0299b" xlink:to="loc_arwr_UnderwritingAgreementMember_0090696b-d986-4fb9-942f-89a90fca54df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_f8596514-92f7-4fd4-ab7c-3c19f9a06b6c" xlink:href="arwr-20240331.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c04f6122-5006-4336-8627-bb3be1e0299b" xlink:to="loc_arwr_AtTheMarketAgreementMember_f8596514-92f7-4fd4-ab7c-3c19f9a06b6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c909c660-e6c8-4e2c-87dc-b214ce126819" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0951dd47-3407-4f12-89d9-600127f7f8d5" xlink:to="loc_srt_RangeAxis_c909c660-e6c8-4e2c-87dc-b214ce126819" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c909c660-e6c8-4e2c-87dc-b214ce126819_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c909c660-e6c8-4e2c-87dc-b214ce126819" xlink:to="loc_srt_RangeMember_c909c660-e6c8-4e2c-87dc-b214ce126819_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c8e05676-0c3e-4d7a-9c51-3f881183f4de" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c909c660-e6c8-4e2c-87dc-b214ce126819" xlink:to="loc_srt_RangeMember_c8e05676-0c3e-4d7a-9c51-3f881183f4de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f8be03ca-0ffe-4339-a7bb-ba36636fd76c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c8e05676-0c3e-4d7a-9c51-3f881183f4de" xlink:to="loc_srt_MaximumMember_f8be03ca-0ffe-4339-a7bb-ba36636fd76c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_73368861-6c17-47d3-b1f3-7177f2196999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_73368861-6c17-47d3-b1f3-7177f2196999" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_71f1d624-c344-49ab-8cef-3f323f70ad7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_71f1d624-c344-49ab-8cef-3f323f70ad7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a2365ae7-e875-415d-9983-c578fd52fded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_CommonStockSharesIssued_a2365ae7-e875-415d-9983-c578fd52fded" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6f63ba03-00c4-424d-9053-7ead77a1a211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6f63ba03-00c4-424d-9053-7ead77a1a211" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d340e1d7-eb70-4b6b-b7c9-9e1144873319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d340e1d7-eb70-4b6b-b7c9-9e1144873319" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_92a585cf-0b2e-43ca-bc3b-43d2ad40d91a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_92a585cf-0b2e-43ca-bc3b-43d2ad40d91a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8287e288-e3ea-42e4-93b4-0ba44f431ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8287e288-e3ea-42e4-93b4-0ba44f431ddb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ec0a96f2-e641-479b-aea7-69b425df0586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ec0a96f2-e641-479b-aea7-69b425df0586" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a5ec7d7b-155e-4036-a99b-bdceebca4fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a5ec7d7b-155e-4036-a99b-bdceebca4fd5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eba3530b-52b2-437b-8500-39d49add2fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eba3530b-52b2-437b-8500-39d49add2fcd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_072afab7-e426-4e0c-bf5c-c295c70f281d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_072afab7-e426-4e0c-bf5c-c295c70f281d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockAggregatePurchasePrice_b6f03026-0822-4e3b-939e-d2f532e37b2d" xlink:href="arwr-20240331.xsd#arwr_SaleOfStockAggregatePurchasePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_arwr_SaleOfStockAggregatePurchasePrice_b6f03026-0822-4e3b-939e-d2f532e37b2d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0a0469a4-53b5-480e-81d8-d57aea1b3c07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0a0469a4-53b5-480e-81d8-d57aea1b3c07" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_8111d4a1-b806-460b-89e5-cc0c8cfbeb2f" xlink:href="arwr-20240331.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_8111d4a1-b806-460b-89e5-cc0c8cfbeb2f" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_07cab9f9-e187-4c0f-b6a8-ddff581eab9a" xlink:href="arwr-20240331.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_07cab9f9-e187-4c0f-b6a8-ddff581eab9a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6ea12c00-ba0a-4d55-8246-5fc987734b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_SharesIssued_6ea12c00-ba0a-4d55-8246-5fc987734b40" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail" xlink:type="simple" xlink:href="arwr-20240331.xsd#CommitmentsandContingenciesNarrativeDetail"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_823a911a-c4dc-42a4-94bf-e30930bfe659" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_2ec8da0e-3a44-415b-b6eb-5d9941c5c7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_823a911a-c4dc-42a4-94bf-e30930bfe659" xlink:to="loc_us-gaap_OtherCommitmentsTable_2ec8da0e-3a44-415b-b6eb-5d9941c5c7e9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189369de-c366-4663-bab5-7a812d6f9afe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ec8da0e-3a44-415b-b6eb-5d9941c5c7e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189369de-c366-4663-bab5-7a812d6f9afe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_189369de-c366-4663-bab5-7a812d6f9afe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189369de-c366-4663-bab5-7a812d6f9afe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_189369de-c366-4663-bab5-7a812d6f9afe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35993693-b07f-4820-bd1c-faef457446b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189369de-c366-4663-bab5-7a812d6f9afe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35993693-b07f-4820-bd1c-faef457446b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_b3d6ab6d-d3d8-4f54-8f0d-161d1c369a4d" xlink:href="arwr-20240331.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35993693-b07f-4820-bd1c-faef457446b9" xlink:to="loc_arwr_DrugManufacturingFacilityMember_b3d6ab6d-d3d8-4f54-8f0d-161d1c369a4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_61a26fb2-88ae-4d09-814a-d3a7183e36c7" xlink:href="arwr-20240331.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35993693-b07f-4820-bd1c-faef457446b9" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_61a26fb2-88ae-4d09-814a-d3a7183e36c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_cedad5c3-84e5-4ab2-8587-820608329ab8" xlink:href="arwr-20240331.xsd#arwr_FacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35993693-b07f-4820-bd1c-faef457446b9" xlink:to="loc_arwr_FacilitiesMember_cedad5c3-84e5-4ab2-8587-820608329ab8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_619ab7f6-8aa2-45ed-bc82-9a699f9b27a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ec8da0e-3a44-415b-b6eb-5d9941c5c7e9" xlink:to="loc_srt_StatementGeographicalAxis_619ab7f6-8aa2-45ed-bc82-9a699f9b27a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_619ab7f6-8aa2-45ed-bc82-9a699f9b27a8_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_619ab7f6-8aa2-45ed-bc82-9a699f9b27a8" xlink:to="loc_srt_SegmentGeographicalDomain_619ab7f6-8aa2-45ed-bc82-9a699f9b27a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ed50c88f-4c54-40fd-9df7-60f15d9e6ced" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_619ab7f6-8aa2-45ed-bc82-9a699f9b27a8" xlink:to="loc_srt_SegmentGeographicalDomain_ed50c88f-4c54-40fd-9df7-60f15d9e6ced" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_1628b808-89fd-4661-8998-9c96f0c64f10" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_ed50c88f-4c54-40fd-9df7-60f15d9e6ced" xlink:to="loc_stpr_WI_1628b808-89fd-4661-8998-9c96f0c64f10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a45c8293-3012-4dbe-9030-2e24d09661f0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ec8da0e-3a44-415b-b6eb-5d9941c5c7e9" xlink:to="loc_srt_RangeAxis_a45c8293-3012-4dbe-9030-2e24d09661f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a45c8293-3012-4dbe-9030-2e24d09661f0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a45c8293-3012-4dbe-9030-2e24d09661f0" xlink:to="loc_srt_RangeMember_a45c8293-3012-4dbe-9030-2e24d09661f0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_261f8a1b-afb8-4fbe-ae85-2dcb23924297" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a45c8293-3012-4dbe-9030-2e24d09661f0" xlink:to="loc_srt_RangeMember_261f8a1b-afb8-4fbe-ae85-2dcb23924297" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b4eec7aa-cd2f-426b-9638-39951f6663ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_261f8a1b-afb8-4fbe-ae85-2dcb23924297" xlink:to="loc_srt_MinimumMember_b4eec7aa-cd2f-426b-9638-39951f6663ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7babc32f-1736-464f-a087-e15fbed34700" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_261f8a1b-afb8-4fbe-ae85-2dcb23924297" xlink:to="loc_srt_MaximumMember_7babc32f-1736-464f-a087-e15fbed34700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_edda8d78-6f61-44d4-8bab-821fd3b750a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_823a911a-c4dc-42a4-94bf-e30930bfe659" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_edda8d78-6f61-44d4-8bab-821fd3b750a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_27e3a531-f212-4370-9555-27d77b79f5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_823a911a-c4dc-42a4-94bf-e30930bfe659" xlink:to="loc_us-gaap_AreaOfLand_27e3a531-f212-4370-9555-27d77b79f5c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate_7b67f202-dcdf-40c6-aee2-54bbcd5aab93" xlink:href="arwr-20240331.xsd#arwr_CommitmentsCapitalExpendituresIncurredToDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_823a911a-c4dc-42a4-94bf-e30930bfe659" xlink:to="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate_7b67f202-dcdf-40c6-aee2-54bbcd5aab93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_77de5813-c177-4761-8b65-a29f1b1a9960" xlink:href="arwr-20240331.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_823a911a-c4dc-42a4-94bf-e30930bfe659" xlink:to="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_77de5813-c177-4761-8b65-a29f1b1a9960" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a69045a9-cc16-4259-a55e-33a3788b8d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a69045a9-cc16-4259-a55e-33a3788b8d3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_414f9746-e7d6-4298-9ff8-bee9eea5f2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a69045a9-cc16-4259-a55e-33a3788b8d3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_414f9746-e7d6-4298-9ff8-bee9eea5f2c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_414f9746-e7d6-4298-9ff8-bee9eea5f2c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_414f9746-e7d6-4298-9ff8-bee9eea5f2c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_414f9746-e7d6-4298-9ff8-bee9eea5f2c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82a20b6e-6f5c-4cdc-b946-cd90c826dcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_414f9746-e7d6-4298-9ff8-bee9eea5f2c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82a20b6e-6f5c-4cdc-b946-cd90c826dcfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_99a39b7b-2e5e-40c7-9a91-5dc7c4944447" xlink:href="arwr-20240331.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82a20b6e-6f5c-4cdc-b946-cd90c826dcfa" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_99a39b7b-2e5e-40c7-9a91-5dc7c4944447" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_52d37702-5bed-4fb3-b010-05c7968d1180" xlink:href="arwr-20240331.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82a20b6e-6f5c-4cdc-b946-cd90c826dcfa" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_52d37702-5bed-4fb3-b010-05c7968d1180" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_c46fc5f7-e9bc-403b-a6e7-dbc819300f61" xlink:href="arwr-20240331.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82a20b6e-6f5c-4cdc-b946-cd90c826dcfa" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_c46fc5f7-e9bc-403b-a6e7-dbc819300f61" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8b05a0f3-3750-41c1-b2d5-628b8bc6c866" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a69045a9-cc16-4259-a55e-33a3788b8d3c" xlink:to="loc_srt_StatementGeographicalAxis_8b05a0f3-3750-41c1-b2d5-628b8bc6c866" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8b05a0f3-3750-41c1-b2d5-628b8bc6c866_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8b05a0f3-3750-41c1-b2d5-628b8bc6c866" xlink:to="loc_srt_SegmentGeographicalDomain_8b05a0f3-3750-41c1-b2d5-628b8bc6c866_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_534984a1-cf02-4336-a851-3afed9f41a17" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8b05a0f3-3750-41c1-b2d5-628b8bc6c866" xlink:to="loc_srt_SegmentGeographicalDomain_534984a1-cf02-4336-a851-3afed9f41a17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_8f4ff4b0-7365-486e-b818-8dc0cb59f60d" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_534984a1-cf02-4336-a851-3afed9f41a17" xlink:to="loc_stpr_CA_8f4ff4b0-7365-486e-b818-8dc0cb59f60d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_47c35f2d-9803-45c4-8629-1141925dc20b" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_534984a1-cf02-4336-a851-3afed9f41a17" xlink:to="loc_stpr_WI_47c35f2d-9803-45c4-8629-1141925dc20b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1dadc320-f5ed-4707-8c3c-c1911d8aaaa0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a69045a9-cc16-4259-a55e-33a3788b8d3c" xlink:to="loc_srt_CounterpartyNameAxis_1dadc320-f5ed-4707-8c3c-c1911d8aaaa0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1dadc320-f5ed-4707-8c3c-c1911d8aaaa0_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_1dadc320-f5ed-4707-8c3c-c1911d8aaaa0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1dadc320-f5ed-4707-8c3c-c1911d8aaaa0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff088ea3-53a2-4351-817c-b5044ff57e3d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_1dadc320-f5ed-4707-8c3c-c1911d8aaaa0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff088ea3-53a2-4351-817c-b5044ff57e3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_7ece3307-438f-4b30-94ff-c795293181a0" xlink:href="arwr-20240331.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff088ea3-53a2-4351-817c-b5044ff57e3d" xlink:to="loc_arwr_ColoradoOwnerLLCMember_7ece3307-438f-4b30-94ff-c795293181a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fe2b6774-1e0f-4f0d-9a91-4747720e5afb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a69045a9-cc16-4259-a55e-33a3788b8d3c" xlink:to="loc_srt_RangeAxis_fe2b6774-1e0f-4f0d-9a91-4747720e5afb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fe2b6774-1e0f-4f0d-9a91-4747720e5afb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fe2b6774-1e0f-4f0d-9a91-4747720e5afb" xlink:to="loc_srt_RangeMember_fe2b6774-1e0f-4f0d-9a91-4747720e5afb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b44d9a5d-6d67-44fe-9b80-717a6be57dec" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fe2b6774-1e0f-4f0d-9a91-4747720e5afb" xlink:to="loc_srt_RangeMember_b44d9a5d-6d67-44fe-9b80-717a6be57dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a6e0a311-5e96-4e78-a10f-0cfce91218d4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_b44d9a5d-6d67-44fe-9b80-717a6be57dec" xlink:to="loc_srt_MaximumMember_a6e0a311-5e96-4e78-a10f-0cfce91218d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_c94c8094-ecd8-4d01-b963-bb125dc7eb24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_c94c8094-ecd8-4d01-b963-bb125dc7eb24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_f82e6b90-2962-46d6-a50a-d7939db0fb77" xlink:href="arwr-20240331.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_arwr_NumberOfOptionsToRenew_f82e6b90-2962-46d6-a50a-d7939db0fb77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7673f343-7f35-448d-a1bb-a96b16c288b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7673f343-7f35-448d-a1bb-a96b16c288b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ef614b05-3bce-43fa-a22d-f317f19b5fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ef614b05-3bce-43fa-a22d-f317f19b5fd6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MaximumAdditionalTenantImprovementAllowance_07dfa7b0-7523-4326-bb10-2d566d0fa044" xlink:href="arwr-20240331.xsd#arwr_MaximumAdditionalTenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_arwr_MaximumAdditionalTenantImprovementAllowance_07dfa7b0-7523-4326-bb10-2d566d0fa044" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_fb2b7c23-1fe8-44f6-9744-061e1b5f9b17" xlink:href="arwr-20240331.xsd#arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_fb2b7c23-1fe8-44f6-9744-061e1b5f9b17" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalTenantImprovementAllowanceLiability_22e49664-5125-4b47-a216-40aa0f500504" xlink:href="arwr-20240331.xsd#arwr_AdditionalTenantImprovementAllowanceLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_arwr_AdditionalTenantImprovementAllowanceLiability_22e49664-5125-4b47-a216-40aa0f500504" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_c211475d-5036-4249-bfb5-539c3d6766c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_us-gaap_ShortTermLeaseCost_c211475d-5036-4249-bfb5-539c3d6766c4" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_2f6a1196-4856-43d6-aee4-6e997db01e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2e07ac16-0cca-4214-b03e-d4378182d1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2f6a1196-4856-43d6-aee4-6e997db01e6d" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2e07ac16-0cca-4214-b03e-d4378182d1b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d67bf6c4-d3af-427b-9f62-755afee22722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2e07ac16-0cca-4214-b03e-d4378182d1b0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d67bf6c4-d3af-427b-9f62-755afee22722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d67bf6c4-d3af-427b-9f62-755afee22722_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d67bf6c4-d3af-427b-9f62-755afee22722" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d67bf6c4-d3af-427b-9f62-755afee22722_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_36e0668f-fe65-42ac-a7d5-9c21430c6c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d67bf6c4-d3af-427b-9f62-755afee22722" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_36e0668f-fe65-42ac-a7d5-9c21430c6c8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2076e10e-7d70-40d2-9017-df56e992981e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_36e0668f-fe65-42ac-a7d5-9c21430c6c8c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2076e10e-7d70-40d2-9017-df56e992981e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4d39a2a5-c0a9-4e71-9f59-c1d1547734f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_36e0668f-fe65-42ac-a7d5-9c21430c6c8c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4d39a2a5-c0a9-4e71-9f59-c1d1547734f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_337e4ffd-5244-4c1d-ab5a-e80fb501dc47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2f6a1196-4856-43d6-aee4-6e997db01e6d" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_337e4ffd-5244-4c1d-ab5a-e80fb501dc47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a4482cfd-612b-4c3d-9077-6c0f3f06311b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_337e4ffd-5244-4c1d-ab5a-e80fb501dc47" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a4482cfd-612b-4c3d-9077-6c0f3f06311b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_03992b28-e85b-44f3-930d-b783e15a6781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_337e4ffd-5244-4c1d-ab5a-e80fb501dc47" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_03992b28-e85b-44f3-930d-b783e15a6781" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c1c3bfce-86c7-4b3e-87fe-e41be8d8f9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_337e4ffd-5244-4c1d-ab5a-e80fb501dc47" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c1c3bfce-86c7-4b3e-87fe-e41be8d8f9c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_b686c56f-b0c9-4ece-9291-3110739486fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2f6a1196-4856-43d6-aee4-6e997db01e6d" xlink:to="loc_us-gaap_LeaseCostAbstract_b686c56f-b0c9-4ece-9291-3110739486fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3c61cde6-d368-4f21-b3a1-603be9acac0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_b686c56f-b0c9-4ece-9291-3110739486fd" xlink:to="loc_us-gaap_OperatingLeaseCost_3c61cde6-d368-4f21-b3a1-603be9acac0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_eac8d3fa-b0ae-420c-b63f-d0b365393f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_b686c56f-b0c9-4ece-9291-3110739486fd" xlink:to="loc_us-gaap_VariableLeaseCost_eac8d3fa-b0ae-420c-b63f-d0b365393f51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d08dea54-593e-4df4-b779-d9041b4d5b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_b686c56f-b0c9-4ece-9291-3110739486fd" xlink:to="loc_us-gaap_LeaseCost_d08dea54-593e-4df4-b779-d9041b4d5b4b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e682f975-18c4-4f9b-9b36-b8c9df0dfd40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e682f975-18c4-4f9b-9b36-b8c9df0dfd40" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6722252f-c9b0-44ea-9304-61431cdea630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e682f975-18c4-4f9b-9b36-b8c9df0dfd40" xlink:to="loc_us-gaap_PlanNameAxis_6722252f-c9b0-44ea-9304-61431cdea630" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_6722252f-c9b0-44ea-9304-61431cdea630_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_6722252f-c9b0-44ea-9304-61431cdea630" xlink:to="loc_us-gaap_PlanNameDomain_6722252f-c9b0-44ea-9304-61431cdea630_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_6722252f-c9b0-44ea-9304-61431cdea630" xlink:to="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_65e3e3a6-9da3-41da-b09d-d2a7a0838dbc" xlink:href="arwr-20240331.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_65e3e3a6-9da3-41da-b09d-d2a7a0838dbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_258c2031-d8fd-4bce-a898-7815597de33c" xlink:href="arwr-20240331.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_258c2031-d8fd-4bce-a898-7815597de33c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_ca748f0a-b112-46bb-8531-ba408d7fa0ee" xlink:href="arwr-20240331.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_ca748f0a-b112-46bb-8531-ba408d7fa0ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_bf8d6318-db97-4456-b910-d83fd33495d3" xlink:href="arwr-20240331.xsd#arwr_InducementAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:to="loc_arwr_InducementAwardsMember_bf8d6318-db97-4456-b910-d83fd33495d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaESOPMember_f8bd9564-da6b-4056-b712-3155b20fd83b" xlink:href="arwr-20240331.xsd#arwr_VisirnaESOPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:to="loc_arwr_VisirnaESOPMember_f8bd9564-da6b-4056-b712-3155b20fd83b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d1ec8730-1c8f-4819-aa5f-dad38add63ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e682f975-18c4-4f9b-9b36-b8c9df0dfd40" xlink:to="loc_us-gaap_AwardTypeAxis_d1ec8730-1c8f-4819-aa5f-dad38add63ae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1ec8730-1c8f-4819-aa5f-dad38add63ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d1ec8730-1c8f-4819-aa5f-dad38add63ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d1ec8730-1c8f-4819-aa5f-dad38add63ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda50d84-b2df-48d4-bd61-de07e6a2a848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d1ec8730-1c8f-4819-aa5f-dad38add63ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda50d84-b2df-48d4-bd61-de07e6a2a848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_eecd592b-d7c5-4fd4-ab05-00a9138a6cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda50d84-b2df-48d4-bd61-de07e6a2a848" xlink:to="loc_us-gaap_EmployeeStockOptionMember_eecd592b-d7c5-4fd4-ab05-00a9138a6cc6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bc2fa798-c7b7-4b82-a667-e8906170df48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda50d84-b2df-48d4-bd61-de07e6a2a848" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bc2fa798-c7b7-4b82-a667-e8906170df48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_776898e6-27e0-435e-ba47-aa0f04257b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_776898e6-27e0-435e-ba47-aa0f04257b7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bcf28116-7e78-4a63-a8ee-650526c89d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bcf28116-7e78-4a63-a8ee-650526c89d6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c61a0805-6c2e-43c4-95a9-e18bdcf67e18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c61a0805-6c2e-43c4-95a9-e18bdcf67e18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4aa2bb6d-4b52-4711-8c6f-81987b286e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4aa2bb6d-4b52-4711-8c6f-81987b286e23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a45f095f-0044-429f-8bf7-2f65728aefe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a45f095f-0044-429f-8bf7-2f65728aefe3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_98c5a613-f6ef-41fd-8585-b052923810e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_98c5a613-f6ef-41fd-8585-b052923810e9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_97a7e9af-9db0-4040-afbf-024af16d2b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_97a7e9af-9db0-4040-afbf-024af16d2b4a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_86ce84f5-e10a-4f2c-89c2-f1dc6bb7d663" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_86ce84f5-e10a-4f2c-89c2-f1dc6bb7d663" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_273f5866-f604-4807-9c36-ba01fbaae3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_273f5866-f604-4807-9c36-ba01fbaae3b2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1bf2f43a-baf2-43fd-bca6-2c043207d6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1bf2f43a-baf2-43fd-bca6-2c043207d6e1" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ccf0375-b08e-4b5c-b57f-10646dc99a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e861f10-b267-4771-94f3-7ef3763bb764" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ccf0375-b08e-4b5c-b57f-10646dc99a5d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e861f10-b267-4771-94f3-7ef3763bb764" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_288e3cac-b65d-45ed-b755-ae345223efdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e861f10-b267-4771-94f3-7ef3763bb764" xlink:to="loc_us-gaap_PlanNameAxis_288e3cac-b65d-45ed-b755-ae345223efdb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_288e3cac-b65d-45ed-b755-ae345223efdb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_288e3cac-b65d-45ed-b755-ae345223efdb" xlink:to="loc_us-gaap_PlanNameDomain_288e3cac-b65d-45ed-b755-ae345223efdb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a1935c10-1696-4fe6-9e58-afecdaca0640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_288e3cac-b65d-45ed-b755-ae345223efdb" xlink:to="loc_us-gaap_PlanNameDomain_a1935c10-1696-4fe6-9e58-afecdaca0640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_fab7ac18-8d09-41ed-a691-19f2ace0cac5" xlink:href="arwr-20240331.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a1935c10-1696-4fe6-9e58-afecdaca0640" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_fab7ac18-8d09-41ed-a691-19f2ace0cac5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_c4ecc23d-629e-46cf-859f-6c91e83d5895" xlink:href="arwr-20240331.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a1935c10-1696-4fe6-9e58-afecdaca0640" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_c4ecc23d-629e-46cf-859f-6c91e83d5895" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_b37bd9a5-79fc-4b5b-9f10-3a1aa5944923" xlink:href="arwr-20240331.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a1935c10-1696-4fe6-9e58-afecdaca0640" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_b37bd9a5-79fc-4b5b-9f10-3a1aa5944923" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_3ffefebe-6771-4a99-b332-964609e3df8a" xlink:href="arwr-20240331.xsd#arwr_InducementAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_a1935c10-1696-4fe6-9e58-afecdaca0640" xlink:to="loc_arwr_InducementAwardsMember_3ffefebe-6771-4a99-b332-964609e3df8a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cd6770be-cb16-4f24-946a-a57d19f9deec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e861f10-b267-4771-94f3-7ef3763bb764" xlink:to="loc_us-gaap_AwardTypeAxis_cd6770be-cb16-4f24-946a-a57d19f9deec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd6770be-cb16-4f24-946a-a57d19f9deec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cd6770be-cb16-4f24-946a-a57d19f9deec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cd6770be-cb16-4f24-946a-a57d19f9deec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_014d6be6-65c9-4eeb-8afa-d6272d666317" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cd6770be-cb16-4f24-946a-a57d19f9deec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_014d6be6-65c9-4eeb-8afa-d6272d666317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_898b4649-95c5-4e5f-85b9-7616beb7f370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_014d6be6-65c9-4eeb-8afa-d6272d666317" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_898b4649-95c5-4e5f-85b9-7616beb7f370" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4137a2f1-890f-4c0c-86c3-c435d1df602d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ccf0375-b08e-4b5c-b57f-10646dc99a5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4137a2f1-890f-4c0c-86c3-c435d1df602d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2d6ced83-2920-4a8b-80ba-756e597e90ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ccf0375-b08e-4b5c-b57f-10646dc99a5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2d6ced83-2920-4a8b-80ba-756e597e90ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_4d34b996-e09e-482c-8d35-cb08a9bd183a" xlink:href="arwr-20240331.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ccf0375-b08e-4b5c-b57f-10646dc99a5d" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_4d34b996-e09e-482c-8d35-cb08a9bd183a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3c742e44-1e59-4e56-8bcd-fa47a751cc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3f6b61d2-f7a1-4cf5-aedf-4874922c1729" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3c742e44-1e59-4e56-8bcd-fa47a751cc7e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3f6b61d2-f7a1-4cf5-aedf-4874922c1729" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_63c69ffd-ebf2-4265-85f9-226e8290dfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3f6b61d2-f7a1-4cf5-aedf-4874922c1729" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_63c69ffd-ebf2-4265-85f9-226e8290dfcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_63c69ffd-ebf2-4265-85f9-226e8290dfcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_63c69ffd-ebf2-4265-85f9-226e8290dfcd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_63c69ffd-ebf2-4265-85f9-226e8290dfcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73229a75-9865-405a-8d01-8880d3acceb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_63c69ffd-ebf2-4265-85f9-226e8290dfcd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_73229a75-9865-405a-8d01-8880d3acceb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7d7b2ed-7fbd-45ca-940e-a9431195e6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73229a75-9865-405a-8d01-8880d3acceb8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7d7b2ed-7fbd-45ca-940e-a9431195e6ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2f882f9e-d005-4233-85eb-73410434ca37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73229a75-9865-405a-8d01-8880d3acceb8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2f882f9e-d005-4233-85eb-73410434ca37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a049f27f-11c4-49d1-b78c-6ff7b9f4e94a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3c742e44-1e59-4e56-8bcd-fa47a751cc7e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a049f27f-11c4-49d1-b78c-6ff7b9f4e94a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockBasedCompensationSummaryofRSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0717cc59-b795-4059-bfc1-dc1e9f106b25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e1b00b-e089-4a32-989c-210e337fc787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0717cc59-b795-4059-bfc1-dc1e9f106b25" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e1b00b-e089-4a32-989c-210e337fc787" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_58fe114a-3c7c-4373-96a9-8eff1a7d59a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e1b00b-e089-4a32-989c-210e337fc787" xlink:to="loc_us-gaap_AwardTypeAxis_58fe114a-3c7c-4373-96a9-8eff1a7d59a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58fe114a-3c7c-4373-96a9-8eff1a7d59a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_58fe114a-3c7c-4373-96a9-8eff1a7d59a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_58fe114a-3c7c-4373-96a9-8eff1a7d59a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a20de75-f02a-4c29-b2a7-117ac180993e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_58fe114a-3c7c-4373-96a9-8eff1a7d59a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a20de75-f02a-4c29-b2a7-117ac180993e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_547350fd-658c-4e43-8433-5fd98c8cd10c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a20de75-f02a-4c29-b2a7-117ac180993e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_547350fd-658c-4e43-8433-5fd98c8cd10c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_836026bd-c714-48b5-a06d-064b86ff5807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0717cc59-b795-4059-bfc1-dc1e9f106b25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_836026bd-c714-48b5-a06d-064b86ff5807" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_90542aaf-d979-4dd0-95d4-03e695708dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_836026bd-c714-48b5-a06d-064b86ff5807" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_90542aaf-d979-4dd0-95d4-03e695708dec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3f6a78a2-0a2e-4b02-9e1c-75c6ec9eee4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_836026bd-c714-48b5-a06d-064b86ff5807" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3f6a78a2-0a2e-4b02-9e1c-75c6ec9eee4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c8f3804a-4f52-49b9-a13a-2f40213d017a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_836026bd-c714-48b5-a06d-064b86ff5807" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c8f3804a-4f52-49b9-a13a-2f40213d017a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_68b87a52-8754-407b-baa4-8614e9d92894" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_836026bd-c714-48b5-a06d-064b86ff5807" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_68b87a52-8754-407b-baa4-8614e9d92894" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_adad7290-88c9-4f24-b3eb-59bf4d4b780f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a307bc5a-239f-4641-9d29-1f702b0d63b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0717cc59-b795-4059-bfc1-dc1e9f106b25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a307bc5a-239f-4641-9d29-1f702b0d63b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3562211-7760-4eb0-82e0-d35946a68b42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a307bc5a-239f-4641-9d29-1f702b0d63b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3562211-7760-4eb0-82e0-d35946a68b42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_db93188d-900a-4fdc-82fe-170ec22594af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a307bc5a-239f-4641-9d29-1f702b0d63b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_db93188d-900a-4fdc-82fe-170ec22594af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9f52727a-f2e0-4447-9b85-d10e8238e5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a307bc5a-239f-4641-9d29-1f702b0d63b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9f52727a-f2e0-4447-9b85-d10e8238e5cc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_71465362-a19e-47ab-9f9c-aa12706889a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a307bc5a-239f-4641-9d29-1f702b0d63b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_71465362-a19e-47ab-9f9c-aa12706889a9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_05ac9a85-029b-44db-83a8-f54dbe739767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5bf6d2cd-c69e-45ed-9dc8-a21cc646da8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cc985816-5abb-45e2-95f6-0490cf9beec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5bf6d2cd-c69e-45ed-9dc8-a21cc646da8d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cc985816-5abb-45e2-95f6-0490cf9beec3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_563290f5-9af1-463f-88b3-b54748c0eebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cc985816-5abb-45e2-95f6-0490cf9beec3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_563290f5-9af1-463f-88b3-b54748c0eebc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_563290f5-9af1-463f-88b3-b54748c0eebc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_563290f5-9af1-463f-88b3-b54748c0eebc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_563290f5-9af1-463f-88b3-b54748c0eebc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_edae9609-ee0e-4185-9741-f328e9288754" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_563290f5-9af1-463f-88b3-b54748c0eebc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_edae9609-ee0e-4185-9741-f328e9288754" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_902effdf-af3b-49b1-9f4b-d974eb0ef22a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_edae9609-ee0e-4185-9741-f328e9288754" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_902effdf-af3b-49b1-9f4b-d974eb0ef22a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_480a8d9c-135e-45bb-848c-51ae47f9f6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cc985816-5abb-45e2-95f6-0490cf9beec3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_480a8d9c-135e-45bb-848c-51ae47f9f6e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_480a8d9c-135e-45bb-848c-51ae47f9f6e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_480a8d9c-135e-45bb-848c-51ae47f9f6e7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_480a8d9c-135e-45bb-848c-51ae47f9f6e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f37efe14-e074-4ff8-9060-07c5b570f3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_480a8d9c-135e-45bb-848c-51ae47f9f6e7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f37efe14-e074-4ff8-9060-07c5b570f3e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9229791e-fa79-4e9c-8b35-493d4caf382f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f37efe14-e074-4ff8-9060-07c5b570f3e4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9229791e-fa79-4e9c-8b35-493d4caf382f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7fd053bf-ef2f-45d4-9d31-1390d3d5d75b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f37efe14-e074-4ff8-9060-07c5b570f3e4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7fd053bf-ef2f-45d4-9d31-1390d3d5d75b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ddda589c-8231-4002-9047-f1d8a720ebb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f37efe14-e074-4ff8-9060-07c5b570f3e4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ddda589c-8231-4002-9047-f1d8a720ebb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a47f8e76-b6a4-4b83-b58b-686fc7becc72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cc985816-5abb-45e2-95f6-0490cf9beec3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a47f8e76-b6a4-4b83-b58b-686fc7becc72" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a47f8e76-b6a4-4b83-b58b-686fc7becc72_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a47f8e76-b6a4-4b83-b58b-686fc7becc72" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a47f8e76-b6a4-4b83-b58b-686fc7becc72_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a47f8e76-b6a4-4b83-b58b-686fc7becc72" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_60bcbeaa-cf0f-4181-a9dc-a97468996343" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_60bcbeaa-cf0f-4181-a9dc-a97468996343" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_cb473c0f-bdab-4161-9c0d-2b7acc3d303b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_cb473c0f-bdab-4161-9c0d-2b7acc3d303b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_89b4ac52-6a31-4a4c-9267-bba5429e6a00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:to="loc_us-gaap_MunicipalBondsMember_89b4ac52-6a31-4a4c-9267-bba5429e6a00" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_029a908d-a472-48e3-8e4b-3d5bbc46f858" xlink:href="arwr-20240331.xsd#arwr_CommercialNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:to="loc_arwr_CommercialNotesMember_029a908d-a472-48e3-8e4b-3d5bbc46f858" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_daf4fa46-e0ff-40a2-afc5-b9e7ab419d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_daf4fa46-e0ff-40a2-afc5-b9e7ab419d1c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_73225542-88d3-4d51-a8e4-9edafdfa36a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cc985816-5abb-45e2-95f6-0490cf9beec3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_73225542-88d3-4d51-a8e4-9edafdfa36a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_73225542-88d3-4d51-a8e4-9edafdfa36a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_73225542-88d3-4d51-a8e4-9edafdfa36a1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_73225542-88d3-4d51-a8e4-9edafdfa36a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13fc9803-98c2-4e49-8a58-9499a5d1bce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_73225542-88d3-4d51-a8e4-9edafdfa36a1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13fc9803-98c2-4e49-8a58-9499a5d1bce6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2358e1fc-bbf9-4cdc-9d6a-778db3db3183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13fc9803-98c2-4e49-8a58-9499a5d1bce6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2358e1fc-bbf9-4cdc-9d6a-778db3db3183" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a40ebf9e-89f5-48cb-9536-46a7ddcf2127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13fc9803-98c2-4e49-8a58-9499a5d1bce6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a40ebf9e-89f5-48cb-9536-46a7ddcf2127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_b4c45050-f652-4725-a6d4-1cbbd5f97bec" xlink:href="arwr-20240331.xsd#arwr_CommercialNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13fc9803-98c2-4e49-8a58-9499a5d1bce6" xlink:to="loc_arwr_CommercialNotesMember_b4c45050-f652-4725-a6d4-1cbbd5f97bec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba0c8766-56b0-490e-b7cc-9c0550784aed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5bf6d2cd-c69e-45ed-9dc8-a21cc646da8d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba0c8766-56b0-490e-b7cc-9c0550784aed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_905b3220-8b69-4e6e-8400-bd318e7d74be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5bf6d2cd-c69e-45ed-9dc8-a21cc646da8d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_905b3220-8b69-4e6e-8400-bd318e7d74be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f3e5531f-2ba9-4c94-94fe-eed8e6474984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5bf6d2cd-c69e-45ed-9dc8-a21cc646da8d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f3e5531f-2ba9-4c94-94fe-eed8e6474984" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21e05616-2faf-45ce-b306-fe27b95349d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21e05616-2faf-45ce-b306-fe27b95349d4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bd9800d6-2ce5-4989-b63b-6c0e55a9265c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21e05616-2faf-45ce-b306-fe27b95349d4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bd9800d6-2ce5-4989-b63b-6c0e55a9265c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd9800d6-2ce5-4989-b63b-6c0e55a9265c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bd9800d6-2ce5-4989-b63b-6c0e55a9265c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd9800d6-2ce5-4989-b63b-6c0e55a9265c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b0936ef-ba9f-4164-aa29-1a0e9fc96616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bd9800d6-2ce5-4989-b63b-6c0e55a9265c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b0936ef-ba9f-4164-aa29-1a0e9fc96616" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_53b6adb2-1ce4-41e9-a547-f314c79bb64b" xlink:href="arwr-20240331.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b0936ef-ba9f-4164-aa29-1a0e9fc96616" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_53b6adb2-1ce4-41e9-a547-f314c79bb64b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b495963-859d-41dd-8241-2f0be72606d6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21e05616-2faf-45ce-b306-fe27b95349d4" xlink:to="loc_srt_RangeAxis_7b495963-859d-41dd-8241-2f0be72606d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7b495963-859d-41dd-8241-2f0be72606d6_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7b495963-859d-41dd-8241-2f0be72606d6" xlink:to="loc_srt_RangeMember_7b495963-859d-41dd-8241-2f0be72606d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52c9f2e0-e9df-4c38-817e-52b85dbf5c6f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7b495963-859d-41dd-8241-2f0be72606d6" xlink:to="loc_srt_RangeMember_52c9f2e0-e9df-4c38-817e-52b85dbf5c6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_42e651f1-efe3-4638-a0be-b7f1151a3d7a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_52c9f2e0-e9df-4c38-817e-52b85dbf5c6f" xlink:to="loc_srt_MaximumMember_42e651f1-efe3-4638-a0be-b7f1151a3d7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5046eaae-a374-41af-a537-77c36b38519b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21e05616-2faf-45ce-b306-fe27b95349d4" xlink:to="loc_srt_CounterpartyNameAxis_5046eaae-a374-41af-a537-77c36b38519b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5046eaae-a374-41af-a537-77c36b38519b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5046eaae-a374-41af-a537-77c36b38519b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5046eaae-a374-41af-a537-77c36b38519b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d633576-9ad0-4fdb-9f73-e04a1464da2c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5046eaae-a374-41af-a537-77c36b38519b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d633576-9ad0-4fdb-9f73-e04a1464da2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_e6459fb8-e59a-4bbe-bdf0-2f96d89ec67a" xlink:href="arwr-20240331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d633576-9ad0-4fdb-9f73-e04a1464da2c" xlink:to="loc_arwr_AmgenIncorporatedMember_e6459fb8-e59a-4bbe-bdf0-2f96d89ec67a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_83443037-eb14-4ab0-af59-2c8b77a36984" xlink:href="arwr-20240331.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_InitialTransactionPrice_83443037-eb14-4ab0-af59-2c8b77a36984" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_30d4d639-e27b-43f7-adc6-078169f28b0f" xlink:href="arwr-20240331.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_30d4d639-e27b-43f7-adc6-078169f28b0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_5722ed72-7738-4ace-ab6f-723f0faabf8f" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_MilestonePaymentReceivable_5722ed72-7738-4ace-ab6f-723f0faabf8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_50c394c0-ba36-4529-8f02-dbe9df1e8677" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_50c394c0-ba36-4529-8f02-dbe9df1e8677" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_e488362a-614f-481c-81e7-8bd2928b74a6" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_e488362a-614f-481c-81e7-8bd2928b74a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_c79571f4-a3a1-412c-a2aa-cc334d70d8ed" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_c79571f4-a3a1-412c-a2aa-cc334d70d8ed" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_c3768dbf-14a0-4278-8900-cc4c4a7162c6" xlink:href="arwr-20240331.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_RoyaltyPaymentThreshold_c3768dbf-14a0-4278-8900-cc4c4a7162c6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyalties_7a7ec931-c147-4254-81db-23e0a1ffeaff" xlink:href="arwr-20240331.xsd#arwr_LiabilitySaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyalties_7a7ec931-c147-4254-81db-23e0a1ffeaff" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_0ecd3b15-f15f-4e1f-9f6f-46e64d9fc29e" xlink:href="arwr-20240331.xsd#arwr_LiabilitySaleOfFutureRoyaltiesInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_0ecd3b15-f15f-4e1f-9f6f-46e64d9fc29e" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#NetLossPerShareAntidulitiveDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b9ff47c-31bd-419a-a43f-1ec8c8304cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5f93094-0f5a-4307-8569-61fd9175d855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b9ff47c-31bd-419a-a43f-1ec8c8304cf6" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5f93094-0f5a-4307-8569-61fd9175d855" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5262261b-81a3-4776-9aa1-a21bf2a22249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5f93094-0f5a-4307-8569-61fd9175d855" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5262261b-81a3-4776-9aa1-a21bf2a22249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5262261b-81a3-4776-9aa1-a21bf2a22249_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5262261b-81a3-4776-9aa1-a21bf2a22249" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5262261b-81a3-4776-9aa1-a21bf2a22249_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_39fd4f1f-d7cf-44e5-85ac-a906c7aee155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5262261b-81a3-4776-9aa1-a21bf2a22249" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_39fd4f1f-d7cf-44e5-85ac-a906c7aee155" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_851f8656-ece3-4c6f-bd75-8abc676d1b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_39fd4f1f-d7cf-44e5-85ac-a906c7aee155" xlink:to="loc_us-gaap_EmployeeStockOptionMember_851f8656-ece3-4c6f-bd75-8abc676d1b99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ffb70541-191b-4f50-b2b9-d55bc5306bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_39fd4f1f-d7cf-44e5-85ac-a906c7aee155" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ffb70541-191b-4f50-b2b9-d55bc5306bb5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c3ca2a52-f6aa-45b6-ab11-c7b5ec31f4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b9ff47c-31bd-419a-a43f-1ec8c8304cf6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c3ca2a52-f6aa-45b6-ab11-c7b5ec31f4d9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TradingArrangmentsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch12PlanMember_b1609143-b6a0-4184-9f00-bbe5d5540e03" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch12PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_KenMyszkowskiMarch12PlanMember_b1609143-b6a0-4184-9f00-bbe5d5540e03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch28Plan1Member_446f8f19-4781-4e5f-9f2e-00b20b3dbaaf" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch28Plan1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_KenMyszkowskiMarch28Plan1Member_446f8f19-4781-4e5f-9f2e-00b20b3dbaaf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch28Plan2Member_7fc1e9f1-9c17-4fc3-b12f-f54aa92cb382" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch28Plan2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_KenMyszkowskiMarch28Plan2Member_7fc1e9f1-9c17-4fc3-b12f-f54aa92cb382" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch28Plan3Member_dd000a58-97d1-428b-80f0-b193bd86826f" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch28Plan3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_KenMyszkowskiMarch28Plan3Member_dd000a58-97d1-428b-80f0-b193bd86826f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch28Plan4Member_6adf6d52-a6f7-4358-93ee-21887e10f821" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch28Plan4Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_KenMyszkowskiMarch28Plan4Member_6adf6d52-a6f7-4358-93ee-21887e10f821" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonMember_e969a59a-fe6a-413b-91e0-9e50e80e5863" xlink:href="arwr-20240331.xsd#arwr_JamesHamiltonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_JamesHamiltonMember_e969a59a-fe6a-413b-91e0-9e50e80e5863" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMember_85c3504b-52e9-4134-9886-004628fb1125" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_KenMyszkowskiMember_85c3504b-52e9-4134-9886-004628fb1125" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienMember_7cd2b535-36d9-48ed-8d6e-b9517528d06b" xlink:href="arwr-20240331.xsd#arwr_PatrickOBrienMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_PatrickOBrienMember_7cd2b535-36d9-48ed-8d6e-b9517528d06b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_WilliamWaddillMember_5d46228c-d0a4-41b4-9dd6-c7101cec7b65" xlink:href="arwr-20240331.xsd#arwr_WilliamWaddillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_WilliamWaddillMember_5d46228c-d0a4-41b4-9dd6-c7101cec7b65" xlink:type="arc" order="5"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>arwr-20240331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:ac9daf9b-fe65-44cf-acd3-206171097241,g:5004fc8e-4246-4d68-a802-ef4d83a3dac9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_eb9f6dff-cf27-4766-b3d2-cc9a562a9e4f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_6634961d-c072-4ab1-8cfa-14979c3a0f0c_terseLabel_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_bfd153d4-3b06-4c39-8658-499e81eb5898_periodStartLabel_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Carrying value as of September 30, 2023</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_a3cef6de-10e3-409f-a104-f2bbe2630d80_periodEndLabel_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Carrying value as of March 31, 2024</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_label_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalties, Liability, Noncurrent</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_documentation_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalties, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent" xlink:href="arwr-20240331.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltiesLiabilityNoncurrent" xlink:to="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_ca00e31b-512c-4d25-b5c1-3a6b96a367ca_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office space leases (in sq ft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_27452275-b882-4e50-ba1b-6d071e59d6d4_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss attributable to noncontrolling interest, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_8e566ec8-4a32-4a5b-aabf-0d997b322b26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_4395cbed-3201-4670-aa80-923d94e9bca4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_ea931b7e-04a5-48c8-8d2e-0c63ac0ccc10_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued expense</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2f0082f5-994c-4227-8620-5b09f2d4d619_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WI_e70a5919-fdad-4119-b74e-3a4d7414bc10_terseLabel_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Wisconsin</link:label>
    <link:label id="lab_stpr_WI_label_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">WISCONSIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WI" xlink:to="lab_stpr_WI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_8a4c9a21-5335-4438-b923-6bad4cf0c348_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fb46c975-f272-4f55-a763-ea26a0057dd6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ea517d93-2276-4a56-a28a-353b87af5758_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment award (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d1c90a26-7de4-4f19-b3dc-01abf43e0abb_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f55d81b5-107c-4d0e-903f-d8b89da5bca7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_3699718a-aac7-48e3-8f33-3f6685cb6ede_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization (accretion) of note premiums/discounts</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_646b8e1a-1b8e-4b8c-8185-440ff56b2ce4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_edefda75-cb13-45c6-b931-d9d2c8626ab5_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a12e293a-57e9-4cb4-b291-2ca9f1f8d2de_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_f253c69f-78a4-4c39-91b1-034aa836275f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_94484361-8a6a-4ddf-8e22-6156ddd19c26_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_52e16c7e-0bdf-4203-b181-b24872298346_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_8e428328-bd27-4cf5-89dc-09104596f3c9_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_8c6487f3-4333-4d54-8a3f-3d30b0347333_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other expense</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent_cdc9bfdf-df21-41ef-a821-44764443dc6c_terseLabel_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued R&amp;D expenses</link:label>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="arwr-20240331.xsd#arwr_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_arwr_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_8d97dd8b-59bb-4553-b53f-8127b7927529_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_21101d3f-8b92-4db7-aa7a-4652efb94635_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options Outstanding, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_0534b881-c697-4984-a910-cca3dee9b5ee_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_338a297a-f7d5-4175-8d48-aa8cbfef17ba_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_eb51d15c-cc5e-4cde-9c59-dcf6cefe6d7b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_d49c45e8-79ee-4b9a-acff-dba94bd76631_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the issuance of common stock, net of offering costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_8c8eaab3-5f47-489b-ba01-03cb35833cee_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_4b047489-c7db-4ada-bbf9-1b2fd0a5bfe8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9fd17c03-2d0c-4d0e-a7f0-40c96990b41c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_5e69c413-98f7-4197-9c7e-70187f042509_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_09a4d8e9-aa75-46af-9c9d-a1c48487ce0e_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_20b46f1a-6d26-4dd1-891d-31adc642ace8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_e67828a8-9780-4571-9f3b-3f588a929c67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0711c196-bc18-4e03-875b-66d7b6ee7606_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_204e6635-13b7-41f3-ac95-e2d36986c45b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_1091bf12-b22f-44b4-add2-92d3d430c1da_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted net (loss) gain per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_64a394fe-405f-45d1-949d-dd285a648c52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_38a9293d-a06d-472d-a142-9eda27ce1dd6_terseLabel_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_label_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Received As Due Under Collaboration Agreement</link:label>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash received as due under collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:href="arwr-20240331.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:to="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_0322dd15-e645-45ee-8109-3ad0a889968b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a39a7795-85d8-4400-b30e-d8d4826047ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9b61717d-ede3-47e8-9d53-954202766c79_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_05797dbf-9b70-4821-9131-c4ee45521686_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_4267f9ef-d85c-4460-b0a7-539f4beb61e9_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d98026e2-78f8-423c-b9cd-51c7a744d533_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_406a1aa9-629d-4461-8a61-c808e3c56a92_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_8b6534a1-263d-4003-941a-ebd02a83991b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1e7e0a2f-8831-4907-af5d-8a4322b7fa51_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_546a06ba-0c40-4dd1-b57e-c2044dd73097_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1db005b3-e4a2-4636-b4fb-ba7606447bd9_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_538be915-02c3-4d81-9233-82d12e91afef_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_873e76c9-e354-446e-885f-b42542924930_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_125f37cf-b9fd-46b4-b74c-79a958dd82b2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_c6ecbb14-7775-4f2e-8721-8ad2c2d671be_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_1b1ee458-804c-4016-81f8-f3230e04ebd6_terseLabel_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock shares value reserved for future issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_label_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Capital Shares Value Reserved For Future Issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_documentation_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common stock, capital shares value reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:href="arwr-20240331.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:to="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_99c52a9f-fed0-41a3-aff0-2cf16f45e550_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8b0a9282-0837-4b8e-8e01-04abef523c2f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_d8abf326-bfec-42cf-80c1-b09075f1408a_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_df395203-6ff7-4797-bb31-76af7791a222_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Current investments, Available-for-sale, Adjusted Basis</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_0a1235bd-0619-498c-9f86-6c054c9e940b_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_3b345937-c156-41ec-b51d-7eaca79664ef_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_aeaf5826-90df-4906-b72f-a60cd44714c7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities included in deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_352cb010-a9a6-4f2c-a92a-5f74ba6a0d39_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c95b465a-a00d-4cb9-bdae-0ef8cc7012c2_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_823ee9bb-10a6-4be9-b3a4-1bf1bd388f76_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_daeaee13-238f-4a0d-bc94-832a52ba00c3_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2013 Incentive Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousands Thirteen Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousands thirteen incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:href="arwr-20240331.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_627f5d06-0104-4283-a83b-43161e2d3cb6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_043be586-89b7-4237-94bc-a66ab1cff5d7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d9720d85-3355-448b-88b0-73fd1c641545_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_a507c5b2-59d7-4e6b-a92b-789c003f4679_terseLabel_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-related milestone payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_label_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Related Milestone Payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_documentation_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-related milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments" xlink:href="arwr-20240331.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SalesRelatedMilestonePayments" xlink:to="lab_arwr_SalesRelatedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_a5b5ac1a-b507-4497-9f38-0aa80ad20479_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_1906a4ff-96d8-4eb1-8e24-791e13ba8c7f_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_03599ffb-8fbe-4f34-a897-fde74e47b0f1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_92a14cea-f98d-484d-8290-58c6dbfe130e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8699939b-ee05-4fcb-a91d-316a84e01e7a_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_709bf58e-29b8-424c-9a13-32dff3cbf1de_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_878baf08-d409-4fea-bb38-4fa6aa75fd6e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, share reserve for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_59869c61-ba79-47d7-b542-a7bbf022bb48_negatedTerseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Current investments, Available-for-sale, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:href="arwr-20240331.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:to="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_ef40e3f5-26ed-4317-9654-f97543194fad_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_aa3aa997-1796-47b7-b0e5-2d747f7cf958_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8534d8c2-d94f-455c-98fe-dbee3e9eae71_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_36cb437f-77ef-40be-86d3-272b17407c40_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_ec14e27d-e265-4b22-8b77-a33c13e581f9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c7717469-feb5-414c-b692-59cedb66a6c6_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_ade45198-e4fb-4215-99db-e195decc1cce_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_c79a134e-d23c-4011-82cb-a1ef1d739498_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of distinct performance obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_label_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Distinct Performance Obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of distinct performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:href="arwr-20240331.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:to="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_b7de387d-7e86-4c18-b101-997be14325d7_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of commission to sales agent</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_label_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_documentation_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of commission on aggregate gross proceeds from sale of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:href="arwr-20240331.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:to="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_5e529694-4fa3-4208-a805-9ebbffb9e538_terseLabel_en-US" xlink:label="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional tenant improvement allowance interest per annum</link:label>
    <link:label id="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_label_en-US" xlink:label="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Tenant Improvement Allowance, Interest Per Annum</link:label>
    <link:label id="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_documentation_en-US" xlink:label="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Tenant Improvement Allowance, Interest Per Annum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" xlink:href="arwr-20240331.xsd#arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" xlink:to="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialNotesMember_78dccd89-b334-47b6-9807-110a2664549a_terseLabel_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial notes</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_label_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Notes [Member]</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_documentation_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember" xlink:href="arwr-20240331.xsd#arwr_CommercialNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialNotesMember" xlink:to="lab_arwr_CommercialNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_bbb6134e-b71d-4292-9201-2c05c6febe53_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_9fc880c2-7d05-4608-bfab-14e33baf7e0b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_1ae4b837-f09d-4102-bb69-6fe889cf9848_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_7d298953-5b05-4457-baa0-176233ab4bbf_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_d8341fc3-c364-406d-b290-20327daa4b14_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ProceedsFromSaleOfFutureRoyalties_c5eed074-65bf-4ad2-9395-60770663e141_terseLabel_en-US" xlink:label="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of future royalties</link:label>
    <link:label id="lab_arwr_ProceedsFromSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_ProceedsFromSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:href="arwr-20240331.xsd#arwr_ProceedsFromSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:to="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_14b1a360-62b3-4065-9274-a8ba8fb2712e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_99ce9889-88da-4571-961f-2dcec6d8b8fd_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1151a37d-f040-4fd6-8c03-3f01e35cdfd0_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_43b8e12c-2eb6-4aef-ae6e-9550cd2c63af_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Facility in San Diego</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Facility In San Diego [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Facility in San Diego.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:href="arwr-20240331.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:to="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_31c75cec-53e5-4a02-a400-e2222e0e27a2_terseLabel_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20240331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_b14f485e-325e-42e9-93d2-e65f6088da63_terseLabel_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued R&amp;D expenses; co-development</link:label>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Co-Development Expense, Current</link:label>
    <link:label id="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Co-Development Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:href="arwr-20240331.xsd#arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:to="lab_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1f0f4a52-25a6-40c9-a352-cf468169e6bd_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8e730405-01db-4e6d-a8bc-90e7be0b9a17_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_c566b4c7-7487-4108-acca-3ee255e53f0c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_4fd9256e-fad5-4554-8914-58e0d8934b33_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_34fc11e9-9b3a-4295-b980-22ccd5fc33a6_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Lease Assets and Liabilities and Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_e97becc7-5151-41c4-a163-6cb0d52b7b68_terseLabel_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Short-term and Long-term Investments and Marketable Securities</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_label_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held To Maturity Securities And Marketable Securities Table [Table Text Block]</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_documentation_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:href="arwr-20240331.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:to="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_f4cb3666-0333-4a9b-b9f4-83acd8251127_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_69d563ea-cee7-42d8-9dfa-ce41c772b100_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalTenantImprovementAllowanceLiability_802ae54f-6e13-4f58-b81c-d9784d381061_terseLabel_en-US" xlink:label="lab_arwr_AdditionalTenantImprovementAllowanceLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional tenant improvement allowance liability</link:label>
    <link:label id="lab_arwr_AdditionalTenantImprovementAllowanceLiability_label_en-US" xlink:label="lab_arwr_AdditionalTenantImprovementAllowanceLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Tenant Improvement Allowance Liability</link:label>
    <link:label id="lab_arwr_AdditionalTenantImprovementAllowanceLiability_documentation_en-US" xlink:label="lab_arwr_AdditionalTenantImprovementAllowanceLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional Tenant Improvement Allowance Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalTenantImprovementAllowanceLiability" xlink:href="arwr-20240331.xsd#arwr_AdditionalTenantImprovementAllowanceLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalTenantImprovementAllowanceLiability" xlink:to="lab_arwr_AdditionalTenantImprovementAllowanceLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_215d0bf6-9085-4aa3-8ff6-76ac5a0b0575_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f83edbc8-8f9a-480b-8d10-e4ffaf829ba4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a62e4856-6e92-41d0-9777-3e0489ec8225_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_ea097ed6-2e2d-42a4-8fd7-f97d0fe217aa_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_ebf93618-4f4c-4b6e-bada-1beae48cfad6_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_1de90389-e9cf-496c-980a-03395f849a07_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a7a99910-c69d-4266-a7cc-df6cba3afeeb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_487d5fa5-86d0-4d00-a8b3-216f7b36d1e9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_cc4c5eda-9127-45a1-9c1c-d9f2407b4d09_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures included in accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_0c702553-0000-4471-835a-16a3ed8c5802_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_b5d2e70d-310e-49f8-8cb0-dd1a707220a1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_7e4838cf-9b85-4ef3-bcdd-886641f24a44_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_154909d3-01b3-4a75-a6a9-cd4962b01580_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c43f7ad4-f41c-4b8c-a7c7-5520a3fbc3bf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_8d816ea0-8a32-46fd-b5ae-1ce1c0dfa14d_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for amended operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b4470efb-e817-49d9-a041-5d65c5dd0f7f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 (remainder)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_866f59f1-4427-493d-be91-526376bcf136_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_6ad0defc-e39a-4d0e-a3f8-6bacc248c6b3_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_3f64c87d-9678-4a7f-951c-4acdb645bb19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_89974a57-baab-417e-be14-abc7bed6986c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Share Activity Related to RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f31daecb-e2af-4b11-86b5-261ff190a86e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_3159147f-30bf-44b8-8a89-f3143bb658ab_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_b591969c-3588-432a-8018-604db7d44736_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_8d3bc69b-f21b-4c03-8311-7a5abab5a28b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_47287878-e5aa-4a9b-91e9-e8b2c4e3e440_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_041c9da4-b2c4-4e5f-b609-88745a29c107_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_ac8227a7-76f5-42b1-85de-f514f397c83a_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_dd52ad3a-b4b6-48b6-9b7e-7fe7c814dab8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_5644f821-6140-424a-a3c7-a72ee4e0e2e8_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_95419916-ad5f-411f-90bf-69e7eb04cc3c_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Company's Current Pipeline</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_label_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Current Products [Table Text Block]</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_documentation_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Current Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:href="arwr-20240331.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:to="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_19a55916-f9f0-4062-aa62-94c8a420ab5c_terseLabel_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_label_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceuticals Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen Pharmaceuticals, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:href="arwr-20240331.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:to="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3776b9aa-4e67-4817-90ce-c2762b8fba18_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_76c57a8b-ba1f-4438-a9c4-7b541acbb9c6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Shares of Common Stock and Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_936811e2-28a6-4cd1-b91b-5f415df67ba7_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7b332289-a048-491d-b60c-dd82a1b32229_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">BEGINNING OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1530834a-19f3-4a49-95ee-f62dfcc8005b_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_cfecd323-476b-4d7a-9b90-f393cce5f415_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InducementAwardsMember_22878fe1-854d-40ad-a9b3-bfd57de4c9de_terseLabel_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement Awards</link:label>
    <link:label id="lab_arwr_InducementAwardsMember_label_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Awards [Member]</link:label>
    <link:label id="lab_arwr_InducementAwardsMember_documentation_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inducement Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember" xlink:href="arwr-20240331.xsd#arwr_InducementAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InducementAwardsMember" xlink:to="lab_arwr_InducementAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_bc9ab7d4-9258-449e-b5d8-89631cef7dd5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchEquipmentMember_1f851ff9-e5a9-4953-a1cb-f30881750407_terseLabel_en-US" xlink:label="lab_arwr_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_arwr_ResearchEquipmentMember_label_en-US" xlink:label="lab_arwr_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Equipment [Member]</link:label>
    <link:label id="lab_arwr_ResearchEquipmentMember_documentation_en-US" xlink:label="lab_arwr_ResearchEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember" xlink:href="arwr-20240331.xsd#arwr_ResearchEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchEquipmentMember" xlink:to="lab_arwr_ResearchEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_8cac3d8e-59e1-47a6-a252-926473dc6ca8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock offering price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_4465bb97-2aa9-4ba9-9b29-92f277eff5e0_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InitialTransactionPrice_89931f3e-990f-4451-94e0-02c6dd2dc32d_terseLabel_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial transaction price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_label_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Transaction Price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_documentation_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Initial transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice" xlink:href="arwr-20240331.xsd#arwr_InitialTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InitialTransactionPrice" xlink:to="lab_arwr_InitialTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_79d948fc-5ae2-4d62-98d5-de8ac049ecfa_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_52c9f7ce-fd16-496d-b8d3-502d96d1dbc0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_897e4f3b-05b5-4b33-9b81-b723e061deb1_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_3ea2b561-f136-4c21-8520-8ca828bfd55b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_2aa7a287-cd50-4804-8ecf-83f60b81e285_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_4c86b374-6f9e-4bbf-8085-690ef3819597_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_87ec5e09-0410-4062-aaae-f231858ca009_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_8b3d2b40-54ed-48f9-80b9-bfa95f87c0b9_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_5e4de9ba-c1e3-4ec8-8c97-bcc8a0a7ed2b_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d1a69e45-abd9-4acf-a15b-bbd0e3cc868d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_0744919a-cf4e-4c2d-a871-44e102fc8462_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Liability Related to the Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_label_en-US" xlink:label="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Liability Related To The Sale Of Future Royalties [Table Text Block]</link:label>
    <link:label id="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_documentation_en-US" xlink:label="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:href="arwr-20240331.xsd#arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:to="lab_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_95ba6a5e-94d7-4311-8dcb-2e5bebd4682e_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4bb23fa6-bc31-4509-a3b7-d8530cb2c42a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_12835816-ec4a-44ab-96bb-cc0b913b0a19_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1436c63f-9d7d-4805-9324-6790661d35aa_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_0f738069-42b5-4cb4-849c-023b69631bc6_terseLabel_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial milestone payments at first commercial sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_label_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Milestone Payments At First Commercial Sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_documentation_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial milestone payments at first commercial sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:href="arwr-20240331.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:to="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_aae6fd6b-2a43-42b0-a2fd-a88d22c4dce6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period to recognize pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_6bf2d854-6e12-46c5-b1bf-3170318036d8_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_05b9d704-c197-43f2-87b5-461d8bdac202_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_233133a8-c112-43d1-b5a2-66914a60c243_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_079a30ce-c485-4569-99f7-da8a07ee9875_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_534df052-3cf8-44c5-9222-c5695a02471d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_8f8fcdf5-31f5-4995-a688-ae3590453bdc_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_e25cf7c8-e5eb-476f-8429-13893da3b584_terseLabel_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Remaining Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20240331.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_89517e3a-98b9-42fe-aefa-5bf4c4c00d00_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021 Incentive Plan</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Twenty One Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand twenty one incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:href="arwr-20240331.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:to="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_a70de6f4-e1ab-42c2-9eef-a1ac6af0f7a2_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_c3ea1321-7d5f-49e3-a6e9-2e3babce1182_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d22ce7ed-cac7-4609-9917-436580c7164a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_KenMyszkowskiMarch28Plan3Member_label_en-US" xlink:label="lab_arwr_KenMyszkowskiMarch28Plan3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ken Myszkowski March 28 Plan 3 [Member]</link:label>
    <link:label id="lab_arwr_KenMyszkowskiMarch28Plan3Member_documentation_en-US" xlink:label="lab_arwr_KenMyszkowskiMarch28Plan3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ken Myszkowski March 28 Plan 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch28Plan3Member" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch28Plan3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_KenMyszkowskiMarch28Plan3Member" xlink:to="lab_arwr_KenMyszkowskiMarch28Plan3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GSKLicenseAgreementMember_3de8750e-d1aa-43c0-b953-f19564f0aaed_terseLabel_en-US" xlink:label="lab_arwr_GSKLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK License Agreement</link:label>
    <link:label id="lab_arwr_GSKLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_GSKLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK License Agreement [Member]</link:label>
    <link:label id="lab_arwr_GSKLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_GSKLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GSK License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKLicenseAgreementMember" xlink:href="arwr-20240331.xsd#arwr_GSKLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GSKLicenseAgreementMember" xlink:to="lab_arwr_GSKLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0e1fa032-5b76-4189-8891-2a9ec852c577_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_e0fab95c-aadf-4856-9870-94223906a4bb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_ff25e249-256e-4c31-b978-dca66cc2bb79_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_03caef8c-ccb5-41dd-82ed-ec0c89936318_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued, net of offering costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a53db390-d02e-485b-8be8-0c1d30c6823e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_dcd7b23a-4e68-4bcc-bc66-c7c866e3cd39_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_KenMyszkowskiMarch28Plan4Member_label_en-US" xlink:label="lab_arwr_KenMyszkowskiMarch28Plan4Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ken Myszkowski March 28 Plan 4 [Member]</link:label>
    <link:label id="lab_arwr_KenMyszkowskiMarch28Plan4Member_documentation_en-US" xlink:label="lab_arwr_KenMyszkowskiMarch28Plan4Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ken Myszkowski March 28 Plan 4</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch28Plan4Member" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch28Plan4Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_KenMyszkowskiMarch28Plan4Member" xlink:to="lab_arwr_KenMyszkowskiMarch28Plan4Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b87c1910-fcfa-4ae4-b635-0f08b027d72d_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_bc7442dc-c070-4a74-afd8-fe3f82e43138_terseLabel_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_label_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Visirna Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember" xlink:href="arwr-20240331.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VisirnaTherapeuticsIncMember" xlink:to="lab_arwr_VisirnaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentEarned_e5ffe898-163a-41f4-a625-690c0b045fa2_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_label_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Earned</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payment earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentEarned" xlink:to="lab_arwr_MilestonePaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d393fb3e-b0f1-4d6f-b6f6-56ae64aef77d_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_234c5cbf-47ca-4ea9-91af-7e77f2745f75_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_04088ce8-4905-4767-8108-098ba44c09e0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_bd56da02-3ecb-486f-9341-84ee407112fa_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate_96233c78-4f69-4656-84de-98163922904b_terseLabel_en-US" xlink:label="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital expenditures incurred</link:label>
    <link:label id="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate_label_en-US" xlink:label="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments, Capital Expenditures Incurred To Date</link:label>
    <link:label id="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate_documentation_en-US" xlink:label="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments, Capital Expenditures Incurred To Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:href="arwr-20240331.xsd#arwr_CommitmentsCapitalExpendituresIncurredToDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:to="lab_arwr_CommitmentsCapitalExpendituresIncurredToDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_42c2db5f-4371-4b46-9854-21c403b7c571_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c94325ff-7a38-4aba-9245-d63daab2b53d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_20c61511-ea39-4d7c-902f-e76b1643a1ad_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_2362cacd-3a5e-44ce-a5a4-e5033f7f48c2_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:href="arwr-20240331.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_c36dbedb-546e-4234-95f3-ece4d8e6e198_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_91a7f4f1-197d-4d87-b0d4-da1296ec62a3_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_bb9a4a80-771d-4795-aa39-dd2a19b3dbbc_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_517d05eb-89ac-4d09-9891-3a12c53d6d0e_verboseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OlpasiranAgreementMember_8cc3d708-e0cf-4678-bf0e-5418156c2515_terseLabel_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Olpasiran Agreement</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_label_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Olpasiran Agreement [Member]</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_documentation_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Olpasiran agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember" xlink:href="arwr-20240331.xsd#arwr_OlpasiranAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OlpasiranAgreementMember" xlink:to="lab_arwr_OlpasiranAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_3eac612c-4ca7-4db0-8667-dbb00cdbbc78_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_1d799272-0e71-4d7d-88f5-9c317cd72895_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_05b4a698-046e-4b29-8b02-64d452c70f06_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of noncash investing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_KenMyszkowskiMarch28Plan2Member_label_en-US" xlink:label="lab_arwr_KenMyszkowskiMarch28Plan2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ken Myszkowski March 28 Plan 2 [Member]</link:label>
    <link:label id="lab_arwr_KenMyszkowskiMarch28Plan2Member_documentation_en-US" xlink:label="lab_arwr_KenMyszkowskiMarch28Plan2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ken Myszkowski March 28 Plan 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch28Plan2Member" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch28Plan2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_KenMyszkowskiMarch28Plan2Member" xlink:to="lab_arwr_KenMyszkowskiMarch28Plan2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8c22f843-0515-4174-b32c-ed4f869a35d6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cde0e6f6-9ac4-4f37-91d8-c13cef1a41c8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_357e57a9-d5a1-4024-b313-d23d1209e307_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d69bd565-eae6-48bb-b749-f896a60e28a0_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_bb393d9b-0ea9-48cc-a80d-195e3527c510_terseLabel_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Drug Manufacturing Facility</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_label_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Drug Manufacturing Facility [Member]</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_documentation_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Drug manufacturing facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember" xlink:href="arwr-20240331.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DrugManufacturingFacilityMember" xlink:to="lab_arwr_DrugManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_f039923c-833f-4382-9410-67e4087ae59c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_87ee8c49-8327-4088-bf7e-903e56d32be2_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock - restricted stock units vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_112d83c9-d787-4157-9f29-3d8e927f88f3_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</link:label>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_label_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:href="arwr-20240331.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:to="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_00581b2e-70ba-41df-a45c-aba88325d813_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:href="arwr-20240331.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_771de546-8359-4b3c-92f8-29ad5103d6b3_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_ab7d23e1-17e3-4d7f-ab25-2923faf53fa0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_2d51a698-c85c-4a40-af00-5219c34b4643_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_ac861389-7e9a-4728-a0de-989b4a1948bd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_4f27e27f-be09-4d20-a248-0302c439b4e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_b7373ec6-65d9-40b3-8bb4-5634cad80a0e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_0cbe9002-2381-4e5d-aa13-3a1bab2829c3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_67a38417-b3aa-4094-9843-d2dd1f6468e9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_WilliamWaddillMember_label_en-US" xlink:label="lab_arwr_WilliamWaddillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">William Waddill [Member]</link:label>
    <link:label id="lab_arwr_WilliamWaddillMember_documentation_en-US" xlink:label="lab_arwr_WilliamWaddillMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">William Waddill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_WilliamWaddillMember" xlink:href="arwr-20240331.xsd#arwr_WilliamWaddillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_WilliamWaddillMember" xlink:to="lab_arwr_WilliamWaddillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_7a818f91-faf2-442f-b7ca-f031be398051_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_8b83b66b-4333-46c4-a635-cb2241cc2c1b_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:href="arwr-20240331.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_e6383892-ade8-4522-b552-b7c06f55eb4f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_910187fb-b8e4-44f8-8812-fec9d48e10ce_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in unrealized losses on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_36de256c-7975-4fd6-b492-a57d157ecf73_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyalties_3127392e-0821-4995-8125-5e7606f69285_terseLabel_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability, Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyalties" xlink:href="arwr-20240331.xsd#arwr_LiabilitySaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyalties" xlink:to="lab_arwr_LiabilitySaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_50d58d84-eb13-4d20-b6b9-7b7183df7a7a_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:href="arwr-20240331.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DevelopmentAndSalesMilestonesPayments_c7ef4812-7139-49cf-9993-806de9974498_terseLabel_en-US" xlink:label="lab_arwr_DevelopmentAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development and sales milestone payments</link:label>
    <link:label id="lab_arwr_DevelopmentAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_DevelopmentAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_DevelopmentAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_DevelopmentAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development And Sales Milestones Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentAndSalesMilestonesPayments" xlink:href="arwr-20240331.xsd#arwr_DevelopmentAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DevelopmentAndSalesMilestonesPayments" xlink:to="lab_arwr_DevelopmentAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_00e91b84-34b7-43e2-acd7-335bb74f81aa_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_ffb59836-b4c4-41a7-86e7-a220a98043b4_terseLabel_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_label_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties [Roll Forward]</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_documentation_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:href="arwr-20240331.xsd#arwr_LiabilitySaleOfFutureRoyaltiesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:to="lab_arwr_LiabilitySaleOfFutureRoyaltiesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_75f75382-5db0-4421-b7bd-e5fe689bc772_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_d58e7561-bbc8-4db1-a0ca-6090f2f1c947_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_d83b9834-c656-4b81-a73a-04541cce9291_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_e1cabc42-4468-4610-8091-e5e3ffd49da0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8a6d320b-5bf3-48a8-a2d7-50debebee4c4_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8c8904c5-d2a2-4116-a52a-eedcf5f7e1d4_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_2322b86d-37b1-4c86-a8fb-932ca0e53fea_terseLabel_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options to renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_label_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Options To Renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_documentation_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of options to renew.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew" xlink:href="arwr-20240331.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfOptionsToRenew" xlink:to="lab_arwr_NumberOfOptionsToRenew" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_9153518f-c274-4bd1-b0ae-ff9559df2bf1_terseLabel_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_label_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceuticals United States Of America Incorporated [Member]</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Takeda Pharmaceuticals United States of America Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:href="arwr-20240331.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:to="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ae6dc5cd-24dc-4749-82d5-3279de33292b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_ffcb63cd-3963-480c-b257-8bacffb5fff0_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities (includes current portion)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_0fb07690-b4c4-48d3-84b1-625fcd6bd57d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Awards Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_6b73e3be-5539-4bbf-bdfa-bb9d164c08b1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6fafbee4-841d-48a0-b5be-227aa081788a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_53415742-01b0-44d6-8ffe-7786d19aaa64_terseLabel_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Horizon</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_label_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Horizon Therapeutics Ireland DAC [Member]</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_documentation_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Horizon Therapeutics Ireland DAC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:href="arwr-20240331.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:to="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0192d19d-0a89-460d-aa80-23b88276d650_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2c1f9001-2b7b-4871-97e0-d2c5f4ca6428_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e7255840-f852-40a1-a07e-950da7663d1a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6a9806ea-5ce5-41d9-9492-070e31c9d1a4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares reserve for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_697affa6-11f1-4575-8d31-e795687abc2f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_b2fb0a1b-e4ae-4a92-9cae-b20f79bfb41d_terseLabel_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability Related to the Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Text Block]</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:href="arwr-20240331.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:to="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_87827c02-5724-41e4-9358-44e629662f3a_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JamesHamiltonMember_label_en-US" xlink:label="lab_arwr_JamesHamiltonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">James Hamilton [Member]</link:label>
    <link:label id="lab_arwr_JamesHamiltonMember_documentation_en-US" xlink:label="lab_arwr_JamesHamiltonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">James Hamilton</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonMember" xlink:href="arwr-20240331.xsd#arwr_JamesHamiltonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JamesHamiltonMember" xlink:to="lab_arwr_JamesHamiltonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_6abb697e-bbaf-4de6-8d08-6cfc4f93bb94_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_e0b53531-3ca0-4bbf-a0f5-378f097265a9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_ca5e74fa-1698-45a5-b93a-5e7b00ce8254_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 124,133 and 107,312 shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_c0b7b258-396a-43dc-b185-88331cb9de05_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. government bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_632de713-8797-44e7-9a17-7db644eb812b_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_KenMyszkowskiMarch28Plan1Member_label_en-US" xlink:label="lab_arwr_KenMyszkowskiMarch28Plan1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ken Myszkowski March 28 Plan 1 [Member]</link:label>
    <link:label id="lab_arwr_KenMyszkowskiMarch28Plan1Member_documentation_en-US" xlink:label="lab_arwr_KenMyszkowskiMarch28Plan1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ken Myszkowski March 28 Plan 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch28Plan1Member" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch28Plan1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_KenMyszkowskiMarch28Plan1Member" xlink:to="lab_arwr_KenMyszkowskiMarch28Plan1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_b33d7c48-7202-44a4-ae68-ab869333d5bb_terseLabel_en-US" xlink:label="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:href="arwr-20240331.xsd#arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4e6a465d-1c75-42a1-8f5a-d167c0531655_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_33544fd5-f519-42d7-9633-a96bd3b05a1f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receivables included in accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_60b4ff2d-66ca-4721-91cd-e55e86457cb8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplementary disclosure of cash flows:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_8d9683f6-2d50-40c2-9c92-c5f4e7fd5ec4_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ec8c6a0e-5bb1-4fb2-8504-cafb638b8e3e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_705d8829-c343-4b17-a16d-2d221fb3f889_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_a6ce5053-5de4-440a-9597-3506b50155c3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_a2146429-7290-49e9-9c53-eb32ae616457_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_label_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Abstract]</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_documentation_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:href="arwr-20240331.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:to="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NovartisMember_a09653a5-e0bb-40f0-8c8c-aab549fe81a5_terseLabel_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_arwr_NovartisMember_label_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_arwr_NovartisMember_documentation_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novartis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember" xlink:href="arwr-20240331.xsd#arwr_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NovartisMember" xlink:to="lab_arwr_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_77d8a0a8-0628-42c6-a697-889316e84f11_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3c26a42f-147f-4b8e-90af-951fc9be08cf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_59254faa-f1a1-4c92-9bd4-fafa6333dc0c_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_53e2c7c7-669b-43f6-a474-cc8916c73ac5_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_fd6ebe45-dda6-4b21-948a-3c23e7cbe1f4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_e83c4334-220d-4d05-8cea-b5abedb3311a_terseLabel_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (decrease) in cash and investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_label_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Cash And Investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_documentation_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase decrease in cash and investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:href="arwr-20240331.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:to="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_d55032be-a55c-404f-a4a5-11df9794ae10_terseLabel_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License and Co-Funding Agreement</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_label_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License And Co Funding Agreement [Member]</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_documentation_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License and co-funding agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:href="arwr-20240331.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:to="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_cff45e73-c114-4c3a-b0e8-5e76636fb4c0_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b3de0085-e7f9-4d2b-8cc2-8f3cbd2fabd7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_4c3b7ee1-61a9-4f77-9c7e-48037c16176c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_5dd5ca04-8810-4e30-8c3a-295f692d3072_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, at fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_acc0aa48-c1c6-40af-b93e-4be2c9e00d80_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current investments, Available-for-sale, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_2fd3dd50-408e-4246-8466-ee0e836aa8b4_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Planned area of the site (in sq ft)</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_babd1cf2-d150-4a05-bb52-62ea860dcf87_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_66ba5fd8-39af-4131-978a-3f4b7e838a80_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization expense for property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_a3f0691a-c3db-44d5-90ae-092c310b3c9c_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:href="arwr-20240331.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_b738def2-6e23-4428-96b9-8200a84f4195_terseLabel_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At The Market Agreement</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_label_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Agreement [Member]</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_documentation_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-the-market agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember" xlink:href="arwr-20240331.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AtTheMarketAgreementMember" xlink:to="lab_arwr_AtTheMarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_dd7df492-6349-454c-89ba-38bab058282d_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_b40bf869-9a3c-45b5-bc75-42586f33a3fa_terseLabel_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Headquarters In Pasadena</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_label_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Headquarters In Pasadena [Member]</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_documentation_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate Headquarters in Pasadena</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:href="arwr-20240331.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:to="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_10b08c75-6b88-40c6-827b-1933bc659ef7_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_79926eba-b055-477a-95a1-d9c0f35a9958_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Arrowhead Pharmaceuticals, Inc. stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_bb3fb45e-f637-40f8-aea9-292c650a4d0d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctBundle_627d4dca-34ff-4b97-980c-1be392b95668_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of distinct bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_label_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Distinct Bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of distinct bundle.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle" xlink:href="arwr-20240331.xsd#arwr_NumberOfDistinctBundle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctBundle" xlink:to="lab_arwr_NumberOfDistinctBundle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e661cd04-6e47-41b8-a166-c5554c69bca8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_c75e0962-151c-4ed3-9827-21c4f5d19998_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_label_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_documentation_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold" xlink:href="arwr-20240331.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPaymentThreshold" xlink:to="lab_arwr_RoyaltyPaymentThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_cbb489d4-e855-4feb-bf2e-646e59366205_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_9b375538-6d46-4330-9631-8dc04de3085a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_8abcd9a6-c12e-4583-9734-40c4084a33c3_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FacilitiesMember_c5832fec-40a7-479a-94c1-ec20426473ce_terseLabel_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facilities</link:label>
    <link:label id="lab_arwr_FacilitiesMember_label_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facilities [Member]</link:label>
    <link:label id="lab_arwr_FacilitiesMember_documentation_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember" xlink:href="arwr-20240331.xsd#arwr_FacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FacilitiesMember" xlink:to="lab_arwr_FacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_d142dfab-4f17-4da1-8870-3cc717d1d9a9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f6dbbea7-ba6e-4faa-b044-388ea9bdc999_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Loss) income before income tax (benefit) expense and noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_4a0b99e0-88ef-4f04-b527-855c6a06deab_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_19c25669-4274-4500-a3d7-d9ff3582313f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_29a0b647-d9ed-4461-aae0-11ec8a519e15_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_c62d43e0-b53c-43dd-98e1-00a0e3ad9c6f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_1c4e1bdb-dd03-4a09-9757-aa6fd75fa0b4_terseLabel_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense on liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_43b3fabb-2197-4f17-be13-2c2d0a2e2523_verboseLabel_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense recognized</link:label>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:href="arwr-20240331.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:to="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1107b9b0-38e8-4661-a9cf-ef7eac710cf6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_1da4739e-c78b-4765-afb3-16f49dce307b_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_103eb9fd-89a8-4f1a-8958-5111c81891bd_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_label_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Pharma Agreement [Member]</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_documentation_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember" xlink:href="arwr-20240331.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPharmaAgreementMember" xlink:to="lab_arwr_RoyaltyPharmaAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5b47f36e-4602-48d4-83cf-62ddd1f6de92_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7dd8c871-7b5a-43a6-81a1-c0be9e53f13a_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_3b491a06-5696-40cb-97de-b632a4dbdd5d_terseLabel_en-US" xlink:label="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_label_en-US" xlink:label="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:label id="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_documentation_en-US" xlink:label="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:href="arwr-20240331.xsd#arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_15ae9b36-d08f-46d7-9154-0d52535579c2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_30ea4386-4516-47a6-9794-08d24228e41b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful Lives</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_174e5f94-bfb1-4c1c-b9d2-2dd09a69b90d_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cb08b671-f276-4191-a142-5773f56bf351_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0e3f1b5d-47ee-4acf-82e6-75ba76a9784a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bd79dfde-811b-4912-b2e6-ba57ff63c239_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_ab26ecbd-3343-433b-81a7-8d033ad54ba2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_06aad373-5d0e-4887-b365-9fea7f3dc0ef_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_1b276f6c-7f8d-47e9-b7a6-5b21356f9c71_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_2e1d0896-8df6-460f-a5f9-8bf31a6a61e5_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_8848e658-825f-4c03-a8fc-521f1095fb9a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_dc75a61c-5a8b-463c-894b-724fc17bb516_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmgenIncorporatedMember_fc9d602c-af41-446c-a68d-2622a5675d35_terseLabel_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amgen</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_label_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amgen Incorporated [Member]</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amgen Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember" xlink:href="arwr-20240331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmgenIncorporatedMember" xlink:to="lab_arwr_AmgenIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c9d79a46-10cd-4906-8d93-351836b9953b_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3438c05e-e527-418a-95dc-94e2d4c95385_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b58ad717-2fbc-4c28-a970-df85e5e07344_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total noncontrolling interest and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e80f90d7-7a6c-4074-9667-09055bd35516_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_1ebf5d83-2352-40b5-836b-db1283632354_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_7746b753-d709-4218-8e98-191c150134fb_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_26b3ffd6-23a8-4ca8-8baa-ea0bdcd3b7ed_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, reclassification</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Transfers and Changes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_7c1210b1-7ed2-496e-a62f-e3e9c15fd745_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4115b729-457f-4b32-8ef7-eea0c4f6bc44_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_0771cce0-5929-41dc-b159-d664854d2d18_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_92f60bce-9f72-4cf7-a53f-db7d683ae44f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summarized Information about Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e284ca57-089a-4375-ac76-fe8c88628347_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_51520fdc-a8cc-48c1-af5d-3e77b971539b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_47bcb8d2-f4fe-4ffa-9b48-9ec06eb5fa11_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a81743ff-a71b-4872-9793-82d853b3b70d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_f809b184-c103-4451-844e-0f2d107c797a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_0ed462a5-baaf-4511-926b-f217d3fa0123_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income including noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_18dc5c64-3751-4db9-8716-2446113496ce_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_8faee02e-49d0-4f08-809c-9470f7bb0a8a_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (loss) income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_2ba4f01b-7e51-4de7-a253-7897489c4d97_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasuries</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_c7c883cb-0532-4d39-af28-e0779d61cd71_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1d7407d4-ea7f-4651-bb07-af4d867a0b95_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_74339ff9-982c-43f5-8b48-7e189249ba67_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_51dc39d1-aabb-4f51-875a-68d8587200bb_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_bfa96319-d6a7-4fbe-a188-236367f06598_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2255d502-48c2-4104-8f64-bafdac503907_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9f6b5b34-21e5-448a-8080-5169c3ee4706_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities, Noncontrolling Interest and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_bee6a52e-1ffd-476a-9e1a-2718bda4b1ed_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_4ba74555-7bb7-483b-9d2d-809fa9d3bc45_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_94cff73f-4d9e-4d5e-b0c5-171b641a7902_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_907b97c4-6c8e-4ee3-abbf-30ec42b90ba0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic net (loss) gain per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_75650496-e224-4906-ad33-e8297c10d366_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_8ecc8065-f682-4047-907e-6e48c29cc296_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_KenMyszkowskiMarch12PlanMember_label_en-US" xlink:label="lab_arwr_KenMyszkowskiMarch12PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ken Myszkowski March 12 Plan [Member]</link:label>
    <link:label id="lab_arwr_KenMyszkowskiMarch12PlanMember_documentation_en-US" xlink:label="lab_arwr_KenMyszkowskiMarch12PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ken Myszkowski March 12 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch12PlanMember" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch12PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_KenMyszkowskiMarch12PlanMember" xlink:to="lab_arwr_KenMyszkowskiMarch12PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_8f45d374-447f-4a6d-8163-32b77f8b5e9e_terseLabel_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029 and thereafter</link:label>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_label_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee Operating Lease Liability Payments Due Year Five And After Year Five</link:label>
    <link:label id="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_documentation_en-US" xlink:label="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee operating lease liability payments due year five and after year five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:href="arwr-20240331.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:to="lab_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_8b8e23e9-0b4b-4b22-b061-e29e565e870f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_ae03835c-6f7d-4db6-a26c-e0a2dfbd1cb0_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon FDA approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon FDA Approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon FDA Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:to="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b658b9f6-c7be-48c3-9319-8a8335f12b24_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VisirnaLicenseAgreementMember_43811876-7d37-4b24-ad89-d9ccb0fb152a_terseLabel_en-US" xlink:label="lab_arwr_VisirnaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Visirna License Agreement</link:label>
    <link:label id="lab_arwr_VisirnaLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_VisirnaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Visirna License Agreement [Member]</link:label>
    <link:label id="lab_arwr_VisirnaLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_VisirnaLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Visirna License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaLicenseAgreementMember" xlink:href="arwr-20240331.xsd#arwr_VisirnaLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VisirnaLicenseAgreementMember" xlink:to="lab_arwr_VisirnaLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_562559bf-4d3f-46eb-aa67-03a8f57c015c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_e38be127-a4cb-43bd-a0ed-871babd8bfcc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024 (remainder of fiscal year)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_0875a841-88bb-454f-adc0-a97d481e54a1_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_36a22a9b-c3bb-4825-96d2-d4a28d46dbdc_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_853cc524-ca48-4a57-967a-091735b6a762_terseLabel_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_label_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_documentation_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:href="arwr-20240331.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:to="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SaleOfStockAggregatePurchasePrice_04ba4377-2559-4deb-80a8-7062f853d091_terseLabel_en-US" xlink:label="lab_arwr_SaleOfStockAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate purchase price paid by investors</link:label>
    <link:label id="lab_arwr_SaleOfStockAggregatePurchasePrice_label_en-US" xlink:label="lab_arwr_SaleOfStockAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Purchase Price</link:label>
    <link:label id="lab_arwr_SaleOfStockAggregatePurchasePrice_documentation_en-US" xlink:label="lab_arwr_SaleOfStockAggregatePurchasePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Aggregate Purchase Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockAggregatePurchasePrice" xlink:href="arwr-20240331.xsd#arwr_SaleOfStockAggregatePurchasePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SaleOfStockAggregatePurchasePrice" xlink:to="lab_arwr_SaleOfStockAggregatePurchasePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_69a64466-c4bf-4d6e-8ed4-50b8e99f4fdc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Accounts</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_2b7f7b7a-2582-44cc-8e8e-639b73dc4ff6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_f7c900fc-e6b7-4b7f-b577-ee86fdbc881a_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceived_9f72e78f-8f16-4e20-878e-a3af1e8b3210_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceived_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceived_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceived" xlink:to="lab_arwr_MilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_04900b1d-3bd9-4acd-bffb-731270b0b268_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2004 Equity Incentive Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousands Four Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousands four equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:href="arwr-20240331.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_24dc7cbe-a2c7-4518-b845-859a69867e41_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_7a76f20a-36d4-4af0-b781-83755b711467_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d2b31d4-84a0-41c5-9b99-a41ca2f5356d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_694ed0d8-c340-431f-ad42-f5721a175cb6_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_label_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Eligible To Receive Tiered Royalties On Net Sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_documentation_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:href="arwr-20240331.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:to="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_14d35324-cd6e-4910-a830-55bbfd9f3f68_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_6c9a35e2-6454-4ec3-a467-050e4de88f36_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash flow from operating activities</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_c3d8263a-d699-474c-b695-4589cc06c4d4_totalLabel_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_label_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_documentation_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:href="arwr-20240331.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:to="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4fc3e1a9-8eaa-42ff-bd07-b1909ea5575d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_c48f3303-f938-4519-939a-8f3ec8abecb1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock - restricted stock units vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_4eebab03-00d1-44f5-a006-fed0991c79a4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_22d1ff6b-fa22-4937-bd06-e6263583956b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_e4a3907c-4492-43da-8aa2-1361bf5ac8d6_terseLabel_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_label_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited [Member]</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_documentation_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:href="arwr-20240331.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:to="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_386d34ae-be99-47d9-b570-599c3a3a9377_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_178a98c4-6044-486c-96c6-9ec2eee7bb8e_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ComputerAndSoftwareMember_65d016db-af38-497e-9068-65b0ccc33c1a_terseLabel_en-US" xlink:label="lab_arwr_ComputerAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computers and software</link:label>
    <link:label id="lab_arwr_ComputerAndSoftwareMember_label_en-US" xlink:label="lab_arwr_ComputerAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer And Software [Member]</link:label>
    <link:label id="lab_arwr_ComputerAndSoftwareMember_documentation_en-US" xlink:label="lab_arwr_ComputerAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer And Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputerAndSoftwareMember" xlink:href="arwr-20240331.xsd#arwr_ComputerAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ComputerAndSoftwareMember" xlink:to="lab_arwr_ComputerAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_8e6db972-8ed2-4493-be13-aed649bae561_terseLabel_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Colorado Owner, LLC</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_label_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Colorado Owner L L C [Member]</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_documentation_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Colorado Owner, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember" xlink:href="arwr-20240331.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ColoradoOwnerLLCMember" xlink:to="lab_arwr_ColoradoOwnerLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_ea713d61-6ea5-4a21-a6ae-cf8e2f539fa2_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Municipal securities</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_e1a69598-99f3-4d4d-8d82-59b0d8ecdca1_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current investments, Available-for-sale, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:href="arwr-20240331.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:to="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfAgreements_d7ec4735-6f78-4cc7-a5bf-e46c5f4e460c_terseLabel_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_label_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_documentation_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements" xlink:href="arwr-20240331.xsd#arwr_NumberOfAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfAgreements" xlink:to="lab_arwr_NumberOfAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_472c98d5-9931-4651-b58f-cd409c26d871_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c7a7ba32-fb68-4af8-9a5d-c05287e7e803_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_f550a1f5-8d0e-4d59-a644-92ad2a34fb8e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MaximumAdditionalTenantImprovementAllowance_f2af9542-31ca-40b6-b184-7aaf7c27b66b_terseLabel_en-US" xlink:label="lab_arwr_MaximumAdditionalTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum additional tenant improvement allowance</link:label>
    <link:label id="lab_arwr_MaximumAdditionalTenantImprovementAllowance_label_en-US" xlink:label="lab_arwr_MaximumAdditionalTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Additional Tenant Improvement Allowance</link:label>
    <link:label id="lab_arwr_MaximumAdditionalTenantImprovementAllowance_documentation_en-US" xlink:label="lab_arwr_MaximumAdditionalTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Additional Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MaximumAdditionalTenantImprovementAllowance" xlink:href="arwr-20240331.xsd#arwr_MaximumAdditionalTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MaximumAdditionalTenantImprovementAllowance" xlink:to="lab_arwr_MaximumAdditionalTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_ca373c5e-1770-49f3-9dc5-e4327dd4b20b_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_b39ac1b9-cf06-473d-91a7-8110bb417c66_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bae32935-2ab6-4845-914a-7477d5c72178_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_17b7a63d-af9e-46f1-bdb5-aa786acee7bf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_547df38d-6099-42fc-80f7-1d91fa2c5aee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_eddbd174-7e19-41c1-8270-64ea7438a366_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_3063562b-8553-40fd-9c36-44ffeaf57809_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3e395062-0e8b-40c9-9469-9cb15ad667e6_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_3435bc09-8da9-4355-91f5-9582d8ee685d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_a358fb7f-2556-4d1a-8d82-dd0dcc26e9db_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_88ce92cf-3bc6-4701-b983-7c80b10203c1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_fb5d1b58-6e6a-4e12-a7c3-c8a2e6b9d18d_terseLabel_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount intends to invest for buildout of the facilities</link:label>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_label_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amount Intends To Invest For Buildout Of Facilities</link:label>
    <link:label id="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities_documentation_en-US" xlink:label="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount intends to invest for buildout of facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:href="arwr-20240331.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:to="lab_arwr_AmountIntendsToInvestForBuildoutOfFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_438fdf78-9628-4877-a118-7064a77c8e25_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VisirnaESOPMember_2c4accf9-4a9d-4f5e-8538-d6eafaf53bd2_terseLabel_en-US" xlink:label="lab_arwr_VisirnaESOPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Visirna ESOP</link:label>
    <link:label id="lab_arwr_VisirnaESOPMember_label_en-US" xlink:label="lab_arwr_VisirnaESOPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Visirna ESOP [Member]</link:label>
    <link:label id="lab_arwr_VisirnaESOPMember_documentation_en-US" xlink:label="lab_arwr_VisirnaESOPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Visirna ESOP</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaESOPMember" xlink:href="arwr-20240331.xsd#arwr_VisirnaESOPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VisirnaESOPMember" xlink:to="lab_arwr_VisirnaESOPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_826a3b0f-3524-4168-8941-cfd71da4aecb_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_eff4f07d-f783-4eb3-a5a8-c1e82c92b55b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_8f77c507-5891-4a7b-a94d-afd1c0bafe60_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable upon receipt of royalty payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:to="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_635adc6f-b5a9-4243-ae9e-9c1d856d2c26_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_6427f6bc-9e68-4376-b328-0cf9b8d914ba_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued, net of offering costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_e1f8833f-21d4-40da-ae40-8a8a3343ac95_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_fd025872-82cc-4d3a-8a00-8f834472276e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7c56d524-ed67-43ef-a570-1142586ae9c0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_bda3c33b-127f-43e2-aa05-e5e0cc66712e_terseLabel_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future royalties, interest rate</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_label_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties, Interest Rate</link:label>
    <link:label id="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_documentation_en-US" xlink:label="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liability, Sale Of Future Royalties, Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:href="arwr-20240331.xsd#arwr_LiabilitySaleOfFutureRoyaltiesInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:to="lab_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f6f2a123-f8a1-44df-846b-16a662e1f5a6_verboseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_1ac7cea2-3f35-4a9e-b3f6-141cea2f837e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_8ed407c2-1a23-47e0-96ce-90df102641e8_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_66f55078-95c0-4df3-bbd0-c4587e410765_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_KenMyszkowskiMember_label_en-US" xlink:label="lab_arwr_KenMyszkowskiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ken Myszkowski [Member]</link:label>
    <link:label id="lab_arwr_KenMyszkowskiMember_documentation_en-US" xlink:label="lab_arwr_KenMyszkowskiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ken Myszkowski</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMember" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_KenMyszkowskiMember" xlink:to="lab_arwr_KenMyszkowskiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_6037e7cd-395b-465b-9a37-64abef40b2da_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c2260767-d398-4678-85f7-e3b316755bb1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_337751f3-86f8-4eb8-ace2-b12468b32268_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_95a8c459-fa1d-481f-85a2-24c2fbf077e1_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_559cc621-9814-496a-a0e0-705644926ff6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_c57d0e53-1407-4873-96a1-2a0d61d1c2cd_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_770eb30c-451d-4c1e-a3cb-a918ac1b22a0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4cc1dfaf-5cb6-4b74-97e3-1c6e19f19646_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average diluted shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_0c2813af-2193-4383-a63f-ed2e3cc1c54e_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Receivables and Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_d6bb8abd-b269-4e0c-a13b-fd4defeceb76_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b10305c8-dcd7-4eb0-b6ce-259033b2d55d_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_80e34e6a-95da-4668-af90-ec86f889f962_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_25cb3568-115f-4a7c-9325-a0f1bac05156_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AccruedCapitalExpenditureCurrent_5ff84d29-f18c-40eb-8ee3-083d136628d7_terseLabel_en-US" xlink:label="lab_arwr_AccruedCapitalExpenditureCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued capital expenditures</link:label>
    <link:label id="lab_arwr_AccruedCapitalExpenditureCurrent_label_en-US" xlink:label="lab_arwr_AccruedCapitalExpenditureCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Capital Expenditure, Current</link:label>
    <link:label id="lab_arwr_AccruedCapitalExpenditureCurrent_documentation_en-US" xlink:label="lab_arwr_AccruedCapitalExpenditureCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Capital Expenditure, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedCapitalExpenditureCurrent" xlink:href="arwr-20240331.xsd#arwr_AccruedCapitalExpenditureCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AccruedCapitalExpenditureCurrent" xlink:to="lab_arwr_AccruedCapitalExpenditureCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivable_9ff3c80d-43ee-4222-99de-fa3099d1fc35_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivable" xlink:to="lab_arwr_MilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_7827757a-b824-43b4-b901-15cf57b27cb9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_2432fb6b-614d-42a3-a6d0-0baae9456517_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_c48cd50a-6a4d-4444-9820-3833af5e2afd_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0febd80a-fd72-4c5c-991b-a948e498b042_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_UnderwritingAgreementMember_aa4f65e3-ba32-4a9e-b36c-f1bd4f2e5bea_terseLabel_en-US" xlink:label="lab_arwr_UnderwritingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriting Agreement</link:label>
    <link:label id="lab_arwr_UnderwritingAgreementMember_label_en-US" xlink:label="lab_arwr_UnderwritingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriting Agreement [Member]</link:label>
    <link:label id="lab_arwr_UnderwritingAgreementMember_documentation_en-US" xlink:label="lab_arwr_UnderwritingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Underwriting Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UnderwritingAgreementMember" xlink:href="arwr-20240331.xsd#arwr_UnderwritingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_UnderwritingAgreementMember" xlink:to="lab_arwr_UnderwritingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0fcf5569-cdea-4094-b982-4b8c90eda3e5_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_a7e92449-a40d-42f6-bab7-3446a1ee11d2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_73c174c5-4dec-4913-8a84-88b4120a3096_terseLabel_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_label_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_documentation_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:href="arwr-20240331.xsd#arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:to="lab_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_38282bfe-02c3-4120-be32-1c3f4526ab42_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_5c116d30-33dc-49f8-a4a6-5cdf834580e0_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_f6a06d02-132b-443e-bcd9-1e36d0a1def3_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HorizonLicenseAgreementMember_1d5a8ee5-2a4c-411a-898b-96d25fa453b6_terseLabel_en-US" xlink:label="lab_arwr_HorizonLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Horizon License Agreement</link:label>
    <link:label id="lab_arwr_HorizonLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_HorizonLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Horizon License Agreement [Member]</link:label>
    <link:label id="lab_arwr_HorizonLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_HorizonLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Horizon License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonLicenseAgreementMember" xlink:href="arwr-20240331.xsd#arwr_HorizonLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HorizonLicenseAgreementMember" xlink:to="lab_arwr_HorizonLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_29e46f46-d2ab-4a88-aa9d-798a03d16206_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_2c63dd9e-ff67-4b36-b573-06cc03e11b1d_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_d653758b-80e2-4b6a-8eaf-ae1d81526da8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_038ebf4a-a4a3-454d-a6a4-834324bc36f6_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GSKHBVAgreementMember_1aac2005-7bd2-41ad-9388-a3b383eb61dc_terseLabel_en-US" xlink:label="lab_arwr_GSKHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK-HBV Agreement</link:label>
    <link:label id="lab_arwr_GSKHBVAgreementMember_label_en-US" xlink:label="lab_arwr_GSKHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK-HBV Agreement [Member]</link:label>
    <link:label id="lab_arwr_GSKHBVAgreementMember_documentation_en-US" xlink:label="lab_arwr_GSKHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GSK-HBV Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHBVAgreementMember" xlink:href="arwr-20240331.xsd#arwr_GSKHBVAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GSKHBVAgreementMember" xlink:to="lab_arwr_GSKHBVAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0d099193-336a-4619-b7ff-faa89ec5e8f5_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_97503a1f-ed02-4dfa-a09c-096f5eb80638_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average basic shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_3f9c2db0-0a89-4618-81fb-f3b0e51a1707_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_578b0dfc-e570-471d-adfb-686a4af2475e_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating (loss) income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_e37f0a24-19af-45c9-8990-ccdd44b913e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Realized gain on investments</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PatrickOBrienMember_label_en-US" xlink:label="lab_arwr_PatrickOBrienMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patrick O'Brien [Member]</link:label>
    <link:label id="lab_arwr_PatrickOBrienMember_documentation_en-US" xlink:label="lab_arwr_PatrickOBrienMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patrick O'Brien</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienMember" xlink:href="arwr-20240331.xsd#arwr_PatrickOBrienMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PatrickOBrienMember" xlink:to="lab_arwr_PatrickOBrienMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_20ead9ca-6e04-4786-ba9f-0c2c6cb60c97_terseLabel_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory and Office Facility</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_label_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory And Office Facility [Member]</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_documentation_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory and office facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:href="arwr-20240331.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:to="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_2c128368-d1a6-4fed-81d8-b0f12df299fc_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Facility in Madison</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Facility In Madison [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research facility in Madison.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember" xlink:href="arwr-20240331.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInMadisonMember" xlink:to="lab_arwr_ResearchFacilityInMadisonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_fba06114-016b-42c3-ac16-d3f8d8470f2d_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income, net of tax:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3c8a4284-6c8a-4fc4-a5c0-2a5645795093_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_fab34fab-0b65-46e9-8155-410f7d6b02ba_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_73952950-9c2e-4c17-bc23-8c571bd3a97d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest and stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_656caa61-7af4-4c63-8bdf-ff271062af7c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non- controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>arwr-20240331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2024 Workiva-->
<!--r:ac9daf9b-fe65-44cf-acd3-206171097241,g:5004fc8e-4246-4d68-a802-ef4d83a3dac9-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Cover" xlink:type="simple" xlink:href="arwr-20240331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e06d0aa2-787b-43c4-87da-0225c1333174" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_DocumentType_e06d0aa2-787b-43c4-87da-0225c1333174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_ffb44546-3bb1-4045-860b-a818e96be601" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_DocumentQuarterlyReport_ffb44546-3bb1-4045-860b-a818e96be601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_ee473e15-147e-4aaa-ba41-bb69e6db8a85" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_DocumentPeriodEndDate_ee473e15-147e-4aaa-ba41-bb69e6db8a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_7ad04a11-27fd-4878-9b35-7e9f169944e0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_DocumentTransitionReport_7ad04a11-27fd-4878-9b35-7e9f169944e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_73e44583-127f-413a-b599-e356ee54c4c3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityFileNumber_73e44583-127f-413a-b599-e356ee54c4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e70b4cac-f70e-402f-95a5-181c720e445d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityRegistrantName_e70b4cac-f70e-402f-95a5-181c720e445d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1b01b4f7-7133-438c-aa7d-ba5deb4aeb62" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1b01b4f7-7133-438c-aa7d-ba5deb4aeb62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_78a313f7-a0a4-43f6-9f26-7e7213e5eb6b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityTaxIdentificationNumber_78a313f7-a0a4-43f6-9f26-7e7213e5eb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_138b05da-f5d6-4ce3-a78d-432d2f28951e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityAddressAddressLine1_138b05da-f5d6-4ce3-a78d-432d2f28951e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_acfd69c9-adf6-49db-be8f-bdc4f0c04dd3" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityAddressAddressLine2_acfd69c9-adf6-49db-be8f-bdc4f0c04dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_f5de7749-bf85-4205-a3e2-571358e092bf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityAddressCityOrTown_f5de7749-bf85-4205-a3e2-571358e092bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_496d5704-80a7-45d4-9438-e2eda1d4ee9b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityAddressStateOrProvince_496d5704-80a7-45d4-9438-e2eda1d4ee9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_648c390e-5256-4a23-a436-3dc8bce92d87" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityAddressPostalZipCode_648c390e-5256-4a23-a436-3dc8bce92d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_03a2c44f-d6c8-41d2-b19a-1b78465401cf" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_CityAreaCode_03a2c44f-d6c8-41d2-b19a-1b78465401cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d130ab3c-b988-4582-a3df-dd959d51d2b4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_LocalPhoneNumber_d130ab3c-b988-4582-a3df-dd959d51d2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_88610086-12f0-41dc-9848-e77d49db957b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_Security12bTitle_88610086-12f0-41dc-9848-e77d49db957b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_47a07e81-a7b4-4197-8c36-7736034b3571" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_TradingSymbol_47a07e81-a7b4-4197-8c36-7736034b3571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d2aedd57-77dc-4708-9faa-2e968d63f2e6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_SecurityExchangeName_d2aedd57-77dc-4708-9faa-2e968d63f2e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_df32c12e-dae2-4679-96da-8a4e4952230a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityCurrentReportingStatus_df32c12e-dae2-4679-96da-8a4e4952230a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_9dd941cf-834e-4310-a12a-07053fbdf48a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityInteractiveDataCurrent_9dd941cf-834e-4310-a12a-07053fbdf48a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_6ef93329-2a7c-4010-845f-08d3f1253cd0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityFilerCategory_6ef93329-2a7c-4010-845f-08d3f1253cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_24d30b61-ed6b-4862-ace9-5f464224e8e2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityEmergingGrowthCompany_24d30b61-ed6b-4862-ace9-5f464224e8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_d08ca30d-eba0-4b86-90bc-da40338e9e3e" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntitySmallBusiness_d08ca30d-eba0-4b86-90bc-da40338e9e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_bf7eb05b-32df-4bee-8dfa-a8788772ade8" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityShellCompany_bf7eb05b-32df-4bee-8dfa-a8788772ade8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_3023d6f1-4b42-4223-842b-227c95e5677d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_3023d6f1-4b42-4223-842b-227c95e5677d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_6bd48c5c-7296-468a-874b-cb9e3567a677" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_EntityCentralIndexKey_6bd48c5c-7296-468a-874b-cb9e3567a677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c1306e7c-0729-467f-b53d-95bc7c68c004" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_CurrentFiscalYearEndDate_c1306e7c-0729-467f-b53d-95bc7c68c004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5e227082-a2c8-471c-83df-533aabb23cbd" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_DocumentFiscalYearFocus_5e227082-a2c8-471c-83df-533aabb23cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_31f5907d-0796-4f0c-a1fe-04d0ad442563" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_31f5907d-0796-4f0c-a1fe-04d0ad442563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_bb0aed55-d2bd-4848-bbb5-12d47294830b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_265ae511-8407-43d4-b56d-ef35b261b05f" xlink:to="loc_dei_AmendmentFlag_bb0aed55-d2bd-4848-bbb5-12d47294830b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20240331.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b168b839-6d63-4557-91f4-d6751fc5e9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_0cf2e770-ffba-4ce2-95e0-0cebcbf464f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b168b839-6d63-4557-91f4-d6751fc5e9c8" xlink:to="loc_us-gaap_AssetsAbstract_0cf2e770-ffba-4ce2-95e0-0cebcbf464f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_894ade48-f4e3-4e2c-87ee-83d67151d5ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0cf2e770-ffba-4ce2-95e0-0cebcbf464f6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_894ade48-f4e3-4e2c-87ee-83d67151d5ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58333f56-20be-4b15-83c7-a980e51c1807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_894ade48-f4e3-4e2c-87ee-83d67151d5ed" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_58333f56-20be-4b15-83c7-a980e51c1807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_36998c5b-ecb3-4d86-96c8-f0cc8aad9701" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_894ade48-f4e3-4e2c-87ee-83d67151d5ed" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_36998c5b-ecb3-4d86-96c8-f0cc8aad9701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_6e8d061e-e04f-444d-bf78-878106329cdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_894ade48-f4e3-4e2c-87ee-83d67151d5ed" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_6e8d061e-e04f-444d-bf78-878106329cdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f2755b45-cc67-4b24-868e-a2d9b68426b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_894ade48-f4e3-4e2c-87ee-83d67151d5ed" xlink:to="loc_us-gaap_OtherAssetsCurrent_f2755b45-cc67-4b24-868e-a2d9b68426b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_75b6546e-3eea-4157-b2dd-25ce7769765d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_894ade48-f4e3-4e2c-87ee-83d67151d5ed" xlink:to="loc_us-gaap_AssetsCurrent_75b6546e-3eea-4157-b2dd-25ce7769765d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_88567ba6-a31b-4a3b-b059-f71a13a3039f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0cf2e770-ffba-4ce2-95e0-0cebcbf464f6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_88567ba6-a31b-4a3b-b059-f71a13a3039f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_99d9bf95-3a97-4652-b29e-16568fafde1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0cf2e770-ffba-4ce2-95e0-0cebcbf464f6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_99d9bf95-3a97-4652-b29e-16568fafde1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_96e9d9d9-a3b5-4ae2-82fa-e82b8dbea1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0cf2e770-ffba-4ce2-95e0-0cebcbf464f6" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_96e9d9d9-a3b5-4ae2-82fa-e82b8dbea1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_4fc1a5e0-892b-4eed-a055-76c219443ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0cf2e770-ffba-4ce2-95e0-0cebcbf464f6" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_4fc1a5e0-892b-4eed-a055-76c219443ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_6b7eb38d-09e6-4b87-b4d7-cc4f4c4c4932" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_0cf2e770-ffba-4ce2-95e0-0cebcbf464f6" xlink:to="loc_us-gaap_Assets_6b7eb38d-09e6-4b87-b4d7-cc4f4c4c4932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd727874-9bcb-4a03-bb45-785b3e126740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b168b839-6d63-4557-91f4-d6751fc5e9c8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd727874-9bcb-4a03-bb45-785b3e126740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_076fcc7d-b9cb-412d-812d-947ab67dc547" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd727874-9bcb-4a03-bb45-785b3e126740" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_076fcc7d-b9cb-412d-812d-947ab67dc547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_837f8f3e-bbd7-4a85-87a2-8b6d47bb8e80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_076fcc7d-b9cb-412d-812d-947ab67dc547" xlink:to="loc_us-gaap_AccountsPayableCurrent_837f8f3e-bbd7-4a85-87a2-8b6d47bb8e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a64dfdbf-9418-405a-a12f-edace3c3f54c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_076fcc7d-b9cb-412d-812d-947ab67dc547" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a64dfdbf-9418-405a-a12f-edace3c3f54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1b578e3c-4103-4759-9a4e-b6eaf29b266d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_076fcc7d-b9cb-412d-812d-947ab67dc547" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_1b578e3c-4103-4759-9a4e-b6eaf29b266d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_dcb12971-937f-4541-afeb-f3a5121c75da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_076fcc7d-b9cb-412d-812d-947ab67dc547" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_dcb12971-937f-4541-afeb-f3a5121c75da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6c1474af-3765-4492-bfd2-707743fe6004" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_076fcc7d-b9cb-412d-812d-947ab67dc547" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_6c1474af-3765-4492-bfd2-707743fe6004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5b0801f3-1a0c-45c3-8bda-45d9946c0bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_076fcc7d-b9cb-412d-812d-947ab67dc547" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5b0801f3-1a0c-45c3-8bda-45d9946c0bd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0a99fe32-1bec-495e-a668-143609dcf4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_076fcc7d-b9cb-412d-812d-947ab67dc547" xlink:to="loc_us-gaap_LiabilitiesCurrent_0a99fe32-1bec-495e-a668-143609dcf4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a8d6342-fa6b-4f10-9d66-b40f21bdc12d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd727874-9bcb-4a03-bb45-785b3e126740" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a8d6342-fa6b-4f10-9d66-b40f21bdc12d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4c58e39d-80e7-4ff0-897c-7365134e5f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a8d6342-fa6b-4f10-9d66-b40f21bdc12d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4c58e39d-80e7-4ff0-897c-7365134e5f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_1f0a7062-a3da-4c34-85fb-450322db6263" xlink:href="arwr-20240331.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a8d6342-fa6b-4f10-9d66-b40f21bdc12d" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_1f0a7062-a3da-4c34-85fb-450322db6263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_517cf689-8edf-460e-b453-147f9d1b7c38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_8a8d6342-fa6b-4f10-9d66-b40f21bdc12d" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_517cf689-8edf-460e-b453-147f9d1b7c38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_805b8e08-4404-4b11-a70a-e781cc986b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd727874-9bcb-4a03-bb45-785b3e126740" xlink:to="loc_us-gaap_CommitmentsAndContingencies_805b8e08-4404-4b11-a70a-e781cc986b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_29a1358e-a567-49c9-b2f5-4808f45d3fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd727874-9bcb-4a03-bb45-785b3e126740" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_29a1358e-a567-49c9-b2f5-4808f45d3fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_4146c95b-da75-462b-93b1-a30b3ca781a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_29a1358e-a567-49c9-b2f5-4808f45d3fd0" xlink:to="loc_us-gaap_CommonStockValue_4146c95b-da75-462b-93b1-a30b3ca781a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7dcb15f9-e293-4bc7-b36a-6dc422997ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_29a1358e-a567-49c9-b2f5-4808f45d3fd0" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_7dcb15f9-e293-4bc7-b36a-6dc422997ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6955ed04-441b-45fe-b7cb-f87e7ea837a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_29a1358e-a567-49c9-b2f5-4808f45d3fd0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_6955ed04-441b-45fe-b7cb-f87e7ea837a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_38fcaa17-51ef-4f8d-bb54-fcf34b02d6d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_29a1358e-a567-49c9-b2f5-4808f45d3fd0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_38fcaa17-51ef-4f8d-bb54-fcf34b02d6d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_42ba6456-682a-47ca-9f9e-92b1e6d39898" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_29a1358e-a567-49c9-b2f5-4808f45d3fd0" xlink:to="loc_us-gaap_StockholdersEquity_42ba6456-682a-47ca-9f9e-92b1e6d39898" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_8c3bfdff-219a-447b-926b-28a26bb35213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_29a1358e-a567-49c9-b2f5-4808f45d3fd0" xlink:to="loc_us-gaap_MinorityInterest_8c3bfdff-219a-447b-926b-28a26bb35213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4e5c1089-c0bb-4707-bc55-62451d7a601c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_29a1358e-a567-49c9-b2f5-4808f45d3fd0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4e5c1089-c0bb-4707-bc55-62451d7a601c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c973b604-7280-4cf9-a3e8-29bcba6e89f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_bd727874-9bcb-4a03-bb45-785b3e126740" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c973b604-7280-4cf9-a3e8-29bcba6e89f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arwr-20240331.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5fd6dff2-d75f-4962-b0ee-6a923c319685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c751001c-2468-422c-8255-b1cae8b9a019" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5fd6dff2-d75f-4962-b0ee-6a923c319685" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c751001c-2468-422c-8255-b1cae8b9a019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_249dc505-0cc6-4739-b753-483d842bafa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5fd6dff2-d75f-4962-b0ee-6a923c319685" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_249dc505-0cc6-4739-b753-483d842bafa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_106cb672-1e02-422a-8f63-3674929d21d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5fd6dff2-d75f-4962-b0ee-6a923c319685" xlink:to="loc_us-gaap_CommonStockSharesIssued_106cb672-1e02-422a-8f63-3674929d21d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1b3fa84b-135f-46dc-b8ad-a46d2c33cbc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5fd6dff2-d75f-4962-b0ee-6a923c319685" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1b3fa84b-135f-46dc-b8ad-a46d2c33cbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="simple" xlink:href="arwr-20240331.xsd#ConsolidatedStatementsofOperationsandComprehensiveLossIncome"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_5925b43f-8adb-4bb0-a1c8-fce7260f45d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_62a592e0-ac44-46ba-8557-6b9602888dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5925b43f-8adb-4bb0-a1c8-fce7260f45d7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_62a592e0-ac44-46ba-8557-6b9602888dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_bcaabeb3-ae06-4d23-8be8-e3cfe2da0146" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5925b43f-8adb-4bb0-a1c8-fce7260f45d7" xlink:to="loc_us-gaap_OperatingExpensesAbstract_bcaabeb3-ae06-4d23-8be8-e3cfe2da0146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_62405848-7053-47e8-a9ad-42cd391f370e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bcaabeb3-ae06-4d23-8be8-e3cfe2da0146" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_62405848-7053-47e8-a9ad-42cd391f370e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6c83f272-a055-4418-b97f-38bac79c017e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bcaabeb3-ae06-4d23-8be8-e3cfe2da0146" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6c83f272-a055-4418-b97f-38bac79c017e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_93c89a03-db51-4edb-b3b7-5e143fa1e131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_bcaabeb3-ae06-4d23-8be8-e3cfe2da0146" xlink:to="loc_us-gaap_OperatingExpenses_93c89a03-db51-4edb-b3b7-5e143fa1e131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_a1ae6f69-864a-478d-bde5-858699a2569e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5925b43f-8adb-4bb0-a1c8-fce7260f45d7" xlink:to="loc_us-gaap_OperatingIncomeLoss_a1ae6f69-864a-478d-bde5-858699a2569e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_074a2514-491a-47c8-b25f-7039bad155e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5925b43f-8adb-4bb0-a1c8-fce7260f45d7" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_074a2514-491a-47c8-b25f-7039bad155e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_decdadc5-5d1f-414e-924a-8affcafcd3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_074a2514-491a-47c8-b25f-7039bad155e7" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_decdadc5-5d1f-414e-924a-8affcafcd3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e6d86d16-7ab2-40ae-9830-f276e3de2934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_074a2514-491a-47c8-b25f-7039bad155e7" xlink:to="loc_us-gaap_InterestExpense_e6d86d16-7ab2-40ae-9830-f276e3de2934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1df624a0-4f2b-4c57-83d6-30a991465206" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_074a2514-491a-47c8-b25f-7039bad155e7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1df624a0-4f2b-4c57-83d6-30a991465206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_bc65a8d3-282a-4477-b641-74aac3520726" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_074a2514-491a-47c8-b25f-7039bad155e7" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_bc65a8d3-282a-4477-b641-74aac3520726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ee75584-0614-4bb1-a1bd-37727e9323ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5925b43f-8adb-4bb0-a1c8-fce7260f45d7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5ee75584-0614-4bb1-a1bd-37727e9323ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_058d4848-21c4-44b3-a485-7b674e080a27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5925b43f-8adb-4bb0-a1c8-fce7260f45d7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_058d4848-21c4-44b3-a485-7b674e080a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ec2fcfe0-0f1f-470b-bb6a-e57e06dcc105" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5925b43f-8adb-4bb0-a1c8-fce7260f45d7" xlink:to="loc_us-gaap_ProfitLoss_ec2fcfe0-0f1f-470b-bb6a-e57e06dcc105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a7f624c-cfef-496b-b864-ae7d3e67a3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5925b43f-8adb-4bb0-a1c8-fce7260f45d7" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_6a7f624c-cfef-496b-b864-ae7d3e67a3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d1db63c-f337-4a0c-9627-74c35720cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5925b43f-8adb-4bb0-a1c8-fce7260f45d7" xlink:to="loc_us-gaap_NetIncomeLoss_8d1db63c-f337-4a0c-9627-74c35720cc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_8f03c3de-8d91-4428-9ed9-73cc73357b7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5925b43f-8adb-4bb0-a1c8-fce7260f45d7" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_8f03c3de-8d91-4428-9ed9-73cc73357b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_f10db320-9b7f-4fa9-be89-605826a23e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_8f03c3de-8d91-4428-9ed9-73cc73357b7e" xlink:to="loc_us-gaap_EarningsPerShareBasic_f10db320-9b7f-4fa9-be89-605826a23e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_15d3fd29-f115-49b5-85a0-d466a12b5696" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_8f03c3de-8d91-4428-9ed9-73cc73357b7e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_15d3fd29-f115-49b5-85a0-d466a12b5696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_dfca0ca8-dad8-4ea4-99e2-9189926c3a25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5925b43f-8adb-4bb0-a1c8-fce7260f45d7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_dfca0ca8-dad8-4ea4-99e2-9189926c3a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf41a94a-fde9-49ea-a03c-86abf5ce0901" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_dfca0ca8-dad8-4ea4-99e2-9189926c3a25" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bf41a94a-fde9-49ea-a03c-86abf5ce0901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90673d1a-e6ea-4f24-878d-968570041aca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_dfca0ca8-dad8-4ea4-99e2-9189926c3a25" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90673d1a-e6ea-4f24-878d-968570041aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_15c50413-695c-4bda-9012-ae7e185693e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_5925b43f-8adb-4bb0-a1c8-fce7260f45d7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_15c50413-695c-4bda-9012-ae7e185693e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a3feee4b-922c-43d6-97f0-0445c1b7372e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_15c50413-695c-4bda-9012-ae7e185693e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_a3feee4b-922c-43d6-97f0-0445c1b7372e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cf9cd14f-d69c-4c2c-9a78-ff63fcc8837f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_15c50413-695c-4bda-9012-ae7e185693e7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_cf9cd14f-d69c-4c2c-9a78-ff63fcc8837f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_60d554ad-e870-477b-904a-6c3943fde0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_15c50413-695c-4bda-9012-ae7e185693e7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_60d554ad-e870-477b-904a-6c3943fde0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20240331.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ab6c643c-688a-4e31-b07e-100f9606c79e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_94e325a6-188c-41b3-bbaf-6cb0d94ab70f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ab6c643c-688a-4e31-b07e-100f9606c79e" xlink:to="loc_us-gaap_StatementTable_94e325a6-188c-41b3-bbaf-6cb0d94ab70f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_04bcd26d-7d7e-48ac-9c77-0160d2da545f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_94e325a6-188c-41b3-bbaf-6cb0d94ab70f" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_04bcd26d-7d7e-48ac-9c77-0160d2da545f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_04bcd26d-7d7e-48ac-9c77-0160d2da545f" xlink:to="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9bf0785e-90d0-46c1-8507-7c95e6c83f60" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:to="loc_us-gaap_CommonStockMember_9bf0785e-90d0-46c1-8507-7c95e6c83f60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_da3bbbc4-4a04-484d-92bf-96121ab932a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_da3bbbc4-4a04-484d-92bf-96121ab932a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f623831e-edfa-421c-810b-696044ba6ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f623831e-edfa-421c-810b-696044ba6ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_8ac5bb4c-4e00-4e3d-81e5-3fdb091cf9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:to="loc_us-gaap_RetainedEarningsMember_8ac5bb4c-4e00-4e3d-81e5-3fdb091cf9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_f428e9cd-b29c-45a1-946d-f31888921134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c4f1ffec-ec63-49d9-a211-48d0d34b7527" xlink:to="loc_us-gaap_NoncontrollingInterestMember_f428e9cd-b29c-45a1-946d-f31888921134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_391ddd79-4f28-4335-8ac6-0c04eba4553a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_94e325a6-188c-41b3-bbaf-6cb0d94ab70f" xlink:to="loc_us-gaap_StatementLineItems_391ddd79-4f28-4335-8ac6-0c04eba4553a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_391ddd79-4f28-4335-8ac6-0c04eba4553a" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_214f8657-926c-41d0-b3d5-d5fdd2bb1edf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_214f8657-926c-41d0-b3d5-d5fdd2bb1edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_cd0bced3-352f-4642-940a-658025c74dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_SharesOutstanding_cd0bced3-352f-4642-940a-658025c74dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f0513a27-d293-42cb-a624-b8f02726ab88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_f0513a27-d293-42cb-a624-b8f02726ab88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_07ec84f2-c006-469d-89ae-3c97a90a83ff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_07ec84f2-c006-469d-89ae-3c97a90a83ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_792a6061-f984-4d5c-8949-fce5553f4a64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_792a6061-f984-4d5c-8949-fce5553f4a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_5fa69201-c7f7-46b8-be3c-1b13790d4ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_5fa69201-c7f7-46b8-be3c-1b13790d4ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_bd6b836f-00de-4e81-8f5a-cb1378f1eb5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_bd6b836f-00de-4e81-8f5a-cb1378f1eb5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0198efd7-7451-4928-b2a6-8648a755b0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_0198efd7-7451-4928-b2a6-8648a755b0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_329b8050-66c4-4efe-bdec-3baaa964f010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_329b8050-66c4-4efe-bdec-3baaa964f010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2fe589fa-aed2-4a45-a064-a82d9aea8b72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2fe589fa-aed2-4a45-a064-a82d9aea8b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1770867a-2bc4-4170-804c-139b6eaca26c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_1770867a-2bc4-4170-804c-139b6eaca26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_8857220b-f45f-4c57-aa8e-21c1d15a5644" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_ProfitLoss_8857220b-f45f-4c57-aa8e-21c1d15a5644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5ec130ca-d2e9-4a6f-827f-dec2c27bf135" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5ec130ca-d2e9-4a6f-827f-dec2c27bf135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_dc268a0b-84e8-459e-8c4a-fa35b7051e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_03d1cfb8-1d22-4c11-8223-3e0a4a33c1f8" xlink:to="loc_us-gaap_SharesOutstanding_dc268a0b-84e8-459e-8c4a-fa35b7051e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20240331.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_337c238c-c4eb-428f-90c5-4bde7fdd68d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a8b53db-f0c5-4743-bac1-5b3c0bf10245" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_337c238c-c4eb-428f-90c5-4bde7fdd68d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a8b53db-f0c5-4743-bac1-5b3c0bf10245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_5ac676dd-411f-497e-9d6f-8e15e836ddda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a8b53db-f0c5-4743-bac1-5b3c0bf10245" xlink:to="loc_us-gaap_ProfitLoss_5ac676dd-411f-497e-9d6f-8e15e836ddda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_72d4677d-f4d2-4459-bd30-9a97b596ca6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a8b53db-f0c5-4743-bac1-5b3c0bf10245" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_72d4677d-f4d2-4459-bd30-9a97b596ca6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_cdf9e161-3522-4767-a5cd-8b4c1fff4b71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a8b53db-f0c5-4743-bac1-5b3c0bf10245" xlink:to="loc_us-gaap_ShareBasedCompensation_cdf9e161-3522-4767-a5cd-8b4c1fff4b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_7bbd991c-1cc8-401f-b911-3b615d3fc34e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a8b53db-f0c5-4743-bac1-5b3c0bf10245" xlink:to="loc_us-gaap_DepreciationAndAmortization_7bbd991c-1cc8-401f-b911-3b615d3fc34e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_bcae1a5a-a585-4a3d-90c1-7a6878c6d8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a8b53db-f0c5-4743-bac1-5b3c0bf10245" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_bcae1a5a-a585-4a3d-90c1-7a6878c6d8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_4da0dcf1-fd42-4215-a491-0490541287ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a8b53db-f0c5-4743-bac1-5b3c0bf10245" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_4da0dcf1-fd42-4215-a491-0490541287ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_67fded33-c724-4091-9aa2-10b04c460695" xlink:href="arwr-20240331.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a8b53db-f0c5-4743-bac1-5b3c0bf10245" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_67fded33-c724-4091-9aa2-10b04c460695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_234bc64f-2226-450e-adae-9d5b49c84c04" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a8b53db-f0c5-4743-bac1-5b3c0bf10245" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_234bc64f-2226-450e-adae-9d5b49c84c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fa1d6117-f845-496f-974f-96a59a8f3394" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_234bc64f-2226-450e-adae-9d5b49c84c04" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_fa1d6117-f845-496f-974f-96a59a8f3394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8bab22aa-1516-4697-b29d-09e6f690a49e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_234bc64f-2226-450e-adae-9d5b49c84c04" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8bab22aa-1516-4697-b29d-09e6f690a49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_912864db-7d6f-444f-8d43-8239379d0cf9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_234bc64f-2226-450e-adae-9d5b49c84c04" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_912864db-7d6f-444f-8d43-8239379d0cf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_be313d92-6ef0-456a-aed4-26fd648b63a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_234bc64f-2226-450e-adae-9d5b49c84c04" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_be313d92-6ef0-456a-aed4-26fd648b63a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_105a83f4-351c-4316-b6ee-98a1ca3a6f75" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_234bc64f-2226-450e-adae-9d5b49c84c04" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_105a83f4-351c-4316-b6ee-98a1ca3a6f75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c92b9a41-1e3a-4ad1-b642-25a6c9f51379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_234bc64f-2226-450e-adae-9d5b49c84c04" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c92b9a41-1e3a-4ad1-b642-25a6c9f51379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13f4b5e6-d081-4e2a-a740-4cd3c77defed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4a8b53db-f0c5-4743-bac1-5b3c0bf10245" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_13f4b5e6-d081-4e2a-a740-4cd3c77defed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3afc8c74-0e12-43e0-9377-df9ade145d57" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_337c238c-c4eb-428f-90c5-4bde7fdd68d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3afc8c74-0e12-43e0-9377-df9ade145d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cd142236-43fb-4468-9d0f-85269e3ed78b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3afc8c74-0e12-43e0-9377-df9ade145d57" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cd142236-43fb-4468-9d0f-85269e3ed78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_4d7a1e78-8c41-4e8a-a3ef-2f9fba285da5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3afc8c74-0e12-43e0-9377-df9ade145d57" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_4d7a1e78-8c41-4e8a-a3ef-2f9fba285da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_45645b8a-3812-49a2-bfe9-e970037d938a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3afc8c74-0e12-43e0-9377-df9ade145d57" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_45645b8a-3812-49a2-bfe9-e970037d938a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9309a3c2-d816-419b-a060-9be9c350a4ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3afc8c74-0e12-43e0-9377-df9ade145d57" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_9309a3c2-d816-419b-a060-9be9c350a4ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dce67dee-7ea1-43d1-b9fe-d925dc0385b4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_337c238c-c4eb-428f-90c5-4bde7fdd68d4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dce67dee-7ea1-43d1-b9fe-d925dc0385b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_bef3f613-5934-4185-9caf-842b5f624782" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dce67dee-7ea1-43d1-b9fe-d925dc0385b4" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_bef3f613-5934-4185-9caf-842b5f624782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9f929556-de76-45e0-92c1-9ad2e87d364d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dce67dee-7ea1-43d1-b9fe-d925dc0385b4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9f929556-de76-45e0-92c1-9ad2e87d364d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromSaleOfFutureRoyalties_6171c875-ac0c-4a6e-8201-2c361c2e5e35" xlink:href="arwr-20240331.xsd#arwr_ProceedsFromSaleOfFutureRoyalties"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dce67dee-7ea1-43d1-b9fe-d925dc0385b4" xlink:to="loc_arwr_ProceedsFromSaleOfFutureRoyalties_6171c875-ac0c-4a6e-8201-2c361c2e5e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e32127be-40fa-44ce-8584-20a09d25d4e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_dce67dee-7ea1-43d1-b9fe-d925dc0385b4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_e32127be-40fa-44ce-8584-20a09d25d4e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_803d7fa4-93c6-42c6-978f-930861c6049a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_337c238c-c4eb-428f-90c5-4bde7fdd68d4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_803d7fa4-93c6-42c6-978f-930861c6049a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96b15450-9d2e-44c7-8b8c-ecccb12050ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_337c238c-c4eb-428f-90c5-4bde7fdd68d4" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_96b15450-9d2e-44c7-8b8c-ecccb12050ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_baf3e349-95f8-4c53-a436-adfcd202a0db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_337c238c-c4eb-428f-90c5-4bde7fdd68d4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_baf3e349-95f8-4c53-a436-adfcd202a0db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52880749-004b-4b05-aad7-610d0f0865a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_baf3e349-95f8-4c53-a436-adfcd202a0db" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_52880749-004b-4b05-aad7-610d0f0865a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_12c739dd-c834-4839-9035-1d424ed0936b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract_baf3e349-95f8-4c53-a436-adfcd202a0db" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_12c739dd-c834-4839-9035-1d424ed0936b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_e4eb496e-8e9b-49b9-86bc-aa13ff2928ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_337c238c-c4eb-428f-90c5-4bde7fdd68d4" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_e4eb496e-8e9b-49b9-86bc-aa13ff2928ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_49213ab0-26c8-4f83-9eb9-295bf214cc53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_e4eb496e-8e9b-49b9-86bc-aa13ff2928ea" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_49213ab0-26c8-4f83-9eb9-295bf214cc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3def8c5d-e515-41f1-9b2b-ce5241e48203" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_337c238c-c4eb-428f-90c5-4bde7fdd68d4" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3def8c5d-e515-41f1-9b2b-ce5241e48203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_477aed19-a123-4f46-9dd9-8834306bd9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_3def8c5d-e515-41f1-9b2b-ce5241e48203" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_477aed19-a123-4f46-9dd9-8834306bd9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="arwr-20240331.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_58e2c6c5-732a-42d1-bd04-1169cd3f74b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_21c74633-6313-43a3-bd2e-5ede11bc753b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_58e2c6c5-732a-42d1-bd04-1169cd3f74b3" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_21c74633-6313-43a3-bd2e-5ede11bc753b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f85f549-6a61-4e93-ae5b-1620bd37a831" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7a2ccb76-1d73-417a-b641-32df8491a061" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1f85f549-6a61-4e93-ae5b-1620bd37a831" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_7a2ccb76-1d73-417a-b641-32df8491a061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccounts" xlink:type="simple" xlink:href="arwr-20240331.xsd#BalanceSheetAccounts"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1aa4a6fa-8c3f-495d-8b73-3105fd903add" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_ef051a14-b2d8-404b-a7ed-8b1e6c6e7efc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1aa4a6fa-8c3f-495d-8b73-3105fd903add" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_ef051a14-b2d8-404b-a7ed-8b1e6c6e7efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Investments" xlink:type="simple" xlink:href="arwr-20240331.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b8c2f65a-0526-49dd-801e-bedac74c7b9b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_bea20f6f-0dd2-4f7f-98ab-e6400e839c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_b8c2f65a-0526-49dd-801e-bedac74c7b9b" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_bea20f6f-0dd2-4f7f-98ab-e6400e839c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="simple" xlink:href="arwr-20240331.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d2cdd32-eb2c-4ceb-a923-9d2029a7f4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_5be7159a-78df-425b-a960-a13f8fa00c5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8d2cdd32-eb2c-4ceb-a923-9d2029a7f4f4" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_5be7159a-78df-425b-a960-a13f8fa00c5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c6e1571e-3e75-4b7d-884a-da3813adf522" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5fae12a7-acfd-42bc-9444-31124a158cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c6e1571e-3e75-4b7d-884a-da3813adf522" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_5fae12a7-acfd-42bc-9444-31124a158cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arwr-20240331.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97ef1a95-abee-4a1d-a5dc-80cb6ce64bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6ce72a7d-4f16-43c7-bfd7-e21cea22fb84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_97ef1a95-abee-4a1d-a5dc-80cb6ce64bfd" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6ce72a7d-4f16-43c7-bfd7-e21cea22fb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Leases" xlink:type="simple" xlink:href="arwr-20240331.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a8bfa201-89c2-481a-ac4e-223dc107f108" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_86792a6c-ec61-4e5b-abe2-efb22ba53933" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a8bfa201-89c2-481a-ac4e-223dc107f108" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_86792a6c-ec61-4e5b-abe2-efb22ba53933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc813574-9e87-4c9e-b28b-53fbb8870aec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_75e11cd1-d618-453e-8aa9-45d518ca1bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc813574-9e87-4c9e-b28b-53fbb8870aec" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_75e11cd1-d618-453e-8aa9-45d518ca1bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="arwr-20240331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4b3c50c9-33e7-4094-a719-cf62c7e597c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_294fd985-caee-4364-9792-2fc9b4367f16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4b3c50c9-33e7-4094-a719-cf62c7e597c6" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_294fd985-caee-4364-9792-2fc9b4367f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="simple" xlink:href="arwr-20240331.xsd#LiabilityRelatedtotheSaleofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_8f9eb016-8dd8-4a2c-9f4c-f071c0b7df67" xlink:href="arwr-20240331.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_3b3955c4-6845-4d82-9a5e-f88c767091e5" xlink:href="arwr-20240331.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_8f9eb016-8dd8-4a2c-9f4c-f071c0b7df67" xlink:to="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_3b3955c4-6845-4d82-9a5e-f88c767091e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossPerShare" xlink:type="simple" xlink:href="arwr-20240331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1ad6348c-8b64-4d58-8ef9-a808529e4d16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_b59d5b23-53ea-4587-832e-dec65fc5a11d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1ad6348c-8b64-4d58-8ef9-a808529e4d16" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_b59d5b23-53ea-4587-832e-dec65fc5a11d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arwr-20240331.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b6ae0c89-f3c3-405e-a940-3cca02d02c86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f7664d7f-1b0f-4b53-813f-3927df07b1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6ae0c89-f3c3-405e-a940-3cca02d02c86" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f7664d7f-1b0f-4b53-813f-3927df07b1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="arwr-20240331.xsd#OrganizationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8492bf37-05b6-4250-b317-621c1cc3ccb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_75d190ab-41ae-4798-81fa-78f6dea7d210" xlink:href="arwr-20240331.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8492bf37-05b6-4250-b317-621c1cc3ccb0" xlink:to="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_75d190ab-41ae-4798-81fa-78f6dea7d210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef1ac68a-ff5c-44d2-8c4c-3a292a8a4697" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e8c5dd45-e7da-4387-b5af-65b786512bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef1ac68a-ff5c-44d2-8c4c-3a292a8a4697" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e8c5dd45-e7da-4387-b5af-65b786512bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_10e69b7e-715c-4448-b20f-197a3a7e2487" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ef1ac68a-ff5c-44d2-8c4c-3a292a8a4697" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_10e69b7e-715c-4448-b20f-197a3a7e2487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables" xlink:type="simple" xlink:href="arwr-20240331.xsd#BalanceSheetAccountsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc654c64-0ef4-4223-9728-f0694a6e4603" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b96bb6b7-4c69-4ca4-9502-eb1a68510664" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc654c64-0ef4-4223-9728-f0694a6e4603" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_b96bb6b7-4c69-4ca4-9502-eb1a68510664" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_baa99451-1d77-4e2b-bb89-0b03b2e1f240" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bc654c64-0ef4-4223-9728-f0694a6e4603" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_baa99451-1d77-4e2b-bb89-0b03b2e1f240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="simple" xlink:href="arwr-20240331.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c74142a2-abab-4f96-98e2-5cc638f66800" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_677fe338-4b52-4bca-9bc3-ecf16d141fda" xlink:href="arwr-20240331.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c74142a2-abab-4f96-98e2-5cc638f66800" xlink:to="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_677fe338-4b52-4bca-9bc3-ecf16d141fda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="arwr-20240331.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24337109-5233-494d-b0e9-010428958125" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_014dba02-c9cb-44b0-85a1-b3a798fde830" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24337109-5233-494d-b0e9-010428958125" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_014dba02-c9cb-44b0-85a1-b3a798fde830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_88997e43-bfb8-4b1c-b21c-3d4ae54a057e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_24337109-5233-494d-b0e9-010428958125" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_88997e43-bfb8-4b1c-b21c-3d4ae54a057e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_0de4c324-ad5f-4ff3-bdfb-eb4d5d1ad4c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_e1e2b420-52b8-4751-b094-b0be81e883a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_0de4c324-ad5f-4ff3-bdfb-eb4d5d1ad4c2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_e1e2b420-52b8-4751-b094-b0be81e883a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="simple" xlink:href="arwr-20240331.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_db1d331e-806d-433d-9f5a-83ae5f94fe5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_17b9f770-86a9-4c86-bdf8-4fc0c02760da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_db1d331e-806d-433d-9f5a-83ae5f94fe5e" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_17b9f770-86a9-4c86-bdf8-4fc0c02760da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_27964ebd-d7a5-4459-a39d-bfa29eff2130" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_db1d331e-806d-433d-9f5a-83ae5f94fe5e" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_27964ebd-d7a5-4459-a39d-bfa29eff2130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9dc2751-87f9-4ce8-b9d2-cdfedfc6769f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_93b31a7e-0537-4102-a742-0a3a3785952a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9dc2751-87f9-4ce8-b9d2-cdfedfc6769f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_93b31a7e-0537-4102-a742-0a3a3785952a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ff1946d4-b8bb-4634-b00c-b1df00ae3389" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9dc2751-87f9-4ce8-b9d2-cdfedfc6769f" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ff1946d4-b8bb-4634-b00c-b1df00ae3389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9222cfd4-d783-4fb7-b732-c93593513fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9dc2751-87f9-4ce8-b9d2-cdfedfc6769f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9222cfd4-d783-4fb7-b732-c93593513fc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ac1f0418-2685-409a-a3f3-37f17309be95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c9dc2751-87f9-4ce8-b9d2-cdfedfc6769f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_ac1f0418-2685-409a-a3f3-37f17309be95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="arwr-20240331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_37491bc4-ef40-4f47-8902-b2d6ec28bf19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_13ffd915-1c4c-4b6b-a475-5d45ea872f76" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_37491bc4-ef40-4f47-8902-b2d6ec28bf19" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_13ffd915-1c4c-4b6b-a475-5d45ea872f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables" xlink:type="simple" xlink:href="arwr-20240331.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_1d3bd18a-f060-4884-ab94-22af24b431b5" xlink:href="arwr-20240331.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_345d2ed4-a65f-445c-8bbd-2a29731881f4" xlink:href="arwr-20240331.xsd#arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_1d3bd18a-f060-4884-ab94-22af24b431b5" xlink:to="loc_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock_345d2ed4-a65f-445c-8bbd-2a29731881f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="arwr-20240331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c31c3655-0e2a-498d-b539-010f8db17fbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7449ef4e-dcc2-4d0e-baa3-947a402fb14b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c31c3655-0e2a-498d-b539-010f8db17fbe" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7449ef4e-dcc2-4d0e-baa3-947a402fb14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3ff3ccde-fb0d-4430-a282-d47313c36057" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c31c3655-0e2a-498d-b539-010f8db17fbe" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_3ff3ccde-fb0d-4430-a282-d47313c36057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail" xlink:type="simple" xlink:href="arwr-20240331.xsd#OrganizationandSignificantAccountingPoliciesNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_542d96aa-05a5-4086-9758-bcafb24749b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_bbc0146b-cd6f-4102-8cbf-c745a13a6d8e" xlink:href="arwr-20240331.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_542d96aa-05a5-4086-9758-bcafb24749b8" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_bbc0146b-cd6f-4102-8cbf-c745a13a6d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_dcd8250c-bfc1-4040-843c-c1b25e7edf41" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_bbc0146b-cd6f-4102-8cbf-c745a13a6d8e" xlink:to="loc_srt_CounterpartyNameAxis_dcd8250c-bfc1-4040-843c-c1b25e7edf41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9d05d78-0761-4f45-9df9-b53084df78be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_dcd8250c-bfc1-4040-843c-c1b25e7edf41" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9d05d78-0761-4f45-9df9-b53084df78be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_9b211632-4fba-4c1b-90a3-b5f8a03aac92" xlink:href="arwr-20240331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e9d05d78-0761-4f45-9df9-b53084df78be" xlink:to="loc_arwr_AmgenIncorporatedMember_9b211632-4fba-4c1b-90a3-b5f8a03aac92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2e1a652d-6e60-48a9-8ef0-ebe0ad579c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_bbc0146b-cd6f-4102-8cbf-c745a13a6d8e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2e1a652d-6e60-48a9-8ef0-ebe0ad579c6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e9319c79-82f3-4c40-96cb-295ff0e5f65c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2e1a652d-6e60-48a9-8ef0-ebe0ad579c6d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e9319c79-82f3-4c40-96cb-295ff0e5f65c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_4f290e29-e59b-4268-8c12-13bcae009270" xlink:href="arwr-20240331.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e9319c79-82f3-4c40-96cb-295ff0e5f65c" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_4f290e29-e59b-4268-8c12-13bcae009270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_4503b3b4-6c90-492c-a06d-d4b2d53f6ce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_bbc0146b-cd6f-4102-8cbf-c745a13a6d8e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_4503b3b4-6c90-492c-a06d-d4b2d53f6ce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_728c56df-6949-462b-bb36-44e139c354cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_4503b3b4-6c90-492c-a06d-d4b2d53f6ce6" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_728c56df-6949-462b-bb36-44e139c354cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UnderwritingAgreementMember_4b5e5520-00f2-424f-8480-310ef11deec2" xlink:href="arwr-20240331.xsd#arwr_UnderwritingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_728c56df-6949-462b-bb36-44e139c354cc" xlink:to="loc_arwr_UnderwritingAgreementMember_4b5e5520-00f2-424f-8480-310ef11deec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:href="arwr-20240331.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_bbc0146b-cd6f-4102-8cbf-c745a13a6d8e" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_322bba83-db47-4c6c-bb63-c54590979968" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_322bba83-db47-4c6c-bb63-c54590979968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d98bcca7-cc67-49db-9bbd-cdecfd2e2641" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_d98bcca7-cc67-49db-9bbd-cdecfd2e2641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_a8bf70ce-2eb5-4969-97fc-5c020b55d90d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_a8bf70ce-2eb5-4969-97fc-5c020b55d90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d28106ae-1c19-4900-a3e9-02d6554cf366" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_d28106ae-1c19-4900-a3e9-02d6554cf366" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_b612db3d-2932-4853-a988-fc480a510583" xlink:href="arwr-20240331.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_b612db3d-2932-4853-a988-fc480a510583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a716b691-b215-4b4a-a80c-0fa2ad3a1151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_a716b691-b215-4b4a-a80c-0fa2ad3a1151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_454f8f7e-6ab4-49df-a877-7990cac90089" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_454f8f7e-6ab4-49df-a877-7990cac90089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_13be3a54-7ef2-47a0-ad6a-3b693d0d8e77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_13be3a54-7ef2-47a0-ad6a-3b693d0d8e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockAggregatePurchasePrice_6bd0a9d0-95ff-4878-9df9-10f58a3d224d" xlink:href="arwr-20240331.xsd#arwr_SaleOfStockAggregatePurchasePrice"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_arwr_SaleOfStockAggregatePurchasePrice_6bd0a9d0-95ff-4878-9df9-10f58a3d224d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_dd59fc80-b502-4ced-afc1-a1a653aefd73" xlink:href="arwr-20240331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_dd59fc80-b502-4ced-afc1-a1a653aefd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e9293e76-de3b-4cef-ad9a-32cfe0381916" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_24281049-672f-4f2a-a7b8-477830590805" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e9293e76-de3b-4cef-ad9a-32cfe0381916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4253567-6ebe-43a7-b746-84a26013f8d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_0c4633c5-c2b7-42e7-8967-7bcb7cb7abdd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e4253567-6ebe-43a7-b746-84a26013f8d6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_0c4633c5-c2b7-42e7-8967-7bcb7cb7abdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_dcc17c03-845f-44c3-aec8-ee678b4febb9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0c4633c5-c2b7-42e7-8967-7bcb7cb7abdd" xlink:to="loc_srt_MajorCustomersAxis_dcc17c03-845f-44c3-aec8-ee678b4febb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_dcc17c03-845f-44c3-aec8-ee678b4febb9" xlink:to="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_6ab73c56-aa42-47a2-a6da-57490b9916c9" xlink:href="arwr-20240331.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_6ab73c56-aa42-47a2-a6da-57490b9916c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_62807b0d-ed7f-4977-9eda-2cb1e6662b67" xlink:href="arwr-20240331.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_62807b0d-ed7f-4977-9eda-2cb1e6662b67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_aa1d3484-8440-491f-8a3f-d9ec2f548c06" xlink:href="arwr-20240331.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_aa1d3484-8440-491f-8a3f-d9ec2f548c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_2b6e3298-1fd9-4be9-b657-b27d28f1cb1e" xlink:href="arwr-20240331.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_2b6e3298-1fd9-4be9-b657-b27d28f1cb1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_076f3ace-339f-4d63-bdac-15d837d9b1a3" xlink:href="arwr-20240331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_d88c20c7-c720-4ad6-81d4-973720320843" xlink:to="loc_arwr_AmgenIncorporatedMember_076f3ace-339f-4d63-bdac-15d837d9b1a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c6171171-7797-417a-ae73-f44db1c69b71" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_0c4633c5-c2b7-42e7-8967-7bcb7cb7abdd" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c6171171-7797-417a-ae73-f44db1c69b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fad2de4e-81a3-49ef-a488-3680e86bea32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c6171171-7797-417a-ae73-f44db1c69b71" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fad2de4e-81a3-49ef-a488-3680e86bea32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_267b6ed3-a6ca-46e8-9fd6-61d8cbeaf349" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_876db4ed-ec6d-4084-a9c0-b640144f9b80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_267b6ed3-a6ca-46e8-9fd6-61d8cbeaf349" xlink:to="loc_us-gaap_AccountsReceivableNet_876db4ed-ec6d-4084-a9c0-b640144f9b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_285bcd03-beea-4c44-8ade-ce990feab597" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_267b6ed3-a6ca-46e8-9fd6-61d8cbeaf349" xlink:to="loc_us-gaap_ContractWithCustomerLiability_285bcd03-beea-4c44-8ade-ce990feab597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_e82d929c-c675-4ec3-aa06-7ccb3cb04c0a" xlink:href="arwr-20240331.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220859c4-8118-47aa-ab90-b39e6dc377a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_e82d929c-c675-4ec3-aa06-7ccb3cb04c0a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220859c4-8118-47aa-ab90-b39e6dc377a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a08b6bec-3550-48cb-b9d9-23a28f491f43" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220859c4-8118-47aa-ab90-b39e6dc377a4" xlink:to="loc_srt_CounterpartyNameAxis_a08b6bec-3550-48cb-b9d9-23a28f491f43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_767ef64b-f40c-4cd0-b78a-79a3a72906f8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a08b6bec-3550-48cb-b9d9-23a28f491f43" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_767ef64b-f40c-4cd0-b78a-79a3a72906f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_9f59ab20-ee9f-455b-8014-e971792f2c96" xlink:href="arwr-20240331.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_767ef64b-f40c-4cd0-b78a-79a3a72906f8" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_9f59ab20-ee9f-455b-8014-e971792f2c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_43c1c6f4-85bb-4ffa-a811-22c28b3c7225" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220859c4-8118-47aa-ab90-b39e6dc377a4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_43c1c6f4-85bb-4ffa-a811-22c28b3c7225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4bd9f7c5-9661-43b8-a594-2c83208d9d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_43c1c6f4-85bb-4ffa-a811-22c28b3c7225" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4bd9f7c5-9661-43b8-a594-2c83208d9d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKLicenseAgreementMember_1990f605-1855-433e-8329-7333242cae1e" xlink:href="arwr-20240331.xsd#arwr_GSKLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4bd9f7c5-9661-43b8-a594-2c83208d9d27" xlink:to="loc_arwr_GSKLicenseAgreementMember_1990f605-1855-433e-8329-7333242cae1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GSKHBVAgreementMember_04a88e34-f96a-4f56-adbf-be125573aa91" xlink:href="arwr-20240331.xsd#arwr_GSKHBVAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4bd9f7c5-9661-43b8-a594-2c83208d9d27" xlink:to="loc_arwr_GSKHBVAgreementMember_04a88e34-f96a-4f56-adbf-be125573aa91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d2179b52-3820-4017-ad2b-66ef5e337aea" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220859c4-8118-47aa-ab90-b39e6dc377a4" xlink:to="loc_srt_RangeAxis_d2179b52-3820-4017-ad2b-66ef5e337aea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_688b7754-b480-410e-b6cd-82e8a215d8ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d2179b52-3820-4017-ad2b-66ef5e337aea" xlink:to="loc_srt_RangeMember_688b7754-b480-410e-b6cd-82e8a215d8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee89ebad-ddbc-4121-a301-09264e8da4cf" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_688b7754-b480-410e-b6cd-82e8a215d8ae" xlink:to="loc_srt_MaximumMember_ee89ebad-ddbc-4121-a301-09264e8da4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_220859c4-8118-47aa-ab90-b39e6dc377a4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_a1cb8562-8057-42df-80ef-0f82fd1b8aeb" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_arwr_MilestonePaymentReceivable_a1cb8562-8057-42df-80ef-0f82fd1b8aeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_1b20c40b-6bee-422e-a9e6-6d02cafe40e1" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_1b20c40b-6bee-422e-a9e6-6d02cafe40e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_acd19659-277b-43cc-992b-94695dbb3d37" xlink:href="arwr-20240331.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_acd19659-277b-43cc-992b-94695dbb3d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_b412b19b-071f-45b0-b764-80612698ede2" xlink:href="arwr-20240331.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_arwr_SalesRelatedMilestonePayments_b412b19b-071f-45b0-b764-80612698ede2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_67b732b8-a8b5-46c7-a15f-c888693fbb33" xlink:href="arwr-20240331.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_arwr_InitialTransactionPrice_67b732b8-a8b5-46c7-a15f-c888693fbb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentAndSalesMilestonesPayments_50a6b05b-472a-4397-9a5e-ae0c75d478e7" xlink:href="arwr-20240331.xsd#arwr_DevelopmentAndSalesMilestonesPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_arwr_DevelopmentAndSalesMilestonesPayments_50a6b05b-472a-4397-9a5e-ae0c75d478e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_547c783e-76a4-4782-b32b-8cc6785c6105" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_547c783e-76a4-4782-b32b-8cc6785c6105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5b65c64a-0419-4aff-8a40-e758f5c6a827" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_2d016811-20a1-49f4-803b-219111259ea3" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_5b65c64a-0419-4aff-8a40-e758f5c6a827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_8d1439bc-0c85-4acc-a8b9-ce1b6073fad4" xlink:href="arwr-20240331.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65fbb230-5195-4aac-928c-4d9899771f38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_8d1439bc-0c85-4acc-a8b9-ce1b6073fad4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65fbb230-5195-4aac-928c-4d9899771f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_75b5c88d-ef57-4ca4-9dea-39e29558b098" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65fbb230-5195-4aac-928c-4d9899771f38" xlink:to="loc_srt_CounterpartyNameAxis_75b5c88d-ef57-4ca4-9dea-39e29558b098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32173e14-3e65-435d-918d-ed2ebcd2f7da" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_75b5c88d-ef57-4ca4-9dea-39e29558b098" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32173e14-3e65-435d-918d-ed2ebcd2f7da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_b67ad5c5-02ec-4ee3-bea0-ef2a91011286" xlink:href="arwr-20240331.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_32173e14-3e65-435d-918d-ed2ebcd2f7da" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_b67ad5c5-02ec-4ee3-bea0-ef2a91011286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4f4aabef-6dc7-4c60-a9fe-12242fc90d0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65fbb230-5195-4aac-928c-4d9899771f38" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4f4aabef-6dc7-4c60-a9fe-12242fc90d0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb73cf11-d71c-411e-9c63-e8199eb8cde5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4f4aabef-6dc7-4c60-a9fe-12242fc90d0c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb73cf11-d71c-411e-9c63-e8199eb8cde5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonLicenseAgreementMember_aeb4df95-7a04-4ee5-bb5c-1672eeeb8812" xlink:href="arwr-20240331.xsd#arwr_HorizonLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bb73cf11-d71c-411e-9c63-e8199eb8cde5" xlink:to="loc_arwr_HorizonLicenseAgreementMember_aeb4df95-7a04-4ee5-bb5c-1672eeeb8812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8e85c5-d129-4740-9113-0af1b26c488e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_65fbb230-5195-4aac-928c-4d9899771f38" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8e85c5-d129-4740-9113-0af1b26c488e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_d299243e-0996-427e-a7fd-750f7df09e34" xlink:href="arwr-20240331.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8e85c5-d129-4740-9113-0af1b26c488e" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_d299243e-0996-427e-a7fd-750f7df09e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_e3f92a73-1863-4267-b515-8fbbb0d28abe" xlink:href="arwr-20240331.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8e85c5-d129-4740-9113-0af1b26c488e" xlink:to="loc_arwr_InitialTransactionPrice_e3f92a73-1863-4267-b515-8fbbb0d28abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_23dfe1d1-44ac-4590-b53f-b4666ee9b557" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5b8e85c5-d129-4740-9113-0af1b26c488e" xlink:to="loc_arwr_MilestonePaymentEarned_23dfe1d1-44ac-4590-b53f-b4666ee9b557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1fba346b-5601-4c6f-a204-e06a8a487cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13fa7617-9d6c-4de4-9e37-ea6e0aa394c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1fba346b-5601-4c6f-a204-e06a8a487cc6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13fa7617-9d6c-4de4-9e37-ea6e0aa394c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d2af20d3-32b0-47dc-8f9d-896eb6e6751b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13fa7617-9d6c-4de4-9e37-ea6e0aa394c9" xlink:to="loc_srt_CounterpartyNameAxis_d2af20d3-32b0-47dc-8f9d-896eb6e6751b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07f5e04a-9a07-4894-a6af-6caec70c0510" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d2af20d3-32b0-47dc-8f9d-896eb6e6751b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07f5e04a-9a07-4894-a6af-6caec70c0510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_30d36630-4606-49a3-bbb3-e140ed92b677" xlink:href="arwr-20240331.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07f5e04a-9a07-4894-a6af-6caec70c0510" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_30d36630-4606-49a3-bbb3-e140ed92b677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_1f10001d-3e4a-4a6c-9aac-d5ec42e49820" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13fa7617-9d6c-4de4-9e37-ea6e0aa394c9" xlink:to="loc_us-gaap_TypeOfArrangementAxis_1f10001d-3e4a-4a6c-9aac-d5ec42e49820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93a17622-658b-443d-8dc4-69351d2b5934" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_1f10001d-3e4a-4a6c-9aac-d5ec42e49820" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93a17622-658b-443d-8dc4-69351d2b5934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_2e33963e-f862-4516-8e9f-683a9d8fa49b" xlink:href="arwr-20240331.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_93a17622-658b-443d-8dc4-69351d2b5934" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_2e33963e-f862-4516-8e9f-683a9d8fa49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_31dc0928-9158-478d-ab33-9bed541b2730" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13fa7617-9d6c-4de4-9e37-ea6e0aa394c9" xlink:to="loc_srt_RangeAxis_31dc0928-9158-478d-ab33-9bed541b2730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d1826c02-0d06-4f87-a2ff-59ddc3fba31d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_31dc0928-9158-478d-ab33-9bed541b2730" xlink:to="loc_srt_RangeMember_d1826c02-0d06-4f87-a2ff-59ddc3fba31d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3b86169f-265a-4d27-bb66-9f5fd1cc003e" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d1826c02-0d06-4f87-a2ff-59ddc3fba31d" xlink:to="loc_srt_MinimumMember_3b86169f-265a-4d27-bb66-9f5fd1cc003e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_9cd716bf-051b-43be-b619-03284a98cb99" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d1826c02-0d06-4f87-a2ff-59ddc3fba31d" xlink:to="loc_srt_MaximumMember_9cd716bf-051b-43be-b619-03284a98cb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_13fa7617-9d6c-4de4-9e37-ea6e0aa394c9" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_836aa0ca-3a19-41fb-8945-a767aa682b57" xlink:href="arwr-20240331.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_836aa0ca-3a19-41fb-8945-a767aa682b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_bcfb06ce-2f1e-42cd-b2f8-00776c64a49d" xlink:href="arwr-20240331.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_bcfb06ce-2f1e-42cd-b2f8-00776c64a49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_25191209-647f-425d-a3e7-03762647b05e" xlink:href="arwr-20240331.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_arwr_NumberOfDistinctBundle_25191209-647f-425d-a3e7-03762647b05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_7e74d0ee-cee6-4708-95f7-2aa89a6b08d2" xlink:href="arwr-20240331.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_arwr_InitialTransactionPrice_7e74d0ee-cee6-4708-95f7-2aa89a6b08d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_7b6ad4a2-b271-417a-b15c-d472266a7e62" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_arwr_MilestonePaymentEarned_7b6ad4a2-b271-417a-b15c-d472266a7e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_716a09bd-b00d-4b1e-ad01-f4158f97614a" xlink:href="arwr-20240331.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_716a09bd-b00d-4b1e-ad01-f4158f97614a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_b6c50b07-9423-4a14-b101-92723ace39ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_88035434-d0ec-48be-bd7a-6835bfff999b" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_b6c50b07-9423-4a14-b101-92723ace39ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4d5bc9e7-c355-4614-8e1d-f5b403c7eb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7a20e8-8567-4942-a7af-00bf910e1cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4d5bc9e7-c355-4614-8e1d-f5b403c7eb8a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7a20e8-8567-4942-a7af-00bf910e1cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_659e285c-8b1a-4bd8-941a-69f6bbf8ffd8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7a20e8-8567-4942-a7af-00bf910e1cb0" xlink:to="loc_srt_CounterpartyNameAxis_659e285c-8b1a-4bd8-941a-69f6bbf8ffd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f28939a-8433-4478-9933-4b2b41a7c955" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_659e285c-8b1a-4bd8-941a-69f6bbf8ffd8" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f28939a-8433-4478-9933-4b2b41a7c955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_28e3a9e9-6646-4176-b285-e25bb4ededd9" xlink:href="arwr-20240331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6f28939a-8433-4478-9933-4b2b41a7c955" xlink:to="loc_arwr_AmgenIncorporatedMember_28e3a9e9-6646-4176-b285-e25bb4ededd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4a3622bb-b31d-4431-9d89-a27b1d5addb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7a20e8-8567-4942-a7af-00bf910e1cb0" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4a3622bb-b31d-4431-9d89-a27b1d5addb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7615f5a0-6657-4128-bd82-655682a3aa53" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4a3622bb-b31d-4431-9d89-a27b1d5addb4" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7615f5a0-6657-4128-bd82-655682a3aa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_324f4894-65d7-4988-883d-f26233ff7159" xlink:href="arwr-20240331.xsd#arwr_OlpasiranAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7615f5a0-6657-4128-bd82-655682a3aa53" xlink:to="loc_arwr_OlpasiranAgreementMember_324f4894-65d7-4988-883d-f26233ff7159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e83c98a1-06fd-4082-bfc2-2d15c558deb0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7a20e8-8567-4942-a7af-00bf910e1cb0" xlink:to="loc_srt_RangeAxis_e83c98a1-06fd-4082-bfc2-2d15c558deb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4aad494b-69c1-4949-8e00-8952100e3878" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e83c98a1-06fd-4082-bfc2-2d15c558deb0" xlink:to="loc_srt_RangeMember_4aad494b-69c1-4949-8e00-8952100e3878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c35364ee-92c3-4c56-8ab0-9cf93aa552ca" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4aad494b-69c1-4949-8e00-8952100e3878" xlink:to="loc_srt_MaximumMember_c35364ee-92c3-4c56-8ab0-9cf93aa552ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e7a20e8-8567-4942-a7af-00bf910e1cb0" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_effb56d3-188f-4156-ae78-72cc53464b63" xlink:href="arwr-20240331.xsd#arwr_NumberOfAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_arwr_NumberOfAgreements_effb56d3-188f-4156-ae78-72cc53464b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_b78cac2c-d706-4527-8229-9518b2bf7fc5" xlink:href="arwr-20240331.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_b78cac2c-d706-4527-8229-9518b2bf7fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c9419768-9d91-4767-837a-c080b060b1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c9419768-9d91-4767-837a-c080b060b1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived_47335863-c862-4e42-a3ee-adbbacd77431" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_arwr_MilestonePaymentReceived_47335863-c862-4e42-a3ee-adbbacd77431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_53788916-ef80-494f-a49d-4d576e4c8dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_53788916-ef80-494f-a49d-4d576e4c8dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_071a19da-ab92-4b8e-a388-41d331369df1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_071a19da-ab92-4b8e-a388-41d331369df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_8d5dbf3f-a040-4a49-8bee-3b4b4a5b4568" xlink:href="arwr-20240331.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7c73a0f1-4218-495f-9cc5-84eb78dc7442" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_8d5dbf3f-a040-4a49-8bee-3b4b4a5b4568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60077613-f2a1-4976-bb33-227bed03b7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b037a215-c963-42b6-aa3e-cb6e0acb4440" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_60077613-f2a1-4976-bb33-227bed03b7a1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b037a215-c963-42b6-aa3e-cb6e0acb4440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_06d18c43-464c-4b2c-91cd-08303ccf44ed" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b037a215-c963-42b6-aa3e-cb6e0acb4440" xlink:to="loc_srt_CounterpartyNameAxis_06d18c43-464c-4b2c-91cd-08303ccf44ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5433a09f-030f-4df4-991a-658b10e21aac" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_06d18c43-464c-4b2c-91cd-08303ccf44ed" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5433a09f-030f-4df4-991a-658b10e21aac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_8a7d1660-f52d-4b6a-ad62-adf3c2c3a743" xlink:href="arwr-20240331.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5433a09f-030f-4df4-991a-658b10e21aac" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_8a7d1660-f52d-4b6a-ad62-adf3c2c3a743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_aa09a91e-20ca-481a-b701-9bb4726bd204" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b037a215-c963-42b6-aa3e-cb6e0acb4440" xlink:to="loc_us-gaap_TypeOfArrangementAxis_aa09a91e-20ca-481a-b701-9bb4726bd204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b10c535-be43-430a-8b0b-d2cdddc9d25b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_aa09a91e-20ca-481a-b701-9bb4726bd204" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b10c535-be43-430a-8b0b-d2cdddc9d25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaLicenseAgreementMember_1007759e-a716-48b2-a194-e6b6dac21e78" xlink:href="arwr-20240331.xsd#arwr_VisirnaLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b10c535-be43-430a-8b0b-d2cdddc9d25b" xlink:to="loc_arwr_VisirnaLicenseAgreementMember_1007759e-a716-48b2-a194-e6b6dac21e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6580e33-cc5e-4d69-80f5-b3f39f570e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_b037a215-c963-42b6-aa3e-cb6e0acb4440" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6580e33-cc5e-4d69-80f5-b3f39f570e8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_32efa31a-96b9-489f-959a-783eca1a1d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6580e33-cc5e-4d69-80f5-b3f39f570e8a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_32efa31a-96b9-489f-959a-783eca1a1d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_af2ede14-dd85-4f2b-96be-304519a1358e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6580e33-cc5e-4d69-80f5-b3f39f570e8a" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_af2ede14-dd85-4f2b-96be-304519a1358e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_52138194-d2e1-45bc-9217-0e27670475cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_e6580e33-cc5e-4d69-80f5-b3f39f570e8a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_52138194-d2e1-45bc-9217-0e27670475cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail" xlink:type="simple" xlink:href="arwr-20240331.xsd#BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_55ca5202-8134-479e-8fc8-68b06179e742" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_da306ed4-6bb1-422a-af97-7e421fbeafef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_55ca5202-8134-479e-8fc8-68b06179e742" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_da306ed4-6bb1-422a-af97-7e421fbeafef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_266b30a4-8f06-4fd5-839f-1e7af631fd12" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_da306ed4-6bb1-422a-af97-7e421fbeafef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_266b30a4-8f06-4fd5-839f-1e7af631fd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_266b30a4-8f06-4fd5-839f-1e7af631fd12" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_f04a153a-da82-49a0-90a9-589634f7dae9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_us-gaap_LandMember_f04a153a-da82-49a0-90a9-589634f7dae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_5955bc11-a324-4fbb-9734-df5b8a6bd300" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_us-gaap_BuildingMember_5955bc11-a324-4fbb-9734-df5b8a6bd300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentMember_ca7e4ba9-eadd-42f2-a888-4c70170c99dc" xlink:href="arwr-20240331.xsd#arwr_ResearchEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_arwr_ResearchEquipmentMember_ca7e4ba9-eadd-42f2-a888-4c70170c99dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_582df5d6-da32-4da8-9ea7-49385fc234cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_582df5d6-da32-4da8-9ea7-49385fc234cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputerAndSoftwareMember_e773447e-6449-4f37-b17b-6527445fcfb8" xlink:href="arwr-20240331.xsd#arwr_ComputerAndSoftwareMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_arwr_ComputerAndSoftwareMember_e773447e-6449-4f37-b17b-6527445fcfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_87e33f43-842c-4723-a6c1-9a2dffde0aab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_87e33f43-842c-4723-a6c1-9a2dffde0aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_b74e1a34-21cc-4671-b1a4-938343e96a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_633756c2-517e-4ae4-bd6f-462d9c931bc7" xlink:to="loc_us-gaap_ConstructionInProgressMember_b74e1a34-21cc-4671-b1a4-938343e96a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_da306ed4-6bb1-422a-af97-7e421fbeafef" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_90734f57-aef3-40c3-b1d9-c0ae62320a81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_90734f57-aef3-40c3-b1d9-c0ae62320a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_671a7386-5f0c-4708-ba52-c36db4c9cb26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_671a7386-5f0c-4708-ba52-c36db4c9cb26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8031abd7-9c83-4a9e-b8fe-82a724b7f8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8031abd7-9c83-4a9e-b8fe-82a724b7f8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_e6c62372-7360-47bf-a374-1c64b378242c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_e6c62372-7360-47bf-a374-1c64b378242c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_6c66e71c-b660-4bb4-b93a-433206e71c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTransfersAndChanges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_6c66e71c-b660-4bb4-b93a-433206e71c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_de3b833c-f2bc-4265-9c71-afa52caae58e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9b72165b-531a-4af0-87a2-72953c92da80" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_de3b833c-f2bc-4265-9c71-afa52caae58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#BalanceSheetAccountsAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8da8f686-c68e-429d-8a8d-34b5d063099f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent_009728b1-ba52-45bc-b409-1dc0f590c1ee" xlink:href="arwr-20240331.xsd#arwr_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8da8f686-c68e-429d-8a8d-34b5d063099f" xlink:to="loc_arwr_AccruedResearchAndDevelopmentExpenseCurrent_009728b1-ba52-45bc-b409-1dc0f590c1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_808d78db-0005-4f83-a1b9-d9c31d439f47" xlink:href="arwr-20240331.xsd#arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8da8f686-c68e-429d-8a8d-34b5d063099f" xlink:to="loc_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_808d78db-0005-4f83-a1b9-d9c31d439f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AccruedCapitalExpenditureCurrent_9728e702-57df-4d85-bd20-7e6e1c20e824" xlink:href="arwr-20240331.xsd#arwr_AccruedCapitalExpenditureCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8da8f686-c68e-429d-8a8d-34b5d063099f" xlink:to="loc_arwr_AccruedCapitalExpenditureCurrent_9728e702-57df-4d85-bd20-7e6e1c20e824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5025b047-bf39-4ad9-a8ad-4491fc5f09f0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8da8f686-c68e-429d-8a8d-34b5d063099f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_5025b047-bf39-4ad9-a8ad-4491fc5f09f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_70629ca9-d134-431a-bb3d-93ccae6e33ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8da8f686-c68e-429d-8a8d-34b5d063099f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_70629ca9-d134-431a-bb3d-93ccae6e33ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_248d5e91-21ef-4924-a107-ad7f038833c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_f8652386-b7ba-4503-b540-844d9768d430" xlink:href="arwr-20240331.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_248d5e91-21ef-4924-a107-ad7f038833c9" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_f8652386-b7ba-4503-b540-844d9768d430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fe26efe6-8bea-47e4-8036-55b1f08f0e92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_f8652386-b7ba-4503-b540-844d9768d430" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fe26efe6-8bea-47e4-8036-55b1f08f0e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74bc47a3-d754-4d94-b465-246ea11045c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fe26efe6-8bea-47e4-8036-55b1f08f0e92" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74bc47a3-d754-4d94-b465-246ea11045c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_5f24676c-901b-49cd-a2f0-c83e59c2589f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74bc47a3-d754-4d94-b465-246ea11045c6" xlink:to="loc_us-gaap_DebtSecuritiesMember_5f24676c-901b-49cd-a2f0-c83e59c2589f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_7c751e76-0a0f-4b0a-ab98-f4ba877dba76" xlink:href="arwr-20240331.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_f8652386-b7ba-4503-b540-844d9768d430" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_7c751e76-0a0f-4b0a-ab98-f4ba877dba76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_8a6c5fbf-63ec-4368-873b-dd57c0ed3599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_7c751e76-0a0f-4b0a-ab98-f4ba877dba76" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_8a6c5fbf-63ec-4368-873b-dd57c0ed3599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_7f8766c5-7635-4c92-9b6d-782e5858604a" xlink:href="arwr-20240331.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_7c751e76-0a0f-4b0a-ab98-f4ba877dba76" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_7f8766c5-7635-4c92-9b6d-782e5858604a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_885add97-f397-446f-907a-2b57688c0ac6" xlink:href="arwr-20240331.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_7c751e76-0a0f-4b0a-ab98-f4ba877dba76" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_885add97-f397-446f-907a-2b57688c0ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8bd0694f-7dd8-4d56-a1f2-cdcf6b49b390" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_7c751e76-0a0f-4b0a-ab98-f4ba877dba76" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8bd0694f-7dd8-4d56-a1f2-cdcf6b49b390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43a9e201-1de1-4c27-90c0-c1aafd8316e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_39fdcda7-f518-4050-bc36-9f21c0f83d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43a9e201-1de1-4c27-90c0-c1aafd8316e5" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_39fdcda7-f518-4050-bc36-9f21c0f83d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_d94fd28e-d4f9-46dd-82aa-cba9b9e1c93d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_39fdcda7-f518-4050-bc36-9f21c0f83d8a" xlink:to="loc_us-gaap_AssetAcquisitionAxis_d94fd28e-d4f9-46dd-82aa-cba9b9e1c93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_45419ae9-47da-401e-a4c7-e792a3e89579" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_d94fd28e-d4f9-46dd-82aa-cba9b9e1c93d" xlink:to="loc_us-gaap_AssetAcquisitionDomain_45419ae9-47da-401e-a4c7-e792a3e89579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_76786e66-fcb4-4738-925e-9ee745f9a7cb" xlink:href="arwr-20240331.xsd#arwr_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_45419ae9-47da-401e-a4c7-e792a3e89579" xlink:to="loc_arwr_NovartisMember_76786e66-fcb4-4738-925e-9ee745f9a7cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70fbc6bc-c340-4f9d-b0d4-b213311eb78f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_39fdcda7-f518-4050-bc36-9f21c0f83d8a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70fbc6bc-c340-4f9d-b0d4-b213311eb78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_842a3b51-9912-4703-8f2a-f0e2157cfb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_70fbc6bc-c340-4f9d-b0d4-b213311eb78f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_842a3b51-9912-4703-8f2a-f0e2157cfb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_337462ec-0e7b-4a43-8a58-34e1f6d63467" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_842a3b51-9912-4703-8f2a-f0e2157cfb1b" xlink:to="loc_us-gaap_PatentsMember_337462ec-0e7b-4a43-8a58-34e1f6d63467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_0ae9e160-b32e-49bf-a220-76b1f816a3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_842a3b51-9912-4703-8f2a-f0e2157cfb1b" xlink:to="loc_us-gaap_LicensingAgreementsMember_0ae9e160-b32e-49bf-a220-76b1f816a3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_39fdcda7-f518-4050-bc36-9f21c0f83d8a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e93bd0fd-bc45-488b-aa31-5499a4e9afaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e93bd0fd-bc45-488b-aa31-5499a4e9afaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_57724b52-03a1-415d-b7cf-089720b70010" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_57724b52-03a1-415d-b7cf-089720b70010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_f06f24d4-c3dc-4b5f-af9a-76bae05e4c8e" xlink:href="arwr-20240331.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_f06f24d4-c3dc-4b5f-af9a-76bae05e4c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b4e69499-0c09-47ae-9ca7-ac68c651299d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_b4e69499-0c09-47ae-9ca7-ac68c651299d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_12be652f-93b2-4804-bf7c-799535f6b020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_24c1152b-0614-4ce5-829a-54eb07de985e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_12be652f-93b2-4804-bf7c-799535f6b020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c0fe9894-18a9-4edb-b7fa-ef3fd9de4b03" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_43a9e201-1de1-4c27-90c0-c1aafd8316e5" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c0fe9894-18a9-4edb-b7fa-ef3fd9de4b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#IntangibleAssetsExpectedFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ceae3eac-c6c7-4f2d-bb48-e0e2b8d5c931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_fcb92d73-de3f-4acc-b1da-aa8b86faa1c5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ceae3eac-c6c7-4f2d-bb48-e0e2b8d5c931" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_fcb92d73-de3f-4acc-b1da-aa8b86faa1c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4e266962-b48f-48da-83f8-36c61aedea0d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ceae3eac-c6c7-4f2d-bb48-e0e2b8d5c931" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4e266962-b48f-48da-83f8-36c61aedea0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ea6b69a5-2ea1-4afa-bb7f-f699c85a94fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ceae3eac-c6c7-4f2d-bb48-e0e2b8d5c931" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_ea6b69a5-2ea1-4afa-bb7f-f699c85a94fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_939ea0c4-4d65-4b89-b5b1-42b7789dedb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ceae3eac-c6c7-4f2d-bb48-e0e2b8d5c931" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_939ea0c4-4d65-4b89-b5b1-42b7789dedb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b40ab213-0c23-453c-9ea2-3f0220bc18d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ceae3eac-c6c7-4f2d-bb48-e0e2b8d5c931" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b40ab213-0c23-453c-9ea2-3f0220bc18d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_a87cd9a6-6d2f-4245-9da3-a2e4057d13b3" xlink:href="arwr-20240331.xsd#arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ceae3eac-c6c7-4f2d-bb48-e0e2b8d5c931" xlink:to="loc_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour_a87cd9a6-6d2f-4245-9da3-a2e4057d13b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_82b66a9d-35f1-4532-a2af-2df0d99e1a14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ceae3eac-c6c7-4f2d-bb48-e0e2b8d5c931" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_82b66a9d-35f1-4532-a2af-2df0d99e1a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e2135980-e85c-40d2-bf28-c6fc74a5f54a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_0951dd47-3407-4f12-89d9-600127f7f8d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e2135980-e85c-40d2-bf28-c6fc74a5f54a" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_0951dd47-3407-4f12-89d9-600127f7f8d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_05f2a763-5a0d-4e31-8b6e-923f21dfb2ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0951dd47-3407-4f12-89d9-600127f7f8d5" xlink:to="loc_us-gaap_PlanNameAxis_05f2a763-5a0d-4e31-8b6e-923f21dfb2ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0b284140-2796-4076-b92e-6dc6fea50a09" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_05f2a763-5a0d-4e31-8b6e-923f21dfb2ce" xlink:to="loc_us-gaap_PlanNameDomain_0b284140-2796-4076-b92e-6dc6fea50a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_7e544e0d-53c8-4cde-a6f3-97c7039c0efa" xlink:href="arwr-20240331.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0b284140-2796-4076-b92e-6dc6fea50a09" xlink:to="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_7e544e0d-53c8-4cde-a6f3-97c7039c0efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6948a7a0-e9ac-4b40-9ed1-f22f45daa931" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0951dd47-3407-4f12-89d9-600127f7f8d5" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6948a7a0-e9ac-4b40-9ed1-f22f45daa931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c04f6122-5006-4336-8627-bb3be1e0299b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6948a7a0-e9ac-4b40-9ed1-f22f45daa931" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c04f6122-5006-4336-8627-bb3be1e0299b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UnderwritingAgreementMember_0090696b-d986-4fb9-942f-89a90fca54df" xlink:href="arwr-20240331.xsd#arwr_UnderwritingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c04f6122-5006-4336-8627-bb3be1e0299b" xlink:to="loc_arwr_UnderwritingAgreementMember_0090696b-d986-4fb9-942f-89a90fca54df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_f8596514-92f7-4fd4-ab7c-3c19f9a06b6c" xlink:href="arwr-20240331.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_c04f6122-5006-4336-8627-bb3be1e0299b" xlink:to="loc_arwr_AtTheMarketAgreementMember_f8596514-92f7-4fd4-ab7c-3c19f9a06b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c909c660-e6c8-4e2c-87dc-b214ce126819" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0951dd47-3407-4f12-89d9-600127f7f8d5" xlink:to="loc_srt_RangeAxis_c909c660-e6c8-4e2c-87dc-b214ce126819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c8e05676-0c3e-4d7a-9c51-3f881183f4de" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c909c660-e6c8-4e2c-87dc-b214ce126819" xlink:to="loc_srt_RangeMember_c8e05676-0c3e-4d7a-9c51-3f881183f4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f8be03ca-0ffe-4339-a7bb-ba36636fd76c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c8e05676-0c3e-4d7a-9c51-3f881183f4de" xlink:to="loc_srt_MaximumMember_f8be03ca-0ffe-4339-a7bb-ba36636fd76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_0951dd47-3407-4f12-89d9-600127f7f8d5" xlink:to="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_73368861-6c17-47d3-b1f3-7177f2196999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_73368861-6c17-47d3-b1f3-7177f2196999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_71f1d624-c344-49ab-8cef-3f323f70ad7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_71f1d624-c344-49ab-8cef-3f323f70ad7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_a2365ae7-e875-415d-9983-c578fd52fded" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_CommonStockSharesIssued_a2365ae7-e875-415d-9983-c578fd52fded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6f63ba03-00c4-424d-9053-7ead77a1a211" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6f63ba03-00c4-424d-9053-7ead77a1a211" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d340e1d7-eb70-4b6b-b7c9-9e1144873319" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_d340e1d7-eb70-4b6b-b7c9-9e1144873319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_92a585cf-0b2e-43ca-bc3b-43d2ad40d91a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_92a585cf-0b2e-43ca-bc3b-43d2ad40d91a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_8287e288-e3ea-42e4-93b4-0ba44f431ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_PreferredStockSharesIssued_8287e288-e3ea-42e4-93b4-0ba44f431ddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_ec0a96f2-e641-479b-aea7-69b425df0586" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_ec0a96f2-e641-479b-aea7-69b425df0586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a5ec7d7b-155e-4036-a99b-bdceebca4fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_a5ec7d7b-155e-4036-a99b-bdceebca4fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eba3530b-52b2-437b-8500-39d49add2fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_eba3530b-52b2-437b-8500-39d49add2fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_072afab7-e426-4e0c-bf5c-c295c70f281d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_072afab7-e426-4e0c-bf5c-c295c70f281d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SaleOfStockAggregatePurchasePrice_b6f03026-0822-4e3b-939e-d2f532e37b2d" xlink:href="arwr-20240331.xsd#arwr_SaleOfStockAggregatePurchasePrice"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_arwr_SaleOfStockAggregatePurchasePrice_b6f03026-0822-4e3b-939e-d2f532e37b2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0a0469a4-53b5-480e-81d8-d57aea1b3c07" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0a0469a4-53b5-480e-81d8-d57aea1b3c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_8111d4a1-b806-460b-89e5-cc0c8cfbeb2f" xlink:href="arwr-20240331.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_8111d4a1-b806-460b-89e5-cc0c8cfbeb2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_07cab9f9-e187-4c0f-b6a8-ddff581eab9a" xlink:href="arwr-20240331.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_07cab9f9-e187-4c0f-b6a8-ddff581eab9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_6ea12c00-ba0a-4d55-8246-5fc987734b40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_191a39b2-76b1-459b-af5f-8942aeb5bea5" xlink:to="loc_us-gaap_SharesIssued_6ea12c00-ba0a-4d55-8246-5fc987734b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail" xlink:type="simple" xlink:href="arwr-20240331.xsd#CommitmentsandContingenciesNarrativeDetail"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4ea534da-bfd4-4ea4-86e5-afe5e681fe92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_2ec8da0e-3a44-415b-b6eb-5d9941c5c7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4ea534da-bfd4-4ea4-86e5-afe5e681fe92" xlink:to="loc_us-gaap_OtherCommitmentsTable_2ec8da0e-3a44-415b-b6eb-5d9941c5c7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189369de-c366-4663-bab5-7a812d6f9afe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ec8da0e-3a44-415b-b6eb-5d9941c5c7e9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189369de-c366-4663-bab5-7a812d6f9afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35993693-b07f-4820-bd1c-faef457446b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_189369de-c366-4663-bab5-7a812d6f9afe" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35993693-b07f-4820-bd1c-faef457446b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_b3d6ab6d-d3d8-4f54-8f0d-161d1c369a4d" xlink:href="arwr-20240331.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35993693-b07f-4820-bd1c-faef457446b9" xlink:to="loc_arwr_DrugManufacturingFacilityMember_b3d6ab6d-d3d8-4f54-8f0d-161d1c369a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_61a26fb2-88ae-4d09-814a-d3a7183e36c7" xlink:href="arwr-20240331.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35993693-b07f-4820-bd1c-faef457446b9" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_61a26fb2-88ae-4d09-814a-d3a7183e36c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_cedad5c3-84e5-4ab2-8587-820608329ab8" xlink:href="arwr-20240331.xsd#arwr_FacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_35993693-b07f-4820-bd1c-faef457446b9" xlink:to="loc_arwr_FacilitiesMember_cedad5c3-84e5-4ab2-8587-820608329ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_619ab7f6-8aa2-45ed-bc82-9a699f9b27a8" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ec8da0e-3a44-415b-b6eb-5d9941c5c7e9" xlink:to="loc_srt_StatementGeographicalAxis_619ab7f6-8aa2-45ed-bc82-9a699f9b27a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ed50c88f-4c54-40fd-9df7-60f15d9e6ced" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_619ab7f6-8aa2-45ed-bc82-9a699f9b27a8" xlink:to="loc_srt_SegmentGeographicalDomain_ed50c88f-4c54-40fd-9df7-60f15d9e6ced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_1628b808-89fd-4661-8998-9c96f0c64f10" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WI"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_ed50c88f-4c54-40fd-9df7-60f15d9e6ced" xlink:to="loc_stpr_WI_1628b808-89fd-4661-8998-9c96f0c64f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a45c8293-3012-4dbe-9030-2e24d09661f0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ec8da0e-3a44-415b-b6eb-5d9941c5c7e9" xlink:to="loc_srt_RangeAxis_a45c8293-3012-4dbe-9030-2e24d09661f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_261f8a1b-afb8-4fbe-ae85-2dcb23924297" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a45c8293-3012-4dbe-9030-2e24d09661f0" xlink:to="loc_srt_RangeMember_261f8a1b-afb8-4fbe-ae85-2dcb23924297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b4eec7aa-cd2f-426b-9638-39951f6663ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_261f8a1b-afb8-4fbe-ae85-2dcb23924297" xlink:to="loc_srt_MinimumMember_b4eec7aa-cd2f-426b-9638-39951f6663ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7babc32f-1736-464f-a087-e15fbed34700" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_261f8a1b-afb8-4fbe-ae85-2dcb23924297" xlink:to="loc_srt_MaximumMember_7babc32f-1736-464f-a087-e15fbed34700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_823a911a-c4dc-42a4-94bf-e30930bfe659" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_2ec8da0e-3a44-415b-b6eb-5d9941c5c7e9" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_823a911a-c4dc-42a4-94bf-e30930bfe659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_edda8d78-6f61-44d4-8bab-821fd3b750a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_823a911a-c4dc-42a4-94bf-e30930bfe659" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_edda8d78-6f61-44d4-8bab-821fd3b750a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_27e3a531-f212-4370-9555-27d77b79f5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_823a911a-c4dc-42a4-94bf-e30930bfe659" xlink:to="loc_us-gaap_AreaOfLand_27e3a531-f212-4370-9555-27d77b79f5c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate_7b67f202-dcdf-40c6-aee2-54bbcd5aab93" xlink:href="arwr-20240331.xsd#arwr_CommitmentsCapitalExpendituresIncurredToDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_823a911a-c4dc-42a4-94bf-e30930bfe659" xlink:to="loc_arwr_CommitmentsCapitalExpendituresIncurredToDate_7b67f202-dcdf-40c6-aee2-54bbcd5aab93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_77de5813-c177-4761-8b65-a29f1b1a9960" xlink:href="arwr-20240331.xsd#arwr_AmountIntendsToInvestForBuildoutOfFacilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_823a911a-c4dc-42a4-94bf-e30930bfe659" xlink:to="loc_arwr_AmountIntendsToInvestForBuildoutOfFacilities_77de5813-c177-4761-8b65-a29f1b1a9960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2a2b51bb-9d19-4c7d-90b8-eaacbd5fe5e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_a69045a9-cc16-4259-a55e-33a3788b8d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2a2b51bb-9d19-4c7d-90b8-eaacbd5fe5e9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_a69045a9-cc16-4259-a55e-33a3788b8d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_414f9746-e7d6-4298-9ff8-bee9eea5f2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a69045a9-cc16-4259-a55e-33a3788b8d3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_414f9746-e7d6-4298-9ff8-bee9eea5f2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82a20b6e-6f5c-4cdc-b946-cd90c826dcfa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_414f9746-e7d6-4298-9ff8-bee9eea5f2c3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82a20b6e-6f5c-4cdc-b946-cd90c826dcfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_99a39b7b-2e5e-40c7-9a91-5dc7c4944447" xlink:href="arwr-20240331.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82a20b6e-6f5c-4cdc-b946-cd90c826dcfa" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_99a39b7b-2e5e-40c7-9a91-5dc7c4944447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_52d37702-5bed-4fb3-b010-05c7968d1180" xlink:href="arwr-20240331.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82a20b6e-6f5c-4cdc-b946-cd90c826dcfa" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_52d37702-5bed-4fb3-b010-05c7968d1180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_c46fc5f7-e9bc-403b-a6e7-dbc819300f61" xlink:href="arwr-20240331.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_82a20b6e-6f5c-4cdc-b946-cd90c826dcfa" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_c46fc5f7-e9bc-403b-a6e7-dbc819300f61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_8b05a0f3-3750-41c1-b2d5-628b8bc6c866" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a69045a9-cc16-4259-a55e-33a3788b8d3c" xlink:to="loc_srt_StatementGeographicalAxis_8b05a0f3-3750-41c1-b2d5-628b8bc6c866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_534984a1-cf02-4336-a851-3afed9f41a17" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8b05a0f3-3750-41c1-b2d5-628b8bc6c866" xlink:to="loc_srt_SegmentGeographicalDomain_534984a1-cf02-4336-a851-3afed9f41a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_8f4ff4b0-7365-486e-b818-8dc0cb59f60d" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_534984a1-cf02-4336-a851-3afed9f41a17" xlink:to="loc_stpr_CA_8f4ff4b0-7365-486e-b818-8dc0cb59f60d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_47c35f2d-9803-45c4-8629-1141925dc20b" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_534984a1-cf02-4336-a851-3afed9f41a17" xlink:to="loc_stpr_WI_47c35f2d-9803-45c4-8629-1141925dc20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_1dadc320-f5ed-4707-8c3c-c1911d8aaaa0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a69045a9-cc16-4259-a55e-33a3788b8d3c" xlink:to="loc_srt_CounterpartyNameAxis_1dadc320-f5ed-4707-8c3c-c1911d8aaaa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff088ea3-53a2-4351-817c-b5044ff57e3d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_1dadc320-f5ed-4707-8c3c-c1911d8aaaa0" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff088ea3-53a2-4351-817c-b5044ff57e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_7ece3307-438f-4b30-94ff-c795293181a0" xlink:href="arwr-20240331.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ff088ea3-53a2-4351-817c-b5044ff57e3d" xlink:to="loc_arwr_ColoradoOwnerLLCMember_7ece3307-438f-4b30-94ff-c795293181a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fe2b6774-1e0f-4f0d-9a91-4747720e5afb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a69045a9-cc16-4259-a55e-33a3788b8d3c" xlink:to="loc_srt_RangeAxis_fe2b6774-1e0f-4f0d-9a91-4747720e5afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b44d9a5d-6d67-44fe-9b80-717a6be57dec" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fe2b6774-1e0f-4f0d-9a91-4747720e5afb" xlink:to="loc_srt_RangeMember_b44d9a5d-6d67-44fe-9b80-717a6be57dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a6e0a311-5e96-4e78-a10f-0cfce91218d4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_b44d9a5d-6d67-44fe-9b80-717a6be57dec" xlink:to="loc_srt_MaximumMember_a6e0a311-5e96-4e78-a10f-0cfce91218d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_a69045a9-cc16-4259-a55e-33a3788b8d3c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_c94c8094-ecd8-4d01-b963-bb125dc7eb24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_c94c8094-ecd8-4d01-b963-bb125dc7eb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_f82e6b90-2962-46d6-a50a-d7939db0fb77" xlink:href="arwr-20240331.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_arwr_NumberOfOptionsToRenew_f82e6b90-2962-46d6-a50a-d7939db0fb77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7673f343-7f35-448d-a1bb-a96b16c288b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_7673f343-7f35-448d-a1bb-a96b16c288b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ef614b05-3bce-43fa-a22d-f317f19b5fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_ef614b05-3bce-43fa-a22d-f317f19b5fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MaximumAdditionalTenantImprovementAllowance_07dfa7b0-7523-4326-bb10-2d566d0fa044" xlink:href="arwr-20240331.xsd#arwr_MaximumAdditionalTenantImprovementAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_arwr_MaximumAdditionalTenantImprovementAllowance_07dfa7b0-7523-4326-bb10-2d566d0fa044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_fb2b7c23-1fe8-44f6-9744-061e1b5f9b17" xlink:href="arwr-20240331.xsd#arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_fb2b7c23-1fe8-44f6-9744-061e1b5f9b17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalTenantImprovementAllowanceLiability_22e49664-5125-4b47-a216-40aa0f500504" xlink:href="arwr-20240331.xsd#arwr_AdditionalTenantImprovementAllowanceLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_arwr_AdditionalTenantImprovementAllowanceLiability_22e49664-5125-4b47-a216-40aa0f500504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_c211475d-5036-4249-bfb5-539c3d6766c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a46fa298-82aa-4971-997a-410082479eb4" xlink:to="loc_us-gaap_ShortTermLeaseCost_c211475d-5036-4249-bfb5-539c3d6766c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2a492360-9f70-4608-8fc8-b5afbda1f050" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2e07ac16-0cca-4214-b03e-d4378182d1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2a492360-9f70-4608-8fc8-b5afbda1f050" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2e07ac16-0cca-4214-b03e-d4378182d1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d67bf6c4-d3af-427b-9f62-755afee22722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2e07ac16-0cca-4214-b03e-d4378182d1b0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d67bf6c4-d3af-427b-9f62-755afee22722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_36e0668f-fe65-42ac-a7d5-9c21430c6c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d67bf6c4-d3af-427b-9f62-755afee22722" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_36e0668f-fe65-42ac-a7d5-9c21430c6c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2076e10e-7d70-40d2-9017-df56e992981e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_36e0668f-fe65-42ac-a7d5-9c21430c6c8c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_2076e10e-7d70-40d2-9017-df56e992981e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4d39a2a5-c0a9-4e71-9f59-c1d1547734f6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_36e0668f-fe65-42ac-a7d5-9c21430c6c8c" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_4d39a2a5-c0a9-4e71-9f59-c1d1547734f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_2f6a1196-4856-43d6-aee4-6e997db01e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_2e07ac16-0cca-4214-b03e-d4378182d1b0" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_2f6a1196-4856-43d6-aee4-6e997db01e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_337e4ffd-5244-4c1d-ab5a-e80fb501dc47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2f6a1196-4856-43d6-aee4-6e997db01e6d" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_337e4ffd-5244-4c1d-ab5a-e80fb501dc47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_a4482cfd-612b-4c3d-9077-6c0f3f06311b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_337e4ffd-5244-4c1d-ab5a-e80fb501dc47" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_a4482cfd-612b-4c3d-9077-6c0f3f06311b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_03992b28-e85b-44f3-930d-b783e15a6781" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_337e4ffd-5244-4c1d-ab5a-e80fb501dc47" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_03992b28-e85b-44f3-930d-b783e15a6781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c1c3bfce-86c7-4b3e-87fe-e41be8d8f9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_337e4ffd-5244-4c1d-ab5a-e80fb501dc47" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c1c3bfce-86c7-4b3e-87fe-e41be8d8f9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_b686c56f-b0c9-4ece-9291-3110739486fd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_2f6a1196-4856-43d6-aee4-6e997db01e6d" xlink:to="loc_us-gaap_LeaseCostAbstract_b686c56f-b0c9-4ece-9291-3110739486fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3c61cde6-d368-4f21-b3a1-603be9acac0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_b686c56f-b0c9-4ece-9291-3110739486fd" xlink:to="loc_us-gaap_OperatingLeaseCost_3c61cde6-d368-4f21-b3a1-603be9acac0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_eac8d3fa-b0ae-420c-b63f-d0b365393f51" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_b686c56f-b0c9-4ece-9291-3110739486fd" xlink:to="loc_us-gaap_VariableLeaseCost_eac8d3fa-b0ae-420c-b63f-d0b365393f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_d08dea54-593e-4df4-b779-d9041b4d5b4b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_b686c56f-b0c9-4ece-9291-3110739486fd" xlink:to="loc_us-gaap_LeaseCost_d08dea54-593e-4df4-b779-d9041b4d5b4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1b3090fa-ff1d-4031-8a5a-86399c3f4502" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f6e56ec9-1e5e-4967-bb1d-b497e729237e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b3090fa-ff1d-4031-8a5a-86399c3f4502" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f6e56ec9-1e5e-4967-bb1d-b497e729237e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9928c945-00d5-4a88-b93f-7ecec8ee6e3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b3090fa-ff1d-4031-8a5a-86399c3f4502" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_9928c945-00d5-4a88-b93f-7ecec8ee6e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20fdf678-0101-4bfc-a8ad-93a5a68b34ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b3090fa-ff1d-4031-8a5a-86399c3f4502" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_20fdf678-0101-4bfc-a8ad-93a5a68b34ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e885f9d0-0968-408f-bf7e-91500289fdb2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b3090fa-ff1d-4031-8a5a-86399c3f4502" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_e885f9d0-0968-408f-bf7e-91500289fdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_99dbf6bf-f781-4814-92e1-64db492c1870" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b3090fa-ff1d-4031-8a5a-86399c3f4502" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_99dbf6bf-f781-4814-92e1-64db492c1870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_c1becbf2-0029-4c95-a6e6-81709e4d08d6" xlink:href="arwr-20240331.xsd#arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b3090fa-ff1d-4031-8a5a-86399c3f4502" xlink:to="loc_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_c1becbf2-0029-4c95-a6e6-81709e4d08d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e60e6aee-62f1-4c53-880f-37398a12a7e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b3090fa-ff1d-4031-8a5a-86399c3f4502" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_e60e6aee-62f1-4c53-880f-37398a12a7e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_38dd351f-fd52-4303-b241-dd24158b8134" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b3090fa-ff1d-4031-8a5a-86399c3f4502" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_38dd351f-fd52-4303-b241-dd24158b8134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_15c95a82-ab08-4420-9adb-b201c67183b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1b3090fa-ff1d-4031-8a5a-86399c3f4502" xlink:to="loc_us-gaap_OperatingLeaseLiability_15c95a82-ab08-4420-9adb-b201c67183b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a2a00897-1030-45b6-bf3d-f366fbde1c14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_54b9f491-cd2a-4085-ba7b-70d0a8a333b1" xlink:href="arwr-20240331.xsd#arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2a00897-1030-45b6-bf3d-f366fbde1c14" xlink:to="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_54b9f491-cd2a-4085-ba7b-70d0a8a333b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_8466c124-045f-433b-937f-dd5cfa1cdc16" xlink:href="arwr-20240331.xsd#arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_54b9f491-cd2a-4085-ba7b-70d0a8a333b1" xlink:to="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_8466c124-045f-433b-937f-dd5cfa1cdc16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b18a1323-b256-4a7a-8258-6d7190a8d6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2a00897-1030-45b6-bf3d-f366fbde1c14" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_b18a1323-b256-4a7a-8258-6d7190a8d6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_5b3cc19f-3d1d-44d9-b339-dad05a5111b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2a00897-1030-45b6-bf3d-f366fbde1c14" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_5b3cc19f-3d1d-44d9-b339-dad05a5111b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_62587492-5878-435e-97cc-619552d1570b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_5b3cc19f-3d1d-44d9-b339-dad05a5111b8" xlink:to="loc_us-gaap_OperatingLeasePayments_62587492-5878-435e-97cc-619552d1570b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3375d4d2-c0fa-458d-b8c9-92a11166cea8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2a00897-1030-45b6-bf3d-f366fbde1c14" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_3375d4d2-c0fa-458d-b8c9-92a11166cea8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ee5213ce-85a2-4185-8a1c-8a10507e69ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a2a00897-1030-45b6-bf3d-f366fbde1c14" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ee5213ce-85a2-4185-8a1c-8a10507e69ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3d273943-6c31-418b-b0d1-164d831c28ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e682f975-18c4-4f9b-9b36-b8c9df0dfd40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3d273943-6c31-418b-b0d1-164d831c28ab" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e682f975-18c4-4f9b-9b36-b8c9df0dfd40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_6722252f-c9b0-44ea-9304-61431cdea630" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e682f975-18c4-4f9b-9b36-b8c9df0dfd40" xlink:to="loc_us-gaap_PlanNameAxis_6722252f-c9b0-44ea-9304-61431cdea630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_6722252f-c9b0-44ea-9304-61431cdea630" xlink:to="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_65e3e3a6-9da3-41da-b09d-d2a7a0838dbc" xlink:href="arwr-20240331.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_65e3e3a6-9da3-41da-b09d-d2a7a0838dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_258c2031-d8fd-4bce-a898-7815597de33c" xlink:href="arwr-20240331.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_258c2031-d8fd-4bce-a898-7815597de33c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_ca748f0a-b112-46bb-8531-ba408d7fa0ee" xlink:href="arwr-20240331.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_ca748f0a-b112-46bb-8531-ba408d7fa0ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_bf8d6318-db97-4456-b910-d83fd33495d3" xlink:href="arwr-20240331.xsd#arwr_InducementAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:to="loc_arwr_InducementAwardsMember_bf8d6318-db97-4456-b910-d83fd33495d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaESOPMember_f8bd9564-da6b-4056-b712-3155b20fd83b" xlink:href="arwr-20240331.xsd#arwr_VisirnaESOPMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_fb84dcda-4447-4174-8b18-c937ae45cf22" xlink:to="loc_arwr_VisirnaESOPMember_f8bd9564-da6b-4056-b712-3155b20fd83b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d1ec8730-1c8f-4819-aa5f-dad38add63ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e682f975-18c4-4f9b-9b36-b8c9df0dfd40" xlink:to="loc_us-gaap_AwardTypeAxis_d1ec8730-1c8f-4819-aa5f-dad38add63ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda50d84-b2df-48d4-bd61-de07e6a2a848" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d1ec8730-1c8f-4819-aa5f-dad38add63ae" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda50d84-b2df-48d4-bd61-de07e6a2a848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_eecd592b-d7c5-4fd4-ab05-00a9138a6cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda50d84-b2df-48d4-bd61-de07e6a2a848" xlink:to="loc_us-gaap_EmployeeStockOptionMember_eecd592b-d7c5-4fd4-ab05-00a9138a6cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bc2fa798-c7b7-4b82-a667-e8906170df48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_dda50d84-b2df-48d4-bd61-de07e6a2a848" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bc2fa798-c7b7-4b82-a667-e8906170df48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e682f975-18c4-4f9b-9b36-b8c9df0dfd40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_776898e6-27e0-435e-ba47-aa0f04257b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_776898e6-27e0-435e-ba47-aa0f04257b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bcf28116-7e78-4a63-a8ee-650526c89d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_bcf28116-7e78-4a63-a8ee-650526c89d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c61a0805-6c2e-43c4-95a9-e18bdcf67e18" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c61a0805-6c2e-43c4-95a9-e18bdcf67e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4aa2bb6d-4b52-4711-8c6f-81987b286e23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4aa2bb6d-4b52-4711-8c6f-81987b286e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a45f095f-0044-429f-8bf7-2f65728aefe3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_a45f095f-0044-429f-8bf7-2f65728aefe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_98c5a613-f6ef-41fd-8585-b052923810e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_98c5a613-f6ef-41fd-8585-b052923810e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_97a7e9af-9db0-4040-afbf-024af16d2b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_97a7e9af-9db0-4040-afbf-024af16d2b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_86ce84f5-e10a-4f2c-89c2-f1dc6bb7d663" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_86ce84f5-e10a-4f2c-89c2-f1dc6bb7d663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_273f5866-f604-4807-9c36-ba01fbaae3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_273f5866-f604-4807-9c36-ba01fbaae3b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1bf2f43a-baf2-43fd-bca6-2c043207d6e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_343f5498-f942-4d36-98a9-1b1800063876" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1bf2f43a-baf2-43fd-bca6-2c043207d6e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ac86799-7df5-4156-8655-0613e2a89e17" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e861f10-b267-4771-94f3-7ef3763bb764" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4ac86799-7df5-4156-8655-0613e2a89e17" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e861f10-b267-4771-94f3-7ef3763bb764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_288e3cac-b65d-45ed-b755-ae345223efdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e861f10-b267-4771-94f3-7ef3763bb764" xlink:to="loc_us-gaap_PlanNameAxis_288e3cac-b65d-45ed-b755-ae345223efdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_a1935c10-1696-4fe6-9e58-afecdaca0640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_288e3cac-b65d-45ed-b755-ae345223efdb" xlink:to="loc_us-gaap_PlanNameDomain_a1935c10-1696-4fe6-9e58-afecdaca0640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_fab7ac18-8d09-41ed-a691-19f2ace0cac5" xlink:href="arwr-20240331.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a1935c10-1696-4fe6-9e58-afecdaca0640" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_fab7ac18-8d09-41ed-a691-19f2ace0cac5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_c4ecc23d-629e-46cf-859f-6c91e83d5895" xlink:href="arwr-20240331.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a1935c10-1696-4fe6-9e58-afecdaca0640" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_c4ecc23d-629e-46cf-859f-6c91e83d5895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_b37bd9a5-79fc-4b5b-9f10-3a1aa5944923" xlink:href="arwr-20240331.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a1935c10-1696-4fe6-9e58-afecdaca0640" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_b37bd9a5-79fc-4b5b-9f10-3a1aa5944923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_3ffefebe-6771-4a99-b332-964609e3df8a" xlink:href="arwr-20240331.xsd#arwr_InducementAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_a1935c10-1696-4fe6-9e58-afecdaca0640" xlink:to="loc_arwr_InducementAwardsMember_3ffefebe-6771-4a99-b332-964609e3df8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cd6770be-cb16-4f24-946a-a57d19f9deec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e861f10-b267-4771-94f3-7ef3763bb764" xlink:to="loc_us-gaap_AwardTypeAxis_cd6770be-cb16-4f24-946a-a57d19f9deec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_014d6be6-65c9-4eeb-8afa-d6272d666317" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cd6770be-cb16-4f24-946a-a57d19f9deec" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_014d6be6-65c9-4eeb-8afa-d6272d666317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_898b4649-95c5-4e5f-85b9-7616beb7f370" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_014d6be6-65c9-4eeb-8afa-d6272d666317" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_898b4649-95c5-4e5f-85b9-7616beb7f370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ccf0375-b08e-4b5c-b57f-10646dc99a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e861f10-b267-4771-94f3-7ef3763bb764" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ccf0375-b08e-4b5c-b57f-10646dc99a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4137a2f1-890f-4c0c-86c3-c435d1df602d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ccf0375-b08e-4b5c-b57f-10646dc99a5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4137a2f1-890f-4c0c-86c3-c435d1df602d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2d6ced83-2920-4a8b-80ba-756e597e90ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ccf0375-b08e-4b5c-b57f-10646dc99a5d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2d6ced83-2920-4a8b-80ba-756e597e90ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_4d34b996-e09e-482c-8d35-cb08a9bd183a" xlink:href="arwr-20240331.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0ccf0375-b08e-4b5c-b57f-10646dc99a5d" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_4d34b996-e09e-482c-8d35-cb08a9bd183a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d7a6983-cc7c-4a8d-a63a-e6cfed3f1552" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3f6b61d2-f7a1-4cf5-aedf-4874922c1729" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6d7a6983-cc7c-4a8d-a63a-e6cfed3f1552" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3f6b61d2-f7a1-4cf5-aedf-4874922c1729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_63c69ffd-ebf2-4265-85f9-226e8290dfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3f6b61d2-f7a1-4cf5-aedf-4874922c1729" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_63c69ffd-ebf2-4265-85f9-226e8290dfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_73229a75-9865-405a-8d01-8880d3acceb8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_63c69ffd-ebf2-4265-85f9-226e8290dfcd" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_73229a75-9865-405a-8d01-8880d3acceb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7d7b2ed-7fbd-45ca-940e-a9431195e6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73229a75-9865-405a-8d01-8880d3acceb8" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d7d7b2ed-7fbd-45ca-940e-a9431195e6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2f882f9e-d005-4233-85eb-73410434ca37" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_73229a75-9865-405a-8d01-8880d3acceb8" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_2f882f9e-d005-4233-85eb-73410434ca37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3c742e44-1e59-4e56-8bcd-fa47a751cc7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_3f6b61d2-f7a1-4cf5-aedf-4874922c1729" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3c742e44-1e59-4e56-8bcd-fa47a751cc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a049f27f-11c4-49d1-b78c-6ff7b9f4e94a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_3c742e44-1e59-4e56-8bcd-fa47a751cc7e" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a049f27f-11c4-49d1-b78c-6ff7b9f4e94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ea5a43a-b238-4af1-a76c-9a742adc8fee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b97202cb-5b41-4b79-9d5c-e9ef6169a7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ea5a43a-b238-4af1-a76c-9a742adc8fee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b97202cb-5b41-4b79-9d5c-e9ef6169a7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e566032c-9837-41a3-8fdb-f2f14d7bb522" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b97202cb-5b41-4b79-9d5c-e9ef6169a7b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e566032c-9837-41a3-8fdb-f2f14d7bb522" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f00c2014-81e7-486a-b338-6e93638d7483" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b97202cb-5b41-4b79-9d5c-e9ef6169a7b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_f00c2014-81e7-486a-b338-6e93638d7483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_151b1b4d-975e-4923-82c9-499c4da068c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b97202cb-5b41-4b79-9d5c-e9ef6169a7b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_151b1b4d-975e-4923-82c9-499c4da068c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3d395f54-4f4f-4da7-856b-302bfcdde277" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b97202cb-5b41-4b79-9d5c-e9ef6169a7b6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3d395f54-4f4f-4da7-856b-302bfcdde277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3becf60e-7636-4abe-9ec6-c64509f0fc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_b97202cb-5b41-4b79-9d5c-e9ef6169a7b6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3becf60e-7636-4abe-9ec6-c64509f0fc4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_447c9863-4392-4fe0-a3d4-4f39aa13cf24" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ea5a43a-b238-4af1-a76c-9a742adc8fee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_447c9863-4392-4fe0-a3d4-4f39aa13cf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86e3b670-b837-4d66-a701-d8c04c38e094" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ea5a43a-b238-4af1-a76c-9a742adc8fee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86e3b670-b837-4d66-a701-d8c04c38e094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5f94b43-dedd-4a27-a1b1-98bd56581e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86e3b670-b837-4d66-a701-d8c04c38e094" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f5f94b43-dedd-4a27-a1b1-98bd56581e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ab80c3ef-db33-4478-9314-0a9cad7fbe08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86e3b670-b837-4d66-a701-d8c04c38e094" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ab80c3ef-db33-4478-9314-0a9cad7fbe08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_186d09fd-1555-4ad3-88e4-a67b578efe50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86e3b670-b837-4d66-a701-d8c04c38e094" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_186d09fd-1555-4ad3-88e4-a67b578efe50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16ff250a-d487-4a63-bbfb-666a9572a042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86e3b670-b837-4d66-a701-d8c04c38e094" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_16ff250a-d487-4a63-bbfb-666a9572a042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7d8e68c7-4416-41be-8fe9-565ea321a78a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_86e3b670-b837-4d66-a701-d8c04c38e094" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7d8e68c7-4416-41be-8fe9-565ea321a78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7953d230-11b8-43de-add8-764a7309cdf8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ea5a43a-b238-4af1-a76c-9a742adc8fee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_7953d230-11b8-43de-add8-764a7309cdf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c7758c9e-11d4-465f-9e12-64db37962114" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ea5a43a-b238-4af1-a76c-9a742adc8fee" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_c7758c9e-11d4-465f-9e12-64db37962114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0fbea394-aa18-4ee2-a6c5-a2f5a75a98b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ea5a43a-b238-4af1-a76c-9a742adc8fee" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_0fbea394-aa18-4ee2-a6c5-a2f5a75a98b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0439ac2f-e8d7-4f80-8f6c-cbef85db73bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ea5a43a-b238-4af1-a76c-9a742adc8fee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0439ac2f-e8d7-4f80-8f6c-cbef85db73bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_670ad553-00df-4246-8345-c224694a8732" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ea5a43a-b238-4af1-a76c-9a742adc8fee" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_670ad553-00df-4246-8345-c224694a8732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#StockBasedCompensationSummaryofRSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_762c29df-b6df-43c6-b533-fb572ff525fb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e1b00b-e089-4a32-989c-210e337fc787" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_762c29df-b6df-43c6-b533-fb572ff525fb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e1b00b-e089-4a32-989c-210e337fc787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_58fe114a-3c7c-4373-96a9-8eff1a7d59a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e1b00b-e089-4a32-989c-210e337fc787" xlink:to="loc_us-gaap_AwardTypeAxis_58fe114a-3c7c-4373-96a9-8eff1a7d59a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a20de75-f02a-4c29-b2a7-117ac180993e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_58fe114a-3c7c-4373-96a9-8eff1a7d59a1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a20de75-f02a-4c29-b2a7-117ac180993e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_547350fd-658c-4e43-8433-5fd98c8cd10c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6a20de75-f02a-4c29-b2a7-117ac180993e" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_547350fd-658c-4e43-8433-5fd98c8cd10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0717cc59-b795-4059-bfc1-dc1e9f106b25" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_12e1b00b-e089-4a32-989c-210e337fc787" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0717cc59-b795-4059-bfc1-dc1e9f106b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_836026bd-c714-48b5-a06d-064b86ff5807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0717cc59-b795-4059-bfc1-dc1e9f106b25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_836026bd-c714-48b5-a06d-064b86ff5807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_90542aaf-d979-4dd0-95d4-03e695708dec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_836026bd-c714-48b5-a06d-064b86ff5807" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_90542aaf-d979-4dd0-95d4-03e695708dec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3f6a78a2-0a2e-4b02-9e1c-75c6ec9eee4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_836026bd-c714-48b5-a06d-064b86ff5807" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_3f6a78a2-0a2e-4b02-9e1c-75c6ec9eee4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c8f3804a-4f52-49b9-a13a-2f40213d017a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_836026bd-c714-48b5-a06d-064b86ff5807" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c8f3804a-4f52-49b9-a13a-2f40213d017a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_68b87a52-8754-407b-baa4-8614e9d92894" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_836026bd-c714-48b5-a06d-064b86ff5807" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_68b87a52-8754-407b-baa4-8614e9d92894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_adad7290-88c9-4f24-b3eb-59bf4d4b780f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_836026bd-c714-48b5-a06d-064b86ff5807" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_adad7290-88c9-4f24-b3eb-59bf4d4b780f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a307bc5a-239f-4641-9d29-1f702b0d63b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0717cc59-b795-4059-bfc1-dc1e9f106b25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a307bc5a-239f-4641-9d29-1f702b0d63b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3562211-7760-4eb0-82e0-d35946a68b42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a307bc5a-239f-4641-9d29-1f702b0d63b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a3562211-7760-4eb0-82e0-d35946a68b42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_db93188d-900a-4fdc-82fe-170ec22594af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a307bc5a-239f-4641-9d29-1f702b0d63b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_db93188d-900a-4fdc-82fe-170ec22594af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9f52727a-f2e0-4447-9b85-d10e8238e5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a307bc5a-239f-4641-9d29-1f702b0d63b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9f52727a-f2e0-4447-9b85-d10e8238e5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_71465362-a19e-47ab-9f9c-aa12706889a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a307bc5a-239f-4641-9d29-1f702b0d63b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_71465362-a19e-47ab-9f9c-aa12706889a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_05ac9a85-029b-44db-83a8-f54dbe739767" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_a307bc5a-239f-4641-9d29-1f702b0d63b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_05ac9a85-029b-44db-83a8-f54dbe739767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e4a4ac47-6f2d-4848-9758-3c056e154b69" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cc985816-5abb-45e2-95f6-0490cf9beec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e4a4ac47-6f2d-4848-9758-3c056e154b69" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cc985816-5abb-45e2-95f6-0490cf9beec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_563290f5-9af1-463f-88b3-b54748c0eebc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cc985816-5abb-45e2-95f6-0490cf9beec3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_563290f5-9af1-463f-88b3-b54748c0eebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_edae9609-ee0e-4185-9741-f328e9288754" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_563290f5-9af1-463f-88b3-b54748c0eebc" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_edae9609-ee0e-4185-9741-f328e9288754" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_902effdf-af3b-49b1-9f4b-d974eb0ef22a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_edae9609-ee0e-4185-9741-f328e9288754" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_902effdf-af3b-49b1-9f4b-d974eb0ef22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_480a8d9c-135e-45bb-848c-51ae47f9f6e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cc985816-5abb-45e2-95f6-0490cf9beec3" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_480a8d9c-135e-45bb-848c-51ae47f9f6e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f37efe14-e074-4ff8-9060-07c5b570f3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_480a8d9c-135e-45bb-848c-51ae47f9f6e7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f37efe14-e074-4ff8-9060-07c5b570f3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9229791e-fa79-4e9c-8b35-493d4caf382f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f37efe14-e074-4ff8-9060-07c5b570f3e4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9229791e-fa79-4e9c-8b35-493d4caf382f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_7fd053bf-ef2f-45d4-9d31-1390d3d5d75b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f37efe14-e074-4ff8-9060-07c5b570f3e4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_7fd053bf-ef2f-45d4-9d31-1390d3d5d75b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ddda589c-8231-4002-9047-f1d8a720ebb0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f37efe14-e074-4ff8-9060-07c5b570f3e4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ddda589c-8231-4002-9047-f1d8a720ebb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_a47f8e76-b6a4-4b83-b58b-686fc7becc72" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cc985816-5abb-45e2-95f6-0490cf9beec3" xlink:to="loc_us-gaap_FinancialInstrumentAxis_a47f8e76-b6a4-4b83-b58b-686fc7becc72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_a47f8e76-b6a4-4b83-b58b-686fc7becc72" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_60bcbeaa-cf0f-4181-a9dc-a97468996343" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_60bcbeaa-cf0f-4181-a9dc-a97468996343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_cb473c0f-bdab-4161-9c0d-2b7acc3d303b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_cb473c0f-bdab-4161-9c0d-2b7acc3d303b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_89b4ac52-6a31-4a4c-9267-bba5429e6a00" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:to="loc_us-gaap_MunicipalBondsMember_89b4ac52-6a31-4a4c-9267-bba5429e6a00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_029a908d-a472-48e3-8e4b-3d5bbc46f858" xlink:href="arwr-20240331.xsd#arwr_CommercialNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:to="loc_arwr_CommercialNotesMember_029a908d-a472-48e3-8e4b-3d5bbc46f858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_daf4fa46-e0ff-40a2-afc5-b9e7ab419d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b28d2dc9-ae34-417b-bd52-a318f6377719" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_daf4fa46-e0ff-40a2-afc5-b9e7ab419d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_73225542-88d3-4d51-a8e4-9edafdfa36a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cc985816-5abb-45e2-95f6-0490cf9beec3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_73225542-88d3-4d51-a8e4-9edafdfa36a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13fc9803-98c2-4e49-8a58-9499a5d1bce6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_73225542-88d3-4d51-a8e4-9edafdfa36a1" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13fc9803-98c2-4e49-8a58-9499a5d1bce6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_2358e1fc-bbf9-4cdc-9d6a-778db3db3183" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13fc9803-98c2-4e49-8a58-9499a5d1bce6" xlink:to="loc_us-gaap_MoneyMarketFundsMember_2358e1fc-bbf9-4cdc-9d6a-778db3db3183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_a40ebf9e-89f5-48cb-9536-46a7ddcf2127" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13fc9803-98c2-4e49-8a58-9499a5d1bce6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_a40ebf9e-89f5-48cb-9536-46a7ddcf2127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_b4c45050-f652-4725-a6d4-1cbbd5f97bec" xlink:href="arwr-20240331.xsd#arwr_CommercialNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_13fc9803-98c2-4e49-8a58-9499a5d1bce6" xlink:to="loc_arwr_CommercialNotesMember_b4c45050-f652-4725-a6d4-1cbbd5f97bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5bf6d2cd-c69e-45ed-9dc8-a21cc646da8d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_cc985816-5abb-45e2-95f6-0490cf9beec3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5bf6d2cd-c69e-45ed-9dc8-a21cc646da8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba0c8766-56b0-490e-b7cc-9c0550784aed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5bf6d2cd-c69e-45ed-9dc8-a21cc646da8d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ba0c8766-56b0-490e-b7cc-9c0550784aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_905b3220-8b69-4e6e-8400-bd318e7d74be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5bf6d2cd-c69e-45ed-9dc8-a21cc646da8d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_905b3220-8b69-4e6e-8400-bd318e7d74be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_f3e5531f-2ba9-4c94-94fe-eed8e6474984" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5bf6d2cd-c69e-45ed-9dc8-a21cc646da8d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_f3e5531f-2ba9-4c94-94fe-eed8e6474984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_2f889d02-9d0d-4bc0-93ce-0189cdf3afec" xlink:href="arwr-20240331.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21e05616-2faf-45ce-b306-fe27b95349d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_2f889d02-9d0d-4bc0-93ce-0189cdf3afec" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21e05616-2faf-45ce-b306-fe27b95349d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_bd9800d6-2ce5-4989-b63b-6c0e55a9265c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21e05616-2faf-45ce-b306-fe27b95349d4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_bd9800d6-2ce5-4989-b63b-6c0e55a9265c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b0936ef-ba9f-4164-aa29-1a0e9fc96616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_bd9800d6-2ce5-4989-b63b-6c0e55a9265c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b0936ef-ba9f-4164-aa29-1a0e9fc96616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_53b6adb2-1ce4-41e9-a547-f314c79bb64b" xlink:href="arwr-20240331.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8b0936ef-ba9f-4164-aa29-1a0e9fc96616" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_53b6adb2-1ce4-41e9-a547-f314c79bb64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7b495963-859d-41dd-8241-2f0be72606d6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21e05616-2faf-45ce-b306-fe27b95349d4" xlink:to="loc_srt_RangeAxis_7b495963-859d-41dd-8241-2f0be72606d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_52c9f2e0-e9df-4c38-817e-52b85dbf5c6f" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7b495963-859d-41dd-8241-2f0be72606d6" xlink:to="loc_srt_RangeMember_52c9f2e0-e9df-4c38-817e-52b85dbf5c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_42e651f1-efe3-4638-a0be-b7f1151a3d7a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_52c9f2e0-e9df-4c38-817e-52b85dbf5c6f" xlink:to="loc_srt_MaximumMember_42e651f1-efe3-4638-a0be-b7f1151a3d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5046eaae-a374-41af-a537-77c36b38519b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21e05616-2faf-45ce-b306-fe27b95349d4" xlink:to="loc_srt_CounterpartyNameAxis_5046eaae-a374-41af-a537-77c36b38519b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d633576-9ad0-4fdb-9f73-e04a1464da2c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5046eaae-a374-41af-a537-77c36b38519b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d633576-9ad0-4fdb-9f73-e04a1464da2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_e6459fb8-e59a-4bbe-bdf0-2f96d89ec67a" xlink:href="arwr-20240331.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9d633576-9ad0-4fdb-9f73-e04a1464da2c" xlink:to="loc_arwr_AmgenIncorporatedMember_e6459fb8-e59a-4bbe-bdf0-2f96d89ec67a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_21e05616-2faf-45ce-b306-fe27b95349d4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_83443037-eb14-4ab0-af59-2c8b77a36984" xlink:href="arwr-20240331.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_InitialTransactionPrice_83443037-eb14-4ab0-af59-2c8b77a36984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_30d4d639-e27b-43f7-adc6-078169f28b0f" xlink:href="arwr-20240331.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_30d4d639-e27b-43f7-adc6-078169f28b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_5722ed72-7738-4ace-ab6f-723f0faabf8f" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_MilestonePaymentReceivable_5722ed72-7738-4ace-ab6f-723f0faabf8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_50c394c0-ba36-4529-8f02-dbe9df1e8677" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_50c394c0-ba36-4529-8f02-dbe9df1e8677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_e488362a-614f-481c-81e7-8bd2928b74a6" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_e488362a-614f-481c-81e7-8bd2928b74a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_c79571f4-a3a1-412c-a2aa-cc334d70d8ed" xlink:href="arwr-20240331.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_c79571f4-a3a1-412c-a2aa-cc334d70d8ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_c3768dbf-14a0-4278-8900-cc4c4a7162c6" xlink:href="arwr-20240331.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_RoyaltyPaymentThreshold_c3768dbf-14a0-4278-8900-cc4c4a7162c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyalties_7a7ec931-c147-4254-81db-23e0a1ffeaff" xlink:href="arwr-20240331.xsd#arwr_LiabilitySaleOfFutureRoyalties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyalties_7a7ec931-c147-4254-81db-23e0a1ffeaff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_0ecd3b15-f15f-4e1f-9f6f-46e64d9fc29e" xlink:href="arwr-20240331.xsd#arwr_LiabilitySaleOfFutureRoyaltiesInterestRate"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_23754d68-4dbb-47f9-a9bd-5a44f8aeadec" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_0ecd3b15-f15f-4e1f-9f6f-46e64d9fc29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_e8ee4d5c-f3f1-4c8b-99a6-e2b4a192cab5" xlink:href="arwr-20240331.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_b99b90ce-879b-404e-a1c3-1f1bc7d4c8ea" xlink:href="arwr-20240331.xsd#arwr_LiabilitySaleOfFutureRoyaltiesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_e8ee4d5c-f3f1-4c8b-99a6-e2b4a192cab5" xlink:to="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_b99b90ce-879b-404e-a1c3-1f1bc7d4c8ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_d92c0e76-d6b1-4116-a8b2-576d88fab785" xlink:href="arwr-20240331.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_b99b90ce-879b-404e-a1c3-1f1bc7d4c8ea" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_d92c0e76-d6b1-4116-a8b2-576d88fab785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_b6de621a-3be3-4b87-954c-62969507a5cc" xlink:href="arwr-20240331.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_b99b90ce-879b-404e-a1c3-1f1bc7d4c8ea" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_b6de621a-3be3-4b87-954c-62969507a5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_b9b298a1-fc9b-4f36-a470-93f9820a8429" xlink:href="arwr-20240331.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilitySaleOfFutureRoyaltiesRollForward_b99b90ce-879b-404e-a1c3-1f1bc7d4c8ea" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_b9b298a1-fc9b-4f36-a470-93f9820a8429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#NetLossPerShareBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_5bda85ae-49ee-427d-9a83-1032535144d0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_17e8bbe6-0665-4adc-af58-6d516ac8ed99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5bda85ae-49ee-427d-9a83-1032535144d0" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_17e8bbe6-0665-4adc-af58-6d516ac8ed99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5117c250-cb2e-453d-9c78-fbc90caeb20f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_17e8bbe6-0665-4adc-af58-6d516ac8ed99" xlink:to="loc_us-gaap_NetIncomeLoss_5117c250-cb2e-453d-9c78-fbc90caeb20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8ed94ac5-98d4-4e03-92e1-bbec86a01f47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5bda85ae-49ee-427d-9a83-1032535144d0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8ed94ac5-98d4-4e03-92e1-bbec86a01f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6ae5e6b-f25a-4822-a203-add4f0a64d33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8ed94ac5-98d4-4e03-92e1-bbec86a01f47" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e6ae5e6b-f25a-4822-a203-add4f0a64d33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e2061d4f-31f5-4e1b-92d2-b9f38113ffd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8ed94ac5-98d4-4e03-92e1-bbec86a01f47" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e2061d4f-31f5-4e1b-92d2-b9f38113ffd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f629f495-b025-4b82-8156-bb49f3a4d6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8ed94ac5-98d4-4e03-92e1-bbec86a01f47" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f629f495-b025-4b82-8156-bb49f3a4d6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7089a482-4a74-49a2-be67-899e97c82e7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5bda85ae-49ee-427d-9a83-1032535144d0" xlink:to="loc_us-gaap_EarningsPerShareBasic_7089a482-4a74-49a2-be67-899e97c82e7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8869b93b-c1b4-4a4e-b794-8cc9940ea3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_5bda85ae-49ee-427d-9a83-1032535144d0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8869b93b-c1b4-4a4e-b794-8cc9940ea3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails" xlink:type="simple" xlink:href="arwr-20240331.xsd#NetLossPerShareAntidulitiveDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_37e5b143-3ee8-4392-9cfb-80667a011881" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5f93094-0f5a-4307-8569-61fd9175d855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_37e5b143-3ee8-4392-9cfb-80667a011881" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5f93094-0f5a-4307-8569-61fd9175d855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5262261b-81a3-4776-9aa1-a21bf2a22249" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5f93094-0f5a-4307-8569-61fd9175d855" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5262261b-81a3-4776-9aa1-a21bf2a22249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_39fd4f1f-d7cf-44e5-85ac-a906c7aee155" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5262261b-81a3-4776-9aa1-a21bf2a22249" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_39fd4f1f-d7cf-44e5-85ac-a906c7aee155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_851f8656-ece3-4c6f-bd75-8abc676d1b99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_39fd4f1f-d7cf-44e5-85ac-a906c7aee155" xlink:to="loc_us-gaap_EmployeeStockOptionMember_851f8656-ece3-4c6f-bd75-8abc676d1b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ffb70541-191b-4f50-b2b9-d55bc5306bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_39fd4f1f-d7cf-44e5-85ac-a906c7aee155" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ffb70541-191b-4f50-b2b9-d55bc5306bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b9ff47c-31bd-419a-a43f-1ec8c8304cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b5f93094-0f5a-4307-8569-61fd9175d855" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b9ff47c-31bd-419a-a43f-1ec8c8304cf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c3ca2a52-f6aa-45b6-ab11-c7b5ec31f4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2b9ff47c-31bd-419a-a43f-1ec8c8304cf6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c3ca2a52-f6aa-45b6-ab11-c7b5ec31f4d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch12PlanMember" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch12PlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_KenMyszkowskiMarch12PlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch28Plan1Member" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch28Plan1Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_KenMyszkowskiMarch28Plan1Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch28Plan2Member" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch28Plan2Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_KenMyszkowskiMarch28Plan2Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch28Plan3Member" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch28Plan3Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_KenMyszkowskiMarch28Plan3Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMarch28Plan4Member" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMarch28Plan4Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_KenMyszkowskiMarch28Plan4Member" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonMember" xlink:href="arwr-20240331.xsd#arwr_JamesHamiltonMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_JamesHamiltonMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMember" xlink:href="arwr-20240331.xsd#arwr_KenMyszkowskiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_KenMyszkowskiMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienMember" xlink:href="arwr-20240331.xsd#arwr_PatrickOBrienMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_PatrickOBrienMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_WilliamWaddillMember" xlink:href="arwr-20240331.xsd#arwr_WilliamWaddillMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_WilliamWaddillMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>arwr-2024331xex311001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arwr-2024331xex311001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M[ "I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIK-AE ZF@"
M)#FZE]@*GJO'_P ?<W_ :L4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !4;_P"MC_&I*C?_ %L?XT 1Q?Z^0^X_E5BJT'^ME^H_E5F@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *C?_6Q_C4E1O\ ZV/\: (H/]?*
M/0C^56:JV_\ Q\S_ %'\JM4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !4;_P"MC_&I*C?_ %L?XT 0V_\ Q\W'^\/Y5:JK;_\ 'S<?[P_E5J@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *C?_6Q_C4E1O_K8_P :
M (;?_CYN/]X?RJU56W_X^KC_ 'A_*K5 !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4QO]8GXT^F-]]/QH @M_\ CZN/]X?RJU56W_X^KC_>'\JM
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !15&_UG3-*:)=0U"UM#*<
M1B>54WGT&3S3K+5M.U)I5L;ZWN6BQY@AE#E,YQG'3.#^5 %RBHYYX;6WDN+B
M5(H8E+R2.P554#)))Z"DMKJWO+6.YMIXYH)%W)+&P96'J".#0!+16>FNZ1*+
M4QZI9L+MF2V*SJ?.8'!"<_,0>.*LWE[:Z?;FXO;F&WA! ,DSA%!)P!D^IH G
MHI,C.,C/7%4]1U?3=(C234M0M;-'.U&N)5C#'T&3S0!=HJI+JNGP6"7TU];1
MVCJ&2=Y5",#R"&S@YJV"" 0<@T %%58M2L9[Z6QBO+>2[A :6!) 70>I7J*M
M4 %%%% !1110 4444 %%%% !1110 4444 %,;[Z?C3Z8_P!]/QH @M_^/JX_
MWA_*K55+?_CZN/\ >'_H-6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#S+XL22KJ_@M873S#JR,D<@.UF#)@DCH!G]?:NUC2_N-*DBGGM['6I8F_>0
M;7V[6.T@,#N49'4=ST)J;6- TO7XH8]4LTN4A??&&)&UO48--A\/:9;RSS)
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "F/]]?QI],?[Z?C0!7MO\ CYN?^NO_ +**MU4MO^/FY_ZZ_P#LHJW0
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M113)9HX(FEFD2.-!EG=@ !ZDF@!]%4;?6=+O%=K;4K.<("6,4ZMM Y).#Q4
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M\M9(FE2YA:-/O.K@A?J: )Z*K-J-B@4M>6ZAAE295&1ZCFG0WMK<.4@N896
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MH$WS2)&F0-SL ,DX Y]20/QJ"*],NHW%G]DN4$*(WGN@$4F[/"G/)&.>.XH
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M** "BBB@ HHHH **** "FOVIU&,T 5;/K-_UT-6JKVO_ "T_ZZ&K% !1110
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M65HU96.6!&0?K0!Y586-M>ZUX8TN35[[4-/FM+T"5I)(//"LI7&&!*CD YY
M]*]!\2:A]@TDI',D5W>.MI:LS8_>R':I_#.[CL#6KY<>Y6V+N484XY'TH:-'
MV[T5MIR,C.#ZT <%I$!\'>,H+*X:SM[+6;<1PQQ-@">$*HZXY92/J5'K64US
ML@%]!?727"^+?L@4W;D;#-M9"I.""N3C'3'I7J+Q1NRLZ*S*<J2,D?2D\B'_
M )Y)][?]T?>]?K[T >:6DNB:CX]+V>H16MIIT[;Y#=?O+Z[<_<&6R47/0<$G
M&#BJ/@[Q#;R^,]-VZA^XO+*</YMVTDLDP<$><#\JOM!(  P#CIBO5Q:6RN'%
MO$&!R"$&<TX00J<K$@.2>%'4]30!Y3X:F@'AKP7;WUPT.B3077G-)-Y2-.&^
M0%@1_P!-"!GG'J*L6SW%SK'A6PFU*]DT^XN-32-Q<NIN(%_U66!RPQT.<D<C
MK7IQ@A,0B,49C'1-HP/PI?*CRA\M<I]WC[OT]* /*QK,D6E>'8Y]7:#299[V
M&:]G>1TWK*1$LCAU.-H;!+8X%=QX?U/3HK#3=-764O;B6%G@>1B'G16/S $D
MD#L<G(&>:VS!"8_+,2&/.=NT8_*J[Z9:R:C;WS1*9K="D1VCY,\9!QGID=<<
MF@#DO$+II7Q+T/6=0<1Z:UI+:"=\!(9B=PW-VW#(_"KGB_5],OO!/B!+2^MK
MATTZ8MY,@?:"I R1TR>@[X]JZJ6&*>)HIHTDC<89'4$$>X-1PV5I;6YMX+6&
M*$G)CCC"K^0XH X61_[)\1ZS:6^I74EN_A_[;NGNFDS)OD'F DX7C'W<#IQ6
M/'JY:R\,P:OKGV"VN=$21;BY:3;+,<;LNLB_,!@C)/4UZJ8(3UB3[NS[H^[Z
M?2DDMK>:-8Y8(GC0@JK("%(Z$#VH \_2ST^Y\8^$?M5S+?2G3)GCGE+(\C*8
MBCE<_*2 WU[U>^)+HL7AH/>?9!_;D!\\%08QLDRWS CCW!%=H8HVD$C1H77H
MQ49'XT20Q3 "6-' Z!E!H Y@WVE3:1?Z=<^)9+_]R\[W4<B!X(^ /FA"@'/3
MN>>N*Y/3;_6K7PWXCM[F6Y/B73;010H2Q9K<+\DP7<0SGYB2.<@ ^_J*VUNB
MLJP1*&Z@(!FG^6GF>9L7?C&['./K0!Y8NJBU\/WNIZ?XG_M&(I;&Z2S27$$1
ME&]\M([(^PL",@\9QQFKFK7^GPV-K?Z'K\T]C_;EBURPNRT4$>0K+O)^Z>"R
MDGKSBO0X;2VMT=(;>*)')9U1 H8GJ3CK35L;-+5K5;2!;=L[H1& ASUR.E '
ME>NW]GJEKK"PWSW%O:^)+1V=+ABD<+K$"=P. N\/[ ],5NPQ-KOB+Q-I5MJ=
MR+-]-M#9R173D1EE?:Z$'OA2<=>^<UVYL+,PO";2 Q2 !T\L;6 Z9&.<8%3+
M'&ARB*IP!P,<#H* /,(=8U?4/!U]J4(N8+_1+)K,JI9O])!Q*Q'1\*JD9SC<
M>];?@N:">_DFMO$T6JH]LI>"W5S'&<\,Q>1RKD'&W(SCIQ79I%'&&"1JH9BS
M;1C)/4GWIEO:6UHC+;6\4*L=S"- H)]3CO0!R6EXL/B?XB^V*8C?V]M):2.<
M+(D:%7 /J#R1U[U@:K!#J%G\0]8C);3IK-4MYDD*I-+%"ZLP(/S#)"^A*XYQ
M7IES9VM[&([NVAGC!R%E0,,_0T]88E@$"Q((@NT1A1M ],>E 'G>H:?IW_"3
M_#^*$OY+I<%0+A_N^06&.<]3_3IQ2MK?V2PNWO;Z9;!?$LMM>2F5\Q0X)5=P
M.57=Y8XXP<=*]!%M HC"P1@1@! $'R = /2E>WADBDB>&-HY,[U900WU'>@#
MSC4;^PL4TR&V\2/_ &'>75R6O;F9Y(E?"E(Q*KJ=@R^,L1D<].)+& WGB+0M
M._X2.^OK-]*FD^T17#1BY*3)M)P>< D9') Y)%=^]A9R6@M'M(&M@ !"T8*#
M'3Y>E2B*-2I6- 4&U<*.!Z"@#F_&-[-:-HZM*8=,FOECOY@Y3:A4[06!!4%]
MH)X].]<9XJDF/@WQ?:RW,LNGV5_ EC*\Q)Y,9=-V<L%+,.<X_#CU>:&*XA:&
M>-)8G&&1U# CW!IB6EM';K;I;Q+ OW8P@"CZ#I0!%+/:Z5I4EQ)(4M+:(R,[
M,6P@&<Y/)XKSZX.H^&M<T7Q'J=M:0)=S-9W\J7!9B)CN0L"B@!" .IP*](D@
MBFA:&6)'B8;61E!4CT(HFMX+E-D\,<J YVNH89_&@#C#&][XN\3B34;U5LHK
M>6&".X9%4F)\G /0^G3(SUK"TE[FV\'^&+R>_OY8-4GB_M*XFNWPB[6"C=GY
M 6*@D8SP#G//IYMH#OS#'^\4(_RCYE&>#ZCD\>]-%E:+:?9!;0BVQM\D1C9C
MTV]* //-0M=3FL/$2Z?>74T6D7<=Q8M]I8[]JJ\L!;.67J,$\9QVQ5:SO=1U
M36Q:11WEOI?B$Q7MHYFDW110N#(,Y^7S% ( Z>8*].AMH+> 000QQ0@8$:*%
M4?@*<(HP4(C4%!A>/NCT'I0!Y0&N+&*XU."]NEE'BYH!&)2(]C3;6!48W9!_
MBSC'&.<VK'49=1\57)O/%$5A?VVL&!+!C('D@#@+&(_,"D,N#N"$C.<\5Z/_
M &?9?-_H=O\ /)YK?NE^9_[QX^][]:<;*U:[%V;:$W(&T3&,;P/3=UH \OT?
M75D\5Z5+#J<DBW$M[&PFO69[@C.W=#G:@S@*!R<4:/?V.I>(/ ^I?VFUSJ5Q
M]H-XKW).R0PME?+)PF&R  !TKTQ-+T^-]\=C:HV_S,K"H._^]TZ^](FDZ;'<
M_:8]/M$N-Q;S5A4-D]3G&<T <]XX\SS_  P(IXX)3K481Y(]Z@^3+CY<C.>G
M7O6=KGAQ=,M;B_EOW;4-4U>P:>Z5%0(%E14"*<@!1ZY]Z[B>TMKKR_M%O%-Y
M;;D\Q VT^HST-+/;07*JL\,<H1@ZB10V&'0C/?WH \TN=4FTZ+Q/:SZEJ!M[
M75+6& ?:3OPZH2AE8Y16.<MG@$XK.L=4N[VPCT^'6YT \5_9 \%X966V,3%5
M#MDLN0<$]<9[5ZQ)IUC,)A+96[B<@R[HE/F$=-W'./>F_P!E:=C'V"UQO#X\
ME?O 8!Z=0.AH \]U87=K>^+[>+5]31-,T>.YM5^VL29-DIWDYSP5 QG![@\5
M<AO)=*GEFN=<OC'/H#WLKRN)?+D!'[Q$Q@8W=  .!Q7=-96KO*[VT+/,FR5C
M&"77T;U'L:1;"S5@RVD 81>2"(QD1_W.GW?;I0!Y3!XKNH?[3-MJ4FS^QH;C
M;]L^U21,96#R<Y"N(_F*+P.*W-6U:UL-#N+W1/$,EQ9S36:SR27+3BSB9R&?
M=G>-PP",@CJ,5W$&F6%J0;>QMHB%* QQ*N%/)' Z4D&E:=:VLEK;V%K%;RDM
M)%'"JHY/4D 8.: .!FOI;*/35A\5I>P2:];*SP.S+'&R,?*+EV+!B >6XSZ5
M3O+JWU)7$^ISW$-OXLCA1UNI%"1LJD*"&'0YP>QSC&:]);2=->Q>Q;3[0V;\
MM;F%?+/U7&*:=%THVLEJ=,LS;R.'>+R%V,PQ@D8P3P.?:@#B=1UV:QE\5-:W
M\DMO;/8'/GE_(AD"^8Z\DCY<G(^M/U+4-,LM/:YL/$]W=6MQ?6R+%'?!U0D'
MY#,2616'S$YR,<=>>Y6QM%,Q6U@'G*%EQ&/W@ P WJ ..:8NE:<MHUHMA:BV
M8[FA$*["?4KC&>!0!YAINJ2:CIVB"XO1<R0>+&C!,YE*H%EV#<>2,=">HK;T
M.\EL_%<CW]Q)>0W;W)M]0COV,(1&),;PDX0IM(W =C79QZ1IL*!(]/M$17$@
M585 #CHW3J/6F1Z)ID$US/;Z=:07%RI66:.! S@_WCCG\: +5M<P7EM'<VTT
M<T$B[DEC8,K#U!'!KS1;V9_"GA&.PU&:WCN]9:"62VDP60M-D9Z8R!7HFEZ;
M!I&F0V%ODQ1 \MC+$DDDX '))/ QS0FE:=&D:1Z?:JL3^9&JPJ C_P!X<<'@
M<T >=V.MRV>G7,&H:I=?V?%XEFL9[F2X;S(H A* R9RH+A 3D'!/-=GHEYIM
MO;""+7A?)/=2+;/-.'8G[QC5NK[>>Y/J>*U3I]D8IHC:0&.=M\J&,8D;U88Y
M/UI5LK1%A5+6%5@.8@(P!'_N^GX4 %I>VNH0>?9W,-Q%N*[XG#+D'!&1W!KA
M-!UJ/4[.+45UB<Z^C7(ETHW!Q)(H?$1B/W0,#! !XY)R:[;3=-@TNW>& </*
MTK':!EF.>@  ]/PJ6.QM(KI[J.U@2XD&'E6,!V^IZGH* /+[#5[FY\-3:I'X
MMCDO'T>XDGL8RYD6819+'=(WEE&_NJH.1[5+/IL1T_P7>ZKJ5_<)=S++<7%Q
M?.@C)M7;"E2H4$CKUXZ\G/I":;81&<QV5LAG!$Q6)1Y@/7=QSU/6G2:?92V\
M=O):6[P1$&.-HP50C@8&,#% 'G.O7<][X-\?B:[F=+:[=(<3, J^5'\HP?NY
M8\=#FM"^:?PEJ-C=:=+>W>G:C;M:10274DRI=$;HF!9B</ROH.*[1M,T]XYH
MVL;9DF;?*IB4B1NN6&.3[FJ$NBW%QKEO=S7X.GVI#P6*P!0L@4J&+9R0 20,
M#!P>U #=0L)(/!5U8M/<7,R6#QF;>WF2,$/S9!SDGWKS[2;.WNKCX=VT5W<+
MOTRX,K17+%T8PPD@')*=N!C':O7*IVVDZ;9>7]DT^U@\K(C\J%5V9ZXP.,T
M>4IXHN)/!ND/=:Q.VH-87DH1[IK</L=E5VD7!9AMP$YW$Y/3-:F@7=MJGCO0
M[^2^DD,OAM'W_:74/+YJJ1C(!Y!RO0D<C->AG2]/9(D-A:E(23$IA7"$G)V\
M<<^E(FD:;')!(FG6BO;Y\EA"H,6>3MXXS[4 ,T5((M)A2VU&748@6Q<RS"5G
M^8YRPX.#D>V,5?J*WMK>S@$-M!'!$"2$B0*HR<G@>YJ6@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO(K1=7LS/+(T21B499U."OUR",5.VMZ8E^+)KZ%;DN(PA;&7(R%STW8YQUH
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M!G\V4#+(JJ1@#(!8D_2M'0-<36HKI'C6&]LKAK:Z@5]^QQT(.!E2,$' _0T
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M'^S%T< /LWA3NSSSC-;>E^*4;4]2M-6N[&W9-0:VLUW[&D4*N,@GKEL=L]J
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M@"G:<O-_UU/]*N53L/NS?]=FJY0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5ROA6PU+0M!U5)[$O<B]NKB"%95_
M?AF+)@YPN<XYQBNJHH 9$SO"C2)Y;E063.=I[C/>GT44 <UXATV]N_%'AB]M
MK<RP65Q,UPP91L5HBH."1GD]LU+XNL;J_LM.2UM&NO+U*VFE0,HQ&CAF/S$
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MZBB@#S>YT+4/MMOJ']F2-#-XE2_-NJC=%$(2GF,,\$MACWY]:N^(-+NYYO&
M@TR21KO28[>VE5!\[8D!0'KU9<]N/:N[HH Y'2;2[A\76<K:?-%;#0HX3(5
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M** "BBB@ HHHH **** "BBB@ H-%(2!@>M %.PY6;_KLU7:I:=]R;_KLU7:
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M$?\ 9AF/E>7N\SS$VGG(Q@>QK*M?!4MMI^C60U0-'IFHM?*3;\ODN=GWN/\
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M=H)I84\O(8$?*,G& >.3TK5K+?653Q/%HGV=RTEHUT9@?E4!PNTCU.: ,/\
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M<0,ZEBNTRHH; ?&0"<X!/6NFBUB&7Q!<Z,(Y!/;V\=PSG&TJ[, !WS\IK1H
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M4LEN)EAU&W=SY>_9&'&\GCICK7)^,#;0ZQJL<-A]EN()[%XB+9Y'D170%HV
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MVO$S("H##:L>.Q#AB#Z(*]$K,T70X=%AD5;J\O)I"#)<WDOF2L!T!.!P,G
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MV2WMU<L<#(C8HQ1]WH1G/TKU2B@#FO&B6Y\,B"YOQ:JTL06>:+S4W*=P\Q>
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MEXBJD&+ZMNSC\>,5IZW/IVH>(KNWUJ_O[03M;SZ28(%9Y$V(V(GV,RMYBMD
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M0!GGQ%9:.?$5['8K&\.I16\\DETWENS+&!(Q(/EJ PS@'I74Z9=O?:?'<R+
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)#' I +!&;DG X4$]30!:HHJI::I9WUY>6EO-OGLG6.X7:1L8J& R1@\$=*
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MJ'A;0=52W2^TBSN%MD\N$/$"(U]!Z#@<5HVMI;V-I%:VD$<-O$NU(XUPJCT
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MT%K&% ^U^7EN.3M)'&.W?)/;V_AS2;2]2[@LQ'+&[O& [;(V;(9E3.U2<G)
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M4?[)_F1_2M:LK01C1;/''!_F:U: "BBB@ HHHH **** "BBB@ HHHH ****
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M;4=)L;R55VJ]Q;I(P7K@$@\<FF#PWHBZA%?KI-D+N( 1S"!0R@  8..P  ]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1=D#>:O)4G/?_9)^G-6O[5TX20Q_;[7?, 8E\Y<R ]-HSSGVKS+3M->\\/\
MA33M3T>YGFLM6=;TRV;%",2@MDCE"S1G/0\>AQ%XMLI(;_5;:QT:YMXH[FQD
M46=BSK<(A3+%P"%" ;0BXZ9YSP >J/J-C'*(I+RW60OY81I5!+\?+C/7D<>X
MJB?$=A.^HVUA<VUQ?62MN@,ZKEPN[;GL.@)[5YO?:)+>:'XQGBT:X>_DUF*6
M!S:-YK1;XC\F1G P^<5VVD2B'QKX@M)+&Y7SWBGCG,!\IE\E%(W],Y!X_P#K
MT :6G:_;W.@V.IWYCT[[5&&\NXE48)[ G&?7Z5K!@5W @C&<UQ7CH2I<0SV3
M3K>Q6DVU&L6NK>Y0[<PN /E+$+@^@-:'B2VU/5/AY=06T'EZA-:(6MTX]"\8
M],C<H^M &M/KFEV^GW-^^H6QMK8$S2+*K!/8X/7VK/7Q7:/K=O;"6V%A+8-=
M_:S., B14VGL/O>O7BN<U*V&KW-_?Z787*0MX>GMY4>!XRTC8,2;2!N8?/T!
MQGW%-MHK76M?TZ231[C[.FA2H@N[)E"R;T&,,,!L*WX=.M '?3WEK:QK)<7,
M,*,<*TCA0?H32M=VR.$>XB5CMX+@'YCA?S/ ]:\ALX+RWTOPZ=7L=7;3VT9[
M-A:6IDE24O\ ,KJRDJI4* 0!T/:NBT/0[/\ X3:S9]*G%O:Z%;K ;V+<T4BR
ML0"Q&WS%!7H<CM0!WT\\-M"TT\L<42_>>1@H'U)J.2_LXK9+F2[@2!\;)6D
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M.D3$1@DA$8AAM/! R.XH ]91TD0.C*RGH5.14,=_9S-,L5W [0?ZT+("8_\
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MMK%H8U ?SKIR5(=@Z@!P <X+'+-@XKU>@ HHHH **** "BBB@ HHHH ****
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MF=21GA1A01UY/%,U74KB_L+BQU&&$WFF:UIZ&:)<)(&GB974$DJ=K8(R>_-
M'=T5RT'B:X;QE)HMVUM:'S#Y$$L;;[B+9GS$DSM)W9!7&0 >:F\4:[>:/):)
M;?9U29927DC>9RRKD*D2$,V>26SA0.: .CI"0 22 !U)KS^W\<ZOJ7V$65G9
M1M<:(VIN9BS!&5PI QC(/IQUZ\8-JW\57OB"QMH+);6WN)M(&H7!E5I @?A4
M4 KU.3DGC X.: .TBECGB66&1)(V&5=&!!'L15'5=%M=7\AIGN(IH&)BFMYF
MB=,C!&0>A'8UB^ 9##\,]'E R4L@V/7&:H:7XOUNY'ARXO+.Q6TUJ-@OE,V^
M*01EQG/4'!X[>IH ZS3=*M]+200M-))*09)IY3)(^!@98]@.@Z5>KS_2/&FM
MWOA_3-3N[;38?[7GCMK)8S(Q1RS;F<=QM4D $=,9YR+$OC2^LK^^T>Z@MFU&
M&]M;2":,,(I/M&2K%<DC:%8D9YP.>: .XHKD[W7]=TUH+&XL();V[NV@M98/
MNR1K&7+F-G&#P1M+^^>U1VWB/7IKC3]*NM-@L=5NGG8M*PD188]O[S8K9^8L
M %W<8/)QR =;'-%,I:*1)%#%258'!!P1]13Z\V\$ZC?6.F:3;(;9EO=8O89]
MR,",&5\J<\?<(P0>O7BK#^-M:.E6LL%K8/=3ZZ^D /O5, L _4D?=YZ]: /0
M:*XJ7Q3K_P#:5QI]KI*W=U8");H0)F.21E#D*[.NP;2,9#9)]N;%IXINKGQ@
MVCS?9K,K*0+6XC8331>62)(WSM;YN"H!P 3F@#K:*Y_6;V1O$^@Z2K,L<[37
M,Q4D;EB483Z%G4G_ '?>L[4O%MY8>(X+%8K:6.2_BLS"@9I%1USYK2 [4.>B
M$9(&<\T =C02 "2< 5S&C^)9-2\37NER36L;VS2AK-H72<*K@)(&)PZL,G@#
M&0.:LZIJ5[+K0T/34L_.-FUS,]V"Z!=VU5V@@G<=W.> #P>E &W%+'-&LD4B
MR(W1E.0?QIMQ=6]I%YMS/%#'G&^5PHS]37FGAWQ'>Z3X4\.Z)IUD]S?2:5]M
MRD7FJJ;@%!4,O4MR<\8Z'-:5R=6UOQ/X:COH[:VBDL9[F?3[BW\T*X\M&!.X
M9.)" <<9/!S0!W44\,ZEH94D53M)1@<'TX[U)7FVE^(#HVB6<6D:-86R3^('
MTPPH65>K#?GDY.S^7I6G/XSU"UMEM'M(9=6DU%[",0J[1G:@<R;>O /W<_C0
M!UFHV$>IV$MG++<1))C+V\S1.,$'AE.1TIUC%:V]G'!9E3!$/+7:^[&.#D]S
MGKGG-<M:^)]8FDTW3+JPCL=4OI9PKRH3'Y40!\S9N!^;*@*6&,DY..9OAXLB
M>&)$F6-95O[P.L0P@;SWR%]O2@#IXIX9PYAE20(Q1MC [6'4''?VK+U#PU9:
MAJ)U#SKRUNVC$3RVERT1= 20& .#@D_G7*VOB2?3K.V_L_1[&WDOO$$UA+$"
M4&X%@9"1_$=G/%=5X>U*\U&VNQ?I MS:W<ELQ@R$?;C! /(X(XR: +=FMCI]
MJEK#.@1,_?EW,23DEB3DDDDDGN:N @@$$$'H17FFG:5;R>(O%1D\*V^J6[ZD
MJ;RL.$_=1EAAN?XL\#GZUK^)=>O_  8;&"WLX9-)DA^RVS;26BN N(E<EP"I
MQUXZ=: .UI@FB:9H5D0RH 60,-P!Z$BN9NM:ULWITC3XM/EU6VLDNKGS-XC9
MF) C3GC)4_,3QQQZ8=UJ>IZ1K_BC5+:RM \-G93W22N3T5\HI Y/7YCQ\HX.
M> #T6BN+U_QC?Z+KAMS;VAMA/;Q(A<M+*)"%+_+D1A2<?,/FP<5%>>-M1LK;
M6;U["W-KI>IK9R+O82.C&(!AQC/[PGL.!]: .RFLX9KF&Y9<3PY"2+P0#U7W
M!P,CV!Z@4^>%+BWD@DW;)%*-M8J<$8X(Y!]Q7&ZYXRO["YU);2UA/V&XM[<0
M3JWF3F4@!U(/"C/H<X/(J6[\5:O_ &I-#INDF[AL[E+>X"HQ+DA2Q1N NT-T
M(YQVS0!U\<:0Q)%$BI&BA551@ #H!2@@YP0<56U*^BTO3+J_G.(K:)I6^BC-
M<+X UJ236]0L[B\\\:C&NJ6^[(VLW$L2Y R%8#&.WXT >B45S=KK6KZE>RR6
M-G;-807[V4JNY$N$.&E!Z  _PX)('45%X%U35=9TN[O-3EMW!O)HX5B0J5"N
MRX.3R.!C]<T =0"&&001[4M>3:[-I]M<^*HH]*D:>:]CMK6\3");3O"F"7SE
M!O.[(&,GU-=A_:FI:'-X6T>\:.[N+Y6@N;DDY\Q(MQ8>N2#Z4 =065<;F R<
M#)ZFEKC+K4)-6BT.6XBC5XO$$EN0O()B\] W/3.W/M4MMXLU&^U55M-'DET[
M[<]I),JMN4(2IDSC&-ZXQUQS[4 ==17,^&?%'_"075Q$6M$>#(EME9A/ P;&
MUU8#\QQD57\=,\<OA=D=U)UVW1MK$!E(?(([]!0!UU9ND:);:*U^;9YF%[=O
M>2"1@0'?&=N ,#CWK&\?6-K/X<NKF:TO9Y88'\N6U<[K<XSYNW>N=N >.3C%
M4]8\82Z'H]I<V@AO;3^S?M275Q-A[DJ%^55&6W%<L6(P.] ';T5@V?C'0[N^
MMM.^WPIJ4Z(XM"27!9 X'3T-4-'21?B3XD^:0PBVM" SD@,=Y. >GX4 =;17
M 65G/IWCR&XU_3XGN;^63[%?VUW*RJP5B(FC) &(P0& Q\OJ:M:9XBEB\'#7
MC')<W>HWC)#$Q/&Z8I&G&<!5 Z=<'N: .UHKC;C5M2U#PGK%Y=6%QIUSIR/<
M6LN&02[%+*VTX('!5E([^];TNJR_\(S_ &M;6RRR-:BX2%Y1&.5!P6/  [F@
M#4HK@X_'MU/9ZHUK9074EC<VD2R*[I%.L[*H*[ESD$_0@@@U:;QI=6]SJUC=
M6-N+ZTO;:T@6.9C'(UQC9EBN1C//';B@#L0RL2 P)7J >E+7%^#?M'_"7>,?
MM7E>=]JM]WE9V_ZD8QGGIBK6O;E\=^$BKN [W2LH<[2!"Q&1TH ZJD9@JEF(
M '))[5P'CFPN1J::OJ&GQZCH5O&J/%'=R0RP9;YY<*0&ZCCKA1TYIWC;7IKG
M0?%>FV,4 BTZR\NZDF8C)D0D*@ ZA2.O4D#UH [X$$ @Y![T9YQ7/VGBGP_;
MWEKH7]I6R7X1(UM0>02H('ITQ571\K\1?$R[W*_9;(@,Y(&?-SC/2@#JJ*\_
MTZSNM.^($4NOZ?')=7[2FRU&VN)2BD*Q\EHR=H(C!P<<X]<FK=CXJFM?!$.O
MW%O-/<ZC=?N;9<L1ODVQJ ,\! #P.<'N: .UR!CGK17%S:GJFK^$]8NYM.FT
M^^T\/-8S,C)YA5"58!P",D%2#U![@U<.H7!U;PUJ,)\NWU=#%<09S\QA,J-]
M1L9??</08 + \)6RS7'E:CJ45K<2/++9I.!&Q<DOSC<,DD\,.O&*WD18T5$4
M*J@  =A6%XFU^;0HHW2.W",CMYMQ)@%@!B-57+,S9/0<!365#XQU744TQM-T
M>V(O],:_4S79'EE2H*G"<CYQR.N>V* .TI P894@CU%<C8>+I_$%IIL>F64(
MNKVP:]DCN9#LC0$)MR!DY8GGT!^E2?#7=_PK[2MP ;;)D#U\QJ .J5E<$JP(
M!P<'O2UP6E^(WLK/2XM.T*")M3U*[@>$7!&R1"^6)P<YV$D_D#4H\3ZQ=G1?
M+CLK:635;FPND=V9&:-90-K8!P2F>F<X% '<45R'_"87LNJK#9Z1/<6HU!K&
M1DAER@5BK2[MFS:&!&,Y[Y[#/D\>:Q!X>U?6I=#MEMM/FD@ %X29'681D?<X
M&"3GU'2@#OZ1F51EB /4FN57Q1J0EURV?2X3=Z<('2-;D!667.-SD87: 22,
MC'3-<UXD\1'Q!X&U198X5GL=1M(R\#,T<@9XF#*6 .,-CIVST- 'J%%9^M:K
M'HVF-=N@=BZ111E@H>1V"J"3T&2.>PK*N->U;3U>&]TN%;F6ZCMK*1)\Q7!<
M$DGC<NT*<Y'...M '2U#=6T=Y:36LN[RYHVC;:Q4X(P<$<@\]:Y.Z\97VG_:
M;:ZTI&OH+ZVM@L<WR2I.V%=21P>&&#W'6HM2\3ZVEG<1);6EK>VVJVMG(1*9
M$:.5HR"/E'.' /XD=J -NS\,QVTT#SZGJ-\D!#0Q74JE$8# .%49(]\^O6MR
MN6_X274X]6U"VFTN'[)IJH]U=+/_  F(N2J8R2#V].^>*-*\47=Y)HAO;&**
MVUN%I+9HI2QC.SS CY SE,G(Z$8[B@#J 01D$$>U+7/>" L?@ZR4<*OF@?02
M-5"V\87EPFFWYLK=-*U2<V]K+YI,@8Y\MG7 X;;T'(R* .PHKD-+\5ZC?6<D
M4UE;Q:LFIFP-MYAP  &9\]<;-S#UXIEGXUN]2U.%+'1;N>PGD>))_)D15*Y
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M:SW^IRW4<PGCU![G-RC@8!#8P!@XQC'M2S>";26&Q(U+4X[ZR=W34%F!G8N
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M.W@DFE<)'&I=V/10!DF@#G)/!-I);V?_ !,]3%_:2/)%J/G!I\N &!+*5((
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MY/Y5H^(=9CT/1+N^WV_G10/+%%-+L$A49P._Y5>LIS=6-O<%0IEB5R!VR,T
M8^E>&!IVK+J4^H37MREI]C225%#M'N#?.P W-P.>._K5O6M#M]<6P$\TT1LK
MR.\C,1 )=,X!R#QR?\:31]9?4_[2\ZT-I]BNFMSNE#;@%5MW'3[W2J7AOQ-/
MXD>2X@T^--+P3#=+>)(SG(P"B\H<<D$Y'2@"YJFDW6I/-&-5FM[2>#R98$C0
M\<Y96()!(.._05DZOX"L]3E4PWUU91#33IC10!"#"2#@;@<'CKZ>E7I_$L2>
M+K#0H/)F-Q#-)*ZR F(IMPI ]<GKZ5JZC=FPTVYO!$9?(B:38#@M@9QDT 1Z
M;IR:?86UL7\]X(UC\YT4,V!CL!5>UT1;7Q#J&KK=3,U[%'&\+8V+LS@K@>YZ
MYJ!_$UK!X0M_$-R%ABFMHYEC>0#YI "J;C@=6 R>.])9Z_<G1)=2U/3EM,,%
MBBAN4N#-G 7:5P,EC@"@!UEH$T5[!<ZAJUSJ+6Q8VPF1%$988+':!N;!(R?4
M\5G6WA=)_#MSX:NDGM[>WG,MI=P. P!D,B,I[.IX/'8'O4^M^*#IM_INDVZV
MC:K?!R$FN-L<>U02&(&>20%XY_2IH?$DCZ->7+Z?)]OT_ O;%6!=#M#'8>C_
M "G*],].#G !#/H.HQ^%K_3/[2GU.ZO5,+3W;*H1'^5B H &%)/J35_6/#]I
MK/AN70Y2\5L\:Q@Q$ IM(*X[<%1QTJ^E[;/8I>B>,6KQB02LV%VD9!R>V*Y[
MP]XKDU^,ZFB6<6B-Y@69KC]ZC(^T;UQ@!L,1@],4 01^ HVM[Z&[UO4;H7SP
M23,PC#%HB"N,)P/E7CT%7+_P7I]_-J\[SW*3ZE)!,9$< P20J!&\?'!& ><U
MN&^M! DYNH!"_P!V3S!M;@G@]^ ?RJ#4M7LM*T>?5;J=19PQ^8TB_-D=L8ZY
MXQ]: *&A^&4T74M2U$ZA=W=UJ)C-P9M@7<@(!5548X.._:KE]HT%_JNF:B\L
MJ3:>\C1!"-K;UVD-D'MZ8K/M_%-M/XBN;(3VGV".RBN4NQ,-KEW=<9SC'R5M
M3WMI:A#<74,0?[GF2!=WTSUH S+_ $&;4KR7[3JMRVG2E2]@$38<8^7=C=M.
M,D9[GM69KO@2#6+O49H=2NK)=4B6*^BC5&68+PK?,/E;'&1752RQP1F261(X
MUZLYP!^-0OJ%E'#YSWENL6XIO:50N[TSGK[4 %G8Q6=K;P+F0PQK&)9 "[8&
M,D@=>*JVVB16NNZAJZW$[37T<<;HVW8H3.W;@9_B/4GK5R:]M;8(9[F&(/\
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M 'G'Q!LKS4+W5X+32[T2-I81+FWM6E-T=S$1!L%44<D]&;(YX&:][H\FI_\
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M1110 4444 4=(_Y!=K_UR%7JHZ1_R"K7_KD*O4 %%%% !1110 4444 %%%%
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M?]<U_P#0:NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME#*6EQ&7W@J'.< XR1GU]ZDTK4X_$$'@B!=1NX[6[EU".=8[ED<X#%48@YR
M1CZ\5ZR]K;R*JO!$P1MZAD!VMZCWIPBC7&$48Z8'2@#RU99G\6WEE=^)SI]S
M::A&+2U:"62:6 !=H0^9A@V&#?*W<GKQK^';N2+Q<(+BX74OM/VEH+^"Z)&
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ML%BF 221T .3N !SS7!:=JT%SJ'A:^L;Z.ZUR72KQIUDN-S&Y*)A2I/RDN&
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MC'>.&DCO-/CN"H"A=JL2,+@="#WK=M='L+6VC@6UA?; MN7>-=SH   QQR,
M<=* /.-7UMK_ ,07%A>^(H]*M7TZ"73KAUDP[,"6DC9'0,P.W&=WH!US6\47
MT4]AXNL]=U-A/:V42:?')(T'G Q EU3(W%GR#UZ8KU8V-HRPJUK 1#@Q QC]
MWCIM]/PHN+"RO&#7-I!.RC ,L88@?B* .?\ &4SO\.-4N+&5RWV(R12P.<\
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M%Y,TL/BIK>3_ $QV,:XD(7?D$X&,-UQ7J[Z'I$D,T,FEV313OYDR-;H5D?\
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MI8-I'E.@7:W..2> .E;7AZ\U.]LYWU2.!95N&2-H$=$>, 8(#\GG(ST...*
M,:'XB:;+>Q0'3]4CBDO6L#=/;CR4F#;0I8$]3TQGKSBKMIXPL[W4_L<=G>J'
M,RP3.BA9S%PX4;MW!!&2H!QUKE?"NFWNM:??6N;9+&'Q%-</()"9<QS;PFW;
M@9(7G/3M5W2O"7B&PUZUU"XDTJZ>*>=YKIFD$TZR< 'Y2!M7@ '']0!TOQ,B
MN--L[S3-$U.6&ZGBA2>:-8XR6DV%02W+<'IQTR>M;#:M;6&M:O=WUS?P):Z?
M#<303%3#&A+\H%))?*L#ZD#&>*RH?!6H1?#W3=#%Q;#4=/N4N8I,L8F99BX!
MXSC!(Z=:N:IX4O->EU==0DMHH-0TV&TS"69DEC=W#X(' +],\[>V: +UQXKB
ML[>>:ZTS4(/(>!65U3)$S[%8$,1UZC.1Z5E^+O%0A\-^*8K9;NVO=+B1?,!4
M',GW&4@GCZX-/O=#\5:QX8O+'4M0TL7K-$ULUO"X0-'(K[G).<DKC &![UFZ
MAX+\0ZO;>*!>76FQ2:Q';K''"7*(8\<DE<\@=A0!T.L>,;'1;FYBFMKN5;18
MWN98D79$)#A<[F!;Z*#3QXHM;G7[K0X+:_>XMY%BFFBARD6Y-X8MG@=!R.IZ
M8!(YSQ3X)USQ%?W\C76GR6T\40M8[C>QLW7!?9@8^8C[W7!Z5T&B:+J&G:YK
M^HW#VK'4F@DC6,M\K)$$8'(Z9 QUXH H>&O%!^R^'=-OHKN6ZU&U:1+QRI1V
M498$[MV[&.,?R..DTO4DU2P%XD,D,99@OFE?F"DC<-I(P<9'/2N(U/3TA\-:
M-X5:_CA\20F*2T>W!8H0^&D&1]T+OSG_  KO+6R@LM.AL(%*P0Q"%!Z*!@?I
M0!QDWBI]5\6^&!IJ7RZ;<378\[Y5BNPD+8P,Y(##(R #U&:V[#Q=9ZA'HKQV
MMTJZL\T<1;9^[:,,2&PQZA&QC-8&C>#M=TRY\.P2W&G2V.B23;)%+K+(CHR\
MKC (W>O:C2O"&OZ=-H-N)M,%AI%U-*C(TADD1PXVX(P#AR.M $^J>-=/OO"^
MI72PZY:VD(PUW;Q"-LB;RR(V)P3D<^Q]<@:>I^-;+2Y]4ADL;^8Z8D<ER88U
M(6-P3OR6'  .1U] >:S[CPEJEY\.;WP]--:+?7$TDHE5F,?SSF;GY01U(Z=J
M=K/A+4M1_P"$I\BXMXCK-I!!&2S?NR@8-NXZ$-VH T]6\7V.DS7,9M[FY-I;
M"[NC %_<Q$G!.YAGH3@9/'TJUJFM-8^%;K6H[25_)M6N1"Q4-@+NYYQ]<$^V
M:\^\1NB^*[D7%_HD+"SAMKBUO;J6U^T\;N,<21DG'(/<>N>\FBE\1^"9[<QB
MSFU"P>+8P)$1="OH#@9]!0!CW/B&[L_$=O--::BR2:7)+]@C"-\RNN7R&VCY
M<\LWL.3@W;GQUI%OIUG>(9)EN[8W<:!DC81#&2=[*!UZ9R<''2F0:+K4U['<
MZ@UB'&ER63F!W(+LRD, 5&!A?UK)@\':_IEEHDFF7FF_;K"R-E/%=1L\$JYR
M&!&&!!_SZ@':Z;J-MJVF6VH6;[[:YC$D;8QD$>G8U:J&TCFBLX8[B1))E0!W
M1-BEL<D#G ]JFH **** "BBB@ HHHH **** "BBB@ HHHH **** *>F?\@VU
M_P"N2?\ H-7*IZ9_R#;7_KDG_H-7* "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HK!\;#/@37_;3YR/8A"17"0PHSM=>"Y1+=/H
M,HO6@F+YFPODYR?]9GS,=\#Z4 >LU4O;FYMWM5M[)KD2S".5A(%\E,$ESGKC
M &!SS7CD,>F3>#-?O-/U34;R[?2=MU&]J(8XG!4_-M1=TF<X/)P&YKKKC3=&
MT^[\&FW @-S?^>6WL3(QMVY)).<MY8_$4 >@5E:UKB:-+I<;P-*=0O4LUPV-
MA8,=Q_[Y->?0JLYMBS./&46L[9/F_?F#SB3GI^Y\DY_N]*S)+RS?5/#YU&)1
MXI3Q$%O-T9\T1%I F#_SSPT>,<4 >O:C=SV5NLEO8S7CF14,<)4$ G!;YB!@
M5;KDOB JOINDJ9!&6U>T ;/^WS^F:X_6A;Q0>+-5$DHEL=;MC'*DSGRUW0[\
M*./[^?7GTH ]=HK \9Z GB3PK>6&Q6GV^;;L1DK*O*D?7I]":X9X-1U35+:\
M73C%8>*K5;>6!T \EAAWD8$XR4$I!&2<)G!H ]%TW64U+4=5M$A9#I\ZP,Q.
M=Y**^1Z?>Q5F&ZFDU&YMGLY8XH50I<,1ME)SD =>,<Y]:\JUR**VC\3WT#/"
M]IK=F(I(Y&41C;"K< XZ9%:.K74\>N>.Y+9YW2*"P>18')8)SYNW!X.P'I@T
M =YK6LQ:+:P7$L3R++<Q6P"$<&1PH/T&:TJ\NU670+S2A+H,LSP3ZMIX<+O6
M(,)!P@.,-MY;'M73^%([:SUSQ+86DQ:&*ZC81F4OL+1+NZDD<@_E0!KZMK=O
MI6EZA>X-P;%-TL49&[. 0/8D$'\:NSS/%:23) \LBQEA$I&YB!G:.V3TKROQ
M-)HVFGQXWD0KJ;M%MV)B7RI(X0S XSMWDD^]7;U8;#7?&-M%-*EN^A"=0\K$
M%R'!8$GK]W]* /1[69[BS@FE@>"22-7:%R"T9(R5..,CI4U>3:OK5K"FE7J2
MVVH3)IUJ'TJYE:*9]PWJ]N>[G(!4 YP!77_$1T3P7<EIW@)FMPLB.58?ODS@
MCOC- '545YAXEMM*T?7K?2;^_GTW19K%S;RR,TRFX+G?\SEB'VE2"??%9TYT
M^36M9L]7U2\9(M#@EMOM4YB=F"M\Y (^?D<>IY&: /8**\PL+O;);VGCJX%M
M$^D6_P!F>YF"!I<$3'.?]:"5]P/K45G8G6_$?ANQUF:ZF,FB/).AN'C9R)%V
M%]I!SCGWQS0!Z;;7EM>"4VTR2B*0Q2%#G:XZK]13(+N:6_N[=[*:**'9LN'*
M[)LC)VX.>.AR!7&?#-=-@_X2"TMDB2[@U6X61%7#)&7.P?3@X^E4M4D>75/&
M%F-6CLF-Y8>4;DL8SF-#L;!R$=@5./4T >E5G:+J\>M64EW#&R1+<2P*20=_
MEN4+#'8E369X'N3<Z Q:Q2S9+F5&CBF\V,L&Y*-_=SG [8QVKA]!M[4V&ERV
M-Y*->CUN2-H([@DB'[2YE5H\X"^62V<=QZT >N9JII]W->0R236,UHRRLBI,
M5)90>&&TG@_G7FGABZBN_$<7]HZ]-'KL-].LEA'"0[#<WRLV3NB"X([# QTY
MCTY)KK3?#L,T]UMD\0W<<A$S LG[[@G.<<"@#UJBO*+J_M]*T*)!?H-.MO$,
ML;P7,S!9(AN/E[CG@'D \'&*ZOX?"W/A^22"_AO/,N97_<W)F6)"Q*1Y)XVJ
M5&.* .LHKQV*-9X]6GL]1E'B"W\3O%91F[8X0S*&4IDY387)XZ+[5?,,@T;Q
MCJMI+J#:E::E<0*5G<F.$LA?8F<?=).<9R..E 'J=%>/:K<:5_PC5W=:/X@N
M;FVDOK(RLF8HH?WF#@@##$<L/8$U;OI++2#KRV]W<MHS7=BL1-X?($S%O,5I
M#N_=XV%P,]>W8 ]6HKQ:UOFO+>VLVU(M"GBT0#[),\:B!XB5"8;(0MG;S]#5
MS6HHH?%&H:3?:Y-I,,$=NND1K$\LCQA1GRFW9W;P0>YXS0!Z3X@UN'P]HTNI
M3Q22QQO&FR/&27=4'7W:M2O&?&.I:=-8>((M5N436HM3MQ;0S.580!HL%%)^
MZ5WL<=R<]J]1T^YTB76=32RN5DOP8S>1B5FV_+A#M)PO'H.>] &K1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 &**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** *>F?\@VU_P"N2?\ H-7*HZ7_ ,@JQ_Z]T_\ 015Z@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH IZMIT>L:/>:;-))'%=PM"
M[1XW!6&#C((S@U/;0+:VL-NA)6)%0$]2 ,5+10 4444 %%%% !1110 48_2B
MB@ HHHH **** $VJ&+;1N(P3CFEHHH :T:.RLR*Q7E21G'TIU%% #71' #JK
M '(R,X-9$7AV"/Q3>:XTI=[F".$PL@*KL)PP/7/)K9HH :\:28WHK8.1N&<&
MG444 ($522J@%CDD#K2/&DJ[9$5U]&&13J* $5510J*%4= !@"FB*-9#((U#
MGJP')_&GT4 -\M!(9 B[R,%L<X^M*0#C(!QR*6B@#)UK1Y=5:UD@U"2TDMV9
MAB-)$;(Q\RL,9'8]LGUJ32-)_LM)B]R]S/.P:21D5 2   %4  <?7WK2HH Q
M]$\/0:))J#HXE:\O9;S<R ,AD.2H/I6O@ DX&3UI:* ,;Q!X>AUW2H[#S?LT
M:7$<^40')1MP&/<@5J^1$(O*\I/+_N;1C\JDHH :(T4$!% )R0!W_P @4-&C
MLK,BEE^Z2.1]*=10!&\$4CAWB1F'1BH)%5X-,M[?4KK4%WM<7*HCLQX"KG"@
M=ADD^O/7IBY10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTJ\>\T.QO9RJO-;1RR$< $J"?PJ*V\0Z/=O,D&HV[-#'YT@W@8C_ +_/\/\
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M ^T'!)ZY.<9'%9VG>+]>DO+F-K\7,,FCSWD-Q]G58Q-&V#Y71FC[9<9.,]*
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MJTBL2,AB'&.>  >]/US7[Z3QI%X=LI[RR4V#W!N(+02GS-ZJI(92"@!.2.Y
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M8 $8'(&:N6_AG2;6]6[BMW\U)))4#SR.B/)G>RH6*@G<W0=SZU6L_&FB:C'
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M*H.0&5 ",CKR*U** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MWGM[73;2""?)FCCA55DR,'< ,'BDAT32K?3'TV'3K6.Q?.^W6)0C9Y.5Q@T
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M,31Q+MS@X).2<]>/ZT <9J^IZN;3QE?Q>(+V&71KT?9;>,H$P0I"L-N6!)(
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MI;34IVG5K*4&)3YN"WR\#YTYZ?D<$.G:M+'JEAHUO?"&YL+OR_M]H\,UI*[
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MXR,[" 2,'Z<U0\,Z#'=CP3'J>B7,L4=A<PW"W%DYC1MP9 ^1C'4C/'I7L%%
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M!54>I)Z4J.LB*Z,&1AE64Y!'J* '4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% #(_P#5K]*?34^X!3J "BBB@ HHHH **** "BBB@ HHHH ****
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M;KWH P[/7M86;0)[B6&:UUV$LJ+#@VLAB\U<'/SK@$'..1GVK.\,>*]>OO\
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M110 4444 %%%% " 8%+110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 4]3U6QT:Q:]U&X6WME95:1@2 2<#./<BL^Q\8:#J,5]+
M:Z@KK8X^T91E*YZ$ C)![8SFJ'Q(>1/!%RT*(\HN;4HCG 9OM$> 3Z5DZ[X5
MU3Q!/K.IQVJ6=S+:6\%K!<LC>8T4PF)?:2,$@*.>@.<4 = GC?P\UM+.]^8$
MBE2*07$$D3(S_=W*R@@'U/%-@\2V.I:SIBV.K*(;A+C_ $=K9@9]A )#$#;M
M(/US7.W?A[5+WPW<!/"^GV%[-<6CR06\J%I?*D#,6;@;<#"CD]:Z#6=*O;_Q
M7IT\<)%FEC=6\EPLBAHFEV8(!Y_@/(]: +EAXJT;4[X6=I>;Y7W>63$ZK+MZ
M[&("OC_9)K./B^"[\5Z/INF3I/;7/VGSY/+;&8U&-CGY3SG.,]*RK70-;O+7
MP_I=]:BV&C*ZO>"162;$31)L .[D,&.X+C'>JFDZ+XGL;WPC!+I,8AT59K>X
MN%N$*R1NH4.HR&Z 'D4 =]J&J6>EQQO>3%/,;8BJC.S'&>%4$G@'M5%O%FAB
MSM+L7P>&[1G@,<;N75>&.%!.!W)%5?$5KJR:UI.L:39Q7K6JS03V[R"-C')L
M)96/&08QU[$U3:UU:PUVSUW^Q_M'F6+VUQ:6<J;H"9-ZE=Y4-G.&.1R 10!N
MQ>(=*FO+*TBO4>:^B,UL%!(E0#)(.,=/>HY_$^CV\+RR7GR)-) =L;L=\9P_
M &2%(Y/3WKEI?!^IV?A#11IRP'7=+N6N("Q^0"61C(A/'R[7Y]=O%)J_A:[T
M_5-#N[+2DUFRLK-[2>W>15D)8AO-&X@$DCGZF@#I9O&'AZ Q"358 9HDFCQD
M[D=@JD8'0D@5:A\0:7/J7]GQW:FZ)8*I5@'*_>"L1AB.X!..?2N=T/0=1L_%
MD5W+IUI9V(T?[.J6K#9!*9BY11UZ$9/3(K(\/^%M3LH?[%N] M-\'G)'KOF*
M6*,K!6"_>#_-@]!C- '0S^*TN/&&CZ3IMQ#)#,;C[5NB?)"+QL?A3\W7&>E.
M\2^*1X>\0:#;W$L45A>?:/M$CJ2PV("H7'J3Z&N?T;1_$,6K>#Q/HS00:);S
M6=U+YT960,BJKH V<$J"<@'D\&N@\1V%\WB?P[K%K9R7<.GFX$T43*)/WB!5
M(#$ \CGF@"Y9>,- U&XLH+/4HYI+X,;8*K8DVYW8.,9&T\'^M:=MJ%K=Q3R6
M\OF)!(\4A"GAT.&'3G!]*\[O-#GTGPK)<F:WL==;5GU/3[=G!VR.^T0 #[VY
M3M('&6]!FO0=+L!IFF06@=I#&OSR,<EW)RS'W))/XT <G<^/8[K2(]1TYD@M
MTU6.UFENXV53#OVLX)P >#ZXQR,UJ7?BG3KOP[?7^F:Q;0K;2+$]S+ SI$Q9
M>&3@G(8#\:YV/0=9&@6^CG2Y";/75NO-,L>R6'[0TI8#=G[I P><FFZOX8UJ
MXT3QC:0V0D?4K^*XM<2H-Z@QDYR1C&P_G0!V[ZWI\.I)ILES_I;$+M6-B Q&
M0"0" 2.<$YI=7UW3-!MXY]4O8K6*1]B-)G!;!./R!KE;_3]9;Q:-0TBSOK.2
M2XA%RTDL;6MS#M7<S)NW"1<%00.PYQTT_&.G7FHS>'1:6C3K;:O#<SD%0$C5
M6!)R1G[PZ9H N/XOT%([>1M1C\NX1'1PC%0KG"%CC"Y/3=BDN?&7AVTO'M+C
M5[:.>.80.A)^1ST!].O4\5R6L^%;N;QEJEQ/X=CU>RU$1&&7[68E@945")%W
M#*_+G@$_6J3V%SJ%WX_T2TTOSI+R2")9$V+%&QA7DY(/!^;@'\Z /0KWQ'I&
MGW@M+N^CBFPI8$$A-QPNY@,+D],D9JKJ?C3P]I%\]C>ZE''>)M!MU5F<EAE0
M  <Y']/6N=_X1S4].M_$>F)9-?PZQ$OD7"L@6-_*$9\P,<C& V0#Q[\5<T+0
M;^Q\2ZT\T#F"33K6VAN79<2M&C!CU)')'44 ;WAO7[?Q-HD.IVT<D<<F?D=2
M"/S SQCD<5C^&/'.GZJL-E?7]I'J\TTZK;(2#M25U7UP=J@X)R:M^!+*]TWP
M;IVGZA:26US:Q^4ZNRMNP?O J3P??!]JYZR\-ZD^G:7H]QI;1FSUAK][QGC*
M!!,TB[<$L2P('0=\T ==;>)M&O-2.GP7\;W7SX7# -L.'VL1AL=\$TEOXHT:
MZ6=HKY=D$7GR.R,J^7V<$@!E..",YKA+#1_$,7B#1]2N-#NC]D:^2:))H4A
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRZEY3A79=R&-B1P1W4?E7:UB:_H#ZU<:9/'>FVDT^X^T(?*#[FVE0#DCC!-
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M[CM+6)S(D=PSC(*N\:D  -G*\8[Y%2>#[N]N]2\3-?JD<R:B$\N.4R(@$$6
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M8#&8;BS\[9)SB5&W*58 ^_2K6MZ"=7\)W&A+=F+SH! ;ATWG'&21D9) ]>M
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M8R-_JQ^;/3''%<G%>WX\47%Q:):?;Y;MY(["[TV?SP?N@EQA%&T##],=2>:
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M<%68OC#QMM&,^JXKE](TJTOM$\"6-]I,I:"[FBO%GM'4#*MPQ(&1DI[9X[4
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M_%'<IJ-O]E\M6!5LM))CE.FTY[C%=K\.;&"'PAI]\ID>[N[6+[1+)*SEB@(
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ML >DY&<9&?2C()P",BO'8[JU3Q]IMZD1@:+6+J"Y>1&:9BRL%WR8 V' ")V
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MZLJR*5# [6)(//K61?>,=0LO$L=@18O$VI16?E1QN[K&XX=I =JMG/R$9P*
M.XHKS^#QMK+3V\DEM8"T?7VT=@N_>PR0'!S@8*].<Y[8Y4^,]<BNRTMOIQM%
MU]=(.T/YC!B!NZX!&??/H,<@'?T5P=SXPU>VMKMREBSVVOQZ8?W3@/$VSG[_
M  PW]>1QTI+SQQJ%IXNM]+*6+0RZDMEY2!WD1"I(D:0':I/9",XSZ4 =U'-%
M*9!'(CF-MCA6!VM@'!]#@@_C3ZY#P%U\4?\ 8?NOY)6?-XWUBVE\07\MC8G1
M=&N)8)&$CB>1@JE !@C[S#)]#TXY ._HK@+_ ,7^*=(TG4+RZT%)5@\IXI%4
MQJX9PK)MW,<C.=W0^@J:Y\8:UI,NIV^K:99K<1PPR67V>9F21I'\L*Q(!&&(
MR<>M '<T5P^K^+]5\.PZG;ZC#92WMO8?;K:6)72*50VUD())# D8YYR.E5;;
M7?%UUXCT&TNFTJT2\AEN2D*R2AHU"<$DK@_,?8$ \T >@@@@$$$'N*&944LS
M!5'4DX%<QX?G6U\5^(-#A0K:VYANHEW9"&4'<JCLNY2V/5C7,^)+C5[Q_']K
M<SP2:7:::GEPM">&,;N"IW8!!P2<'/RXQB@#LKOPS;W>JMJ4.H:C9RRA/.6U
MN-J3!>!N!![<97%:UK:PV5K';P*5C08 ))/N23R23R2>M<E!X@UC3[R^TJ?2
M[!7M-,6\M8HKHA0NXH(W=P ,;?O=*P;_ ,>ZE<^$_$SV\UL+JPM[=H[NVAD5
M6,Q*X4,<G&.'S@]<=J /4"P52S$ #DD]J 0P!!!!Y!%86K1W)\!Z@FH-%+<'
M3I1*4C*J3Y9_A)/\S7.>$_$>KQ#3M'NK"TV#0%OK;RICN8+L0*Q8  G.?04
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M+I8$CO[ZWCCTL:2ZQLA\V = Q*]<]QC-=%!JNG7/E>1?VLOG,5C\N96WD#)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 <UXWM=1N-(M9]-M/MLMG?0W3VF[;YZ(>5';(R&&
M?[OKBL2^AU'4TT[6K?P[/9PVNJK>36;[1<3CR]C2%!QN&1@9R0O8X!] HH \
MNO/#VHZE>7^KKIDQM;[6K&=;"9%5O*A 61V4]-W/!Y('(YI==T'5=WBF>#3I
M9%DU.QNX$C )G1-F_:!W!!ZUZA10!PEIH=SJ/B/Q+?3Z4;66]M8/L5U.JLT3
MB(@XQD@@X/X57TBPU"[N/",+Z3<:?/HJ.MVYC"Q[?+V;58'Y@QPW&?>O0Z*
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M5AL+#CINKU6B@#E?A[#-;>%S#/8SV3B[N&$,\6PA6D9EX],,*ZJBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **Y+QVVHC3HC!9WT^GINDO#IUUY-
MPH&,;>[#J2 03@>];VB-;/H5B]E<2W%JT"M%+*Y=W4C(+$\DT 7Z*** "BN
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MTBZ;+#'<RHJ[5$NW# D\_?7CK[<5-K?C6TT674%^QW-TFF1QR7K0[<Q"3.W
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MB@ HHHH **** "BBB@ HHHH **** "BBJL5U.^I7%L]E)'!&B,ER64K*3G(
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M>9'S@':!P>,^M=>S!5+,0 !DD]JCMKF&\M8;FWD$D,R"2-UZ,I&01^% '/\
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MGQ>5NV*I)9F.?4XXQQMZ\UO7UW):"W,=G/<^;,D3>3C]V"?OMDCY1WQDU:H
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M#RW(Y." V,8/0T0>"+T^![K0KBYM(KC[0]U9S6J,BP2&0R+P>@#''':NXHH
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M"R*0#GAC\O&?6L>7P'J-HL<.F75H\3Z$-'F>XW*5P2?,4#.2=QX)&/>O0**
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M)).=B91S&K$GIC&,].*DM=<CBL;"R>]9=%GU^\M[J83D*D09C&A?.54Y'<9
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MAUF\:RGDNM/TA;@L+@A)(MS':$Z!LH><9HU3P.-4C\3+)J!0ZX( 2L/^I$0
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MM-2?4&9K<_.S.[;0-WRXWGGGH* &V7CB*_U>"UM].N);2:XDMA=("P5DR-S
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MD G# $$C!&>]9]GXEC\/:9K%N-.FQI5Y%'+&UX9?]>5(V,RYP"XX/O70>)M
MD\06]C%'>BT:TO8KQ7\K>2R'('48YK#UKP+?ZC=ZRUIK$5M;:J]O-+&UKO99
M(MN,'<.#M&1CM]<@$NK>/QI-UK4;:1<2PZ.T/VJ995 V2 $%0>IY''UY%:<_
MB67[9=1V6E7%Y!9W"6UQ+$PR';:3L7^(*&!;D8]\&L_5/!#ZI;>)(I+^-&UM
M8-SK ?W1C4#INY!V^V,GK2OX1U*/7+N[L->:SLM0=)+ZWCARS.  6C<G*;@
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M=N2=WS9'TZ"I;GP?=WVI6=Q>7MHXM+B*:"5+4K/$$5=T:ON^XS D@@\,?8@
MGAU.ZTW7=9TE?.U&6.W34+. N-Y5V96CWMQ@,N1D\!L=JZ2!WD@CDDB,3LH+
M1L02A(Y!(XXKG_[(O+GQ#K&KPN+2Z:UCL+.62/< JDN7*YY!9\=ON>_/0Q"1
M84$K*\@4!V5< GN0.U #Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2V>G4@5:9@H)8@ #))[4 +16':>,- O=4@TVWU%'O+A2T,>QAYB@$[E)&",
MG(X.*W"<#)Z4 %%5=-U*SU?3XK_3[A;BUF!,<B]&P2#U]P:M4 %%%55U*S;5
M'TP7"&]2$3M#_$(R<!OID8H M4444 %%%% !156;4;.WO[:QEN$2ZNMWDQ$_
M,^T9; ]A5J@ HHHH **** "BJL.I6<^H7-A%<(]W;*C31 \H&&5)^N*74-0M
M-*L)KZ^N$M[6%=TDKG 4=/YT 6:*1&5T5U.589!]12T %%%% !156QU*RU+[
M3]BN4G^S3-;S%#G9(H!*GW&15J@ HHHH **** "BFR2)%&TDC!40%F8G  '4
MU#8WUKJ=C#>V4Z3VTR[XY$/#"@"Q115:;4+2WO+:SFN(TN;HL((B?F?:,M@>
MPH LT444 %%5Y;^U@O+>SEN(UN;G=Y,1/S/M&6('H!WJQ0 455U'4K/2+"2^
MU"X2WM8L;Y7. N2 /U(%6NM !1110 4444 %%%% !1110 445#%=6\\\\$4\
M;RP$+,BL"T9(R P[9!!H FHHHH ***K7NH6>FPB6^NX;:,G:&F<*"<9QS[ _
ME0!9HJL^HV4<=M(]W J73A(&,@Q*Q&0%/<D GBK- !1110 4444 %%0Q7EM/
M<SVT5Q$\]N5$T:N"T989&X=LCD9J:@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N9\?321>$Y
M8XV*BXG@MW(Z[))55OT)%=-5+5M-BU?2KBPF9D69<!U^\C#E6'N" 1]* .7\
M9ZI=V+RP:=>7$<T&FS7(M[98QLV])'9P?E&" HY)_1MQ?SRV?@76&"O?W4L,
M4K 8W)+ S2<#ME5;VVBMR[\+Z7K(MIM<L+6]O88O*,I7AAWX]"><'.,T^/P[
M9P7>EO OE6VF1R+;VRYVJS #=U[+N _WC0!L5@>+99I-+73+6*26>_?R2D3*
M'$764C<0/NY&<CEA6_5=K&V?4([]H\W,<;1(Y)^56() '3DJ/R% ')^ 9Y;(
M:EX:N+:6V;39MUK'-MWFVD)9,D,0<'<N0<<#OFN?TO\ Y%/P1_V,,G_H5S7H
MS:/8-J_]JF _;O*\GS@[ [/[O7&,\_7FJ\'AK2+:*TBBLPL=G,9[=#(Q$<AS
ME@">O)_,^IH J>+[K5;/3[>72XII@)LW,5LRB=HMK9\O<""P.#C'(!K.T;6K
MFZE\-^5J,MW!=VMSYK30+&TCQE0"1C*D$D$#BNEU+2++5XHX[R.1A$V^-HYG
MB9#@C(9""."1U[U!_P (_IL7V5[:TABGLHY$M'VDB+>/FXSSGOGK0!Q&C:OX
MLU35=#W37*>;-<_VLB6ZF")(V(C$;E<$-P,AB3[5)I.K^)9H])OIM96:&?5Y
M;&2W:U10T:M(,E@,[OD[8'3CJ2_1? 4UA>6\W]G6=A<0R1O)>6>I7!$H#!G4
M0X"J&P1CH,\#@5U\/AS28(;>**U*QV\YN8E$KX60DDMUZ\G\SZT <#XEU74-
M2^'WC4S7;+]BU22UCV(@S"#&-AXY^^3GKTYK:NM9O]#\27-G]KGU"VM/#TU^
M%E5-\TBR<9*J.W P/UKHI?#&C365[9R62M;7TQGN8R[8ED)!+'GV'Y#TJP-%
MTY;Z.]^RH;F.W^RK(Q)(BSG;R>1]: .8N]4OK+0GU<>*K0VTNG&96N(D(23*
M_.@0 LOS8VG)R5]:PG\7:^++Q'Y-Q<126EQIZ6GV^WB\U%F*[MZH .0>G49[
M&NQMO GABSM;VV@TB%(;U2DZ;F.Y2<X&3\HSSA<<\TV+P!X6@BGBCT>()/&L
M<N7<[U5@PR2>3D YZG H X[Q?J&LQ:3XPT^?5YI%LX[&2*2.-(R!*[!UX'W<
M >_'7K7=Z[J;^&_"-]J1>2\DM+=G5I ,R-VSM &,D9P!Q5B[\/Z5?F^-S9I(
M;^)8;GYB/-1<[0<'MD_G5BWTVSMM.&GQP+]DVE#&Y+A@<YSNR3G)SGKF@#SK
M4[R\T'QG=:H;Q]2GA\+33HTB(%)$J'C8!\N>>Y]ZORMKUUX?U,WNL6SVEQI+
MS1&":.28L!R5Q$H\L@X/4CC!YKI;#PAH6F3":UL L@A-N"\KR8B)R4^8GY?;
MI3=.\&^'M)M[N"PTR.".[4I,%=CN4YRH).0.3P,"@#G/#UQ<Z=:>"K>WOKJ:
MRN[!Y&AE2,L0L*LB@A0<#/'.?4FKWAW4-1U2'2M;;6XS;W\<AET]T3"MM)58
MR!NRN#NR3G!Z5OP^']+MWT]X[0!M.5DM,NQ\D,NT@9/IQ]*@L/"6@Z7JLVIV
M6F0PWDV[?(I/\77 SA<]\ 9H XS2/%.O:SIWANTBO((KZ_L9KF29F2(R,KA0
MJCRW' R2-O('48YD&J^*)]9.FOK=I%)!H1NII;.)94>83.F5+ =D (QQR!CK
M75W7@OP[>:5:Z9/I<36EH2;= S*8LG)VL#N&3[U9C\-Z/$ZO%8QQ,MI]B'ED
MKB').S@],DF@#D]'\2:GXF@M;.+4O[-OVT:*\5_+0^?*^X;L,IRBE1D*!][&
M>*EU;Q7J6DS:P_F07(LM#AO$$:?(\S,X+9Z[> <9Z5N7W@?PWJ5O9076E1/'
M8KLMPKLI1?[N5()'L<BM :)I@N'G%G$'>V%HV!P81T3'3 R>W>@#DI+SQ?#I
M]R\-Y97<DMM%-;Q+/&\Y_> 2%/W2+@J>,AOFQUSBM_PEJJZQI#W N[FX99WC
M9;N!8IH2,?NW50!D>P[BH(?A_P"%[:RFM(-*6**5UD;9-(K95MRX<-N4 \X!
M K9TS2K+1[5K>RB,:,YD8M(SL['JS,Q)8].2>PH \^L_%>M2ZS80B_,]M?)?
MCSA#&(=T62IAXW$+PI+Y!.<>M)HGBK7HSX=O-2OS>PZCIMS=36\=LBX,2JPV
MX&23GGMGH!76P^!_#EO<1W$.G;)8C(8R)Y/DWYW!1NP%.X_*..>E7H?#VE6[
M6#0V2(=/1H[7:3^Z5AA@.>0<#K0!P]K<7>H>*O 6JW5^;EKVWNYO+5$$<):)
M3M7 SQG'S$]*Z3Q%?:HOB;0=*T^]6TCOEN3,YA61L(JD;<\ \GU'J#5FT\&>
M'[&]AN[;3Q'- [/"1*Y6(M][8I;"@]P !6I<:=:75[:WDT(:XM-WD29(*;@
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MRHL8[Q#! 8Q&6D=2O+$L/E')J\WA329K*ZM;J*6Z6ZC6*>2>=VD=%.57?G(
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MSJ?,E$KRJP49(Q\N>YR1BNT\,6]U#H4,U^BK?W9-S<A0<!W.=O//RC"_\!H
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M$"%X4L68G 4 9)))P .37 Z;J.L7T'AB-=<NE-W>WT-S)Y<9,BQF0@<J<$;
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M*6VEO;.&>2UD\V!I$!,;>H_SV'I5RBB@ HHHH **** "BBB@ I-J[P^T;@,
MXYQ2T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!@>)_#*
M>)3I:S-#Y-G>K<R130^8LRA64IC/?=UY^E7UT+25L(+ :99_9+=@\,!@4I&P
MS\P&, \GGKR:T** *.I:+I>L"(:GIUK>"%MT?GQ*^T\9QGZ#ZXHN]%TK4$A2
M]TRSN4@&(EF@5Q&./NY''0=/2KU% %*[TC3+^:*:\TZTN98?]4\T"NR<Y^4D
M<?A40\/:,NK/JHTNT_M!QAKCRAO/&.OTXK2HH PD\':!;V-Y:V6D6%L+N,QR
M%;92#Z9!'.#@X]15V/1;!=!AT66!9["*!+?RIAN#(H &?7H*T** ,E/"^A1Z
M3)I2:19K82-O>W$(",V<Y([G@<^U.A\-Z%;QB.'1M/C0.K@+;(/F7[K=.HR<
M'J,UJ44 4Y](TVZCFCN-/M)4G<23+)"K"1@  S CD@ <GTI)='TR?[3YNG6D
MGVH*+C? I\X+]W?Q\V.V>E7:* *4VCZ9<"43:?:OYL/V>0M"N6C[(3C[OM52
M#PGX=ME=8="TY%>,1.!;)ADSG!XY&<'\!Z5L44 5Y=/LIVA::T@D:$$1%XP3
M&",$+D<9 [5FV_A'PY:7\=];:'I\%U&<I)%;JI4XQD8'%;5% &=IV@:1H\T\
MVG:;:VDDYS*T,04MSGG'UIFH^&M$U>Z%UJ.E6EU.(_*$DT09@O/&3]3^=:E%
M &5!X9T.V$P@TJUC$\ MI0L8P\0& A'<8'2H[[PGX?U(0"]T>RG^SQB*+S(@
M=B#HH]AZ5LT4 54TVRBTS^S8[6)++RS%Y"J FPC!&!VYJ"?0=)NM)CTJ?3[>
M6PC"A+=T!10.F!VQ6C10!RFI>";*[U3P^\%M:1Z=I1GS:A-H.]0 5QW!&:VV
MT+2FT^&P.GVWV2%@T40C "-ZCT/)YZ\GUK0HH S1H&D*MFJZ=;*MDYDM@(P/
M*8]6'N>Y[U)_8VF_VO\ VM]A@.H;-GVDH-X7IC-7J* *<VE6%QJ4&HRVL;WE
MNI6*<CYD!Z@'\:K#PUHBHB#3+8*ES]K4!.DW]\?[7O6K10!D7'A70;N"2&XT
MFTEBDG-RZO&"&E(P7/OBEM?"^A6-S'<VND6<$T<C2H\<04AF&">/;BM:B@#)
MF\+Z%<63V<VDVDEL\QG:)H@09#U;ZGUJ==$TN.2R=+"W1K)66VVH!Y((P0N.
MF15^B@#"@\%^&;9UD@T'3XW7.UT@4,,C!P<9K5L;"TTRRCL[&WCM[:/(2*-<
M*N3DX'U)JQ10!FPZ!I%O]C\K3[=/L3.]MA/]4S_>*^A.>:9)X;T::#R)-.@:
M'SS<["./-/)?'][/>M6B@#-N- TB[NQ=7&G6\MP H,CH"S!3E<GOCWJ4Z3IY
MGO)S:1>;>H([EL<RJ!@!O7CBKM% &='H&DQ&U,>GVZFTC:*W(3_5(PP57T!%
M59_!WARZM;:VGT6RD@M05@1H@1&"<D#TR>:VZ* ,:V\)^'[.6UEM]&LHI+4D
MP,L(!C)Y)%2-X:T5M.&G_P!FVXM5D,JQJNW:YSE@1R#R>1SS6K10!GC0M+6&
MUA%C#LM)/.@&W_5OSE@?7D\]\U5O?"^E7=OY0M(8LWJWS,J?-YP(RX/9B!C-
M;5% %34M*L-8M#::E:0W5N6#>7*H89'0U3A\*Z!;($@TBSB03).%CB"@2(,*
MV!W&3S6O10!F7/AW1[RVN[>YTZWDBNY/-G5D^^^,;C[\#FGZ9H6EZ,9CIUE%
M;M.0960<R$9P6/4GD\FM"B@ HHHH **** "BBB@ HHHH 9(<*/J*Y7P(H\K6
MY /OZG-^F*ZI_N]<5S'@3;_9VI8Z_P!HSY/ONK>G_"G\C&7\2/S.JHQ116!L
M-8 KS7FU_P#\4E\1XKQ&$>G:J )AT&\\9_/!KTLUROC[1SJWAF?RP?/@_>(1
MUXZ_I^H%=.%FE4Y);2T9AB(MPYH[K4Z>-MP/.2.#BGUSW@S6?[9\.6\[\31@
M12Y_O =:Z#(K"<'3DXRW1K"2G%2746BBBI*"BC(HS0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#3'M!&PT2YEC?PBT<L20NAEFR"T;,!D.>?\ :K'A2^NK3Q# -)U)I+O0$BC
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MAZ4 >C)/#)(\:2HSI]Y58$K]121W$,Z%H94E4'!*,#C\J\>T.TTV?396N?\
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MK2D+::593Z>]Q=V*:I)<:E'9PL7C#?< 1ERRJ<$Y% F:WA>=?#WC'4='9_\
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MVJ&8#<?04T7,!D>,3QET&74.,J/<=J\6\2217/AJRB^PRB\;PY$@GFMI)2S
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M#Q +M(Y&"" ,COBNBHH P(O"T2:AH]_-J-]<W.F)*B/,ZMYOF#YBW'7IC&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]^@_&O2-/L+?3K**TM8Q'#$H5%'85D^%/#D'AW28[944SM\T\@&-['G\A70
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M7:BA5'0#H*>:ER4MMBHKE0HX%%%(>E(HY[QO<?9?!NIR9Y\DK^?%>(6EW?\
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MWMF^Z*49Z5E5PTJ<>>]XOJC6%93?+LS0HHHK U"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_"NI^'^BC3?#J7$Z_P"EWQ^T39ZC=T'Y?J37%6^G"^U/0?#2QN8K11<W7RG
M8X9L^G4#ZUZ_"@1=H4*!C@5Z..FHQY8_:U^2T7^9R86/,[OI^8X@4ZBF%AW]
M?6O*.X<>E</XG\7S#4%T+0@)M1D^5W[1#_&D\4>*IGNSX?T,&;49CL>1>1%W
M/XXS6%=6[>';=="TLBXU_45S<W!&XH#UY[5Z.&PJ5I3W>R_5^1PXC$:-0?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ$)?!V@=Q[]0/I6V$IPUJSU2V7=]#/$2EI3CI?J7;6VMOA[X?-U=GS]7NS@
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M/PH\-'^+5A_W$Y__ (JNXHH X@?"CPP.IU5OKJ<_]&H_X53X9['51_W%)_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $Q1M&<XI:*
M$VC.<4N*** $Q2XHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>arwr-2024331xex312001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arwr-2024331xex312001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***BD<B1$7J<F@!0?
MWK?A4E1#_6O]14M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I
M4$G_ !]Q?[IJ<]*KR?\ 'W%_NF@!P_UK_45-4$?$TGU'\JGH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** #M4+_\?4?^Z:FJ!_\ CZC_ -TT "<S
MR'W'\JGJ%!ME?W(_E4U !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5$PS<K]#4M0L<7*_0T +&,NY/K4M11?>D^M2T %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !4#_P#'TGT-3U __'S'_NF@!T7WI/K4M11?>?ZU
M+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %02?\?4?T-3U _\
MQ]1_0T /B^\_UJ2HHOO/]:EH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !4#_ /'Q'^-3U __ !\QCV- #8/];)_OG^E6:K0?ZV3_ 'S_ $JS
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN=,M;B&\^TZDF^VA6'+-['G@T =+16+8^+-$U!+YH;T(VGC-XDZ-$\'&3N#
M$#@\].*+/Q187EY;6PBO(6N\FU>>V=%G 4L=IQQ\HS\V#0!M45A:1XLT[79-
M4CT];B5]-D,4R^7C+C/"Y//W3^E:.EZC%JVFP7\,<T<,Z[T$R;6*GH<>AZT
M7**I6FJV>H:5_:5A(;JV*LR-$"2^TD$ 'OD$5CZ+XZT3Q!87MUILDTILN9H/
M*(E _P!T]>A_*@#I:*Y6]\?Z5I]G'=SVNI^0]LETSK:,PCC8D*7Q]W.TXS5W
M1O%=AKD\$5O#>1_:+<W,#SP%%EC!4$J?^!+Q[T ;M%9-[XAL[.^>R"7-S<QH
M))H[6%I#$AS@MCIG!P.IQP*HZCXXTC31I187<RZJ%-FT-NS"3.,#G&"<C@T
M=)169IFN6^IR7<:P75M):%?-6ZA,> 1D$$\$8':L\>.-$9'G5[MK! Q:_6TD
M-N,'!_>;<=1UZ>] '1T5SMYXY\/6"NUS>3)&D_V8R"SF9/-_N!@F"?H:?>^-
M-!TVQDO+ZZFMH(I5A<RVDRE7*[@"I3/([XQ0!OT5DWOB32]/M[66XG8-=_\
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M* 'T4R6:*WA>6:1(XD&6=V "CU)/2LZW\2:)=R(EOJ]E([C**LZY8>W//X4
M:E%8:^,O#+E0NO:<Q8%EQ<*<@=2.?8UL6\\-U;Q7%O*DL,J!XY$.592,@@]P
M10!)169+XBT6"[:UEU:R2X5PC1M.H(8] >>#[59OM2L=+M_/O[RWM8<X#SR!
M 3C.,GO@&@"U15&PUK3-4EFBL+^VN9(<&1(I Q3/3('2GSZKIUM=I:3W]K%<
MR8V0R3*KMDX&%)R<F@"W152ZU2PLIXH+J]MX)IB!'')*%9R3C@'KSQ3KG4+*
MS=$NKNW@=_N++(%+<@<9//) _$4 6:*IWFK:;I\B1WNH6EL[C*K-,J%A[ GF
MKE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %0M_KT/UJ:H'_UZ?C0 V#_ %LG^^?Z59JO#_K9/]\_TJQ0 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7G'C2TNK#XD>
M&?$TD3RZ3:J\%PRJ6%N6##>V.@^8<_[/TKT>B@#-M=>TK4=XL;^"Z1$+/+ W
MF1IC'#./E!YS@G..:\7^%6KZ7H7AV35+_P 0B(V\LX_LHR+F4LJ;65/O%B01
MW'TYKWJB@#QO7OM=U\<$BTW4/L&H/I)$+[4?$FUF"L&!'3KWQ6U\'[RUCTK4
M='EMC;:[:7+-J"R-EY6)^_\ 3MQQQGO7I5% 'E_PE93KGC9-PW#5"2,\@;I/
M\#4/@21$^+GC?>ZK\V[DXX#<GZ<BO5J* /)O@SI\MQX;M;Y-3G,%M>3AK/Y?
M+W%0 V0-V<-T)(YS@&IK$-=?%7Q_;VL@-Q+IT21!7P=WDH/T) ]J]3HH \V^
M%NK6&C>"%TO5KJ+3[ZPED%S!=N(F3+%@<-C@@]:W/$M[#JJV6@VEN;LWR?:I
M[8.(B;92,YW8(#,5&.I&ZNHDMH)I%DEAC=T^ZS("5^AJ0JI8,5&X @''(!__
M %"@#RSX3:E)I%YJG@?4#LNK"9I;=6<,3&<$J,<9&0W']X^E2::Z_P##1&KC
M<,_V6HZ]\1'%>E_9H!.9_)C\X_\ +38-WIUZT"V@$YG$,8F/60(-Q_&@#SW4
MY8XOC]HP=@IDT=E7/<[I3C\@:K?#B6+PS=^)M-URXCL[W[>UR#<N$\Z)NCJ3
M]X9!Z=,\]:],:WA>99FAC:51A7*@L/H:2:UM[G;Y\$4NWIO0-C\Z /(/"%E)
M:^$M4O[J/R=/O?$%K-;F4;5>+[3%\^#_  D'K[5:C\-:AX,\>:;9Z?N?PSJ-
M\)E0DG[-,$;CVR.GJ![5ZN\4<D?ER(KIQ\K#(XIS*K8W*#@Y&1T- '&_%<@?
M#+6<D#*1@9_ZZ)47A7PG;S3:-XIN[^6]NH]-BBM 55$A0IVP.3ACR3W/X=K+
M%'/&8Y8TD0]5=00?PI8XXX8Q'$BH@Z*HP!^% 'DOPS>/2?A]XGM+R18YK?4)
MXW0YSN,:*HQUR6& ,9)J/Q[%<1?$3P+##)%%<JH1&D&Y ^X 9&1D9]"*]6;3
M+!KU;UK&V-VO2<Q+O'_ L9J66V@F=7E@CD9?NLZ D?2@#QOPIJ6DVQ\90>+H
M7CUJ4D:D WRR0D[?W8&, ;L]R00?8;6@V^M>#?$FBZ5;ZZNM>']3#I!')S)
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M% !4+?\ 'P@]C4U1$9N%/L: (X?];)_OG^E6:KVW.\]_,-6* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBL?Q7<W5EX2U:]LKAK>YMK22>.155OF12P!#
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M/XB@"Q11UHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *C;B13]:DJ)O]:OXT ,MNC_]=#5B
MJUJ<J_\ OG^=6: "BBB@ HHHH **** "BBB@ HHHH **** "LOQ)8W&J>&-5
MT^U"&>ZM)8$\QMJ@NI7).#ZUJ44 8D5YJ%KJ6EZ:;2%H'MOWTBS$O$RK_=VX
MVY &<CD]*KZ_X??6M?T6:6&"73[7[0+E)3G<)(R@ 7'/7UKHZ* .3TO1-9L!
M?Z%+)'/H#QM'9W#S%KB%67&P@CY@"2 2<XQ^&3:^#]33PO?Z0VEZ';SMILEF
ME[;C$ERQ7:K-\@V#C)Y;)^E>A44 <5>>&]6GM)($CMOWGAYM.),Q&)B,?W>5
M]_TI'\)ZA-'9V[M"L2^'9=*ED#DE9'$8R!CE1L/YUVU% 'G1\)ZG>^%-3T^7
M0=%TZ\>P>W2:TVEKB3 (.=J[%)'0Y//MSJ#0]6N]=N]7FMX+<W.A_8A 9MQ2
M7>[ $@8QAADC/.>O4]C10!DZ/!=Z7X2L;9K?S+RULDC,*N/F=$ P&Z<D=:YS
M6/"MY_PC=O=Z;%._B"WGBO4C:];RS.7!E^5FV $-)T'>NYHH I17-Z]_'&^G
M^7:M;B1IFF4LDF?]7M'7CG<#BL?5_#[ZSJ>J07$8%A>Z8EOYH;E9%=R,#KQN
M!S[5TM% ' W?AK7'TC0Y+KR[_5H=6M[R^DB*H"D8(^7..@QQW))[U8FTV*_^
M(8DT^ZMWLVC6;58HV#$S0MB'.#\IR<XX_P!57;56M=/LK%YWM+2"W:XD,LQB
MC"F1SU9L=3[F@#D3I^K6_C7[5IFFW=G!)<,]])]HC>WNX]APP0MN67.T= ..
M346DV6NO?ZCJ&JZ'+_:%XDD*2"XA,=M %8I$N&R26QDX')]!7>44 >=:!X<U
MS1[2;2VBG-GJ6G(DD[3(TEG<B/RR,YRR8 (QG;T Y-7-(T75KB3PO%?V;6AT
M&-TFEWJR7!\ORUV8)."/F.X#TKN:* /-I_!VNPV=VEG)'NTR_P#M.AQEL##.
M'8-STPS(,^_K5SQ%H=]:Q68T6UU+^TK2R\F&]MI(RCGO'*DC %20&S@]37>T
M4 >:WNA^(;?Q5J/B"TL6N)H;JUFC@WKY=TGDK%*%R?E=?FPQQWZYQ6RD.HV7
MC#6==_LV5K>32H?*4R(I:1"Q,9)/!Y')X]Z[&FNB2(R.JLC#!5AD$4 8]Y O
MBOP=- R/;C4;,KMD',9=>,XZX)[<'%9^@ZAJ>GZ?8:-=Z!>_:;>%(#/$R&W8
M* N_>6R 0,X*Y]C7544 <%XDT'4-2T_QI##82&2^C@%LRE/WQ5!P"2, ,#G.
M.^,TS6O#>KZAJ_BH6\)CCU#2X8;><N K.F[*'G(SG&<5Z!10!YZ+"ZU+PUX@
M\OPI=Z?J5SISVN;B[$KS.0P"*2Q^4$YR<=>!79:#%-!X=TR&YB,,\=I$DD9(
M)1@@!&1QP:T** ./^'_A:WT+0+26?28+36/+:.XE"+YC MG!8=1PO?M60/#N
MH1VTPN=-:6-O%C7^P;7S 3P^,].AQU]J]'HH \XO=.UFQCU62+2))_,\1+>*
MZ)')(L!C53)$">'!4@9'&<U!I6C:F1I]O=:-=A+?Q'->R-<;'_=NLFQCACD@
MNN2.ASZ5Z=10!YO%I>LZ6+N_72YKAK?Q-/J MT(WS0/$T89.<$_/G!(Z5?N;
M2YN;CPY>0Z#)8*=7>[GA5070-&ZF27;P&+,,\GW[X[FB@#R[2+76!XET.YFT
M"^MHK6[O$DCB1!!&),[67YLD'[S$]SQV%=3\/;&ZTWP596=[;R07$<D^Z.08
M(S,[#]"*ZBB@#BO#<5[X.TJZT:?3KN\$,\DEG+;1[A.CL6 )SA&!)!W8'0YK
M,/AF_P!#\/\ AZ.*VEN[A-=2_NXX?F\H.'W8]0NX#/?\:](HH Y01W:^-]<E
M-C<?9IM,ACCGV_*[H9"5'J?W@_(UAZ;;ZOHUGX>N[C1KV^MET4:=/8Q*A>"0
M;26()&58* >>,#UKT>B@#S;5])FM=0F2Y\,ZA?:9>V,,$=GIMT42WV;MT3A7
M4%?FR#R.M;'AG17M_%_B.]NM-\KS'MC;2NH;@0!6"M['(-=C10!RFK+<:?XV
MM]7EM+FZTZ33GLV%O 96CD\P-DJH)(8<9Z#;[UF:+I.I:3:^#K:6TFD-O-<-
M* .+>-U?8&/3@,H_"N^HH R?$2W,^F?8;5)2U[(MN\L:AO)C;[[G/'"YQ[D5
M@6>E:CX?\=13JUQ?66IVWE74JP(JPO'CRR0H'4$KGZ=A7:T4 >87/A@#P-K@
M.@EM1FU*5OE@!EFB-T'&#UV[ ./:MNYT^/1/&-EJ$6FM_8S:=);"*SLV?R93
M(K%BB*2-R\9QVYKM** /-H/#^N:3X6T&]L;??JNGW,FRUD[6\SD>62,XV@H?
M;:?2FZ9X7U/36UG3KA9+NSL;>:73IBF#))<)\X4#T82<<_ZSZ5Z710!YAIF@
M7D,?@PVEC+97$>CW4=PXMRFV8Q1A1(<<'=N(SW%4](T\'0Y%E\+:V^JV6D36
MTHNP4AF.S#(A4Y?>PR,?7.:];HH \?%EKLS:_-;:??NUSI]G@36AA$J1L1+$
MHP,';E0K<D>H-=/X=Q<?$/4[^WTN]M+.73H8U:>R> ,ZLV1\RCG!'^17<T4
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M%% !1110 4444 %%%% !41_UJ_C4M1'_ %J_C0!%9_ZHG_;;^=6JJV?^I/\
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MYG9O.CMWECA9XXY7("HS 8!.Y>#TW#.,BHQXKTDZM%IPED,DTK01R>6?+:0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY5>N-8U2T_L\3:3%ON;OR)$2ZW&--V X&WYN/F(XP >>*W:* "BBB@ HHHH
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M[9_,@GC66-\$;E89!Y]C7!WNJ7]W;WNEZAJBJ;/1#=7$UE'&RW3'>KX#@@J
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MLR@+#(&XCYF (!Z=>1Q3++Q%;Z3,--O)M1N?]*6 W<\2[8I)>4A9@<D@,!N
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M2KVYTS5--=[>/<TDLX,4?&07(.0* ,VT\!:7:"'-UJ$_E6;V*^=/G]RP VX
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MUV]([*B,['"J,D^@H \RTWP[XDD\1Z5>:AISH(([N&YF^V(T8\P *8X@<(F
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M+7,%SH8M+:0,H#R9D)4\\'+CK@5T]K?VE\UPMK<1S-;RF&8(V=CCJI]^:LT
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZT 3T5%-=6]N"9YXH@%+G>X7"C&3SVY'/O3?MMKO"?:8=YC\T+O&=G][Z>]
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M4D4_;8?96H BT8?\2:R_ZXI_Z#6A5#1^-(L1_P!.Z'_QT5?H **** "BBB@
MHHHH **** "BBB@ HHHH ***CGGAMH'GN)4BA09>21@JJ/4D]* )**K66H6>
MHQR/974-PL;F-S$X;:PZJ<=#4D=S!+/+!'/&\T./-C5P63(R-PZC(Z9H EHJ
M&2[MX;F"WDGC2>?=Y498!GVC)P.^!UJ:@ HHHH **** "BBB@"AJU]%8VJ^?
M:7=S%,WE,MM TI (/)"\X]ZP_#\3>'-%NBFGWYLY;\M:6J*9)(HGVC)4G*C=
MN8@G(!Z9XKJZAM;NVOK=;BTN(KB!\[9(G#J<'!P1QU% $U%%% 'G_B;2K>Z^
M(EM=ZGI^HSZ<NDM&)+..=L2^:" 3%S]W/7C]*S(+"]L/"][!:Z%>3:8-6BEL
MHKF M<1)D,\K1@AI-KY*AN2,9R!7IR75O(D;I/$RR,50AP0S#.0/4\'\C4M
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M[?QQ777-I!=B(3Q[Q%(LJ#) #+T/OCKS4] 'E%SI\<D>I7J6%PUU!XGBD1S
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MUU(@^:>8@NY)R2<<#KT' '%<]#X)2'PY)HZZE,5>^%[YAC7(82"7;CTW#ZT
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MD D_("&4GE<?C3M+\*ZMI>G/8)XHN7@BB,5D&MDS /X=Y_Y:;0 !T[^V*J>
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M1%I%=B"XC?. K8'!!QDXZT 5+E[W6/B)?Z-<HRV":<C+Y-X\;)N=OW@P!\_
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M)&0\K@,H$@;8!@\DGC&.N!3;OP]XDU+0)[&^UVW,VU5B>"!HUD"L"3+\Q)W
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ME/W23QTK3\3:/+K.F1I;2)'=VMS%=VYD^X9(V# -CG!QCVS6%KGAG6-:T3Q
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MWQ9$$!/S$ORH_'_/6N8N-*U:TN/$]E_9DNH6VN-OMY-T>R-FBV,LN3D ;1R
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MV,5];/=H"7@693(H&,Y7.1U'YUY^VCB#Q5J%CJ'A_5;R&[O8[FSFMKB1;14
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M85GN)+F0R-DEW.6/YUH444 %0FUA:\6Z9,S*A16))V@G)P.@SQD]3@>E344
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M\-J@F+\%A@*Q/08YQSG@"M$^,[%;F&(VE\JR7$5HTC1!5CFD *HV3G(R,X!
M]:PM$\%:Q86OABUNKBQ,6BW$LA:,OND4A@.HZ_-GV]Z=JGA/Q!>:W<WJOIUP
M%O[>[LWN9'WQI&5)B VD(#@DE>O<4 :A\?Z2)Y$^S:@8XK_^SY9_(_=QS;@N
M"V>1D]L_RJ2/5]1UNVUZTMK2[L)[.5H(9U\IV)"(W +$;CNXSQ@CG.:RSX)U
M!]*O;-KJVW3Z_P#VJC#=@1^8'VGC[W!]JW=(T_4[#7=8DE^R'3KRX^TQ,K,9
M=WEQI@C& /D/<]10 #6I;!+*PN[:XO-4^R+-<K:A#MZ*S8+#(+9X&>E:>H7]
MOIEC)=W+,(D('RJ6+,Q"JH ZDD@ >IKF_%WAF[\07$9MX+5)(D4VU^)VBGMI
M-QR1A3N7&/E)'0_4:GB31IM:T/[+#<+'=Q217$,CK\IEC8,NX#L2.?K0!EZ]
MXY32="U6ZCTZX-_IX0R6<Y52JN<*Y(8@IG^Z2<C'%4+CQ9-I?C;4#?1WXL(M
M)CNFM517,&'8.YVDC "Y/)]O2E\0^#M3\1VNL7$PL[?4;NPALH$69GC4)*9&
M+-M'4D#IQBI;WPQK.I7VO7<_V*)]1T/^SXU25F"RD/R25'RY;KUXZ4 :^J>,
M=*TK!?SYP(%N9# FX11-G#MDC@[6X&3QTI8O%^FW.L#3+6*\N9<1,9(8"T:I
M(I97+?W<#K[_ %Q@R^%=>M]5@OK.#1+I9=/@M;F&^#-Y;Q@@,A"\CYCQQG';
MMM:#HNHZ=XCUJ]NY()+>\2V6$QD@CRX]K97&%!)) !/6@#1U/6[;3)HK=HY[
MBZE1Y([>W3<Y1,;FYP !D=2,YP,FLV\\<Z+9V<5R9)Y4DMA=D1Q'='"?XV!Q
M@<'CKP>*37M*UDZ_I^M:&UF\T$,EM/;WC,JR1N58$,H)!#(.W-9VI>']?;6$
MU6U@T.\FN+1(;N*\5PBR+N*M&<,<?,00>N!TH UCXRTM]0GL+5;N[N84C=UM
MH&<!77<K;N@!&.216;I7BD>(M.\/7TAO-,:]NF\N)4#+/M1SL+<_*0,YXY6M
M#2]&U"U\1ZW>W+6QMKV&WCA$605,:$-E<<#+'')XK'T;PMK6GZ;X8L9A8LNC
MW3.\B3-F2,QNF0"G7,F<>W7F@"M<^+;E-7U6ZO#J]C8:7=I&_E6\4D.P(K'S
M.K98OU4\#;[UU&KZQ!#9:@GFW=O]GLQ<R7,$8<Q*VX @<Y/RL<8(P*S%MHM&
M?Q+-XCN-/@TG5+D-&SS8R#$L95MP R0@.!GJ:@T/0K\_#F[LVG\^]O[5XXGN
M!Y>(S'Y<0; .,(%)XZD]S0!HR>+]+TYUL9Y;NXNXK%;M]MLS,8\'+G:,#H<U
M;NO%&EVA :5W/V3[<PCC+%(.GF$=<>W7@\<5C?\ ",:FVKW]VQM0EUH:6&!(
MV5E&[_9^[\W7K[5SNL1WJ:I;V:+ICW4&C)9:BOVX6[%6Y(!=3N3 X(P1N.>H
MP >DVNIV=YI4>IPS?Z%)%YRRR*4&S&=Q# $#'//:J%MXITZ[G6"-;D320&Y@
M1X64SQCJ4SUZCCKR*KPVL'B/P&]C%"+."ZM'MHT1]ZQK@HI4C[R\ @]QBJ=A
MHNJW6MZ%?:G##;_V/:2PYBEWB>1PBY P,+A">><D>E '-GQ;J\WAR#7K>XU#
M.H7ILUM_LZ&.)6FV*R<9W!1CDD%CTKI=)OTT[5-7COO$-[=K:6R7$L-W;*GV
M=&!(.Y5&XX!Z?SK(3PIK=M\/M,T9(87O;'4EN#LFPKHLQDR"1QP<8Q5S5O"V
MJZAK/B6>!HH4OK.VCM97;(\R(EOF'4#) _.@#>B\5:5*;Q=\\<MIY?F0RP.C
M_O/]7A2,DL> !SGCBH?^$TT)8'DFNI(-ES]D=)('#)-C<$(QU(Z=CVYK%U/1
M_$_B31"=3LM*@N[:>&XMK82&6.9D)WB0E?NL#@ 9QZU+%HNJ&UTMQH6EV$L6
MJ)<S063@*(PC*6)VC<WS9X'3% &S9:^FHZE(("J6$%FEQ,TR,CAI,E1@XP J
ML3D=QZ&G)K!UBQN/[(,L=P(EF@DGMV5) V2I&<95MI![@'MQ5*VM7LO%_B!B
M%=]2MX9K=7'RN41D9<^QVD^S"J7AK2;KPQ+J$T@EL]#6W#I927'G>5("2_E_
MW4QC SUH Z'2-;MM6\/6VLJ?)MY8?-;S"/W>/O GIP0?RJK;>+]'N8+B=9ID
MA@M3>&22W=0T S^\7(^8<=N?:JOA31[W2?A[9Z: J7PM7($PR$D?<V&'< M@
M_2N6MO"GB86E\L]I"TU]HTUE/+)?&1C.P.& VA53G 5> /U .TTSQ?H>KW!@
ML[PM*+<71#Q.@\KCY@S  CD9P3BLVT\5_P!I>.[33K*1VTZ73'NLR6[Q[VWJ
M%92P&5P3TXJE<^$]2NXK>T81QQGPY)ICS!\[)6V=NX^3K[U+I6EZ\?%NE:G?
MZ?%#%;Z6UE,R7"ME]RMN  ''R_K[4 :FL:EJ%KXNT"PM9HUMK[SO/5X]QQ&H
M;Y3V)SCN*UM1U2STJ*.2\E*"6011JJ,[.YZ*JJ"2>#T':LW5M+NKKQ5X?U&%
M T%E]H$WS $;T"@@=^14?BZUU:ZM]/72X3,JW:M=*DBQR&'!#;'.-IY'((.,
MX- #Y_&OAZVL[:[GU$1PW+2K$6AD!9H\[QMVY!&",$9)X%22>+M$B$1>\8)(
M(R)/(DV+Y@R@9MN$)R.&(/(]:Y;2/"VL6VH^'II[*..+3K^_ED'VCS#LFW;"
M">6QN'7GBG7'A2[C\6:A/_PCFFZG!?3BYBOKB0!K9MJC:RXRP!7(QZ]J .TU
M;6=/T*S%WJ5R+>W,BQ[RI(W,< < U1/B_0Q8PWOVQC;RQF4.()#M0-M+,-N4
M7((RV!Q5;QQIE[JVAP6]A;F>5;VWF90RKA$<,Q^8@=!61XA\.WLWBN6_&@6F
MN6-W;1Q&.>98S;R(6P?FZJ0YZ9/'Y@'42>(M+COEL_M+/,S(O[J)W12_W SJ
M"JY'(R1P1ZU2M_'7AJZU*'3X=5C:ZFD:%(]CC+KP5)(P#P< ]>V:PAH6KV^O
MVUYI]A-I\RSP17)MYXS9W-NJHK$QEMRL%#*N%[#\,?0]-O->T&?3([%UA7Q#
M+</>&1-JJDY8X&=V[C XQSUH ] 'B72#?_8OM>)?.-ON,;B/S0,[/,QMW>V<
MU7_X33P]]O%C_:2?:#<_9=GEOQ+Q\I.,#.<#/4]*YS_A%M4?0[CPW);.(GU7
M[6NH>:FWRO.$V<9W;^J_=QGG.*>WA_5OL-^HL&,D_B6._1?,CSY"O&Q;[V.B
M'CKTXH ZI?$6EOJ7]GK<.;C,B@"%]I*#+@/C:2.XSFN9N/&+:?<>%Y)M6M;C
M3K\W1N;M8"@8(I*[1G(YP.Y.*DT_2M9M?&"7EI;7-E8W$T[:A#)<));R==DD
M2[BRNQP3P!UK-L/#VM:79^$+J339)GTB2\-S;Q21F3$@<*5RP4]1WS0!T=YX
MC^U)H%SH=U!<6M]J(MI'QD%!'(S8]""E:*>(M*DU8:8MXINRQ4*$;:6&<J'Q
MM+#!R,YXZ5S-IX7O;8:?*UKDR>()-5GB$B@6Z-'(JCJ,D$H2!GG=U%-T/PY>
M:=J(MKK0+2<17TMS%JC3 @([L_"?>$@W%>F/?U -7QGXH/AR'3DC!\Z]NTAW
M^0\HC3DN^U1\Q '3KS[5/9^)K&">/3=1U.!]1+["8X71/F.8U).0K%63@G))
MXI/%%G?W4^A26-H;@6NII//AU7;&$=2?F(S]_H/2N=O_  ]JT^EZWX<^QR%-
M2U W4.I*Z%(T:17.\$AMRX(& <X'- '71>)-'GU8Z7%?Q-?*[1F$9W!E&XCI
MZ<U)J6O:7H[!;^\2%BI?!!)"CJQP#@>YXK+\+Z3=Z;JGB.:Z@$:WNH&>!PRG
M>FQ0.AR.0>#ZUF>(=)O$\4S:C_PCZZY9W=HEOY8E17A92QP=Y V$-S[]J .E
MG\0Z3;7Z64MXHN'9550K$9;E1D#&3Z9K.TWQQHNI:?/>B=X88K@P?O8V#.=Q
M48&,DG:>!R.^*R[K1[^W\36USHEE/:9EMX[M&V/:30*HRP&<JZCY00/X1VYK
M/BT_7K'3A:)H<LBQZS/-+,C1&40R.[!X"S<'# $G! )QZ@ VM5\;6MGJ?AYX
M;NV_LG4&N?/N'S\OEQD@#T.[C&,]JOS^(HKC^P;C2KB"YLM1O# TBY.5\J1^
M#G@YC Y%<;I'A_6-.;PW-/H]TZ:3?WYF3S(W=EEW;'7+?,/F&23GCH:T;+P]
MJME?:9.+5_*EUZXU&>)64^0CQ.B9^F1D#/4]: .FM];@@@U&YOM4LY;>&\:!
M3"A'EG@")N3N<$XX_(5G7_C*VM-7T=A=6_\ 8][:SSM<,IS\FP#'UW],9XK)
METF]O;;4X+[2=0B#ZY)<03V4R+)&H3"3+D\Y*X(/][I4VE:?X@GU7P[=ZO:*
MTUO:7J7$VQ!M+NGE\ \,57G;ZD=Z .A?68[JYT1]/U"R:VOF=@&R6G0(3^[Q
MW!QG/;WIUMXJT&]OH;&VU6UENIBXCB1\LQ3.[\L'\C7)^&]%U73],\#17&G3
M*]@;@70!4^3N1U!//()8=,U):Z#?BR\/A=-:&6WUV:ZN<[ ?+8S8<X//#H/7
M\J .IG\4Z%;7XLI]5M8K@OY81WQE^FT$\$\CCJ,U<U+5+'2+0W6H74=O "%W
MN>I/0#U/L*\UL3'IEY8SZA9ZF-*@U.>YM9DMTEC#2LRJS2K(24^?(^0')')Q
M78>+H]08Z5+8:>UVL5UNF>%8S/$FTC,>\@ GH3UP3B@#03Q-HCV=O=C5;46]
MQO\ *D:0*'V@E@,]Q@Y';%/'B#2&TI]474;9[%"0TZ2!E!!QCCOGC'6O.] \
M/ZNL_AL7>AW445EJEW/-]HDCDVK(&*-G<2Q!(R>N1FKMGHNM:?-]L_LV6:.#
MQ)=WC6R.NZ6&0,J2*"P!QNS@D&@#I_"'B4^)[74[E?*,%OJ,MM \8(WQJ%*L
M<]SN]JM_\)5H'GK =9L!*Q8!#.N3MSN[]L'\JR_ ]G>V@UYKVQFM/M6K374(
ME*Y:-PN#\I..AK#E\,W\NG6072]L@\5&_D4[,B S.=QY_ND<=: .V@\0:/=:
M9)J4&IVDEC$2)+A)044C'!/0=1^=03Z[:7&E?;=-U/3VC%PD+32R9C!+J&7(
M/WL'@>I%<GJEMK-K;^()(-#-Q&VL07,&(EDD*!(U>2-"<%EV97/<YQ6?::3K
M4VB:U8SZ;J(EFU^"\1[C86:'=$Q)(."55#G!Z\4 >@2^)-$@NQ:2ZM9)<&7R
M!$TRAO,X^7&>O(X]ZK6?C'0KZ^U"TBOX@]B<3,[!1P,D@GL,X)Z5RGB#P[J%
M]I7B]+?2V:YOM1MI+9L(#(B>2"0<\ ;'Z^OO3M5@U:SE\8BVT62]>ZGM[B /
M#OCD0+&K8&1N==K$+ZJ/Q .NEUZSN]+GN-*U33F='$8EFDS$KG!PV".<'CZB
MI;WQ'HNFR-'>ZM96\B,J,LLRJ02,@$$]QS7#QZ=J5Q:^)T%CJ\LEU<6=Q"UZ
M$4RJHBSC!"AOE;(XP H.#Q4_B/P]J&H+XW$&EEYKVWMTM)?ES+A,, <Y&".^
M* .P.I>7J]VDU[IZV5O;)*R[R)8R2?F?G 3 X_&I;+6]+U*YGM[+4+:XF@P9
M8XI0S)GU Z5R/B'2-3U"+7X[:PF8W.@Q6T1)4!I5:0E.O7#K[=>:KW6BSV^J
MBX?3I8K$^%I;-Q"50K*64[,CA6QG!Z9H [:SUO2M0F,-IJ-K/*/X(Y5+>O3K
M5^O.?!4A.MV4^JVFHVVI_P!G#3X!-8-!&8XSN.22V7/L0,#I7HU !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5$?]8*EJ,_ZP4
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MI=G4/LR3VEQ+/!''E)'C9%)Y/<.<=<>] '?T5P>@^(/%&M/I^J):0C1[DN9
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MMX2TGMVL;I[27S"I5I%^]M(.2.1R0.M4]/UPW;Z_J@%Q-;:=-):1VL";F<Q
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MV=X8\[/M$"R;<]<;@<5QOA+Q>8]-M(M5%],UYJ=Q:I>. 8Q)YC[(R2=W08&
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M:*WB6)"YRQ51@9/KQ5FBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M88;_ *9%5['P?KUOXBLM4N)M+FD@OIII+@^89I8Y RA2<8&U6P%'''USW]%
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M3R-B]_EP.OJ*T*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ J-A\P-24UNU "1_ZM:?110 4444 %%%%
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M50S;L\?,<8P>%]^-J[U>]L;WQ6]G8VSSVGV5E:*W)D=64;F?!RY5<D#C@8H
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M9B[C$TRLCQMG#?+G!&TG;^&: .VHKD8?%FI?VC8:2VB^=?SV"WLGE72A%7S
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M6VCN]]PD'F*A94 !."!G!Z^E=.]]:1EM]U NV,2-ND PA_B/M[T-?V:A2UW
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M#C<*M:1XAFU8PW*V,<>F3)(XNOM()0JP55=<#!8'/!/2MWS(]JMO7:W0YX-
M'+:AX)^UR:FMMJUS:VNIH@NH517W,JA=P9LXR  ?7'45O7MI<W.G""&\\FX!
M0^<8@P;!!(*Y&0P!!&1UJSY\0Q^]3G 'S#G/2G+(CE@KJQ4X8 YP?>@#DXO
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MQ6Q1G ;<'8EC\W7IQSTKJ**A>Z@2ZBM6F03RJSI&3\S!<9('MD?G0!-1110
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M^L6.M>'9KK3C'%;Z#]@N&\Y#Y<BLA'0\YV=O6NQT^_M=4L(;ZRF$UM,NZ.0
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M?:8KVWRD$C;OWL,IZAR1\H/1L\8KOHI8YHDEB=7C=0RLIR&!Z$4^@#SC14U
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MEDMD(^5<$#&2&/"CDGK7,31I8S>+X=-M_*U!=5BEN!;Q$2_8CY1?! SM/S'
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M[:5+I$NQYFH2GGS74$'@;CEN<D^F:K)>P7/@SPW=76HV=U<1V$[O8:E,1'=
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M68:$/'<!HP60R?PN') R!D <<ULW'A+2;F\N[ETG!O=ANHUN'"3[!A=RYYX
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M+\IV[B '8 $D#/L* .)MK[6M6TCPC?O<6U[>R:K<M"64Q+PLX&XY/''& #C
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M58P0!C>-IQCG)Z=*HWG@J[N["^M3JL*_:=574E86A^3:5.P_O.?NKSQWXYX
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M 4444 %%%% !1110 4444 %%%% !36IU-W '% #J*** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !43?ZP5+VJ)O]>OT- $M%%% !1110 4444 %%%% !1110 4444
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M7-K:X.R:9EP[!V4J #GC;UZ<^U<[KAN-:\7ZEI=Y%=I86FFI,IM;PQ,"6?\
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M[L:;]M02E0P1@0"=K$JV<<'!YHE\+:A)K-KJ!U7?-#ILMFTQCPYD<Y\P8.
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M'FR22C;6/R@C[N<<5U/A%0ES>K%XD35X'6.18T+N(,@_QO(['=C.TGC&<<T
M=517GD?]H7?B_P 6W2:GJ+#2&B>TL8IR(G8VX.UE[@L.@QSFJ&C:C<G23K%M
MXT@EGGTV61[:X21ECE R9'#2/Y>UN,!0IZ =* /4J*\MM[V]^PZEJDVKWMG8
MP:.BR(M\ES*MQR'D4!V XP 25YYP.369?:SJEEI7BJ&/5Y(&@DL6M8QJ37,T
M8=U5R7/."",@9 )(!H ]EK)L?$-IJ5M9W%K%=2174TD*NL#$(4+*Q<CA1E2
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M*** "BBB@ HHHH *B;_6CZ5+43?Z\?2@"6BBB@ HHHH **** "BBB@ HHHH
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M#D@D=.M '<T5QG_";7?GZS,NF0R:5I)9I[I+GYF7R1(NU-OWN0""1CWJO?\
MCO4M.TF^U";06,5O:+<))^]1&8N%*$O&.<-D$9SB@#NZ*Y'_ (2W4X-7OM+N
M]%C6ZCTXZA;+%=;A(H;:48E0%8$CU'7FJ'_"Q)?(UIH["VNFTMK;YK>Y8I,L
MS;?E)09(/X'UH [VBN*USQEJF@63RWVEV44J6TEQL-]GS"K'Y$ 7<QV@,3C
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M9LO$<EG9Z9I6CZ/'C^PTOXTDN2J1J-H"$X)/!/.#DXZ=:6[\>2)X=L]8M["
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MG^UVUII@TW3]!W++=VT-J%>9U8' (P #@ G&>M=-110 4444 %%%% !1110
M4444 %%%% !1110 4444 %1-_KA]*EJ)O]<#[4 2T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% %+5M)LM;T]['4(?-@8AL!B
MI# Y!!'((/<52D\+:;-I^H6DHGD&H*$NI7F9I)% P!N)X&,C ]3ZUI7M];:;
M:/=7DRPPIC+-[G  '<D\ #K5&V\3:-=P7,T%_&RVW^O!!5HSG&&4C(/MC- %
M^VM4M;**UC9]D:"-23E@ ,#FLB#PAI=OI5MIL?VD6UM<B[A!G8E) 21@^F23
MCIS4P\5:$8(YCJ<")),8%\PE#Y@ZJ0<$''//;FI;?Q#I-WI;ZE!?126:.8VD
M&>&!QMQUSG'&,\T 5)O!^D3VU[;/'-Y-[>"]G02D!I00<^PRJ\>PJG<^ -*N
M=0EO&NM2C+WBWPBBNBJ),,990/[P&#S],5I_\)3H(LX;LZK:K!,',;-(!NV#
M+\'G(QR.HI@\6Z =0AL/[5M_M,P0QIN^]O&4&>F2",#J: $_X173#!#"XF=8
M;_\ M%"TI)$^2=WTR2<=.:BMO!VF6FMRZG;O=QB60S/9K.PMS+G/F>7TW?IW
MQGFLZ_\ $NJ0:-XGNK7['+<:9>B"W#HVQEV1-AL-G.9",Y[=*Z"/7M*E>_1+
M^$MIX+7?S?Z@#.=WIT/Y4 8Z^ M-2&%4O-026&]EO8YTE59$>08<#"XVG)[9
MYX-26_@G3[5+!(;N_"6-Z]["K3!\.^<J=P)*_,WOR3G/-;\EW;Q69O))D2V5
M/,,KG"A<9R2>V*JVNN:5>VDUU;:A;R00?ZV02#"<9Y].* &ZKHL.KS:?++<7
M$36-R+J/R6 #, 1AL@Y&&([=:H7W@ZPO==.KBYO[6>0*MREK<F-+D+P!(!UP
M..,<5H1:]I,UA+?1ZA;M:PMMDE#C:AXX/H>1^=(WB#2%TU=1;4K86;-L6;S!
MM+>GUX/'M0!RFF^#;B\U7Q#_ &K)=Q:==ZD9Q:*Z>5=)A-I;@L.5.1D9XS6Q
M>^"[&[O+N1;FY@M+X@WUE$5$5R1QDY7*DC )4C.!6C<>)-$M((Y[C5;..*2'
MST9IE :/(&X>V2!FJ]SXOT.VO-+M6OXG?4ANMRC J5P3NSZ$C'U- $]IH%K9
M:GJ5]%)-G4!&)825V+L0(-N!D?*/6LZW\$V5O:Z-;"_U!XM(G\ZV#NAZ#:%8
M[.5 R.W4\],;,>L:;+J3:='?6[7J EH!(-XQUXK$U#Q=%#XPT30[*>TG-Y),
MMTH;<\86,L,8.!R,'.: 'KX*LA;VL,E]?R_9M3.J1L[IGS26)'"@;"68XQW/
M-<D-%UY=8OKJP.MV>J374D@#I;O:C)P#O8%BNW''48P!Q7HVI:MI^CVOVG4K
MV"T@R%WS.%!/IS3;K6M+LK*.]N=1M8;60@1S/*H1\],'/- %?Q!H,6OV=O"]
MS/:R6]PES#-!MW(ZYP?F!!ZGJ*R;7P+!9SV[Q:M?F&#4#J*POY9!E((;)VYP
M=S=^_&,5T5QJ>GVB1/<WUM"LO,;22JH?Z9//6BXU*QM)HX;F]MH99?\ 5I)*
MJL_;@$\T <]+X$M)89Q_:%W'<-J+:E#<1[ \$K=0O&"N.,$'-7O#?AH>'CJ#
M_P!I75[)?7'VB5K@(/G(P2-JCK@>W QBM-]2L(S<![VV4VV//W2J/*STW<_+
MGWILNK:; I:;4+2-0JL2\R@ -]T\GH>WK0!SU_X$M[U-4A74[R&VU"Z2\D@1
M8]JRJ5)8$KGDHO4^OK5G4O!MIJLVK-=7=R8]12(&-2%\AX_N.A R&!YYS^5:
M#>(=+775T8W<0OF@^T!"P'RYP/Q/)QZ FFZ;JV[2;>?5;G3H;ET9V^SW :(A
M2<E6.,@ <^G- "Z+HTFDK,9]4O-1GEV@S73+D*HX4!0 .I.<9.>37'V'AJ^U
M;Q-XI2[N+JUTFYO8S);-; +=H$4'#L,[25(.WMZ9S7>/J%E'9B\DO+=+4@$3
MM* A!Z?-G%2P7$-S'YD$T<J?WHV##\Q0!BV_A2TB;7%EFEFMM8(\ZW8 *@V;
M"%P >5 'X5RGB+P9?6'@#5[.#4]4U=_LPAM+:0!MB;U. %&6. .3T XQ7?IJ
M5A),D,=[;-*Y8*BRJ68K]X 9YQW]*BO]16&RN&M9K5[M87>*.68*K$<<GL,X
M!/;- '/GP6-3LKQ]6U2XN[R\LQ:+<^0L+119W8"@==V"<^@'%-7P)(S7CW&O
MWLTEX(//<Q1#<T3!E887 Z 8Z8SU)S72+J5O%;1->W5K#*8U>1?.&T$XZ$XR
M,G@U-<7MI:!#<W4,(D.U#+(%W'T&>M '.^(_!2^(=2:[.J7-JLMDUC/%$B,)
M(R2>K E>3SCK@=*+7P:UK?"X&L7+J]@ME<H8D'G[0X5B0.,!SP/09S6T+Z5=
M7N8)3;):10(X?SAOW$G(9>PQMP>^33KG4H8[.]EMI(9YK:)I&B$@X."0&QDC
M./2@#!'@H6L.E/IVJ7%I?:=:BS2Z\M',D']QU(P<8!!]:LVGA&TL;K1Y[::1
M3IJ3IAE!\[SL%V;&,-N /''48]+FE:Y#>>&M,U>]D@M!>6\4I#R *&=0=H)Z
M]:O37]G;W$5O/=P133<11O(%9_H"<G\* */A_0;?P_X=MM%CD>XMX$9 TP!+
M*23@X&.^*S=+\&KI\EE%)J$MSI^GRM-8VKQJ/)8@@98<L%#,!]><X&.ECFCE
M+B.1'V-L;:P.UO0^AI] &+X<T%M AOHS=FY^UWDMV6,>PJTARPX/3-5G\+N^
MM:WJ/]H$?VI:+:[/)'[G:I"L#GG[S'!'IZ5T=% '+V7@]K.>TF_M)W>WTDZ7
MS" '7((<\]1@<5F'X;D65I:QZY/$D.G-IKE8$)>(DDD;L["<X)'4"N[HH X^
MW\""(2"34WDWZ*-'R80"$&</P>O)XH;P1/#=P76FZ[<V$XL8[*Y:*%&$ZH,*
MV&SM8<\\_P"/844 <IJ'@F._DUACJ,\?]I645ED+EHU3/.2?F)R<U2G^';75
MMK<,^LN5U>&&.4):HBH8\!2H'0!5QCWKN** *.I6E[=Z3);V=^+.\8+MN1"'
M"D$$_(3R#@C&>AZUR:?#MH].,<.I06]T-3CU)&@L]L$;H,8$6\X!Y)^;K^5=
MU10!Q,W@.[DU.2Z77 J-J2:B$:T#,SJ%&UFW<J #@ #&>_%23^![F>WU"(:V
M\7FZ@=1LGC@ :UF+9R<L0XY(Q@#DUV5% ')GPGJ<\^D7-_X@-W<6%X;IW>T"
MAP4V;%56&P8R?XN35:;P'/+:74*ZLB-/K@U</]ESL((/EXW\_='S?7BNUHH
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M] !4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !VJ)O]>OT-2GI4+?\ 'PO^Z: )J*** "BBB@ HHHH
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M($_>;:6Q^2FIZ .4O]&U#5=6L_$6AZLVGS-;?9Y8;FU+J\>XL,J2"'4D]?\
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M-XL<0MU&!F,D9D.<LQR>,#BO2+&]@U'3[:^M7WV]S$LL38(W*PR#@\C@U8H
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M4QZ5$?\ CY3_ '30!+1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M73[9Y98/L\CM$"7B_N$]U]NE1GP]HI>!SI5D6MXC#"Q@7,<9!!5>.!@GCWH
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M110 4444 %%%% !1110 'I43?Z]?H:E/2HF_X^%/L: ):*** "BBB@ HHHH
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M*G0J ,*?;*H?^ U7U+PC)=:]-JMCK5[ISW4*PW<< 4B95R 1N!VL <;AR.U
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M8PS*'0NC(2#ZJP!'XB@">BBJ=MJEE=ZC>6$$V^ZLMGVB/:1LW@E>2,'(!Z4
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M]BS&!& A#2@*!CL$'/7/7/2M3P5J.H7L6M6^HWAO)+#5);2.=HU1F150C(4
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MM[5[2,O=.V(VZCDGV^F!Z4 <[9^,-;UFUTBVLXL7USI0OI6ACC;+%MH $CJ
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MKJ"PLB 299Y.6/4#:H(],D$9'6J]UXK\26,$"SZ%$)Y]2BLX6EE\I)E<$[L
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M"\(V.K6&H6T-M)J#6Z82[6]TJ&U 0*<8D4 R-NQR"PZDGU /1J*** "BBB@
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M[>?Q%4? ND:CH'A6VTG4HX%DM2R(\,I<2*6+ G(&.N,<]*IS^';^3QA'J]I
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MR^S&>,VF])F (&\HS$*@Y&<G)]*3XC6ESJ'@/4K.RMI;BYF"+''$A8DAU/\
M(&LG6[.:\\775Z^D7EU83^''MV14*EV,F[R\GHQ'ZT =?!KNDW-K/=0ZE:O;
MP8\V42C:F1D9/0<4Q?$6BO8"_35;-K1G\L3"92I;^[G/7VK@&T[Q%#I#1VD%
MUJ%MI^HVEQ%Y]N(+BYACY:,YQN*X3!(&<8[5?U8WMU;V&I6GA:YM#)J!EF98
M4>\C'E[3*$SM#'&W)S@8/I0!OZKXF\B;P\^FR6MU::I>"W:4'<-NUCE2#C^$
MBN@GN(;6!Y[B:.&%!EI)&"JH]R>E>4:7IFK6MEX=MIM'U)7L]?EGE,B!R(V+
M_.64X.-XR>_.,UVOC>"]DT[3I[.SFO!::E!<SV\."[QJ3G /4@[3CVH T[7Q
M'HM[ L]MJMG+$TPMU=)E(,A&0F<_>/I4O]LZ7]FEN?[1M!!#)Y4LAF4*CYQM
M8YX/L:\LB2[U:+7+VTTV[+0>)[:[DM3&!,$0(6^7/7OC-69EUB6VU&YB\/:@
MC3^(([N,R6P:6&,1@>:B$X+ IWR!D9!H ])_MS2?(CG_ +4LO)E8I')]H3:[
M#J <X)%5+'Q9H>I:S-I5EJ5O/<Q1K(?+E5E8'/"D'D@+DXZ BO/8=(U&>ULK
M.YT;428O%7VZ1KB(-N@8N=Q*Y!QE<]N>*V-9T34CK7BJUL;.3;K&F116TL:X
MB1D64,C-P%)X'']X>^ #M8]<TF6"6>/5+)X82!)(MPA5"3@9.<#)X&:L6]Y:
MW<32VUS#-&K%6>-PP!'4$CN*\LU/2VUKPAJS6GA?6;74'@MH)5O)9'\P).K%
M$5F.Y5 8AL#@\=37J-C8V6GVHAL+2&U@)W>7#$(QD]\ #F@"C8ZU"-)ANM4U
M#2T:1I )(+D&)@I/W6;&2%'/H0:T+>]M;NU%U;7,,UN<D2QR!D..O(XKS'1_
M#]\=.\&6UWI4I6VU*[GGCEAXB0M(4+ \#JI%=AX'LY[#1;JWN+>2!QJ%TZHZ
M%<JTK,I'J"".E $,_CBPFM[";2Y8+E)]46PE/F#]V,N"_!Z'82,]0<UOQ:KI
MT]D][#J%K):(2&G292BD>K X%><Q:1>3Z%IVE7.D7,GV'Q,7F5X"4DA,DC>8
M,C#)AQS1JVE:C#I^I/:Z3?-!!XC^VF&TS%)+#Y07=%CDD/@^^* /3+6[MKZW
M6>TN(KB%L@21.'4XX/(XJ--2L9+Q[-+VV:ZC&7A652ZCW7.163X0M;6WTN:2
MSTR^T^.XG:8I?.QED8@9=E8DJ21T]LXYKDO#HNX]-73-5\*7]SK6G?:Y/M;Q
M[896<.25E_B+[@N!D\Y[< 'H-MJVFWC2K:ZA:3F$9E$4RML'^U@\=#UI8M5T
MZ:S>\BO[62U0X>=)E**?0MG ZC\Z\JLX+B6V>/4-+UQ;.ZT1+-HH=,=3 ?,Y
M2, $X0$_?R6QD9J_<IX@.D>9=65UJ%O9ZHDLDEG9FWN+R+R2NXQ,!EE8IVP=
MO'2@#TRWN(+N!)[::.:%QE9(V#*P]B.#4:ZC8O>M9)>6[7:C+0"52X'NN<UC
M>#;.WM=(G:TL=0LHKBY>?R[_ (D)8#+;?X 2#\OX]ZY"RT>^.EZ#IKZ=.FM6
M6MK<W=R;=@CH)'9Y!+C:0RMTSGG':@#J+/Q9)JWB*YL-)73KFVM)5CF/VS]Z
MRE58R(H!!5=V.O)SR,<]37'^#H9(M?\ %;365Q"9=1,D4LMNR+(A11\K$#<,
MJ>GMZUV% !1110 4444 %%%% !1110 4444 %%%% !1110 'I4+N%G4'N*FJ
MLZYO(V[!30!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7X+>-EU^.!66"+6;A$5NQ^4OCVWES^-<!>PVPT/4H4NY4G_X2P(?](+,B"<
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MY 'Q%_Z_H?\ T7#6IK5Q?Z/XGO;$ZA>,FO6XBTS$A;[-/N"OM'; <.#V"D4
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MBP^USZ7<6 8@Q+.ZDR(0"&^4G'7H<&N"GO9KJVUS7=4_M& Z=J+6Z&PU%E.
M8T\O& -N3NSU.30!Z2+&T6WC@%K (8O]7&(QM3Z#H*<;2V:[6[:WB-RJ[%F*
M#>%] W7'M7*ZQX^CTB]UB Z1=SQZ0D4ES,CH%"R#(QDY)]OKTJ?Q!XV@\/.[
MW%A.UG"(S-<%E0?.< 1@\R$9R<=/KQ0!O:;IUMI5DMI:H5C#,Y).2S,Q9F/N
M22:232--E:1I-.M':1Q(Y:%3N<=&/')&3S[US>J_$"VTF[U.&72=1D3398H[
MF:,)L42 ;6R6&?O#CKS6GJ7B9;*2\6VTZ\U 66P7/V10Q0M@[0I(+$*0Q Z
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% "'I4;?ZX?2I#TJ-O\ 7CZ4 2T444 %%%%
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MD"SVT\<\39Q)$X93CCJ*\^@T'4D^(\$5YJ-A<HVGR2S1C30B2JTB(P*A\;B
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M<>6FW<P*GY20?E., Y[XH Z6BN0L/'!N+Z%+O3Q:VD^DG58Y?.WL(QC(90,
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M)!YF_! VG)^4#&1CKD]*DU_Q;_9.JII=I9-=WOV;[4Z9< 1[MHQL1SN)!P"
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M#:7+2V<]L5!\LEB%(8$<;BIR"",'U +CPG;'1(=&MP/L;WBW-V9.3+B3S6X
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MM[;0YX-26)[@7@9VMY0@1C'\OS+@< D9]JZ^PU*/4)+Q$@N8C:SF!C-$4#D
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MV\]O#I%BD%PV^:-;==LA]6&,&I+K1M,OC:FZT^UF^R$-;^9$#Y1X^[Z=!^5
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M2RMX[>WCSLBB7:JY))P/J2?QJQ0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 'I43<3@^U2U&?OYH DHHHH **** "BBB@ HHHH ****
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MTP%LPTV"XC"JJ@%7?[H)!/WAC//?(!VGB34M3TGPS<ZE8VD-S=VT?FO S'#
M<L%(&20,XXYQ6#=>/);;6KJR\JV>(Z7]MLI%9LRRD+B(]LG<#QSAE]:["V6>
M33H4OUB:X:)1.$^X6Q\V,]LYKGK?P#H]M9Z5; 2.NG7GVN-G.69L$*I/H!L
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MT#JHR7VDJX*Y^Z1VKJ/#>BOHUG=F=D:ZOKN2]G$9)17<C*J3R0  ,\9QG H
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M)] !WR >D:=J=CJUK]IT^ZCN(=Q0O&<@$=1]:74-3L=)MOM%_=16T.X*&E8
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MBB@ HHHH **** "BBB@ JO+8V\U[!>2(6F@#"(ECA,C!('3.,C/7!([FK%%
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MP4.KE6&PC/R]CW]N7:KX-U6\NO$\]O<6:/J$]G<V1D+, \ 7(D7;T)7MG@T
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MOG&6ZL&QC;[^N-KQG'<R:MIZQ:7=3Q26UQ#)=6D(DE3=M 0$\(&[L>PXQUH
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M=^'UN")[II1))Y@PX!. =N>@'%6-9CT]/BQHTM[/Y3-I\OE;[AD#2"1-J@9
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M*H--TRQT>QCLM.M8[:VCSMCC& ,\FK=% !1110 4444 %%%% !1110 4444
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MHH KP6-K;7-Q<P6\<<UR0TTBK@R$# R>^!56_P! TG4[E+F]T^">9  '=>2
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M'3BNSHH XS0O!$<%M<Q:E#MMY9H9HK-;V6X$3QDD/O?!R<@$ 8PHZYKLZ**
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AZ5&3B=>?X:D/2HF
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MH&AW&HLAD>-=L40ZR.Q 5![DD"@#%\3ZA<ZQJ2^%]*D*22+OOKE.?L\7H/\
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M_A6_H7AS3_#UL8+*)F>3#332_-),P_B9NYH T=/L+?3M/MK.V0+#!$L: 'H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@#IJY+7_  QJMSX@36]"U&"RO#;&UE\^$R*R$@Y&"/F!%3_\+#\'?]#/I/\
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M0UGPGJDC0OI<C30_:#M(A)R<CL!PW_ _:@#T*30-$CC:1M(LR%!8A;56/'H
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M_A1_PKKP;_T+6F?^ R_X5TU% ','X<^#3U\,Z9_X#K2?\*X\%_\ 0L:7_P"
MZUU%% '+_P#"N/!?_0L:7_X#K1_PKCP7_P!"QI?_ (#K7444 <O_ ,*X\%_]
M"QI?_@.M'_"N/!G_ $+.F?\ @.M=110!S'_"N?!G_0LZ9_X#K1_PKGP9_P!"
MSIG_ (#BNGHH Y;_ (5OX+_Z%C2__ =:0_#3P61@^&M._" #^5=510!R9^&/
M@D_\RU8?]^Z3_A5_@G_H6[$?\ KK:* .1_X5?X)_Z%NQ_P"^*/\ A5W@C_H6
MK'_OBNNHH R=%\,Z-X=65=(TZ&S$IRXB&-U:U%% !1110 4444 %%%% !111
M0 4444 %%%% !51C_P 3%%[;#5NJY4&\4XYV&@"Q1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% %2XTK3[N[AN[BQMI;J'!BG>)2
M\>#D;6QD<^E1+H.D+J0U%-+LUO@Q;[2L"B0DC!)8#)X)I-6UW3]%6'[;/B6=
MMD$$:EY96]%0<G\*HR^,=*MX+J2X%Y ]K ;B6*6TD5Q$" 7 (Y )[>_I0!9M
MO#&@V;7+6VC6$1NE*3[+=0)%/52,<CVJ6/0-'AN;>YBTNSCGMUVP2)"JF)>>
M%P.!\QX'K4VFZG:ZMI=OJ-HY:VN(Q)&Q4@E3[=:CT;6;+7M-34+!W>W=F4%T
M*'(.#P>>U $2^&M#39LT>Q79-]H3;;J-DG'SC X/RKR/2G'P]HS:M_:ITRT.
MH9S]H\H;\XQG/K1K.O:?H,$4E_,5,SB.*-%+/(Q[*HY-5K[Q7I6G^&HO$$SS
M'39$1Q*D+,0K="0!D#D#\: ))/"V@R_;=^D6;?;2&NAY0_?$-NRWKR ?K4UG
MH.DV%[]LM-/MX;GR5@\U$ ;RP  N?0!1^59]AXSTO4)K6.**_C6[3?!--92)
M%(-A?AR,?=!/7M6II&K6>N:5!J5A(9+6<$QL5*DX)'0\]0: ))-/LY=0AOY+
M>-KN%2D<Q'S(IZ@'WJG-X9T.XU">_FTJTDNYT,<LS1 LZE=I!/<8XK5HH KV
M=A::=91V5E;QV]M&"$BB7:J@\G 'N34=OI5A:00006D216[EX5"\1L002OH<
M$_F:N53U75+31=+N-1OI#';0+ND8*6(&<=!]: *4^@PV@O[[1+6SM=8N4;_2
M9(R0S'G+XY(S3=,T)4TV]CU6&VFN-1D:2]6,$QN2 N!D9QM4=?>MB*5)H4EC
M;<CJ&4^H/2LY?$%@?$C:!NE74!!]H"M$P5H\@9#=#R<?@: *R^#?#HM)K5M*
M@D@FE$KI+F0%@,#[Q/ !.!T&3@5(WA+P^RA6TBT8"02C,>?G P&^H'%6=6UK
M3]#MEGU"X$2NVR-0"SR,>BJHY8^PJ/3/$.G:K=3VD$CI>0 &6VGC,<J@]&VM
M@X.1STH 4^'-&,M[*=,M2]\NVZ8QC]\/]KUI^E:)IVB0R1Z?:K$)&W2,6+NY
MZ#<S$DX' R>*SI/&_A^&[N()+\+Y"R,\I1O+^3&\!\8)!900.YQUHT?QMH.N
MZD=.LKMS?*C.]O+"\;H <$$,!@\]* -&/0]+A:P,=C"IL-WV4A?]5N!#8^H-
M,3P]I4>I_P!HK:*+G>9,[VV[SD%]F=N[!(W8S@XS6G10!AIX.\.):+:KHUH+
M=)O/2/9\J28 W*.QP!TJ+6/!^EZEI=[9QV-FC7L@DGEDAWDMR"X_VP"<'L:Z
M&B@"*UMX[2TAMHL^7#&L:9.3@# J6BB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "JY9?MBKD9V]*G(R*@(3[6G'.T\T 6**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \JUC?8_'W2+S47\
MNRFLVCM99.$#[6!4$\ Y/_CP]:Z[QQ<VA\'^(8/.A-U'IDQ*;AO564@<=0"1
M^.*W[RPL]1@\B]M(+F(\^7/&'7\C44.CZ9;6\EO!IUI%#+_K(T@55?Z@#!H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *@_Y>P.VVIS4+'_2 /:@":BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *KG_C[ ]5S5BJY_X^P?1<4 6**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@!#43#_20?:I3TJ)O^/@?2@":BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH 0U&P_?@]L5+49^_B@"2BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *9C+DT^DP,T +1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%)D9H 6BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *3'.:6B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBDH 6BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *;N .*=3"N6SF@!]%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4E+10 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !111F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "DI:,4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
ME+24 +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
< !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>arwr-2024331xex321001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arwr-2024331xex321001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %03?\?$/_ OY5/4$W_'Q#_P+^5 "1_\?LO^Z*L57C_X
M_9?]T58H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H)O\ CXA_
MX%_*IZAE_P!?#_P+^5 #8QB\E/JHJQ5>,YO)1Z**L4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !44G^OB_&I:BD_UT7XT 1Q_\?DWT459JM'_Q
M^3?\!JS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %12?Z^+\:E
MJ*3_ %\7XT ,C_X^YO\ @-6*K1_\?DW_  &K- !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#2>2LN&\HO\ W1)C86]LYJSJ?B+2=&NK>VU"\6">YX@C*L3(<XPN!R>1Q[T
M:E%4K#5['4Y)X[2??) 5$J%65DR,C((!Y%53XJT(:V-&_M6U_M$MM^SA\MN]
M/K[=: ->BJ$VMZ9;WXL9KV)+DE5V$]"WW03T!/8'DT3:WIEOJ*Z?+>PI=,5
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MS+;''E\$)D;L?\!W5M#1]-753J@L+<:@R[3<B,>81C&-W7&*NT >4:FVG?\
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M34KZ9W1'/<)D\LS,<X'0#Z5Z;7/7'@;PQ=Z@U_<:-;2W;OYC2ODDMZ]:Z&@
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MAC@DEU&T2.XQY+-.H$O^Z<\_A3I-4T^*:>&2_M4EMX_-F1IE!C3^\PSP/<T
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MXD)#.K@JN.N30!-14<%Q#<Q"6":.6,\!XV##\Q3+V\@T^QGO+E]D$"&1VQG
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M]+O3S/+W+OQG;GG'K3J .-\9:7.FI^'M:M+1YH=-O6EN8H$R^QUP7 '+8/)
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MMPYW/R!CJ<#/8 5T503VD-S)$TR[Q$V]5)^7<""&QW(QQZ5/0 4444 %%%%
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ML+^Z:[E21@561NNW@8!XXYZ4_5-%MM6N-/GGDE22PN!<PF,@98 C!R#D8)H
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M2Q?RBC,9/,(W;-X7=V#5I7V@6FIP:A;W[SW-M>A0T+R?+%M''EXY4Y&<YZT
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MF:8UTMR5R@<H[#@]AM'7J<CMS;\.>*+'4=+M4FNV^V+81W-PTL+1@KM&YP2
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M:?:F8QP[-Y,JE"JXSDA@"/QK@[KPEJQ^'&K:/'#&]]/?O<Q()  R_:!(!D\
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MRWENDZQF5HVE4,$'5B,YQ[]*XSPI;WECKWDP07$NF2">4M?6;13VCLX)19"
M)$8Y/&3P#6AXLTZ_&JZ-K6DVHN+NWE:UE0]##*-N6]0K;6/MF@#?&KZ<\4+Q
M7]H_VA7,&)UQ+M^]M.><=\=*H1^*-/B_LNWU&YM+:_U"/<D"W"NH..S< C/
M/<]*Y[PQX?O+"?4-/O;;?9:7YT6G2LG^N6?#L<=./N\>I':LS1;*[L+KP#+=
M:;>A8-.F@FQ:NQA=@@4. /E[\G'>@#LO"WB1?$.CPW<RPV]S))*OV=9=QPDC
M)D9P3]WTK>KR_0M&E@TSPG)<:;=0WD.L7#22"V821Q$SXW'&0A+)UX(->H4
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M(KE_'9N?M?AB.WO9[99=7CC?RMOS?*Q!.0<X*].G/(/&.<MK[4M)U37[ZTO
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M\K,'6-@1C/RDX) .",C)Y]JY?X@22ZI(FBV_VZ,PQ_;3/:6\DNV9?]2C!%;
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M5K8QOYSJKB-V$F[:#DD@;3P.M5[KQAKT5U?21Q:9]CL]9CT]E*R&5D<H,]0
M1OSGG/H,<@'?T51UK5(]%T2]U.5"\=K"TI4=6P,XKG;OQ#K>AZ9-J&JIIUQ;
M/%#]G>U#QXFD<*$;<6RHW [^.,\4 =A5'2M)M=&M'M;3>(FE>;#MNPSL6;'M
MDFN1UOQ?K/A_^V+.Y6PN;VTTT:C;S1PO'&R[]C*R%V.0>A#<^U4O$/B[Q!9Z
M=XIMF-E;W5A:0W$$MNK-M61B"IW'EACAL#_=H ])I@EC,K1"13(H#,@/(!Z$
MC\#7">*O%VM>&;5G+Z;*\%O%*RF!RUP6?:V%60F)5&/F;<"3@59UG7+W3=:\
M22VVG6+-I^CI=I<O&=[\N=CL.WR,0* .UHKA'\<:AI\]^FH6EM*(])CU.V^S
M[E)W,4"-N)Y+8Y'0>M.B\8ZU91S)J^E%9)9H(+&40M"DLLIV[&!9B-IY+9Y'
M;/4 [@,"2 02.H]*"ZA@I8!CT&>37(>%VO/^$S\5I?/;-*K6I @!'!C."02<
M9 _,'FKFJ74*>.M!M7L()9GM[EXKEP=\) 4$*?<'F@#I**XC1O&.J7SZ!)=V
M=DMMJTDT*F"5F960.=W(Q@[,8_'/:NWH **** "BBB@ HHHH **** "BBB@
MHHHH *BD_P!=%^-2U%)_KHOQH KZ?_JY/>5JNUG:.=UM(<Y_?/S6C0 4444
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MZ:[CN(5MF,C/&  "NW<"&SZ>_%=-I.K6>N:7#J-A(9+:;.QBI4\$J>#SU!H
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M"FDZ?]@%M%.HL"QMP;F1@FY0I&"W(V@#!X%<_;^*]6FTX3K]E\QO$1TW#1G
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M7$4DL5VC1Q/Y;G=@J_\ =(ZYY%2,I0Z$$CUG3I/FTZ^>212APR&0?O$/U)+
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MBH(_"^GI;6L#-/(EK?-?Q;WY$K%B>@Z9=CCWJYJ&LZ9I31KJ%_;VID5F7SI
MN0N,GGL,C\Q41\1:,NHPZ>=3M?M<P!CA\T;FR,C\QR/6@#*A\":7;W\-W%<7
MZ-!=O=PH+C"([YW@#'(;)SG)[9QQ3['P-I-C8VMFDEY)!:7HO;=)9RPB<$D
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MUT2*SECC =H)AMR-O<'U']WTJ#0_"NI:?>: +NV$B6]E>))DJRQ&1T9$Z\X
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M@GMDX)P*XO4K/[%JFE75W:3&SO/$<MS%:F!F8(8B,^7C/+ OC&>>E>LU1O\
M2+/4KBRGNHV:6RF\^!E<KM?!&>#SP3P: /-[SPWJ$.=0M['41ICZS)=FRL9&
M@G6)H@@D5000=VX[>#@]LFK-AX:C.N^%BN@7<6FQ_;F=+W]\REPI5I,YVEB&
M.">/K7IM% 'E]Y;ZB/$5K(FB7L45KKHD\FUMAY)B*%/.+=68\=, #C'>K*6-
MPV@7EA-I-V94\1K<8,#,)(S=[RZGTV Y/^->CT4 >=:KI=[-;>*=-FTZXDO+
M^Y$^G74<98<J@3,G1-C)SDCCIFLW6] OY;+Q>_\ 9<T]S)J%G+ ZP%FD13%N
M*''/W6SCTKU>B@#@YA<V_CX'3HKB;S[I7N[6ZLR8XQY80W$,V, [0%VYYR>*
M[RBB@ HHHH **** "BBB@ HHHH **** "BBB@ J&0@74(]0W]*FJO+_Q^6_T
M;^E %+0>-/Q_TU?^=:M9FAE6L,J,?O'_ )UIT6 **** "BBB@ HHHH ****
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M%M")DB,*R!!N6,D':#V&0./:@#@?#=_J[+X+N+O6;BZ;4X93<1LJ!"!$648
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M# J;P-I.JZ5!JJ:G=32^9J$[Q+)'&N5,C-Y@V_W]V<'IT % '5T444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(QP.M)DU@>+/
M$D?A_2#-PUS*=D"=V:JA!SDHQW9$YJ$7)F?XK\7_ -G2KI6EH;C5Y^$C4;MG
MN:9X9\%QVDIU362MYJTGS-(_S*F>R@T[P7X9-A$^K:D#)J]Y\\LC?P@\A177
MA=N<=^M=-6K&BO94?F^__ ,:=-U'[2I\D(J*.E07EY!96,MU<N(X8E+.QXP!
M4EQ<Q6L#S32+'&BEF=C@ #O7@WCOQ_=>*I?[.T>"9K)'^544E[@_0?PU.%PL
MJ\O);LUJ5%36AT_PWOI]6\=>(-212MK/D\=,[OE'UQFO2=9O%T_1[N[<X$,3
M/^0K$\"^'H_#OAFTMRA%Q*@EF9A@LYYQCVJE\2+QVT.'28B//U&980!UVY&3
M6U3DKXI*&VWR1@DZ6'=]_P#,N?#^W:U\(V\L@^>X)F?ZL:R_'VHSWLEMX<L#
M_I%Y( Y'\*]>?3UKK08=%T9=YQ%;0@$^P%<CX$M9=5N[WQ)=99[B1E@)&,+T
MS_2G2E>I/%2V6WKT)FGRPHKKN=?I&E1:/IL%E;@".-?S/<UH]*,<"D;I7!.3
MDVV=B22LNA7OKJ&RLY;FX<)%&I9V/H*\UD\/W'BG1-4UZZ4FXG!>S0_PQKTX
M]QG\ZVO$TTGB+7;?PQ;,P@7][?.O3:.BY]3BNRBMXX8$@C4+&B[0/;%=<9O#
M04E\3U^7_!.:<%7;B]E^9S_@;6#J_ABWD<[I8<PR9/.5X&?PKJ*\Y\)*=$\;
M:QHF0L<JB:(>XZX_ UZ(3@5GBX*%5N.SU^\TH3YH:]-!U%1ES@8.#]*56)XK
MG-A]%(#D4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0R@F>$^F?Y5-3&^^O
MXT 9OAYBVCP$[L\]:U:R] (_L:WYZBM2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *CG@BNK>6WF0/%*A1U/\ $I&"*DHH J:;
MI=CH]DEGIUI%:VRDD1Q+@9/4^Y]ZMT44 ->*-V1G169#E21DJ<8R/3@FG444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV%MX$TYU>VGT5''1C<1DC_QZMQ?$F@*,#6M-'_;U'_C53_A!O"__ $+FD_\
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M5!_X%7JRA*&$E3ZK5KR?]7.",DZZGT>A5N/'OB"W^'6JZL9X6U'3]4-F)1"
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1AD@^E+36.,4
M4-#XT>U_W:T:S]%_Y MG_P!<Q6A0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112'K0 9
M'K7!^/O$#1^7H5E.L=S<\S2EMHAC[DG^E='XBUJ#0-*FO9>6&%1?[S'H*\;U
M/2;R'Q/X2U;7B1'J%]F=9"/+7[NU6_#I79AXJG%UY[+;S9S5VY/V4>NYZCX>
MU'P]8:;!IUG?P%E0MZ&3 RQ'KT)KE/$LZ6NIZ?XXT!H[NS#E;@Q-\K#.UC^F
M/PKT#6;:UGTZ222.,R012-"6 !4E"#C\":\,\-^(]3TW1O"NCV4L=[#?"[2X
MTUHE(/[U@O/7IS4X>M)5>=ZWW]&55IQ4.7MM\CUR;Q]HJZ,+RSN4NI';9'!'
MG=O_ +I^F:RK;3XXY3XF\8W$:%"/*BF(*0@_=X]<UY#I=YJ?AN&75XX83Y>H
M/8ROY:L\+<9VYX!/3)S70:[XAO/$/A;3XK_4F^UQ:[&@A 0'RLML=OEY89'0
M[?:M:EJ4'[#6^[_0R2]I).H_D>U+KVE_V)_:RW\!T]1DW&_Y  >><=L57L_&
M&@:C/#!::K;323'$81B=Q]N*I^,+>&Q^'&NPP(L:#3Y_E10HR5.3@<9/6N>^
M'$ERGA&P.IK;+I\=O$;20'<P;=(#NSG#=.:\\Z]STDXY]J1V5226  '<]*\G
MO/'5SH/C2\T_4M9:YL01/;?9X8V8KS^Y;"^N.3@UD6FJ^+OB#>W#QO\ 8]"6
MX:&9%91(JA,X .6+'/T].];1H2;7/HB)3MHM6=?KOBFYUO43X>\-L[3-Q/=J
M,+&OM_C72>&O#%GX;LQ'%A[A^9IR/FD->>^ 1JG_  B(U73+BWC@,-UYT8A5
MI/-7/ED'';N":/#7C+Q#J&K^"(+G4/-CU:WNWNAY$:[VC\S:1\N1PHZ5K6K1
MY?9T=(_BS.G2DWSU-_R/5[[4+33K.:[O+B.&WA&9)&/W?K^8_.IX71T$B.&5
MP"#G.:\.L]4U-/AQXSUH:B\UQ'J;KLGBCECROE $@K_=(X]A6W=>(=?T;Q#8
MV5W>R266JZ9NT\);Q9CNL)QPO0 DXZ8/M7*=!ZWD'O1G S7ENLZ_XI_X2J;P
M[HUPKW5K817 ,RQKY[EAN+9'"XR/E[FM_P"(\VH1?"_5)+8%;DP()/+.<*64
M28]MI;\* -V+Q1H4]VMK%JUH\SN455E!W-Z ]":LZGK&G:- L^I7L%I$QPK3
M.%R?:O./$Z6*_L^1?9A%Y0L[5H\?W]Z9(]\EO?K5?[)>7?B;X;)J=Q+YLNG3
M":-U5ND(W [E.2PX;.?;!H ] NO&7ANQE$5UK=C$Y56 :4=&&0?Q!!K;!# $
M$$'D$5X:T$FF>%_'=ZLL<\UAJI2$7%K#(@.Y%)VE,#Y3C P!C@5UYU_Q#K'B
MW4-#T>[MK-M,MK:4":,%9]X5GW<$@!6P-N.: /1**\VM_$_B?6O&5_;Z2J_8
MM,U-+:XA<1*I@Y#L2QW[B1E<<8'>I/#FI^*-<\6:]:C6XX['2M25/+>T1FDB
MW-E-P QP.O)_J >BT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110!0T<8T>T7_IF#5^J.D?\ (*M?
M^N0J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML Y4@@LH.TD$ Y(Z@5;T[0=-TJ^O[RRMO*GOY/-N6\QF\QN><$D#J>F*T:*
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MNGFLH52">0-WS G],T =C17&Z3X]CN?#L6J:E9FT:XNY+>VB\V,>859QC);
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M&: -FBN;\;:U<Z#HD5Y"9(X3=1I=7$<?F-;PG.YPI!!QP.AZ]*N^'IS=:?\
M:4UE=6M9<-!<;4#8P,@[ !G.3T&,X[4 :](>E<Q)JEYK?BK4=$TZ^-C#ID,3
M7,\<:O*TD@)55W@J %&2<'.<<5J:7;:K;27B:C?+>PEU-L_EJCA<<A@H )SW
M% &-X[\81>$]#,JD27UQE+6+U;')/L.M>9^"[V'3)9O$.I.UYJUP3Y$*@L\C
M'JW'0>@["NO^*WAMM0L8-:1F_P!!!250A?;$S#>X7^(@#.*D\(:3HFD:=-K%
MKJ$5[IRPAA=%!O1@/FZ=.HX/(KT*-7#TJ+3NY/\ JQR5H59RLMBS:^'=2\2S
MK>^))G6VZI8(<*.XSCK7<06\-O"L4,:I&HP%48 KG8?%NF.UW%),\<MN%+QO
M&0QW$!2HR<Y)  ZYJO=^,;:W6%8[:]DE^VI9O'Y>UD8C=DY.",8Z5RU:TJFC
MT2Z&U.E&&O7N==@9S2US5IK-M!J&KO<7UQY=GY0E@>+Y82R9 7 RQ.>@SR<#
MFII_&.DVEIJ%Q=M<6_\ 9ZHUQ'+ P<*_"L!W!/&1W!S6)J;]%9>EZ]9:O=7=
MM;+<)+:[?,6>!HB5;.UEW 94[3@^U4/$FK7^FZQX>AMI(UM[V^^SSJT>6(V,
MW!SQT]* .CHKG/%%SJEG;FYL=4M+5EQY-O,BG[2^>5+,1C\.:H^,-?N].U&S
MM(;Z;2K9EW3:BVG&X@5B0JHS9"KW).>.,X% '8T5R-[J>KRZI/I5C?Q1OI^F
MI=37#P!C/(Q(4;<X"G8Q..>1BKUUK<EU\/Y]=L7\J5],:[B.T':WEEAP?>@#
MH**YC1O&6F75FL=S=L+F#3DOKB1XBJ,FT;W5L8(!R#COQVJS;^,-(N+>ZF\R
M>);:!+AA-;NA:-_N,H(^;/0 <YXQF@#>HJCI6J0ZO:M<0PW,(5RC)<PM$X(P
M>589[BN2T/QU;Q7NHV6N7TGG#69[.V<VY"*@(5%9U7:#G/4YH [NBL>7Q/I<
M&H1V<DL@:2X%JLODOY1F(R(]^,;NOMD8Z\5'_P )=H_V]+0S2@R^8(9?(<QR
MLF=ZHP&&(P>!UQQF@#<HKG]-\::)JUU9V]I<2N;U&>W=H'5)-OWE#$8W <D=
M15O5_$6F:%+:Q:A<&.2Z+B%1&S%RB[B!@=>F!U)( H U:*YD>/O#QT^UO?M,
MWE7,LD"#[.^X2("60C&0W& .I)XS5FZ\7Z19N!-+,(P8Q+*('*0%QE1(<?*3
MQUZ9&<9% &[16)'XJTV2;68OWZMHZ[[O?"1M7!8%?[V0I(Q3;?6[:76)]^H/
M'$FGQ736T]OY8B1BQ\PN1Z#!!Z;3[T ;M%<9:^+6NO'DMKYTL.D1:.;QOM$'
ME#/F#]YE@#MV_P!<]*UK?Q?HT\=V[33V_P!EC$TJW-M)$WEDX5PK*"02"!B@
M#=HKDO#WB*YUCQEKMFWGQV5K!;/##<6_E.A<,6)! ;G ZUI1>)[67Q'J&C^3
M.K6,4<DUPR8C7<&/)[#"]>^3Z4 ;=%9.E^)=,U>Z:VM995G">:J3P/$9(R<"
M1-P&Y?<9[>HJ37=0DTW2)IK=!)=O^ZM8S_',W"#Z9Z^P- &E16%HGB:UU'P;
M#X@N7$,*VYDN<J?W3(#Y@(Z\$'BJ\WC_ ,,V\$4\NHLD4K%8F-M+B0A=QV_+
MSP>W?CKQ0!TM%8MUXLT6RE2.XO&C#;,R&&0QQ[_NAWV[4)R.&(/(]:2;Q;HT
M$&HS23SA--?R[O\ T28F(XSD@+DKCG<,C'.: -NBN/\ $WC&*RMK<:;<KYWV
MNS$[20L%6&9NN2,9(![Y%;-OXGT>ZM+JYBNF,=K((I@T,BLKG&U=I4,2<C&
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MTV^TCPK%9ZC;?9[A9YG*;U?AY&<<J2.C5TM%% !1110 4444 %%%% !1110
M4444 %%%% !1110!2TK_ )!=K_UR3_T$5=JGIG&FVO\ UR3_ -!JY0 4444
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M,@9JYXSO8;'0/,GDEC1[F&/<DIB',B\.X'RH>C'T)K:2UMXX?)2WB6+.[8J
M#.<YQZYYI\L4<\312QK)&PPRN,@_44 >4Z=J45_IZ61UI@O_  DWDYM+UU_=
ME"556W;MA(..><<5-<ZS_9]A>VT-[/'IT?B=+*X>:=F:*W,:%QO)+*I?=SGH
M:]*.GV3=;.W/S!^8Q]X# /3J!WIQL[4I*AMH=LQS*-@PY]3Z_C0!R'@&6Q;4
M/%*:?<1S0#4]R%)?,X,2<YR<C((_#VK)UJ#6+;5M?T#3Q<RMJ")J5A)YSD0E
M/]8N<Y +*H"YQ^\],UZ-;V=K9J5MK:&!6.2(D"@G\*EVKN#8&X#&<<XH \R3
M6-1U#0;/Q&TT]I_:6L64<<*R%0D"NJ,I&?XF\PGU!%1>*"!:?$OD?ZJU_P#1
M*UZ;):6TT @DMXGA'(C9 5_*D>RM9?-\RVA?SL>;NC!WXZ;O7'O0!A>*CGX;
M:P1T_LJ7_P!%&N2N[C4]"VOHM_?7LDF@23RP2S^<L+CR]DBH>A.7^4<';P.*
M]/6-$B$:HJQ@;0H& !Z8J"UT^RL0XL[.WM]YR_DQ!-Q]3@<T <MX-G@N;V2X
MMO%*:K%-:HWV9?,/E\GYVWR.58YP5XZ=.*(?M5YX[\0*U]>>580VLEO:QS%8
MR[(Y.0.H..G0]P<#'56MA9V7F?9+2"W\QMS^5&$W'U..IJ06\*SM.L,8F8;6
MD"C<1Z$]: /+M!N1KVD"\?Q=]HGDL)OM>G+)*DA?;DY!E.S:W]U5!!QT-17V
MJVEAX<T&&QU:8%M+D?R_[3>*,.(XSN+[BQ89&V/I\W:O4(=,L+>:::"QMHI9
M\^:Z1*K29_O$#G\:A&@Z.L<"+I-B$MR6A46Z8C)ZE>./PH X_3=6O)[7PY</
M?2O+<>';B:;]YP\JB AB.FX;FY]S6;X<O+Z&[\!SS:O?7#:M;3_:A<7!9'*Q
M[E^7H"#WQD]R:]'BTO3X%B6&QMHQ$I2,)"HV*>H&!P.3^=/2QM(Q$$M8%$))
MBVQ@;,]=OIGVH \Q\.:O=W>FPZS!XH6ZU..UG>?1V$F^:4(3L*-(=NU@,%4
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MBZ=L9 C+]E3!4'< 1CIGG'K0!R5W!J2^-/[#7Q%JBVHTF6\W!T\POY_ SMZ
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M?&:VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH IZ9_P @VU_ZY)_Z#5RJ>F?\@VU_ZY)_Z#5R@ HHHH **** "BBB@ HH
MHH **** "BBB@ KB/B&5BG\.2%KO;)J:0RI;22!I(RCDKA",\J/?BNWK!\2:
M!<ZY)I<MK?16LFGW8NU\VW,JNP4@ @.IQ\Q[T 5-/B%G;W^HZ/I^I-*%$8L[
M^>2,2;?FW)OW$$[L=LX_&HK'QY;7>BW.MO;>5I=K;+)/+YA+K,0-T(4J,D9
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MF[NK6Z8#3]JJ\+(0 !)]T[%&.PS3?%&A3V\&OW:7;F+6'MTD6.Q,Y@5%"L6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!5L1MLK8?\ 3-1_X[5JJUD/]#M_9%_E5F@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***8W^L7\: ([4;;:('^X*GJ&#_ (]XO]T5-0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %-89(]J=2,<4 10?ZE!Z
M**FID6/+3'I3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I",T
MM!H B@_U2?[HJ6HX1B-/]T5)0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %!HH- "*NU0/2EIJ$E%)ZD4Z@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *:QP0/6G4Q_OK^- !'_JU^E/HHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "F-_K$_&GTQQEE/I0 ^BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *1AFEIK'! ]: '4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !3&_UB?C3Z8_5: 'T444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !37[4ZD(S0 M%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4C'%+37ZK0 ZBBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *8_P!]/QI]1O\ ZR/\: )**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ I",D'TI:* "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH ***0F@!:*** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ IK]J=37[4 .HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "F/]Y13Z8V=ZX'KF@!]%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 444$XH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ ID@R5YI],;[ZCZT /HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "F/]Y:?36!)&* '4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !110: "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *#110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !44CE9H@.ASFI:0J"0<<CI0 M%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 444&@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BB@T %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 444QG"NJG^+- #Z*** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ J&8@3PY3=G//IQ4U,= S*QS\N<4 /HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "D) ('K2TQ@=RX''.: 'T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !4,C[9XEY^;=T]JFJ*1PLT8(Y;.*
M ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J-R/-CS[U)4
M4@S-&?3- $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4UE
MRRMGIFG4&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "@T
M4U^U #J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J.1@)$7
MN<U)44JDRQ$=L_RH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>arwr-2024331xex322001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arwr-2024331xex322001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ+>1-L[$9%
M"0G._P!G-35##QN]V-34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !4!_X^E_W:G[5 ?^/I?]V@!8/X_P#?-35!!P7!Z[S4] !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 5 W_ !]+_NU/4!_X^E_W: "$9=V_VS_3
M_"IZ@A.'=?\ ;/\ 3_&IZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ J!O^/I?]VIZ@;_CZ7_=H 2'F63_?/]*L57A_UDG^^?Z58H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J['_2T_W35BJ[?\?B?[IH (?]9)
M_OG^E6*KQ<2R?[Y_I5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *KM_Q^)_NFK%0'B[7_ ': $C_UK_[Y_I5BH(!DN3UWFIZ "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HKD]5\87-CXZL?"UMID4\UY;F=)Y+HQJH
M<D$!&/\  ?SK8M]5DAM9)M;CM-,Q-Y<;&[#I*N 0P8A>OS<$9^6@#4HKG?$G
MBVVT/P]?:K:?9]1-EL,L,=R 0&8 9(#8Z^E7SK$7]DW%TIMVN;>'=-;_ &E/
MW<FW/EL_1>>,F@#3HKC)/'PM-3\/VE_906R:M$[M-]N5TMRH.06 VL.@R#WK
M9UCQ#'I]O82VD<-]]LN4A0+<HGRL<%P3]['' ]: -JBLNU\0Z;>:Y>:/#<HU
M[:*C2IN'\6>!SDD8Y],BL[QAXINO"E@+]-&>^M%91-(LZH4W-M&%P2QR1QQU
MH Z6BN1\4^-;GPY9?;H] N[NRB5&NIS(L0B#XP #RYY&<<#U].D6^C?2UU!(
MY7C:$3*B)N<@C(  ZF@"U17)Z!XSFU;Q1?>'[_19],OK:'SPKS+('CRH!RO&
M?F'0GOS764 %%%% !1110 4444 %%%% !1110 4444 %0-_Q]J/]DU.>E0L/
M])4]]IH (>K?[QJ:H8>0?]XU-0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 >7^,-&N+OXKZ1?3V&HRZ2NGM#<3V:2$H6\T8S'\W\0R!V-=+J M]9\*:
MCIDNEWLMHD*V\0DMV229\<,JL,@ [?F/0@]ASU=% 'C<.F:XOPFU[PY=:->'
M4X941)5C9Q=KO7:RGOM5,>@ 6M"WTBY@U3QH+30[JUL[S1XX[51;[0SB';L
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M!YQR.N#S724 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(.22#@<  =^M9^I:IJ^B>*M"M9Y;S4O,M[LR06J)NFVLNPD?*N0IYY X./<
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M@DC?YCA<(RAF!((! .<5F:UXM5],LKG1;C.[6(+"X\R$JR9<!T*N 0<'T[T
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MB7USXKT?5Y9;<I96TT<H7<"S2;<;1SP-O<UIG5[1=;31RTGVQX&N IC8+L!
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MHMJ&BZC>ZCYEV%7^V#U%SL(>-?3"LJCIR.O4U)>>%=6ETSQ+:I'"6U'58KN
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MV5Q:_8(0G]O0ZI'F\WGRQM+)N(R2-H&3UKH=1T'49O$FM7L,4;P7ND"SC/F
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MFAM5$D<!MU=F+'RRVXJ22<Y///-5K#PKHVEW37-I:%)"I0 S.RHIZA%)(0'
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M6EA#K( LC(0RG((92""/K5%_"&AR0W\36;;+]HWN0)Y!O,>-G\7&,#IC/?-
M'-ZAXHU6#Q0((;Q9;==6@LGBB@'E1HXY#NP#&7.3\I( QGK6GX'DOKIM<GO-
M0N)]FJW$"1R! JJC *1A0<X'KCVJY<^!O#MWJ$U]-8,;F:99W87$JCS%QA@
MV >.H%:-CH>GZ;?WE[:0-'/>/YDY\UV#-W(4G /T H T**** "BBB@ HHHH
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ME4X"L_;<>!^N*W=*L1IFE6UF&+F*,!W/5VZLQ]R<G\:\V\-Z7J/B'2+[3O\
M18]/C\033/.)295V2[]FS;C)('.[H>E '8'QUH0\1KH9N#]H:3R!("NSS?\
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MW@J",81^?;% 'I<-S=-J%Y%/:)#:1!##<><&,N0=V5Q\N#@<DYJR98U7<TB
M9QDL.OI7FWBD226?C1;>PN)FE>Q8?Z.YW@A%+)QDLHR>.A%,\5Z/IFC:GID#
MQ7]IH<L$R%K.W6X59F*DEU='Y8#&0,]?>@#TUI$3[SJO&>3BE#J6*A@2.2 :
M\MFT;2Y)Y8);&YE6T\,DV[:@FY\!WVEATW=#@C(R.AJ/0K*2UO/#[Z?$8;NY
M\,R"20##23X3&\GJ00< ],>U 'JHD1BP#J2OWL'I]:;-/%;V\D\TBQPQJ7=V
M. J@9))KQJSM;"3PSJTUC+K3:FFC30W=O-:)$B-MZ,5C7>V[.#DGK[UJ7&G6
M]AJ^I+9VCRP3>%))Y8LLXFEW#&<YRV.G>@#TVVO[:[LH+N&93!.BO&Q.,@C(
MJQ7CU^NFPZ%H=Q91Z>YM[!!+IEQ;E/M18@MY)&#YVZ,C@=3S7=>,[BY/@XSI
M;S>4SP->0HI:06Y=3*H [[<@^V: .CN+B*TMI;F9MD42&1V/90,DUF:-K<FK
M6\=VUA);V<UK'=0SO(I5E<9P1U# 8)[<]:XB\2QO+?Q8^CI:R^'WT?*B%083
M=@/@H.FX#9G'?;WKL_#T5K8>$;)K6WB2,6B2,D*!0S;!GIWXH BL/%::FME/
M:Z5J$EC>R%(;L",I@9^8C?N"G:>2OUQ705Y;92P:1J>DW/A#5"UKJ=U']IT&
M0AC"K\NZK]Z/;U(Z?H*;H1M9_%;+J6H7D?B*WU"5A:10*"ZEFP3)MRT.W'!/
M&![9 /4R0JEF(  R2>U4HM26[AL;BQB:ZM+KGSXV ")M)#$$@D$X''/->=>&
M6T35+2VBNH;B3Q''#<IJ,1C;EB#N\_/#+D#:#GDC ZXE\/7.ABQ\!"RDMXLN
MRR*C;=TWV8ALC^)MVT9Y.<"@#TZBO*+)FDLM-D\XKXOCUDQW(!_?&(S'<)%'
M)C\K!]  ,&F60LX5T?5)IW^UGQ/-;%WG8[5+RC:%S@#E>U 'JEY<BSLYKEHY
M)%B0N5C&6( SP/6JC:NAT>WU&VM;JZ6X1'BAA0;V##<,Y( X[D@>]'B"?[+X
M;U2XW!?*M)7RP) PA/('6L[2=0L;7P1HSW.I0V<<UG#&D[2HOS>6#@%N,\'\
MJ );/Q9IUUH,^KR":UBMY7@FBG4"1)5;:4P"06)P  3G(K<4EE!*E21G!ZBO
M+X#>16&CQ7$\=S8#Q/MANM@!N(SN*.V  Q,A/S=R :@^(UU;+J>J,MT8]0L[
M2"6'SICE<N<^0@QS@$LQ)Z#CO0!Z='?P2:C-899;B)%D*L,;D/1E/<9!!]#]
M1FU7+ZC+)-XY\,2V;AX)+6[:5T.0T9$14\=1NVXJCXC-I/XVM+/7I%CT5M/=
MX3+*8XS<B09^;(&X)TSZG% ';5%<W"VMK+<.KLL:EB$7)('H*\LTR.YU75/#
M&F:Q=W+1S6=Y@"X9'EC60>4Q*D$G: <]\?6O2->_Y%W4_P#KTE_] - "0ZU:
M3^'XM:3S/LLMNMP@V9<J1D#:.K'(&/6JMGXGM+G2+O4[BTO]/MK7/F?;K9HF
M( SE5/)]..IXK&T?^Q+OX6:+;ZW- NGSV=O$WFS>4K, "!NR.<KZ]JS(D:QT
M)((+BXO-)3Q#;1VDDCE\P%X^ W\2+(6 /L* /0;BY2VLI;J0-Y<49D88YP!D
M\>M4++7[2]CTN0)+$FIVZSVS2  -E=VPX)PVWG'L<$X-<AXPO+=_%%UI^L7)
MAL?[%DELT>9HDDGW$-R" S ;< ^IQUILDXF^''@EK.1'F^T:<D;*<X<8#C\
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M[Z]\T >MT5YB]Y>W_BG5%N_$\>D75GJ*QVUJRR%Y(?EV;4\T(^_)'W&.3UZ
M7] NW@\:F"]F>[GO/M#6]Y;7K/$Z*V=DD).$9,X! P?KF@#JM1\06FF:C:V$
MT=P]S=*[0)%$7WA,%NGID=:LZ?J,6HK,8XYXVAD\ITFC*$-M5NA[88<URGBK
M!^(/A0?;FLSY-[^]79D?+'_?!'/TI_B%X[GPU=6=KK]Q)JMLRM!/;R[&>9V)
MBC;80K9P 5].<#B@#M*SM4U2SL);&UO$9_M\_P!FB4(&!;!;GVP#7#1>(?\
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M,):42%6)<'G:NWY3D<Y-<PIEUS4_ %[JMS.MS=BY$LD%Q)$KE$.QE ( W>H
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MU_\ 0:N53TSG3;7_ *Y)_P"@U<H **** "BBB@ HHHH **** "BBB@ HHHH
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M\.Z/:K9K!IUO&MDS/;!4_P!46^\5],U/8Z>EG->3E_,GNIC)(Y&.  JK] H
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M:LKSC;NW(#C*@'KT_,9!XUTJ:VMYK-;F\\^%IQ';1;G5%;8Q*YSPV1@9/!H
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M=QR3CN3W-.2\MI(TD2XA:-VVJRN"&/H#W--.H606-C=P!9"50F088C@@<\T
M8TGA.VN6UY+R=Y[;6"K20E0/**H$!4^N%4_4"J]UX0N+FVTXC7;N'4=/1HHK
MZ-%WO&P (<'(8G:#GU%=,DT4DLD22HTD>-Z!@2N>F1VI] ' SZ-K%OX]L(['
M49T1=(E1KVZ@,XD<S*S#JH5CP>. !@#%:<7@B+33I\VBWS6=W96[6PEDB$JS
M(S;VWKD9.XEA@C!)KJZ* .=LO"<5C?Z7>+>2O+9+<"0NH_?M,P9V/H=PSQ5K
M2M$FTO5M4NA?F2WOI_/%N8@/+<JJD[LY/"#TZ]ZV** .7U'P@]Y+JZP:F\-I
MK 7[9"T6\\+L)C.1M)4 '(;H.E.OO"$=Q;:]%;7?V<ZO#% V8@RPJB;/E&1G
M(]^*Z:B@"CJFG'5-!O=,DFVFZM7MVE"YQN4KNQ^.<4VVTJ./P[%H]P_G1+:B
MU=@-N]=FTG&3C(]ZT** .9L/"<ML=*6YU!;B+2(V2Q7[/M(RNQ6D.X[B%X&
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M6NBM]BMFGT_4;EVC^U_*T4P;YL[>HW?7KZU9F\+:L8;N>&./[3!X@.K6T;2
M+.F "I/.TD;NHZXKOJ* .'D\/:K=7=_JKVB17%WJ-E,+4SA@L4##))QC<?F.
M!GH*BN?#5])=Z^MQI<=[9ZCJ$4NT3A'$8BQO0Y&UU=5Z]LUWM% &/X8M-4LM
M#BM]6N&GN$=]KNVYQ'N.P.W\3!<9/KZ]:V*** "BBB@ HHHH **** "BBB@
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MS\N8V5MA)ZD[<9/?FKECXHMKXP0I9Z@MXX7S+=[21?))Z[F90N!]>>V:W**
M/,383O9S:;<V4[^(!K:W<4X@<@Q^<I\P2XVX$65Y/;&,T^_\/I?Z=>,^E3K<
M?\)*LJ@VK;I(S,H9@<<(5#-NZ<>]>ET4 >9:O9PV&G>-$_LZ:VT]KVR=/+A:
M-9%_<A_+QC)W*W*]SQ4>KV5E%'K5[H^C--8.EG&T0AE1&F60GS-BX+A%*$@=
M<8]:]$U73(=8T]K.X>5(V9'W1-A@58,/U JZ.!US[T >02VINEC@EMKR=?\
MA*K>=W>P>$-$T"@L % "Y!XZXQGDYK9N?#L5]I?B*VM+86UYIVJ?;]//D[45
MQ&C+M[%6*L#BO1JS=8T6#6H8X;BXO(HD;+);SM$)0>"KXZJ?2@#)T.^BAT(^
M)+VUEAFU5XYI(XXVD90P5(Q@#. N">.YKJ*15"J%4  #  [4M !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %4W8C4HU[;#5L].N*I2$_VK&-O&P\T )I'_ ""+#_KW
M3_T$5?JAI'_()L?^O=/_ $$5?H **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG^UK6."^=XMK;U78TJ8XR5/W3P,#GK1JFC>)3?6HT:[TN+3[2)4AANXY)#N
MQN.",D=!UQUZ] "EXZ\0:IIGA-_L),=^D,4MS-C_ %*LZK_WTQ)Q[*WH*[FN
M.\3> K7Q'I$_FB)-9FCB#W8+A"R[<G:#C! (]JZRVMHK.UBMH%*PQ*$12Q.
M. ,GF@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHJKJ&I66DV;WE_=16UNGWI)6P/_P!?M0!:HKS;4/B=J>V[N]&\)W5Y
MI-LK2-?S.84= ,EERO(Z^_M7?:7?IJND66HQ*RQW<"3JK=0&4, ?SH MT444
M %%%% !117->(/%T>B>(="T9+8W$^J3;#A\>4G W8QSU_0T =+1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5 >+M?]VIZKL?
M],0>JF@"'2_^058?]>Z?^@BKU4M+_P"099>UN@_\=%7: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBB@ HHHH **** "BBB@ HHHH **** "JS_\ '['_ +IJR1D54DS]OB&. IH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?16!J2N=T7P)X:\/7_V[2M+2VN=A3>KL?E/4<D^E=%0 4444 %%%% !1110
M4444 %%%% !1110 AZ5&W^O'TJ0]*C;_ %X^E ! /W,8]%%2U'$,1I]*DH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN02B+M^^Q]G4YY],5*GCF*XT:RU.VT^4P7$#SM),XCCCV':4+G(+DYP.X!-
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M9Y54'(4N5!"@D'!8CH?2@#J**KV,KSZ?;32'+R1*S8]2 :L4 %%%% !1110
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MT%?#UQ806EU)864MI=0&8INWE6W(Q']Y>X'%=U2,P1&8YP!DX&3^0H \ML_
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M]HK6@(MR(5!A!ZA./E_"@#SK2_$$QLO#%OK&IS0Z?<F]2:[>Y,;2/'(5C1I
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M_:-Q&UCJ-N+;][@*'5,J/4$LW'3ICI6I8QZI?^,]>+ZS=1V6GS1I#:H$VG?
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MZ?V1.++2'D6[N_-7"A8]^57JQ/IVR*J6?Q(LI5O)+NQN;>"WMQ<"41R%6R0
MGS(OSDLH &0<\&M*R\*^2?$<=W>">UUJ1G:-(C&T09-C#=N.>,<X'(/KQ17P
M7?W?A^ZT;6?$4U_;O$L=N5MUB:$J058D$EV!5?3OZT .O/&EQIL^K07ND!)+
M#3AJ "7.X2(21M)VC:V0?4?6K=SXNAL/M4MY:LEM!IJ:AOC?<S*21LVX'.1Z
MXY[5S\>A:K=>*=8TK5K]KM+[05A-XMGY:;M[J. 2-PW%L9YSZ5HKX&NKB)H-
M4UK[7#+IO]GS+':B(E02593N.#R,YSG';I0 K_$"""UO9[BQ94MX8ID=)"T;
MJ[A &8J I!8%AS@'(S1?>)]:6;1%MM/LA]NO'BXO=ZRHL;,"KA.AP#DC/&,<
MYJS:>'O$5M8M#+XI6XD4(D1ET]?+" C(90PW$@8SD8YQUJC;^ 9K*VM!8ZE;
MVMQ;ZC)?KY=F?)!>/846,R948Y^\><\4 =O156TANXI+DW5VLZO*6A41;/*3
M PI.3NYR<\=:M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !4;?ZS\*D-1-_K?PH EHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ****  U$W^N'TJ4U$W^O ]J ):**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#TJ-O]</I4AZ5$W_
M !\#Z4 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'I43#
M_25/L:E/2HV_UX^E $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 AZ5&W^O'TJ0]*C;_7CZ4 2T444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% "'I4;?Z\?2I#TJ)O^/@?2@":BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH 0]*B;_CX'TJ4]*B;_ (^!]* )J*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@!#TJ)O^/@?2IJ@/_'U^% $]%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57)_TL#VJQ59O^/U/
M=30!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JS?\?J^R
MFK-5V'^F)_NF@"Q1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M (:B8C[2!WQ4U0,O^E!O:@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH 0]*C;_ %X^E2'I4;?Z\?2@"6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH 0]*B;_CX'TJ:H/\ E[7_ ': )Z*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ /%0D8N@?:I3TJ-O]>/I0!+1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 !YJ!I%%T%(Y(J>JC1?\
M$P63_8(H MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'I4
M;?Z\?2I#TJ-O]>/I0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %0$_P"D@>U3U!_R]_\  : )Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@!#TJ)O^/@?2IC4+'_20/:@":BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH #Q4)'^D@^U35!G-V!VQ0!/1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %5S_ ,?B_0U.:B./M(]A0!-1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %0'_CZ_"I^U5R?],4>J
MYH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5<C_2P?05
M8JJS#[>J[AG:>,T 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JHRI_:2M_%L-6ZJN#_:"'_9(H M4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%%  :A(Q<9[XJ8]*B;_7#Z4 2T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%%  >E1-_KA]*E-1-_K<^U $M%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 &HF/[W'M4AZ5&W^O'TH EHHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** $/2HF_X^!]*E/2HF_P"/
M@?2@":BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH #TJ)O]<#
MZ"I#TJ-C^^QZB@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *KLQ^V*O;!JQ4! ^V#_=- $]%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 'I59B/MR#(SL/&:LGI6<\6-75Q 3\A!>@#1HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "H=Y%R%SQCI4IJ%E!N5/<"@">BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@/_ !]CZ5/4!!^U
M@]L&@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]*B;_C
MX'TJ4]*@9_\ 2D7U4F@"Q1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 (:I-,/[36/RVSM/S'I5ZJ[+F\4^@- %BBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH 0U"Q'VD#OBIZJLW^G*/]DF@"U1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %4V_Y"2#_8-7*JL!]O4]]IH
MM4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%!J.*
M(1!@"3DYYH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJL?^/U?]TU9/2JK?\?J>RF@"U1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 !J K_ *6#GL:F/2HF_P"/@?2@":BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *KL3]L [8-3GI438-R.><4 34444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !59C_IJ_0U9JJV?MR\<8- %JBB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ",U 3_I0^E3U ?\
MCZ_"@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0U&P_?@
M]L5+4;']YMH DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MHB/WN[TJ6FX&<T .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBDW#UH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:
M5R<YIU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %)2TE
M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3=PW8[TZF%<
MN&S0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *2EHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHS0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !24M)0 M%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4E+24 +1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exhibit101-arrowheadindu001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101-arrowheadindu001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@P1/(21PHZLP' 'N37#?&+_4:/\ [TO\DJ#XCW#IX.\.VX)V2(KL/4K& /\
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M5[X=ZS_:_A.!';,]I^X?/7 ^Z?RQ^1KCV_Y+C_VW'_HFL\/ATJE6%17Y4_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKFWOY"AAZTJL:E:2?+M;S.=\??\ (CZI_P!<U_\ 0UK*^%'_ "*#_P#7T_\
M):[2XMX+N!X+F&.:%^&CD4,K?4&FVEE:6$/DV=M#;Q9W;(D"C/K@5BJZ6'=&
MVK=S5T&\0JU]$K'F_P 8O]1H_P#O2_R2M/Q9X?GUWP%IQM$+W5K#'*B#JZ[
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ]F^H:-?64;*KW%N\2LW0%E(&?SK/&5:<L1&4'HK%X.E4CAY1FM7<X/X/_\
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MG:WD1EMM UB:,'!>*$, ?3(-;-AXXTO4O#U]K%LLY2R4M/ Z@2+@9Z9QS]:
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MK,&L7=A<B(1 V_! &>^<]ZET?PE?:7JD5Y-XGU2^C3=FWGD)1L@CGGMG/X4
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MN<*YF/R/C(+8 &"<'CF63QSX@M=#O]<N8]-^R"^DTVS@2*0N9!<>4LCL"?E
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MF.V/!VD@<5S^I:3)9Z9K=[I^BW.AZ%*^G1QV4^U3).+M"T@C5B$&TJ.V<=*
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M-F_=]_Y1@=6QQS2Q?$6-XO/DT'4X;:&\%A>S/Y6VUG+A-I ?+C++\R@C##W
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MR VW>%+<E0V.3V.*LS>#K"878:>Y'VK5(=4?#+Q+'Y>U1Q]W]TN>_)YKH:*
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MX?Z986UK;Q75ZT=K!>6\?F2*QVW+AWR<9)!'!_/-=910!B1^&+.,>'P)9_\
MB1KMM\D?/^Z,7S\<_*<\8YI^M^'XM9DL[E;NXLKZR=FM[JW*[TW##*0P*LI&
M,@CL/2MBB@#@-8\"S :.EA=WTERVM"^O]1,B"8$02('Z;< [%"A<8XQC-:Q\
M"V,UC=QW=[>W%]=7$=T^HLZK.LL>/+9-JA5"XX&,<G.<FNIHH Y:3P3%>6.H
M0:GK&I7TU\L:23RLBE$1MRJBJH1>>IQDYZU:U/PP+[7$UBUU6]TZ\^S?9)'M
MQ&PDBW;@"'1L$$GD8ZUOT4 <I:^ K*PM-)@L]1U"%M+NIKF"7>CN?-+%T8LI
MRIW$9Z^^:(_ EK:6VG+INI7UC=V"2Q17<1C9VCD?>R.&4JPS@CCC KJZ* .<
ML/!>G:?-IL\<]U)/8W$]T99'!:XEE0J[2'')PW; &!VXJ*\\#V=S--<Q7UY;
M7;ZD-3CGC*$Q2^4(L ,I!4J.A!ZGFNHHH Y*/P#9_:;FYN-3U&ZN+FZM+N:6
M5TRTENVY, *  > 0!T'&#S76T44 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *9)%'* )(U<#H&&:?10!$MK;HP98(E8="$ (IZQHC,RHJEN6(&,_6G44
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MJWD@M5N%T?37AM6 ES(5Q*V]_*W!@F,C:,YKVZH+R\MM.M7N;N=(($P&D<X
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M;?VAY$'S-9^7"T@^49*;CN8#K\WO7INB:';Z%;31PRSSRW$S3W%Q<,&DFD(
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M3(M&3POX9?[3IMC<6D%Q#,FJ6 DLFGRF]).04FP%P>I&1S7O%% ',>"99)_
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MSRI@C:7<EMN">,X&: ..M=%N[OQV;6+7M1MA'X>M2\\7E^;(3+-MR2A&!SP
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M6'-IY,SQ/#QCY75@PR"<\\]Z+;P?H%FI6WTY$!N8[LX=CF9/NN>>6]3W[YH
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M\[;T_O Q9_6K=QXGNM2AN+RVU:]CM+[5!::?#86Z2SSQ11GS/++<*2X<EFR
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M\D1GBEEN+<02;T<J5=!P&&,''!(SWJ-O _APV<%K'IH@B@D>6'[/-)"T3/\
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MO<MO>;S&1BS-ZY3@#@ X[5!!X,@AT;3-.%Y(5L-2.H*^P9=C*\FT^V7(S[4
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MBY\_;CTSQ]*S+WX=27=CK&FQZ[-;Z=J=Q)=21I;(9!([;B#(>2N[MC..,XH
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MN6D$#HN2DG&>A)##J5/ J.U\>W>EZ+X;TV[N]*AU"YTJ.\EN]0N&6/9@!?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** (Y[>&ZA:&XACFB;[R2*&4_4&B"
M"&VA6&")(HE&%2-0JCZ 5)10!%#;06YD,,,<9D<NY10-S'J3CJ?>I:** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8&. 4*("3P<@=_:O6$LK2.[>[2UA6Y<8:81@.PXX+=3T'Y46UE:V<;1VMM#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M16LMU<R(J;BL;*H55X50H  _6N.U*_LYO+UFU73K:].MH%EFO'EU+BY"L&4
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MC(W[APG^[@\]1BL75_$4_B'PYJUU+!%$L^CZ3=[5C 8-).VX;NI7C@$\?B:
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MW#K;[!E+V(!O+SUR<2+CU2@#T*6*.:-HY8UDC8897&0?J*1+>&-0L<,: +L
M50/E]/I7G&D^,-:EBM[.^O+6&_TRWOI=8ED0"(&([(R<#A6)#\<X4T:+XFUG
M_A)]&M9K_4+VTU&&8NUYIJVL8=(]X:'A7*^S \$<T >C0VMO;J%@@BB4 @!$
M"@ _2H[?[$LTD%M]G$L.%DCBVY3/S $#IG.?QKS?1];\57>@>&9;C74-WXC=
M%$@M(PMHBQ/(Q48^9V"@?-D YP.U1AO$>DZIXM%G<O?WHO+%9)X88_/,!BY*
M1G"&0#MT/7':@#T^2UMYH/(DMXGAZ^6R K^52>6GR?(OR?=X^[]/2N/\,ZE?
MZYIM[;Q:[-]KM;I S76G"&YB3Y6,<L9 7)&X!E&,'/45I^,=6N]'T#S; QK=
MW%S!:122+N6)I9%3>1WQNSCU H UG-E),]F_V=I77S7@."S+G&XKW&1C/M6?
M8:!]EU^\UBYO9;NXF3R( Z*JVT.XMY:A0,\GDGDX'I7!ZQ?:KX/\3:UJ=S??
MVM-;>'A);M+$L;9\_ #A  1N.<@#CCMFIO[5\2R">PGFU66VNM/N#+<W>FQV
M_P!FD5,@IC@J>1ALD<<T >BV=G;6SW,]N.;N7SY'W9WMM50?IM51^%2M:V[7
M"W#01&=1A9"@W >QZUY1INN:Q9Z5X5T"UN]1VMH<5]+<65C'/-@A52, C:%'
M.6()/'KFM&/7?%FIMX?TW[2=*NKN>\AGN'LUWND0!201MD*Q&,CH"3Z"@#T5
M[6WDE\U[>)I-NS>R G;Z9]*CNUL(4^U7@MD2-@WFS!0%/0')Z'H*\WU#7/%<
M&F>(M5AUN,+H^I+:0VS6B%)U_=9\P]?^6AQM(Q[]G^(M7UO15\0:9=ZC'J8B
ML+6]ADGM(QL+SM&R[0,%?E!&<D>IH [?3-!^P:WJVJS7DES<:@8UPR*JQ1Q[
MMB #KC>W)Y-:<%M!:H5MX(X5)R1&@4$^O%>>:MJ_B9O^$TO;/6EM8-!<M;6X
MM4<2[;=)2KDC.TDG&,'D\]!4=_XLUO4M?OK/3WU&TBLK>!E^PZ>MSYDLD?F?
MO"W10"!@8)YYH ]'BM;> 2"*"*,2'+[$ W'U/K3XXXX8UCB141> JC 'X5G^
M'KZ[U/P[I][?VOV6\F@5IX?[CXY ]LUB:[=:S<>-=.T/3M4_L^WGL)[F:18$
MD?*/&HV[@0#\_<$8SQG! !U$5M! \CQ01QM(<N40 L?4^M.$485%$:!4Y4;1
MA?IZ5YKI&O\ B9K#PYK%[JT<R7VI'3I[1+5$0J&D3S-WW@^8]W7;SC%._P"$
MC\0_\(G_ ,)K_::?9OM/_()^SIY?D>=Y6W?C?YF.<YQGC;0!UOB#1K>^6T:]
MU+[)I-K*LT]MA%CF97#)O8C( 8 X'7O6G-JFGVT-S+/?6T4=J0+AWE51"2 1
MO)/R\$'GU%>8>)KK6]?\$:[JQU58;*.^>V33O(3;Y<5P(\L_WMY*[NN.@QWI
M?%K76J-K=H+E;>*#Q'IL.([>,EPPMSE\K\Q!;//H >.* /3H8]/OK+S8$MKB
MUN0)=R!724'D-D<-GCFK2(L:*B*%51@*!@ 5Y[-XCU?3_P"T/#?VI7UK^T(+
M;3Y_)49@F&X2;0,'8J39XQ^[]ZZ'Q?JM]IUGIUOITB0W6I7\5DMQ(F\0A@S%
M]O0G"D 'C)% &[]G@\PR>3'YC$$MM&21TY]J?L3<S;5W,,,<<FO-M?\ $7B'
MPTFMZ8-22^N8+2VO+2[F@167S)_*9)%4!2.,@@ \GTS7:1V6L6_AVYMCJQN]
M4,<GDW;P(F'(.WY ,8!Q0!I06T%JA2W@CA4G)6- H)]>*)[:"Z0)<01S*#D+
M(@8 ^O->90?$NZ.HZ=?SE$T0:<HOP5 *7ABDF*Y[8$17'JXJ>77-?>.PLY]8
MNX]2_LZ.XN+?2],6>599"3^\+*41!C &03@G- 'HGF6JW@AWPBZ:,L$R-Y0$
M#..N 2/SK.E\.64WB!-6D16VV;6GV<HIC(,BONQCKE:XC3/$.N^((M)FM7MH
M=4O/#5Q<I((%/[]9(@.2"0I)Y7..?85)J'Q$O)=,GUC2T4VMCHRW=S"RYS<S
M$+'&QZC9M<L!ZB@#TGRTW*VQ<J,*<=/I4;V]LUS'-)%"9UX1V4;A]#UKB?#N
ML>(?^$CM+.\_M.[L[F&0S2WNGI;>1(H!&PKU4\C!R1QS4_B"WN9/BCX4>.^D
MBC%M>$Q*BD';Y189(S\P('MMXQDT =7$MA?&*_A%M<<?N[A-K\>S#^E2M:V[
MW"W#01&=1A9"@W >QZUY3X1N=<T;PEX1O1JHELKR\2S:P-N@18W9P&#_ 'MP
M(!ZX[8I]AXS\3:A!#K5M%J4L<MYM%@NGK]F\CS=A_??>WA><YQD8VT >B:[I
M$&LV=O#<3-$D%W!=!ACDQR!P#GL2,5?CM;>*'R8X(DBSG8J +^5<E\3X9YO"
M"""Z>W(U&RR456W9N(P.H/0D-_P''3-8.H>)_$<^JZW;Z?-J0&DNMO"+?34F
MCN)1&KLTS'D EL83;@<YH ],GMX+J/R[B&.5,YVR*&&?H:<T:,FQD4I_=(XK
M@(M8\1ZOK]R([[^S+:STNTOY;3[.CN9)!(6C+'H/DP<<\#&.<T--U/Q==Q>$
M'D\0H#XAM2\P%E'BWQ")0T?'+$#!W9&3D#C% 'IQ12X<J"P! ..0*CBL[6%9
M%BMH8UDY<(@ ;Z^M>=-K_BEM&$<<US<FTU:YLKR[L+6)[IHH\[&6)OE)SM#8
M!XZ"NL\':JVKZ#YTFH"^EBFDA>0VQMY 5/"R1D#:X!&> .XX- &U+:V\_E^;
M!%)Y9RF] =I]1Z4_8N_?M&_&-V.<>E>6WGC#5X;F'4+75;J\MVU6.V>.+30M
MCY33B/ F90S, ?O*2-PZ8J;4M>\31:5XHUV'6$CAT74)(H;/[*A6:--A(=B-
MW1B!M(Q[T >BW,%C]E;[7%;_ &:(&0^:J[$QR6YX'?FIXW22)'B96C8 JRG(
M([$>U><^(;K6]>T_QH;755LK/2XY;1+7R$83XMP[M(Q^8 [\#:1C&>>E;MUK
M,GA[X6KJ\,:R2VNEI(B-]TMY8QGVSC/M0!TR6T$<[SI!&LS\/(J ,WU/>GJB
MH,(H49)P!CFN%UF_\1>#]'N]1N=;M=4/V,LD-Q"D3+/N50R; ,QC=R#DCCGF
MDU#4=?\ #&HVUK=ZQ_::W]E=.K26T<;0311[P5V@ H>1ALD<<F@#N/L\!E,G
MDQ^8Q!+;1DXZ<^U)++;6\B&:2&)YV$2;R%,C8)"C/4X!X^M>>66O^(=.3POJ
M6HZH+Z'6+622>T6V1!$RVS3CRR!N_@P<DYSD8Z55<ZY?Q>!-:U'5TN(K_48;
MAK18$1(2\$C*(V'S$ $@[B<]>.E 'I%D=/$ -@;80N[ &#;M9@2&''4@@@_0
MU+;RVUTBW5M)%,CC EC(8, ?4=><UY9ITE]JFL>"KK[8+;_3]44QP6\:J0DD
MHZ;>K*,$^Y/7FK?AC6=9U^/2M(M;^/2P-/DO9Y[:UCW.3.\:HJD%% VDDXR<
MCI0!Z8R*^W<H.TY&1T/K48L[4222"VA#R8+ML&6QTR>]>=6WB/Q%JE]I&CIJ
M,5K<->W]E>7<5NK>8+?&UT5LA2?3D D\' %*VN^*3HT\$4T]W+8ZS+975U9V
MT37+0*FX,D3?(6RR@X!XR0* /1S#$493&A5CEAM&"?>H8K&WAO[B]13]HN%1
M)&)ZJF=H_#<WYUC>#-6?5]&E>74#>RP7#PN\EJ;>5,8(26,@8< C.  >"*Y:
M;Q%XA_X12]\:)J:+;6]S+MTK[.FQH8YC&59\;_,(4G(.,D#% '>M?:6VKI8M
M=69U-8RZP&1?."=R%ZX]ZLPVT%OO\B".+>=S;$"[CZG'6N*\(V,\?C[QE=37
MKSXNH4VM"@ZP1,.0,\ [<9QW//-5O%GB'4X-4U6'3=6O$>QMU=;?3].$X1]A
M;]_(Z[5!XPH8''/>@#T%HT<Y9%8X(R1G@]11Y<?R?(OR?=X^[VX]*\_L]7\0
M^)=8L[6UU==+@FT"UU%S#;)(PFD9P0-X(V\#(]AC'-0Z5XZOK>RT75]<EC&G
M7^ES/)L0*%N8,LQ'?YT#$#U2@#T)K.U:*2)K:$QR'<Z%!ACZD=S4:2V(NEL4
MDMOM$*"06ZLN]%Z!MO4#MFJ?AV;4'\-65SK3J+Z2'SIQM"B,M\VW_@((7/M7
MDUOXBCBUJW\<-::FK7&ILDTSV,JP#37"Q)^\V[<#9')UZDT >LVGA^TM=9U+
M4V FEOIHYL2(#Y3)&L8V_@H-:@10Y<* Q !;')KS3Q+XPU_2O[9TRR>.758;
MT36N8QS9^0TY&,?],I(\^I%6;KQ?=WD-_>V>JK:Z?)?065BR6AGEDQ'OE,2*
M"6<EMHR"!L)H []+6W2=YT@B69QAI @#-]3U-.2&.-G9(T5G.7*J 6/J?6O+
M&\7>(H=*U^WBNYS=65[I\5K/J%FD<NV>158.BX&.3C@'!K=@;Q)=^(;C0$\1
MM&VFV<4\EV;.+?<R2O)M!7& BA,';@DGJ* .P@^Q7:"[M_L\RR8(FCVL&QT.
MX=<5/Y:;F;8N6&&..H]ZXOX<6]XW@KP[*+U4@C@E6>!8P1*Q<X(8\@#!^N?:
MNVH B@MH+6/R[>&.%,YVQJ%&?H*?L7?OVC?C&['./2G44 -9%?&Y0V#D9&<'
MUJ/[':^9))]FAWR8WML&6^I[U-10 PPQ%&4QIM8Y8;1@GWJ&*QMX;^YO44_:
M+A421B>JIG:/PW-^=6:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L_6-%LM=LUMKU'(219
M8I(I#')%(O1T92"I'J/4UH5A>)]?N-!@T\VNG_;KB^O4LXXO-\L!F5B&)P>!
MMY]LGM@@$$7@70H[/4+:2&>X&H,CW4D]R[R.Z?=?>3D,.,$$8P,=*?#X*T=+
M;4(IUNKUM0@^S7,UW<O+(T6#\@8G*CDGC')SUK)O?'EWI=KJ,=]HJG5;&>UB
M:VM[K<DR7#A$='*CON&"!RO7G-,O/'E]97R:5-8:3;ZK';BXNDNM6$4*!F8(
MJ.8\NQ"Y^Z .,F@#6F\$:7,(&%QJ45Q#!]F-S%?2)-+%DG:[@Y8 DXSR.V*O
M6'AO2M+N;6>RM1 UI:&RA56.U8BP8C'<Y4')YKEY/B9%<0Z.VG6UFK:E;R3J
MVI7PMHP4?8T2N%8,^[/ XP,YK3D\5:I<7EIIVFZ&CZE)9+>W,-W=B-+="2H7
M>BON8D-C Q@9S0!I1>%]*AT^QL4A<065W]L@7S#E9=S-G/?EVXHG\+Z5<7<]
MU)"YEGNX+USYA&980H0_@%''>LA?%^KW&MV.DVOAMEN9K)+RY%U="/[.ID*,
MO"G<01D8ZCTKGK#7]6N-3\*MHUO/<"ZM-0W6]YJ#;,I-& \C[23CD#Y21N Z
M9- '<2>%]*DTJ\TQH7-K>7+74R^8<F1I/,)SV^89Q574O!&C:I>75Q,+N,7F
M/MD,%U)'%<X&!YB*0#P #ZC@YK&G^)"16]K;FSMK?5YKJ>TDM[R]$4,+0X+L
MTNTY7#)C"Y.X<#FM[PKXGB\36ETP2*.YL[@V]PD,XFCW8#!D< ;E(8'. >H(
MXH U+O3;*_TR73;JVCDLI8_*>$CY2F,8]JQK;P1H\'V@R&]NWFM7L_,N[N29
MHX6'S(A8_*#QDCDX'-<C9:[J6G^(_$FJ7]H]S<#4H]*L+:+4I"F]TB*H(RH1
M1R7,F,CYA@]3M7_CN\T.VU5-8T9([^PM4O$BMKHRQW$3/L)5RBD,#P05[CUH
M O:OX1MO[&U"/3+&VGN+JWM[=X;R5Q')'"?E7<IRC %L,.0<'M6-HO@1[G4-
M6NM9M)(+:^T\:>T$NHR7<TBEB69I&Z<8  /8GO5X^*_$G]K1:,/#-J-2EM6N
M]K:E^[2,.%PS",G<<C@ \]\<U'H_CR]U(Z%=3Z&MKIFLR&""4W>^5)0C-\R!
M<;3Y; $-GH2!G% &I?\ @;1M0OKJ\D-[%+=HD5S]GO)(EGC5=H1@I (Q_,^I
MJQ<^$-%NEN4>UVI<V\%LZ1N541PL6C4 =,$GI6/X;\<W'B/4(TATZT^R2/(C
MB._#W-KMSCSH2HVYQC@MC(^M=I0!@WW@_2-0CO%ECG1KN[2]>2&=T=9D555U
M8'*D!1TJE;:!<W?C]O$%_9P0I96AL[-EF\QY@6),C<#;@9 ')^9JSXO'VHO8
M7.IOH")IL5\+!)3>?/))]J6 D+LX7DMUZJ1[T>/_ !)/:Z9XBTNU$MO<6VCB
M^2[BE*L"TC)@8Y!&S.<]Z .OU32[36;$V5ZA> R1R$!BOS(ZNO(_VE%9.H^"
M=&U.\N;B9;I!>8^UP074D<5S@8'F(I ;@ 'U'!S61K'Q#&GZKJ-E:0:?*-,5
M?M)N]26WDD8J'V1*5.\A2.25&3C-1W'Q'\Z_2WTBRL[@/9PWD:7=^+:6Y25=
MP$*E2'('7+ 9X]Z .OM-(LK'4;N^MXMD]TD4<N#QMC!" #H,!CTJKJWANQUB
M]MKV5[JWN[=&C2>TN&A?8V"R$J>02 ?PXJ]>7<EKIDUVEK-/)'$9%MTQO<@9
MVCG&>W7%<;#\0IXM0N+*_L=.\]=/GOHUL=2%P5\H F.3Y%V$YX/(X/I0!NZ=
MX-T32I;62SMY$-K<2W,6Z9VQ)(NUR<DDY&>O<YI]UX1TB[@O(Y(9 ;J\%\TB
M3,KI.%50Z,#E2 HZ>_J:R-.\;7TEWI)U71H[&QU:W>>UF6[\UTVQ^81(NP!<
MKD\%NE95UXHUS59/"=Z---AI>HZG$T4L=X6D>(QR%5E0*  PPV S#CGG% '8
MZ+X:T_09KR>S^T//>%6N)KB=I7D900"2Q/8_RKDO%GA/4]6U/5#;:5;RI?P+
M"MQ'J4MLOW<?Z1&O$NTDD8'(^4UT_B?7[C08]-%IIWVZXO[U;../SO+"DH[;
MB<'@;.>.F3SC!Q;SQY=Z;:WT5YHJMJUG=6MNUK!=;DE%PVV-T<J.^1@@<J?K
M0!N:9X7T_3H4RGFS?V?#ITKL3B2*,, -O3^)OSJG:> M%LY;"13?2_V<X>R6
M:\D=;? P%4$XQ@XY[<55C\4^(;F\GT^T\/6DNH6,2R7R-J)6-&?)2.-O+.]B
MH#<A0,@9IMMXYN-<:UB\-Z4EW-)9+>SB\N?(6%69E"$A7RY9'&,8&WK0!M1^
M%]*BTJRTU(7%K97*W4"^8<K(KEP<]_F/2I]-T*RTJ^U"[M//5K^7SIHVF9H]
M_=E4G"D]\=<"N8OOB#)#>06$-A:6U_\ 9$NKF+5=06U$.XD",':VY_E;H, 8
M)/-2VGCR77(],3P]ID=U=7EJ]U(ES<^4D"(_ED%E5]QW@J,#!P3G% '3:9I%
MGI"W2VD;*;JX>ZF9F+%Y'/)R?H!CL !69+X(T&:T%I):%H!J/]IK&9&PLY.2
M1SP"2?EZ<FL#P;XHO&@TRSOX)GN-3U+4D)FFW-;B*1R$[Y  V\$ 8XJY?^.[
MBW69+31_M-R-;_L>*,W(0.WE>8')V\#L1S@9//2@#:/A+1#<ZU<-9*SZTBQW
MV6.)5"E0.O'!/3'K5:S\$Z39W]G?&2^N;JR#);R7-Y)*8U92I4 G&,'TSP/0
M5@WOQ(GM+B\@-AIBS::B_;HYM56-S(4#LD *?O, CD[03Q4UY\1=VHQVVDV=
MG<;[*&]C6\OQ:R7*2 E5A4J0YP.<D#) ]Z -]_"6D/X>L]$\F5+2QV&U9)F6
M2%DX5E<'(8>N>Y]:J+X!T);>ZC*7;RW,T=S)<O=R&;SD&%D#YR& /;MQTXK4
MUO5SHWAF_P!8:V9S:6CW)@9@I.U2VTD9QTQGFN6N/']]:FRMKK2]/LK^^5[B
M!+S4Q'$EN N&D?9PY+8V*&Z$YP* -AO!]K#IT]O97-U'<7-S#/<7DMP[S2>6
MRG!;.<;5V@=.>G7.SJ>F6>L:;/I]_")K:9<.A)'?(((Y!! ((Y!%<3;>+F\0
MZUX5EMG: ?VC>6MY!#<>9&SQV[G&Y>'7[K X]. :L)X^NHM9TZTO]-LK:/4+
MK[-'"-15[N(G.UI(0N #CG#'&10!KVO@C1K>:[FE2YO9;RV-I</>W+S&2+/W
M3N/3Z?UI=/\ !FD:?<^?_I=U(L#6\1O+J2;R8F^\J;B<9P 3UP.M<MHWB+5K
MB:V&LQMND\37%G";:^;"A5F^5AL7<BA  #][AC@C!OV7C[4;F#3M1ET".'2+
MV_%@)OMFZ57,IB#[-F-FX8^]GG.* -1? >CQ65C;PR:A"UBK1VUQ'>R":.-L
M9C#YR4X&%.0,#%7;'PIH^G'3FM;9D;3S*T+&1F):7[[,2<L3U).:Y[4/'NHV
M^FWVM6F@)=:+:W+6WG&\V2R,LGELX381L#Y&=V>,XK3^(6I:GI/@VZN]**+<
MK)"N]I-A56D53CY3R<X[<$G/'(!?F\+Z5/8:C920N8-1N?M5ROF'YI/EY![?
M<7@>E&I^%]*UB>ZFO(7=[FWCMI2)",QHYD4<=/F).:RIO%.M2WE]:Z9H,%V^
MF(GV[=?%!YK(',4/[L[R 1RVP<C\--M;.H^"VUS1P',]D;FW$K;.JY&3@X(^
MAZ4 32>'--EM]8@>%C'K&?M@WGY\QB,X]/E4#BJ=_P""])OYQ-F\MI3 MM*U
MI=R0F:)>BOM(W8R>>O)YKC-#U_Q5<:EX:\NVCO+JZ\-B>2*6^9(2=\>)G.P_
M.0>@4X+$9QS6P_Q(C;3=):.TMH-0U%IU,-]>K##!Y+E)"TNTY^;@87)SVYH
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M+?+QU'(FA^(XC^WQ7EMIS7,&G3:A"NGZD+E)%B&6C9MH*-R.Q!&<'B@#7E\
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MZ+&+6V,TL:MD;@,[0<#// XYKB/!&LZE8W5_H]_J U;4)[%-5MP;C=B0C$L
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MQP0/3CGC/\4^+=:OO#&H7FEZ=Y.F1WBVJWT=X5F)2=4=U0+]S<&7.[)'.,4
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MUCO[&W:U(N[7SX9HVVDAEW @@J""#ZCG-;^IZG9Z/ITVH7\XAM81EW()QS@
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M.2%S O5U#*-P'MS3M(\::-K=]':6<ER))HWE@,UK)$LZ+MRR,P 8?.O3L<T
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M1V.%554$LQ] *SHO&>BR65S<O+/!]EFB@N(9[=XY8GE8+'N0C.&+#!Z>_!H
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M 0J@$[,%CG&",'/KOMXUT3^S;"^AGGN5O]PM8;>W>2:0K]_]V!N&W'.0,=Z
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M\T/5KP2 26ZZ/86,,^X9D>$2A^.H^\IY]?:NG']GVC7=T/LT+,P-S+\JDD*
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M6:* .7NM(OCXG\.7\5N&@L+*ZBF^<#:SK%M'X[#T]*Z"QFN+BP@FN[4VEPZ
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MDMWMBNY9&!R&S@C'T-<7IG^O^)O^[+_[6KG]/U!O"EI;WR9"ZKHTL8([3!F
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M2/\ KW'\S0!T-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %,DBCE $D:.!TW*#3Z*
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MWO[MTTN<S0D[<G+!MIXZ9%:?B?PM8^*;&.WO#)&\3[XIHL!T/?&>Q_PK<HH
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MBUTZ%W>.W38K/C)'OBKU% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !112,P52S$
M!0,DGM0 M%(K*ZAE8,K#((.012"1#(8PZEP Q7/(!S@X_ _E0 ZBFNZ1(7D=
M41>2S' %#R)&H9W502 "3CD]* '4444 %%(S*B%W8*JC)). !2@@@$'(/>@
MHHHH ***B:Y@2X2W::-9G!*1EP&8#N!U- $M%0W%U;VD8DN;B*%"<;I'"C/U
M-/\ -C"*_F)M? 5MPP<],4 /HHHH **** "BBD=UC0N[!549+$X % "T55&I
M6!.!>VQ)_P"FJ_XU85T<$HRL 2#@YP1U% #J*** "BBB@ HHII= X0LH=@2%
MSR0.M #J*** "BBB@ HHHH **** "BFET5U0LH9L[03R?I3J "BBB@ HHJ**
MY@G:189HY#&VUPC [3Z''0T 2T44U'21 Z,K*>0RG(- #J*** "BBB@ HHJ*
M>Y@M4#W$T<2$A0TC!1GTYH EHILDB0QM)*ZHBC+,QP /<TV"XANHA+;S1RQG
MH\;!@?Q% $E%%% !13=Z>9Y>Y=^,[<\X]<4Z@ HII= X0LN\@D+GD@4Z@ HH
MHH **** "BBD)"J68@ #))[4 +12*P=0RD%2,@@\$4M !1130Z,S*K*67A@#
MR/K0 ZBFNZ1H6=E51U+' H5T<L%96*G#8.<'T- #J*** "BBB@ HIJ.DBAD9
M64]U.10CI(@=&5E/1E.0: '4444 %%%-9T3;N95W':,G&3Z4 .HHJ)+F"2:2
M%)HVECQO16!9<],CM0!+1110 44U71RP5E8J<-@YP?0TZ@ HHHH **BEN8+<
MQB::.,R-M0.P&X^@SU-2,ZHA=V"JHR23@ 4 +12*P90RD$$9!'>EH **** "
MBFET5U0LH9L[03R?I3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y;QS,S:=
MINE@D1ZKJ4-E,1WB.7=?^!*A7_@5=36'XKTJ?5=(1K(*;^RN([VU5C@-)&V=
MI/8,-RY[;J .:\5^*=1TS4=0MK#5+. V5NLD5I#ITUY([;2W[TI@1+P,>W.>
MU6;O5'>?P3XC1!')J3):7$:G@QSPF0#WVNBD?CZFM"[\%V>HW=_=&]U.TCU1
M5^W6<,RJDQ"!.3@LIV@ [6 .*#X<<:EX<LD5SI.AQ>8DDC M+*$,48X_NJ78
MG Y*X[X *_Q'07OA^ST5LD:OJ-M9N >?+W[Y/_'$:N:BO)[UO#/A*^D+WVFZ
MR4NG?_EI%;1F6.0_[P,)SZDUV?B&SNYM7TF]MM*>^:P=Y8_]+6)0[(4Y!!S\
MK''3K6++I5_-XI;Q$_A,F^:S:S8#4T"%"<DXV_>P,9STH ?;>+=2N?"?A_4
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M[.("XAMO.CCG4\'CAA^-5[WP-87ES>NM_J5K:W\GF7EG;3A(IVP 2?E++D
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M.W<&5N1DX88(SUJ.;P5I_P#H36%U?:9+:6PM%ELY@&>'KL;<&SSSGJ"20>:
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M^/=@;6]#\PQTK>7P!I0AO5:ZU"2>[N([MKIY\RI/&,+(C8X..,8QCC&.*)/
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M4\2WNH[=)NXKJ%(HFU&!I7L2H()B7[ISG=U7GN:I'X<7[: ^GF^MO,;P]#I
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M;M>6=W)'/8PQ?-EH)#\X))& ,=3D 4 =]'X@TJ6PLKY+Q&MKZ58;:3!Q([9
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M9A80M)@ =6R$&.<[N.:M/XJL;NQMKK2[^U9'OXK.3[0LBE69@"FW&Y9,$8#
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MCJEQ>HUW((Q<0RMO5T)X; .T@<@KB@#L=&UJRU[2HM1L9&,#Y!#J59&4D,K
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M8MI..-Y&<]_NY[5=T+0=,\0:^D6K6B7D,?AG3BL4N2@8^;\V.F[C@]1DXZT
M>JD@=3BBO%M!GTFZ@T"3QM-#)IQT"+["]^_[II@["7D\&7:(L=\=.]=O\+V5
MOAU8- TC(9;GRS,3N(^T28W9YSZYH ['(SC//I6?I&LVVLQ7,ENLBBWNIK5A
M( "7C8JQ&">,CBO)K Z4/#VB3VLD9\>MJ$*W.&_TLR^://64?>\L)OX/R@8Q
MVJ"9= &D>)9;9X?^$P&NW/V !O\ 21+]H/EB,==AYSCY?O9[T >L6_B."[O+
MFVM[.\E:UOQ83,J*51O+$F\_-]S# 9ZY/3O6SD9QGFO*7)'B>3!(SXVC!_\
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M+;9R^Y2 #CHH7J>11)XMUS6M2AMK5M3M8X]+M;N0Z79Q3,\LREOF\W("#&
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M[!>7ELN8'>1XR"L2C>,J"!C.3CF@#T!U5T*NH92.01D&HTCMY-LZ)$VY,+(
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MU*KM)[Y)Z\TEEXO\3W]LFN6\>J2*]X5%D+.$6GD"781YA_>;]H)W9QNXVXH
M]1N)+.Q22]N7@MU  >>0A0!G RQ]\5+Y,7F"3RTWC.&VC(SUYKR?Q+<:SK_@
MC6]8?5S#:I?O;)IWDQ^6(HK@1_,V-^\E=V=V.0,5WGC+5[O1O#KW%B8UNIKB
M"UBDD7<L1EE6/>1WQNSCVH W=B9SM7.<]._K7+CP67N[?[7KFHW=A;70NH;.
M;8<.K;D#2;=[*K<@$]AG.*P=?UG7O"9U.S.LR:B7T.ZO[:>>"(26\L.T=$4*
M4.\8!'5>IKLO#MOJ,.EJ^J:FU_<3XEW&%(UC!4?(H4?=!S@G)YZT 7;=[&]3
M[7;-;SI("OG1E6#8."-PZX((_"IC%&S;C&I;&,D<XKRNVUSQ'-H6D3PO?I9.
MET;B31K2"2=9%G94S$RG]WM!SL7)/6N^\/ZFVI^%+2_CO8;V22#/V@1&%'<9
M!)4\KR#D=N: -9H8FD61HT,B_=8J,CZ&G;5R3M'S=>.M>6Z7XMUK3'$FO7>H
MK>&RGF>QN[*,03R1QF3%M-$,$ *>&+$CGK4F@Z_XHN;C1)YGU6:+4L+=">RA
MB@@#H65X&'S':<<-NR,GB@#TM980J[9$VEMBX88R.,#WX/'M4=I)9S"62S>!
MQYC)(T)!^=3A@2.X((/I7C^CZ=?'1O!!&MW8#>(+L*/*A^4_Z3R/D[[6Z_WS
MZ+BQ::]J5DT.CZ>;V/[=K&K3336,"2S!([@_*@?Y1DN,D@X Z<T >OA0H 4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0A Q:5RGRM\RC:H;)/7BK.G?$.._CM$6WMI+A]772YS;70EB4F)I!(C@?.I
M'& <Y!Z4 :J^!]"6_%T+>?:MQ]J6U-S)]G$V<^8(MVS=GGIUYZU<D\,Z3+IF
MI:=):[K74I));I"[?.S_ 'CG.1T'3&*Q-9\<2Z7-K$46E_:7T^ZLK9%$VTS&
MX*CN.,;OQ]JAN/'-]I#:I:ZSI$*W]K%;RV\5G=&1+CSY#$B[F12IWC!XZ<T
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MKYK75LMI+\[#,:N74#!X(8DY'-0>&-<NM<MYY+B&QV1L!%<Z?>BY@G!&?E.
M01T((^A-</XHUOQ!&/'J%PEM8QVOV8P7+"2,L5("C:,;@22<\' Y'( .WM/!
MNCVE^+_9=7%YY#VS3W5W),S1-C*'<QXX'';GU-0+X"T..TLX(?MT!LT:*WGB
MOIEECC/6/>&W%.!A2<#'%16WB?5XM8N=,U318H[D6#W]LEG=>;YBJP4QG<J@
M/EE]N>O%9^G^.[VZUR+1Y;;1FO+JUEF@2SU3SC"Z '9-A/ESG[P!Z'@T ;4G
M@C0S:6-O;P3V?V%76WEM+F2*50YRX+J<MN/)R3D\]:U=+TNST;3H["PA\JWC
MR0I8L222222222222>236#\/=2U'4/ .F:AK#HT\D D,HD+EUZ[FRHP>O R!
MZU2M?'&H26>G:U<:-%#H&HSQPPS"Z+3HLC;8Y'CV!0K$KP&)&X=: -6S\#Z%
M8WL-S#;S[;>0S6]L]S(T$#G.62(MM4\G&!QGC%:VFZ9::1:M;649CB:628J6
M+?.[EV//JS$UYA)K_B=[(33(DDZ>+?LL,<-XP#J"X,3'8,1C"\\YY)&>O077
MQ!GT>VU2+6=/MH=1LI[>!$BO/W$QGSL/F.J[ ,-N)' 4GF@#H+_PGH^I27DM
MS;.9;N2*625)G1U>(81D8$%"!W&*L:/H-CHBSFT$SRW#AYY[B9I992!@;F8D
MG X Z"N//Q.2WL-9::#3KN\TZV2[ TR_%Q%-&S[" ^T%6!Z@CN#WXOR>--1T
MHZA'KVD06L\&FOJ$"6]V91,%;:8\E!A@3&.,_?H WKGPUI%X-46YM!*NJ;/M
M:LQP^Q0JD<_*0 .1CD9ZU3B\$Z(EM?PRQW-T;ZW-K/+=7<DTAA.?D#LQ*KR>
M!CGGK7.ZIX]6\\)M*NG2[I=%N;^\CCNC$]N8R$\L.!G<7W@-QC835J_\=W-K
MX@GTBSLK!Y;9(6\B[U 03W0=0?W"LNU\9QDL,D$<=: .METFRFO;"\DB)GL
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MN=*O#<?97<)YR-&\; $\!@'R,\<=JZ.HI[F"UC\RXGCA3^](X4=">I]@3^%
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MV0-]=Q''6N@T;2[JS\4>);Z9 L%]- \#!@2P6%4;([<@UJW6I6-B";N]M[<
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MI+?58W2X:[$5HL5Q)"I>="'"C.[@\<9.#R,<U8CU"RFLS>17=N]J 29UD!3
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MW':37EO'<R_ZN%Y5#O\ 0$Y-4=,\06VH?VF7 MDL+YK)FE< .P"G(],[P,4
M<QXOT'4;W7)+VRTBXDF-JL=M?Z;J'V2>)P6^67+ .G((X;'S<5GW/A/7+;5_
M[3N[:\UB>ZT^VAN&T_57L2MQ$I#$@.@9&SG/)'/'->F221PQM)*ZI&@RS,<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!XQD#VJ/4M,6SU;55;3V_L&#Q';7-W;Q0$QF(VBY?8!\RB4HS8!Z9/2O7**
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M%G9HD<NI2-8&<"4P?))-&""V'9N3]TL#2)I,=]8G87OM.N_$EDS*FG?9K9P
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M5QI5O)=%E=G(.'9?NLR]&(P,$@D8JX^C:=)#J$36D9CU'/VM<?Z[*!#N_P"
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M=B4S!P#@2'JX7[H;_:QFFW?@SPY?W\E[=:1;RW$C!W8@X9AT8C.-W'WL9]Z
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MV1+S6;W3TMM+LIT2R<1%Y)HR[2MP<@$8 ^[P<BN\_LNQ\V]E^S)OO5"W+?\
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M"VGA4G A+0NS$>G(_2L73)-6\17NF6LVNZC;0MX6M+V3[-($9YV+ N6P3VY
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M%KY<JJP=MQ)&T$_*"22 !UJ]:>!K6WD@N);ZXGNUU/\ M.:8JB^;+Y1B VJ
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M N%W,J'[H)[#.<4^U\$+:30PQ:Q?#2(+K[7%IP"!%?<7"[P-Q0,<A<^W(XH
MYSX;>)IM0BM]!L1&?L1N)K^:XSN(:>0*L0XW>[=!P.2>.N\6:Y/H=E;20W&F
MVHFF\M[G4)=L<0P3PH(+L2  H(ZY[57LO!%GIXTA[:ZN([C3)9G2<8W2QRNS
M/$_&"I+#W!4&KNO>'?[9N]-OH+Z6ROM.=V@F1%<8==K JP(.1WZB@#F-)\?W
MUS DUQ'9RV\&L+IMU<P)(BE)$4QRJKG*C>Z*0<]<@U;N_&5Z+#4+Z Z7:V4>
MIFQ@N[Z4H@5!B20C(WGS RJJX)QG-78/ UJFE:[87&H7EU_;+^;/-+MWK)L5
M=R[0 ,%5(&.,4LO@BV&D:)9V5]<6L^C/YEM<A5<LY4JQ=6&&+;F)Z<G(Q0!S
M<7C.35XE@O(+&]>TUVQMTN(%EBC<2%66158[@5R>I(..XIVG:_<Z+H-X\=UI
MML)O$&H1M=:E+A(P)I" $!#.QP %!'KVK=B\!0+=375QJM[=7$]_;7\LDH0$
MR0]  % "D #'8"A_ D236]U9:G<VM[;7MU=Q3;$< W#$R*588(]#U&* .4N?
M%&J^([71FMELGO[3Q,+19$$D<$P^S.X?:WS 8?.W/.W@\YJ]KNMZC<#^Q]46
MW6_T_6]*8S6FY8YHI9U*G:Q)4_*P(R>G7FM<_#N+RFVZYJ0N3J@U47)\LN)Q
M%Y?]W;M[[<8[=*M+X'@DCDDO-1N;J^FOK:]GNF55+F!@T:!0,*@QC YY)SDT
M <U>_%&>&XU&YMS8-:6-V]O]A9)3<W"HVUV5A\JG(.%(.<<D9KH/B;-=K\-M
M9EL9EB8VYW,P.=AX(&",'FI)?!)\Z[CM-=U&STV\N#<SV<!09=CN?9)C>@8\
MD ]SC&:V=?T:'Q!H-YI$\CQ174?EL\>-P'MF@#D]-N==MS?:)X<LM$MX=$"Q
MRHT<BI/,Z^:4C ;Y!AQ\QW<D\4_3?&6K^(]9TV#1;:QBLKC3+?4IGN][.BO(
MZM&H4@$_+P>G!ZYXUM1\)/<:G>WNGZU>Z8=014O4@6-A+M7:&7<I*/MXR/0<
M9&:LZ5X6L-%U*.[LB\:1:=%IT<.<JL<;,P.>I/S'- &?\1M<71/!]QBZCM9[
MYUL89G;:(VD."^>VU=S?\!KE?#GBVWT;PSXBL=&NH-3AT"83P-YGF![)R'(R
M#DL@\Q?^ KZUZ%>Z'#?Z]IFJS2R$Z<)?)A&-F]P%+GOD+D#_ 'C4-_X:M-0U
M^+5I'=9!9RV4\0QMGA?!VM]",C'J: .9O?B-):ZKXCMTM(I+>QM=^GR G_2I
M@$#)]-\T2\>IJ'Q-X[U307O\W.@QRV, E-D[/+/<X0,Q 1OW0SD#<#TR<"M&
MV^&FDV]CH-L;FZE_L>Y:Y61V&Z=F?>1)QR-P0_\  !4M_P" EO/[:@BUJ^M;
M#66:2[MHDCRSL@0X<J6"D 9'UZ T 02>+=7EUV_2V@L8])TVS@OKJ2;>96C=
M78J@!QNPAY/'MSQES:AXBU'5/ ]_J45A%9WM]YR1VQ??#NMI2J.2</P>2 N"
M.ASFNOL/#%I975_,\CSB^M(+69) -I6)67MZASFLRS\"FVN](:77=0N;71Y"
MUE;2"/:@V,@#,%!;"M@$G/'N: ,[PYXXU#5]?AL;M]+MY)'D673)!)#=VX7.
MT_.<2]!G:!USDXKIM6UF;3]?T#3XXXVCU*>6*1FSE0D+R#'XJ!6=;>"=E[I\
MEYK=]?6FFSF>SM[@(61\$#=)C>X 8XR?3.<5I:_X?&MFQFBOIK&]L)C/;7$2
MJQ4E2C JP((*L10!SNH>,]6BO+BSL;.S>9=>CTF(S%@NUK<2[VQW!/;J!Z\T
MV3QGK-B-1TR[M;";6(;ZVLK9X=Z02&< JS DLNT;B1DYQQUK1L_ EO;2+++J
M5Y<S_P!JKJKRR[,O*(O+QP  N.< <=.E6-0\&66HW&J7#W-Q'/?2V\ZR1D!K
M>6$81TR.OUR#TH Y*[\0:IX7\2^)=4UN.UGEM=(L_*%J62.4M/*JDABQ3YFP
M>3P,^U6K?XAWB?VA%+)IM_)%ID]]#-912I&CQ+DQR!R2<YX8$9P>!6Q_P@4-
MVVJ2:OJMYJ$VI6T=M*[!(_+$;,R&,*!M()SWY&:G'A"XN8;U-4\0:A?FXLI+
M)=P2-8T<89MJ !GZ?,?P YH N^&[K6M0T9;W5DL8I;E%E@CM@Y$:,H(#ECRP
M)ZC KS>SN_$4VG>&)6N+6YO7\27L<32%PH %TIW\DD#!( QP />O7+*U6RL;
M>T1BRP1+&">I"C']*YRR\$0V5S:N-1N9(+34I=1MX75,1M() R9 R5S*QYYZ
M4 8U[X_U#1K'4;?4X;$ZI;:G#IZ2Q[UMV\V,2K(PY8 *6R 3DC@\UJ^$?%DV
MN:E?Z;<O:W+VT:3)=V<<B12*Q(*[7R592OJ<@@U8O_!5G?SZE<&[N8;F\NX;
MV.:(J&MYHHU163((/"\@@YR15_1M%N-.N+F[O=7N]1NK@*I:;:B(JYP$C4!1
MU))ZGUH X'Q!%H]Q\4-436-#O]61=-M3$EI;O+Y1+2Y)VGC/'Y4S1+2_L-:\
M.)/!=V=C-KEV]A9W4A:2&W^R/A6Y.!N#$*3P#7HMOHD-OXDO=;660S7=O%;M
M&<;5$9<@COD[S^5&IZ)!JFHZ7>322*VGRR2(J]'+QM&0?P<GB@#BH?B%?#6]
M.MY;C19X[R^%I)9V;/++;;B0I:4$H2,#(P.O'2I3XS\1+87&M-::8-*M=6;3
MY(AO\Z1!<^3YBMG:I&1P0<X/(SBKUI\/%MK;2;-M=OI+'2+F.>RM_+B4+L.0
M'(7+\$C/'7/7FM%_!MH_AVYT8W,_DW%^U\S\;@QN//P..F[CZ4 =)7F^IZY<
M^'O$/CO5+>)9Y+6ST]DBD)"DGS!CVZUWUO:S0WEW-)>2S1SLICA<+MA 4 A<
M#)R1GG/)K$U3P79ZI)KCRW,Z'6(H(I=N/D$1)!7CONYS0 S2]9UQ/%G]AZU'
MI[&:Q:]ADLPXV;75&1MQ.[[XPPQWX%,\6>)+K1KVUMH;W2+%)8V?SM09G9V!
M ")$C!CZELX''6ME]&A?Q+#KAE?SHK-[01\;2K.KD^N<H*H:GX8>\\0+K5EJ
MUSI]V;7[)*8XXY \88L,;U.U@2>?S!Q0!@:1XWUCQ+;Z/;:7;V,%_=6\]S<R
MW =HHTBE\GY5!5B6;D9(P.N:S_#>N:S;6R:5;PVBZQJ6M:B7:=F>&!8Y"SD
M8+<E0!D=>V*W[3P!%IEI8+I>KWMK>6/GK'=D)(SQS2&1D<,,,-V"#U!'URZ#
MP##:6-NEKJU\E_;7DUY#?L$:3?*3Y@8%=K*V>1CTZ8H YG3[V\M[Z^&JVMM+
M=/XN@A(1WV(3;QX=.0>G.#D#/.>M+I&JZC$;5]9-M>;O%5S!&_[P&#:D^2/F
M/ "X4'@ ]S@UU%IX$@MU+3:G>74S:LFK22RA,M*J!-N   OR]!TZ4Z'P/!%?
MB<ZC<R0)JK:K%;LJ;4E=9%=<@9*GS">>F![T 9=MXQUTZ5I?B2ZM+!=#U&>&
M-8$W_:(8YG"1NS9VL<LI*@#&>IQ43^,_$26-YK)M=,&E66K/I\D7S^=(@N/)
MWJV=JD9'!!S@\CI6I:^ HK<6=F^KWLVC6,ZW%KISA-J,IW(I<+N9%/(!/89S
MBK<G@VTD\/7NCFYG$-W?-?,_&Y6:?SL#CID8^E '25P'B'QQJ&D^);G3@^EV
M,40C^SC4A)&+[< 6V39")@Y7!W'(KKK*WOX]5U.:YN3):2O']EB./W8" -C
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MMK<K;D,2F]I.G.-V1R<<@*.V:36&UD_%*WBT9K-96T5R[W89D4><O\*D$DG
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M="@TF%WFAA# -)C+;F+'./K6#!X 6!M-@&MW[:;I=RMS961$>V,KG"EMNYE
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M2]U?6;W3DO)TM$C!5. 7;<RJ,G@ <G!P*A\->+I[ZPT*ZOKRZ,EY_:+F(6Z
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MR'/3M4>M:5JD?B6S\0Z/':W,T5K)9SVMS*8@\;,KAE<*V&#+T(P0>V* .?\
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MT7T+R"WN8-DKQ[;B,HQVDC<!W4XR#W% %JBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH 0*H)( !/4XZTM%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %1K!$DK2I$BR/]YPH!;ZFI** "BBB@ I&170HZAE(P01D
M&EHH ;'&D,8CC140=%48 _"G444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.25+R23=#9R7TOEINV1(0,GZDX [D'TJ&R\9:7=W4UO*MU9-':F\#7L)B62
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MW:1@YQ@_44 ='17,^#/$$WB.VU:YEW!(-3EMX5>(QNB*%^5E/.X$G.:RM/\
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MY5-*C66Y9EX$;1^8'7U!&?Q!%37VNVFF^'9-<NA+':1P"=P4^=5(!P5]>>E
M&G165J'B&PTR\-K<M()1937WRID>5$5#?C\PXK.TWQSI.IWEM L5[;K=PM/:
MSW5N8X[A%&YBK'T!SSC(Y&10!TU%<--X]2^U?PY;Z9!>1VVI7I3S[BU*QW$(
MBD;=&Q_V@AYP2#QQ6I#XYTF:[CC5+P6LMQ]EBOS;D6TDN=NT/[L-H.,$\ T
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M +,L;W4Q,DEFV8)'E)AD:)0=HQO&0,#>*]DHH \O!L(-<TC7#H5S:^'DEO0
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MZUZ910!QO@&?^S?"&@Z7<P7,5Q*LZQH86P@1V.&.,+\N,9QGM79444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !6=KNK)H>AW>IR1^8MNF[9NQN.< 9[<D5HUSGCBSM=0\,36=
MYJL.FPS.@,\H!!(.X+U'7'Z4 4-$\::KJ]]:1/X4O;:UN,'[4SDHJD9!^X.#
MQW[UV5>92PW_ (*\5^'K6UUJ]O[347\B6"YDWA0"J[E'8?-D8_N]Z],# D@$
M$CK0!S?C'Q6_A6UM)8['[8]S-Y03S=F#C/H:SX?%GBF2:-'\%3HC, S_ &H'
M:,]?NUG?%M7>QT58WV.UZ K8SM..#6K9>'/%D%];RW/B\SP)(K21?95&]0>5
MSGC(XH T/^$H'_"<#PW]CY\CSOM'F>V<;<?UK5U6^_LS1[V_\OS/LT#S;,XW
M;5)QGMTKB#_R7$?]>']*ZSQ5_P BCK/_ %XS?^@&@#-M_&]F/!$/B:_B-O'+
MN"P(V]F8,RA0>,D[<UC2?$#7K>S&IW'A"XCTLX8R^=\P4_Q$;?\ ZWO7(WZL
MOPN\)7,BEK.&\D,XQD?ZQ\9_ -^=>C>*]1UJ'2EU#0SI<NGB!Y9VNB2&7&1M
MP<'(S^E #-=\=6^E^&=/URSMOMD%[*L:J7V%<AB<\'D%<8J/Q!XTO=*\31:'
M8:(=0N)(!,NV?83][(QM/0+ZUQGBG6+C7?AAHNH720I+)J!!6%=J@#S ,#)]
M*TO$]K?WGQ>L8-,OA8W36/RSF,/M'SYX/J.* .@TOQS<3:_;Z-K.ASZ7<7*D
MP,T@=7QGCH/3WJW9^+C=>(=;TK[%M&F1&3S/-SYG'3&./UKCKJ'4_#GC_0;G
M7KZ/66N6,$#8V- 20NX*./XOY^@JWI'_ "4#QK_U['^0H ['PGXB'BC1%U(6
MOV;,C)Y?F;^G?.!4/B+Q0=!U?1+ 6GG_ -ISF'?YFWR_F09Q@Y^_[=*R/A-_
MR(\?_7Q)_2JOQ"_Y&[P5_P!?I_\ 0XJ ':W\0=9T'?)>>%)([;SC%',UT '/
M./X>X!-7O^$L\0II5]?7'A.2#[*@D"/=<R+_ !8PO8<_2J'QB_Y%*S_Z_P!/
M_0)*]!P"F",@CD&@#F&\<:>O@D>) ,H5P(-WS>;T\O/U[XZ<UKZ%J%UJFC6]
M]=V?V.2==XAW[RJGIDX')'.*\OA\+6W_  M)]!,KG28V^WBU_@W;1\N/3G'T
M&*]AH Q/%?B*+POH;ZC)%YS[UCCBW;=[$],X/;)_"CPIXCB\4:&FHQQ>2^]H
MY(MV[8P/3.!V(/XUPOCS6H[CQSI>GM;7-W::81<W,-M'O9G."!CTQM_[Z--\
M!ZS':>.M2T];:YM+/4R9[:&YCV,K#)QCTQN'_ 10!U&C^/+?4O%]]X?FMOL\
ML$DD<,GF;A,4)!&,#!P,]^]7[3Q,;GQGJ/A_[)M%G LWG^9G?D*<;<<?>]>U
M>9_V!/JNJ>+M1TXLNJ:9J7GVY7JPWR%E^O (^F.]:W@361X@^(.K:GL\MIM.
M3>OHP$:MCVR#0!H:=\1]:U:T:[L/"$US;HQ5GBN<\@ D8V9[BNK\,>)[/Q1I
MS7-LCQ21-LF@D^]&W]1[US'P>('@ZY).!]M?_P! 2H_AX1/XN\775L0;-[KY
M67[K'>YR/\]Z .A\8^*G\*VEI-'8_;&N)O*">;LP<9]#6.?B'>Z=>VT6O^&K
MC3;>X?8+@S;P#[_*/YU6^+GF?V=H_E8\S[:-N[IG'&:6]\)>+/$]Q:1>(]0T
MY-/@E$K1V@;<Q_$>F1G/&>E '7>)M>B\-:#/J<L?FF/"I%NV[V)P!G]?PJOX
M1\3Q>*M'-ZL'V>5)&CEAW[MI'(YP.H([5QGQ'U:.Y\4:3HY@N+JUM&%U=PVZ
M;V;G@8^G_H50>#]<CM?B/?0I:W5G9:QF2.*ZCV,)1STZ8)WC\10!N2>/M5FU
MO4M-TSPR]\;&8QNZ7..Y .-O&<&KFC^.9=3GU'3YM%GM=8LX&F6S>3/FX' #
M8&"<CMWS7'Z7;^(YO&'B]_#M[!;RQW),B2H&\WYGP 2#CO\ G6O\-1%JFK:E
MK.H7DTVOC]S/%)&$\I>!P!U^Z!VQCIW(!+<?$77+74;?3Y_"$B7=P,Q1&[&7
M^GR^U:&I>.-0TC0;;4-0T!K>>>[^S_9WN.0NW._.WZC%4?%'_)5_"_\ N-_-
MJ/B[_P @32_^O]?_ $%J -WQ-XPCT&ZMM/M;*74-4N1F*UB../4G!QT/;L:H
M:9XZNCKL&CZ_HLFEW-S_ *AS)O1SV&<?AWY]*S2ZVOQQ9KLA5GLPML6Z$[0.
M/Q#BNOU'7='L=<L-/NV7[?<Y%N!'O*Y('4#*Y_+@^E &=:^,3<ZSKVG_ &$+
M_9,9DW^;GS<#IC''ZUA6OQ(UJ\TTZE!X0FELER6ECN<@ =?X.U5-+_Y''QY_
MU[/_ "-9_@VS\97O@Y;?1[K38-/E:1-TV[S!DD-V(H ]-\/:]:^)-&AU*U#*
MCY5D?JC#J#7.Z#\1;77/%4VC+:^5'F06]QYN?.*GTQQD GKVJIJ$"_#OX8SV
ML=QYEW+F-9 ,9E?J1]%!/_ :X&>]73-%T&:STK4K>_TN4RS3S0;8Y-QR1G/3
M. ,CH: /6/$GB/6-$N6^Q^'9+^T2'S9+A9P@7KD8P>@&?QK.\/>-]8\02VLD
M?AB1+":38UT+D,J '!.-HSBN@U&\AU#P;>7MNVZ&>PDD0^QC)K%^%O\ R(-E
M_P!=)?\ T,T 6M"\90ZK'K4UU MG!I<I1Y#)NW 9R>@QTZ<UCQ?$#6M1C>\T
M?PG<W6G(2!,TNUG ZX&#^F:Y2VBFE\(>/%A!+"\5B!_=$A+?H#7I7@F[M)O!
M.EO;R)Y<5LJ28/W74?-GTYR: (+3QO9ZCX1O==M(69K-&,MM(VUE8#.">>#Z
MU)X7\7V_B;0IK^*'RIX-PFMR^XJ0,CG'0COCU]*\_P!+9;BP^(EY:_\ 'C+O
M\MA]UN7/'X']15:SAG\'Z;I'B2U5FT_4;7[/?QCG#$'#?U^H/K0!ZCX3\0GQ
M/H2:D;;[-N=D\O?OQ@^N!6Y7$?"C_D18?^N\G\Z[>@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MCGU!YS6M10!F:#H5IX=TM=/L3(8%8L/,;)R>O.*TZ** "BBB@ HHHH ****
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M-S*,9('4@9&3[B@"6BBHGN8(YXH))HUFFSY<;, SXZX'4X[T 2T45%;W,%W
MD]M-'-"_W9(V#*WT(XH EHI"RA@I8!CT&>32T %%(S*B[F8*/4G%+0 4444
M%%-DD2&)Y975(T4LSL<!0.I)["JIU;30CN=0M J+&[-YRX57.$)YX#'IZ]J
M+E%%% !145Q<P6D#3W,T<,*XW22,%49..2?>I: "BBD#*7*!AN !(SR >G\C
M0 M%9U_X@T;2IU@U'5["SF9=ZQW%RD;%<XR Q'&0?RJW:WEM?6ZW%G<0W$#_
M '9(7#J?H1Q0!-114<L\,".\TJ1JB%V9V "J.I.>@'K0!)138Y$EC22-U>-P
M&5E.0P/0@^E,2Y@DGE@2:-IHMIDC5@63/3(ZC.#B@"6BBB@ HHI%977<K!AZ
M@YH 6BBJEKJNGWUU<VMI?VMQ<6K!;B**96:$G. P!RIX/7TH MT444 %%%%
M!1110 4444 %%%% !1110 45%;W,%W")K::.:(D@/&P9202",CT((_"I: "B
MHK>Y@N[=+BVFCFA<922)@RL/4$<&I: "BJRZC8LZHM[;EVE:!5$JY,B@DH.?
MO  DCKQ5F@ HJ*WN8+NW2XMIHYH7&5DC8,K#V(X-%O<P7<(FMIHYHB2H>-@R
MY!((R/0@@^XH EHHJ*:Y@MO+\^:.+S'$:;V"[F/11GJ3Z4 2T444 %%%16]S
M!=P)/;31S0ORLD;!E;Z$<&@"6BBB@ HHI-R[]FX;L9QGG% "T4QY8X\[Y%7"
MECN..!U/T%$,T5S!'/!*DL,BATD1@RLIY!!'4&@!]%%(S*@!9@H) Y..3TH
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M1&1RCQNIRK*RD%6![BLU?!.B?8+RUGBN+HWCH\\]Q<.\S,GW")"=RE>V",4
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M>2WMS'"Q9$9VR$4D#(5<#\#ZUTE !1110 4444 %%%% !1110 4444 %%%%
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M-@E69B?+=-P)V\88$?3F@#>T/4+C4]*BNKJT6UF8L#&DZS(<$@,KC[RD#(.
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M,\;OOP4W@J0>A#>OK6E8^$)K>ZT6ZN-3\^?3YKB:0BW"+*94*X4 _(JYX'/
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MW6)V5'V22I%LP5#!NK D G%6_P#A"_\ BG1I/]H=-6_M+S?)_P"GKS]F-W_
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MAA1MH7+9Y56 & #DUK)X7U5? 5KI?V91>)K0NV3S%_U?VXS;LYQ]SG'7MUH
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M0O!+'*H."R,&&?PJ&X%C!<QW=Q]GCG"F))I-H8*2"5#'G!(''L*X'X>W%O\
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M&IC^3]UYF3!YFX@E@H8@XP!0![='(DL:R1NKHPR&4Y!_&FO<0QRI$\L:R/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FR2)%&T
MDC*B("S,QP !U)IU<YXTTN34M"N&^W306\%O+))#%QYQ"Y4,?0$=.^:NG%2F
MHMV(J2<8.25S?@N(;J!)[>5)87&5=&!5A[$5)6!X)_Y$O2O^N _F:WZ*D>2;
MCV84Y<\%+N@HHHJ"PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"]M4OK
M"XM)&94GB:)BO4!@1Q^=3T4T[.Z$U=693TG38](TJVT^%W>.!-BL^,D>^*N4
M442;D[L(I15D%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exhibit101-arrowheadindu002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101-arrowheadindu002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M1HT@>5?MHWA5+<8[U1\5^&?^$5U.S\3>';!"D+A;FT5-PQG[RCG'ID=.#ZT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$R74LHQD'H[$=AS0!JT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(.<8ZXK2T;7+;6X[@PQ7$$UM+Y,]O<Q[)(VP& (Z$$$$$$@YKS:XO---G?\
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MTO3IK>XPW1V2$#'J,HU $J^.]+FM+&:TM[^[FO1*8[2&W)F7RFVR;E)&W:Q
M.3U/&:W-,U*WU?38+^U\SR9ERHD0HPP<$%3R"""*\^F\':BNGV\5SHMMJ*1W
MU]./)O&M[F'S9R\;QR@CC:?F7CG'7&*[#PMI^IV/AB"SUJZ:XO!YFYVE,C*A
M8E5+D L54@%L<D4 5+;QWI%S=0(D=ZMI<S_9[>_>W(MYI,D!5?W((!( )Z$U
M4\&:[J?B#6==GNFN8;2VNGMH+62U5%4+CDORQ?KD=!D5EVWAKQ$WAW2?"-Q9
MVL=C87$!?4EN,^;##('7;'C(=MJ@YX')R:ZCPQI5UI7]L_:@H^UZI/=1;6SE
M&VXSZ'B@"MJ/CK2],FNQ+;ZA):V<@BN[R*V+0P-QD,W4XW#) ..]9.J>*M4M
M=:U.UBDC$5OK.F6<8,8.(Y_+\P?4[CSVK&\3^#O$NNVWB"TEMFO)[J60V5U+
MJCI;Q0G!1! .-X'&2,9YS6SJ/A75;O5]1NDCB"7&KZ9>(#(,^7!Y?F9]_E.!
MWH [/4M0M])TN[U&Z;;;VL+32-Z*HR?Y5R'A/Q5JCV6IQ^)HPNH6EO'J(C@C
MP3;R1[@H'=E970^I ]:UO&>BW7B/3+71XL"RN+J/^T&\S:WV=3N95QSEB%7C
ML36:W@MM)\4Z5K.C274^-]KJ"7M]+,7MW&1@R,WW7"G ZY- &U#XMTB?5M-T
MR.X+7.HVGVVV&WAHL9!SV)&2/H:I#QWILT-L]C9ZE?O/ ;E8[6V+,(MQ4.<D
M  E3@9R1VKBW^'7B&#1KO['-;KJEK=+!I4A?[EDJR1J">Q"SR''JHK=U3PQJ
ML>IV]K;6LU]H<%A%;6EM'J;VB0R)D$RA,%P1M]<8/'- &M-X_P!&6+3'MH[Z
M];4X&N+6.TM6D=D4@-D=L;N<^A[UFZ]\08H[>(:3%=G?J<%DMZUJ3;R$SJDB
MJWJ!O&>F1P2:C\'^$M5T6Y\.O>I"!I^EW-I,4?/SO-&RX]BJFJA\-^)8/#]I
MX7AL+62SM-2BG%^;D#? MR)<;,9#XX/;@X/.* .G_P"$TTXZFUHMO?O$EU]B
M:\6V)@6;.W86Z_>.,XP#WKHZ\WOO"NMOXCFN]/L(M/NY+Y9O[4LKYXXI(-X)
M$MODAW*@J>,$\Y'2NWTW4)[V[U*&:T\E+2Y\F*0/N$R[%;=T&.6(QSTZT 9L
M_C33H=1FM?L]_)%!<+:SW<5L6ABE;&%9AS_$N2 0,\FK$WBK3(-,UG4':7R-
M'D>.Z(3D%45SM'?AA7):WX5UNYUZ\NM,L(K*^FN$>'5[*^>%?+&W(GAR1(P
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MSA*@P NX%5ZOGVZ=:XGQ3I7]D^,-*O(-NG:/%820QR0Z;]ICAF+*3E /E+*
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ME4M',[H$< 9)!Z$8!/TKS2_MRNK:-J]K97.BZ&HO!$7T]K@12O(I$IA(S&)
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MX1DMCK@ YQ7,ZU8#7!X@N]/TZ<Z/>W>E1A#;,@N'2X'FR!" =NTJ"V.=I]*
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MHUN[Q<.X>0HF#)L 4E1UP,\4 >@6VOZ->VTEQ:ZO83P1,%DEBN494). "0<
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MDA79M4@P0Y*^Q;=T[YKJJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MG&6^4,<D;OI72>#I-6M_$.IZ;>&5+1((IH[>ZU!;N>%R6!RV2VQ@ 1N/4'%
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MM)M+6X<%3)%$ 0"<D#T&>PXKC]$\=:A=^)=&L)K[2[^'4_,5Q8VDRK;.L;2
M"9F*2CY2. #WZ4:3XO\ $UQIWA[6KY=+^PZM=I:-:PQ2"2/<6"R!RY!Y7[NW
MH>M '?V=G;:?:I:VD"00)G;'&,*,DD\?4DU2B\.:+!?O?0Z9:I=23_:6E6,!
MC+M9=_\ O89AGW-<Y9>,-0NH=-L#!;#6Y=5DL+N,*VR-(LM)(!G.#'L(R>LB
M]:E\>OJBW/AA=.O(K<2:ND;B2)G#'RW(SAURO!R.YVG(QR ='/HNEW<=['<6
M%M,E\0;I7C#"8@ #=GK@ #\!2:5H>EZ'%)%I=C!:K(VZ3RUP7/3)/4_C7G%G
MJ^OZ#I_B;6+5M/;3;37KCS+>6)S+,IE4,0X8!,9X&ULXJ_XL\=ZEH=QJSV]]
MI&-.&Y=/%O+<33*%#$NZ,!#GG&5., G@T >@6]C:VL]S/!;QQRW+B2=U7!D8
M *"3WX 'X56N- TB[2^2XTZVE6_*&[5XP1,5QMW>N,#\JYS0I]3N/B9X@,EW
M$UB+*S9(/*;<H;S2,'?@'AL\<Y'3'+_%7B2]TS5XK&VU/2[$-;^://MY+N:5
MMQ&U8HV#!>/O<Y)P!Q0!TXTZR746U 6L(O&B$#3A!O,8.0N?3)SBLVV\&^&[
M.=9[;1+&*5)!(C+$,HP.05_N\\\8KEK#QEXB\0#PY#I<6FVTVIZ=->7#W,<C
MK&8W12% 8$@ENAY&>O&#2/Q,OY#-J%N+>2SCO&@73EL+AIY(EDV,XF'R!N"P
M7!&."<T >B'1M,;39M-:PMVLIB[26[1@HY9BS$CIRQ)^M1:7X>T?1&=],TZW
MM7D4*[1)AG )(R>IY)Z^M5O%6M7&BZ9 UE%%)>WEW%9VXF)\L/(V-S8YP!DX
M'7&*Q]1UKQ1H<"VUVFF7=W>WD-II]U&CQ1EG#%C)'N8C8%)X;YL@<4 ;]_X9
MT/5+]+Z^TJUN+E5"B22,$E0<@'U /8U/9Z-INGO"]I8P0-#";>(QH!LC)W;!
MZ#(SBN*UGQAX@\.)J=C=QZ=>ZC;PVUS:S11O%'*DMP(65U+,58$\$$CD''!%
M3W?B'Q5I=UJ^GS+IE]>V^F#4K8P0/&K .0\14NQ)P/E8$<GD4 =-=>&-#O;&
M.RN-*M9+:.1I8XS&,([$EF'H22<XZY-7-/TRQTFU^RZ=:0VMON+>5"@503U.
M!7':O\0OLD5_J%A#'=:;9:7%=LW.YYIV A0$=!MY;@GYEJG:>.]4CENH9GM=
M0_XE\]TD]OI]Q;I!+&N[RW\PG<IYP00?E/'(H [-?#FBI?37JZ9:BYFF2XDD
M$8RTB9VN?]H9//O5B72=.G:[::RMY#>(L=SOC#><JY #9Z@9/YUYXM]XMO\
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M')PNT],&LX>)M6\.?\)7=W%Q;W3/KL=E:HT,F(W>.+#'#,2BJ<[5&20<'YL
M ]%M]&TVT>W>WL8(FMA(L)1 /+$AW/CTW$ FL?Q#X7_M"Q6WT^+3%C:Y:YN+
M6]M1+#<LV<EL?,K9.X,._7.:YQ?B'?VEIJJRI#J4EO#$]K=16<UI$\DDHB$;
MK)D@AF4Y!.0>Q%7-/CUN+XJVJZS/97#?V).8Y;2%HA_KH<J59FZ<<YYST&*
M-OPAX9'AFSO%8VWGWEQ]HD2TA\J&/Y5141<G@*@Y/4Y-3W/@[PY>7<]U<Z)8
MS37&?-9X0=Y(P21TSCC/6L#Q5K\FA:[J]U;6=J]S9^'9+N.:16+$K(<(<$?+
MD9]?>KFG:UK\'B?3]-UDZ?)#J=G+<Q?98G1K=HRF48LQWC$@^;"\CI0!T8TN
MQ7[7BTB_TM0MQ\O^M 7: WK\O'TK&N?#4EYXATF>5K1-(T@>9:6T<)\P2["@
M);. J@G  ZX]*Z2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y;QOHEYKD6APV;3Q
MF#58IY9H'57A14D&\;N#@E>,'.>A%=365KNNPZ%;0.]O/=7%U.MO;6T &^:0
M@G R0 , DDD  &@#,'@>SDM[C[9?WMW=W-U;W4]W(4#N8'#1IA5"A 1T [GG
M)S5G5/"XO=6;5++5;[2[V2$6\\EIY9$T8)*A@ZL,C<V&&",FJC^-E@MPEQHN
MI1:H]T+2+3RJ%Y9"F_*ONV%-N26W<8.>>*CF\?VEI8W4EYIE_!>VES!;3V.U
M'E#3$"-E(;:RG/!![$4 37_@'1=0\+6?AUQ/'96KB1&23]X3SORQ!SO#.&]=
MQJYJGA6QU:_>[FEN8W:P>PQ!)LVHSJVX$#(8%!CG'M69+X^@LK/5Y=4TF_L;
MC2XHIYK9S&[/'(Q564HQ!Y!R,\8J1?'5M;S7L6LZ;>Z2;6R-^/M.QO,@!P2-
MC-A@2!M//(H 9-X!M[^*_P#[5U?4+^XO+%M/^T2")&BA8Y(4(@&20#D@]*FO
M_!,-U=7TEMJ^HV$.H@"^M[9H]LY"A=V64E&*@ E2,@>O-.M?&4?VM+?5M+O=
M',MO)<P-=F,B2- "_P!QFVL 02I[?0U63QM<7%GY\7AS5(H[FUDN+&601[9@
MJ[@&P_[LD<C?C/UXH U]/\-V&F:A<W=IOC$UI!9^2"-D<<._9MXST<]2>@J7
M2=#M-)\.6NAQ[YK2WMQ;#SL$N@&/FP .1[5R6@^-2]AI6HZY+=6K-X>.HW"E
M8S$X4QYE&TD@G=POH>0#6S9^,A)>6]MJ&C:AIC7D3S69N?+(F"+N9?D8[7V\
M[6QP#Z&@!EAX'M[.?3Q-JNHWEEIC;[&RN&0QP$ JIR%#/M!(7<3BMG1='@T*
MP:SMGD>-IYIR9""=TDC2,. .,L<>U8.D>/H=4ETAFT;4;2RU<8LKN?R]KOL+
M[2JL67(5L$C!Q]*W;S68+'6=-TV:.3=?B7RI1C8&10Q4\YR5R1_NF@#*3P19
MI>23?;[UHFU1=52W)39',-V[!VYVL6R02>@QCFIM0\'6&I7.HSRSW*M?R6DD
MH1EPIMWWICCN>OZ8JA9?$'2]6T6TOK2*ZQ>7;V<2;5W@JC.7QG&W8N[Z$>M9
M%CXPU2XN]+MK:&[FLKCPXU_]JF\D2%\)B1P#VS@@#JW0@9 !O3^"(;FY99M7
MU*336NQ>G3G9&C\T.'&&*[PNX9VAL?AQ6OK6BV^NVMO;W,DJ+!=0W2F,@$M&
MX=0<@\9'-<OX2\;7%[IWAJ#5=,OXI-4M4$5_+Y>RXF6+>_RJVY<[6() SBM+
MQ9KVI:-JGAVWL+*2XCO[\PS[#&,J(G;:-S#!RN<^BD=2,@'2RQB6%XV) =2I
MQ[UR=KX!@TYK4Z9K.I6)BL(M/E:(Q$S11YV9+(=K?,>5QUK+T'QW=PV#2:KI
MU_-:C5I[)M2 C$:$W+1QC;N#%1E%+!>OKS6Q>^.H+26_ECTJ_N=,TV4Q7NH1
M;/+A88WX4L&8+GYB <<]<&@"?1?!>GZ%)I;VT]T_]FVT]K")6!RDKJYW<<D%
M0 ?3KFM/1]'@T6WN8;=Y'6XNIKMC(02&E<NP& .,GBIM0U&+3]+FU QS7$<4
M?F!+:,R/)Z!0.I-8">.(;:YN[?6],N])>WL7U#]^\<@:%" Q!C9OF!(X]^,T
M -?P%:&2YDBU/4(9'OVU&V=#'FTF;=O*97E6W$%6W#'I6IHGA^+1I+RY:[N+
MV^O75[FZN"N]]HPH 4!54#. !W-9J^-X[>WGN=7T74M+MTM&O$EG5'#QKC(^
M1FVOR/E."<_6DC\;[+]++4-"U&PGDLYKV,3>6P:., D95CAOF'RGI0!)JG@B
MSU2\U:>2_O8HM4BBCN8(RFPM&1M<94D' QUQ@],U=U+PQIVKZE+>7H>42Z?+
MI\D)(V-%(RLW;.?E'.:9'XHM)8_#SB&<#75W09 _=_N3+\W/HN.,\UA:7XY5
M]*T:"SL]1UB]N[#[;AVABE,>=NYLLJEB>R^G:@#9TOPJ^GW]M=7.N:IJ(M(V
MBMHKET"Q@@ D[%4NV!C+9_/FI]9\.IJE]:ZA;W]UIVHVR/''<VVPDQMC<C*Z
MLK#*@\C@CBN<\0^,+BSM=4O-/COQ=1>'_P"T(K2>)$6(EF&YPQ#;EQROHO&3
M5A/&$5C/-=:L;ZW\G1X;N6U98W4%I'4%=A)+L0!C./N]\T 6E\"VUL+2;3]4
MU"SU&W656OD9'DG$C;W\P.I5LM\W08/3'2K&G>#-.TRYTZYAFNGGLFN)#)*X
M9IY)\>8\AQR>.V!^%5I/'*6270U?1K_39HK&6_BBF,;>?%&,N%*,0'&1E21U
M%3:5XQ74-5L[&?2+^P%_ UQ92W'EE9U7!/"L2IPP.& X]^* $N_!%G<6TT<5
M_>VTSZH=52>(H6BFQMX#*05QG@@]:DN/!FGW.A:II+SW(AU&[:]>0,H>.4N'
M!7C& R@@$'WS4FM^)_[(U:QTJ#2[S4+Z]BEEACMRBC$97=N9V 7[_7V]<5F6
M'Q"@OSI\O]BZE!8WMS]B%U*(PJ7&2"A4,6P&4KN QD4 32>!(;NYN[K4=9U*
M]NKK3IM-DDD,2@128SM54 !!&0<=^<\8A\;:+/J?A>U\-6-E<S&9HHUO%=%%
MF(V0^8Q)!S@'&T')&.,U/>>-OL,QEGT+4DTM;M;-K]Q&J[RXC#!"V\IN(&['
MN,CFK$WC*R@TS5;M[>X$FFWGV)[;"^9)(2H0*,X(?>A'UH NR:7/#/HL>G3F
MVL;$E98%;"R1"(JJXQSAMIZCIWJ/7/#J:S=Z?>QWUS8WU@SM!<0!&(#KM8%7
M5E((QVSQ4^N:W;Z#IZW4\4TSR2I!#!  9)I7.%1<D#)]20  363)XV6TMIOM
M^BZE;7Z3QVT5D51FN'D!*"-PVPC ;)W#;M.<=P!G_" :>VBZSIDU_J$RZM.M
MS//)(OFK* F'4A0 <HIZ8!Z #BK5IX+TJR\0V6LPB59[/3UT^*/</+V+]UB,
M?> )7/H35*X\?VNGV=^^I:5?VEY8M );,A'=EFD"(Z%6*LN<]#G((QTJGK?C
MN]M=!\0B/1KRQUC3K#[9'#<-$X,;;@),JY4A2IRN<\<9H L0_#JUAM+*Q_MK
M5&T_3[I+JSM<Q!8F1]X!(3<XSD?,3P?7!&HWA#39-%U/2I6G>WU&ZDNY#O 9
M)'??E"!QM8 CZ=ZKMXHOXX;:.+PWJ5U=M:K<3JK1(L0.0 7+A68X)VJ3QUQ5
M!_'6GM]GUB*2^:S;0KC5/LP1 &2-H\YR<B09P!G;R?:@"TO@2*:ZN;O4-;U6
M^N;BR:Q,KR)&4C+!@5\M5PP*YSWSSGBKVD^&!I^KMJUYJEYJ=_\ 9_LJ2W(C
M79%NW%0(U4$D@$DY/%0:7XP74-7M;"XTB_L#>P-<64MQY9$Z+MW<*Q*G#*<,
M!P?7BF:YKVI:?XU\.Z5;64DMI?"8SNIC'W0/[S @+G<<#GC&>10!9U3PN+W5
MCJEEJM]I=[)"+>:2U\LB:,$E0P=6&06.&&",FBP\(:;ID^CR6AF0:5#-#"I?
M=O\ -*EV<D9+$KG/')-4K;QY;7#6MS_9=]'H]W<"VM]3;9Y<CEMJG:&WA6;@
M,1W'0&JL_P 1[>"'4;LZ)JC6%A=&SENE6,AIA,L6U5W;FY8'..G'7B@#:UGP
MVNJZG9:G!J-UI]_9I)%'-;B-LH^W<I5U8?P@YQGBJ=AX%L-/:W9;R^F>#4WU
M0/-(K,TSQF-MQV]#N)^OMQ5.3Q_-%-?6K>%M6^VV,0N9X \!VP$$A]WF;23M
M8;02<@U8G\=P-<10Z7I5[J;-8QZ@ZP&-66&3)7"NP+L0IX7/ZB@#;L='@T_5
M-4U")Y&EU&2.256(VJ4C5!MX]%'7/-8%_P##^VOH]7M1K&IV^G:M(\UU9PF,
M*9& #$,4+@' .,X_#(KII;^.'2GU%HI_*6$S&,1,9,8SC9UW>W7/%8-KXR+:
ME%8ZCHE_ILEQ;27-L9VB;S%0 L"$<E6 8'!_.@ O?!45Q<3S6NL:C8&[@2"]
M%L8\7"JNT$[D.UMO&Y<<?053UKP*C:?J7]BWU]8FYLO(EM+9TV7&R/8F2ZDJ
M< *2I!( ^M2Z1X]BU2;2"^C:C9V>KK_H5U/Y>V1MA?:0K%ER%;!(P<5F:GXZ
MNKQ-&FTO3[^#3[W5[>WCU!A&8YXS)M8;=Q958 X) S[9&0"]8^"6>QTZX.HZ
MAIEX=+M[&^BMFCQ*J+]TDJV""S#<I!P>M3K\/M+73!8"YO/*&C-HP.Y<^2V,
MM]W[_'7I[5LZ[KL.A6L$DD$US/<SK;VUM !OFD;)"C) ' )))  !K)D\;+;V
M^RYT74HM3:Z%I%IY5"\TA7>"CAMA7:"2V[C!SS0!=U3PQ#J#Z?<07UU8WVGH
MT=O=V^PML8 ,K!E*LIV@X(Z@$8JHW@F#[);!-5U%=2M[A[I-2,BM-YCC#Y!7
M9M(P-NW' QTS4$WQ M;.VN/MFEZA#?V]U!:RV("/)NF.(V4AMK*W."#U!'%/
M'CNVM[?53JFF7UA=::(3):OLD>02DK%L*,0Q9@5QG@]: -/P]X=A\/)?>7>7
M=W+?7)NIY;IE+&0HJG&T  ?(.,<=N,"LZZ\#6US<W834]0@TZ^G^TW>GQ,@B
MFDX).2N]0Q W!6&>?4UA7_B[4EUG6([RVU'2(+3P]+>-#^Y=PP?B2-@64D#(
MP3C(Y'>DU+QEJ$%UXD@FBOH=.L-*MKF.[@$)D0OOR^">2V  ,8&TYQD9 -R[
M\!6ET][ -3U"'2KZ<SW>FQLGE2NQRWS%=ZJQY8!@#D^IJW=^#["\M/$-L\UP
MJ:Z +C85'EXB6+Y...%'7/-5]0\;):7.H+;:/J%_:Z8<7]U;^7MA.T,0 S!G
M*J02%!QGUXJ.Z\=1+>W%KIFCW^JFWM8KR22V,:IY,@)4@NPR2%.!U- #/&GA
M5M4T?5KFR66;4I-&GTZ"$,H5P^&[]\J.^*DM_ UO*A.K:EJ&I?Z%)91+<N@\
MB*10'"E%&6( &YLG Z]<I+X\MY9+./2M,O-3DN;!-2"0M&C"!\[3AV&YC@_*
M,].<<5NW&HR?V!)J5M:SM)]F\Z.WD7RY,[<A2&(VGU!(H Q++P.EM?:/=W.M
MZG>/I!(LTE\I453&8R"$0;OE/4\\#ISFU!X.L+?1-'TI9[DP:5<I<PL67<S(
M20&XQCYCTQ7(Z-XVU^ZN_#3RZ9>7<FH:&UP]I"85$D@:+]]N+ *N"V 2#\P&
M,UU$/C);W2;&\T[1M1NY[N26(6JJBM"\9*R"1BP1<%2.O/;- %30-#DF\=:Q
MXHN=.GL?-C2UMXIV4LY&!)+A20-P2)1SDA.>M;?B#0(]?MK6-KNYLYK2Y6Z@
MGM]NY'4$=&!!&&(P1WKE]3\>WKV6F3:7I-T)WUD:=>V[F+>C*"60$OM);C#
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M&WVK,YSNCV2891VCR1ZUJ_V#XBU?4M-N=<?38DTQ)3$+.1W-Q*\9CWMN4;%
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MBBO;&[CO+<S F-G3/RMCG!!89'3.:QK_ $'Q1K CO[N[T^"]L[R*ZL+.,M)
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M)!%M8*1AE!C.0<=JS_"_@V_TGQ&FIO::7I42V[Q3V^E2R&.[=BN'9"JJF,'
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M4 %%%% !7*^.;,W5A82"UU*0V]V)1<:8X^T6IV,OF*A!WCG:5QT8G!Q7544
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M$6EP5>)I//5!Y2X(&TG/#'.0,= :M444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/^><><>K&DN?"_B(:!JOA.V@LFTW4+B=EU!YR&AAFD+N#'M^9QN8 @X/!.*
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M1\:Z'ITNC*U_:R1ZM,8H)EN$V8"L=V<\C("\=V K0_M_1_[6_LG^U;'^T?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJT\AU$QV%K:74LR-;G!\B54>0/GD Y7 '/7M5NS\8Z;<"Z-S%>Z=]FMC=O\
M;K<Q PCJX/3 [CJ/2@#H**P=*\7:?JM]%9B"^M)IXC-;"\MFB^T(,9*9ZXR#
M@X.#G%3ZQXBL]&GM[5XKJZO+D,T5K:1&21E7&YL= HR.21U H UZ*P(O&.CR
MQ:=*)I$BOYGMHWDC*".9<YCDS]Q\@C!ZD56;Q]H_E6#PQWUP=1:9;)8+8LUP
M(R S*/[O.03@$ GI0!U%%<O-X]T6'3;:\(O'-Q=-9K;);,9A.H),93J&^7]1
MV.:6Y\=Z7;-(&MM2801)+>-'9NPLPRA@)<?=8*<D#) ZT =/17-WWC?2;&YF
MB$=[=1V\:27-Q:V[2QP*XW*6(]5^;C/'-+J'C72].OKBV>*^F6TV?:Y[>V:2
M.WW %=Y'L0> < Y- '1T5R4/BP6_BG5K#4'Q;)>VMG:,B='EA#X8^[9 /J0*
MZ"UU6UO-3OK"$LTUB8Q.=ORAG7<!GN<8)^H]: +M%<O=^/=(LKO4('BOW73I
M E[/%:LT=OE0VYF';!SQG&"3@5-<>-=)M]:ETO%U)+ BRW$T4!:&"-EW!W<<
M*N >?8^E '145S5EXXTN^GAB6WU"'[3$TMFT]JT8NU5=Q\O/4XY ."1SBK:>
M*-,GL](N()G==7'^B;4R2-A<DCL  <^AXH VJ*Y"Q\;V2Z3I6][S5+NZLENV
M-G9-N\KIYK("=@)S@9).#C.*@T#QU'/X5T>\OEGO-1U$2M%;V4!9Y%1R"VWL
M -N2<<D=S0!VU%<XWC;2396EQ;K=W,MU+)#':0V[&??'GS%9#C:5QSG';U%:
MVDZK;:SIZ7MJ)51F9&2:,QNC*2K*RGD$$$4 7:*Y"U\;V-MI^GBXFNM0NK^6
MZ6W%M9$-+Y,I5E" G&T8&2<$*3Q6]HFMV>OZ?]LL_-"K(\,D<T922*13AE93
MT(- &C17,S>.M)ANF1H;\VJW0M'OEMF-NLN[9M+_ .\=N<8SWIU_XXTC3KRY
M@E6\DBLW6.[NXK=F@MF.#AW'L03C.,\XH Z2BN;N?'&D6U]-;LMXT$$XMI[U
M+=C;PRD@;&?UR0"1D GDBFW'CO1[:[GC=;PVMO/]FGOUMV-M%+G&UG]B0">@
M/4B@#IJ*YN7QOI$.K7VGNMV#I^XWEQ]G;R+<"/S,N_097I[C'I68OCI;OQ5I
M%G%#=V=E/:W-S/\ ;;4Q%D14*.I/;ELCKTR!Q0!V]%<YIOC73=2U"SM%M]0M
M_MRL]G+<VK1QW "[CM)_V?FP<<5!IWQ!T74Y;$01WZV]])Y-O=RVK+"\O/R!
MCWX(],@C.: .JHKF_P#A.-(_M#[.%O#!]J^QF^%NWV<3[MNS?Z[OESTSQFDB
M\<Z1+>)$JWGV:2X^RQWYMV%L\N=NT/\ [PV@]"> : .EHJC?ZK:Z;<6$-R64
MWT_V>%@N1OVLP!/;(4X]ZS(_&NBS6]]-%.[BRU :;*JH=QG+*@51W&6'/L?2
M@#H:*X6V\;3_ -L:%IZ++?Q:A<WD<EREH4V^5(R!0,X^4C#'T&>,TWPK\0H;
M_3=-&J17:W%W</:B[%HRVYEWL%0-TR0 ,],\9S0!WE%<YXQ\23>&M/LKB"TD
MN6N+Z"V8)&7PKN W (^;!('OBL:'XA166I>(8]4@O6MM/O%7S8+-F6VA,4;9
MD8?[3/GJ0!TQ0!WE%<_J?C#3=-O)+40WMY)!$LUQ]BMVF$$9SAG(]0"0!DX&
M<5=OM9AA\-3:S9@W<(MC<0^4-WF+MR"/8\4 :=%>=V/Q!NI;WP^UQ8W;)J.C
M-=-:V]HS2-,&CY4=DPS$$G&,<YQ6[#XKLM1N-$N+.]=+:]%R3 ]L=SF(?,I)
M(*%2#D8.>E '3T5R-K\1M&O+"*\M[;4WCN&1+0?8W#7;,"<1 _>VA6W'H,=>
ME3>$O$<WB&_\0;ED2"SO4@ACEA,<B#R8V8,#SD.6_IQ0!U%%<[<>--,MM1FM
M3#?21V\ZVT]U%;,T,,K;<*S#_>7) (&>2*;>^.-(L;NYBD6\>"SD$5W>16[-
M!;N<<.X],C.,[<\XH Z2BN8U+QWI.F7U_:/!J%P^GA7O&MK5I%@1D#AV(XQ@
M_7@\<5"/&D?_  F4VF-$RZ9'I:7_ -M,9V8.XEBV<!-J]<=<CM0!UM%<Y8^-
MM+OIDC,-];>="T]LUU;-$MRBC)*$]>.<'!QSBH]*\>:1J]U80P17\::BI:SN
M)[5DBG(7<55CW !/H<'&: .GHKF[7QQI%W?001K>>1<3FV@O6MV%O-*,_*K]
M^5(!Z$C@FDM?'.D7EW!%&MX+:YF-O;WSV["WFDR1M5^^2" >AQP30!TM%9NL
MZY9Z%:QS79E9II1#!##&9))I#DA54=3@$^P!)KEO$OCX0>%+^ZTF&[CU."XA
MM9(9[4^9;-(R@,Z'J"IRIR03@4 =W1532O/.E6IN9I9IFB5G>6(1.21GYE'"
MGVJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7*^.XVCL-*U3&8=+U2"[G]HOF1V^BB0L?93755C
M>(O$&F:#;VHU-D$=[<):A790/GX);<?N@=: ,KQ!'XAGDU*RCT>QU?3;R$);
M>9*L8@8KM82 @[ES\P*Y/;'>J5SI4T!\"^&S.;FXL)$NKB?_ *9P0E"Q_P!Y
MW0#ZGTK:TOQ7I5Q<W=C)-:V,EK>M8PPR3JIFVJARB\?W@,#/2KJW]M%J&IRW
M4=K:I:+&C7;SIED(W?-W0 L<!NN<CK0 S7]:M-+T^X1]1LK:^>!S;)<W"1;W
MP=OWB.,XYKB)3HJ?#'3?"T.OZ,7$=K!=DW\6-@=#.>O.0'^N:]"@FTW6(%NK
M>2TO83D++&RR+^!&17-7FLS/KE]I>A^%[?47T\(+J26=(%5G7<%7*DL=I![#
MGK0!B^(]7L[SQ'')'K%A>:5]D$<4$.OK:+%/N.7DV,"ZE2H&,XP?EYJAX333
M=,F\-?VAKFB*NFV]Y-,5U&-LW4\@Z?-D@*7Y]Z[JQU31+CP_!K%Y;0:9#)D.
MM^J1&-P2I5B>,Y!^O45>D;18K#[?(VGI9[0WVAB@CP>AW=,4 >;2W%@-'FCN
MKOP_J45_JES>7UF=3B23:S?N6BDW !E54[CV(Q4NF7,+?\(_%JGB72Y+6RU&
M>]*S:K'++%&(V6"-GS\Y!<DGGH.3UKL;_7_#5A)I*LUC(FJ3F&WEC,93A68L
M3GI\N,C/) [U9@O-+72FO]2@TZPB662,M)-$4&URH._IDXSCJ,X/(H \OL=.
MTE -(NK[29;<WLDMQ?2>(G\J:%I"_%NLH_>$$ Y&T')YZ5O-?V\/ASQ*UCXD
MT>#6=2OI+B-UU&('RPRHBA\G:3$@ /\ "6KNS)H:VL=T7TX6TH)CF)38X ).
M#T/ )^@-/LQH^HVPN+$6-U 3@2P;'4GZCB@#RC-JVIWFHVU_IEJ5T:XMK-+K
MQ MS+]ID*C<[,Y"C [$]_7 NQWZ3V6C63ZEH-I#X?@+0%-4B;[7<+"T46T9^
M1/F+'=SG QWKJ+_7UBO=0CTSPLVIV^F,$O)8=@;?M#%(DQF1@K D<=<#)K6:
MZL#KUMI,&G0R226YNIF*!?)CSA<C&<LV0!Q]UCVP0#S1[*SBT2XLK;7]$#IX
M=ATB!O[1BY=V)N'Z\<;3[XK:2_T*'6/%)NM7T==*O-.BMK>9=0B8K%'&RE-@
M.<Y=S[\5V]M=>'KR\DL[6?3)[J/.^&)XV=<=<J.161-JNB/H.HWNHZ1;>9I=
MPT4UJ8ED/G CRPN1R7#(5/'WQTH P/AW>._AEM46XL-3\3W5G%BR2\0&.&-0
MJ1D\E>I9N/O.17I8S@9&#Z5RE]KMWI<TJV?A9IGM;1;B]D218D0$$E(V*CS&
M&T^@Z9(SBM&'Q+;S7&B[8V^QZQ!YMK<$XR^P.$*]B4W,.?X2/3(!A^(M(U0^
M-[;6;30;75[9=-:U:*>=(]CF0-N&X'L,?C1?6.N:SX;N=%7P[9Z/'>R"&=UG
MCE586'[QPH49? "CW(/:NWJB=:TH7D=F=3L_M4A*I#YZ[V()! 7.2001^% '
M%1>%M<TW2M+M+:"WN/\ A'M1\ZP!D"?:[8HZ[6X^611(1DC!*@]SA-=T#Q%X
MCDL]5O=/B7[#=EX=,CO6BE:%H]C9F0@!]QR #C P3S7<3ZMIMK>Q65QJ%I#=
M2_ZN"295=_HI.35R@#R75-&OM&TN.]CTB"UN[K7K P6\U]+<.X1@%\V5F8 D
MDXVC &.M:NL^&==\26_B*_FLX;*[N].BL;.T:<.2$=I"SL. 26P,9P!SUK;T
M7Q98>)=?U#26L<"R?S+::7#+<!)&C9TXXVR*1^(/>NB6_LVC@D6[@*3MMA82
M#$AYX4]SP>GI0!EZVFN:CX.N4TT#3]9F@^16E!\M^,J' (SC(#8X/-<?9>$]
M8_X2)=2CTL01'3+FT9=4U%[UGE?85\P%C^[.TC"GUX'%=_=:OIEE#)-=ZC:0
M11OY;O+.JJKXSM))X."#BA]7TR.SCO'U&T6UD!9)FG4(P ))#9P> 3^% '&^
M$?#VKZ7KL,L=E-I&EI;.EQ9-J)N8I)25VF)23Y:C#=QG(&*U?$&E:G/XJTO4
MK*U2X@2SNK.?,H0Q^:8R' /W@-AR.O-7M<\5Z5HNDW-XUY:2RQV;W<-L+A0\
MZJI;Y/4$#J :TX[V(Z='>S.D,31"1FD8 (",\DT <C:^&-2BT#P)9ND8ET>2
M%KP!Q\H6VDC.#W^9A7/Z3X OK"'3]'ET=9X[2Z1FU";5IS"\2/N5A '&).!Q
MC:#SR.*]%;Q#HB1SR-K&GA+=PDS&Y3$3'H&.>#[&IKK5M-L+1+N\U"TM[:3&
MR::941L\C!)P: ,;QCH=UXEM]/TE<KILMVLFH.LI1O*3+!5QSEG"<CH :Q-2
M\ 21:PD^E7-Y)!?V5QINI-=WLD[K$ZGRW4R,3\KYX!_B-=Q%?6<YA$-U!(9D
M,D6R0'>HQEEQU'(Y'K4D4\4QD$4J2&-MCA6!VMUP?0\CCWH X6STSQ-<ZCX3
MBOM*M;:WT61OM%PET'\T_9WB5HUQD*2P)!P>1Z9I=/\ "FIV_ASPC921Q";3
M-2^TW(#C 3$W(/<_.M;WAWQ;IWB"SMW6>W@O)O,(LC.K2@*[+G;UQ\N>E:;Z
MMIT>H+I[ZA:K>N,K;-,HD8>RYS0!Q]SX5U276+JY6./RY/$=MJ*G>,^2D"(Q
M^N5/%(_A35#X%NM)$<?VN363>*-XQY?VT39SZ[.WX5U/B+7K/PSHEQJM\3Y,
M./E! +$G  R14W]LZ7YL,7]I6?F3X\E?/7,F1D;1GG(Y&* .(O?"6H-:7B3Z
M/;:E#+K<][Y(N3#.L;KA'BD!&QP>H)Y&>121>'O$\&E:1-*CWL]AK1O(K6XO
M0\L=L8GC"&4CYF!?//;C)Q7<6NLZ7?74EK::E9W%Q%_K(H9U=T^H!R*(=:TJ
MYNUM(-3LY;EDWK"DZLY7KD*#G'O0!R3^'_$-KX3U6UT]_*O;C69[L"*<1O);
MO<%RJO\ P,4.,]O:LE?!6KW$OB-TL#9Q:EH3V, NM1>ZE\TEL&1F+8SN[$@
M>IQ7HBZSI;7TEBNI69NXP2\ G7S% ZDKG(K#\/\ C6UUR+5+U_L=KI=G.T*7
M3WJ,7VNREF7&$!*Y&2<@T 9ME9^)-)U5]9AT2.X:_L8+>XM/MB*]O+"7"D,1
MAD8/SCD8Z&CPQX0U'1-7T>XN3#(MO87B7#QMPLT]PDVU0>2H^89]AZUV"ZKI
MSV27J7]JUHYPDXF4HWT;.#42:]H\A@$>JV+^>5$.VX0^83G 7GG.#C'H: ,S
MQ3I=_<W>C:KID4=Q=:7<M+]FDDV"9'C:-@&Z!@&R,\<8[USFI>&=>U:UU_5'
MLH8+Z^EL#;V!N <);2A_F<#:&;+=,@<<UW4&K:=<WLME!J%K+=Q?ZR".96D3
MZJ#D5FZMXLT[3;JVM(Y[>ZNY;V&TD@CG7S(?,;;N9>3@4 92Z#J<\/C.22W2
M*7684%O'Y@;#?95C*DCT8$9_&L.7P5J-EJ(O?[+EU,7&GVT#QV^JR6C031)M
M.=K ,AXYY(P>.:]+GGAM8'GN)4BA0;GDD8*JCU)/2L?5?%VC:7X=EUS[;!<V
M2,$#V\R.'8D# .<9Y]>@- &/X;\*W>C:WID[P6L5O;Z,UHZV[N465I@Y"[R6
M*]>2:P;GP%K<<^M3V?V<R6DZ3Z &?A29S<2*WH"QV?05V$7C+23K%_8W%W:6
MT5LL!BN);E%2X\U2PVYZ\#L3G-:][JNG:8L;7]_:V@E.(S/,L>\^@R>: .*A
M\%ZC8BSBMHK.X6'P]-8/]KRT<UP[HQWJ.2K$.21ZUF1>!M8OK'5=,BAGT72[
MK37M_L<^HF[C^T$@JT8R2B#!!Y&<]!BO2+O5=.L-OVR_M;?< 5\Z94R"<#&3
MZD"J>O>(]/\ #B637\JQB[N4MH\NJ@%OXCDCY1W/TH Y?P]X9O(_$5A?76A"
MQ%E%)NFGU::[9I&7;^Z4N0JX+9+#/08'6K'B[PQ<WWB:QUN"REU"..U>TFM8
M;][2098,KJRLH/((*DCJ#VK8TWQ=IM[>7EI/<6UI<07SV<44MPH:<J%.Y0<$
MYW=!FM&[UG2["YCMKS4K.WN)?]7%-.J,_P! 3DT <+)X(O\ 4/"T7AR:RMK"
MRU"\>ZU)HKAYWC0$,J*TA8M(Q"Y?@#!P.14$Q\0Z5K_@VWFTZWN[ZT@OK?9%
M*L0GB41!9$[*Q&T[3@=1Z5Z%>:SI>GL5O=2L[8@@8FG5.3T')[X./I1J,T%I
M8S:HT"3/:022H<#=C;D@-VS@4 <;9>%-7.J:?JMU%#'-)KDNIW4"2[A C6S0
MHH./F;A,X[D^E4=6\%ZA'K.NRP:2VI1ZI+Y\,G]K2VR0L45&66-&&Y<KG*@D
M@X["NVT;Q)IFM6$,\-Y:B9K9+B:W$ZL\ 90WS <C&>I K1^UVWE0R_:(O+G(
M$3[QB0D9&T]\CIB@#S?6?!VJK*5TO28XKI+.&WLM2T[4)+4PE$VXF4L?,4$9
M'#';P>>:D\0^%M>NM1N;BTL%_M22"-+?6;&_:U97" $W$><2 -DC .5P.,9K
MT;SX?M M_-3SBF\1[ANVYQG'7&>]5Y=3M5L1=0W%O*L@;R2)E"RL 3M#9Q_"
M?R/I0!P^N:$]OIGC*ZU:]M[9+Q+>:UNV<+B:&%</CL1(F<5O^!;*YM_#,=YJ
M";-1U.1K^[7^Z\G(7_@*[5_X#6;K7B^SCMYX]0T6*Z%M86FHF-I$E3=+*8P
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M-P(0-B%R22#V!J/3/%<DFK/I.MZ6^D7H@:YC\R=9(I8E(#%7'=<C((& 0>E
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MI:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX[>?[3& G27&/,]VQW/-/N/#VCW<=['/IMM*EZZO<JR B5E  8_[0P.>O H
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M#KCL<^:LDY@C=_\ @(,GXYJU'K&N&&TN)-9-E)J.B:CJ*/=/B*W9I(C"6SP
MB.![<UZ+-H&D7"Z@LNG6[C4=OVP%!^_P,#=ZX%32Z3ITTB22V4#LD#6R[D!
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M+)J5Y&PNT,#N'6!681\A2,8QG!'-=]8>$/#NES^?9:-9P2[63<L8R%;@J/\
M9]NE)9>#O#FG3Q36FC6D,L+[XG5/FC."/E/\(P3P..: .#T2;58?#_@_7Y==
MU*XN[^_BMKF.:;="\3EQC9TR, [NN>]:>BR3:AID7B6_\2WEE=-JCPM 9,P*
MHG,2V_E=,D #=][)SFNV31=,CL[2T2RA6WLY%EMXPORQ,,X(]",FJ_\ PBVA
M?VQ_:W]E6OV_?YGG>6,[\8W^F['\76@#S*RUGQ/>:<GB(-=Q7#:@4+S:G$EH
MJ"?RS 82>#M^7/WMW.:]!\9W=SIFE6NJV\[QQV-[#+=*IP'@+;) ?4!6+?\
M :M'PIH!U?\ M4Z1:?;O,\WSO+&?,_OXZ;O]KK6I=6L%[:36MU$DUO,ACDC<
M95U(P01Z$4 >3:=XFUJ^OCI;WTPD\07L%[IS*<-#9&20N%/;$4 _&7WJ6T$^
MK^*?#4]Y?7C/'K>K1+MG( 2-I-J_3 "_3BO2X]&TV*XL[B.Q@6:RA,%LX09B
MC( VKZ# %03>&M%N(XHY=,MF6&Y:[CRGW)B2Q<>A)))^M 'FFBP7FE>$=)UN
MVU:_65M>,!MO-_<>5)?-&R&/H<@D[CSGOCBNM^)MJMUX8M5::>(#5++F*0H>
M;A%[>F<CT(![5T@T73%L8[(64(M8YA.D6WY5D#^9N ]=_P WUJ74=-LM7L);
M'4+:*YM90-\4JY5L'(_(@'\* /,;S3;A;CXB:C;:QJ5K+IQ66W$$^T&1+.-@
MS_W\X (;(Z^M)/JNOZ_K6J(O]HB*QM+9HOL6H1VJQF2$2-*X8_.,DCG*X0\=
M:])CT72X;:ZMH[*%8;M EPF.)5"!,-Z_* OT%5M0\)>']6:%K[2+6=H8Q$A=
M.=@Z(?5?8\4 5;.6ZU?X>137\R?:KC3MTTMI*-I8IRR,O&#U&/6N!\.Z-]LF
M\!6HU'4((W\.2RR/#<%9"#]G^0/U5<D=,=,=*]?6.-(A$B*L:KM" 8 'ICTK
M-TWPWHVD-$VGZ;;VQA5UC\M,; Y!8#T!*KQ["@#@M)UG51>Z192ZE<S+%=ZQ
M:L\CY:98"1&7/<@ <U!I/]IOH/@T77B#56/B(QF]N6N,%-L#R+'&<?(6( )'
M)V]<FO2$T/2XY4E2Q@61))9%8+R&EYD/U;O23Z!I-SH\>D3:?;OI\2JL=NR?
M*@7[N/3'8CI0!S/@BU%EXG\86PO9KP1WD $LS[W'[A/E9NY'3)YXYYKMZS]+
MT/2]$CD33+&"T64AI!$N-Y QD^I]ZT* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "N<\9:W?Z#I=O<6,*D27"QSW+V\EPMK&0Q,C1QD,PR ."/O9-='6
M9K6CG5X;?RK^ZL+BWE\V&>V89!P0058%64@G((H XR;XAW$/A^QE2\TBZNKV
M_>TBO+99'@5%4N7>($N& &/+SU(YQ3!X_P!6_LN\6""SN[V"_L[6*X\B6""X
M6=PH.UOF5@<@\L.A[XK='@*S^RN3J-[_ &FU[_:']I+L659]FS(4+LV[/EV[
M<$=>>:F'@R*6W9;[5=0O;A[V"]>>5E!+0LK(JJ%"JOR\@#)R><T <GXNUSQ'
M%X<\7Z1=W-BMY9Z;'=QW=G%)'NBD+JR[2Y*L-APV2.>E7-4\<:I::W>:.EWI
MD%QIT,9GDEL;B1;F5UW[4",?+4 KR2QYZ<5TVK>#[#69M7DN9;@?VI8)83!&
M VHI<AEX^]F0]<C@<55D\&3?:'NK;Q'J=K>7$"0WL\2PYN0H(5R"A"N <;E
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MB1Y]3\0ZIJ%T+>6WMII!%']F$B[6=%1 -^.-QS6I<^&-.N?"#>&61ET\V@M
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MR@!*YRQ#E"V-W.W..W3B@"OJGB3Q-_:/B=-,72H[70D24?:8I'>XS")"GRL
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M+_O!C/S#;R.G-<UH/B2?1=$T+4M5B@O)8?"T]]]H4.)BJF$B,DL02V1EL<D
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M)TTR2=K1)=F$24 %"0H) Y()YYZFBX\$6<C33P7MY;7K:B^HPW417?#*R!&
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ML\_'3.=O'3K[<U7N_!FHO87<#6NCZE#<:M<7KV=[D))')]W$FPE'4]P#W&:
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M&#-M<".1#LXY.7'7'>DU/P??WNB^,;..:V$FMW EMRS-A!Y42?/QP<H>F>U
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M5F)6-6?YF"@@ GGB@#F=&^(=V?#NGW.I:+?S7^H7MS:VT-N(OWA1Y" /GP
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MKN R0>F#MY%4K;X>:C%#K"QQ:39)?W6GW$=O:E]D0@E#."=HW$@9W8&2>0*
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M(M+@VUQJ:!/*C<-M8[=V]E5N"P4C@]<5T.J:C'I6F37SP7$ZQ@8BMH]\CDD
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M=D;.UP.=I&0<>N:Y9OA_>W&G:JL>FZ#I,MU'#%##9;G&$E61F>4HI.=HPH7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUE&NU+.W5?*$&%B4#RQT3I]WD\=.:BM-&TNPMI;:STVSMH)L^;%# J*^>#N
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9^W )R: +]%9]_KVCZ5/%!J.JV-G--_JX[BX2-G^@)YJ^S*JEF8!0,DD\ 4
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MV\-S>K;WNGO%/IDY4GRQ*542;B[KMY/?)%=Q_P (5HWKJ?\ X-KK_P".4?\
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MS_+#Q*$E$6#N4,6Y .-V>U=AX!M6C?6[T27LD-Y=JZR7-H+596"!6=(\ @'
M&2!DKFMN?Q1I-M<7$$MRRR6]Q!;2#RVXDFQY8Z=]PY[=ZV* /*M?M9S=^-+.
M.PNFN+J_TZZ@*6SE9(E:V#%7 P<%6R,YX)[&FZIX>-QX3\9!M*>2XNM>5US
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M2TN8+B!HF#J@5P0P!/?GH:ZNJ<>IVDNK7&EI(3>6\*3R)M/".6"G/3DHWY4
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MO4=0U.TTL6QNY"@N;A+:+"D[I'.%''3ZU)97L.H6YG@\S8)'C^>-D.58J>"
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M]#T29WT[3+"QEN#AC;P)&9#UQP!GN<5-J>C:9K4"P:IIUK>Q*=RI<PK( ?4
MCB@#S"?5M<M/!^EWMCJ)OM>AU">WL+6&X:X2]BW,&CD/RARB@GS,=4Z_,<K<
M7EU=Q>$-.L+ZYU2RU""XN9Y)M1>S>[G&W*%U!9=I9SY8Q]W'\->H0Z7I]N]N
M\-C;1M;1F*!DB4&)#C*K@< X' ]*K7FB:%-8O:WNF:>UI+,97BE@38TK'[Q!
M&-Q/?K0!YM"VIWT&CZ3=:M.EN_B&:T/V/47DD$ MW8PO-A2Q# C/4#'.1FKT
M=O9RIXFN-6\0:GI[:)<BWMG6]DS:PI$A1RF?WI<DDE@Q;I7H<&DZ;;06L,&G
MVL45HVZW1(5 A.",H /E."1QZFH+G1-$U+44OKG3;"YO;8@)/)"CR1D<@;B,
MCKF@#SN^N-2U&XU.UAU(L?\ A(BD=E/>RVOVJ,6D;>2LB\Q\DOMX!(.:2+5U
MN-'M-$5==^V'5YK5K%M27)*1^88C= [C$ P/7><;:])NM#TF^MY[>[TRSGAN
M)/-FCD@5ED? &Y@1RV !GKP*@;P]X?GTY=(;2=.>RA8,+0VZ%(SV.W& >O-
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M0RLZR3//+(I!+*"Q))/( S4UMH.CV>G_ &"VTJRALRXD-O' JH6!!#;0,9!
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M66WC5LJ<[\X['G/8T <!I[WFLWGAZQNM3U 6]QJ6L+.(KIXVE2.5MB%@0<#
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M9.\,N.0@(8* >]=//X)M976:#4=1L)WMH[:Y>RE"?:$087<"#@@$@,,'!ZT
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MKIN(."F0<]ZGU'Q;K-AXHFM[VZ@TNW6\2*VCO+"3R+F$[<M]I4E5<Y; ( !
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MK(L<GS*"#TYY!KI1X#TV.*!K>[U"WOX99)O[1CF'GN\F-^\E2K [5X*X&T8
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M/&9V!+QS.IS$%( Y&>2?:NHU#P99WM[/=P:AJ6GR742PW0LY@@N%48&[*G!
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M(&1(XX1N>5W8*B*.Y)(%8<_CM=.@U+^U]'N[&[L;%K\6[/')YT*\$HRDC(.
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M=TSM9D0*2,]N*Y2Y\&ZZ=(U+PU;7=@NAW\\KF=]_VB&.5R\D87&UCEF 8L,
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MTU.8SBZU*U\R>T=@ VT;2)!D;@"5P2>HKT&UMUM+."V3:$BC6-=JA1@#' '
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M)*8%4$X\P$C83C ;(/!.3VIJ^*;&SMKF?5+ZRC5+Z2UB$!=RQ7^$KC)< '(
M(&*Y9?#^HK\//L0L)!>'7OM1C"_-L_M#?O\ ^_?/TJO<:)>10SS3Z;JZ,NO7
MEQ%>:9(!<6Z/PKJA!$B-T(_0T =1J'CW1[1]#,$\=S!JURT"31DD(%5B20 >
M0RA<<$$^U6_^$V\-?:+N ZS:B2S5VN 6P(@K[&W'H#NP,=>1ZBN/@MO$"6.@
M7]_IUU<FSUV68^7;1QW#P-%(BRR1H0-Q9^<<XP2,YJ;^S-9T_P $ZBEKII-U
M+KTUPX^SI+(L+71;S8T;AG"X*Y]!Z4 ;VH>/]#MO#FK:M9W*W9TV'S)+?#1O
MD@[ 01D!B, XQ5N?QIH%G:6D]WJ447VJ+SHUPQ;9W8@#(4'N0!7!3Z'K>I/X
MM=+?6+D7WA_[-;3:DL:232 R':%0*$'S# (!ZFMRRNKW2O$-WK<V@:K<6^IV
M%O'$L< :6!XMX:)US\H.X,#TZY- '37_ (N\/Z8MLUWJUM&+I!);D-N\U20
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M:6RHY0$@%E8YP>I3UQ2ZEHVH>*+OQ#JUMIUS8!M.@BLEN4$<DUS#(TR.5SD
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M_&KQ;)S<2M&6A2*1XRQ*O(B?*'/4X]>><T 7X_$.D3+IK1ZA PU//V/#?Z_
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M@KA=%T'5(]<T74)["2"&74]1O9(6P?LT<R$(KX. 3U('=C2>#-*N4\7W=A.
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MSC'2@#:3X@>$Y& 37;0Y3>IW'##T!Q@MR/E'/M4__"9>'?[,BU(ZM;K:2S-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:SN/(3S)?+E!VI_>_P!WCKTHTWQ/H>L>=_9VK6ESY"[Y/+E!VK_>_P!WWZ4
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M=8LEL[D%H)C,NV3'7:>Y[8]: ->BN6U+Q_H-A:Z3=1WUM<6VI7?V9)4F&U<
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MZM)XY[>50T<L3!E<'N".M9EIXM\/7]_'8VFLV4US)G9&DP)8@9('J<<XZXH
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M6$ZD$[E(P0 .23T&.<XQ0!R<V@ZQX@\:ZIJ8OKC2[:UA&G6N;5)//0@/*^)
M>"Q5<CKLK(GM=0TOX0Z_X:OX9I);/?IMA*Z8^U)(0L!7L3\ZK@="M=9=>--,
MTV_?2S:ZM<7-O%&\J6UC+<&-7!V[BH/)P>OH:DDUSP[JVD6NMF4W%E:W:X<J
MR^1+G9F1#@KM+<[A\O7C&: (?'UA=WOPWUFQM8I+F[DLRB)&I9I&XZ#O67>:
M/=2ZIXZF^PR-]KTB""W?R\^:1%*&5?7DKD>XKM-1O[?2M,NM0NV*VUK"\TK
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M^$E,['2_($_F*A)VG_9ZYYZ4 4_']G<W_@75;:S@DN+AHU9(HQEGPZL0!W.
M>*S+"REO=?\ %FI-IUQ'%?Z=:I ;B HS_NY-R8(SD$C(K2C\=:4;NWM[JWU2
MQ-S*(8I+W3IH8VD/1=[+@$]LFMV_U"UTRT:ZO9EA@5E4N<]68*HX]20/QH \
MET[2=9T:33;R[?7[5)?#]C:@Z;91W#QR1H=\4BO&[+RP.>!G.3P*]$\%::^D
M^#M-LI(;B%HXR?*N75Y(]S%@K% %XSC &!T[5I6NJ6MYJ-_8PNQGL61)P5("
MEU#K@]^"*NT >:>#/AW93^#=.CUU-6,A5C-83W\ZPYWD@&'<%QT.,8J/Q+%J
M\FL>(K."UU&UBN+=(K5=,TZ-Q?#RL?O9V5@N"2N#MP!QG->C-J%JNIIIQF7[
M8\+3K%SDQJ0I;\V _&EDO8XK^WLV24R3H[JRQDH N,[FZ _,, ]>?2@#B/!^
MD74'B#3[N[L)8O+\+V-KYDL9&V17<NG/1A\N1]*QM&TG598_#UE]@O;2:QDU
M2&::6%E5#(&,;ANA4[A@CO7K%59M2M(+^.QDF NI(7G2+!R40J&/X%E_.@#S
MZP,[^%=)T >$[O[?I]D\,TL\!2.V98&0O&^")"[' "GD,22*IZ)>?\(_XHTY
M;W2+^>>/PG8PO]FM6EDA8/)E"HY&2,9Z KSBO3-+U*VUG2K74K)B]M=1++$S
M*02K#(X/2E73K1=5DU,0@7DD*V[2Y/,:LS!<=.K,?QH \PL;'7-#M]!MIK6\
ML(Q:7!:ZT_3UN[B%I)MZVV=K!%"E><8)7KQ4GA70M2BN/"IO=-NT-IJ6J2RF
MYC&Z,/O*,Q4;>=W4<9Z5ZK5+5=4M=&L&O;UV2!72,E5+'+N$7@>["@#SRZT[
M4+&:XO?[+O)(8?%XOBD$!=VA-N%,BJ.6&X]O>NA\<VIE_LJZ2'54>VG=EOM+
M422VI*$9,6UMZMT(P<<5U]07UY#IVGW-[<,5@MHFFD(&2%4$GCZ"@# \##4O
M["F.IVXBD:[E:*0VHMI)XR<B22,?==CG/0]"0,UP>G:1H]M<ZN-<\):_<W<F
MJW<JS6]M.4>-I6*$%6 Z5ZY!=17-E%>1$F&6,2J2,?*1D<?2JUEK-EJ&@PZU
M;NS64MO]H1RI!*8SG'7I0!S-G8-<^-9=233;B*T?P]#;Q&>(AE/FR$QG/1L;
M<CZ5F:#HE[::7\-D;3Y8GL4?[6/+(,):V<'=Z98CKW-=_I]]!J>FVM_:L6M[
MJ%)HF(P2K $<=N#5F@#Q[PLTNL^"/"&D6.CWL,UK>P7<ERT!6%$20NSB3HQ<
M9&!S\QR!5W1+#4-!ET#5K_2KV:VMEU*"2.&W:26W>6Y+I)Y8^8AE4C(!X([&
MO0;5=*\/Q:;HMOMMDDW16D&6;.U2Y )ST )YJ;2M4M=:TV*_LG9[>4L%9E*G
MY6*G@^X- 'G%SI]W9>&=7\4FSDLWM=9;6[2VE 1Q"J*DH8?PF1!*=OJPSS5W
M2_#U['>^#+R[M&DN7N;O4-0?9D1331,0">V"0@_W17;ZMH>GZY'!'J,!GCAE
M$JQ^8RJ6'3< 0&'L<CVI=:UBST#2+C5+]G6UMP"Y1"QY( P!R>2* .!GT&]'
MA/Q!#%ILHN)_$RW4:K%\SI]JB;S!ZC:"<^@-9%YH.J)#X@T6Z_X2.5]0U&::
M."RMH?L]PDC[E<SM$WEE1C.YLC;QVKT"R\;Z3=ZC;V$D6HV5Q<L4@%]82VZR
ML!G:K.H!. >,UTE 'GUQH=TUO\2,V,LDE_$$MV,>3<8LT4;>/F^?</KFK.AP
M7ECXWA:XL;L176@VD G$1,:21M*75V_A.&'7KFNOU#4+72M/GO[Z98;6!"\D
MC9PH'TI8KV.:^N;14E$EN$+,T9"'<#C:W1NG..E '&>)Y-3B\8Q-#'?VMHUA
MM6^TS3EN9Y7WDF$LRL(U VD9&"2>>*R/!VA:C;S>"FOM-N8FL8=4$WG1\PL\
MR[,D<9*YP1P1G%>E7M['80+-*DKJ9$CQ%&7.68*#@=LGD]AS5B@#RVUTR_TC
M7(-9GTN[EL;76M29XH8"[JLVWRYE0<L.&'R@GY\^M=)X$AF5O$=U+IMQI\=Y
MJ[W$,4\>QF0Q1#?CW()^N0><UUU% 'CVI:)J<+^*-,N1XBE&J7LLL,%A:PO!
M=1R !<S-$WEE1\IW,,;015[7-$U*Y\50:[!I$T]GHOD17$#AO,U0KD[U' <Q
M;MRDCYFW =!7I1U"U&IKIIF7[8T)G$7.?+#!2WYD"K- 'G3--I-SXIM;OPW>
M:L^KW/VBU"VY:*YC:)$6.1\$1A2I!WXP.1FL34=%U2VG\46-TGB!AJL[216^
MFVL,L%RCQJH1I7B8QE<%<L0  "*]@JEJFJ6NCV8NKQV2(RQP@JI/S2.$7I_M
M,* /.+6Z72/$/BVPDT74-1GEM;2W#0P^?YI%L%\N1@,+G.=S87DUI^&]+U'0
M?$^B6]];7,O_ !3L%B]U'&7C6:-F9@S#[O'0GK7;V^G6EK?7=[#"$N+PH9WR
M3O*KM7CH,#CBK5 '#^*Y-2B\66;P1WMK:&R=?[0T[3ENK@N7'[K)5O+7 !R1
M@GN,5RNF:3J&GZ'H\MU:>(=.OK>;4%%[9P+/+%YD^\)+"$8.KC!W*,97L#7I
M]_X@TS35U W-QAM/M?MERBJ2R1?-AO?.QN/:M"*19HDE0Y5U##Z&@##\%+J"
M>%+-=3M(K6Y!D_=QP"'Y=[;6,8X1F7#$=B37GOAUI=8\#^']$L-'O8KF+4H[
MIKHP$0QI'<%VE$GW22 5P#NRQ&,5[#7.WFIZ+X'L-/L%MKE8II&BM;>U@DG=
MFP78 #)]30!R;^'K\>$K\KI<DDB>)I=1EM=@#W4"W9?@'[V4 (SUP*NR:7_P
MFGB34KEM/O+/2Y]&;3Y);NW:!Y96<,I"-AOD ."1U;BNFT;Q7IFN7DUE;_:H
M+V*,2O;7EK)!)L)P&"N!D9XR*VZ /)I=(\0ZQX(\2ZCJVG3C6KBUBT^&W"DL
M4AQN91Z/(9&^FVIM=MKRRT;QQHTF@W]_=:O)-/:2V]L9(Y5>)53+]%*%>AP>
M!MSFO2KK4+6REM8KB98Y+J7R8%.<N^TM@?@K'\*6RO8[^ S1)*BB1X\2QE#E
M6*DX/;(X/<8- 'F-[INJ:9XCU:ZF?7X[?4+.V6$:9917(DV1;&B??&Y0[LGG
M"_.?>K>C6-SX0U&UGO-(U.[M9=$M[*(1I]JDMWC9RT+E !@AU^; 7Y>2,5Z'
M+>QPWUM:,DIDN Y5EC)0;<9W-T7KQGKS5B@#F/A[97&G^ ],M;JS>SFC5PUN
MXP8\R,0/R(KFO FAWUGJ'A>6]T^:+[+X<>!VEC(\J4RH=IST; /'IFO3** .
M9\!65QIWA86US;O;NMY=LL;KM(1KB1E./0J01[&N)ET^6Z^$]GIK6-Q>2V.M
M!+ZWMT+R$)=EI" .>5^;Z$5Z/<^(M.MH[EO->7[+=1VDZQ1EC'(^S:#_ -_%
M)/8&KEO86UK=W5S!'LENF5YB"<.P&T''3. !GO@>E 'G?A_288_'.GWOASP_
MJNDV:PRIJ<E\CQK,FW]VBJ[$E@_.0!@9]:U-%U*/3]:\3:D\4SV=[KD%E$8D
MW 2".*%G/HOF#:3ZBNYJG::58V-E!9P6R""W.Z-6^8JV2=V3DELDG/4DF@#
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M@UM?%*V@N/ \IN"P2.\M'R)&3'[]%))!'&&/7Z]0#777-K;WMN]O=013P/\
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M'YF1M.,8W9Q@]<XJCI'A#3=,N[F\EM[:ZO);V>[CN9+=?,B\QBVU6Y.!GU%
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M>P6MR8X[G V_./4J "5()'6G7_@S3KNZ-S;W%]ITKP+;2FPG,0EC7(56&".
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M<MOYGG.+6,X8Y&U< #CGD^E=IHOA^TT3[3)"]Q/<W;A[BZN9-\LI PN3Z <
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M,F_?E1C^]DX8D#/ I]QX TBZNKZ1Y]0$-_/Y]Y:K<D0W#<<,OIP 0,9'!R*
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MB O%<R0:XVS 3$XMT(]-SMN^@J.XUZ\U9(;BXBMFBO\ 2]7FMG\D>8D"F,1
M-U&Y2&/KD>E==<^!M#NVUYI()-VN*BWA5\?<&%*_W3GGZ\U9E\*:7*MFOER(
MEG8R:?"J-@+"X56'UPBX- '+_#[_ )#L_P#V+VD_^@S56UO5;WPYXU\6:W]H
M\^&RT2WF2U,8 8[I@J[NH 8$D^_M7;:5X=L-&N6N+02!VM8+0[VR/+A#!/Q^
M8Y-17_A73-2U>;4;D3,UQ:&RN8!(?*GB^; =>Y&]L'CK0!RFF^)_$4=^D5PM
M]>036DTDLTVBRVB6LJ)N7#,,,AP1@\YQSS4%CK/C"XLO"CR:O9>;XAPYQ9#%
MLGV=I#CYOF;@=<#/;'%=39>"=.M)UFEN]1O6B@>WM_M=R9!!&PPP3W( &3DX
M'6KD/AK3[>/0T02XT5=EIE^@\LQ?-Z_*: .(/B+Q7:Z5J.I3ZI9RQZ1JRV#Q
M"SVF[0RHI9CN^1L2#&T8RO?/$TVO:M%J=S9Z6;&TEN?%!L&E-L#F/[()"[ $
M;GR!R3V Z5ULOA/3)M.U"Q<3>3?W@O9L/SYFY6X/891>*!X3TP7PN\3>:-1.
MI_?X\[RO*_+;V]: .9D\2ZQIUIKUA?:M8BYT^^M[>*_EMFRZ2HCX$*9+R ,P
M & >/>N>UWQ!J^I^%/&>ES7T[I9V4%Q%<7&GFUE=)"X9"AQQ\G#8'4UZ%J'@
MW2]1FO)Y&N8[BYN8;OSHI=K12Q($1D].!CG(.34(\!Z0T>JBXEO;E]5MEMKR
M2>X+-(J[MI_V2-QZ8'3B@#GM3\3ZVGB&\T6WO+I#IMO#ON+;1I+O[1,ZEOF"
M9"*!C@<G)YXKL=%U6ZO_  K:ZGJ%I]@NWM_,G@GS&(G YSD9 R,\]JH3^";*
M:19DU+58+HP+;SW,%T5DN47./,.,$C)PP (SUK8@T>PM]$71HK95T]8/LXAR
M<>7C&,]>G?K0!P&D>,=6DU_0(Y-1-_;:I*T4VW2I(+=#Y3N##*X!<97'?(YX
MIVC^)/$[Z3X:UV^U"TEM]4O4M);)+7:%5RRAP^<[LJ"1C'..V:Z.S\!Z;:7&
MF3->ZG<-I;[K(3W)981M*[0, $8.,G)X'-7(?">F0:1I>F()OLVF3I<6^7YW
MJ21D]QR: .#UR^UWQ!X-&N/?6Z:;-JL"+8?9^4B2\1%/F9SORH)XQ@D8[UWW
MBK4Y=(\/S74-W:VDN]$6:Y1G5=S '"*-SM@G:HZG%9]S\/\ 2+F5\SZ@EJUT
M+S[''<D0+,'#[PONPR1TR2<9YK9UO1+37]/%I=F50DJ31R0OL>*1#E64]B"*
M /+=<\1:C?:)XETB\N+BZ@BL[6Z@GNM/:SE^:?:1L(&5^4$' []:[CPI_P C
M/XS_ .PI'_Z2PTK^ -)F-Z]U<:A<S7T"07$TUP69U1]Z]L+@^@ Z\5N6.DVN
MGWFH74 ?S;^83S[FR-P14&/3A!0!QEWKWB.YT_Q%KUA>VEO::-/<11V,EON\
M]8/OEWSE2Q#8QTXSFN9\12WEY;?$&^^UDVTND6<B6[1 8#JS*,Y[<_7/M7H-
M]X%TJ_N;MWFOHK:^?S+RRAN"D%PV "67W  .",XYS3]2\%:5JES?S2O=1K?V
MJVMS#%+MCD1?NG;CAAD@'WH PK[Q'KGA34+I=6NX-2A_L:YU)5BM_),<D)3*
M Y.5._OR,=:BT#Q/XAFU73$NDO;RWO4;[26T:6UCM&V%E*R,,,F1MYYY!SVK
MLKS0=/U#4DOKJ(RNMI+9E&/R-%(5+@COG8/UK/TWP5IVFWEK<?:M0NOL:-'9
MQW5R9$ME8;3L'KMXRV3CB@"M\/[W7-7\-VFM:S?P3F_MXY8X(;?RQ#P<_-DE
ML\'M@YKA_&VKQ:CXHU2[A^V-=^'HXUTSR+*:9'N@RRR@LB%5RJI&<D=6[5ZO
MH^E6VAZ/::79AQ;6L0BCWMD[1TR:9H^C6FAV3VMH'*R323R/(VYG=V+,Q/?D
M_P J .0U3QU/;1_;;-HY++4=%^UZ6&7DW.Y5V$]\F6+CV:J]GXWU2ZL48SV%
MO/8:5/-J<ER"L27*R&% <<JNZ.4X')  %="O@/0UM-,M?*E,.F7IO;13)_JW
M+%MO^YDYQ[#TIY\#Z$T&NPM;.4UN3S+SYR"6[;2/NX.6^I)H Y6S\8:O#J\E
MJU]-?02Z5<W<<USI3V>V6+;C8&P70[^X[#FI['6/%5Q;>'+>75K5;OQ!$;KS
M5LQBTB6(.R*"WSL2RC)Z?-QTKH(_ ^G_ &T7MS>ZE>78MI;7SKFXW'RI  5P
M  .F<@9SUS5JZ\*:?=:5IMB'N8#I@46=S!+MFAVKLX;OE>"""#Z4 <-9W7B3
M2+?Q0UMF[O!X@1+NXM+7S'6$VT7[Q(MWS-]P$9.,D@'&*['P9K3ZSIERTNI1
M7TD%P8]XMGMY5& 0LL; %7Y/3@C!J*/P#I$5E- DU^)9;T7_ -K^TDS+/L"%
MPWN!@CIR>,<5JZ+H-KHB7)ADGGGNI/-N+BYDWR2L%"@D^P     Q0!Y=>PZH
M+/7BNH1RRGQA:)")8?E63=!AC@Y(P5&./N^]=/-X@UK1)_$6GW^K6$LEE96]
MW;WMS 8D3S6="KJF=V"G ')R![UN2>"]+DOKJY,EV!<WD-\\(F_=B>,J0X'8
MG8N?7%2ZKX1TK69KZ6[68O>P0P2,DA4J(G:2-EQT8,V<^PH X:;Q'K%XFOZ.
M=1N9H6T*:\BNKG2VM'5E(5@JMC<I#=<<>IKL_#\L^G_#RPGN+N!Y(=.67SIQ
MY48 3(W8SA0, GVS20>"M-COIKZXN+^]NI[-[&:6ZN"Q>%B"5P  .G\('4U=
MMO#EE!X8/AZ5[B[L&@:W87,A9S&P(VEN#P#@>@ H XW0O%NJS>)]%LY=0>_M
M=3CE\QVTJ2UB1UCW@PNX!=>".<\8.:HVWB_Q/%X/T/5;N]BFN=?DBBA2VTYI
M/LB['9W"J2TC$*,#@ D]A7967@FPM-1TZ_DO=2N[G3@RVKW-SO$:LA0KC &,
M'KC/ YXJ9O!VE'PW8Z$!.EM8;&M94E*RPLGW65QWY/YD4 4_!^LZKJ%SJ5IJ
M,-V\-L8VMKVYT][0S!@=RE& Y4KU'!##BN*\7Q7PE^)+M>^9"NGVN(3$!U#%
M><]N?KGVKTK1?#]KHCW4T<US<W5VRM/<W4N^23:,*,\  #.  !R:IZIX,TO5
MKS4;B>2[3^T;9;:ZCCFPDBJ?E)']X9(!]Z ,&_\ $>N>$]0NTU:[@U.$:-<:
MDJQ6_DF.2$H"@.3E3O[\C'6JVD>*O$9O;+[0E[>0W<$C7!?19;:.T<1EU*NP
MPR9&WGGD'/:NVO-!T_4-26^NHC*XM);,HQ^1HI"I<$=\[!^M9MCX'TVRN()6
MNM0NA:Q/%:1W5R9%ME9=IV#UV\9;)Q0!S^B:_P")?)\'ZGJ6H6MQ;Z]MCEM8
M[79Y1:!I596R23\G(/'/&*T/'4=Y+K?A".PGC@N6U.0++)'O"#[-+D[<C)QG
M'/7%;D7AC3H;+0[1!+Y6BLC6F7Y!6-HQN]?E8U;OM)M=0O=.NYP_FZ?,TT&U
ML#<49#GUX<T >?WWC/7-)2[TB:9;K4$UB/3X[V*R9V\IX!.7\E/O.!D8''0]
MC5;5-9U74-!O;/48;R2&WU+3'MKVYT][0S!KE-RE& !*D=1P0PKN+WP=I-^U
M\\HG66[NH[PRQRE7BFC145XR/ND!1^9]:B3P1I8MKF.>6\NIKF>">>YN)MTK
MM"P:,9Q@*".@ ')]: .+\87VNZ_X(\6WT5];P:?:S3V:V1M\ETB;:[E\Y#$@
MD #& !SG-=7\31(?A[J8AV^:3#LW],^<F,^U/U7X?Z1JS7RRSW\-K?OYEU:0
M7)2&63CYROKP"<<$@$@UM:WHUGX@T>XTN_5VM9]HD"-M) 8-U[<@4 <G>ZCX
MJTS4;C1EO[:_O;G2YKVRE%J(]DT3(#&5!.4;>,'J.>36AH?BF3Q+KEM_9Y4:
M:FF1W=R2,MYLQ_=QY[%55R?JM7+3P[#H;W6J6YO=4U+[/Y49N[G<^P<B)6.
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M)YCR94#.!\VT+S@ <FMB;PGK.LR^?K.L0"6"QGM+.2R@:-D>50K3-EC\P &
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*?F Z\UU?@SQ'/K%Y>VT^JVMX841PALY+.YB)R&#Q/GY>!A@?4>] '7!U+E
MPW 9*YY IU>?W4.MS_$[6UT:]M+,C2;1GDN+<S9(>?:H 9< \Y//08JA_P +
M$O\ 4H]$A@8:?+=Z4FHW,T>FS7V"S%0BI'T&58Y8],#KS0!Z:74.$+ ,02!G
MDXI2ZJRJ6 +<*">OTKRMO%-R^IZ-K^IV,D,]EI.KO+$8GB\T1-"=RJXW ,%!
M /(SCM5P_P#"03>*? UYJ]W8S17,LTOEV\#1F!VM9#M!+'>N">< Y'OP >D%
MU5E4L S?=!/)^E+7%>-([^7Q7X0339H(;DW-SB6:,NJ#R&R=H(R<9P,]:JIX
MMUG3[UK74C:S)I^K16-_<11% \4\8,4H!8["'=%8<CG/% '?TC.J8W,%R0!D
MXR?2L3PWJUSK:ZE>.(Q8B]D@LMHY>./Y&<G/.7#X]@*\WNAK!L]3)OK>>8>,
MK=(!)"RJKAX\$_,25^Z-HQT/// ![)17G&I^,];\-?VU8W[VM_>6WV/[)/%:
MN@)N'9,/&K,3M*$X7ENG6M3PKXCU._UV?3+OSKRW%MY\=\=*GL@K!@K1D2<$
M\@@@],YZ9H ZZ6ZMX&"S3Q1DC(#N!_.I%974,C!E/((.0:\R\516,OQ4B%]X
M8D\0(-$&V!((93&?//S8E90/3CGFC3UU#PGI.L7\-O9^'+*_U"$6=E>'S!;*
M5"NRQQ$@NQ!(C4T >G4A(4$D@ <DFO+_ /A/-;BTCQ'Y3PWESILEC]EGGL);
M02K/*$(:-CGC!PPZY%.U!?$%GXP?^TM5LKWRO#MW+)&MDR1R+O7Y=OF''\//
MH".^0 >G*P90RD$$9!'>@.I<H&&X#)7/(%<!I&L:YK8MM-T273]-2RTBSN96
MDMC(&DF0E8U4,-J )R>3R .E5=6\2:QI=WK,\=AIB:O%8:7N(#,K/+.\;*7X
M)09...,GK0!Z517$3^(-;T+4;W3M3O-,N9/[+DU"VNG1K:*-D9599/F;Y<NI
M!'.,CWK,L/&VJ+JTEHU]#J,,FF7%W',-+FM%22+;PI<XD0[NW(P.>: /2J*\
M_P!*U_Q.T_AB6_NM.>'Q# V(HK5E-J_D&53N+G>/E((P/:K_ ,,/MI\#6LE[
M=+<.\TY5A&5('FOD$ECDYR<\=<=LD [&BO.D\6>(/^$;B\8M)8_V3)<*#IP@
M;S%@:7RPWF[N7Y#8VX[>];/AO4M>UG6]6EN+BRCTNQOI[*.W2 ^9)MQAR^[
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M!MX;2\L942>#=A7CN02ID(P0N!R=OO0!Z'1110 4444 %%%% !1110 4444
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M*WVCV>HZA?RZB?L[7%[*C&WC?Y788"]%W$#!.<5L:CH-EJ?AR?090Z64UO\
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M>M97Z$QRQF%$ +;24<,N00#79-?6J:A'8-.@NI(FF2(GYF12 2/8%A^=4?\
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MR7!\S B4-M.X]!SQCKR/6K%AXET74[6YN;34H'AM1FX9FV>4,9RP;!48YR:
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M.* 8"*Q +-U.2!R>V*AF\&ZZVAW7A6*XT\:#<W$C_:69_M*0O(9&C"8VDY)
M;<..U=-XJ\1P>%O#5WK,R>:L"96,-C>QZ#.#BLD_$/1[;7;ZTOKVVM[2*VM[
MBWF).Z42;]QQC@#:.>V>: ,H:?;:Q\7'EL;D2V-G''<ZC$HRJWD8>.($_P![
M8Y)'_3-#Z5HR^#KU_#]_IXN+?S+C7/[35LM@1_:5FVGC[VU2/3/>M[4/$VAZ
M3#;S7FI6\:72[X"#N,JXSN4+DD8(YZ<BM"VN[>\M([NVGCFMY5#I+&P964]P
M1U% ''>(O LNOW6O2//;JE_%9?9UD0N!);N[XD7H4;<!C/3-9P^'UW-IVMQK
MIGAW29;W39+&%-/B)RS]7>0HK8X'R@'\:ZW3O&'AW5KN*UL-7MKB:9=T2HW$
MG&2%/0D#D@<CO3U\5Z"VK_V4NJVQO?,\KRMW_+3^YGIN_P!G.?:@"M?>'I[O
M7]&OA-&L-E975M(#G<3*(@"/8>6<_453\-VFO^'],\.Z'<PV4T4$;6]Q-!YA
MQ''&!&^2  20 0<]>,X.)]5\:Z1;+>VMGJNG'4[9&9HKB1E1-K8;>5!(Q5W4
MO%F@:1?"SU#5;:WN,!F1V^X#P"QZ*#V)Q0!!XBT?4+[5-"U'3FMO-TVZ>1X[
MAF571XVC;!4'D!LCC%<^/!FN?V$OA0W&G_V"MP'^T[G^TF$2^8(]F-N?X=^[
MISMS73ZQXIT71)%AOM1MX+AXS(D;MSMZ;CC[JYXR<"I/#6K/KOA;2]7EC6)[
MRUCG9%.0I90<#\Z (/%^C76O>&YK&RDACNO-@FB,V=A:.5),-CG!V8X]:R_^
M$6U&;2/%\$\MJMSKR-Y>QF*1,ULD1R2 <;E)Z=,=^*V-.\5:#JU\;*PU2VN+
M@ D(C?? ."5/1@.Y&:BL_&?AO4+^&QM-9M9KB;_5HK_?.,X!Z9QSCK0!RNH?
M#N8ZM/?P:9X?U1[JUABD&JH<P21H$W(0C;E( RIV\CKS776_A^)/!X\/S-'Y
M;69M96@B6)3N4JQ5!PO4X%9>N^/M)TV5+2SO+6YO_MT%H\&\\%Y51@"."RAB
M<=1CFKP\4V%G%=2ZMJ.GV\<=[):Q,LIQE5W;6R!A\ Y SVQ0!S&@^ ;O2KS3
M6;2?#$7]G@G[9;6_[^[8*0I.4_=9."2"Q]*T="\(ZKHNN)K1U"*>\U#=_;2,
M6$<AZQF(8X\O[@!ZKUYK=A\5:#/H\VK1ZK;&P@8I+,6VB-N/E8'D'D<=>1ZU
M)I/B+2-<>5-,OX;F2%5:5$/S1@D@;@>1]T\'TH X5?AQJ']E:+'=V^B:C/HY
MGAB@N@S0W,$F""Q*$I("HZ!AU]:U-*\$75E/I%P8])M#:ZE+>S6]A#Y<:HT#
MQ*BD*"Y&X$LP&>?0"NBU7Q5H6B7*VVI:I;VTS+OV.W*KG&YL?=7/<X%)J?BS
M0-'D6._U6WAD:-9E0MEF0YPP R2/E/(]* ,#5?!VI7+:W/:3VGGW6JVFHVRR
ME@O[A8@5<@9&3&>1GJ*V_%.CW7B'PA>:7')##=W$2X9B3&'!#8SC.,C&<?A6
MK%?VD^GK?PW$<EHT?FK,C;E9,9W CJ,5Q%I\4=-NH]%NG,-O9W[W23/(Y)B:
M+&T#CDMD<#UH V+#0=174==O[U[59=4M+>+9"S,J.B.K<D#C+#'>N8'PTN+0
M:?,-.T'5YDTNVL;B+4U;:DD*[1)&P1C@YY4@9P.17;CQ3H1T4:R-4MO[/+;!
M/OXW9QMQUW9XV]:M:7J^GZU:FYTZ[CN8@Q1BAY5AU4CJ#[&@#GM"\(W&CZMI
M-T9+/RK/3)K21+>$0J9))4D)1 ,!?E;WY^M:GA?1I]#TJ:TN)(Y'>]N;@&/.
M-LDSR <]P&&:VJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KCOB#I5_J%OHUU9?;&
M73]06XF2R"&;9L==R!P59E+ XP>,XYQ78U0U+5[;2I+!+C?F^NEM8M@S\Y5F
M&?080T >>QZ9>2:7XFF32M8U&76!#91?VOY:>:0&7S'C1$,:)NY8\G:,8XS5
MD\+:U:>$7T(6]W-<Z9JT-^][;A?,U&/=N+@R9!E7NK9Y1<=17K=5++4[34);
MR.UEWM9SFWG^4C;(%5B.>O##I0!Y;J.@7VKZ7XCN8;;Q!=R7%E!:H^J+%&\^
M)=Q58DC4X4$_,W7<0!QFNKU,7&B^//[;;3+R]L9M,6S0V</FO#(LC,05'(#!
MAR.,ISCBNRJIJ>IVFCZ?+?WTOEV\6-S;2>I ' ]R!0!YW<:'?7<EW)-X5\NW
MF\/B'^SK:81A7^T,_EJX& X4AO3/?O55HO$S66L_8K.^U2U^QQ+$^MZ?$+D,
M)0611A?-"IN8;AC<!@G->LU0EU:VAURUTA]_VJY@DGCP/EVQE V3ZY=?UH \
MPN=+UK4-1UJY$6NWL=QX9N[2*?4;>.)GF)4B-8T5=H]-PY.?2M>."^UF]\.I
M#H=[IZZ/:3BX-Q$$7+0&(0QG/SC)#9''R#O7H]5-,U*TUC38-0L9?-M9QNC?
M:1N&<9P>>U 'E.FZ%K.BMI%[<CQ!;QOH%G:'^RH8I9(I8P=T;JZ,0#N!!&!D
M'/:NT\*$>'=%T#0I[&^AFNUG91-(DODD$R;9&4*,X;@*N!C';)ZVFF.-I5E*
M*9%!"L1R <9 /O@?D* .-^(FGZM+966I:#;M/J=LTL"JO7RYHS&3]%;RW_X!
M6%I'A"_TW7;_ $U+1QHNEV\\NF/VDDN(T4@>ZE9O^_E>HT4 >.W7AO6G\.B!
M=-N#+_PBEA:;0O/G)*2R?4#DUWOQ T^?5?!&HV5M;M<2R^4!$HR6 E0GCZ U
MTM4+'5[;4+_4K*'?YNGRK#-N&!N9%<8]1AA0!QOBK2]0@\<6^M12:S'8MIWV
M3?I$4<LD3B0MAD=&.U@1RHZJ,]JK^&O#EW9:WX:N7T^]BABAU*5_M;I(\+S2
M1LNXHJJI8;CM XR1FO0(KL2W]Q:?9[A3"B-YKQXC?=GA6[D;>?3(]:AU;5[;
M1;2.YNM_ER7$5N-@R=TCA%_#+"@#A+70+^+PKI-N-/D2>/Q.;N1 F"L7VMVW
MGVV$'/I6-K%EXBU#2[ZT>QU9+C^TQ-]@M+.&.R$8N _F>9MW2L5 ;AL[CR.*
M]CHH \U?0=0D\1><]A*T/_"6B]W%>/*%F%$GTWC&?6NFT*QN;;Q?XJN98'C@
MNI[9H7(P),0*K$?0C'X5TE% 'E.KZ+J=IK7BA)5\131:M()+=-,C@:*X4Q*G
MER,\;&,@@C)(&"".])K?AC5+N\TR>TTAGC\.64"R1W#EFU0J48P[AM#A-NX,
M1@N1P!FO2(M7MIM<NM(7?]JMH([A\CY=KEPN#ZY1OTJ_0!Y9JFGZE!XEUZ_*
M>)!;:O%#);IIL$+AP(@ABE$D;%"#GKA?F/?-:_AGP[=:9XD@+VLT,4/ARULD
MEDD$I1UDD+)O  8@;>0!GBKH^(NE>6+LV.J#26DV#53;?Z,?FVALYW;<\;MN
M/>ND@U.TN=2N]/BEW7-HL;3)M/RA\E>>ASM/2@#A?#JWMGH&A^&I_"\TEYI[
M;9[B>,""+:&!GCDYW,V> .?G.<<UAVVCZEINB:*?L.O6&H)HD-L;C3XDN$E9
M=V89X64@8+9!. =QY&*]AJCK.JVVA:->:K>;_LUI$99/+&6VCK@4 >?,OB6*
M]LEOK*]L"=)MXRVA64+M+,-V^%I&5A&JG&T<+\Q^:JOANSU/P\?"5W?:!?S+
M9Z3=6UQY,/F/;R-,A' Y.0I''8YZ9KU@'(!'>L;6O$UGHMS;V;075Y?W +16
M=G%YDK*.K$9 51D<L0* .%M_#.LSRV$HM);/[7=ZK<!3ULUGC(CWXX!).<#H
M2:B\.Z)J!D\,6%U!XE\W2I$>5+@6\5K;%$*DHZQ9D!S@ -DALDC%>@:)XELM
M<FN;5(KJTOK;!GL[R+RY4!^ZV.05.#R"16PS!$+,<*!DF@#G/%=E<WEWX::V
M@>5;?5XYIBHSL012@L?;) _&N.N].U1?!VM>#AH=Y+J-[>7#17HC'D.)9BZS
M-)G@J".#\V5X'2O0['7+74DT^6SCN)K:_MS<0W"Q$1A1MQN)^Z2&X!ZX/I6E
M0!S'A;39[+6_%-Q<6[)]JU%7BD9<>:@@B7(]MP8?G6=XDM+W_A,)IHK"ZG@N
M]!GLTEA3<J2[BP#>F1T/K7<44 <!'H=\MI\/HHK62%K&%DN&5<?9R;-TY]/G
M('UKGM \.ZG%:^'=%O(?$C3Z;=Q22QMY$=G$8SGS%E$6YP>RAMQW$$CDU[!3
M)IH[:"2>9U2*-2[NQP%4#))H Y[Q18W5WJGA>2WA>1+;5?-F91GRT\B5=Q]L
ML!^->?Z3X:U2#3M-\/WJ>)9;BVOTD=$\B.S&V7S//$WE%L?Q;<[B21[UW%KX
M_P!.N);-I-.U:ULKV18[:^N;79!*S_<YSN7=Q@L!G(K2UKQ3IF@:AIMC?/(L
MVHR^7#M7(7E5RQ_A7<Z+GU84 <-]AU>TU\1Z58:K SZOYTUC=1)<6!0R[FG2
M4@&,D$N #D,<8HL+'5[/7K*WTVPU6")=3:2YL+V))[*&,NQ:6&<@,I(8D '.
M6QBNWUSQ1;:%?6-B]E?7EU>K(T,5G$'.(]NXG)']X4:/XIL]8U&?3OLU]97\
M,0F-M>P>6[1DXWKU##/'!X- 'F]EX:U2+38O#UXGB6:==0\QDB\A+,CS_,$X
MF,18<8;&=V>*[[P?IT]A)XA>XMFA:YUB>="RX\Q"%"M].*Z:B@#B)GNO#_C+
M7;^?1K[4;?4X8/L\EG")<&-2K1,,_+R=P)^7YCS5/PAX=U31M5\-)>6[ 6NA
M7$$S*=R12--$RQY]@"/^ UZ'5"YU>VM-8L-+DW_:+Y)7BP/EQ&%+9/;[PH P
M]?4P^/?"=Y)_Q[D7=KN/19'167\Q$XK U.TN;+X=>-H+FV=9;^_NX[5&',IF
M8)$1]688KL]<N--$NF:?J,3R&^NPEOM'W944RAL@@C'EGD=Z-7N=-CU+1;:_
MB>2:XNS]DP,JLJQ.V3SV4-C.><?6@"AXOBU*/P?Y5A:K>7*/ '!@69E4.NZ1
M$;AG4 L >X%8GA6SU(^/[O4KE=9FM)=+2%+O4XHXF=UE)*A$5=H^;@$ ]>U>
M@T4 <#J6J#2OBS/.=*O+W=H4*[K2'S'3]_+QC.<-CKT&!G%<Y9^&=;T.YTB_
MN1K%M";&>%TTA(II+5WN&F$;*R-E=K*N5'!0=L5ZP-/M5U-]2$(^V/"L#2Y.
M3&&+!?3JQ/XU9H \UT#PY=VNJ>%;A]/ODBBFU&XD^V.DCPF7&TML554MDG:!
MQDC-1+I.IZ=X@_MN32[FYM;77KR9H8DW2&.6%$29%_BP01QS@G%>@6VKVUUK
M-]I4>_[391Q22Y'RXDW;<'O]PU?H \MN=)U6[U.Z\3QZ1=+:#6;6\&GNH6>6
M.*%HVDV9X;<P8*>3Y8[XKH?"PN+KQCXDU9]*NK&UNXK186N8_+:8H) S%>HZ
M@8/.,5V-% '"S-=:!XH\27$^AWVI0ZLL+VSVL0D#;8A&87Y^3D$Y/R_.>:B\
M(>'M3T76-"CO8F(M/#OV664'*++YJ'9GO@ _@*[^B@#E/$,-TGC7PU?QV5Q<
M6T<=U;RO F[RFD$>TMZ+\IR>U86F:#?V_@KP!:?V?)'<6-[!)<Q[,&$>7(&+
M>G+<_6O2** /+I?#&J2?#.&UAM;B*[@UE[Z6"(()98Q=N_R[P5+;=K ,"#@5
M4U#PSJ?B&P\036BZ_+/+8PV\<VJF&!I]LPD,:QB->P(W-Q\Y&",FO7*CN)OL
M]M+-Y<DGEH7V1KN9L#. .Y]J .#\-V-Q=^+[?4Y%\22+:V<D1GU988 I=E_=
MA$C4O]W.<[1CC.:VFTZ=OB<NHFV8VRZ,8!.5X#F8$KGUP,UT5O-]HMHI_+DC
M\Q ^R1=K+D9P1V/M4E 'FFC>']0MO#/P_MC82PS6-VSW*A,&$&&<$MZ?,R_B
M:JVNG:H_@_1?!_\ 8=Y#J-C>6[2WIC @013!VF63.&+ '@?-ESD#FO5:H:-J
MUMKNDP:E9[_(FW;?,&#PQ4Y'U!H X1] U ?#R_M%T^3[9)KYNA&$^9D^WAP_
M_?L9SZ5%J^DZC<2^)]._LJZE%WK=C>QR>7F*6$-;!\'U&Q\CT%>GU0O-6@T^
M6<7,<\<$%JUU+<^43$J+U&X?Q8YQZ4 <;XKT6YO/$.LS_P!D7-]:2Z1;1[;>
M7RG9TN'<[&_OJ,,!WP!WJWX*75QK&HM<F_GTTPQ+#=:I:)!=,X+90[0"Z@$8
M+ <DXS71VFO65[JHTZ R&8V4=\"5PIC=F5?QRIXK3H \Y\1QZW+XDUB&*WU.
M"WGMHTM6TNTA/VP[3D33.IV88D $K@'(/-/\$Z-?6FJZ'<7EC+#]G\+P6;O(
MF-DH?YD^O%>AU4OM3M-.:U6ZEV&ZG6VA&TG=(P) XZ<*3SZ4 >;^&]/U+PQ-
MH^IWFCWL\"V5U9M%;P[Y+=S<M(IV==K+@9'3 SQ75?#^SN;+PU(EW826$DE_
M=S+;.!F-'G=E'''0CIQ74T4 >81V%W<>!-3TF&!YKZU\1[I4498@WR3[_IY;
M!OI5F_MY]-\$>/S=VSJ;V[NA;*P_UWFQ)''M]<L<"N^CL;:&^GO8X@MQ<*BR
MN"?G"YVY'3(R>>O3T%%W8VU]Y'VF(2""59HP2<!US@X[XSD9[X/4"@#F_%FD
MWUS\,+[2[>)KF]%@L81.LC*!G'N<&H-*M)[SQ5XAU633KB&&]TVTCA^T1;6)
M EW(1ZC*Y'N*[.J>JZE!HVD7FIW6_P"SVD#SR[!EMJ@DX'K@4 >56&A:SI!\
M/W]P->MHU\/V]B_]EPQRRPRH2Q1T=&(!R.0.J\]J[WP9ILFD^#H+:6"ZMW)E
ME,-U*DDB;W9L$HJJ#SG &!G'.*VKC4;:TTJ74[B3R[2* W$CD$[4"[B<#GI4
MT,L=U;1S1G,<J!UR,9!&: /)O"?VG6_!G@?3+31KNV-C-;WDUU)&%A6- 265
M\_,7SC Y^8YQBH-/\-:I#IMMX>O$\2S3Q:@)&2/R$LR!-Y@G$QB+?[6,[B>*
M];T^PM=+T^"PLH1#:VZ".*-22%4=!S6=;^*=+O)=*2VDDE75/-^S.$(4^6,M
MG.".G'% ''WV@Z@W@7QM:Q6$INK[4[B:% OS3*63:P]1@?I4US'?:/-XNL9=
M!O=1?69FEM98(@\<JO"L8CD8GY-I4_>P,'(KN[J[%J]LIM[B7SYA%F&/<(^"
M=S^B\8SZD>M6: /--,T[4O"<MY;WVDW>K&]TJSMHY;9!(K210F-XW)/R@GYL
MGCYCS6[HNCWS?".TT5E:UU!M&%KA^#%(8MO/I@UM:YKUIH%O!)<)/-+<2B&W
MM[:/S)9GP3A1] 22<  =:@T7Q/:ZS>7%C]EO;&_MT622TO8MDFQB0'&"0RY!
M&03R.: .&\.:/?2W_AJWN8/$N_2OFD6\%O%;6I6(IA&6+,H.=H"MT.2>*M:=
MH&H0>!/!MF=/D2XM-5AGGCV8:-=[EF/I][GZUZ54<\\=M;R3S-MBB0N[>@ R
M30!Y7]AU.#PMIOA=_#]]+>V6L0S272Q PE!="0S!\\DJ>1]X9.1@5>BT'4&U
MFUDDL)3$GBV>])9>!$;=PLGTW8P?6NZL]7@OWM#;17#P7=J+N*X\HB/:=N 2
M>C$,#CT!]*T* /,=:TB_BU[5=16S:2&/7K&]C@RJF[5+=481[B S!N0,\E*U
M/"UZVH_$CQ+=?V;/8@V-BNVX4+(_,WS, 3CTP>< 5UVIZ58ZS9-9ZA;K/ S!
MMK$@A@<@@CD$'H1S6._]A>![95MK.8SW\VU(H0T]Q<R!?5B2<*#RQP .HH R
M)FNM \2^)II]"O=2BU81/;/:Q"0.%B$9A?GY.03D\8<\]:A\%^&]1T77+ 7\
M!8VWANVLVGZJ)!*Y9 W? V_I720>+=,FT&\U8^?%'9NT5Q!+$5F248_=[?[Q
M++C'7<,=:VT8LBL5*DC)5L9'L<4 <[X L;G3? ^F6=W \$\2,&B<8*_.Q''T
MQ7)^%])U%+WPE%=:5=0G29=12=YH\*I?E&4]P0V ?K7H;:I;IK,>ER!TN)8#
M/$6'RR!2 P!]5RI(]&'7G!8ZK;ZA+>I!O*6<Q@DE( 1G !8*<\XS@^X([&@#
MS74?#FL">2_C@U".&V\2W%XRV2H9C$\(02QJX*MAB>,$X)QS73>"-/FAO=:U
M*5-7 O9(@LNJ&-9)MB8W>6B+LZXYR3M'2M"T\::1J'A^]URS::>PLYGBED1,
M\(1N<<\J =V?0' -= CJZ*Z,&5AD$'((H 6BBB@ HHJA9ZM;7VIZC80[_.T]
MT2;<,#+H'&#WX(H OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5RGC7_C\\)_]AV+_P!$S5U=
M->-)"I=%8J=RY&<'U'O0!X9<:C;32:;K5H+.WN)M<B59IM0>74'4W(5U=  J
M)MR-I) &!UJQJ*PZ;:^*H]/>"WE?Q)$E_F=HREFRQG+E?F6,L2"P[%J]D&GV
M0EEE%G;B24@R/Y2Y?!R,G'/-5EOM$D+3K=:>QGA9VD$B'S(DX8D]U7.">@S0
M!Y4T:0V?B"TAUS2]/T\PVOF1Z>\\]M#(9N"[  (KK\KA6&!\Q]:K:@+&3P?X
MITV6QLHQ:&SN7;3[UI[(9DQE 0/+;:"67TP:]FM;:P2R"6<-L+25=P$*KY;@
MCKQP014<"Z5$!I]NMF@EC,HMHPHWIP"VT=5Y STY% &'XOE>U^&U_)H4C!$M
M%\F2U;<5AX!9"/1,D$>E<<[^%]'\8Q77AZX\R"'P]>SS)83^80 8B&7)($C
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MVI^&[[1% M;>[MI+?]R@&P,I!('3O5FTL[33U"0Q0Q/)@,RJ%:0@=3CJ< T
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MVP')?SW4[L%PP4$YRO'2O6MHV[<#;C&*K-IE@\$<#V-LT49W)&8E*H?4#'%
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MM1->2R+ C*5*(&8@+@]/8>@H Y*S\0ZC=Z'X;@AU.[@GFT>*ZEM]'TY))BS
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MB<C!&=IR*-#MK*_O=%T6\O[E-)CT"&ZMHDOY$$TS,?-8N&#-L 7"YPN[H.,
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M?+NVMP-Z,99_E(#$, .<@8Z<UT?PZ;R_AAH#A6<+I\9VJ.6^7H!ZT .'Q"T
MR@[[P69E\D:@;*7[*7W;<>;MVXSQG./>M77?$>E^&X;:;5+GR$N9UMXSM+98
M@GG'0  DGH*\S-U%I'@5]1T+Q!97_AZ.(L-!UB!'8#.3 &!W!P?E"L&YP.:T
MM>%]XN\67EO;Z*-0T_3]/:RD22Y6'R[BX0%SR#EECVCV+&@#N=<\16'AY+4W
MHN6:ZE\F&.VMWF=VVEL!4!/12?PJ#2_%VE:MJ1TZ+[7;WWEF5;>]LY;=W0'!
M90ZC< 2.E>>G4=5UK3?!-NUS'::]8ZO+87<DL?G!)HK>4$E<C=N7#=1]ZM*
M:A#X[GC\5:LO]H6NGSR:/<06XC@:-@/-?;DDR+M7*Y/'(ZT >FU3?5+2/68=
M)9R+R:![A$VG!1&56.>G5UX]Z\Y\%SRZ=K^CV]XT\LNH6DACO;75GNK>^VJK
M&1XY/FC;'0CC+$>E;'B#28-9^)VCVUS)<+ -)NW=8)WB,G[V$;2R$'&2#C/8
M4 =U5.]U2TT^YL;>XD*R7TQ@@ 4G<^QGQ[<(W6O)$OM7N#HFAF62ZLOMNIP;
M;G4I+8W'DS;8HVF4,QPN3M_BV\]*O:=->M<^'H;JYAN%M_$LT4 CNWN?*06D
MI\MI652Y5BPSSQ@9XH ]-U'5+32DMWNY"BW%Q';1X4G,CG:HX]^]&H:I::6M
ML;N0H+FX2VBPI.9'.%''3ZUY)&EK>>'O"6MW>J7+ZW=ZY:_:HY+MR&D\[YXO
M*)VKLQQ@#&WW.>R^)BP/H^CI<W3VL#:S:!YTDV%!N/(;^'Z]NM ':T5Y9?P7
MEG?>(['PY>W<L&EV]IJ4,1NGEV7"N[/#N8DD/&@RI)'S9[UT_@[46\1WNJ^(
MXYY6TZX=+:P0L=OEQ@[G Z9:1G&?1!0!UE0W=U%8V4]W.Q6&"-I9"!G"J,GC
MZ"O*O&EX;NY\4W-L;MCI<00W,VL/:1VD@B#CR8XQER<@Y8?,> <5VUW<27GP
MQGN9GWRS:,TCMZL8<DT 06WQ%\/W'V9G_M&V@N618;BZTZ>*%BWW?WC)M&<C
M!)Q765YKI7ASQ'XD\#Z-IVIZKIL>C26MJ[QVUFXG>-0C!-[2$ G R0OTKG_%
M>J2FRUS7;%[M6M-1,,5_<ZN\1C=)%4QQ6Z#:5X(PV"0230![/--';P233.$B
MC4N[-T4 9)-5+;5K2\GMXK=I)!<6PNHI!&VQHR1@[L8!^8<=:\_O])36-5\>
MW%[>:@ZV/R6L"7DL<<>;-"WRJP!R3T.1Q[G.,^HWFB^'[0Z+=SXC\'M<+B9I
M0DGF1;I "3RH9L>F,#CB@#U^_O8M.L)[R<2&*%"["*,NQ ]%&23["K Y%>6>
M*(]+T#PWJYT3Q!J)NYM%EG6+[;).'"E<3[R3L;G ((W9/!QQ+>QV-]XE\:'4
M];O+<Z?#!);HE\\(M@8 3*JJP!.X=\CCW.0#TZBO'IM2NM=M/,O8[J2]M-&M
M9KPSZLUA!:2/&7+JL8W,QZDD8& !WJWX?2;Q7?\ AV+5K^_D@E\,17,T<5W)
M$)9=X&]BA!)Y/?K]* /39K^UM[RVM)9E6XNMWDQGJ^T9;'T%6:\AT:--0U#P
M!=:E=W,LZ2:A )9+IP7\IV$><,-Q^49S][H<UUOB]_M'B/PWI-U=36VE7KSF
M<Q3-#YTB(#'&74@@'+G /.V@#L:AN[N"PLI[RZE6*W@C:661NB*HR2?H!7D]
MU)<2W$FA6FJWS:1'XEM[2&=+IS)Y;VY:6'S<[B Q(ZY&>O KLO&NF6]O\*]>
ML(S.88-+GV;IW9_EC)&6)W-R!G).1P<B@#=AUBRN-4.G12EKG[*EWMVG'E,Q
M53GZJ>*OUY?I_A[3M5\:6]JUQ>-91^&[8JL-]*N\F:7DNK;FQS@$X_(8Q[/4
MM:UF+PII]RYO()=-FE*SZG)9_:I4EV?-(BEG*K@[>,Y).<4 >T5R3?$?0$^T
M,5U0P6\CQRW*:9.\*%"5;+A", @Y/M4G@">\G\-N+R\BN_*NYHH9([AI\1JV
M ID95+E>5W8YQU-<MX3L/%.H>'M2M].U32K2PFU&_CW2V;RS(#/(&(/F!2>N
M./SH ].M[B&[MHKFWE66"5!)'(AR&4C((/H14E>6:E8VMK?+X=M%N[F#1=*@
M1_M&KM8V\"_,!)F,;G<A>3@@8&,9JMX:%SXLG\(PZIJ6H/$_A^2ZF$-W)$9I
M$EC56<J021DGW/6@#TM=<L)'C6&5IM]V]GF*-F"RJ&W!B!QC:1D\9XK1KR#0
M8X],NK&*QN;A#)XQO()T-U(^Y%6YVA@S'T!]R 3D\UI>&&L;C2]$U_4M=OX=
M<N[XQS(MS(XDE+,IMS#DJJC&/NC;MSD<F@#T2PO8M1LH[N 2".3.!+&4;@D<
MJ>1TJS7D&ARC5[CP=9ZOJUXL%S87[/']L>/[2ZSIM5B&!.!D]?X?3(I8-2DO
M8K/11+J&I1_VE?)8J-1-NES;Q%0#+./G<*6(&,YVY.<4 >O56OK^UTVV^TWD
MRPP[TCW-_>9@JC\20/QKR+2[J\U'2]/TYM2N4@'BR6R)M=0DD(@$#L8A,<,R
MYR,]>F.@I_B&QAAT[Q+I$ES=MIVGZSICVZRWDI,(D:'>-Y;=M^9B 3P3D8(!
MH ]7L]2M[ZYO;>'S/,LY1#+O0J-Q56XSU&&'(JY7&>-+-8M#L;?3;N"U:XOH
MLI+<R0B^PA'E-,F6!8*/F/7: >M2> +L26FJ6)BO8)K*\,<L%S>"[6$E%8+'
M+U9,'.&Y!)'' H Z^BO(]0>W>Q\=ZI-KE['J>EWDOV)5O746Y$:-&%C!P0[\
M8(.>E5K^\UK5=0\23WQCMI]/6,1-)K4MG]A7R5?S!&B$/EBQRV<XVXXY /9:
M*\WTFVN=;\77$^J7]T[V6DZ?<K%;7,D<)G82EGVC&0=O0CH>16)HFF//IOP_
MFEU75VFUF-DU!SJ$N9D%NT@7[WRX**,K@XSSR: /6KB]BMKFU@D$A>Z<I&4C
M+ $*6^8CA1@'D]\#O5>+7M+GBLY(KR-TO)GM[<C/[R1=VX#Z;&_*O.],EN8M
M9TW21>WC6<7B2^LU5[AV8PBT=@A8G<0">,G(P/2LC1=)TL:3X'=YIQ_Q/+M)
M3]NE 4[;C ^_\I^1?3//]XY /;*IZKJEIHNEW&I7SF.UMUWR,%+$#Z#FO'TO
M=<N;*[UMI[>WU*/57A%S/K4R^25GVK ;41E<%<#').[=GTD\4);:EX.\8:GJ
MFJ7,>J6]_-;1Q?:W58XUD BC\K.TADPW(R=V<\< 'L%_?VNEV$]]>S+#:VZ&
M261NBJ.IJQ7(?%&!+CX9>( ^_P"2T=QM<KR!D9P>1[=#65;V-K+XZORVH:@=
M-TG3+.YMXH[V5DW;IB7/S9<X3&#D'/.: /1**\9TV^N(=4\'ZC;M=1+JEX 9
M[K66GGO(GC<DO !Y:C.T\'Y3@ 58M8)XO"NG^)/[2U%M2_M\0;VO)"GDF^,)
MCV9VE=OMGWH ]>K*T_Q!9:IJM]I]HMP[V3F.:8P,(@XQE Y&"PR,@5YS'<S6
M'B)-3NKF>^MI=:-NE_8ZHX="TI06\MJ_R[5)"G;S@;AZUGR0RZ-I=_'ICSI'
M>>*WLKII-1EB'D@$A3(=QCW-M4N!DYP3TH ]KHKQR^DU:RT?Q#81WXLXH[G3
M1'#:ZG+=26;R7"J^)'52 RX.W)QSV-6]1L+F'QA<>'X5DFTZRT^.>VANM>GM
M22[N9)=X#-(00!R<+Z<T >L45XW%?ZYJ\_AO3KR>#4H)-,EG!759;..[D67:
M&\Q4W2%4VG& "6+<\5,C:KJ.D:+;-JEIJ#)=7BI8_P!JS1?;(D8!1]I507>/
MD<C#=>V: /7JK3WL5O=VMLXD,ER6$96,LHVKN.XCA>!WZUS_ ('U>UNO#=I'
MY]RLHFGMUCOKE996:-V#*KC_ %@7& PSP!GO3?$S22>+/"UEYTR6]U)=QS)'
M*R;U^SMU*D'CJ#V/(H UM$\067B".>6P6X:"*0QB:2!D24@D$H2/F ((R*U:
MXSX664-GX!L6A\W,K2,^^5WY$C#C<3@8 X&/7J:XB[U25ET[7[)[M%N-;CBC
MO;O5W\V93<;&C%LHV!-N1@X( SUH ]JHKR'58)SX=\9^(/[2U(:AIFJ3?8F6
M\D5(%0H=H0':0<G.0>#BM+7+W4;'7M3\)Q7=R)=?N(9=/F$A+0Q/D7(4]1L6
M-F&.AD% 'IE5H+V*XO+JU02"2V*ART9"G<,C:3PW'ITJ2*:!GDMXID:2#"R(
M'RR9&1N'49'/->8^)+N^DU7Q#:Q:A=P*=8TB!&AF93&LGEAMOIG)H ]3HKRB
M^T..*[\:VD>H:LEMI=A'=648U&;]S,T4A+@[LGF-3@D@<\<FF213Z]_PD=W>
MZCJ :ST*SNK=8+N2)4F:&1C)A" 3E1UXZ\4 >M45Y4KW^BRZ)J&GW=]<W^I:
M!=W-PD]P\JSSI'$Z'8254[F( 4 8.*J^&Y]5BN/#%_#<V_FZ@,SN^MS73:@#
M$S-^Y,85&#8.00%P5[T >IZAJEII8MC=N4^TW"6T6%)S(_W1QT^M/LKV*_BD
MDA$@6.5X3YD90[E8J< ]1D<'H>U>1P1VEUHG@K6KC5;J76;W5[9KI)+MV#R;
MCO3RB=J[#P, 8QCOS:74);\P:5*VH7MQ-J^J,EL-0-K$\<<Q $D@^;"[AA%_
M$8% 'J5W?VMB8!=3+$;B98(@?XY#G"CWX/Y59KQ&W\O5=%TM-1NG>&S\7-:1
MM'J4LBQQ;"=HERK, > QYQTZU)?7NM72^(M5:X@MKVRU*6&"ZFUJ6(6@5\1I
M]F6,JRL,'!SOW?3 !Z]9:I::A/?06TA:2RG^SS@J1M?:KXYZ\.M7*\LEDN[)
M?%&MV\DB2:5X@CN[B.)B!+"+:$3*1W&QF89[J*ZWP;<3:K!J.NRS2/#J-VQL
MT+$JENG[M"HZ#=M+^^\4 =-1110 4444 %%%% !1110 4444 %%%% !1110
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M!7NK9Y9)--L)KR69U8*-D0&43.<EN0?E]30!VEQHNE7=BUC<Z99S6C.9#!)
MK(6))+;2,9)).?<TZVL-,%K;1VMI:?9[9RUNL4:[(F&5)4#A2,L./4UYM9:O
MK'B2^\"7TMVEO,;V^AF46Q <Q+*A8J6RI*J1CL3[8JYH6O:IJ46E:+I9LM-E
MN7U"YGG2V!5(XKHQ@(F0-S%@23[G&30!WUQI.G7<=S'<Z?:S)=8\]9(582X&
M!NR/FP ,9]*?8:=8Z5:BUT^SM[2W4Y$5O$(U!^@&*X >*O$<^HV>@QW%E'J
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M<)YV#2R_94W2$$-ECC).0#SW%<#HGCK7]2.DZD+>\N(-0G19+&/1;A8X(7.
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MM96CM<,UK"6N5"3DQC,J@$ -_>&">#ZFHHK/3LW$<5M:Y9%AG5$7E0/E1AZ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI+.WEMXQNP"D@4-GUX04[0]%@T'1H-*@GN)[:!=D?VE][*@X"YP. .!7,/\
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M.4#=N3U&<9JO;?$":>.UO7T"XCTJ>_\ [/\ M9G0D2&4Q!MG4IN &<@^QZT
M= GARQ0Z(1YO_$F4K:_-V\HQ?-QS\I/XUFIX$T^VM[".POM2L)+*W-JDUM.
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M 9!R%.UL'/ID#-9VM>--2O\ 3["[TW3;F#2[C5[:WBU!9US(GVA48E.H1L,
M<Y.1D#- &Y#X!TZVLM/@MM0U2";3T:*UNH[@>;'$<?NLE2&3Y5P"#C J[9>$
M-+L'TV2'[0TMA+-.DDDI9I))00[.3]XG)K$A\8FS86]K8WVHW-WK-Y911R7"
M95H]S'!( 6,!3@<D#UJPOCL_89%DTB9=8341IHT]9E;?,4$@(DZ;-AW$XXP>
M* +]YX,TR]M[V(RW<+75^NHF6&7:\<ZJJAD...$'!SWK0UK1+;7M'?3+QYA$
MQ1A)$^V161@RL#ZAE!JCH'B.?5]5U33+S2I+"[TY83*&E617\P,058=1A>O'
M7IQ56_\ %]U%?:E#I>ASZC#I>!>S+.L>&VARD:G[[!2"1P.0,YH NKX3T\:9
MK%@\ES)'JX(NW>0%V)B6(D''!VJ/QS4%[X+L;JY>X@O=1L)98$M[AK.?9YZ*
M,+OR#R 2-PP<'K5!O'DMY<S1:%HDNII%90WYE^T+$IBE#%1SSNPIP/KDBN@L
M]7&J>&8=9TZ%I!<V@N8(G(0G<NX*3R >U #+#PYIVF:A%>6<;1-%9)81H&RJ
MQ(Q91SSG)/.:GT?2+70])ATVSW_9X=VW><GYF+')^I-><Z1XL\2W2^!YVM);
MNZU'3[J26!9U1)R!"5E<XPH&YN #C..]=$?B#%_9MLPTV1=4N+R:Q%C).BA)
M8L^86D/R[ !G/?(XYH MVO@/2[.XMC'<Z@;*UF^T6VGM<9MX9,D@JN,X!)(!
M) ["IH/!>DVPLWB-P+JUNWO%N_,_>R2/G?O;'S!@<$=, =,"I_#GB./7UO(F
M@^S7EC*(KB$2K(H)4,K*Z\,I!Z\=P0,5B:9K^HP)K[+:W.J3)KLEK;Q!PJQ)
MY:-\S'A$'//J>G- %Z/P'I<5PFVYOQ8QW/VI--^T?Z,LN[=D+C.-WS;<[<]J
MNMX4TJ32=2TR6.22VU"X>ZF!<@B1F#94C!&& (]"*Y/6?'NI2>'-1?3[%8-3
ML-1M+6X5;E)4"RR)RKXP=P;;T!4DGM6IJ'CYK2[OH8-*^T#344WQ^V1H4<H'
M*1@_ZQ@I'H.<9S0!;/@339HKD7MWJ%]/<>2K7-S,&D5(I!(B+@ !=PR>,GN:
M6Y\#:;=75P[W6H"SN;@74]@L_P#H\D@(;)&,\D D @$]JI3?$%)M1:VT?3#J
M(CMHKI@+E(I9(Y%W+Y4;<R';].>.M6-*UK5KKXAZUIDUOC3;:TMI(B77*%_,
MR<8R=V,8SQL]Z &W?PZTJ\M[RT>\U-;"ZF:X:R2YVQ+*S;RP&,_>^;!)7/:I
M;[P'IM]?ZC=->ZE$-393?00W.V.X 0(%(QD#"\X()R><5-J7B>YAUJ?2]+T>
M74IK2!)[LI,L8C5R=JKG[SD*QQP.G/-8GAOQ/JX\#^'I1I\VIW=S8B>>ZN)Q
M#$N,#YI&!^8YX '8GB@#?N_!NC7OV_S89 +V."-A&^SR_)),1CQRI4G.1Z"H
M4\)+:VVIR0ZCJ%QJEY:FV2]NKC]Y&N#M"E0 @!.<@9SSS6&OC?4-6O\ PC-I
M5D5M-1N+F*ZB>9,[HE=67.#D J6!!YP/6K,?Q(MW9+O[!C1GNA:K>_:DWY+^
M6'\K[P0MQG.<<XQ0!V=K$\%I##)*TKQQJC2-U<@8)/UKF$^''AV/2;73%@E^
MS6NH#48P9.?,YX)[K@[<>@ K6\0:ZF@V<$GV:2ZN;JX2UM;>,@&65LD#)X P
M"23T -85WX^.EV6IG5-'G@U#3U@D>TCE63S8Y9/+5XWXSSD$$#D>^: -:^\)
M:9J%Q?SS^=OO9+627:^!FW??'CCCGKZU?TS2;;21=BVW_P"E74EU)O;/SN<G
M'M69I'B2ZO==GT;4M)?3KQ+=;J,>>LJR1%BO5>C CD>_4U'J_C&#1YM:AGLY
M6DTZTBNHE5AFY$A9%5?0[UV_B* .EHKSGQ5XZ\[PC+-I"SQRR:5#J8FB;YHE
M>5%5/]YOG'_ 35S5O&-Q#I^MV>JZ5>:7<0:5)?Q-;W2,[1+\IPP!"."1V(YZ
MF@#NJ*Y2Z\6W27EW::3H=QJG]GQ1O>.LRHP++O"(#]]]N#C@<CG)K&_X2W6+
M/Q%XI>#2;O4+*SCM[@I),L/V=# &955N2YY)7CZT >B45!8WD6H6%M>P$F&X
MB66/(P=K $?H:GH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K'U[1I-7FT>1)EC%AJ"7C!AG>%1UV
MCW^?]*V*H:MK-AHELEQ?S&-))!'&J1M(\CG)"JJ@LQP"< =C0!RFL>!;B?7M
M3U+3X]$F.I!#)_:=EYS6\BH$WQGN" /E/&1G/-:EAX5>QU:2Z%TCQMI$.G "
M((=R-(2^% 4 [^@ QBKUKXIT:]@M9H+T,MU<FTB#1LK><%+%&4@%6 4G# 5)
M=>(](LEU!KF^CB73BBW18']V7 *CIR2&& ,]<=: ,2T\&W%O8>$[;[<H;0[=
MH7D12#(3 8LKZ8)SS6)I?PVOK)]$WOHT9TR[CN)+FWM&%Q>[006D<G()#$D<
MY/<8K7U;XA:;:V5K=V5PAC&HPVEXMS#)$\"."<E&"L"0..,'WKH-'\0:9KRS
MG3KAI&MW"31R1/$\9(R-R. PR.1QS0!A:-X,GTO4M)NGO(Y!8MJ+,H4C=]IF
M$@Q_N@8-;'A[1I-%CU)9)EE^UZA/>#:,;1(V0OU%8NJ^)-5D\7S>']+N=(L)
M(+:.??J2L[7!<L,1HK+D#;R<GDCBDN/&EYH]OHD>N:6;>^O[][.580\B!5#G
MS4VJ20VU<*<'#'^Z: ,X_#F>">YMK4:)]AGNVN1=3Z<LMW$KOO:,%LJW)(#,
M. >AQ6A=^#=0N=<D\1#4U368KA?L9 ;R8[4<&!ESSN!8LW][:1]T5K2^,_#\
M&IMI\FH 3+,('?RG,22GHC2XV!N1P3FEO/&.@6&I-87-^$GC=4E(B=HXF;&T
M/(!M0G(X8CJ* .9N?AW<"\U);(:)]FU"Z>Z-S=Z>LUS;ESEU0GY6&<D;NF>A
MQ6X?"$<Q\4PW,P-KKBI'MC7#1*(%B/MGC(HTWQ=!(]^FIR10-'J\FG6J1JS-
M-@*1\HR2>23C@ 9XJ_XFUT>'M'-VMN;FYDECM[:W#;3--(P5%SV&3R>P!H P
M+OPOXGU;1+G2M1UJS6W.G36:?9H&7SW=-@DER3C YVKW/7M4/B3P-J&NB6V>
M72+BVE@2*&6[M,SV+!=I:%U()Y^89(P>^.*L7VM^*O#-O%JFO+I%SI?F(ET+
M&.2.2U#,%#@LQ$B@D9X4XY]JU+GQQX<L[V>TGU';+;R"*X(AD*0,<8\QPNU
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M5HOB-I1I%Y]J$2JS.L3JN#TPQ !/!R <CO0 OAK1I-"TN6TDF65GO+BXW*,
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M\6CW$;V<%JR:M:><8S$FQ70CU4#*GJ0#D5U-GXKT2^M+RYCO1''9+ON1<QO
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M J8:1-K897V9(R.N/6K"Z]]M\1V>FZ>8Y(#9_;KF8@G$;?+$%]V(8Y/9#ZY
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M.I)M;66/#YSWQ(^/]JO5Z* /-+[0]7EN-;L1I4[QW'B*SU*.?<GER0@VX?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7*>-?\ CZ\*_P#8=A_]%2UU=&*
M/%8/#NES>&-%U"2S0WMSXF>&:X&1(T374J-'NZ["O!7IR?6K&KZ59VMUKVBV
MENMMII\0:0!;6X\M$\SRM^T+C;GVKV' ]*,#TH \DU'PIH2WGC^%=*M5@L]-
MBFM85C CMY6AD+/&O17)1/F&#Q67?LESK%U+XCNM$2)M+M&LFUN%W)0Q R&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MB31ZQ:('L/E 5(9PH+@D <;A@9STKIKO3YI?B7I5^;9FMH-+N4\[;E4D:2'
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M6YB@=X+::Y,TBC(C#0,HSZ9)Q0!'X'\43^+=,GU-A9I;F9DAC@=F= "1^\)
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M_CN+N*WN(+>ZAM]ZLK2%=F2I!Q\ZDX/0\^E=!!#%;01P01K'#$H1$48"J!@
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M@!0EY%A!9L]02F?08K1U/4;;2--GO[MB(85W-M&6/8*!W))  [DBLWPSH?\
M9OA^PBOU2?4%027$S@,QE)+MR>P9VQZ51\<$E_#4;?\ 'O)KEN)O0X#LF?\
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M=2IY(P,-SCMU-8XN[W6;K0X]7ET^:W;P[:W,2ZI?26\<LK ^;("H.YQ\O7D
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M)XII)HHK1+=$6,),R!MPY)(7Z<UQ?B6VO4'Q$=;]I/\ 3; )')&NT,?(*DX
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MTU&2>5["\$,<ES L,S(T2.-ZK\H/S'ICC' - '7T444 %%%% !1110 4444
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M4X5LL#QQU_6@#6TSP;I>FZE'J)DOKV[A4I!+?WDEP85/!";B0N1P3U]ZCMO
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M'"A58DX/3I7+:;X@UVWUKQ7)>::TES;&S2*R2\W0)N4Y<.P&U/XF.W/!X)%
M'2VG@_1;/[!Y5NY^PRR7$7F2L^Z9\[I7R?G?D_,<D9.*B?P3HILTMHXIX%AN
M7NK=X+AXWMW?.[RV!RJG)^4<<]*Y+6_'VI3^&/%4%FFGQ:II=FLXN+'4/M$0
M5]PR&V AUVGY2!U'-:^H^.[FRU(Z4MKI2W]M;)/>"[U401J7SMCC8IEVP,Y*
MJ!D9/- &U:^#]'M(;>-(96:"]^W^;),SR23[2N]V)RQP2.>.GI3=4\&:/JU[
M/=7 ND-TJI=QP7+Q1W2J, 2*I ;CCZ<=*LZ5XBL=5\+0^(8RT=G);FX;?U0
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MQ=K,<@9P."!P.WTQS%IXLECFET_3;"6[U*ZU:\@BCNKT^6JQ'+N7VDH@R,(
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M3*L0$<OS,HQ\O(!Y'7J*ZZJ.K:Q8Z)9?:]0G\J(N(U 1G9W/15502S'T )H
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M=^[[NWC&W&[-36WC+0[F"]E:ZDM191":X6]MY+=TC.</MD4$J<'! ]J ,O\
MX0B>XBGGOM4674KK4K6^N)H[?;'B!E*Q(FXD#"XR23DD^U=#K=A=ZCII@L;_
M .Q7 =760QB1&P<E77(W*1P1D=>M5;#Q=HNH_:?+N9(&MH?M$J7EO);L(O\
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MHNYO+^U3K;P_*2&D8$A>!QG!Y.!V[BJ#>+-#6+4Y#?J5TR9;>[Q&Y,<C8 7
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M@%<;E49&1@^X-7+7QEI\6C6%S>W@NKB\\SRDT^SF=I0C$,5C +@#@$GC/U%
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M +(.[VJY'XOT&71I=6744%G%+Y,C.C*RR9 V%"-V[D?+C)R*Y/3/#>I0>%O
MUI)8%9M/U3S[I#C]TNR?YCSZNO3UJKK7A;6+BYU*]AM[O;%XCCU!([61$EFA
M%JD9:,MQN#$D XSM/M0!VJ^,- ;2I]2;4DCM+>18IVF1HVA=B H=6 9<EAU
MZYZ5GZA\0=%@\.ZQJEE,;J33(/->W:*2-R2#LX9<A6(^]C'?M7+3>&M0O].U
MBXBT[5F>ZNM.53J=PC331PW"N[% ,*%!;&221G@<9V/%GA_4]3U/Q(UI:EUO
M/#1LX6W !YM\I"<GK\PZ\<T =4-=L%\/#6[B8PV0A\UY'C8;%[D@C/Z5(=:T
MU=6?2S>1B^2V^UM#GD0YV[_3&:@MH%UOPJ+6]LY[=+JU,$UO. '4%2I!P2/U
MKRT^$/%LVEPW[VQ76IY#I-PP<96R,"PF7.?[Z>;C_:H [6]\;8A>ZTZ:RN[=
MKO3XH@%D#B.X906;.!DALKC\:V?#NLS:R-5,T<:?8]1FM$V9^94(P3GOS7(:
MEX8U :CJJV5@WV5M1TA[?:1@Q0LF\CGHH'Z5T_A+3[K3UUO[5"T7VC5[B>+)
M'S1L1M;\: &IXPTVSM6EU74;12]Y<6T/D)(=QC<C9C&2X P0.IZ9H@\?>%[F
M6VCBU5&:XD$2?NG 60MM".2N$8D8VM@USNE>'=3AUW1YY[%A%!K>JW+L2/EC
ME\SRVZ]]P_.BY\.ZFWA77[5+%OM%SXB%Y$@(R\7VF)M_7^ZI/KQ0!TEQX[\,
M6EY):7&K11RQS&"4LC[(I,XVN^-JG/3)&>U3V7B[0;^VOKB#44$5BH:Y,R-%
MY2D$AB' .T@'!Z''%<G>^&]2E\)^);1;!FGO-?%U&G'[R+SXFW=>FU3^5+XQ
M\+:MK6H>(S9P-MN-/L!"P<)YSPW$DC1@GH2,#)X^84 =;IWBO1-5%P;6^4?9
MX_.E$T;0E8_[^' .W@_-T]ZQ'^(-C=ZY8V.DW$,L4]K<SRR312)M$:J489 R
MARW(!!QQ7.W/A;4?$::KY=MKD,KZ3-:17&LW,>2[E3Y81 <K\HRQ./0&M"_3
M5_$&M:;.OAJ\L8[33KR&5IS&,221J B[6.1E>O0\>] '1GQEI-EIVGR:C?1M
M<75HESMM()904(&7"JI8)GH6 J.7QOIW_"1Z'I=LWVB+5K:2XCN8PS+@%0F,
M#!SN/.>,<]17*P:?XBLUTJUFL]6BMXM%M($&DB!7>=5(=)I'^90.,8(').<T
MFA:#K6FVG@M+C3KE6M[&\L+IHBK&V>5H]KGYAE?D)R,]J .VM/&&@7VI+I]M
MJ*/.[M'&=C!)&7.Y4<C:Y&#PI)X-5_"WBJ+7+&T%TT46H7 N'6! 0&CBF:,D
M$_\  <\]ZXC0/#&IP0^'M(O+#76DTRYB>9I+N-;*,1<B2,@%FS@87 /S$$CK
M4E]I^J^&_A_I&K16VS6M*OY_*@<C,JW$[IL]\^9&V/\ 9% 'I=OJME=VEQ=6
M\_FP6[R1R.BDX:,D.!QS@@CC/2N>T;X@:3J'A>WUN\<VBSS-"L/EN[LX)PJ
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M)X7O;(A2!B9UB")U[[6]N*OZ%HM];:SK,]Q:%4GTFRMXV./F=$E#K^!9?SH
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MR\9.< AA][IT-:,>M6$?@W2=$:\C_M6+Q*BRVF[]['_Q,"V67J%P1R>.1ZT
M>QY&[;D9ZXHR,XR,^E>,POI^G^,(KB,Z9JES)KC+C+V^K0,TA!##)\R)0>AV
MJ4 K-*R2&\EO+_1[;Q,-68*[Q2/J2OYW[M4 ;)C*;< #;M)SWH ]YI 0PR""
M/:N4^(C2+X67+2K8F\MQJ!B)#"U\Q?-Z<XV]<=LUP7B/^R(K7Q2GA%K8:/\
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MOLD.R)=DC!T^7._$?<E<G[N!BKT6MZM%-#875Z+Q[7Q2FG_:)H(]\D)@\P9
M4 ,"V-R@'CZT >C>5'YOF[%\S&-^.<>F:Q='TNV76M2U@:H^I74K&VR2A6U1
M&)\E0@&,%CG.6.!GI7&0:UXE70H/$DNN,Z#6OL1L?LT0C>$W9@Y.W=N Y!!
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M/5+O1]/NS9/JGB>[CDNU17:-$@$A"A@5W': "0<<\4 >D))97$[PH]O+-:L
MZ*06A) (!'\)((/TI\-S;7$LZ0S1220MY<P1@2C8!VMCH<$'![$5R'@JWNK3
MQ1XPAO+TWLRW=O\ OV159A]G3&X* ,XP#@ 'K@5SUU_;-D_Q#UG3=:DLQIUT
MURENL$;K,Z6L3$.6!.T@ ?*5(Y.3Q0!ZKM48PH^7IQTHVKG.T=<].]><>(/$
M6I37=XNG:IJ:26ME',+;2[&.18I&0OF>252N",$*"#CGN*1/'6HZ=I\6I:DR
MRQZCH$5_8Q*@ ^U *'B&.3N:2(C)]: /2-JX VC Y Q3?)B#L_EIN?[QVC)^
MM>:7&M>)GUJ31'N]6\[3;"W:>?3+*"1IKB0,2SAQ@(-N J@9YYXKJ],UR_;P
M"NMZE:!+Z*S>::!>A= <XP3C.W/4XS0!T)C0L6**6/?'-(8HS*)"BF0# ;'(
M'UK@H]1UW2?#=OXFO/$$5ZLVG27<NGRQ1HC/Y)E58"H#<8P=Q;(R>*?!?:]I
M$OAF]O-<;4HM9G2WN+9H(T2-GB:0-"54, "N,,6R#GK0!WFU>?E'/7CK05!7
M:0"/2O,-&UKQ+_8OA?7[S7&N/[3OH[6>S-M$L6QRR@@A=P<8!SG'M4FG:]KL
M>OVL.M:GJ%DUU=R0*K644EC*IW>6(9D&Y7^Z?WA.2""* /0I+BP^T6XDFMO.
ME=HX-S+N9E!+*O<D!3D#T/I5A6CF0E65TR0<'(R#@C\Z\H\)/?66F>$[4:C)
M(M]JVHQLTD,1:,*+DY0[.#N7=^)'W>*F\#WFHZ;IW@^R&H2S6^H7E^)DDCC^
MZ@E( (4'[R[O7)(Z8% 'I\P@PAG$> PVE\<,3@8SWS3\#.<#/3->5^(+O4=:
MDDA;4Y85L_%]O:P&&./*)LB8?>4Y*LS$9]><CBDO?%/B:ZN->NM..J Z9=RV
MUK!#:0M:R^5C/G.WS_,<\J5V@@\T >IS316\$D\\B10QJ7D=V 55 R22>@ I
MMNMN(5>V$7E2#>#&!A@>_'6O-=9O-:\2Z#XQN4U1]-MM.ADMDL1%&RR?Z,LC
MF5B"W.\@;2N,9YKIK[6)?#_PO;5H(A+-::6LJ(W0L(QC/MGK[4 =,L,2$E8T
M4L=QPH&3Z_6CRH]Y?RTWMC+8Y..E<)-/X@T+Q%HMI/XC?48+ZVNI)EEMXE(D
MCC# H54?)D]#D].3FLW2M4\3W.D>%5N/$+FZ\2*DCSBUB M46%I&$8VX+-A1
MEL@8) [4 >F^5'YOF^6GF8QOQSCZT&*,RB4QKY@& ^.0/K7G4OB+6]*UM]#D
MU(W?V?5K"+[7)"@DD@G#9C<* NX;.H X(J3Q/XFUJQN/%45A>)&UB-,%KNB5
MA&TTI5\\9.1CKT[8H ]$JOYEE!-'8[X(Y959T@R SJ,;B%[@;AD^X]:\^UCQ
M!KOA&YUNVDU1M5\O25O;=[J&-#%*9?+.?+504Y#8//'6F:E9ZYI'C/3Y#K8U
M.[&BZ@]LUY''$$F'D]2@4;"=O7D<\GL >F50O=3TG2;B#[=>6EI-=N(HO-D5
M&F;LHSRQY'YUR/@_6M1DUT:=J]_JJW4EJ9#9ZI8Q1DNI7<T,L0",@SC')Y!S
MUJ+Q0L]M\2=-U$7DY2UT>]N1;JD9!V-"2H)4D;LC)SD8&".<@'H'E1^;YNQ?
M,QC=CG'IF@11B0R!%$A&"V.2/K7GMKJFOV%CX8UR[ULWR:S<017%D8(UBC$R
MY4Q%0&^7C[Q;(!Z5J> 9]:U73#K.JZN]RD[S11V@@C1(PDS(&R!N)PO/..>E
M '33W%A9K+/<36T 4KYDDC*N"3A<D^I( ^M6=B[2NT;3U&.#7CGB2UNT3XB2
M+J,KDW]@$CDC38K$VY4\*"=HPO7D#G)YK;UGQ#K?@VXUJ*;4GU<1:/\ ;X#<
MPQH8Y?,\O'[L+E.0<'D8ZT >CQQI$@2-%11T51@"J&J:WHVB^6=6U.PL?.),
M9NITBWD8SC<1G&1^8KDO#VJ>(H_$EC:7AU:ZL[J&0SR:C:P0>5(H!!C\ODJ>
M1M.2..>M)XU>Y3Q[X2:TTN/4I?(OL6\DJQ@C$7.6!'% '9Z=JFFZO"UQIE]:
M7L0.UI+:59!GT)4FK3Q1R,K.BL5.5)&<'VKS::VU319=;\3W*67AV2\AMK*"
M"W4W3,PD/SE54!Y#OVJ #VSQ5"Y\6:_I<'B>%;S4V-KHPO[235;6".9'WLIP
MJ  J<#[RYR#0!ZNQB#JK% SG@'&6(_G44,MGJ-O%<P2074!.Z.5"'4XXR".*
MX";2M6@\?^$FOO$5U=2M%>2-BWA10 (BR !,[3G'))  P0>37\,:OK7B*/1]
M*CU1M-7^S'OIY[2WB#R,9FC55#*451M).%R<CI0!Z.TUF]\EL\D!NU0RK$2-
MX3."P'7&>,U.%4=% XQT[5YGJOB#6=-&H'^TK.YN[3PS=7(N[>%"&FCE*AN0
M>F.5^[G/%7YM5UCPW?Z6=0UY+R#4K.XDF:XA1([:2.+S-Z; #Y> 002QZ<T
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MW"@87S%5@&P.!D5I7E@3H$^G620#_1C!"ERIDC^[M <9R5]>>15^B@#SO0/
M]S%XBLM1O-.@L(;*UE@$::E->&0N N%,@'EQ@!L*/7VKJY_"ND3Z%9:.UNZV
MEB$%KLF=9("@PK*X.X$#C.?6MFB@#GO^$)T(Z5/I[VTKI<3+<2SO<2-.TJXV
MOYI;?N&!@YXQ20^!]!A@O(OLTTOVTPM=237,DCS-$VY"S,Q)(/Z8'08KHJ*
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M[>[DTF;3;<M(P15?)P>O\7);!/6I].\#:)90%9+:2X9[0VC+<W,DRI$P :-
MY.Q3CH,=O05TM% '.V/@C1+"]LKU$NY;FQR+62XO993"I4H57<Q 7!QCZ>@J
MW#X9TF#3--TZ.V(M=-E2:U3S&.QES@YSD]3US6O10!FZ9H5AI%S?3V22QF^F
M,\R&9V3S"2695)(7)))QC-4+'P3H>GWL%S;PW&+>1I;>W>ZD>"!SG+)&6*J>
M3T'&3C%=#10!E:[X<TWQ'#;Q:BDQ%M+YT+0W#PLC[2N0R$'HQ'7O5&#P/HL$
M-Y"3J,T5W;/:S1W&I7$JM&XPP =R <=QR/6NCHH HKH]BNHVU^(3]IM;=K6)
M]Y^6-BI(QG!Y1>3SQ7,7?P_M)=?TF2W$EOIMC;72KY%U)',DLLB/E64YQQ)G
MGOC&*[6B@#'M/"^CV(TX6UIL_LYI&MSYC$AI 0[,2?F)R<ELG)S5:R\$:%I]
M[!<P6\V+=S);0/<R/!;N<Y:.(L54\GH.,\8KH:* .7\/:#=0^)=8\1ZG:VMO
M?7PC@2."0R;8HQC)8@99CUXX"J.U:,7AG28+'3[..V(@T^X^TVR^8WR2?-SG
M.3]]N#QS6O10!C7?A31KZ._2XM"WVZ=+F9A(RMYJ*JJZD'*$!%P5QTJ"'P7H
MD-O-$T$\[3SQ3S37%S))+(\3!H\NS$X4@8&<=>.37044 9=]X=TO49[V:[M?
M->]L_L-QEV >'+';@'CEVY'/-6+73+:TTI--7S9;98S%B>5I&93V+,23U[FK
ME% '-#P)H:65E;1+>P_8E:.VFBOIEFC1NJ"0-NV<#Y2<# Q6UIFEV6C:?%8:
M? L%M%G:@)/).223R22223R2:MT4 <U8^ _#^GW,$UO;3A;>4SQ0/=2O"DI)
M/F",L5W<GG'OUI]QX'T&ZOI;J6WFVS3"XFMEN9%MY900=[Q!MC'(!Y')'.:Z
M*B@"EJVE6>MZ7/IU_$9;6< .H8J>"""""""" <CTK)O/ VB7S!Y5O0[0);S-
M'?3(;F-1@"4JP\SCNV3R>:Z.B@#/M=$TZQOS>VMLL4WV6.T&PD*(HRQ10O08
MW'M4%OX9TFVL]*M(K8K#I4GFV:^8Q\MMK+G.>>';KGK6O10!D?\ ",Z3]L^U
M?9CYWV[^T-WF-_K_ "_*W8S_ '.,=.^,T)X9TF/2[735MB+2UN5NX4\QOEE6
M3S0<YR?GYP>.W2M>B@#EY?A]X=F$B26]RUN\QN!;?;)1#'(6W%U3=M4[N>!W
M/K5RY\(:)>7.I3W%J\G]IHJW<9F?RY"N K;<X#C:N&&#P.:W** ,&T\&Z+:Q
MWBO!->->P_9[B2^N'N'>+GY-SDD+R>!]:-+\':/I&IIJ5NEU)>)"UNDUS=RS
M,L1(.P;V/ *C'X^IK>HH ISZ79W.IVNHS1;KFUCDCB;<<*LFW>,=#G8O7TK*
ML/!.A:;>P7-O;S_Z,S-;0R7,CPVY.03'&S%4ZGH.,\8KH:* *FF:9::/8)96
M,1CMT9V52Q;!9BS<GGJQ-9^K^%-*UJ\CO;A+B&]C3RUNK2YDMY=F<[2R$$C/
M8YK;HH YX^"-!&DP:;%:20103_:8I(9W299N09/,!W%B"022<@TU/ OA];34
M;9K261-2$?VMI;F1WE9"2K%BV=P)^\#G@>@KHZ* .:C\!^'UCO%EMI[EKV)8
M;B6YNI99)%5MRY9F)!!Y!&",#'2IH?!FB1VU[!/!->_;HQ%<27MQ).[HN2J[
MG)( ))&,<\]:WZ* ,*P\(:3I[W,B"[FGN(/LSSW-W+-*(O[BNS$J._&.>:V+
M6VCL[2&UAW>5#&L:;F+' &!DGDGCJ:EHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBJNIZC;:3IMQ?W;%8($W-@9)] !W). !W)% %JBN>U+
MQC9:9J2Z>]CJES=_9TN'BL[-YS&C%@-VS(!RK?E6C%K-M)J%M8LDT,]S;?:8
MEF3;N4$!EYY#+N7(/]X>^ #0HHK%T#Q3I?B5[]=,E>064WDR,R8#'U4]U.#@
M]\4 ;5%4=3U:UTE+9KDO_I-S':Q!%R2[G _#N?8&C6-6M=$TR2_O"_DHR(0B
MY8LS!% 'N6 H O45F3:]9VTQBN1/ 3=I9Q-)$P$TC@$;/[PYY/0;3Z5;MKP7
M4MR@AGC^SR^46EC*ASM!RF?O+SC/J#Z4 6**** "BJ6KZK:Z)I%WJEZS+;6L
M1ED*C)P.P'<T:GJEMI&C76J7A9+:UA:>7C+!5&3QZ^U %VBN67QW8JT!N],U
MFQ@GD2);BZLF6(,Y 7+#.,D@9/'-=30 4454M]2M+J_O+&&7?<6>P3J ?D+C
M<HSTSC!_$4 6Z*KO>!-1BL_)G+21-)YHC/EJ%(&"W0,=W [X/I1?WUMIFGW%
M_>RB&UMXVEED.2%4#)/% %BBJD6H)->);+!<?- )Q*8B(\$XV[O[W?'7%6Z
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M\R9(@(8RY4L<;CCHH[GL*;9:E::B;G[++YGV:=K>7@C;(N,CGKC- %JBBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MF&1H(+-VB/=#B+CH./:DN/#4LL4=E<^*Y7CFD;RX)+.R(D<99L*8N2.2?QH
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MJ\4UI)(#KEDVD1[2<)<LX\I@/7#R\_[(KN%TRU74HK]8PLT5N;:/:  L9()
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MMI1-!-!*8Y(GP1E6'L2".AS0!YZ/%_B*+3-:MX[J4W5IJ-A!;3ZA9I')LG=
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M4*@7  (&6ZG'2L'4/$7B06>M22*3]E\3VMO;I;W1#LFZ#,/W5&TANI/)<@C
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M"OEK(#L4R;&+R':W) '&2>:2^\9G3+C4]1ETN_$]MHUK=O9RW& "\LB[-F"
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M0K+YBATQRK8&000>@ZUF:7X)_LV_TJ];4&GN+6:[N+EVBQ]HEN,;B #\@!'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %07=]:6$/G7ES#;Q9QOE<*,_4U/7.>*K?0X1;ZSKF9$L]PBA;#+(S#IL/
MWCQ^E:4HJ4U%_@9U9.,')?B;UO<P7<"SVTT<T3?=>-@RGZ$5+7*> ],N;#2K
MJ>XM_LBWMR]Q%:?\\4/08[?3Z5U=%6"A-QB[I!2FYP4I*S84445F:!1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7.^(_"4/B2ZM9YK^[MS;<QB!@,-G.[
MD=>!^5=%15TZDJ<N:+LR*E.-2/+)71F:+I#Z/!+&^IWU^7;=ONY=Y7CH/:M.
MBBE*3D[L<8J*L@HHHJ2@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exhibit101-arrowheadindu003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101-arrowheadindu003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&1@1P<'D>]/S0 444$X&30 4444 %%%% !1110 4444 %%%% !1110 4444
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M=S)<R7!,RS( %D5QRK#';CMC'%/'@?2VM+V&ZGO;R6]:(SW-Q/NE81,&10<
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M>ZC$WFV]Y<7J9?CS)]V_/M\QP.U$'A33+?2=(TU!-]GTF5)K;+\[D! W'O\
M>- '$P>(M;B\-:1/:0/9Z=+)>_:KG3=-%P8F6=E0>4O12-Q9@#R.V<U/#?7V
MM>*O U^FLVLZ2VUX9&M8#Y<A0H&P&Y4D<$'E2#72_P#"#:9'!9I9W-_936GG
M"*XMI]LFV5][J<@AE+<X(XP,5)%X+TJW&D?9FNH'TN1Y(9(YSN<R'=()"<[@
MYY.?TH Y2P\2>(G\'V>NZAKVGV_]HRK%%$+!W:(!F!\M4RTLC!<[< #GKCG*
MUC7=8U?PIXCL)KV4&PO;#R[B>P-O+)')(GRM&<8P><X&1VYKT!_!>EG1-.TN
M*2[@739?.M)XI<2Q/\P)!Q@Y#,,$$8-0_P#"!:0UIJL$DM]*=5\HW4TER6D9
MXSE'#=B#CIQP.* ,[[?XEU2^UN+3M4M;5-%*6X\VU#_:IO*61F?YAL0[@ %Y
MZG/:H-%\2:YXJUZP%E=0:?I[:39ZE-&UOYKL9&<-&&)& 0O7&1@>M;-WX&T^
M[DDD-]J<+7$*0WAANBGVQ57:#)@<MC@L,$CO6I9:!I^G:BU[:1&)S:16813\
MBQ1EB@ [8WG]* ,KQ1J.KPZYH&E:5<PVQU&2=)9I8?,**D>_*C(YXQSQSWZ5
MS*>(O%5OIEQJ=QJ5G+%INLKIDD*VFW[4AG6(N6W?(V'! ''R]\\>@7>DVM[J
M>GZA*'\^P:1H<-@9==K9'?BJ,GA/3)-.N[%A-Y-U?"_D^?GS?,63@^FY1Q0!
MQ7B+QMJNFRZG>6>II<+8W8C^R6VF22P! RJ5EN" %DY.0#P<#!K7U7Q9J>F3
MZ_I1\IM4$UNND93 D6X^1,COL<29]EJ[=_#O1[V&]M9+G4EL;N9KA[-+HK$)
M6;<6 QG[WS8)*Y[47&@W&K?$2QU>[L$AM=(AD6WG,H9KF20  [1T"#?UYRW%
M %OQIJM_H7@^YOM/:)KV-H$0RKE26E1#D#V8UR]_XA\0V.O'P_)J=Q)+:VJW
M,][9Z(]PTC2,P1-B9"* O)/+=L8-=YJ^DVNMZ;)87@<P.Z.=C8.4<..?JHJE
MJWA>TU74$U%;J]L;Y8O(-Q93>6SQYSL;@@@$DCC(R<$4 <UI_B/Q'X@GTC2U
M T6]ELIKN]DEM"7^241*$C?&T,?F^;.!@>]6%U+Q->ZU:^'#J-A:W<5F]U=W
MMO#YHD E,:*JL<*2 2V<X/ ]:U7\$Z4+33X;-[NPDT]&CM[BUG*RA6.7#$YW
M!B 3N!YYZTP^!=)CALULI;VQN+59%2[MK@B9Q(VY]['._<WS'(//(Q0!BZ9X
MRU)+ZR&KO;"T6[N]*NYD3:GVB+YHY!DG 9%<$=CBJ#^-M<GCT6#]_;/JL4^H
M&2VTY[J2&V#@0H$4'DJREF(P.G<5UMSX(T.Z\*OX<E@E-B[^8Y\T^:TF[>7+
MGDL3G)]S5G5?#-CJK6<OF7%G<V0*VUQ9R>6\:D %>A!4X'!!' H X]/$_BF]
MM]'L4Q87MWJ<]DUU=:>\?F1)"TBRK$Y!!('3.,@]J[/5M4'ASPM<ZE?RB=K*
MU+R.%V^:X'8=MS< >]5[+P?I5B;!HA.TME<R7:RR2EGEED1D=W)^\2&/Z>E7
MM7T:TURUBM;T.T$<\<Y16P'9&#*&]5R <>U 'F'@34(=&\2V5EYMX)==LV>]
MDN+*:$#4 6D8@R*H.Y7<<9_U8K2M_'^J_:_#L%PL "NT&NMMQY<AE-O&1_=!
MD5C]*[S6-%M-;BMDNPX-K<QW4+QMM9)$.00?S!]B:RKKP'H5W'KR202 :X4:
M[VR8.4Y4K_=YRWU)- '-_P#"7:M>6FG2G54L_MZ37<,-IITEW=-"9,0_(H(5
M-F"7/4G Q3+#Q5XEUZR\+V]K=VUC=:D;^.YN'M-VW[.^T,(RW!..03QN/I76
M77@_3Y[NUNK:XO;":WM19AK.;9O@!R$/!X!S@C!&>M+I?@W2-'.G?8UG5=.:
MX-LKREMOG-N<$GD\],F@#A?%5[K^N^!?$U^-0MH[&VGELQ9FVYD2*0([E\Y#
M%@2 .,8'.<UJ^(?%&MZ3XAO%NKK^R]/BDC%I+-I[2VDZ$+N\V9<F-LEAR !@
M'G-;>I_#_2-5:]66?4(K6^D\VYM(+DI#))Q\Y7UX!.."1D@FI=1\#Z9J5U>2
M27%_%;WS!KRTAN"L-P0 N67J,@ ':1D#F@#I001D<BBD "@   #@ 4M !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+HT=G--#--N:21X+=8(\L2<*B] .@SD\<FN5@\#ZU%;:=I9U:R_LG3=32^A
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MU2UA@ "G]V4C9"??.<T 51XUEU"5$T+1Y=1464-].QF6(QI*"R*H.=SD G'
MZ<\U9\!WUS>_#S1+Z\FDGN9+)))))&RSMCDD^M9MAX/UC0A VBZG9I))IUM8
MW?VFW9P6A3:LJ88<X)^4\' YK=\/:,^@>$+'2))A.]I;"$R*N-Y ZXH Q-(\
M>W&H6VBW]YH4MEIFKND5O<-<*[+(P)4.@'"L00#D]L@9IUSXYN+'4+5+W13;
MV5U>K91O+=J+C+/L5S#C.PG!ZYP<XK'\%^'-;U#PGX3CU>\MUT_3TANT@6W9
M)V=5^1'). %)[#)VCIS20_#.^BAMH/M6DYMM0CO3?"R)NKO;,),2R%N/3(SG
M Z#B@#HU\:1-I?G_ &)Q>_VI_97V/S!GSM^,[L=-G[S./NUF?\+%N_(BO%\-
M7#V,M^^FI*MRF]YA(T:X0X^4LH&21C)X(&:CTS3(=5^*VH:O:M,=/LHQYBO$
MR(;_  8F9<@;BL0 )''S#FM&+P9-'H5AIWVQ"UKK)U,OL.&7[0TNS&>N&QGV
MH CD\?BQL]2_M32VMM1LKF&U%JEPKK,\P!CVR$* #GDD#&#44GQ&CL['5GOM
M/5;S3K=+HP6MVLZ31,VW*N .0>""!VZYJ36O ?\ ;%SK%PUW$LEW<VMU;"2'
MS$CD@7&'4GYU;D$<<&JTO@2]O=)U>WN)=)LY+Z!((X]/L1''&%;<6)^\Q/'&
M0!@<=Z )[WQAJT,>J64VB&QU*/3)+^TS<I(KJI"G<0,*REE..0?6J=EX]U"*
MRT>QDTR&XU:XTR.]D66_2'S0<@>62OSN=I)7  R.:Z'5?#3:IKKWYN1'&^E3
MZ<4VY(,C(=WX;>GO6!-X*URYT>QL+R?0=0B@LUM6@O+ O&A7(65#G<&*X!&<
M9 P10!V4NH^3H4FIO;2Q[+8W#028#KA=VT]<'M6;%XHCD_X1K_16']NJ63Y_
M]3^Y,O/'/ Q5G3M!6R\(P:!+=2W"QV8M&G?[SC;M)KGM*\(Z[!>^'&U'5;&6
MUT$-'"D%NR-,IA:(,Y+'#8(X''7VP &E_$"YU"'1[Z;0);;2]5G%M#<FY5G6
M0[L90#[I*D YS[5GZUXRU34--L+S3=-GM]*N-7MK>*_6X :1/M"HQ:/&0C88
M Y).1D#-;-KX,FM_#'AS23>(SZ3>17+2;#B0(6. ,\9W51_X0C6H["ST2#5K
M-=%L[^*[A#6[&<HDPE$3'=MP.@8#)P..M $E]\28+.;4)DL4ETO3IVM[JX-V
MBR[E.'*1'EE4YSR"<' -:EGXHNM0\67NCVFCM):V,B)<WYN%55WQ+(NU<9;[
MV#Z<'OQAS_#RY2[U".QDT=;2^NWNC/<Z<LMU;EVW.J$_*P)SC<.,]#BNHTC1
M&TS6=;OC,KIJ,\4J(%QY82%(\'U^YG\: *^J^([JWUL:-I.E'4;Y;<74P>X$
M,<498JN6(.68JV!CL<D5E-\0)+D:3%I6A3WE[J"W(-M).L1@>!E617)R."3R
M,YP/7C2U/0M47Q&==T.[M(KF6U6TN(;R)FC=59F1@5((8%F]B#VQ531O!3Z3
MJ.D7AOA/):)>-<N8]IGEN'1V8#/R@%3QSQB@#8U_71H=A;RBU>YN[J=+:VMD
M8*9)6S@;CP  "2?0&LFW\8WS7&L6=SX=N4O]-@AE\BWF67S_ #2P78<#CY>2
M<8YXXYD\>1(=&M+S?/#-97L5Q#<16YG$+C(W2(""8\,0V.0#GM7(66BZIXTG
M\4S2:C&T5W'910W*V<D5O+Y3N[QA6;<T9W!6.>=S8Z8H UM4\=-_9VOV.H6;
MV=U9Z:U[NT[4%D8IG:</M&QP<=5/6M#4?&M[:W^LVMAH$EZFCQI+=2FZ6,%&
MCW_*"#N;&>.!QUYK*G^&]Y=+JA,^DV(OM)?3EM["S,<4)+!@_7YCUST[>G/1
M_P#",R?:/$TGVE,:S$D:#:?W6V'R\GU]: +M_JD,O@ZZU:(S"!]/>Y0QMLD"
MF,L,'G#8[\X-<]%XUOB'L]+T*?4&L]/M[N:2:\5,I(A(&2/F?Y3VP>>16]_8
M;_\ "$_V!YZ^9_9WV+SMO&?+V;L?KBJ6C>%9=+N-0D:Z2076GVMF $(VF%'4
MM^.[]* -2TUJ"^\,PZ[ CFWFLQ=HC<-M*;@#Z'%<O%\1+A])T^]FT(V[ZJ4_
MLV*6]1?.4H79W;&(U 'N3D<9.*Z'2]"?3O!5IH#3J\D&GK9F8+@$B/;NQ^M8
MM]X&:X\/^&[5)K22^T.)(XS=V_FP3@1"-PR9R < @]00.M $,OQ*MX;"0RV4
M2:A'?)8O"UXGD*[H75S/C&PJ#SC.>,9JY=>,[RSTJRN)= F-Y=Z@+".WCN$9
M78HS+(LG0H=O7 (YXXYKQ^#]5BTN=8[K2([B>Y6:2T334%F\07;Y3+]XCG=N
M)SGMCBL&^\(:EH-II,>G2VL-U<^(X[L16MLWV6U'D2+@)G(4XY.1RW&* .BG
M\?)IUKJ":IIKV^IV<T$/V1)U=9FF.(BLAVC:2&R2!C::C'Q%M[:+4$U*R$=[
M:11S)!:7*W"W D?RT".,?-O(4@@8R#R*BO? -SK,&H76J7MJVKW4]O-&T=N6
MMX?(),:%&.74[GW9(SN[8H_X0*YO;+4$O)M,LIIUB%LNF6*QI"\<@D61B?F<
MEE7(R!@>O- $7BGQ7XDL/"^JO_8;Z??01QR1SK<++%M9]IP^W&\=UQWR":ZO
M5-;31/#<NKZE T?DQ!I((CYC;S@!%/&26( Z=:P=2\,>(-?TG5+;5=8M4>YM
MEA@AM86$,;*V_P Q@S$L20!U&!ZULZQHDOB'PI+I6H7"17,T:[YK=3M252&#
M*K'H&4'!- &1<>+M5MC+97NA?8M1FLY;FQ'VM9$EV ;E+!?E90P.,$'G!J7X
M<_;&\#:=>:A)=2W-Y"ER[W%TTY?>BG(S]T'KL' IJ^&M8U+4X]0UV_LGDM;2
M:WM8[.%D4-* &D;<Q.<  *.!D\FMG1](?3/"FGZ,;@F2UL8[4SQC!RJ!=P].
MF: ,*+QS<+JVF6NH:*;*'4I_(@WW:&=&VLR^9#C*@A>Q.,C-0P?$"YEBAOGT
M"6/27U#^SVNS<J65_.,(8)C)3=@$Y!'/!QFL_2_AO>V+:(K3:/&-*NDG>:VL
MBL]Z5!4M*Y8G<0Q)ZY/.:V5\&3#PC%HGVQ-Z:F+[S=AP1]K^T;<9ZX^7/XT
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MBB@ HHHH **** "BBB@ HHHH *I:KJ]CHED;O4)Q##N"#Y2S.Q. JJ 2Q/H
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MK<9 .5[]J[O6K&[OO!ES93V5OJ%W):!);8R&*.9\#< W5<G.#VXZ4 1Q>-M
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MYP,9Z$UF6>@ZWI>H6'B5]*DG?[??7$^FPR(98$N-H4J20K,/+&X _P ;8SW
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M/3@U<_X3'0?[&AU47I:UGE,$06%S*\@)!01A=^X$'*XSP:PM,\/ZA;_\*_\
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M1<]>?F8=,]:HZGX3UAYY[]+:[(@\12WPAM+A8YI8'@6/?&Q. P.3@D9 ([T
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MT >N:QJUOHFB7VJW*R/!9PO-(L0!8JHR0,D#/'K3[2^^USSQBUN(EBV%99%
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MV%"+FVN%F329&E9AY.Y1/)P';(R,C.034_AW1['3?#7PYUBT@$>I75U#%/=
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MM?#S0&P$-E@6Q!A5OWV0F.,?3C.?>O0J "BBB@ HHHH **** "BBB@ HHHH
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M!MX!P0<8ZU:U;6-9\&W<4DNJRZRESIEY=/%-&BA)8(PX9-B@A#G;@YQQSUR
M>ATR.&*$,(XT0,<G:H&37FFAZUXG6]T::<ZO/#?H?M9OTM$A!,9=7@\MMW!
M&T[LJ<]12:%JGB"/2O!6N7NO3W9UF:."ZM7AB6(*\+N&7:H8,"@R<X.3P!Q0
M!Z6;>!HUC:&,HIRJE1@'V%+)%',A25%=#_"PR*\VT#7=9M]<TY?$&HZC ]W)
M(C"2"&73[DE69!!+'RAP,C><D @\\U3M_$^L"^T+4(=2U>\M=0U*.WDEEM(8
M;&6.0L!Y2G$O  (;G.#D\T >G27]C T?F7,",\HMTRXYD/(0>_'2K*JJC"@
M>@%>3Z,][I,1*:C/<"X\8O;.)XXC\NZ3<1A!@MQD^W&.:M1:YKH\'VGC9M9E
M9IKJ/=I?E1^1Y3SB/RQ\N_> ?O;NHZ8XH ],6&)7=UB0._WF"C+?7UJ&\NK/
M3K)[J]FAM[6 ;GDE(5$'J2>!7FU_JOB)-&\2>($U^X3^R=5EAM[-88O*>)9%
M!5\KN.0Q&01C [UT?Q3_ .28Z_\ ]>W_ +,* -#3_%OA34K\0:?KFDW%Y-P$
MAN$+R8]@<FMW8N%&T87H,=*\R\02:YJ.N:#HOB*RTK3+6>]CGAOK65YRTL3!
MQ"I9%\MVQP3U&0,GBJU[XF\3WDVOW^GKJRG3KV:WM8H8[7[&1$<'SC(PD^;!
M)((P",>X!ZH((0SL(D#.<L0HRWU]:=L7!&T8)R1CO7!1WFM>()O$%]'X@;18
M]*G$,,)2)H5VQ)(SSE@2RG>1P5P!GKS4,FHZWJ]GXFUFV\0/8KI$TL5K;PQQ
MM"_E1JY:7<I9@^>Q&%QCGF@#<U7P8VK2WD4VNZB-,O6W7%CE&4C #(KLI=$;
M'*@]SC&:Z5H(7V;XD;9RF5!V_3TKB]%\37^IS:_/+)Y44.EV=W!$5'[EI(7=
MN<9/('7TK.T:^UWQ)?Z-:/X@N+.*7PY;7\YMXHO,DG<D%LLA 'J /3ISD ](
M(!!!&0>H-)L3GY5Y&#QU%>9:/K/B#Q-J.CZ<^M2V2/97INI[2&,-.T%RL*NN
MY6"[NIP,<D#UINC:OXB_L[POK5YKLURU_J9T^>U,$2PM&#*H;A=P?,88G=CD
MC&* /3DABCB\I(D6/IL"@#\J411@8"*!QP!Z=*\EL?%/BF_LX]?@CU9O,O=H
MMF2U6Q\@3;"FXL)-^!][^]QC%6KS5?$2:-K_ (A77YU_LO6)8(+-88O)>%9E
M4J_R[B<$C((Q@=\F@#T+4[*+5[*YL4O9K68A<S6DH66(@[E.?PZ$8(R.0:S-
M,T6#1]:^VZAJ\M]JEY']FA:94CQ&N7*HB #U)//:LWPM:2Q?$'QI*U_<RI]H
M@'E.$V_- C \*#\H^4<].N3S3S+<7?CSQ$\0W3Z9I4,5FGHTID=C^)CC'_ :
M -6^\4^%X-373;[6-,6]5P!!+,FY6[ @]#^M:HN+26_:U$L+7<*"0QY!=%;(
M#8Z@':1^!KCO!MEHD_PDL1=QPR65S8>;J#R<[Y"N9F<]<[MV3U&/:L>75+33
MM5UF_P!,U#[+:#P]IPM+J2)YR%:298R%/S.QR  >22,T >FI!#$,1Q(@SG"J
M!SZT[8H &T87H,=*\K75_$ZZEJFEV5WK(D;19+ZU.K0VXE\Z.10-HC'"L#@A
MA]*;<_$>_P#[1O=3MI ^C7%@T.FQA1\UZ(XI%YQD[O.*X]8S0!Z='-93WMQ%
M&\#W4&T3*N"Z9&5W=QQR*F\B'>S^4F]QAFVC)'O7F=CI>LOXC\5,OB6>TNK2
MVLS))%%$1+,+<9>0,I^7(/ V]3[8:?%&I^(+6TFMK[5XYVTJWNI+32+6'$,L
MBEMTLDWRX/901P"3U% 'J(4 D@ 9Y/O5:.:Q2^:SC>!;L)Y[1+@/M8D;B.N"
M01GVK@-#UO6O%[Z)9OJLVFB30HM1N);../?-*[%,#>K *-I) '\0[5B:OX@U
M71_% ECO8+R631K>"[UJ"-6AM4^U2HTQ0'D@]AP""3P,4 >M(]D+J>SB,27&
MP2R1I@-M8D!C]2#S[51N=2T'PEIMI;WM_:Z=:JHA@^TS!00HZ L>3BLC7-VG
M>)/!]S'.\TLL\FGRR-C=-&\+/DX 'WHE;@8ZXJGXYDO(O%W@U[&QBOKD3W6V
MWEF\I6_<-G+8.,#)Z=J .JTG6M&UN-I=(U&RO4C^5C:RJ^S/8X/%6KG[+%:2
MO=");9%+R&0#:H'))SQ[UYQJRZ_HKZQXTGL=/TRY%A'806\,IG&6F7]]*VU0
M=N[@>F>:E\1R:IH/GZ5<:S<ZK;:GH]\[?:HXP\,D48.Y2BK\IW$8.<'&#0!W
MUO?6%U/Y5O<P2RK"DNU&!(C?.UO]T[3@]\582&*/.R-%R2QVJ!R>IKRIO$>I
MZ9;M;V4T<9.DZ/##(\2D0-/*\;2'C)P,$ G&1[FMS6?[=\.Z?J$UKXDDU%[.
M**_^RW"1&X:)'/G#Y5&49 0.,AAP: .Y$,2NSB- [')8*,DTH11C"@8Z<=*Y
MSP[K$^OZUJ][!<;]&A:.UM%4#$CA=TDF<9/+JO7'R&NEH R=9T:74Q;O:ZG=
M:=/ [,KP;65\C!#HP*L/J,@C(-0:;X5L[&PDMII9[R2>\%]<3S, TLP*D,0H
M  &Q<*!C"BMVB@ (!&",@TFQ1CY1\HP..E+10 QHHV4JR*5)R01QFEV+MV[1
MC.<8IU% ##%&TJRF-#(HPK%1D?C0T4;NKM&C.H(#%02,]:?10 WRT+*VQ<K]
MTXZ?2@HK9RH.1@Y':G44 -V*=WRCYNO'6E**>J@\8Z=O2EHH :8T+*Q125&
M<=*;'!%$H6.)$"YP%4#%244 -6*-#E45>O08Z]:1(8HV=DC16<Y8A0"WU]:?
M10 W8N%&T87H,=*AM+*"QCD2W0J))7F?)))9CDG)^OX=*L44 ,\J/>7V+N.,
MG')QTIVT9)P,GJ?6EHH 9'#'"NV*-(USG"J ,TX* 20 ">I]:6B@!I1"VXJI
M/KBEV@$D 9/4TM% #%BC21I%C17?[S!0"?J:4HA# JIW=>.M.HH 3:-V[ SC
M&::\,4D9C>-&0]5*@@_A3Z* &/#%)%Y3Q(T?]PJ"/RI?+3!&Q<$8(QU%.HH
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M** "BBL76/%.F:%JFF:=>O()]1D*0[%R%Y5<N?X06=5!]6% &U1110 4444
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M]U<NH5I9'ZM@<#@  =@!2/J7A_PM9V>G76IV.GQ1PA(([JZ6,E%&!C<<GZT
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M*A;3[)[06C6=NUL.D)C!0?\  <8H \6M7AFTK6-/&JZ;:V<6O0""+?*]A)F
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MH@A\S!+KCYO3GO0!P?BP:--\1M$MM>N(X[&33;HK%-+LBED#Q8#<@'C<0#W
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M7)S'%NV#D]M[<]\UG/X(T0VEA! EU:FP@^S6\UK=212K%Q\A=2"R\#@YYYH
MX7_A*;U=2M]7O$CN+W2=+UJ-VC7:D[6\L0# =MVT9';FM06NKQ^+/ ]WJ6MG
M4!<FXD:-H(T$;FV<_N]H!V8.,-D].:["U\*:)9_8Q;V*(MI;RVT2;B5\N0J7
M!!/S%BH))R>OJ:JZ?X&T/3=0L[V".[:6QW"T$UY+(MNK*5*HK,0%P>GL/04
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M .@K4H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.WE_Z\+"\6,9^7._/?I6=I/@&[TIK"RCO]/_ ++L9A)&RZ>OVJ1%.5C>0DC
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MJ$EZ)?*X3=,)=N,\],9J6?PBTVE^+;/[: =?:1E;R_\ 4;H$BY&?F^[GMUH
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M&ML5GD$1W1([[BN%(7D*"=HZ<UT&@:*=%CU!#.)OM=_/> A=NWS&SMZ\X]:
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MUNH9,YRN[:I##'(QCGK3/$/B._TBZ,5KIUH\20^:]S?WXM(B<GY$)5MS<9/
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M,BN-2AOK>R:WM+U98W,W^K=)< $$@@Y (P:;<>/=:M8]:\WPQ%YNAJ)K_;J
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M9;!"L;VFG+%//\I53(Y+#(Z_*!D\^U #O#7CN?Q"$N4TR V,D+S![2^6>6#
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M!C'O0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P M)F(6-?Q8J*XWP]X<U'^U]#:]T?5(/[-!>6>]U<SPJXC*#R$#G.<G[P7
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ML^^: /7/M5O]I^S>?%Y^,^5O&['KCK6+I7BB/5]:U2S@M2MGISF*2]:9-K2
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M-=5 P/EW;L=LY[U5\2/I5OJ^J7ED-/O6F:WEBTN]LV6><"-/+-E-&=P4@#
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M^4I4M%YGEDX.#M8\C- 'LL=U;RP">.>)XB<"17!4\XZ_6F'4+(1>:;NW$?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JKJ.G6>KZ?-8:A;I<6DZ[9(G'##K5JB@"DFD:?'JBZFEI$MZMN+43
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJGJNIV^CZ7
M<:A=%O*A7)"#+,2<!5'=B2 !ZD4 7**Y?6O&L>@BX>\T+6FM[>,22W,4"-$H
MVAC\V\=,X/N#6C9^(+>[NK&W:WN;:2^M/M4 N$"D@8W(1GAU#*2/?O@X ->B
MLW7];MO#NBW&J7:2R0P[04A4%V+,%4*"0"26'>LZQ\8V]SJMOIM[I>J:5<W(
M;[.+Z%568J,E59&89QDX)!P* .CHJO:79N_/S;3P>5,T0\Y0OF8_B7GE3V-%
MQ=F"YM81;3R_:'*F2-05BPI;+G/ XQWY(H L45GZGK%MI+V"3K([WUTMI$L8
M!.]@6R<D< *2?I6AF@ HHJIJNI6^CZ3>:E=%A;VD#SR;>3M4$G'OQ0!;HJC<
MZK;V>A3:Q<+)';PVQNI%8#<JA=Q&,XSCWK%L_&4]]]G:/PGXA6*?:5E>* *%
M;HQ_>YQSGI0!U%%%% !15>*[,M_<6OV:=!"J-YSJ!')NSPISDD8YX[BK% !1
M6?K>L6V@Z1-J5TLCPQ%!MB +,68*H ) R2P[UH9YQ0 445375+5M:?25<F\C
MMUN74*<*C,54D],DJW'L: +E%&<]*1W6-&=R%51DD]A0 M%<?8^/CJ=C!?67
MA3Q%-:SH)(I5A@ =3T(S+FNCM-5M;V_O;*!F::Q9$N 5X5F4,%SW.T@\>HH
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MZN9YQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6N_]Z@_M$MEEZ@;2.3QR/6O7E@A69IEB02L,,X4;B/<TQ4M9)Y6186E!"R$
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M\37(+$DQ1$,J#URRH#D],^M:>H:;::I%#%>1>:D,\=P@W$8D1@RG@]B <=*
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M &:UW]F$']HC[=M\SR_-\G'3/.W.=O/M6M:^!KZ!M%MI/$+RZ9HUPLMI;&U
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M,F3>Z.7+>N4]/XJGUW1-0U*XBFL=52V C:*6WN;87,$JD@Y*;E^88X.>_0T
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M#Y,,2J#@(F6P3DDDDD\>E9]YX+2[UBYU WS*9]1M+_9Y><&!0H7.>^.O;WH
ML>']<U"]U?5-(U:SMH+VP6&3?:RM)'(DH;:1N4$$%&!KD/%FJ:ZE]X[MQ,B6
M-KH*2P[)V#QL5FPRC& Q*\\]%7KV[NTT5;7Q)J>L"<LU]#!"8MN GE;^<YYS
MYGZ5D:[X,DUB_P!7GCU0V\.JZ9_9]S$8 _3?M=6R,8\P\=_:@"K;^+M2TNXM
MX?$6GVUM;3:;-?126]PTKHL(4NK@J.<.#D'&01[U3T/XF1ZCJFE6]P^C&/56
MV0Q66I">>W;:642H .H!!(Z-@=\UT>I^%K?5;^PGN92T-K97-F\.W_6I,J*W
M.>,!/UJIH_A34].N+!+GQ"]Q8Z>NV"!+41/(-NU?.<,=^!Z!<G!.: +OB;6[
MK18+9K>.Q597*R76H78@@@ &<L>22>@ 'U(KGM/^(<^IZ5"+.RL[G5)]3?3(
M1#=%K9V1/,,HDVYV;.>F<\>];GB/PS+K6IZ7J5K>PV]UI_FA!<6HN(F$@ .4
MW+AAM&"#QSUS69#X E@MY'36Y3J7]J-JD%XUNO[N1HQ&ZE 0&0C<,<8!'/&:
M *?B#6?%L1T6$V-K9W#:U';NRW3&*Y0QLRX(7<%."&!&05'4&M.;QG)%X6U3
M6/L2%K+4GL1%YAPX6X$.[...N<4EUX-U&]M$DG\0R/JB:A'?I<&WS#&R*4")
M#N^5<$Y^;))R356]\ 7=U#J%A'X@:'2KR^-^UL+12XD,@D(\S=]PL,XQGWQQ
M0!'XK\>W?AN:_D>'2([>S 98+O40ES=KM#$Q1@''4@9Y)!X%:7A^[DN?''B<
M&61H1%9-&C,<)NC8G [9JAJ/P]GO/[?@@UI;>SUIWDG_ -"5YU+*%*B4M]SC
M[NW.,@$=:Z'2- &EZMJ%^;DRO>16\;+LVA?*0KGJ>N<^U '-^)_$>LW>G>*8
M=%L('M-+@D@GN'N6CE:4P[V\H!2/D#*>2,G@8ZU5A\3R:/'=78M)+AK+1]-N
M+IVN&.8F9P[!>0&50S9_BZ'H*V-5\&7=U-K"Z;KC:?::RO\ IL/V82'>4$9:
M-MPV$J%!R#TXP:NZ?X3@L[RZFFG^T17.FV^G21,F 5B#@GK_ !"0\=L4 9/B
M?Q0OF7]G':&>TL9-/$DT=PT9,LTZ;5!7L%*L>>=P'0UE>,_$VN7_ (2\3SZ5
M90IIMDTMF;C[4R7!="%=T4+@*K9'WLG!/H#M67P^ALO!_P#8/]I32NUY%=27
M<B O(8Y$901G^[&B9SVS4>K> ;N^M-7TVSU]K+2M5E>>>W^RB1UD?E]K[AA6
M(R003R<$9H K:Y\24T[6-2L;:314_LP+YRZAJ0MY;AR@<I$N#T! W'@DX[$U
M.GC75=7NIT\.Z7:3P1:=;Z@);NY:/<LJLP3"J?F^7KT%7;[PA>G4]1N]'UH:
M>FI;3=(UH)B'"A-\;%AL8J!U##(SBK]AX:2PU/4+Q;N67[79V]KB098"(.-Q
M;^(G?STZ4 9%KXSU#77T^+0--MY)9],BU.?[9<&-8DDR$C!522Q*MSC  [YJ
MS\.;J>Y\!6-Q>-)YQ><R>:^YEQ,_!/?&,?A4%IX'NM(ATQM'UK[+=VFG1Z=-
M+):B59XTY4[-PVL"6(.2/F.0:V_#6A#P[X>M])^U/=B$R$S2* S[G9CD#_>H
M YVW\<:F^GV.OSZ3;Q^'KZ>.*-Q<$W$:2.$CE9=NW!)7(!R W?I6EX;\0:MK
MVI:@7TZUM]+M+JXLQ+]H9I9'CDVY"[<!2/?.0>U4K?P'/%;6>DRZV\OA^RN$
MGALOLP$F$;>D;2[OF16 XV@\ $UOZ%HJZ';W<*SF;[3>SW9)7;M,KE]O7MG&
M: -6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ K.UK6[/0K2.>[\UC+*L,,,,9>260]%5
M1U/!/T!-:-<[XJTN^NY='U/38HY[K2[LW MI'V"9&C>-E#= V'R">,CWH PH
M?&TUY>:WF>6PM[.]L+>-9[,F1#*5#(RDC[Q. W0 Y&16[_PFFF'4S:+#?-&+
MK[$;Q;9C )\[=A;_ 'N,XQGC-<U<>'/$.JRZS=W-A!:O>ZCIMQ%")PY6.!T+
M[B.-V%)P/IDTV[\+ZY_PD<MUIVGKIUW)?K,VI6=^R030;P3YMN2=TA7*GC!/
M.10!HV7Q$MTAUFXU6TNK>"RU3[#"4MF)?(4*,<DMDG@>JU6UKQS-:Z5K&HV\
ML\!M#8,;2[L2DENDLVQRW)+%E!P,<8'7--E\,ZT]Y>V_V2(VS>([?5H[CSA\
MT89"XV]05V?CFI/$GA;6;ZZ\23V$4#O>G36M1+)A6,$I=]WH,?G0!L_\)UI,
M=KJ,UU%?6;Z?;_:IH+JV:.0P\_.H/WAD$>H/!Q5[5_$5MI4GV8I++=O9S7<4
M4:%MRQ[=WXY=:Y36/#.N>+3K%S=VD.F22Z-+IEK"TXE+N[!R[%1@+E5 ZGDG
M Z5:33O$6L^);34=0TN#3H(=+N;0K]J$K&20Q\\#&WY#COQR!Q0 _0/&JZC:
MZ9?ZE<_8EFT0ZA<P26Q51@INE#DG"#<<#!R#G/%:FG^--,O[J.W,%]:/-"T]
MM]KMFB%PBC)*9ZX!!P<'!SBN.@\#:WJ6BVNG7\$5B8O#4FCEQ,)!YH:+8_'\
M)V$^W2MN33O$/B#5=)N-2TR#3H]+29V*W(E\^5XFB 3 X3YB<M@]!B@#0TKQ
M[H^KW.GQ017\<6H@_8[B>U9(IF"EBJL>^ ?8X.":TM3U'[)K6BVOVOROMDTJ
M>5Y._P [;$S8W9^3&,YP<XQWKGK/PQJ4.@>!+-HXQ+HTD+78#C"A;>2,X]?F
M85L:UI5U?>)/#=[ JF"PN)I)R6P0&@=!@=^6% %33?B#HNJ2V @COUM[]_*M
MKN6U9(9),$[ Q[\'VR",UJ:_XBL?#=K;W%\)V%Q.+>)((C([R$,54*.23M('
MOBN9L?"NJ0>#_"&FO'&+G3+Z&>Y <8"KOS@]_O"MWQ-I-UJEQH+VRJRV6J1W
M4VYL80)("1ZG+"@"K-X]TN#?NM-4;R(EFO EF[&S5AN'F@?=..2!D@<XJ:_\
M;:58SO&D=Y>+% ES/+9V[2I#$X)5F([$ G R<#.*Y?5_!M^FO:[<V^DOJ<>J
M.)H7&K2VJPOY:H5E16&Y?E!R 3@D>E)K/@[44,*6&C1F:#3XK:SO]-U"2TD@
M9%(VR;F)>,'!&=QQD$'K0!U%[XVTRSU&6P2WO[RXB@2YD6TM6DVQ-G#9'TZ=
M?0&G7'C32D%H+-;O4GNK87<<=A 96\D]'/H">!GDD' X-<Q87'B+3?&^L0V]
MA#J]V-*T]+F3SQ#F8"8;^1]TG<3CD<8!JE!\/+[0Y;&86<FL*--CM9TMM2DL
MVCE1G;<"&4,AWD8/(P,#DT =K-XTTA;73YK0W-^^H(TEM!:0%Y'1<;F*\;0"
M0#NQSQUK.B\=Q7OB;0[#3[:>:RU&WGD>4P,&C>-U3:<XV[26#9''R^M9^F^&
M=7\-3:1J5CI=K<2Q64UK=6-O<L ADE$H9'E)+?-D-DC.<CTJ\NG^)'\0^'=9
MO;6UEDB2[ANXX)=HMTE>,I@G[^U4P<8R>E &]K/B&ST1[:&9+BXNKHL(+6UB
M,DDFT98@#H ",DX'(]:Y;Q+XZ=](TUM ^UI->:B+*9_L1>2V902Z&-L8DX&
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M$39APK ,A 4Y&2.>*U/#GA>ZT77[2<PVT=K#HD5D1;LQ591(S,%#DMMYX)-
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M7UI);I<1W4#P.<)*L@*L?8]#7C[: MA\/?!%Q!9P6EMF";59'L#/\WDML>9
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M0!DGYLMD$<5=U:759-(\<:VNNZG#/H]Y+]BABFQ$@2*-\,N,."6(P<C'3'-
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M_-(OVME*'U^48QZ"DAUZ_P!/G.MWFH3'3+7Q!>6%XKO\B0NVV-CZ!'"#Z,:
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MY' X#8"]<C.*Z;Q=K.JZ6^C6VCQVC7.I7OV7==!BB#RI'W84@G&P<=^G&<@
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M*"U1UDA<0F5079B&! (Z#!/>@#I[_P +Z'J=\E[?:7;3W"J$WNF=R@Y 8=&
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M9;/+;0M!"WE@;(V7:4&/X<$C'2M2B@"HNEV*O9.MK$&LE*6QV_ZI2NTA?3@
M53LO"VA:;J+:A9:5:P7;;OWB1@$;OO8[+GOC&:UZ* ,K3_#.B:4ZO8:9;6[)
MYFWRTQM#[=X'H#M7CV%-TWPKH.CWC7>G:3:VT[ KOCC *@G)"_W0?08%:]%
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M[N5>24W5I!9R))@KLB#@=NIWG-;-% '+Z9X+&FRV,8US5)M.T]MUI8NZ!(\
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MK'+<]\$XSZ 4S4?!5CJFHZI<SW5T(-3MTAN;92H4M&<QR*<;E9>V#CVKI:*
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MJO8WUKJ5FEW9S+-;OD+(O0X)!_4$4-?6J:A%8-,HNY8FE2+NR*0&/T!9?SH
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M5II\-K/H326-F+.*=[2;>8\@G/[S')4$\=: .:NX[O6[.WT.75K^:"?Q2UM
M[2 R-;P+O?<V/FP\38]..N*TK[4-237Q<-K-\FF7%[#;:;J%FZ3VJD%4:&>+
MAMS.'7?D\L.5Q6HWA+5VCLXROAX+9W#7-OBUG!CD9BS-D2YY+'(/!S3$\%ZE
M'JG]HI%X=%SYQG_X]9]@E_YZ;/-V[_\ :QF@"Y\1O])T"ST@==6U*VLS_N&0
M._\ XXC5<\<W]U8^&'6PF:&^N[B"SMW7JK2RJF1] 2?PK/UGPSKGB"*&+53H
M%RD+^9&&M9QM;&,C$H[$U5LO!.I:?M^S1^'TVS).N;>X;$B A6YF/3<WYT 8
M^MZAK=S9>)]7M-;N[=;?5(]/TJVA*A#*#'$2V02P,C-\O3@]>,/UW4=9T2]\
M16MIK5Y=2+IML@:;:=EY<3-&A0 #;@<X^E= /#>N+:QVP_X1[R8[K[8J?9)L
M";>7W_ZWD[B3]:)O#>N7%S)<R_\ "//-+-%.[FTFRTD7^K;_ %O\/:@#E=1N
M;_2]5\5Z]IUU=W%X+JTT.S$C*5#,$W'#8'RM,<9(&>M37&O>(/#G]J%1?[8[
M!&V:O=VTSQW$DRQQR8B8D(=SD@@#Y.,5O-X1U9UU)7C\.,FIL&O$:TG*RL.A
MQYN >^1@Y /:DMO!^J6FG7=A%%X<-M>#%RLEI/(9N,?,S2DMQTR>.U %6/2K
MB'XEZ'8RZW>:DMG9SZA,MT5)24XA5A@#:&$C_+T&WCO7H=<;H?@^XTR[D,T&
MC?9[B$V]R889O-ECP<*7>1L\GOGCCTQUEI:P6-G!:6T8CMX(UBB0=%51@#\
M* .$\?Z)%XA\6>%]/DE>%VBO7AGC^]#*JQLCK[A@#7.2>+]037M1O)[=4\0:
M+X;NTNH,?+YR21E7 [HPPX]CCM7K<VGVMQ?6U[+ K7-J'$,AZH' #8^N!4+:
M+IKZM)JC64)OI+?[*\Q7EHLYV'U&: .,GCU#2;_0+=?$=_?IK:RP7/F.A/\
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MW"%\*&8C +="WKBN\N/#6C76B0:--81MI]N$$,.2/+V?=*D'((]0<U#%X/\
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M73[691I=Q;P_O)4+F1_-8%AG@ <?*<UV>A:CJ%[X%MK^_:'[>UF6D>"1'0N
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M^\ ,@GGGW[<#O*Q]*\+:+HET]UIUBL-PZ>6TQ=G=ER#@LQ)(X'TK8H ****
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MV'@V"QT_PU:+>2.NA.7C8H,R_NWCY].')_"N?\(>#=2D\.:/!K.HW*V=K/\
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MS-&:,W>'XPML\1V^OS,* +MOXZTNYN856"^6RN+C[-!J+08MY9<[0H;.>6&
M2 ">AI/'FJWVDZ):2:?>)9RW&HVUJUPZ*XC220*QPW' .:Y+1_A[>Z<FG:5)
MI%E+%97*.VI2W\S+)$C[E(@! $G _P!D$9YZ5V7C/09?$6F6-G'%#+''J5K<
M3QS8VM$D@9P0>N5!X[T <U<>(M8T76K:Q7Q)::XMW:W4C!+>-)+4QQEUD^0X
M*DC;R.I&*VK#QD5T71_-L=0U+4KG3(;V=+& ':&4?,<E5&3NP <\=*U9/#FF
MVFE7]OI&EV-G+<V[QY@@6+<2I R5'K7'GPIKZ+IEM<VPU&RM])M[5+9=3DMH
MH)T7#LZI_K%/RX/.,'CF@#H'\>Z4R:8;.WO[Z34[9KFUBMH-S.JE0P.2 I&[
MN0.#SG&;^G>)K/5;&QN[.WO9([N9X"/(.;=TW!A*/X,%2N?7'K7.>$/".J:)
M<>'7O!!C3M*N;.8QOG+O-&RE?;:A^E7]%@U+PW!!9/:1SF_UF[=V20_NHI'E
ME5NG/& 0<=>OJ :^O>(K/P]'9M=QW,K7D_V:".WB,C/(59@,#UVD?SP.:H)X
MZTK^S;JZGAO;>:UN5M)+*6#_ $CSG *(J@G<6# C!QCOP:L^(-)N=2U+P]/;
M[-EAJ'VF;<V#L\F1./4Y<5S^J>$M6GUC5-5M/LYF&JVFHV<<CD++Y4 B9&(!
MVYRV#@\XH U7\>Z5;6&HW-_!?6,FG+&]S;7$.)51VVJX )#*3GD$]#WK2@UY
M)?#]QK$NGZA;1P1R2-!<0[)BJ GA<]P.*Y#6?"VO>)/[7U"ZMK:SN;BUM[.V
MM1/YF$2?S79VP!D] !GI[UZ(RAE*L 5(P0>] &)%XNTB;6K#2HYV-S?67VZ
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MC09+(Y7E0<XR.1G/:KWA3PY/8:Y<ZG-HUMIJFV%O&OVV2ZF;YMS$LQVA>!@
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MDV\106S@\M@9<_,< 8Z#-='XSTF[USPE?:?8B,W4@1HQ(VU6*NK8)P<9VXH
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MT'3K.;;YMO;1Q/M.1E5 ./RH Y%?&ES'J6AVD*7&H17^I7EM-,+94*B(R *
M&Q\I49/=5)ZG%;.F>-+'5;RWB@L]16VNF=+:]>#$$Q7.<$$D?=."P&<<5@VW
MA;6M..BW,,%O/+9:S?74D1GV9AG,H!!P>0) <?AFH=)\):U9^(K*ZAL+;23'
M<M)?W%C>O]GO(R&X%L>%))4DGI@\F@#T>BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *@O;N#3[&XO;EPD%O&TLCG^%5&2?R%3UR/Q MK[6-,L_#M@KJ=5N!'<7'
ME%TA@0;W+=!SM"X)&=U $_AKQG;ZWX>N=4O[?^RGLVQ=03R@^2"H=26.."C*
M?Q([5SNG_%3^TAHL<-KI NM6D)BA;5U_=1 +CS,)D2$G 0 Y(/-2II6MZ#XT
M-Q>7 U.UUNS:VN'M[(Q+#+$I,3, S=5+KGCHHJ#PWI-Q"?AP9=/E0V^E3+<%
MH2/*?RXL!^.#D'KZ&@#H8_&,CS6\!LK;S9M+N-0W+?*T0,3JNSS -N#NSNZ#
M'2M2?Q+H^GV]H^JZKIUA+<QJZ)-=HN[(_A)(W#W%>8Z;I.I)H-E&VGW2NOA/
M48"IA8$2-(A5.GWCV'4U+=?;U>ZLFM)K%WTFVAC\G2'N9K_]SRN\@H@5B5P1
MQR2: /1&\5:6OBR'P[]HB^V36IN5_>KR,@!0,Y+$$M]!FI[#4]!N]3NH=/OM
M-FU 8^TI;RHTO''S@'/'3FO-["ROXX=!C6UNH+RY\'M803&W?]U=!4PKMCY"
M,'EL=*B\/:?+//X9M =5:XTU29+8:2+46H$3*R/,0 P8G'RD[CANV: /4;/7
MM'U&\EL['5;&ZN8<^9#!<([ICCE0<BJNK>*--T;6M)TJ[GCCGU)V2/?(JA<*
M2"<G/) 4>I-<%X/CN+37=!LK.&ZNK.WCDC>+4=*,,^EIL/'G@*KY("XP2>N>
M]=1XL7R?%7A*_DMII;>&ZF262*!I?++PLJ%@H) W8YZ"@#?77=(;53I:ZK8G
M41UM!<)YH[_<SG]*M75W;V-M)<W=Q%;V\8R\LKA%4>I)X%>30VKGP99^&%TJ
M\'BB+44D>8VCA5D%P':Y\[&W:5R<[LG.WVKM/'=M++::/=?99;NSLM3BN;R"
M*,R,T05AG8.6VL4; !^[[4 +'XVMKRXU5--%G=PV*VK)<B]18IA,[*</C V[
M3W.3QQ6U)KVCQ:HNER:K8IJ#8VVK7""4YZ83.?TKS'48/[4?QE>:5I-XD%W)
MI+1L;-X_M!2?YW52 3@=3CMGH<T_5HKBRU[4(]-MKN:>;5$G.D7VEF:*X;<G
M[Z*X4#RQ@;OF8[2I&!TH ],EUS2(-333)M4LH]0DQLM7N$$K9Z83.3^59>E>
M--*O[JXL[F[L[.]COIK.*VENE\R;RW*[E4X/..@!KE;4VVGQZQI&J>'[K4-5
MNM9DN(D%L^VX5I0T4@F"[5"+MZD;=F*KW>A2?\(+XM9-+D-]/KLT\>(#YC@7
M"E77C)&!D$=J /0[WQ#HNG7D=G?:O86MU)C9#/<HCMGIA2<FI)=9TN"_CL)=
M2LX[R1MB6[3J)&;&<!<Y)QS7E7B_[?>)XQLDM)K:>XWK%:6ND//)? 1*%E:<
M@J!VP,%=O'S5LVN@W-]<>,IH[0Q7]UIMM%9W4T>TA_LQ'RL1QACSCH>M '<6
MOB+1+ZZ-K::QI]Q<!S&8HKE'?< 25P#G.%)Q['TI\.N:1<:G)ID.J64E_'G?
M:I<(95QUR@.1^5>:QW%E<:]X"L[+1;O3[RT\^%GGLFA$)^R2 QAF #\C.5R.
M,YY%9WAW2KQ;;PWI%S)J@U&QOHY9K9-)""%U8EY&N" &1N>0Q+!NYH ]CO+V
MUT^U>ZO;F&VMXQEY9I B+]2>!5>+7-(FT]=0BU2R>R9@BW"W"&,MG&-V<9SV
MK \;0.+WP[J,UI-=Z98WS2WD441E*@Q.J2; "6"L0> 2.O:N1U'3'UN[U2\M
M-+N/[&O]8TH"*2V9/.V2 32^60"%*E06(&=I/2@#U6SOK34;..[LKJ&YMI 2
MDT,@=& .#AAP>0:PCXSTN?7M/TO3;JSU W1F622WNE?R#&F[# 9Z].<=*L>*
M--N+KP5K&FZ2BQ7,UE-' L>$&YE. /3)/7WKCK>6QU+Q7X5?2]#O;86-I<PS
MO)8/"+?,0"Q$LH!.0>F1^?(!V,7BG2X=+T^ZU;4=,T^6\C#I&]]&58GLCY <
M>XJ[J&MZ3I*1/J6J65FDIQ&US.L8<^VXC->1VMC-I^A:)))_:6G7QT"&V<2Z
M2U[;W(&XF!T"[D<$^JY#=\5O:?*=)UB'4O$FARPQ76A6MO!%;6;W"6SKO\V#
M:H8KG<F >N,9.* .Z&LPI?W<4\MI%:P0PR"<W2Y/F%@-R_PC@8)/S9..E4-4
M\8Z7:^&=5UG3;JTU0:=$TDD=M<JW('W25SM/X5YQKMFT'A_Q)+)H4]C9/I>D
MHEDV6VA9WS$&Z$@$ CMD5=\61'Q FLW>@Z7>);1>'YK27-E)"9I6=#'$J,H+
M%0K]!QNQWH ](36H5O+V*[DM+:&W>)%D:Z7+%P" R_P')P >O:IK#6M*U2WE
MN-/U.SNX8B1));SK(J$>I!XKSKQ!H]S>ZGX@C?3YIK>XU;1SCR2RR1J8]YZ<
M@#.?3O2^,]!U"ZU#Q7%I-E*HN=(L?]3%@3E+B0R(.S-Y8QCT('>@#T33=:TK
M6%D;2]3L[X1';(;:=9-A]#M)Q1J6MZ5HJ(^J:G9V*R'"&ZG6(,?;<1FN(\*P
MF\\:1:A%<ZA<)!I[P22R:4+*( LI6,Y"EF&"1@$+SSS4OBJYN8?&J 1-9Q'3
MPJ7\6EO>RSDNVZ%<95,8!Y!SN]!0!WL,T5Q"DT$B2Q2*&1T8,K ]"".HKA;;
MQUK]WHDVN0>%(I-,B,Q++J8\TK$S*Q"&,#/RDXS6C\,[>XM/A]IEO=V\UO/'
MYJM%,FQU_>O@$=N,=./3BN>\(>!5U#PDB:K?:[#'-/<B;3Q=-#$4,\G!4 $!
MASUYS[T =HWBS0(K"QO+O5[*SBOH4GMQ=SI$SJP!& Q'K5F\UW2-.\O[=JMC
M;>8%*>=<(FX-P",GG.#BN \0+-!XCU2PM[1K"#[!#;VQMM):ZDOE"M^[5R"D
M:J3MP1WR3BCP7HKR:KX<FU'3)#]F\+0P[KF _NY1(,K\PX; Z=<4 =3HWC6Q
M\0?9'TQK:6*:[GMI-UV@=/+WX8*,[MVS( _A.[H*T8=4T&?6YK:WOM-DU=$V
M211RH9PHYP0#N 'I7GFB6=T+_0K..RNH+BRUS4VG9K5U5!(MP8VW$8*D,N""
M1R!5WPJUI;Z3X<T.;P[=OK5@_P#I+/;/&+:0*PDG,I&U@Q)Q@G=O_( Z^#Q5
MI<>DVM[JNHZ9I[S1+(4>^C9 "<##Y 89!Y%7KS6M*TZQCO;W4[.VM),;)YIU
M1&SR,,3@YKR?PO/::#JOAMM:TZZ$D7AD)D6;RM QF.0R*I9<CC./;O4]K%J.
MDVN@I/8MIL!:^F@NGTU[N2S22;=' $7[C%".2#C;M% 'I[:[I"6,5\VJV(M)
M@3'.;A!&X ).&S@X )X]#6-K_BGPM%HUE?WD^G:A87-Y%;Q2>9%)&&9@I;).
M,*"2<= *XGP]HUU/)H$=[IMVT,?B2^N'%S:>7A##(R.R@!5!8J1VR<=:M:OI
MLUHVOSC39S:1>)["]VQ6S-F)5MS(ZJHRPX;. >AH ]/>XM;6S-P\T,5JB;C(
MS!45<=<] *Q+_P ;:!:>&]0UR#4[.^M;&,M)]EN4?+8X3(.-Q/ '>JWCJ:1O
M"2O;:>MVCSVY<2VSS"&/>I,IB7#/LZ[?;GI7!W5CJ.IGQH\<=]?B[\/".&=M
M--LL\BF3Y43:"<;AC.2>W&* /7K2]M[ZQBO+:>*6WE3>LD;AE(]B.#56Q\0Z
M)JDTT6GZQI]W)"-TJ07*2%!ZD \"LW4KPW7P\O+G3M->]+V#^792Q/&9?E(V
M%" W//'!/;K7#6$=Y=^*M$GB:ZN[>+3[N%GCT=K.&$F-=L8W#<?NGJ2!@=S0
M!Z7;>(=$O;LVEKK&GSW(C$ODQ7*,^PC.[ .<8(.:LC4;%K:"Y6\MS!<%5AE$
MJ[9"WW0IS@D]L=:\[TG0WL_#_P -##ICPW%O+&;G; 5>+=:R;]_&1EB,Y[XH
M\/Z;<CQM_P (W)$?[*\.W$NH0-_"WGC]PO\ P#?./^ K0!V>L>*--T/5=)T^
M]GCCEU*9HHR\BJ%PC-DY/0D!1[L!3H?$=BFGF[U.[L+%?-F0%KU&4K&Y4G=P
M,],C^$G!K(\8+Y/B#PGJ$EM-+;6U_()GB@:4QAX)$4D*"0-Q49Z"N;T319Y-
M6\,&[TZ4QV^I:Q*WFPG";I7*,<CC.<@]^U 'H$7B30II[6"+6M.DFNUWV\:W
M2%IAZH,_,.#T]*DDUS2(M432Y-4LDU!\;;5KA!*<],)G/Z5YR- >#PQ>^1I3
MI<?\):+A-EN0_EB]7#CC.W9GGICVK(N-)OQ;:QHU[-J@O[K5))D@MM)$AFW2
M[HYDN"-H 7;R6&W;CTH ]LJIJ4U[;V$DFG6<=W=#&R&2;RE;D9RV#C R>G:E
MM[Y)[VZM%CG#VVS>[Q%4?<,C:QX;WQT-6J .,T'Q7XBUK4[JV;PU:P0V5Y]D
MNI?[3WE&VJQ*KY8W<..XK0\,^--*\1V%BZW=G!J%U#YO]G_:E>5!_N\$\<]*
M@\'6T]OJ?BQIH)(UFUEI(BZ$!U\F$;AGJ,@C(]#7*:/H4EIX%\"K'I<D5W!J
MD,LX$!$D>3)O9N,CKR30!Z,=<T@:J-+.J60U$\_9/M">;TS]S.>GM4/B'6AH
M.GPW9@\_S+NWMMN_;CS95CW9P>F[..^*\G@TF_6P?0[V;5!J;:JTQ@@TD,7;
MS]ZSBY(QMQ@[BV0 5]J]&\=V\]UH-JEO#)*XU2Q<K&I8A5N(R3QV !)/M0!K
MR:[I$.J)I<NJV*:@^-MJUP@E.>F$SG]*B;5= L=8:R:_TVWU2Y*EH#,B32G'
MRY7.YN.E>;7MLR>$M>\-2Z1>2^)+N_GD@E6T<K*[REHIQ,!M 52O)8%=F*=K
MT-U9:QJJZ?!=SW5Q>Q3-I-[I9G@O7 0"6.=1^['RY^9CM*G@4 >F-KVCIJHT
MM]5L5U$]+0W""4]_N9S^E7)[B&U@>>XECAAC&YY)&"JH]23P!7E&H17%EX@O
M(].MKN>675UN&TB^TLRQRL77,\5RH 0 ?,"S':1C Z5V'CZTFN='L9%M9;RU
MM=1M[B\MHDWM+"K98!!][!VMM[[: +.J^-=$T_PK?>(+?4+.^M;5&(^SW*,)
M' R(PP)&X^E:&A:C-JFB6]_<+:(\JEB+2Y^T18R<8DP,\=>.N:\W\26S:]%X
MOU'1M-NOL4VA"VR;1XC=7 9B"J,H9BJG&['?':NW\::=>ZAX!U?3]*4B[EM&
M2)$.TMQRH]R,C\: -&T\0Z)?I<O9ZQI]PML"9VAN4<1 =2V#\O0]:DN=6LX;
M99([JU>26!YK=&N%43*J[LJ?[N,9/( .:\ZT0(_B+3]0$FJ3PZ=83"9/[%^R
MK%&5'[EAM!=L@$(N[E?>J?A[1[_28]5^VZ1<HNJZ9.=*4!I/L$7SM]D;^X?F
M5AZG*_PB@#T?_A)M)MX+'^TM3TZRN;R))$ADO$^;</X"2-XSP".M4KSQGI]O
MJ^JZ1#);/J&GV0NS'+=)$KDACL+$_+@*"21P&!KSV\M)K"PB,<=_;WL^B6D,
MEI<:2UY;:@5B($7RC=&P)*D%AU!QWK0UV"[,GB1)M)GBN]2\)QQPQP6[R)YR
MI/OB#J",C<H )R>,9H ]"N/$FBV/EK?ZOIUI,VT>7-=HIW$ @<D9X(/T-3W^
MM:5I;PIJ&IV=HTYQ$+B=8S(?1<GG\*X6WT/SI_&\MQIC.]QI]O%$TD&3(!:X
M*KD<_-V'>J^D)_8]XMQKNCWU['>Z%96\!CLGN"I1&\R!@ =A)8'YL ]SQ0!Z
M9;W$%W D]M-'-"XRLD;!E8>Q'!JG;Z[I%WJ,FG6VJV,U]%GS+:.X1I$QURH.
M17-_#^*67X2Z5%:GR9GL&6(Y^XQW;3GVXKF].A2XT;P=HEEHUY;:SI=W;O>,
M]F\8MP@_?L92-K!_F'!.[=0!Z5:ZSI=[=O:6FI6=Q<HI=X8IU=U4':25!R!G
MCZU'<^(=$LKH6MUK&GP7!?RQ#+<HKEL [<$YSAE./<>M8?P[TI-/\.-))8_9
M[N6\NVD9XMLC W#X)R,X*A<>V*Y:\N]-BUWXA65QI-S>7EZ\4,7DV;RB;-K&
M%CW $*03GYB!SGL< 'I&HZYI.D/$FI:I9633'$:W-PD9?Z;B,U3E\4Z9#XLM
M_#K7$0O)[9KE,RJ,X90% SDL021[*:XS38_^$:U2^_X2G3[J^DNM,LX(IHK-
M[H2[(MLL/RJ<$OEL' .[/:LVUT;6-/M]&LY[:XBU"?PQ=6$$HC9Q!<,R-&C.
M 0A"C&20/EZT >D+>^'->O6M4N=*U&ZM22T0>.9X3GJ1R5YJ:W\1:)=WJ6-M
MK&GS7;IO6"*Y1G9<9R%!R1BO-?"]C)-J?A: 2:F)M,!,D!T@6RV@\HJR/(0-
MP).,*3N.#VS4^DZ%):^!? ZII<D5W#JL,LX$!$D8+/O9N,@8/)- '7:=XVT_
M606TQ[6<)J1L)-UVBD ;AO49.[=M)4=2.>U:J^(=%;5#I:ZO8'4 <?9!<IYN
M?39G/Z5YW;6LXN8[--/NEFM_&+W,G^C.J^2YF*.&Q@K@CD'C(SC(K)']HWD&
MBK]CN+>6#78+B?3+;1W1;0?: 6=YV!+\')*D9R3C - 'J^@:T-=M+J<0>3Y%
M[<6FW?NW>5(R;N@Z[<X[4]?$.B/?I8)K&GM>.6"6XN4,C$$@@+G)P00?<'TK
M*\#6\]MI6I+/#)$S:O?.HD4J2K3N01GL0<@UY_;-;W_A/5=#L-,NCK=QKUQ)
M%,MH^S>MV2)O-QM 11CKGY<8Y&0#UG^V]*-_]@&IV7VSYO\ 1_/7S/EY;Y<Y
MX[^E5X_%&@SV=W=V^LZ?<0VBEIWAN4<1_P"\0>/QKA;OPW<W?AWQZ;?36.H7
M6IR&,F/;)/"$BRJL>H8;U&.,DU:E-MKWB;3KK1-+N8+:STZZBO'DL7MQM95$
M<&&4;B&&<#(&/>@"YHGQ$74-$?6;ZWTZVL19/>CR=32:4*NW",A5<-\V#S@'
M SDUU6EZQ;:OH-OJUF\<D,\/FKMD! ..5+#C(.0?0@UYKIVBWQTO3(/[.G#_
M /"$26[*82,3'RL(>.'R#P>>*[?P[*MS\/[(0PS1E; 1&*6%HG#JFU@58 ]0
M>W/6@"Q'XITF#2[2[U74M-L'F@CF9'OHRJ[QQA\@,"0P##@X.*V8Y(YHDEB=
M7C=0RNIR&!Z$'N*\T\#:&XU729=0TQQY7A.RM]UQ <(^Y]Z<CAL8R.M=#X$6
M72OAMIHN[>>-[:V<M"8SY@"EB %ZYQC ^E $C^-($\=KX;-HWEE0AO=_RBX*
M&00XQU\L;LY]!BMO[?I=I;7$GVNSA@MY"D[>8JK$Y()#'H&)8=>?F'K7E_\
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MEVWD[LL<J/O9'6DO3=Z.+:>#4]1>;4O#5[<W32W3N&F1(F6103A""[?=  %
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MF5(W)SRP ^]UY/K6IIR2:)?>#;[^T]2E;4K.5M0-Q=23++BW\P-L8D*01QM
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M,1LH#*5*E1T()]ZB/P_L&L=3MWU'4GEU"XANY;EI4,BS1%2KK\N!RB\8QQ@
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MV@$# P.,5<U/38[&XU/7(+"YU*[NK6*U>RC= )$5FQC<0!_K&SD]!P/7>HH
MYSP+X=;PMX0L=,EQ]I"F2X.[=^\;DC/?'"@^BBDU+P?#?:C=WEMJNI::U\BI
M>I9N@6X"C:"=RL5;;QN4@X ]*Z2B@#'T[PUIVDZDMY9*\6RPBT](0?D6*-F9
M<<9S\YYSZ4W6O#D>KW]CJ$=_=V%]9"18KBVV$[7QN4AU92#M7MD8K:HH Y>R
M\"Z=8^45N[Z5H]4.J[II58M.8S&<G;]T@DX]>F!Q3M9TA+*TU^\M--N=5N-7
M58YK-9$4-B/RQ@L1A<=>2?3TKIJ* ,3PAH/_  C7A33]*9_,FACS/)G/F2L=
MSMGOEB:LZ1HEMHWVXP/+))>W3W<TDI!8NV.. .   !Z 5I44 <YIW@O3=,O+
M2XMYKK%I=7-S!$SKLC,X^=0,?=!)(&>,GDT^V\'Z?:KIH26Y(T^]GO8MS+R\
MWF;@W'3]ZV.G0<FN@HH Y-?AYHHTV*P=[N2"/2Y-* :09,3LK$D@#YLJ,'I[
M5/9^#8X-8L-4N]9U._NK!'C@-PT84(Z[2"J(H/0'/7@<XXKI:* .0M?A]:6%
MI8Q6.L:I;SV&]+2Z5HS)%"^,PX*%63*@C<"0>];^C:1#HMA]EBGN+AFD:62>
MYDWR2.QR6)X'X  #L*T** .6E\"6$GVW%_J$?VB^&H0E)$!M+CG+Q';_ !;C
MD-N&.,5HZ+X>AT>XN[Q[NZOK^\V>?=W17>RJ#M4!55549/  ZFMBB@#F=5\$
M6.K7FJSRWM]$FJ6Z074$3IL;8?E<94D,!QUQ@]*OZAX:T_5=3:]O%>4O82Z>
M\)(V/%(RLV>,Y^0<Y[FM>B@#G=*\)+IU]:W,VLZI?BSC:.UBNI4V0@C!^ZJE
MSCC+EC6C>Z+;7VL:9JDKRB?3C*854C:?,38=W'/'3&*T:* ,[7=%M?$.BW&E
MWAD6"<+EHFVLI5@RL#Z@@'\*Q6\"V]Q=SWE_J^IWMU/83:<\DK1K^YDQD!50
M*"",@@=^<\8ZNB@#"OO"]M>0:.B7=W;2:2ZO;30LN[A"A#94@@J2#Q],53'@
M:R@M+".QO[^RNK%IV@O(60R 3.7=&#*5922."O&!WKJ:* .+OO EK;:/?MI[
M75QJ#:9>6JF:529WGP[,Y('S%E'H #T])-$\#Q06FG-JM]?WSVMGY$-M<R(4
MMMZ;7"E5!8XRN6+$#H:["B@#D;3P!;6QTA9=9U6YATB17L897C"1!5*A3M0;
MOE.,MDXZ$<YO1>#]/BT/3M)66Y^SV%XEY$Q9=Q=9#( 3C&,GT'%=!10!S\'A
M2.TFU)[75=2@2_NUNWCCD0".0$%MIVYP^ &!)XZ8KH*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*PR#SZB@"Q1110 4444 %%4(]:TV76YM&CO(VU&&(326X^\J'H?U'YCUJ_0
M4444 %%%5M/U"UU6PAOK&836LZ[XY%! 8>O- %FBBB@ HHJM?ZA:Z79M=WLP
MAMT959V!(!9@HZ>I('XT 6:*** "BH7NK>.ZBMGFC6>8,T<18;G"XW$#N!D9
M^HIFGZA:ZKI\%_8S":UG7?'(H(##UYH LT451U?6-/T+3VO]3N1;VRLJF0J3
MRQP!@ GDD4 7J*PM+\9^'M9O#:6.IQR7.PN(F5HV91U(# $X]JU;"_M=4T^"
M^LIA-:W""2*100&4\@\T 6**** "BBB@ HHHH **K0ZA:W%_<V,4P:YM0AFC
M .4#@E?SP:LT %%%% !1110 44UW2.-I)&544$LS'  '<FFP3Q75O%<02+)#
M*@>-T.0RD9!!]"* )***K6>H6M^;C[+,)?L\S02X!^61<97]10!9HJM9W]MJ
M"2O:RB189G@<@$;70X8<^A%6: "BH8KJWGFGBAFCDD@8)*JL"8V(# 'T."#]
M"*FH ***K3:A:V]]:V4LP6YN@YAC(.7V %L?0$4 6:*** "BBB@ HJM<W]M9
MS6L,\H22ZD\J%2"=[[2V/R4G\*A76M->6SCCO8G:]>1+?8=PD9 2X!''&T_E
M0!?HHHH ***0D*I8\ #)H 6BJ]C>VVI6,%[9RB6VG021R $;E/0\\U8H ***
M* "BJ+:SIRR0I]LB9IKAK5-AW9E4$LG'0@*V<^E7J "BLW3->TS69[N'3[GS
MVM)/+F98V"ALD$!B,-@J0<$XQ6E0 45#/=6]KY7VB:.+S9!%'O8#>YZ*/4^U
M,L[^VOUF:UE$@AF>"0@$;74X8<^AH LT444 %%%9MUKVF66KVNDSW.+^Z7=%
M"L;.2N<;CM!"C/&3@4 :5%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<IX
MY<M#H-FW_'O>:U;13CLR#=( ?8LBC\:ZNLKQ%H_]MZ.]JDHAN$=)[:8C/E3(
MP9&^FX#([C(H Y#4UOM+UOQ?-9Q:=>VU]!')=23701K';#MQ(N"60J-PQZL/
M>H+/[39>'/AE=2;A?"2"U<-]XQR6S;U/_?*GZJ*[*^\+Z+K%S%>:II5K<7:H
MJLS+D$ Y /\ > .< BG7>CM>^(]/U"9T^S:?&[01#J9G&TN?HF0/]\^@H P_
MB+LEM-!L[H@:==:S;Q7NX_*T>&8*W^R75 ?K6CXBU#1;:YL+6^@^T7L>^]LX
M(U)9#$A)?C[HQ\N3P2P%6/$.EZCJ]L;."32C92IMG@U"Q:X#\^TB ?D:P](\
M(:OH+2-I<WANV>4 .ZZ3,68#H"QN,X]NE &1#=:G!I7A37FUN[GU36;RVWVH
MES;M%+\SHL?0!$R=W7Y<D\U!)J6I3^#8?& UB\74[N]1;.Q27$&&GV+!Y?1B
M5SDGYLY.1BMS3_!FJ:5>F\L'\,P7&" Z:1-\@/)"_P"D?*#W Q1!X,U2VU0Z
MG"WAE+S>T@D&D2_*[?>8#[1@,>Y')H Q]3U+5A9^)O$L>K721VFI?8].M@^(
M$(*0,[C^("0LV.GRGUXBUB,^'_%L4S:S>WZ:-H]UJLRWDHD*S;?+1AQ\NX,_
MRCCC@"NF_P"$=U_^RYM,-UX;-C-O\R Z1*4?>Q9LC[1SDDG\:I0>!M0MK>X@
MB/AE8[F(13C^R9B94!) 8FXR>3WH HZ<-4OK_P"Q:CKFH0VFDZ%;-J#0R['E
MN7#.Q+=1A4SQ@\CG&0:=AJNJZOHVBVDMSJ]Q/!I<=[?_ &6XCM<"7)C:68L&
MR%5N%'N3VKJ6T#Q$_P!NW7OAT_;QMNO^)5-^^&W9AO\ 2/[O%4[KP7J=]<03
MW+>&99((A"A;2)L>6.BD?:,%1V!R!0!S>CM=>*7\"_VE?WA9(KO5'83;3Y2-
MLA9B ,MB11N[X/K5[P[J&J>)YM*L+K4[RWM[NTGU>5H9"DLB/.1#$K=514()
MQS]VM<>#M4W6967PT&L86M[?;I4P\J,C!0?Z1TQVHO/!NJZA:VEM<R>&GALT
M\NW7^R9AY28 VJ1<9 P ,=#B@#$T[5-7U:]TO0[;6KH6_P#:M]B^4@RS6<"[
M<%L8;]Y(%W8_A!Y-=3X&EN9+?6DDO+FZMH-5F@M7N9#(X1 JL"QY(WB3&:CM
M_#WB"TF@EMKKPW"]O ;>$QZ1*OEQ$@E% N.!E1^536>D>)]/M_L]IJ'A^&+>
MS[$TJ8#<S%F/_'QU))/XT <1KOBC6HI-:TVTOYHY-,U5[NZFW<QV@\HI'GL&
M,A_X"C5K0ZSJ6I:QI%T;^XM[/5KV>[CC5MH2P@A(4X_VV9'/LRCM6M-X6UJ?
M^T?-G\-/_:05;W.D2_OPHV@-_I'.!Q4QT#Q"TT4QO/#A>*!K:,_V1+\L38R@
M_P!(Z':O'M0!PVBZ/->Z5X-LEO[R.;5[V;7;B5I-[JBAF4C<" 298^?7FN[\
M#27#QZY')>7-U:P:K+;VK7,AD<(BJK#<>2/,#XS5;3O"FM:08#87'AR V\30
MQ%=*F^1&8,RC_2. 2!^0JY9Z1XGT^ P6FH>'X8B[R%4TJ8 LS%F/_'QU))/X
MT 5/!HBE\2>+[JY*G5%U(PMN^^ELL:>2!Z*02WN2:XS4X(]?U358K*:5-+UG
MQ%9VT;6[[5G,4>ZX<8ZCY",]"RY[5UFK>"=2URY6YU-O#-Q.J[/,;29@Q7^Z
M2+CD>QXJ>Y\*ZU=VMG:S3>&C!9.LEM&-(E40L!@%0+CC@XH Y34H;D6/CCQ'
M;ZKJ$#V\RV-BL$VTO)"BQJSMC+_O788/'7(.>+>K:MK5]JNOF5]0CL=&5(%E
ML[Z*U5)/*61Y9-Q!8988!^7 Z$DUT?\ PC6O&R-D;KPY]F:?[08O[)FP9-_F
M;C_I'7?\WUJO>^#-4U+4EU&\;PS/=KM_>/I$IW;?N[A]HPV.V<XH K6(UOQ)
MK\%E?:I<V<=EHUM)J"6,H3S+J4DX##H $SQ_> S@G-GX@F]N[_POI&G1P27<
MVI?:PEPY6,K;H7^8@$@;BG8\XK0ATGQ1;W5Q<Q:CX?2>Y*F:0:5-ERHP,_Z1
MV'%))H_B>6_AOI-0\/M=0(R12G2IMR*V-P'^D=]H_*@#F?&=AXA?2KG7-8ET
M^&6RM)K:PMK N^9[D"$,SL!TW8  ZG.:J^(+Z:ST[5GL)]8&F^'[46B/;74=
MK#%-'&">^^4\H,%=O8 ]:[&[TCQ/?Q)%=ZAX?FC21)55]*F(#JP93_Q\=00#
M^%9=[X%O]1N[BZO!X8GFN!B8OI$Q#\8R1]HQG'&>OO0!7AFU35M9FAU+5[RT
MM-+T2W?4!:/Y1DN7#.QR.5PJ \8/([9!RX]0UR]\,Z#/+=WUZ+;35N-5MK"[
M$%XOF -%*3QOPJN"N1D\\]*ZH^'_ !"RWP-YX=(OUVW7_$JF_?#;LPW^D<_*
M,53O_!.I:FT+7C^&I6AB$*'^R9A^['1#BXY7V/% '2^&Y_M'AS393J#7YEMD
ME6Y>,1M*K#(8KV)!&?>M&XN(K2VEN9W"0Q(9'<]%4#)/Y51T[2H[9H;NYBLV
MU)+<6S3VT)B7RPV0BJ68A1Z9-6[RSM]0LIK.[B6:WG0QRQMT=3P0?:@#QBWU
M#5+%+#QQ<^']0@\S47O;R]>2$Q_89PL87:)"^%186Y7JAZ5J^)M>U^TNM6T'
M3;Z4ZA'=MJ=N^[)-F(3+L'L94,?T->HSV-K<V$EA-;QO:21&%X67Y2A&"N/3
M'%01:+IL-Y%=QV4(N8K;[(DNWYA#G.S/ID4 >?2^))]8MIM0MM0U/[+JFJ):
MZ;;6&T23QQ1DN%=F"QY<.2^>B "LXZOKL5AKVF+?W]G);ZOIT$)FN5N)[=9F
M0.ID&0W7.#G&<<UZ5)X6T*71[?2&TNW^P6S!X(57 B;GE2.0>3R/4TEOX5T&
MTB>.WTJUC1Y(Y7"IC<\;;D8^I!YSUS0!R\%A<W'B>_T*7Q%JUO;:58PS6[_:
M?WDK2-(6ED8CYPNT* ?EXY!KFM%_M>7PIX6AL)KJ[M4TLR366F7Z6UUG?@3
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M)C<<DGG'UH \S\$W.IZ?I>FVEA%I?]L:]/=W$U[) _$<,A#-( ^9&W. HRN
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M/@!3M9E+("%&=I]Q@U'>> 8;HZO!#K%_::?JY+7=I"(\,Q0(<.5+ $*,C/\
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M+W3Y[>3RWBNE7G(!!5E)5A@]0?8XKF/'6O:U:7\%EX>?$]E;/JMZFP-YL*$
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !01GK110 4444 %(JJBA44*HZ # %+10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;#32H9B0"8GR1]:J_;O$</CGQ6-(M;6ZA@CM9"MW<,@)\HG8@ ."?4\=.O8
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MBZA1(;T6<]Q]EAU!H"+:67.T*&Z\L, XP3P#4B^--):Z%F//^W&^-C]C\O\
M>B0#<6VY^YM^;=TQ0 [6O#+ZIK5MJ<.H-:O':36<J>4'$L4FTD<D;2"H.:;'
MX3ACM?#$!NF9=" "Y0?OL0-#SZ<-FH_^$ZTK[5L\F]^Q?:?LG]H^0?LWF[MF
MW?U^]\N[&W/&:KW7Q&T6TEN?-@U'[-:79L[F[6U9HH90VT*2.3DD= >HSC-
M!IG@R\TO[%90^(;D:-92B2"T2(+)M!RL;2@Y9!Z8!( !)K7UO08]=N=+:YF/
MV:QNA=-;[01,X4A-Q] 3NQW(%9I\?:3#8ZI=7D%_9'3!$US#<6^V0)(<(X )
MR"0??@\5%?>.X8=*U:2+3[Z'4;.Q>]BM;NWV-*@X#@9Y4'&[D$=P* +FK^#[
M#5-2L;Q0MN;=9H94CC %Q#*FUXVQCCH0>Q%4;+P5>V]_HDMUXAFNK7178VD#
M6ZJ2IB:,>8P/S, W! '0\<YIMGXR@"PWNJ74EG"-'6^GMI;;&WY]I<,"3R>
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MI8S6M[]DB6>Y56N#Y:/E0<?\],8&>GO6]//#:P23W$L<,,:EGDD8*J@=22>
M* /,1X'UNYTO6K*UA.DV-S8B*#3Y]1>ZC^T!PP=2<^6N!MP.N<X&*OZAX;U_
MQ7J5]-J=G;Z7;W.AW&FJJ7/G.LCNC!C@ ;?E/ ]/?CL'\1:'%9R7DFLZ>EK%
M*89)FND")(.J%LX#>W6II]8TRVTY=1N-1LXK%@"MS).JQG/3#$XYH Y/4+3Q
M?KOA^_TJXL+&QC?2Y[9MMQYOVB=DVH5.!L0<GGGD#'&:U)=#O&\0>&+Q0GDZ
M=;3Q3_-R"Z(!@=^5-;,.K:;<(CPZA:2))((D9)E(9RNX*,'DE><>G-1:CJT=
MG&WD-;331SPQ2Q/<K&8_,8 $D]\'('5N@ZT 9FMZ;J,OB[P]JUE;QSP6@N(+
ME6EV,BR^7\XX^;&P\<=:R++PGJ<'@[PIICK%]ITR_AN+@!^ JLQ.#W/(KK5U
MG2VO39+J5F;L!B8!.N\!?O';G/'?TIMKKVC7UO<7%IJUA<06P)GDBN4=8@.3
MN(.%Z'K0!YQ?^#/$NHP/'=VOVJ_34%N/M\VJ2&-HEG#JL<'W4.T!<$#H>3FN
MT\.:;J.EZUXA6XMX_L=[?&]M[A)<D[HT4H5QP1LZYYS5YO$^@*MRS:YIH6U(
M%P3=QXB)X ;GY?QJQ<:SI=GIZ:A<ZE9PV3@%+F2=5C;/3#$X.: .+\0^%]:O
M[OQ5#;6T#VVKQ6SPS-/@J\6T%&7'< G.:O>*_"%UXCU:[*R)%;7.AW&G^:3R
MLKR(RG'<?*<UTLNLZ7!:1W<NI6<=M*I>.9YU".H&20V<$8K-U3QIH>EZ?87S
M:A:S6M[<I;1313H4RQP6W9QM7J2.E '/^'?"U[#K^G7MUH5M8BRC??,VI373
M/(R[?W2EL*N"V2P)P<8[UJZ_X8E\2>*=/>^:5-(L('DC^SW+PR-<L0H.4(8!
M4#=^=YK<;7-(74ETUM5L1?L 5M3<)YISR,)G/Z5?H \[N? -U:OX@L=*=CIV
MIVJ7$+7-R\LD5_&V58ER6(.$).>-E5[+P#JL>K:!=3O (G_TC6U5L^9.LKSQ
M[?[P$LK<^BBO3** /*-=\&>)=7MM4@N+87=Y+=M+;WLVJ2"%81(&1$@'RJP4
M!>1UR<FNCN?"%UJ-CXULII$A76Y=UO(#G:/(C0%A_O(>/2NTHH XRVL_$NI>
M*]$U'4],M+*WT^">.4QW7FF1W51E1M&%^7OSSR!CE/&/A>XU37-,UBWM!?BU
MAEMYK3[6]LS*Y4AD=2.05Y!X(/J!7:44 >?Z5X/O[2;1+C[%:6GDZO-?W$,5
MQ)*51K=XER[DEWY7)&!Z#C)30/"^M65]H*7=M D&DWE^YE2?=YL<V\HP&!@Y
M?!'M7H-% 'F^J^!=1O'O+L113NFO-J,5L;EHO/A:!8BN]>4;@D?3G@TD?@N_
MDL[J2/2[6PDGU&PF$1O)+B3RH)0[&21B03]["J./4YX])HH SM?TH:YX=U+2
M6D,0O;:2W\P#.W<I&?UKAISKL_BOPA8ZOI]K:+&EU$98;CS?-?[.0648&U<<
MX///MSZ53&BC>1)&C1GCSL8C)7/!P>U 'G>E>'_$ZP>$--N["SAMM F7S;A+
MK>9PL+QJRKM&!\P)!YY]JS_^$,\2W3:8]_:_:-0L]4@N[F_GU2219D28,?*A
M^ZGR]L#&,<YS7J]% '":;X3U.U\06-[(L7DPZQJ-X^'Y\N96"?CR,CM4%AX*
MU%=/\-6=UY:+917T5TR/DJ)E8*5]>M>A44 >8:!X'U"RFT6UN=&M%_LR1&DO
MWU&>5)/+&%:.'< K$X//"\@ U/H?A36K#Q!87$-A!I"Q3.^H/97SFUO%(882
MW.0A)*G/&W!Y->D44 86OZ3=:CJOAVXMPGEV&H&XFW-@[/)E3CU.7%<JOA;Q
M#_PC">##:VHTY+@?\3/[1R8!-YG^KQGS,#;UQGG/:O1Z* ,'PQI-SI1UHW(0
M?:]4FNHMK9^1@N,^_%8GB+0M;U#Q)/*;9]0TV2W1+6$:E):Q02#=O,J)_K <
MKSSTQBNYHH X/P=X3U31;O09+Q80MCHDEA*4?/[PRHPQ[84UO>$=(N=&T%[.
M\"B5KRZF^1LC;).[K^C"MZB@#RK2/A[>Z?'I^DR:/;316=RC-J,NHS,CQ(^Y
M2( PQ)P/]D$9YZ5KIX8UU?&'_"8[;;[>\WV1[+(V_8,X'SX_UN1OST_AKOJ*
M /*;7X>WMI$ND'1[:YA6\,@U";4IO+,)DW\P*P_> <8'RY .>U;=QX3U.3PU
MK%@JP^?=ZZ+^/Y^/*^T1R<GUVJ>*[NB@#S7X@:7?6UKXIU=!%Y5S::?#!N.?
MWD=PQ.X>GSK^M:%[H.N>)+R^O-0M+;3F&CW.G6T2W'F[Y)MNYV8*,*-B@#KR
M2<=*[>6*.>,QRQI(AZJXR#WZ4^@#S2Z\&:YK5FOVB*WL9QHL5FH,WF*)XIQ(
MN2!RIV+GTR15[4]%\0^)[HW5_I]MIWV73;NV@B6Y\UIIID"Y)  5 !]3GH,5
MWM% ')IX?OEN_!LF(]NDPNES\W0F#RQM]?FJ_K6DW5]XB\.7L(3R=/N9I9\M
M@[6@=!@=^6%;M% '!)X2U6'PAI]O$+<ZEIVKR:E'$\F(Y09Y6"%@#@E).N#@
MXJMK7A?7O$HUC4+FTM[*XN+."RM;3SQ(=J3>:SNP& 3T &>GO7HU% '/-H]V
M?&]YJP"?99=)CM%.[YO,$DC'CTPPYJ;PEI5SH_@O2-*N]HN;6SC@EV'(#!0#
M@]ZVZ* //_"/AG6M-N?#C:C;01+I.FW%@[1S[_,):$HXX& 0C<=JHWG@/47:
M"]:VCNWMM6U"Y^R+=M 98+B0L")%QAAA3@\'D9KTZB@#F?!NAS:/;W\MQ86]
MC)=W'F"&*XDG<(%"KYDCD[FX[8 &!SC-9MUX,O-0\-^+]+EDBA?5K][FV?)(
MQLBV[L<CYH^?:NXHH \Q'@*ZUA;F&YT>#2E?3Y[;SWU&:\D\V1=N4!;"H.<Y
M&3QP.M6))==N/&OA*VUC3K:S"17<>^&X\WS7\D LHP-J_7GGVY]&IC11O(DC
M1HSIG8Q&2N>N#VH \ZTKP[XGCM/">E75C9Q6N@7*-)<K=;C.JQ/&K*NWCALD
M$YJ[H'A/4].O_#LUPL.VP_M+SMKYQY\P>/'KP.?2N[HH \I?X>WL0O=,&CVU
MY#<WDDJ7T^I3+&L4DA<AX%8989(&, \$D<UMZGX3U.ZT'QK9Q+#YVKW?FVN7
MX*^5$OS>G*-7=T4 <1XL\&WGB34M3V21Q076C?8TD8GB43>8,@<[>!FLJ+P;
MJ%U]I<Z%;6$BZ=<0(\NIS73O-(FT;-S81.N202>.!C->F44 <HOA^^6]\'2X
MCVZ3#(ES\W0F#8,>O-<W%X2UA?#&D:9J'A^QOETUYH_W=ZT4^"04EBE&-G<,
MIYZ'/&*]/HH Y[PUI&I6OA3^SM:NGFN)/-&6F,KQQLQVH9" 7*J0-Q'.*YVT
M\.^(YM(T#PW>6EI#9:1<6\DE^EQN\]+<@H%CQE6;:N<G YQFO0Z* ,+PMI-U
MI%MJ<=T$#7&IW5U'M;/R22%ES[X-9&I6WB5;F_M+C1-.\2:9<2F2V^TSI$8%
M('[MU*$$ YPPR<=:[2B@#RU?AY?Z=!H4S0)JKV=E+:7%M'>R6VT-)YB^6X(R
MJ\IAL9 !ZBKUEX3U;2%TC5K/3K(7MI<74DVGQW+D,DX4?ZV3.Z0;$R3@'GIW
M]$HH XF;3O%%UJVA:S=VMF\MK>3E[2.?'D02)L'SD8=EY)Z9S@=,U0TGPQKO
MATZ3J5M:V]Y<V\-W:W-J9PA,<MQYJLC$8R,#(..OM7HM% ' Z=X2U:/5]-U6
M[6W69M9N-2NXHY-RPJ]LT*(I(&XC"9.!R370:%I-UI^M>([J<)Y5_>I/!M;)
MVB"-#GTY0UO44 >=ZW\-I93"VF:UJR^9JT=].CW"!5^?<[K\F=P'W<D] .U7
M+[1O$.FW^O#1K6WO(=:1")I[CRS;3"(1%G&#N4A5;CG((QWKN** //=2\(3P
M)I=K%X?TW6K:RTZ.S@DGF,$D;J,'S#SOB88.WL0>#FFV'P[E-QHUGJ4TAT[2
M+%A$]I<R6[R7<K9E<%""% R ,_QFO1** .4\->&9_#'B'5H[0N^B7H2Y3SKA
MI9([C[LF2Y+$, IR3U!JE<:5XBTJ[\0PZ38VEY;ZS*;B.::Y\O[/(T:QL'7:
M2RC:&&WGJ/>NXHH Y'PKX6N/#NKREG62U32;&QBDS\S-") Q([?>6NNHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *Y'Q_;QS:?ILTC7\)MKU94N[2
MW%Q]F;8X#R1$'<G)!P."0>,5UU% 'D*W.H+HL#3:7:BW_MQG&K?V3*%QY61<
MFV!W;BV4W'Y>^.E5&L[N32/%L\EK>W,9U33KM)&TXPM,BM%YCK$%SC"MVR0,
MGK7M-% 'D^JVB7-_KE\\.IP6QU6RNK6[MK/S/)Q:*!(T3*=Z DJ1C()[8X;!
M;WNH:5%YFG1S1KXFM)4O(=/>V^UIE-\K1-DKC&"W0[<UZU10!X]JNEZDM_<7
MGEW$-A;^)Y9YF6S-QM4VR*DHBQ\ZJV1D9QG/:G?V8DVE:KJ#R:U)!+JMM/'>
M0:8L821%P9UMR"73H&^7G&1TS7K]% '&?#^6[E76&G@A>$W2M%J$=BUI]M.Q
M=SF-NXP%W#@X]JY;5(IK+Q!?)IUO<W$TNK).=(O]+,B3-O7]_%<*!L4 ;@6)
MV[2"!TKURB@#R'7YY;3PWXXT$Z?J$FHWM]+/;1Q6DCK+$X0APX&W PV><Y&.
MN*U;TV6FZSXNBUW1;G49=3=&LUCM'E%U#Y*J(5=00I#ANI&-V[WKTFB@#RNX
MT'SO#?Q(DET<B[N-X@5HM[MMM(]@0XRV'S@CO74^,8+BY^%NKP1Q2RW,FENH
MC52SLQ3ICJ3FNKHH \R\3:0VDZ_X>O+938:3;V<L7F6^G?:5@F;R\,T8'&54
MKOQQC'>L_2K$Z5/HNL7=MJ$^C1W]]*WFV!0PM*$$<H@4$JA*R8X!'F9P,UZ[
M10!XY8R0?9KG5+'3[J/3[3QE]JEC2V??'$;=5+^6!N RX.,9 /2K5]]HUB\\
M0WUK87OV>XU;2'@:2V=#(B21[G"D [1@\D=.:],L-+M=-DO9+9&5KVX-S-EB
M<R%54D>G"CBKM 'E5[X;NKKP?XX^QZ<PU*ZU69E;ROWLT(:,LJD]0R!@!T.?
M>L^\LY-3MM9N+&;4+QH_#UW;G;H_V-/F3Y82" 7<$9  ..?6O9:* . MO#UK
M%XU\,LNDQK!;Z),A;R/E1]T(4$XP#@OC//+>]<K;:;J&GVWAB\G^TV-A:#4(
MMXT\W/V:1K@E"8\94% 0&QQTZ&O::* /)=$T(R:EX;>6TN[BR;5[ZZ'VJR$*
MJ#"=K"/^!2X+*& .3G'2G7^GM90ZI.VG3?8[?Q?!=E8[9GQ#Y<.]U5025SNS
M@'G->L44 >0Z@DMIKMX--M[FXEFU5+C^R+_2FD65BZ_OXKA0-@ &X;B=NT@@
M=*]4M;^*[N;N"-)E:UD$;F2(JK$J&^4GAA@]1WXJU10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM8[32U^W1?<CA(7)W?*/,=ORJE8W$?A;4D?2[C2-0C;1K:PB=M2BC%O)#O\
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M._<9IEEXWTJ^F6)(M0BDEA>>V6>SDC-TBC),61\QQ@XZX/2L[Q;X3O/$>KW
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M ;/_  F=E:VUG'<1W=U?/9QW4\=E:O,8D8?>;:#@$@X'4X. :FN?&NC0?9!
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MZ9&,YS@XZU7N= \1M<16\]K>7=DNG6\%M%:ZF;6*&55(D\[8P9QG'(W<#&*
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M;&5*A^1G&#P2,5@7GAK7-:U2XUJ>P2TDFOM-*6C3*S+#;REV=R/EW'<< $\
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MA3;F*0R7\J,""Q"X6(,!QU;'.!U -K4?$6EV+ZC,GA5[C3-,D,=[?1Q1!8R
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M]K):WEO%<6\@P\4R!U8>X/!J:B@!L<:11K'&BHB *JJ,  = !3J** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY+>&66*62&-Y(26C
M=E!*$C!(/;@D<>M244 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2KIVH&UB* @LOE1OELD\Y<],=JS--\=V:Z?-<:W-%;.=4N[&W6&)V,OE.P
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M-Q,%0#&<\*&Y]ZWG\(^$XDWR>'M%1?5K*(#_ -!H?PCX4C3>_AW154?Q-91
M?^@T <38Z'JNH:AH&IZPD2W<EZD]X//1A:PP1.(8^O):1MYQGD^PJDNF:YJD
M.EVVHPZAY_\ :<4VJ,UY"EIL63>?*C1OF4D+U&>YR:[32-&\(:RMZT'A?2T%
MI=RVC[["+ED."1@=*=IVB^"]5-Z+7P]I!^QW#6TI:PB&'4 G''3GK0!S\^BW
MESX-UVV,4:W^NZLS3KYR92W:94R3GM"N<#U]:DO-+OY/#_C>2&*(:GK-R\$
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M@6FAZ1I=KI%E;PF\ E:-=LN&VVZB-OEW;CO8'&"0,Y.&ZI970\0VFLQV&I)
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M=)\2R:7?:3-9&TMA+%HMHT=IYOGKM;.]E\S;D$#MMS71:]9W$7B>[\(PQO\
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M)GY?N^9C/&??%>QM@*2V,#GFH+2[M=2L8;NTECGM9T#QR(<JZGH10!Y!JO\
M9C7&AM8"TM?":RWGE-K$+26)GW+M(7> $(\SRR>.N!R*[7X;1^7X>NO*NH[B
MS:^E-J8(&BA2/CY8@S$F/=N(.<<\<"NQ*@K@@$>AID\\5K;23S.L<,2%W=N
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M_P )7")=9:^S8HH_TMX=J>2+4\'KG[I'S9S396\-)>^(O^$IMS)KS:ENLXU
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MTW4))H8$"&.1T@B8F3*DMN&!C(Q6IJWB/58M6UJTMKO[/YU[IEI%-L4_9EG
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MT9BDB8?*R$8(^F* .'L8M1U;79]#&OZA9VVF:?;2(\)C$L[R[SO9BA!5=H
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ML%NY671;G[1&Q49D.R1<'T_UA_*A_!EN]])=?:Y07UA-6V[1PZQ"/9],#.:
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M."_\1VOB[QI-I5M9W%M:R6\K)=3."Y%LA,<>!A3WR>,D<=36E'X_@6.]NKF
M1V8T>+5[-L_--$RG<I']X-M'']\5-?>#+JXU36+NS\075E%J^Q;N%(4;"K&(
M_D8\JQ ///7IP*SM>\-0ZIK_ (9T>UTZZBLM)VO+<;<0FW4 K#G^(EXXLCT4
MYH V]:O-63X=WU[MBM=5&FO*ZJQVQ2>7E@#UR.<'U KD-)N_%$GB>P2T-A)=
MR>&K>25[F63RA^]DP<#DL1C)]CUX%>DZC91ZEIEW83%EBN87A<KU 92#CWYK
M%T'PJVCWT-Y/J4EY/%IZ:?N:)4RB.S*<#OAL?AF@#FY?B?YEEHBI_9VGW>H6
MSW,SZA,1#"$;85&.7);..G )]JZCPAXD7Q1HK7NR)98IY+>7R7WQLR'[R-@9
M4@@CCO6=;^!#IUOIC:5J\UI?V$4L N#"KK+%(^\HZ'KAL$$$$8]ZZ#1M-DTK
M3Q;S7]S?S,[227%PV69F.3@#A5'0*. * .+U/XAW>EZKY<S:)L%\EJVGI=^9
M>!&D$8D.W*J>0VT]N,YJ>Y\8Z_%:Z[JL>FV)TK1;J6*53*WG3QQX+LO& 0#T
M.<D'IUIY^'+_ -FMI2:]<)I@O/MD<*VZ;M_F^;AWZN-WT/3DXJI8>#=2U+_A
M(K6^U*[M-*O]5G>6S$2_OXCM^ZYY56 P>OMC)H O7'BGQ!/J&OC2=/T^2ST?
M8VZ>5P]R&A24JN!A3ANIR.1QU--A\;:AJ.K-_9UI:#2(-/MM3N+BX=A((90[
M%54#!;"$\G''O4">%=6OO$OBS9J=UIFG7\L,95(4831BWC5C&Q'RG[RYYZ=,
MBNCL/"MCI]]>S19-O=65O8_9B/E2.(. ,]3D/C\* ,6S\6ZVL.B:GJ>G646E
M:Q-%%$D,K-/;F49B+Y&UL\ XQ@GO5>Q\:ZZ^D6&OWVG6,>D7-VMJZ1RL9HPT
MOE++R,8W$?+UP<Y[5H6/@>2W;3+>ZUNYO-+TJ19;*T>)%*L@(CWN.7"@\=.@
MSG%9'A+P7J,GA[3(-9U&Z6SM[IKK^S'A4$.LK,@9^I3.&V^N.<<4 ,U+Q1JU
M_H>NW=WIEB='LK][)5%Q(LTKI<J@;*XVKCWSD>AJ7Q5\0KSP[<Z@[-HBQV3
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M20W@L6M3;-YZ3E2P0H.<D#@C(.1S6EHGB&TUW[6D,5S;W%I(([BVNHO+DC)
M89'H0<@@UR:^%=:O=9BUN[@@@GGUJ"\DMEEW^3!% \0RV,,Y)R<<<]3BNDTG
M2KJS\5^(=0E51;WQMS"0V2=D>ULCMS0!'J?C33=+O;JU:"_N39*'O)+6V:1+
M8$9&\CVYP,G'.*QM7\<W$6IZO9Z? SP6^@G4;:[$6Y&<J[*V<X*848XY.14D
M^F>(=(O_ !"FE:=;7T&LR^?%-)<B/[/(8EC82 @EE^0$;<GDC'>LZ3P9J^GQ
MM8644=W;2^%QHYG:4(4E19-I*GJ&+ <'B@#=T'QQ8ZDMA;W,5Y;3W-I]HCFN
M;<Q13A5!<H3V&<\XXY'%6--\;:7J=W:0QPWT,=[G[%<W%LT<5U@%OD8^J@D9
MQD#(S6;JGA.\U./P[;,5CBM;&XM;IPW*&2W\L%1WYK(\/^#+^UO-$BN]$BB_
MLUE::\DU6>=)"B%5:&+?A22<_,,*,C!H Z_P]XKL?$QD;3[>^^SH.+F6W*1.
M02"JL>I!!!Q7+:[X^OK-/%JQ6SVXT::V2*=X"5*LT>_/)R2')&!TP:ZCP7I-
MUH?A*RTZ\5%N(?,WA&R.9&8<_0BN;UWPQK5[=^*H+>UA>VU62SN()S.!AHC$
MK(RD>B,<].U &]!XXTE_MPNX[W3VLK;[7(EY;-&S0Y(WJ.21D8QUSQBBW\:Z
M?+//!<6>HV,T5H]X$N[8H9(DQN9>3G&1D'!Y'%9_BC0=>O-:O=0T2:.WF?1F
MM(92^TB7S@^!P<94$!NQ(K#B\':O)K,E\FFR6L4FD7=D?M>J/=3-+)LVEBQ(
M"_*1P?J!0!U>E>-]+U>_L[6&"_A%]&TMG-<6S1QW( W'83[<\XR.1FCQ%XEG
MT;Q!X?T^*SEGCU*XDCE9(RQ55C9ACGKD G_9!JM%X>OTE\$,4CQI$;+=?/T)
MMC'QZ_,:M>)M.U&XU;P]J6GVR7)TZ\>2:)I1&2CQ/&2"1CC<#CO0!C^&?B#%
M=V%FNJPW@FGO9;/[8MJ1;^9YSK&F[U("C/3/&<UKW/CG2;6[N(G2\:VMIA;W
M-\EN3;PR9 VL_L2 2 0.Y%9$/A35$\#:9I)2+[5;ZPEY(-XQY8O#,3GUV'IZ
MUBW'@"_1]4T]='COHKV]EGCO)M4GCA6.5]S+) CC<1DCY>&XR1S0!VOCK5KO
M0O!.JZG8.J75O$&C9E# '<!T/7K6#<ZQK>@:OHL<WB2QUF/4+Y+1[5;58I0K
M YD4JQ^[C)R,8]*W?&^C7.N>!]3TBQ5&N+B$1QJ[8!^8'DGV%7=.\,Z!I%Q]
MHTW1-.LYL8\RWM4C;'ID#- &:/'6E&[BC^SW_P!EFNOL<=^;8_9VEW; H;K]
M[Y<XQGO69XA^)%O8:5KKZ587UU=:6LJ/*;5C;I*G\+/D>H/':L&7P?XGO5LS
M?VKW.HVVIPW4U]-JKM%)&DX?$,/W4^4#@@8P>236_<>%-1G\&>,-* B6YU6Z
MNY;;+_*1(!MR>W2@"\GB^TMI]4N;^ZGB@MK>UD-H]H5DB:4N% P279R  N.,
M=\\-N?&5K/ T:/>:5>0W5K'+#=V>7*2RA5PN<;6Y7<"=O/'&*QKWPMKNJ7FH
M:J;6"UNV_LVYM[>2<,K2VSR,T;,!P"& !QW]JOZK8^)_$=L!<V-M8P1WME+%
M;&8228CG5Y79QQ]T !1GI[XH NR_$#1X;B[1HK_[/97)M;N[%L3#;N#CYF].
M1R,X!!.*FU7QMIVDW%Y&]KJ%Q'8J&O)[:V+QVX*[OF/?"D$XS@=:XZVM==UK
M2_%^@6=A;FTO]6NX#?/.!Y*L0')3&6(&<8ZY&<8J?Q%X2\0ZH^NV;V\M['<Q
MF/3IGU1X;>WC,87#PK]YPVXY((.1R* .GO\ QWI5C=W-JEOJ%Y);0I<3?9+8
MR!(F&X.3TQ@?7T!P:CM_&'VSQK9Z3:V\DNGW6F"]CNEB.&W$;3G/"[3Z=2!4
M&B^'=1LY];DGCC7[;IUI;Q .#\\<3JP/XL*KZ!X>UC1M5\-3/:Q2PV^@QZ9=
MLLP!AD7:VX#'S E<<4 =-=^(-/L;^YL[F1HY+>R-^Y*_+Y0)#$'N1CD>X]:R
M+WQOI<GAN._M+R6'[;I]S>6\WV?S#$D299V3(SM)'RYY/%0>._"]]X@DTU].
M:-6WM:7N]L;K.7;YH'J?D7 ^M9"^!=42+QC%^Y:*ZLKFTT>,-C8LY>1P?3YW
M4?1!0!->^+M4AN-22&>-HX+W2H8F,0!*7#(),CW#'Z5V.N:[9>'=.%_J#2+!
MYJ19CC+MN=@HX')Y/:N-N?!^K2R7Y5(L3W>DRI^\'W;<H9/_ $$X]:Z;Q9I-
MUK&GV,-HJL\.I6ER^YL?)',KM^. : ((O'.D?9M1ENTO+!].5'GAN[<I)M<D
M(549W;B"!CG/%5;_ ,>6\&C:Q-#87T.I6%B]XEG>6Y1W0# <#/* _>P<COBJ
M?B7PCJ>K:[J5_:&!2;>P>U\UOE>:WG>4JV.0I! S[^U-U#0==\3W6H7M[90Z
M:3HUSIMM";@2L\DV,NQ48"C:H Y/)/% '1VVK37?@X:L(G@G:S,VR1-I#!2>
MGID9'M61X4\=6^L:?HD=[%=PW>H6J,D\ML8X;B41AG"'\&(SC(!QD5JV5M?S
M>"EL[NU6VOC9- T(E#@,%*CYAQ@\'\:YG3M \0WUGX7TK5K"WL[;1/+DEN(K
MD.9V2%HU5% ROWLG/I@9ZT ;MKXYTF[NX(XTO%M;F8V]O?/;D6\TF2-JO[D$
M D $]":T]:URTT*UBFNA-(\THA@A@C+R32')"JHZG )]  :\\T3P#?V":3I<
M^CQ2)87$;OJ$NJ3M%)'&VY62 .,2<+P1M!YY'%=GXHTN_NKG1]5TR*.>[TJZ
M:86TC[!,C1M&P#= V'R,\<>] &5IOCN)[OQ)<:AY\%E83V\,,$EN5G#N@^3:
M.68N>,9SD8XYK6B\::2;:_EO1<Z<]A$)KB&\A*2+&V=K #.X$@@;<\C'6N3U
M'P?KVO+K5[=V=O;7$]_9WMM:B[(WK"NTH\B8*L1GD=#CKC-,G\ WFL:;K*#2
MXM*DN+>**V^T:C-=2NR2B7#OO(5"5487GJ<]J .J7QSIBP7LEW;W]B]I:/>M
M#=VY1WA7[SH.^.,CJ,C(&:@7XAZ6]PMM'8:N]Q+%YUM$+%MUS'W=,]AQ]['4
M>HKG)O!>HZA9ZL4T*.PEDTFXM(#<ZK+=R-+*N,*6<JJ<#)(R>.F*ZN/1;Q/%
M^DZD53[-:Z3+:2'=R)&>(C ],(W- "GQOI+Z?IMU:I=WCZBK-;6UO 6F8)PY
M*G&W:>"21SQ0WC?2?L%K<0K=W$UU,]O'9Q0$W'F)G>I0XVE<<YP!QSR,\@G@
M+4K6WT6[ELOMLEI'=P7%I#?O;-MEG,B.CJ1DCNI..?45=L/"FKZ-+INM6>EV
MOVN"XNFFT]+QV+1S!!GS9"=T@\I,]%/./4@'0>#/$,WB--:FD#K';:F]M"DD
M1C=$6.,[6!YR&9JI6/CR(3>(FU2VGMK?3+Y;6%A Q,N5CVJ ,EG+.< #H5J]
MX.T[5+%-:GU:WAMY[_4GNTBAD\P*ACC4 G Y^4YK!OO"^N27^L/;V]NP_MB#
M6;*1Y\+,R)&K1,,97A&PW(Y% '5Z/XDM-8N[BS6"[M+V!5DDM;R'RY-C9 <=
M05)!&03R,'%8=WXTDTOQEK&FW%K>W=O;6EO<11V=J9&0-YGF,Q';Y5XZ^@/-
M6](T_5KSQ=-XAU.RCT]5L1906PF$KME][.Q' Y   SW/%3VVCW<7BW7]194^
MSWMG;0PG=R63S=V1V^^M !/XTTU5M/L4%]J375JMXB6-N7(A;[KG. ,]AUX/
M%6-+\5:5K%Q9PV<KL;RS-Y S(5#QA@K#G^($C([9KB;3PIXDM++1[&[MI;ZR
MMM)@MA;6^J/:QQ7"Y#M)LP9%(VXZXP?EYI__  A7B"V^'^AVM@]O!X@TSSHE
M??\ )Y<N]'P?HRN/=!0!U!\<Z4\%I):0WM[)=F4P06T!>1TC;:TF.@3.,$D9
MR,5KZ3JUIK>G)?63LT3%E(=2K(RDJRLIY# @@@^E<7K/@8V^IZ3=Z=I[WUG9
MZ<-.-I%?O:2*JD%'5E(#=P03Z&NC\'Z/+HNA>1/:V]K-+/).\,$TDH4LV1EW
M)+-C&3P"<X% &'X7^($5YIMI_:T5VLLUW):&\^RE;?S/-943=ZD!1GIGC.>*
MUKGQSI-M=SQ.EXUM;3_9[B^2W)MX9,@;6?V) ) (!ZD5S5IX<\2S>'+7PO=Z
M?:PVBWXN);Y;D-^Z6X\X*$QG>< >G.<YXJG/\/[Y#J>G#1X[Z*\O99H[R;5)
MTA6.1R["2!7&YADCY>&X)(YH [/4O&NEZ;>7<#PWTZ60!O;BWMFDBM<C=\[#
MT4@D#. <G%,U#QSI=A?7%FEO?WLUO EQ*+*V,H6)@2'R.,<'W/8&N6U/P/?Q
M:IKGV?25U*/4YC/!,VJS6\<)9%5EEC5AN4%<Y7)(..*Z+2/#=UINJ:TXCA6V
MN-.M+6WV,<9B212,$D@?,N,D_6@#HH-3L[G28]4CN$-C) +A9CPOEE=V[GH,
M<UCZ;XTTW4[JW@2WOX/M:,]E)<VQC2Z &X[">^.0#@D<U%8>&YW^%]OX8O'$
M-PVD"PE=#N",8MA(]<&N>T+PGJ%KJ.DRW.@1Q-IJEY)Y-6FN!+($*KY*%\+G
M)Y<< D8[T =18^--&U&2RBMII&FNEE<QE,- L9PYE!^YAOEY[]*9IWC;2]2N
M[2&.*]BBO21974]NR0W) )PC'U )&0,@<9KG-.\%ZS;:C?:C<&W,OB.&6+5X
MHMH^RD@B(Q' W;0=K?WB=U0^'_!=_:7.B6]WHD,?]FNK37LFJSS)(44A6ABW
MX5B<'YAA1D8- '0V_P 1-%N;*>]2'41:QL(TF-HVV>4OL$<?]]]W&!_0T2^,
M+6Z\F*.6ZTVZ34+>WGM[JTS(1(?E7&< , <."<8-9L/A/5K?P-HUI&D!U/2M
M0^WK"TF$EQ*[;-P!P2KG!QP<58O[#Q-K[6DUW9VUG!;ZI:7$5KYP>18XV)D9
MF'!)R,*/3KSP :=GXTTV^OX;>&WO_(GF>W@O&MB()9%W J&^JMR0 <<&FIXY
MTA[M8PEY]D:Y^R+J'V<_9C+NV[0_^]\N<;<\9KG++PMKEMXDMKFTT^/2G%\9
MKVYL[]A:W<.XDC[,2<.P(STP<G)JA8?#Z^LX8-'?1X[F**[#_P!H3:K/Y+0B
M3>";=7'[S&!C[NX9SVH W/%7Q BL=,OO[*BNVEM[E+7[9]E+6XE\Q5=-WJ 2
M,],\9SQ76ZOJMKHFG/?WA<0(\:$HN3EW"+Q]6%<'>^'/$L7AR^\+V>GVL]K+
M?-<Q7SW(7]TT_G%2F,[P21Z=\]JZSQEI-WKGA6[L;'R_M3-%+$)&VJS1R+(%
M)[9VXS[T 2ZKXHTW1YKR*[:4-:6+:A+M3.(@2"1ZG(/%4(O'-A</-#%9ZBDX
MM'N[99K5D^U1KC)CSUZKP<'D<5S^L:!XD\1RZ]=3Z;;V1O-!?3K> W0D;S"Q
M.6(& #GMGI[X'0ZAH5Y=>(]%O(P@@M;"ZMY26Y#2"(+@=Q\C4 8%OXYO;[PO
M%J8E-K?2>';C41:M:_(TB*A\Q6+'Y06P%YR#G/%=WI=Q)=Z197$I!DE@21R!
MCDJ":\YL_!_B!]$MK2YLX(9;;PQ=:.,7 </*PC",#C@'83[5Z-I=O)::196T
MH DB@2-L'(R% - %NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(U_Q)IWAN.S?4)5C%
MW<I;(6=5 +'ECDCY0.2:UZX_XAQI_9ND74ML\T%IJUM-/LA,I2,-\QVJ"2.F
M<"@#0T[QAIEY>WMG<7-K9SP7SV44<UPH:<JJG<H."<[\8&>E:$^HZ/I,Z6]Q
M>6-E+<N62.25(VE8GD@$C<2:\WU+0DG\&_$.X&EE[VXOIG@<P$R.!'&4*<9.
M#G&.^:KZ]9SP>)/%']J33(FH)&+95T<WGVF+R@OEHW\+!MWRG'+;N^: /8*Y
MG3/&=MJ?B^_T!;9XQ;[A#<EAMN&CV^:JCL4+J/?GTJ075SX<^'L=PT5U=7=E
MIRXB=-TTL@0 *P4GYB< X)[\UPTWA7Q-X8\/Z/JQOX+Z;1I_MDMK;V+":7S2
M?M"[_,.XD.Q^[R5'2@#O/$WBW3?#6F7MQ+<6TMY;6[7"V/VA4ED &>!U_'%:
M$^MZ5:SI!<ZG903NXC6*2X56+D A0"<YP0<>XKRCQ)':IX6\:Z;?:3=76LW]
MU-<VC)9/(9HV ,+JX4@!% !&1C:1WYTM>T(7-I\3;AM,,MS-#&MLYAW,^VU3
M&SCG#>G<4 >@RZ[8M9ZC)87=G>3V,;-)"ET@VL 3M<YPG3J>E++K^E6D,;7^
MI6-F[*A*2W2#!89 R3SGG'KBN"\1Z+]FN[Y-/TXQQ-X/NX,00X#/E-J<#EN3
M@=>M6M)T.*YU[79;[31+G1;&&-IH<Y^23>HR/9<@>U ';'4PNJ2VSB%+>.U6
MX,YN%SRS Y3J% &=W3MVJAJ/C'0[#PY?:Y'J%M>6EFA+FUG1\MV4'.-Q],UY
MQ:Z5//H2Q:A8:F\3>#[&&5;:+,P=9&) #<%EX)7J1Q@YQ1<17NI^'_%]O!;Q
M:LCZ0-FHPZ6]I++(I;$)0\.P!)RH&,X]* /55U[2"8!_:ED&N-@B7[0F9"V=
MH7GG.#C'7!H@UW2+F\ELX-5L9;J($R0QW",Z =<J#D8KB["UM+_Q=J^M0:2;
MJ--%M38^9;F,E@TQ*IN *MD+Z$<5S>CK-<:IX+>.(!+>YQ-:VNCR6\=B&@D4
MQO(^68Y.#SSC)[4 >EZ/XOT;6-%FU:.]@AM(9I(I'FF0!-CE,L<X .,C/4$5
MHKJ^FO8I?+J-HUHYPDXF4QL?9LX/2O*M.@CLX-':]TVX-EI6M7[:C#]C=O+9
MWE,$I7;\Z@,/F&0-P/:GW>EC5[N[N+73)O["O?$.GO'"]LR++M&)I/+(&$/
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M3+&ZAM;O4;2WN)O]5%+.J/)_N@G)_"BXU?3+2]BLKG4;2&[F_P!5!).JR/\
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M<O;W5\98VFLQ:HYV*&>./.0I(ZD#)R>^: +GB;QG;>&M3TZSEMGG%R=T\BL
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 9FEZ#::5=WUW"]Q+<WKAI9;
MB8R-@9VH">BKDX ]36G110 4444 4M(TJUT32;;3+)66VMDV1JS;B!]:NT44
M %%%% !1110 4444 %%%% !5*PTJUTV>^FME97OKC[3/ELY?:J9'IPBU=HH
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M[ZPL]3LY+._M8;JVD&'BF0.K?4&K%% &9;>'-$L[*>RMM(L8K6=0LT*0*$D
M[,,<]3UJ32]$TK0X7ATK3K:RC<[G6"()N/J<=:OT4 9>I^&]#UJXCGU/2+*\
MFB&U'G@5R!G.,D=,]J-1\-:'K$D,FI:18W;PC;&T\"N5'H,CI[=*U** *_V&
MT^V1W?V:'[3'&8DEV#<J$@E0>PR!Q["K%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLN-RAAM)4$!CZ$=ZP?[-NI_"UAI^B/<G69]4GN=)NS:&T2SBS^\<+EML+ L
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M_<X9)N!N9F& #DYY]ZH7;K(SV<]I96LW]C6D2-=:=)>3WH\HG9"NX*F&)4@
MG/)KUO4]5L-%L7O=2NXK:V4@&20X&3T ]2?0<U4TOQ3H>LQ7,EAJ4,BVPW3A
MLHT0QG+*P! P#R>.* /-M(BB@D\,3WML1-/X2:VCE> DF<"/Y2<<-M#=?>GZ
M$-.TR72+CQ7:!K-_#=E#9/<6QDCC<*WG1XP<.<IQU(&.U>MQR)-$DL3J\;J&
M5E.00>A%.H \E\(Z"9]=\/IJVF,T$.EWKV\-W%N\E&NE\E2&Z,(F P>0..U=
M?\.[<VGA0VWE&)(;^]2*,K@*@N9-H ],8Q[5T9O[5=133S,HNWB:98NY0$ M
M],L!^-6* /%DM8H--TBYNK@Z?<13:FL<M_I_VFS8-=,2CC(*.0 0PQD9&3TK
MT;P.6G\$:>L^F1V*F-D^RJK! @9@"%?Y@K## 'H#BNCHH \7T6/3[2P\,MJ-
MEC3-.O+Z/48VM6*0W)8^2\BXY 7(#8(&X<UVW@2-/M7B&YL(&@T2YOE>Q0QF
M-6_=H)'12!A6<$CL>3WKJK"_M=3L8KVRF6:VF&Z.1>C"BRO[7486FM)EFC61
MXBR]G1BK#\""/PH \?OXM).F^-+ Z;(WB.]U2<V!^RL99'R/*>-\<!6Y)!XP
M2>O*:[9RQ:WXHCUV[MXYKS8+<2Z,UW)<1>4H58'#K@A]WRCD-SWKVFHIKF"W
M:)9IHXVF?RXP[ %VP3@>IP"<>QH Y/Q-;7*_!_4K:0SSW0T5T8R)B1W\K!R
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M*TMX4BMHD$<<2C"JH&  /3% 'GZ-J.F+X6NU\0WU^VN2+;W4<CJ5820N_F1
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M5.K,>K,3R2?4\U1O?"'A_4-2.H7>EP2W+%6=F!Q(5^Z77.&(XP2#TH YOPG
M]Q\0]?U&2>[5Y+&PE:!I/D!=93M(QT7MZ9-9?BVR_P"*E\:W'VJYX\*%O*W_
M "<BX7&,=!C/U)KTN*PM8+ZXO8X56YN519I!U<)G:#]-Q_.J=_X<T?5+W[9>
MV$4UP;=[4R'(+1,"&0X/(^9NOJ: .'BFU/PM<:"\>J7VHK>:5<236UPRE"\4
M2NFP #9SD8'8^O-5?#NJ>)F?PWJ<S:@R:E(GVI[V^M?L\RR(6_<QAMRL#@J
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MSR1F>:*YMKJ1$#>9#(G*8Y.T@ @CTK;MM:O7;X=J;UB=2A9[D9'[_%HSY/\
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MNE**R219"X4+M*$8!0@C ]>:T=!\.#1[S4+^>]DO=0U Q_:)WC6,$("% 50
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M<DKJ@8$N3M1?F&2??\>;N_#VK7;)HEI::W9VHU5+G[,[0M91(LXD9UEP'92
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MX   (R3U%5=+\,W^@V^FV&GZM/)8V]X\CI*J B!E8B/(7+8<@YX/OQBM+7=
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M'E=9--EDDC5<8<O&T9S^#9K-MO!MI;:%H6DK<S&+1[B.XB<@;G*;L!O;YNU
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MYW+)$H?;Z8*!S_P&N:L?'=_JVB6,5QIT$>H3+>_VA;DMMACA0YQ@Y^8O"/\
M@9KJ?%7A:S\6Z7%87LDL:1SK,&B(!X!5E^C*S*?8FH(O!EA%KVMZNDLHFU:
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MII?BF._U--.NM,U#3+N6$SP1WJ(/.C! 8J49AD;ERIP1D<5SVM^"]3UBZU^
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M;C.<XKFX?!7B"#2=4AT]H]+@N'MS#I<6I32(%1B90)=H:+S%.WY!@8]^(O\
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M 2 2 <8Z5R6I>"M2N-;OM8.B:1?3ZG#$9([F\D06DRH$.&5/WB8 /13P?7@
MZ)_'.GR:I8Z?I]G?ZC)>VL5['):QJ46"1BH=BS# !'(Z\CKSC/MOB;I]U!87
M$6BZT;;424LI?(3$\H!/E@;\@\'D@+P><<U<T'PM<:-KT%UFU%M%HT-AMA4H
M/,21V8JO9?F&.:I:9X0U&ST/P99226QET6Y\VY*N<,/*E3Y>.3EQUQWH Z/0
M->AU^UN)8[:YM9K:X:VN+>Y50\4B@$@[20>&!!!(P:SX?&=O<ZD]M!I>IRVJ
M7C6+7T<:-$LP.T@@-O #<;MN/?'-6?#^D7&E7FO2SM&5O]1:ZBV$DA#%&G/'
M!RA_2N5N_!FKS^)#>P6FG6=R;Y9SK%G<R0R/ '#&.2$+MD8KE"6.#G/M0!-I
MGC^6V.JG5;+4)[6UUB>S:_CAC$-NGF[(U;D,V,C)"MC/)K9U?QK#I$E\QT?5
M;FTT\9O+R")/+A&T,?O.&? ()V@XK.N?"&HS>#]?TE9+;[1J&IRW<1+G:$:<
M2 ,<<' ]#S63XD\#:WKDGB"&6"QO3?[_ +%>7=[*!:1E  @@"E<@@D,#WR>1
MB@"WJOBG5(=3UA+6\ @@U+2H8/W:G$<[)Y@Y'.0QY/(SQBNK\1ZC_9EG9R?:
M9K?S;^V@W0Q*Y;?*J[2&Z*<X)'(!R.:YB?P7JD\EZ^^U!N+O2YU&]N!;E/,'
MW>ORG'K[5T?BC1[G6K*QAMFC5H-2M;I_,) V12J[8P#S@'% &8?B'8"25O[+
MU3[#!?&PN+[RD\J*42>7S\^XKNQR 0,C.#D"Q>^-K2TO+R*/3=2N[:QD$5Y>
M6T2M% Y .#E@S8# G:K8S6=-X0U&3P9JND+);_:;O5GO8R7.T(UT)@"<==H]
M.OYU(-'\3Z3<ZO;:(=/^S:G>-=QWL\K"2T9PN_\ =[2),$$K\PZX/2@"32?%
M;I?7T&I/)-YOB!],L]B+A!Y(D ;IQPW/)Y%7K_QGINGSZA;R0W4EQ9SPVWE1
M1@M/+*H9%CYY.#SG &#VYK$N?".LQ":[M#:374?B$ZO!%)*R++&8?+*,P4[6
MY8]".!4$GA'Q%=WM_K,YTZ+46U&VU"UMUE=HOW41C,;OM!Y4GY@.O:@"S9>.
M736O$LNK0WEE9:;;696TGB0RK)(9 0I0G>6(0##$9].:W])\2QZEJ3Z;<:=?
M:;?+#]H6"\5,R19QN4HS X) (SD9'%<KJ/@S7/$@\0SZFNGVLE_'9?9(8Y6E
M5&MY'?;(=JY#%AD@="?3FWH?AR\T>_O-8_L/2-.>*Q>*&*WFDG>1\AB6?:"$
M^4#:%)/7VH [#5-032M)N]1EBEECM87F=(0"[*HR0H)&3@>M9:>,=(?7X-'$
MK^?/I_\ :"28'E^5GC)S][ )QCH#6I8R2WVD6TE];"&:>!6G@/.QF4;E_ DB
MO,F^&&M#0'MH]0MEU!;SR89]S?+I_DFW"=/O;&9O3=CF@#0U?X@S1Z1J.J:3
M'>R,+&RN8;::WC"PI,[@29W9)('0]/E]3BW_ ,)O?6?B778)])U2[MK6VMK@
M6]O%$6M59&9]YW $Y'0%CP<<4[7O!5]?-X@%@UK''>:=9VUHCL0%:"1VPV!P
MN&4 C/?BM&QT/4S?^(;^[2VBDU6T@C6*.4N(W6-E8$E1D9;@XY]!0!+/XTLS
M);1:987^K33VB7OEV:)E('^ZS%V4#.#A<Y.#Q5C3/%VEZO=:=!9F9S?VLMU$
MQ3:%6-U1U;)R&#/C&.QKGM)\-^(?"YL[G38;"^E?2;2PO(9KEH@LL"D*Z,$;
M*G<P((!X!]J99>$==\/2:+?:>+'4+RVANX[R*69H$9KB592R,%;A6&,$<CWH
M MW/CF6;7]#M=-TZZEM;J_N[.Y;;'G,(=3C+C@,N[/\ ='KQ6MXDU.[T_4O#
M<-K+L2]U/[/.-H.^/R)6QR..44Y'/%<[I_A+Q!IW]BW9_L^XO+/5KR[N$$K(
MC1W!DR5.TG(WYP1VQFNFU_1[G5-0T">!HPFGZC]JFWD@E/)D3Y>.3EQZ=Z ,
M6P\<PI9Z; L&JZO?7RW,D(CMXD=Q%-L8'Y@JXR,$GD#U.#/I_P 0]/U%]/:/
M3=4BL[Z?[+'=S0JL:S\YC8;MV05*Y *Y&,U6\,^$-1T?4M&N+F2V9+*UOH9-
MCDDM-<+(F,CIM!S[^M%KX0U&'PYH>GM);^=8ZR;^4ASM,9FE? X^]AQQZYYH
M @C\97JZEH5M:Q7FH07VIWMM/*T,2,!$90$ W@84J#GJ57U.#K#QQ;"[MEDT
MC5(K&YNQ9PW\D2")I2VU1MW^8 6& Q4#I65;^$M:T\Z/<6XLYIK'6+V[>-YF
M0-#<&4##;3\P$@.,8X(SWK(3P#K\SZ:]Y;Z?-?V6IPWDVJ3WTLLERJ3!R$0K
MB+Y>P..,=#D &M9^,KV\:\%Y%>:>L/B"+3X72&)Q(I91Y;?.<=?F8= PQGH-
M1O'VGJ[3?8-0.E+<_96U41I]G$F[9_>W[=WR[]NW/>LQ_"6LM>7<6+/[(WB&
M#5XIO.;>4#*70KMX(V\<G.>U0MX1\0'P[)X/"V']CO<%OMYF;SA 9?,*>5MQ
MOYV[MV._7B@#5O?B'864FHDZ7JLMIIEQY%]=QQ)Y4!X.3EPS## G:"0.HKKZ
MXB^\(:C<^%?&6F));B?6;F:6V)<[5#QHHW''!RIZ9KIK6[O'UR]LY;95LX(8
M7AG&[YV;?N4Y&.-JG@G[PS0!HT444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 56O]1LM+LWN]0NX
M;6V3&Z69PBC/3DU9KD_'DE['9Z6]K:&1%OE::Y2R-W):*%;$B1#DG.!G!P&)
MQ0!KV_B;0KO3FU"#5[&2S601-.)UV*Y( 4G/!)(X/J*;:>*O#]]:RW5KK5A-
M;PNL<DB7"E49CA03GC)( ]>U>9-I&IZA'XB\^RU6\BO-3TJ19+RR$37$:R()
M&V*H  "G((R  6KK-5\-G6?%^OVLMO)'97^@P6_V@(0OFB6;!!Z%E!0^HXH
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M21%9DV,&1RC9'U4UYI<^&M0?X?SK!8W$=ROB"6]N(XX%,TT(NF;*JXP_RA&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSM(*A>"N3NSF@#TW6=$L=?LEL]1CDDMPX=HTF>,/@$8;:1N4YY4Y!]*T  H
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M.] $1D(DL()6\R5G^9HU)QN)P/8<#L* .HHHHH **** "BBB@ HHHH ****
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MU5-/>Y= N%1]A8+CVX'OB@!MSX,TO4/$ESJVI6MI>Q2VL$$=M<6RN(C&TAW
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M=:1VD3B2.!(5"(P.0P7& 0><^M1:EH6GZI8WMI/;QJE[M^TLB*&DQC&21R<
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MID\C*EUYV$9.[&1@9]JMZE_;5]KG@>2+5+%KZYCO)#=Q0%X51HT/[M=PW<8
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M+QKEGW?+CS.,#MSUXEU7Q=KGA0Z_!J$UMJ<UK9VMU:O';-$ TTK0[64%BP#
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MBPSD\*#T.*FMO&GB&ZL8[:"6#[9_PD"Z6+FYL7B+1- 9 [0D@AAD<9&<=LT
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MZ+HFB13M9:;I]A'+_KC# D0?_>P!GKWJ_!!#;01P6\210QJ$2.-0JHHX  '
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MHA,A;_=8!,>I%58/&\XU73+;4-#FL8-3E,5LTMPAF5MK,/,BZID*>YP< XH
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MMB]Y;Z5%IEREU&_ER"/)5U*G((+-QW![8J&[\!7K7]OJ9ETK5[\V:VUV=7M
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M=@%DQ_LDT <KXE\.:D?#/BG6]8N8KO59M'FM((;2)EB@BVEBJ@DLS,V"2?0
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M%(@WR*S-O  7Y,#OD'MBI[3QEH%[!=S1Z@L:6D0FG^T1O 4C/1\. 2IQU'%
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M<W<,%&=W;TJW9^#(/%/B+6-3\4^'U"W=C9K$)2-T;A'\U5*G(()49^E>CT4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5PWQ-MM-ET_0Y]42#[+%K%MYLDY 1(V.&W$\ =,YKN:K
MW\UG;6,LVH2016B+F5[A@$4>Y/% 'D.J:-I\GAKX@:[Y6=1L]1FDM+D.=T!2
M.)E*8/R\]2.O>D\2D7/BGQ,=;N='A,"1FR;4II$DBA\H'?;A>^_?DK\VX8]*
M]2TG6M"UZ&;^R=0L+Z-3^]%O(K@$_P!X#Z=ZL--IEWJ1LVDM)KZV42F$E6DB
M!Z-CJ ?6@##O)=9C^%TLMM+)/K*Z06258RKO-Y7W@I&0Q/.",YK@_#*Z?'K.
MBR6^H:$L$UI,U^EG++(]Q#Y1W&YSPI#8.Y\'.1WQ7IE]XN\-Z7>/9W^OZ7:W
M4>-\,]VB.N1D9!.1P0:NV7]FWEN;NQ^R3P7(R9H-K+*/7<.&H \F\.3WJ2W9
M+WC.-,N6\("Y_CB&[\Y,>7C//EX_VJ9X0$0U7PO/8ZAHZWLV3="TDFENKE?+
M/F"X!Z$-@Y?HP '7%>S&.,E"44E/N\?=^GI51I=,LY6F9[2"26586<E5+R-C
M:A/=CD8'7D4 >1Z=I5A9_#OP_J4P=(=0OXDUF[:5LM;!Y,*[9^6/=Y:GH,=:
MUY3H$&L:3;^&I7^R+XAMQ*L#YM5<VTV5BQQG !8#C..]>G^5&(O*\M?+(QLQ
MQCZ4Q8+>"%42**.*/YE 4!5]QZ=Z /'="EM=/\1Z9+;OIVJW%S?31)=03/#J
M(8[\BZB.=ZKT.<8PIQ5+PX99/[ NWU#28?$$FH(MTRO*^H2/O/FQ2H.BXW Y
M^51@C'%>V;;*$27^VW3*;GN, 97&<EO3%+ EG,5OK=(',R K/& 2ZD9!##J,
M8H Y#XFO9IIFB?VC.T-BVL0+<.'*#80^0Q'13W]LUR&L1V)M?$EGH$P70#<Z
M4BFSDQ%'<-< 2B(J<#Y?+)V]"?7->IZSHL.M?8/.D=!9WB7:A0#N901@Y[?-
M5Y+:".$0I#&L2\A%4!1SGI]: /*/%-D/#]_K%CH4<EI;0Z# 2EL6W1QM=OYS
M+WSL+G/6CQ"^@6&AZPO@B<K*;.%KLZ?*6MTA,RAG8H3B387Y'S;03V%>M;%W
M[]HW8QNQSCTIL-O!;J5@ACB5CDA%"@GUXH \W\$1P0>,WCTR\T46K:>6GM='
M>22(G>NR1B?E5\;AURP.><59UU=$N?B!=0>+Y+==.338GTY+R39"6W/YS#)
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M%;?DX!&<KFO3V574JP!4C!!'!K#O-=\*:%(VGWNIZ/8.0':WFFCB)!Z$J2*
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M*\Y 'I7I=M+9WUF)[5X+BVG&X21D,D@/?(X-/DMX)GC>6&-WC.49E!*GV]*
M/%=:9;K6?$3ZS<Z;!)#'$;)M7EDCN88?)4J\(7^+?NSMYW#'H*[3P2;D^*=9
M-Y*9KHZ9IGG2%"A=_+DR=IY&3DX/2NVEMH)G1Y88Y'C.49D!*GV]*D"*'+!0
M&;&3CDT >9ZJ/#MQXN\3#QE/#&((H3IPN9=FR#R@6>'D?/YF\$KSD >E0^&-
M<?2]:TRY\4WRV<\_ABW+/>2>7YCK*Y;KU?#*2.O->@R:AHUQK*Z7)<V4NIQ)
MYPMF96E1?[VWJ.W-7I8(9RAEBCD*'<A=0=I]1Z&@#QGPU'IIO/!%]?[8YIM)
MOEBFD_UAE69"@7/)<!FP.O)J3P:FFQ:WI-@%TK5%U"UFB:]T^=UFD39EC>0M
MG).,9)X8XP,U[$;>$A 88R(SN3Y1\I]1Z5%(+'3H[B]D%O;(JF2>=@$ 4#)9
MF] .<F@#Q+19]#?POX4TI8-*D/V2::?^T;SRK-95**P=0#OF (^4XP,GO5OP
M_##K%KX8TZYD$]A_;VH1".)W$;1+'*RH,G/E], GIQ7L7V2RGB4_9[>2-F\T
M?(""3_%]?>IA#$&W"- V2V=HZG@GZT >/RP6MA>76D7!\CPK!XE$=S$7(BBC
M:T5T1N?EC,S#(Z9(]:B(TJ"?Q$N@RH; :[HZH87W1C]Y&&5#_=SD8' Y%>RM
M#$RNK1H5D^^"HPW;GUIJVT"($2"-5&,*$ ''3\J /(-4TFT;PQXSUYD<ZI9:
MQ,UI<F1M]OM=" G/RC).<=<\T_Q,^A$^-Y/$MPD6M1;_ .S/,E*RK!Y"^48!
MG/+[]VWOG=Q7KQAC*LIC3:QRPVC!/O7&>)-(LY]3>RO?%LUE%K)\K^SW:(M)
ME0C+"7!9 PP"%[DXP30!K12*GP]CDELI+]!I:E[5.6G'E<H/4D9'XUP,.KV6
MEVVEOX6\8'5HI;B"*/0+QH[B3:6 *J<"2,HN3\V0-O->G7NI:3X=TZ.2_O;6
MPM(P(T:>4(O X4$GDX%,T^\T2^MVU;3KBPFB;.Z[@9&!QURX_K0!Y3<Q:78W
MNOVY:*V@?Q/$-5$;[&6R:%""^#D1F4@$].3[U-JTEM9GQ'!X5F*^'4@LC>FP
MD)BA8SXG\LKPI\GEMO3KUKU\P0EW<Q(6==K-M&6'H?44100V\0BAB2.,=$10
M /P% 'D?B5/#D&FW<'@Z6$S&?379;=]]DK_:DV%MIX<]\<E0#Z5UW@!O+CU2
MSU LWB*"Y/\ :<DC9,Q/,<B^D97&T#@8(Z@D]/#_ &<LTMA +42QA99+= H*
MAB=K%1TR5.#['TJR$02%PJ[R,%L<D4 <-8ZG8^&?'GB2/7+J&R&IR0W-G<W+
MB..9%B5"@<\;E93\N<X8&N4\4W=MJL?BSQ#9SR+HK+IMF;R D"=TN09'C8=0
MJN%W#OG'2O8I[>&YC\NXACE3.=LBAA^1JAKFB0:YHYTV1VAB,D4@,8&1Y<BN
M!],J!0!YAK=KHDL?B>T\-"VGT<^&YIKJ.T??"+D',+<$CS,!R>YP">U0ZK/'
M##<G0I\6(\.V19[%\[83=N)V4KW";\D<C!]*]B2.VM0(D2*$2,<(H"[VQD\=
MS@$_A4=B]C/;K-8-;O#\T8>#!7Y6((R/1@01ZYH \IUC^Q;2758O!TT!L6\-
MWTFH+92[X58*/)8X) D/[SGJ1G-:,6D66AZSX7ET\36TM_IET+V:(L\DY$*,
M&;J7<')'>O2H[6WAC:.*"*-'R654 #9ZY%/\M,J=BY7A3CI]* /(_ 4EE8>)
M='MK<Z5?-=VD@%_I=PZR.JJ#NNX3GYB0!N)R&)'>NB\5#3)_'>FVWB9X1HC6
M$K0)=/M@>Y#KG=G@L$Y /^T178Q'3X=0DMXOLR7CIYSQIM$C+G&XCJ1GC-3S
M00W$9CGBCECZE74,/R- 'C^GV-OKEWX>TZX::YT%]6U%+-7D;;-:K&2@SG+(
M&!QD\@#M7L,,,=O!'!"H2*-0B*.P P!21^3*D<D?EN@&8V7!&".Q^E24 %%%
M4DUC39=7DTF._MGU&*/S)+59 9$7CDKU Y'YB@"[1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7+^.;"'4]-L+0W]O:7;7\4EF+F,R133)EA&Z\9! /?MGM7451U?1M/U[3VL=
M3MEN+=B&VDD%6!R&4C!4CU!!H Y"RO9K#QI;-XGT:RLM2DL9U@U*PN6:&6)-
MK.KJ0"N.",Y[X-<=IVN/::GI_C6;3=4A>^U"0WMQ+:LL(LI]J1?/Z*$@;\6]
M:])A\!:!%%=H\-U<M=V[6LLMU>S32>4W5%=F)4'O@C-;%YI%AJ&C2Z1<VRO8
M2P^0T/(&S&,#'(X].E 'GHN=>M/&OC>;1]"L=55)K9G2>Z,4A(MD^5!L8'/N
M15;2'U.U\$6E]H-P95U74Y;R[BTM(UE@1@=T4"3<95E&X$9^]@5Z3I^BV&EW
M%U/:1,DMUY9F=I&8N40(O4G^%0/?O6=-X)T&83XM9(6FNS>EX+B2-DG(P70J
MP*$CKMQGOF@"/P5JKZIH\_FZA<7DUO<O"YNK3[//%C!"2H !N 8<@ '(KSRX
ML;U+/5!%JL[2OXTMXXVECC*QOOC^? 49/(X)Q\HX'.?6-(T:QT.U>WL8W59)
M#+*\DC2/(YQEF=B2QX')/852/A#16OI[PVTGF3W45XZ_:)-GG1D%7";MH/ S
M@<X&<T <O<:UJF@S>)M-NO$#RBTM[2:UO;JU5Y$:9W0ILC50YR@VC'5N<BL>
M]U76+BW\3Z+<7VL_96\/S7D;ZE;V\<P9258*$4?(PX.Y<CG&.M>B:CX6T?57
MO7O+3S'O8XHYV$C*2(F+1D$'Y2K,2",&H+;P7H=M<3W/D3SW%Q;-:3S7-U+,
M\L38RK%F.1QQZ<XZF@"I##)!\+#'+<R7#C2&/F2!0QS$2!\H X!QTZ#G)YKG
MO#EQJ^B1^"5N-:DNK/5+/RYK:6&-8X ML9%*$*&&-N#N)SG/%=U9Z'8V.A#1
M8EE:Q$30[)9GD;8V<C<Q+8YP.>!@#I3?^$?TS;IBFV!73%*V@+L0@,9C(//S
M?*2.<T >>6GBC6?[0T"\CU/5+RUU*_6WE>6QBALG1PQ'DY EXP""200#GK6K
MIOB36+NZTOP\]UG6(-0GCU*81K\UO!AMVW&!Y@D@' 'WSCI6W;> ?#UK):,E
MO<L+*59;1);R9TMR#D>6I8A1[ =..E:L.AZ;;Z[=:U%:JNHW42Q33Y.65>@Q
MT]/K@>@H \VT?Q9XHU&TT[7HX]5=;NZ3?:O;VZV:P-)MPKY\S>HYR3R1C'-=
MUXQU.33-&B,-^]G-<7,<"/%;>?*^3DK$F""Y .,@@<D]*;'X'T&+4$NTM91L
MG^TI;FYD-NDV<^8(MVP-DYSCKSUK2UC1+'7;1+:_C=EBE6:)XY6C>.1>C*RD
M$$9/0]Z /-9/%/B.ULO$5I%>WR36D^F_9)M4MX1,HN)MCAEC 4K@'&0&Y/L:
MZW19]4L/&M[H5[JTVIV_]GQ7L<EQ%&CQL9'1E^15!7Y01D9'K5N+P-H$0NO]
M$E=[MH&N));F5WE:%]\;,Q8DD-W]..G%:XTRT75WU41?Z:\"VQDW'F,,6 QT
MZL>>M '$^(==UB?QG=:-8MJ\%M96D4Q;2[>"21Y)"^"QEX" )T R3GD8K,U;
MQMXBT3P[HFM7)MQ/>12VD]A(  DJ[L7(*Y(0!<N,D!6]1SW>K>%M+UJ[2[N4
MN([I(S#Y]K=20.T9.2C,C E<\X-%MX5T2SEB>#3XU\JT-E&A)*)"3DJ%)QSW
M.,GN30!R&JZQKL6OVGAZ*^U:X$&F)=W%YIEM;M+<2.[*#B0;50;"?E&3D#/K
M'!J_BK6;CPUILFHOI,]U%??:Y(X(F=_)>,(P!W*I(/(Y W,/3'52>"-#>VLH
M$BNH#8Q&"WFM[R6.5(C_  ;U8,5Z<$D#'%7++PUI&GOI[6EFL)T^*2&VVLV$
M60@OWY)*@DG)S]30!R^G7>N:M!>:Y_PD:V,-MJ4ELEI-%$+?RHI?+(D)7?O;
M!.0P )'%9G]L>(9M*MWM'NS;_P!IZBEW_945O]J").RQ[$<;6 _B(!;IZFNR
MF\%Z'<:F]]);2[I)A<20"XD$$DHQAVB#;&;@')'4 T3^#-$FABC6">!H9YKB
M*:WN9(I4>5BTF'5@V&)Y&<=..!0!QDOB_5+N#0--LK_4;J2Z%TUW=6=C''=?
MN65?+\N7Y48%QN..W &>.M\%ZAJU]IUY'J\<XEMKMH8I;A$266/"LI=4)4-\
MQ!QCIG S4TG@O0GTZULEM98EM9&F@FAN)$F1VSN;S0V\ELG))Y[UH:1HUCH=
MD;33X3'&SM*Y9V=Y';JS,Q)9CZDT >?W&L^(H/#^O^)CKKL-+U.YBAL!!%Y4
MD,<Y78YV[MQ' (8?P]><LUW4]?DT_P <ZDNLLEKH[RPV]E]EB9&_T=&^<LI)
MP7R!]<Y'%;NC?#ZR@N+ZYU1&FEGU6>^6)+J3R7W2EXR\>0C,!CJ#T'7 K?G\
M-:3<66JVDMKN@U9R]XOF,/,)14/.<CY54<8Z4 <V]SK>N:OXA6TU\Z1%HYCA
MA00QLCN85E+S%U)V?/C"E> 3FL:]\3>(M2U36AI\VI*FFE(K?^SK:"2WE?RE
MD+RM(=Q4EN I'R\YS7:ZGX-T35[N2YNH)@\R+%<"&YDB6X0=%D56 <#ISGCC
MI3-1\$Z%JES)//;31M-&L4Z6US)"DZ*,!9%1@' ''(Z<=* (=9\1WNF_#B;Q
M ;6.._6P6?R6.Y(Y&4<$CJ 3Z]!63>WFN>&-4L+:?79=434;:YW>?!$IAECB
M,@=-BCY>"-K9ZCFNUDL;2;3VL)+>)K-HO),!4;"F,;<>F.,5D6'@O1-.E:2*
M&XE<P-;(US=2S&*(]43>QV#ITQT% $'@7^UKGPS9:IJ^K27\^H6L-QL,*1I#
MN0$A=H!/4=<\CM7%0S:QHGA[Q3XCL]9=(['6;R5=/\J,Q2J)CN5R5W[FYP0P
MQQP>:]3L;*WTW3[:QM$\NVMHEAB3).U%  &3R> .M8?_  @?A[[=)=?99LRW
M)NY8?M4ODRS%MV]X]VUCGID=AZ"@#D?%OB;5K<^(+S2]5U1SI8)2*RL8C:PL
MB!F6>2498^H1N 1@9J37O$&OVNHW5[->ZA8Z7''#)!<6-I%=6T0V*TGVE<&4
M<D]" %P<UU5]X$T#49KU[FVG:.^)>YMUNY4AE<C&]HPP4M@#G'4 ]1FEN_ N
M@WLSR2V]P!*B1W$4=W*D=PJC:HE16 ?@ <@Y'!S0!R>I^)=>U'7-=32Y-5C@
MTTI%:_8+:"2*1S$LFZ8R'=M.X#"XX&<YZ=C/<:QJ7@7[598LM:FL5FC4!7"3
M% VSG((S\N?0TW4_!>AZM=RW-Q!.CS1K%<"WNI(5G0<!9%1@' ''/;CI6[##
M';PQPPQK'%&H1$48"J!@ #TH X >-IM5BN]4LK^*QTRQT99YGFBWJMU,-RJP
M W'8HY48R7 K,76]834I=-N;K6+BSO='O)2=5M(8#YD87F,( P&'.0P],$\U
MW<7A'0H=*U'2X].C%EJ,LDUU%DXD=\;CUR.@QC&,#&*KP>"-#@N1=-%=7%R(
M7M_/N;R65_+<89,LQX]NW7K0!B>!-4NW:'3I)A]CMO#NFSQ)M VLZR!CGKT1
M>OI6#9>+_$&KV_AZR\[5-\^BIJ%U/IEO TTKLQ4#$@VJHVDG SR.E=S<>!]!
MN6M2UM/']FM5LU\FZECWP+TC?:PWK[-GJ?4TZ7P5H<EG86T<$]L-/B,-K+:W
M4D,L<9QE=ZL&(.!P2: '>#]0U/4?#R2ZO$4O(Y9(6+*JF0*Y"L54D*Q&,@'@
MYKC(]:\13^&M&\4KK[QC4M2MXI-/,$7E1PR7 38IV[]X'!)8_P 7 XQZ+I>E
MV6C:=%8:? L%M$#M0$GJ<DDGDDDDDGDDUY^? .H7>KVOVC3]/MXH-26_>[M[
MV8H^V3>-EL1LC=L ,P/][KF@""^\0^)+/2_$&MKJLDHM]6DTNTLUMHRB!IE1
M78X!9EW' R <#/<U:MO$.N:5)J:WUS?Q6":;)<I>ZU;PJT$RD#[L.-Z'=G&,
MY&,\UVA\.:2^G7^GO9H]I?RO-<Q.Q8.[G+'D\<\\8QVQ5*'P/H,<-Y%+;37?
MVR#[-,]Y=23N8NNP,[$JN>>".>>M ')66KZVWB"'29=1UPVVH:;<N9=1L[>%
MTD0)AXE500/F/#J>W7FLO0]7U>T\.^#M"L[G57CN-'%[++8P0/.% 15C3> H
M4;N20S=.><UZ)8^#M&L-1AU!([J>]AC:))[J[EF<(PP5R['Y?;\>M0KX#T"/
M3[6RAANH4LV9K62.]F66#< "J.&W*N !MSCCI0!RT>M>*M070]+>^FTVXN=2
MNK26Y>"(RR0QQ-(K%/F57XP<<9!.,<5L?$FUG/P[DB^WSB2.:U#S*J;I3YR#
M)!4@<G=P!R!VR#NV?A71M/%@+:SV&PEDF@8R,S>9(I5V8DY<D,<EL]:NZKI5
MGK>F3Z=J$7FVLX = Q4\$$$$$$$$ Y'I0!YW)9:NGB/QK<67B"YM'LK:VD#)
M!$S3R+;YS)N0C''(4+U/3BK%UXBU+5C8+:ZEJ<<TFEP74EKHUG'(Z22 D-))
M*"BJ<<+D$X))Z5V=MX=TVUCO$CAD;[;$D-RTDSNTBJFP98DG.WC/4]3S5*7P
M/H4DD3B"XAV6R6C+!=RQK+"@PJ2!6&\ $CYL]30!R6@ZYXA\63Z#;G6I-/2Z
MT/[;<O:P1%WE$@3*[U8*#G)X/MBNL\&:C?:UX.M[B^N-UX6G@>>- I8QRO&'
MVXP"=H.,8S5S2_#&D:-);R6%IY+6UL;2+]XS;8B^_;R?[W^%7--TRTTBR6SL
M8O*@5W<+N+?,[%V.3SRS$T >0Z'I]^^G>!X8-8N(YI=5U';.T4;-"H6<-M&W
M&3@G+ X+>@ K7O/%.OZ9:7.D+>7-Y=KKZZ9'>I;Q&?R3 )LA<*ADZJ"0!WQ7
M;6/A#1=.N89[:VD5H+F2ZA5KB1EBDD4JY52V "&;@<9.<9I]UX4T:]AOHI[/
M<+VX6ZF82.K><JJJNK Y1@$7!7'3W- &5X.U'69]0U.QU)+][:!8I+:?4(XD
MG.[=N5A%\I *@@X&<GTK%E36'^*'B/\ LG3]*O,6=EYGV^9H]O\ K<;=J-GO
MGIT%=IH_A_3]#^T-9I*9KE@T\]Q,\TLI P-SN22 .@S@58@TNSM]5N]3BBVW
M=VD<<TFXG<J;MHQG QN;IZT <GK^HW]M-I6F+=W%E=26[S3V>AVRSRL05&5:
M1-J1@D\L 22.G-8^A>)]7OIO#ZWDNZ;[1JEO*\L,8D;R<A"VW(5N!G:<'W%=
MSJOAK3=8O8+RY%S'=0HT:SVMU) Y1B"4)1@2I(!P:AL?!VA:;]F^R6/E"V>:
M2$"5R$,HQ)@$]_T[4 4/A\^KWWA:QUC6-7DOIM0M89A&88XTARN?EV@$YR,Y
M)Y'&.E<=H]U%X;\=ZWKUP_EV-YJEW8W;GHI2%)HF/X"4?\"%>IZ=I]KI.FVV
MG64?E6MM$L42;BVU5& ,GD\>M9MYX0T*_L+VQNK!9;:]NA>7",[?/+\OS=>/
MNC@<?F: /-="N+G0[GQ7J<]V+#4;^SL+J21X3,R2SRS$(J#EF 944>H&>*NS
M^*=>TQ/$L"WFJD6^A/J%K)JMM DR2J2N0$ !7IPRYR/2O0-0\*Z-JCWSW=H7
M>]2%)F$K*2(B6C*D'Y2I8D$8-55\"Z!_I;2V]Q/+>6K6=S+<7<LDDL38RI9F
M)[<>G.,9H X;Q/J&N>%]4\/:B\L^N:@;+4)AF%$6 %;<L=J $HN&..6/3/>M
M35->U9+W0M&LM2U&^2YL'OI]0TVW@::<;E"[ XV*GS9Z$XVCN37=R:392W]G
M?/#FXLXY(H&W'Y5?;N&,X.=B]?2LI_!&@FRM;6*VFMTM'=[9[>YDCD@WG+!'
M5@54_P!W./;B@#BHYM;U?7?"#:G=WEI<6^JWD"MY<*O*BV[LKNH#!6*_(P!Q
MU( .".N\?6DK: FK6B%[W1ITU"$+U8)_K$_X%&7'XBK7_"&:$MC96D=I)&EE
M<&Y@>.XD602G.YBX;<Q;<<Y)SGFMYE#*58 @C!![T <*FH0:QXGU+Q$ES$--
MT+3S%;7$@)C$LB"620X[*GE#CU:LS1?$.LCQ/X?@EOM7N[35$F$S7]E#!$S+
M$9 T( $@&1T;/!ZYKM].\,:-I.@2:'9V*)ILBNKP,Q8,'SN!)))R#CZ<54LO
M!&AV%[97D<5U+<6.1:R7%Y-*85*E2J[F.%P<8^GH* .6^&NIW?E>'M*\W_0C
MX?%SY>T?ZSSMN<]>G&.E4HO&&NZA:Z#9)-?M)>?;I[BXTZ"%IV2*<QHJ!_D
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M737?@?0[TJTL=X&\A;>5X[Z9&N(UX"RD,#)WY;)Y-2W_ (.T346A9[>6W:&
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M[9NSSG'7GK6M9:9::?+>2VL6Q[R?[1.=Q.^3:JYYZ<*HP/2@"W1110 4444
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M8-,MBEQ/)=-'(9&BWXB 4Y*JRG)(R3CWIL_P[FU$:O-J.J6S7NH:<^G^=:6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %5[N^M-/A\Z\NH;>+.-\KA1GTR:L5C:[H]KJ'DW4EE%>W=JK&V@F?
M$;$CG(/!_+M5TU%R2EL14<E&\=S5@GAN85F@E26)QE71@RD>Q%25QWPY"0Z-
M>V9W)=07L@N(",+"Q_A7DY7C^==C55J?LZC@NA-&I[2FIOJ%%%%9&H4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 5BZYX<AUF>VNENKBSO;7/E7%NP# 'J
M#GJ*VJ*J$Y0?-'<F<(S7++8R]"T&UT"TDAMWEEDED,LTTS9>1SU)-:E%%$I.
M;YI;A&*BN6.P4445)04444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
:%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exhibit101-arrowheadindu004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101-arrowheadindu004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF([HRC+" NUB2,#J3G- &IX7UG6+G7IK"\:\N[/[+YPNKG2I+(QR!@"F& #
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MU?2M4U/54N;BTN+B>1$C*HHDCV".,$DA5QGG)))]:S]0^'SW4US>)<6CW?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQRR7"R>6.^ ,C.,?+0!Z!156RN9[E9S/9R6ICF>- [*WF*#PXP3@'K@\U:H
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*KW]A::I8RV5];QW%M,NV2*095A[U8HH B@MH+6UCM8(8XK>) B1(H"JH&
M.PJ6BB@ HHHH **** "J5AI&G:7)=26-E!;O=2F:=HT ,KGJS'N:NT4 %%%%
M !1110 4444 %0&SMFODO3!&;I(VB6;;\P0D$J#Z$J#^ J>B@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2GTO_0U51-)$N\/AB H*$$\\<TNL^.KY+&V_L_2[F._CUBWL+VTD,6^/>5.
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MR[#4XU9QI&H0W\B*,DQ+E9,>X1V;\*Z>JFI:G8Z19/>:C=16UNI ,DC8&3P
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M0JXQWRQSGC;[T ,\(^'WT&TN_.M=,M)+F?S/L^FPA(HE  "[L N>"=Q ZXP
M*Z*L>R\5Z#J.I'3[/5;::ZRP"*WWROW@IZ-COC.*B@\:>&[G4(K"'6;5[F5S
M&B!^KC/RYZ;N.G6@#=HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAK]I$L;*SACLVC$P82F3;ND8J-QPV=QZ5T=YH=[)I?Q)5;%VEU(2"U^7F?\
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M&C0*7/J<=: .2^%ME!9_#G36M851YD:1_P#:;<1D_@!7"6TNBG2?"UR]\?\
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M]@2>*W=+U#1]7MDGTJZLKR"$[4>V=76,XQ@%>G%7TC2/=L15W'<VT8R?4^]
M'B%PD&G:5JEKI[VMO&_BIH=3#SM&JV^7\L2E?F2,M@9[YQTS4US')'H/B.SM
M-0LDL_M6FJ(-*GE>.VD:X4-LD( !9=N54\$9XSS[*;2V+3,;>(M,,2G8,N/1
MO7\:2*RM(;<6\5K#' #D1K& H.<YQTZT >>R>$=%D\>-HK6K_P!EP:()$M?.
M?9O:>3YCSR1DX)Z9K+\+6:6T'PZU=9)VU#4=\=Y<23,S3H;:1@K9/(!5<>F*
M];\M/,\S8OF%=N['./3/I35MX56-5AC B_U8"CY.,<>G% ''>-VMI-=\-VFK
MS>7H4\LXNM\A2*24(#$DAR.#\YP>"0*XNZL-.U"Y%K !=Z#;^)K6"P8R%T4/
M&/.1&SR@<=N <@5[+-!#<PM#/$DL3<,DBAE/U!I%MH$BCB6"-8XR"B!  I'3
M [4 <OX^4)HNE*HPHUG3P!_V\)7G&H274\NOWEY?Z5::S!JDD<$\]U-]KMP'
MQ"L<2J<H5VX"@A@3G/->Y/&D@ D16 (8!AG!'0U$]E:R7273VT+7"#"RM&"Z
MCV/44 >0ZW/;V'B/4M4FFLM3DAU&(,@NI+;4;9OD CB4Y$D?<  !@QZ]:75I
M[73_ !1?ZF\UGJ;1ZM&N%NI+?4K9BR 1(AR)(^> ,!E)Z]:]=>RM)+I;I[6%
MKA!A93&"ZCV/6H)QI<6H12W LTO2C-&\FT2%%QN()YP,C/IF@#F/BC;6<_A.
M"2^5#!#J5F[M(<*BF=%8D]AM)_.N6O\ 0M+O4^(NI;6>2S17LI8YF A*64;*
MZ8. >G/< 5ZPIMM0LU=3#<VLZ!E(PZ2*1D$=B"*5;:!4=%@C".,,H0888Q@^
MO'% 'D6O7MGJ]Y=K>QV,D]KI=NTDVJW[1JA="V;>)%RS$GEL@Y  Z5/X8T^W
M\5ZGHRZV9;V(^%+.5XY)6VO(7D!=@#RW7D^M>GO'IKZC%&Z6C7T4>^)6"F1$
MSC*CJ!DXR.*>#8VMS#;@V\,\B$11C:K,J\G:.I R.G3/O0!SWP_=[_X=:6MY
M(\^Z!HF:1BQ90S*,GJ> !7F-B(8O#/A6PMGT]=.EO;U=1CNKEHX&N%)\J.8K
MDCY<D*>"0/:O=HXTB0)&BH@Z*HP!4#V=CY<D,EO;[+A\NC(N)&Z\CN>/TH \
MCA@:ZTZQT\ZA#-IK^*(H4CL)Y3'$GDMOB61@"R9S]TD#<1VKL_"%I#I7BOQ3
MI5DIBL('MI(;<,2L;/&2VT'H"0#BNM2UMXXHXD@B6.(YC14 "'V':GK&BNSJ
MBAWQN8#DXZ9H =1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<KXZD+V>CZ:?]1J
M6JP6LX_O1_-(RGV;R]I]F-=56-XGTB76-'\NU94OK::.[M'?[HFC8,H/L<%3
M[,: .=^(FD0S2:+JLL]RSP:M8)#!YI$2$W*Y?:.K$'&3G Z8YS9AM;?4?B?K
M27\$<ZPZ5:I DJA@$D>;S, ^I50?H*Z2^TVVU>U@COH21'-%<JF\C;(C!UY'
M7# >QJIK'A?3=;N8[FY^TQ7"1F'SK6Y>!VC)R48H1E<\X/3MB@#A-/GDM?AK
MX3U57)FL=3BAA;.2T#W!M]ON#&P_('M79^+=3O-$M+'5()0MG!>1K?H5!W0.
M=A;/4;2RMQV4T7_AU;B30M/MH8H-'TZ5;AHUXR8AB% /0,=Q/^P/6I?%MIJ&
MH^&[O3M-M+:YEO8VMG^TRE$C1U(+G );''R\9]: .-U+QCK<LT8LI+A;74]5
MEM;-[6V266."",[V0-PS.ZM@MD!1G%2IXFUNVTC48+Z[N[1H[R"&SO+JP!NI
MED&2BPQ@AI!A@#C&""1P:ZO_ (1#2G\.:?HDL<A@L%C^SRQR-'+&Z# =74@A
MNN2#SD^M1?\ "#:&=/DM6BN6>2Y6[:Z:ZD-P9E&%?S<[L@<#G '&* .)E\7>
M(K/3?%,,=W>-/8)92V<VIVD4<H\Z4HP94 !7Y>,@'D^QK4UV?Q5HUS;VSZMJ
MUU9K;M))>Z=86\LPE+' DBVD^6%'&T9/.370IX%T%4O@\%Q*U^L2W4DUU([S
M>6VY"S%LY!_3CH,5:U;POIVL7R7LS7<%VL7DF>TNI('>/.=C%",C.3STR<4
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M5POF-\\F5.<YX^XO ]*??>'-*U.XO)KRU$S7EH+*<,QP\(+,%QGCEVY'/Y4
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M9RJW=J\%LMH)+2[DA9X5Z(Y5AN ]^>30!)I%_>ZIX)AO=2MA;7LMHQGB'0.
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M:;<FS>Y+GYNG0 =?7@ N>)_%:>'[FPLHHH);Z_+^4MS<BWB54 +,[D' ^90
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M57QODG#!0N>%W$KD^WM5N]\<WVCK?1:OH2Q7EK:"^$=O=^:DMN'"R,&**=R
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M)P&#QLJ.#A3G8<XP<-GM@$V;CP7J;WMMJ@OM,NM4^Q)9WC7UAYD4^PDK(%#
MHWS'/)!SVP*M0^$+VTN/#ES;ZG"\^E"9)VEM0!.DI4OM5" A^7CKCOGN 6/%
M/BO_ (1VZTVT2&U:>_:01R7MW]F@78 2"^UOF.1@8YP?2FW'B;4X])L+E-#6
M.XN=_FK=7JQP6X7NTH#9#<;<+R#SBK7B31K_ %46YL[FS$<>Y9K2_M?/@G!Q
MC<,@@C'!![G(KF8_AK+:6VD"WN]/G>Q>Y<VUY9%[4&9@V8XP_P FS&%Y/!-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !6;K6OZ;X>MH;C4YVACFF$$>V-I"
M\A!(4!022=IQZGCJ:TJXSXAS3VZ^&9;:U^US)KD)6#<%+_NY> 3P#Z9XSCI0
M!K0^,-%FM)+@W$L7E7,=K+%/;R1RQRR,%161E##)88.,<YS53Q?XLCT+1]8-
MG)&VIV%DMYY4J,5",Y4$G@'E6X!SQ7/:GH&NZP-:UM-+:VN9I]/>VT^6:/S)
M%M9?,)9E)16;<0.3T&2,\0ZYHOB/Q&WB:[70WM?MND06EI!<3Q%W=)78A]K$
M+][U/'?/  .EN?'&GS:1J\NFO(+ZST^6]BBN[62+S4520ZAPN],X&1Z^XI;'
MQ9;K!>W6J7]K%!:V5K<2HL3@PF52>3R&W$84+SVY)%8VLZ9KOBFXGNI-%DT[
M[+H][:11RSQ,UQ/.J@!2K$!!LZMC)(X&*J3^$-;D2_ECM4\U(M(E@C>50L[V
MQ+21D@G'89/&2* -O5/'=O\ V6\NE[UO(;NSAEM[ZUDA=8YIE3=L<*<$%L'I
MD>V*V_\ A)](_LJ74OM1^RQ7)M'/EMN$PD\O9MQNSOP.G?/2N:UN#Q#XFM)
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M9Z8MJUUI&H)#<Q2 _<;<X1XSP1][!SQS79PZ1JVH_#MM'U>Y3^U;G3GMIYD
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M>)I-["TNJ:=(5U#4!/.\,$NYV?+LH !;"@DGGV% '3R_$/P]",/)?"7R!<M
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MKB)R))8E0%0C'*@KUX/L* -]_'ND7-G<G3YI3/\ 9)KBT:>UECBN0BDDQLP
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MV"Z;,T=YK<+S1*3( 8UB#*IEP <DYQP.IJ;29G\/>"],\4K#(PT74KR"XA6
MQ$VLLS#:(SRH#>4P7L!0![,)$(8AU(4X8@]#[URWAK5=*U6_UG6;;28+-!*8
M)-29HP]UY;%"6P<A04XW=1BKOA'2)--\+6]O?*KWER&N;W(SNFE)>0'U +$?
M0"O-[#3M.L-+T*XU"PACT--:U$W_ .X'EAA+*(&E '**> 3P,K0!ZCJFO6VF
M0:?-@SQWMY%:1M$P(!D. V?2DTC7[75M(?4C_HT"3S0,9F P8Y&C)STP2N?Q
MKS98X9-0>?1H2N@2>)=/>S\N,K$S@?OGC']TMCD<$@TRP2TMQH-QX@A4Z#%>
MZMYAGCW0QW!N6\II 1@#;YF"> 3[B@#U]9HGV;94;S!N3# [AZCUH\Z(KN\Q
M-N[;G<.N<8^N:\?+?V/IMWXKTJTE.DZ9K336,*1D![:6)8I?+7^X96+C''RY
M%2^%M%U"Q\3:?X5O$E>"VD77IIG'#2-"J%<_]=S(^/:@#T^TU6.;3(KR[5;$
MNF]HII4RG..2#C\C5J6Y@@@\^6>..+C]X[@+STYKR3P1HMIJ>H>&DU/3X[F*
M+P](PCN(@R!_M &<'C."?S-,T>&SL[;PU+K]MO\ #]M_:4$:S0F2*&;[21$7
M&#@>6'52>!^- 'L*2)("4=6 ."5.:YV7QKIBAC"))MFJQZ4^"!B1R!NZ_=&[
MK[&LKX7_ &,:3K7]GPM!9?VS<^1&R%-J?+@!3R!Z#L,5R-QINERMJFDFRA69
M_%]LUQ L.TM;LR;<X'*'Y_;DT >Q0W,%Q$98)XY8P2"Z.&''7D407,%U'YEO
M-',F<;HV##/U%>1^*M)DLKWQ79Z-:);6+1Z7-<PP6Y,9C\V02GRT(+#8HW $
M$J"*V? L<$GBZ]NM/O\ 3[BU^PI',-)TUK:U+[_E)8R,#(!N& .A&3T% 'HD
MMQ! 4$TT<9=MJ;V W'T&>IK,T;Q%9ZMX=M-:9A:6]RFY1.X7;R1@GIVKDM<_
ML6#Q[J$OBV"*2RFTZ&/36N(3(F=TGG(G!_>$F/@?,1C'2N5T^>U@T/PA:WEK
MIML%TR5H[S6X7FB4F0 QK$&53+@ Y)SC@=30!ZW=Z]866I:982RYFU%G$!4@
MJ=JEB2<].,#U)J\+FW-R;83Q&<#<8MXW >N.M>,>'(;*!/!MQJ-M&(8-6U&W
M#S6AC$9+2&)=IR8_F(*J>AQ532;64QV%I=W]A#XD75!)+'%I#MJ(E\[+,93*
M 8RN<MC;L.* /9M9UJST&R2ZO6*QO/% NW&2TCA!U[9.3[9JG9ZSI=]KM_&Z
M117>GRBS2:5E!DWQQRD(>N#N7([E:ROB=;VTOA.*:[MXYH+?4+.60O'O"1B=
M-YQ@\;=V?;-<O>Z%I.I6?Q)U Z=;W#B(&SE,0)55LHV0Q\<<X/'H/2@#U66Y
MM[=D6:>*)I#A [A2Q]!GK1=3K:VDUPP++%&SD#J0!FO%]34G6]4E\07>E11W
M-A:BT.JZ9)=-+'Y(WK"PD7#>9O)4#=D@^E>EZ=#<P_#N"&ZEN)KA=,VN]Q'L
ME8^7_&N3AO49/- &1%\19UT6WUV^\+:E:Z+-''+]M$T$@2-\8=D5]V.03QD>
ME=G)>6L,L<4MS"DDGW$9P"WT'>O.O"W@J?6/ 6@PZMXAU6;3I+&V=]-VPQQD
M!%(C)5 Y4=,;LGN:YKQO-;7G_"8Q"UTNVOE+*D4]I)<W]QMB7;)$=P\M/0J"
M%P3ZT >TSWMK;9\ZXBC([,X!Z9_E6;I'B.#7(M/N;&"1[.]M3<+.S*-G*X5E
MSG)#9XX&.>U<EI.AZ=K7C+7[S4=/@O9%L;'R'N(A(%+1/N*Y'4X&3[5RN@Q2
MS:#HT.@1[-0C\*7\!$2;&6[_ ' (/ ^?=CKWH ]CNM2BBL[R:VVW<UK&S-!%
M*NXD G;R< G'?%2_;K=5C\Z:*)WP CR '<1G'7DUY+?OX1F\'W4.@::QU*/0
M+N.9[6(H8!Y7*W'3+%AP&R<Y/J:'E\*Q>(?%*>(;:*6XDLK1(%EA+L^;<92+
M@_/G' Y^[Z4 >N7%W;6BJUS<10AC@&1PN3^-++=6]NA>:>*-0-Q+N  /7FO'
MYI&6XT^R\00:7!J46AVT<EQJ]K)>/<,0V]((@P!<$?-@DDD<$"IO!FE6^KW?
M@Z/5K);I(/#D_P"[N8]RK(LT2 $-QD D8/2@#TR]UZPL-0TRRFE_>ZD[) 5(
MVG:A<DG/3 P/<BK-U=O;W-G$ML\JW$IC9U90(@%+;B"<GICC)Y]*\FTZTL++
M_A#Y;^UB6SM-<U*V1Y8=RQ+NG$*\C@;MNWW KN/%BL?$7@]E5F"ZG(3@=/\
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MK#.,@TZB@#F].\&VUC?65S-JFIWXL PLX;R962#*E<C"@L=I(RY8X)KI***
M,K6=#75VMI5O[VPN;9F,4]I(H8!A@@AE96!XZ@].*?HFB6VA63V]N\TK2RM/
M-/.^Z2:1NK,>!G@#@   <5I44 %%%% !1110 4444 %0W=LEY9SVLA(CFC:-
MMIYP1@X_.IJ* *NFV$6EZ7::?;ES#:PI!&7.6*JH49]\"K5%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MS?B2X6V^+,DC:,VKC[&H^RK&')XZX(/2NBAFAN_"7B&9?#!T21;*5/G@$;2
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M<=>: ,GXDZV;OP!83V4A6#4I8PQ!_@*EMI_$#/T-=%=>!?#USH:Z6;"**-5
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M-4\E[36)BR")B6"DN><C@_,/6LVQT#QWX<MFTS2+[3KFP!/DR7 (>($^F/\
M&@#'T@?V8GC_ $.W9C8P6TSQ*3D(=K#'Y8'_  &JW@/4;GPK/8+>O_Q*=<C)
MC<](Y@2O/Y 'ZCTKLM)\$3:9X8UJWDNEN=7U6&033MD+N96 'KC+$D^]+_PA
M#7?PY@\/7S1"\@0M'*A)5)-Q(.<9QS@_4T <OX5T6Y\0?"&]T^TD"3O=,R!C
M@-MV':?KBJ=Y=V]MIEMI?BSP=)90PE5%]9(%.1QUQ@Y[_-S73:=\/[P?#^?0
M+VYCBNC<&>*6%BR@X&,\#W!^M07OA_Q[K>EKHFHW>EI9':);A-QD<*01VY/
M/04 >A63PR6%N]O*986B4QR$Y+KC@Y]Q4]5M/LH]-TVUL823';Q+$I/4A1CG
M\JLT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M98HHU! ^:1N-QSPHR>">!0!LT5QB_$.VN;+1Y+'3IIKO5#.(K:6:.+886VR
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MKBUBG1H3)NC,A7:'+<8^;'UH R;_ .&\QU#5'M+/P]=)J,YG^V:E9"6XM78
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M55 +$C!R,9&#F@#DX/ 6IVGABPTAUT/5(+>:Y::UO+;;#())"Z.I"LT;+DC
MR.?8&NG\+:!)H7AB/2;NX%P09"0I;9&KL2(TW$G:H.T9.<"I5\6:"VBG5QJ<
M/V$2>49#D'S,XV;<;MV?X<9]JRK_ .(FB6QTDVTXN4O[XV;$*X,!"%F++MR"
M,*-IP?FST% %&U\':X-,TKP]=WMBVB:;/#(DR*_VB>.%@T:,OW5Y5<L"<XZ#
M-/C\&ZHMVRO<V9M$U_\ M>$C=YA5MY=&&,9!88(]\XK93Q38VEA<7>J7]FD:
M7TMI&8-[%BK$!-N,F3 Y"@\@XXJ1O&/AY=+CU-M6MULY)C;K(Q(_>@$E",9#
M84\$9H Q-?\  ;ZY<ZY,\]M_IKV<ULLL7F('@R<2*>&5LX(]":H/\/;NYTW5
MHA9^'M*DN[=+>*+3;0*HPX=F>38&.=H&W&!CN>:ZR#Q;H5SI4^IQ:C&;2WD$
M4SE64QN2 %92-P.6'4=ZVJ .5\4^$I-?UG1KV*Y2%+64"[1@?W\(D279_P!]
MQ)^!/K6*OPXN4T+Q38+?0M)JA:*R+ XM[?>TBH?HTC]/:O1** . \4^!]2\0
M:A=-C2&65E-MJ,D31WE@  "$9 -^""1EAUP<BH=3^'<SZMJMS9V7AZ\74G$O
MVC5+,2S6LFT*Q7Y2''R[@I*@$GJ#7HM% ',>+K06OPPUNSB 81:1-$H1 H.(
MB!A5&!] ,5G6GA[7=8;3+O6KFQ"6%G(ML+97W2R21;-\F[[N%)^49Y/7C%=Q
M10!QH\):E9Z1X5:PN;4ZIH-JMMB8-Y,ZF)4<9'*\J"#@].G--/@R\O\ 2/$)
MU*Z@&JZPZ2A[=3Y=LT2@0[<\G:5#$\9/85VE% ''6W@VX@TWP["]U%)<V&HM
MJ%]*0?W\CI+YA7ZM+QGL*H1>#?$$&GZ5H<=[IW]CZ9J$%S%(5?SY(HY0XC8?
M=! XW G.!P,FO0** /-9?AI(EU>PV]CX<EMKN\>Y%]>6"RW4*N^YD 92K\DA
M22, C@XJ_JOA'7OLOB+3=&N]/33]<\R1VN5?S+=WC".%"\,#C(SC;D]>E=W1
M0!@>(-!GU?P->Z#%-&D\]D;99&SM!VXR>^*@_P"$9N/M'BF3SXL:Q"D<0Y_=
ME8?+^;\>>*Z:B@# FT&[D\!?V!!?FUO!IZVBW46?D<(%W#H>H^M<SIOP_O+7
M6K'4!::%IR6]O/!)%81N6F,B ;VD8 MR!P>F3R<UZ+10!R5MX2NH-(\&V9N(
M2^@M$TS#.)-MN\1V_BP//:K?B7PR/$U_I,=[Y,ND6DKSW%K("?/DVE8QZ8&Y
MC]0*Z*B@#CH_ -AIWB*.\TBVM;33[FSEL]2M%4@3*V"C #C(.X<]FK!C^%EZ
MVAZ;:7&J127<=Z6OI]I_TBU*I&8_J4BB'IP:]/HH \]U_P !7VKZUJ]RR:1=
MQW\:I;W&H1M))8#R]I$:8VGG+ Y4Y/.:UM"\)SZ=>K-=S0R1G1+73'2//+1;
M]S<CH=_'>NLHH X&U\(^(HK?0-*EOM.;2]$NHI8Y%5_.GCC!5%8?=4@'G!.2
M.U;'C+P[=^((=/6W-M-%;7'FS6-VS+#=+M*[7*@G@D,.",CD5TU% 'E5YX2D
M\-:=?:E<36%D3J=K?6OV&T;[/:NB^7AT&#Y>"06&/O%L#I4=G8:EXXO/%,HO
MK*:*YM;*WANK9'^SAHY'D9%8\O@$9([MCM7K-% '%>)O!1U3Q(FN06&C:A(U
MJ+66VU:'<@"L65T8*Q!^8@C'(QTQ6?<?#=A!H\ZVN@WUW912Q36MS8K':R"1
M@^455.PJ1@'!)!.>37HM% '%:7X*N;&;0YR=-@-E?W%Y-#8VH@B DA>,(@4#
M.-R_,W)Q]!3KKP;=W&@>(-/6YA$FIZH+V-CG"+NB;!]_W9_,5V=% 'G&H_#F
M9]3U:6SL?#MPFI3FX%UJ-D)9[1F #;05(D&06 )&"><BMV'PI-!_PDR)-"(]
M5@CA@ 7;Y>V 1<@# &1G [5U5% ''V7AO5=(UBPO[>>SDBAT6/3KA7#[MT>Y
ME9,#D%CR#@XZ<UT>D37MQHUE/J4*0WTD"/<1(" CE06 R2>#GO5VB@#AO#?@
MW5-)N- -Y<V<D6CPW=NAAW;I4E,90D$<,-C9'3I5:_\ AW+=+]H8:;=W$6K7
M-_%;WL)D@DCFX*.,<$<$, <$=#7H5% '.^$O#TFA07C36VE6LEU*'%OIELL4
M42@8"Y #.>IRWK@ "L_4O!=S?SZ]/'>10S7E[:7UF^PL(I($C WCC(+)V[&N
MRHH X#6?!FN>)H]1N-4N=/@NY=.:PM8K;>T:!W5W=F8 DDHHP!P!WS5K4O!=
M[=:EJFHVUY!%=2:C;:A9;U+*KQ0K&5D''##<..F<]J[6B@#BY?"%_K;ZU=:]
M-:+<W^G?V=#%:;F2!,LV[<P!9MS ]!C:.M9]M\.;P77AZYN=0BDEM9))M5*J
M?]+<RB=<>RRC//:O1** .,M_!MW#JMK=FYA*PZY<ZF5&<E)(G0+TZ@L#Z5G>
M)]$.E2ZAKLMZD#/K%M?6LODM)'"5@$)\X#!"$;@6'3<#VKT2B@#@? ES>:KX
MJ\2:S/<6UU;S16D$,]HC" E!*65&;E\;QEO4D=JC$'B*7QQXNCT:2QCBF2U1
MFNU?,;&'&]-OWL?W3CH.:]"HH Y/0_!B:+J V3"2Q71K?2U4Y#GRVD)8]N0X
M_6L^U\'Z[_9VD:!>WMBVBZ7/#(DT:O\ :)TA8-$C*?E7E5R03G'09KO** .3
MMO!SP>/IM>^TJ; AIXK3'*73JL;R>G*(!]6:LMO VHIH%AIK1Z+JD$+7)FM-
M0B/EL9)6=71PI964''3!SVQFO0** //+?X;3-I\%A?:B)8?[(N]/D9=Q9#-*
MKKLW$G:@7:,G/ J\WAKQ#JUSIS:Y=Z=Y>FI(8?L@?,\K1-&'?=]P ,QVC/)Z
M\5VM% ')6_A.ZATOP;:&YBWZ$8S,PSB3;;O%\O'JP//:LS3_  -J47B6PU2Z
M_LF&:TF:2:_L(FBGOU*L LJ !!G()^]RO&*] HH YGQQX8N/%.AI:V5VMI>1
M2[XIV!.T,K1R#CU1W'UQ5*Q\#&Q\6:EJ<=Q&+&6V,=I:@']S(Z1I(WXB&/\
M\>]:[.B@#SB;X<W\F@C3Q>VP<>'H=(W8;'F(^XMT^[^M==XKTBZUWPS>Z;97
M?V6XF"A9"2 0&!*DKSA@"IQS@FMFB@#R36O!-UI6C^(=76RT>QB/AZ[M#9Z;
M$PRS ,'+$ N3M(Y QQUK??1-<OX;;4M;GLBNFZ?.+=+17W3221;2[[ON_+D;
M1GECS7>44 >=>%-#US5=!\'OJT]DNGZ=!!=Q+"KB:5Q#M0.#PNT.<XSD@=.E
M9FO^'FL_#?AKPK#?A?$ F>*-X%)_T>7>D[>RA&)R?XE6O6** *XLXX=.%E;J
ML<20^5&HZ*H& *YCPQX1NM"N]*FFN89!9Z)'ICA,_,ZL"6&>U=?10!C>%=&E
MT#P[!IL\J2R1R3.63.#OE9QU]F%<_H?@W5-.FT);JYLW@T>ZNWC,6[=)'*K!
M<@C 8%^><8%=S10!P.J_#V34?MTS-83S-K/]IV\-W%YD+KY*Q&.13Z@,<C.#
M@UL>$O#<FAR7]Q-9Z/9M=,@6VTNU6-(U4'J^T,Y))/(P.PZUTU% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %<?\ $#2+[4K?1[JR%VXT^_6XFCLV03%-CIN3
M?\I92P.#U&<<XKL** /-;3PM<ZOIGB:01:M#<7BP_9+G5)4\UY8<M&_EJHV!
M7P.3D@=N]:[\-Z[JOA)]6N+2XAUFZU>+4[FTA=1*L49"I&A;Y=RHH8 \;LUZ
MG10!Y+J'AV_U;2_$5Q#8ZY/)<6<%K&^J21B2?$N\J(E48"@GYF/.X@#O70^*
M]#U#4==U![2U9XYO#-Y9(XP 9G9-B9]^:[FB@#FX;:YUGX=-8"&>PN[C3GM0
MEPNUXGV%,G!/?GZ5S]M!J6KGPEIW]@7>G-HT\<UW-,%$<8CB:/9&03OW%ATX
MQU]*]$HH YSP+876F^$X+6\A:&=;BZ8HW4!KB1E/X@@_C7 WFF^);^QA@GL=
M7%U#JT<\MI!%!#8Q1K<A]R;1ND)'/4G)).*]AHH Y[QIH]WK/A_9IX1K^TN8
M;VV21L*\D3API/;.",^]4AXCU[5;JQM=.\.WU@QF5KV?4HU$<40^\J[6.]CT
M&..<FNNHH \KFTK6!X+O?!0T2[:]GNY-FH +]G*/.9!.7SD$ ],;LCCUK4U/
MPWJ4WCD6T,&?#VH7,.IWCY&%FA!&S'?>RP-_P!J] HH \?N_#&J1Q:[HT]KX
M@NO[0OYIHTM9H4M)HY7W!GD*ED*@X.<GY1C/%=%<>&-0O;7X@6L:&&750L=K
M.Y_UH%JB<GTW!A^==]10!Y98:#?ZK>Z?&]OXCADM+2=&EU&:%(K5WB,85 B9
MDZ]B   <YXJ>S@U2=/!&F-X;O+9]%N$%W.ZIY2!+>2/Y&!^96)!R!Z9YKTRB
M@"MJ,;RZ9=QQJ6=X750.Y*FN'N="U";X*Z;HILG:^2UL8Y;8@9!1XBX/T /Y
M5Z#10!PWB==8_P"$LB:&'4X].-D%6?2((6FDEWDF-WD!*)C:1C R3D\5E^#_
M  ]JME-X/:^T^6)K"'4UG,A#>4TDRE,GOE<\BO3:* /+9]"O8!+--IFKH1K5
M]/%>:7*!<6Z2$;6"$$.C]QVP./11%XKCL-&:[MKR.(7-V9;JRLK<WR(Q'E%E
MP50N-V\J,],XYKU&B@#R;2]"UNQC34Y]+U"86GB.2_:UG='GFA>W$8DX.UG4
MMG /8@=JUM5.I7]SIVM1>&;B&&VUN.=D2-1=31"WDC,KKGLS  $YVCM7H=%
M'F-MH^K:5JMIK4FEW%S#::SJ<DD$(!D\N=_DE52?FQCH.<.:4:%JFHZ]%K3:
M5-;V]SXBM[L6TH7?'%':O'YK@$A26QQUZ9KTVB@#DK2*\TCQ'XKU,Z;<W$5Q
M+:&!( I:;$:HQ&2!P>N>PKK:** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'Q;JEQI
MNDQ163[+Z_N8K&V<C/EO(<%\=]JAFQ_LUO5R_CF!QIFGZHBEQI&H0WTJJ,DQ
M+E9"/HCLW_ : *GC+5-?TJ72(].$,6GM?6<-S=2/NED#SJAC5<<<<ECZX'/(
MU-6U&XTKQ/HQ:4FPU%FLGC/1)MK21L/J%=3]5]*?XETF77M.L8[26(>5?VMV
M6<G#)'*KG& >2!Q5+Q'$=4\4>'-,BY^RW)U.X8?P(B,B9_WG<8]E;TH V]8U
M6UT/1[O5+U]MO;1F1\=3CH!ZDG  ]37*>"M9UQ]0URU\33 7$4<%\D(0 6\<
MJN?+&!D[2A&3DYIWCB+3[_4]+LM=U""#14W7,UON<27,@XC'RCA%)+=<DA>.
M*P-VA:7KE]?>'/$%M8"YTPVP:4RSLLZON1\.#E<%@1G\* .NTCQM#JBPSMI5
M_:V-S;/=6UVX1XY(U )SL9BC8.<-COW&*;IWCB"]MA=S:3?VEE)9O?074GEO
M')$H!.2C-L;!!PV._<&N)TZ[M[2\U.^L=6T;09KFT,:P6+2SP27&X-YS(T:J
MO *X )PQR>!58II\]GX@2'4M(T5=3T][7['8RS20/,QYE8&-0AQE?E4\$DYH
M ]-C\3VK_P!@@V]PCZTADA1@N8E$7F$OSQ@8'&>2*Q+7XEVMW'ID\6A:NUMJ
MA=+*39'F:103M"[\@$*?F("^IQS7-W&J#4KU[^XUC1K62'1[BRL+:%Y76&:3
M:-Y<Q@D84=!QZ'K6G:ZAX>M=5\-NNLVGV'1-/DMT0*^YI66- V-N,!5?OGYJ
M -E?']M]DA9])U#[;)J3Z9]B01M)YRH7/(;;MP/O9P,\XP:HZYX[O%\.W1TS
M2KN'6DU"+36MI?*+0RR%2K??VL"K @@D9(S@ XXV#5X]/\1Z3]EU/3;BYL_M
MVI7)E:18II;B7"H'"$J0A;G:>F.^:TFN++S;+4'UO3+B_?61J=_&QE2/ B,2
M)&=A)V#:1D#<1VS0!U@\800WNH.4U"XF-W'I]OIRI&29Q$)'"$'L'^9F;:-A
MQ[S3>/+*STS4+F_L+VUN=/GA@GLRJO)F4J(RNUB&!W=CG@\9%<;!<V.GO8:I
M;:SIEQJMO?WMU-#*TJ12K<,> X0E2JA #M/0BGK-IMUJ,.I:CKVGFYGU6*^O
M4B$FQ(X8V6&*/*_-AMK$G&>>.U '?:/XD&J:M>Z9-IMW87=M%'/LN#&=\;E@
MK HS '*-P>:BU+Q6+34KFPL-)OM4GLXUENQ:^6!"",@$NRY<@9"C)QZ9%8FE
M>(-!M/$FNZM<:S:M]O:%(50.2D4:8 .5Z[FD/'J*R)]<6RU'7?[%UK2?(UB4
M3?:;EI1+:/Y:QG"!")!A 0-RX/6@#J9/'5G)-I\&E6%[JDU_8B_@2V5!^Z)
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M]FLK:"((#.T0_>.I9@ BG())'(^E9DO@S59M U&0W=I'XANM275(9%W&&"9
MJH@.,E=B;2<<[CQ46I_#M7TCPW%;P6.H3:,CH]OJ&1%=>8!YC%@"58L P.#W
MXYH TKCQ_9VVGK-)IFH?;?MZZ:^GJJ&9)V0NH/S;2",88''S ^N'R^-G626&
M'P]JEQ/:0I-?Q1&+-KN&X(<N [[><+GC'J!698^![N""P86^D6+Q:RFH26]D
MA6-(EC9 @;:"[<YR0/PQ46N> I[CQ)JFJ6NE:%J7]I+&<ZGN5K614"97"-O4
MA5.WY><\\T ;DOC:UEF@BTC3[W5S):)?.;0(!' ^=A.]ERS8.%&3P:/!=]>:
M_P##[3KRZNY/M=W;,6N%50X)) 8#&,CCMCBJ%MX9UKP]?K<Z#_9DPGL(+.YB
MGW0(CQ;MLB!%;CYVRG'0<UM^$='N= \*:=I5Y+'+<6T>V22+.UCDG(S]: .4
MM].UZ7QQ?:&WC361;V]A#=*XBMMY9WD4@_NL8P@[>M;:>.89+O54BT;59;;3
M'DBN+F.)64R)@[%4-N8G(Q@8Y&<=KUOHMQ%XYOM<:2(VUQ806JH"=X9'D8D\
M8QAQW]:RIO"FJ_\ "-^);"TOX[>[U._ENH)4=AM5BGRL0 5)"E21TSD4 6%\
M;+#<7EOJ>C7^GW%O82:BL<K1/YL*8W8*.0&!(X..M,LO'EM<7%JMWI6HV%M>
MVSW-I<7"H5F1%#MPK%E.TY 8#(_*L&#X?:@-0O+R*PT;3$N='N=/,-M+)(Q>
M3:5=Y"@+#Y2,8X]\\=!-X9OGD\,/%<P1MI-O+%(Y!;YF@\L%1C! /.#CB@";
M1?& U@12MHNI6MI<6YN;>Z=4DCD08//ELQ5L$$*V">>XQ4=GXT$^HZ?;7FB:
MCIT6I!S9SW7E@/M0N0RJY9#M!.& Z=CQ6!IG@36+;4?M4*:7H<HM)H99=*ED
M*W4KIM61H2JHFT_/QDYXSBH=-^'FHIJ>AW=S9:/;M8,XNYXKB6:>[#0O&6WN
M@*\MG;SUZ\<@'1V/C<:A]GFM]!U5K&\W"RN]L>RX(4L.-^Y VT[6< 'C)&:R
M?#7C*YU*P\-W>KM<V<MY'=2. L7DRK&H;>2"2H /'0Y!SQ@G0T#1_%.E6^DZ
M/)<Z?'I>F@1FYB+--=1*I5$*,F(_X22&)^7C&:S-,\":HMCHMAJ4MG]FTV*]
MM6:WD8M+%,@56P5&&Y.1DCIR: -JP\<07D^GM-I.H6=CJ;A+&]G";)F(+*"
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MF+#?Y9G,H"J_]TGL?8UP.G66I:>-'N;C1M0ECT;5[][F%8"S,LSRF.:(?\M
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M(B 0"H[<$CCL:X.R\2:]KDND6MM=167]L&ZOHK@P!VBLXV58E53P68.K$G.
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MG$2"9E"-(%&XJ,D GK@9/YFJT6CZ9!J#ZA%IUI'>R9WW"0*)&SZMC)K@M/\
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M7I]HX>VL+6%@S,&CA52"V-QX'4X&?7 I+;2--LKJ6ZM=.M(+F;_6S10JKO\
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M &DMM]E$F[C9G/3UY(SZ$BJUUX.TB\T/4='GBD:TU"X>ZF'F$-YC/O)4]OF
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]2M-'TRYU&^E\JUMHS)*^TG"CV')^@JTIW*&&<$9Y% "T453U75;+1-.DO\
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MD$,0!;RHFE;DXX5 6/7L* +-%<_I7C70M:U4:993W)O3$9O*FL9X?D!P6RZ
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MK4H **"0!D\ 5F0>(=+NI].BM[I96U&%Y[4HI*R(FW<P.,?QKUZYH TZ***
M"BBB@ HHJO%>PS7UQ9IYGG6ZHTF8V"X;.,,1@]#TZ=^M %BBJ8U.T.L-I(D/
MVQ;<7)CVG_5EBH.>G4'BKE !1110 4444 %%4-9UFRT'3FOKYW6(.L8$<;2.
M[LP5555!))) P*M6TZW5K#<*DB+*@<)*A1U!&<,IY!]0>E $M%4TU.TDU>;2
MED)O(8$N'3:>$<LJG/3JC<>U7* "BF32I!!)-(<)&I9CC. !DU%I]];ZGIUM
M?VC[[:YB6:)R"-R, 0<'D<&@"Q15>ROK74;87-G,LT)=T#IT)5BK#\""/PJQ
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&LITI-X4D$J#OS@D#CV%4U\.7MJ]C9+KND0M 2]G -)B4QG!R8UW\<$\CU-
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M,T>B1JY<@@MN#9SAF&?<^M/L_!=U::R-52]TH7;/NDGCT:-)7S][YPV<D=Z
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M&>QL=MEB:V1XDQ!M_B08^7''(Z4LVB:1>:6FG3:;93:>,,ENT*M$.X(7&.]
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M&<DC:C%^2<9STK0UX-X>O+JQT'4[Z:*Y\/WUS/&][).8G15\J969B5+%F'!
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M;S2WDH+",$D*NP*%P3G(&<\YH YA/'6KZ2E_->Q76I6D&G37?GMHUQ8B*6,
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M:^'[G45:Z:V:]GO;/19KC"E]J1K$A;'(;+,>@'&37;ZSI%MKND7&F7AD%O.
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MVUT=&#JRG'4,H/2@#DY=<\37=KKVI6%Y816^BRR0"WEMBQNVB0-(6;=\@))
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M01/F.1B!MPW]TDCGTK%N-8\1>'M2LK75;RROUU"WN"C0VQB\B:.,R8'S'<A
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M;]",, >O3/:M.JVGV%MI6G6]A9Q^7;V\8CC4DD@ =R>2?>K- !1110 4444
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MU#:T/7H6$0Y'8[?6NSTJXU">34!?0QQI%=M':LBL/,A"J0QSWW%AGH<<<<T
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M"?0V\(G3IK:!M7:V(?4L'>;@C)ESU^_S0!T%UJ$^G>-["TDE9[/5;>18T/\
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MPHX_G5NN&^)MKITVGZ'-J:0_9HM8MA)),<(B,<-DG@#I0!U6F:O;:J]^EN)
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MI^)?#^FZ8TUQHZZE>!H_-)@W"V!9(B.L>>H!QG<.G%03RVFF:=J.B&$-8_\
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MQ>:I"_(/O$*6[,0CD#T4U2\ S2#P/:2W-^MU&OFF.X^< Q!VV\N Q 7 #'J
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ML@@D*Y7?G'4 $UU=GH]GX>^(^E0:8CPI>Z7<M=#S&;SW1X=KOD\M\[?-UYH
M[RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME._@X^\6W#)X-=3XHO[]=5T+1=/NS8MJ<THENU17=$CC+D(&!7<>!D@X&>*
M.B%O".D,8Y!^Z.HZ?E22VT$[QO-!'(T9RA= 2I]1GI7#:IJ6IZ7#;Z5-XF>X
MNGO716L;-)KZ2(1A@A0*8U<9!+%0-N. 363;>(O%5WHUW!#)J$LMGK)M9F6&
MW6_-MY(D^5#^[+@L,X&=O;- 'J:JJ($10JJ,  8 %1Q6MO!)))%!%')(<NR(
M 6/N>]>92^,M3.E:=86=_?W5Y=:G+:S3?V>D=Y;HD9DV&)L(9,8^;&W!S@UT
M_@S4=8NIM4M-42\:*VDC-M<7L4<<TB,N2'6/Y<@CJ ,@CB@#J418T"(H51T"
MC %9UQ>:)#KEM;7,]BFK3*3;QNR"9U&<[0?FQP>GH:Y"ZU+7]1MO$^L6FMFP
MCT:>:&WLQ!&T4GDH&8S%@6^8D_=*X&#S2>%Q/J7Q'O\ 5WO)U6;1[&?[,R1X
M42><0F=N["GD<Y))SGC !WKV=M),9GMX6E*[2Y0%B/3/I2R6MO--'-+!$\L?
M*.R E?H>U<=XHU6]_P"$A73+'4]3C9+42M;:39)--N9B%:1Y5**G' X)P><5
MC:#KWB+Q5+X>M?[8:P%WI$UU=206\1=GCF2,%=P8*3NYX(ZX[$ 'IABC(<&-
M,2??&T?-QCGUXKFO%%_X:U*QO/"U_K]A9W%Y%Y)B-S&LJ[NF%)Z^@J?P3J=[
MJOAI)M1F6>[BN;BVDF"!/,\J9XPV!P"0H)QQFN._LV]MM%UB33['1_$WAR_G
MN;B8&0P77S.WF+N(*N5.0"2IX% 'HLTNFZ+:37=Q):6-OD-+-(RQ+DG +,<#
M)) Y]:;=7&D:'!+?7<UCI\4C#S+B5DB5F/3+'&37G7B'5M-\0)X7T>&RU&]T
M:2S74KF&"!II?*,>V!7QD\L223WCJA-J]WJ7PXT6VDA,FJZ9KUG8RPW>8B[I
M*NPOD$KN0H2<'J>#0!Z78:YX<UH-8Z=JFE7X"Y,%O<1RX7_=!/%:9MH&B>)H
M8S&_WD*C#?4=Z\X3^T-4^)&C6>L:9IVB3Z>'O;=K>4S->@H49$?8H &[+*>>
MG&.:],H IO+IUI%'$\EK#&LJQ1H2J@2'&U0/[QR,#KS3K[3K;4;*YM+F/,5S
M&8I=O!93QC(Y[G\Z\CGLKY;+4Q'JLK2OXT@2-I8HRL;[X_GPJC)Y'!./E'3G
M.OJ_B77_  S)KFF#4)=3FC:P%I<S6\?F1FYD>-LJ@56QLRN0.2 : /3@   !
M@#M4<%K;VN_[/!%%O.YO+0+N/J<5Q_A74M<;Q%/IU\-4FL#:>?'/J<$,4J2!
M@"H$6 RD'(XXP1DTWQ/JMZ?$7]FV&J:G&T=JLK6VDV4<TH9F8!I'E4HJG;PN
M03@\XH [541"Q557<<M@8R?4U'%9VT+2-%;PQF4YD*(!O^OK7G7A_P 0Z[XN
M30;+^U'TV2726O[JXMH8R\SB3RPJAPRJ."QP.X Q3-&UWQ#K5Y8Z%-K1@F>X
MU$SW]O;QAI$MYA&J1AE*C.X$D@G ]\T >FJJHH50%4#  & !6;!HL%OJNH7B
M',=^$:>W904,BC;O^I4*#_N"N 76_%$R0:8-=47+^))M,:\6UCSY"V[/]W&-
MV1G/K[<4V[U_Q-+J6LVEI=ZN[:/LMHGMK*W>.XE$2NSS[L$!BW1-N!SF@#T^
M&UM[<GR8(HL]=B!<_E5/2M)CTLWD@D:6XO+AKB>5A@L3@*/HJA5'LM<E9:GK
M_B?4KN./4FT0V%C:S-!'%')OFE0N=Y8'Y%QMPI!.#S69:>)]5U71?#JMK&H"
M]NM,%W<1:38QR3R,3@.Q=3&B9!'0$GOQ0!Z5+#:M,K31PF5QL4NHW,.N!GKT
MSCVJ78F\/M&\#&['./2O)].U#5/$%[X"U2\U"XCN/,OTE6.*(;_*WJ21@@%E
M7!P<<G;CK3M#\6>*-1@TC6@FJ2I?7,?G6KVL"V:0.V/D?/F;E!SDDY((P* /
M32-/TZ0.1:VKW,@0,=J&5ST'^TQYXZU-/:V]TJK<013!3N42(&P?49KDOB)%
M<3VF@16MR+:=];M@DQ4-L.'YP>"?0'O6;>:]JFA3:[H]SKIE:WBM);2_FM5D
MF7SG9#'Y<:@.^4.WY?XAG(% '6ZUHDFI1PFSU";3YHI"Y,2*\<N1@B1&X<=_
M4$#!K.B\&FWTF:W@UF]COI[O[;->J$!EDVA=K)C:8]H"[,8P!WYKE8O$/BB.
MZUS3+*>_GG33HKJS.KP00S!VE*-@*%4@@?*' ^88Z4V7QIJ6D:%K9%YJ4^HP
MI;^1::O8)%<0F641%\QA4D3+#&.XP3S0!W&A^&H])>]N+BY:^O+UD::62-47
M"#"*J*,*!^>23FM>XM;>[0)<P13(#D+(@8 ^O-<9X8U/7AXE^P7O]JW%A+:M
M+YVIV\$,D<JLHPOE8!0ACU&00.>:F\1>*+CPMKEU)>OYFG3:8\]G'M (N(C\
MT8(&27#I@'^Z<4 :^M:%=:C<P7%EK$]B\:&-H_+2:%P2""488##'##GDCFDT
MO1M(TG3[?0&DBNI!YESLNBK2RL7W/*5Q_>?D@8&X"N5O=1UU)K+2IM;U)]2B
MT^.6ZBTBPBDD\YB?FD9U,:IP0J\$X))K"'B74KJQL?$;2JFIKX/U"X$BH,"5
M'BPVWD=5SCI0!Z\]K;R1O&\$3(_+*4!#?4=^@I&M+9YTG>WB:9!A)"@+*/8]
M17(ZQXEOM,OM!97\R&?3;R[N(0JYE:*)&7!QD<D]/6L3P]XB\3W%QH-[/_:E
MQ%J3)]KCN+2"*VC5T+!H64[_ )3C[Q;<,G@T >GD9&#5)X],L(DA=+2VCN)0
MBH0J"20\@ =VXZ=>*Q?&6J36$6GVUMJ,]I-=SE-MI:_:+F50I)$2D%0>A+,"
M ,]\5PD^IZSK-O;Z?/>W$5S9>*;>"WN;R"(3HC0%QO5/D+#<<<>F1U% 'L!C
M0R"0HI<# 8CD#ZU%%9VMNDB0VT,:R'+A$ #?7'6O/+_Q%KNB7VH>'UU/[7.;
MBPBM=1N(4WPK<NR'>J!58KL)' SN&<U/J5[XFTB_U+1;/5Y-1N1I9U.TEN((
MA*&CD :([%"E7!P#C(YYH [^6WAF@,$L,<D1&#&R@J1]*588D"!(D41C:F%
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M7M8M-<UNVTZZBMY!J&E6T4AMT;:)FVMNXRW7N>.V* /1(K>"!=L,,<8P!A%
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M4X=+6TWF72;:&XE2;<>98W!8QX QL&2<\T =P$0.7"KO(P6QSCTIK0(;9H%
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M("D*H P.U2T4 0Q6=K# T$5M#'"V<QJ@"G/M4A1"X<JNX @-CD"G44 %%%%
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M](PL8 9L[<G<.,F@#T&UTFQLM(32K:W6*R2(Q+$I. I&#SU_'K5>'P]IEO\
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MD>9V3!0^86W K@8P1BLWX6K>2^!K+4+]YI+J^1;AY9;Q[@R;@/FPP C[_(O
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MZ??'% #O#G@FZT2?16N-3BN4TBWN+6 );F,O'(8RNX[C\P\LY(ZY'3',5QX
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M<]*T-(UNQUR"66S>3,,ABFBFB:.2)\ [61@"#@@^X- &C1110 4444 %%%%
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MG4DDB11M)(ZI&HRS,< #U)H XE-'\06^A^,6L(([?4M1O7N++S&1L@PQ+SU
M.58#/&>>E9%KX:UFY\26]\=/U6&W&FW=K))JNI+/)YD@3!"*[*J_*>5Y/<#
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MQEI-Z=%5&E1]71W@250K)L'S!P3P<_+WYK:6[MFN6MEN(C<*,M$'&X#U(ZT
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M@3W5O:QB2XGBB0D -(X4$GH,FJ.A:S%KVG->PQ/&BW$T&UR,YCD:,GCL2N:
M.,UW1O$.ORV.LS:5);_8KUW33[6\$%V\#1;"QE5]OF9Y # ;>":V_!>C3Z?)
MJE[<6%S9O>RIM6[OFNIV1%P#(Q9E!Y. I. !S6Y::HDME]HNU6S^:0;)94/R
MHQ7=D'&" #[9YYJY%+'/$LL4BR1L,JR'((]C0 ^BBB@ HHHH **** "BBB@
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MFV23-<7D*""2.*7YLE'D(" @="2RX^HJ:_OK;3+&:]O)A#;0(7DD8'"J._%
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MJF6+[1,L$6<_-(V<+^.#0!S_ ,/;=[;P;;1^=+)$9)6@,ML;?;&78J%0LQ"
M?=R<[<=*\_M8[ ^&-,TZ&TQX[CU&)YF\@_:5F\\&65WQGRRF[DG:5(%>TT4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKU60 _OR7\QU4>A8*G/\ ]:W+72(+36=1U1/]??+$L@ P,1@A?J?F//I@=J
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ML]UXPLM4NS:?8=*B=-/BC0^:'D559G8\< $ #UR>E;E]86NIV4EG>P)<6TH
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M5-.AMVEO(KBZ@6:0*ZN5)X[KOZAB.0*]&NO#NCWMO=P7.G02Q7<HGG5ESOD
M #^S *N"/2H[;POHEG9"SM]-@2#SUN2N,EI5(*N2>2P(')]!0!YQXR@NK/2/
M&^AMJNH75G%H\-]%]IFWNCLTJLN[&2IV+P??%=[XDN[GPWX"U.[L7EGN;*RD
M>)YCYC%@I(9CWQU_"M.YT;3;R2Z>YLH96NX!;3EUSYD0W84^WS-^=2VFGVEC
MI\=A;0*EI&GEK%U 7TY[4 >;ZEI\FD^)O#\\6O7M_))IU](IN)1(2PA4^8G'
MR@\<#CI@"M&WUV]:Q^'+?;)))=0B#W(W<W&+-W.?7Y]I^N*Z73O!_A[2;M;J
MPTFV@G0%4D5>54C!49Z+[#BDL/!OAS2[R.[LM'M8)XG+QNB\QD@@[?[HPS<#
MCF@#SO0=9\3WECH?B!VO%>^O(Q.UQJ$"VCH[[3$D1;*L!PN!NRO.<D5UOQ%@
MDNK3P_!%<26SR:W;*)HL;D^]DC((S^%;,/A'P_;ZK_:<6DVR7@D,HD"\*YZN
M%Z!CZ@9K2NK&UO?(^TP)+Y$JS1;A]QUZ,/<9- 'E^LZOK7AZ76]&L=0OKF,7
MFGQ0S3RJTT*W!8.%D?CG8 "W +5%JFI>)='TW7;9+F\LU6UMYK<7M_%<W,,C
M3JA8;26\M@?XN,@@=<5Z=<Z'I=Y]M^TV$$POD5+D2(&$JKG:&SZ9.*J6WA'0
M+.SN+2#2X%AN2K3@@L9"IRNYB<G!''/% '%ZHNL6OBNV\,VESKFH6L6GF]9X
M[^.*>5VD*_-(VW*J /E7^\,\8JQX>UK69M6\+6VH7@<RKJ,<NR:.03>4R",N
M8R5W@9!QWW5V>K>'M)UT1?VG8Q7#0Y\MSD,F>N&&" >XSS45UX4T&\TVUT^;
M2K8VEH<V\:KM$7;Y2,$>^.M '"G5=4U.[M;2+6;J&.?Q3=V;2P.-WD)%(VP$
M@X'R\>G443:CJMC<7WAU-8O#;_\ "06U@M[*X:>&"6!92H<CJ6^4$Y(W_2N^
MM?#FC6*6Z6NFV\*6TQGA6-,".0J5+ =CM)%/N=!TF\BOHKFP@E2_96NE=<B5
ME "D^X"K@]L"@#S#5;F^\*:CXS;3=1N;JX$6EPI-/(KR6ZR22*<LW!(#$@MT
MR,\"I[[4/$6B6/B&+S;ZUB70I[J);[48KBXCF3@2)M)8*<G.> 0,8S7H-GX4
MT&PM[NWMM*MEBO$$=RI3=YRC. ^<[OO'KZTRT\(>'[&UN[:WTJ!8KR/R;@$%
MC(F,;222=O)XZ4 2^'K"33M+1;C4KN^GGQ,\EU(&.XJ,A0  %SR!VS6M5633
M;.6[M+J2VC:>S#"WD(YC###8^HXJU0 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@GD+@]Q6+:)X?M-(O$M;33+<:KK\]K)))-Y$5M#$3LCF*\A6$0(0XW;_ 'Y
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M=Z]AI=JGRRVD994A\I1RB'<'+# .XY)Z4 >QZ-JT.MZ+9:I!'+%#>0K-$DP
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M)=C_ %CH[.&0MU*XXV].*S$5Y#/+=W^CVWB?^UF7>T<CZDK^=\BJ V3&4P
M-FP_6@#WFL+PUXLTWQ4EZVG^</LDWE-YJA=XQE9%P3E&&<'V/%5O'FI7%AX6
MF@L& U+476PL^<8EE.T'_@(W-_P&N3M;36?!GB;19[N#38-/N[5-$Q:2.P$B
M@M;L^Y1SD,N?]N@#T'5=9MM(^Q_:%D;[7=QVB>6 <.^<$Y(XXK1R,XSSZ5XA
M8KX<-AX-DWQ?\)6=6M_[1^;_ $DR[CYOG#K@-TW<?=Q4L7A_39O#>EZD]O\
MZ=<>*'MY+D,1(8FNY(VC# Y"%<@J..2>IH ]AO+LVD*2);3W.Z5(]L"AB-S
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MTA\+6_B9Q9SEL01QM:,K;6Z"/SBP!Z9/%0:Y-I&M0>)]1E-M=:;'XBTU_/D
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M;8)[](:>GA2XB4K'XIUQ 3G"FW'/_?FJ/PK@>#X<:1ON9I]\9<>9M^09(VC
M''&><GD\U8\7W6IKJGAS3].U%[$:A>R0SRQQHS;!!(_&X$ Y48..OKTH E7P
ME.B%$\4:VJDY('V< G_OS2OX4N'*E_%.N,5.5)-N<'V_<UR%_P")=>TBWO\
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M\:-DX"L5+<=/X1S4[(KXW*&P<C(S@UY3I-WXFN[/P7/+XHN]_B"(K= 00XC
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MCH0.35PQQR,DC(K,OW6*\CZ>E>6Z7#,^FZAH,]U]KFU#Q2\$LQ4 R1($ED)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8F_L:XOHYW<C:R,JXX![,3]0*P$\<:II6D^';2\;2X;F[TU+@WFHW3I#,V
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M.>O- '1IX-NK>62VM->N+?1I;PWC6<<0$@8OYC(LH.50MDD8S@D9Q19^!H;
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M2*5< ,CH>&4X'H00,&L&W\:W UG1+"-9K^*_O+R&6X6UV;!$[*% #?PD<MW
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M)SR.>AJU)X[TBVTN_O;Q+RT.GO$MU;SP$2Q^8P5&VC.5)/4$]#W&*4^-K;;
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M@<@,(FQ@\C!]*JP_9M*F$IM)(5TWQ=-<7A2U8>7!(LZQN<+RGS#D9P#7L5%
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M !1110 4444 %%%% !1110 5R7Q%U"YMO"LFGZ>CR:CJT@L+:.,@,2^=Y!)
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M=8OTT\^(9;(WC3GS_*%LLR1>;][+.2,YW8&,UT?@V26+Q'XITTZK<ZA;65Q
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MW%Q# B37+*TSJ,&0@!03ZX  H \J\7V*+J7Q'N//N2P\/PML,S%#N6<?=SC
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MHVOAS1;&Y^TVNF6L,WGO<!TC (D9=K,/<@D'ZT >:WNJZU8M+X?MKR_N8/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:9R<+&JJ22!EB">*=KGAN#6KBUO$N[JPU&TW""\M&4.JMC<I# JRG X(/04
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MP.3Q0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\T>\NIH+I@R&:)$=2@ &W)8C XQB@#T"XO[6TN;6WGF5)KMS' AZNP4L0/\
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M%)B\(D-PR\Y!)("D[1M-5=!O]7\9ZEI:7FK7UC#-X?AO)8[)Q$7F,KKO!P2
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MH [ZBO/O%&H:Q=^.8]#LXM3>TBTX7933KF*WDD=I&3)9R,JH4<#NW/:LF_\
M$WB+2O!^DZT+E;K5HYY[4V"R),+Y 6 8^5D"1 H9MO\ =8=Q0!ZO17G*_:[W
M5/"6F)XIO);6]TZZN9[F"0(UXP,)&TX^4#>2 ,$ $>M4([_6=2O-,T+^W+V.
M(:W>V#WL+*)IH8H2XRV,;@?E+ ?PD]: /5:*\?N-3\33IX@NK675=VD7,EK;
M3F^MHK:,1 8,ZNP+;OO,Q'1OEQ5WQ!JFMP:AJ.J37>H#3K9(G$VD744JZ>1&
MK.L\!(+\DMG)^4C&* /4ZK6M_:WLMU%;S+(]K+Y,ZC^!]H;!_!E/XUYMXAU7
M5+;5M4U9K_47T>V>-HKK2IXI$LE"(S+/;M@L3DL3R=K# %*;^ZTR3Q-K=I.Z
MP6/B*.:[1>DML;>%9,C_ &0V_P#X!0!ZC17.>$[ZZU@:IJ\D[-9W-X\=C'GY
M5AC_ '>X?[S*[?0BN.O+S5%T+Q=XA7Q%>+<Z1J%PMK;AU\E5C((B=,?-NSCG
MD C&.X!ZI17F&H:EK$-SXVUQ-2O1_8BAK33PP\D,;1&.\8RP#-NQD8(/K5Z2
M&_TC5O#]I#XCU"]76TF@N#-(KX(A9Q/%@#9@@<#C##B@#OIIH[>"2:5@L<:E
MW8]@!DFFVMS#>VD-U;R"2":-9(W'1E(R#^1KS:R\2ZOJ\%O9"ZDBO-&T^YDU
M=DXW7";H8U/^\RO)_P !6I-"N=2\3W,%M=:Y?6*VFAV-TAMW5&FEF5B\KD@[
M@"@&.G)S0!Z#87]KJEC#>V4RS6TR[HY%Z,*LUXKH&HZO-I/A30K)=0EM?[(>
M[<:=<1023,)=@^=R/E'7"\_,,\5M:5J.NZSJ&D:!J>ISVD9^W,\]M<Q&><0N
MBI&SQY4. Y+!<$E>W- 'H]I?VM_Y_P!EF67R)F@EV_PR+U4^XJO;:[IEWK%S
MI-O="6]M5W3QJK$1]."V-N?F'&<\USOPYB:"PUV%[MKMH];NE,[XW/@KR<8&
M?7'>N4M1=Z7)JT-IJM["=1\5C3Y9VD#&)&B1BRY& YP$W>X]* /7J9+*D$+R
MR,%C12S,>P')->7>(]2U?P[_ ,)!I%AK-W,L5G9W4%Q<,));9Y+CRV4MCD$#
M(!]^U=W]CET3PQ>1+J%Y=RQ0RR+<74@>3.">H '';B@#3M;J"^LX+NVD$D$\
M:R1N.C*PR#^1J:O,M&?5/$NIZ79W&NZC;6[>&+*\D%K($:2=V<%RV">W('7C
MTKK/ NHW>K>"=*O;Z7SKJ2+$DF "Y5BN2!W.* .AHHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?YUO'*"5+-G:YQUP!@GO59_'NMVNAWNN7=KIJV0O9-/M(P9 [2BX,2NYY 0
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MYU-8V-MIMC!96<*PVT"".*->BJ.@%9F@^(4U;P;9^()XO(6:T%Q+&IW;,#+
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MVR,W+@.5W*K_ ,0![G&,U9L_&MG<7T=K>:?J.F&:W>Y@DOHE1)8T +$$,<$
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M]M[N2[>:7:/-=X3%C:!A5"G@#T[\U2L?A\EFVE1'6[^:PTFX$]C:.L86/ 8
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MQ#-#$EQIEM! [DG$\-P\PW ?P\J/SKIK?7=(O+%;ZVU2RFM'D$2SQSJR%R0
MNX'&22!CKDU6\1>)]-\-Z3?WUY<1%K.W\]K<2J)&!R%P"?XB"!ZF@#F+_P -
MZ_XJU*ZDU>VL]-M9M%N=- AN#,XDD:,[_NJ-OR].O'OQ%H7@Z^@U73Y[G0]-
ML_L,;A[A+V6X:60H4!C5L!!R2<Y.#C'>NLD\6>'H(K22XUS381=H'@WW2#S
M>,KSR,\9%1KXLTIO%L_AS[3"MY!:K<MF9>^[Y<9SD*NX^@8'O0 _PAI5QH?@
M[2-+N]GVBTM(X9/+.5W 8.#7,W'A76I-6OD6*U-G-K]KJT<_GG=M3RPZ%-O!
M'ED@YYSVKK+#Q+H6J/.NGZSI]VT"EY1!<HY1?4X/ ]Z6S\1:)J-ZUE9:O87-
MTJ[S##<([A?7 .<<C\Z .6\3^";W7[WQ!(DD")>6UB+;>S8,D$KR$/CD*=RC
M(YY/I4_A?PU<67B!]3GT2RTQ$MC BI>27,K,S L=S8"I\HXP23SQC%:&J>-=
M*LK^TL+6[L[R]EOHK.:WCN5\R'>2"Q49/'IQUJW#XET^+3OM>J7NG6(,DR@F
M]1D(C<J3NX&>F1_"3@T 9'B?PS?ZQKYEA6(V-[I%SI5RYEVO )""'48.[IC&
M165X>\&7UIJ>DO=:)IML-/!,MVM[+.TSA"H,2' 3.23G.!P!WKMCKVCC2!JQ
MU6R_LTC(N_/7RNN/O9QUXJ33]5T[58VDTZ_M;Q%QEK>59 ,C(S@]Q0!R5EX2
MU*W\(^$M+<P?:-*O89[C#_+M3?G:<<GYA3]5\*ZC>67CJ*(P[M;C5;3<Y'(M
MUC^;CCY@?7BKWC#QG'X3:Q!LVNC.S23A7V^1;ICS)CP<[=R\<9SUKHA>6QN5
MMA<1&=H_-6+>-Q3.-P'7&2!GWH \\\0^#M9O]2NI[*PLH;Z18Q:ZS;7LEM+
M H!\U%'[W!!QV(('&*ZWQ5HEQKOAQ[*VFC2\22&XA>4?(9(I%D4-CL2N#CUK
M1BU73IX+::&_M9(KIBENZ3*5F8 DA3GYCA6Z>A]*KV/B30]3O7LK#6+"ZNHP
M2T,%RCN .O .: .9O-"U[Q#?7.H:C:6E@T6E7-C:V\=R92\DP7<[-M "C8H
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MW=]6W&"19TVD ?*>O.XX48ZFKNO:N-&TX3+%YUS-*EO;0[MOFRN<*,]AW)[
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M5!X:UP>(M#34EA$(>::(*'WC$<KQYS@==F?QH UZ*** "BBB@ HHHH ****
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MFV(A6(65N(EE\]4\I<"3=NW@8^]NYSUSS5:;1-$743K$^F:>+V,;C>/ GF*
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MX>$22^<P61@I&21SCH<\C@5V<G@W3+OQ'J&KZE;6E_\ :D@6.&XME?R3%O\
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MWK@#H<#([X% ' :BE[X8N-.N=(N[^XO+W1+Z:5+BY>83SQQ(\;;6) .XG[H
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M4@I\HX8'D5.?!&EC3K:VBFO8;BVG>YCODG_TCS7SO8L00=P)!!&,=N!0!1\
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M8[2>!Z>XST$^M6-MX??7)92M@EM]J:0CGR]N[./7':L2+PG+ GBB.*:,1:K
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MZ14DN990NU H)X78>3QEN,ULW\,DOBKP3:*I$UHD]U..Z1B#RN?JTBC\#Z4
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M2+(*R.^-SN5'(SG=QC%=-<^'+_4&^(,4<1MWUB*.*UF?@/\ Z*J=>N V1^=
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M&%> /LR/]HM&/^V=96G>&_$$OAE;C4[)SJSZIIL;(""1;VLD:[_H2)9/^!4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML[P(JEW9I+>7) D).#P2,+R*TM$\26%EK]Q>:G.VG1WGAZQEMXKZ7]XV#-N
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MTN#<V<%PT,D!E17,4N Z9&=K8)&1]:KW.J06FJ65A,KJUX'$,F!L+J-VS/\
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MP-K#<,;BO8$AORJ_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M* $*J6#%06' ..13'MX9)4E>&-I$^X[*"5^A[5)10 FQ0Y<*-Q&"<<FEHHH
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M]><8ZYK(T[QYI-[>ZN7O;./3;%X$2\,N%9I%.0V?ND$8Q^= '645SA\?^$Q
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M@WAC_H#6_P"O^- '':K'KMK>ZLEII^H6<T-C'#IT.CV,/E3(L6=KS,AP%<L
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M[6WM"UNZA$15#$9XSEEZ<\UZQ6?K>K66AZ/<ZCJ#,MK$HW[%+,<D*  .222
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MWEMJQ+$C';_>/]X@>M=S10 4444 %%%% !1110 4444 %%%% !1110 4444
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ME<$9&20 6&"17K'^BZA:$?N;FVE!4CAT<="/0U##H^EVMA)8P:=9PV;YWP)
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M7!ZG/2KNGZWXD\4WLL%M*FB26=A;33P36WF,\\JLQ1LD$(NW'&"<GD8K8NO
M^G74AE^V:G#-) EO<RP7;(UTBC \TC[S8)&X8//6GW/@G2)G@:W^U6/E6RVA
M%E<-$)(%^[&V.H&3@]1D\T 5_ARRQ_#+0'D8*JV*%F)X  Y-<0^D'0_"!74=
M!L-9T&,&[_MW2YU6[";MXG(89+CJ65S7JNDZ5:Z+H]KI=FK"UMHQ%&KG<=H]
M3WKGO^%<:(%:V6?4UTQFW'3%O7%J><E=F?NY_ASCVH YJ[UB_P!$\1>--:M;
MM;E5MK!;>&2,!"TI98R2.=JEB3Z@FM#7/$NN>!Y&_M*]BUB.;3KFYB_T<0M'
M-"JG'RGE&W?48ZFNEO/"&D7^H7MW<1RL+ZU%K=6XE(BE1<[25_O#)P1@BH[3
MP7I4$DTET]WJ4DMLUINOYS-MA;[R#/0' R>IP,F@#G/$\'B*U\$ZX=3UFSOK
M>XT6Z:2/R!$\<HCR/+QG<F"<[N1P<\UI^!=>O/$)NYI3]DM[,1VR:?)'MF7Y
M0PEDSR-P(V@<8ZDGI93P!H_V>>&XEO[M)+22RC^TW32&"%QAECSTR !GD\#F
MKMUX9M'GN+RT,L%]+8&Q,D<K(&7!V%L=U).&'(R: +/B&34(?#FHRZ25&H1V
M[O;[EW N!D CWQC\:X2;XFS)JUQ>QK&VA'2V>WP,L]V(4G"9[Y20#'J#7HUA
M;O::=;6TDSSO#$L;2O\ >D( !8^YZUSR?#WPY'I5KIJV;?9;6_&H1+O/$H)Z
M^JX.,>F!0!QVM75_)::O::DMN;RWFT(SRQ0JC/(TR%\D=0"#@'H*Z_P1_KO%
M'_8=G_\ 0(ZT+WPKI=_<7LTZ2E[V2VDFPY&3 VZ/'IR.?6KVG:5:Z6UXULK
MWERUU+N;.78 ''H/E'% 'G6N^--6L9KZ]L]4-S':7PA-M;Z8[VHC\Q4*R7#
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MRYBUKS+W3[<ZG8Q6JPV=GY44&R0L,#=SG<<YQS[<4 ;^E>)+ZY\1'1M4T?\
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M16SP-_9MF8#=%BIWS?,<D;>!V)/- &MKVN7VES0PV6F1W&]&D>XNKH6T$8!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"91L1WVP1[F=UW,  0#MY(P: /0'=8T9W8*BC+,QP /4T-(B1F1G4(!N+$X
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MX$=,5O+J_B/5Y=8?1[JPLK?1RL*136QD^TRB)9&W'<-B?.%&,GJ?:@#NJ0D
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MD\E@]G(Z3!P04?G@IPP Z^U4?"NKW/B74_"\5^^\V>ERWDI/_+6X63[.'/T
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MU>[EOA=ZCITUY"L5XEI,$\] #A7X/(!(W*0<<9I+G03-K>@P0VZPZ/HR&:,
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MM?D=<O*Z+MV]9&( ZXY7IS5B;QR=.CO!K&BWFGSPV$VH11/)&_GQQ#+JK*Q
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MC41[EW!5#,"[;<' ]1SDXH L7VCC3]1U'Q!86]W>WES D,NGI,BQW&W@$[^
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M'D!QR&8<$CID<5;H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ K'\1:=J6H6<#:1J/V*^MIUGC+Y,4
MV 08Y%!!*D'\" >U;%4]3U6QT>S-WJ%U';P!@H9SU8]% ZDGT'- ')S>$=6\
M1ZD;OQ*^FP*MC<621Z;O9G$RA6+NX'  X7'4YS530?A_-I]]IWVG3/#,$-DI
M#W5E8J+BZ.TJ"25_==<G:22>X%=1%XP\/S:9-J*ZK MI!*L,TDF4\IV( #!@
M"N<CKCK3;;QEX>N[6XN8=4A,5LZ),6#*8RYPF00" 2>#T- &7H.@^)=(@TO1
M_P"T+)=(TXA1-$K&>XB4$)&RD;5[98$D[>,9K.L? .H?8=*T[4;FT:TL/ML.
MZ MODAG0J"01@,-QSVZ5W1O[4:B-/\Y?M9B,XB[[ 0N[Z9.*DGFBMH))YY$B
MAC4N\CMA54#)))Z"@#C;3PQX@G_L*QU>ZT\Z?HTJ3));!_-NFC4K'N4C"=<G
M!;)':GV_@V[A\)Z+I!N8#+8:E%>.XSM95G,A XZX./K6SIOB[0=6GD@LM2B>
M6.(S%6#)F,=7&X#*^XXIVE>*=$UNY:VT[4(YY@GFA "I9,XW+D#<N2.1D<B@
M!_B;3KO5_#&IZ;8SI!<W=N\"2OG"[A@GCGH36;XMT1YO [V.F0[I;$03VL*_
MQ&!U=4'UV;?QJ;5?%MII7BG3=!D7,U]!+*'Y^7:5"C '.XD]^-OO5/PGX_TC
MQ'8:6KWEO'JE[;B0VR$XW[=S(K'@D=QG(QS0!GZIX<G\3:S#KUM'I.J:=<V4
M8MX=4#LEL<EO,2, JQ(89!VGY1S5=O#UQI_A3PQX+>6.>X^V1R321 A1!!+Y
MK/[9(1?JXKJT\6Z ^K?V6NIP&\\PP[!G!D'5-V-N[_9SGVK5N;B*TMI;F=PD
M,*&21ST50,D_D* .+TO3]1@M/$.@6-[]AU"'4'OK29DW*\4S^:,CNI;S(SCG
M@^U7;33[^TURZ\6>(YK&W-OIYMEBLV9D2(-YCNS, 2<J,#' SUS2^"?%EQXF
M@NUO[);*\A\N9(02=UO*@>)SGO\ >!'8J:CO/'^E-JNE:?I=W;7DMW?BUD )
MP$VN69#T;#* <9 S0!;\$:?<V7A:-KM&AN[V::]EC(YC::1I-I]P& /N*Y*R
M^&VIPOI33IHIN;"_BNIM2VN]U>A7R=S,,H2.< L"0.@KKO\ A/O"OG>4=<M
MWS<EB%RHR5W8QNP/NYS[4_\ X2JPO;*VNM*O[.2-[^.SD,Y=2&)&4 QD/@C
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M26TU*U ($Z-@H0.F0<CGLQJU)XWT>ZD6#2M5L)KA;F&*42EPH#R!" 0/O\X
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MK=ZK;H;I%DMP"6\U2< KC.1[U7;QYX66X,#:W:*X+J2S$*&7.Y2V,!N#QG-
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MZQR7;F.!6X\Q@I; ]\ G\*J7?B/1[!;QKK4(8A9LB7&X_<9P"J^[$$8 YY%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !03@9-%<?X
MUUN**6VT#[:EFUZ-UQ<.VT10<@X/]YL$#\:TI4G5GRHSJU%3AS,ZJUO+:^@$
M]I<13Q$D!XG#+D=>14U<5\+[F"3PF+>.56EAE<N@/*@L<9^N*[6G7I^RJ2AV
M%0J>UIQGW"BBBLC4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JW.FV-Y
M()+JRMYW VAI8E8@>F2*M44TVM4)I/1F3X>\/6GAS3S:6F6RQ9I' W-ST) &
M<9XK6HHISG*<G*3U8H1C"*C%:(****DH**** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>exhibit101-arrowheadindu005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101-arrowheadindu005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M HHHH ***SQKVCLP4:M8EB< "Y3)/YT :%%%% !1110 4444 %%%% !1110
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M!R1RO&1]WKS733^(M:T:3Q#IU]J]@\ME%:36]]<6Q0 3,ZE3&F2[#8=H'4D
MUO-X+TMKZXN?,N\3WT6H-#YW[L3QD$,!CC.!GUQ3]4\'Z5J]S>7-SYZSW2VX
M,D4I5HV@9GC9#V8%B: .!U7Q%J]]H?B_2)+^XEBCT)KR&YN=-:TEQ\ZNNQL9
M4A>&P",GKBN];4)M \ R:E<O]KEL=/:X8A=GF;4+ 8'3IBH8_ VE^;?S7,]]
M>37]DUC=27-P6,D1[<8"XR<;0.I[\UKV>DP6NBII4DDUW;B(PL;IM[.AR,,>
M_!Q]* .#FCUX>*/!EWJVHVMXL_VF0QQVWEB)S:N=JG)W+CCGGCKSP>%=9UOQ
M!9Z7I^EW-EI26^C6UY,4LPRN\NX*BID!4 C.<<\@#%='8^!-,L;^QNQ=ZE.V
MGJZ6<=Q=%T@1D*%5![8/4Y/ YXI1X$TN*WL([2XO[)[.U%DLUM<%'D@'1'..
M1GD'J,G!&: (?AD''P\TD2[?,"R;MO3/FOG'M6#I/B3Q.^E>&]=O;^TEM]3O
MDLY;)+7;M5V90X?.=V5!Z8YQ[UWFB:-:>']'M]*L%=;6W!6,.VX@$D]?QJE#
MX3TR'2-,TQ!-]FTVX2X@R_.]6+#)[C)- ')R^*/$(\,7'C-+NU&GPW#XTPV_
M+0),8SF3.1(0"W3&<#'>M3P;%>+XK\9-/>^=$-251'Y07!\B(@YSV! Q[9[U
M=?P'I$ERY,E[]BDN/M3Z<+@_9FEW;MQ3TW?-MSMSVK3L]!M;#7-0U6WEN%EO
M]K3PF3,1=5"APO9MJ@9]J .+GU672-9\:SP7MK9R/J5E$)KB-Y<;K>('9&@)
M=\9PO<U4/C;7K?3O$T<<[7$^GQV<MI/?:>UJS>=(4(>,XX^7@X'7VKLM0\&Z
M7J,MY/(US%<7-U%>>=#+M>*:- BLGI\HQ@Y!R:Q/$/P_BFT'6DT^2ZNM2U..
M"*=[JYR91'(&SG@*0I8<8'3B@!-0U?Q5H=_<:6DUOK%[<:9->6>+<1%98V16
M0@-@J?,!&2#D8SSFLU?'M[INC:Y<RWIOKJSMHY([.\TY[2YCD9]GS)C#QY9>
M5YZC/2NJ7P-I+QWBWLM[J#W5O]E:6[N"[I%G(5",;>0#GJ2 23BEB\$:45N_
M[0EO-4>ZMOLDCWTV]A#G.Q< 8YP<]<@<\4 97AO7M<E\10V%XM_>V<]N[O<S
MZ/+9"WE7&%RPPRL"<=P5ZG-7]5D-[\0M"TM_^/>WM;C4F4]'D4I&GY>8Q^N#
MVJYI7A2TTS45OVO-0OKJ.(P0R7MP9#"A()"\#K@9)R3CK2ZQI5Q)K^C:S9('
MFM&>"=-P&^WEQNP3W5E1OHI'4T <7J/C;5;6[-Y;ZFEW"FII;/;6VF2-:K$T
MPBP;D@ R ')P<;N,5-?^)/$\6F>(=<BO[1+71]2DMTLS:Y\^-64'<^<@X;C
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M2REMVR02Z@?/'G;@KDYXSR#6;/XEUBZ.K:0=2N)X)]#N;N.YN-)>T9'C*@A
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M;<-)%%%Y:*RD\_,P9CZ@KZ5U%SX+T6[O=:NY8',NLVPMKLA^J!=N5]#C'/\
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M9G=/S4@_C7&0Z)XHO/[!-[8:NUY9ZI!/>[[B&.SC57Y\F-&^88.1D9P#WXH
MZGP_\0M.OU,&I3K!>?;Y[,;+>00AEF9(U,A!4.RA3@MDYX'(K5O/&N@6&H26
M5S?%9(76.:002-%"S8PLD@4HA.1PQ'6N,32=>N/"]UX5?0)X'NM4EF%^98C"
MD)NC+YAPV[?CHN/3D<XL7FEZY:Z)XG\-0Z'+=MJ]S=26]\)(Q $N"3F3+!@4
MW$8"G.T8]@#MW\0:5';:G</=JL6ELRWC,K#R2$#G(QD_*0>,YSQ5*\\;>'["
MY,%Q>NK(J/,PMY&2 ,,KYK!=L>00?F(KG-9\(:E+X@LK:T42Z1J,=O'K$A8
M_P"C'<IQU/F#"''8<UFZGX8U6WU#Q) +#6KZ/5;AY[<V5^D-NX=%4I,"P*XP
M02 <KC'/% 'I6H:G9Z58-?7LPBME*AI,%@-S!1TSQDCFJTGB+2(K[4+*2^C6
MXT^W%S=(0?W41!.X\8Z ]/ZU%>:#%?>#I= EXCDL?LN=Q;;\FT')Y..N?:O-
MO^$-\47]K97UY:"/4=8FDM=<7S5/EVK&(9SGGY(, #_GJ?>@#L+SQC+'.#93
M6=Q$^JV5H%\F17CCG5&.[./FPV1C@ @$9S6OX5UBXUS2);NY2))$O;FW C!
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MX)'E>1<[D$07?N&#D8R,<UEZG\1-*M;'3[NS\ZYCN=16QE MI@\!ZN&39N#
M8PI )SQFL(67C!-,TS[5'J3VZWMPTK6_V;^T%@(_=;F^YDG=N*G."/>JMKX>
MU^RL+FY;1[Z5X_$D.II!)=1RSRP")%)W%\%P0<C.., D8H [5?%EE:17DE_>
M12;-0>SACM+:5Y"P4-LV %G<#))48Q^-8_B+X@11V>D?V#.K2ZC>FV,TUA/*
M( JL7#1J V\%0-I(/)., UGW?AV_\B]EN-&O9@VO3WD<EC=B&ZAC:,*LD1W
M'G(*D]">#4VG:/XCF709-0CN)5M=<DN%-TT7GQVIMY%4RE/E+[F[9.",]Z .
MC;QMH,-\+*6]<RB<6KS+:R^0)LXV&7:4#9XP6Z\5)?>,]!T[47L;F]998F5)
MG6"1HX6;&T22!2B$Y'WB.HKS_5-$\4ZE83VUQ8:M)>KJ2S;([B&*Q$2W <%%
M4AG)4#AAG.2><5T$<&N:(^O:;;^'_P"T3J6H275M<R-']FVR;<B8%@PVX(P
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M;,*,,AG&S*+[M@5STGA[6-3U5]9DTQ[9;K7;*Z%K(Z%XX84VF1\$C<3S@$D
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MP?KD$ 759=9BC>\R?,:-IG0H6Z[=O&WI0![+6=KVM6WA[1I]4NTE>"$H&6(
ML=S!1C) ZL.]6+2_M+\W M;A)C;3&";8<[)  2I]^1^=<S\4/^2=ZG_O0?\
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MYWY(R?*SLW]LXYJT8+>7PUI*W&LZ6]FNIW1LDU"WD.FRICB,LQZ*=WEL21V
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MZ,-3DL%N#J5Q/<V\48D=8;HQI&F5*CA@2<9.WW)H ]-VKS\H^;KQUI0 !@#
MKR]-;\0W6KV?AU=:D1TUJXT^6_2&/S)HEMO.&05VAQG;D#&1G':NI\'7=_)+
MKNFW][)?'3=0^SQ7$JJLC1F*.0!MH )&\C.!G% '1-]GM(C(WE0QH.6.% 'U
MJ-)K*ZDN+-7@E> @3PC!V%AN 8=L@@UR_P 48'G\ 7H2YE@VRP$F/;\W[U!@
M[@>.<\=P.V0>=ELM6AUKQU=6?B&\M7T^*WD5DBA8SR):*=TF4((..BA>I]L
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M8MF@#T:T-I-9126GDM:RH'C,6-CJPR",<$$&AKNV6\2R::,7,D;2+"6&YD!
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M6F:_XBU:VT"P.JW%I-<:M?6-S.8H3,8X5D*YP"@?Y0,KD9YYH ]350JA5
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MRH_*Y6/#.<;CM,F?O#[O/6@#TW8A</M7>!@-CG%12W5K!=00RS1)<7!*PHS
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MN-2#:',5:Y6,2(?.BS]Q5&#VXXYY] #MS=VPO19&>/[48S*(=PW% 0"V/3)
MS[U-7GWCC7=1TG4]4-C<"(P>&[F[C/EJ2LJR(%;)&>_3I[5<L)M8TOQEI-C>
M:U/J,&IV$\\J311J(I8S%S'M4$*1(1@D]!S0!VM%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 56U#3K/5K":QO[>.XM9EVR12#(859KG_%FO7NA6^FC3[**[NK^^
M2RC264QJI9'(8D \ KSQTS0 [2O!NAZ/?K?6MM,]TB&..6YNI;AHE/4)YC-M
M'TQ3;?P5X?M=12]BLF#QRF>*(SR&&.0YRZ1%MBMR>0HKF=2^)%QI^H7>G2OX
M?M[S3HHS=QW>I>3YTK('*0Y7) !'S,!R<8X)I]]\2F,]B-/CTZ"*[T^*^@;5
M;HV_VDOG]U&VTJ&&!G)ZL..] ':+HFFKKS:X+1!J36XMFN,G)CW;MN.G7OC-
M9TG@GP_)J+7S63[VG%RT(N)! TP.?,,6[86SSDKUYZU1G\1:_<^(9=(TK2K,
MO#80WDDEW<D!3(7'E_(IR?DZCCK[5DW'Q1MY4TJ.V;3+"XO+1KJ5M6O!#'"%
M<QE 0,NV]7'&.%)]J .T30]-2WU"W%HC0ZC(TMW&^665F4*V0?4*!@<52TSP
M?HFDW#3VUK(\IA, :YN)+C9$>J+YC-M7IP,"L'3O']SXABTZVT.RM)-1N1<-
M-YMR3! L+A&8.H)<,S+MP!D')Q39=7\3R^,O"UO/:06*3)=_:K?[265RA4;P
M0.1M(9<X/S'(&* -S3_!'A_2]0M;ZULY!/:;A;&2ZED6 ,I4JBLQ"K@G@#'3
MT%;=W:PWUE/9W*>9!/&T4B9(W*PP1D<]#6/X@UR[T^^TS2],M8KC4=1:3R_/
MD*11I& 7=B 2>J@ #DGM7$^*M<UG6;.'1)+6VM[N'6K>SOXTNY%297 >/:ZJ
M&V,.O0C&.: /1)M$TZ?3K73Y;8-:VCQ/!'O8;#$08SG.3@J.O7'.:J:CX3T;
M5-1:_NK>;[1)&(I3%<RQ+,@SA9%1@' R>&!ZU!XDUD^$O"\=S#;(ZQ-%!\[M
MY4*DA=[L 6V+U)P3_.LRU\:W3V%G/)#IMRMSJD-BEQ87@FAD209WCC((Z%3Z
M=: .@T[PUI&DR6LEC9B%K2W:U@Q(QV1,P8KR>F0/ICTJK/X+T*>*%!:RPF&2
M66*6WNI8I$:5BTF'1@V&8Y(SCVX%4-6\:MI=]K5J+$3R67V..V02;3/+<,RJ
MI./E ('//&:R?&&J>)K?PQ=K?:=#%-%=6+V\]C='9-NN4!C.X!E/8G!!#?44
M =))X)T!H;...TEM_L:.D+VMU+"X5SE@71@S GDY)R>>M(/!'AY=.2PBL#!!
M'<-<QF">2-XI2,%D=6#+GO@@=:9HVN:I+XBN]#UFSM(;F*UCO(I+29I$:-F9
M<'<H((*_CGM6)XRL;J3Q)#=ZAI6JZOH"V@1;?39RK0S[B2[1JZE\KM ()Q@\
M<T ="/!N@BUL[=;)E6SN#=0NL\BR"4YW,7#;F)R<[B<]\TLW@[0YK&WM/LCQ
MI;2R30/#<21R1/(Q9RLBL&&2QR,XKAVU6\@\.Z2OAO5Y;N%M?2W9-0:2*:W4
MG(MI,@N0.Y;G!'45O7?C+5UMM7U:RTFUFT;2)I8IR]PRSS>5Q*T:[=N%(; )
M^;:>G% &_9^%]%L!8BVL@AL99)H&WL6$CJ5=V).78ACDMGK3+[PQ974<X@!M
MY+F^AO9Y%9B7>,I_M<96,+Z>QK*D\4ZQJ-YJ(\.:7:WMKIVP2&>X,;W#M&LF
MR,;2 0K+RQQDX]ZQ=+\6S0^-=<T&V3S]6NM25X[>XFVK;0"WA+L3ST.["KU.
M>V30!W^IZ99ZSIL^G:A")K6==LD98KD9SU!!!R!R*JVWAO2K6WO8(K=RE[$L
M5R7F=VE58Q&,LQ)SM &<Y/7KS53QI>)8>&7N)(6F475JFQ)FB.6N(U!W+SQG
M..^,'@U@7GCG6K>WUC4X](LVTK2+Y[6<M<L)I55E!9%VX& P/)YY''4@'07O
M@S0KX6_F6LT;6]N+5'M[J6%S".D;,C LOL2:TAI%@NBG1TMECT\P&W\F(E (
MR,8!&"..XYJOXDUM?#V@W&I&!KAHRB1PJVTR2.P1%SVRS#GM6'>^)_$&AVTG
M]K:+:R32M#%9-9W1,<LTK[!$Q90RX)!+8(QGOQ0!TK:58MHQT@VR'3S;_9O(
MYV^5MV[?ICBL>Z\!^'+P*LUC)L$"6SJEU*@FC0859 &'F8'3=DUDZEXVU3P_
M#JL.L:;:&]M--;4;<VL[-%,BL%93N4%6!*^N0:G;Q9K.GW\MKJ^EV<1DTR?4
M+;[/<,^/*V[HWRHY^=>1QUH WX/#NE6PN!#:!?M%K'9R_.QW0QA@B]>,!VY'
M//6AO#FDO%8QM: I8V[VUL/,;]W&RA&7KSE0!DY-<U8^-=42;1Y]9TRTMM/U
M>VDGA:"X:22'9%YN'!4#E0>AX/'/6J&C_%.&_O=*,TFC_9M4E$44%MJ ENK<
ML"4,J8QS@ X/RDCK0!V]CH6FZ;<1SVEL(I([2.R1M['$,>2B\GMD\]?>JT/A
M+0H(884T]/*AM9+)$=V8>3(0SH02<@E1UYK(TCQ+XAUJWL]4M-%M&TB^9A"?
MM)$\:<[)7!7;M.!D D@,.O2L'PSX@OC8>%[C7,32W%W?[;A+E_E5%E)++@!O
MNE0#D  $<T =A9>"]!L?.\NUEE\VW:U/VFZEGVPMUC7>QVJ>.!CH/2K.E^&M
M)T:2*2QMW22*W^RH\D\DA$6XN%R['(R3_+H,5SUIXSU=K;2-7OM)MH=%U::*
M* I<%IX1*<1,Z[=N&)7(!^7<.O-5[3QSK4UI8:M-I%G'I-SJ0T\E;EC,"9C"
M)-NW&W<!QG..: -F'P!X;A> I8RE+>9;BWB:[F:.W=6W QH7VIS_ '0.XZ<5
M9F\&Z#.=0\VQ+#4)5FN!Y\@!D7HZC=A'_P!I<'CK4VNZR^C/I;F!9+>ZO8[2
M9RV#%O!"-[_/M7_@5<U9?$5K^.^2'3U%RFK16%HC2<3Q.^T3=.!A)6QZ)0!O
MP^#M"AL;FT^R/*EU)'+</-<222RLC!D+2,Q8X(&!G%;-Q;Q7=M+;SKOBE0QN
MN<94C!''M7FMGK6JSZIX633$2"TN-4U&.>*6ZD8R>6TH.20<C@L!T!P. ,TW
MPUXFUW3/#]E=75G;SZ5)J\MDTSW+&X/F7;HKA=N-JLP7&<X'X4 =_'H>FPR:
M;)'; -IL1AM#O;]TA4*1UYX4#G/2J5QX,T*Y6,&UEB>.XEN4EM[J6*1))3F0
MAU8, Q/(SCVXJC\0+[5;'2=.?29(TEDU2TB<O(R95I5&W(!X)X/L3UZ5SJ^(
M?$6D77C6_@LK6[LM-O//G$]TZMM%M$S)$-I P 3S@$MTZT ;VL>#UA\,ZAHO
MANQLX4U9V6\>YF<A R;&E ^;<^ .,C)Y)SG/46%E!IFG6UA:ILM[:)88U]%4
M8'Z"N'UGXDQVFLW6GV<VC0FSACEE_M2_%NTS.N\)&,'^$C+'C+ 5TD/B.&]\
M$_\ "26D3-&]B;Q(GZ\(6VGWXQ0!:_X1_2O[.O=/:RC>TOI));F)R6$CR'+$
MY/&3SQT[54L?!VAZ?]I*6CSM<P_9Y6N[B2Y8Q?\ //,C,0G^R.*YO2/!T>M^
M$[/5KO5=1&O7MJEU_:27<@,,CJ&&Q P38N<;<8('-:<NOZ]-J5]INC6-E>OI
M,<:W<US,T/GRL@?9&%5L?*0<DX!8#MF@!MMX$M--\6:?J=@A%I#9W%M.EQ<R
MS.0YCV*N\MA %?C( STYJ]IW@;P]I5Y:W=I92":S+&U,EU+(( 5*E4#,0JX8
M_*!CIZ#%#3_B!:72FZN(3;V$FD#5H)6;YF1<B5"/[R';TZ[JR[KXCSPS6EC*
M-%TV_:QCO;E=4O\ R40R9VQ)QEFP#D]!QUS0!V&G^&])TN6TDLK01/:6[VT!
M\QCLC9@S+R><E0<GGBJG_"$^'_[2^W?8GW^?]I\G[1)Y'G9SYGD[MF[/.=O7
MGK6%:^/=1UU]%C\/Z9:ROJ5G+=.UU<E4A\J18W&54[N20".O!Z50C^+5M)*E
MWYNC_P!G/=BV%N+\?;=IDV"7RL8QGG;G.WGVH [_ %;2;+7--ET[48?.M9=N
M] [*<@A@05((((!!![5!%X=TJ&WOX%MF*:A&([K=*[&51&(QDDYSL &>O?KS
M7"^,?$NN:CX2\0W.F6<$>EVLSVGG_:66X+1R!7D4!<;0P(QG) )]CZ%J>F6N
ML6+V=XLK0.02(IGB;@Y'S(0?UH RY_!.@7%P)GM)5/DI;R)'=2HDT:#"K(JL
M!( ./F!XJ6V\):)9SZ9-;6C12:9$8+4I/(-D9_@/S?.OLV<5R?@CP]IXO=>O
M7-[)+IVL3PVWF7\[*B*B$*5+X;J>H/6K%AXT\07?A:TUV?2])L[:^$30R7&H
M;$@0JQ9Y2RCC(&T+DG<,XP: .IU7PWIFLW4%U=QSK<P*R)-;W,D#[&QE2T;*
M2IP.#Q4=AX2T/3#:FRL%A^R3R7$ 5VPDDBE7(&>X)XZ<URMO\2+F?2;B6"SL
M+Z\@U6#3E-I=EK>?S=NUU?;Q][!X.,'K5NY\;:KI-MKT>IZ7;-?:7';S#[+,
M[1/',Q4,25W*$VL6X/ R* -+Q'X>FN-$U6QT2ULQ-K3L+V2ZE?:H:,1F0#!R
MP"KA?E''7UW=-L(-*TNUT^U7;;VL*PQCT51@?RKE;#QCJ%WH.H7\4&D7WV<Q
MB&XL]27[.X8X8NS<Q[.IR"2.F3Q6?;_$SRTUA)TTW4);&&&6%]*N_-BF:60Q
MK&6(^5M^,]>#GVH WI_ 'AJY:?SK&5XII3.T'VN80B0G)=8P^U6SSD &M&?P
MWI-S::G:RV@:'4Y/,O%\QAYK;57.<\<(HXQTKD?%^L>,+'P?K)FLK.UFCMTD
MBO;.Z8J,MADY4,''!!Q@@]0>*GN?%,FC:MK1FT\2ZDD6GPK%%=,8YIIF=%4;
MAA #U;&2.HX% '67.B:;>7<UU<VB32S6ILY"^2'A)R4*],9/I5/3/"&B:1.T
M]M:R/*8C &N;B2<I%_<7S&;:OL,"L#5/&^J^'(M2AUG3+1KRWT]M0MS:3LT<
MR*RJZ'<H*L"R^H(/:M33-?U@^)X]&UG3[2W:YLWO+=[6X:3:$959'RHY^=>1
MQUH ET[P+X=TN\M;JULI!-:%OLQDNI9! &4J50,Q"KAC\HXZ>@Q>B\.:3#8:
M98QV@6VTR19+-/,;]TRJ54YSDX#'KGK7.:Y=:U'\2M/M]'CAE+Z3.76YF9(D
MQ+'\Y"@Y/8?[W6JEU\3%@M+""2/3['5+BXN+:<7]YY=O;M VV0[\9;)*[0 ,
M[NV#0!T,O@?P_*+C_0Y4,]T;PM'=2HR3'.7C(8>63N;.W&<\YK2TG1K'1+1K
M:PA,:/(99&>1I'D<]69V)9CP.23T%9G@_P 4Q>*=/NI5^S&:SN6MIFM9Q-"Y
M #!D?C*D,/<'([5B3>-]9AL]6U=M(M?['TJ^FMIS]H;SI(XY-K2(NW' YP3S
M@].,@&U=>!/#E[>2W,]B[-+,+AXUN95B,H(/F>6&"[\C[V,FGZCX*T#5+Z:[
MN[-V>XV_:$2XDCCN-O3S(U8*^,#[P-8-MK=[ITWBZXA6&?9K,<2-=W0AAMT-
MO"2S,>BC).%!))]\U%9_$EYK;48E@T^_OK>ZMK6V;3[O?;W#SDA/G(^7!#;N
MO3B@#K9_#6CW%S-<2V8,LTT$[D.PR\)S$< X&W'3H>^:G.B::=>&N?9$_M,6
M_P!E%QDY\K=NVXZ=>^,US.K>,-5\,Z9<3:]IME%*9X8+2>.[VVTK2$_>9AE
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M#+*\DC222N>-S.Q+,>!U-<7+K'B!_%7A*XU>TMK*RG%S.1;7+/M'V=FV2 J
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MDW'Y%?;N&,X.=B]?2N"U3XK06-YJCQOH_P!DTRX:"6WGU )>3E#AS''C'!R
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M,AB"IM#H0X^;!/48Z>G+)M"2/4/"?AZRCD^P:*!=R2,.T<;11*3W9F8M_P
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MYK6=*OO!OABUURWUW6)M0M7MEGANKUYXKG>Z(ZE') SN.",$'%6O&&IQ^)-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !2,RHA=V"JHR23@ 4M<MXZE9]/TO2\D1:KJ<%G/CO$=SNO\ P)4*
M_1J .F,T0B64RH(VQM?<,'/ P??(Q]:!+&9FB$BF55#%,\@'(!QZ<'\C7#?$
M32S*^B:@U[<B*WU6P2*S1@L08W*@NP RQP< $X&.!DYK2\3R'3O$?AC4HN'F
MO3ITP'\<4L;, ?H\:$?CZT =/++'!$TLTB1QJ,L[G 'U)J.VO;2\W?9;J&?;
M][RI V/KBN0^)[RS>'++2;>W%S-J>HV]N("X7S%#>:XR>@*QD9]ZP;=H=(\=
MVUU?:#I_A<6VF74R&"1"EVHV;A(R*-H3@\@]>.F" >J45YSHOBO6I?$VBV=U
M=&YCU%)GG1M*EM8X0B;MT3R8+C)5>1SN!XZ5)H_BC6I-?\C5;R"TE0S27.FW
M-JT6(%SMDMY02)<?+GV)^[B@#T!)8Y0QC=7"L5.TYP1U'UIU>:^&=7UO7;>V
MLM.>RTEVL4U2^N%M V7N'=HU"9 SM!9F.23CIDFN[TZXNXM#AN-9>T2Y2'?<
MR0,?)! Y8$]L<\]* +;3Q),D+2H)7!*H6&Y@.N!WJ2O$X/$%IJ_C31/%3S3"
MZGU=;.UMW@D41631R1J<D;<N[ASSW4=JZ?7?$FO2Z/XFUG3;NUM;#2'EMHH)
M(-[W+QC#DMD;?F)50!U&3G.* /0([F"4H(YXW+J77:X.Y1QD>HJ6O*X;ZZ\.
MH=,L(+476F6VEZ/;RM"&<S3,#*"W7:%VMCUYKI]3U_5AKVMV.D0PW#:?I231
MPOQONI&?8A.1QA.G^T.: .MH!!&1TKRF_P#$VM7/@WQ$T.L1R3Q6T</ES636
MUW;7$C; C1GC:V1M8'KG[U7I;[7M*_M#1['5+6&P\/:-%)/=O:;F:3#D*J[L
M ;$7.<_KD 'I%%>;-XOU_1_[+U#6I;62&YTBXU"ZL8("I@$4:,,.6))+.%YX
MY]LU-H7BCQ!<:KI7VQ+J6*]W?;(3HT]M'9#RRX997 # $!3GKNR,=* /0Z,\
MX[UYOIWB;Q-<Z?X;UB:YM%@U?41!'9+;\M Y=@Y?=D,(USP,<<YS6G\.8[V:
MRU;5[N]%RNHZC,\7[K9A8V,0/4\%8U(';WS0!U=QJ5C:2>7<WMM"^,[9)54X
M]<$U8CD26-9(W5T89#*<@CZUY;!(-1\9^*;^3P;-KT?VJ.R@EQ;%(_)C 9?W
MK@CYV;.!CIZ5-HEMXCT>YL?#-@]CITMVMYJ5R@C\Z.PC:5?+CC&0#C<P[#.3
MR!@@'IU%><?\)/XA_P"$57Q>+RU^P>>BQ6!MOFGA,HCW%]V1(V=P &!D#GK5
MZY\6:E&VL:7"(7UK^U?L&GH5X"/$DHD<=U169CZ[<=Z .W66-I'C5U+IC<H/
M*YZ9':B26.( R.J!F"@L<9)Z#ZUYTVN:N-,U35-.M49WUEK26YM;,2S?9H1Y
M;2[ 09&#J1WP&X!Q3&\52R6VBR7MSIVJVAFN[XW44!R;>VC+!BC?ZN42%0?3
M';.  >E45P<.M^)+2/P]JFH7-H\.L744#Z='!CR%E4LNV3.69<#=D8/.,52B
M\4>)+C3++6UNK-+2\UH6=K9BWRTT#7!C#,^[@[ 6&!VR<YP #TFBN E\1ZZO
MC!K"6[@L0]XL=G;7-JWD7D'&XI< G][C<0O'( P>M=_0 R26.%0TLBH"0H+'
M&2> /K3ZY#XB_P#("T[_ +#-A_Z4)6+JGB/Q/'9^+-6M;ZRBM= NG2.V>UW&
MX5(TD8,VX8X; (&<T >DTP2QF4Q"13(%#%,\@'H<>G!KF?B"TTGPUU^2WF\A
M_P"SI7W;<G&PDC\1D9[9S7.6UEKTWCUH++5[>WG7P]:F:Y:TWECYLVT!-P '
MKUZ>] 'IE%>6I\0-5U.WT&WC\RTGN].-[=SV>FRWI!#^6%1%SM!(8DMGL.^:
M[7PCJNH:OH0GU2TEM[J.:2%O,MW@\U5;"R!'^90PP<'H<B@#=HKRO2_'NO:E
M'9ZM!;WD]O=72K_9T>BS[$MR^W<+C&TL%^8G[IP1[ULGQ7J@+:+F'^W?[:%B
MIV<?9S^^\W;_ -<,C_>% '=T5Y7!X]UZ]5M5L[>\GA^V-%'IL6BSNKPK*4)^
MT ;=^ 6_NC[N.]6]3\2>)XK#Q3K%M>V4=KH5X\<=JUKN-PB(CL&?=QPV!@=>
MM 'I-%<5X?6];XF>*9)+T/;B"SQ#Y6,95RO.>W/US[58N[_7-7\5:CI&DW]O
MIT.FV\+R2R6WG-+)+N(&"P 4!>>Y)ZC% '3SWEM:M$MQ<PPF5MD8D<+O;T&>
MI]JFKRG2;J\\6^./#&J7C6R;=-NI&MS;B14DBGCC<H2<C+#(;J!QSFNL\7ZW
M<Z9<:?:V^IPV7VCS"VRSDN[E]H&!'$@.1D\L>G'KP =517,^!==O=>T.XEO^
M;BVO9K4OY!A+A&P&:,DE&QC([&L"S\5:TGBB*SU>[33FEOG@6RNM/=8I8LL$
M,-P"59R IP<9R1@4 >BT5Y3H&I:Y86S:;!J$,E[JOB.^MDN)K?Y8!&\KR/MW
M?,2$^5<X&>^*TKOQ7KVEZA=>'9)[2YU(W5G!:WY@*J$N-_S/&&Y9?*?H0#E>
MG- 'H3RQQ;?,=4W,%7<<9)Z >].KS7QA-K.DZ?9/J\\6IQV^M64MN;2 K<2#
M<<H8QQG(PI!YSVQSU7@[5;O7M CU>ZF@(O&+Q00J<6ZYQY;$\LX((8X'.0!Q
M0!O22QPQM)*ZHBC+,QP!]30LL;NZ*ZLZ8#J#DKGD9]*\I\8W^NZ]X)\67T-Y
M:P:=:S3V:V;6^6D2)MKN9-V0Q() QC  YSFM?4/$%YI.L>)+R""U6VT^_LOM
MC+" \EN\2[V9NY7=D$] N* ._>6.+;YCJFY@J[CC)/8>]$DL<*;Y'5%R!EC@
M9)P!^=<!J'B&[O=51Q#:RZ;'XAMM/MO-A#'<JMYL@)Z$.=H(Z;3ZUD:W?Z[X
M@\'Q:X]Y:IIL^K6ZK8BW^9(DO$16\S=RY*@D8Q@D=LT >L45Y=?>.=>FO-9G
MTR*Z9=.NY+:WL8M&GN%NC&<-NG484L<@8^[QG-6[_P 0>)[A_%=U87EK9VVB
M(DT4$UH7>7_1DF9'.X;1DD<#//MR >BDA5+,0 !DD]J1'22-9(V5T8 JRG((
M]0:\_N-9U[Q,NMIIEU:V-O86<68I8/,-Q)+ )2"V1M4!E (YSD]L5TG@?_D0
M?#G_ &#+;_T4M &]17'>,]9UC2KZR6U-Q;:8\;M<7UOI[7C1R KM5D4Y5<%B
M6P>@'%8$^L7MSXA\*ZW_ &K:W$"Z/?7$HLXB8Y3&8M^W<<C/ P1E2".<T >H
M45P%KKWB.TM/#NM:C=V=Q::S/!%)916^S[/YPRA1]Q+;3@'(YY(Q5GP]J?B;
M7;.P\0)>Z>EA=SG.GR0E2D&XJ"),DF3@'&,')''6@#M(Y8YHQ)$ZNC=&4Y!_
M&G5Y9\*_$%UJ5IIVC0XM+73[,RRB>,^9>;G< QYX\M2""W))XX')ZCQIJVL:
M7_9YT]+A+*1W^V7=M9&[D@  V8C!S@G.3@XQTYH ZNFM+&CHCNJLYP@)P6.,
MX'KQ7G\/B36M5'AJUTW5]-=M0-VMS>Q6S$ 18P5C8@J_."IZ$GJ!55=5OK[Q
M;H%CJ3Q2W>EZ[<6K3Q)L69?L3NK;<G!PX!&>HH ])CECFC62*171NC*<@_C3
MZ\H\/SWVHZYX%N8Y[>TADLKYFMH+8*GRR(&P >,@CZ8/K78Z_J>IMXBTO0-*
MGAM);N&:YFNI(O,*1QE!M1<@%B7')Z 'B@#IJ*\WG\4^)#)#HL5Q9)J::Y_9
M<MY]G)1XS;M,L@3=PP&,C.,CT-=/XBU:]\->#);XM%>:A$D40=DV(\KNL88J
M#PNY@2 >G>@#H:*X;5M2\4^&;5O/O].U%[M[>VM)'@,)BGEE6/+("0T8#9Z@
MY&.<Y%37/$GB#PJNK6=U>VU_,FC3ZE:7(MO+*/$55D=02"/G4@\=P<]: /1*
M;YL8E$6]?,*E@F>2.F<>G(K@TN_&#^)H-$;6;!/MFGM?F9;')MRKJI1 7PP)
M=>6YX/KQCZ5?ZYXF\2>'KZ"\MK&]FT.Z%S,(/,'RW$:G8I/!+*#SG )]J /5
M&EC61(V=0[YVJ3RV.N!WIU>=67B6]O=7T2*]M[-[V"YU*TFG6'JT"XWQY)*!
MAC(S[4W1/$?B9K/PAJVI7MG/;:ZZ0RVD5KL\HM"\BNK[B2?DY!&.>,8H ]'I
MCRQQ[=\BKN8*NXXR3T ]Z\R?QOJL>I6,\>IPWL$^J1V<L%MILIMDC>7RQMNB
M &<9!XX)R,5!I<]]9+,UU/;WPF\8_9P)K8?NSN(+KR<'ICTQ[T >KT5YP_BG
MQ#_PC,WC-;FT&FQW#8TPV_S- LIC)\S=GS, MTQVQWJ/4/$WB>'3?$6N17MD
MEIHVHR0)9FUW&>-67.Y]W!PW&!VYSG@ ]+HK#\7:U/H/AR>^M(XY+HR100"7
M.P/)(L:EL<X!;)^E<OKU]XATT7FAWNJP77V[2;JY@NX[3RWB>(+O4J&(*D/P
M>H/K0!WUM>6U[&9+6XAG16*EHG# $=1D=ZE9E12S$*H&22< "N5\'VD^E?#?
M3Q:16\UU]@6:*..(0J[F,%5.._0%N_6N9L_$^I7]AJ=AJNH!;F32;B26PN].
M>TFCD"<^43E9$Y.>2>ASS0!Z@CK(BNC!E89# Y!'K2UYQX8U#7M)B\&6][?6
MEQ8ZK9^7Y"V_EFWV6_F*0^X[N%P<COD8Z57L_&VK-JNC/_:45_;W]\+6:.WT
MR5+5 P;!BN6 #D;1ZYYX% 'I]%>72>,/$MMH4VLRW-M(EQJ<FEVEM%8M(8R+
MAD$K;6W.0JM\@')QSUJW!XG\4_9-9@M+*\U&6"U2>TNKC29;0LQ?:Z%'VAV5
M?F&",]/>@#T:F2310E!+*B%SA=S ;C@G _ $_@:Y/P9X@GU:ZO[6YU1;MX%C
M<136+V=U%G((>-N"O PP]P:BNYVO?&^M&15>/1M(0PQN,J9)_,+,1W^6)5^A
M;UH [)'26-9(V5T8 JRG((]0:=7F^BZMX@U>31M*TR[L=+MV\.6E^S)9A]CL
M2NU%W !>!QV P.N1+I'BG7?$Z:'8VL]MI]U<Z?+>WER(/,'R2"(+&I.!ELDY
MS@<>] 'H/FQ^;Y6]?,V[MF><=,X]*=7EVJ:EK&D:U?:C=R6;ZK9>%KN3S+<$
MQ,R394[3R,@ E<\'(S71:UXJN=(O-'8JCV\^FWEY<(%^9C#'&P"GM]XT =:T
ML:,BNZJSG" G!8XS@>O -$<L<T:R1.KHW(93D'\:\T8Z_=:QX$U+5;^TGAO+
MMIO(AM_+\AVM96"JVX[EP2"3SD ]\4WP[K6N:I!X:TO3)K#3([O2I[N9H[,,
M(RDJ*!&F0!]_O[T >GT5YWIWBG7M972-(CN;6UU&>6^6ZO1!N7;:R^7E$)QN
M8E3R2!S[5O\ @[4]4U"/68=7EMY;BPU)[19((RBLBQQL#@DX)W$GGVH Z6BO
M+]?\;ZKIT^H7=KJ<-PEE>"(V=MILLL(CWJI$ES@*LG)R < X&#7J% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5B>*M)GU;2%^Q[?M]G<1WEH&. TD;;@I/8,,J3_M
M5MUA^)_$+>';:Q>+3Y;Z>]NULX88W"$NRL1DG@#Y>3VSGM0!<U+2[?6[.VCO
M$D013PW2J& *O&X=0<9'4#-4M3TNXU3Q/I$LB :?IN^ZW%A^\G*F-!CKA59R
M2>Y7'?&/<^/;B"YN+5-%5[FQA22_B:^C3RF9=WEQD_ZQ@N#V'(YJ_:>-]-NF
MN9"&BM(],CU6*=CQ+;L&+''8J5P1[B@"OXRT.]UBZTV6TM9W>R9Y(YH-1%JR
M.PVG^!L_*3Z=36&OA34'BOEOO#SZC+>VYM9)[W73)(L1YVH?+PHS@\#J!6JW
MCZ61[>WM-'#WILHKRYAGO$@$"R E$W-]YR >, #N13D\?_VA/I4.AZ//J#ZC
M9M>+NF6+RD5PCAR>X)QQGG\Z ,R'P[K"WPO;S1)-1N/LLEFS7FMAPT3XW+@1
M #[O4 $Y.<U#'X4U80^3/H]Q<QQVLEI;"?7 WV:.1=K!#Y(YV\9;)Q6]H'C>
M3Q!>1FVTDG3Y99(A<)=(\D)7/,T0YC!VGN>2,XS56U^)%O<O:W7V )H]W<BV
M@N_M2&0EFV*[1=51FP <YY!( H HWOAO5KN0-'H+V:M:I9S)::WY8GA3.U'_
M '6>,L,C!P2,UHZC9ZUJ7A]M#D\+V\.GM&L1B@U8)^[7'R?ZKA2!@CTXK9\4
M>)(_#5E:S/"LLEU<K;1"2988PY#-EW;A1A3Z\X&.:Y_7/%6O1Z=H\UII#6T\
M^KQVLT;SH5D0\C8^""K?WL C!XH M:I!KFKZ=%8S^%[9(8I8IH_*U4*4:-PZ
MX_=<<J/PK$O_  KJEV]ZS^'YC;7-P+R6QBUP+$\P8-NVF+JQ49!.W)S@'FMR
M\\=2P)J5]!HD]QH^F3/#=WBS*&!3_6%(SRRISDY'0X!Q4UUXQN6O+^/1]#GU
M6WTX)]JEBF522R!]L2GF1@K XXZ@=: .;B\/^)+VTOFO]!2*YN]4_M..6'55
M26W9558QGRV!VJH'<')J<>%M0^RZA$_ALR27TT5Q+</KA,HEC V.K^7D$%<^
MGMCBK&E^,9$\2ZWI2B:_U"74PMI9EMIA@\B%F=L_<0%CVR2< $UT_B?Q#%X9
MT?[?-%YNZ:.!%,@C7<[!06<\*O/)- ''2^%]7N;6[CNM&FGN;IX'DO9-:7S@
M86W1@8A"@*<G&WN<YJW/HNKW-EK-K-X<1EUC'VMSK W, BQX!\K@;5_4^M:-
MQXUN;'1#?76@S^=]LAM8X8)TD6<R$!6CDX##)QSCD5F>)O%NH)H&LV4MK+I.
ML6D=O.GESB0/$\P7<K@#N&4@@8]\T 6;S3]6O[Z6ZNO"EK*9;%M/:,ZK\GDL
M<L,>7WP.?851L_#NLVQ9Y=&FO)1;/:0R76N;VMXF&"(_W0 ) 'S')X'-&K^)
M]3M)9ETB.XF<>)8K*87%PN,%(VV)E?E1L_4')SS71V=_/:^.KS1YI7DAN[-;
M^W#MGRBK".5!_L\QL/=FH R8].UB+^Q0GAB +HR%+1/[6&!^[\O)_=<D*2/Q
MJ3P_:^(/#>DIIEGX?22VC8F,3ZN&* _P@^4.!75ZE>KINE7E\R%UMH'F* X+
M!5)Q^E<DOQ N/L&GS2Z"\$^JG=I\,UY&OF1; [2.W2, $<<G)'% $VCQ:_HE
MG);6GAFW*R3RW#M)JP+,\CEV)/E>I_*G1KX@CUN?5QX9MS=36Z6Q)U4;51&9
M@ /*XY<Y_"HX_B!%-;"&+39)-9-]]@%@DZ,#)L\S=Y@X\O9\V['MC/%73XFU
M1;)M_AF\74%N?LYA,@\G&W=YOG8QY>.,XSNXQF@#G;;PSJEM/ 1X?:2SMI_M
M-O82:UFWADR6#*OE9."20"2 >@%7X=-U>#Q1<>(E\+6YU">(1%FU;*J  "5'
ME\$A5!/^R*</B(!IMS*VD227MMJ,6G/:V]PDH9Y I4H_ (^8=<8.<XINJ^+Y
M([*_LM3L;O3=0M9+20I:W2MYD4LZHK))MZ;@58$#C([YH H_\(WJ\=KI\5KH
M3VD]@93!=0:R!*/-;=(#F$JP8\\CL*DL?#NH6,HD7PK#,3;SV[^?K&_S!,X>
M5FS%RS$#)_"K>F>*-;^W>*_M&E37:6.H);VD-NZEN8XL+T&!\V\L3P"?2L_7
M_&UY+H6OV7D?V=JMC#;SA[:[692CRA>& !!X((([B@!^G^'M9L+BVF.B2W1L
MXVCLEN=;WK:J1M^0>4.<<;FR<<9JS!I&K6]AHEE'X8A^SZ,ZR6JG5QRRHR M
M^ZY.&)^O-:4.LW@U'Q FG64]_-:W\<4D4]VJ(@,"/E,KPO(XYY).>U0:;XVO
MM4T5]0M_#D[[KK[-;^7<*T<H&=TIDP L8((W8.3TSF@#+T_PQJ5K?6>=$D^P
M6MS]H@LWUD/#;N2?F5?*#'&XD M@=J[NQLA8PO&+BXGWRO+NN)"[#<<[03T4
M9P!V%<%K/CW4I?#>I/I]BD&IV&H6EK<*ERDJ!99$Y5\8.X-MZ KDGM6D_BU=
M-O\ 61);7L]Z+NUM8K+SE96FEA5@D9P J\DL2>Q/M0!TVKZ/:ZW:PV]WOV17
M$5RNQL'?&X=?PR!5.;PKIL^F:WI[^=Y&LR/)=8?G+HJ':<<<(*Q[SQZVDVFJ
M?VMH\UO?Z?#%<&VCF64312/L#(^!G#9!! _7-:.D^)+J\U^71M2T=].NOLPN
MXOWZRJ\>[:<E>C D9'(YZF@#6U#3+;4](N=+NE+6MS T$B@X)1EVGGZ&J6E>
M&[72;P7B7%U<7/V1+,RW$@9FC1F9<\#G+GGTQ6C?W0L-.NKQD+B")Y2H.,[0
M3C]*X^/X@SMINGW,N@O!+JI!TZ&6\C7S8]F]I';I&H&/4G(XSQ0!HCP+ID-I
MIT-E<WUE-I\30P75M,%E\MCED8D$,"<'!'!'%;&CZ/::'IRV5F)#&&9V>5R[
MR.Q)9F8\DDDFN<3X@0/8R#^SY&U9+Y-/%C%,CAY77>I63[NPIEMW8 \9&*@U
M#Q!JTNIZ!;W%A<Z5-_;*V\Z"3?%<1FWE<;7 &Y<@9& 05H T8O >EPW$92XO
M_L,=S]JCT[[1_HRR[MV0N,XW?-MSMSVK1/AO33XJ'B/RF_M$6WV7=N^7;G.<
M?WNV?3BL6?QQ<6>H6:7NAR6UE>7JV<4DMR@GW,VQ7,/4*3COG!!Q3]+\;2:O
MJSP6FDM)9I=R6DDR72--$R,5+20]53*]<YP0<<T 3-X#TMKAR+B_6Q>Y^U/I
MRW&+9I=V_.W&<;OFVYVY[5<F\*:;/I6LZ<_G>1K$KRW6'YW.JJ=IQQPHK-TC
MQM)K6I^5:Z2SV0NI+5IDND:6%D++NDAZHI*]<YY''-<Q+J^IZO?^&;"R;4A8
M75]?>?)_: CF<Q2NI4LJ@[%QD#N,#MF@#T"'0+6W\13:U#-<I// D,T0D_=2
M!<[6*X^\ 2,^]5]5\*VFIZD=1CO+^PO'B$$LMC-Y9EC!)"MD$<9.",$9.#6'
MI'B^232M)M-+L;O4M0O(YYPEU=*I2*.4J6DDQZD  *?TS6A+XJU(VEL\'ANZ
M2>1':=;V9;>.#8VW!D((8D\K@<CGB@#0L/"^EZ7=6$]E"T/V&T>S@0-E1&S*
MQSGDG*#G/KZT:OX:MM6U"UU 7=Y97MLCQ)/:2!6,;$%D.001E0>F1CBN73QM
MJ&KZCX0FTNS*V6I37*7,;S)G,8=6&<'(4J6!!^; JQI7B]VTW3;33;*[U+4;
MQ[MTCN;E04CBF9&=Y,<+D@* ">0.Q- '2:#X?LO#EI/;6)G,<UP]PYFE,C%V
MQN.X\G)&><\DUG1>!M,BO(I/M-^UI#=?;(K!I\V\<NXL& QGAB6 S@'M5$^/
MV?[';0:)<2:I/>2V$EF944PS1IO.6Z%=N&W#L>F>*VO#FO-KL%Z)[)[*\L;I
MK6Y@:0.%<*K95AU!5U.<"@"D_@72G6[43WR>?>G4(RD^#;3DL6>(X^7)9L@Y
M!STQ3AX&TEK&[@GDO+BXNI8YY;Z6<_:/,C_U;*PQMV]@ !UXY-5+WQQ- =4N
MK30Y[O2M*E:*\NUF56!09D\N,\N%[\CH<9JS:^+9M1\43Z3IVDO<6UL(GGOO
M/545)(]Z$*>6/L* '0^"--1Q-//>W=V;J&Z>ZN)0TCM%GRU.  %&3P .I]:U
M--T2TTF[U">S\Q!?3?:)8MWR+)C#,H[%L GU/-4=7\13VFLPZ/IFF-J&H/ ;
MET,PA2*(-M!9B#R3P  >AZ8KGY/&FHZAK7AA--LGCAN;RYMK^WFD5722)&#(
M>#]TC=D'G ]: -35?A_I.K&_22YU&&TOW\VZM+>XV122<?.1C(/ )P<$C)!K
M6/A[3VEUAW1I!JZJMVC-E6 C\O ';Y17&>&O&FJ6VC6LVI:9<3V,FJ2V3:B]
MPI8,URZ(0G4H"57.01CH0*T;[XCP6DM_.EAYNEZ=.UO=77VI%D#*<.4B/+*I
MZG(/!P#0!LVWA#2K31M*TN)9A;Z9<+<P9?+&123ECWR6)/UJE<?#_2;B5@;G
M48[0W0O!91W&(%F#A]P7&>6R=N<9)( /-3V?BBYU#Q7>Z/::/));6,B)<WQG
M4(N^(2+M7JW7!].#WIVI^);F#7'TC2M(DU*Y@MUN;G$ZQ+$C$A0">KMM; X'
M')% $5]X%TR^N;QS<ZA!;7S^9>6<%QLAN&P 2PQD9  .TC/>K[>&=.:+6H\2
M!-87;<@-C \H1?+QQ\JC\:XOPUXL:+1M$OM3FU&>4Z->WLHW@AUBD3.Y,9+X
M.!SQR.]:T7C/4M0T"_O;;1T3;8/=6MQ#>1SQ$@?=9@/E<9SC!!P>: +]WX&T
MRZ<F.YU"U$MLEK<K;7&P7,:#:H?CJ 2,C!P<9Q5RPT%M,OM-%K=3+IUCIQLE
MMVE)#D%-CD=,A4(SU^;MWY[2_&FKO:Z!8'0Y+W5+W34O9&%RB*$!52[$C&3N
M!P!U./>LZV\2ZF^H^%CI4-]?)=Q:D'M[BZ4;C',@#2/C&%^8#@GD#WH [35_
M#EOJU]!?+>7UC>0QM$)[.4(S1L02K @@C(!Z9':JJ>"-(A&D"W-S#_98D$6R
M7/FK(0TBR9SN#$ FH+#QM%>W.FVCV$L%W=7T]A/$[@_9Y8HFD.2.&!"C!'9@
M?:LSQ-XQU&(20Z1:'SK37;33YBTJCS%?RF(&0<!A)MSVZT :]AX&TRPN;-Q<
M7\]M8/OLK.>X+PVS8(!48R< D#<3CMBB#P-I<%Y%*LUZ;2&Y-W#I[3YMXYLE
MMP7&>&)8#. >0*SX/%PM&OH8;6]O=1FUA[*"TDG4@N(E=MK8 2-5R>YZ]<XI
M]QX^-C:7BWFC7":G9W5M;RV4<JN6\]@L;H_ 8'GKCD$'% &G:>#M*L4T<6WG
MQOI.\6T@?YBCYW(W'S*>#CU /:K6L^'[?69K6X-U=V=W:[O)N;20(ZA@-RG(
M((.!P0>@JMH?B*XU'5K[2=0TMM/OK2..;9YXE1XY"P5@P YRC @C\Z@O_%%X
MFL7NG:/HDFIR6$:/=L)UB"%AN5%SG<^WG' Y'/- &5?> E_M7P^NGS7D-M9R
M7<]Q>)<8G\V4 [R3]XL=V>",=L5N6?@[2[)[&2,W#S6EU)>>=)+N>:9T9&=S
MW.UO;&!C@5S"Z]>>)_'?A_[ ;M=%DTXZ@OE7?DESOC&9% RP7)4IG!R:V]<U
MG5K/QWX<TRT@#V-VD[3GS%7=M"\\C/R@YP#SGVH L0>"],M1HWV:6\A;2#)]
MG9)<%E<@NC\?,I('Y5=UKP]:ZU):SR37-K=VC,;>ZM9-DD>X88<@@@@#(((X
M'I7&^$/&FJ+H&A/JNF7$EK>W)LQJ+W"L[2L[!24Z[<C;G.?;%:'_  LBVW&[
M^PC^QA=?9?MGVI/,SO\ +W^3][9NXSG..<8H V+7P;I5HEGL^T/+;7K7_G22
M[GFG9&0LY/7Y6(QQT&.E:NIZ9::QIEQIU]$);6X39(F2,CV(Y!'4$=#61XVU
M>\T?P^&TYD2^N[J"RMY'7<L;RR!-Y'? )./4"J\7A74M.O;*[T_Q)J4[I*OV
MR+4)O-CGC/WL+C"-W!7 ]1B@!W_"!:5-'<C4+B_U&6>%8//N[C,D2*P=0A4#
M:0P#9ZD@9)Q2_P#""Z;+;ZC'>W5_?37]J;.6YN9@TBPG^!< !1GGIDGKFJ<O
MCUH[>;51HTS>'X+@V\FH><N[Y7\MI!'U,8;(SG. 3BHK_P"(<UE_:=ROA^YF
MT[3+W['=7*3H&W$J 40\M]]<\CKWYP =0-&M1K<.K#?]IAM&M%^;Y?+9E8\>
MN4'-8@\ :7%]A:TO-1LYK&&2&":WG"L%D?>P.00<GU'Z@&JUSX]ETRWUDZKH
M<UM<Z;;17?D).LOG12,R@@@<,"I!'Y$U=M_%ERFH-8ZKHEQ9W#VDEY:QQR+.
M9T3&] %QB0;E^7D<\$T 6;7P?I-F-.\A)@;#SC&QD+%VF'[QG)Y9CDG/J:?#
MX5TV'3M$L$\[R=&D22UR_.5C:,;N.?E8UF67C2X?7+;2]3T?[%-=P230!;M)
M6&P!BLB@ H<'W'!YJOI7CZYU%-$N9M FM;#6<):3O<(Q\PQLX5E'(4A6PW/0
M9 S0!8C^'>DQ0VML+S4VL[.Y2YM+4W/[NW=7WC:,9(SQABV 3C%6U\%Z8M[-
M<"6\VR:@FI>29<QI.N?F48X!SR,]ATJ.R\9P7UAH4T-G)]HU6X:W^S%AN@9
MWFEC_L;"/<X]:H/XAN_##Z=X;\O^U=5-JUPTEU?+%Y@WD;59AF1^V,#@ G&:
M +S> ])>X;,U]]@>Y^U-IHG_ -&,N[?G;C.-WS;<[<]JMS>$],GTC5=,?SOL
M^J3O/<8?G<V,X..!\HJ^-4B30_[5NXI;.)+?[1-',N'A4+N8,!W'/Y5S6F?$
M".\O-.2\T\65MJ>?LDOVN.1L[2X$J+S&2H)ZGI@X- '3ZKI=IK6F7&G7\7FV
MTZ[77)!ZY!!'(((!!'0BLFV\&V,+W4US=W]_<W%JUGY]Y/O>.%NJK@ #/!)Q
MDX&2:S+?Q[/.NDW9T&=-+U:Z2WL[HSJ6(<G:[IC*@@9')]\5>;QG"OAJ?6OL
M<FR+4#8&+>,DBY\C=GTS\V* -J+2K2/1$T@H9+-;86I1SRT87;@GZ5B6W@73
MH2#/>ZE>B.VDM;<75QO^SQN K!.!R0 ,MD\=:P-5\3ZI:RNND1W$[?\ "2I8
MS"XN%P1Y:-L3*_*AS]1SSS6__P )I"-+GG-E)]MBU/\ LO['O&YIBX5<''0J
M0^?[M &@?#.G,FCHRR,FDH4MP6Z@Q&([O7Y2:R[7X?:9;#34-]JDT&F3)+8P
M2W.4@V] !CD8X^;) Z$5H>*/$D?AJRM9GA662ZN5M8A),L,8<AFR[MPHPI]>
M<#'-9]SXU>QTB">\TF2&_N;O[);VIG39*VW=O67IY>T$[L=L8S0!>;PAI3Z!
M)HS+,;9[A[H,)")(Y6D,N]6'((<Y%5QX'TV2WODO;F_OIKU$CDN;FX_>JJ-N
M0(5 "X;YN!UY.:II\0;=;.]$]@XU.UGAMA903I*)GF.(MD@P"#SDG&-IR..;
M!\77EI+#!JN@SV<\M[!:J5E$D3B7.&5\#.-IRN 1QZT :.D>&[;2;Z>_:[O+
MZ^FC6%KF\D#N(U)(08  &23TYSS5>\T24^+/[1A3?:W]B;&^ 8 KM+-&XSU^
M](I[_,O8&JVM^-X=%;6P]A-.=*6T9A&PS+Y[E %![C'XUBZWXHUBU@U>;[!<
M6.K6^@S7:6QNTDACVNP#\+@N -WH0,>] '6:7X9T_1[FWN+7S=]OI\6G)O?(
M\J,DKGWY/-4?^$&TR*ST^&SN+ZSFL%D2"ZMY@LH1VW,I)!#*3@X([#%9 \8K
MI3M>ZREY'+#HD-U+ DRO&Q:5D7:,#]XQP,YQR!VS5J/X@1VYNTU;3OLTT%C+
M?HEM<I<B6./&]05QAQD<=.>"<&@"_;>!M#M4=%AE=)+*6RE$DI;S4E??(6/4
MLS$DG/>F:?X&TVROK:[EN]0OI;:![:+[;/YBK$P *8P!C '/4]R>*E\-^);G
M77_>Z6L,#PB:*YM[M+B)N<;2RXP_(..1[TFK>+X-'N=7@N+60O86*7L05A_I
M(8LNU?0[E"_\"% $-CX#TRQOM.N5O-2E73'+6,$UR6CMP4*;5&,D8; R21@8
M.*N:3X3TS19K"6T\[=8VCV<.]\_NW=7.>.3E1S7/:QX\M;GP_#-!%>(MSIL>
MH2/;3!)(%:5$5,D'DEF'3HC5E^(?%/B"&+QJ-DD4.FW5FEJ\$J[U#-"2H  )
M+AB>3QG% &UKGA5K2"P&D:?<W(AN[BY:2VO!!=1/,2S&-FPI4DD%6[8]*O\
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M6;V5]%/("ROO<1XSM/1=I)W!N?R- %R[M+G4_#,]E<%(KNZLVBD(&51V3!_
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M'!522P;/RE>><8)S4D?C7P_)87EXU_Y,5EL^TBXADB>(,<*61U# $]#C'Y4
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M#@;R%5"Q4$XW8P>.:F7Q7%>:WX>ATR2"YT[58+F7SP#G]ULQCICEB"",\=J
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MR2PW D_-DGIQTIMSXV\/VFH/9S7S"1)A;R2""1H8Y"0 C2A=BMD@8)[TV_\
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M3Q3[Z#4O#WC*\URSTN?4[#4[:**ZBM63SH9(MP5@KLH92KX.#D$5V.><=Z*
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M%MK9B;1I(V89"W .#D=2C*K_ $#5[!5*71].GU:#59;*%[^W0QQ7#+ET4YR
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M QA""5R,]!BJVC:!K&GGPS'/ILQ'_"-MI=PZ,A%M,?+/S_-]WY2,KGFO3**
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MV ]NF>*[JD95=2K*&4C!!&0: /%@/(TK6([>^LF\/C4;$7T6D^9]F@B+?O\
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MMDT)&$,A)3<9G&['3(&<'MFNZB@A@W>3%''N.6V*!D^IQ3]J[MVT;L8SCG%
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M0RW%[K+:AK$EKL19%CC,< ?)VQH!P6(RQSSCI702P0SJ%FB20 Y =0<'UYH
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M:PD\.7WB:S\+0-9"30(K@Q6N1\_G.KR #^/R\\CG@=ZL>#([2+QE9C1[[0Q
M]C(US;Z/YCK*N5V/*22 X.<$_,<MUKU+:N[=M&[&,XYQ3(H(8-WE11Q[CEMB
M@9/J: )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+(D0!1MOS*CD8! X!+<=,=3XNU*_TK1K&"RN1'=WM[;V(NY$#>5O;!DV]"<
MX'3)'TJ]9^&-'T_^S_LMDL7]GB3[-AV^3S/OD\_,3W+9/>KFIZ99:SI\MAJ%
MNL]M+C<C$CH<@@CD$$ @CD$4 >9^,Y-4LM*\3^'9];N[RW.@R:A'/+'$)DP2
MC1L50 HWK@$8.#7<7":AIG@:9;"\6;4(K-OL\]YL0%]OR[L!5 S@= .F:6'P
M;H<-EJ%JUM-.NHQ>3=R7%S++++'@C:9&8L  3@ C&:UKJPM;W3Y;"Z@2:TEC
M,4D3C(92,$&@#RG4M7O9/"OBK3=2OM8%R=#GF%EJUI$CY (9XY8@$9/F QR1
MD5MF_P!6\,:G8QWWB!KFUN])N;F5KN!!';20K&0R[%#;,.<J23QUS70P^!]!
MB@NX7M[BX6[MC:2-<WDTS>2>L:L[$JOLI';TK0OM TO4I(GO+19C%;RVR!F.
M/*D #J1G!R%'7TH X31-?UE/%6@6\M[K-S::G',)FU&TA@C=EBWAH54"11QT
M8'@CO6?:^(/%$7@OP[J,VKWMY>>()HHB(+6#-NH1W8Q @ NP4#YB1G) Z"N\
ML?!.A:?>V=[%!<R7-ED6TMQ>33&%2I4JN]CA<'&.G3N!5A_"NBR>'[?0FL_^
M)?;!?(C$CAHBOW2KYW!AZ@YH XQ=7\7#3M7L[<7QDAEMC:RWPMH[QXW8^:B@
M'RRX"G86 SGOBM_P3JTM\VI6ES?ZC-/:R(3;ZG:+#<P*R\!B@"N"58A@/;)J
MZG@K05TZZLFM))5NI%EFFFN)'F=U^XWFEMX*XXP>.U7=(T#3]#\]K-)C+<,&
MFGN)WFED(&!N=R20!T&<"@#A]<UW6],U^_N;W4-1L],@N4$%Q:VT-S9)%A=R
MS@#S5;);)R ,@CW6[U'Q ]CXPUJ+Q"\*Z)=3"UM!#$8F6.-9"LA*[CG) P01
MUYKJKSP5H5_?S7<]K*6N'62XA2YE2&=EQAGB#!&/ ZCG'-9=E\/K&34M9O-7
MB,_VW43<I%'<RB.2/:FT2Q@A7(96."".: ,"\\3^(-7U?5Q8#6;6.P2)8([&
MWMW3S&A60F8RG<1\X&%QP,YSTU+#4=>\6:F]I_:<NAFTTRUN9$M4BD+SS!R<
MEU8%%V8P.N3S70ZKX.T36;R2[N[>82S1B*<P74L(G0=%D", XY[YXXZ4NH^#
M]$U-X7EMI(6A@^S*UI<26Y,/_/,^6RY3V/ H \Z\77M]JFC>(K:75894BTG3
MYFFL8X_+G9I)5?!()*' .,\8XZG.GK/B+5] N=?M+:XDN9XY--M()V@B,BF8
MLK.0 JLWH#A<XZ#-=I)X1T*6"X@.GH(KBVAM9$1V53%$28U !X +'IBIKOPU
MI%\=1^U622_VBL:709F_>!/N=_E(SP1@YYH X&X\3^)-"L]8W+J,D*6:26T^
ML1P++%*TJQG(B(#)\^[D#&TC-:MIIU]IWQ3TQ+S6;C4PVCW15KB.-70^;!N^
MXJC:>, C(P>370VG@_1+2*\3[+)<F]B\BX>\GDN'DCYPA:1B=O)X'%&E>#]%
MT?45U"UAN&O%A-NLUQ=RS,L1(.P;V/RY48';GU- &!XPUO4-+UC5OL<RQ&W\
M,W5Y$WE*2LJN-K9(SQZ=/:I--N=:T[Q1H-O>ZU-J$.KV4\LT4L,:+#(@C8&/
M:H(7YR,,6^M=+J'A_2]4FGFO+7S7GLWL9#O8;H'.67@]SWZ^]3-I%BUY8W9@
MS/8QO';MN/R*X 88S@Y"CKGI0!SOBVQDOM?T-].O[*+6K03S6MK?1L\4Z$*K
M].0RY7!'(R>"#7+ZCXDO?#QUXMH<.G^)YULP\MI+Y\,R22F)955MH##+## 9
M^7)(Z>AZWX=TOQ###'J5L9# ^^&6.1HY(FZ95T(9?P-5+7P7H%KI][9?83/%
M? "Z:YE>:2;'3<[DMQVYX[8H XR?Q3XC\/VNLR21ZG/;PZ8US#)K$<"21SAU
M7I"1NC.[/(XVD9YJUXPT[5;'P=KT%UXLEO$GT:YD,,T<*RET4%C'M0?NR"58
M$$C<,,#S75V/@_1; 76VVDN&NX?L\SWEQ)<LT7/[O,C,0O/0<5':>"=!M([F
M,6LLRW%LUH_VFYEF(@/6-2[$JOL,=O04 <=>:]JN@'4+>WO/.EBTS3$AN+B&
M/*///)&7;:JY"@@@=/E]SFWKVJ:YX3?4+-=;N-1\[0KV^AEN8HO,MIH%7##8
MB@J=_0@\K750>#M"AM9[;[$9HKBU6TE%Q,\I>)2S*I+,3P7;!Z]/089;^"]"
MMX+V(V\\_P!MMFM)Y+FZEFD,)!!C#NQ95YZ CUH Q=,NM;T_Q+X>AO=:FU"+
M6+.:2>*6&-%BD148&/:H('S$88M]:;X^UJ 7<'A^\^V0Z?/";B]FAM991*@)
M"P QJ<;B#NSCY1C^+CKCH]BUW871@_?6"/';-O;Y%8 ,,9YR%'7/2KK*'1E8
M95A@B@#RCPWJ$6J>%OAOI<9?[-)(OV@/&R;FM[<R*OS 9&\(<C(.W@U)XN\2
MZM;#Q#?:5JFJR'2RWEI9V<(M(2B LLSRC+G.<[#QD #-=CJ7AB--&TJVT:-(
M)=&FCEL4=SMPH*F,L<G#(S+GGJ#SBDO? GA[49;U[JTF>.^8O<VXNY5AE<C!
M<QA@N[@<XSD ]>: *NI3M!XY\*747ROJ$-Q:S@?Q((_-7/\ NLAQ_OGUJOXC
MM)IOB9X2D2_N(5$-V3'&(]IVB,D<J3\P.#ST Q@Y)VAHCR>*;74)=HM-.M#!
M9Q[BS;W(WNV?1551UZM5O4=#T_5;RQN[N)VN+"0RV\D<KQE"<9'RD9!P,@Y!
M[B@#S3PA)K&B^$_!-\NLS2V]]<1V<EBT48A6)P^-I"[]P*@Y+'//&*DO?%.K
MQRPZK9:IJMW;MJL=N66SACT\Q-.(RBEAYK$ XWJ3EAZ5Z'%X:TF'3M.T^.TQ
M:Z;(LMHGF-^[9<[3G.3U/7-9Q^'_ (;8X:SF:(3?:(X#>3>5%)NW[D3=M0[N
M> .I[$T 4/ MI-#KGC&1[^XG4ZPR^7((PH/D0G=\J@YP0O7&%'&<DXOB#5_$
M48\:ZE:Z[+;Q:#*C6EJD$11_W$<C+(2I8J2QZ$$9//3'?6FAZ?8ZM>ZG;1/'
M=7I!N")7*.0  VS.T'  R!DXJ.X\-Z3=6^JP36FZ/5CF]7S&'F_($['CY5 X
MQTH Y"\U?5O#>J:C;7OB(RPMHK7PN+NV0K;S"0)\JQJ"5.X84Y.0.3FJVG:I
MXAD\2?V-'J.M(M_I=Q+%-JUM;HT<Z% KHJ*"%^?E7'ICO7<:CX:TC5Y)9+^R
M6=I;4V;[F;!B+!BN ?4 YZC'6JEMX2TS2[H:G96\T^J0PO'#-=WLTC$$#Y"S
MLQVY ['') ZY ,;PUXHOO$VJ:3'$_DI;:>TVK1A0?](+&)8CQQAHYCQC[J]C
M2:[8W6H?%'3(;75)M._XDUP9)(%0R,OG1?*N]6 YP2<'@8[YK7\(>'Y=%AU&
M[O(K:/4=4O'O+E;<ED0G@*&(!. ,DX&26-6M7\+:3K=[#>WD4PNX(VCBG@N9
M(716() 9&!&<4 >?_P#"7^(+NYL="\V_DE2XOHKF\TV"'S[A;>144J)/D7.X
M%L \C@#/':^"M0U6^TNZ35XYA-;7;PQR3B-99(P 5+K&2H;YB"!CIG S4\W@
M[0I=-LK%;-H(K$EK5[>9XI8B?O$2*0V3DYYY[YJ_I.CV.AV/V/3X/*AWM(V6
M+L[L<EF9B2S'U))H \Q\13:OKW@?6-;FUF6*!=1:W731%'Y2Q1W0C 8[=^\E
M=V=W?&,5:U/Q'XDO=3\12:<=6B&EW#6]K':P6S6Y9$5B9S(0Y!+?PXPN".:Z
M^^\">'=1NIY[FRD;SY1-+$MS*D3R#'[PQJP7=P/FQFI-2\%Z%JU[-=W=K+YE
MP%%RL5S+$EP%X D16"O@<?,#QQTH X>?5;R*_P!?OT58+F>]T02(560+YAC#
M+SD=&(R/J*U9_$6L1WESX9%V?[9?5TBMY_+7(LW'G>9C&#MC62/..JCO75S>
M&-&N)+AY+($W$L$LN'8 M"08C@'C;M' X..<U.VB::^OQZXUJAU*.W-LL^3D
M1D[MN.G7OC/)]: /-/\ A*_%%Y;WFMV<>K,8;Z2*&U6&V%D8HY2A5V8B3<0#
M\V1@G@8ZW]1U[7K*+QEKPU21[?1+AX+73_)C\MB88R"[8W$!G!X(Z')YKJYO
M!&@7&H/>26<A,DPN)(!<2""24'(=H@VQFR <D=>:TH]$TV./48Q:HT>I2-)=
MHY++*Q0(<@\8*J!@<<4 <!%XA\2:),\]Q'K%Y;?V?<SS#5(K:+$L<>]3%Y1S
MM.""ISC(.>M*EKJ@\0> M0O]>EU#[7-+*\3Q1JB.UI(V8]J@A<$C!+=N>N>P
MTSP=HFD70N+:WF>58C!&;FYDG\J,]402,0JG X&.E16'@;P_INH6E[;6DHFL
MRQM0]U*Z6X92I6-68JJD,> ,=/08 %UC4KNU\8>&[&&;;;7AN1.FT'?LCW+R
M1D8/I7+7?B#7;F9[6UU0V[/XK.F"5848I;_9RY4 C&01D$YYZY'%=OK.@:=K
MT<"W\4A:WD\R&6&9X9(FP02KH0PR"0>>:K6?@_0K"*&*VL=BPWOV]/WKD^?L
MV;R2<DE2<YZDYZ\T <?<:YKNF7&IZ NKR3RC5;*RM]0N(HS+#'.@9B0JA6(P
M0N1U89S6?K%]JOA#7_$D\6H3:E=_V=IT5O-/'&9(Q)<2I\P4*K$%B1D#.5!]
M:]&N_#.CWPU$7-DLG]HF,W.7;YR@ 0CGY2,#!7!R,]:J6_@CP_;QWRFR>X-_
M$L-V]U<23M,JDE=Q=B<C)P>HX]!0!QUQK_B;2;'7AOU;R8M&GNX;C58K998I
MT'&T1<,ASGE>"O7FNZ\/VFH0Z.#J&K37US< 2F5HT3RMRCY4"J/E!R1G)YY)
MJM!X)T&&"]B:VGG^VVYM9WN;N6:0PG/[L.[%E7GH"*WXXUBC6-!A$ 51Z 4
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M8*?[N<=..*U-*TFQT73TL=/@$-NA)"Y+$DG)))R223DDDDT 7:*** "BBB@
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MF*JYSGC&SWZUBV7@G5=-T6PTZU\1JR6<36ZQW%B)(983C:'CWC+KCAP1U/%
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M[HX)ZG<PX([>]6M'T34[/49+[4]9%ZYA\F.&"V%O$HSDL5W-N<X'.< = ,T
M5-4\0:T/%4F@Z-IMG-(EBEXT]W<-&@W.Z;<*I)/RC'X^G+- \:'7;S1H5LO)
M74=,EOFS)DQM')&A3IR,N>>.G3FM=-%5/%4^N^>2TME':>3MX 5W?=G/??C&
M.U8%MX$N=,@T9M*UK[/>Z;;S6OG2VHD2:*1PY!3<,$%5P0?SH B_X3C4KI].
MM]/TJWDNKZ_O;)!+<%$06[,-[$*3R%)P![>]5XO'6N"T:^NM%LH[2TU,:9>E
M+MF<R&41;XALP5!93\Q!//3&3J:1X'72I=)D.IRW#Z?=7=R6DC :4W&[.<'
MQNZ@<^@J27P6DNC7^G?;F O-5&I%_+^Z?.679C//W,9]^E '-V'B37=&M?$V
MIO8Q76D6&KW)F>2Z;SO*##=Y:[2,(.<$C."!CO9UGXGPV.I:I#:R:-Y6F$++
M'>ZD()[EMH<B%,'H" ">K9';-79O 5Y-'JEB=?<:1JMW)<W=K]E&\AVRT:2;
MOE4@8/!/7&,U9N_!MXM]J4NCZW_9UOJ3"2YB^R+*R/M"%XG+#82%'4,,C(H
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M?V01QVHAC5=^[(&YCG.<\_EC%+J/AR^?79=8T75UTZZN8$M[E9+83I(J%BC
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M#V\H88,9AW#"  8&[(.3DY-7_"_AR/PSILULDRRR7%R]S*R1")-[XR$0<*O
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ML0C#OC+>IXX'7H.E 'FGA_6?%-W)X*E7R+J\N])NG8S73B-AN@(DDPI);DC
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M#8A@SM7Y0."HQ@\DUK3>&=;>\O[<6D1MY/$=KJT5QYX^:-6B+J5Z@@1GZYH
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M6QOFM;FWE+9RL@8 QD=NQ'>NVT.SUFT\(V]IJ%ZLVL);E6N&.\;^=N3@;L<
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M6 &20<X/ )KRF5&L;;PZ^I6MC;7-^MUJ,U_J5M)<1P33,K&(1JRCS-K  L>
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MSM# L54XP#T%8R%-.M]-LIK*RM;:'5-4%O>:A;2306JB<A46)64;F4G:6.
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M""#SW! (]Q3Z** "BBB@ HHHH *IR:1ILU^E_+I]H]XF-EPT*F1?HV,BKE%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4R6*.>%XI8UDC=2KHXR&!X
M(([BGT4 1P6\-K D%O%'##&-J1QJ%51Z #@5)110 4444 %%%% $8@B$[3B)
M!,RA#)M&XJ,D#/IR?SJ2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*DT&VF\11:U
M--<RS01E((7D_=0DC#.JX^\1QGT)]:U:* "BBB@ HHHH **** "BBB@ JAK&
MD0:U8BVGDGBVR++'+;R%)(W4Y#*?\<BK]% &3HWAZVT66ZN%N+J[O+LKY]U=
M2;Y'"@A1P  !DX  ZFM:BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTL-K+(L"LH8,Y52%7GJ3C\C0!U%%<VOC31[U+Z*QO"EQ!:/=H\]K*L;QJ/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3.'EM(EQ@D<\<=/UH XV[T^ZU&QU2ZMH;J*X&GRV=BNIZNDLV^;"NP D9%4
M#J<G'Y[^H6@BUG2O[,DM!9Z/I-PEH?M$8!N&5$C7&<C"JW.,<UI:E9>%=.?2
MP?#^FS+J-VMK$\=I$0"4=LGCIA#T]:T&\.>&$1W;1M("Q_?)M8L+]>.* ."2
MV*>%?#>GW.E3M%9684O97\,=]:72C;O#>:$*,-QZGJ,CT[+PM-J\6CZ5;ZC
MEU<2I*UY>0R1[8W!RH8+]YR#R5&,@^HJ['X9\-RQK)'HFDNC#(9;2,@C\JET
MPVMJMU:P:?'I\$$Y1 H1$E^4,64+TZD<X/RGM0!IUSCZ7>'XE0ZL(?\ 05TB
M2V,NX?ZPS(P7&<] 3G&*T-4U_3](TK^TKB8-;&6.(-$0V6=P@QSZL,_C5YKF
M!&C5YHU:3_5@N 7^GK0!Q-WX=U.70?B#;I:9GU9YC9+O7]Z#:QHO.>/F!'.*
MRK[PSJUCKVIWB6&L7L>HP0&,:;J2VX21(A&4E!=?E^7.X;NIXKU"HHKF"=W2
M*>.1D.'5'!*GW]* ,2TL[[0/ 45GIUDLFH6E@$@M4EROFA>%#N1D ]SVKD;G
MX;7VG^$+,:;JNHW.LZ:R7MO!+.ODO<J=S\$#&XEQR?XN:]*2>&21XXY8VDC^
M^JL"5^H[4)/#+(\<<L;O&<.JL"5^H[4 >;ZGIOB&#0_%FD6OAZ6\;7#-<6\P
MGB58S+$JLDFY@0RD$# (/'(YJ[+X;U1K+QN@M,OJ>FQ06OSK^]=;8H1UX^8X
MYP*[M+B"5Y$CFC=HSAPK E3[^E.\Q"%(=</]TY^]]* .%U?P[JES/8-!:;EB
M\.WED_SJ,3.L01>O?:W/3CK5GPQH6H:?KCW-W;>7&=#L;0-O4_O8_,WKP>VY
M>>AKKA<P-*(A/&9&&X('&2/7%5-+UJRUA[Y+1RQLKEK:7/\ ?4 G'MSU]C0!
MYWIW@_6H=(T^WN='AN#%X9DL9;>>=0C3&5&\LLIR,A3AAP#WJ2+P_P"(KO2O
M$5A!#JT.G76CS6T%MK%W%-)]I8$*$=68A #CYFZD8KO->UVU\/Z/>ZA<'?\
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MH4LP(C:12O//(;KFO1XI8YHUDBD61&Z,IR#^-(UQ"DR0O-&LK_=0L S?0=Z
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MSDPJ[< R"+SAQS@@>E>R44 >/^))/"=QX:UT>$K.,R_V6JRSV,>VW4"5=J2
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M]-S%#,F3D6R8S&OU"A>>Q)ZU<M='@M-<U#54.);V.&-U P,1[L'Z_.?P _$
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1L]*\4ZKKL4TC27X&V%ONP9P9-O^^P5C[BH?#O@R'P]<6$L=Y),;/3?[/ 9
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M[LC.6W_>8G(Z^GO0!;HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *9--%;P23SR+'%&I=W<X"J!DDGL*?7*^.I"]IHVG'_4:CJUO;3C^]
M&-TA4^S>7M/L30!LW7B#1K":WAO-6L;:6Y ,$<]PJ-(#TV@G)JX+F W;6HE3
M[0J"0Q9^;:20#CTR"*X[QAI*7NE>(?["BTN;4[FW\G43<REF6,1G:H'(5MIR
M <#G)JO-?PFV\ :WIYFV7,L=H/.^^\$T#$AO4AD1OJM '>LP52S$  9)/:LK
M3O%&@:O>/9Z=K6GW=R@):*"X1V '4X!K$^(1-Q9:)I4CLEGJFK0VEW@XW1$.
MY3/HQ15^AQWJYKT7ARQ?2A>QQPSVCO<:?' I5@8XR6"[>B[<Y!XZ>U '2T5Y
MU%JWB"#2_#GB&XU=I)-8O+9&TL11^0L4_.U#MW[D4[MQ8YVGC%59-;\1W&BO
MKT6M/&DVN"TTVSC@CV2Q&Y$.)"5+'*AB,$8ZY/8 ])GO+:V25Y[B*)88S+*7
M<*$09RQST'!Y]JD1TEC62-@R, RLIR"#W%>43R7\5[XLU6VU*:2;4-7M]$M8
MI8HF0 ,@8XV<[=\P /& <Y/-6M6UKQ#)H_B?6K367M;>PU VFFVT,$1$CJ4B
MVN64DJ9"PP,'D\]  #T^H6NK=;M+1IXA<NC2)"7&]E! + =2 2.?<5R,_B>Z
MM'\:ZA-.OV#1HDC@3: /.6'S'YQDDET7!]/>N?O/$/B"WM-1"W2-JEI8:=81
MR- F3?7##>WW>F&0[>GM0!ZI17F^K>(=;\,:IK*'4FU00:;!,$GB1$AN9IS%
M&!L (3@DAB3@=:T;=M>T[QWI&CR>(9=1@FM)[R]26WB5EV;47;L480M)D Y/
MR=3S0!VS,%4LQ 4#))[5!8W]GJ=G'>6%U!=6TF=DT$@=&P<'!'!Y!'X5QWQ$
MU@E+3PS;)>22ZES>FR@>62&S!Q(<("06X0'_ &B>U<]I6MSZ7X&UNST4-87:
MZ^;*PCN8"AA^T2HRYC8< "5C@CH* /6J*\UUSQ!K/A>?Q#:G6)-0,6CK=PR3
MQ1J;>X>0QHHVJ!M)P0&R?EZFIM1UG6?"6I;;_6GU-6T6ZOKF-X8T$$D(3:R;
M5!"L6*X8GIUH [FWU73KIXDM[^VF>97>)8Y58NJ-M8C!Y ) /H35NO(]/U/4
M_#M@NF6?E>?96.FZ9$98@0MY<OF1V/WL %6VYP:Z'4KO5?#D-Y ?%1OIY_)A
MMDEM8Y;F*=RQ.V.-5!!16*AAP5))(!H [NJXO[,S00BZ@,EPC/"@D&9%7&2H
M[@9&2/45Y3J.OZXFD^,+ WVJ[;73X/*DOXK=;A+B9F54'EC;M8;>"-PSQC@U
M=GU'4/#%P^CZ?<+='3+&QTVVDN84XN+F8HI)51\JHJ<#&>,\\T >HT5YOKFN
MZOX/N;^V?69]4SHD]ZIN(8E>&=&5(\;%4;79\8(/*]>M:6FS:_9>,=(TV_UE
M[Y[G39KB^A,,:1Q,AC53'M4,,LS#DG..U ';57OK^TTRREO+^YAMK:(9>:9P
MJJ.G)/O7/:O>:CJ'BZW\.V%_)IT269O;JYA1&E8%]B(F\%1R&).#T &,UQUY
M/J7BA=%T6;6)]R>(+B W,440^T16P,@D8%"NY755X 4G.0>, 'I_]JZ?_90U
M3[=;C3S'YOVHR@1[/[V[ICWJGI_BKP]J]T+73==TR\N""1%;W:2.0.IP#FL#
MXFM,WA2VTFWB^T3ZE?V]HL98)Y@W[V&>@RL;<X[UGZ_'K,ZP:YJ.CV.D66@B
M742R7(FFF=8G"H,* J\\\G. ,4 >@6MW;WMN)[6>*>%B0)(G#*2"01D>A!'X
M5-7E5I<WNEZ-IVBVE_JL2Z7ID4E^-,M86=)W7>3))/\ (!C)VCGG).,5=T?6
M_$?B.3PS9C4?L+W&C-J&HRQ0(78.RK%M# A6/S'H1UXZ4 >D5A7'C;PK:7$M
MO<>)='AGB<I)')>QJR,#@@@G@@]JA\"ZA>ZIX4@N[ZY:Y=IIUCG955I(EE=4
M9@H R5 / %9U_;0:A\5M*MO(C*:=IL]Y)\@Y>5UC7/X+)0!UME>VFHVD=W8W
M,-S;2#*30N'1AG'!'!Y%3UY=J?B77+J[UZ33FU.SM-+E>VM!:6T#0/(B@LTS
M2<[2QQA=N!SG)XU?[5UO4]>OM^I/I6G:5I]M/>10Q1NYG8-(Z;F!PH3:#^&,
M<T =Y17ENFWWC"Y'A S^(&6\UN*6:XA^RQ>7# (]^X#;GS!NC&2=N3RI[S1:
MSXCET&XBM-0N;Z2'69X?,A6 7LEE$2C-&I4(S"3C.WI[XH ],HKG_!M]+J.@
M"YDU-M10S2+'-+!Y,JJ&QLE4  .I!!P!TZ5T% &'<^,_"UG=26MUXDTB"XB8
MI)%+>QJR,.H()R#6S#-%<0I-#(DD3J&1T8,K ]"".HKR:RU'7M+M/%UY8>'=
M/U.SBUF[:0RW+"7&1N_=^6=P YP&R><"G6E[>:'HGA/P]HU[=7-O?07-[)=Z
M5!&SE-X<)$LORJH,N.02 HX'8 ]0U'4[#2+)[S4KR"TMD(#2SR!%!/09-3Q2
MQSPI-$ZO'(H9'4Y# \@BO)M1?7-:L=$BU*\OK26V\2);Q2-% )94*%DD=<,H
M=>1@8!ZD=,*/%GBBZM[S6;--6?R+V2*&T6WMQ9M%'*4*N[$2;R%)W @ GICJ
M >MT5YIJ'B#7[)?&6N#4V>UT.=X;;3_(38Y,$; NV-Q 9P>".AR?1UCK/B:S
MOTCG;5Y[>>SG>:74K>VB\J5$W*T7EG)4D$%2&QD<]: /2:*\TTO6/$%E!X/U
M6^UJ6_36X2;FT-O$B(?LS3*8]JA@<K@Y)!ST%7-&U#6VT#2O%5YXA21+V'[1
M-ILD4:Q$-&76.$A0^\<#EFS@\4 =_17EGA[Q)XHNSH&IR#5)X]2EC^U13V]O
M':)'(,@PL#YF5R/O$[@#P#TLZ1KVMP^(;)-<U#4+8W5V\(1[2*33[@'=Y:PR
MQC<K8"GYSS@C% 'HDMU;P3P02SQ1RW#%849P&D(!8A1W( )X["IJYS7KV>V\
M5^%+:,H(KJZG24%%8D"WD88)&5Y Z8].E<CHNL>)/[%\)Z_>:[)<G5+V.UN+
M,V\2Q;'W@$84,&&T'.[!YX H ]/>1(P"[JNXA1N.,D]!4=O=6]UYOV>>*;RI
M#%)Y;AMCCJIQT(]*Y#XAVL]S+X7$-_<6A_MJ)<PK&>2CX;YU/(P<=N3D'C',
M>;K.DZ1XOU^QUF6!+'6YW2R$,;12C>FX.2I;D' VD8]Z /7*9--%;023SR)%
M#&I=Y';"JH&223T %>9:KXC\17NL^(5TUM6B32IOL]M'9VUN\+N(U<F<R'=@
MEL87;@<YS75ZY<S7OPRU*ZN(1#//H\LDD0.=C-"25SWP3B@"Y9>+_#6I726M
MCXATJYN'X2*&\C=V^@!R:T[>ZM[L2&VGBF$<C1.8W#;74X93CH0>HKS&#2-=
M\3>$M%TW_A'=/TZ +:3?VD;M7D14*-N153(<@8Y(QDTMKJDUE8WEK;ZA<VLM
MWXCOUV65J)[F95=B1&&!5<<$LPP![F@#U.BO*+;Q+XDGM1IZ:C<V]POB./3A
M<7=O"9Q \'F8=5&S<">"/09'45UWA:ZU%-=U_1;_ %&74$L)(&@N)D19"LD>
MXJVQ54X(.#@=: .G$B&1HPZEU +*#R <X)'X'\J=7EFIWNH>'_$GCG5;6_D>
M5(["..*9$,2-*VQ6.%#$)DGKR,YSQCH[6?5M#\8Z;I%WK$VJVVI6L\F;B*-'
MADBV9(,:J-A#XP02"!S0!V%0_:K?[8;/SXOM(C\TP[QOV9QNQUQGC-<7XRO]
M>MM:C6SEU2/3%M-[/I$$,\R3%C@R1N"QCP!C8,DY]JS+7[7XD\;6-S8>('@2
M;PY%))>6=N@:8^<W19 P09R2",]LB@#TVBO,8/%&J:GH>@))JMZE]<13M<1Z
M39))<3^7)Y8?YU*1ID<Y')( QS4%AXA\2ZQ::%IZZK+97-SJM]8W%RUO$9C'
M"LA&5 *!_E )7C/K0!ZK17E%UXB\43W&N&RFU=GTF8VMN(+6V:WF>-%+-.6P
MWS$_P;0H((J?6O$7B&VO;B_NKG4=-TZ.*&2&6SM8;NVAS&K2BY !E&"3RI V
MX.: /4*1F5$+NP55&22< "L#QAK5QH_A&XU'3VB,[&&.&1QN13+(L8<CN!OW
M?A7)^*6UG2HKS1)_$%W?0:CHUY.)9(85E@>$*3C:@78X<K@@D=C0!Z!IFK:?
MK-J;K3+VWO+?<4\V"0.NX=1D54B\5>'IM5.EQ:YISWX;9]F6Y0R;O3&<Y]NM
M5?#,2Z?X#T\7-Y+)&E@CO,X565=@/\"@84<#C/'.37"26=SX>\#6T=_IVE:[
MX2M4CGCO;.1K>Z6,,&6;;T9AP258$\^M 'K0D1I&C#J77!90>1GID4ZO*KN^
MU#0M>\;:C9ZC(\TES86T2SQH8XC,(U$APH)V!L 9P>^3S5OQ%X@UOP--<P-J
MDFKK-I<UU"UY%&K02QO&N3Y:J#&?,S@C(V]: /1+JZM[&UENKN>*"WB4M)+*
MX54'J2> *FKS/QQ9ZIIG@K7X;[Q+_:44^DS-Y%S'$DOF+MRT>Q5^3!Y!SC*\
M\UT'@[6K_7[K5;F^=[1[>;[.-(=%#VR@95W;JS."#P=H' R030!UE0W-U;V4
M!GNIXH(@RJ7E<*N6(4#)[DD >YKA/%/B'7--U;5=&LKI5O;]+4Z,S1J1&7<Q
MR]OFV[=_.?O5E7'C/4M9T*?4[69$MK>'3(Y8VA1Q]JFGC,H.X'E491[%L]0#
M0!Z6NJZ<TBQK?6QD:=K=5$JY,J@ED S]X $D=<"I9;JWAG@@EGB2:<D0QLX#
M2$#)"CO@<\5Y=9?\C%8?]CE>_P#I-+70^-+:YN_%GA""TOFL96N+G]^B*SJ/
M(;.T,",D9'(..N#0!VU%>6ZCXKU[3&N- 2ZN+RZ368[%-0A@C,YA:W\_A3B,
MR 97.,=\9KI/!NHZS/?:I8ZFE\UO;^4]K/J$<23L&#;E<1';P5!!P,AO:@#K
MJ*X>>XUK6];\1I::^VD0Z.R0P((8V1W,2R%YBZD[/GQA2O )S5(:GKVM6?B+
M5[7Q +)-(D>*W@@AC>"4QQ*[/(6!8JQ;C:5PN#R: /1:*\R@UCQ#XD;6;JVU
MJ;2X+33;6]@@A@B<B22 R%7+J25!'08//6F:AXB\1W5KIVHK/J5O8S:1;W1D
MTBVAN#%<.I9C-&X+^7C&-O\ M<T >G>8GF>7O7S,;MN><>N*=7EES>73^*+_
M %^RUJ27'A);N)HXD$3G]YM(#*6"[AOP3G)P21Q6II-]KUKJ'A);_6I+T:RL
MLUPC01HJ8@#A$VKG ;GDYH [^BO+]1\8:V+RXTRVEN6>?Q!-9)+:0QO+%!';
MI(50-A2Q)/+9P,]<"G+XC\2Q6[Z7))=V[W&J6UG:W]]#")TCE5F8LB?(6&P@
M$@ [EX.* /2$NK>2ZEM4GB:XB57DB#@LBMG:2.H!P<?0U)YB>88]Z^8!N*YY
MQZXKB?#%G=6/Q%\207>I2:@PL;$I-,B+)MW3\-L 4G.>0!QCZUC^(+Z\\/>,
M_%FN6]W+(UKH5O+';.J>627F50V%W;5(+=<\G)Q@  ]0J%KJW2[CM&GB%S(C
M2)"7&]E4@$@=2 6&3[BN1BFUG0/%&A6-WKDNK0:L)HY5FAB3RI$C,F^/8HPO
M!&#GJ.:/%>KWNG^(D2UD1 NA7]R"8U8B2,Q;2"1G R>.A[@XH [2FNZQHSNP
M5%!+,3@ >M><6^LZ_H[>'=0OM7EU*/5;&::XM6@C1$=+?SAY950PZ$<ELYJS
M8MK4OARPUF^\2I*FIV32364L4:1Y>$NJP$ -E?\ :+9 )XH [RWN(;NVBN+>
M5)H)4#QR1L&5U(R""."".]25Y_X"U.[+Z#I1E_T)?"EC<B/:/]8<J3G&>@ Q
MG%4O#NNZ[XJ;2-/.LRV1;3I;Z>ZMX8C),WGM&BC<I4* ,G R<B@#T>VNK>\B
M,MK/%/&'9"\;A@&4E6&1W!!!'8BIJ\;TK6M7T_2-&T2UENVEO=0U22ZN=.@C
M:5A%<-GRQ)\HR7SDYP!QZUWW@O4-6O;*^BU>.X\RUNC%#+<I&DLL>U6!=4)4
M,,D<8S@' S0!TU%>4>*/%>KV::UJ>FZIJ<XTZY*+';V,0L4"L R2/(-[MG()
M1N"< <5=U?4?$<@\;W]MK\MK%H+%[2WCMXF5]MLDI60LI)4DGH01D\G@  ]*
MHKSW5/&&I://J2S,)'OM-ANM'CV@?OF(B:+I\W[QXFYR<.>PKN[**>&QMXKF
M<W%PD:K+,5"^8P'+8' R>>* )Z*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q_$VCR:SHYBMG6
M.]MY8[JT=_NK-&P9<^QQM/L36Q7.^,/$K>&-.MKA8H#]HN5MS-<R&."#(8[Y
M& ) ^7'3J1R* ':CX/T?6KEKR]MYXYYXECN5M[N2)9U'19 C .!DCGMQTI]S
MH;7.OZ1+LBBTS2HVD@B3C,Q4QKQT"HA;'NP]*YC5_$OB&YTO0;FRBT^-Y]92
MV=H+_P R&X3!*E752=C8.<@$8Q@@U=N_&NJ):ZIK%IH\$VAZ7/+%.[7)6>01
M'$KQIM*X4AL L"=IZ<4 ;'BC3+W6;,Z?'I^F7EE(,RK>3R1D,#D%2BD@CKG(
M(-86E>&=:TBYDNH=-TF>ZDC\HW%YJES<2;/[@:1"0OL.M79?%6KWUYJ7_"/:
M1;W]IIK*DS2W1CDG<HLA2(;2,A67EB,DX]ZQM'\72Q^+M<T&W4W>JW&K%X[>
M>;:MM;B"'<Q// );"KU.>@R: +.G>$M5TJ[AN;;2=(+6X86R2ZI=2); \$1(
MR%4XXX XXZ58B\/ZU!I^FV$>CZ$+;395FM4_M"X.QU! )/EY;[QZYYYKH/$F
MN?V!I:7$=L;JYGGCM;: /L\R61@J@MS@<Y)] :YW4?'&HZ!!JL6L:5;_ &ZS
ML/[0A%K<,\<\88(PRR@JP)'8YR* (X?"VKP7!F32='R;XZB%;5+ED6X(;+A2
MF!G>QP!C)SC@5,/#^M+ID6FC1]"^R170NUC.H7!S+YOF[B?+R?GYP>/PKI-,
MNM5?2Y+C5[&&WN1N98+68S?)C(&2J_-U&!Q[UR_AOX@2ZTINIH=,%D+9[B86
MM]YD]EM&=DT3*ISU&1G!'XT 5K[P5J&I7-Y-=Z/H\BWCB2>'^U;H0NX &\QA
M-N["@9QGBKK^']:DG>=]'T(R27J:@S'4+CF=%"JW^K[!1QTXZ52TCXHPWU[I
M?V@Z.MMJD@CABMM26:YMR5++YT8'&<8."=I(!SUK6T3Q-KFLI8:E'H</]BW[
M'RI$NLSQQX)65T*A=IP. Q(W#KS0!2U/0?$EY'J3+I/AQY=26-+L3W<[K-&G
M 7&P;>"<$="<\U1\.^%/$^C:Y=:PEAHZ37%M';"*74KB9D569B3(Z$L22/8!
M0*W+3QF]SX<\-:L;%5.LW45N8_-SY6\,<YQSC;[=:QKKQ=J6I:)=7]SH\<6E
M1:BEI&\5^ZS22+>+%NP%X3J<9YP1C!S0!L6^G>([;5;O4XM,T(7MVJ)-*;Z=
MB50':H!CPH&3P,<G-8>M^#=>UG48II--T-8I;M;N]47\_P"_=(6CC_@^7&0<
MK@Y4?6F6^NZKNU0ZM&LT*>*;>T@\F\=3'EH@!]T909!Q_$2P/J9+WXL6MK/>
MW(;2/[.LKIK>2*34E6]D"MM>1(<<@'. 3E@,\9% $=_X(UVYTS^SX]/T9H;B
M\AN+Y[C4+B>2Y6,A@CNZ$D?*!C/ Z5<3P?JBV=[;2:3I%PMZBQSO<:M=2R-&
MIRJ;V0L%'H#CK5C_ (3NZF\4W.DV]IIQ^SW:V[6T]]Y5W*AQF:-&4*R\Y W9
M(![\5O>*]>F\.:)]O@L_MDIN(8$@\S9N,DBH.<''WJ ,*Y\.ZS=P:A#-H^A,
MNH3+<7!_M"X#&10H5@PCRI 1<;<8Q54^#M4:Q:V;2]*+-<+=&Y.K71N#,HPK
M^;LWY X'/0XZ4_4/'U[IVH+I%VOA^SU2*W%Q=&\U3R8/F9@B1L4W,Q"Y)P N
M1US4,GQ/6YATF2PATZW6_M6N%EU.]\F)G5RC0HX4AFW \\#&#SF@!Q\%ZB;*
M_M3H^D%+]HI+ESJUV9)'C(*/O*;MP(!SG/%69?#6L3VU_!-H^ARI?F-KDR:C
M<LSM&JJAW%,@@*N""#D9Z\UMZ?XBFO-?M]+FL/L[RZ6M^^9@Y1B^TIE>#C^\
M#S7(W/B?4=6NM$U*R46\DNFZLP@,Q\LM$\:*Q(')X)''&: +L?A'55MKF&32
M=(N#=-&T\MQJMU++)Y;!D!=D+;00/ESCKQR:U!9>)1J[:J--T+[:T MC)]NG
M_P!6&+8QY>.I/.,_E7/Z3XFO;72]'O=1@,]\OA:;4"ZW;E9 @B/S*5 WMD$M
MSCD#.:U[/QIJ45WIK:UI=M:6.IVDMU!)#<F5XA&@D(D4H!DJ<_*3@C'O0 W5
MM U_6;F*YN;#2H[F)&C6>UU6Z@DV'!*%D0$J<#@TZUT'6K&73Y+71?#\)T^*
M2&U"7LX$:OM+\>7@D[1R>>O/)IEMXRUQCH-U=Z';1:=K<Z1P.EV6EA5D9U,B
M[ ,E5[$XZ4GQ(&I3_P#"/6%HL;6UYJ:Q3JUW) 9/W<C!"4!.T[<D@]5'!R<
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M.L=,T**UMHQ'$GVV<[5'3DQY/U--BL/$L&K7.J1Z9H0O+F..*60WTYRB;MH
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MQ<1DN!S]T MSQQ4-SX&EU>'56US5OM5Y?V7V%);>W\E8(@=WRJ6;+%L$DGG
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MM5JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[>6-8<)/ 09,R#[H&<XQS5V\T*35_A-;:>T3"ZCT^)XT9<,)$0'&.Q."/QH
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MI"G'<9KJZ* .)O=5UKQ7%>Z;I&EW5C8R6%Q'+=ZC;O YF9-L:QJ<'@DDL1C
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MAB[9+,=IR22: /.7TO6)-*\6SM9:Q=&:_P!-NH6NK=5GN4B>,N0B*HR A^7
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M^;_265(F7/S<8+'[N...G%=;\/I)6\-2P2S2S"UU"\MHFF<NWEQSNJ L>3@
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M;;0M%L]*LP1;VD2Q)GJ0!U/N>I]S3-1TO1KF1;W4[&PE>%=JSW,*,4![!F'
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M8L""#SSCR]JG=Y><=<#=CVS72L2%)49..!4,=E:0RI+%:PI)'%Y*.L8!6/\
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ML<.HR7B0R&YP?F< JQ 7(''2O1O!_P#R&?&'_89_]MX*V+72-#^RA;33M/\
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M67KSM&0" <<T 8&I^*-;TWQ-/'J%W_9EHMXD=L)]/9[2XA.T$M<+G8YRV,X
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MXO-MIUVNN2#UR"".000"".A%8UMX'TN*ZNKF[FO=2FNK-K&9KZ<R;H2<[,8
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MO59H)<9V.592"&5E(Y!! (/M6+_P@NF21W/VRYO[V>X\D/<7,^Z0+%()$08
M 7<,\#G/- &7-KNMZ%J6L:?J&JZ?<^3I0U""ZN83!'$V]D*N%))7(!&.>W-9
MMGXPU>'59K5KZ:^@DTFYO(YKG2GL]LL6W&P-@NAW]QV'-=EJ_A32M<GNIKZ.
M1VN;,64@5RH\L/O!&.C!N<^U5$\#Z?\ ;/MMS>:E>7?V:6T,US<;B8I  5P
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M)<2F>XGN)-\DKD 98_10,#  %5IO">F3Z1JFF.)OLVISO<7&'YWL03@]AP*
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M;XCM_*\I_)!(7D[E],\\=3GCH;;P+I<-[]KNKB_U"4VLED?MUP9087QE,?\
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M+XET2^N;"ZL8-)CE 6YU,W2Y:/8$A7)VH,DY;#<** /2J*** "BBB@ HHHH
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M5)$O[F)&60-\JS.NW@#[N N>^,UR=YXJ\1XO7>"0_9_%,%I#'!.NZ2,A,P]
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M6L4>GV(CCCYR79C\S$\<9 &.YYH U]-\574NL+IVLZ.=)DEM7NX&>Y60.B,
MP.!@, RDC)ZGTJQ!K3ZOX&EUJ*&2T\^SDGA!;Y@N"4;V)&&]LU@_$>Q36Y-'
MT:TDN(]5FN,*\43$);.K1SEFQ@#83WSN"UV-U8)+H\VGP!8D>W:!,#A 5VCC
MT% '"6'C!=*TJ&_OVOKJ6#PS9WLP\X%'+DC.".&)^\Y.,?2I]<\8ZU_P@VNZ
MA::=%;W%M:^;;W=O>)<0,#G+*^WEEQDJ1W'-7+?P5?6D2_9=62"X30[;2TE$
M <!XF)+%6X*MG!'7&>:H+\.)I[77Q++IMA)JMA]C\K3+8QPALD^:RD_,V3CM
MQW.: +]WXYN+>]DT^'2H);VT@26]234$B$9<$JB%A\[8&>@'(YYJ6/QP=4>S
MC\.Z6^I//8I?R;YU@$43DA020<N2K#;T^4Y(JA=>"-3EU*?5%.@SWM]!&EV+
MRP,J)(@VB2++9 VXRIZ[1S5V/PGJFDWEM>Z)J-H+G[#'8W7VJU^24(699%6,
MJ%8%WXZ$'MC- %KX?:A<ZCX%T^^OI97GD\TNTYRXQ*X /T  _"J=MX\EF@L=
M3ET66'0;Z=(+>^,ZE_G;;&[QX^5&)&#DGD9 K9\+Z%)H/ABVTBYN1=O%YF^;
M;MW[G9LX[?>KG[;P3JJ:=IV@7&J6LF@:?/%+&%@87$J1.'CC=MVW (7+ 9(7
MMF@!T?Q N6B%\V@2II*ZB=/DNS<KN5_.\D.$QDKNQDY!&3P<9KJM7OY=-TU[
MFWL9KZ8%52"' +$D#DGA5&<DGH :YX^#)CX1?1/MB;VU/[=YNPXQ]K^T;<9Z
MX^7/XUH^+] E\2:&+&&>*-EGCF*3H7BF","8Y%!!*-WH Q'^(HM+77#?Z8BW
M6DV\=R\5K>+.DB.Q488 88%3D$>GK4T_C>_L9+Z"_P##DL-S#I[ZC!$ETLAF
MB1@'4X'RN-PXY!SUK-E^'-Y<0ZT&N=,M?[3L([18+*T,44&QRP(&?FSN.3Q7
M3:CIT=OXC3Q+<SJMI::9/;2Q^66)#/&Y;C.0!&>,=Z )H/$=O>:Y9Z=9H9TN
M+'[>TX;"I&2!'QW+9;'^Z:S-;\9R:=X@?1;+38[N[CMEN626\6!I%8L L2L#
MYC?*<] ,CGFJ7PQT0Z;I%W?-YQ2[G*68G0JZ649*P*0>1\N6Y_O59\5^%+_Q
M!<2JKZ3<V4T C$&I6?FFV?G,D3*0<G(X/=1@B@"K=>+K[3_&=_\ ;K=H=#M-
M$2_D#.-Z<N2VW&2V5V;<]L]ZO6WC&YBO;*'7-%?2X;]'>VF-PLO*H7*2  ;&
MV@GC<.",U3N/ $LTB6[ZB)K";0UT>[,J$S,%#;9%;.-V6R<@]*G3PKJ^IWFG
MMXCU&SN;;3DD$26L#1M.[QF/?(2QQA6;@=SG/:@"-?%VIZAI'VQ= NK;3KZU
MEDM+Q9@[H/++HTB ?NPP'!R>2 <9I_@7Q4?$&EZ=!;J]XMO80?;M0:3Y1<&-
M28QW=^<MV&?7BFV?A7Q##IMKHTVN6_\ 9=E T$1A@999U\LH@E)8C"@@G:/F
M('2IO#O@MO#-YITNGW$4<0L([348%CPMP\:@),N/NMU!ZY!]10!:\0>+!H^J
M6NE6MM%<W\\33[9[I;>..-2!N9R#R2<  '.#TQ5 ?$:PCTRTU2[M7M].:XEM
M+RX,@<6<R9&UMN<JQ& P..5]:L>)?"3ZKK=IK5FNG274,#6SP:C;>=%)&6#
MCNK @\\\$BJ;> I;[2[/2=5O+>73!+)<7MM:VPMUN)"?D0!>D:=><DE5R>*
M+?\ PF%Y+%I<-MH4K:GJ4<EQ%9S3B/RH$(^>5L':3N3Y0"<MCL:R9_$^NR>,
M-(CMM&NUFFT^[$NG3SB-%D26(>87P05QG:P!SO'')Q?3PKKEJ=*O8-7MY]5T
MV*6T$MU$Q6YMG*D"3!R'&Q#N'4@\<\6]+\,ZC;>(+/6-1U47EQ':W,,H$>T9
MEDC<!!DX10FT Y/O0!'!XQN;W1+6\LM$E>ZEGFMYH99UCCMGB9E?S)<$ 97
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M:\CLFCA$D+O)A$D)+J"5R2<'<PX[ '7Z%XO.IZTVD7MI#:WIMS<Q>1>+<(Z
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M/(K#E\4W*:UJUD\EE;Q6>IV5G$\L;L9%F6,E?E/WR7(4\ <9JYHVFW=KXO\
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M6VB>9Y@!DE40%CCOQQWKAM%DU'PWXCT2V?1+F]N8/"EK!/%;-'YD3JY!'S,
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MTM%<97S'/5L=E 9C[*:HS^(9(=5FM#J&GCR]2M[38T$N\"2(.4)'&\YR"/E
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M"...N15I8HT145%"+T4#@5Y5X?EGTN^USPSH]K?Z0M[8?:M(^V0!"L\<8CD
M!R#R(V_%J;_PLR\&H1:RSC^PO[-\IX-@_P"/_P C[1MSUSM&S'J?6@#UC:-V
M[ R>,TQ8(47:D2*ISP% '/6O-;W4==7&GOK.LSZC9:="]S'I5I !'.REBTTD
MHV8/91C@<]14FC:OK_BC4?#T9UF6PAGT&+4;D6T,9,LN\ CYE.%.3D#T&,4
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M">.S26XF+01LP10H!D;YCE@0.>,"@#T:62*!&GF=(T126D<@!1[D]!3P HP
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MDKD=..IYKN/#U_+JGAK2M1G"B:ZLX9W"C W,@8X_$T :5%%% !1110 4444
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MJ#+;2A. 0P..AZ'M6YK/B/6;:SO]-UFQMK26]TF[N+.6TN&<HT:99&RHPP#
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M;7#2-#($,@CD!4 Y56Y7N,>]=;0 4444 %%%% !1110 4444 %%%% !1110
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M:2S17-N5<HQPK+R0PR".#QCFM&[U[3[#4C8W4IBD6SDOF=A\BQ1LH8D^VX4
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MBU"Y%K FSY_-+%2I';:5;/IM-6-:U^TT-;99TN)[BZD,=O;6T?F2RL 2<#T
M!))P!0!S]QX"FEMKS2DUN2/0+R=IY[$6X+_.V]T67/RHS$G&TGD@&K%WX.NS
M=:D-,UV;3K'5)/-NX(X09 Y4*QBDR#&6"C/#8/(Q531_'D,MKK=[J'GB&#5A
M8VEN+8B=F,49$>SJ7W,_X#K@9K53QKI(T^^NKG[39O8,BW%M<0$3*7^X HSN
MW'A=N<GCL: *;^ X1Y\UO?/#?_VH=2MKH1Y:%BJHR'GYE95(.3SGVK:UW15U
MRUM87G,7V>]@NP0N=QBD#[?QQC-9C>.])@L[^>^BO;![")9YX+J I)Y3':'
MY#+G(X/&.<5#_P +"T[[1+:C3-:-XD0G6U^PMYCPG(\P#^[D8YP<X&,T 6-2
M\,7<FN3ZOH^K#3[FZA2&Y62U$Z2!,[& )&UAN(SD@C&1Q43^$+JWFL;S3-<G
MAU&WM/L<MS=1"X^TQYW?."1\P;)!!XR1@CBN@TW4;75],M=1LI/,M;J)98GQ
MC*L,C@]*M4 ><>&_"&J?V#I%RNH3:?J^G7-^HDN;82>;'+.Q)=,K]X*C @C\
MC6SIG@9=/FT^9]4FN9;34KC46>2, RO,CJP..!]\G@?A7744 <F/ \2>$M,T
M6/4)([C3)EN+6\$8)60%L$J>""&8$=P:2;P;=7]G=#4]=FGO9)89[>:&$11V
MCQ'<A2,EAG/WLDY''%=;10!SNC>'+VQ\07>M:CJ_V^ZN+:.V*K;B%$5&9AM&
M2?XCU)YS] S6/"$>LZY+>RWC+:W6G/IUY:^6#YL1+$%6SE""Q.>:Z6B@#E;#
MPG>KJ.FW.KZX^HQZ6&-G']F6+YBI3?(03O8*2. HY)Q75444 %%%% !1110
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M,[FP?,E\O9^'R'FN;U'P?K)@ME@TF(W\6FP6UMJ5CJ+VLL$B)M(EP<2*&Y&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %<=\1)Q#INF"2SMY8FOTWW%U$\L-KA6(D=$(+#.  3C)!/2NQ
MHH \)O$C&D^*VNHFNK"74M)D)@T]K9+E?-0.8XN2<X(SSG'N*T?%36-Y9^*M
M1T.V*:0-#6"X>* PI+.),J%! RRID$]MP%>FW\6E^(VN=(EE9Y+*>WGFC3*E
M&#"6/G'.2H/%2^(K/3M0\.W]KJTHAT]X3]HD+[-J#DG=VZ4 >=:HFG:C<SR^
M%K!X;:V\/WT%Z8[5HA\R+Y4)! RX(8XZCGUJ>72-,T1?!5U=:7''HL-LYN]M
MMN5+EHHQ')* #D\2#<1P6]Z]05@RAE.01D&EH \6U!-/C2*\EL)!X:G\5PS6
MMN;=L,@MF$CK'C.PR!FQCD G'-6-5L8-7_MN;3;)FT&]U/2D55@*),ZS 3.J
MX'R[2@+8P=I]*]3U'2;75)+%[D/NLKE;J':V/G"LHSZC#&IKR^MK!(GN9-BR
MRI"AVDY=SA1P.Y/7I0!YIXCM(]*O_%BVNB1S61TW3XQ;I$RPX,\V\E8\$JN[
M<RKU&<]:RX[5M0UG7Q +>_BN/#,\:266EM;022!AM102V]AD<Y/7 Z&O9Z*
M/%%\G^T--OY;BVL])?1(8+62ZTAKF(2*S">/;E=CDX)R/F_"N]\%7$&D>&=
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M5G+@%-N#NX 7(]J]SHH \3\6KIMGX3\;6FLZ9++K4]U/<03&T9R\9(,+K+C
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MFC2(8PI#2.N&N63UWG"C'793;&VANKYIM-O%G\C1[J*1+'13:(J% %CE8O\
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MXD6]R]WX=N3(L>F6UU(UU)):&ZCC8QD1N\8(R <C/0$@UWC,J*68A549))X
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M%JA2!3'_ *M3R5!ZX/ITK1CT_3K6X@FBMK>&6*'[-"RJ%VQ9!V+Z#Y1P/04
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M-JEY#:77B"^MY)TF*R>7$A9(5?JN2.W.%..M>@KH>EJ,+80 ?:%NON?\M@
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M$!;RW!#)GT()X]S0!Q,)G\+:KH3-K6H2VUYI=S+>?:I3*BF*.-PZ)T7&6X7
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MIJ0-?ZG=BUA>X!,<?R,[.P!!;"H>,C)(YK>K+UW0X-=M8(Y)Y[:>VF6XMKF
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M[Y%0W/@C3KF"ZA>XN@MSI"Z0Y#+D1+NPPX^]\Y]NG% %!=:\1:I?W]GH"Z9
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MDSR:UJES#I#$V-M,T>R-2C)M)"!GPK8!8DC YZY=9^!H;&2VAAUC4QI5K/\
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MF6+ L6*QO\IWAE.<AOE]*T/ ^C:A::OKVL7XOU_M P)'_:+QF=A&K LPC^1
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M%8GPP!+A0[8#$#<Q]\U7M_A[:V[V4?\ ;&IO86%X+RSLF:/RX7#%L9";F')
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M*-A@.Q![$'!K"'@2*:>[N=1UK4K^YNM-ETQY9C&NV&0@G:JH &&.N.<G.>,
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M+F&>Y9[+[7Y8=EP?M$@D?.!V(X]NN: ,&U\8:Y?K8Z3$EA%K4U_=V<MPT;M
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M;>=;66VCF6>3804<DC&#\P)!R/0BNG?P19?\(YINCP7EW#_9MP+JUN5*&1)
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MCK>EJUW'):FX@5<*7^7('S$ 'V)%<YHGCB[N?#V@"72+N]UO4+%;IK>$Q+E
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M92JR%&#+@')!3&#CK0!0\)^-I[VP\.0:KIM_#)J=HODW\WE[+B58M[\*V5R
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MV6-)3,)&VKM9&*9SUR1CJ>.:R->\>7MIX>\1>3I%U9:UIEF+D0S-$XV/N"R
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MOXAUB/X=^&[R/5)H;JZG*37 /)&6Z_D/RK6M]+OVNH@OQ,28EP!&%3+\]/\
M6=Z /1**\L\6^,-4\/?$.,1S2R:;%%&\]L.5VG@GV/(Q[XK;U;7;AO'?AB&Q
MO6.GWL32,J'Y9!@D'^5 '<45Y?;CQ#XB\:Z_86WB6YT^&RE^15CWC!.,8R,=
M*U/#6M:SI_B^X\+:[=+>OY7G6UT%"EAC.#^&?H0>M '>45Y#X$\5:S<>+TM]
M2OI9[2Z,T$0D/ = &_EQ^-$/BK6;WXEQ1Q7THTJ34&MDB!^1@@ /YY!_&@#U
MZBO*)+W5=4\;:W8-XN;1[:UD_=!]I!]AEA72:5;WMCINKW)\7?VT4M6*! H\
ME@"0>&/I^E '9T5YG\,_&EWJ4TFDZQ.\ES(#-:S2=9%'#+[XP2/Q]*E\+-KG
MBGPU?H->N+2YBU-E6XV;R(PH^3&1QDYH ]'HKR72;7Q/J?BK5=$_X2^[C^P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,].XKHOAGHUUHOA%5O(VBFN9FG,;#!4$  $=CA<_C76K;P(VY(8U8=PH%24
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MD2ZM@\Y9 2[,,G)]L_ABN;\?65KX=^'5OI^CR.+*>\4.WFE]P(9NOH2H/'%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110!S.@^&[G2O%&N:I+-$\6H.K1HN=RX
M)Z\>]8FH^!];BO\ 5QH>IVL%AK!)NHYU.Y,YW;< ]<GTZ^V:]!HH YE_#VIZ
M;X>TO2_#^H):_97'G22H#YJ\EN,'!).:Z:BB@#S_ /X0K7M!U&ZF\)ZM;V]I
M<MO>UND)5#[<'^GXUI^%_!\^EZI<ZWK%]]OU>X&TR!<*B\<#\AV''&*ZVB@#
MF->\,W.K>*M$U:*>)(M/8M(CYW-R#QQ[4OCGPU<^*="CL+6:*&1;A92TN<8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH:;)/D_UX^SM#QSQ][/>@#GK[Q=K&JIX:O;?3);+2=0U6 0W*W>7EB.[ DC
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M.,8)+R.0=JC'7!.2!BN83XCG^S+V5M*26]M-0@L'@L[Q9DD:8KM*28 /WNA
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ML1:*T?B^ZUSSP5GL8K01;>04>1MV???C'M56?PT\VI>(KO[4H&K645JJ[/\
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MM^R:_!'_ &FF>0MJP;./1PPC/X4 ==XI\2Q^'/"%WKRPM.(H?,CCVL-Y/3.
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M+DVC) 9B <]Q0 MAXSMEL;VYU>1(/*U6XL($AC=WE\MR% 1<LS8!)P.U6O\
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MUN\TO[/(C6L,4IE)!5Q)O  P<@C8>M:% !1110 4444 %%%% !1110 4444
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MJB[F8*OJ3@4K,JC+, .N2:\4O?[-?5M)$;6%OX6%G.+#_A(8F>U:7SFW%,L
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M+DXSG)88W 8[4 >W!U+;0PW>F:7(YY'%>/:9H5C8?#ZW\6P6B_VK8:A)>S7
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MG_Q;,;_O<?=QVKI?AY=:!HFD7MHAL[.Y.MW%K)%&@5M[3R>2C #^Z!MSVZ4
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M\8RFU1A2)#\O/05!\0;\RWFBZ!'9W5ZMS<"\O(+5 [FWA(;!!(&&D,8Z],T
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MLA(HW(?*DL#N(ZC%6M6FU/Q"?%^-:GTZ#2X!%#;Q*FQ]UN)&>7<I)!W;1@C
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MRYAU;47\3V!\27T$6B6R0Q$K%F<M!YC23?)\P.[;@;1A3WYKK/!7_(A^'?\
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M^EN3+9QE" H$B#G?G(R1@ YY% &_J?@W0-7O'NKVQ+RR(J3;)I(UF4=!(JL
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M@F9I;=W4M&),@!L@8)&,'UJYX,UW6?$EA_:E[965K82AA;K%*S2DJY4E@1@
MXXP30!U%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3#,'V;6?H,MCGIR,XS4^H^-M)TV\NH)$O)8[+ O+B"V:2*UR ?G8=, @G&<
MY.* *5KX"2SM$AM]7O()(](@TM)X,(Z^4Q99 ?4D\CH1QWJ.3P +]-9DU75#
M<7FIV/V%YH+98 D>2<[1G<V3U)[8&*T;[QMI5C>SP,EY/';;!<W-O;-)%!O
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M+=GCB5UW*SN. ".]0:GXGEL/'&DZ$+25X+RVFFDG$1(4JR <YP -QW>GR^M
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M'M\IP>XKE-.N?&?B'08_$5CJ-E9_:8_M%GICVF]6C/*+))N!W,,9*X ST.*
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MD4+JNFJIG4QI(>=_R_>([^M &O>^"[*\U#5YQ*8H-5T_[%=6Z( K$;ML@]&
M8C\O2J=K\.[*WNO#EPU[/))HRR;BP'^ENYW;G]PY+CW-36_Q#T6ZLY;N*+43
M;(ZQ)+]C?;/*6V"./CYVW<8']#4O_"=Z/'8:E=7:7ED=-\HW4-S;E9(UD.$;
M'<$YY&>AH R[WX<R75EK&G1Z[+;Z=J=Q)=21I;(90[MN(,AY*;NV,XXSBMT^
M%;25O$*W4C30ZYM$\>-NT"%8B ?HN?QJO'X[T?;?&Z6]L6LK<73I>6KQLT1.
M Z@C+#/&.N<#%2P^,M,-O?RWD5[I_P!AA%Q,EY;-&WEG.&4<[N01@<YXQ0!5
ML?"%]#K.EZAJ'B">^_LQ)([>-K=$RKKM)<C[S8 YX''09-7/%GA2V\6Z?;VE
MS/)"(+@3!XQR1@JZ'V9693]:9:>--,GN+BWNHKW3I(+5KQA?VYBS"I 9P3V&
M1D=1GI6?>_$.QBTB^N+>ROUN8[&2]M8[JT>,7**!\RYZ@94GH0#G% $Y\!V#
M:IXCO6N)\:Y;_9WC4@>0&3:Y0^K84GW JO:>!;F.ZT>:[UV25-)5TMXH+98%
MVO$8R3M.=^"#N! &.G-2V'C""0Q7>HW9LX!HXOY[>:V*;!O(,F[.<<8"XZ8.
M>:LP>.-*E\X3PW]D\=J]XB7=JT1FB099DSUQQD=1D<4 0:?X,GAUK3=1U+69
M-1?3$=+5GMU24[EV9ED'+G:3Z<\G)J'QE!/#JVE:G9Q:E%<0I-$;RPMQ<E%;
M:=DD6"65BH((^Z5]ZOZ5XVTK5]0M;2&.]B-Y$TMI+<6S1QW*@ DHQZX!!]QR
M,BDU_P 33:/XD\/Z9'9RS1ZE-(DKI$6VA8V(Q@]<@$_[(- &'X0\)71M+._U
M*6[CN(=8N=2C2Y5?-D61&C'F!>%)#;L#ITJ[?^ I;J;74M]:EM;/6R6NXUMT
M:7)0(0LAY"D <8/?!&:K^'/B%#<VD*:K'=B634)K+[4MHPMU?SF2-"_3) 49
MZ9/)S6K<^.M)M;J5'BOFMH;@6LUZELQMXY=P7:7]F(!(& >] $NG^%8[!]2?
M[6\C7UI!:OE -HBC*;A]=V:HQ^ X8SIB?;W:WMM(_LBYA:($74&T#KU0Y&>*
MMZ'XFFU;Q3X@TF2SEBCTV5(XY6B(# HI.23C)+9'JN#3]4\9Z9I5]<VLL-]-
M]D57NY;>V:1+8,,@N1[<\9P.: (-+\+:A9RV4=WXCN[RPL4*0VWE+'Y@V[1Y
MS+_K,#V SR<FJ=OX"G@_LJU.OW#Z5I-REQ9VA@7("YVH[]6 !P.![YK?/B+3
MP=7^=S_9*![HA>@,?F#'K\IJC=^-=+MC"L<-]>226JWC1VELTK10MT=\=,X.
M!U.#@4 6]?T'^VA930W<EE?V,WGVMRBAMC%2K J>&4JQ!''UK)3P,))C>7VJ
M2W.HR7]O>S7'E*@809V1J@^ZHR>Y.23FJ,?Q#MTU_54V75]IL=G:W=LUC:M(
M5C=69G8CMPO!YZX'6NRCU*SETE-42X0V+P"X$W1?+*[MWTQS0 FJZ=!K&D7N
MF7.X07<#P2%3@[64J<>^#7-6O@J[^WV=WJ6OS7SV=K+:0K]G2-0DBJI)QU;Y
M1D]..@[WM-\9Z;J>H6MFMOJ%LUY&TEH]U:M&EPJC)VD^QS@X.*S[?XF:#<Q6
MDT4.IF&]!^R2_89-MPX',:<<MU]N#SQ0!H0>$H8;#PQ:BZ<C02AC;:/WNV%H
MN?3AL_A5"W\"-IMOIC:5J\EK?V$4L N&@6198I'WE'0D9PV""",8]ZNIXWTA
MM(.H$7:L+HV7V1K=OM!N!_RS"=2V.?3'.<4U_'>BP:?+=W/VN!H;E+6:VDMF
M$T<C_<!0<G.1@C.>U #6\+:FEI;>1XFO3>QO*TTMR@EBG\SDJT60 !@;0"-H
MSUR:KVO@B?2].MH-*UR:VF22>2?? KP3F5MS9A&%&#]W&,#(YR:N0^.-':RU
M*XN1=V1TT(;F&ZMV210_W"%YW;CP,9R>*RE\?(/$=^EQ!=VFG6&CM?W$5S:E
M)5(?[P!ZC;Z=_<4 ='X;T"#PUHL>G02M*!))*[LH7<[L7;"CA1DG '05D:5X
M(_LRXTQCJDD\.F7=Q<6T;0JI59E<%"1UP7)S0OQ#TE[@6\=GJSW$D?G6T*V#
M[KF/^^@Q]T>IQU'J*LGQQI#V6GW%HMW>OJ$;26]O;6[/*54X<E?X0IX.<<\4
M 07?@B*XDO;B+4)H+R;4UU.WG1 3!*(EBQ@\,I52"#UW&M71=*O;"2ZN-0U>
M?4;FX*YROEQ1!1@!(P2%ZDDY)/X"J$OCK18[2PG0W4YOWDB@AAMG:4R1_?0I
MC*L,'(/3!SQS6=JGQ"ABT[3[O3K*[F,VJ+I]S"]LWF0-_&I7L^,8['- &[I_
MARVM-5U;4IV%U<ZC,KEI$'[M$0*B#V')^K&L8> 1:7C7FEZK)9W"7LUW:GR5
M=(1,!YL94GYD8J&QP0>AKH]7UFRT/3S>WSNL998T1$+O(['"HJCDL3V%9#>.
M]&AT_4+N\%W9G3Q&UU!<P%)8U<X5MO=2>XST/I0!7LO PMA$UQJL]U.NL?VN
M\KQJ"\GE>65P. O<>G2K%]X-@OK#Q-:->2(-><-(P0?NOW21\>O"9_&M?3-5
MBU33OMPM[NUCRWR7D)A< =RK<@=ZR;#QQI6H7ME!'#?Q1WY(LKF>U9(;@A2W
MRL?502,@9 XH 9/X+@GU"YNS>2!I]4MM2*[!PT*(@7Z'9G/O2ZMX,@U:XU>9
M[R2,ZDMHK (#L^SR%QCUSG%8FC>/+^>;PQ;75H\S:H]V)IHH#A1'(R+C!P,8
M!;T'/>MZS\<:/>W=O%$+M;>ZE,%M>O;LMO/(,_*C]#G!P>AQP30!4U+P1/JM
MP\5WK<TVEM=K=BVEA5Y(V#!]B2GE4R.@&0. 0*=+X(\R^NY/[4D%K<:I!JHM
M_)7Y)HRA(W=2&\M1CM4D?Q T61;V0)?_ &>S9XI9_LC^695D\ORU('S.6(P!
MUS]:K:KX_@M=!UVXM["]CU+3+(W0M+NV9&92"%? /*94Y(/&#TH M7OA*XE\
M1WFKV&KO9/?01P7(^SI(X5,X,;G[APQ[$=\54M_A]#;6^BVZ:C(T6G6,NG2H
M\0(N;>3;N4\_*?D'(]ZFMO&%K&]Y=ZC=O;6UOIUO=26\MJ4:+>SKG.26+%0
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M>YT[Q+K]Y(!]FO#;>0V[)(2(*<^G-87B/0M?U+7]0W6]Q>Z?- B6*QZFUK#
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M;!E8>H(ZT 5]*MY+31[&VE $D-O'&X!SR% -96@:1=Z?X@\37EPJB'4+R.:
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MY\Y=_P HR?ESG@=: ,CQ9I5]JECIUQIZ1O>:=?17J02OM67:&#)NYP<,<'U
MKFM:\-:]XE_MC49["*RFN+2VL[:T:=78JD_FN[L/E'7  )Z>]=Y9:II^IB0V
M%];70C.US!,K[3Z'!XIEMK.EWDK16NI6<\BL4*13JQ# 9(P#UP#^5 %B[6X>
MRG2UD6.Y:-A$[C(5\<$CTSBO,].\*>(9-4\-WM[8W/VFPNA)?W-WJS3F4^6Z
M$Q1Y*JN6ST4]!CK7I:WMJT4$JW,)CG($+B08D)&0%/?@$\>E9.E>*M/OO#=O
MK=Y+#IUO,SJ/M,RJ 5=E^\<#G;F@#EK'PKK5A;^%P;5)3927L5VJ3A2D=PYP
MZD\' YQUJCH7@2_L1HVFW.C!QIT\;R7\NKSO"ZQG*M' 'X<X7@C:ISU'%=SJ
M/BO2--ETE);N)UU28PV\B2KL.%9MQ.?N_+C(SR0.]6(=:MUL)[S49+:QABN)
M(=\ETA3"L5!+9P"<9VGD=#S0!RP\/^(;/P+=6%@WE7[ZG-<,L4XC>2![EI"J
MR?P,4. >Q]*RE\%:O<R>)&2Q:TBU+0GL8!=ZBUU+YI+<R,Q;&=W8D #U.*]'
M.IV M8[HWML+>49CE,J['X)X.<'@$_0&GV=]::C;BXLKJ"Y@)P)() ZD_4<4
M >>WGA/7=9%_=26L-E<RV.GB&*28.OG6T[R%6*_PGY>?]KVJ?6M#\0>*FO[N
MYTV/3FCT6\L+6!KE9'FFG51DE> @V #//.<"NWN=5TZRN8K:ZO[6"XF_U44L
MRJS_ .Z"<G\*6;4["WN4MI[ZVBG=E5(GE569CG  )R2<''TH PI-$O6U_P +
M781/)TZUGBN#N&0SHBC [\J:Z>LC4/$>GZ;KNF:/<2JMUJ&\Q NH V@=<G/)
M.!QR<U<35=.DU!K"._M7O4&6MUF4R*/=<YH MT444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P_
MQ+M+NXL=&FB+?8K;44EO,6QN J!&"NT8^^JN5)';KVKN** /'18R3V.K7=I)
M<WD-QJVEG>FG?9H9&2=-[QKDDX& S8 ^4<G!J34=.@G?7])DTYVDF\4V<[Q_
M9FVR6S- "<XP5X?//'.:]>HH \I\8:'>-?>+;?1;%XTN-+L&9+>'B8+/)YB@
M# 9O+&,=2"!WJC+:_;X=?N=/N9KS;X=NK=S;:.;2(EE^2-LG+.,'  . 3TSB
MO9*@>\MH[V*R:=!<RHTB1$_,RJ0&('H"R_F* */AO3;32_#]E!:6D5LOD1EU
MCC"Y;: 2WJ>.IYK@+""9_ &@6XB=[FV\2H+I54DJZWK%R?YY]#7ILMY;075O
M;2SHD]QN\F,GYGVC+8'L*H:$-+N4N=6TF5G@U"3S'P"%,B_(S!2 03M /KMS
M[D RK8&3XKZB\7^KBT:WCG(Z;S+(R ^^W<?QKF_%%@L^N>*'NH;];8KI;K/:
MVXF\MD>0[RA!$BJ<%EP>.U>AV.F6]A->31!C+>3&::1SDLV H'T"@ #T%7*
M.'^'TT\MUK6^&UEA\R(IJ=M9/:B\;:0<QL<97"@LO!S[50N] FO-5^(ES:62
M_P!JRQ1QV%RR88-]D4#8QZ<DC(_I7H]% 'C.D:?+>W&D0Z5=SK?6EE.@2'1C
M:?9282NR:0L/XRN ,DLH/3FI[&;1A=?#VQMM,EM=4L[GR;G?:-&86%M('1F(
M )9AGJ<X)KU^LG6(--EOM&>_:0317FZSVAB#+Y3CG Z;2_7 Z>U 'FMK=E?#
M6@>'OLE[_:=GK\37,7V63$2"[+;RV-NT@J00><^QQ9MM&-[KFF17NGM-;?\
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MUO97<B*?]&>,*'=O3,#./K&M>D:MJUEHFFRZAJ$WDVT6 S!2QR2%  4$DDD
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M+C)7/!S5.ZCN-0\,>+H4M;;4HVMK=H]2MM->V-Q(&(V&,Y#,H_B7LV*]GHH
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MQ/''=QSW32QW"/$SNRQD[4V$ C8!@#!KT#2]/ATG2;/3;;/D6D*01[L9VJH
MSCZ55L?#.A:9?O?6.D65M=/G,T4*JW/7! XSWQUH Y_X:VUQ-X<AUF]U34+V
M[NPZN+BX9XT"R,%VH> < <]37:U#:6EM86R6UI!'! F=L<:A5&3DX ]R:FH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N7\<SN=-T[2U8JFK:C#8RD'!\HY>0?BB,O
M_ JZBL+Q9I5QJ>D1R62A[^PN8KVU0G =XVSLSVW+N7/;=0!RFN:E';:IKT(T
MRP<0:AI$>7C.7WR( 6P>JY^7&,8'6M^TE-A\2KW3X^+?4=/6_*=EFC<1LP_W
ME:/_ +XJ>Z\(Z?J4UY=S/=QO?S6ES*H91M:W(9 .#CD#/7VQ3['3;B7QEJ.M
MW49C1($L;-21ED!WN_\ P)B /9,]Z ,+7M;O],\1Z^VE:7#<WL&F6<BNL+22
MLK32JV54Y<(H+!1@GGGFM+P9XAEUT7Z2ZII^H"W9 KV\$EM*N0<B6%R2AR.#
MGGG@8JWJ?A*QU2^O;R2YO(;BZ@@A+P2A#%Y3LZ,AQPVYCUR#@#'7,NC>'(]*
MO[O4)K^[U#4+I$CDN;K8#L3.U0$55 !9CTR<T 8.IZYXFFUSQ#::5+IEO;Z/
M;Q3JUS;O*TQ9"VPX=0H^4\\]1Q26/B77/%%U#;Z*]C8!-,MK^XDNH&GR\X)2
M-0'7  4Y;)ZC KI!X?M!>ZO=^9-YFJQI%.-PPH52HV\<<,>N:R_^$'MH%LFT
MW5=2TV>VLH[!I[9HRTT*#"APZ,NX<X8 $9- '.:/KFK^(?&OAR\,\%K&VGWJ
M7-J(V<>9%/'')M;>!R0-I(X&<YSQT?BC5M;M]<T32-$:RBDU$7!>>[B:01"-
M58$*K#.<D8SW'IS+;>"M.L;C1IK"XN[4Z5')$@C=3YR2,&<2;@2<LH8D8.<\
MUJ7>CV]YK.G:I(\HGL%E6)5(VGS  V[C/\(QR* //;OXB:L)M4FM?)==-N7M
MEL%TNYD>[,9VN1,ORH20VT8.,#)YXN^*?&VHZ;<ZB;+4=-A^QVZSQ61LIKJ:
M;Y-Y$OED>2.PR#QR>*W+KP-;7%Q>F'5=3M+*^F\^[L;>5%CE<XW')4NN['.U
MAFFWO@2TO)]4V:IJ5K9ZKS>V=N\824[ A.XH77*@ @, <4 8.L>.M7M;I)/-
MLM)LY+.&XM9+ZSFE@N7=<LK3H0L6.!R">_3BMA]9\0ZSK.JVNA3:9;PZ6L2E
MKF)IOM,KQB3 *LNU,,HW8).>G%2W'@2"6![>'6M6MK::UCM+J&*2,K<(B; 3
MN0[6*\$IMS4ESX(M6N))=.U+4=)$\"6]Q'9.@69$7:N=ZL58+QN4@X_"@#&T
M_P 6Z]XJO[&#16L+"&YT:+47DNH&G9'9W0H '4$?+U]CP<\1#QSJ%YHFAW)O
MM+TN6]MY'FW6\EW(TB-MQ%"A#;<@G<2<<#KS76Z;X8TW2-0BN[)7B\FPCT^.
M$-\BQ(Q9>V<_,><UE6_@"TL&LY-,U;4[&:VMVM3+$T3-+$TADVMO0CAB<$ &
M@#EHM:UGQ1>^"K^V-I;:BTFHPR220/Y:B/Y"XC)#9.W[I(P3STJW>:O?ZEJF
MB6.H?9_[0TSQ+]EDE@0B.7-G*Z.%))&5<9&3R#S6Y'\.]/MK;3HK+4]4M9-.
MFN)[:=)49U:8Y?.Y2&')^\#UYS5VU\%Z?;)9DW%W-/;Z@=2>XD=2\\Y1HR7^
M7&-K8PH&,#'2@#+TOQAJ&I+H5CY-NNK3W4\.I1A3MA6WR)649R,L8PN2>''6
MI_%9V^,?";8!P]X<'H?]&:D\*Z'*OBC7?$UWILNGRW[)'#;2R*S*JJH=SM)4
M%RJ\ ]$!/6M_4=$MM3U'3[Z9Y5EL3*8@A !\Q"ASQZ'CIS0!Y/;^+1HMWX>U
M"*Q@CGO?#5O%!$BLEM SS* 7/.R-21R3Z#O75ZYXOU*PUZ+05O+:WN(;)+FZ
MN_[+GN5=V9@$6.-LH/E))9CV [FMFT\":/;6\-NXGN((]*&DF.9E(> '.6P!
M\WN,?2F'P3'']CEM-;U6UOK:U%F;Q'C:2:$$E5D#(58C)PV >3SS0!R]MK>K
MZSKMCJEK9);ZP?#M]Y=O/&X1I4GB ^4[6VL5R,X.&%=-HWBU_$.K:9%IR1_8
MY=,%_>,P):,N0L<8YX.5DSG^Y5JV\,V>AO;ZC:+>W5Q86$MM'$TH=IPS+(V2
MV,N64<D@<]NU3P'X>;1+'4;N>T-I<ZG>RW1MF<.8(RQV1Y!(X!)P. 6- &9K
MNI7^D_$6>_:ZC;3K+P_/=R6WE,694<$@'?@,2!SMZ#&.XL6VO>([";0+K67T
MZ:SUF58##;0NCVKO&SI\Q<B0?*0>%YY'I6YJ7ABTU/6X=4EGN$=+:2TFA0KY
M=Q"_)1P5)QGG@@U3T[P3;6-W82S:IJ5]!IN?L-M=2(8[<[2H(VJ&8A20"Y;
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MWD\L+31H(Y1%M1 RD[FR>3P!W-=%HGA*PT&>TFM9;EVM=.CTY!*RD&)&+ G
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MHH **** "BBB@ HHHH **** "LK7==AT*WMV>WGNKBZF%O;6UN 7FD()P,D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** #I1110 4444 (RJV-R@X.1D=#2T44 %%%% !
M1UHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H+J]
MM+&,27EU#;QD[0TT@0$^F34]<EXTT34M;N-)CLH+66&&5I)5NFPA.!MR!R1U
MZ5K1A&<U&3LC.M.4(.45=G36M]:7T;26=U!<(IVEH9 X!],BIZY7P1=1/#J-
MA_9MK8W5E<>7<):C$;GLP[]OTKJJ5:'LYN(49\\%(****S- HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>exhibit101-arrowheadindu006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101-arrowheadindu006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQG?C.WZXYQ4U !1103@9/2@ HILDB0Q-+*ZI&@+,S' 4#J2:4$, 000>010
MM%%% !1110 4444 %%%% !1145S=6]G;M<74\4$*?>DE<*J_4GB@"6BJT6HV
M,]R+:&\MY)S&)1$DJEMAZ-@'..1S[U9H **"<#)Z44 %%,$T1F,(D0RA0Y3<
M,[3P#CTX-/H ***J76J:?8RQQ7=]:V\DGW$EF5"WT!/- %NBBB@ HHHH ***
M* "BBHQ/"9V@$J&95#F/<-P4Y ..N.#^5 $E%%(S*BEF8*JC)). !0 M%-1T
MEC62-E=& 964Y!!Z$&D,L8F$)D3S2I8)N&X@<$X].1^= #Z*,T9QUH ****
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MY^U#3OM!^S"7=NW;/3=\VW.W/:MG3=)M=*-X;8/_ *7<O=2[FS\[8SCT' H
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MR0S-(DI5HY(AB-T(Y4BH1X'TI[#4[:[DO+R34XA#<W-Q.6E9!G:H(P% ))
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M +?AGQM+XEGMW@TH"PN-^V>*[25X2,D":,#,9..F3SP<5IZYX@ETV_L=,L+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.N?NSSO(TD2_2-7W?[Q7TKO=?O)M/\.:G>6\;R3P6LDD21J69G"D@ #J2<4
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MC.2&GE5!P,GDGL*\[\.Z=<_\)F/#4D3#3/#=Q+>P,?NN)A_HZ_\   \X_P"
M+6_XKTQ-3\5>$5GL_M-K'=SO*&CWHN('VENWWL8SWQ0!L6VOVCVE[>75Q9VU
MG;S>6MP;M&1DVJ0Q;.%SNZ'GH>XJMJGBW3K&SM+JVGM[V&>]@M6>&X4K&)6
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M110!F:-H5GH:7/V9KB66YE\V>>YF:621L #+'G    [5IT44 %%%% !1110
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M%F.<Y!X QR.>M3>*-9N]*@T^#3XX6OM1O$LX&G!,<9*LQ=@""0%1N 1DXYH
MYR[^'MQJ.KF:];1WB:\6Y>]2P"7DB+()%C+ [?X54N!DJ.G-=U>V5KJ-G+9W
MMO%<6THVR12H&5A[@UR5YK/BG3KFST:9=,EU'4+LQ6E\L;K#Y2Q&1W:+>3N&
MT@#?@Y!R*HWWC'7]+%]IDL.GW&K6M[8P)*J/'#-'<OM4E=Q*,"&!Y/0'VH Z
MNV\+Z%9Z?/86^E6L=K<,&FC$8Q(1T+>N,#K6O7!W'B;Q-I9\06$UM9ZEJ-A:
MV]U;M9V\B!TE=E;='N9B4V,V <L..#5$?$:>UT#4;PW^E:I+%-;P6Y@@EMW6
M25MO[Z!BSJ%Z\'+ $  T =I9^&-"T[47U"STFT@NWW9ECB /S?>QZ9[XZ]Z3
M3_"V@Z3?->Z?I%G;7+ CS(H@" 3D@>@/?&*XI_B#JEGIVNL3;:A)9::U]!=I
M83VT193@QNKDG/(((;D9X&*T;G6?$]K?R:5?S:8)+[2[B[MI;>"0?9GCV HV
M7^<8D&&&WD=* .AA\(>'8-0:_BT6R2[:7SO-6$!@^<[AZ'//'4U<_L?319"R
M^Q0?9A-YXBV#;YF_S-V/7?\ -GUK*\ -=O\ #_0)+V=)Y7T^!PZH5.TQJ1NR
MQRV.I[GG Z55\4ZD=.\1Z*4M;>67[+?2I+("6C*1J<+@C@]#].U &S+X<T6:
MXOIY=+M'DOT$=VS1 ^>HZ!_7H.OI4=KX5T&RL;BRM])M([:Y(,\8C'[W'3=W
M..V>E<UH_B?Q')<>%[C5%TUK3Q!$2L-M$ZR6[>09E^<L0X(4@\#&1UJ#PYXS
MUC5M7AL+RZTNTO9TE\S3+BTF@N+9@"5VEFQ...=NWCD&@#L]6T'2M=CC35+"
M"[$1)C\U,E">#@]1GOZTG_"/Z/Y1B_LNT\HVWV0Q^2NWR<Y\O'3;R>*\[\-Z
MYXIA\-^&+"VN=/GN]6FNQ]HNH9#Y2IN;+?/ESD-W'4>A)WYO%VJ6WA/Q;J,D
M=HUWHD\L,6U&$;[(HWRPW9ZN>AZ8H W;/PEX>L#NM='M(GV-'O$8W%6 #*3U
M(( &/:KL.CZ;;AQ#901AX$MFVH!F) 0J'V 8X'O7$ZUXM\26\WBFXL5TQ;+P
M^D<I2:)V>X!@65ER' 0C)PV#U''!)DN/&6L:!<WC:Y'93P+HTNJQ):(R-&49
M5,1+,=V=Z_-A>_% ':1Z781&R,=I"IL4,=KA1^Y4J%POH, #\*9JFC:;K=NM
MOJ=E#=1(V]!*N=K>H/4'W%<3HOCC5)]5M+6Z:VO%O(9';[-I]Q +214+A6:0
MD.IP1GY3G''/!I/BKQ//9^%]2O\ ^RA:Z_MB$,,$@>!VA>17W%\,#L.5P,9Q
MD]: .LN/"N@76FVVGS:19M:6QS!$(@!$3UVXZ9[XZU:@T;3+5;);>PMXEL=P
MM5CC"B'<,':!TR"?SKG?AG)J,W@V*74;N.YD>YN=K*C*P G<'<2S9Y!QTP,#
MG&3H^*-9O-,CTVUTU(#?ZE>+:0O."8X_E9V=@""V%0\9&21S0!>N-"TF[MKN
MVN-/MI8;N3S;B-XP1(^ -Q]\*O/L*A7PKH*Z0VE#2+/[ S^8T!B!4O\ WC_M
M>_6N$BUC6= \1>*'N4L[K5;B;3;.V:-6CA=I-RJS*22H&22,GIP>:T]4\8:U
MX6EO;+5DL;^Y^Q+=64MM&T"NQE2'8ZEGQAI$.0>1GCB@#K+7PYHUE9Q6EMIE
MK%;Q3BX1%C&!*#D/[MGOUJVMC:I=SW2V\8N)T6.60+\SJN=H)[@;F_,UR6KZ
MQXL\-Z+J%[?_ -E7B111/%-!"\05VD561D+L2,-D,".G(I_BSQ;?:#>:E#;0
MV[K:Z%/J2>8K$F1'"@'!'RX/U]Z -X^'-%-L+8Z7:F$6OV/R_+&/(SGR\?W?
M:K%YIT5RQG0+%?+!)#!=! SPA\9QGCJJG!X.!7'IJ_C.3Q#!HIFT6.6\L#?I
M-]FD86X5E4QE?,'F'+KALKWXZ"L[_A8][<V>APJ;2PO+VUEN+JX>UEN8X_+D
M\O"1H0QW-D\D  =S0!I:#X!DT_Q!9:I=QZ-"UD)"O]F67DM<2.I0O(<G  +8
M4<98G-=7JNAZ7K:1)J=C#="%BT9D7)0G@X/49KB[;QKKNIQ:+:V=M9PWM[?7
M%G+-<02B+$49<2HA*M@@ [2>O&>]4=7UKQ%?V,%HUW907UAXFM["6:*!_+G!
MV.C;/,! ^<;ER<XX(H [^U\.Z+9>6+72[2 13>?&(H@H639LW #H=ORY]*AU
MG2;F6POUT7[%:WU^0+B>>$N&&W9D@$98+C&>.*C\4:U=:+IUH+.*&6_OKN*R
M@\W(C5W/WFQS@ ,<#DXQFN:UGQAK_AJ'6+2^33[V_M;*.^M9H8GBCE5I1&R.
MA=BI!/!#8.?:@#M='TNWT/1;+2[08M[2%84SU(48R?<]:)-'TZ6"]@DLH&BO
MB6ND*#$Q*A26]> !^%5[2?4=/T.>ZUV6UEGA5Y7-G$R($ S@!F))Z\]_05R]
MOXF\216.AZQ?C3/L&LS0PK;0Q/YEKYP_=$N7Q)R5##:O7CI0!)XG\$WFNZE<
M2JVBR131"**6\L!)/9C;@^6P(W?W@&Z'VXKJ=-T:QTN. 6\*^;#:QV@F(^=H
MXP=JD^V2?Q->5:<^OS:?X0D^V6D]\^OWZPR2Q/M0 7(8M\Y+8^8@ CC"Y[UO
MWOCS5-'L;ZTOULI-4@U:/38[F.&3R2'B$HD,8+-PI.5!Y('- '9'PWHK+8*=
M+M<:>2UG^['[@GKM].WY4S3?"V@Z-=M=:=I-I:SL"N^*, @$Y('H">PQ7%R?
M$#5[?1M9:.*VOKFR-J;>Z^R36T,XEE$94JY)5ESU!(Y!]17<VCZI::(\FJRV
M4]]&CNS0*88CC) ^8MCC&230 [5M"TK78HXM5L(+M(FWQ^:F2AZ9![4EMH.D
MV8MQ:Z;:PBVD:6$1QA1&[ JQ4#H2"1^-</I7C^]?7=+MKJ_TR_MKZ.9I?L%I
M,BV[)$9,+*S%)1A2.,'OTJQ;^*/%#67AW6)ETHZ=K=U @MEB<2VT4HW*=^_#
MMMQGY1@GO0!V%SH.DWD%W!<Z=;2Q7CB2X5XP1(X  8^X"K@]L"HK;PQH5G8W
M-E;Z19I:W0"SQ"$;90/[P_BZGK7%OXY\06NA7NN74>F_9?MTFG6<"12%S(+@
MQ+(Y!/R@ DJHR<<$9P#_ (6/=Z;::O)>+%J2VED+F"YM[*:U1G+A/*99-W.6
M4Y!.1GCB@#LK7PIH%E8W-E;Z1:1VUUCST$8/FXZ;NYQVSTK8KS6/Q]JMNMZL
MKVFH%=-N+N.:#3[BW2"6)-PC?S"=RGG!!!^4\<BK,&O>,IM4TFP:318VUBQ>
M\C<6\A^R;-F5(\S][GS%&<IW/L0#K;+PYHNG3":STRU@D65YU:.,##N,.P]"
M0 #3KGP_I%Y:W-M<Z;;2P74OGS(\8(>3 &\_[7 YZ\5PK?$6_;3M%@<VEIJ%
MZUV+BY-M+<11BWE,1*QH=QW-C&6P!G)/%3P^.-<O;+38;2WLQ?7&KOIK3SP2
MI$Z"%I!,B,0P' ^4GJ",]Z .XTS2-/T6T^RZ;9PVL)8N4B7&YCU)]3[FIH;*
MUM[JYN88(TGN2K3R*N#(5&T$GO@ "O-/$&M>(KC2;W3I;NRBO]-UVPMWN8('
M5)DD>)E^3S,KRXW#<00".,Y':^)M9NM"T**6".&?4+B>"TA#@K&99'"!CR2%
M&2<9SQC/>@#5GL;2YN8;B>WBDFA5UC=U!*!AA@/J ,UF6?@_PYITT<UIHME#
M+$XDC=8AF,C/W3_".3P..:XG4-9U7PKXKUO5M9^R7LMIH,30FUC:%9<SL "I
M9BIW'&03QS[4]O%^H7MO?Z9>2V]]'<Z7<R>?:Z?/;"WD5,[&\PD,""<,,'*\
MCF@#T!-'TQ+2VM$LH!;VL@E@B"#;&X.0P'8Y)-.U/2=/UJT^RZE:174 8.$E
M7.UAT8>A]Q7F^FZ]<Z/IMS=V=A:N^GZ%I-Q.Y1C)+ ?,\P9#8RJ*Q7CJ3G-:
M^O\ C^?3IM3>RBMYK2V:ULX965V#74QW'.W)*)&R,0!DDXH Z:#PMH-K#)#!
MI%G''(8VD5(@ YC;<A/J0QR">]79M,L;B>6>:TADEF@^SR,Z [XLD[#GJN2>
M/>O/9/B%JEEIFNN1;:A)8V(O(+I+&:VB8[MK1NKDG(R""&Y![8JSJGBW7=(U
M&ST6_N],@OYX7NY;J.PGGCBC!"K&(U;<S9W98D# Z9- '6Z7X8T/1)S/IFE6
MMK,4*&2*,!BI(.W/7'RKQ["G:GX<T76IXI]2TVVNI8@51Y4!(4]5]Q['BN3L
M?&FLZRFE:=9P6MKJ=W+<K+<7%O(81'!MS(D9*L=^], D8R<YQ5WX?"]!\3C4
M/)^UC6Y/,,((0GR8>0#D@$8.,G&<9- '26NAZ78O"]II]O T'F"(QQA?+\Q@
MS[<=-Q )^E97B+PS)JFC3:/IQL[.ROY6.H$PEG=7.7*8( <\\G/7/:L.Z\6>
M(#I&K>);1-._L?39YT^QR1N9IXX6*R.)-P"'*L0-IZ#)YK3TG6]<UCQ?JEM"
M;"/1M.FCC):-S/,'@208.["X+=<'(.,#&2 =5'%'#"D,:!(T4*JKP !P *BL
MK*UTVRCM+*".WMHAA(HUVJHZ\"N7\1^++S0=1U&V,$#C^S!<Z=D$&2?S/+,;
M<\C<\/3!^8URGB7Q=>>(/ -] (($/]@27.H@ YCGW^6$7G@;DFZY/RB@#TF'
M0-(MTLUBTVV1;%VDM0(P!"S9W%?3.3T]:5M!TA[*]LVTVU-M?2-+=1&(;9G;
M&68=R<#GVKDKW6]=T^>[TS6TTRZCN=&NKR)8(70(8PH:-\N=ZD./F&T\'@4F
MEZYK^KQBQ\/II=FFGZ=:R2"YA>02221;UC3#C8H&/F.X\].* .D@\(>'+>.6
M.'1K-1+$T,O[H$R1MC<K'J0=HZ^@JWJ>AZ7K-M';ZE807,43;HUD3.PXQD'M
MQQQ7"1S>)?\ A,?$]QIQTZTGCT^RFN([I'G&\)(?+4JRX&<Y;GMQ74G6!JGP
MX;6FMH_])TDW1@?)7YHMVT]"1SB@"PWA;21!8V]M9PVMO9W@O(XX(U5?, (R
M...O;Z=ZT;_3[/5+*2SO[:*YMI!AXI4#*WX&N$T_7O$>H%[#15TBSAL=(L[L
M&>"20%I$8B, .,+\G7)(]#GCJM(U6XU[P99ZM;B.VN;VQ6= ZEUC=DSR 02
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M;W=IHME;W]P;B\B@1)YB<[W &3G SS["N9N/AEH5SH^K::TEVL.I7WVV1ED
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M;3+[39(%U#3+K[1"MP2(Y 49&1B 2,JYY ."!Q6]574=2LM)LGO-0NHK:V3
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M)W]/:@#-N_!U]/X3\2:2L]N)M4OY;F%B6VJKNK -QG/';-6I_"]W+!XSC$T
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M3^U[06+R&$3M( N\ DJ<]#@'@\U9TG7-,UVW>?2[V*ZCC?RW*'E&]".H/UH
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MW*1%C&D<<1B6-"1ECC!R0,DGI4]SH7B*PU'6VT)]->VUAQ,S7;NKVTOEK&S
M*I$@(53@E><\UM67BK0=1U(Z?9ZK:SW8W 1H^=Q7[VT]&QWQG%-3Q?X>?51I
MBZO:F\,AA$8?K(.J ]-WMG- &!8^$]8\*S*WAM["YCDT^WLI5OY'C*M"&59
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MC[+%-87+NT<NQF&Y709!"GD'B@"II?@S5[>?2KB]NK.2:VU.^OIS%N"L)TD
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M:N:7JUAK=@E]IMU'<VKDA98SP2#@_K0!F>+M'O\ 6M*MX=-FMX;J"]M[I&N
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *Y;QG:73R:%J,%I+>PZ;J(N;BVA&YV3RW3<J_Q%
M2X;'7CCFNIHH \YU 7E]JUAXCA\,7$=E9:EYLL?E!;JZ4P-&)C$><HS  'YL
M D <52U+3=4U&XUCQ#;:/>);MJ&F7$5H\>R>=;:3=(X0G()!P <$[/I7J=%
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M>[*G!50V_P T>I6/SQGW6O1JSSHFG'7!K+6P;4!%Y2RL[':O?:I. 3W(&30
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@8V39G;M*ELC'))->Q@!0   !VJ 6=H;<0BV@,&[S @0;=V[=NQTSNYSZ\T
M>+^,-35K/Q#K-FQCGL[]HH[V[U=TGCD1E79# BX"<' 8\@DG-:/B*Y6PU_6-
M7EN5U&"UO8MS6^HR6][8X"?NTB8;)%/7 ^]O/4UZC)HNE2W4MU)IED]Q*I22
M5H%+NN,8)QDC':G2:1IDU['>RZ=:/=QX"3M ID3'3#8R* .?^)#3+X(N?(N)
MK>1KFU02PN5==UQ&#@CV-<EK6FFS\8Q>'X8K8Z3!IOVBVM]0U>>W5Y&D?S'#
M@,791MX)^4'(ZUZE_HFH6_\ RQN8"WLZ[E;\LAA^!%0:E9Z5?+#!JEM9W"L^
M(H[I%?+X)^4-WP">/2@#RS29(=3U/PM:>(=;%Q:RZ=>E&CNY%CNBLZ",,S!#
M(0F>2/F*YYIUC$==NO#^EW%[>3Z,^IZE# RW3@W-M&I,8+@AF4$8!SR%%>A7
MWA6PU'7;74+J*&:"WLY+06DD*M&0SHP.#QQY8XQWK76TME\G;;Q#R!B'"#]V
M,8POIQQQ0!XOJ3WSR^)YYKNQM+G3;MX;2YNM7GBELXU5?)*0K&P8$8;N7)(-
M6O$%S)::GJNL7EU'?BU>!IA;ZA+:7E@PC0E8HV&QU8\@8&[<1R:]8GTG3KJ\
MBO+C3[6:ZB_U<\D*LZ?1B,BB?2=-N;V.]N-/M);N+_5SR0JSI]&(R* /)=<N
M+V^UCQ9/>7%E;R6$@%K+=:M-:R6<7E*R21Q(C!LDDYY+'*XXQ6Q;Z7_PD6OZ
MTNM7-Q,UOH]C(%@N)8HQ,Z2EI%4%2#E>,C(]*]"N=)TZ]N8KF[T^UGGA_P!7
M++"K,GT)&14LHM+43W<P@B!0>=,^%RHSC<Q[#)Z^IH \>M[B:2;1=;\QI=<?
MP7)<6[/*VZ:Y41[?ESAB<GC'/6I?#DE]!>^';NQO--\^\B=I0FKW%W)?CRBQ
MWQF,*K!L'<2-O*]\5ZS_ &=8$VS?8[8_91_HY\I?W0QCY./EX]*;;:5IME=R
MW%K86D%S-DR2Q0JKO]2!DT >26<>E3:=X%U(ZG+-KMWJ<#7BR73,TDNUO,#1
MDX78W X&WIWKV&"ZM[KS/L\\4WE2&*3RW#;''53CH1W%0+H^F)>/=KIUHMR[
M!VF$"AV8="6QDFG6.G6^G?:3 I!N9VN)2<<NV,]/8 ?ASDY- 'C=_<ZG<GQ%
MJ,]YI]IJ5IJ<L4%U<:K/'+:A7Q$JVZ1L&5EVG SOW'\-?Q+>/#XSDM4O[N/0
M)I+8Z^\3'9:RG/EJKY!17^0/CH,'C<:],ETG3I[Z.^FT^UDO(_N7#PJ9%^C$
M9%)=1Z99V-T]VEG!9R$O<M*%6-B>"7SP<\<F@#S'4O[(EO?'UQJ&KS0WNGRA
MK-1>-&;;_1HRC1J&')?CH<XQWYEC@U#4=3U_4[G[4^KZ;HUG<VMLLSJB730R
M$G8" QW*!@@CKZUVFE^&-)6_O=7"6E]]NN$O+>0PHPA'E(@\MN>"$!R,=:WE
M@B2:298D660 .X4!F Z9/?&30!Y%X7DNHM0\,7<%_IZ27JL;AH]5N+N:^7RB
MS%XC'A6#8;.1M(V]\4SPY=#3=0TEYKT79OXYUCU?3[^25KC]VS%KBV<9!&W/
M'W6P..E>L6VDZ=9W4MU:Z?:P7$W^LEBA57?ZD#)HM])TVTO);RVT^TANI?\
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MS^N\*"V<[<C&*["V\":-:W5O)&;PVUM/]HM[%KEC;PR9)#*G;!)('0'H!0?
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MW?2WL<XBR(V:?SD!7/(!P#R,^U %C7O&EIX>OKV"\MW,5IIPOFD1AELR>6$
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MC/N!6;=Z?XELKGQ'$NCMJ,NM64*)<P31I%',L'EOO#,& SR, Y!Q3M.M-?\
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MO)7;C:!R3G%6K[1_$8T/5O#L&A2R^?K+7J7OVB(1&%KH3="V[>!D8QCC.?4
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M?:+B15+$[@&954%N.2>3TH MIXRM1XNU?1KE'@@TZTBN6N7AD"<[R^YRNT*
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MNKA/,3Y(C),=V<X/#KP,GFL2[T#Q5J%M#%=Z?JDU]#JD5Q*?ML4=EY2W ?\
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M"V6Y7Y"/ES4[:/XAT_P+X2T^WMKI39QQ)J45C)$+E0(B/W;.=OW\9(.2,X-
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M#YMRBD;C-*8UR>^[H/7I0![!:VMM8VJ6]I!%! GW(XE"J,G/ 'N:E9@JEF(
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M5E#*P(/0@]:6O)WTL6%EXJ?2+<1CP_K<>H65M$,*H$$32HH[!E:08'&6KKO
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MI.3TR:L6M[]HAEEEMY;41S/%B? W!6(#C!/RG&1WP>U>+PKX?_LCPX+D0?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MCMK?V,V9CC$+0&\,&TC;NW8YW9["@#M=/TVS\+6VH:C?ZG+/)<.);J^O"BG
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M*4V%05QC&.,4M% ";5P1@8/;%(40E254E?NDCI3J* &E%9@Q4%EZ$CI3J**
M&F-" "BD*<@8Z4ZBB@! BABP4 GJ0.M& .PI:* $**RE64%3U!'!HP/04M%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%4]5U.WT?3+C4+HMY,*Y(499CT"J.Y)( '<D4 7**SK
M'6;>_P!3O]/2.6.XL1$9@X& 9%W  @G.!U_K3WU2"+6HM*D5TFFA::%R!LD"
MD!E!S]X94X]#QG!P 7J*SM<UJV\/Z1+J5VLC0QLB[8@"S,[!% !(YRPJU>W7
MV*QGNO(GN/*0OY4";I'P.BCN30!/12*=R@D%<C.#U%1W4_V:TFN/*EF\I&?R
MXEW.^!G"CN3V% $M%9]GK%K>W\]C'YBW5O#%-/&ZX,0DSM!/3=\IX&<?C5V:
M:.""2:5PL<:EG8] !R30 ^BLVSUF'4$TZ:UM[J2WOX#<1S^7A$3"D;\\@L&&
M!CL>F*TJ "BBB@ HK,UW7+?0-.%W/#/.7EC@B@MU!DED=@JJH) SD]R!3-3\
M00:/X;;6K^VN8HT1&:WVJ90S$*$P&V[LL!UQ[T :U%07ES]CLI[GR)I_*C9_
M*A7<[X&=JCN3VJ5&WQJQ5E+ ':W4>QH =16?%K%M-KUSHZ+(;BVMX[B5L#8
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MVT332O@G:B@DG Y/ JE;:_9W>KIIL0E\Y[)+Y6*@+Y;,5'?.<CIB@#4HHHH
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M@[R6<I=LV[I9QN&3GY3NQDCK@5ZTRJZE74,IZ@C(-)Y<9#@HN'^\,?>[<^M
M',>*8AJ/PNU47$8G:329),,,Y<1%@?KN -<CHFA>'=>\4:9";>UO--3PW$T<
M2-NA+F9]QP#@D'=]#GO7JV !C''I3(X(80!%$B # VJ!@=: /$8I+BZT_P )
M6VIS6#Z3]ENT3^V)'^SR3)-M17(X+",':&_VL<UZ)\.-_P#PC,H%[%=VRWDP
MM7A#F-8MW"(S\L@.X \C&,=*ZE[:"6'R9(8WB/\  R K^52*JHH50%4#  &
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MM12W4>?/&LLV -_EYC7)[[N@]:[D*H8L% 8\$XY--DBCE $B*X!# ,,X([T
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MU"%I;.XCGC21HF:-L@.IPP^H((K-TK14T6XU#4KS49+N[NV4RW,X1-L:Y"(
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M0O#(MHEB$^AZK+*$&-[8B&3ZG  KVM88T;<L:*>>0H'7K0(8@ !&@"@@?*.
M>HH \9EOX]/TOS9UG>#_ (1#2T9(IS#]^9UR7 .Q>?F;'"YJ&&WLVU?Q%IMM
M'HOV:;PW/+);:0S/ 948;22>&D&>H .",]17MGDQ8(\M,%=A&T?=]/I38K:"
M%56*&.,*"%"*!@'KB@#Q4_8+B?P];>9H)T'^PT>U7492+5KC>?.(VG:9!\O7
MD9..]>@>!-0B@\+:3;76J1W$ET\RV3'>#+&K,0%W_,P5!P3U !KJ&L[5X!"U
MM"T0.0A0%0?7%-GL+>XN;2XE3,EHS/#S@*Q4J3C_ '6(_&@"S1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7+^-;[4[2+1(-+O?L<M]JD=K)+Y2R$1LDA. P(S\H(]QZ9%=152
M^TRTU%[1KN+S#:3BYA^8C;( 0#P>>&/!XYH \_N=>U[2;C5-"75GN9AJ5C9V
MVH7,,9DA2X&6+!556(P=O'4C.:;XCUS7O"BZYI\6L2WSQZ2-0M;FZBB\R%Q*
M$*MM4*RG.1E<\&NWN_#.CW_]H_:K)9?[1\O[3N=OG,8PA'/RD=BN#GGK56/P
M3H265]:R6TUPM^BQW,ES=2RRR*OW5,C,6 '8 B@"]INGWUII<EM>:Q<7MR^X
M_:FBC1DR/X5"[< \C(/OFO*/#VGWTNG^ ((-8N8I)9;]A/Y<1>%-ARJ#;CG!
MY8-C<?8#VFL/3O"&B:5-;RVEK(C6TTLT :XD98FD&'V@L0 1VZ#D@4 </<^*
MM?L[0Z.MW=75U_;TFFB]A@B-P85A$W"G$9DP=N2,8!.":Z?P9J&L7%WJMEJ:
M7K06S1-:S7Z1).RL#E7$1V\%>#@9#>U:=SX3T6[MKJ":S)6ZNOMLC+*ZN)P
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MWOOL-[IGD7%S!$9-D\JAE8!0IQ@X.W(S["NW;PUI#W#SM:9E>]74&;S'YG5
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M9 O*_O&8L-IY&",59B\,Z1%;WT'V4RI?PI!=>=*\AF14V ,6)).W@GJ>IYH
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M:?J'C358[W7(M,T*&Z@T:..:>6:]\HR(T0DPBA&^;&>I Z<\\5-3^'-U??\
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MA41:7;RI=DNN(R8 @[\\CM0!MIX@TV0Z2(Y]_P#:JE[/:I/F*$WEO8;<<GU
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M>-P*]\@8X]159O%T=[JWAV/3)%>UU"YN(+D2QLLD;1Q,VTJ<%6#*,@BL+5M
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MG3M8O&LX5NX+KRO.6&[M7@:2/.-ZAP,C)&<=,C.,UL22)%&\DCJD: LS,<
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M^MA.+.WLY7E"C 9M@!(3/0GKD8S4EWX\T&TM=.G$\]R-121[1+6VDE>4(0'
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MN,$=L,*XCPM;:SK_ ((\.Z4-)%O90WD=T^H>>A0QQ3&0!5!W[R5 .0 .3DT
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M=3U*_OK:&<V\WBW3Y(V:)EW((HAO (SMXSGTH ]46^M'G,"W4#2J"QC$@+
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M3::Y92RHR.6^:)FC'R\!6&[(//<4 =)HGB!-5LKJ6YM9M.GLY3#=07)7]VP
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M,G:/7;G)SFN?U5='@?QG;>(; SZQ>3.;#=;-))/$8E$*PL ?NMD8!X;)..M
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M?SSMSG^,+@9ZCF@#U6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MSZU!X@BN=4\!>)-4O-<OTFM;Z2S6V,W[I8XY@BHR8P68 -NZY88XXH ]CHI
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M3M*MK:<J4WHG*J3DJO\ =&>PP*M:AH^G:K):R7UG%.]I*)H&<<QN.X/:KU%
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MLLI*IN!.XCKT!H TJ*C>XB2V:Y9QY*IYA<<C;C.?RKFQ\1?"9./[9C_[]O\
M_$T =115 ZUIO]D'5A>1-8!=QG4[EQG';WJS:7<%_:175K()()5#(XZ,/6@"
M:BJ#ZUIT>LQZ0]RHOY4\Q(=IR5YYSC'8]^U9VI^-_#FCWC6E[JD:3KPR*C.5
M^NT'% '045GIKNF2:.VK1WL;V"J6:9,D #KTY_"I;?4[.[TQ=2@G#VC(9!*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(!4$<$@GMUQ67/XWDTY;]=7T6>RN+?3I=1AC\Y)!/'&/G7<. XRN1R/FX)H
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M.T%Q&S##[2<':3CO0!GZ;X,U'2)?#4EOJ,-P=,MI[6Y\]6^>.5D;Y.21MV
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MU4::M^/M)F-N,Q.(S*.L8DQL+<'Y<YR,5H:GJMCHUBUYJ-REO;J0NYLG+$X
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M;J7?D!(L[=Q/0<\#N>U4K;QGH%U%>R)?,@LH#<W"S021,D0!)?:Z@E>#R :
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M QR/E)SS0!I:G:-?Z3>6:L%:X@>(,>@+*1G]:PK7PO/;W/A64W$9&BV;VT@
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ML08PI&XC,F,LBN1M) !^7<3Q71:MK>GZ)!'+J$YC$K^7&J1M(\C8)PJ*"S'
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M'4,I((X/L: 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/ORQ+ AE^[C'.T8XZ7-2T#5QK&IZI#8/<)!X@MM1C@5E#7,26RQMLR0-P))
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M,FO2]"T&/1%NY#=3WEY>2^=<W,^T-(P4*.%   50  *U<#).!D]: /&/$/\
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MAU4TBQ1JQ944,3DD#DGUH \7T+PSI#Z%\.IGLU:;4)&CO)"3NN(_(D?RW/\
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MXWR+F7CDD@$,/O=.E>J+X\\("Y^RCQ)I*S!MGEFZ0$-G&.O7-;$$]C)=W%M
M\#7$15YHTQN7<,J6'O@XH \B\*OI^G^*-'^S-I>J3SW4T?VB O!J<>0Y8W4>
M3O48P2V,':0*]GI@BC61I%10[=6 Y/XT^@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KF_%E
M[<6=QX<2WD""YU>."7Y%;*&.0D#(..0.1S7255O=-M-0>U:ZA\QK2<7$)W$;
M) " W!YX8]>.: .4^&=K);:%J/F7MQ<YU:]4>=LXVW$@)&U1RW4^_3 XKF/$
M\FJZ[X(\3:O+K4T$4%[+:IIX2/R1%%,$PV5W;VQNSN[@8QU],TW0]/T>:\EL
M(&A:\F,\P\UF4N222%)(7)))P!FLW4/ OAS5;JXGO+!G-RP>:-;B1(Y'' =H
MU8*6X'S8S[T <AJNO^(K_6O$0L#K$2:5+Y%JME':F#<(U<M.96#$$MT& %Z'
M/1DGB3Q'K>K7D,4>L6OV*TMF":4MJZB:6(2,9#*WS*"=H"\':>?3MM4\&Z%K
M%[+=WEHYEF4)/Y5Q)$LZCH)%1@) .GS \<4NI^#M"U:<37-FZ2>4(&-M<20;
MXAT1_+9=R^QR* .4L[_Q%XDU>RLYM6FTD/H,5[.ED(G/V@R,I(8AAMXS@>@Y
MZYKZ%K.OM!X.U>[UMYSK:2)<VTD4:0)B!Y%9<*&!!09.3G)Z< >@V^B:;:7B
M75O:)%*EJMFI3("PJ250+T !)[5##X;TBWMM,MHK-1#I>?L:%V(BRA0]3S\K
M$<YZT <7X5UG68]<TRVUZ_U2*ZO8W#1W$$,EG=.%W@V\L7W0 "0&SD>_-;GB
MB?4Y?%/A[2+'5)K"WO5NC<O"B,Y"*A&TLI .2><="?;%_3/!NA:1>Q75G:2+
M) &%NLEQ)(EN&X/EHS%4R./E XXK4GTVTN=0M+^6'==6@<02;B-@< -QG!R
M.M 'F<WB?7X+:#14NKVZN&URYT\WEO%#]I:&*/S  &VQ[R,#..@)QFIDU_Q+
M$/[&EFO+7[3JMO:07MZMN;J**2-W8,L9*;OW>%)'(<<'%=O<^%-$N[2XMIK(
M&.>Z-ZY61U83G'[Q6!RC<?PD5&G@W04TN?3C8EX+B433-),[RO(,8<R%B^X8
M&#G(QQ0!ROB'4]9\.I#I-KK=QJ4UYJ,4"LB0M>6T31NY'.U"S>6=I8#@GK@5
M7_M7Q<MGJEA!]O!CFMC;M?26B7K1N6\V-<$H6PN5+ 9R>N*[%?!F@#39[!K)
MI8IY5FEDEGD>9I%QM?S68ON&!@YX[4U/!6@+I]Q9-9/(ES(LTLLMQ(\SNOW6
M\TL7RO8YX[4 <BFMZU/H5]::=J&IR:A!?0K):W\,-O?10NN2B,?W4C':Q4XZ
M9') -.C\33IH-U:G7-7BOAJ,5NL-UIJ&_C#KN\I0/D=F"L0^, 9SG&:ZP>"M
M _L^:S:SDD2>59I)9;B1YFD7[K>:6W@CL0W':D/@C0#8/9M:2L'G6Y:9KJ4S
MF51A7\XMOW < [N!Q0!PDOB;Q%9Z9XJM8KS4(9K%]/:T?4XX&GC$\NU@PC^4
MJ0.,\X/TK;O]:U'P)?S)J>J76JV<^G236C7*1AS=1MDQC8J_?#K@?[!KH8O!
M/AZ*.[06#-]L\HW+R7$CO,8FWH68L22#W)SV/'%0^(= NO$&NZ.MQ#9_V1I]
MPM\79B9GF4,%0+C 7)!)SSC&.] #[R^U/P[\.[C4+UQ>ZI8Z:T\K%0!)*J%C
MPN.,^G:L5+C6-"U'PV\^O3ZHFL.T-Q#-'&%5O):021;%!4 IC!)X/KS7=R1I
M-$\4B*\;@JRL,A@>H(K$TSP=H6CW:75G9N)8D,</FW$DJP(>JQJ[$1@^B@4
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MWB"_FMK422+I]M;^=N=VVO-*X$8&!@*,?=).:ZZ;PSH]Q)/))9*6GD@EDP[
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M,Z(&"@EB3QN;GKS0!YW%XLU[7I=&MD&JHLFAV^HW#:0EOYDDLA(Y,QP$&T\
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M:B2,K<2%WC=-PR.5Y# Y4'VK5T[0]4L++8=:$EW+>+<3R_90(S'D9B1,_(I
MQG)())YH WZ\S^(FLSRZTFFZ?K$=A/I5FVJ$-<"/SY@V(83R,A@LF1[K7IE<
M]8>$;&"_U2^U".#4+K4+HS&2:W4^6@4*D8SGA0O7N230!B7^O#5M4\)7^GW$
MBVE_8WD^U7(!_=(1N ZD$GZ'-:GA7498?A?I&I3B>[FCTF.=P"7DE81!B.>K
M'^9JII_@%=.N[9HM1/V6TFO7MK?R<")+@#]V#NZ*=Q''?':MS2]"_LSPC::"
MMY+FWLEM!=1#8_";=Z]<'OWH YO1_'UUJ6EWNH_9=+GMX+"2\#6.HB4QLHSY
M,JE596/J 1P?;.M+XJ:-O#P^Q@_VO!),?WG^JVP^9CISZ=JSH/ 4MQJ37NLZ
ME;W4OV*:R\RULA;22K( &:5MS;VP..@!).*;;^"]4@ETNXOM=6]31[>6&VAB
MLO*WJT1CRYWG+8QR,#@\<T &D^-M5NK70=2U+1H+33=::..%H[HR2Q.ZEDWK
ML VMC (.1D9')PRS\=:K)IEMK=WHEO!HLMX+1I%NRTR9E\H2;=@&S?@8SG!S
M5?P=X4U:7PYX6_MO4F:VTZ&&XBL&M/*E241X59'+<A,G "J>!G.*A\+>$M7O
M?#5C::MJ#Q:9'>O=-I[VFR8E+AG13(6^YD*V-N??% #+;QH=!M+N&::"2[O-
M?OK>W;4+OR88D1R26<YPH&  !R2 *MQ_$F2XM$CM+&RO=1_M2/366VO@]NQD
MC9UD64+RO'(QD8;KCF]+X#( N+74EBU"+4KG4()I+82(!,3OC=-PW+@]00<@
M'BIX_!]S(+.6^U?S[F#4TU!C';B.+Y49!&B;CM7YLY)8YSZT 9-SX\U^RM-:
MGN- LL:#(!J!2^8AU*JX,/[OD[6!.[;Z<]I=;^(Z:?K&I6-I_9&-,53.+_4E
MMI)F*A]D2E3G (Y.!DX]36IJ'@Q;^P\56OVXI_;Y!+>5GR,1)'Z_-]S/;K4-
M]X.O3JFHW>D:O#9+J04W*S60G*N%";XCN7:Q4#J&&1G% %9/&^IZO=S1^'=(
MMKF&/3[?4/.N[HQ;DE#%4P$;YOE^G7-5;7Q9JFI>*M'O;2W!TFZ\/R:@UKYQ
M\S.Z,\*%PSC(4#."&/(Z'I--\,KIVJ7]XMY)+]KLK:TQ(N67R1(-Q;/)/F<\
M#I[UEV/@:;3O[#^RZPT9T[3&TR9A!\TT9V'<IW?NV!0$'YJ #PAXTNO$\\9^
MSZ8UM+ 92;/4!+):MQ^[FC95(;GJ,\@CT-2^*O&$F@ZO9:;$FGQ/=1/*MQJ=
MV;>$E2!Y:L%;+G.<'&!ZTS2_!EW!XAL=8U35+>\N+&)XHI(;$02R[@%)F?<V
M\X'0!1GG%:.OZ%J&J7$<MEJ<$4?E&*:TO;/[3!("<AMFY<,.><XP>E %%_%&
MK75W8Z9IND6XU.:Q%]<I=W>(K="=H&^-6WDL#C Q@9]JUO#FNC7M*:Y>W-K<
M0SR6US 6W>5+&Q5@&[CC(/<$5@V7@.?0XM-?0=7%M=VEH;.1[FV\Z.>,N7Y0
M,NTAF;;@\ XYK?\ #VAIH&EFT^T/<S2S27%Q<2  RRR,69L#@#)X'8 4 <;9
M?%>VNIK.Y_XE7]FWETMM'&FI*UX@9]BR/#C@$X) .0#GU%:.G>.KK4_$<FGP
MV>G[(KU[62W:_"7L:J2/.,3* 4.,X#$X(//2GZ;X'O-+^R6-OK:IHUI.)8H$
MLP+@J&W")IMW*#I]T$@8S1=^![O4-3MI+[6(KBSM;Y;V#?9 W2%7WB,3[ON
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M>"[N+C6-1^SJ0PP "0Q=R0Q/H.3UKK=1\,7[ZU>:CH^L#3VU"%(KQ'MO.W;
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MP>8LJ,FQUQN&"1T.3CT- $GB'79]+GTZPL+1+O4M1E:.".67RXU"J6=W8 D
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MMLR!=I3=(')X09.!W!!SQ3;WQ]ILFDWLD,UWITRV4EW;S7E@X62-0,R(IQO
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M_6K%% !1110 4444 %%%% !1110!&EO#'-+,D4:RRX\QU4!GP,#)[X%2444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "LW6-971HHI&L-0O/,8KMLK9IBON0.@K2HH
M X^T^(^DW>DSZLMCJ\>GPP-<&YELF6-E4X.UNA/M[&NP!R ?6O)H?^3:I_\
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MWGFX9=DI+(%4\D9SEL]\4 >EUDZUXAM=$ELH)8+JXN;V0I!!:Q;W;:,L>P
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MMXS^%=034--COKR=!=2C4[B>XN\J3+')#Y>U2.3R0$*@9'==,G@N= \,:2\
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MXFN+>6X:[8AHUMP8HC+G/EEP!UYP.>>0#V>BO)I2]E)XAGT*ZGFTOP_=6M]
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MQF0@9()4CG;@4V_TN6'2K6_NI-"7Q5';6TL=R^6B-J[21"0')0/N7KQTSQP
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M;E& QD>N<<5A:#J/B+6K&R\1_P!KVD-G<W3 Z=+"%18/,* !_O&7@'T)XP*
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M< #\*@FTRPN+R.\GL;:6ZB_U<SQ*SI]&(R*M44 ,6&)9GF6-!*X =PHW,!G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML<4LL\T\AEGGF;+R.>YK5HHHE)S?-+<(Q4%RQV"BBBI*"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>exhibit101-arrowheadindu007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101-arrowheadindu007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ K*\2:G-H_AV]U"W5&E@3<JR E3R!S@CUK5
MKGO'7_(DZK_UR'_H0K6A%2JQ3VNC*NW&E)KLSB;+Q_XSU* SV6A07$0;:7BM
MY&&?3(;W%:FE^*?&USJUI!>>'EAM9)5663[-(-BD\G); XKE?"'C+4- T=[2
MUT9[R-IFD,BEN"0!C@'T_6NS\/>.M3UC7+>PN-!DM8I=VZ8EL+A2>ZCTQ7KX
MBBX<W+2C9=;_ /!/(P]93Y>:K*[Z6_X GC#Q?K7A76(!]DM9M,FP5?:P?C[R
MYW8SZ<=ZV];\5V>E^%O[:A=95F0?9E/_ "T8C@?AW^AJQXGT>TUO0+JUNW6-
M0ID69O\ EDP&0WT]?;->%Z-%+K>I:;H=S?%+/SB$W'Y5W<G;[G''N:RPU"CB
M*:DU;DW\T;8FO6P]1Q3OS;>3/8/!VO:UKND7&IZC;VL,'(MQ$C OCJ3ECQGC
M\ZJ^ O&.H>*9[Y+V&VC$"H5\E6&<DYSDGTKK/LT-GI9MK>,1PQ0E$4=  .*\
M-\%^)KKPW->/;::UZ9U4,%8C;C/H#ZU-&C'$PJN$==+>15:K+#SI*<M-;^9Z
MMXY\17?AG1(;VSCADD>X6(B8$C!5CV(Y^457NO%-[!\.4\1+%;F[,:-L*G9E
MG"GC.>A]:\_\8^,[WQ#I$5I<Z.]DB3B02,S')"L,<J/7]*Z34?\ DAT?_7&+
M_P!&K5K"*G"FJD=7))^A#Q;J3J.G+11NO4V])\57M_X!N]>EBMQ=0I*RHJG8
M=O3(SG]:Y>P^('C+5(FEL-$MKF-&VLT4$C 'T^]5SPY_R1O4?^N5Q_6N:\&>
M,;KPYIUQ;P:.]ZLDN\NKD;3@#'"GTK6&'A^]Y8)M2LK]C*>(E^ZYIM)QN['1
MVWQ*U73]3BMO$>CBTCDQEE1T91_>PQ.1]*Z;QQXDNO#6B07ME'!(\EPL9$H)
M7!5CG@CT%>9ZWX@_X3+7]/AU58])M(B5+-N8@,1G)Q[#'  KLOBP$'A&R$>-
M@NTVX.1C8^*B>&IJM24H6;W70J&(J.C5<972V?4LWOB?Q&?#>CZCI6EQW<]V
MC-.J0NZITQC!R._6N;N?B1XLL[Q+2YTBUAN9,;(G@D#-DX&!N]:[[P5_R)FD
M_P#7 5P/CW_DIND_2W_]&&IPRI2JRI2@M+ZEXGVL:4:L9O6VAT?ASQ'XNU#7
M(+;5=#6ULW#;Y1;R+MPI(Y)(ZXKN:**\RM4C4E>,5'T/2HTY4XVE)OU*6L:E
M'I&CW>H2XVP1E\'N>P_$X'XUPGA#XCWNMZ_'IVHP6L23*PC:%6!WCD Y8]0#
M^.*/BSJS+9V>BP$F2X?S9%'4J#A1^)_]!K \8>'7\)P:!J-F-DL**DK#IYRG
M?G\26_!:]+"X:E*DE47O3O;RL>;BL35C5;I_#"U_F>ST54TO4(M5TNUOX?\
M5SQAP/3/4?@>*MUY+33LSUDTU=!1112&%%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M84G/7FM"N3%585:KG!6N=>&I3I4E";O8****YS<**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!/4@CZT =-17)67Q L+J]M+>?3=4LEO2!;3W-OMCDSTP03UR/SKK: "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *XOXIHS^!KA44L?.CX S_%7
M:44 >6WOCF#4O")T+2]-U&XOY[46N/(^494*QSGTSVJCK_AN]T'1?"<TAN%A
MT\M]KDM0&>!G8.6'4<'(S[#UKV"B@#S;PBEEJOC1]3M+S5]0^SP&,WMRJK&P
M/\'W0<\_I5+PQ'(O@'QDI1@6DN< CK^[KU;&.E% 'C6H0N_PY\'(8V.+WYEV
M]MS=:Z?Q7&Q^)7A1U0D OD@=*[ZB@#S/1;>:37?B%&D;EI594&/O$B3&*P[;
M48;KX+7VE1+*;NR9/.0H1C=<9&/7BO:** /+-52;2-3\'^))[6:?3K:PCBG\
MM-QB.P_,1_P('_@-6M/N?^$N^)MGK>EP3+IMA;&.2YD0H)&(<8'K]\?D?:O2
M:.E 'F'@>%E\$>*@T9#-+<#D<D>770_#)63P#IZLI4AI>",?\M&KKJ* /-M8
MN#X6^)TFOZC;S/IEW:B)9XT+"%@%&#Z?=_\ 'OK2>'!+K?C+7O$UM;2P:9+:
M&")I%VF9L+R!_P !/YBO2J* .'^%",G@E ZE3]HDX(QZ5U6M G0M1 &2;:3_
M -!-7J* .,^%J,G@6V5E*GS9.",?Q&O/;(+H%EJVC:OJ&L6ERTKA;2VC!2[#
M #()4]?7TQ7NM&* /)M:TL6FF^!+-8+H1K>9,=R 9%#.IPV..];7Q$C:37/"
M0"%E_M ;L#/&Y.M=_10!P%Q$3\;+2382HT\_-C@'YJR-/MT>\^(27&G3WL#S
MKF"'AW&^0Y7W'7\*]6HH \2TR_N++4-,A\*:UJ=V\DJK+IEU"Q$"]P6/RX[9
M 'KFO;:,44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>M<-]F'_  AP\.?V7<_\):-2\SS?LCY\W[1O^T>=C;MV<[MW3Y?:M"ST^_\
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M\U:WMXY99G2,*L2DL?WB] *FM?!-I%J-K?7NJ:MJ<EH_FVZ7USOCC?!&\*
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M;!X_&G6NM:5?7;6EIJ=E<7**':&*=7=5]2H.<<BO)TCN+O7=/EMV>[A32;V
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M,-]<:C/9V-O;7)@$TEVFUAA2"QS\A.?NGGC/>GOJ\3RZ:;-K:ZMKV1E$Z7*
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MH"$9!Z<8S7-Q#3]"\2:C-KVERR6UWIUM'9,MB\Z[55O,A 53M8L<[3C=GVH
M[V\UC3-/*B]U&TMMV"OG3JF<G QD]S7.1_$72+B"RN+9XW@GU.33I)&G0"'8
MLK>8<9&T^42.F00:YWP?X<G36_#ZZUII<VN@.JBXCWB%C."B$G(#A"!Z\&JE
MGID=RNE:9+IDC-:^+KB:YCDM6"B,_:6C?)&&7!7!&1R* /5+'4++4[87-A>6
M]W 20)8)5D4D>X.*R+/Q?IDVK:CIUW<6UE/:W@M(EFN%5K@^6CY53@_\M,8&
M>E5/#-D;+Q=XN"6Q@MI;FWDCPFU&)@0,5['D<X[UR&HKI\5QX^L[S1+J?4-3
MGV6;+8N_VG_1XU14<+@;7R<DC&<]J /3;[6-,TR2*._U&TM'F.(UGG6,N?8$
M\_A5;^W$_P"$IFT5HMOE6"WIG+\8+LF,>VW.<]Z\RO;"_P!,UW4SKEU,OVK3
M[6*)QI)OA<!8@LD:L =K>9N.WC.X&DU'0-6.GO:16FH7!3PU91NDJ?O942Y+
M21'!(+F,$%03G/O0!ZG;Z_HUY;S7%MJUA/#"0LLD5RC+&3P Q!P/QJV;JW%P
MUN9XO/5/,:+>-P3.-Q'7&0>?:O.+S3M/\9>(%BT:REM[ Z/<V=[<&T>W4E]G
ME1X91ED(9N!\OXUS;P>)KV"/Q%]@O(M3U@-H,T9C.8(VCC02D=E65)6W>CB@
M#VFWO[.[;;;7<$S>6LN(Y QV-]UN.QP<'O5BLK3H]-L[YM.M+0Q36UK$AD\@
M@&(9"+YF,-C!XSQGWK5H **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ H(!!!&0:** .;T_P1I&G7=K-&U[)'9L6M+:>Z>2&V)!&40G' ) S
MG /&*Z2BB@ HHHH **** (GMH9+B*=XE:6(,(W(Y7/7'UQ4M%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% $4]M#<JBSQ+(J.LBAAD!E
M.5/U! (]Q4M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<]
MJG@S2]5O;FYEEOH?MBJEW%;W;QQW*@;0'4'GCCC!(XKH:* &0Q1P0QPPHJ11
MJ%1%& H P *?110 4444 %%%% !1110 4444 %9D>A6B>(I-<9IY+QX/LZ[Y
M24B3*DA%Z#)52?I6G10 4444 %%%% !1110 4444 4O[*M?[;_M?:WVS[-]E
MW;N/+W;L8^O>KM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%9^MW5Y9Z6\MA:O<W)>-%1
M%W$!G"LV"1G:"6QD=* -"BN1O_$VI6?AJWE^Q>7KFHW+6MC9S+C#%B%+@$Y5
M4&\G(X';.!-HOB^"7P+IVOZQ(D#SQJDJQ(S;IL[2B(,L26!  R: .HHKBD^(
M5BVL:E))+]GT;3+&*2\DGMY$EBGDD951E(R.%SC'\0/2KC_$+P^C7$9DO3-
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MW5_':17,I\Z8V\-PUM(+>649!1)2NQCD$<'DCBJS_$7PS'*5>]F$:SO;-/\
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M3]7!L)7-])?ZA$ZAF@=,Q1(Y7;N/7 .",#&<>BVVH"5KH3Q?9A#.T2M)(N)
M%#;A@\#D\'!X-6$N8)+?[1'/&\."?,5P5P/?I0!YKIGA76Y(M&L+JP>UCL9=
M2CEN?.C8,DX?9(H#9Q\X&" 015JUTK7[W3?#&@76B-9+HUQ;RW%\9XVBD6 8
M'E!6+DO@?>5< GK7H$-Q!<*&@FCE4C<"C!N/7CZ&L+6?&>FZ,=7CD$DL^EV2
MWLT28RR'=@#)Z_(?S% &!#X8U9/ 6G:8;0"\AUI;N2/S$XC%\92V<X^YSC.>
MW7BNB\8:+<ZWHB)8/&NH6=S#>VOFG"&2)PP5L=C@C\:V8+J"X+"*:-V3AU5@
M2I]#Z4L=S!-))'%/&\D9PZJX)4^X[4 <NFI^*]6O;&WBT*718$F5[ZXNIX90
MR#K'$$9B2W W$+@>]<_%H&OGPA:^"6TAE2&YCW:KYT?DF%)A)O"[M_F$#&W;
MU.<XKL/$OB5/#XL8DM&O+R^G\B"W65(\D*S$EF(  "G\<"MD3QF(2%T"YP3N
M& <XQGZ\4 <#=>&-5E\+:_9+9@W%WKXO(D\Q/GB^T1/NSG ^52<'GCI2^*O#
M&K:GJFNS6MH)8KNWTV.(F1!O,5RSR#D\84@\]>V:W8/&5K/?V]HMK,&FU2?3
M Q(P'B1G+?0A#CZU/XD\1MH#:=%#IL^H7.H7!MX889$0E@C.<ER .%/>@"E-
MHU\_B[7;\0 V]UI$-K"^Y?FD5IB5QG(^^O)XYKF!X.UQ]!FLS:*LK^#8=*&9
M4Q]I4/E.#[CGI[UV6B>)CJFIW.E7NEW>EZE!$LYM[AHWWQL2 RLC,",@@]Q6
MU#<V]SO\B>.78=K;'#;3Z''2@#SZ_P!#UO6;Q]^ES6D6I^'9-+ED::(FTERY
M!<!CN!R/NYZ\XJEI_A+4;^73K:[TO5;0VD$BRW5[JQGBC<Q-&# @D.<[C]X+
M@>]>FQW=M-,\,5Q%)+']]%<%E^H[4@O+5@Y%S"1&H9\./E'J?04 >9^'_"FI
MPR>'[&]TC4U.ER1O-<W&KF2T!C4A6AC#DDGL&50H)%=EKNEW=[XE\,7D$(>"
MQNII+AMP&Q6@D0'!.3\S <43>+;9'UI8+>2Y&DPPSRM$P(DC<%B4]2%4G'?H
M*NG7+8:I86G6+4(&EM;A3E)"H!*_7:=P]0&]* .2O/#.K2^&/$]G': W%]K8
MN[=?,0;XO,A.[.<#A&X//%9/BKP_XHUF#Q+8M9:G<2732"P,%_';V?E%0%WJ
M&#L_4$,""<<@5ZG//#;1&6>6.*,=7D8*!^)I1+&VS$B'>,I@_>'MZT >;>*=
M(GNO%ND:?;E%CURV6WU6'<-PBMV63<<>H9XR?]L5UOC+2+K6O#%Q9V(0W*R0
MSQ)(VU9&BD60(3V!VX_&M!+'2K?4+K54M[2.\=1'<7050Y5<8#-UP..#[57O
MO$-G97FDP$B5-2E>*.9'!1=L;2$D^F$(H XW6-#UWQCJ.IO)H\FD07&@S6$<
MES-$SF9I%8 B-F^3@\_7@<9;IGAW4;G4[.>?1M5MVL[:8-)J.K_:%$KQE-L*
MB1@0<GE@O&.,UZ1%-%<1++#(DD;='1@0?Q%->YMXIDADGC263[B,X#-]!WH
M\JL_"&LZ0=,NIM/U:YSHEI930Z7J2V\D$T*D$-^\560[NH)P0>.:NZ5IE]X4
MU;1WM].BN;IM+EAFTR*^4RQ S^;O5I2-XW.0W/IC(KKSXF63QA_PCUM9M,\4
M*S7-QYJ*L(;=M&TG<Q.P]!QD54\63:"+:\F\1Z+#=V.FVPNA--'')DDL"J*3
MD-\H] <CGK0!Q6B1:_?:!87=K;71L9-4U*6\CTF>))LM,VSRY'*Y3.[)!!/!
MJS:>&?$%CHT\G]DSR3Q^)8]4CMGOEEEE@"(#^\=L%Q@YW'J#@D8KTF";3K.W
MMH(9+6WA90MO$A5%([!0/Z5<H \DN/!FJK'J^E/I6J7B7][+-',NK&*S,<K[
MCYJ!PP*Y((53NP.>:[7Q[83WO@+5+>U1I9DA65(QR7\ME?;]3MQ^-7W\160U
MZSTJ-A*US!/-YR."B>44# \]?W@_*M0S1 *3(@##*DL.1C/'X4 <W;P27OC6
MT\16X5]*DT4HMQO&"S2(XXSG[HSGI3/A_&Y\/7%^05CU+4+J^A4_\\I)6*'\
M5PWXU-I.K:5J^EV5OIE@'TJ\$\3 ;%2,*2""F<X;G '8\XK>AFM2[6T$L.^$
M &)&&4';@=* /-]+T/Q!I,>BW3:++-)HMW?(\"3Q;KB*=V82Q$MC(XX8J>37
M4>%M/OTU/7=:U"T-D^J3QM':,ZN\:1QA 7*DKN."< G QS70I=6\D[P)/$TR
M??C5P67ZCM4M 'G=UI>OV-AXHT*UT1KU-9N+B6WO1/&L48G7#>:&8.-O/W5;
M( Z59LO"VHV5GXOMA%YGVVSAM[20NN9REHL7//'S ]<5VHN[8S+"+B(RL"0@
M<;CC@\4KW-O'.D#SQ+,XRL9<!F^@[T >8GPKJ^F:DEZ;#5[M+C3+2!DTO4Q;
M/#-$A4J^74,ISD,"<'/'-=CHN@/:> XM#=%M)&M'B98Y6E$3.#G#-RV"W6M\
MS1!68RH%4[6.X8!]#[T--$F_?(B[%W-E@-H]3Z#@T >?6NEZ_?:?X7T*ZT1K
M)-&N+>6XO3/&T4@@7 \H*Q<[N/O*N 3UKH_!&EW6C>%8+*]A$-PL]P[(&#</
M,[*<@D<A@:W$N8)(5F2>-HFX5U<%3SC@TPW]F$B<W<&V4XC/F##GVYYH L44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5QWQ L8M2'AJUN(!/;OK</FQD95E\N7(8=QV(/!KL:
M* /'-:\-Z9#I'Q(E@TJ!)+:16LRD('DG[/$^8N/E.\DG;C)J]J9T"'6?%B^+
MK:.6\N=G]G^="7:6#R5"I!Q]X2;\A><D'T->JT4 >6>'="GO?$:S:U9I<:Q:
M>'-/*/=('\NY!E);G^,,!SUZ^M8'A:U!E\,P&_L8];@NT>Z@M](<7ZMSYPGE
M,OW6^8%B,'(('05[4U_:KJ*:>9E%V\33+%W**0"WT!8#\:L4 <7X\6 7WAV?
M58_,T"*\=KX.FZ-6\MA$T@_N!^YX!QFN-U"PT_4++7)M-L8I- ?6-,-F! /*
M:3S8UG:($8VD$ D<'YO>O9J* .3^(<"I\/[V"WB"HC6ZI'&N  )H^ !V KBM
M;LM&76O&MK<K]BGDOK*Z$L5D)<1;(27D3C?#Y@.\9ZY)KV&B@#@_AQ<)+/K<
M<-MIAA66)OM^E(\=M=,5(.U"2%90J[MI(.1WKG/$FB6ES8_$S4);!);V.5#;
M3-'EXRMM$04/4'/<>@]*]?HH \I\2:'+IFIZM;>%[(6L\WAB0*MI'M,CK* .
MG5]I8 ]>:HZ+!9RZM;OI-_ID@ATRX2>+2=(>W C,>%2X9I6PP;! (+9#>I->
MIW.NZ79O=)<7D<;6OE>>&S\GFMMCS_O'@5:O;VVTZQGO;N58;:!#)+(W15 R
M2: /*='\+:1M^&^[2;<^?8NUWNA'[YOLZO\ O./F^< @-G! JD+;2;+4-)BU
M:T1=&M/$&J 1O%F&%>=F5Q@(&/T%>L2:_I44\D+WL:R1RQ0NISD/+_JQ_P "
MR,5++J^G0XWWD/-RMIPV<3-C"''1N1Q[T >0:A;O)I\UQIJQ0>$F\0K,OG6C
M2VXB\@!G,0*YA\_GJ%SSTI9-/AO=%UA;>ZM[W3;O5M,0KI]@UM:%O.42&/\
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M=K-S;74%W/!;Z99WZ:RLK6HM9)M10K<C,CS%OW:E1GH5VD*#7KD7C'P_-?\
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M=P7%S 9+A4<-L8DH1TW?[0K8?2M0;QBGAX>)M9%E'I)N6D\Y?.>0S, 2^WH
M>@ Z#\>HM_">A6MC/91:;$(+B1)9@Q+-(R$%2S$DG!48R>,5H?8+7^T3J'DK
M]K,/D&7OY>=VWZ9YH \V\.:AK)@\#ZO=:W>74NLNT-W#(5$)7R)'4J@ VD&-
M>>^33/#EWJ_B23PQ9W&N7\$5QHDMW<M;N%>5UE11\V./O=L=*]$AT+2[>#3X
M(K*-(M.;=:*,XA.TKD?@S#\:+'0M+TY[9[.RCA:V@-M"5S\D18,5'ME0?PH
M\S3Q#X@N[7P_HZS:A=--<:C'/-:RQ0W$ZVTI1%WN0 <'+8Y.WZUU7A3^U]2L
M+FVU*]NH&L-3_=$7,$DSQ@*WE3F/<,Y8@]&(VGOFMNX\+:'=V"V,VG1-;I,U
MPBC(*2,Q9G5@<J26/(/<U&_A/2AI]E86MM';6UK>1WJK&O)D1MV<GJ2>I.21
MGZT 4/'[EM&T^R/^HOM5M+6?WC:4;E^AQM_&L/Q3KFIV=_XI2WO)(UM8=+,
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M^TU6PFL;ZW2XM9EVR1.,AA63<^"?#=XT)N-)AD,42PC<6^:-?NJ_/S@>C9H
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MBS>*6_NKZ:65II9[ELEF;K@# 51V4  5@CP3>P7FHR6'BK4[&WO[I[J6""&
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ML8(  !JI;^/M9U#2=/\ L%KI\M_<ZQ)I9D;S%A.V-W$H!^8#"@[3[C/>MQO
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MW&;JQTE;>&VLW8^5F2/>TC+T8G(4$]-IKHM(\.PZ1J-U>QSR227%M;6[AP,
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MV=[I\QFMYD17 )4H058$$$,?<=C69#X"@2ZENKC5;RYN)M0M]0DDE"9:2(8
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MC\EY P!.4;*X*DG'XT_4_&=]:ZKJ6EVMI;R72:C:Z?9F1B%+2PB0M)CLHW'
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M_GMUMF1(4#&'/^K1!M&,L2<G)_#% %'7O'QTI]6EMX()[2Q2VA21F(#W,[<
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MY;., A@,G@Y[X/L*X"?P+J%]I6O"'1['3)KO3C9VZ->R7$C,6#,6=N%3A<
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MQ.VF6FCOA0MR&\YYV!WDJ-V4(SG'0&MS4M"DF\+_ !+8Z6\EW=W,QM_W!+S
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MVOA_1;G5+S>88%!VQC+.Q("JH[DD@#W->>7FA3'P+XLV:7(;V?799X\0'S'
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MD0)>!+E"ZXZY4'(QW]*S-&\:V/B"&QGTUK:2*XO)K:0-=H'CV;\$*,[BVP$
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MN]J /7@0RAE(((R".]+6'X-L9-,\':392K<H\-NJ[+G'F(.RMCC(&!QZ5N4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=6[B2":-9(W QN4C(/Y&@"6BBB@ HHHH **@DO;:*Y6VDGC6=HVE6(M\Q12
MS =< L/S%0V>KZ??K;&UNHY#=0?:85SAGBX^?:><?,O;O0!=HHJ":]M;>=()
M9XTFD1I$C+?,RKC<0.I R,_44 3T57L+ZVU/3[>^LY1+:W$:RQ2 $!E(R#SS
MTJQ0 45#!=V]TTRV\\<IAD,4NQ@=C@ E3Z'!''O4U !14,-W;W$L\<,T<CV[
M^7,J,"8VP&P?0X(./<5-0 4456FU"TM]0M;&68+<W2NT,>#EPF-WMQN'YT 6
M:**K-?VR:C'I[2XNI(FF2/:>44@$YZ=67\Z +-%%% !1110 457OKVWTVPN+
MZ\E$5M;QM++(02%51DGCGH*FC=98UD0Y5@&!]0: '455N-2LK5Y4FN8UDB@-
MQ(F<LL8ZM@<XX-36\\=U;17$+;HI4#HV,94C(/- $E%%% !15634;2+4H-.>
M8"[GB>6.+!RR(5#'/3@LOYTL]_;6UW:VLTNV:Z9EA7:3O*J6//;@$\T 6:**
MAN+NWM3$+B>.(S2"*,.P&]SG"CU/!X]C0!-114-U=V]C;/<W4\<,"#+22,%4
M=NOUH FHJK!J-I<7]U8Q3!KFT"&>/!RF\$K^8!JU0 445SM]XZ\-:;>S6EUJ
M:K) VV=DB=TA/H[JI5#_ +Q% '144V.1)8UDC=71P&5E.00>A!IU !1110 4
M444 %%%17%Q#:6TMS<RI#!$A>221@JHH&223T % $M%5(M3LYM1:PCG5KI8$
MN#& >(V)"MGIR5/Y5;H **AEN[>":"&6>-);ABD*,P!D8*6( [X )_"IJ "B
MBB@ HHJK9:C::BL[6DPE$$SV\A (VR(<,O/H: +5%5K74+2]N+N"WF$DMI*(
M9U (V.5#8_[Y93QZU9H **** "BFR2+%&\CG"("S'T JI9:QI^H):M:7<4OV
MJW%U H.&>(X^?!YQ\P_.@"[15:2_MHM0@L7EQ<SH\D2;3\RIMW'/3C<OYU9H
M **AEN[>">""6>-);ABL*,P!D(!8@#O@ G\*CT_4;35+075E,)H"[H' (^9&
M*L.?1E(_"@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 54U'3;3
M5K,VE[%YL!=)"FXK\R,&4\$=" ?PJW10!YGK?E_VU8>%='T6^OM'TJ1;S48;
M1T8F0DO%$QED7(W9D(R>BCH:QK6$ZM\/?#?AV5KNVE.NMI\T"R;66.&61V5M
MI(.$C'<@'!KOTTC6[:\O9-)U'1+:&YN&F=3IDCN6.!EV$XW-@ 9P.G2JL?AC
M7(;I;F.^\/+.LSW"N-&ER)'&UV_X^.I'!- '(+;S6MSKM_8ZEJ(NM0UVWT6W
MD>Y9B(T9/,;GJ1B?'H,U:MM5D35OMR7+P)J?B&ZGFE0GYK.SA*$<=5+1K_WU
M72IX9UV-80E]X> @N'NH@-&E^65MVYQ_I'WCO;GW-)!X7UNV-OY-[X=3[.DB
M0XT:3Y%D(+@?Z1_$0"?6@#E[?4]9;6/#5VD^KK)K%^'5KJ[01RVQ5I& ME+!
M0$ Y^\#C)R:IV<VHVM@DVE37\D_B?7;@%Q<@.+>+> $9_E5V6(#=UQTZ"NJL
M/ E_IES#<64GAJ":%BT4B:+)NCR",*?M' PQ&!QS2_\ "#:A_9DFF^;X;%D\
MWV@PC1I0HD_O#_2/E/N,4 /\)Q7=^^O:;J/GOIL<D<:07-\+F6-]N9(V=225
M^X=K$_>(Z<5TT6E00WT,L%S<1"'S&>!9<I*TA!+.#DL1CCGC)JIX;T:]T.V-
MI++I?V11^ZBL;!K?:Q.23F1]V?P/UK4CL+2*_GOH[>-;J=%264#YG5<[03Z#
M)_.@!;R[AL+&XO+EPD%O&TLCG^%5&2?R%>-65[JNE+I7C*]\/WUMYM_)<ZC>
MO+"8S:W)50-H<OA (",KQL.<5[+>V5MJ-E-9WD*3VTRE)(G&5=3U!]J+JRM;
MVQEL;F".6UEC,;PNN592,$$>F* /,]7;4[BS\>ZJFO:G ^C3.UC%!/MC0I;1
MR<K_ ! D]#D=<=35K7/$6JZ-?7]HD[O/KEE"^D!CQ'<L5A=5]@7CDQ_O5W*Z
M'I:6=Y9K8PBWO!BYCV\2C8$^;U^50/H*S;GP]/?^*].U"Z>T_L[2U9K*%(SY
MGFLNPEF)Q@#. !W&>E $/B^\O/#W@&YEL[IQ<P1PP_:Y/F90SHC2G/4@$MSZ
M5@>)))O"5E=QV'B>]>:XB@!CO)//>W5YTC>Y5FZ !SQ]W(![&O0YX(KF"2">
M))89%*/&ZAE93P00>HK+L?"N@Z;;7-O::3:1PW2[)T\L,)%Q@*V>J\GCIS0!
MQ'B2XO\ PK-J=AI^L:A<1S>'KR\(N;@RR6TL04)(K'D!MQ&.F5XQ4HTZ[37_
M  SI<WB;6#%J-I=75UF[*M,X$!"J1@H!EF 7&!D=#78V?A/0-/M+NUM=)M8X
M;N/RKA0F?,3&-I)Y*X)XZ<U3UKP=9:[KFDW5Y%!+96%O/#]G=><N8]K*>V/+
M/YT <C9ZIJ=_J-CX;FU>[6Q.KWMJ;Y)-L\\<**Z1^8.^68$CD^4>>M1W]]JL
M5U<^'K;7+[[/#K]G:)>^9NG6*6+=)$7Q\Q4G@G)&1G.*]"E\-:)/H\6DR:7:
MG3XB#';B,!4(Y!7'0\GD<\FG6_AW1[2S@M+?3;:*"WF%Q$BH %E'\?NW/4\T
M <#KK7,=WJFGV%]XAO/[(LT#RI?K;QVK%"^Z20MNE8@@_=(  '>J,,]U>W]C
MKTE]=+?OX+:[+1RE5,F%YVCC&3G'K@UZ1?>%M"U+4/M][I5K/=$!6DD3.\#I
MN'1L=LYQ1)X6T*5;-7TJV864+06V4_U49&TH/]G'&* ..T5[SQ3J#6E_K6H6
MD=GI%E-&MK<&%I7E0EYF8<M@J!@_+P<CFJ>@7VJ^+K_0;>^UB^AAET>>>8V<
MGDFX9+A8T?(Y&5.[Y<=?3BN[O_">@:I';)>Z3:S+;1^5%N3[L?\ <S_=XZ=*
MOQ:98PW,5S%:0QS0P?9XV1 -D60=@QT&0./:@##\"7MY>>$(I+R>2ZN(9[FW
M\V0C?((YG12Q[G"C)KC[2_U%/!^B>+_[<O9M3OKRW66T:;,$@EF"- L712H)
MP1\V4Y/6O3[.RMM/M_(M($ABWL^Q!@;F8LQ_$DG\:SH?"F@6^K'5(M)M$O2Y
MD\X1C(<]6 Z!CW(Y- &'X)AN[V^UC5;S5K^X,>IWMI#;/-^YCC68A<+W(QP3
MV..U5IUN->\1>*([G7+[38])\I+9+6?REC!A$AF<?QY)(PV1A#QUKMK2RMK%
M)$M8$B665YG"#&YV.68^Y))K/U3POH6M727.I:5:W4RKLWR)DE<YVG^\,]CD
M4 >9VLMQK=XNMWTUPMW<>#3<21K(5C9CN4_+TVG.['J<UI:*E]X?3P3+!J>H
M78U&R=+BVFEW1MMM3(@1,83!4 8[=<UW]WX?TB_NH+JZTZWEG@C:&*0IRB,,
M,H]B"1BIQI=BIL2+6(?81BU^7_4C;L^7T^4D?2@#ROP]JOB2XMO#FN22W8;4
M;J(7,ESJ<7V:9)"=T<<.?E9>=H W97!SS75^ (;N\M[O6;W5K^ZDDO+NW2"6
M;,,:)<.JX7U&WKUP<=,5MV_A/0+35?[3M](M([W<SB58P"K-]Y@.@)[D<FM*
MSLK;3X#!:0)#$7>0H@P-S,68_4DD_C0!YKK-]KNI^*O$D$']HI#I2Q);FTU"
M.V2'=$',KJQ^?))^]E<+C'6I=+&J^*M9FAO];O+94T2RN"FFW6V,SR>;EU9>
MH^7H#@\9S@5VNJ>%M"UNY6YU/2K6ZF5=F^1,DKG.T_WAGL<BKT6GV<-U)=16
MT23RQI$[JN"R+G:OT&XX^M 'E^@S7.LZ[X3UF\O+DWDOAB:>0I*55W#0\E1Q
MSG)'<@>E1Z#9W6OZMX=N9M5OX[Z[\(LYN$N&!$A:(;O?EMWN0#VKT@^&=$(T
M\?V9;?\ $N4K9X3_ %((P0OH.!Q[4V7PYIBQV3VVG6BW.FQ%-/=DX@XP ,<[
M>!Q0!R_A/Q!J'B;5]-BDEDB.DV3#58U. ]X6,6QO8>7*V/\ :4T_Q+8K-\2]
M$F-Q<H1I5Z=B2E5.UHN,>AW<^N!Z5O\ A?09-$MKV6[>"74=0NGN[N2",HA<
MX "@\X"@#GKR>]7[_1=-U2XM;B^LH9YK1B]O(ZY:,GK@^^!^5 'FGA:"[T70
M/A[?0ZO?RC4#%;7%O+-F'RFMW<!4Z*5*+@CD\YSFJYUO4C+HFMV=UK4EM?:S
M# +RZNT2"XBDFVE$M@QP-N<$@-\N:]331].CM[&W2SA$-@5:U0+Q"0I4%?3"
MDC\:SX_!?AJ*X,\>B6:R>8)0PC^XX8-N7^Z=P!XQS0!D?#ZQ6UNO%+BXN9"=
M:F3$LI<#"H<X/<YY/? ]*P=5U'4]/UR_U6\O=1ETR#441;W3;U'AMDRBF&:V
M)'.206&X_-GCI7HUKH^G66H7=_:V<4-W>8-Q*BX,I'0GU-5)_"F@7.J_VG/I
M-J][O5S*R<LR_=8CH6&!@GD8% ' JRZ0_C.5-1U2.:YUV&UB6W<22.SQP':@
M<A59LE=Q/RC'H*HWVLZWI%OXPLTN-1LVMM*ANX([N^%U+!(SNI.\$XR /ER?
M7O7IEWX5T&^GO)[K2;666\55N':/F7;C;GW&!@]1@4R+PAX>@AGBCTBT5+B+
MR9ODYE3.<,>K<^M '%>(KS5O!E]?BPU6_O2^@7-YMO)/-"31O&!(HQ\HP[$J
M/EX'%/N].&D>,O#TL7B&YN2^FWT@EOY_-5#Y:'SAGHIZD#Y>. .:]$ET^TFO
M%NY;:-[A8FA$C+DB-B"R_0E1^59VG^$?#VE7(N;#1[2WF *ATC&0IZJ/1?;I
M0!QWA"]U&RU[2[76)M5$]_:N4E>]6\L[YE56,B'[T7&2!M P?85I>+]4OK/7
MIH;:[EBC'AS4+D*C8 E0Q;7^HR<'WKH=,\*Z#HUVUUIVE6MM.5*AXTP54G)"
M_P!T>PP*N76E6%[,9KFUBED,#VQ9ER3$^-R?0X&?I0!P^DC4--UOPA(^LZA=
M_P!L6LIO8[F;?&S"$2!E7HF#D<=CSFM3QG>2'4=)TJWDU22>Y\V7['ILBPO,
MJ  EIF9=BJ6'0Y)(]*Z7^S++S+.3[+'OLE*VQQ_J@5VD+Z<<5#JN@Z5K@A_M
M*QBN3 2T3./F0G@X(Y&>_K0!S_PXU"]O='U.*^FEE>RU2>U3SIA,ZHNTA6<?
M>(+$9KE;R_UFR\-^)?$,>L:A)=1ZM/I]O$TP$-O";H)N"D8W*"<,W X["O3]
M-TG3]'A>'3;*"TBD?S&C@0(I; &<#CHH'X4+I6GI:7-H+.#[/=.[SQ% 5D9S
MERP/!R2<T >6:N^LV6D^)=/N?M<=E+X>NIC;ZAJ4=U,'48#I@E@I!(/;(&,5
M/KVH7EQ'J[V%QK4G]EV4>7MKM+2WLW\D/\WS;I2003E2 ,"N^L_"/A^PM;NV
MM=)M8XKN/RKA0F?,3&-I)YVX)XZ<T77A'P]>WIO+K1[2:<JJLSQ@[@HPNX=&
MP.F>E 'G_F7$^M3:Z;VZ6];P:EWE)2J^80_.T<8S\V/7FM+1VO/%.HRVE_K6
MH6<=EI5E+$MK<&%I&EC+/,Q'+8(Q@_+P<CFNRD\,:'*]J\FEVS-:6YM8&*<I
M$5VE!_LX)&*9?^$] U1+=;W2;6<6\?E1;D^['_<S_=]NE '":!?:KXNO]"@O
MM8OH(9=&FGF-G+Y)N'2<1K)D<C*_-\N.OIQ4%M>>(-4TC1D2]NM1,/VZ.XM+
M;45M+R817!C27=QO"A<$9&2P)S7J,6FV,-U%<Q6D,<T4'V>-D0#9%D'8,=!D
M#CVJA=>$] O;6&VN-*MGBA=Y(AMP49R6<@CD;B23ZT <%9X\4:]X2*ZKJJI_
M9E^DTQ(AN7*2Q(R,5Z$,.2IYV]>:GTK6-56YT2RDU&YF6/5=4LWDD?+31PI+
MY>\_Q$8'/M7H-MHVFV;VK6MC;PFTB:&#RT"^6C$%E7'0$J/RJ,Z%IJX>*RA2
M5))9HW"\K)("'8>YW'/UH \]T*ZU"U\/>"=<&O7]_>:K/!!=133[XY4=#N 3
MHK)C.X<_*<YS6_\ $&Q6\NO"@:XN8O\ B=1I^YE*=8Y#GCOQP?<^M7/"?@;2
M?#.G:<%LK1M3MK987NTCP6;: S#T)QR>I[UN:IH^G:W9_9-3LXKJ .'"2KD!
MAT(]#0!YO>WVHR>$_$/BTZY>V^I:?>7*06JS8@C$4A1(6BZ,7 &2>?GX(XKH
MOB;#]K^'5X7:6$AH'(C<J<^8@P<=1S^8%;<_A30+G51JDVDVDE[N5_-:,9+#
MHQ'0L.Q/(K0OK&UU*RFLKVWCN+:9=LD4BY5AZ$4 ><2Z))/XH\8F/6-4MOL5
ME:>4UO<E&9Q"V'=NKGCH>#DY!JI%K6O^)-0TZV*ZA*@T&TOF2PODM&DEE!W2
M$D@L 0  . 3R.17I=IHFF6,4L=K90Q)+$D,@4?>1%VJI]@.*JWOA/0-1MK2W
MN])MI8K2,16X*8,:8 V@CG;@#CIQ0!!X-O-0U#P=8W&H3PS7I1U::*19%?:[
M*K;D^4D@#..,YK'^'4MA#\,K<7;Q+Y"S+J?G$?+,&;SO,SWSDG/8UV=O;06=
MM';6T,<,$2A(XXU"JBCH !T%8]]X+\,ZGJ#7][HEE/=,07D>(?O".A8=&_'-
M '*Z2]MXEUD:;8W^H:7H=II-M<:?;VLC6SR+(7&\_P 1"A% '3GG.:HZ)?ZK
MXIO?#MI=ZS>QP2V%^T\EI)Y1NO)N$CC?*],C#97'4]C7H&J^&M%UORCJ6FV]
MR805C9TY53U4$<X/ITJU%I=A!/;S0V<,<EM";>$H@7RXS@E%QT'RKQ["@#S+
M1[C5HM)\,:U-KNI7%S<:P=/E267]T\(>6, H!@MA =W7.>:1;S48/"=[XF77
M[^;4;;6)8(K8SYB*"[,8@,?0Y4\$_,,C!P*]*31=,CMK>V2RA$-O-]HA0+PD
MF2VX>^6)_&L+P_X#TG27-U=6=I<ZB+R>Y6Y\OD%Y7=>O\2AL9Z\<4 <5XFUO
M44M-8UW3;K6G6ROS$EVUVD%JA614,2P[B9!G*DLO))P:T]8&I7<WCV\77=3M
M_P"QP)+&*WGV)&PM4D.1_$"W\)XZ\<UV-QX+\-75S<7%QHEG++<$M*6C!#,>
MK8Z;CZ]:T6TFP9;Y6M(BM^,78*_Z[Y GS>OR@#Z4 <!JOB?5-%EF8S/+)KFE
MPR:6C'Y4O,K&44>A,L;X]F-;?CBQ:+X3:U:2W4\KP:5(&G+D/(4CZL>^2.?7
M)JW=>'I-1\2Z7<2O9C2](S):VZ1GS/.V%!N.<!5!)  ZX]*Z&XMX;NVEMKB)
M)8)4*21N,JZD8(([@B@#S>VT#[=X\-I_:VJ011>'K4EX+DI(Y,LV"S_>..>,
MX]<XJI8ZUJ&O:1X;M7N-8O;^33GN)[?3YDM2X#A!+),64CD$;5ZDDGI7H^G:
M%I>DE386,-N5A$"E!R(PQ8+] 68_C52X\(>'KJ"UAFTBU:.U4I -F-BDY*C'
M8GJ.E 'G.CR7.NR>!;B_O[MYH]4U"W\Q;G)98UFVY9<!CA0"W<9]:[+QKK<O
MA>YTO7))W&F1^?!>1!OE.Z,O&Q'KNC"C_?K8;PMH+VD-H=)M!;PW'VF*,1@+
M'+DG<H'0\GIZU=U#3K+5K-K/4+6*YMF*LT4J[E)!!''L0#0!Y9H^O^)(Q#H-
MY=S7&L:6;C4+TY.98A KQH?]DR3A<?\ 3(BM&SN+W3].\'ZY'KU]?76L7-O'
M=0S3;X9EE0L^R/HFSJ-N.%(.:]"CTZRBU*;44M8EO)HUCDG"_.RKG )]!FJ-
MEX5T#3=1.H66DVD%V=Q$B1@%=WWMO9<]\8S0!QEOKU__ ,(#X?NGU&7[7<:]
M';/(7^9U^V,I0^OR#&/053T^>YFU./1DO;BRM-0\1ZG]HFMY/+D;9EEC#CE=
MQYXYPI%=V/!_AQ=1>_&C68NVE$YE\L9\P,&WCT.0#D=2.:L7/AS1KRREL[C3
M;>2WFG-RZ,G64G)?V;/<<T <[X!MQ::IXNMQ>RW@CU8+YTK;G/\ H\/!/<K]
MW/7CGFL/4K[5K6+QSX@AU2^>71YY(K*T\S]P@-O&2S)CYL%]V#P-ON:]#TO1
MM+T2*2#3+*"T21@[I"H7<V N3ZG"CGVJ6.PLK?[44MXD%V^^X^48E8J%RWKP
M /PH \UM[GQ!I=Y"/MTUE#=:?<N\^K:I%<*76/<DZ*#D!3]X+\N&Z<5%:ZEJ
MNDVM];WTNLVU_/HMS/ 9;U;RWN'C0'S8I =R$9'RX P?85Z!IWA/0-(EEDL-
M(M('EC,3E8Q]P]4&>B_[(XI=,\*Z#HTLDNGZ5:V[R)Y;,J?P?W1GHOL.* .7
MO]8N7;P="+UR+[3KB2=0_P#KL6P(8^O)S61X(L5?Q#X0G-Q<@CPE&^Q92$.#
M$N"O3'.<>H!KN[#P=X<TR8366C6<$@W .D8! ((('H,$\#CDU9'AW1UETZ4:
M=;B334\NS<)@P+C&U3Z8 XH YGQOJE]8:Q!%:W<L*'1-3G*HV 9$6+8WU&3C
MZU4T@:AINM>#Y7UG4+LZQ:R?;8[F;?&S"$2!E7HF#QQV/.:[F[TNPOY1+=VL
M4SB*2 ,ZY(CDQO7Z':,_2C^S+(/9O]ECW62E;8[?]4"NTA?3CB@#E?%EBMSX
M\\%N;BYCQ<7 Q%*5'$#-V]<8/J,BN4TB"\TOPC8:[;:M?K*=?:'[,)OW'E/?
M-&R&/H<AB<GG)ZUZGJ.CZ=JXMQJ%G%<?9Y1-"9%R8W'1@>QIHT73!8I8BRA^
MRI-YZQ;?E$F_S-V/7?\ -]: /+;S5_$MY'X@UB![R&6PU":""5M2BAM(%B?:
MJR1,1N##!);D[N".*]?C9FC5F&&(!(!S@UD77A/0+W5!J5SI%I+>;E8RM&"6
M9?NDCH2.Q/2MF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD?'TLS6N
MBZ6D\D%OJFJ16EU)$Y1O**NQ4,.1NV!<CL3775G:YHEGX@TQ["]$@0LLB21/
MLDB=3E71NS @$&@#&3P=X=T+4['4]-2/1Y(F*,MMB-;M2I^1U_C/&X'K\M9-
MMXOU_P#L;3/$]S#I_P#8M_/"GV1$?SX8I7"1N9-VUCEE)7:.IP>*V;/P>5U2
MUU#5M;U#6)++)M$NA$J1,1C?MC1=S8)&3G&34-MX!M;<VEL=4OY='L[@7%MI
MCE/*C=6W*-P7>RJ>0I;' ZXH Q)_&/BE;6YU.&#26LX=:?2DMW6022_O_)5]
M^["X)7(VG.">,@5/?>+_ !%I-MK]M/%IMWJ6G2V(@>*-XHI5N) F&4LQ!'S<
MY/8X[5OGP=8G2Y+#S[CRWU3^U"V5SYGGB;;T^[N&/7'?O67XT\(OJ&F:S-I_
MVB2]U-[%)$1PNQ(9@=RGC!"ECU[#% #I/$>MZ1J%]INJ?V7<7"Z8^H6L\>ZV
MB^1@K))O9L %E.[/3/ Q678>/K]M3N+1[S3-20Z7<7L4]I:30HCQ;?D)=B)%
M.[JI!XY R*VY_ 5KJ-OJ"ZOJ=_J-Q>VPM?M$OEHT40;< @10H.X DD') SQQ
M3O\ A"!/?B_U'6]1O;K['-9;G$2*(Y ,X54 !^4'/Y\8  ,S3O$OBB2;P^UZ
MND^7K]L[01Q12!K:00F5=S%CO4@$' 7'J:N:/XQNM:?PY;PV\*7=Y'-+J2$$
M_9A#\CJ.>#YQ"C.> :UAX:M85T%EDN&.AH1;@%<R?N3%\W'H<\8YK)\%Z$]O
MJ^O>(;BPFL)-4N 8;6=E+Q1J,DG:2%+R%V(!/44 7/%VOW&BFQC@OM,L1<,X
M:>^5I2-H&%2)65G)SV/&/>N=L/'6NZK;Z5;6<6G_ &V[U*ZL))Y895CQ$C.)
M!&2&&0/ND^V1UKJ]9\-_VGJUGJMMJ5UI]_:QR0K+ L;[HW*EE*NK#JH(-4]+
M\"V.EW5I<)>WL\EM?3WP:=U8O)-&4?<0HR.2>W)].* ,E/&.N"-]*>*P?6_[
M9_LM)U1Q 1Y(F\TINW<)D;=W7O5GP@-27QMXL756MGN0+,>9;*R(Z['P0I)*
M^XR>G6M&Z\%6-S]MD6ZNH;FXU!=1CN(V7?;S+&L8*9!!&U<$,#G<:LZ%X:71
M;[4;^34;N_O-0\LSRW.P<H"!M"J HP>GM]: .:USQMJ>F>)[FQDFTS3H(I(U
MMDU&"55O58*69;@'8A!)4 @G*\]:U+CQ3>0VGC6588"="5C;9!P^+99OGYY^
M9B.,<5)J_@I-7EOXWUG48M/U$@WEBIC:.3  .TLI9 0!G:1[8-1ZIX#M]2N-
M4,>KZA96FJQA+ZUMS'LEPFP$%E++\H .",XH KIX@\1:U?W-IH8TV!K&T@FG
M:[B=_.EE3>(UVLNQ0,?,=W7IQ6+'>>)HO$WBZ]L$TVVD@M;2XN(KI7FRX@),
M:E67 X/S<]N*Z>Z\%HUPT^GZQJ&FR36T=K=&V\L^>B A2=RG:X!(W+@\^PJS
M8^$=/TZ/4HK9YUBO[>*V92P.Q(X_+7:2,YQU)SS0!(?$44?@C_A)I86$0T[[
M>T0/./+W[<_I6%<>(O$^AZ%)KVKV^FW-B+)KAH;0/&\$F 40LS,'!S@L N.N
M*Z>WT6TA\.1:%(K3V26@LV$AY>,)LYQCJ/2L)/ %K+"MMJNJ:AJEG%;/:V]O
M<L@6)'7:>452S;> S$D?7F@"%]>\1Z)J-C;:V-,G&HPS&$V<3IY$T<9DV-N9
MMZD*WS#;R.G-9MIXI\87&D>'+MH]%$NORQK"@CEQ;HT$DA9CO^8_*#@8[C/\
M5;UMX,5;N*XU'6=0U-[:"2"T^T^6/)5UVLWR*-SE>-S9XSZFJ&N>$KDV/@[2
MM+GNXX-*ND#7<;)YD2);R(KG(P>=H(P0<GC% $$_C+6;*>YT2:&QFUM;^WLX
M)T5TMW69&=9&7<6&T(^5#') P>>&:OXRU[P[!K%G>PZ?=ZE:6]O=6TL*/%%-
M')-Y15E+,58'/.X@Y!]JUSX%LY;&X6YO[V;49[J.\;4BR+,LR#"%0%V@*. N
MW&"<YR:23P);7=MJ U'4KV]O+X0K+=R;%94B?>B(JJ%5<Y)XR<GF@#.U7Q%K
M^CS6UC?ZMX>M;IXFE,@MIIFE.[ 5(%??@#J^3D\ 5GZ?X@UGQ%KO@;44FM[6
M&\M;M[BV\MR&9"BN?O#M]W(RN3G.:ZO4/"WVO7GUBSU:]TZYFMUMKC[.(V$D
M:DE?OJVTC<W(]:JV7@2TTV'04LM1OHCHSR^2Y*,9(Y&W/&^5.0< 9&#QUSS0
M!A>&O$.IZCIVB:/H5OINGRR6,E[-)+$\D42"4HJH@<$DG)R6XQWS4T/C+Q!J
M%[IND6MOIT&HRW5Y9WDLJN\4;P!3O0!@2&##Y20>>O'.M#X#M[&VTT:7JE]8
MW=A"]O'=1B-FDB=MQ1U92K#/(XR/SJSIW@S3],NM.N8I[J2>R>XD,DKAFGDG
MQYCR'')X[8 H D\)ZQ>ZO8WJ:DD O+&^ELY7MP1'(4QA@"21D$<9/UKG[KQ=
MX@_LC5?$MI#IW]C:;/,AM9$<SSQPN5D<2;MJG*L0NT]!D\UUVDZ-!HYOS!)(
M_P!MNWNY-Y'RLP (&!T^45AW7@*VN6O+<:I?Q:1?3FXNM-C*>5(['+C<5WJK
M'DJ&&<GIDT &DZYKFL>+M4MH1I\>C:=.D;,R.9Y0\"2#!W87!;K@Y!Z#&3-J
MNKZQ/XI&@:(UE!)%9B\N+F\B:4!6=D1%167DE&).> !P:U=.T6WTS4-4O(7D
M+ZC,DTBMC:I6-8P%P.F$'XU4U;PW_:&JQ:K9ZE=Z9J"0FW:>W"-YD1.[:RNK
M X.2#C(R?6@#D$U_6M;\2^%"LMM:/'>7UK>VX5W1I(05<@[AD$#*Y'RD\YZ5
M5\':QK^C^%/#4\O]GOI5W?"R\D(_GJ'E<"3?NV_>_AV].]=='X'LK:+2!9WM
MY;S:9<27"SAE=YVDSYOF;E(._)R1@CMBIH?!UC!H6E:2L]P8--NTNXG)7<S(
MY<!N,8R>V* .0?XG7C/<7]N+5[.&[:!=/%G.UQ+&LFQG$H^0-P6"[3QP3FNG
MT76->U?Q/JT1&GQ:1IMXUJ1L<SRGRT<$'=M&"X['/MCE#X'C266*WUG4K?2Y
MKDW4FG0NBH7+;V ?;O52W)4-W/0&MK2]'@TJXU*:&21VU"[-W('(PK%%3 P.
MF$'ZT <OXF\:7&G^)_[$L[FTLS%:K<S7%U:37 8LS!458R,?=)+$^F :KV'C
M'Q!X@NM'L]-MK&RFO+&>XG>\BD<1-%*L9VKE2RL6R,XX(/;!Z/5?#/V[5EU:
MQU2[TN_\C[/)+;B-A+&"2 RNK#())!'(R:73?"EGI>H6-Y%<W<LMI926:F>7
M>9 [J[,Q(R6W)].3QTP <<FNZ]K>J>#)A/:6LIU&]MKJ)4=HY'A25&(^<<$*
M2 <X)!YQ@P6%]J=WJ/A'^SGL["WEU+5%>W6*1D8H\P+$>8,D@$^S$GIQ76_\
M(1:QQV'V;4+RWFLM0GOXIDV$[IBYD0@J05(D8=,CCG-">"+6"+2Q:ZA>02Z=
M>3W<4J["6\YG:1&!4C:=Y'3(&.<\T 4M,\8WVH1Z%9_9[==6N;N:WU"+#;8%
M@R)6'.>3L"YS_K!UH\:#4&\4^$!I9MUNC=7 5[@%D0>0V20""V!GC(R<<BG>
M%=$<^+-=\3W&G3Z>;UDB@M[AE+@!5$DF%)"[RJ]^=@/>MC7_  VFNW&G70O[
MNQNM/D>6WEMBN0S*5.0RD$8)XH Y._\ B#J.E>;I%ZEDNLQZBMF;E8I&M_+:
M'SA+Y8)?.WC8#U[XJ)_%\^I6#P7MK:WK6FKZ?&ER+:6&*599E =48[E="#QD
MC(!YSBNA/@2S-GSJ%\=4^V?;O[4RGG^?MV9QMV;=GR[-N,=N]2CP9%-;.M]J
MNH7MQ)>P7KSRLH.Z%E9%50H55^7D 9.3SF@# N_&'B6&QUK64BTL:;I.I/:-
M T<AEGC60*6#[L(<-Z')':K6I^)_$3P>)-1T:/3!8Z&TD1ANHW:2Y>.,.Y#*
MP" ;L 8.<=LULS^#K&?0]6TEI[@0ZG=/=2L"NY6=@Q"\8QD=\UR'BS0=6NKG
MQ#9:=I^M0C55VC['<0?9+EC&%\R4N-\1'1@OW@HZYH Z;Q5>WTOPMU34+69;
M>[;2GGW@-\G[O<VW!!!QG!SP<'G&*SK/6O$W]M6&B12:5Y<.EP7UW<R0R9*E
MV4JJA^NU1R2>0>N>.IET6&[\,/H=TS&"6S-I(R'!*E-A(]\55TCPQ'I=\E])
M?W5Y<K8I8EYP@W(CLRDA5 S\^/H!WR: .,TGXEWVH2:;>XM9+._N4B^P16<_
MGP1NVU9#*?D;&06 4#&<$XYFU;X@:AINH3,+S1Y8H;]+9]/AAEEE$9D";FF5
MMB/SG:5XZ9S706/@>/3Y+6"'6M3_ +*M)O/M].WH(T()(4L%#L@)X4MCIG(&
M*JR_#JWDL)=,_MO4TTLW)NH[-/*"I(9/-^]LW,-_(!)_' H P5\4:MX<7Q7=
MW-Q;71?7DLK5&CDVQN\46"<,QV*ISM49)!Q][ LI\1+ZUM=565+?49K>&%[6
MY@M9K:*1Y)!$(W60D@AF4Y!.0>Q%=!=>!K.[GU5VO[U(]0N([P1QL@^SW*!0
M)8VVY#?(O!)'7CFG'P9%=VFH1:QJNH:F]]$L+22LL?E*IW+Y:HH56#?-NP3D
M#Z4 96G)K<?Q5MEUF6QF;^PYS'+9Q-&I_?PY4JS-TXYSSGH*O>*_$=WI.IV]
MG;ZCI5@LD)DWW<3W$LC9P%2&-E;'JV3Z8JWI?A1K#7QK=WK-_J-ZMHUFIN!&
MJB,LK<*BJ,Y7KWR?;#]1\+F\UXZQ9ZM>Z==26PM9C;K&PDC#%A]]6VD%CR/6
M@#E'^(6J3>'M"U(I:Z;!>Q3&YOYK.:XABDC?8$VH59 V&.6/ &.M=MHNJM?^
M&[;4[B2T<O"9)'LI?,B.,Y*-W''X=*Q[7P*FEZ?86VDZYJ=D]DLJ)*&23>DC
M[RKJZE6P>C8S[GFMO0]#M- T6+2[4N\,>\EI2"SLS%F8X &26)X '- ')VOB
MWQ -*T?Q'>0Z=_8^J3P(+6-'$\$<S!8W,A8JYRRY&T=3@\5!;^,/$K:;;:[-
M%I8TQ]5_L][=(Y/-*&Y, D#[L @X^7:<X/(S@;%IX"MK5K*W;5=0FTFPG$]I
MILA3RXF4Y0;@N]E4\J"QQ@=<"K8\'6(\/1Z+Y]QY$=]]N#Y7=O\ M'GXZ8QN
MXZ=/?F@#DK_XEWT=UJL]G]D:WTZZDMUL&M)WGNA&VURLJ_(A)#;00>@R1GCL
MO%7B-?#GA.ZUI8?-**@BC;(W.[*BYP,@989[XS5*X\$1R7%XMMK.IV>GWTYN
M+JRMV0*[D@L5?;O0,1DA6'?&,UMZQH]IKFCW&EWJN;>=0#L;:RD$%64]B" 0
M?44 <"WQ#U.TM=6WM9:@]OI<U]#<064\$:21@?NW5R<YSD$$9P>!6BFM>,I-
M>MM'+:)'+>V+7T<OD2L+8*RJR%=X\PY=<,"G?CM6E)X)^VVE_#JNO:GJ!N[)
M[$-(8T$4;=2JHH4N>/F()XK670K===M=6$DOGVUF]FJY&THS(Q)XSG*#\S0!
MR5AXO\0ZV/#EO81:;;W&I6MU+=2S1O(L+02(A**&4D$L>">XYXYI3^))KK7/
M#]QJ<<:7.E:CJ%O=_9\[',=J[;D!Y *D'!/!.,U>F\$75KKOAV'2KZ]M;73[
M6]!O4,;,KRR1L%964A@?G[=AWQ6U:^"--MCI[--<3R6D\]S(\S*3<R3(R.TG
M'<,>!@# '2@#*M/%'B**UT+5]2BTTZ;K,T,2VT".)K7SA^Z)<L1)R5#85>O&
M<5+8^,K^[@TJR,%L-9FU.6RO(@&V1+#EI7 SG!0(5R3S(O6K=CX%@M)=/CEU
M;4+K3M,D$EC8S%-D+ $)E@H9]H/R[B<<=<57\.Z(\OCC6O%%QIT]CYZ);6\,
M[*68@ 22X4D#=LC YR0F3UH P=.^)U[?-9Z@@M9+*[NEB&GQV<_VB.)GVB0R
M_<)'#%=H&,\Y%=/X9UC7M;U75);D:?%I5I>W%E&B(YFD,;X#EBV ,<$8ZC/&
M<4EIX'CLI(((-9U)-)@N/M$6FJZ"-6W;@N\+O* G.TMCMTXK:T?1H-%CNT@D
MD<75W+=OYA'#2-N(&!TR>* ,U?$%T=8\36?E0^7I5O#+"<'+%XV8[N>F5'3%
M8EEXG\2ZY>:;9Z:-*MGN="M]4EFN(9) KR$@HJAQQP.<\8/6MC5?!T>HZI>7
ML.K7]B+^!;>]AMRFV=%R!RRDJ<,1E2./SJSI'A:ST:\M;F":=WM],ATQ0Y&#
M'&20QP/O<\]O:@#GM,\8:UXC31K33(K"SOKJQDO;N6X1Y8XPDGE[44,I.YL\
MD\ =ZY_2?%M[H6F0::[6EMJ%_JVIR33R0R7$4 CG.[")AFRS@#D<<FNRB\"6
M]E:Z<NF:I?6-W81R0QW<?EL[QR-O9'5E*D9P1QP1]:;#\/[2SL[1+/5-0@O;
M2XGN(;[<CRYF;,BL&4JRDXX([ T 8R^.M<N]-LHK*WLCJ$^L?V89YH94@D0P
MO()E4D,.@RI)Y##/0UU>MVNI7?@N\M&U&WM-3FM#%]KCS'&DK+C(R25&3QR2
M/K4$/@^W1;%KC4;ZZN+74#J)GG=2TLI1DP0!A5PW"J !@>^=?5M+M-;TJYTV
M_C\RUN4*2+G!QZ@]B#R#ZB@#S;3++3-$US11>^%+KPO?"X6%+VR=);>[9@5\
MJ1U.2&/3>N<@<BI!\3KR5GU" 6KV2WA@73ELYVN'B$FPR"4?)NX+;<=.-V:Z
M:W\%.;JS?4_$6JZK;64JS6]M=>4%#K]UG*(&<CJ,GKS0O@>.*5H;?6=2@TI[
MDW3:=$Z+'O+[R ^W>$+<E0V.3V.* (+76_$VL3WM[I,.FG3[2_>S%K,K^=.(
MWV2.)-P5.0V 5.<=>:YVUOM2B.H-J;6E_&?%\%O$KQR Q$M&-RG>>@*[1T!!
MSG.!U5QX'@FN;H1ZK?P:;>7/VJYT^,IY<DF06^8KO4,0"0&&>>F33F\$6K7M
MS,=0O/)GU*'5/L_R;$G0@Y!V[L-M&02>G&* ,:?QAKPT.^\5PQ:?_8=I<2I]
MD9'^T20QR&-Y!)NVJV58A=IXQS4>H^,/$L-GXDU:UCTL:=H5V\30R1R&6Y15
M1VPP8!#A^#@Y/8=]B?P#:S?:+7^U+]-&N;@W,VEJ4\IW+;V&[;O",W)4-CD]
MCBKEQX/L;C1M>TQI[@0ZU-)-.P*[D+HJD+QTPHZYH NZ_KUIX=T&XU:\;$,2
MC"Y +L3A5&>,DD#GCFN(^']ZDOC;Q+]HUJTOK^[M[.9O(G5T#8EW)'@\J@*C
M]3R:]&EM8+B#R)X8YHN,I(H8''L:R]/\,:9I>NWVK6L"1SW<<4;*L:A4";ON
MX&1G=SZX% ',^&HI=$\:>+I=6U>6\,=C93SW,P"*@_T@G:HX5 !TY[Y)/-8V
MC^(;?6?B;HNL3:O;;;VSNH[:R%PA\B/=#Y88 \2OEF(Z]%_AKT6'0[6+6M2U
M0EY)-0@A@FB?!3;'OQ@8[^8<Y]JK-X3T@Z_8ZQ':Q13V<<D:)'$BJ=Y0[CQG
M(V#![9- '!:A+=ZEX;77K=8WO[_Q/ L E)"K'#<F*)#CHOR%CCN[>M=7;W%]
MJ>HZKX1\1"TF=[%;B.XLXVB5XW+(059F*LK+D$'N#QBJ\7@XW5EJ&@W4EU;6
M46IC4K&YMF"L-SF7:"0<%9-_;H5K1AT6?0H=4U=)[K6=;G@"*\^Q2P7/EQJ%
M"JJ[F)/'<DT 2>#=6N-6\%:??W9#W7E-',V<!Y(V*,?;)4G\:YC2_'VH3Z]H
MUM->Z1>0ZC.T$D-A#*?LS;&8?ORQ23[N#@#U' KK=$\/1:7X/MM F8S(ML89
MW!QYC,#O/MDEC^-9=GX"2W?1O/US4KF+1I%:RA<1*J (4 ;:@+?*<9//YG(!
MDV/C#Q++IVEZW<Q:6--O-373VMHXY/- :<PB0.6QU .W:>.]9_B35]>\0>#K
MC5(Q81Z,^I10QP;'^T;([M4\PONVY++]W;T/7-=G'X.L8]!L=($]QY%G?)?(
MY*[BZS>< >,8W''TJC=_#ZVN4FM4UC4H-+ENA>?V?$8_+67S!(<$H6VEAG;G
M&30!V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<W
MXXO]3T[P^)M,,Z$W$:7,]O!YTL$!/SR(F#N('L<9)P<5TE8_B*QU6]LX'T6_
M2UO;:=9E$N3%. "#')CG:0>HZ$ T <UX7UN!KVZN+3QDFLZ+#:O+<K>E!=6K
MJ0=V%13L(W9##@@8[UK:=XTBO;JP2YTG4+"WU('[#<W(CV3X4O@A6+(2H+ ,
M!D ]^*RIO"6K>)-5>]\0QZ;8J-/N+$+ITCRO*)E"L7=E7@ 9"X/)SFJN@^ +
MBROM-^U:1X=MXK%2)+NT1FGNCM*@@,H$77)PS'L* -NR\;KJ!MYK;0]4?3[M
MF2SO0L>R=@"1QOW(K;3M9@!TSC-9'AWQG<ZAI_AZ\U@W-D]TUV7 6+RI4C4M
MN;!)55 X[Y4YXY.AH&B^*=(MM*T4W.GII6G$(;J-F::YA4$(AC9-J'[N6#'I
MQC-9ECX"U1K#2=-U&6S%K8?;H"\$C%Y(9XV53@J &!8Y&2..IH V]/\ &\-Y
M<:?Y^D:C96>IMML+RX";)B5+*"%8LA8 D;@,_7BJ]C\0[:]^P3C1M3ATZ]NO
ML<5]((]GG%BH4J'+8+ C=C&:AM?#?B*Z70;#5WTU;#1IHYA/;2.TMTT:E8\H
M5 C'.3\S<C Q3K?P=?P^$=#TEIK8SV&IQ7DK!FVLBSF0@<9S@^G6@#I]9U:#
M1-+EOK@,X7"QQ(,O+(QPJ*.[,2 /K7->$-7\0WFAZY+J$<5YJMMJ,T,=NCB.
M-<*A$8;'0%B-Q!)K>UWPY8^(4M5O6ND-K+YT+VUR\+*^"N<J0>A(_&LSP=X2
M;PO+J[O=W$_VR]>:,274DN(R!C._^/KD]^.3B@"#PCKM\VAZW>^);NW$EAJ%
MQ'+)&-L42(!PN>2!SR>357PSXFU2[UOQ-<:T#;6%M:VUW;6I4!H(F$I._OO(
M0,1VZ=JOV_@R*XTK6=-U9B]O?ZI)?+]FF=&"EE906&"""HZ5GVOP[%MJWB&?
M^T+V2WU*P2TB$]]+,P.V17+ACAL;AMY..>F>0"U8>)[BTT#2+B\M[F^U;6RT
M]O96^T%%(W[<L0JJB%023R?<TNI^)YTT.#7TM[NR2QO5AU"SN4 ;RRPC?ID'
M;N5PRD@A?<U0TVQU/4='\,:MIZVPU;18I+*YM+IV1&.U8Y5W*"5(:,$'!R/K
MFG^([76+SPDVBZK<03:EK=\L,<5N/DMX=P9@#@%@L:.2Q ))QZ"@#J==UNVT
M"P6ZN(YIFDE2"""!0TDTC'"HH) R?<@  FN3\3>.[RT\+:_]GTN\L-<L;43>
M3-Y3%$?(68$,5=00<@$G(QBNB\4Z+<ZS96;6,L4=]87D=Y;^<#Y;,F1M;'(!
M5F&1TSFN=U;PAKGB*VU^ZU!K"VO[_31IUK!#*\D<2!BQ9W* DDGLO '>@#9G
MN]1T+X>W5[LOKF_MK228+>O$TVX GYRA"$#KP>@[FN>L/&>N/KUE$VD:A=M<
M:%#=FRB\@%9#(X:0L6"@$!<#=GD< YQW.L6+:GH5_IZN$:ZMI( Y'"EE*Y_6
MN?\ #7A[5K'5[;4-3-DK1Z/%IS);2,X+1R.=P+*."I7\<CWH D7QS:7=II;Z
M5I][J%UJ4+7$5I&$1TC4@.TA=@JX8A>O)Z9K8T36K?7=/-W;I+$4D>&:"90)
M(9$.&1@"1D'T)!ZBN#_X5M=0VNBS26>DZK<V-O-;36MX[+$ZO*9%9'"$JPZ<
MJ<@FNQ\):&^@:*;66&QAEDF>9XK&+9$A8\*.[8  W'DXH PM+&L^,UOM43Q!
M>:59)=S6]C!91Q<B)RADD+HQ8EE/R\ #'UK1'B#4M'M=-TS4K0ZIXAN$D8PZ
M=M571#@RDN5"#!7(S]YL#-58-&\3^';B_@T!=*NM.NKB2YB2]EDB>U>0[G'R
MJP=-Q) ^4\XS4<?AC7]+N=+U:UOX-5U6"WFM[P7TC1).LKB3Y& 8IM90 ,$;
M>* +H\=V<EE;M;Z??3:C/=/9C30J+,LR#<X8EMH 7!W;L8(QG-96E>.)EDUV
M74+2^:4:LEC8Z=L3SMY@C8QC!VXSO;<6QCG.,4L/@W6;.:#7(9K&77!J$][-
M S,MNRRQK&8P^"PPJ)AMO)!XYJG>> -6U:*\O-3&DS7SZNFHQ6K%VMV00+"8
MG)7/0'Y@#R <=J .RT37TU>>\M);.XL;^R*?:+6XVEE#@E6#*2K*<'D'L1VK
M8KC- \-ZGH=OJMU9:9H-C>W1C$%K;AO*15Z^9*%#.3N8CY0!QZFNSH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@!  ,X &>3[T8!(.!D=#2T4 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,*J>%]$UBXU#Q)J4][JEJ^H16\%O=7<42S@QA\N(P-JK\X !'."3UKT&B@!
M"% )R0.OK2T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 444R::*W@DGGD6.*-2[NYP%4#))/84 /HJD=7TX"3-];CRS&)!Y
M@RADQLW>F[(QGKFKM !15'5-9TS1+87&JZA:V4).T/<2J@)]!D\FGV>JZ=J%
M@M]9WUM<6C=)XI59/^^@<4 6Z*** "BH4NK>6YFMHYXGGA"F6)7!9 V=I(ZC
M.#CUQ4U !16/'XK\/2ZK_9<>N:<U_NV?9UN4+[O3&<Y]NM;% !13'FBC;:\B
M*VTM@L <#J?H,C\Z;;W$%W;17-M-'-!*H>.6-@RNIY!!'!!H EHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3D,#R"#W%/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR62\CFMM0M'MK-[\+=6QC,L"_>= >N,C@X/(XKG]1\+:_K^G^*+Z\MK:UO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C
MHLB,CJ&1AAE89!'H:6B@!J(L:*B*%11A548 'H*26&*90LL:2 ,& 90<,#D'
MZ@C-/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\VSWA'D#"2.4%L.A#8&-I'7-3_\ "$7<^GSFXU&UBU$W<-W:O9V0CAMGB^Z
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI&941G=@JJ,DDX % "T4
MB.LB*Z,&1AE64Y!'J*C:ZMT9E:>)65E1@7 (9ON@^YR,>M $M%%5KG4+*R95
MNKRW@9AE1+*JD_3)H LT5'#/%<1"6"5)8VZ.C!@?Q%24 %%07%Y:V?E_:;F&
M#S&")YL@7<QZ 9ZGVJ>@ HHHH **** "BBB@ HHJ-IXEF2%I4$K@E4+#<P'7
M [T 24444 %%%% !13(Y8Y0QCD5]K%6VG.".H/O3Z "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5
M>^O;?3;&>]NY1%;P(9)'/8#^?TJQ7*>.F+1>'[9O^/>YUNV2<=BHW. ?8NB4
M =3&XDC5P& 8 X88(^HJA-KEA;SS0R22AX9HH' @<@/+C8 0,$<C)' [XKBO
M$VK:GHNM:KHMO=SF?7XXO[(9G)\B5B(9@OH$!67 ]6JKJ=_J%EJNK6D6I7OE
MV^L:-;Q[KAB0C&(.,Y_BR=WKDYH ]&M-0MKV6ZB@?,EK+Y,R$$%&P&'![$$$
M'N#5DD*"20 .237*Q,8?BO<Q1<1W.BQRS@=-Z3,J$^^&8?\  ?:K?CF"\NO
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG+.[>OT "CT"@4 >5>,W6[U/Q9:FTLK:Y> 1QQRZ=)=W5^/)&UHFW;44$D<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MI+F5#UDG?,L@'^[DCZ** .GHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@#"NO#<ES=2SC7M7A#L6\N*2,*OL,H3C\:B;PM,
MRE6\2ZX0>H,L7_QNNBHH YT^%92FP^)-<*XQ@RQ8_P#1='_"+3?]#+KG_?V+
M_P"-UT5% '.GPK*Q!/B77#@Y&98N/_(=:VFV#:=;&%KVZO"6+>9<LI8=./E
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MH1D6L?FS"0&,HG/SD, =O!YZ<56_X371)],U*\L[U)C86K74D;*R-L"DA@&
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MD88 G!P3B@#H:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** .,U%;[0/'<^N)I=WJ%A?6,5M(;-0\D$D;N1E"02K!^H
MS@CFJFLW'BG4]$N)WTQ[>SFO856T6&.:[BM1R\A5MR%RVTA<':!GD].CN?!W
MAJ]NI+FZT'3IIY6+2226ZEF)ZDG%0_\ "">$_P#H7-+_ / 5/\* ./@TO5Y+
MSQ+J%SI&IZE!+8V]E!;ZA*BRW$#,YGQMP%.#PO!X&<$\02Z-K5_HVK:;#:ZC
M<6%PMM96D^IQ(MW'$\H\]2P^8QJ@!RW.?7&:[?\ X03PG_T+FE_^ J?X4?\
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MRKN<N_& ,8 &35;1/"^JZE\/K1[R1!K&H7]MJEX\V5R$EC8+T)!$<:C'KZ4
M:<GQ":%]0A?PQK(N].C$]W /()BA()#[O,VMD!OE!)RIXJ[/XTA:X$.E:5?Z
MLRVT=W-]E$8$4;C*9WLN6(!(49/Z47'AR[FU7Q1=++ $U73XK6 $G*LBR@EN
M.!^\'3/0US$OPYNK>Z2ZCTS0]6DEL+:VE74'=/)EBCV;T(1MRD 94A3QUYH
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M%)8L\NU"<G&   ,=\T 6-8\1:EIOC^VTVULKO4(9=+>86EOY8^<2J-Y9RH
MR.O4CBK \=65Q9Z>^GV-[>7M\TJQV**B2H8CME\S<P5-K<')ZD8SFJDOAC4]
M%U^SO_#%MIQLK>P>T-G=3R1Y+2^9D.%?&#ZYSD]*R+CX;7'EZ;?20Z9JNH12
MW4MY;7>Y()6N)/,;8P5BI5@ "5.1G.* -Y_']D(;01Z9J,M[<W<EC]A1$\V.
M=$+E&RVT<<[@2,$'.*>GCNS_ +,FGET^^BOHKX:<=.*H9FN"H8(I#;2"IW;M
MV,9/:L[1_!-W87FB71BTNU^RZA<7D]O9(515D@:)54X!<C*Y8XS^ %0ZU\/[
MG5&U.=C8S/)K,>IVT%QN,4BK L31R<<9PW(SC@^U ">*?&]]'X7U1+'3K^QU
MFVEMXI8G\DO DSA5E!+E&!^901G#=0 ":KZAXHU/0],U!+7^U;V]M;S3[>6.
M\%N6A$WEEAN5@K$AMN>0&8?PC-2KX"O)-&U:*.PT72YKR6U,4%GN*HD4JNV^
M38"Q.#@;0!^)-7=:\'ZG>MXCFM9K3S;^\L;JU65F"YM_+)5R%.,E#R,]: .J
MOM373M'DU&>VN2(XP[6\2>9*2?X0%)!.3CKCWQS6)'XWMX)[Z#6=-O-(DM+)
MK]A<&-PT ."08V;D' QUY&,U<\2Z;JFM>$I[&TN([/49DCR5E8)D,I=-X 8*
MP!7<!G!SBN'NO #QC6+^\LM.TO3Y]%FM)8=-,EQ,K;E<2%BBF0_*>,9X YSP
M =5;^.%;4K6QOM"U33Y;N&6XMS<+&0Z(NXYVN=K8(^4\C(JO9_$2&^T^SNH=
M"U7.H%1IT++$'N\J68K\^%50#DM@8QC.:YRRU34/%GC'15%_HUZEM879E?2Y
M6E5"Z*JM(2!L+'HG)&&Y-:M]X!N+CPSX4MGBTZ]O="@6)[:Z+?9[@>4$<;@I
M*G(!!VGIR.: -D^.;*.PFDFL;V+4(KM+)M-*H9S.XW*HPVT@J=P;=C )SP:B
MN/'UG865[)J.F:A:W=E) DUD51Y,3.$C=2K%64G/0YX(QFL*;X;S7>B,K6&A
MVUTNHQWT5C#&QMBJ(4\N1]H9LAF.[;P2,#BI(O 5X]G=%+#1-+DFN[*5(+/<
MP6.&99&W2% 68X.!M 'XDT :4GQ!:%[^!_#&LB[T^,3W4 \@F.$@D/N\S:<@
M-\H).5/%7I_&4+7$5OI.F7VK3-:I>2+:^6OE1/G86+LHW-@X49/!I+CPY=RZ
MMXFNUEA":KI\5K""3E61902W'3]X.F>AKFY_AU<PW5M=IIFBZM(=-M[.>+4)
M'0121+M#QL$;*G/*D#H.: -]O'MG/)IT.E:;?ZG/J%HUW D 1,(K!6#EV4*0
M3@Y[\=:HOXYN+W4?"ITO3;I[/4Y[B*Y1Q&KHT:N&0Y<8*LI)QG(7@DG!MZ#X
M2N='UC2KHO9B&TTJ6SD2WC\H&5Y4D)5 ,!?E;OFJ5KX0UC3QH<UO)8RSZ?JE
M[=2))(ZJT5PTG0A2=P$@XQ@D'GO0!J>+M?U'1+WP_#86,MRM]J'D3>68\[?+
M=MHWL,$XSGIA6Y!(SBZ7X\N;1=5?4]/U"XLK769[1[]%C$<"^=LC&-P9@,KD
MA3C/4\UT/BO2-1U,:1<:7]E-SIVH+=^7<NR)(H1T(W*K$'Y\].U95QX.OYO"
M&N:0LUL)[_4Y;R)BS;51IQ( >,YP/0\T 7M9\9_V.U_*="U2XL=.&;N\C6-4
M0;0Q*AW#/@')*@_B:;IGB*^OO'VJZ0;*7^SK>SMIH9\QXR_F98_-N(;: !CC
M:<XR,\YXC^'^KZW+K\<D.E7AU N;2^O9Y6>T0H (UAVE1@@X8,#SG!(Q72Z9
MH>J:=XMDU$_9'LKK3K>VG_>,)(Y(=^-HVX93YG4D'CI0!8U7Q0+#56TRRTJ^
MU2\B@%Q/':>6/)C)(4DNR@L=K849)P:K/XVBFE2'2M'U/4YOLJ7<\<*)&T$;
MYVAO,9?G.#\HR>*2_P!)URQ\37FLZ$EA<?;[:*">&]F>+RWC+;'4JK9&'(*X
M'0<U4@T+Q3HVI3ZA8W&G:I<W]K#'>M>,UOB:,$"1=B,"I!^[@=!S0!/_ ,)_
M:74UG!H^F:AJDUW9?;8E@"(!'N*G<9&4*01@CUJJ/'%QJ&M^%5TO3[E].U9)
MVF+"-60IA2""^1L.2V,YXQGI4WA?P9<>'=4LYVNHIXH=+-K(V"K/,TQE9@.@
M7+''.:JZ?X/UG2U\,O#)8R2Z9/=_:%:1U!CG<G*':<LH(X( )[]Z -)?&Z"[
MLQ/HFIV]A>70M+>]F6-5:0DA<IN\Q5)'!*CMTS52#QM%:LMLEOJFJ7=WJ-Y;
M6\:QQ*VZ%SE<[@ @'1B<X'/-8%M\.]:\S27NH=(DO;#4(KJ?5)+B66XNU63<
M>&3]V2.P)&0!P.:WM,\'7]EKMC?236QCM]1U&[8*S9*7!)0#CJ,\_IF@"R/'
MUH=/BD73;W[?)?MIPL&,:R"=5+,I8OLQM&<[N<C'/%;VCZFVJV33R6%W8RI(
MT4D%T@5E9>N""0R^C D&N3O/!VHR6FJ1_9](U"&\U=[YK.]!\N6)HU4#?M)1
MP5R" ?UK7\%Z#>>'M*N+>[D0"6Y::&UBG>:.UC(4"-7?#$9!/0#+' H Z2BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "JU_J%EI=F]W?W<-K;)]Z69PBCTY-6:Y/QY)>1V>EO:
MVAD1;Y6FN5LS=O:*%;$B1#DG.!G!QN)Q0!OZ7K&FZW;&YTN_M[R%6*,\$@<*
MWH<=#[5G^(/%FD>'H)UNM0LTOEMWFBM99U1Y< D #KR1@5@> 8+Y/$/B>ZNU
MU%X[I[9X;F^M1;M.!&5)"A5 P1C!&[&,]:H:S')I\OC:SO-%O[^765WV3V]H
MTRS+Y"H(RR@A"K*Q^8CKD4 ==_PENCVNDZ;>ZMJ-GIS7T"3)'/.J]5!.,XR!
MGK6;X@\;QZ;XATK1;"33);F]C:9FNKSRE6,;=H& <L^X[>@.TUR(T_5-(U>*
M]NI=8M8+G1;.WC:RTQ;LAD4[X74QN4.2#T .3D\5HZ5H-[8OX9B%E?".WT._
MB;SU#-$SM$4C8J-H. 0 /[N.U '7#Q=H]II5G=:MJNF6<EQ;QSE?M:LN&'!1
MN-RY!PP'.*??>)+2R>"<W-BVGR6<MV9_M2ABJ;<%!T92&Y;.!QZUR?@K1KJW
MUC0I[S3IH_(\*6UL7FA(\N3=\T9)'#8QD=:H^'M$U*%/#<3Z=<Q"'2]4A</$
M5$;/,GEJ<CC(' /4"@#LO#_BVV\11Z=<6CVGV>[T_P"ULHNE:6)LJ"A0=EW$
M%NQ &.:O:=XET+5Y9HM.U>QNY(!ND6&=7*CU.#T]^E>7P:-K&K^'K.SM-/OK
M:YC\'2::WVB!X<7"M"#'E@/O;6P>XYK?E8Z_K7A]]+T6_LDTR"X^TFXLW@$:
M-"46!=P&_P"8J?ER/ESGI0!V%EXIT#4K\6-CK5A<W3)YBPPW"LQ7&<@ \\$&
MK>HZI8:1:&[U*\@M+<$ R3R!%R>@R>_M7 Z9HES:^&OAK&FFRQ36<T37*B$A
MH,VL@<OQ\N6(!SW(K;\6Q2V_B+PYK+V=Q=Z?8/.)TMX6F>)G0!)=B@EL88<
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MYOGR!COGO0!Z'++'!"\TTB1Q1J6=W8!5 Y))/05EVGBKP_?6EQ=6NM6$UO;
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M9K?PE'87-I<VUS:3S1R)/"R9)D9@5)&&4AAR,BN0N/M\?ABY\-#1M4>^&O\
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MIBWF[8A#PN#&Q0[CGG"G<<GBM;PIX<FL/$>BFYL+D16OAX0*]TH<Q.9@?++
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MZ>>RRQ*I<J06QGOWZUV?P_DED\+R033S3BVOKRUC>5R[^6D[JH+'DX4 9]J
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M=X=1M%O&"6L]W920Q3L>0%9AU(Z XSVK+\?:%8V?@RZET_3((XXIK:6Z2W@
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MF<LVWY2L89CECR0!DF@#L:*Y;Q[>QVF@V\4AN\WE[#;(EM<"W,C,<['DZHA
M()'/8=:\_CGN(G\6:2FIVNDQ1_V>4C349KB")WD<-&TN T8<!58C &>M 'M-
M%<-X!N1'J&LZ4]K-:SVWDRO"NH&\ME#A@#$Q&Y<[22I]B.M=S0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %1S6\-QL\Z&.3RW$B;U!VL.C#/0C
MUJ2N=\5:I?VDVCZ;IDL<%UJEX;<7$D>\0HL;R,P7."V$P,\<T ;I>"<RVY:.
M0J-LL>0< CHP]QZU5GT32+E[>2XTNQE>U4+ TENC&(#H%)'R@>U>:3:SJ_A7
M4O%3R3)>ZC/>Z?:0SI;$_P"L3 8Q*<LP&?E'4@=,XINOZQKUYX/\5V%P]^]J
MFE-/%?W6EM:-GD/"00 <C!!'(R>N* /5(;"SMV1X+2"-D5E0I& 55CD@8Z G
MD^IJ2&"&W0I!%'$I8N0BA06)R3QW)))KSJ^\2ZU'K;Z'!>7:?8+.&26YM=(:
MZ::63<1N5<A% 4>Y).",5-::]XJUW5-%L$>/19;C3'O+Q)K0NZNDJIA58@@-
MG//0>_- '=2:=8RVLUK)9V[V\S%I8FB4HY)R2PQ@DGGFH5L-)T^T@MDM+*VM
MDE4PQ"-$19,_+M&,;L],<YKSV#Q%XNGTG2-675+(+J.JOIPMFL\K&GF2()"P
M8$L-F<< ]/>K%QKFJ033Z9J,MKJ$MCXAL+9+B2U4;DE\M\[>@==QPP] : /2
M&4,I5@"I&"#WJG8:/IFE^9_9VFV=GYIS)]G@6/>?? &:X"X\1^)X]+U;7QJ-
MJ+73M8DLULOLH/G0K<"/YGSD-@\8].<YINI>,M?GU+7#I:W@&F7#6UM:PZ1)
M<I<NB@MYDJ_=W$X&,8&"<YH ] M-*TK2//FL["RLM_S3/#"L>['=B ,_C4Y%
MH2M^1 2L1VW!QQ&<$X;^Z< ^G KS[4M4U_Q+IWB=K.YBTVVT^V\HVD]ON>5V
MMUE<2$D%0 X48[@DYZ5M'_DCQ_[ '_MO0!OV6DZ1:/)<V&GV4+7(S)+!"BF4
M'GD@?-5@65HL=O&MK"$MB# HC&(L# VC^'@D<=C7 :9=^(]'LO#%M-J=M<1Z
MO;?9HT6V"_9)1;F2-E.<NHV8.>O7CI5_0?%M]KUWH%I&$CN#;2SZPNW_ %;1
MGRM@],R[C]$- #D\"3/JMM/?ZM#<V\%TMRN+%4N961MR++,&^<*<'A03M&:Z
MN:"PUBQ,4\5M>V<O5759(WP?0Y!Y%<KXCAO'^)7A$PWOE1>7=%H_+#9PJ%N?
M<''M7,^$[W7M&\*>&;W^T()+"ZU$61L?LP&U))G4-YF<[@>?3MCO0!Z9'HNE
M16[6\>F6:0O&(FC6!0K("2%(QC&2>/<U)8Z;8Z7;_9]/LK:TASN\NWB6-<^N
M  *\TM?'/B&_3^UK.WOYXFO#&FFQ:/*T;0"4H3YX'W\ MG[N>,5WGBO6QX<\
M+:AJNW?)!$?)C R7E/RHN.^6*C\: )WT[1-4O%OGLM/N[JW?8MP8DD>)E/0-
M@D$>E+>Z7HLUVEU?6-A)<L/)2:>%"Y!!&P$C/(SQ7FW@34;/PWKYTF,WS0:A
MIZW+O<V<T&^]B7]\5\Q5R77#<?W34L]SKVL:?X,UV^U"V>UU#5;6X^Q) %\@
M.&*!7SEB <'/4\C&,4 >D7>CZ7J#PO>Z;9W+0?ZDS0*YC_W<CC\*DDCLH&DE
ME2WC-P5CD=@!YIZ*I/?K@#WKS>/Q%XNFTO3]734[()>ZP^F+;-9Y54\Z2(2%
M@P)8%<X& 0,>]6+O6]5MI+S2]1EM=1DL==TV&.XDM5&Y)FC;[O0,NXX8>QZT
M >BI!#';K;I$BP*FP1A0%"XQC'3&.U9]GHVAVQDCTZPL+=XG.[[+"B-&Y7K\
MHX;:?R-</=^(_$\6F:YKR:C:K:Z5JLEJEE]E!\Z)90IW/G(.&XQZ<YSQ-J&M
M:U;WGB(:39_ZG6(8;B6SLUEG6$VR,7"9'F-N*KSDA>QQ0!IV'@::'5K*\U'5
M8+M+*;SX_+L$@EFEVLBO-(&/F$!VZ!<DYKK/L-I]D:T^RP?9FR&A\L;#DY.5
MZ<DDGZUY?J.IW^O:/H30Z]'++%XAB@:1;(Q2+P2HEB?&UU[CH<@UK)KOB!H_
M$VJRZQIUK8Z7=3VD$-Q;G82H7:[N#NX+8VJ.<>_ !VUGI6G:?:-:V5A:VULV
M=T,,*HASUR ,5%;:'H]I:S6UII5C#;W'^MBBMT5)/]X 8/XUYO<^(]9NAK&D
M-J5U/!-H5S=QW-UI36CJZ%00BM@LI#GDC(XY-:7A^ZU_4$L-!LM7BM%L='MK
MF:Z-HKO*TNX(@4G 553D]3QTH ]"^SP_:!<>3'YP3RQ)M&X+G.W/7&1TJE>:
M7HTMC%97UC8/:;PL<$\*&/<>@"D8SUZ5PUGXG\2^(+K1-/M+RTTZ>XBOA>3"
MV\U=]M,D>Z,$CAB3P3P&]173>+KMK./0]L4$IEU>VB/G1A]H)/S+GHP[$=*
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M\Q5*R7!  DY.=IP#Q@T1/KU@?'>KZ9J-M#!8ZC+<?99+??Y[);Q,P9LY4%0
M,<@Y)STH ].6:)Y9(DD1I(\;T# E<],CM42V%FCJZ6D"LDC2J1& 0[9W,..I
MR<GODUYA=>*I]+U#Q)J=A"?M-_+I<,(,32^698NNQ>6(!/RCJ<"NF\)ZUK%W
MK5U87T=]<6:VZS17MUICV9#[L-&00 W&""/?.<9H ZJ$6B7-PL(A6=BLDX3
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M"V&D*Q;CSZG'6J5KXUF6_MXM8T=M-MKNSEO+:<W"RDI&%9@Z@?(P5@>"P]Z
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M+>74I988TPTJW6\[%R< @/CW]JYS1Y-2U?6O"-BE_)>6FERM)+&VF26\D*+
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M[*V@UF:QGTAX8(]9,1N/M!/"(ZG<4QG.X]<8/6MF==6TOQ#XJ=/#=U?QZI'
MEM+"8]KLL(0J^Y@57)Z\C[WMGN(;LRWMS;&VGC$&S$SJ DNX9^4YR<=#D"K
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M;2>*YZ8CW0JH4CW(QQ78 @C((/TJIJ=W9VFCWMW>L#900223D#=\BJ2W Z\
M\4 <+X TJZ37KY+HB2T\/!])TYMV[*L_F,?J$\A/^ M6SK4%]IOC:S\0Q:;<
M:C:?8)+*2.UVF6%BZN&"L1D'&#CD8%;NC6>FZ=H]M#I=M':V14/'&HP/FYR?
M<YJ^2!U('UH \XT?PYJJ:]H^IW6GF!)-7O\ 4)(2RL;5)82J!L'&XGDXSRQK
MIO&J:K)H"C286EF%S"TGEQQO*D0<%FB$GRF0#D9_GBMFSO#=VS3/;SVVV1TV
M3@*WRL5W<$\'&1[$57U+6;;2[C389ED9M0NA:Q% " VQWR>>F$/3/:@#D_".
MF:E#XUU/4KFWU46<^GPQ13ZG*C2NRNY.0G"#YA@8'KWJU=KJ&A>,M6U1-&N]
M4MM2M((XC:["T;Q[P48,PPK;P<].N:Z.^UFWT_4]+L)DD,NHRO%$R@;5*1M(
M=W/ PAZ9YJ^"",@C'K0!P^C:+J46K:S=76FP6K7&C6EO&EMCRUD43;XT]@64
M?E53PKX>U*QGMWN[)H]GA6SL26(.)D,F].O;*^U>A[EP#N'/3GK0651EB!]3
M0!YW8>&M372/ -LUL\#V%I)%=L",P,UJR<\\_,>W>LKP_P"&=3AB\.Z3>:?K
MIDTRXB>9I;R,64?E=)(\ LV>,+@'YB"17K)(49) 'J:SWUFVC\0QZ*RR"X>T
M:[#X&P(KJA&<YSEAVH SO%.GW5]>>&WMH3(MKJR3S$$?)&(I5+?FP'XUS=GX
M=U.+P)X:L#8LMU:ZS#<SQY&407+.S=?[IS^->C4FX;MN1GTH X*/PSJ0\?\
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MUQ1N&[;D;NN,T +15+3]5M-3:\6U<M]CN&MI25QAU ) ]?O#FK@8,,@@CU%
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M%$L4T=T&^RQ(;9'1) I&(O,8G'W<D9XKVL1HI)"*"3G('>@HI5E*@ANH(ZT
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MA'I0D-OI,#?98[@;BKJ22HDV]0O/"DU[EM'/ YZ^]-2*../RTC14_N@8'Y4
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M Q\MX?LCEU3UB,F\ #@C(Z5WGC0V6A?#VZA2S/V**.*W6&&4PJB%U3EP"50
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %8GB37)](2PM[*V2YU#4;D6UM'*Y1 =K.S,0"<!
M58\#)X%;=8_B#0O[;AM&BNGL[VRN!<VMPJ!MC@%3E3]Y2K,"..O6@#'N?$NO
MV)MM-N='M?[8O+LVUHRW!^SRH(S(TI.-RA0""I&20,'!S5>;QOJ%B;O3+O3;
M=M=BNK>VACBG/D3>?G8^XKN4 (^X8)^7C.:M2^#+NX"7EQK]P^M170NH;P1
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ME==BA<<%@#D]",54N/ 4DUO=Z5'K4L6@7EPT\U@(%+_.^]T67/RHS$DC!/)
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M1%@'RA@HV\CKD[C6OJOA?67NM6O;2WAFD?7+/4K>%IMGFI%'$K+G!VG*-UH
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M)2P4+*>@.2.F>"">M2W/C_2;6YOXWM]0:'3IO)O;I+8F*W/'+-Z8()P#@<G
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M]<:J\_G@9#&*,_*B\YQA2,  &@#L%\<:4]^L"PWIMFNOL8OQ;G[.9MVW9O\
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M\Q P2=QYYZUTGPRTBVT[P;9S"QC@O)C*9Y#$%D?]ZV-QQD\8QGMB@#LZ***
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MJ ^%1#(1EV+D;SC:.G2L"^U76='3Q=9I/J-GY.A"\ABN=2-W+#)O9=P?)*Y
M'RY/3/>@#UZ2\MH;J"VDGC6><,8HRWS.%&6('?&1GZBDL+ZWU.QAO;20R6\R
MAXW*E<@^Q (_&O/Y_#RV'C[PGYFJZK=2M#>2M)<7CME@(C@#. I.<J!CMT%4
MO"]W?^)U\.:;J6KZA%"VA"^9H+EHI+F8R;26=2&(48. ?XAG- 'IHOK8ZD=/
M\P_:A")RFT_<)*YSC'4'C.:L5Y%J^N7UKI^LK8^(KF^CMO#3RQ7@.TM*L\B;
M^.-P"[=PZXS6Q>7;>%=8LFBUZ^NK2[TN[NKQ[B4W&P1(K+<(IX7DD;5PIR,#
MB@#T6BO*M$O=4L_&'A9&?5XK?5(Y_-&I:BLQN0L)<.(@66/D _*1UQBHM"?4
MX?#G@O79==U2XO-1O(K>Z6:Y9HGC=7&-G0$8'S=<CDT >J6MW;7L32VL\<T:
MNT99&R RDJP^H((/N*FKS_P!I,*^'&_XF5_%LUNZ?_C[;YREQ( ASG(;JP_B
M/-;'CF]NK73],M[>[DLTO]2@M)[F(X>*-LYVM_"20%SVW>M '445Y1XEO-2\
M/'Q%I&EZS?/%%8VEU'+-.TTMI*]QL*AVRQ#*,X8GOV->BV&GG1=(>"*YO+UD
M#.'O)C+(QZXW'M[4 6;6_MKU[E+:7S#;2F&4@' < $C/0XR,XZ'(Z@TL]];6
MUU:VTTA66Z9DA7:3N(4L>0,#@'K7G>EW5QI7PY\(^((KJ3R8FCN-3 ;Y94N,
M^:[#N5>3?GMM-/TS5=3O-7\.:D][<"UUK5+J2. N=@M5MW$(V],$()/JU 'H
M%A?VVI6BW5I+YD19ES@@AE)5@0>00000>XJS7*>&6,7B_P 7V2?\>Z74$ZCL
MKR0J7'XD!OJQ]:YR]GN[[3/&&N3:]?65YH]S<1VL4-P4BA6) 4W1_=??U.X'
M(; Q0!WU]KNF:;%>27=['&+*-);@<L8E8D*2!D\X/Y5H5XGX@@>ZMO'&H2R7
M,5U-HVGR/$9F*(S[R1M)QP1QZ<^IKH-:N=2\':KJ*Z?J.H7V?#UU?>7>S&8"
M>)XPKJ#]WASE1@<#B@#TRHEMH4NI+I8P)Y$5'?N54D@?0%C^=>9Z'/KEGJVB
MN\]T+>_MY3.;W5UN/M.(BXDB3^$@X.%P-IZ=*Z'X;6UR?!^G:K>ZI?W]WJ%I
M#+*;J<NJG;_"O1>#SZXR>: .PHKSFQD?4+34/$.H>)+[3[BVU>2W"+,?(A1)
MO+6)H1\K%UQR1NRX(/2LVYO]0;P7JOC ZU?1ZO:WLRQV@N"($\N<QK;F'[IW
M*!R1NRV0>E 'K%17-S%9VLUU</LAA1I)&QG:H&2>/85Y?J_]I3Z?X\U<:YJD
M$VCW#FQBAN2L<12WCDY4<,"3R&R.N ,FI-3:?Q!:^,[B_P!8O+(Z;;A+>"&X
M,<:(;99-[IT<,S,/FSPN!@T >F6US%>6L-U;OOAF19(VQC<I&0>?8U+7 ^$=
M2ECU=;6>Z9;2'PWI\ZQN^$4_O0[@=N N3["LCPO=W_B=/#6FZCJ^H1POH7VY
MW@N6BEN9C)M):12&(48. ?XAF@#T]KRV6]2R:>,74D;2K%N^8HI +8] 64?C
M4<FHVD.I6^G23!;NXC>6*/!^94*ACGIQN7\Z\^TFVAN?B'H,ZZW=:F(]'NU%
MUYK()3'<1I@J.#U(/9BH/I6CXIL8]2^)'AFUEOKFT5K&^_X]IC$\N# =@8?,
M/7@@_+Z9H [JBO,+76M1TVUAU.?4[BXTS2-=FTZXEEDR);5\(LCGHQCD91N]
M%;WKK?!DUYJ&@'5;V68MJ<SW<,;L?W,+']TH]/D"D^Y- &DVNZ8IMA]MC;[3
M=-9Q%,L&F4,63(Z$;&SGTQ6A7BUEI ;2M"MHK^^C,OBZ[1I!<,SJ%^U#Y2<[
M20.2.<G/7FK^K:KK&AIK6BV-_?3PIK-E:QS37.9HHIHE9E$KYQEOE#-G&_Z4
M >M5@:IXUT#1M2?3KV\D6[1%D:..UEEVJV<$E%(&<'\JQ_![ZM;>)-2TV[,J
M6BVT4R6UWJ(NYX7+,"=W+;& & Q/*G'6J;'7A\4O$/\ 8:Z:Q^P67F_;FD'>
M;&W8#[YS[4 =MI6KZ?KE@M[IEU'<V[,5WIV8<$$'D$>AYJ[7FEWIMWH%K#97
M%[>7&K:]JLMW+;Z01;^:1'RBR,P,:*%4EL[CCWK(BU+67L+[2?[3O[0Q^)+2
MR5OMOGS0Q2*A=/-/WL%FZYP>.<4 >K76K6%F;H3W**]K;_:9D'S,D7/S%1SC
MY6QZX-0ZKIL'B#2#:O=74,$X!+VTIB=E(Z9ZX(/-><:KIIT'7O%T]IJ>IM<6
MGA=98I9KUW?=_I !))YQM!'H<GJ:TX#/XAU76(M0UW4-/BTRQM6@-M<F(+OB
MWM.^/O\ S9&&RORGCF@#N;":Q1I-,LL+]@6.)HE0@1@J"H!(P?EQTS5VO)=1
MUR_FBU41>(;A(#J&CQQWL9V!8Y5CWNJGA0VXL1TYYJ]JVHR>&+_7M,CUG4VL
M1IL$ZR&3[3/;SR3&(*C2'J_& QP",\"@#TRD)"@DD #DDUY#+J.L:1?^(K$2
M:G9*/#-S?)#>:G]KECE0X60')V'D\!L<>U:GV6\LM1T*!M:U6X76=-N?MHFN
MF(+K$C!T'_+,Y)^[CB@#T6UNK>^M(KJUF2:WF0/'(ARKJ>A![BJJZ[ICR64<
M=['(;V22*V*982/&&+@$<<;&_*L+X<6B1_#+0HQ+.PEL(F+-*Q*ED&0IS\H'
M8#I7!Z'I FT[P/;1W]]$)]5U$O(EPV]0JS@A6/W<A><8/)/4YH ]IKE==\+:
M-,]Y>W^HWMI9WA1;R!+LQP7!.$ 8=MWRKA2,\#FN5;4;JTCO_#YU'6;EDU[[
M):)!./M,T?V=9C&9G8%5!+'=G=@8%8^H/>7GA_Q-I=]<7T<6GZOIOE12:@T\
MD6^2+<K2@Y8<DX).TXYXH ]J1%CC6-%"HH 50,  =J=7->-;ZZT+P->3V$[Q
MS1+%$MPYWM&K.J-(2>I526R?3FN:\2,_A:)[73_%%_OO/LR2K=3F=[:-YUC>
MX5WSMX8C'3."!Q0!Z54=Q/':VTMQ,VR*)"[MC.% R37E_BBXO_##:[IVF:OJ
M,T1\/3WW[^Y::2VE1E575V)8!@S<9QE.,<UK^*=4E;6[.RBO&,,V@:A/+"K\
M/@1;&([]7P?K0!VUK=P7MC#>V\@>WFC66-\$;D(R#@\]#4=CJ5GJ6EPZE9S"
M6SGB$L<H!&Y",@X/->;^'5FUJ(6=WK-[IUOIFA6$ELMM<&$?/$2TSC^, J%P
MV5X.1S72^ O^24Z'_P!@M/\ T"@#I=/O[;5-/M[^RE$MK<QK+%( 1N4C(.#S
MTJS7D?A=)=%\*^ M0L=9O;F6_DM[6:VDN"\+Q-&=RK'T4Q[>HP?E.<YJMI.K
M>);S3=/\1-)<Q7-QJ"I(\^JJML5,VPP" \ @94<;MPSF@#V6BN.^(FI:C8Z9
MI5OIQE1K_4HK65XI1$X0JS85SPA8J%S[\<XK 2?4[33O%%K?:M<:5!900W5N
M\NHBZGM)/F.&(^9D;:N%;.<L!U% 'J%%>1'7M7O_  -J.K7VJW.EZO)JEI;7
M%NC%!IJ>=&N K?WD;>6/WMV.@J;Q3JFI^$)M9L=(U*\N(CIL%P6NK@S/:2/<
M+$6#OG *,S8/ *9QC- 'J]17%Q#:6TMS<RI#!"ADDD=L*B@9))[ "O)[_5/$
M?AB'56@:XA4:1+<"&^U-;V59%90)T!R0H#-D?=R!Q5_Q;I5MI_A76K9/$VI7
M+7.A7,WV:>Z:4S;%!\U6S\@YP5&%8-C'% 'IB.LD:R(0R, 5([@TZO*9GU:X
M\00Z#:_VG/96>DP3Q)!JIMI':0MND9R=SA=H &<#N.14^B7FJ>)+W0]+U?5Y
MHXSIDUR9=.N]ANY%F\L$R1XSM3!(7 RW/ H ]%L-1M-3@>>SF$L:2R0LP!&'
M1BK#GT8$5):W=M>Q-):SQS1J[1ED;(#*2K#Z@@@^XKD_AH@'A&>,737(&I7P
M^T9&9?\ 2)/GR..>O'K7(Z#'+;6&DZ1%J=_;6FIZ_J$-S.+EM^(WF*QJY.4+
ME1DC!.#SDT >P55MM1M+RZO+6WF#S6<BQ7"X(V,5#@<]?E8'CUKG/"DUQ!XB
M\1:(;VXO;*P>!H)+B0RR1F1"6C+GEL8!&<D;JYFYLEDUKXAZB-=O;":QDCFC
M6WN3&L;"TC(=U'#@D8PV1\IXYH ]3J.>>.UMY;B9MD42%W;&<*!DFO)!JWB+
MQ'J-^9H[^+['86DBI::D+-8&D@$CR,I^_P#,6'S94;",=:[B&[N[_P"&1N[^
M2&2[FTIGED@8,CL8SEE(XP>O'K0!T-I=07UG!=VS^9!/&LL;@$;E89!Y]C5?
M3M)M=+EOI+8.&OKDW4VYL_.553CT&$%>>:!%<: G@.==7U"6/4;4QW<4\Y>+
M:+4R+M3HFTH -H''7-4+35M22\\+ZM!<:R;?4]12(W-]?KLNXI Q^6V5F5!C
M!'0C SUH ]@HKR%O[5?PQ<ZPOB'5EO)]>-A'BX/EPQ?;Q'A4Z$X!&3G@XZ<5
M<N],O(]0\7V*>(=<6VTNPBO+0?;G++*Z2$DO]YES&,*3MY/% '5ZP=#E\8:1
M#?WEV]^@\ZVL8Q(\602!*ZJI (R0&8@?B*Z265((7ED;:B*68^@')KR2Y^T2
MZMJ&N"]O4OSX,6\!CN&51*5D'"@XQGD#H&YZUN:KJ\[R>%(%OG9;W2[J6=!)
MGSL6ZD,P[\G.: .ZL[ZVO].@U"VE#VMQ$LT4F" R,,@\].#GFG6MU!?6D-U:
MS)-;S('CD0Y5U(R"#W!KFO#4(N/A-H\+/(@?1(%+1N58?N%Z$<@UR'A*&2\L
M?!V@/J>H6VGRZ"+XB&[>-YY?W:[ X.X*H8G:I'4=A0!ZU6>^NZ8A@'VV-OM%
MT;.,IE@TP#$ID="-C9SZ8K&\#7MS=Z;J5O<7<EXECJ4]G!=2'+RQH1@LP^\0
M25SWV^M>?VND Z7I5M%?WT9E\97,;2?:&9U"FY'REL[6(ZGKDYZT >TT5Y+J
M^J:OH*:YHUC?WTT*:K8VT<T]SNFACG0%P)7SC)X#-G&ZNB\(/JUKXFU#3;LS
M1V@M8YTMKO4A=SQ.68$[N6",!T)/*G'6@#N**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"J>IZ7I^L6GV34K2&Z@+!@DJA@&'0CT/N*N5QGQ"%X5\,C3_ "?M9UN'RS."
M4!\J7D@8) '. 1G&,B@#</A;03HYT@Z19_V>7\PV_E#:7SG=_O>_6D3PIX?C
ML7LDT:Q%K(R.\/D+M=E^Z2.Y'O7,W/B_6M)EOM-OEL;B^M+RP03Q1,D<L%S*
M(\["Q*N,/_$1T/M5[7O%&K:?JNLV6G6$=X]GI4-Y!&J,SN[RR(V0#\P 0':!
MD\C/(H V;?POH-GIMSI\.DV:6=SS/#Y0*R_[V>OX]*+7PMH5E92V=OI-I';S
M.DDB",?.RD%2WJ00,9Z8KA;KQ?)J'@_Q UQ=Z-K*6L<+",6TMNX+. 5E@=MP
M X(.[GTXYO:IXK\3Q0^*=0LAI2V/A^=E\J6&1I+E5B21AN#@(<,<'!SQP,<@
M'5:AX2\/:K>/>7^C65S<.NQY)80Q88QSZ\<<]*GO/#^CW\=U'=Z;;3+=.LDX
M>,'>R@!6/N   >V*XO6/'UZ-=U&PTZ>UM%T^.(XN+">Y-S(Z"3;F,@1@!E&3
MDY/3 Y9JOC[58TL;D+;Z)9W.GQW2S:E8S31O,V=T+NA41;<#E@<YSCB@#L8?
M"N@6\,L,.CV<<<RJLJK$!Y@5MR[O7#$GGN:T'L+22[-V]M$UP8C 9&4$F,G)
M7Z9[5P.O>-]5T^]0?:=+TZT:SBG@N;FWEGMKN1@2RBX0A8U' !().<XQQ7H4
M$GG6\4N4.] V4;<O(['N/>@#+TWPMH&D32R:?I%E;22H4<QQ $H?X?9?8<4[
M2O#&AZ).\^F:5:VDKKL+Q1@';G.T>@SV'%<OXJ\13:!K>O7EK8VCW-EH,5RD
MLBMN?]](-C$,/EXSZY)YI;[6/$]I=WFD7UQIOFW.D7%[;36T$B^0\9560Y?Y
M^'&&!7D=* .JU3P[H^MRQ2ZGIMM=20@A&E0$@'J,^A].E/M=#TJRDA>UT^V@
M: R&(QQA=AD(+XQTW$#->=6/C'4]-T;PQHS7UI%<S:/%>RWLEA-< (0%1!&C
M9+'G+%@..G.!H0^,_$6JQZ%::?;6-M>W\UW!-+=02^6OD@$2(A*L58<@'U'/
M'(!V=SX?T>\LY[.XTVVEMYYC/)&T8(:0G.__ 'O?K4FF:-INBQ/%IEC;VD<C
M!G6% H8@ 9..IP!S7G5Q\2=45M0NH/LLD=A<O;_8$T^X>6Z\MMKLLH.Q"2&V
MJ0W;)]-#5O&VJ6'B6>TEN-.TVW2:)+6/4;695O(V"EF%R#L0Y+ *5)RO/7@
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MJB@"*WMH+2TBM+>)(K>%!''$@PJJ!@ #T XK(;P=X;;3DT\Z)9?9(Y#*D0B
M".>I7'0GVK<HH @LK*UTZSBM+*WBM[:(;8XHD"JH]@*IQ>'-&AO)+N+3+5+B
M2X%T\BQ@$R@,-_\ O89N?<UIT4 4IM'TVY6]6>PMY5O0HN@\883 # W9ZX%1
MZ3H6E:%')'I=A!:"4AI/*3!<CID]3BM&B@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5YX!CU#56813:6)[IHE.=K1;G( Y[G@5I?V58![UOLL>Z]4+<G'^M 7: ?\
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MNKJGIFDV&C68M-.M8[:#<7*H.K'JQ/4D^IYJY0 4444 %%%% !1110 4444
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MF37EOI$MY'>V#R>6$ (=<'E9!P0<D'(/&*Z_4O!=IJ=SJUQ+=3QRWYMI$>+
M:WD@R4="<\Y.>::_A*[O;#5K?5M?N[Q]0LFLLA%CCA1@066,<%^>6.>@' H
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ME+*OSKM8%3UXZ'((K-M? <<%S]HFU6ZN9FU6/57>5%!:18O+V\  *1VQQC%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5F:YHL&NV<5M<22)''.DWR8^8KV.>U:=%5&3B^
M:.Y,HJ2Y9;!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
=44 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>exhibit101-arrowheadindu008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101-arrowheadindu008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBB@ HH)QUHH **** "BBH(+VTNIIH;>ZAEE@.V5(Y S1GT8#H>#UH GHHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMK@QQ3JJ[5W*/1<#C&0 #F@#G-/37=6\:ZE<:=J<%C))HVGRS.UL)2SGSBH
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M4C3(51G))Y[>M7FUG4K#75&I/HOVZ#0;J>2\ *QADF0#+XW*A&"RC.#ZX%;
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MT6S#2VUQ/9RW-W<66FO=L2DIB 1!G:"5)).<<#O7HJ:/:1ZW_:R*PN?LHM
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M)*@ $9P.2HZ57TOP;KEO-X:COM5LI;+P^VV!8;9E>=?):)2Y+$!@&' XZ^V
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M.0N&'&2.,GKVLZM\.;J_N]<\J;2C'JBE5NKJS,MS:J8PGEQMNP%XR.F,G@T
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M4+6\3 L2S*N >_+?C7)7^F'7?B1HZEV:6QMUDUH10NL#O&5>W4%NOSLS 9/
M.:V_B1#<7'@'4HK4/Y[>5LV+N(/FIR!WQUH AG\=?V.UVOB+2WTYX;)KZ(1S
MK.)HU(5E! &'!9!CI\PP34=MX^_TAK;4=.BMIGM);NW6"]2X#B,;F1BH^1\$
M'N.N#Q4>H>![[Q,;M_$FH6SN]B]E;"R@*+'N96:4AF.6)1..@ QSG-%GX+U#
M?,UV^B6X^QRVR#3M.$1D=UV^8[')&!GY5(ZG)- #[7QU?W5CILJ^')$N=6(;
M3K=KM/WL>S>TCG'[L 8XY/(XJ6[\<36,%K!=:-);ZO<W$D$=K/<+'$1& S2>
M<1@QX(P0,DG&,U+/X4O(].\.-I][ FIZ'"(HWFC+13*8Q&ZL 01G ((/! ZU
M1U#P5J>I_8]1OK^QO=6MKB658[JUWV@CD55,00G( VJ0V2<Y..<4 ._X6(K6
MT"PZ2\VHOJ0TV2UBN48+(8C(K"3HR$ <\$9/&1BJ6O>-=9&A7JVVF?8]6L=3
MM+2YB-PKJ$E>,@J^WD,KA>@(R3VK0L_!5U&=.FGN;%)K;5/M[QVEHL,2KY3Q
MB-0.3C=G<Q)//2G:QX+N=0_M^2WOHHYM1NK.Z@\R,LL;6_ED!@",@F/MCK0!
MU\3.T*-(@20J"R!L[3W&>]/J.#S1;Q_:"AFVCS#&"%W8YQGG&:DH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "LCQ)J[Z+I!G@19+R:6.VM8VZ/-(P5,^P)R?8&M>N4
M\=H8[31=0/\ J-/U>WN+@_W8SNC+'V'F!C["@#,U[QI>:?XI?18=6\/6(@MH
M7DEU1F0RRR%_E0!QP H/?[PK2N]9U^ZUO^Q=(_LP75K8QW5Y<7".\9=RP5$"
ML",[&.XDX&.#4.M'4+?4=8B'A&/4HK^W6.&XMA$IE^4J4N"[ X!Z$ C!]16;
MI&D:SX(N;:9=.N-9671[:RF-JZ!DG@WXSO9?D8/C/;;R.: &WWQ"OI-%LM0L
MDL[0MI=SJ$R7@+[WA95:!"&7G<6&[GM\O-=9IVKW&J:W=10QJEC:1(DK,#N-
MPP#% >F$4KGW?'&TUDZ9HMQH7P^M;>?38-1U6U5IHX2@=1<2.6X)Z ,_+>@)
MK$O/#NM:;?P6UG_:%Q(([9K:[AE*1"X,[/=23*& .]2#R#D9 H [*TU>4^*+
M[1;I4#+"EW:NHQOB)VL#_M*X_)U]Z75_%&DZ'<1VU[/+]HD0RB&"WDG<(#@N
M5C4D+[GBLPH;OXJI+%S'I^D-',P_OS2J57\HF/XCUJ*\CU+0_&M]K,&D7.J6
MNH64,(^RM'YD,D3.<$.R_*P?.0>".10!H7GC?P[8Q64DNHAUOHC-:^1$\IF0
M$ E0BG.-PS^/H:OZQKNFZ!;0W&IW(MXYI1#&2C,7<@D* H)R0IQZ].I%<=X5
M\+:II.LZ%/>6R*L-C?F8HX98))[A)5C'K@;AD<<'UKH/%6F76HW7AQK:#S5M
M-7CN9N0-B".4;N>O++TYYH @'Q%\+[-QU"50LGERA[293;MG \T%/W62>"^,
MU<U3QCH6CWLEI>WCK+"H>?R[>218%/0R,BD1@_[1'K7,ZQX<U2YT7X@00V1:
M;5)@UF-RCS0((E]>/F5ASCI4TMMK.B7OB:"#09]436)?/MIXI(PH8PI&8Y=S
M J 4SD \'UXH Z*Y\7:':ZO!I4E[NO9UC:.**)Y,JY(5LJ" I(^\3@<9QD4S
M3_&6@ZI?QV=I>L\DQ80.T$B1SE?O>7(RA9,8/W2>E<[H/@_4+":^LIVPC>';
M/34O 009$657P.O&Y3S[5E^'_#.II)X=L;W2]95M+DC>:6YU%6M(S&A4-"JD
MLV>@! P"<T >BZOK6GZ':I<:A/Y2.XCC549WD<]%5%!9CP> #TKF/$?Q M+3
MPNVHZ-)YURUW'9A9;28^1(SJI\R, ." V0IP3P!U%7O%-C??VOH.MV5F]\-,
MFE,UK&RB1DDC*;DW$ LO'!(R":YZ[T'6=5.JZK_9DELU_JNFRQ6DCIYBQ6\B
M;I'P2H) )P"3A1WXH Z/7_$TGAGP6FL72_:[C$2GR[>2-79R!G9\S(.2<'Z9
MR:S_ /A8FGVFO:M::D[16MK%;S0M'9S-((WCW,TH )0#CE@N._-:GCK3[S5/
M!M]:6$!GNB8G2(,%+[)%<@$D#.%/6LVTTS4+B^\77SZ?+ -4L[<6Z2E-Y80,
M"AP2 0QQUQZ$T ;.H^+=%TMK=9[IY'GB\^-+:"2X8Q?\]"(U8A/]H\5J6EY;
M7]E#>6DZ36TR"2.5#E64\@@UY?#X8UC2;FPO9;36IDDT6SM)$TJ[2.2&:)2"
MKAF *G=P03@@^N:[/P]H4MEX#BT>2(V<SP2JR><9C$TA8GY^-Q!;_"@":P\9
MZ!J=^EG:WQ:27?Y+M#(D<VW[WER,H5\8).TGI1IWC/0-5OHK.TO6:2;=Y#/!
M(D<^WKY;LH63'^R37-V-GKMWX9T_PK)H'V-K:R:TN+^=HVB3$+1J\&UMQ9B0
M>0,#.>:2VL=;U.W\*Z1/H,VG_P!C7$,UU=221F(^5&5 BVL6;<3W P,YYXH
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M331AK65//11DM%N4>8/]S-9GA_QU'KMII%XS0VD=W%<O+;RPR[SY6TY1B "
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MM?R2Q-9IC@R@[M[#N%VY[&H9+76M$N?$UM%H<^K#6)//M[F)XU3<T*1E)=S
MJ 4SD \'UXH W]3\;>'](N7M[N^;SDA6X9(8))B(FSB0[%/R_*<GH.,]12V?
MC7P_?W9MK:_WOY3S(WDN(Y47[QC<KM?&>=I-<]HGA34=)?4()8Q,!X=L]/BG
M##$LL:RAP,\C[R]?6HI=!U&WT;PAOM"@TS2)XKSYE_=,;95QUY^8$<9H Z;2
M_&N@:S=6]O8WK2-<J6MV>WDC2< 9.QV4*Y Z@$D<^AI(/&WA^YU"*RBO)"\T
MI@AE-M*(99!G*+*5V,>#P&[5Q_AR+5=?\/\ @>W719;&#3$@O)+N5X_+=5@*
MH(PK%CNW@G(&!GO5*'1/%%Y_8)O;#5VO+/5()[W?<0QV<:J_)AC0C<,'(R,X
M![\4 =T?'GAL7WV3^T&\P7)M'<6\OEQS!MFQI-NU6W# !(SQC@BKS>)-(33+
MO46O +6TF:WG?8V4D5MI7;C).X@<#G(QUKD)_#>JMX#UK3ULC]KN=;DNHX]R
MY>,W@D#9SC[@SZTR]TB>7XI#2XBITJZ:+6[M ?NRP@Q@$>C,(6]S&U '3MX@
M.D0SR:\1'YEZ\-C';022231@97"+N9FX;) Z#/ K3TK5K'6K$7FGS^;"69"2
MI5E93@JRL 5(/4$ UA>-]-DOX-/D33;R[%O.7,NGW/DW5OE" \9)4-UP03T/
M0U/X*@UFWT:9=9,Y<W4C6WVKR_/\CC;YIC^4OG/3MC/- '/M\3HFLX[Q8?(@
M773ILQG@E'[K]YAER!ESL'R@$C.",UTUOXPT*XTR]U 7WE6]DP2Y^T1/"\3'
M& R. V3D8XYSQFN2AT+6#<I:R:5,J6_BMM2\\O&4D@<RL&7YLY&Y<@@')&,\
MX7Q-X3U?4]0\07-K!)A[K3KJW5)A&UQY.=ZJV?E;T)XR!0!U4?C70'L;R\>]
M>"*R"M<K<V\D+Q*QPK%'4-M/8XQU]*GTCQ3I&N7<MI8W,C7$2"4QRP21,4)P
M'4.HW+GN,BO/[_POJ6K6&MSP:5JXEFLXK6$ZK>I)++^^5V4*&*A0!U)R23Q7
M;/IMV?B-;ZH(3]C729;=I<CB0S(P7'7H": +FK^)=+T.:&"]FE^T3*72"""2
M>0J.K;(U)VC/7&*?:^(M)OGT];6]CF.H1/+:E 2)%3&\YQ@8W#@X/Y&L34X=
M1TCQPVO0:5<:G:7.G)9LMJR>;"Z2.X.'905;?V/!45@6&AZYH-SH>L2:1+=,
MD^HRW5E9R1L]N+F170+N958+MP<'J<C(H Z+6?'>GZ;<:=' )+D7.IOI\S1P
M2MY3(K%_NJ<D$ 8[Y)&0IJ[#XRT*?5%T^.\<RO,UNDAMY!"\JYRBRE=C,,'@
M'/!KCXM'U^"PM+^719FGB\3RZG)9Q2QM((721002P4D;QD9[&BTT;7;/Q#;C
M3-.U/3A_:1ENXVNHYM->$N2[HK$NKL#D!0N&)[4 ;^D?$'2[[2[V_N_-M([?
M4)+*-6MY=TI#LJ!5VY9V"DE0"1T/2KP\<>'?[.FOI+\P0P3K;S">"2)XI&QM
M5D90PSD=1BN1?3_$MI:75I!IM]'"NOW%W-/:F!II+>5I&5H"Y(!!*AL@'!..
M]5K;POKDE[?3/IM\(I]9TR[C-[=)+*8HF'F,Y#$ C&=H[$ 4 =W:^,M!NK*_
MNUOC#%IX!NA<PO"\0(RI*NH;![<<]JPY?B!%<:KJ-O82Q0V]IHTM^TM]:31M
M%(K8!=" Q3!SP,GL:K>)O#&K:EK.OW-I;*ZR6^FR6X=PJW#V\[R-&?3(VC)X
MY'O5;6K'7/$EYKMW'X>NK-)_#=Q80"YDB$DLS'(7"N0!SP2?7IQD Z:[\=^'
M]-=X+V_8W$$:27 @M99!$K*&#MM4[5P<Y/%6M1\7:'I<L,=S>,SS0_:%$$+S
M8B_YZ-L4[4_VC@5A6.@ZC$_BUI+3'VZRMXK<[E_>,MN4(Z\88XYK,T6/4O"^
MHG;IO]HSS:)8Q7$$5U"LEF\2.O[P.P_=MD_,,\JW!H ] T[5++5M,AU*QN%F
MLYEWQR@$!E]>?I6;IOC'0M6O$M;2[<R2HTD)DMY(TG5>K1NRA7 SU4GCFLWX
M<([?"_15,4>Y[3(1ON'))'X<_E7,:9X<UYFATRRM=6TJQ>TGM[R"]N8[BV@W
M1%4^S-N,@PQ![#:.1GB@#N=.\9:%JU]'9V=ZSR3;O(9H)$CGV_>\MV4+)C_9
M)XYI(/&>@7.I+817Q:5Y6ACD\B00R2+G<BRE=C,,'@$G@UQ?A_PWJ7VCP]:7
MFF:U&VELKS2W6HJUM$R1E0854DMG. "!@$YK3\-6^N:7H^C^&)/#^382!)M0
MF:-H#$N?WD>&W^8W& 5&"3GW .KB\1:3-8:;?1W8:VU-UCLWV-^]9E+ 8QD9
M"GKCI6/<>.](N%DBTO4H3-%<1Q2O/:S&(9F6)DW  ;\M@#/!()XKFM*TSQ"-
M*\'Z'-H%Q#_8E]&]W=/+$8F5$D0-'ABS [@>0,=*NIX;U5?A[#IHLB+P:V+I
MH]RY\O[?YN[.<?<Y]>W7B@#0M_'27TNI11&.T:RU>&P#W5O,5D5C&.#M&')9
M@!T'RD\')UI?&>@PZFVGO>L)4F%N\@@D,*2GI&TH78&Y P6SGBN4N]#UE[K5
M[--+F9)O$=GJ<5P'3RWA#0;L?-D%?+8D$?3-93>#]5CM;[0IM/UJ[%Q?22)+
M'J*QV3Q22F3>XSN5@#R IR1QUH ] N/&6A6NIM837CK*DRP/(+>0PI*V,(TH
M78K'(X)[BM/4M2L](L);[4+A(+:(#<[>YP  .222  .237GFKZ-KL>NW\NB:
M=J=G>SWB2I+#=1OI]PN5S)-&YRK8!!VKG(!!-=+X^T2]UO0K9;!9'GM+Z&[\
MJ*41/*$;E58\*V#D$\9 H MQ^,]!DT^]O6O6@AL=INEN()(9(0WW2R.H8 ]C
MC'7TJK+X]T1M.U.XM)9IIK&U-T8'MI8VD3LRADRRD\;@"!UKD+[POJ6JZ7X@
MF@TK5A-<6<-K!_:MZDDTV)=[#:&*JHYP2<G)XKIO$&AW^H>)[BXMX,P2^'[J
MR$A8 >:[H57KGH#STH B/CU%T8:M^[*#16U$V?V>99BX('!*\)DXSC_:^[S4
MVD^-EO\ 46-QY5MIJZ+%J3RRH\;(S/(KYW8^4;...>N2"*PX-!UK4+1=^ES6
MCGPI+I92=X\B?( 'RL1@XR#Z=<'BJE[X5USQ!IEXG]GS6,DWAZULU2XD0$S0
MSNQ0E6. P Y]&'N* .\TWQ;HNJR2QV]VZ/%%Y[+<P20$Q?\ /0"15RG^T,BL
MF+Q[9:CXGT33-*D\V&^\YI'FMI8RR+&65XRP 921C(R*YY_"NH>(3>(UEK5F
MYTNYM4N=7OUD*R2J%VHJ%LKQDL<=!@5JVJ:UJ?B7PM+/X;N+"'2TF6YEEDB*
MJS0[ (]K$LN1UP.W'7 !N:SXIBT?Q-HFCO!*YU)I 9%BD8)M7C[JD<G&>>!R
M>.:=%XU\/S:DMA'?$R/,;=)#!((7E'!C67;L+9!& V<\56\26E\?$_AK4K6R
MFNH+6::.X\EE#1B2/:'PQ&0#UQS[&N8@T776\(:=X*?19HWM;J'S-3,D?D>5
M%,)/,7YMY=@N-NT<DY..: /1+O4K2QN+."YF$<EY+Y, *G#OM+;<XP#A3UZX
MJE>^*=%T_P"V?:;X(;.6.&91&S'S' 9$4 $LQ!!VKD\U%XOTJXU;PY.ED!_:
M%LR7=D2<?OXV#H,]LD;3[,:Y=/#NL6FE:)K+6)N=4AU235=0LDD7<QE1T*J2
M0I:-64#D [.M &MK'Q!TRQ\-7&K67FW+P7,5M);O;RI)&[LH^="NY?E)(R!G
M@#DBM"^\:Z#ITHBN;N57$2SR!;65_(C;D-+A3Y0_W\5R.KZ)K>M6WB75X](F
MMY+S[ MM8R21B:5;>;S&9L,5!() !;^'G&:AU#0M636=<O1IFO3QZPL<\$5E
M>QPA&\E4,4X+\8*_>&X8/MR >FR75O%9M>23QK;+&96F+#8$ SNSTQCG-8NF
M^-= U6^ALK6\D^TSHTD,<UM+$9$ R77>HRN.XXJCK>A ?"FYT-IX;(1Z6(#)
M+*3'%M0#YG./EXP2>U<[J=QJ/B7Q9H5C<:1)I+OIM^@>2:.0Y>-%+)Y;'Y 2
M,$XSZ<4 =EIWC+0=5OH[.SO6>2;=Y#-!(D<^W[WENRA9,<_=)J*T\>>&[Z\M
M[6WU!G:XE\F*3[/*(FDY^3S"NW=P?ESFN/\ #_AK4UG\.V=YI>LJVENCS2W6
MHJUK&8T*@PJI);.< $# )S5^T\-ZK%X%\.Z>;(K=6FLQ7,T>Y?DC%TSLV<X/
MRG/'- '3-XST%-4.GF];S1.+9I/(D,*S'CRS+MV!\\;=V<\=:1_&OAZ/4KJP
M?4 L]F'-SF)]D.U=QWOMVKQSR>>U<!'X/U6&RFT"?3]:N@]\[B9-16.R>)IC
M)YC#.X, >5VDEAUP<UTATC7;30?&GV"TB_M"^U"6>S678PE0QQ*#@\9^5L!N
M,@9XH TSXWTNZL]0&GRR_;;>RDNXX;JUEA\Q%'W@'5=RYQR/6J.D>./-N9/[
M7-O;6PL-.G$B(_\ K;DN,'DX7<% )Z9Y-<^-!UN\UPWBV.MO ='O+7S=5NHF
MD,KA-H"(VU0=N,C&3UX -:&E^#[JYMM5L=4MS!;7F@6%EYA93MEC24-C!ZJ6
M4Y_*@#NQJ-HVJMI@F!O$A%PT04_+&6*@DXQR0>,YX-6JXGX:K>W^BS>(]5"_
MVAJI3)4Y'E1+Y:8]B0[C_KI7;4 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4M2>/R([:>QE
MO(;M_L\B(@955@<EP3]SC!Z]1Q5VN4\:DBX\+8)&==A_]%RT =2BI$B1)PJK
MA1GL*JZIJEKH]B;R\<I#YD<654D[G<(HX]68"O)K?1[&#P9:>(4@ U=?$>%N
M\GS%4Z@8R@/92I(*]#D\5V/Q3MK.?P2TE]#%)#!>VDC-*H*HOGH&;GH-I8'V
M)H Z.RUFVOM4U/3XED673I4BE+@!6+QJXV\\\,.N.:T20.IZUY'=Z!H>J2?$
M&^-K!<"VMXFL9%.5A LD96BQPIZ?,.P%9E](M[K-S)XCN=$$7]E6DEFVM%_N
M&(&1X2"/GW[LD?-]WVH ]I@M+>VDGDAB5'G?S)6 Y=L!<G\ !]!4V021GD5R
M^FG5E^&,317$MUJPTLF&:2,H\DGEG82K<@DXSGG->>^#TM_[6\+RV&H:,FH.
M2;M;))6NYU\L^8+K).#NP<OT8#% 'K.B:S;:]HMMJMJLB6]P"R"4 ,,$CG!(
M[>M:)( R3@5X-8@RV?A:'4WTA=(.ERM"-9#?96N/.;=W"[PFW&[L6Q6M8"T:
MV\+Q>(+V"Z\,-+?>6\X9+4ON'D(WF?>0+Y@0MP<#VH ]7N=4M;34;&PE<BXO
MBX@4*3G8NYLGMQ_.GV-X;VQCNGMI[7>#F*X4*Z\XY )'ZUY:(/"G_"1>$+JT
MB3^RUO[R&VGN\&,MC*+$Q_@WYV>_2J6@?V7+;^%X_%36_P#89TVX, O6 MVN
MO/.=V[Y2P3[N[_:Q0![10#D9'2O'-,L;?5[[PW8SJ]QH3ZMJ(L8Y68K+:K$2
M@YY:/<#@'@@#M79^ ;>*Q/B73[9/+L[369([>%?NQ(8HGVJ.PW,QQ[T =AD9
MQGGTK&B\0QW'BBXT."QNY6M41[FZ 011%@653EMQ) [ CD5YAJAT<Z-XFFU"
M1!XW2_G%EEO]+5]Y^S"$?>V%=GW>",Y[UUWA32K.#XA>*[K[%;QW@%KND1 "
M"\6Y\'W;D^M ';RRK#$\C=%!.!U.!FLS1M?AURWL[FVL[M+:[LX[R.:5 %P_
M1"03\X')'3GK7$:^N@2>,/$ \7/"H2SA.E?:&P0FUMY@_P"FGF?W?F^[7)NS
M+X*EVLRX\"6I!!Z'>W- 'O&0!G(QZTI.!D]*\D\3Z)8:+X@T;3EATBUT%[::
M7;JNXVLMWE 6D.<&38,C=_M=ZK60M38>'HM:O8+GPJVHW@+,'6TX'[A"7/S1
M!O,VDG:<+[4 >KW.J6EIJ%A8RN1<7S.L"A20=BEFR>W J[D9QGGTKR+R/"0\
M2^%KFRBB_LM-3NX8)[G'D[_+RBPL>-GF?= XW XJC:G2_P#A&].GADC_ .%@
M'4HUEPW^F&;SQYJN/O>5Y>[@_+MQ[4 >UYYQWI 01D'(]J\B;0]*F\.^,M5N
MI&MKLZM=0&_$;2F&+SERNT'_ %9YW 8X+&K/A>;0D3Q'I^H6VB+I8M8I;NZT
M>X;["RDL,%.D<F!DX)R",F@#U1F5%+,P55&22< "L>S\1)?6EM=V^G7\EO<P
M2W$4BQK@HI&WOP7!!4=QUQ5/QX9E^'.OFRSY@TZ;9MZXV'./PS7/>)C$NL:4
M+4XM_P#A&]1\K;TV[8-OZ4 =G#K<,FHVMC+!/;3W5K]IB690,XQO3@G#KN7(
M]^,X.-,D 9)P*\[8M_9/PS:$G[49H ,=?+^QR>9^&,?I4GQ!N;%]<T;3[ZWT
MUT>*>97UBX,=F"NP8*XQ))SD XP-QH ] HR,XSSZ5POPIE#^%[R-)(WA@U.Y
MCA$2LL:INRH16)(3!R!Z$5@6!\->9<SZ\Q/BU=:=0(F_TT'S_P!RL8SN\KR]
MO ^7;NH ]8R,XSSZ4N0"!GK7BER=+_X1J^GDDC_X6"-2D6++?Z8)O//EJH^]
MY7E[>!\NW-3:QH]C)X7\>:X\ ;5++5)VM+HD[[<IY;#RS_#R23CKGF@#V3(S
MC/)K)M?"N@6.IG4K71[*&])9O.2$!@6^\1Z$]R.M>8>,6T^S\3:WJ$KZ7J%Q
M%+"_V*\9[?4(R$3:+209)5CR  ,L6&:OZUK=AIL/Q)L[Z[2VO+N+?:V\C8DE
M#V:(-B]6^8$''3!S0!ZA<VEK=- US#'*8)1+$7&=C@$!AZ'!/YU/D9QGI7CM
MQHNGZJGB^YO[=;B2ST*TDMC(2?)?[.YWKZ-E5^;KQ5AM-M=*NM&GLHO*GU'P
MW>O>RAB6N7"0L&D)Y9LLQR>>: /6<CGD<=:,@#.1CUKR'3/"VC&Y\ *UDC#4
M=,D:_P!Q)^V$0QN/-_O@,<@'('%5/.L(+.QT2YM[%K2/6-4CMAJMR8[*)(I2
M%1EP0Y ;Y5.,8)[4 >NZAJMIIGV3[2Y4W=PEM#A2=TC9P/;@'GVJ2TNS=>?N
MMIX/)F:+]\H'F ?QK@G*GL:\1M(])F\-6KZD-/DTVR\7&,/LVV\,#("0N\G;
M&201S@Y!K7E:V:]9-8<#P\WBB\%\9&Q"3Y0\H2'ILW^O&=N: /8 <C(H!!&0
M<BO%[BVL+N\EL=*8-X8?Q#81VZV[D0EBC>>D9'&S[H(7C):NT\)V%KI'C3Q3
MING0);6*)9S);1#;&CNKABJ]!G:N<>E '9D@8R>M8][XACM/$5GHD5C=W5U<
M1&=VA"!((@P7>Y9AQD]%R>#Q7$:L/#4GBOQ/_P )I);J\:1'3OM3X*P>4,FW
MS_'YF_)7YLX]J;X1TPS>,="O=9LD;6/^$:CFFEEC'F^:'5=S$\[]O![]: /1
M-1U6#37LXI%>2:\G6"&*/&YB023SV50S$^@]<"KU<IJ9/_"T/#XF_P!3_9UZ
M8?3S=T.?QV9_6N,T9K4>.+>1C/\ \(@VH3#2"Q'D_;L#<1_L%O-\OMNW8_AH
M ]0TS58-46Z$:O'+:W#V\T4F-R,O/;L5*L/9A5TD#&2.>E<KHN?^%D>*1'_J
M?L]B7]/-VR9_'9Y?Z5P/CJXTV^U'Q7YL&D)>6D0BC?4I6DNBWDAE-K$,;!D\
M$'ELD]* /::9(L<D;QR!61@5=3T(/8UQ_B"=[CX+ZA<-(7DDT%W+DY+$P9SF
ML*'PAH7_  G&D6+:?&]K<Z++/=1/DK<RI)$%>4'[[#S&Y;)R: /2[>W@LK2*
MVMXTAMX4$<<:C"HH&  .P J4G R>E>%Q&273?"5OJ,NG?V,L-[&G]L%FM3,D
MY5%?D L(P=N[C@XYJ_I^FV^K)X6TZ[N(K_2I=9O1$D(D6$PB!R(U+'+1A@<<
MD$<=* /9<C.,\U2L])TW3KN[NK2S@@N+U]]Q(B -*WJQ[]3^9KQGQ+#X;L_#
M?C*#5Q##X@@DFCT]&)$Z6X0" 0]_+V==O'WMW>I->$<VN^(SKEUHL$L:1_86
MU+S/.CA\I=K6V".=^[[OS;NO:@#V_.*"0!DG KS;0-&@U7QV\^M(;V\L='TV
M5'E5EQ-F4F38>C97OR,D>M:'C7[ _BCP_%XA,0\/,EQY@N3BW:Y^3RQ+GY?N
M^9@-QGWQ0!W.>,T5XP+*SU1K#3X=TOAJ3Q48[%0Y\MX?LCEU0]XO,W@ <8R.
ME=YXUMY--^'-];:1')!'!#'&$MLAHX RB3;CG(CW=.: .K!!Z'-("#T.:\CU
ML^%;>QNT\(L1;M%;'5&TE\P+:^>H<ML/^L*%^?O;=V:JZ_\ V-##XE3P@UM_
M97_"-W#7HL&!MQ-D>4?E^42%?,SWQC/:@#V?(.>>E("#T.:\NU31=.T'6K%-
M-6:P%_H-^+R:T!::0JL160CJ\@+,0>I)K!TV9K&UU.U\.1Z1=:A+H4[PWV@2
M,I)7;M,\/($IS\K9+9!% 'MKR+'&[GD("3CVK+T;7X=<MK&YM;.[6VO+-;R.
M:1%"@-C"$@GY\'..F.]>?V8\-1ZYX=_X0R2W:62&8ZC]E?):W\EN;C'\?F;,
M%OFSGWK"B>^7POI_V!IA-_PA<1/D9WA/.3>5QSG9NQCF@#V276;:+7[71BLA
MN+FWEN$8 ; L;(K G.<Y<=O6KX()(!&1UKR+S_"6G>+UNO"PBEAA\.WLLT>E
MOUP8BN".!*1G)^]]W/:J'AX::?&/A1+1-!2.]AN([F+39&F>1# S!;B0X#L2
M,X89)!/K0!ZQI^OVVJQV,]C#<SVMX)2MPL>$38<?-DY&3G'';M6KD$D9Y%>(
M>&A%!IOAJ+01 NHQP:NKQPXR+D*NT./[V-G7MBM#1_[ 4^#9/#DD3>(9+B/^
MT3$^;AX_+;[1]I'7AO[_ $;&* /7\C.,\^E96J^&=#UR:.;5-*M+N6-=JO-&
M&.WKMSW'MTKR_2M'L;7PEX7UV& +JKZ]%&UYD^84:Z9"F[^YM.-O2NS^(1B%
MOHJZ@Q70VU%1J9)(3R]C[!(?^>?F;,YXZ9XH W]8U6S\-Z!-J,L3?9;5% BM
MT!)Y"JJC@<D@#H*6368[/P]+K.I6\]A%! T\\4H5GC502<["P)P.Q->3:[9Z
M/<Z7XLAT>&VF\/0M8/"(@&MX[HR[9?*Q\H^0H&V\9/N:[[Q]IEH/A=KME%:1
M>1!ILODPJ@VIL0E<#M@@$>F* -J#7+6XUR724643QVD5V68 (4D9E4 YSG*'
MMZ5ID@#).*\NTO0/#/B'QHR?8[*]TN/P_:^1&F&AYEF!( XR,'!ZC)KF+.66
M]M_"ZZW<:4VF_P!B?Z.==+&W>82,'YR 9 @3&><9QWH ]XKEKCQO"+F[33M%
MU;58+.1HKFYLHD,:.OWE&YU+D=PH/IUH^'GF?\(9:;[O[7%OE\B78ZCRM[;
M-_S%0. 3U %87@_Q+HOA/PW)HFO:E;Z?J.FSSB:*X?8\H,K.LB \N&# C&>3
MB@#N],U.SU?2[?4K&=9;2X021R#C(/UZ'MBK?2O+[N]TO5_$.CW'BVQBT_19
M]+>2TM-2*K"L_F<[P<+O\O:0#R,MWS69I5A;ZQ?^&+*[22YT5K_4_L4<Y8K+
M:J 8@<\LGH#V"]J /8LCCD<]*7(SC/->,1Z)IUCX?N-1M[<)>6'BH6UI-N):
MWA%ZJ>4A_A3:S#:..35>Z.@'2_%;Q2Q'Q<FM7(T\;_\ 2EE\[]V(A][83UQQ
M][/>@#VXD @$C)Z4I('4XKP[QQ<V%XWBV9X=(BU"TS%&]_*TE[O6)2IMHQ@Q
MIGD$$\[F-=!'HNF^)/$'B6;5K9+WR])LGB\T[@C-%(2ZCLW ^;J.U 'J-%>0
M'5-1\/Z!X;\1VXDN+G6=#ATY\Y.^\\L-;NWKDF12?<5W<WA2(_#U_"\<A_X\
M3;K,3SYFWB3/KN^;ZT =)65?Z_;:7'>S7T-S#;VIB7SVCRDID(4!,')P2 <@
M8S7C[^(=6NF7Q;"LRS:O$?#T,1!Q'.8D*MCMB<3#-7?$FD6%GIWBZPDB22TT
MY='">:,A%3"EO;Y=V3Z$T >KV>LVU[J^I:;&LBS:>T:RLP 5BZ[AMYYX^E:-
M>3R^'] UC4?&]T;2VNH(+&V-BRG*1+]ERK1XX!X7##L!76-J;P?"9-3N1=7#
MC1EED\ARLKDP@DANH/?/;K0!U8(.<$''6ER,XSS7BFBM96WC+2%TTZ#$MQIU
MVLR:,[2;@(U9?.DX#MP2,C/!-7= T:PTW1_AMJEI;K'?WKQ175QDEYT>TD8J
MY_B7*K@'I@8Q0!Z]02 ,G@5Y=H4%Q)XDM/!DBR?9?#MW+>L[9P\/!M%SWQYC
M?C#6SXX^Q-XA\.1Z\T8\/.UQ]H%P<0-/M7R1+GC'^LP#QG'M0!U.JZA8V,$,
M=_AHKV=+1$*;@[2<!2.F#SG/%9/A:S\-PW&IMHFDPV,MM<M8S.L2J6*A6PI!
M/R_,,#CZ5YO?6^BRV+RE+:3PK;>)K86<LV#!'$443!&/ B\S(X^7KBI]5T73
M9?#'Q UPVZ-J-IJ4\EI=9^> HD3*8S_#SZ=>] 'LV0"!GK1FO$O$82;7_%+:
MY=Z-;W,;K]B?4!)]HCA\M=C6NTCG=N^YSNSGM73:!HT&I^/KNZUB/[7>V.FZ
M;)&\JE=LQ$FYPAZ-E>_(Y% 'H]%%% !574=.L]7L);'4+:.YM9<"2*095L$$
M9'U JU10 R&&*WACAAC2.*-0B(@PJJ.  .PI]%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!2%0<9 .#D9I:YKQ?J%];MHVG6%T;.35+\6SW2HK-$@C=SM# C<=FT9!Z]*
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MXX+<Y H [73=,M]'CO9C*7DNIWNKB>3 R3P/H%4*H]E%71'!*RSA(W8K\LF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M"Y7&1M&2V.6''>IWUK7HO'VHJMO'-90Z)%=)9"YPV\M)W/R!BR[2<XP <]J
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M[8UDE:0@9SC<Q)/7N:X+4/B3<Z??7EA,WA^"[TV-/M<=UJ7E&>4J'*0 KD@
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MYBJQ2,&=,$X()4=?2N<M/'5W>>*9M+CM]-3RKTVKVDUYY=YL!QYP1@ RG[P
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MTKMQC=GC.<8/M0!WU%9'B76SH&DBZCM_M-S+-%;6\&_8))9'"*"V#@9.2<=
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MBW5Q;VYDBMRX! 8CGHRDX!P#S6OJNJV>BZ9/J-_+Y5M" 68*6)R0  !R220
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MN(M1NX-,&H6=RMML(&XHX= <':0&&,9!Q[T =PMK%'9"TA41Q+'Y:*HX50,
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M^EW>F^8T8RPN"I+GGJ-O3OGM6I<>-=+1;'[)'>:B][;"\BCLK<R,(#C$C#C
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MV+6?D[>""X?=G_@.,5GQ>.=)FNXXU2\^R27'V6._-N1;/+NV[0_^\-H.,$\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-N"XEF53D]!R>IJW0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M3D=<5F>$O#SS:WX=CUW33*;;092D=W'O\DFX7RU.<X<1D#U'->K4$@ DG %
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M&..XT.U,D-I'L$^VX?>H P"QBRN.O(%>E6%]!J=C%>6WF>3*,KYD31MUQRK
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MGD2XNHT>.![ET)RPB7[SX'.!F@#RWQ3;PI?>/(([0B[N[>TFMRD!S*@VARK
M8/S8R,U/J:Z5;2^,[7Q!ISW.J7\S&QS:M*]Q$8E$2Q, >58$8!&#S[UZC;7$
M5Y:PW-NX>&9%DC8#&Y2,@_D:EH \MTKPZ;F?Q*==T]+J_71K*%I)XP^9/L[>
M9M)[E@,X]!76^$=2B30/#NE7#R#4GT:&X,;QMDJJ(K$MC&0S#C.>:Z6HC:PF
M[6[,8,ZQF-7/4*2"0/3) SZX'I0!+1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7*^,[NY2;0=
M-AO);*WU+4!;W%S"VUU41NX16_A+,H7(YYXKJJJZAIUEJUD]GJ%K%=6SXW12
MJ&4XY!Y[CUH \RUN]U32Y-<T.PUJ^,,%SI9AN9)C)-;F>?:\9=LEAM .&SPV
M.E=]-!)X?\)7:VUQ=74MK;2R1R74IED9@&898]>>/I4EMX:T6SL/L-OIEM';
M&59S&(QAI%(8.?5@0#D^@K490RE6 ((P0>] 'G<%P_ASPCX)U>*Z==-BCABU
M %OD=)T \UO<2E3GT9J@U2YOKCX27_B"ZEE^U33C5+-'/,"B56@1?3Y0F1ZL
MWK6S=>#K^7PDGA6*\M1I1D:&1I(V:06F[*QKS@,!\F3G@ ]:V]9T0:M;V%CN
M2/3X;B.:>(#_ %BQ_,B#L!O"$^RX[T 8OQ1MUN? 5T&DECVSVS9CD*9_?(.<
M=1SGZ@'M7-W.D2C4O']W!K&J6TFGQPO;^1<E<NEFA#N>LAX&0V1UXYKTZ^L;
M34[*6ROK>.XMIEVR12KN5A[BJ]OH>EVEK/;06$$<%Q&L4R*O$B*@0 ^H"@+]
M!0!YQ)JNN^(==DM]NH-%;Z7:7")8Z@MG\\J%FE;/+C(P!RHP<CFNRT/4;^Z^
M'D%_>WUHE\;)F>\5U>$, <2$CY2. QQQUJ[J'A70-56W2^TFTG%O'Y46^,95
M/[O^[[=*U(X(8K=;:.*-(538L2J H4#& .F,=J /+M%U>\T&9#KEUJUL\VF3
MSBX>\6_M;GRT#M-'SN0@9(7 !!QZ4FBW^JVGBSPLK2:S';ZJDPE_M*_24W($
M)<.(59A%R >",9QBN]T_PEX?TN262QT>S@:5#$Y6(?</51Z*?0<4ECX0\/:9
M/%/9:/:030MNBD6,;DX*\'J!AB,#CDT >7:#>ZM=:;X4T.UCO7M#H[79CL[T
M6CROYNWF3()"CG:#_$,\"O1O UWJ%UX</]I3I//#<S0K()TE8HKD*'9."X'R
MGW%7;GPKH-YI]M87&E6KVMK_ ,>\93'E>NTCD?A6A:6=II=C':VD$-K:PKA(
MXU"(@]@.E 'F%M?ZBO@O2_&/]M7SZM=7L*R69G)@??.(VMQ%T!521D#=E<YK
MH_!D%W>ZGK>J7FJZA.8=4N[2&V:8^3'&LG'R=R.<$]!Q6Y%X6T"/5O[6BTFS
M%Z6,GGK&,[CU<=MQ]>M:-K9VMD)5M88XA+*TT@08W.QRS'W)H XG4%GUOQ3X
MCM;K6;W3H-+M(6MDMY_*7YT9FF<?QC(VX;*_*>.:YG1M1U*+PS9VEGJZ6 '@
M^TDADGDVQ1RM(5W$\@$C"YQQQ7I^I^&]%UFXBN-2TRUNIHAM1Y8P2!G./<9Y
MP>*<GA_1TA\E=-M?*^RBSV&,%?(&<1X_N\GB@#S'4-8U+1]$U^SEN-:TG4DL
MX;B-+R]6[2-?."-+'-DM@YP5;'3@=:T/$>HZEX,N;V/2=2O;\/H=Q>LMW,9S
M#)&R!91GH#O;Y1\OR\ 5T>I^!-(G\-:CI.D6MI8O>B,/(L>[(5PP![D<$ =!
MFMG3?#FBZ.LXT[3+6V$XQ+Y<8&\=@?89.!T% ''W/VCPWK.B1V7B*[N8]3M[
MG[0]_<><@"0F1;@9^X P (7"X;I6/I^I:KI,/EZE<:M'>7>E7+PW']H+=VEX
MZ1;_ #8SG=$0.0 H&#["O1=,\+Z%HTTDVFZ3:6TDB[&:., [>NT>B^PXIEEX
M0\.Z=),]GHUG"TT;1.4B ^1OO*/13W P* /.U\_^TKK6/M]Z+T>"HKD/]H;'
MF;9!G&?4;O\ >YZUKZ2;KQ/J=S:ZAK6HV<=CIEG)"MK<F$NTD99YG(Y?D8P<
MKP<CFNRG\-:)<2V\LVF6KR6\#6L+&,92)E*E!_LX)&/>F:AX4T#51;B^TBTN
M/L\?E1;XP=J?W/\ =]NE ' ^&[O5/&.HZ9%J.L:A!"^AK<2"RF,'G2"=T67*
M\C*@' P#D=ABNR\!7UWJ7@G3KF^G:XN<21O*_P!Y]DC("??"C-;<6G64-TMS
M%:Q1SK"+=75 "(P<A![ ]J=9V5MI]JEK9P)! F2L<8P!DDGCZDF@#R3PXL^C
M^!_#6LV6LWLMQ/J,5JUH9\P2(\Y1HQ'T!526W=<J23BMFPU;5)=7M?!KWMP;
M^SU226YN"Y\Q[%,2QDG_ &O,BC/KAJZ^R\(^'M.OTOK/1K*"YC!V2)$ 5R,$
MCT..,]<5#HV@W-MX@U+7=3EM9;ZZ1+>+[/$46.!"Q4'))+$L23[ =J ,KQ[8
MI>:KX0W3W,7_ !. G[F9DZP2G/'?Y<9]"1W-<H+>[T[P]XC\0VNK:A#<VOB*
MX,4,<Q6#;]J"LK1]&R">3D],8Q7J>J:1IVM6JVVIV<-U"KB14E7(5AT8>AY/
M/O2-HVFO9SV;6,!MKB4S2Q%!M=RVXL1W);GZT >9:IJ7B'4+[Q5=PR7L)TJY
M>&VDCU)+>"U5(U96DC;[X8G<2V00<#&*[#Q:VHWWPMU5[<#[?-I;,5@.?F*9
M8*1U[XK3U#PKH&JWXOK_ $BTN+D;09)(@2V.F[^]CMG.*V* .5N[_P +1_#R
M*YNQ;S>'S;1!(U7>'7C8JJ.K9P !SFL&X>ZU@^+M0N-=U#3I='E:.TB@G,20
M(L*R*[IT?<6)^;(P,"NJ@\%^&+?4QJ4&AV"7:OY@D6$?*_\ > Z!O<<U/J'A
M;0=6OEO=0TFTN;E0!YDL0)8 Y /]X#MG- 'G?VS5]?L_$&HW.K:E8R6>AVE]
M#;VLYB6.=[=G8D#J,J/E/'7(JZ)]2TRZTR8:QJ%P^JZ#=W5R)YMR"9$B97C7
MI'R[#"X&,5Z&^EV#M>.]I"3>1B.Y)7_6H 0 WJ,$C\:K7NBV-]8;(88%D2TD
MM;:4+GRD=0I ]OE7\A0!PNEW-UI=IX*U1=>OK^;5]J7L<]P9(Y$-NTC.J=$V
M%1RN.#SDFLVUUC4EN_#.K07.LM;ZGJ4<1NKZ]01W<<F[[MLK,$&,$?=(P,]:
M[[PSX-TCPW9V9@L+07\5JD$MU'$ 7(4!B/3<1D^O>I;;P;X:M+A9[?1+*.5)
M!*C+$,QL#N!7^[SSQB@#@[:75(_#-GXE;7=3>[_MW[-Y37!,)A-Z82A3H?E[
MGD<8. *T+G5M4BUFZ\&B]N/MUSJD<MO<;SO2P?,KD'K\OER1 ]LK7=C1M,%D
MMB+*#[,DWGB':-HDW^9NQZ[_ )OK6;9Z#<_\)?=>(-2EM9)%@^QV20QE3'"7
MW$N23EB=HXP!CW- %?QQ>W5M9:5:VUW)9IJ&IPVD]S$0'CC;<3M)^Z25"@]M
MWK7#>-89K:U\1^'UU34+JP@LK2]7SKIGD@D:8H4+D[BK !MK$X(R*]9OK"TU
M.REL[ZVBN;:48>*5 RL/<&L^W\-:#9:?+IT.F6D=M<L&EBV#]ZPP06SRQ&!U
M]* (?$5U'X?\%WTQOKJ!;>V*K=8\^92?E!&X_,V2.IZ]:X![G5+'6+W3)QJE
MO;76@7DSVVI:BMTY9-H5\ L(_O,, X/H,5ZO=VEO?6DMI=P1SV\RE)(I%#*Z
MGJ"#UK+M/"/AZQ.;;1[2-BCQEQ'\Q1@ RD]2" !CVH Y;X??\AZ[_P"P!I'_
M *#-5F:.;Q!XO\0VEWK5_I\&EQ0"V2TN3" 'CWM,V/O\Y&&RORGBNOM-,L;&
M5I;6UBA=HHX2R+@E$SL7Z#<<?6JNJ^&=#UR>.?4]+M;N6-=BO+&"=N<[3ZKG
ML>* .!\.7FK>+M8T,W^K7]M&=#BO98[24PB>43,H<X[,HR0.#D>E='XY_M.6
M;2;?39V??)(TMA!?_8Y[I0O_ "SDZ_*3DC(SD<UT\>GV<5V+N.VB2=81 )%4
M B,'(7Z9[5#JFC:9KEND&I64-U'&^]!(N2C>H/4'Z4 <+HFO3SZEX6M4O=2V
M_;+^UNHKYE\W?&A(C<J2'V]FR<XSUS69JMU+K,P@FU6:../QL+:*=)/FB46W
MW$)^[R6'L3ZUZ)-X5T&XTF'2I=(M#8PMOB@\H!4;GYACH>3SUY/K2'PEX>.G
M_8#HMC]C\WSO(\E=F_9LW8Z9V\9H X;4)M7M;S6O#^FZS-+%!<V1A^U7Q2:0
MR!S);+.06#$(K G)&[&>16?J+G4-#.FW4VMVUS9>(-/$EO>70>2 221X"S(Q
M\Q>K DY!^@KTM/"V@QZ1)I2Z3:?8)7\R2 Q@JS==Q]6X'/7@4B^%- 32)M)&
MD6GV"=M\L!C!$C<'<WJ>!R>>!0!YUXNU.^^S>)K_ $R[UN3^R=T:72WRVUO;
M2)&IV;-Q,QR0267DM@5H3KJ&MW_BN:36]3MDL+*WFM8K2X,2I(UOO+''49 ^
M4\=>*[";P9X:N+AYYM$LI)'0(Y>($, NT9'0G'&>M:$6DZ?"+@1V<*BY18YL
M+_K%5=H!]0%XH \L,US+>ZKK_P!MNDOV\%0WFY)F51(4EY"C@ $9 [$D]35W
M4]0O-3>=+>XUJXDL=,@DG-M?+9PVKM&7WN^[=(Q&#C:0 />N]F\,:'/) \NE
M6KO!;&TB8QC*PE2IC_W<$C'N:9<^%/#][=QW-SI%G+-$BQJS1@_*OW01W [9
MZ4 >5ZE?W&J^'+J_NY/,N;CP&)97QC<Q8DG\371:QK6J:/?:EH,-W*;G6H[=
MM'=FR86?$4P4]@F!)[;J[<>&]%%L;8:9;>2;7['L\L8\C.?+_P!WVJE)H%Q>
M>,K75KR6U-IIL3KI\,<1$BM(JJ[.Q..@(  '#<]* %\67JZ-X.NI3>W4!1$A
M2>%1),69E1=NX@%B2!DG )S7FFMW6I6D/BG2+@:C!;2>&9[K[+J&H"[D#A@H
M?.6V9!(P"1Q7L=]8VFI64MG?6\5Q;3+MDBE4,K#W!K,A\'^';>.6.+1K-1-$
M\$I\L$R1MC<K'JP.T=?04 97A?\ Y'7Q3_N6/_HDUQGB^P"W?Q#F2ZN1(;>P
MP&E+("S==IXXQQZ<^M>MP6-K;7,]Q#;QQS3A1*ZC!?:,+GZ#BJ5UX>T/4KV6
M\N=.M)[EXQ!)*R LR A@I]<$ \T <-KM[J?@S4-833]1O[T#P_/?*E[,9ML\
M;JH<9Z##DE1@<=*E\.R:W9>)=%266[%K?PR&<7^JQW/VC";A)$H.5P<9"X7#
M=.*] >QM)+T7;V\37/E&#S&4%O+)!*_0D X]JHZ7X7T+1;E[G3-*M+69UV%X
MHP"%SG:/09[#B@##\2M'%\1/"$UZ56RQ=QQL_"BY95V9[9*B0#\:7QCK>GZ0
M]]/:0)-XEMM'N;BW98]QCB7!^;'12V" >N#74:CIMCJ]D]EJ-I#=VS_>BF0,
MI].#572?#FBZ#',FEZ;;6HF_UIC09?\ WCU/XT <7.;GP_=^'9++7K_4#JT<
MJ7"W%P95D40-)YR \)AE7[N!AL8Z5FZ3;:G<0>!9)?$FLLVNVK&__P!*/S 0
M>: @_@.0!N7#$$\Y.:]"T[PKX?TJ>6;3](L[>61"C-'& =IZJ/13Z# JW%I&
MGPK8K'9PH+!=MH O^I&W;A?3Y>/I0!YK%=ZA*^E:/)KU_# /$EWI[7'GGSI(
M4BD98V?J23@ ]>F#G%3W6JW.G/K&@KJ>JW$,>J6UK9-!('N9#)'YCV_FN1C&
M"=Y.0#C.<5U.M^"]/UBZTTM;VPM;>^DO+F!H\B=GB="?KE@<^U:!\+:"=(_L
MG^R;3[ '\WR?+&-^<[_7=[]: /,I=5URT@\3::E]J%D]M=:4(!->BZFM_.FV
MN-YSG( ^4DCGWK=N['5[76=>T#2=9U)W;2(K^T:YN6E=+@2R# 8\A6V*"O3D
MUU\'A30+6-XX-(LXTD,9<+$!O*-O0GU(8D@GG-6;VR?-Q?:=%:+JS0"%)YT)
M&T$D*V"#MR2>/6@#EO#>K#QUJ-W?AG.BQV4-O]F+'8\[@2R[AW*@QICW<5B:
MWJ&I:?K>IZM=7FHS:7;7R*+S3+]62S4; 8I;8D!N2<GYCAL\5W?AC0D\.:%%
M8!TDF+O-/*B;!)*[%G('89/ [  47/A70+S5/[3N-(M);W<K&9HP2S+]TGL2
M.,$\C% %?QIJ']G^&Y&%U=V\L\T5O$UFBM,[.X4(FXA06SC<3QG/:N"-_KEG
M?>(=)BU"XTMO[-@GA75-3%PT,C3%/];\VPN,*!DX)!%>IZAIUGJUC)9:A;17
M-M)C?%*NY3@Y'Y'FJ$'A+P];131PZ-9*D\1AF!B!\U"<D-G[W/K0!P:W^IVN
MGZ[I(O-1T?5?(MY8HM5U!9XU#2["8[CYF&_[@W#Y3@@54O?$&JZ)I>J:<G]L
MV6HM+9@PWUXEQ]GBEE,;213DGK@CY_NG!Q7H]KX4\/V5E<V<&D6:6]V L\9C
M#"4#H&SU [#M3K/PMH5A97-G;:3:);W0Q<1F,,)1C #9ZCV- 'FNM)JT6A^+
M-+O'O(+(Z#+="WNM5%S.LBY^8$'=Y;#((/'&.YJ[J\.JP3)'9W>IWUA::7$S
M16&JB*ZM6.\F5U8@2@@# 9L?(1BN^L/"^AZ9:W-M9Z5:Q0W2[+A1&#YJXQM;
M/48)&#QS5:7P1X8G@MH9=#LFCMD,<2F/[J$YV^ZY).#QS0!-HDD.I0V6LPZC
M=3K=:?$5BD(5&4_,)#&!PYS@GIQCM6-J:SZUX_?1)]2O;*RM],2ZCCLYS \\
MC2,K,67DA0J\9QEN<\5T,6BVD.MG58T"3"T6S554 +&K%@./<\#M^-)J_A_2
M-=6+^U=/M[KRL^6TJ\IGK@]0#W'>@#SC3[O5?$=YX<TR;7=0CMG;58I+JTE\
MI[M()8TB<L!UQW'7GU-=;X^)_L"QLR3Y%YJ=G:W!)ZQ-,H8$^_0_6N@BTG3H
M'M'ALH(S9QM%;;(POE(V,JN.@.U?R%1:]I$>NZ)=:;(YC\U04E49,;J0R./=
M6 /X4 </XMUG4K34/%:6]]/$MM9Z8\(1R/++SR*Y'ID  _2I;R>;4O!_Q#2\
MN9'6UNKH0,S?ZD)!&Z;?3#?,/>NQ_L6SNX7?4;*UENKF*)+M@F5D*'<HYY(#
M$D9]:K:SX<AU+2[G3K=8K:"_N%DORJX:9.-X^K!0I/H30!5UC66M?AV^JW-S
M-9RO91LTL$0>1'<*!M4\%MS #/&>M<]X:NM3LOB)'I5P-3M[:XTJ2X:VU'41
M=OO62-0_!;9D,PP#@^G%=_=VEG?V<MC=P0SVTJ['AD4,K+Z$51T[PQH>D7"3
MV&F6UO.JLHE1/GP<9!;J1\HZ^@H P]6$^L>/ET.;4;VSL8=,%VJV<YA>:1I"
MA)9>2% ' ./GYS6!8Z>NN^-K./\ X2*^NH4T'#7MI)Y#W!6X902R\\8.<8R1
MGIQ7?ZMX?TG75B75-/@N_*),9D7)7/7!Z@'N.]3V^E6%I-'-;6<$,D< MD,:
M!=L0.0@QT4'M0!YC8:OJ&M:7H.GO=:S?WWV:YDEAL;A;4R*DQB666;<IXVXV
MKU))/2F:+J.K:Y:^%K"?6+Z))]0U&WGE@N<R2QQ;]BF0#D_*!N&">O!.:]"N
M?"/AZ[AMXI]'M'2WW^4#&/DW'+ >Q/)'0U9M=!TFR:!K73K:$P2/)#Y<841L
MXPY4#ID=: //([_4EE7P])K%\ED?$DFGM>M,?/$(MQ,L?F=<LYV[NN.,U5U3
M5]5T27Q)INGZQ>W<<>H:?9QR2W :2U27[ZB1N W.-S9QN&>17>>(/#7]H:;+
M;Z?'I\;3W(N+J&[M1+#=';@AQU!X4AAR"HJIX;\$VVEVFJQW]MITJZFR^=:6
M]MLMD15VJ@4YSW))ZDT 5/"3ZO:^*+W3;LSQV?V1)UMKW45NYXWW%=P.2VQA
MZ]UXZUE^+]7U6WN_%L5IJ-Q;F"#2S;LC?ZII)V5R!TY &?7%=WI.@:3H22KI
M=A!:^:09#&N"^.F3U..WI3[C1M-NWN'N+&"5KD1B8L@/F",[DSZ[2210!S>D
M17&C_$&?2%U*_N[.;2UNRM[.9BLHE*DJ3R 0>@XXX K&\6V*/XXU*X,]R&'A
M>Z?8)F"'#;<;>F.<X]<&O1/L5M]O^W>0GVKRO)\['S;,YVY],\U5O]"TK5+J
M&YOM/M[B>%72.21 656&& /H1VH X#24OO#W_"&RV^I:A=_VA8R+<6T\Q>-R
MMMYB;$Z)@J -N..N:H>'=3\1S6_AK6Y)[K=J5S$+F6YU2,V\ZR9W)'!GY67^
M$* WRX.>:]4&F6(:S86L0-D"+8[?]2"NWY?3Y>/I5*V\*:!9ZH=3MM(LXKTL
MS><D0!#-]XCT)[D<F@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P?$^LWFF#3;/34
M@:_U.[%K"UP"8X_D9V=@""V%0\ C)(YK>K+UW0X-=M8(Y)Y[:>VF6XMKF @/
M#( 0&&00>"0000030!@7FM>*-.DL](GCTR34]0O#!:7BHZPF)8C(\C1;BP8;
M2-N[DX.15"_\9:_I2ZAILT.GW&K6EW8Q1RJCQPS1W,FQ25W$HP(8'D]C[5KM
MX%MY8FEFU74)-5-TMVNI[D$J2*FP;5"[ NTD;=N""<\\TY? UFT<K7=_>W=[
M/>6]Y/=R% [M P:-,*H54&,8 '4\Y.: ,2Y\0^,K>;Q#:B71&ET2W2\:?[-*
M!<*R,PC">9\A&QOFW'J..M6[?Q!XFU[5KNWT<:7:P06-K=JUW$\C.\RLWE_*
MZX'R_>[>A[;\WAFTGN=<G:68-K%LEM. 1A%574%>.N'/7/:N:M_!5^OB?5&@
MU34M-L386=I%-;M$3.J*X8'<IPP^7#  C<<4 .TOQAK'BV2TAT%;*Q/]FQ7U
MU)>1-,%:1F58U563O&V6STQQ5.Z^(&JG3=.N&CMM+C=KF&]O9;26[ABGAD\O
M9A"I4,0S!F.,#'6NA?P3:V[V<FBW]YH\MM:+9![78V^%>55A(K D$DANO)]:
M$\%0V5M8QZ/JVHZ;):))'YL;)(9@[;W,BR*RLQ;+;L Y)[<4 <WJ&N7>H*)X
M#I8OY?#%U<"_M6>55*R1@B-@P^4]?4$#G@Y@MO$DWAZRL;[4+>VO+FW\+?:O
M.C1D=_WB!(\EFX.5R?49X'%=78^ ])L$B2*2Y9$L)[%@[CYUFD$DCGC[Q8$\
M8'/2F6_@'3UMDM[Z[N]0C73'TL^>4&Z L&&=BCYA@ 'V]>: *5WXA\2>'KFV
MAUG^S+G[=;7#PFTA>/R)HHC)L;<YWJ0I^8;3QTYINC^)?$3WOAF355TUK37X
MF98K:)U>V80F498L0X(!!X&#ZUH1>"(WE$FI:SJ6I/%;26UL;DQCR%D7:S#8
M@W.5XW-G]35^/PQ:1CP^!-/_ ,2-=MODCY_W1B^?C^Z<\8YH @\0ZQJ-OJ^E
M:+I(MDO=0$TAGN49TACB"[CM4J6)+J ,CO7$>*M0UC7+%=!OCIPN+37K2TNQ
M]G=X+E)-CQMLW@A>?F0DYQU%>@ZYX?CUF6SN4N[BQO[)V:WNK?;N3<,,I# J
MRD8R".P]*HP^";%+9%EN[N>Y.HQZE/=2LOF3S)C;NPH 7"@84# '% %#Q^E[
M8>"[.'2I[>S,5[8PX2)@@3SHU"JJL,+G&1DY4$=\C#-[XDTS6?'>H:=+IFRQ
M>*XG6XA=O/9;2,LJX<>6,#J=W7VY[[Q!HD/B'1Y-.GGF@#/'(LT)&]'1PZL,
M@CAE'4533PI;"UUR&2[N96UF,)=2-M#9\D0DKA0 2%STQD^G% ',:C\0;J75
MY++3Y[.Q6"TAG=KNSGN3*\J[P@\HC8 ,98Y// XKK=(U9M<\)6^IR6LEK)<V
MQ=X) 08VP<CG'?-4)O!:+<"XTS6-0TR9K6.TN'MO+/GH@PI(=& < G##!YK=
ML].@L=)ATV%I##%$(E:1R[D8QDL>2?>@#PC3;**R^'NAZK%X0ETR2);::7Q%
M'+$3&@92\I1&,C KD$$=^:]*N?$GB&]&NW^C#35L-'E>'R;F-VDNVC0,^'#
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MCCJ2>?TQ5K5O#(O]635;+4[S3-0$'V=YK81L)8\DA65U8'!)(.,C)H P-/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<ZD1(!G<W/"X!YZ<5QGC/0-2U+6?$'V&QDD2?2+,8"[5N#'<N[Q9Z%BG&/\
M:%5_$\=SXI>ZN](T;48$MM O[:5KBS>!YGE11'"JL 7P5)X!'H>: .T/C;PL
M%N&/B'3<6Y E_P!)7Y<G [^O%3/K]J;BP>"[L)+"ZMY;CS_M(!*(%.Y!T9<,
M<G/''K6#;:*T7C/PQ.NGE8+/1)X3)Y6%B?,(5<]CC?@?6N8MM"U2/2=(B_LV
MZ4Q6&N1LODL-ADDS&N,<;AT'?M0!Z/8>)]"U6^>QT_6+*ZND7>8H9U9L>N ?
M_P!5);>*O#]YJATRVUFQEO<LOD).I8E?O #/)'<=JY:/2+NU'P_-MIK[K&VD
M651'M$1-H1M<X^7+X'/>N;L(-9NV\)*]KJB&SU&*2YL(])%M:V(VL"%8KN<
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M#97#8P=O7I75^ M/NM-\+K'=6S6AEN;BXBM6QF".25G1#C@$*1QVZ4 9EO\
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MP[XO.H63W>J7&BPP"WCG\RUOO,"[W9<-N48&5QGN=P[5>;QOX66T%T?$&FB
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ME]8"U7>)4.Q4V*PX)/S=><=*W7TZ23XHI?O:,UNFBM"LY3*AS,"5STSCMZ4
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M0&&.":[3P%8RVMAJ=S(NH@7M\\X.H1I%))\JJ7\M578&*YP1GN>M '6T444
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M%MSNJX\PCY%)."W4 G'.* .FHKQ&[NKG3&\8V5L\-DJ>''N#;66IR72Q2AF
M;<P&U\$9 [8-=C8Z='H/CS0HK.XNRNH:=<M=B:Y>43.AA*N0Q(#?.W(QUQ0!
MVC7B+J26/E3;WB:42",^6 "!@MT#?-P.I /I5FO/O&UU<0Z]?)%<2QJ/"NH2
M@(Y #AH\-]1DX-4$LYM!O_#-SI4UY)>ZAIER;@37+RBYD6!70LK$C.[I@#KC
MI0!Z'?ZK:Z;/8PW#,'OKC[-#A<Y?:S\^@PAJ2PO$U"RCNHXIHE?.$GC,;C!(
MY4\CI7D]A#H[-\/;^WU26YU6\NUDNA)=M(TK_9Y/,9D)(!5CMZ#&2*73]>NO
M#/AO0_$\\MQ<V]Q:W5E/&SLVZ822/ <>I*M'G_;7TH ]7-X@U);'RIMYA,WF
M>6?+P"!C=TW<].N,U'<:K:VNK66F2LPN;U)'A 7((CV[LGM]X5YCJ?\ ;GAN
M"2V@O+B;4H/"EQ/(V\L3<&9"[@=R"S8]L"I6LM#M/&.@C0-0DN7ETN]D(%XT
MY;*)MDY)PS<\\9Q[4 >K5'/"MQ;R0N7"R*4)1RK $8X(Y!]QS7F.G^(89M)^
M&<2:GYMQ(%:Y1)MSN%LY-V\ Y.&QU[UB66H?Z;X4U:S8P_VCJ<:BXN-8>:[N
MHGW;A)"JB-5Z< _*<  4 >I^%1I":&(-$1TLX)YH<2%BQD61A(26)))<,<D\
MUM5R?P] /AR[!Z'5;_\ ]*9*X%]8U+3[JWB>]N?)\&SG^T"78^?#+.$C+?WL
M0;GY[T >NS:K:P:S:Z4[-]JNH9)H@%X*QE0V3V^^M1V^AZ?:ZS<ZO'$YOKE!
M&\KRL^%&/E4$D(,@$A0,GDUYK8:1_;FO^%)-8>Y8ZA9:CJ$L0G=.))(62,[2
M#M564;<X^6F:?)YU]IF@ZI?W*Z$FIZI;CS+EU\UHI ((GDSD@*7(!/.T=<4
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MP44R*)884B3.Q%"KDDG XZGDT^@ HHHH **** "BBB@ HHHH **** "BBB@
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MY5PN?WA&TX8CDD8%='XHO'M=2\,(L4+BXU81,98PY4>1*<J3]UN,9'."1WH
MV++2M.TV%X;&PM;6)SET@A5%8^X YIMMH^F65O-;VNG6<$,V?-CB@55DSUW
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M+^U\FVU4Z5:6C6PV[FE1%DD?.?EW]!C..O- 'H,.FV%O$T4-E;1QO&(F1(E
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M5DE#HA?9*NT;"0",@L >* -33O!>F:=>17+2WMXUO$T-LM[<M,L",,,%!]0
M,G)QQFDT[P1I.FW5O-&UY-':*RV=O<7+216P8;3L4]/E) SG .!BH(_'5E+:
M:)<QPL8]1M9;R7+8^RPQIND9N.2&*ICU/M45CXSO)9-)GU'0FLM-U=UCL[C[
M2)'#,I9!*@ V;@.,%L' .* +6G>!=%TV**)%N)X8;26RCCN9C(JP2%2T?/\
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M>0$C;*P7  5MV1QCOD5=\-^*EUR^O=.G@@@OK14D=;>Z%Q$\;YVLK@#NI!!
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M@R1J^\*W<!L#/UP* .>LO ^F6=[IUXUUJ-S/II/V1KFZ9Q$I0H5 Z8(/4C/
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MW-M*8Y8AC:0&'4$  @Y!JC_P@>D+;VZPR7L-U!</<K>QW+>>TCC:[,QSNW#
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M&T/,CF7:?D *X(7)W 8H Z+1M"LM"@FCM?->2XE,T\\\ADDF<@#<S'KP /0
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ML$ 8(&()+,3@*H&2Q/8 $T <GIO@*YLO),NHP2,FN?VN?*MO+7'D^68U7<<
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MM*S3,@4L(P%R_#J?ESD'C.#0!GW'@O47N1(NLK/YVC/I=W)=0EI)"=Y$@(8
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MELE0!RQ&/0 ]"*Z&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MTGFZHVE95  LP5B<Y(^4;2,B@!G@K2Y=)\-103VLMK+)++.\,MP)G0NY;YF
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M[>QNQ:7UL\PEE5=J@,%V-AC\QR2,9& >: .3\#Z3<1^*M0MYBKZ?X<,ECIS
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ML;>4[@_O$ R#CKSQGZUGZ#H<>A6<L0N9KNXN)FGN;J?;OFD.!D[0 ,
M 4 <MXLM])3XD^$KS4(;0.\5U#'-,BY,H\LQ*"?XLEMH]2<5S'AS1=.TSPK\
M.M6L[2.'4;B\ACFNE'[R1'BDW*S=2O X/ P,5[&5!QD X.1FEP* /!M/C9_(
M:ZO]'M_%']K?O,6TCZF)/.^[]_F,IQTV;#7H7Q0-D- TS^TB18_VO:_:""?N
M;OFSCG&.OMFNUV)OW[5WXQNQSBJ&KZ-!K*6:3R2(+6[BNT\LCEXSD Y'3UH
M\IUOR1;>*#X,,*Z!Y%D+IK$$P!_-/GE!'U_<[=^SM[UGZC':IHOBEM(O]%:T
M_L-O/AT.W9+??N&QF;<5$F-PQU(//05[LJJBA54*HZ # I%1$!"(J@G. ,4
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ME$9 SG=:R@_+)V. 3POM7H6@Z$FAP7 -W/>75U,9[FZN-N^5\!1G:   JJ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !5/4]2M](T][RZ;$2LJ]0,LS!5&20!EF Y
M('/-7*BGMH+J+R[B&.:/<&VR*&&0<@X/<$ T 8%SXVTN&UM988[F\FO)9([2
MUM$$DL^PD,RC. H(Y+$8[XJUHOB6WUB[N;%[.\L-0ME5Y;2\15<(V=K@J65E
M)!&03R.<5S3W&E^&OB?++J3VVG6<^DQPZ?+)MBA!$KM*@/"AB2C8[U7\1^)K
M?6=+DFL@\&CMJ-M8W.L(VP2VY;,NQQR$!PA?./F.#QF@#T>L^_UBVTZ^TVSE
M61YM0G:"%4 ."J,Y)YX "G\Q7EVK3VNF/XAG\'.EKI$5A!!>7%B?W23/. SI
MCC>D)<LPZ97/(J._BTJSU_4+OP2L<CZ1H$\X-J_F(UP_RHW4AGVJ^3R3P#F@
M#V6L32_$UMJNI/8Q6=[$ZK*WF31!4/ERF(@'/4L"1QT':N!\'VD!\4Z,=+OM
M(FDAMWFOKC3GDEDN8V3 \]SQN+E6&[GY3C KT'4K+0?(BTZ^AMHDO72&.(?N
MS*R9=5&W!.,$X^M &Q7):GX\CTK4X["?PYKSR33M!;O'!&5G903\A,@XPI/(
M'%=;7(>+_P#D9_!7_84D_P#2:6@#5TSQ)!J6H_V>UE>V=V+5;MHKI%4JC.Z
M'#'G*$_0BMJN!U'0-,U_XK746JVB7<,>APD12$E,F>7DCH2.Q[9.*XJ":XO;
M'PC#JT^G/I9TV81_VS(WV>2=9=H#'."XC V[O]K'- 'N=9VCZS;:W!<RVJR*
MMO=2VC^8 "7C8JV,$\9'%8GPY+_\(KC[;'=VXNIA;21!]@BWG"H7Y91R ><@
M#%8_AGQ+HGAE/$-AK>J6NGW4.KW=P8;F0([QR.71D!Y8$'MGGB@#L]"UFV\0
MZ-;ZI9K*MO.&*"4 -PQ4Y )[@U@S?$.PBCGO%TK5I=(@D9)=4C@4P+M8JS?>
MWE00<L%(X-,^'LJ:7X(\.Z??L+:]NXI'AMY?E=LEI",>H4@GTKC9-5TG3]'O
M[[0_%4VAWJ-*TOAR_:.9?.R28A"PWC>V?N''S<4 >QHZR(KHP96&00<@BL]M
M9MD\1Q:&5E^UR6CWBM@;-BNJ$9SG.7';UHTW5([E+:UN/+@U-K2.YFL\_-$&
MXZ>@8$?A7(>)B1X^F(."/"M[_P"C8J /0*IZ7JEIK&G1W]E(7MI"P5RI7.UB
MIX/N#7FNCZ'I^GS?#VYMX-L^IV[Q7\A8EKI6LV<B0D_-\R@C/3'%<Y9I:1^&
M?#%E VEQZ:;^]34TNW*V_P!H#'RDGVG@[<X#<'"^U 'O-&:\7CLXKW3+'3S>
M6]SI,OBB*)(K%I! B>2_F11N?O(3G[IP,L*O7/A71I;GQZCV2F/3K:(62;CB
MV(M 0R#/RMD#D<\"@#UK.*SSJ]LOB%-%*R?:GM6NPV!LV!PA&<YSEAVKRO4K
MVPU:Y@CU2+2Y)H=%M9'FUNY;:=ZDDP0@99\]6!!SM K2^'UQ-=ZMX7FN)7EF
M;PJ0[N<L2)HQR?7B@#L]8\50Z1K%OI2:9J-_>3P-<*EFB-A%8*2=SKW8?G4F
MB>)[76KRZL?LE[8WUJJO+:WL01]C9VL,$AE)!&0>U<YK]E>W_P 5--BL=6GT
MR4:+<,9H8HY"1YT7RXD5ACD'IGBN4U ZGIFF>+[6]O+JX\5K' 9+UCM\[3O-
M&7B6,#8JJT@8+D@Y.3Q0![317D.BZ-9ZKJM_I.GW^C)9W>DNL\.BF1XPQ9?*
ME9ONK(#G'.XC/7%0W&J:YXC\.ZWKD*SPWVCZ8--VH#N6Z)4W;+CG(55 (YZX
MH ]DHKQBQ2U@N;K^Q[_1%A?1+IKB#1VDD65=@V/*3D*X/0GYCENM:NC:/9:1
MJ'P_N[&(Q76H6SI>3;R6N0;4O\Y)^;Y@",].U 'J5%>/:1K=E+X5^'^EI?QO
MJ4.IPK<6RR9DBV+(K;UZKR0.?45DVOG2K]JNK_2+;Q+_ &L4:1C*VH+)Y_$8
M0=8RF!@#;L.?>@#VS4]3L]&TVXU&_G6"UMTWR2-S@?0<D]@!U)K"M_&]NU[:
M6]_H^K:9'>R"*UN+V%5CD<_=4[6)1CV# 9^M1_$6VGG\++/#"]PME>VUY-!&
MNYI(HY59P!WX!./:EF\=^'KN73;;2[FWUFZO9T6.WM)%D:-<_-(X_@"C).<>
MG6@#JZH:WJ]MH&C7>JW:R-!:QF1Q& 6(]@2*\CNFTW_A&=0O)9T'C]=2D6(>
M9_I8F\\B)$7.?+,>W@#:5R:B\5+H4OASQE+KDT2^)4OID@$DF)Q%N'DK&,Y\
MLQX)QP?F)Z&@#W#-%>+^)ML_BCQ0=;NM&@> )]B;4I)%EBA\H$/;;3UW[N5^
M;<,>E=[J<FLQ_"N>2UEEFUD:3E950J[R^5RP4\ALY('7- '5$@ G/3K61X<\
M0Q>)=-&HVUE=V]JY_<27*JOGIV=0&)P??!]JX"VM?"TNM^';?PLUM<)=PS#5
M(X9/,\VV\EOFN!G[WF; "W.21ZUT_P +;.VL_AMH?V>%(O.M4EDV#&]R!EC[
M\"@#7C\4Z3/XJ;PW!<";44MVN)5CP5B565<,<\,=XX].N.,T6\=:8MY*GV:^
M-E#<_9)-2$(^S)-NV[2V<_>.TMC:#WJJ]K;VGQ6TU;:"*%9-)O9'$:!=SM-
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M8W8 *FY@-O0-F@#V.BO'M0U2WU&Y\17,5X9-#EU^QCOIXI#L-MY"!_F'\!<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%5K^^@TVS>ZN&(C4JO R2S$*H'N20/QH LT5@WGC#2+*S@N'DFE-S*
M\-K#!$TDMPRDAMB+DD#!YZ=^A%3Z+XDL=<EN;>%+FWN[;:9K6[A:*5 V=IP>
MH.#@C(XH UZ*** "BBB@ HHHH ***BNKF&RM)KJYD6*""-I))&Z*H&23] *
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MB:%@3[;_ /LTOL_M/[')]ESG&?,QC;GC=]WWH ZRB@'(R.E% !1110 4444
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M '3T55T[4;35].M]0L)UGM;A \4B]&!^O3Z&K5 !113)IDMX))I"0D:EVQZ
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M6+V)UF(VDCEW@.E6WELQ[E=F"?>IF\*:DUA]@;Q!FSV[/LYTVW\O;Z;=N,4
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M_#;0[=5?R[C38&D!D8DEXEW8.<CKVQCMBMNSTC3-.25+'3K2V2;F18(%0/\
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M*VA1H8_*C*Q@%$X^4>@X''3@5/0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MG@<=.]=>CAXU< @, <$8- #J*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** ,.Z\(Z3>74MS-_:'F2,6;9J=RBY/HJR
M#Z 5%_PA.B_]1/\ \&UU_P#'*Z&B@#GO^$)T7_J)_P#@VNO_ (Y1_P (3HO_
M %$__!M=?_'*Z&B@#EXOA]X?@N)YXTU$2SD&1AJER"V!@9/F<X [U/\ \(3H
MO_43_P#!M=?_ !RNAHH Y[_A"=%_ZB?_ (-KK_XY5:[^'?A^^V+<#4I(5.3"
MVJ7+(YR",@R=B 1[UU5% &?I>BV6CB46?VG][C=Y]W+/TSC'F,V.O:M"BB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ J.&WAM_,\F)(_,<R/M&-S'J3ZFI** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S];FOX-+=],M
MS/=EXT505!"EP&;YB!\JEF_"@#0HKAAKOB34=0MM!M8XM/U-XGO+V:X02BT@
M\QDC554X9VVYY/ !)'8:,&HZKX<&H/XFNX+C2X(DDAU%(A&[,25,31J22V=N
M"HYW8ZT =117-?\ "<:3';7\MW'>V;V, N9H;JV9)/))QO [C(.<=.^*OZEX
MDTO2;O[->W(B<6SW<C8RL42$ LQ[ DX'J<XZ4 :U%8-AXNTZ^FDA:*\LY$MS
M=*MY;M$9(1U=<]0,C(ZC(R.:IP?$'1KFSAN8(M0=+G8+0"S?==%E+8C&/FV@
M'<>@[F@#JJ*YX^,](&E_;F-R&^T_8_LI@;[1Y_7R_+Z[L<^F.<XYJOX?\3R>
M(?%&J6]NDD5A86\*/'/"8Y5N&9RP(/3"JG_?6: .IHKBO&]WXCTQ[.?2M9MX
M5O+VWLH;:2R$F&=L,Q?<.@W-C':K;Z^WAB2+3]<U";5M1NE>:WCLM/(=D3:"
M BELG+9SGIGTH ZJBN:/CG2!=K%Y=[]G-R+0WOV5OLXF+;=F_I][Y<],\9IE
M]X^T33YKZ.3[9(NGS"&\EAMF=("0IRS#@#YA[\'CB@#J**YW4_&FE:5>W%O<
M+=LEH4%W<16[/%;%P"N]ATX(/&< @G%)JGC;2M*N;N*6.]ECL@#>3V]JTD5M
MD9^=AZ @D#. >: .CHKG=5\:Z1I-Q-%(+NX^S1+-=/:V[2I;1D9#2$=.,G')
MQSC%95UX\2/6==MPDD.G:7IZSM>FW9QYK9(QS@C;M('5LGTH [>BN7G\::=I
M:R07CW=T]BB#4+NWM&,4#%027(R%ZY(&=H/-3ZEXTTK3;ZXLMMW=7-O;I<R1
MVENTI$;;L-D<8^4_F/6@#H:*Y?4K[6]2CL[KPU-$;*YM!*DLD 8,SLA0\L"!
MLWD\<<=3Q6]97T=\LS1Q3QB*9X3YT13<5."5SU7T/0T 6J*R?$VLCP_X;O\
M4]GF201'RH_^>DA^5%_%BH_&L;0O%4\'AS5YO$KHM_H<DBWY@3AE WJZKZ%"
M#]0: .OHKF8?'6DS23H8K^(I:/>Q^=:.GVB%,;FCR/FQD<=>1Q6FNOZ?)-I4
M44ID;5(VFM=BY#(%#%CZ#!7\6% &G16/J_B6RT>[ALGBN[J]F1I$MK. RR;
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M;"2012LK80$X"  %B<'@]P*J:)X\AN-+N[Z]\^3?JTUE900VS>=(%Y"[,9W
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MS>*U>\5+NU:)I84&69 >N.,CJ,CBGZ5XUTK5]0MK.!+V)KN)IK22XM7C2Y4
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MTKT&:]M+>:.&>ZABEE.(T>0*S_0'K1)>6L,JQ2W,*2,P549P"2<X 'J<'\J
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M*3>JJ[9 SQFL ^&=::\GMVLH_LZ^)8M5CN/.4AXB<L-O4%<?CGBO0F8*I9B
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M..N:[FXO+:T7=<W$,*XSF1PHQD#O[D?F*1KVT6Z2U:ZA%PXW+$9!O8>H'4T
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M$K9P2!R,X/Y5>H \CUG^RM0GU*?PE;(MFGAR^BOGM;<QQ.Q4>3&1@ N,/QU
M)]:V+'1;32O$?@>2PT^.V+V-Q'</%%M+CRD;YR.OS<\]\UV5WX@TJQFN8KF\
M2.2V$)F!!^02OLC[?Q,"*TJ .'\7_8X/&&A7NNPB30XK>X7=+'OBBN24V,XP
M0/E#@$]"3ZUR]II-O=76E31Z8#I$OBJ1[".6WP%MS:ON*J1\L;2AF P!T/I7
ML%5M0U"UTNR>\O9A#;H5#.P) R0HZ>Y H YCXBP6T^BV)NIY;9(KZ.1;@6HN
M(8F"M@S1D\Q\XSV)4\8S7$,;:;PW'<7>EV!L+3Q';RR7EG:N+>XC(7S)5C;)
M5>BMCY20>M>O6NH6M[-=0VTPDDM)?)G4 _(^T-@_@RG\:LT >,Z@FF?\(_XF
ML+RR:3Q;=7L\EB1;DSR,SYMGB?'"*NSD'"[3G'-:-R-&M-0\40^,-/-[J-TZ
M&T40,TES#Y*!4@8#@B0/T(()R<=:]#;7M,77ET3[3NU%H_,\E8V;:N"068#:
MN=IQDC.*EO=6T_3TN6NKN*+[-;FZF4G+)$,Y<@<XX/Y&@#RF.TO+/Q1J&N7\
M,D^@VVN#SK%T+&%V@A"W)()\S8<#'./F8<BO6+74[.]N[RUMY=\UFZI.NPC:
M64,.2,'@CD9JS'(LL:2(=R. RGU!J.*U@@FGFCC"R3L'E;.2Q "C] * /+?$
M>G?;O$NL03VS2VT^O:0'4H2KIL4-GU&,@UU'A[3X=-^(7B6*SM$MK5[2RD"1
M1[$+_O@2 .,X"Y^@KI]0U&STFQEO=0N8K:UB&7EE;:HK/TCQ9HFNW3VNGWP>
MY1/,,,D;Q.5Z;@K@$CW'% '#>,-#N-0\67/AN..4:?XF\FXGE4';&T"MYF3_
M +6VW'OS60MM=^)O#']K:Q92^==ZEI>G/#(ASY4,J"4_0R/,?H!7M-% 'DOB
M[2H[&Y\86^FV"P6\VD6+^7;Q;4:03R G &,[0/PQ4US_ &%;7WBBW\3:7)>:
MK=7^^TB6%C/<0[4\D0..F""."-I!)QUKU2B@#R+5-!M;CPO\1[^73$?4/MDS
M02M%ND7;#$R;#UX;)X[UVWCNU:_^&^NPB SRMITI2/9N)<(2,#UST]ZZ>B@#
MS30M(T+7?%>I77]FVMU8_P!BV<=N7MQL +3[PH(X.0,]ZYBTCNHX/"=WJUS:
MVM@OAZ.&*74].:[B2?=\ZD;EV.4V8)Z@$"O:[R[@T^QGO+J3R[>WC:65\$[5
M49)P.>@J2&:.X@CFB;='(H=6]01D&@#FOA[;-:>#;6/S)WB,DK0^=;&W*QEV
M*A4+,53'W03G;CI6#X7\1Z=X+T%O#VNM/;7UA-,J+]G=OM2-(SH\6T'?N##@
M<@YS7H5Q<0VEM+<W,J0P1*7DDD8*J*!DDD]!4,>I6<VH/81SJUTD*3M& <B-
MB0K>G)5ORH \^N;Z*?Q+I.M>,M*%G83:6ZPQ72^=';7!DR0_&%=H]G4=F&?7
M,T+18[S7?#:76FLVDBYU::QM[F$[8X"T9BRC#@=2H/08]*]>HH \?M- M+/P
MY;7-OID<5W%XN 218<.D0O2H .,A-G&.F*I3G1I]'\6V%O:;_%$^MW/V(K 3
M*91-^[='QPJGDD' PV>O/MM4-+TBVTA+I+;?BYNI;J3><_/(VYL>V: /(?&D
MD=X?&$!M=/MKXJR+#)82W5Y=E8EVR1L6Q&GIM!"X)X-=%9Z+9:QK_B6YU+3X
MKLG2+)8GN(M_WHY-VW(ZG"YQSP*]+J%+JWDNI;5)HVN(55I(PP+(&SM)';.T
MX^AH \CD?5-#\.^&M1L$E-YKNB6^CR$@Y2Z* PR-_NAI<D^@KO\ 6-,ATOX;
MZCI=FA\JVTF6")0.2%B('XU9U/2]/&J0^(-2OIDBT]"Z1RS!;>)L,#*1C[VU
MB,DXP>F:VJ /$-:AM;5)96^SR74NE6JMIVJZ>T@O-L7 MI4.]6SP0.C<X[UZ
M%XY\ZY^%>LYMY(YY-,<F#.YE8I]WW(Z5UM% 'EWBGP^^GZG##X8L5M+J?P[?
MP@VT>PNX\G8"1_%DM@GG)HL$\/ZAKWA:+PQIZ1FW25-2"6IC$=N864Q3Y R2
M^SY3DY!/K7?P:_I=S-###=J\DT\MM& I^:2+/F+T[;3^5:5 '&?"T6J^ +&V
MBA6*:#=%=1^5L*R@\A@0,G&.:XRQTO3KJ+2-)?3HR8/%MR;NW-O@!<7+1[AC
M!7&W';&!7LU% 'C?B/2IK:[UZWL+=+;2(M=LKBZC%H981$;<;F,2D;U\S86
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M[*Z0M.(I8UCW/'D!P#ABN#G=TS7<7/A+P_=V5I9SZ7;M!: K;J!M,0/4*1R
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MMQ!>)LN%9=WFKC&UB<D@9.!VS43>"O#3O"[:/;,88UB7<I(*+]U6'1@.V<T
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MESG:V/O#V.1S0!R5G<3>+M2UJ9O$-_8VMA!;M9FVD\D;9(%E\]UQ\V2Q&&X
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MW#&)&4 YVK\S@$D'@]!CG#UCPUJU^;W1;.RUJTM[G4A/Y(FA:P"^<':7?@2
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M]BL?(</&@55"JH(/ &?F/.:F\?:9=:SX)U'3[*)Y+B81A51@K<2*3@]L $T
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MGFN(XK);*-9\'"!W8]!R6+#/^Z*J6?@."U:PMY-6O[C2M.F6:ST^79LB9?N
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MJJ[1C<V<@YW'-))X$@O(KQ]2U.\O;V[, DNG"*52&02(B*JA57<#GC)R>>E
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MK-'#'& 68JI!8Y90!D=>O%1:5X1DTZYL3+KVIW=IIZE;2UE9%51MVC>54&3
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ML]5MK&Y74+20VT=F'5XY8XMXC8L2'RH(W +R.G-9NE^-=7UJSO;?[?I"7O\
M9\LS6P@FM[FSE 'RLCMF0#)&Y=N"!ZUT=GX*CBN89;[5M0U 6MN]M:+,R)Y"
M.NUB"B@E]HQN)SCW)--M?!"+=VT^I:Q?ZF+."2WM5N!&IC5UVL2RJ"[;1C)/
MOUYH YZQ\2ZMI?@WPM'/JNC6TEUIR2FYO$DD=_D3:JQ*X=VP<LV<9'3G%3V'
MCC7-8L_#R6-OIZ7FISWEO-),DGEQF D;U7(;!V_=.#SC(Q6E9^ 6TXZ?)9^(
M=0BN;*S^P+.8H69K<$%4(*8RN!AL9]<U:TGP/8Z/)ICQ7EW+_9\]U/%YS!BQ
MGR6W''."3C]: .7U37O$>HV>GPB>RMKZT\2II]P\<<GE3$+N5MN\$+AAE23R
M.M7?^$EETVUU9[;^R--SKLUM)<WCMLX13OV;@TCDX&U2!W[5MWG@BVN;>Z2'
M4+NVGFU0:JD\80M%,%51@,I!7"]"#UJ*;P) ;M;ZTU.[M;]+^:^CG54?:TJ!
M'7:RD%2 /<>M ',-XGN?$5KIZW)@>6Q\46MMY]M$\23*5#A@CDLOWL8)/3(.
M#5WPGKEQI<EI;3+'_9VH:QJD!F;.Z.<3R.@SG&&57'3J!6W;> [2"1Y)-2OK
MB634XM4>28IEID4+V4 *<#@#CM@5E^*/"C-X8_X1K3;:]N'U#4'NA>AD5;)F
MG$KNQR",!F"@ DXP>M '3^%]7N->T1=4FB2.*YED:U"@@F#<1&S9/5E ;\17
M'GX@W\6M6,3W6BSQ7.I)9265HLDDL =]@9IPQC+#@E=H[C.:]#MK6&SLX;2!
M D$,:QQH.BJ!@#\JY"W^'44%II]C_;FHMI^FW4=U9VN(@J,C[P&(3<XZCD]_
M7!H Y[0V8^+]*&XX_M_6AU_WJZ7Q3+JJ>-?"$5E=Q16\MQ/YL;HQ#XA8G.&
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M^E0-!):7CLD4RLJ@D.%)5@4!!VGO6OX/T&30=/N5FM=/M9;FX:8P6"GRXUP
MJEB 7.!RQ ^G% %?4_&\>EO=2RZ+JCZ;9S"&YOU2-8T.0"0K.'902,D*1UQF
MM#Q;KC^&_"M_JT<(FE@0"*-C@-(S!4!]MS#-<+K_ ,/-;UF+6H)(=*NKB[N'
MFMM3O+J5GAC+92,1;"J8 V[E/3G!/%>@>(=%B\1^'KW2+AVB6ZBV>8G)C;JK
M#Z$ _A0!B#0_%EFMM>P^)WO;T2(;FTN88TM9$)&\)M3>A R0<MTYSFGWGCVT
MM)+V4:9J,VEV$Q@N]1B1#%"X.&X+!V"G[Q52!@^AJ"2S\=:E;P:;>7&F6,*N
MAN-1L9Y#-*BD$A$* 1EL8)W'&3C-4[KPIXA72]:\.V3:<=)U6>>3[9+*XFMT
MG8M(OEA2'.6;:=PZC/2@#>G\8Z;;6.N74J7"C1WV31[07DRJLAC&<$/N 7)&
M3Z57OO&\-I/>K%I&I7<&G ?VA<0+&4MCM#%2"X+E5()"!L9_"JNJ^"9;SQ5I
M=[;7$<>EHL0U"W;.Z<P$M;XXP<,W.>P%9&K?#ZY?6-9GM-*T._35)?.2XU!W
M$EHY4*WRA2)%XW 97DD&@#HI?'-BNLOI]O97MRD,$5S<7D03R(89 2)&8L#C
M )P 3@'@XI=.\:P7MS8)/I>H6-MJ6?L-U=*@2<[2P& Q9"5!8!@,@>O%06W@
MUDGU^&:6);'4M,M]/00C:R!(Y$8[<8 PXP 36+H/@"YL[S3$N]'T""*Q!$M[
M;%WFNB$*J0K*!$><DY;T% $^H>.[B]?0I-+L=0M["_U6&"._DCC\JYB)(8 ;
MBRAL9!*C('%=?K&FW>I01I9ZQ=Z8RMEI+9(F+C'0^8K#'TKC[;PKXGBL= T1
MFTO^S=%O(95NO-?S;B*,_*NS9A6QC)W$$CMFO0J /./"FJ:E:>!_^$RUWQ!J
M-_#%;S2S6@A@"X1F&5VHISA>[8YK?3QC/-%!Y'AC6I+B?>T4!6)"8E"GS"S.
M%4'<  3NSGCBJ,/@_4(_A-<^%3-;?;I;6>%9 S>5N=F(YQG'S#M3_$WAK4]4
MU:PN$@M-1T^&V:%]/NKN2",2D@B7Y%8/P",$?2@";_A8%B]GIDMOIFI3W.HS
M36\5HD:>8LL60Z/E@HQM/.<<=:!X^LSIR2_V;?"^:_.F_P!GMY:RBX"[RI8O
MLQMYSNP1COQ6;X;\#:EHTFA>=)8!-.O;Z=UMMRKLG#; BXXQNQC/ '4U)?>#
M]1DMM73[-I.H0WNKF^-G>YV2Q&%$V[MI,;AER" ?UX -D^*V&G1S?V#J_P!L
MDN6M5L3"HDW@$D[BWE[,#._=C\>*KKX[LAIUU-<:??P7MO>+8-IY5&F:=@&5
M5VL5.0P.=V,9SC%<ZG@77H=,MX0UO+:+?O</HK:C.(1"8PJQB;:6(5@7P5VY
M.,<4ZR^'^JV4%W-;KI-K<KJT.J65M 7$"E(O+:-CM!Y&[Y@#DG.!TH OZYXY
MU"UL[<6V@ZC!>C4[6UN+>98B=DC#[C>9L;<,J"#P>N.M6XO&$%HEZ'74+ZZ;
M5GL;>S$48D,@C5RB8(&Q1DEF([Y[5#JNC>*]:T]IKE]-CNH;^UN[2P$K-$@A
M<,P:78&);_=P,#W-0#P?K-O=-JUM)8G4H=9FU&&%Y&\J2.6$1/&S;<JW4@@'
MH/7@ T)?']A:V%S->:=J,%W:W4-K/8F-&F5I2!&1M8JRG/!!/0]^*T=$\2+J
M]_>Z?-IUYIU]9K'))!=;"2C[MK HS*1\K#KP17/3>#]9U.YN=4O7LH;ZZU"P
MG,$4C/'%!;2;MH<J"SG+'[H'('O716VCW$/C74=99XC;7-C;VR*"=X:-Y6)(
MQC&'&.?6@#-U'Q=::%?Z_->27T\-@+(-!'"A"&9B@*8.YLD@D'ICC-))X_MK
M1;\:GI&I6$ME%%<213"-B8'?9YH*N1A2#N&<@#H:KZYX/U#4[W7IH9K95U"3
M36B#LP(%O+O?=@=QTQGGKBM.[\-F_P#%5[?77E/IUWI']GR19.\DNQ;C&,;6
M]: )-5\8:9HUW>6]R)S]CM$NIGB0,!O?9&@YR79@<#';K61K'C29-"UR$Z??
M:/J\&DW%]:K="-MZHA^92C,I*L5RIY&1QBJ=CX U(>#K^QO]1@EUNXG@F2["
MED_T<IY 8<'&(P6]W;%2ZMX8\0^)_MMQJBZ=9S#2;K3[.&WG>53).H#2.Y12
M!\B@  ]^: ->W\8V,6DZI<7HG232+>.:ZW*N9%:(.&3!Y#<@=.013+KQM'!/
M<16^BZI>&SB26^,"Q_Z+N7?M8,XW.%.2J;OU%4=7\$76HZOHL\=S#':)#%!J
ML1S_ *0D+"2(+QSAP0<X^5C5#6O 5S+XAU?4+32M%U(:GL</J,CHUK($"$@*
MC>8N%!QE><\T ;ESXZM1<>5IFFWVK!;..^E:S$?RPR9*$!W5G) )PH)_$XKH
M+C4(;;2I-1D6;R8X3,5$3&3:!G&S&<^V,YKA-<\"WMU%;6\.FZ)>QP6,=M;7
M#N]G-9R*""R-&K$IT(7(QC'>NGO]'U6;P,^CVVK.NJ_81;B_;(9I H!<D<C)
M!Y'(S0!'IOBO[9K,&EWNC:AID]S ]Q;?:O+(E52NX?([;6&Y>#CK46M>(+_3
M_&WA_2(+&66TODF:>1/+XVA<?>8$!<[FXY!&,G(K%T+P5?6/BW3=9.FZ3IT-
MO;S0S1V]S)/+*7"X9I'0%N5Z'IDG)SBM[7M&O[WQ'H6IV0MGCLC-%<QS2,A,
M<H4%E(4Y8;>AQGU% %>U\=V=U):R_P!FW\>E7EP+:VU-U3R97)VKP&WA6/ 8
MJ <CU%0Q_$.TD9)?[(U1=/-\=/>^9(Q&DWF>4,C?N*EL#< 1R.^<8&C?#:XT
MM]-L3I6@M;V-PLAU,[GGFC1LJ/**[5?@ MN/3(%;7_"'ZA_PA3:-YUM]I.K?
M;MVYMFS[9Y^,XSNV\=,9[XYH J>,_'D]GX?UZ31K'4";#=;G4XTC,44XQD89
MMS $X)"D _CC<U+QE%8WU];6VDZCJ"Z<H:^FM53;!E=V/F8%VVX8A03@COQ6
M!J_A'Q*^BZ_H&E-IC6&JSS7"7-S,ZR0^:VYT*!"&^;.&W# /0XY9K/@&YEU[
M5[ZTTK1-174V619-0D='M9 @0\*K>8OR@XRO.10!T(\:VD^NV^E:?I]]?M-;
MP71N+=4\I()20KDLP.!MR1C.#P#@XNZUXBCTBZM+&*RNK_4+L.T-K;;0Q5,;
MG9G9551D#)/4@#-4M"\-3:-K\]WOMS:G3+2RC6)=A#0F3)VXPJ_., $]Z=KF
MD:G_ ,)#I^OZ,MK-=6T$MK+;74C1K+$Y1N'"MM8,@_A.03TH YWQ+XSO+W2]
M,CT6VU6VGN-5%A>")8!/;LJEFB_>-MWL,$-RN,\\C,>B>++ZWO=<O]8&LM%!
M?#3+*R*VY$DF$VJ AR92<DDD)AO;C1@\':HS6UY=3VGVZ37EU:[6-F\M%$1C
M$:$C+$ +R0,\]*@U3P#=:CINHQNUE+*^N_VM;13;C%(NQ4\N3 R,C=R,XX/-
M &I/X]LK#3]2N-3TZ_LKC3A$\]FZH\A25]B.A5BK+G/0YX(QFM6/5[J;P]/J
M1TB\MIT1V6SG\OS3MSCH^WGW85QW_" WL^DZM''IVBZ5-=FV6&"U9G"K'*LC
M%Y2@+$XX 7 _$UZ)/%Y]O+%G&]"N?3(Q0!YMIGCG6[B3PC-+IU[</J>DS32V
MD"P@S2CR2) 2V$3#.1EAUP1G KIX?&D-WI5K=V>DZE<W-Q<26WV)(T$D<D9(
M<.Q8(H!4\EN>,9K-\,>%=9TVX\-R:B;$#2-,FT]OL\KOYF3#L<948XC.1VR.
MM4KKP3K7E1JIM+RV_M6]O)[![N2".=)G+1[G52<IG[I!!S["@"QJOCZZ_LVT
MFT[2+U;E=9BTV\MI!%OC)*ED!+[265A@@D<\D5WBG*@D$$CH>U>:VG@+6=/T
M:[BM8](CN/[=AU:VMXG=(0J+&#&3LR/N'YL'/7 S@>E)N*+O #8Y .0#0 M%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %4=2OWL7L546Y^TW*P'SIQ'@$,?ER/F;C[O?GTJ]7,
M^+[6XN;CPT8())1#K,4LA12VQ!'("QQT&2.?>@#3@\1Z)=:J^EV^KV,M^A(:
MV2=3(".HVYSD=_2I]1U73M(@$VI7UM9Q,2 \\H0$@%B 3[ GZ UYGI$%]9:Y
MI=E86FH/!%J+O+INIZ;N2Q5B^Z6*Z"@'J<<L3NQ77>+].?4=7\*#[(UQ!!JO
MFS?N]RH!!+AF]!NV\GOB@#3G\5^'K9[59]<TZ-KM%DMP]R@\U6^ZR\\@]CWI
M^J>)-#T2:.+5-7L;*20;D2XG5"1TS@GI[UYOK&FWMCK7BJ&Y;5Q#JC*;>*QT
MM+E+J+RE01;RC>65(888J!G([TZ\@U:TGO=,,&H6I.EVUM$]MI@NIM1(BP1)
M.5:-=K$KS@<DYYH ]&U'Q)H>D>1_:.KV-IYXW1>=.J;QZC)Y'OTIVI>(=&T:
M.%]3U6RLUF_U1GG5-_N,GD5Y@MG=6.D:'*4UK3K[_A'[:TD=-+-[#<;5.8)8
MMI9&!)YRN0W7BM;2I;G0]8CU37]"G1;O1;6WB2PLWG2U=-_F0!4#% =RD=N,
M9XH [B^\1Z)ID22WVKV-M'(@D1I;A5#H> PR>1R.12W/B'1K/3(M2N-5LHK&
M;'E7#SJ$DSTVMG!_"N#\%>'KVQU_1)+_ $V2)(=)O#&'3(MO,N@R1YZ!A&<8
M] 1TJC:PZGI.GZ'%]AGL88KS4S]M32WNI;8-.VQ4C .T.I^]M(P!ZT =OJOC
M/2[*UTB\BN;.YTW4;HV[78N%\J-1'(Y;=R#]S&,CK3[SQ;81V.F7>ERV^H6U
M[J$5B)()@50N2"<C/(QTXKSRRL;VVL[*YOM'U6[BA\62WDBR67[TQ&!BLQC1
M0,;B#@#KQ][BM&:QO-2UV76+/3;R+3[K7M/DC22W:-V$2L))BA *J<J,L!]W
M- 'HXU337LDU 7MJ;4ML2X\U=A8MLP&Z9+?+CUXJ6^U"STRS>[O[J&UMH_OR
MS.$5?J37G=MIER/B(WAKRS_9%M=GQ I[#?D+'_W_ /,D'^Z*UOB'87UP^@WU
MLUT+:POC+<&UMQ<21@QLJR",@[MI/8$C.1TH Z6#7]'N;*&\@U6RDMIY1#%*
MLZE7D/ 0'/WO;K3I]<TFU,XN-3LX3;NJ3>9.J^6S#*ALG@D<@&O-_P"SY[G0
M?$Q2QU;4Y-:GAM[=KRT%L'E"X$^Q54QJO!+L 3L&.<54O+:71?"EKI>K:9<7
M5U:>(K:2YF$3/_:6^3<)5)^^Q& 5R<%<=,4 >HV>OZ/J%A+?V>J6<]G#GS9X
MYU*1X&3N.<#CGFET[7M(U>VEN=.U.TNX(?\ 620S*P3C/)!XXYYKS/Q+INH>
M);G6=7TBQOHK!EL%DC>T,<MX89F>1EBD +;5*@!A\VW'--O-'U'7X/$-S8R:
MQ?2R:6EMYEY9+9+<8D#F((41F.T,NXC'SXS0!W&H^/O#MGX>U+6+;5+*^BL(
MR\B6]RC$G^%>O5CP/6KL_BSP]:VUI<7.MZ=#%=KN@:2Y0"0>JG/(]ZX_Q'+'
MXET'7(M'\-7HF&B30"YGM'MW!."MNB,H+]">.!@ 9S6==_;%\2ZCJ[OK=K9:
MG8P+;>1HWVAG"JRM"ZM&S1G=DX.%.[KQ0!Z3J6O:1HZ0OJ6J6=FLYQ$9YE0/
M],GFJ_AO7EU[PY#K#QK;I(9<CS-P4([+G.!_=S^-<3HME)X4U#3;G5--U.XL
MVT**RA(MS=20.KNS1.(P<;E9!G&/DQGBNE^'%I-8^ ]/MY[*6R=6G_T:5=K1
M@S.0"/H10!-H_CG0=6\/R:T=0M+:TBGDAD:6X3"%7*KDYP-P 8#T85MV&HV6
MJV:7>GW<%W;/G;+!('4XZ\BO+M,@N;&+0;B\TG4'M]&U2_\ MD0LW8J97D,4
MR*!^\4!NJYQN]JZSP?#++K/B/5DLY[/3]0N8GMHYXC$SE8PKR[" 5W''4 G;
MGO0!/8>.-)GU2_TZ^O+.QNK>_:SABEN5#SX5"& ..I;&.>E:FH^(M%TBYBMM
M1U:RM)YN8XYYU1F&<9 )Z9XKSJ^C*:?XZT=_#^H2ZAK%Y*+-ULG:.?=&BHWF
M8VJ$;)RQ&.HS4.H:9JFF:UXA34+C5V74885B-EI:W:W:B%4,98HVP[@W#$#Y
ML^M 'JFI:C;:5IEQJ%W*D=O!&7=W8*,#W/'/2N:T'QYI]YX8M=;UN_T?3H[P
MY@5+\. -H.UB0OSC)# 9QZUHVMA-:> HM/99FGBTT0[9"'D+"/&"1P6[<=37
M':)'+X<O-!U+5=,OGMCX;M;)6ALY)GMIEYD1D12RE@5YQU3!H ZW5/%$5GJ&
MGVT$4=W!>V5S=K,DHVXB5" , @AM_7V[TZ#QAI$?A[2=5U:_L],_M&VCG2.X
MN%7[RAB 3C.,]<5PVFZ'JD!TIFTRY@A:WUJ2.W\LG[,DSHT4;8X4D=%^H[59
M\/K+X:NM/OM9TJ_EAG\/65I"\-E).T$D:MYD+*JEE+%E/( .,$\4 >C+J=@[
MLJ7MNS+"+@@2J<1'.'Z_=.#STX-)'JFGS):O'?6SK=J7MRLJD3*!DE>?F&.>
M*\GE\-ZY9>&M%%MI]Q'/J*W.E7,*+EK2VN9B\9;'W1&N1[;L4Y?">MW5AXET
MF&TEACTNQN;#1V?Y1,L\C2':3QQ&(H\_6@#T_3?$.BZS-+%IFJV5Y)#S(EO.
MKE1TR0#T]ZRCXXTF?Q!I>DZ9>6=^]W-+%,8+E6,&R-GR0,YR4([?I7$+I5_K
MLD45C/KAN;?2KJ",W6FI91VK21;%B+>6N_YMI 4D#;FM*P>._P!?\#QVOA_4
M+5M+66.Z>6Q>)+;-LR^7N( 8%@.5)' YY% '7:]XHM?#VIZ3!>M##;7SRK)<
MS2A%A"1E\G/!R1CJ.M7[76]*ODM7M-2M)UNRPMS',K>:5&6"X/) ZXZ5S?C,
M>3XD\*ZA+IMU>VEG<3O,;>W:8PYB(5RJ@G@D=.?3I7/75A<#2?$'BNWLYK2.
MVU5-7L8)HS$[)%$JS,4."OF*)>#@G()ZT >G175O/-/#%/')+ P69%8$QD@$
M!AV."#SV-4)_$^@VVJ+I<^LV$=^S!1;/<*'W'H,9SD]A5'P19S0>'%O;Q"E]
MJDKZA<J>JM(<A?\ @*;%_P" UYSXB36+W2M<LTLM0@N&U)I1IMEI!\N11,")
MFG*D.2HW?*0<\ <4 >QW5Y;6-N;B[N(K>$%5,DKA5!8A0,GU) 'N:Q_^$V\*
M_9C<_P#"1Z5Y D\KS/M:8W]<9SZ<U4^(=A)J?@V:TBM7N3)=6>Z)$+ED%S$6
MX'8*"3[ UG7.BE_%_BNY_LXLD^B0012>3Q(W[[<BG')QLR/]WVH ZC4O$&C:
M/'"^I:K96:3?ZHSSJF_W&3R*+[Q%HNEQQ27^K6-LDJAXVFG50ZD@9&3R,D<^
M]>86UAJNDWFF7UY+JUG#+X>L[5'M=,%VR.BGS(74HS(22#T /()XK5\+^');
M76_# NM.NO(M='N\&\C4F%WFC*HQ4;5;:6 4= ".U ';3>*= M]0?3YM;T^.
M\3 :![E ZDXP",]>1Q[T^X\1:+:ZI'I=QJUE%?R8"VSSJ)"3T&W.>>WK7EFJ
M-_9W@230[W1[N34$UA)6O/LY,+EKP,)A+T)(8+C.[)QC I-0T?443Q+H]X^M
MM+J.HS2Q6]IIJ21W*.P,;"X*$(5&!\S#;MX[4 >KOKVD1ZHFEOJ=FNH.Q5;4
MS+YA(4-C;G.=I!^AI=4UO2M$CCDU74K2R21MJ&XF5-Q]LGFL#PUI3V_C#Q5>
MW%HP>6>V$5S)'S(JVZ E6QR,[AQWS46LL=)\?P:U>V-W<Z?)IC6D<EM:O<&&
M7S-Q!5 6 =2HSC'RX- %_2O&&FW7AH:WJ$]KIUJ;F:!6EG&QBDKH"&.,EMN<
M>_>M&;Q'HEOI4>JRZO8II\IQ'<F=?+<^@;.">#P/2O*K/2-3LM.\,:A]EU+2
M[.SN=2#QP6(GEM#+.3&QB*L2-H(RH.,CL:MQZ5)!I\6ID>([=GU::YAU!+%#
M)"6B"&1K58R?+?!XVY!Y.,T >F2>(-&BTA=6?5;)=.?[MT9U\MNW#9P>:@?Q
M-X>AL$U-]8TY+2<'9<FX0+)MZX;/.*X*QCU.+^PM9U/29)+&QU*[:0VVG-')
M()$Q'=-;C+!MV[/&?FSBKZ62:QXHT"_B\-S6E@-2O)V,T!'F$P8$SH0/++-P
M W/ />@#9O/'%O8BTFF:P-E<:FUE]I2]5DCC$+2B1CC /R_=)Z$'-;MOKVD7
M6EOJD&IV<EA'G?<K,IC3'7+9P,>]>;WFGW%I=)<W&BWES;0^+Y+MHXK5G(A^
MS$"4*!RH;!&.I&!DX%1:UI6I:S_;.LZ;97T&G2ZI8W'D_9<33I"I$DJPN.>2
MA 89;R^G2@#TRS\0:-J&GRW]GJMG/9PY\V>.=2D>!D[CG XYYK-TOQAI^M>)
M7TS3)[:\MULA=&Z@G#C=YA39@?0'KWZ5P5WI%]JW]JZG;KK&IQ@V)G%U8K:_
M;8XI_,=%BV(S$+D9(YSM&:ZC1)DU3XE76K6FEWMO:-I*0&YN+-X!+()2<8<
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M)I!N9-V < #<1SU-7O\ B8M&FE-J0BM/^$BMK<16&I33M;JT3&2'SF53@\'
M)*[L<8% 'L54EU2U;6I-(#M]LCMUN67:<>6S,H.>G53Q7F6J/-H4_B+2+2^O
M+;2$OM,660W+LUK#,V)BKL2R@X'.>,DC%5==:/PYJWBQ_#-Y*TL&A6YYN6F-
MMF9]Q#,6*X0E\<XSG'- 'LE%>0QF^TR:[2UNK.VAFT2ZFD@@UJ>^>7:@V3@N
M@"$$XW9&[=WQ7=^"-+BT_P ,64ZS74]Q>6\4]Q+<7#REY"@R1N)"_08% '1U
MQ.IZYX9M_$USJ=U%J,UWI"K;F5(Y7@CE?: B*/E,S"51P,X/7%<I'<X\&V_B
M0:I='Q8^HK&T7VM^93<;&MO)SMVA<C;MX W>]5=0\.Z<UOX@E*W.Y?%UI"/]
M,FQM8VN>-V,_,>>HXP>!@ ]EM+@7=I#<"*6(2H'\N9-CKGLP/0^U35XQJCZC
M/>^*GDG@MVTJ7R;2>XUN>V:RB6-3&XB5&#Y)W9))<Y':NFT*REUGQWJ%SJEW
M<R2V%I82Q10W$D<*RNCEVV C(.WHPZ9XH ]!HJ*WN8+RW2XMIHYX7&4DB<,K
M#V(X-2T %%%% !1110 4444 %%%% !1110 55N]/MKZ:TEN$+FUE\Z($G ?!
M4$CO@$XST//6K5% $<<$,4DLD<2(\K!I&50"Y  !)[\ #\*DHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ IKHDB,CJ&1AAE89!'H:=10!0T_0](TEY'TW2[
M*S>3[[6UND9;Z[0,TL>BZ5%J3ZE'IMFE^_WKE8%$K?5L9J]10!%]F@^U&Z\B
M/[04\LR[!OV9SMSUQGG%5FT32GU,:FVF637Z]+HP*91_P/&?UJ]10!%';00^
M;Y4,:>:Q>3:@&]B,$GU. .?:JUAHNE:4\K:=IMG9M*<R&W@6,O\ 7 &:O44
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MUI5Y8/?VVIV4UDAPUQ'.K1J?=@<"@"]168VOZ:]M?R6=]9W<MBC--%%<(2A
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** //;C6[?3?BCJMYJ%MJ.R#3H+.U-OI\\XD+,TDF"B$=
MXQU[>U9FKPZG=Q:MXAO-)>&VU6:UL%@N;9IGMK-"S&:2)#DDLWW>PQGN*[JY
M\)Z9=W4EQ+)J8DD8LPCU6ZC7)]%60 #V J'_ (0O2/\ GKJ__@YO/_CM 'F^
MH6]_=6OC.]6.]N(SI=MI]O*=-,!E21VWNL84$A <]">#VQ6EJB2:?XNN;U3=
M06ATV"+24BTAKH2)AB\:C'R.6QD-C(QGI7;?\(7I'_/75_\ P<WG_P =H_X0
MO2/^>NK_ /@YO/\ X[0 S1=*O=&^'\.G6I<7T5DXA67;E)""54XX^4D#CCBN
M0TNW@OM,\(Z/I>F7<5Y87,-WJ$\]H\1MRBDR[G8#<[L2O!.=Q/2NR_X0O2/^
M>NK_ /@YO/\ X[1_PA>D?\]=7_\ !S>?_': *O@"S:V\,M?7%L;>YU"ZN+R5
M'CVLH>5BH(ZC";1BN9?P_P"(O%JZYKHN;6RBU.TEL+6SO;!WECM1N'7S%V-(
M?F(*G'R^F*[#_A"](_YZZO\ ^#F\_P#CM'_"%Z1_SUU?_P '-Y_\=H X[2[Y
MH]4T34M?TR^D7_A'H8[2,6;R[;DD^>N #M<@1C)QQGGK5+PY8)H47A6\UC3;
MB+3!:W5TL:VSR"WNY90Z[T4$@B,LJDCCD=:[[_A"](_YZZO_ .#F\_\ CM'_
M  A>D?\ /75__!S>?_': /.YPD6HZ8NIZ7<1Z9J&N7.LFS^SLS0P1Q+&C/&
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOY9+E%-V+)H3;/YR3D9$9CQNR1TXYR,9S51OB3H4<=P\L6IQFT?;>JUC(#:
MX(:7CY0000?3GL:Q[3PA?A+2Y72Q9N==@O98I;^2YE$,<94-)([L"_LIP!@<
MXJYJ_AC4[NQ\?Q0PH7UE%%GEP-^+9(^?3Y@>M &M?^.M'T_4+ZR=;V633PK7
MC06CR) C*'#,P&,8.>/0^AJ'_A+H;;7M;^VW4*:/8Z?:74<RC.?-,H)R/O9V
MK@#U]ZYZ&77$\2>-K#3-'CO//:WB$K7"QB)S:1C+@\E>A^7)Z\43> =4BM;N
MUM7B?R=/TJ.TDE?"S2VDC.58<D _*,^_M0!TO_">:-'!>2727UF]I"+B6&ZM
M'CD\DL%\P*1RH)Y(Z=\5I:AXDTK2[IX+RZ$1CM'O9&()5(5(!8GW)X'4X..E
M<\=,O=?U_P#M37]-33--@TV>R,,UPCM-YQ3>25)4( F!DY)/05S6A>%M0\3?
M#_6OM%W'+>7:)865P6(62"U;$;9'(#NKL2.S9H [RP\8:5>RRQ2"ZL9([<W6
MV^MV@+0CK(NX<@9&>XR,@5DQ^.H]1\4^']/T^*ZCMK_SW9KJT>+SHUC+*\98
M#(SCWP1QR*QE\$W6LF[CGTBXTL/IMQ:K<7NL37KB250O[L&1E"<<DC)XX%:E
MK:>)-0\0^&I[_18K*WTI9EN)1<H^]FB* Q@<[,^N#R..* -#Q+XHDT#Q-H-F
M8Y9;>^2YWQ00-+*[H$*A0/\ >8GM@5=LO%^D7[6"0RRJ][-+;HDD3(R31@L\
M;@CY6 !X/7'%4O$MGJX\4:#K&F:<M]%91W27$7G+&^)!&!LW<$_*>I P#S7-
MZSIESI/@S6=;U$P6FK-J?]LVMOYH;9(@14B!'WF94VG'=SUH ]!L=5M=2FO8
M[5F<V<YMY6VD#S H8@'OC<,^^1VKA&^)%PUE#>-:36\:^(#ITBM:2%GB_> !
M1U,F4&0.A.,5UWA+29=&\,VEM<G=>N#/=O\ WIY"7D/_ 'TQ_#%<K!X;UL7*
M6\EBBPV_B=]46?SE(DA<RG('4%=R@@^O% '11>-M&?3KZ]F>XM182+'<P7-N
MZ3(S8V#9C)+9&,9SFK>D>([+6;B>UBCNK:[@57DMKN!HI C9VL >JG!&1W&*
MY+Q)X,U/5[[7KF%%(EN;"ZM4^T&+SO(!WIO7YD)S@-V.#6AX3T">TUZZU2;1
MY]/4VRV\9O-3EO)W^;<W)D9%3@8 YSGITH M:KJNK7_BD^'=$G@LS!:K=7E[
M-#YI0.Q5$1,@;CM8DG@ =*=;ZMJ?AZTU"3Q7-!):6S1_9K^WCVM<[^-AB!8[
MPV!Q][(QWJ/5=.U?2_%I\1:-8IJ$=U:K:WEGYRQ/\C,R2(6^4_>8$$CM6;J.
ME>+=>@DU"ZBM[9[6]MKJPTEI58?NF);S)0/O/GC&0N![F@#:'CG1DLM0N+K[
M79MI\2S7,%U;M'*L9. X4CE20>1GI5?_ (6%HYGDMEM=6:Z6,3);#3I?,EB.
M?WBKC[G'4XYP.I%87B#P[K_BI-:OI-,6QEETK^S[6UDN$=Y"9 [,Q4E0.  ,
MGOTKJ?[*NO\ A8']K[%^Q_V5]EW;AGS/-W8QUZ=Z (I?'6BK_9XMS=7DFHVW
MVJUCM;9Y&DCXR< <8SSG'YT]O&VCFRL;FW:YNVOMX@M[>W=YF*'$F4QE=IX.
M[&#Q7$Z);:UX8UWPU8KI0O;RW\/S1W$$<Z*RCSH^59CM/..,CCZ8-L>&O$UJ
MEHTD5S-:W5Q=WE]9:7?BV=)I9 R#S"5+(JY!P1DG/- '3MX\T-=.M+S?=$75
MR]I'"+5S+YZ!MT93&X-\I'2I;3QIH]W'"VZXA>2^&GM%/ R/%.5W!'!Z9&,'
MH<CUKEO#_@_6;&;2&N;2.);;7;N^D47)FVQ20NJ_,WS,=S $GGC-6->T-H-)
M\;75_/#9I<W$=[8W#R ;9(H(RC>Q#Q].I H [6UU2UO-1OK&!V::Q*+/\IPK
M.NX#/<XP3Z9%9%[XYT6QO+B&5KIH;600W5W';.T%NYQ\KR 8&,C/89YQ1X'L
MKFW\-1WE^FS4-3D:_NE_NO)R%_X"NU/^ USUWH7B*#1_$7ANTTR&XM]7N+EX
MM0:X54B2X)+>8A^8LNYL;0<X'(H ZF'Q9IMQXCFT*W2[FNX'V3M';.8H24#K
MN?&T9!XYY((J35O$MEI%Y%9/#>75Y+&95M[.W:5Q&#@L0.@R0.>IZ52\+Z'<
MZ-J>OO,H\FZN86MWW ET2WBCR?3YD:J'BC3=<O/$<$D4%]=Z/]EV"WL=1^QL
ML^XY:1@RLR%<#@G&#P<T 7Y/'>AK::9/$]U<?VFLC6D4%L[R2&,@.NT#(()Y
MSC&#Z5JZ+K5EK^G_ &RQ:38)&B=)8S&\;J<,K*>00:XOPIX2U?2G\*_;+>)/
M[-&I+<%)MX'G2AH]I/)!'KSZUTOA;2[K2UUD72*OVK5;BYBPP.8W(P?;ITH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM:+)N4X<I$>653G)R"<' -2ZEXZN[6[UQ++0)+RVT4*]U.+I4!0Q++E 1\S
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M>;96\=B9U93--'D(F0 H')8GT)]JLWGC6YTJRE;5M#FM;W[3%;6\0G5HKEY
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<@XZ\UK:MXITC1+E;:]N)//:/S3%!;R3,D><;V"*=JY[G X-/_X2?1?-$?\
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M'RR1DDXSR*QW^'UQ;36MU9?V/=3C3H+&X34[/S4)B7"R(<Y4\D%>AXZ8K?\
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M:>'M,@>4R6<(&J[8F$;VZ%)(U9B,',B+@ ]"]==XIT67Q#X9OM*ANOLLEP@
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M3'\I.[=COC&:YRYT+6)-5O[;^RIFA?Q-:ZHESOC\MH0(@W\6[<NPY&/3&:]
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MU-J"S%X[F.33IXRZEI)$<[E<J#D*H.X @GK7HUQ>V]M;7%Q)*OEVZ%Y<')4
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MF*3+!&#MDSG ,A;)S_=&:U+^QUG3)?%5M;Z'/J:ZX@>WFCDC"HQ@6(I+N8$
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M[6SLXAND<_=CC08&3SZ#@DU5T_Q89M8@TK5-&OM)N[I&>U%RT;I.%&6 :-F
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M8W._Y-NWY=^S=G';;FLSQA!I=OXXUN6>"U2]NO"\OV:1HU#R2*)0^TXR6$>
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MM9U#PK9ZC:-<:.9]5:R@NE)#6H9/)#!N2N,%0>P7T%>PHBQQK&BA44 *H&
M.U.HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *YKQIJ,EE864$%[=VT]W=+$B6,"RW$XVLS
M)'N^5#@9+'@ 'N0:Z6L_5]$T_7;>.#4;<RK%()8V61HWC<9 964AE.">0>]
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M>)I 5=NO<,1Z<T ><6_B+5Q>:!J4%_K5U:ZAJ<=N]S<100V<\4A; BBSY@X
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M[R*7\R8RE=W8  8^4YYJO_;UZEX=9U&ZAT^_/A:,R3PHMRJ2F<J"BJ2'R2,
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M9L65C*!D;?NAANQZL>V -[POXFNO%FLVDT#M#9VFFJ][" .;N0X\L_[@1_\
MOL5NS^'K*&XBU*PLH?[4L[0VUHSRNB[0#M1\9RN3W!(R2.:A\)>'VT#3;G[0
M+?[=?7<M[=FW!$?F2-G"YYP!@9/7&>] &;?MJ&M^-[O18]6N],M;*PBN%^R;
M \TDCR#<2RGY5"#@=2>:YV37-=U76_[+M[W4M0@L].@E-UH1M8_M$KEP9#YK
MXVC9@*N1G.>PKO=7\,Z1KLT<VH6A>:-#&LL<KQ/L/52R$$J?0\5#>^#M U!+
M99M/5/LT/D0FWD> K%_<RA!*_P"R>* .-77M8U2RT2UNKK4SJ4EG)-<V>B+
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M,42JQ,;%0 <%,@XSAAFN8>UOAJ/Q U2SU^YL'L;D31Q1!-F];2)MT@9264X
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M<5Y T+.GWER,9&: .'AO?%,7C'Q"+*/3I9HM.LI9O/ED$88";Y4 &?FYY/3
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M\\%E5 N?K@5S=CX$NM+@T]K#Q!-%?6-K]A6X:V1A); @HCIT)7'# @\G.<T
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MK^&TCU_PUX<LKV*436$=CJT0/SM;6Q2178#IGYDY[2UT6H>&]0N#XY,:1_\
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M'U]90P:.^CQW,45V'_M";59_):$2;P?LZN/WF,#'W=PSGM0!ZO1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5S_B[Q3!X5TV&=TAEN+F=+>"&6X6%
M69B!DL<X49R3@XKH*Y3QU9&\M]# MO/V:S:,P$>[:F_YB?08ZT ;,>N6"26E
MK>7UC;ZA<1JPM?M2EB2.BYP6&>AQS4[ZKIT5ZEE)?VJ7;MM6!IE#L<9P%SDG
M!!^AKR[48+:WT7QAHU]I%Q/KVH7=P]ELLV<SA_\ CW9) , (-HZC;L-:,?AZ
M]N+OQS*MLK:U)9P0VEVZ8)E^R!<HYZ?,3R* ._M-7TR_N9K>SU&TN9X>)8H9
MU=H_]X Y'XTQ-<TF2\>SCU2R>Z1PCPK<(75CT!7.0?:O+- L);J^\/PV-U=)
M=V-O(IC31OLHM,Q%2DTA(R-Q' SD@'WIL#:?!I_@/2SHMS;:Q8ZE;QW3R6;)
MY<@1A(?-(P^]@6X)SU[4 >K_ -L:9_:7]F_VC:?;\9^R^>OFXZ_<SG]*@@UN
MW$5Q)?2VMFL5Q+"I>Z1@X3DG/8X!)4\C'->8_9E_X0X>'?[,N?\ A+AJ7F>9
M]D?=YOVC?]H\[&-NSG=GI\OM5V#1WNM;TY+O3WEMQXLOYV$D1*[?*D*,<C&-
MV,'IG% 'I,>K:;-IQU&+4+1[$ DW*S*8P!U^;.*=9:GI^I)OL+ZVNEVALP2J
MXP<@'@]#@_D:\RU#2I;?4]6D&F32:1;>);>\N+:&W+"2+[*@+J@'S@2%6( /
MW3Z5L^#+BPN_B!XMN=.LY+:"2"Q)\RW:$RMB7+[6 (STR0,XS[T =A?:UI6F
M31PW^IV5I++_ *M)[A8V?Z GFB]UG2M-S]NU*SM<!2?/G5/O9V]3WP<>N#Z5
MYGXN>>XUCQ3:"U6UDEMUCB1-*>ZFU$>5P5D.41025P!Q@DD5I>%]'CO/$EM<
MZCIWF@>%["$/<0Y 8M+O7YAUZ9'6@#O+S5M.T^WCN+W4+6VAE($<DTRHKD],
M$G!JKX?UR/7M(;41%Y"+//#@ON'[J5H]V>.#MS^->;^&HET>/PS?>(+&X:P7
M0S:1%[5YA;S>9EE90I*EDV@''.W%=?\ #2V%MX)CA%E+9Q_:[LQVTT91HT-Q
M(5!4]/E(H (/B)I%W%IL]N\;6]Y?3V;R/.@$'EK*V]L$C!$61R.&!KI(=5TZ
MYT\W\%_:RV0!)N$F5HP!U^8'%>6:5ID-ROAW39],<M9^)+Q[N*2U8*H(N7C8
MDC!'*8(R.E'B'1KU9O$"V=K)%I\?B&SNYDCM#*K1"W3>XB'^L ?:Q S]T^E
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M@##D@D84<\9[5Q^O:3(/^$W-OI[ R:CIAA\N'[RC[.6VX'(!!SCT-2-97?\
M:SM]EGV_\)JLV?+./+^R@;_]W/&>E 'H*ZWI+ZD=-75+)K\=;87"&4?\!SG]
M*IZ3XLTC6%U1X+N%8]-N&@G=Y5P-H'S\'A3R 3Z&O*D:ZNX]"*VAM9H=<@FG
MTVVTF139CS_F:6=\ECSR1C.?0&KFJV%PUIK-I!:SQ&W\3K>W:K8M*&M2/E<+
MC$JAL,5&?NGB@#T6XU73DM#K6BP66IRSS0VSS6LJ$N&=5Y=0<[0V<>W:M#1-
M0FU71[:]N+0VDLH),)??MY(&&P,@@9SCO7)>!H/,\0ZSJ,5U<7,$T4,;3?V?
M]DAE==W*J3EF (!;&.@R<5U^LO+'H>H20VK7<JVTA2W4D&5MIP@(Z9Z?C0 V
MTUO2;^[DM+/5+*XN8_OPPW".Z?50<BL_PUXNTWQ)I]I+'<6T-[<1>:;'[0K2
MH,GJ.N..N*\\T$33>*/!<T0#0VYE26.UTA[:*SW6[@1L[Y9CG Y/;)Y(J/P]
M!;3>%O"FD6&D7-OKMMJ,-S,SV;QF)!(6ED:0J!ADR.O.X#MP >LG6-,&I#33
MJ-H+\C(M3.OFXZ_<SG]*E^WV?V1KO[7!]F4E6F\P; 0=I!;..O'UKR66V4>#
MKGP\=,N3XN?46D606C[C*;C>MP)L8VA,'=G@#;[5L7&CWQ\:OX;6UE.AW5^F
MN23;?W8"\O"3TR9U1\>C&@#OI-7TR+44TZ34;1+YQE+9IU$C?1<Y-7*\0O=,
MNQ'KNEWT]VNHW>J22QPP:/YLLP:3,4L<Y(4!5V\DC9M(XQ7L5KJ5O<:C=Z<C
M.;FS6-I@T948<$J0>A^Z>G3% $:ZJBW][!<^1!#;F)5E:X7+E^@*]5YP!GKG
MBIK'5-/U1'?3[^UNTC;:[6\RR!3Z'!.#7F_BK2Y[W4/%4364LT%Q>:,,>62)
M$$J[_J ,Y]*Z:PT];+XGW[VUH(+671[?<T<>U&=991VX)"X_#% '0W^K:;I8
MC.H:A:68D.U#<3+'N/H,D9I+W6-+TUH5OM2L[4S<1">=4W_[N3S^%<=JCV.E
M^.]4O?$%C+<6=WIT,-E(+1KA1M,GFQ853AF+*<?Q?A63IO\ 9NC:CJ4FO^'[
MJ&VO;"U2PMWM7NBD*Q;6M@0&PP;)*G&=P]* /1[W6-,TT$W^HVEJ  Q,\ZIP
M3@'D]R#27>M:586\-Q>:G9VT$V/*DFG5%D_W23@_A7GW@[P]<QZ]HJZY8&2:
MV\-I%FX3>(V,Q^3)XW!< _C6-:67V#1M!FEDO-*N8;:[@2:;3#=VQ0W!(A=,
M;E) 4@C&1QD]* /3KCQ1I=MXBL-$>XC^TWL#SQ'S%V[5*@#KDEMW&.NUO2K"
M:MHE_-'&FH:?<RHZ%%69'*NRDJ0,\$KDCU&:X#2EDAU7P7>7^B_8-^F75J(X
M;9RD4A>+RQC!,>54D!NF2,U5T[2H]$^'7@>^&F/";2\MKG4#%;$RJOERJ6=0
M-QPTG/IDT >E:AJJ6D9\CR)YDGABDB:X6,H'8#))[X.0.K=!UIS:YI*WD=FV
MJ60NI&*)";A-[,#@@+G)(((Q7FE\TVL7GB"^M+*\^SSZQH[PM);NAD1)(PS@
M$ [1@\XZ#/2G7FA#_A"/%<RZ83?R:]+/&_D?O6Q<KM93C.,=".V: /1M1U+1
M(V;3M3O=/5IHR3;7,J NF.3M8\C@TW5]7L/#?ANYU2;:MC9P&0+%M&5 X5>0
M,G@ >XKS3Q.+33M#\>VNLZ3<W%_>M-<6LXLWD62+RAY9$H!51&5.02,8SWY[
M/Q+:2WWPIU*UA@:>:32'6.)5W,S>5P /7/2@"9/'&D?VLUK/=VEO:_8H;M+R
M6Z18W\QW4(">,CRSW_E6W>:KIVGVJ75[?VMM;/C;--,J(V>F"3@UQ&AV&GZO
MXW_M Z<LEH= MXH7GM2H!\V7>N& P>!D?XURFGV.H6%MX3O+Z2:RLH-)DMDE
METYKH03>9T9.J%D  ;'\..] 'M44L<\22Q2+)&X#*Z'(8'H0>]4TUO29;U+*
M/5+)[I\[8%N$+M@D'"YR<$$?@:Q/A[9M9>%@O^E"*2YFEA6XMQ 51G)&V/)V
M*>2 <$ ]!7 6#6-]X0FTC3M.G_X2"77998I5M&X9;PGSO-Q@*J*03GL5[T >
MNC5M-:\-F-0M#= ,3 )EWX7[WRYSQW]*CM]>T>[@FGMM6L9H8"!+)'<(RQD]
MF(.!^->=77AR6X\,>-Y+?2V?4+C5Y6!$>)9H T9=$)Y(9 X '!R?6K<MCI7B
M[Q-;1:382PZ;_95S::C+]D:W4K)L$<7S*,LI#-C^'\: .\U74H]-LIY08'N%
MADEB@EG6+S-@R?F;@#ID]!GFFOK>F07%O:W6HV<%Y.H,=O)<(';/]T9R?PKS
M$6FM:SX3\47^K6<XOK'19=&@0H<S2*A,TJCJ0[; ".NVH?$,#6EYJC6T,TEW
M<Q0,VEWVE-<1:@RQ(%\J5/F3I@Y/RD$X .: /5(]47[5J27(@@@LF4><UPIR
M"@8EA_!C..>HYZ&GV^L:7=V9O+;4K.:U#!#/'.K)N)  W XSD@8]Z\VUJQO)
M=8UN[N-.N);!-:TZYO($B,GF0+;H&PH'[P*^TD#/W353Q':1Z])K]YH^G3G2
M+B'3X)<6S1K=3+=@LP4@%ML9P6Q[=J /5+36-,OXII;/4;2YC@.)7AG5Q'_O
M$'C\:=8:KIVJQO)IU_:WB(=K-;S+(%/H2I.*X'Q-HEO_ ,)!K<4>EW1L;CPZ
ML<J:=" [D3-@*/NLP4].XXP>E3^!IKB3Q-> >3J%K]B0?VJNF-92;@QQ"X.%
M<@$G*@8Z'J* .NUJXT%(([?7IM-6*5ODCOF0*[#T#]365J/BBVT;Q#I'AK3K
M6R>:Z0N4-TL"P1 J.%P=S'=\J@#.#S61?R6&E>.=;N_$-A+<6U[9P1V4OV-[
MA2BAA)"-JG#%CG'&<CTJCX1T6]L]9\)?VA8NDL&BW2L9$W&',T)C1F[,$XQ[
M&@#T6^U&QTRW^T:A>6]I!G'F7$JQKGTR2!49UG2Q9QW9U*S%M*"8YC.NQP!D
MD-G!P ?RKD_'-Q)#KNB9A@@B"3G^TIK&2[$#84!%12 &89^9O[I ZURGAS2)
M;J]T2*\T^>2W3Q'?3%;BS\H;3 S(YCQA 6(('8^] 'K-OJNG7<4$MM?VLT=P
MQ6%XYE82D DA2#R0 >GI4Z3PR320I+&TL6/,0,"R9Z9';->9W>C3P6'B^ZLK
M0PS:;K2:I8H$V*Y2")G"]L,/,4X[L:ZCP+$]QI$^NSHRW&MW#7N&'*Q$!85_
M"-4_$F@!WB7QG;>&M4TVSEMGF%T=T\BL +6+>D?F-[;Y%'YGM70FZMUF>$SQ
M"5$\QD+C<J<C<1V'!Y]C7F\GAS6O&.H>)K_[=;V-E?;M+BBNM/:5S;QY!=3Y
MB[=SL[#CLIK+OSKUWH6D77V.Y_M>XAF\-:BRQG*EF 6?_=&QFW=/WE 'K*7U
MG(L#)=P,MP"82L@(E &<KZ\<\5!9ZYI&HR2QV6J65S)",RK!<(Y0?[0!X_&O
M+[/2]1LHM?M#HTUW:^'+&ZM=.MW# 70G<N I')VQ!$XYY('--L%FN/%6C30/
M]I@33KN%GM=(>TABS&I6,%LEC\IX)XP.YH ]/_X2#1?(FG_MC3_)@VF:3[2F
MV/<,KN.>,CIGK4.A^(8-=N=4CME4Q6-RL"S)('68&)) P([?/COTKS^PT>VT
M;P]\/[^YTDK86T ?452U+,DS0?))(@&3M8N,D':7SQ71_#](/M?BF>SL9;.R
MN-5\V!9(&BWJ8(LN%('!;<?QH ZK^U=.^W"Q^WVOVLD@0><OF$@ D;<YX!!/
ML:J2^(],.FZC=V-[:WQL87EECMYU<C:I.#@G'3O7"WOAVYO=+^(LME8XU:YN
MG2UF,>)'3[/$-J,>QRXX/4FLR*T%_+YEC-=SFUT>[B:.'1?L:Q*T6%BD)().
M[!"@'E3TZT >EQ^)=+32=/O]0OK33Q>PI+&ES<*GWE!P"2,XS3;GQ3IEMXBL
M=$:XC-U>6[W$1\Q0"JE0!USEMW''.T^E>>M)-%<V=O/:K8D:':1),VE27DUW
M\IW1)_ FT]0022V3P*7PO;O8OX"EO[*=&&C7%F6:V9C'-NBVJQ ^7A6P3@<&
M@#T.W\1V"Z1;7VIW=CI[30K*R27D;*H/H^<,,\9'!JW<ZOIEG91WMUJ-I!:R
M8V3RSJJ-GIAB<'->;^!]$\S4/"S:AII86_A@)^_AXCD\Q<CD<-C/OC-5O#UK
M_8TFAWVL:;<OI5O%J-M$JVCS?996NR5)15) :,;0V.G'>@#UFWNK>[C,EM/%
M,@)4M&X89'49%9&D^+='UBWU&X@O(4AT^X>"9WE3 VG&\D'A3S@GKBL7X8>1
M_P (_J7V:U>TM_[8O/+@=-AC7S#A2O\ #CICMTKEFM5A:YCGTV=[6Q\4R7FH
M0+:.=UNPD\J0 +^\56*MA<XQG% 'J]E?V>I6PN;"[@NH"<"6"0.I/U!Q7-ZM
MX_TS3CKT40%Q=:-%')+")5!?<<$+U/RY&>."0*K^%1'=^,=>U73+:2#1[B"W
MC5FA:);B==^]U5@#PI12V.<=\5S/B^SS=>/;06,S7%_96KVY2V8B55X?# 8S
MG&1G/Y4 >GV>JZ=J,DT=C?VMT\)VRK!,KF,^C '@_6FVNJZ7J<D]O9W]G=O%
M\LT<,RR%.V& )Q^-<)XJT"Y&N74'A^R%M)-X8O+>-H(]BE]\>Q,C@'EL>G-4
M/"MJMQXE\/-;3W3-802++$FC?9%MT,>WRY7)&?FQA1GE<].: /0O^)!X:C<_
M\2S2HY 9&_U< 8 @%CTS@L.?<>M6I-5TZ'3QJ$M_:I9$ BY:91&0>AW9Q7&>
M,KK3;+XA>$[G5+=I8([:_*LL#2B)OW #D*"<=1G'&17.D3V=I;3+IJVNF76N
M75U:7%W823+8QF/"MY"D$%VWE=W"[LXR10!ZI;ZMIUW%!+;:A:S1W#%(7CF5
MA(P!)"D'DX!Z>E+/JFGVKNEQ?6T3)C<))E4KD%AG)XX5C] ?2O*M/TV\D\.>
M*;R*.<WEAJZ:M8M+:&V\XI%&253 P' =?^!<\YJTNEMK=EX>UJ[LFF.L>(UU
M&2-X]WEP""58 WL$6/KQECZT >B)XBT21;9DUC3V6Z8K;D72$2G.,)S\Q^E3
M7>KZ987,-M>:C:6\\W^JBFG5&D_W03D_A7F.L>'HQH/Q&>'21]HDO%:V*6_S
M,!#"P*<?WRQX[YJOK]E/!K_BR/4YID&HE?LR+HYNS=0^4JA(W_A8,&&TXP3N
M[YH ]4O-;TG3GV7VIV5JV0N)[A4.3T')[U5?Q-IJ>*H?#QG3[;+:FY7YUP0"
M %QG)8@DXQT!-<=HWAY7U;Q!_:=B]S*NBV-NLMW"&9SY4@<9Y&XD+NP3SBH?
M"L+66N>#IKZTF1YO#*6PD:W8XG'EDJS8^5MH;[V/2@#T:^U&QTNW^T:A>V]I
M#G;YEQ*L:Y],D@5@^)_&=IH%KIKVQM+R?4IQ%;*]XL,9&TL7+X.% 7&0#R0.
M]4/$GDV/CK2M6U:VDFTF.QFA200-,MO<,Z'<RJ"1N4$!L=L=ZYW3](DD?19Q
MI<L=A+XHGN+6&2W*F*V:"7!*$912^6 ('WA0!ZLA8HI=0K$<@'.#]:=110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 53U#5++2XTDO9Q$C;L$@G[J,['CH JDYJY5'4M'T[
M6(TCU&TBN4CW;1(,XW*4;\U9A^- %R-Q)&KKG# $9&#^1IU>:WNG2WNM>+X1
MJFJ6UMI5I ;&"TO'A2%O()W *1G[HX.1UXYI-&GG\6ZG%!K.JWUM'#H=E>11
MVET]MYKRJQDF)0@MM*J,?='IS0!Z40&!! (/!!KG-/\ !&DZ;=VDT<E[+'9$
MM9VT]T\D5L2",HI/8$@9S@'C%<9H%SJ'BJ^\.VNH:OJ'V:33+V24VUPT!NA'
M<)'&[%"#RI#9&,Y]"12Z5>7VI2:!H5_JM]]B>\U.&2=;EHYK@V\NV*-I5(;[
MNXG!!.SZT >K45Y58:E=VLUO NMWEU;Q^,39>;+<%B8?LQQ$S9Y ; P>I&>M
M3:OKTAUCQ+9C4-0=7U.QLK:&QF"N7:(,T2NQ CS@[F!!'/>@#M/%4&DRZ(9=
M9FE@MK>:.1)X6=9(I-P5&4KR#EL?B<\5G6MSX=\(VVI737-Y),;N."ZGG66>
M>:8JNQ%XR_#  (,#GWK@+ZYO8].\9:3<&>."U_LR6.UGU!KUH&>?YAYC<C(5
M3MR<?C6AKL3ZOJMS%=WE\4M_%UM!"L=W)&(T:"(D+M88Y)(/8DD8R: /3]-U
M2UU:!YK4R[4?RW$L+Q,K8!QA@#T(JY7D>H:OK)E?3(;BZD@N?$T]HQ^VM"_E
MK"&2%93DH&8=N3R!UI6O]9LX;G2)[^2TLGUBSM79=1-Q<6<4BDNAF(W#)" $
MDD>9UZ4 >H1:E:3:I<:;'+F[MHXY98]I^57+!3G&#G8W3TJQ--';P23RMMCC
M4NQQG  R:X?PK8P:;\2/$UK;WMQ<HEE9<7$[3/$29CLW,2Q]>23\WIBJFL)_
M;.L>,$U#5[VR32K:,6B0730HB-#O,K*" ^6++\V1A<4 =_8WEOJ-A;7UI)YE
MM<Q+-$^"-R, 0<'D<$=:IZMX@T_19K."\>7S[QRD$4,#RNY').$!( !&2>!7
MEVG7&K:DV@Z/%'<R6EOX:LKB.&WU1K$NS*0TA9>7V[5&,X&<D'-36RWE_J/@
MS4KV[EO-02SU J]M>N4F\IE\O[A"L2,!L##=#D 4 >O45X]X;OM>DA\+ZT]S
M()-2N(Q<S7&L&2.Y#@[T6WQM1EY("X(VX)/-*L6HOX'_ +9&OZNM_>ZPMGO%
MX^V*+[?Y>%7.,[1C..A(Z<4 >P45Y9?VVI#Q=-X=MWU.ZL;#3XYX%;6Y+:5B
M[ONE:3EI-N H!.%QTYIVB7.H>([[0M,UK5YA"=*EN1)I]XT7VN59M@8R1[2V
MU I(&!ELXH ]&T[4K35;9KBRE\V)99(2VTK\Z,48<CLRD5;KC?A@%7P;A+DW
M2#4+T+.2"91]ID^;(XYZ_C6/X=D%UHVD^)=0\0ZA#JEW?&.2$W#M$[EV7[-Y
M.=JXQC.,C&2>M 'I5%>36EW=IX/T/Q8NM7\NMWM];I-;M=,893),$D@$.=B[
M5+= "-N<]:A,>HRZ-%JPU[5TO)?$SV"E;MMB6[7;1% A^4X!R"02,#!P * /
M7Z*\EUJ>[T6#Q-IEOKFHV]K;7VEF*XENWDDMUFD028=R3MP"<$D<GL:D\3:C
MJ'A&77[30]0O)XDTB.Z/VFY:X:UE:81EP[EB,H6;!X^3.* /5J*\BO)];T6#
M5$BN)[6*30;RX,<VM->2ET0%)XR1E.20<$ Y&!Q6C(EWH6H:+)#KU^&U+2KM
M[N:]N&FC61(D=90C$A-I).% &.,4 >F45Y/HVJW'AV4'69]4MVFTF>X6ZCU(
MZA;77EJKM,JO\R,!R!@*<X]*;I,U_!XK\,6[OJMO;ZO#.)OMFL-/)<J("X?R
MP2L1!P<H1C.* /2H=;TZX:S$%R)A>-(L#QJ65RF=WS 8'0]3SVK0KQKP_=7>
MB>&O"ITRXNI&E74Y7@:X>19'2.0HI!)XRH./4D]2:U[*233[/P;J]IKE_>WN
ML7$,=VDUVTL=PCQEI"(R=J;",C:!C&#0!Z=65IWB33-5OI+.TFD:>-79E:%T
M&%D:-N2 .&4C\CT(KSG3/M\7AOP]XB;6M4EO[C6H[:427;M$T+7+1%#&3M^[
MWQG(ZUZE;Z?9VDK2P6\<<C AF4<G+%C^;,2?4F@ GU"VM[ZULY)/](NMWE1@
M$DA1EB?0#CD]R!U(JS7$R3.WCKQ1+)<K:O9:+ MM,XRL2N9F=\=QN1<_[@KF
MM*O-1TH>1>R:HEW>Z1</!<1ZJ;VVO'1 WFKN.^)N<C  ^;'84 >MU4TS4K36
M--@U"PE\ZUG7=')M*[A]" :XJTUJ:6;X;QC49'>^@>2X43$F<"T8DMS\WS8/
M/>N;\+H=)\%>#]6T_5[V6\N;Z&U>W-TS0R1O(5>,19VC8N3D#(*DDT >MV5]
M;ZA TULS-&LCQ$LC+\R,5;@@'J#ST/:K->.KJVMZC<Z5I7F7=S!<7NJLZKJ+
M6KS&*X*I&)1\P"J2=H(R .PJW97VK7 TO0]0U.6*RGUJXM7F@OR\P1(2Z6[3
MC!W;\C(.XA0,YS0!ZA<7MM:/;I<3I&]Q)Y4*L>7?!.T>IPI/X&HII+#39?M$
MS1027<L<.]N#*Y^5%]_8?7WKSG6-.L#J^@64>N:C>1VGB$PG?=RAK?=;._E>
M9G+D8&"22 Q7/)%;OQ'LHKRV\/B:6XC7^VK9"8;AXN&;!.5(Y]#U':@#M:BN
M;B&SMI;FYE2*"%"\DCG"JH&22?0"O,+Z::YT'Q?X@GUV_M=2TFZN8[2..[9(
MH!%_JE,6=K[_ )2=P)._CM79>(YK*?P!>R:_%-'9S67^F+ I+QAE&XC_ '<Y
M_"@ TWQQH.J7T%G;W%PDUP";?[1:2PK/@9/ELZ@-QSP>E=%7F\]SJFC7.@?;
M]4TOQ+I=S?0Q6S/;JES&[9594*DJ^T$DD '&36!%J7B.[T^Y\0>;)!>1ZF\0
MFFU@QP1!9]@@:VQMY4 <_,2=V: /9ZSWUO3DW?Z2'V72V;^6I?;,V,*< X^\
M,D\#/.*X:!UOXM<US5/$6H:?<6&KR6\?EW#B*"-) J(80=K[UP3D$G?QVK,M
M$?2FU22SO;U))?&=O;R W<C9C+Q9!!;N&(/J, \ 4 >N45Y)+>7G_"$W7B\Z
MQ?KKT5^Z+;"Z80JRW!C6V\C.WE<#D;LG.:=JZWTFC>.M<&M:K'=:1?2_84BN
MW6.()%&^-@.&!+$$,",=,<T >LUGP:YIESJ&HV$-Y&USIRHUVO($(<$KD].B
MD]>.]5O$>H:E8^&;BZTFR>\U HHABC4'#,0-V"1D+G.,\XQ7DT7F06OC_3K'
M2=7AFET.)GENHU$CN$G+O(0Q^9RS$8ST/3B@#M(+7P=XMU2[2VO[\K>*+FYL
MQ)-!!>*,+Y@5@ ZG"@E#@\9SFNATSQAH&K7J6=A?>9(^[R2872.;;][RW90L
MF/\ 9)KG-;6SU/6O!T%G,!#+9W;%X3DK;-;[=PQVW&/'N!6%')JQL_ .GL=*
M:SM[V$VUU9SL[744<+@N$*CRUV9W<GD@4 >EOK^EQ^(8M!>[4:G+ ;A(-IR4
MR1G.,=CQG/!]*LKJ%LVIR:<),721+,4((RA)&0>AY!!QTXSU%>.7%SK5[9WW
MC:TT">8C45U*UO!<1C-G"ICV;,[L-'YAQW+YKN]7O8KCQ3X(U*QD#K>//&&7
M^.![=I/RRD9H [&J6E:5:Z-8_8[-66'S9)<,V3ND=G;_ ,>8UBZQ>SP?$#PS
M;+<R1V]Q;WN^(.0LC*(BN1T)'S8_&N-_M.XU2XLH'UV\AM+GQ7>6K2PW3+NB
M$4FV(,#PI( &.F01@X- 'K-%>4WFH7MCJ%[X?M]6O5TG^V[2S-XUPSRP))$7
M>(3$EA\P102<CS,9Z4SQ'=7VAGQ)H^DZQ?\ V:&VL)TE>Y::6TEDN=C()&);
M#* =K$]^QH ]9HKC-(MI-%^(<VDPW]_<64VE"Z:.\NGGQ*)=NY2Y)7(/('''
M2J7BB=]1\47%A;_VG<?8K))9HX=3-A!;[RV)&=3O8X4\8*@#U- 'H%06=[;:
MA:I=6<Z3P/G;(ARK8)!P?J#7/> [RXUSX=:1<7UQ)-/<6F))@Y5VZC.X8.?<
M<YYKSK1WOK?PWX-T?3VNY;;47O);A!J;P-(\9 6-9>2@P6;:N,[3[Y /;:*\
MD,VLSV=CI,VK7,$;>)19[K;4#+.D)MW9H7E !)![GD?+SD9INL6MY;6GCJ>+
M7-94Z#'$=/'V^3$;+:QN2W/SY/4-D<GC)- 'J]W=165G/=SL5A@C:20JI8A0
M,G &2>!T'-/BD6:%)4)*.H921C@^QKS#5S>Z!<ZO#:ZMJ4GG^%KJ]=I[IW*W
M"%0)$R?W9^8\+@<# XI4MKO6[OQ&USK.K1K8Z;:2VR6][)$$D: L7^4C)R!P
M<CKQ0!ZC4$E[;0WD%G).BW,ZLT41/S.%QN('H,C\Q7F1U.Z\0QZ8A?4[NY30
M[:[ND@U+^SX(6D4GS6=2&8G!XP5 'J:K^&GDUO5OA[JE_>W4MU)I=YND%RZB
M0H\6,@$ YR<\?-@9S@8 /0KRST_QCH$:F>[%A<8<^2[P-*G(*,.&VD$Y!Q6Q
M'&D4:QQJ%10%55&  .@%>4>$Y[OQ.^C:=J^K:BL"Z&EXHBO)(9+F5I75F9U(
M9MH5.,X^;)[4:7=:AK]]X;TZYUG4&LFDU6%I[>X:)KV*&1%B9F3!SC^(8)YY
MY- 'K-%<MX$FN&TW4[2>ZGN5L=4N;6&2XD+R>6K?*&8\L1G&3S7'WEY=OX.U
MSQ8VM7\6MV5].D-NMTPAB,<Q2. PYV-N4+U!)W9STH ]9HKB/#=M<:CXS\17
M]WJ6H,MA?B&WM/M+"! ;>,ME <-RV>>A&1U-+J,9UOQ]=Z3?:C>V=E::9%<0
M16MV]N9'=W#R%D()V[5&"<#/(YH [:BO)#?:EKFNII]M>WFJV%MI4$T$T6I-
MIS7!9G#3G: 7QM _NCKCFFK/K^L6>D/)>G5G33F>:UT[6&M)2?-95N59=JRY
M50,$@ @^M 'KM%>37-[?:_#I5WIMWJ&I6G]D)*UI'J9L+Q&W,/M!"X20G;C!
M.W*GUJ1]77Q-]E^P3:W?1PZ3!<2%M1_LY(M^[$LCH06<[3D %1CWH ]-DO[6
M&\2T>=!<O$TRQ9^8HI 9L>@+#\Z6RO(-0L8+RV9F@G021ED*DJ1D9! (^A%>
M3>&))=7U?PGJU[>W4E[)X<N)#(+EU#LLD0!(! .0<GCD@$]!BWX8FN?$[Z)I
M^KZMJ"0KX=MKQ1#>20O<RN6#R,ZD,VW:O&<9;)H ]5K(U?P[::Q<V]T\]W:W
M=NK)'<6DYB?8V-RG'!!*@X([5Y]I-UJ'B&^\,V%UK.H-9N-5C>:WN&B:]BAF
MC2)V9"#G'\0P3SSR<]?X#FN'TK4+6XNI[D6.J75I%)<.7D,:.0H9CRQ XR>:
M -S2=)L]$TZ.QL8V2%"S?,Y=F9B69F8\DDDDD^M0P>(-/N=>N=&@>62\ME#3
M[8',<9(!"F3&W=A@<9S@UYN]Y>?\(3/XO_MF_&O)?L@MOM3>2&%QY8MO(SMY
M7 Z;LG.:Z3P7IT-MXL\93)+=,PU%4Q+<R.N#!"V=K$C.3@'J!@=!B@#6U+QO
MH.E:I-IMS/=&[A56DC@L9YM@897)1".<>M:FEZK:ZS8K>69F,+,5'G0/"V1_
MLN ?TKA!'J\GQ,\4_P!EZS8Z<!!8^8+JT\[?\CXQ^\7&.?7K5S6DU*XU'PEI
M=UKDK&ZN;E+R;3BUL)E6%W"X#$KT49SGJ1CL =Y17D+Q7MEH&K:FFMZN\^D:
M\MI9B2]=E$/GQJ4<9Q)D2,,ODXQSQ4M]++_8OC77#X@U%-0TF_G%E&MXXCA*
MA2D9BSM8.3C# ]<#% 'H*KI6J>)#<([/J.C![=@-P$?G*CD'C!R%0Y'2MBO)
MKZ_NXM;UR(7$M@M_KFGVUW/$VUX8WM4) ;^$E@%SVW5:U2/4]-U/7=)T'4[^
M=;"QM]4BCENWF:.99&)A+L2Q61$^ZQ/7/>@#OM;T:WU[3FL+N6Y2W<_O!;S-
M$9%P048CDJ0<$5?CC2&)(HT"1H JJHP !T KRO5==O=>T/5_$&EZI=VUA+>:
M?8Z>\,A7"^?'YL@'3):0ISV3'2I;G1I4UGQ5IR:YKBVEAIL-Y;)_:4NY)G$N
M6W[MQ'[H':25R3Q0!ZC17D$.I:YXCU)8I_M4J0:-9W*+!JQL/FDC+/,=H^?Y
MACGY1CIS5[1_[1\3:OH=IJNLW1B?06N)_P"SKQXDN)!,%5]R8/(.>,9^G% '
MI4U[;075O;2SHD]R6$,9/+[1DX'L*GKR/2$DU34/ 5QJ%]>S3QW.HP>:;IU+
MB%W5-V" 20H!_O#@Y%>LQRQS*6BD5P"5)4YP1U% #Z*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHKF_&.KZII4&DQ:1]E%S?ZBEGON4+*BLCG=@$9(V@XSST[Y
MH W/L%GYES)]EAWW0"W#;!F4 8 ;UXXYK.U'P]X<OHK.VU+2].EC@ CM8YHD
M(08QM0'M@#@5QE_XTUN#5=0TM+RV2XTJ.-)'71[FX6\G:,.1^[)$2X91U)R2
M>G6C>ZE//XN@\4ZA;0""R\-G4UL;FS)E@(.616+?*^X??V].,=Z /4DT^SCG
MAGCM84EAB,,3K& 4C."4![+\J\>PJK<^']'O+!K&YTNSEM&E,QA>%2OF$EB^
M,?>)).>O)KC?#WC/5[S5]*ANB+N'4 ?.2'2;FW%DVPLO[R3Y77C;G@Y((XXJ
MA;^.?$D?A'1]8OY=/$NN21Q6R064L@M1M=G=E5BTG"9"@#!/7 )H ZW2O!6E
MV.GZKIMS:6ESIU[>M=):FW CB!5%"A>G&S.1CK5\>%?#XT^2P&BZ>+27;OA%
MNH5BOW21CJ.QKBW\=:Y#HVJ&***ZN;6YLX[:[GL)K6*X6>54(*/R&7G)!(Y4
MX[5:U#Q;KWAN?5[+46L=0N8;2VN+.2&%H%W33&$(X+-P&P<@],T =9#X8T&V
M@>"'1K".*151T6W4!PK;E!XYPQ)Y[G-63I.G-(SM8VQ=IUN68Q#)E4 !S_M
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M:@T;0ETR718+"P^PCB6S6)2G//S+[]>:6V\.:)9Z<^GVVDV45G(X=X5A4*[
M@@D8Y((')]!7F'A>;6]+TS3$TV32?[0U_5[Z&:[DL6# 1O.Q9R'RY^0[02,
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M>)M,LI(;:<SP+Y*D1R[BQ=>.&W$G([DU+I>E6^D6\T-L,++<2W#< ?,[%CP
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M9!<BUEOR(U0,6";@A8.R;B!N"^XR*<?&D9UC4[&+1]2FATQF6[NHT5D0B(2
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M=%=_8Y-0B5#&LH;8<+NWE0W!8+@<]AF@ M? FFVK%OM=_,[:DFJ,\TJL6G5
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M[9L+NP0K$HQ4%@& X![C%9=K\3(+O3+#48_#VL?9M1GCM[)BL69W97; &_@
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MB+1[Z&UEM=1MY4NI6@A*OG?( 24_W@%)(Z\47?B+1[!+E[O4K:!;618IVD<
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MQ2NUTK2+#1+/[)IUN(82YD8;BS.QZLS$DL3ZDDU:FD\F&24J[[%+;4&6.!T
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M'3;"WMGMH+*VB@D^_$D2JK?4 8-/B>TNI#-"T,SQ,T1="&*$'YER.AR!D>U
M',?#JTTM_A]X?DM8[:4_88"[KAR) H+ GG!#9X['TI/'EZ=!ATOQ,6?R-,NO
M]*52<-#*IC.1WPQC;\*ZJ"V@M8_+MX8X4R6VQH%&3U.!2SI#+$8[A8WC?"E9
M "#[8- 'D?A?^UAKNG>%=1GG>?[0FOW#LQ_U;1 F//H+@GCT6F>&H;*;4_A]
M>Z@ZF>33[U4DEE(+NLL90#)Y/S-QWKUN9[2UD6YG:"%W*PB5R%))/RID^I/
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MS/N.#&K,P&.G5FYH \PF-SJ'@/2-3BE6/4-4\217#3.NX(QN"B9'<*BHN/\
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M"\YSC(QMID6OZAI8?3-.^T))J/B+4O,FMK<3RHD;%B$1N"Q)')R ,G!KM_\
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MI1F.]2 0<D$Y-/E\"WU]I6K6]W=:;;2WL4<4<=A8B**(*X8D\[F)QZ@# XH
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M;6^A,MO/E2OSJ".1G(/.#VH RD^(V=,N9CI0FO;?4H=.:WM;M94=Y=NUDDP
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M2%RVT.5B0@[R%(ZE1G@&M[2M%?3M;UK47G63^TI(7"!<;-D2H>>^=N:Y[4O
MMV^K:I=:9/I21ZHXDE-[8">2WDVA"\1R <A0=K< \]\4 55\;0V&I>(M5>>:
MZT_R-.:Q@WX#-.K;0NXX7<2N3[9/2K:_$>WMDU!-3M(H[FTMENDCL;M;I9U9
MP@56 7#;V5<$#[P.32W_ ,/4ODU1#?!?M*61MV:!6\J2VSM9EX5@3U7 &,BF
MGP'<ZA9ZC%J5SIUL;F!(H4TNQ$2Q,KAQ(2268[E7C(&!^- $'BKQ3XGL/"6M
M2MH?]G7D%GY\-S'=":-03@C=L&)%Z[<$'L>*L7'BR32=8U*6]LIP;>&P-V@N
M]\-NDLDB%T&T?=(RQ[C'3',VH>%M>U_2M4M-9UNW'VJR:TBCL[=EB1B<^:P9
MB6;@#&0 ,]<YJS#X4ENKG69]9N+><ZMI\-E<1P1%%&SS=Q&23@^9QZ8H 9K'
MCJVTBXU2-K1I5L#;PAA(%\VXF/RQ#/ P"K%B> U3>'O%PUC5KC2;JWMH+Z&%
M;A1:WBW,4D9.W(< 8(/!! ZC&:S8OAZ3X*_L>ZU(7&I&[%^]_)"&#SJP*ED)
MY7:JJ1GD"M3P[X>O--U&XOKV335:2)8DM].LA#&H!R6))+,3QWP .G>@!+OQ
M->IXP_X1^QT8W7EP0W,]RUR(UBC=W4\8))&S('?GICF.U\9I<Z!X=U46+*-:
MN(X%C\S/E;PQR3CG&WVZUI0:*T7BV]ULS@I<V4-J(MO*F-Y&SGW\S]*YFP\#
M:Q;0:'ITVL6CZ7HMXMQ;*EJPEE5=P =MY' 8C@<]: *FB^-YK'PYI%M)MOM5
MOI;QE:\O!"BQQSNN7D8$\950 "?P%77^)5N=,M98K2!;N:^DL'2XO5CMXI47
M><S $$$8*X&3N' YI@^'DMM:Z5);7-C-?6!N5(O;7S(9HYI3(5*YRI4XPP/8
M\<U;'A'5(M%CMX[_ $V28W+SW-M+IR_8YE88\ORP<@+@8.2>.<]  ='HNH7&
MIZ:ES=6+64Q9E:(R"0'!P&5APRGJ#QUZ5S$7CZ[-G)JLV@M%HL-ZUG-=&Z!=
M2)3%Y@CV\INQDY!'/!QD['A#PW_PC&D2V9EB8S7,ER8[>,QPP[L?)&I)VJ,=
M,]23WKD= \-:WK'A^;3;V]A@T:75;F:2!K5A<%%NG<(&+8VL0#G&<,0.QH V
M)O'\ELVMW4^C.FDZ/-)!/=_:%W/(H7:J1XYR649) !/UJ-/B,EN;E-4L(8Y4
ML9;Z)+&]2[\Q8@"Z' &UP"..0>>>*O3>"8[S0?$6E75T3'J]Y)=*Z)S"3LV\
M'@X9 ?>JUEX0U99IIIM0TRRE^RO! ^E:<L1#MC]ZQ8L21CA1@<GK0 ^Q\=%]
M)OM5U"P@CT^VM#="YL;U;N-@.L9("X?IQR/>EN?&&K:7I=]?ZMX9DMHH+&2]
MC,5T)5.P F-SM&Q^>/O#@\\5G1_#=KVXU&;59-.@-YI[V,@TJT, EW$'S7RQ
MRP*C [9/)J[?^%O$>N:3?6&K:];%);"6SC6UMF179P!YL@+')&.%& ,F@"AJ
M7B/4IC-]JL;O2[I]%OKFW1+X.NQ!$5=E &),MQS\N#US5O0/%]]#9Z#%KVF-
M:0ZA:CR+QKD2,[K%O/FK@;"RJS#ENF#@UI:SX5?5;Y+E;M8PNDW.G;2F>9=F
M'Z]MG3WJC9>#M3F?28==U.VO+'28V6WC@MVC:9C&8MTA+$<*S#"@9)S[4 0:
M;\28;ZXTV26R@AT[4YEAM95OD>8%L[#)"!E WL21D9 JCJGC#5M4M-$O;'39
M;72+S6;6**\2Z&^2,S!27C &U' (')SD9 S5W1O =YI4NFVQNM+.GZ<X9)8]
M.474ZK]Q'<D@8XRP )QVHC\#ZQ#::9I$>L6HT73+^&[@3[,WGLD<@=8F;=C
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MDJP!!!!12"#Z\'-9T'@F<+;3W.HI+?G65U:[E6':CL(S&(T7)*@+M R3T]Z
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M,A9D6!8V"L2%+C=SSC((S5^?0]?U6[U>_DTB2U%YJVF7,,,DT9<10LF\MAB
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M9J[K.L1:5X=N]756GC@MS,@B1I-_&1PH)P>.>PYZ5Y_J/A[6(8[9K72=5BU
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MSN^4.4VXSV#8J?0](M]2UOPS!>61FT<3:M)80749*_9M\7E95OX>Z@]MOH*
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M=+%8Z@ZI*L%PUM*L@5L,8I!T;V(JIJ6O6FFW>GVS9EDO;P6@$; ^6Q1WRW/
MPA_.O)O#T"R7>BKH6H:2NJ16LP>+3M,>*<?N2"MV[2G'S[3\PR6 QWJ?2AX9
M,O@*/3X(UUZ&\0:AMC(G1_(D\SSSC.XOTW=>2.,T >RR2)$A>1U1%Y+,< 5"
ML%G/<QZ@D<,DZQM''<* 6"$@E0WH2H_(5QWQ&NK6%M#@O;>P:"6Z=OM.ILWV
M.!EC.#(HP&)R0H8@9YZBJ_PM*J/$L,;6YA74]\0MK9K>':T,9W1QDG"DY(.<
M'KWH [UKB%9%1IHP[':JEADGT%$MQ# 5$LT<9<X4.P&X^U>.ZFWA@W7C^'48
MHI-<ENV6Q4Q[IF?[/'Y8@XSO#\G;R/E)XQ3/$<L-S?:K9ZK;Z/'JD>FP1,VI
M0/=7%VQBR?LT88 #<2,KGYADCB@#V62>&(@22HA. -S =>E4]&UFSU[35O[%
MF:!GDC!88.4<H>/JIQ[8KSKPUI%AK_B+19]7LXK_ ,OPG8.OVE/,42;WRV#Q
MN]^O)]:WOA8FGP>$GM;2*"&Y@O+E+N..,(ROYS[0PQUV;<>V* .S\^+SO)\U
M/-QNV;ANQZXK&T[Q(NJ>(]1TNVLI3!I[".:\,B;#+M5M@7.X\..<8ZBO,=NF
M?\(S]E\J/_A8/]I;O]7_ *7YWVC[^>OE>7W^[MXKM_!6F65IXA\8306-O#(=
M5V!TB53L,$+$9 Z;B3CU)- &EJGC+3=,&JAA+++IGD>>B 9_>L N,GG&>:WX
MYHIMWE2(^T[6VL#@^AKQSQA9Z8FJ^.K<VT$=]=PV$D6V,+))&9%$A4@9QNVY
MQW K1\3:,^D:QK-KX4L5LII_#,I$=E'LWNLH ("XR^UF /7F@#U&.>*8N(I4
M<H=K!6!VGT/I6'X@\3/HFH:;I]OI-WJ5WJ E,45N\:X$84L2791T;UKA?!L5
MB_B[2'TC4-(=8K25;B+1],>']WM&%N&,K88-@@,-V=WJ:Z#QE97=]X[\(Q66
MH3:?+Y=\?M$,:.5^2/C#@CGZ4 6G^(%M:V^H_P!HZ3J%A>V,<4TEI-Y99XY'
MV*Z,K%2-W!YXQ76/<0QRI$\T:R/]U&8 M]!WKSKQ;X6_LSPGK>IW.HWFJ:G<
MI;PM<7(0%8UF4A%5%  R23QR:Y/QQ<6=W'XPVV^DVVHQ2N%2X@>XU&4HB[9(
MCN'E1\9! ( !/K0![C)<0Q$"2:-"2%&Y@.3T%25Y?/H>F:UK7C>ZU"P@O'6P
MM_)>:,/LS;DDIGH<@<CG@5U_A35(9-!T&QGN"VHR:3!<LC EF7:H+$]/O'Z\
MT =#1110!F:KX<T77'B?5=*M+UH@0C3PARH/49/;VK0BBC@B2*)%CC10J(@P
M% Z #L*?10 4444 %%%% !1110 4444 %%%% !4-U:6U];M;W<$<\+$$QR*&
M4D$$<'T(!_"IJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH IV^DZ?::A=7]O9
M017EWC[1.D8#RX&!N/4XJY110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!GZ;H]OI=SJ4\#2,^H7/VJ7>00'V*F%XX&$'KWK
M0HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?E;8>?2KECH-_J%_9O/HVM.;.TG5TU>_3R0[Q&/RD"9+*V2"W   /7BO4**
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MLOG7!NBJ".)3)\D1(Q\P4CH#]T\^NUTJK ;XWUW]H6V%H-GV8QLQD/'S;\C
MYZ8SQ53Q)9ZAJ/AO4++2IHH+VXA,4<LI(6/=P6X!.0"2/?% ')>&O%.IWGBI
M)[V?=HNNF<:2FT#RS V!SC)\Q S\Y^[Q6W!XS2ZU26VMM'U&>TBO382WL2HR
M)*#M.4#;PH/!;;COTYK*U+X9:9!I5L?#EO%9ZM82136<\LKE0R,,ANO#+D'
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M<%RJD%MH./?I6*/ VHIH-R+2ST2QOGU&VO8;6V#+"JPNK!'DV[F)PWS;>,X
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MI77V$6I6\J6]Q+#/:16T:"<EO.DE&0Q88Q@C!X.<DT :%%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !2*H50J@ #H!2T4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !6+K?AR'69[6[6ZN+.]M<^5<0$
M!@#U!SU%;5%5"<H/FCN3.$9KED96A:#;:#:RQ0R2S232&6:>9LO(YZDUJT44
M2DYOFEN$8J"Y8[!1114E!1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
<0 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>exhibit101-arrowheadindu009.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit101-arrowheadindu009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHI'=8T9W8*BC+,QP /4T +14'
MVZTP3]J@P"@SY@ZO]W\\C'KFIZ "BBF/-%')&CR(KR$A%9@"Q S@>O% #Z*@
MBO;2>YFMH;J&2>''FQ)("R9Z;@.1^-22311!3)(B;F"#<P&6/0?4T /HHHH
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M+(D:E@H+, "2< ?4F@!]%%% !13&EC65(FD02."40L,L!UP.^,BGT %%&:*
M"BBF12QSQB2&1)(ST9&!!_$4 /HHHH ***8\L<;QH\B*TAVHK, 6.,X'KP":
M 'T444 %%%% !1110 444$X&30 4444 %%,DECBV>9(B;V"+N8#<Q[#U-/H
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M#=5FUSP9HVIW'^ON;2-Y3ZOM&X_GFHM0TB>*TUF]TB)EU;58HXV\V0;8F"[
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MM-=V#6<AWRE2&0X^7*#!P.IK8\4W^M:9I^L:-JU]!?Q:AH%_<1R1V_E&&2)
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M30;70(;B"REN#!-.\XBEDW+$68LP3T!))Q[UJ4 %%%% !1110 4444 %%%%
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M>=QE,?SA=NW&.,YS6>WB+4[/PUI<NB:PFO0SZW';)</($E\DL,0RDKG?U!;
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M2E6>^OYK^(6=BS[###]GA9W;/W$!8D\9). ":[35;Z33=,FNH;*>]E0 );P
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ML.)!F0[0,\']X.?:@"M+XM>[2*"]LKJPOK76[>QFAM[H,"SA74[]OS(589&
M>U!^(%RL<]Z= E&DVVHMI\]V;E=RL)O*WJF,LN2N>01D\'&:LW7@R:XU6[O!
M>(HGUFUU,+L/"PQHA3KU.S.?>B7P9-)X3U#1OMB![K4VOA+L.%!N1/MQGK@8
MS0!'K_CJXT W=S<:*1IEI*(Y)YKM8I9!QEHHB/G49]1G!Q65J_B;5+>_\:17
MD<Z:;IT-N87M;E4E3=_=.WJV223G&,=Z9J_PSO=2CUV!;K2O^)G-),+^:R,E
MW&&.1%N+8"C& 1_#VSS6KK?@O4-4NO$'E7]M':ZS:PQNK1,7BDCX!!S@J1GC
M&<XH M7_ (QNXKG5/[,T.74+/26V7DXN%C.X*'98U(^<JI&<E>3@9JO+X\N+
MBXO$T30WU*&UM(;UYC<K"K12H77;D$EL \=/4BGWGA;6HKC68]&U.TM['6',
MLXN+=GDMY&0([1D, <A0<'H?7I5G2?!ZZ.^J);W ^S75C;64*,.8UAC9 2>^
M=P_*@#0EU]&\''Q%9VTEQ&UB+V*#.UW4IO"]\''ZUF#Q]IA\1)IFUO(?3/[1
M^UY^3&-VS'KL^;Z5LZ#I9TCPUIFDRNLQL[.*V9PN ^Q I./0XKA3\)V/AX:;
M_:Q\T7_F"?R^?LGE>1Y'7_GEQGUYH 9JWBJZO-'U6[MOM]A=?9=*N/+:XRL2
MS3$84 #:Q7(;UX':NJ\(WES>3>(A<3R2B#6)H8M[9V($C(4>@Y/YU4UKP5)J
MESK4D5W'"NH16,:+Y9/E_9Y6<]^X./:MC0=%?1Y-69YEE^W:A)>+A<; RJ-I
M]?N_K0!Q^F^,M4TRWUV\OM-N+K2;+6+F*6]:X&Z*(2X&R,C+(@(SR.^ <5IZ
MI\0H[*\U-;73TNK32VVW<IO$B<L%#,(HSRY4$=UR>!FJ\W@G6IK35M';5K3^
MQM5OIKF<?9V\](Y'W-&IW;>1QDCC)Z\82_\  %R=2U2736T<0ZG+YS27VGB>
M:U<J%8QDG# XR W .>HXH [FUN8KRTANH'#PS(LD;#^)2,@_D:H+K2-XJ?0O
M);>EDMYYN[@@NR;<?\!SFDLTU"WU@V>V,Z5#91"-_+"L9<L"..,;0O  QGWX
MSM6T+5V\3QZYHU[9PS-9_8IH[N%I%VARZNNUAR"3P>#[4 4(?'L]\FC)IVAR
M7-SJL-Q+'&UPJ+&(753O8CH=W4 ]ACG-5D\72ZEK?AR=A-I\0FU"&_M6DW*K
MP(002.& ()!J[X>\%3:)-H+R7ZS_ -EVEU;N?+P93-(CAO;&W]:9;^!&7489
MY[M)(5O=0N)(PA!9;G(VYSU&>M #-,^(L5]<::\VGK;V&J2B*TF%VCRY8$IY
MD0Y0-CCDX) .*G\.>.)?$=S"UOI/^@3,ZB>.[222$KG'G1 9CSC'4\D XJEH
MG@*\TJ;3(&ET<6>G,"MQ#IRBZN%48178Y (X)91DD=LTMKX%U ^(=/U*_N]-
M,MC*TGV^UL_*N[H%64+*P.W'S9/!R0.!0!=\,^-I?$L]N\&E 6%P'VSQ7:2O
M"1D@31@9C)QTR>>#BM/7/$$NFW]CIEA8&_U*]$CQP^:(D2-,;G=R#@991P"2
M36!8>!K]/$>G:K?W.F--8.[&]M+/R;F\RI4"8@[<<Y. <D#&*V]=T.^NM7T_
M6M)NH(-0LTDAVW,9:*:*3:64X(((**01Z=.: .<U7QKJTR:4FG:<8+Q=;73]
M0M99U!5MA<(&P<JP(8,,<#'<U#9>,]5TJ/Q!=W>F3WNEV6LS0RW37*AHH]Z@
M!$(RP7(SR/;-:$O@C4C9"Y34K5M;;5TU625X&\@LJ>6(PH;<%"8 .<Y&>]6;
MGP9-<>%_$&D?;(U?5;V6Z638<1AV5L$9YQB@"/5?B MC?ZG#::>EU!I9Q>2-
M>)$^[:'98D;ER%([KSP,FEN?'5S+J%Q;:)H4FIQP64-\\XN5B4QR*S+@$$EC
MMX'U_&MJ7@.Z?5=5N=-;1_+U1Q+(]_8">6VDVA6:,YP00H.UN <^N*WM'\.G
M2==U"_%PLD5S:6ELB! I7R1(,G&!SO'   Q0!0M_'^FW.N:5IR1MY>H:<+];
M@L-D89694/N520_\!-9/_"P((5N-:FM+U$.D6UVMLUPOEA99G1#@@;2>"S$X
M"X].:\OPI=M!O]/BU;RII;_S;:<1\P6VUHQ".>R22#/^U70:AX3NI-3O;S3+
M^*R,NG064*- )%7RI'?#*>"C!MI'!QGF@!A\;M::%?:IJ>F>2EN8Q"UK=)/%
M=&0[5$<GRC.X@'(&,YZ58T'Q=_:FLR:1>6D-K>BW^TQB"[6XC>/<%/S ## D
M9!'<8)K 7X9?:;75Q<2:=8R7P@,<&G6I6WCDA<NLC(QPY)P"./E&/>MSP[X;
MO--U:74+P:1#F#R4M],L1$O7)=F.6). ,9P/<\T 3:EXENX=<FTK2M'?4I[6
M!+B[/GK$(U<L%5<@[G.UCC@<<D9KF?#WCFXA\+>'+5HQ?ZQ>6)NI6N[M8%5
MVW<[L#R2<  'H>F*Z._T'5HO$-SJ^A7UI!)>V\<%U'=0M(,H6V2+AAR Y&#P
M>.E847PYGLK719()=-O+VPLC92KJ-KYD,R%MP8#.58'//.02* '/XVO]4U/P
ML=)M<075[<6U]"\RY#QQON3(!! (W@@\X'K4Z_$JV9Q=_8D_L8W7V47?VM/-
MSO\ +\SR>NS=WSG'.,5-'X-U"V@T*6WOK'[=IU[+<R8LQ%"XD1D9%1"-N%;
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MHP7'7H#[<5QUAHWB33=-T"TFLM32TALI8YETIX%N!,9<JKNY&(RO/RGKU[4
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M1?W!N=B0,9S3M:DT_3_%>H7Y;3-3N5U6,_9YF>WU6%LH L##)DC[@8 ()YH
M]GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(UK1I]4DMIK75KO3I[?<
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M+M)<RB:X07,HCG<8P9(PVU\8& 0171T4 9-UX:T>^745N;%)1J)0W09F^<H
M$(Y^4C P1CIGK4%KX0T6TMKZ!+>9_M\?E7,LUU+++(F" OF,Q<  G !&,UNT
M4 -CC6*)(T&$10JC.>!3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<L<CLRF!B"4()YR0.>M5D\!:$+:Z@FCN[E;BV-H3<WDLK)">3&A9B5' Z<G
M]* *>G7&MZ7XRL-*U#5SJ-O?Z?-<%6MTC\F2-HQ\FT [2)#PV3P.:[*J<FE6
MDNJVVIO&3=VT,D$3[C@(Y4L,=#]Q?RJY0 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJ7C!8G=\AVR#&!U7WP'>+?&>JZ7-K<UCJD#'3 62RMM-EN5(5 Q$\PPL9//
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MCQIX@T[1]>D\JYNA:6:W-K>W>DRV0+[]K1,K@!N""".Q/I0!Z?17!FX\8?\
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M3GGOQTH [RFR21Q*&D=4!(4%CCDG %>>VOB7Q%'HFB^*+NYLY+#5+BW1]/2
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M13[8+E@ ,NN,\@ '!&<<YI+WP)IE[<W;?:M0M[6^D\R\LK>XV0W#< EAC(R
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MAG3][&%F B)P %4JN6/7&:ZVV\7W4MKJ2/H-U_:MA<1V\EC#(L@8R!61A)P
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M6DVFC:7#IUFC"WB! WL79B222Q/)))))]ZNT4 <I;_#_ $JVN+%TNM1-M87
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M"0&EW*RS/N)Y!084<<GFB?PMK>M70NM<OK'S+>RN+:U2SB=5+RKM:1RQ)Z#
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M\V">1N/7BIHO .DW6L:EJ.N6%AJ3SNB6J36X<6T"(%5!NSSG<3CU]JZZB@#
M\*^'F\,VU]812QMI[7<D]E"B[?L\;_,8_3 8L1CL:PO^$(U;^R/^$9_M&T_X
M1W[1YF?);[3Y7F>9Y6<[>O&[T[9YKO** ,?1=&DTJ_UNY>99!J-[]J4 8V#R
MHTP?7[A/XU@Z[X,U#5+OQ$(+VU2TUFVA1@\;%XI(^ 00<%2,^^:[:B@#E?$O
M@U/$NHRR7%SY=M-I4^GLJK\P,CQL'';C9TJOH'A*]T_6+:]NX]!@6UB9!_9N
MG+&\[$8WLQ!*8&?E7U.3CBNRHH P/$6@76I76GZII=W'::KIS/Y+S1EXY$<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%(S!5+,0 !DD]J %HJ-[B&/[\T:\XY8
M#FG(Z2+N1E93W4Y% #J*** "BD5E<95@1Z@YHW+N"[AN(R!GF@!:*** "BBD
M9E7&Y@,G')H 6BD!# %2"#T(I: "BD5U?.U@<'!P>A]*6@ HHHH **** "BB
MB@ HHI-R[MNX;L9QGG% "T444 %%(K*V=K X.#@]Z6@ HHHH **** "BBB@
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M'(/RD$@CN#6/XK\/WNM^(/#DUM-<6T5G+.\MU;2(KPDQ$*0&R&R>",$8/(H
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MS2+ZVNK%'B^S6(L(H@V4$0;=]2V>^:M:+H]MH.E1Z=:-(T,;R.#(06R[LYZ
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M(6S,VZ12K*5*YQ@$$C YK5T31;70=.^QVK2R!I7FEEF;<\LCL69V( &22>@
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M0"Y(Z8P.M;- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2U>WU/2_#=EJM_J\;S79GELY(8;G$6PK TCD#*^9EB,,0!QU- 'J%8FK>+]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#FFTK7[?5K^]TZ
M;1(OMCJSM):2M(X4;5W$2@$@<< 55U70?$6MVJVVHR^'YXE<2)FSG!1AT96$
MP*GD\@]ZZ^B@#BK;PMK5G;6EO;CPW'%:3&XA5;&;Y9"""_\ K>6PS<G)YJQ_
M8GB,S7LK2^'6>^54N2UA,?-4 J P,N",$C'O76T4 <%9^"M3T^.X2V3PZHN(
M3;R$VEPQ,1_@!,Q*K[# K0_L3Q(9K*7SO#V^Q4K;'[%-^Z!7:<?O?3BNMHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]PVXSG/&* RE0P((/0@]: %HJAJNL6>CZ5+J5W(1;1;0S(-QR6"@#'N0*OT
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M<8J[JKZ=?6^BWMY_9=HS:(BIIOB4.T6S)YBG)R)>F3@L1M->TM&C@!D5@#D
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MC6OF.P^7!=BN 2" 6X'05'X@UG7?#PU[2+769KEX(+*YM;NX1&D@,MQY3(V
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MHBPI<R[W5GY5R ,*2!T.<&M\^*=7M=*U*^TW2;)M%T-WMI(VG<32B 8E,?&
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MX>O;&UTRV;3I;6XN!,)?-<Q[$,8&"JY^8[L''&.]5?#WA:^BUO2;B[T(VO\
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M$PCO+9HB\9.-RYX//;J.XINK>*+/2K\6'V:^O;SRO/:"RMS*R1Y(#-C@9((
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M:L=,M[FWO+V6YAOGN54!))?-*LI&=X)(';H<CI0!U.I>--*TN]NK:2.]F%F
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MO+W[1+;PQ_?S(<YR>0N3@=Z .FL_&FEWU_#;0Q7OE3S/!!=M;,()9%SE5?\
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M[58+BR3[/E)0ZR*O1P1T!]#S724 %%%% !1110 4444 %%%% !1110 4444
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M9LYW9Z?+[4 >KR:QI<-REM)J5FEQ(YC2)IU#,PZJ!G)/M5QF5%+,0J@9))P
M*\GU304E\'_$*X.F;[^349G@D,&9&"K&4*'&< Y(QWS7;^.9'C\$:FR:=_:!
M,05K8AR&4L Q(3YB "6(') ([T :UCJVFZGYG]GZA:W?EG#_ &>99-I]\$XI
M]YJ-CIRQM?7MO:B1MJ&>54W'T&3R:\X\*>9)\2XKI)DN;9]'EB^TVVEM9P;A
M+&0@R3N(&>YQGZUJZX;&P^(#W^OV;3Z=-I:V]I(;5IT202.9$P <,P*8XYVX
M[4 :&C>(+"]6VUA=.M+(:@D[7-T\T:.HA<(N[.&<'GGHN!GJ*Z#4+^.QM99,
MQ-,(GDBA>58_-*KD@%N![GH.IKRWPUH8O+7PA87.G7$5D^GZO!-%+&08T>6,
M!6ST)&<?2GV=GJ^J:'KTNK6L_GZ+HMQH]ON0YN)=K>9*H[[E6'!'J: /2O[:
MT^+[)'>7MI:W-RBLD$EPFYB>R\_-SQD4Z+4<WU_#,D<,-H$;SC.IW J225ZI
MC'?KUKR36K=;1;EXT<W<^FVROIVH:4UQ%?E8@ L+I\R'/RD9X;G'>M#6K*^N
M;_7;B?3;AK3[5I,][:HAD\R%%S*@ _U@4XR!G.* /3;?5]-N[1[NVU"TFMD.
M&FCF5D4^[ X%.M=3L+Z2:.TOK:X>$[95AE5S&?1@#Q^->4>)X8=8C\3WOAZR
MF_LZ31%MYGBMFB6XN/-RH52 6*IN!('&X"MCQ/IB:1K\LNE:")X1X:O(FMK>
M,HLV'BVQDI@YP6P!SC.* .X37=,N(KIK*_M+N2V1GDC@G5V7 [@$XIVAZHNM
MZ!IVJK$8EO;:.X$9.2@=0V,]\9KRNP62?Q3H\UL\5S"NFWD+/9:0]I#%F-2L
M>YB2Q^4\$\8Z FNY\%7T-KX8\,:-.)8[]M'BE$;1,,*B(K9., @L.#S0!T%]
MJ>GZ8B/?WUM:*YVJUQ*L88^@R>:E6Y@:58EFC,CIYBH&&2O]X#TY'/O7!>.X
MH8_$5C>M=2V,ZVDD2W%QIWVRTD4L"8F4?,KG .1C(XYZ5GZ-?MHVI^&]5U;2
MY=+M7T2:T$<%O*Z12>=&RIM ++N5<@'GMU% ':ZCXJL-.U/3;:66'[/>B<FZ
M,RB.+R@,Y/3J<=>"*T9-6TV'3UOY=0M$LFQMN&F41G/3#9Q7DVG+! GA&^UG
M2KK[)%?:M+();1G^SEYF*,Z@''7KCCKVS3Y;*'R7U)1>Z7I[ZW-<Z9/_ &?Y
MT,*F%59I(6&0CL)"IP,$YR,\@'J3ZHC7&FBU$-S;WK,//2X0!0$+ J,_/DC'
MR],YZ"J.H>*].L]0L+&":"[N+F^6RDCBG4M 2COE@,G_ )9D8XZUP6GPZG>)
MX=-OI\5HZ:EJ(AGMK=X8I-UM+MGV-DQAG;H>,].HJ/34TQHO 5C:Z//#J^G7
M<:WQ-FZM 1"XDWOC!W/@YR=W6@#TJ#7;5='BU'4YK73T=F4^;=(4!#$#YP=I
MSC/Z=JLR:MIL5HEW)J%HEM(I9)FF4(P R2&S@C%>363S66F>&8;JUAL@D5ZP
MU"\L);KRV,Y_=K&I 5F'.YNPP.M+X=T8WC>&[:_TZ62UCU_49&BN+3RU"E)&
M0M&1A 25('0&@#UN/4;*:T>[CO+=[9,EYEE4HN.N6S@8JP"& (((/((KS#6M
M+F@\8/X4M;?;I/B*6&]D"#"1)" +A<=@X2!?^!FO1+;4[6[O[VQA9C/9,BS*
M4*@;EW+@D8(QZ?2@#+/B<MJFHV$5D&:QO+:U=GN%0,)51MPSZ!_N]3CCK6FV
ML:6MW':-J5F+F1BB0F==[,#@@+G)(/%>>:Q9W3^(M:=;:9E;Q'H\BL(R0558
M=S#V&#D]L55O=!0^"O%MR-,SJ#Z[--%)Y&93BX7:RG&<8R1CWH ]/GU33[:\
MBLY[^UBNI?\ 5P23*KO]%)R:MD@ DG %>*:U83+>^++/4YY4N;^[=K>)-&-S
M-<Q%5$7DR[@ 5Z 9&TC/'6O0?&-AJ%U\.;ZRMA/<7AMD5U7B2905\Q>#]YE#
M# />@#9&OZ0]G=7<.IV<T%J"9GBG5A'CL2#P?K5#PMXD?Q)X<76FLXK>*4;X
MHTN1,2FT,-Q &UN>5YQ7)R+IFM>)+*;P[IS):6^F745\PLVA0JRKY4)#*-S!
M@3M[8/K73>#;4VOPVT2#R/)E&E0^9'LVG?Y2YR/7/6@"WX<\4:?XCTRRN8)X
M$NKFV2Y:S\]6DB# 'D#GOUQ6H+VT,*3"ZA,3OY:OY@VLV=NT'N<\8]:\D\,P
MV4VA>!=.TK2Y[;6K*>&:\9K-XFAC"-YS.Y &'S@#/.X>G#H+LIX8T;PZ;2].
MIVGB*)[B+[+)B*/[:7WEL;=I4J00>_L< 'JBZKISZ@VGKJ%JUZHR;83*9!_P
M'.:KV^MVYM'N+^2VL@LLJ#?=(P*HQ&[(.!P 2.JYP:\TMD^P^);>"Q@:[8ZT
MTKZ;?Z8RW%L6D8O.EPG!0!BP+9!4@9SQ5C2M'-UK'AU+W3VDACUG6)666(E1
MEW*,01CG@@GVQ0!Z:NI6#Z?]O6]MC9;=WV@2KY>/7=G&*:NJZ<^GG4$U"U:R
M R;D3*8P/][.*\GU/2;R"*Z\F!K?2K;Q5)/,HLC,B1F!=LGE#&Y!(<G'0\]J
M#I\$]AJU\UUJ3VDFHVDJ7EKI C@25%8&;R229$Y4.=O4 C."0 >L+JVFMIYU
M!=0M#9#DW(F7RQ_P+.*FM;NVOK=;BSN(;B!_NR0N'4_0CBO) GVS0+QKJ%HH
M(=8AGAU?3=+98Y7\O!FDMWSE0<*Q7()P>Q-='X-UA-/L;][Z"!+>?4XX(+ZT
MLI($O9)%10_EG.WYL*6^Z2* .ZFN(;9 \\L<2%@H9V"C). .>Y-5X-6TVZM'
MNK?4+2:V0[6FCF5D4^A(. :Y?XH?9_\ A$H?M<#7%M_:5EYL*(7,B^>F5"CJ
M2.,=ZY/Q-!%K4/BB\T&RF&F2Z5!;2&.V:(3SB;(VJ0"Q5#@D#N!VH ]0?7M'
MCL_M;ZM8K;;S'YS7"!-XZKNSC/M3GU'_ (F%C;PI'+!=1R2><)U& NW&%ZN#
MNZCICGJ*XS5++2?#_CBSN[[3(X]$&FM#;&.T+Q03^9E\JJG:S)M ..=I&:YR
MQL-06ZTV&RAELFN8M<?2H9%,;0QN8S$-I^YR<@=@10!ZS;ZII]W=2VMM?VLU
MS#_K88YE9T_W@#D?C3?[8TP7<MH=2L_M,*EY8?/7>BCDEESD#W->4>%K$R7G
MA:VAN)EO; YE@AT4P/;8C*NLTK,,J2<=RQP0#UK3\*KI$>EZ!HU[H,\_B&WN
M";O-NRM%)\WF3O)@!D;)[D-N YH [SP[K]EXFT6'5-/?,$I(VD@LI!Z-@G!Z
M''O5H:KIQU Z>+^U-Z!DVWG+YF/]W.:YGX8".+P+9V@@>"XM6>&YC>$QLL@;
MG((&>".>E<9';Q?\(A;Z"NFSCQBFI+(TGV5MXE%QN:X,N,;"F3NSR#CVH ]:
MCU.PEO#9QWUL]R 285E4O@'!.W.>#P?>BZU.PL988KN^MK>28XB2654,A]%!
M//X5S'@32(+5]=O7L4CO)M9O3Y[Q8D9#*<88C.T@#VK*U<6-AXK\22Z_I4][
M%?VD*6#+9O.'C5"'A!4$(=^6YQ]X'MP =S<:QIEI:Q75SJ-I#;2X\N:2=51\
M],$G!J2ZU&QL;475W>6]O;'&)II51#GIR3BO%],@N+>W\+:A>7*VNG-X;@A@
MGFTTWD:R9)=< _(S*4Y_B"X[5JZ/9Q:+)X:O=:M[R71(K6\2 W5B1]EE>4,A
M:)=VP%-RKGH, XSB@#U*74K&"Q^W2WMO'9X#?:'E41X/0[LXIHU?36@,XU"T
M,((!D$R[02-PYSCD<_3FO+;.R-M<6.K7.EW/_",)K=W<0VQM6;R4>)5BE\D#
M<%WB4CCCS <"JL-E8ZO<:E'9Z7(NG2>+K-VMWMB@*>2A9F0CA6))P0.&YH ]
M7D\0:+#'!)+J]@B7 S"S7* 2CU4YY_"I;S5]-T__ (_=0M+;@']],J<'('4]
M\''T->7^)XT76/$6G06%K8 VJ101II+W,M^OED@1G.Q%#$K@#@Y)Q3-*O=(T
M_P 2Z3-K]H[M_P (C9('DM7FV,6DW*P"DACTY'."* /0[[Q18Z;KUMIUW)%#
M#/9R7?VN694C4(Z+@YXY\P<Y[5<;4U:]T^*V$4]O=H[B=;A, * 1M7JX.>HZ
M=Z\Z\*^'Y3K/A5-5TQBEMI5\\4=Q%N^SAKA#$AST81MC'48/I5?3=+U".YTR
MVL;>6W:*YUZ.V.PJL.YSY6.P'3'Z4 >I0:II]U=RVEO?VLUS#_K(8YE9T^J@
MY'XTVWUC3+NZDM+74;2>YBSOABG5G7'JH.17G6C7&CQ:)HMI8^&;JXUO3[&0
M2Q+ \#V[B$AP[X&2[?*.3DMN'3-96AAYO$'@N6!(?+@>1)8;+2)+>.S#6[CR
MWD<DL<\<GDC)'2@#U+P_K::_X:LM92 PK=0B81%LE?;-0>&_%6G>)-+LKF&>
M".ZN;=+AK/SU:6-6&>0.>_7%4?A]!+!\-=%AFB>.5;(!D=2&!YX(-<)X8@LI
MO#W@?3=,TJ>VUNSN89[LM9O$T,84^<SN5 PX. ,\[AZ< 'K']L:9_:']G_VC
M:?;?^?;SU\S_ +YSFE&JZ<VH'3UU"U-Z!DVPF7S .OW<YKQJ5Y[N#3V2T2UN
M(M=AGFTZWTJ0RVW^D@L\MPQ.<@YR,9W8'%:4:?8?$T45C UV[:V97TR_TQA/
M 6E):=+A."@!+ MD;>,]J /2H]>M8[*6ZU.:UT^-+F2 -+=(5;:Q .[. 2!G
M;U'0UI12QSQ)+%(LD;C<KH<AAZ@UY!+9B!(+JYEN]-GBU?53#=R:?]JM@'GS
MMD3J-P *L,=#SSSWO@)YG\(6PFT^*PVR2A(X8FB1U\QL2*C_ #(&^]M/3- &
MTNJZ<^H-IZW]JUZHR;83*9 /]W.:6/4["6\-G'?6SW0!)A652^ <'Y<YX/!K
MR6TMXCX2TK0H]-G7QA!J,4DTAM6#I*)PTL[2XP4*;OFSR& ]J[/P+I$%M-K]
M])8I'>3:S>'SWBP[(9.,,1G;Q]* .A74U74+R"X$,$-N(MLS7"?.7R,%>J\X
M SUSQ4UEJ5AJ2NUC>VUTL;;7,$JN%/H<'@UYKXNTV:]O?%\36DLL-Q+HR@",
MD2*)_GQZX'7TKIK'38[#XGW;6EFMO:R:-"&,46Q&=9I .@QD*?RH Z.]U33]
M-\O[=?6UKYAVIY\RIN/H,GFB\U73M.,0OK^UM3*<1^?,J;S[9/-<3JKZ=IOC
MC6;KQ)8O<6MW8016+FT:=2J[_-B& <,25..^1Z5G6/\ 96D:O?2^(M#N(;6[
MTVUCT^">V>Z,<2QD/;@@-\X;JO4Y'7% 'H]YJNG:>I:]O[6V  ;,TRIP3@'D
M^M$>J:?->?8XK^U>ZV"3R5F4OM/(;;G./>O-_"'AV<ZWH2:[IQE>W\.F/%S'
MO$1,W"$GC<$('KUJ'PYH:V/A_P"'4L6FF&ZCOF^T.(<.JM#.#O.,@$[1S[>U
M '=^&_%>G>(].M)XYH(;NXB\W[&9U:5%R1DCKCCKBK5OK=N;22>_DMK(+-+&
M-]TC JC$;L@X' !(ZKG!KRSP]!9R^&/"NE:?I4]OK]OJ45Q,6LW1HD$A:61G
M*@;63(Z\[@.W&AI6CFZUGP^E[I[20QZWK$K++$2HR\A1B",>A!^F* /3!JFG
MG3_[0%];&RQG[2)E\O'3.[.*S=4\7:-I>A?VPU[!<69FC@5X)D8,[L% !SCC
M.3Z $]JX"[B;3(-0@&F0QV9\4.Z3W%I)+!:+Y"D2^4A&X%L@?PAFR:SI+267
M1O&$KV\MU#_:&G722#36@$J*\?F2)%C.,*W/)(&>] 'KEMJ\4S7[RF"*UM67
M;<?:4970HK;C@_)][OU ST(J:#5=.N;/[9;W]K+:[@OG1S*R9)QC<#C.2!^-
M>7W]L9[[4[_[#//HB^(+.[N(UMV(DMA9H VS&657*$C'\)XXJ'7[.+6H_$UU
MHUA+_8UU'IT+A;=HUN9UN0795(!.$*@MCM[4 >JVVK:=>Q32VNH6L\<!(E:*
M96$>/[Q!X_&G6.I6&IQ-+87MM=QJ=K/;RK( ?3(->>>*=#M$U[6(H],NDL)]
M 195TRW7<S+/QA?NL5'.WDE01@]*N>!)II/$6HA1:WUN;6+.K0:>]F78,V(G
M4_*S $G*@8S@]J -[5?&FFZ7?ZGIY(DO=/TUM0>(2*-Z@,=@YSNPA/3@$'O6
MEI6N:?J\2?9KNW>X\I9)+=)E9XL@'# <CKWKA/%\")XJ\0DVCF6^\+O%;2);
MLWF2KYY90P& VTKU/(P*;>Z!):?\(HFAV*VEW_95W!YD4>S:YMQMWD#^_@\]
MZ /0[?5-/N[N6UMK^UFN8?\ 6PQS*SI_O '(_&FIK&ERF81ZE9N84\R7;.IV
M+_>;G@>YKRCPK9;[[PI;QSSK>6#9FMX=%,#VP$9619I6894DX[EC@@'K2?\
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M.&W2,1SR"!CW-4;2]O)[K1/$;SW,^J+X-FO HF8++,OE8!0'!!)R1C!.#V%
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MY(7N[DRO;>=*\<C!Y,D#"@\Y /- 'K%4-9UK3O#^ERZEJER+>TB(#R%2V"2
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ML<@@9&!GG'2NI\6ZMJNFG1;?2!:?:-1U 6C-=(S*BF*1RV 1DC8#C//3C.0
M:?\ 86D_:K*Y_LZU$]C'Y5K((ANA3&-JGL,<8J'3_"^@Z3>27>GZ196MPX*M
M)#"JG!.2!CH">PKEKGQAK>G7%WH<RV-QK"WMK:VURL;1PLLX8AW3<2"HCDR
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MT25I74,-[;1M !7MZ'-6TU'5M#U#QI=7EUI2WJW-DGVJ8-'!M,:@/LR6SC^
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M5T#2TN%L='LK=;E#',(X5&]#_"?]GVZ5=&G62O:.+6$-9J4MR$&8E( (7T&
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MCK74T4 <]I?A3^S[^"[N-:U346M8FBMDNY$VQ*< GY%7>V!C<V35_1K"ZM=
MM[+4KE[NX$9665WW%\D]6P,\'&<#..@K2HH X^U^'MK;Q:7;OK.K36FDSQS6
M-L[Q!(BG0'" N,$CYB3@\$'FIO&NA7FNOX?CM'GB%MJBW$T\#JKPH(91O&[@
M_,RC&#G/((S7544 <N? VGRV-U%=7E]<7MU<1W+ZB[JLZRQX\MEVJ%7;C@!<
M<G(.30/!%K+%?->ZGJ5W?7B1QM?/(J2QK&VY!'L554!N>G)ZYKJ** .4D\!V
MEW%??VEJ>H7UU>)#%)=2F)76.*3S%10B!0-W7C)SUJ6Z\$6-U>ZA.U[?+%?W
M4%Y+;JR>6)HFC*L,J2,^4H(STSC%=-10!BR>%M.E\70^)F$OV^*W^SA0P\LC
MG#$8^\ S*#GHQ%9[^!;4SSI%JNIP:;<7)NIM.BD00O(6W-SMWJI;DJ& .3ZU
MU5% &?K6CVFO:7+I]YY@B<JRO$VUXW4AE=3V8$ CZ5B2^ [2\M]274]4U'4+
MF_LS8O=3-&KQ0GDJ@5 HR<$G:22!FNKHH 15"(%'0#%<_HO@_3]"FTZ6UFNG
M:PL&L(O-92#&SJY+84?-E1TP.O%=#10!S]OX/T^VTS2+!)KHQ:7=_;("67<S
M_/PWR\C]XW3'0<US_AGP',NE0QZS>Z@L2W\UVVEF2,P%OM#O&Q(4MC&QMN[&
M>HSFO0** ,!_"&F2Z3JFFRF=X-1NGNY"7PR2,P8%" ,;64$=>1WIVE>&$T_5
M&U2ZU*^U._\ )^SI/=E!Y4>02JJBJO) ).,G YK=HH YFQ\!:'8Z)JND)%+)
M::G*\LZR/RN0 %4@#:J@#;Z8IUMX.A$DKZIJNHZP'M7M EZZ;5B?[PPBJ"2
M 6.3[UTE% '+:?X(ALM4TV_FUG5;UM,5TLXKF2,I&C+M(.U 6XQR23P.>N=F
M[T>WO=8TW4Y'E$^G^;Y2J1M/F*%.[C/0<8(K0HH Y:[\#VUQ<WI@U;4[.SU"
M7SKRRMI$6.9SC<<E2Z;L<[6&:-2\#6VIR7L;ZKJ46G7S!KO3XW0Q2X '5D+H
M"%&0K#-=310!R>K> ;/59]4/]J:G:6NJH!>VMM(BQRD($#9*%E.T#." <#(/
M.9KWP/IM[!J<3W%XG]H16T;NCJ#'Y!S&R_+USR<Y''2NFHH SK[1;;5- ?1]
M1>6ZADB$4DCD+(Y&/GRH #9 .0!S60O@BWE-R^I:MJ6I3RV<EBDURT8:"*08
M;8$11N.!EB"3@5U%% $%G:I8V-O:1%C'!$L2ENI"C S[\5RD7PYLX[6SLO[8
MU8Z?8W275G:;XPD+I)O R$W,,Y&&)X/K@CLJ* ,4^%M.;Q>OB8B7[>MM]GV[
MAY>,_?QC[^"5SGH<5FS^ ;&=[B ZCJ":3<W!N9]+5T\B1RVYN=N\*6Y*A@"2
M>*ZRB@#F[OP5I]R]W,MS>074]^NH)<1.H>"81K'E,J1@JN"&!!R?PJ'X>V3Q
M7;2ZKJ<M[<W4-Z;UWC\Q)HAA&4;-H&.-NTC':NOHH Y&7X?65W_:;WVJZI=3
MZG;1VUS-(\8)5&+*5 0*O4C &/;/-:FJ>%]-UC4'N[Y9)?,L)=/>'< C12,K
M-VSNR@P0:VJ* .57P'93I*FKZCJ&KHUJ]G&MXZ?NHFQNV[%7+':OS'+<#FK>
ME^%SI^HQ7MSK6J:E)!$8;<7<B;8E.,\(J[F.!\S9-;]% &+K'AR/5;ZVU&"_
MN].U&W1HDNK4IN,;8+(RNK*PR >1P1Q5>R\&:;8/ILD<MTTMC<S7?FR2!FGE
ME1E=I#CDD,>F.@[#%=%10!GZGH]OJMQIL\[RJVGW0NH@A #/L=,-D'C#GICG
M%8<7@&QB:*#^T=0;28;@746E,Z>0D@;>.=N\J&Y"EL9[=JZRB@#EO^$'MFNX
MC+JNI2Z?%>"]CT^1T,2RAMX.[9YFT-R%W8_#BA/ ]L+N!I=5U*:PM[O[;!I\
MKH8HY0Q8'=L\P@,<A2Q%=310!5L;-K*.5&N[FY\R9Y=UPP8KN.=@P!\HZ >G
M<U:HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR/"VR158$HV <'T."#CW% $E%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !534M-M=6LS:7BLT)D23"NR'<C!UY!!ZJ#5NB@#S,6=_9?$46OAK3[6Z
M@T;2]A2]O73RY+F5G)#;').(QU[&HM4T74!KEG+K$EI]NUW5;7S;>T+&**WM
M%>;&Y@"QRO)('4"NL;2]>MM7O[W3FT6(WCJSO);RL[A1M7<0^,@<< 5%-I?B
M:XOK:]EDT![BU#B&0VTV4W@!L?O.X H X^X\0:Q/-IFK6-UK+1ZGJL,5G++Y
M$5I) \GW1#N:0CRPQW$ ]^.E3:KJ.MW.A>)-=@UN[@$.J&TTJW@VA"RND W9
M!+ R;N.G)_#4M? M]97$$]O;>'4DMY?-@/D7!$+<_<!EP@Y/ P/:KR^'-<2P
M@L57P\+6"<7,<?V:?"RA_,#?ZSD[CGZT ='+HUE/?_;98V>?<C9+'&4SMXZ8
M!9C]3GL,2Z?:/8V$5M+=SW;Q@@SSD;WYSDX 'Y"BZL8M2TR2QU"-)HIXO+G0
M9"N",$=<XJPB+%&L:*%10%4#L!0!RGQ/_P"29>(/^O1OYBJ_C^WENE\*00W4
MEK(^MQ 31@%D'DS9(R",XSU!KK-0T^TU73Y["^A6>UG79)&V<,/3BBZT^TO6
MM6N85D-K,)X2<_(X!4,/P8C\: /,]5UW7-!76]'M;^]O"FIV-K;W$AC:>))U
M!8!FPI.00I;H6&>E;_A*YUJ+Q'>Z;?)?+9?94GB34KJWEN$?<5./*8DH1C!;
MH01GM727/A_2;Q;];FPAF74 @N@XR)=HPN?IVQ2:1X>TK0C,VG6@B>?'FR,[
M2.^.@+,22!V&<"@#C?&UP-8\66.A-I-[JMA96[W5]!9A"=\BM%$&WLHZ&5NO
M9>*R[/7-8O?!_A[2?MMUINJ0ZRFD:@X"^<$$;G/.1N9 C9Y&?7%>GV^G6=K>
MW=Y! J7-X5:>09S(57:N?H.*JOX=TB34GU!K&,W;S1W#29.3(BE$;KC(5B*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUO;R7-U/I\<CS7 ,9&RYD+'YF=E.&YRO &* /5-<UFVT'2+C4KI9'CAVY2(
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MXC<2-%L"00A@I=RS#C)Z+D]>*?X<\0)XCTA-42QN;.UEPT!N2@,L9 (<!6.
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9[9[T ;_ )4>\/L7>,X;'(SUK'T;18/#MI?R7-^]S)>7)N;JYN=B;F*J@&
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ME.HH 0*HZ*!^%9&N: NN_989[R>*QBE$D]I$$V7.&#*')!( *] 1G)!K8HH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;!BZ*S.K#'RE=C Y[C%;- !115#2M7MM8BN9+82!;>ZEM7WC'SQL5;'MD<4
M7Z*** "BBB@ HHJO?WL6FZ==7TX8PVT+S/M&3M4$G'O@4 6**@L[J.^L;>[A
MW>5/&LJ;A@X89&?SILUWY-[;6WV>X?S]_P"]1,I'M&?G/;/;UH LT450O-7M
MK+5-/TZ42&>_,@AVKD?(NXY].* +]%5["[^W6$%U]GGM_-0/Y5PFR1,]F7L?
M:K% !1110 45D6WB&"[\1WFBP6EV[V87[1<A%$,;,H8)DG);:P/ QSUJMJGB
MVWT[5&TVWT[4M3O(XUEFCL80_DJV=I8LR@$X.!G/'2@#H**Q++Q9I%]9:?=1
M3NJW]PUI%&\;*XF4,61EQ\I&QLY]/I6W0 4450TS5[;5C>BV$@^QW3VDN\8^
M=0"<>W(H OT56N[O[((/]'N)O-F6+]RF[9G^)O11W-6: "BBB@ HHJAINKVV
MJRW\=N) UC=-:2[QCYPJL<>HPXH OT56AN_.O+JV^SW"?9RH\R1,))N&?D/?
M'0^AJS0 454U34[31]-FU"^D\NVA +L%)QDX' ]R*DOKVWTZPN;Z[D\NVMHF
MFE?!.U%!).!R> : )Z*C@F2YMXIXR3'(@=21C@C(J2@ HHHH **** "BBB@
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MLF%Q[<BK<E]IL.J16<EU:)J$Z'RX&D42R(,GA>I P?UJU'&D48CC141>BJ,
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M !BO7K*+3VB6YL8[4QR9=98%7#9ZD$=<^M2QV=M#/)/%;0I-)]^14 9OJ>]
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MEO9)I)&5]DD^=[Q!V$;-GDDIM.3US6XVG6+PQPM9V[11G<B&)2JGU QQ5F@
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M' ]!0!LT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1S7.?#Z2\-CJEO<W,$T-O?-' D5V]UY"[5)B,KJI?#$^N 0,\5QE_IP@\/\
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M;6^J-JGE-<3:U-E6\_;]G-J(RN-ORA?HV>]=U\4;:"Y\&9N"ZI'?V;$K*T>
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M>BO,=,O-2FUJS\&FYN7GT>]FNKF4R-OFMD :W#-WW&5 ?7RFS6%X?O-9GM-
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MN+J33[&15,[X;<)=Q"9P1PO;CMC)R =C=:C;V=U9VLK$SW<ACA11DG"EB3Z
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M269W9(:,A@ 3T(([$^E.NK_7-8\4ZGI6DZA;Z=#ID,+/));><TTD@9@,$C"
M =.22>1B@#>,>CZ2]N2EC9L1]G@.$C."<[%Z=3S@=ZG73[&.*");.W6.!]\*
M")0(VYY48X/)Y'J:\STZZN_%WC/PCJMTUN@.G7<K6YMQ(J21S1(Y0DY&2.#U
M '?-=#XICO7\?^#OL]Z(8C+<ED\H-G$1)[]QD>V<T =';:3HOV]M6M=/L/MD
MF0UY%"GF-V.7 R?3K1)H&C37TE[+I-@]W( 'G:V0NP&,9;&3T'Y5YOX:O]>T
M7PKI.HI?6S:=+K+6ALC;<^7+=O&6\S=G<"V>F,<>]2_\)YK]U]IU2Q@O9XHK
MQX8M-AT::19HDD*,?/ P'.&/' . 1UH ],:PLVBN8FM(#'=$FX0QC$I( .X8
M^;@ <]A4<EGIL5Y%?RVUJETJB".X9%#A2>$#=<$]JH^*[S5;#P]<7&C6QGO%
M9 %6/S&5"P#LJ9&]@N2%R,D5Y[JNNWNL^'C!'JL%W>6^M:=Y(N+)[::%FF7
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M?2],O]-2RGL+2XL<#; \*O%@=,*1CZ4^#3;&V%N+>RMHA;H4@\N)5\I3C(7
MX!P,@>@K@+/7=<\,6^AOJ=W;WUE=Z7-,;>*W\LP&&$2 *V26!&0<]^>.E)X>
M\7>(;R]T::>*[NX-1(%S"-&F@CM REE9)F&&4'"G/7.1B@#T6WM;>TC:.V@B
MA1F+E8T"@L3DG [D]356+1-)@U)]2ATRRCOI,[[E(%$K9ZY8#)J_10!'#;P6
MX<00QQ"1S(^Q0NYCU8XZD^M2444 %%%% !1110 4444 %%%% !1110 4444
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M\<EK<I<Q7.\[55'&/FW8!! QN!SBI]$\7'4=:_LB^LH[.\>W-S#Y-VEPCHI
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M$>I$7:$1@A6!CX_>?*P8C"T =)H_ANVTB\N+W[5>7M[.BQO<WDN]]BY(08
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M(W*BH,>G"BLO4_!ME?ZK+J<%]J6FWDZJD\EA<F/S@HPN\8() X!QG'>NBHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BB@G R>E !136=%4LS*%'4D\"E!
M# %2"#T(H 6BBB@ HHSSBB@ HHHH **,C&<\49&,]J "BCJ,BC(- !11D'O1
M0 44TR(KJC.H9N@)Y-.H **** "BCK10 4444 %%&1G&>:,@8R>M !103CK1
M0 444TN@<(6 8]%SR: '4444 %%%% !134D20$HZL <94YIU !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9W<LBR7<6;:Z([RQG:Q_X%PWT85?TWP[9:7JUYJ-N9/,N(8;=48C9#%$"%1
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !45S<PV
M=N\\[A(TZD\^P '<D\ #J:EJIJ6FVNK69M+V-GA+I)M5V7YD8,O((/#*#^%
M%._\4:+IELEQ>:A'%')(T4?#,TCK]X*H!+8QS@&GV7B/1M1TN34[74K=[.)B
MLLI?:(V'4-G!4\C@\\BN8N=#MO[8M[;PKJ$=GK.@Q,?(NT>:)XK@[B&).[ED
M^\IXZ>U<]J$D/BJUMK1K5M-U2^\1)9:HMG/N28VZ&1F#8Y4*BXX!!Z]* /7*
M*\NOM0U&?PEK_BC^W;VUEL)YX-/MHW&P&%S&BR+C]XTCKSG^\ ,5>FNKW77\
M07MYX@N-!M]*E6T@\EU5(Y?+1VDD!'SC=( %)Q@>IS0!W?V^U.I'3A,OVL0B
M<Q=PA.T-],@C\*J7'B'2+74ETZ>_B2\9XXQ"2=VZ3=L'U.QOR->;W&JZF_C[
M4HT>2WMKJZM-%EUE%7]TRQ-(4C4DX9WD*Y.0N5ZD\>DOHEDTXN6\TSC;B1I2
MQ!52JGDX.-S$9[DGKS0!I50U;6M-T*U%SJ=Y%:Q,P12YY=CV4#EC["I[&U:R
ML(+9KF>Y:) IGG(+R8[L0 ,_A7*7NS_A<&F&\QY?]D3?8=_3SO,7S-O^ULV^
M^,T =#H_B#2M?BEDTN]CN!$VV51E6C/HRG!'XBM*N%\9:UI^B_VS<Z68X_$B
M6,(EG"%A%"TP16?^'*[F8 \X'I6;XEN=3\(O/:V6N7]XMUHE_<'[5()'@EAC
M#)*IP, EL8Z9QB@#TRBO-8++5G\1:)ITGB?5VAU32Y+N[Q(H/F(8L>6=O[L?
MO#P.P%5M+OM9UH^$]/FUN]B2X&IQW4T+*LDX@E")EL<' &2.>3ZT >IT5Y18
MW6M0:7I^K2^(-0N)8O$(TORY&7RY(!<F'#J%^9B.=W7-27>IZL_A#6O&(UR[
MAOK&[N!%8AE\A5BF*+"R8Y+ #)ZY88QQ0!ZG17E6JW6LR:3XVUQ-=U"WET:Z
MD^Q6\;*(UV0QOAQCY@2Q&#P.U=UXGN+U/"-[-I]Y;V5XT(\J>=PB(QP!\QR
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M>:&3>Z[@R$X! 'RDGIVS0![#165I>DS66D26LNJWUW--N9KF=P74L #MP %
M/(';-<9HOB74=0N=,TVZO3#/HL%Q+KDN/O-$3$F['9R&DP.H44 >D57L;^UU
M.T6ZLIEF@9F577H2K%3^1!'X5Y=INL:O%J_A6[6YUR2VU2Y\J6?4)(5BNT:)
MW#1P*Q:,9"D=,#@YS5KP'?W,5WX<L%G9;6>VU61XL\.ZW:A3]0&;\Z /3Z*\
MDE\2:Y>FPTZVFO;A+W6=3C9[.:..5HH9&\N-'<@*,'/'.$XKL/!%UJLD>J6F
MJ&0BTN@D'VBYBFG1"BMLE,9(R"3C/)!&: +-_P".O#FF:R-*N]16.YSM<[&,
M<1.,!W VJ3N'4]QZBK>I>*-#TB]CL]0U.WM[AP&".W0$X!;LH)X!.*\XUXC1
MM9U/5-,FL-7TL-?3ZAIMY'C8ZK#YR!^020%(#*1[\\:UK):W%A\1YKU0!(=S
MB48(@-G&4R/3EOQS0!Z.6"J6)  &23VK*TKQ/HFN7$EOIFIV]U+&N\K&W)7.
M-P_O+GC(R*YS5FOO^%'W&2_V[^P,O_>W>1\WX]:J>)0%U'PG_8^/-^P7HA\K
M_GE]F^7&.V_ROQQ0!UMCXHT/4M2?3K+5+>>[3=^[1NNTX;:>C8/7&<5>.HV:
MZFFFFXC^VO"9Q!GYO+!"EL>F2!7G<(MQX4^&/V';YOVFU\O9UV_9G\W],YK3
MM]'LM+^+T,UM&PFO-)NIIY7=G9V\^''))X X Z =* .ZHKE/'5S>0VFC0V>H
MR:>UWJL%M)/'C=L8-D#((R>,>^*Y37M<UKP[>:IH5A?WEY&9K!(KB1T::V\]
MW5T#OA<D(-I;H7^E 'JU%>2:EJWB71M)\1PK+>VJQ6$5Q;?;[R">YAD,NTD;
M&)*,/[W<$#K7I&GV$FCZ3)"^IW-VXW2&YOG#$''?  "CKCM0!I,P12S'  R3
M4-E>VVI6,%[9S+-;3H)(I%Z,I&017FGAW4=5M=0T^#6[O5?/U"VE"RF>*YL;
MYA'OWQ,N#%P"P& "..:K^%4OM#\-_#^^36;V6/4&BM9[:5E\@1-;NZA5 X*[
M%YSD\YSF@#UJBO(H=>U7[3H&K6UYK<UMJ&JQ0-=W3PQ6US%(Q&(X Q91CH2
M>,G-/N=4UVS\-:]X@CUB_FN1JTVFV\)9/*MXC=B,, PQO ) 9C@9&>!0!ZU1
M7"^%Y];M?%<FGWBWR6,ED9_*U.^@GG617 W+L8ML()SG@$#&,XKNJ "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !115+5M4M]&TZ2]NFQ&K(@Y RSL%49) &68#).*
M +M%<O-XWM&2S73;&ZU.YO6F^S06K1Y9(FVNY9F"JH.!R<\@8SD!T'C?3SIF
MH75[;7=C/I\R07-G.@,J.^T(!M)5@VX8(./I0!TU%-+H&52RAFZ GDT,ZH0&
M8 L<#)QDT .HK.36;=_$4VBJDAGAM4NI'P-BJS,JC.<Y.QCTZ"K=U=065I+=
MW,R16\*&221SA54#))/IB@":BN./Q BCM4U*XT'5[?0W(QJ4L:! I/#M'O\
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MH-!T.^U:Y21X+.%IG6, L0HR0,D#-7(Y4E7*,#TR,\CZT /HIJNC,RJRDKU
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MI4,P!;@ GK0 ZBL[3M9M]2O=4M8DD1].N!;REP &8QJ^5YZ8<=<<YK1SCK0
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M@$P.&[<&O0KSPR]Y<22G7M7C5VW"*.2/8GL 4/%1GPK,<9\3:Z<<\S1?_&Z
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M+ ^Q/:N4NM"T'4[3XB:BME:W @@5K"95!$*K8QLC1$?=['*^@]*]@(R,'I2
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M^:<!-IV[\8W8'3;GFL^W?3K#QA#)#_9>IW4FML#&RM;ZO SR$$L03YD2@YY
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MK*JKG:H&3DX'4T*BKG:H&3DX'4T 06%]:ZG80WUE,LUM.@>.1>C*>XJQ110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:71/"GA]]!ODETG4XGN[APHAV(S_ #(V[+ [@>!P,YQW .W7QMX;;4$L5U>
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MP*X_7]/U?Q(?%=U%H=[#%>:7:6]LEPJJ\Q2:1F^7)Q][H>W/>@#N;+QAX>U
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MHA=^:(-N&V^9_<WXV[O]G.?:N3\1:%J=UKFNS6]E(\=Q<:,T;+C#B*<M(?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "F/%'(5,B*VQMR[AG:?4>]/H
MH B:V@=95:",B;_6 H/GXQSZ\4RXL+.[DCDN;2"9XCF-I(PQ0^Q(XJQ10!7F
ML;.XGBGGM8)9HO\ 5R/&&9/H3R*9-I>GW$4<4]C:RQQ',:/"K!#Z@$<5;HH
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M^KE>,%D^A(R*L$9&#110!7M]/LK2.2.VM((4D.76*,*&/N .:F1%C1410J*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MB$@P[K20/OX^7+D Y[FO1J.M 'FGA/3+I?&4FBS(?[-\+/*UHV<AS<?-$/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426947734032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>May 01, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARROWHEAD PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,200,230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426947347168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 127,704<span></span>
</td>
<td class="nump">$ 110,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale securities, at fair value</a></td>
<td class="nump">395,410<span></span>
</td>
<td class="nump">292,735<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">11,022<span></span>
</td>
<td class="nump">8,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">7,514<span></span>
</td>
<td class="nump">7,082<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">541,650<span></span>
</td>
<td class="nump">419,521<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">359,252<span></span>
</td>
<td class="nump">290,262<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">9,412<span></span>
</td>
<td class="nump">10,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">44,626<span></span>
</td>
<td class="nump">45,297<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">210<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">955,150<span></span>
</td>
<td class="nump">765,552<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,521<span></span>
</td>
<td class="nump">35,866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">37,055<span></span>
</td>
<td class="nump">39,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">13,741<span></span>
</td>
<td class="nump">17,963<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">5,285<span></span>
</td>
<td class="nump">10,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">573<span></span>
</td>
<td class="nump">435<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">65,175<span></span>
</td>
<td class="nump">105,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">113,632<span></span>
</td>
<td class="nump">104,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltiesLiabilityNoncurrent', window );">Liability related to the sale of future royalties</a></td>
<td class="nump">280,938<span></span>
</td>
<td class="nump">268,326<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">394,570<span></span>
</td>
<td class="nump">372,934<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Noncontrolling interest and stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 124,133 and 107,312 shares</a></td>
<td class="nump">217<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,768,866<span></span>
</td>
<td class="nump">1,300,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,095)<span></span>
</td>
<td class="num">(3,222)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,284,194)<span></span>
</td>
<td class="num">(1,026,030)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Arrowhead Pharmaceuticals, Inc. stockholders&#8217; equity</a></td>
<td class="nump">483,794<span></span>
</td>
<td class="nump">271,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">11,611<span></span>
</td>
<td class="nump">15,819<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total noncontrolling interest and stockholders&#8217; equity</a></td>
<td class="nump">495,405<span></span>
</td>
<td class="nump">287,162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities, Noncontrolling Interest and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 955,150<span></span>
</td>
<td class="nump">$ 765,552<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltiesLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltiesLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866345488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">290,000,000<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">124,133,000<span></span>
</td>
<td class="nump">107,312,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">124,133,000<span></span>
</td>
<td class="nump">107,312,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426973405536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 146,267<span></span>
</td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="nump">$ 208,813<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">101,122<span></span>
</td>
<td class="nump">74,881<span></span>
</td>
<td class="nump">217,613<span></span>
</td>
<td class="nump">158,576<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">25,069<span></span>
</td>
<td class="nump">23,221<span></span>
</td>
<td class="nump">48,674<span></span>
</td>
<td class="nump">44,206<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">126,191<span></span>
</td>
<td class="nump">98,102<span></span>
</td>
<td class="nump">266,287<span></span>
</td>
<td class="nump">202,782<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating (loss) income</a></td>
<td class="num">(126,191)<span></span>
</td>
<td class="nump">48,165<span></span>
</td>
<td class="num">(262,736)<span></span>
</td>
<td class="nump">6,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">6,250<span></span>
</td>
<td class="nump">4,560<span></span>
</td>
<td class="nump">9,052<span></span>
</td>
<td class="nump">7,242<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(7,244)<span></span>
</td>
<td class="num">(5,057)<span></span>
</td>
<td class="num">(12,611)<span></span>
</td>
<td class="num">(7,906)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">610<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expense</a></td>
<td class="num">(805)<span></span>
</td>
<td class="num">(489)<span></span>
</td>
<td class="num">(2,949)<span></span>
</td>
<td class="num">(149)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">(Loss) income before income tax (benefit) expense and noncontrolling interest</a></td>
<td class="num">(126,996)<span></span>
</td>
<td class="nump">47,676<span></span>
</td>
<td class="num">(265,685)<span></span>
</td>
<td class="nump">5,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,313)<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income including noncontrolling interest</a></td>
<td class="num">(126,996)<span></span>
</td>
<td class="nump">47,676<span></span>
</td>
<td class="num">(262,372)<span></span>
</td>
<td class="nump">5,865<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest, net of tax</a></td>
<td class="num">(1,696)<span></span>
</td>
<td class="num">(999)<span></span>
</td>
<td class="num">(4,208)<span></span>
</td>
<td class="num">(1,485)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</a></td>
<td class="num">$ (125,300)<span></span>
</td>
<td class="nump">$ 48,675<span></span>
</td>
<td class="num">$ (258,164)<span></span>
</td>
<td class="nump">$ 7,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="num">$ (2.24)<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="num">$ (2.24)<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average shares used in calculating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">123,285<span></span>
</td>
<td class="nump">106,757<span></span>
</td>
<td class="nump">115,307<span></span>
</td>
<td class="nump">106,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">123,285<span></span>
</td>
<td class="nump">108,143<span></span>
</td>
<td class="nump">115,307<span></span>
</td>
<td class="nump">107,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive (loss) income, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized losses on available-for-sale securities</a></td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,125<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(56)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive (loss) income</a></td>
<td class="num">$ (126,836)<span></span>
</td>
<td class="nump">$ 47,602<span></span>
</td>
<td class="num">$ (260,245)<span></span>
</td>
<td class="nump">$ 5,669<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426861873536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Non- controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2022</a></td>
<td class="nump">$ 418,339<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 1,219,213<span></span>
</td>
<td class="num">$ (136)<span></span>
</td>
<td class="num">$ (820,755)<span></span>
</td>
<td class="nump">$ 19,819<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(41,811)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,325)<span></span>
</td>
<td class="num">(486)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="nump">396,372<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">1,239,178<span></span>
</td>
<td class="num">(258)<span></span>
</td>
<td class="num">(862,080)<span></span>
</td>
<td class="nump">19,333<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2022</a></td>
<td class="nump">418,339<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">1,219,213<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="num">(820,755)<span></span>
</td>
<td class="nump">19,819<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(196)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized losses on available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">5,865<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">465,106<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">1,260,310<span></span>
</td>
<td class="num">(332)<span></span>
</td>
<td class="num">(813,405)<span></span>
</td>
<td class="nump">18,334<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">396,372<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">1,239,178<span></span>
</td>
<td class="num">(258)<span></span>
</td>
<td class="num">(862,080)<span></span>
</td>
<td class="nump">19,333<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,140,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">665,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized losses on available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="nump">47,676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,675<span></span>
</td>
<td class="num">(999)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">465,106<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="nump">1,260,310<span></span>
</td>
<td class="num">(332)<span></span>
</td>
<td class="num">(813,405)<span></span>
</td>
<td class="nump">18,334<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,869,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2023</a></td>
<td class="nump">287,162<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">1,300,395<span></span>
</td>
<td class="num">(3,222)<span></span>
</td>
<td class="num">(1,026,030)<span></span>
</td>
<td class="nump">15,819<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">19,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,694<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized losses on available-for-sale securities</a></td>
<td class="nump">1,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(135,376)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(132,864)<span></span>
</td>
<td class="num">(2,512)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">173,714<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">1,320,356<span></span>
</td>
<td class="num">(1,255)<span></span>
</td>
<td class="num">(1,158,894)<span></span>
</td>
<td class="nump">13,307<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2023</a></td>
<td class="nump">$ 287,162<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">1,300,395<span></span>
</td>
<td class="num">(3,222)<span></span>
</td>
<td class="num">(1,026,030)<span></span>
</td>
<td class="nump">15,819<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">154,347<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized losses on available-for-sale securities</a></td>
<td class="nump">2,125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(262,372)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">495,405<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">1,768,866<span></span>
</td>
<td class="num">(1,095)<span></span>
</td>
<td class="num">(1,284,194)<span></span>
</td>
<td class="nump">11,611<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="nump">173,714<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">1,320,356<span></span>
</td>
<td class="num">(1,255)<span></span>
</td>
<td class="num">(1,158,894)<span></span>
</td>
<td class="nump">13,307<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">17,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">1,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">723,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued, net of offering costs</a></td>
<td class="nump">429,265<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">429,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of offering costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Change in unrealized losses on available-for-sale securities</a></td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income (loss)</a></td>
<td class="num">(126,996)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125,300)<span></span>
</td>
<td class="num">(1,696)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Mar. 31, 2024</a></td>
<td class="nump">$ 495,405<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="nump">$ 1,768,866<span></span>
</td>
<td class="num">$ (1,095)<span></span>
</td>
<td class="num">$ (1,284,194)<span></span>
</td>
<td class="nump">$ 11,611<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,133,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866987088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net (loss) income</a></td>
<td class="num">$ (262,372)<span></span>
</td>
<td class="nump">$ 5,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flow from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">37,444<span></span>
</td>
<td class="nump">40,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">8,788<span></span>
</td>
<td class="nump">5,358<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Amortization (accretion) of note premiums/discounts</a></td>
<td class="nump">896<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">Realized gain on investments</a></td>
<td class="num">(80)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="nump">12,612<span></span>
</td>
<td class="nump">7,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(68,024)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,643)<span></span>
</td>
<td class="nump">20,309<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(8,402)<span></span>
</td>
<td class="nump">6,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(27,279)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(866)<span></span>
</td>
<td class="num">(99,135)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease, net</a></td>
<td class="nump">4,417<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(210,217)<span></span>
</td>
<td class="num">(107,187)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(102,731)<span></span>
</td>
<td class="num">(66,225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(309,982)<span></span>
</td>
<td class="num">(192,528)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">208,615<span></span>
</td>
<td class="nump">141,994<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(204,098)<span></span>
</td>
<td class="num">(116,759)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercises of stock options</a></td>
<td class="nump">1,779<span></span>
</td>
<td class="nump">1,096<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net of offering costs</a></td>
<td class="nump">429,265<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromSaleOfFutureRoyalties', window );">Proceeds from the sale of future royalties</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">431,044<span></span>
</td>
<td class="nump">251,096<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash</a></td>
<td class="nump">16,729<span></span>
</td>
<td class="nump">27,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents and restricted cash</a></td>
<td class="nump">84<span></span>
</td>
<td class="num">(196)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract', window );"><strong>CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BEGINNING OF PERIOD</a></td>
<td class="nump">110,891<span></span>
</td>
<td class="nump">108,005<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">END OF PERIOD</a></td>
<td class="nump">127,704<span></span>
</td>
<td class="nump">134,959<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="num">(3,014)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of noncash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Capital expenditures included in accrued expenses</a></td>
<td class="nump">$ 7,265<span></span>
</td>
<td class="nump">$ 12,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426864543696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Recent Developments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">plozasiran (ARO-APOC3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">zodasiran (ARO-ANG3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">olpasiran</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-RAGE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK-4532990</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">fazirsiran</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-PNPLA3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-CFB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Muscle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-DUX4</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-DM1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Central Nervous System (CNS)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Thus far in fiscal 2024, the Company has continued to develop and advance its pipeline and partnered candidates. Several key recent developments include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.7pt">Completed enrollment in Amgen&#8217;s Phase 3 OCEAN(a) - outcome trial of olpasiran, triggering a $50.0&#160;million milestone payment to the Company, which was paid in the third quarter of fiscal 2024;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Presented final data from the double-blind treatment period of the Company&#8217;s Phase 2 SHASTA-2 study of investigational plozasiran in patients with severe Hypertriglyceridemia. Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Announced an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for qualifying patients with familial chylomicronemia syndrome (FCS); </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Initiated a Phase 1/2a clinical trial of ARO-DM1, being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, being developed as a potential treatment for complement mediated renal disease; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">Entered into an Amended and Restated License Agreement with GSK, pursuant to which GSK received a worldwide, exclusive license to develop and commercialize JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen Pharmaceuticals, Inc. See Note 2.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company&#8217;s financial position at March&#160;31, 2024 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company&#8217;s Annual Report on Form 10-K for the year ended September&#160;30, 2023 for more complete descriptions and discussions. Operating results and cash flows for the six months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending September&#160;30, 2024.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s primary sources of financing have been through the sale of its equity securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded. Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the Company had $127.7 million in cash, cash equivalents and restricted cash ($2.2 million in restricted cash) and $395.4&#160;million in available-for-sale securities to fund operations. During the six months ended March&#160;31, 2024, the Company&#8217;s cash, cash equivalents and restricted cash and investments balance increased by $119.5 million which was primarily due to the net proceeds of $429.3&#160;million from the underwritten offering in January 2024 discussed below, offset by ongoing expenses related to the Company&#8217;s research and development programs, general and administrative expenses and capital expenditures. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2024, the Company entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued 15,790,000 shares of common stock at a price of $28.50 per share. The aggregate purchase price paid by investors was $450.0&#160;million and the Company received net proceeds of $429.3&#160;million after deducting advisory fees and offering expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $2.8 billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes to the significant accounting policies disclosed in the Company&#8217;s most recent Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded an income tax benefit of $3.3 million and $0 for the six months ended March&#160;31, 2024 and 2023, respectively. The income tax benefit is primarily due to the discrete change in the Company&#8217;s uncertain tax positions related to the statute of limitation expiration.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to improve its income tax disclosure requirements. Under the ASU, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This ASU will become effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426869541328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">COLLABORATION AND LICENSE AGREEMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Horizon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">116,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">132,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">146,267&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,551&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">208,813&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"></td><td style="width:59.575%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Receivables included in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities included in deferred revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">866&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;). Under the GSK License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. GSK dosed the first patient in a Phase 2b trial in March 2023 and paid a $30.0&#160;million milestone payment to the Company in the third quarter of fiscal 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible for an additional payment of $100.0 million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0 million at first commercial sale, and up to $590.0 million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">GSK-HBV Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2023, the Company entered into an Amended and Restated License Agreement with GSK (the &#8220;GSK-HBV Agreement&#8221;) pursuant to which GSK received a worldwide, exclusive license to develop and commercialize JNJ-3989 (formerly ARO-HBV), the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. JNJ-3989 had previously been licensed to Janssen in October 2018. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the GSK-HBV Agreement, the Company received $2.7&#160;million in December 2023, upon signing the amended GSK-HBV Agreement. The Company is eligible to receive up to $832.5&#160;million in development and sales milestone payments under the GSK-HBV Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no contract assets and liabilities recorded as of March&#160;31, 2024. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, Horizon and the Company entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#8220;Horizon R&amp;D Services&#8221;). The Company received a $40.0&#160;million upfront payment in July 2021. Revenue was recognized on a straight-line basis over the timeframe for completing the Horizon R&amp;D Services, concluding in the first quarter of 2023. Further, the Company received an additional $15.0&#160;million upon Horizon&#8217;s initiation of a Phase 1 clinical trial in January 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 6, 2023, Amgen completed its acquisition of Horizon and subsequently notified the Company of Amgen&#8217;s intent to terminate the HZN-457 license. Horizon exercised its right to terminate the Horizon License Agreement for convenience, which took effect on December 21, 2023. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop the Company&#8217;s fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit sharing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on net sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Takeda License Agreement, the Company received $300.0&#160;million as an upfront payment in January 2021 and an additional $40.0&#160;million upon Takeda&#8217;s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to $527.5&#160;million in additional potential development, regulatory and commercial milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;D Services. Revenue was recognized using the input method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Phase 2 study visits for patients in the SEQUOIA and AROAAT2002 studies concluded by December 31, 2023, and the Company has substantially completed its performance obligation under the Takeda license agreement. As such, all revenue has been fully recognized as of December 31, 2023. There were no further deferred revenue and contract liabilities as of March 31, 2024</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has recorded $13.8&#160;million as accrued expenses as of March&#160;31, 2024 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company and the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. ARO-PNPLA3 is in Phase 1 clinical trials, which are </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">now being developed by the Company.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on December 11, 2023, the Company entered into the GSK-HBV Agreement, as discussed above, pursuant to which GSK received an exclusive license for JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen in October 2018.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi olpasiran (previously referred to as AMG- 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Olpasiran Agreement, the Company has received $35.0&#160;million in upfront payments and $21.5&#160;million in the form of an equity investment by Amgen in the Company&#8217;s common stock. Further, the Company received additional an $55.0&#160;million in milestone payments; $10.0&#160;million upon Amgen&#8217;s initiation of a Phase 1 study in September 2018,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$20.0&#160;million upon its initiation of a Phase 2 clinical study in July 2020, and $25.0&#160;million upon its first subject enrollment in a Phase 3 trial in December 2022. The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were no contract assets and liabilities recorded as of March&#160;31, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) and the Company entered into the Royalty Pharma Agreement. In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $535.0&#160;million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 11.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022, the Company and Visirna, its subsidiary, entered into a License Agreement (the &#8220;Visirna License Agreement&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#8217;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan). </span></div>The Company also performs manufacturing and development work pursuant to a Clinical Supply Agreement between the parties contemplated by the Visirna License Agreement. The Company received $0.1&#160;million and $0.9&#160;million as consideration for this manufacturing and development work for the six months ended March&#160;31, 2024 and 2023, respectively. There were no contract assets and liabilities recorded as of March&#160;31, 2024.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426947701024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Accounts</a></td>
<td class="text">BALANCE SHEET ACCOUNTS<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property, Plant and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property, plant and equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Land</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">75,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">62,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">56,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Computers and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">104,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">103,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">158,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">166,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">409,223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">332,213&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(49,971)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(41,951)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">359,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">290,262&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property, plant and equipment for the three months ended March&#160;31, 2024 and 2023 was $4.1&#160;million and $2.2&#160;million, respectively. Depreciation and amortization expense for property and equipment for the six months ended March&#160;31, 2024 and 2023 was $7.9&#160;million and $4.5&#160;million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of fiscal 2024, the Company completed the build out of one of its laboratory and office facilities in Verona, Wisconsin, which resulted in the reclassification of $75.3&#160;million from construction in progress to building as of March&#160;31, 2024. Further, the Company commenced depreciation on the newly completed facility over a 39-year period.  </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued R&amp;D expenses</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">14,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">16,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued R&amp;D expenses; co-development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">13,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued capital expenditures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">7,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">14,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total accrued expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">37,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">39,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//210/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426863564336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">INVESTMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">396,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(850)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">396,249&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(850)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395,410&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"><tr><td style="width:1.0%"></td><td style="width:45.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">295,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">292,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">295,699&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,967)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">292,735&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div>The Company has determined that the available-for-sale securities that were in an unrealized loss position did not have any credit loss impairment as of March&#160;31, 2024 and 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866966576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">INTANGIBLE ASSETS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,097&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,445&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,412&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,595&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,262&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the six months ended March&#160;31, 2024 and 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense was $0.4 million for each of the three months ended March&#160;31, 2024 and 2023, and $0.9 million for each of six months ended March&#160;31, 2024 and 2023. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future amortization expense related to intangible assets as of March&#160;31, 2024:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:71.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426864612512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:30.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024 and September&#160;30, 2023, respectively, 11,723,683 and 12,709,837 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, 2021 Incentive Plan, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 2, 2024, the Company entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued 15,790,000 shares of common stock at an offering price of $28.50 per share. The aggregate purchase price paid by investors was $450.0&#160;million and the Company received net proceeds of $429.3&#160;million after deducting advisory fees and offering expenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into an open market sale agreement (the &#8220;Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of March&#160;31, 2024, no shares have been issued under the Open Market Sale Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426863512688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of March&#160;31, 2024. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#8217;s manufacturing process development and analytical activities. During the first quarter of fiscal 2024, the Company completed the build out of one of its laboratory and office facilities.</span></div>As of March&#160;31, 2024, the Company has incurred $247.0 million and intends to spend an additional $37.0 million to $51.0 million to complete the build out of the facilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426863514464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases 49,000 square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for one additional five-year term. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases 144,000 square feet of office and research and development laboratory space located at 10102 Hoyt Park, San Diego, California, which lease expires on April&#160;30, 2038. Pursuant to the lease, within </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease agreement grants the Company the right to receive an Additional Tenant Improvement Allowance (&#8220;ATIA&#8221;) funded by the lessor, with a maximum amount of $7.2 million, subject to a 7% interest per annum over the base term. Further, on September&#160;25, 2023, the Company executed the first amendment to the lease, which grants a second ATIA with a maximum amount of $23.6 million, bearing interest at a rate of 9% per annum over the base term. The Company received $30.8&#160;million</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ATIA from the lessor during the first quarter of fiscal 2024. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increased lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company previously subleased additional research and development space in San Diego, California, which subleases ended during the fiscal year of 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases space for office and laboratory facilities, which expires on September&#160;30, 2031. The lease contains options to renew for two terms of five years. After accounting for additional rental square feet added pursuant to amendments to the lease agreement in 2019 and 2020, the Company currently leases a total of 115,000  square feet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,563&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">113,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">491&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">967&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,899&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Variable lease cost is primarily related to operating expenses associated with the Company&#8217;s operating leases.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was no short-term lease cost during the first half of fiscal 2024. There was $0.4&#160;million and $0.7&#160;million short-term lease cost during the three and six months ended March&#160;31, 2023, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of March&#160;31, 2024:</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:83.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024 (remainder of fiscal year)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">6,997&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,696&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">14,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">13,511&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2029 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">128,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">194,785&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(75,868)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">118,917&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash received for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchanged for amended operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426947306944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#8220;2004 Plan&#8221;) and the 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), 0 and 2,967,887 shares, respectively, of the Company&#8217;s common stock are reserved for grants of stock options and restricted stock awards to employees and directors as of March&#160;31, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2021, the Company&#8217;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), which authorized 8,000,000 shares (subject to certain adjustments) available for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of March&#160;31, 2024, the total number of shares available for issuance was 4,553,827 shares, which includes 158,678 and 134,389 shares that were forfeited under the 2013 and 2021 Plans, respectively, and 3,689,089 shares have been granted under the 2021 Plan.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there were 688,165 shares reserved for options and 637,563 shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,358,377&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">688,165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,078,693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,609,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,844,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">637,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,091,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,967,887&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,876,241&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,325,728&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,169,856&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expenses included in operating expenses:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,097&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,745&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,413&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,147&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,491&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,588&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,613&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,273&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,002&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the six months ended March&#160;31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,263,477</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">22.68&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cancelled or expired</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(30,437)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">61.11&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(154,347)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,078,693</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">23.04&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4.0 years</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">26,788,979&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at March&#160;31, 2024</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,054,866</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">22.72&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3.9 years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">26,788,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the three months ended March&#160;31, 2024 </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 2023 was $2.5 million and $1.4 million, respectively. The total intrinsic value of the options exercised during the six months ended March&#160;31, 2024 and 2023 was $3.1&#160;million and $3.6&#160;million, respectively</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options outstanding for the three months ended March&#160;31, 2024 and 2023, was $0.6 million and $2.2 million, respectively. Stock-based compensation expense related to stock options outstanding for the six months ended March&#160;31, 2024 and 2023, was $2.1&#160;million and $4.6&#160;million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March&#160;31, 2024, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $0.8&#160;million will be recognized in the Company&#8217;s results of operations over a weighted average period of 4 months.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. No options were granted during the six months ended March&#160;31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Visirna ESOP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: On October 1, 2023, Visirna, a subsidiary of the Company, granted 7,500,000 stock options to its employees from the Employee Stock Option Plan (the &#8220;Visirna ESOP&#8221;), which authorizes 20,000,000 shares for issuance. The Visirna ESOP is independently managed by Visirna, including the valuation process. For the three and six months ended March&#160;31, 2024, stock-based compensation expense related to the Visirna ESOP was $1.2&#160;million and $3.2 million, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted Stock Units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,241,640</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">58.43&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,838,025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(876,352)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">53.60&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(112,150)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">44.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,091,163</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">49.58&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March&#160;31, 2024 and 2023, the Company recorded $16.0 million and $18.4 million of expense related to RSUs, respectively. For the six months ended March&#160;31, 2024 and 2023, the Company recorded $32.2&#160;million and $35.4&#160;million of expense related to RSUs, respectively. As of March&#160;31, 2024, there was $112.0&#160;million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 1.7 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426864622272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The Company&#8217;s valuation techniques and inputs used to measure fair value and the definition of the three levels (Level 1, Level 2, and Level 3) of the fair value hierarchy are disclosed in Note 10 - Fair Value Measurements of Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules&#8221; of its Annual Report on Form 10-K for the year ended September 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At March&#160;31, 2024 and September&#160;30, 2023, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">217,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">217,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">390,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,073&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,997&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,070&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395,444&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">482,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">231,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">231,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total available-for-sale securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">261,182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">292,735&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">261,182&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">293,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426864623328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract', window );"><strong>Liability Related To The Sale Of Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock', window );">Liability Related to the Sale of Future Royalties</a></td>
<td class="text">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0&#160;million in cash to the Company in consideration for the Company&#8217;s future royalty interest in olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in September 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0 million upfront and agreed to pay up to an additional $160.0&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0&#160;million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $50.0&#160;million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0&#160;million upon Royalty Pharma&#8217;s receipt of at least $70.0&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $250.0&#160;million from Royalty Pharma was recorded as a liability related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay this upfront funding received under the  Royalty Pharma Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records the obligations at their carrying value using the effective interest method. In order to amortize the sale of future royalties, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods. The Company periodically assesses the amount and the timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success and sales price, among others. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. As of March&#160;31, 2024, the estimated effective interest rate was 9.3%. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity with respect to the liability related to the sale of future royalties.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying value as of September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">268,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash interest expense recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying value as of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">280,938&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426863503872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">NET LOSS PER SHARE<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net loss per share for the three and six months ended March&#160;31, 2024 and 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                            </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:43.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(125,300)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,675&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(258,164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">108,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net (loss) gain per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net (loss) gain per share</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.02)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426947641376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</a></td>
<td class="num">$ (125,300)<span></span>
</td>
<td class="nump">$ 48,675<span></span>
</td>
<td class="num">$ (258,164)<span></span>
</td>
<td class="nump">$ 7,350<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866324432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended March&#160;31, 2024, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.354%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.358%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Adoption Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Plan Start Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Plan End Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Vesting and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Subject to</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Sell-To-</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Cover </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Other<br/>Shares<br/>Being Sold<br/>(Subject to<br/>Certain<br/>Conditions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">James Hamilton</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chief Discovery and Translational Medicine</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3/26/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/6/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/17/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">60,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ken Myszkowski</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3/12/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">6/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">2/28/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">115,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ken Myszkowski</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3/28/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/6/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/17/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">15,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ken Myszkowski</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3/28/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/6/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/17/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">15,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ken Myszkowski</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3/28/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/6/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/17/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">15,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Ken Myszkowski</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3/28/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/6/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/17/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">18,750</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Patrick O'Brien</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Chief Operating Officer and General Counsel</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3/21/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/6/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">1/17/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">67,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">William Waddill</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">Board Member</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">3/27/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">12/16/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">12/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%">7,495</span></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span> This column indicates the total number of shares vesting in connection with equity awards, not the number of shares to be sold. The actual number of shares to be sold will be a smaller number based on whatever is required to satisfy payment of applicable withholding taxes under sell-to-cover arrangements.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_JamesHamiltonMember', window );">James Hamilton [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">James Hamilton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Discovery and Translational Medicine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">3/26/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_PatrickOBrienMember', window );">Patrick O'Brien [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Patrick O'Brien<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Operating Officer and General Counsel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">3/21/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">67,500<span></span>
</td>
<td class="nump">67,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_WilliamWaddillMember', window );">William Waddill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">William Waddill<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Board Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">3/27/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">7,495<span></span>
</td>
<td class="nump">7,495<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=arwr_KenMyszkowskiMarch12PlanMember', window );">Ken Myszkowski March 12 Plan [Member] | Ken Myszkowski [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Ken Myszkowski<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">3/12/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">262 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=arwr_KenMyszkowskiMarch28Plan1Member', window );">Ken Myszkowski March 28 Plan 1 [Member] | Ken Myszkowski [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Ken Myszkowski<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">3/28/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=arwr_KenMyszkowskiMarch28Plan2Member', window );">Ken Myszkowski March 28 Plan 2 [Member] | Ken Myszkowski [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Ken Myszkowski<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">3/28/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=arwr_KenMyszkowskiMarch28Plan3Member', window );">Ken Myszkowski March 28 Plan 3 [Member] | Ken Myszkowski [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Ken Myszkowski<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">3/28/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=arwr_KenMyszkowskiMarch28Plan4Member', window );">Ken Myszkowski March 28 Plan 4 [Member] | Ken Myszkowski [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Ken Myszkowski<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">3/28/2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">18,750<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_JamesHamiltonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_JamesHamiltonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_PatrickOBrienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_PatrickOBrienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_WilliamWaddillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_WilliamWaddillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=arwr_KenMyszkowskiMarch12PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=arwr_KenMyszkowskiMarch12PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_KenMyszkowskiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_KenMyszkowskiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=arwr_KenMyszkowskiMarch28Plan1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=arwr_KenMyszkowskiMarch28Plan1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=arwr_KenMyszkowskiMarch28Plan2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=arwr_KenMyszkowskiMarch28Plan2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=arwr_KenMyszkowskiMarch28Plan3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=arwr_KenMyszkowskiMarch28Plan3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=arwr_KenMyszkowskiMarch28Plan4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=arwr_KenMyszkowskiMarch28Plan4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426955737536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to improve its income tax disclosure requirements. Under the ASU, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This ASU will become effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426869654832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfCurrentProductsTableTextBlock', window );">Schedule of Company's Current Pipeline</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.172%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.508%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">plozasiran (ARO-APOC3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">zodasiran (ARO-ANG3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">olpasiran</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-RAGE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK-4532990</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">fazirsiran</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-PNPLA3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-CFB</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Muscle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-DUX4</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ARO-DM1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Central Nervous System (CNS)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Various</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Arrowhead</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfCurrentProductsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Current Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfCurrentProductsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426864740192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Summary of Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.988%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">30,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,685&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">29,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Horizon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,667&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">116,156&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">132,468&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Janssen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">111&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">355&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">146,267&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,551&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">208,813&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Receivables and Contract Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"><tr><td style="width:1.0%"></td><td style="width:59.575%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.947%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.414%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.950%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Receivables included in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Contract liabilities included in deferred revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">866&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426947717776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property, plant and equipment:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Land</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Building</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">75,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Research equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">62,926&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">56,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Furniture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,540&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Computers and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">923&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">104,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">103,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">158,243&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">166,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">409,223&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">332,213&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(49,971)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(41,951)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Property, plant and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">359,252&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">290,262&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses consist of the following:</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued R&amp;D expenses</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">14,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">16,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued R&amp;D expenses; co-development</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">13,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,895&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Accrued capital expenditures</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">7,265&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">14,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3,699&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total accrued expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">37,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">39,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426864617344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock', window );">Summary of Short-term and Long-term Investments and Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.269%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">396,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(850)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">396,249&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(850)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395,410&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"><tr><td style="width:1.0%"></td><td style="width:45.323%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.284%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.185%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Available-for-sale securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">295,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,967)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">292,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total current investments</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">295,699&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2,967)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">292,735&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426955699632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table presents the components of intangible assets: <div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.361%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,097&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,631&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,348&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,781&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,445&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,412&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">14,595&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,262&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Intangible Assets Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the estimated future amortization expense related to intangible assets as of March&#160;31, 2024:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:71.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortization Expense</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2024 (remainder)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">850&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2027</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866922512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Shares of Common Stock and Preferred Stock</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:30.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.047%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.049%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Par Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">124,133&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866852048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Assets and Liabilities and Lease Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.144%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">44,626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">45,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,285&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">10,563&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">113,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">104,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:17.839%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.298%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,572&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,412&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">491&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">967&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,033&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Variable lease cost </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">160&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">370&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,899&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,003&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,148&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,815&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) Variable lease cost is primarily related to operating expenses associated with the Company&#8217;s operating leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of March&#160;31, 2024:</span></div><div style="margin-top:12pt;padding-left:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:83.996%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.804%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2024 (remainder of fiscal year)</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">6,997&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2026</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">15,696&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">14,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">13,511&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2029 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">128,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">194,785&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Less imputed interest</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(75,868)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Total operating lease liabilities (includes current portion)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">118,917&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"></td><td style="width:39.284%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.162%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.166%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash received for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,929&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Right-of-use assets obtained in exchanged for amended operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,582&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">13.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">6.6</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426948099792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Awards Outstanding</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.381%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.708%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.711%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,358,377&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">32,151&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">688,165&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,078,693&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,609,510&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,844,090&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">637,563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">5,091,163&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,967,887&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2,876,241&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,325,728&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,169,856&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock-based compensation expenses included in operating expenses:</span></div><div style="margin-top:6pt;text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:31.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.370%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,097&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">8,745&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">15,413&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">17,147&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">9,491&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">11,868&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">18,860&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,855&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">16,588&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">20,613&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">34,273&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">40,002&#160;</span></td><td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarized Information about Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the six months ended March&#160;31, 2024:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,263,477</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">22.68&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Cancelled or expired</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(30,437)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">61.11&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercised</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(154,347)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">11.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,078,693</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">23.04&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4.0 years</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">26,788,979&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Exercisable at March&#160;31, 2024</span></div></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">2,054,866</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">22.72&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">3.9 years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">26,788,746&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Share Activity Related to RSUs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at September&#160;30, 2023</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">4,241,640</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">58.43&#160;</span></td><td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Granted</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">1,838,025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">30.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Vested</span></td><td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(876,352)</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">53.60&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Forfeited</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(112,150)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">44.16&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Outstanding at March&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">5,091,163</span></td><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">49.58&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426864732464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.445%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.449%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,963&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">120,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">217,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">217,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,963&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">390,447&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395,410&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">77,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. Treasuries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,993&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">82,073&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,997&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,070&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">87,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">395,444&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">482,480&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Available-for-sale securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">U.S. government bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Commercial notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">22,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">231,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">231,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total available-for-sale securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">261,182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">292,735&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Money market instruments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">347&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total financial assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">31,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">261,182&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">293,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866922512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract', window );"><strong>Liability Related To The Sale Of Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock', window );">Schedule of Liability Related to the Sale of Future Royalties</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the activity with respect to the liability related to the sale of future royalties.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:79.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.688%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Carrying Amount</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying value as of September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">268,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash interest expense recognized</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">12,612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Carrying value as of March 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">280,938&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426869593776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted net loss per share for the three and six months ended March&#160;31, 2024 and 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                            </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:43.057%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.253%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.260%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(125,300)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">48,675&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(258,164)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">7,350&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">106,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,386&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">1,499&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">123,285&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">108,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">115,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">107,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Basic net (loss) gain per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.02)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Diluted net (loss) gain per share</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1.02)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.45&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2.24)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">0.07&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.006%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Three Months Ended March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Six Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">767&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted stock units</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,411&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,931&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">3,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,006&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,350&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,588&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">4,069&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426955893552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies - Narrative (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 127,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale securities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">395,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 292,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_IncreaseDecreaseInCashAndInvestments', window );">Increase (decrease) in cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(3,313)<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_UnderwritingAgreementMember', window );">Underwriting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 429,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock issued (in shares)</a></td>
<td class="nump">15,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock offering price (in dollars per share)</a></td>
<td class="nump">$ 28.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SaleOfStockAggregatePurchasePrice', window );">Aggregate purchase price paid by investors</a></td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Royalty Pharma Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial', window );">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_IncreaseDecreaseInCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in cash and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_IncreaseDecreaseInCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OrganizationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SaleOfStockAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SaleOfStockAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426955726048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 146,267<span></span>
</td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="nump">$ 208,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">2,685<span></span>
</td>
<td class="nump">29,323<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,667<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">116,156<span></span>
</td>
<td class="nump">866<span></span>
</td>
<td class="nump">132,468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">111<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">355<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_AmgenIncorporatedMember', window );">Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_HorizonTherapeuticsIrelandDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_HorizonTherapeuticsIrelandDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426947628720">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Receivables and Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Receivables included in accounts receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities included in deferred revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426864997440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Dec. 11, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Nov. 22, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | GSK License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree', window );">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | GSK License Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale', window );">Commercial milestone payments at first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 590,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | GSK-HBV Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | GSK-HBV Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentAndSalesMilestonesPayments', window );">Development and sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 832,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments at first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommercialMilestonePaymentsAtFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development And Sales Milestones Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SalesRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-related milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SalesRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_GSKLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_GSKLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_GSKHBVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_GSKHBVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426984521392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details) - Horizon - Horizon License Agreement<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>obligation</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 40.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_HorizonTherapeuticsIrelandDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_HorizonTherapeuticsIrelandDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_HorizonLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_HorizonLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426955721920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>obligation </div>
<div>bundle</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,055<span></span>
</td>
<td class="nump">$ 39,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible to receive tiered royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426955916048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Amgen, Inc (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net of offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 429,265,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfAgreements', window );">Number of agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Upfront payment</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the issuance of common stock, net of offering costs</a></td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments', window );">Additional remaining development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 535,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional remaining development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426948008080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Visirna Therapeutics, Inc. (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 146,267<span></span>
</td>
<td class="nump">$ 3,551<span></span>
</td>
<td class="nump">$ 208,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_VisirnaTherapeuticsIncMember', window );">Visirna Therapeutics, Inc. | Visirna License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_VisirnaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_VisirnaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_VisirnaLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_VisirnaLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866618944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Accounts - Summary of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 409,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 409,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 332,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(49,971)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(49,971)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41,951)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">359,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">359,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense for property and equipment</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
<td class="nump">7,900<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,996<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">75,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property, plant and equipment, reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">39 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">62,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,926<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,509<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">4,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputerAndSoftwareMember', window );">Computers and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">923<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">104,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103,813<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 158,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,243<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges', window );">Property, plant and equipment, reclassification</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (75,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTransfersAndChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTransfersAndChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputerAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputerAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426865331552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Accounts - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AccruedResearchAndDevelopmentExpenseCurrent', window );">Accrued R&amp;D expenses</a></td>
<td class="nump">$ 14,443<span></span>
</td>
<td class="nump">$ 16,125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent', window );">Accrued R&amp;D expenses; co-development</a></td>
<td class="nump">13,751<span></span>
</td>
<td class="nump">5,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AccruedCapitalExpenditureCurrent', window );">Accrued capital expenditures</a></td>
<td class="nump">7,265<span></span>
</td>
<td class="nump">14,044<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,596<span></span>
</td>
<td class="nump">3,699<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expense</a></td>
<td class="nump">$ 37,055<span></span>
</td>
<td class="nump">$ 39,763<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AccruedCapitalExpenditureCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Capital Expenditure, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AccruedCapitalExpenditureCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Co-Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Research And Development Expense, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426955909088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Current investments, Available-for-sale, Adjusted Basis</a></td>
<td class="nump">$ 396,249<span></span>
</td>
<td class="nump">$ 295,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent', window );">Current investments, Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent', window );">Current investments, Available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(850)<span></span>
</td>
<td class="num">(2,967)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Current investments, Available-for-sale, Fair Value</a></td>
<td class="nump">395,410<span></span>
</td>
<td class="nump">292,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Current investments, Available-for-sale, Adjusted Basis</a></td>
<td class="nump">396,249<span></span>
</td>
<td class="nump">295,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent', window );">Current investments, Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent', window );">Current investments, Available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(850)<span></span>
</td>
<td class="num">(2,967)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Current investments, Available-for-sale, Fair Value</a></td>
<td class="nump">$ 395,410<span></span>
</td>
<td class="nump">$ 292,735<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426865850464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 9,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,262,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">24,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,857,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">15,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,445,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,595,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">9,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,412,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,262,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">21,728,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,728,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,728,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">14,097,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,097,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,321,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 7,631,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,631,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,407,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">14 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 3,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,129,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,348,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,274,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1,781,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,781,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,855,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FiniteLivedIntangibleAssetsImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FiniteLivedIntangibleAssetsImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=arwr_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426869445952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Expected Future Amortization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2024 (remainder)</a></td>
<td class="nump">$ 850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2025</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2026</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2027</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2028</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour', window );">Thereafter</a></td>
<td class="nump">1,762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 9,412<span></span>
</td>
<td class="nump">$ 10,262<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Amortization, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866322560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 02, 2024</div></th>
<th class="th"><div>Dec. 02, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,133,000<span></span>
</td>
<td class="nump">107,312,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,133,000<span></span>
</td>
<td class="nump">107,312,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, share reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,553,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_UnderwritingAgreementMember', window );">Underwriting Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares of common stock issued (in shares)</a></td>
<td class="nump">15,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock offering price (in dollars per share)</a></td>
<td class="nump">$ 28.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SaleOfStockAggregatePurchasePrice', window );">Aggregate purchase price paid by investors</a></td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="nump">$ 429,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">At The Market Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">At The Market Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance', window );">Common stock shares value reserved for future issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock', window );">Percentage of commission to sales agent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember', window );">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, share reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,723,683<span></span>
</td>
<td class="nump">12,709,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares value reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommonStockCapitalSharesValueReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on aggregate gross proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SaleOfStockAggregatePurchasePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Aggregate Purchase Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SaleOfStockAggregatePurchasePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_UnderwritingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_UnderwritingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866357584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Detail)<br> ft&#178; in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember', window );">Drug Manufacturing Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of the site (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember', window );">Laboratory and Office Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of the site (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommitmentsCapitalExpendituresIncurredToDate', window );">Capital expenditures incurred</a></td>
<td class="nump">247,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities', window );">Amount intends to invest for buildout of the facilities</a></td>
<td class="nump">37,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities', window );">Amount intends to invest for buildout of the facilities</a></td>
<td class="nump">$ 51,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AmountIntendsToInvestForBuildoutOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount intends to invest for buildout of facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AmountIntendsToInvestForBuildoutOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommitmentsCapitalExpendituresIncurredToDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments, Capital Expenditures Incurred To Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommitmentsCapitalExpendituresIncurredToDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866333536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> ft&#178; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 25, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost | $</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California | Colorado Owner, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MaximumAdditionalTenantImprovementAllowance', window );">Maximum additional tenant improvement allowance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum', window );">Additional tenant improvement allowance interest per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalTenantImprovementAllowanceLiability', window );">Additional tenant improvement allowance liability | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember', window );">Research Facility in Madison | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Tenant Improvement Allowance, Interest Per Annum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalTenantImprovementAllowanceLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Tenant Improvement Allowance Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalTenantImprovementAllowanceLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MaximumAdditionalTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Additional Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MaximumAdditionalTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfOptionsToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options to renew.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfOptionsToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426948088736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Lease Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 44,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,297<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">5,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">113,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,632<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">3,899<span></span>
</td>
<td class="nump">$ 3,003<span></span>
</td>
<td class="nump">8,148<span></span>
</td>
<td class="nump">$ 5,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">2,572<span></span>
</td>
<td class="nump">2,343<span></span>
</td>
<td class="nump">5,566<span></span>
</td>
<td class="nump">4,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">1,615<span></span>
</td>
<td class="nump">370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">491<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">967<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426948045888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2024 (remainder of fiscal year)</a></td>
<td class="nump">$ 6,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">15,356<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">15,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">14,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">13,511<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive', window );">2029 and thereafter</a></td>
<td class="nump">128,356<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">194,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(75,868)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities (includes current portion)</a></td>
<td class="nump">$ 118,917<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due year five and after year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866569184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash received for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 8,918<span></span>
</td>
<td class="nump">$ 3,099<span></span>
</td>
<td class="nump">$ 17,929<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for amended operating lease liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="nump">22,582<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 2,046<span></span>
</td>
<td class="nump">$ 1,098<span></span>
</td>
<td class="nump">$ 4,016<span></span>
</td>
<td class="nump">$ 2,196<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">13 years<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">13 years<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866111968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 01, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, share reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,553,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,553,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,588<span></span>
</td>
<td class="nump">$ 20,613<span></span>
</td>
<td class="nump">$ 34,273<span></span>
</td>
<td class="nump">$ 40,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">$ 18,400<span></span>
</td>
<td class="nump">$ 32,200<span></span>
</td>
<td class="nump">$ 35,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,967,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,967,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,678<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134,389<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,689,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards | Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">637,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_VisirnaESOPMember', window );">Visirna ESOP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_InducementAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_VisirnaESOPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_VisirnaESOPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866377600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details) - shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">2,078,693<span></span>
</td>
<td class="nump">2,263,477<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">7,169,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">5,091,163<span></span>
</td>
<td class="nump">4,241,640<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Equity Incentive Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">1,358,377<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">2,967,887<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Incentive Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">1,609,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">32,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">2,876,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Incentive Plan | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">2,844,090<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding (in shares)</a></td>
<td class="nump">688,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">1,325,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards | Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">637,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_InducementAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426865641184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Expenses Included in Operating Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 16,588<span></span>
</td>
<td class="nump">$ 20,613<span></span>
</td>
<td class="nump">$ 34,273<span></span>
</td>
<td class="nump">$ 40,002<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">7,097<span></span>
</td>
<td class="nump">8,745<span></span>
</td>
<td class="nump">15,413<span></span>
</td>
<td class="nump">17,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 9,491<span></span>
</td>
<td class="nump">$ 11,868<span></span>
</td>
<td class="nump">$ 18,860<span></span>
</td>
<td class="nump">$ 22,855<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426867135616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summarize Information about Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">2,263,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(30,437)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(154,347)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">2,078,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable (in shares) | shares</a></td>
<td class="nump">2,054,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">61.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">11.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">23.04<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 22.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted- Average Remaining Contractual Term (Years)</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 26,788,979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 26,788,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866749616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSUs Activity (Details) - Restricted stock units<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of period (in shares) | shares</a></td>
<td class="nump">4,241,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,838,025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(876,352)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(112,150)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of period (in shares) | shares</a></td>
<td class="nump">5,091,163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 58.43<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">30.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">53.60<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">44.16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 49.58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426862494912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">$ 395,410<span></span>
</td>
<td class="nump">$ 292,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">87,070<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">482,480<span></span>
</td>
<td class="nump">293,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">77,080<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">4,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">4,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">48,637<span></span>
</td>
<td class="nump">31,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">3,949<span></span>
</td>
<td class="nump">7,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">120,710<span></span>
</td>
<td class="nump">22,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">217,151<span></span>
</td>
<td class="nump">231,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="nump">31,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">82,073<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">87,036<span></span>
</td>
<td class="nump">31,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">77,080<span></span>
</td>
<td class="nump">347<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">4,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,553<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">390,447<span></span>
</td>
<td class="nump">261,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">4,997<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">395,444<span></span>
</td>
<td class="nump">261,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">4,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">48,637<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">3,949<span></span>
</td>
<td class="nump">7,093<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">120,710<span></span>
</td>
<td class="nump">22,205<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">217,151<span></span>
</td>
<td class="nump">231,884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=arwr_CommercialNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=arwr_CommercialNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426865638416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties - Narrative (Details) - Royalty Pharma Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Upfront payment</a></td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="nump">160.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponFDAApproval', window );">Milestone payment receivable upon FDA approval</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments', window );">Milestone payment receivable upon receipt of royalty payments</a></td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltyPaymentThreshold', window );">Royalty payment threshold</a></td>
<td class="nump">70.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilitySaleOfFutureRoyalties', window );">Liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate', window );">Liability related to the sale of future royalties, interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial', window );">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 410.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilitySaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability, Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilitySaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilitySaleOfFutureRoyaltiesInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability, Sale Of Future Royalties, Interest Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilitySaleOfFutureRoyaltiesInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable, Upon FDA Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable, Upon Receipt Of Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltyPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltyPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426869392832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties - Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilitySaleOfFutureRoyaltiesRollForward', window );"><strong>Liability, Sale Of Future Royalties [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltiesLiabilityNoncurrent', window );">Carrying value as of September 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 268,326<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense recognized</a></td>
<td class="nump">$ 12,612<span></span>
</td>
<td class="nump">12,612<span></span>
</td>
<td class="nump">$ 7,906<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltiesLiabilityNoncurrent', window );">Carrying value as of March 31, 2024</a></td>
<td class="nump">$ 280,938<span></span>
</td>
<td class="nump">$ 280,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilitySaleOfFutureRoyaltiesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability, Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilitySaleOfFutureRoyaltiesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltiesLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltiesLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866648960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.</a></td>
<td class="num">$ (125,300)<span></span>
</td>
<td class="nump">$ 48,675<span></span>
</td>
<td class="num">$ (258,164)<span></span>
</td>
<td class="nump">$ 7,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic shares outstanding (in shares)</a></td>
<td class="nump">123,285<span></span>
</td>
<td class="nump">106,757<span></span>
</td>
<td class="nump">115,307<span></span>
</td>
<td class="nump">106,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted shares outstanding (in shares)</a></td>
<td class="nump">123,285<span></span>
</td>
<td class="nump">108,143<span></span>
</td>
<td class="nump">115,307<span></span>
</td>
<td class="nump">107,893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net (loss) gain per share (in dollars per share)</a></td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="num">$ (2.24)<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net (loss) gain per share (in dollars per share)</a></td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="nump">$ 0.45<span></span>
</td>
<td class="num">$ (2.24)<span></span>
</td>
<td class="nump">$ 0.07<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1.u1</span><table class="report" border="0" cellspacing="2" id="idm140426866794400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Antidulitive (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">4,006<span></span>
</td>
<td class="nump">4,350<span></span>
</td>
<td class="nump">4,588<span></span>
</td>
<td class="nump">4,069<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">595<span></span>
</td>
<td class="nump">767<span></span>
</td>
<td class="nump">657<span></span>
</td>
<td class="nump">779<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">3,411<span></span>
</td>
<td class="nump">3,583<span></span>
</td>
<td class="nump">3,931<span></span>
</td>
<td class="nump">3,290<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>87
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M0=5 Y3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%
M  @ *8&I6&111B+O!0  PQ\  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6RUF?]OXC88QO\5BTW3)I62.!3:6XN4IG2'UO8XZ.VT3?O!30Q$E\3,<:#\
M]WL=(*&5\Y)%Q_UPY-OSU)_XVQ/[>BWDMW3!N2*O<92D-ZV%4LL/G4[J+WC,
MTG.QY G<F0D9,P6G<MY)EY*S(!?%48=:5J\3LS!I#:[S:V,YN!:9BL*$CR5)
MLSAF<G/+([&^:=FM_85).%\H?:$SN%ZR.9]R]64YEG#6*5R",.9)&HJ$2#Z[
M:;GV!\]QM"!_XH^0K].#8Z)17H3XID]&P4W+TB7B$?>5MF#PL^(>CR+M!.7X
M=V?:*OZF%AX>[]WO<WB >6$I]T3T-0S4XJ9UV2(!G[$L4A.Q_LAW0!?:SQ=1
MFO]/UMMGN]T6\;-4B7@GAA+$8;+]9:^[%W$HL"L$=">@[P2V4R%P=H+\S76V
M)<NQ[IAB@VLIUD3JI\%-'^3O)E<#39CH:IPJ"7=#T*F!)U9<DC9)%TSR]+JC
MP%/?Z?@[_>U63ROT/?(H$K5(R3 )>/!6WX&R% 6B^P+=4M3PD<ESXMAGA%JT
M:RB/=TR^(991_:8T3O%ZG-S.05_/W^Y+JB2TN'],+VCKT#4[Z&[X(5TRG]^T
MH)^E7*YX:_#3#W;/^M5$]YW,WL!V"]@NYCZX$WX&/521Y\V2FTAQN6VU/YN0
M4%5#I(L"Z:(>TN>,2<5EM"$3OA12F?!P*R4STTOQ4%5#O%Z!UZN'-^8R%('N
MA 2& 6/EX4Y%MZOL=ZB^(6>_X.S7;)F2P0R23P#5]8A[S5B4&BL2E34$O"P
M+]%"#1,5J@VY#R-.GK+XA4L3&.YA67;;N;2ZU 2'2AO"715P5W7@)GP>ZF$4
MJO&)Q<8VBONXD\FGKQ^'[AT9?W0GCZXW_/(\\MR'Z1D9/7GG)FS4L"&V;95S
MJU4'?)3X0D)C9;K=GI&I@AY*A"2>R!(E-_ ;&-_&$?>[H8D8%S5%/H@3=AWD
M9_9*1@'TV' 6^CDWTJR/6'9[;:MK758,2[BX*2\M>6D=7C<(P#T]VQ^0!WB.
M?$K,]8I;VOT^&9Y#JXB@R02"W$:KP$B.VC0E+Y.1C681G/QY+8SDN.4T"Z%G
M]"W+B'N*:&27V<C&T\U[7$^?02=^%NO$B(K;C5G*H'\P(^DI$I-=1B8;#SKO
M28OQ:BS%*DQ\<YO&/3W7"'J*[&27X<G&,\][T+%(%8O(7^&R>DC&':]LV[HP
MDIXB/=EE?++QS),W5A<^\ZO!<(,>[1FQ3I&9[#(TV7CB>1 ^U-=X(1(L-1TQ
M<:QNV^E6C#FGB$UVF9ML// \APKRH)@1F_[\\@N9<C^34)-&2-S)$W$,<_!4
M"?_;&5DR258LRCCYT3J'V$B6\)&;KP 87\(I0A0M0Q3%8PY$_B!,YF2ZB5]$
M9&(_8N!.ODZ,"PFG2$JT3$H4CS7[VB3#5W_!DCFO3,5'C)[<Z9UK_/+&A4T)
MRVQ$:V4C+Y-2?[MM/]CRJH09)3,N-AUQ_-.X1.7AJJ:<91*BM9+0*%%<;I<E
M]4<XVX,;.7''*LY31"!:1B!:*P+ICU3X>(%0,!?2.!@=\7E@$EJ[Z_L<C, F
MV%H:B4\1A6@9A6BM*#2,N9SKAOL;.*@%3*+QDB5F=-RP<O$!US4%+:,0K16%
MIC&+(G*;I7 [-7=0W*>:[Q0!B)8!B.+Y9<^WX,"'55_#M2-<UQ2O#$*TUO+1
MVUE^FB_IDT^9@EB;Z#G42/R=(L[N/6S=+G(WO86T&MBT2RV+.A"P5B;(,@W1
M6LM('@RI$F+?* GX*_F=F^L1M[+@WV7_JFOUC1"G"#Q.&7@</*_LY\O[,-7Q
M]D\.:0U;V#UBUVY;5VW'&&]Q95/0,@$Y>' I5G4/2>_AHG'D.6)6M6R-RYHR
MEAG(P1/+>\;=0GTU)6[WV;BXBXN:,A[LD>%IQ07 8 L9,>,@<\2@<EC%=?\7
MK'.P3:IG]'SW."6^7H;=[I@65XL=:C??E^V4CV^WMQ^9#@0IB?@,I-9Y'T8\
MN=TQWIXHL<PW75^$4B+.#Q><!5SJ!^#^3 BU/]%_H-BW'_P'4$L#!!0    (
M "F!J5BILL!OK@8  -8;   8    >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL
MK5EM;]LV$/XKA%L4+6#'?-%KFAA(TPT+D'9!TVZ?&9F.B4JB2U).LU\_4E8M
M6Z28=.N7Q+*/Q^?N>/?<46</0GY5:\8T^%Z5M3J?K+7>G,[GJEBSBJH3L6&U
M^64E9$6U>93W<[61C"[;154YQQ F\XKR>K(X:[^[D8LST>B2U^Q& M54%96/
M[U@I'LXG:/+CBT_\?JWM%_/%V8;>LUNFOVQNI'F:[[4L><5JQ44-)%N=3R[0
MZ26)[()6XB_.'M3!9V!-N1/BJWVX6IY/H$7$2E9HJX*:?UMVR<K2:C(XOG5*
M)_L][<+#SS^T_]X:;XRYHXI=BO)OOM3K\TDV 4NVHDVI/XF'/UAG4&SU%:)4
M[5_PT,G""2@:I475+38(*E[O_M/OG2,.%J!H9 'N%N#G+B#= M(:ND/6FO6>
M:KHXD^(!2"MMM-D/K6_:U<8:7MLPWFII?N5FG5Y<BEJ)DB^I9DOPCI:T+ABX
MM>H4F($OM^_!ZY=OP$O :_!Y+1I%ZZ4ZFVNSLUT_+[I=WNUVP2.[?*#R!! T
M!1CBR+/\,KS\EFW,<M@N)\?+Y\;>O=%X;S1N]9$QHQLI6:T!5<K8>>JS9Z<@
M\BNPN76J-K1@YQ.3/(K)+9LL7KU "7SKL^X7*3NRE>QM)2'MBTNJUE-0F+^
M?6OXEI;&<@5,'$T6*BUY82-O?_>Y8:<[:77;BK!=()RFT,1P>VB@1PS!+$=[
ML2/HT1YZ%(1^L:6\I'<EFYER-5,&.5"L:"37G*DIH!JL*)? F-0P'_B=]O@
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M O#[2HCR]8MZP>X^?OP?4$L#!!0    ( "F!J5C]B] 4>@\  "$F   8
M>&PO=V]R:W-H965T<R]S:&5E=#<N>&ULK5IM4QLY$OXK*I;;@BK;& -)R%N5
M<0(AFX +0_;JKNZ#/"/;VLQ(L]*,C?/K[^G6O!E,V+VZ+V![I%:_//UTM^RW
M*^N^^X52N;A/$^/?[2SR/'M]<."CA4JE[]E,&3R969?*'&_=_,!G3LF8-Z7)
MP:#??W&02FUVWK_ES\;N_5M;Y(DV:NR$+])4NO692NSJW<[A3O7!C9XO<OK@
MX/W;3,[51.5WV=CAW4$M)=:I,EY;(YR:O=L9'KX^.Z;UO.";5BO?>BW(DJFU
MW^G-9?QNIT\*J41%.4F0^+=4(Y4D) AJ_%G*W*F/I(WMUY7T<[8=MDRE5R.;
M_*[C?/%NY]6.B-5,%DE^8U>?5&G/"<F+;.+YKUB%M<>G.R(J?&[3<C,T2+4)
M_^5]Z8?6AE?])S8,R@T#UCL<Q%I^D+E\_];9E7"T&M+H!9O*NZ&<-A242>[P
M5&-?_O[:S:71/V1PD8G%1,^-GNE(FEP,H\@6)M=F+L8VT9%6_NU!CE-I[T%4
MGG 63A@\<<(+\=6:?.'%1Q.K>'/_ ;2M51Y4*I\-?BKPJW0]<738$8/^X/@G
M\HYJ%QRQO*,GY&VQ4OQ[./6Y V3^L\W@(.]XNSQ*H]<^DY%ZMX,\\<HMU<[[
M7W\Y?-%_\Q-MCVMMCW\F_?\2L&=.N+D87EW^:WA[>7TEAE<?Q.3RXNKR_'(T
MO+H5P]'H^N[J]O+J0HROOUR.+C].Q(4RRLF$M;E1D8(B']02^9XA>W,OA@XV
M+L 88KR0R*1(%3GT37Q'7)JHQ_LTUOEBZG6LI:,(["$[E7,J%KD5"^64-@)@
MYVR&[+607N0+)7[]Y=5@T'\SLFDFS9K?';[9%](ID3D-HM%8J\P<#(-3##*6
M-2,7I2J&BXPB03(7.4@MQQ*.NYPF2L3:*V2\%].U\#I1)J)M=.I<U=LB67A%
M'Z8]<>=I@1139V%M9ET^0QBLL#-Q<S44Q*@:N"+[R&@UFU&,X*_4QO@,RV*5
MP#RW[O Q+:L.7[YA@YW,:#N$S.?*\2H2#;65@\.@HX)AT0(@\2GY3INXP&>T
M+^Y OLKX[+AP;.-W8Z/OL5T9.CV7;HY"P-;U'LO=*YV-![KVM(8MK1,9\H;\
M*& )N2,"Y9:^TF:AIQ1J4EO=TUIF=QPMA<]41$#FX]E^I^!X.9M1S$O'9\["
MG/SQ)CS(@9&>N-WB-U*X2^0=ERYD!'H0Z5HD (0#.O $IAB9%X3E3.:+%9[B
M$%*G'7Y;N8G<Z!=%+MA]M28E:KH$#-I0>I/T AI0!5D*.[]TEM\:[*@ _.')
M3&>*<O0UB:AT1U(I*:YDJL0D)^W'P3&"RZH7(^EB;5.%<X@(1);8'])K)XW8
M&]Y<=X?CZ]'1/B4DP'O42M$?-MY8=W51+QM,6^MLDI7K:ADI+!7C(DFM07T7
MM/UF>/&Q7'!X,)"M_?3TZ]WH9#CZR?.OXY?;GWZA)!$7D]^ZQR='@]/3?J,B
M/A0S^4.[3>UNY7<52XY9(^;SU>?NT>FKTVHW;Z:31T=/:S6^&G\9UL\?/!R=
MGVW?^;7P$2).:S[<_?/X:?$?OAYN?SA21$V)N$)%L847D[7/52KV1E>3??$-
M1$<?CIWJCH 6XM?6WE92"#1T3N;@D$1.X:E()SHG2D'&CF2BT>@9'1SUN_:1
M1?]E.F)%V<@L39"5+EH$%FEX/C18+*H#65%2Q%72ME<%*M0;>8AD1W2 492&
M[0D,*D?V9;!)W:NHH!( 2<@V8E(HEM@()C'!CZ67L3*RT[*&A,(Y,^EHQ0QF
M01*U#QLT*^!UU!BJGT6H.Z7B;*J,EY)(D'Q0I20_R*3+40"Q S4XUC'YMB<F
M3"N)^*[6<!D7Q;A=%(.'D-1,I"_>L!*)(B.4<>")M&113JO:$16<KT<?AU=[
M<E]T!5KM")E.)0'GP;]U:G:J,A&JTNY)O]='$YDD1)_XK]!>PHA,KODP8K;&
M&Q1SC3"OX)1,:O8M/09-NEC\6<!JI"".:[GS36W-.# ;K)EI@Z?PBA0S9],
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M!BSG].5)H#*4E'MDZ7$/O00"'1-Y/#'J<2'RMG!1N!0K@P9Q#83SA;/%/-0
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M\8GDEQM\DS+M!/#_6BF[WS@'PRMW^B]02P,$%     @ *8&I6#)[Q2/! @
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M_K##M/]:\ NK*G=#GRJ+]WWW-\</+- D@.]G2MGE@ARTGVRC_P!02P,$%
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MQM/K$Y85/?=H68#N.4?[#1LX_(&8_PM02P,$%     @ *8&I6,;Q!]5C"
M=A4  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&ULO5AM;]LX$OXKA#==
M-(!B2_)[F@1PL]W; NEMT?2V.!SN RW1,6\E44=*<?SO[YFA+,N)XQ;[X8 @
MIBC.^\PS(UYMC/W3K96JQ%.>%>ZZMZZJ\G(P<,E:Y=+U3:D*O%D9F\L*C_9A
MX$JK9,I$>3:(PW RR*4N>C=7O/?9WER9NLITH3Y;X>H\EW;[7F5F<]V+>KN-
M+_IA7='&X.:JE _J7E7_*#];/ U:+JG.5>&T*815J^O>(KI\/Z+S?. /K3:N
MLQ9DR=*8/^GA8WK="TDAE:FD(@X2/X_J5F49,8(:_VUX]EJ11-A=[[C_RK;#
MEJ5TZM9DWW1:K:][LYY(U4K66?7%;'Y3C3UCXI>8S/%_L?%G(QQ.:E>9O"&&
M!KDN_*]\:OS0(9B%KQ#$#4',>GM!K.4OLI(W5]9LA*73X$8+-I6IH9PN*"CW
ME<5;#;KJYD[!)'<UJ,"+=@9)0_?>T\6OT$W$)U-4:R<^%*E*#^D'T*%5)-XI
M\CX^R?"3M'TQC (1A_'H!+]A:]B0^0U/&B;^M5BZRB+V_SYFHV<Q.LZ"ZN'2
ME3)1USTDO%/V4?5N?OXIFH3O3B@X:A4<G>)^PO/?H?NPN/]P+SY+)U-5R$#<
MRDRC.@LMQ:7XNE;BUN2E++8B\RX8S8,P#)'OM;1*K*C2S0I_*YTHP?:)S"2R
M4JF0E8BF4_%!N@I<,F-E:L3[[#'M"T@0NG(B,;;$?J7$&AA /"MEG5A9DS-M
M2_;[IE V$'=WMX'8K'6R]OH(]51J>%.@)!>EU9D8AAST:9^5]X<2)!<0Q0E9
M"%-R_58&(%"@S$D34R@ATU33&YF)%2K[8JND%5 F[XM[D/VBU8/YOG>BT>B$
M>V21"@J]M-"?'E+U"" K 4N5R.22/&'L]H@;PRB,Q6]F6R%2]L_@N$H_Y)GA
MK"\^U];5$C+AA6KG)5#K:JWAFHW*'I7(?45">SK"W"2[KMG1!?P%;T7CO:\"
M?K/SR5HZ?MZ[7#U5"F:W,MG[=4FOGL4 Y[IL2361*$MAA.>*&D=TD5CO=>P1
MEE)$JV[<Y8-5BIW[8&&N.]".UI90UN="HA!U2I#%7HFOJ @0?\Q+:QX]HT6&
MQB,+A.?MSS_-XCA\M_CZ<<'+Z-VY6-4$8&*Y;6QTSMA&>TE J_,Z%S(W=<%Y
M<3;MQ\#A+(.\ *UL^1^T%])'BND;F 7C%8JG5):-S@74L,R:[?7I^6MML0,Q
M\/&]*BN5+W$H'G,=# ]#HIY44E-2T>9*6S"7L"MEVYYE ^=2XS@IG$(5I8*L
M/6%//.Q/]@8M$4!=/.P-02I+P>6.P_,WWS&L6U]-@%)Q-@S[LYT(KPZCQ=[?
M(JU9ZM[$!E=(Z$J[!)&EMM 7"S(,BJ'G'KK)(MC2U1;R"*5\-F5:+G6FJZVO
M8TJ="[.ZJ"G1G%.47I1(JXQCN%;N(*'E+G$<DW/VJ8P+?)?(:2.HE%N*ASOT
M %73RH>: "W)ZI3C*'?"R!<.QY#&!4IMM8(>7/XD*\F@HP8*'=0PRSL4@][T
MJ$WMLBWE8^;UZMCQ*GYYT$(IGL2F'4\G%%?*0:PX-%SUT(^2MR\^R50[RJ5O
M>&LPO17'@==+9S#?8VT'4E<RH=AIY7::=/!Q7S4-1D9'NX?',7?8.ZJ-X71U
M/KO@?#( L5NL*.5DDE!QD(UT^L"18)L== J\A4O*#CJWQ>D.JK.#;'!('$9S
MMA<N"P\3.:DMR<E:/TGP(;%0-HK&SWN5-SL!,>"8A.)8(]!G.'NUJ0--[#(#
MRQ@/(%;;%WE6=-4AF(RF[ZCM%\YD.N7T7\J, 97'3B<V@ I!N6ZH8MREX-$&
MM=HJ<-=1X/90WB=.S=W@]R*P\5"\I0ZW1H*#DSL7OP.")(?GP,XO1ZK[3*"Y
M3^()+<9!/,=TXKV+Q#ADTO70W8L=T,[&:.G!>#(4?S?%1?)7V 2B\+/%CAIS
M%+L@BH;!9!A# +0-9X@H4N5@ONYXZ5X_O?;*2[PU-+P=.IE=R\[<K[[CUH38
M?'D-.LY$'(RG,?\.1T/\CN$<=G0PBF+Q-U2;)0PM"(KPW:)I"J</,*IB?-,I
MC*61&".9YY.IB()P.!1_H/=(@$U7@[?1^>M:S(83@6D<Y)-H+(;3\$?D<DK'
M[U[]_<K5=B:&P6P^Y]\P) -G032:L:$S"".]CNFK'?!8X_M69]NV7="PU+JW
MT<-1DII$\X%=.;XHNV<)YAL,JFV#<D/+<&NDT 6!65>'%]UT+;/5BU:Z9W06
M]D=M?R;/86/:;GQ71L7I2G0.N=D,H>I9;OK!!NA=*OX.S[8>N3QF,"MV)7]H
M$8[A@QLBN))H'#]1:*RTP!A'_0;(S0#E-#F82 \!YE+\D[K5@@<@][P(N#K>
M8I9 ]T@/Q@]J$>>(_B28 T9P#G@P#H;C":TGM)[,>8UD'@6SR9S6,X'*'D<1
MK>>[(0*# _>9*)XQ_2[?HODHF )F[C 2"9V7M1\TFCGL3+R=(O,FL_.&X)1'
M8!4/&^XYU) %430+YM%4W-=EF7%' K=$NK58(1*LI>&111?^SL=?O[29W+0E
M2IPNYO]5T/H!:+HEY=IQDIMR$SZ]&ZJT[UK-#,C@T#;"CF<N.S#7FMQ\O#XO
M-;AJ!PE4_/-HYL& 02&:!G.$]%C3,4N:/;Q.ZBE9R^*AU=I7Q:G0=87N5Y,1
M(2T@=Q9[;Y12_U\]$0?AB- =0#V?,<J'T83W(Z3]L6A^X_LPE5Y@NK7R@69G
MJJJ]U8PH%&F>OLY1*OU03/ Q\H)R5]C^.V2&8V_P?RS>'+N%&73NPG)E'_C&
MC^87,/#78NUN>ZFX\'=I^^/^1A)F/= 4F:D52(&)XY[_B-@]5*;DF[6EJ2J3
M\Y(N192E WB_,J;:/9" ]JKUYG]02P,$%     @ *8&I6%S*;]%S"P  +2
M !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&ULK5I;<]LV%OXK&#?3L6<8
MFE>)<A+/V*G;9G<;>^*D?=C9!XB$)#:\J 1HV?OK]SL 2%$R):?=/L3B!>?@
MG._<P;S=U,U7N1)"L<>RJ.2[DY52ZXOS<YFN1,FE6Z]%A3>+NBFYPFVS/)?K
M1O!,$Y7%>>!YD_.2Y]7)Y5O][*ZY?%NWJL@K<=<PV98E;YZN15%OWIWX)]V#
M3_ERI>C!^>7;-5^*>Z&^K.\:W)WW7+*\%)7,ZXHU8O'NY,J_N(YHO5[P:RXV
M<G#-2)-Y77^EFP_9NQ./!!*%2!5QX/AY$.]%41 CB/&'Y7G2;TF$P^N.^X]:
M=^@RYU*\KXO?\DRMWITD)RP3"]X6ZE.]^5E8?6+BE]:%U'_9QJR-PA.6ME+5
MI26&!&5>F5_^:'$8$"3> 8+ $@1:;K.1EO('KOCEVZ;>L(96@QM=:%4U-83+
M*S+*O6KP-@>=NKQ7=?KU]37TRMC[NH2M)2>XWIXK<*<UYZGE=&TX!0<X3=@O
M=:56DMU4F<AVZ<\A52]:T(EV'1QE^ MO7!;Z#@N\(#K"+^Q5#36_\)"J*]X(
MJ^H=?X)G*7;5-+Q:"GW][ZNY5 W<Y#]CRAO>T3AO"IT+N>:I>'>"V)"B>1 G
ME]]_YT^\-T<DCWK)HV/<_Y217N#T^?;]/U]?7]W?_,#>W_YR=_/Q_NKSA]N/
M[/-*:-:\>F(K+IE:-4*P=<$KNN:*K9OZ(<\$0QY@XH\V5T^OYUJ@=""0R[[
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M[,BBA'L*30)L'^%?Q6Y6HW+&?^;C^=(FVJ6,Q113[6135U5NQB8D%KY RP6
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MKRR,!:AI9'6BI%LJ </?O9#X'^O@$KZVEJ^&=)I"GN6041+E^13ND1HB+US
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ME,$2UX6\8YL?T,8SU'PI*X1YHDWC&X862FLA6=F"U0E*0ILW?FKSL -0//T
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M*&$+NLW$Y^+Q%]8("A7?O,C*ZK_HL6X;11,TWY:B6#=@V8-UFM?_TF_-0.P
M@J '0!H V0.<3GL ?@/P*Z%USRI9[ZF@LW->/"*N6DLVM5&-3866:M)<G<9;
MP>5?4XD3LP_RA"2,HR^<)FF^1)><TWS)Y(D2Y;DGY!%4.V_>L%W5;*2'S4<?
MBURL2O1CGK#$@+^&\1& ]Z2R5AYYEG=%0,*/E+]%/CY!9$H"5*XH9R99U]_+
MTNF<WXZ]7]'Z/;2F,3]!=T_H0YZD#VFRI9GI%-2D@9E47?;OR@V=LXN)O*Y+
MQA_89/:W'W T_8=)^$!D'?U!JS^ V.6P"L93FJ$OC*]+5"Q,L] T B#ML2,
M]_']EJL.B15#?VXIEQU&3,U-).?$?-5.BI.JQ:+(Y+*HVB<IE^M4P4M$\T0J
M6Z1S)G=>T5*M,?(8"4IS]..W^4KI1)=S@3YO,X9P1-_@5XO7KQ%-BHV0S21.
MR-48B69H-AG-2PD6=3=$@4HJTG+QU!!,[T+),'_]#OU&UPQ]287\]5*1J553
MKA$,W4@*="NDFIU]><75>[?5]$:_LU*HXZG^WV[O_I!RU,%NY8+[YDOQ!ET7
M#W(L7N'7Z).4SM&O\F@E^H6NTTS( UVO4K9 []-RKMH]533R[.9E1E5'Y$G_
MR))T+D<"^1Z)O.K*PEZU$<H-'-=;T?1D.IVBW*/HGRQ''Y_*O^Z+Q_(^;8[P
M4YK3?*XFT:=ZD"4=)C5=Y&%<;\D?3FL^181Q6)$>3%B#C?UKJ([JW_\OW>E)
M'-9T-U3P='Z//OW]BJ?L^7Q_VC!.JVGSS*?.^\\LES]G<LIL<VG@ZABX_X3'
M)V'3Y:]IEJ5TC;[2))&;Z*J@7%YX;'U7=S1N2(B'HW;3;Z@507P2G(5JC@*+
M5=@N5B&X$/Q6Y&]VKK#=):J^O(Q^=P63+FA6,M.B!,(<E^6H51J!G>I3J59I
M.5]ZA,*<O4)!F*/0N!4:.Y]26"S,VRL6A#F*/6W%GH*=VEN?_UU?1O\QJ0.)
MCK77@<@ZFL]:S6=C!*RS(?4/1-;1CZ<ZW4_A*2[/NC'&P[#N9#'F>)# 5=?.
M70L&.UC%&J,P&'=X+#&*!LE=11,MFC@MS(#]6!@%WYJ%@C!7H?J^"(.W';-.
M7#7*@O%MHC1J&^.6!^M['@S?4.R>.'ES44T[HT28!F.4T"?CO2R,=!6H<Q*&
M,\WE<LG94MU)7#[0-*-W/1=JS1)6+.IAT\,LDEEU>NX]=,38FG5[J3,.A@/)
M?GZ%_!"F.M80AF+K"M>9!\=C>"(>*+LT8S!&$L(Z"F$X"_6Z(@S;FS-&86/$
M':SS#@;C!&"+,.Z(NS>CZC%"#M$AA\!IQ<$7+8Q]O@C#7(7JU$/@]&+U10N^
MO?$V:ALCW! =;@@<10[U10L-X(LPTE6@#C7$$FH.\\6&I6-X<?C"%ZW-NKW4
M\83 N6+_F0ODBS#5L9XP%%M7N(XM)!S#%\E 3VJ:,1CCN0_1H8C H:C/%RVP
MO3EC%#9&Z"$Z]!#XB4RO+UIPNT\<C;+&R#%$YQ@"!Q(7XX,9>XUOC%Q#=*XA
M<#ZQ&Q^,;Q\6&[6-D5Y\G5Y\.&L<:GP6&ASV&A^,=!6H4XMO22V'&5_#LNMH
M<7 6[OF>K56WCSI]^'!LV'L[4K_<PZ1^-?;L@>B_^V]1('>$CWCT>]HQPHN_
M\Z9ZG%?5P[ZK'N/)C:^CD0]'HSYWM,"Z4\:H:XSDX^ODX\,/;'K-T8+K>85H
M5#A&KO%UKO'=WF@!/FEA[/-)&.8J5.<<'\XK5I^TX-MWYT9M8X0=7X<='XXF
M!_LD3$,BTF^48Z0<7Z<<WY)R#C3*LQ<6B''X\M&IO5VW:D<GE@".&D:S)*>U
M66)'NX2/>711SQB1)]"1)\!CV&4PT".89@S&>* 3Z$@5P)&JSRXM,+M=P@2N
MNG04"N#G.+UV:<$=89<PDZO"G;(\.+$XV*6%L<\N89BK4)U\ LNK*IM=6O!M
ML911VQB9)]"9)X 3RJ%V::$!GJ?"2%>!.NL$EJQSF%LV+!T7-)BEM5FWESJU
M!'#< +V2N'KEH!4Z0[%U1TBGGF"4(IU@T"J=H=BZI84Z485N93H6F-TK80)7
M73H'A8YE.A;<$5X),[DJU"DG'+PFQ\+8YY4PS%6HCCWA=];D6/"@5\)85VTZ
M\(3#U.18: "OA)&N G=JEP>IR0E?%MN8O-+:K-M+'5E".&N 7ND[>B5\S&-]
M8BBV[@CIS!..4KP3#EJ\,Q1;=PQTH@K=BG<LL .\<HP<%.H<%#K6[EAPQWCE
M&"DGTBDG&KQ.Q\+8YY4PS%6HCCW1=];I6/"@5\)85VTZ\$3#U.E8: "OA)&N
M G70B0:ITXE>%N"8O-+:K-M+'5FB8]XJ[7EEX.B5\#&/]8FAV+HCI#-/-$I!
M3S1H0<]0;-TQV/D_N=P*>BPPNU?"!*ZZ= Z*'.MY++@CO!)F<E6H4TXT>&F/
MA;'7*\>(/9&./=%WEO98\+!7CA%X8AUXXF%*>RPT@%?"2%>!.NC$@Y3VQ"^+
M=O!I'.Y[I;59W4MOYVL7:\:7U4= 2C0OMKFH/WS1_MI^:.2R^KR&IYO77RF1
MMKE,\Q)E;"&AT[>Q/#:O/_Q1[XAB4WT[XZX0HEA7FRM&$\95 _GW15&(YQUU
M@/;S*[/_ 5!+ P04    "  I@:E8E_>]T7,#  !D!P  &0   'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6RE5=]OXC@0_E=&66E5I"X)@79[+2!!>]7V8;55
M:>\>3O=@G(%8Z]BI[91R?_W-.)"R)]J7>X#XQS???#/VC,<;ZW[Z$C' :Z6-
MGR1E"/5EFGI98B5\W]9H:&=E724"3=TZ];5#442C2J=YEIVGE5 FF8[CVKV;
MCFT3M#)X[\ W527<=H[:;B;)(-DO/*AU&7@AG8YKL<8%AJ?ZWM$L[5@*5:'Q
MRAIPN)HDL\'E?,3X"/A#X<8?C($C65K[DR=WQ23)6!!JE($9!'U>\!JU9B*2
M\;SC3#J7;'@XWK/?QM@IEJ7P>&WUGZH(Y22Y2*# E6AT>+";;[B+YXSYI-4^
M_L.FQ9YG"<C&!UOMC$E!I4S[%:^[/!P87+QGD.\,\JB[=115WH@@IF-G-^ 8
M36P\B*%&:Q*G#!_*(CC:5607IC_<6ACUCVA39 I8J+51*R6%"3"3TC8F*+.&
M>ZN55.CA9#_JC=-  I@FE3MG\]99_HZS<_AN32@]_&X*+'ZU3TEXIS[?JY_G
M'Q)^%ZX/P\$IY%D^^H!OV&5C&/F&[_ ="_BOV=('1[?G[V,!MWRCXWQ<49>^
M%A(G"96,1_>"R?3SI\%Y=O6!VE&G=O01^_0!)?[GE)PU-)9(91/\,;W_CQ'N
M#-P0IEJBXYP/3R&4"+?*"".5T(>6BT#72;C"P]S2!TX^?[K(\^SJ=K:8Q^'@
MJ@?*^P8+F"V>(MV7[+=3\B%MA? H7OFZ/=I:2?@ZRGJ7<%?5SK[LI 1[@(0;
MY:6VOJ$LPRGOJ18+BJ"JQ07"%1V.6LISHUS+UH<GNI(N1D-B3H$65>#CKZ@&
MJ3!,([3>PLF@MZ= \#5*+A60(N#:.H8K$SD<K9 #:2DM6KU5UTG> ]:E"@11
M%(HW*&W*M.V5831ZLZ0\JH 515N* !5W:0'/C6!U@OL9;5#(I=5%'QY+Y6,J
M-TIK6&(,&E<KC)TO$K.V:UO5PFP)L%;&L OR^D,&RX?:UM(9D[TA"TN1&1L
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M;.C\:X?O'#=F9PPNDY52SV[R>SKQ>DX0"DRL8V#T^X$1"N&(2,:_+:?7A73
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M;%-61N%7CGYFOJ 5%06#E5/ 35'(5A@-%T]T73%].?4-!K&F?M$#+CK Z /
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MRAK@]XV4YO!B PS_3N;_ E!+ P04    "  I@:E8?7[CUMP"  "\!@  &0
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MC<Z&_0!,,RL;@W3EY]-"$T\[O\SY]X+&!?#^4FO:&JY ^\.:_ %02P,$%
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M5(HU2+.:T,S AFJMB1ROS:;<:DE/.=GI^1522 H.[MBB1'5X.M4$:AY-LPW
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ME&8!/5\*H;<WQD'_*3;_%U!+ P04    "  I@:E83CS^"> $   X#   &0
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ME0:'';?,<;H$917P?"GQPEO!!NCFU?DO4$L#!!0    ( "F!J5CO5C_IM@(
M #(&   9    >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;)5546_3,!#^*Z>
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M?Q=/HH]'R&8]V>P8^NJ6!%BV D%MX"7Q$"Z8X04P6<(E%ZW];\*[ (XN<3B
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M*16([EX<7<>JQM_R:V7IS>";[D!"[0QH?J-H[_<=MT#_[%O]"U!+ P04
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M>O/3.\'PF@7BE3SO (\DDL[U4IA7*X3/FK7PYV=MBCXIELF_^K)><?U^;E$
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M1F,F"@/]_HQS]7)3/* YQ)O\!U!+ P04    "  I@:E8_/!MW(D"   S!@
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M4#L#^CY5RMY.G(.F:4O_ 5!+ P04    "  I@:E8C[N^!@0%   ,(   &0
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6S-FEMOVS84Q[\*H15#"ZS1Q??,
M-I!8*AJ@Z8(FW1Z&/=#2L4U$$C62LA-@'W[4Q9(5RVJ,G0')@TU)/#^2YT\=
M\IB9[KAXE!L 19ZB,)8S8Z-4<FF:TM] 1.4%3R#63U9<1%3I2[$V92* !KE1
M%)J.90W-B++8F$_S>W=B/N6I"ED,=X+(-(JH>+Z&D.]FAFWL;WQCZXW*;ICS
M:4+7< _J>W(G])5940(602P9CXF U<RXLB\]>Y(9Y#5^9["3!V62#67)^6-V
M<1/,#"OK$83@JPQ!]=<6%A"&&4GWX^\2:E1M9H:'Y3W]4SYX/9@EE;#@X1\L
M4)N9,39( "N:ANH;WWV&<D"#C.?S4.:?9%?6M0SBIU+QJ#36/8A87'S3I](1
M!P;]4P9.:>"\,'"<$P:]TJ#W6H-^:=!_K<&@-,B';A9CSQWG4D7G4\%W1&2U
M-2TKY-[/K;6_6)Q-E'LE]%.F[=1<.SBD2RYH(5L<D"_,U_, R-5: .@IH23Y
M2![H(P24W&VH%L>'5#&?AF3!HX3&S]HD8@H"\MX%15DH/Y!WA,7D8<-3J9%R
M:BK=U:Q!TR^[=5UTRSG1+9O<\EAM)/'B (*FO:F'6(W3V8_SVND$_N:K"]*S
M?R&.Y5CD^[U+WK_[0/@R9.MBZ,LT#D)HZ>FB&WQ+107N[\$M&+<;<P^)QE@Y
MIM>!\5[?FQ.8AOMZU33IY=S>CZ?)5D\-(6B\+B?'E9XS7WGLGZI!'G11TCPN
M2/+G%TTF-PHB^5?;M"BZT6_O1A8U+V6B)^#,T&%1@MB",?_Y)WMH_=JF'";,
MQ81Y2+"&EOU*RWX7?>["5J\/2:Z-@'4:4L7%<_[N2QJ"U&%&?RH>ZV)"GW.5
MVZ3J;.5<J0K8,(=EB]MV[HRM[&]J;@]5P&S40X(U5!A4*@PZ5;CR?9'JF E/
M219N6SW<23C7PP5L<.#AWL@:#%[X=W"D0V\R&O::M3RDCC4<-ZP<-^QT7+D4
M_5,M5-G$7?"/GW0 9_&Z7K?:/-J)/M>CF# 7$^8AP1KZC"I]1F]CJ1AA:HD)
M<S%A'A*LH>6XTG+<^:Y]3:,E",)7)&!2L=A7) &1IR>Q#P?;)ZG?Q_JJ3:WQ
M4?BQFT%ET=F5<R7 A'E(L(8$DTJ"R;D2%%M5[?&3>];KR0^]W=GJN=[&A'E(
ML(:W;:O.AZQ.?]_$3#&=VZ@Z%)%$Z*6F-8FQCI?+EEW+HKO-<[V-2O.P:$U_
M'^2?=J>_;_>;S?U>L]7/G8QS8STJS46E>27M<$;U&Q.JZ6:G=K/SG[>;W8BS
MO>P<QZ#>^&A#C]JHAT5K>KG.DNW.Q.WU>U-=Y9;%+$JC5B%0LV!4FHM*\[!H
M3;WJ3-CNOXV]JHV:+*/27%2:AT5K*EIGU79W6GT'0K]YBJXAVS*!WI&RI=XK
M*4X$^)!IJ!@('0@%?Z:A+DNB%_@85/';1ZMV18N3@T!F73@O5WC,7-U%I7E8
MM*8D=;YN(R7L65"D3R>#(FKNCDIS46D>%JVI5YV_VV\D@;=1,WA4FHM*\[!H
M347K+-[N3N/_CZ X;@N*@Y=1$36G1Z5Y6+2F)G5:;W?G]5B_PG<W<_9+-#E*
M/P;.:'"\:T?-^+%HA13FP6EH!&*='T-+XO,T5L7!:'6W.NJ^R@]XS;IZ<4Y^
M2\6:Z4@6PDJ;6A<CO9**XNBYN% \R<]6EUPI'N7%#=  1%9!/U]QKO8760/5
M/P#,_P502P,$%     @ *8&I6*<BPVU$!0  B2@  !D   !X;"]W;W)K<VAE
M971S+W-H965T,SDN>&ULS9K;;N,V$(9?A7"+8A=(HX,MV4D= XEU2K'9!INF
MO2AZ04NT+:PD:DG:3H!]^%('RU8L,S8P*/8FEBC.-V3XDQR-.-Y0]I4O"1'H
M)4TR?M-;"I%?:QH/ER3%_)+F))-/YI2E6,A;MM!XS@B.2J,TT4Q=M[44QUEO
M,B[+'MED3%<BB3/RR!!?I2EFKW<DH9N;GM';%GR)%TM1%&B3<8X7Y(F(Y_R1
MR3NMH41Q2C(>TPPQ,K_IW1K7@6$7!F6-OV*RX7O7J.C*C-*OQ<U]=-/3BQ:1
MA(2B0&#YLR93DB0%2;;C6PWM-3X+P_WK+=TK.R\[,\.<3&GR=QR)Y4UOU$,1
MF>-5(K[034#J#ED%+Z0)+_^B35U7[Z%PQ05-:V/9@C3.JE_\4O\C]@SZYA$#
MLS8PWQB8QPSZM4'_5(-!;3 XU<"J#:Q3#>S:P#[58%@;#$\U&-4&HW)TJ^$H
MQ]+! D_&C&X0*VI+6G%1"J*TED,89X5VGP233V-I)R9RS!,\HPQ72LHB]"D.
MI30)NETP0J1*!4>_HMMT0;(+=)^%Z(-#!(X3_G&L"=F  J.%M;.[RIEYQ)F!
M'F@FEARY642B#ONIVMY6V&NRXTWOS6WO[TPE\(GDEZBO7R!3-VST_.2@#S]_
M1'C;\ZX6JH$/F$F@40#-P1;8@7%.Q_05&/?D[BDQGAKCD+!IC:G ^&K,[ZND
MP>@*3'#ZF(VZ,2TM])N9T"^Y_?=GPEJJGS&<+6K]W\II\9EFX;$:Z$]YR7&Y
M&G/TSR=)1O>"I/S?KCE2-6/0W8QBK[KF.0[)34]N1IRP->E-?OG)L/7?NN0(
M"7,@82XDS(.$^9"P  C6DNR@D>Q 19\\,AH2$G$T9S1%8DE0S/D*9R%!=(Y"
MFJ9R39=;2/CU F4R#I*%=#XG+,X6\BD7O$N>2I?GRK."V26L"*/6DX%Y9=J6
MKNMC;;VOO<.:;VJXD WS(&$^)"P @K4$936"LI2"FLKME<EU#"4QGL5)+&+2
MJ1$EY5R-5##K^,@[D.Y<ZT!H(]L^T*,'Z=.'A 5 L)9 [$8@ME(@91R(OJ,_
MDASS6.YZNS"Q2R=*V+DZ@80YD# 7$N9!PGQ(6  $:PEOV AO^&-$9T-(R4+"
M'$B8"PGS(&$^)"P @K4D.VHD.U*NE9]7Z8RP(NC"NU?I[\JWR[O1P5YHMO>E
MJ=+GN9*"A+F0, \2YD/" B!82U)7C:2NE))ZSF6D+U>T'+\>4]#507C3+Z+M
M@P!GJO1TKI @82XDS(.$^9"P  C6$I*A[_)^^O__[EC[W%>?:5A=ZE.W[ESY
M@=)<4)H'2O-!:0$4K:W!O=RSH=3@0YP0*3$9C]4+6K>HE)!S0[*:MK_%6IT+
MI /JUP6E>36M-=$Z>^%WU=2[:@8=-8VW-=L#;>X&VCPMKX Y)T=&64DX>Y3-
M=Y,*H Y=4)H'2O-!:0$4K2VE79;>4&943TY1J3%GZZG_OIY L^>@- ^4YH/2
M BA:6T^[%+JASJ$K,EJR] &_Q.DJ[108:*(<E.: TEQ0F@=*\T%I 12MK<5=
M]MVP?HPDEP&:P >E.: T%Y3F@=)\4%H 16MK=_=AP'CGRT 4Q87X<((8*0Y-
M%2^*$5F3A.:E0!E9K!(L*'LMCYEP+&-_E&[? +CZ%0#T0T)-VP]TK>XDB0/J
MV 6E>: T'Y060-$J,6I[YYM2PA;E63>.0KK*1'78IREMSM/=EJ?(WI1/C6NG
M.A6WPU2']!XP6\1RY4S(7"+URZ&<3:PZ]U;=")J7IZAF5 B:EI=+@B/"B@KR
M^9Q2L;TI'#2G#R?_ 5!+ P04    "  I@:E8E9@>D;(#   &$P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970T,"YX;6S-6-MNVS@0_15"6RQ:H(UNENQX;0&)
M):$!VB)(>GDH]H&1QK90B=22M)T"^_%+7:):L4+'#1_VQ2:I.6>&9T:DR-F.
MLA]\#2#0?9$3/C?60I13T^3)&@K,SV@)1#Y94E9@(;ML9?*2 4YK4)&;CF7Y
M9H$S8@2S>NR:!3.Z$7E&X)HAOBD*S'Y>0DYW<\,V'@9NLM5:5 -F,"OQ"FY!
M?"FOF>R9'4N:%4!X1@EBL)P;%_8TMJT*4%M\S6#']]JHFLH=I3^JSE4Z-ZPJ
M(L@A$14%EG];6$">5TPRCG]:4J/S60'WVP_L<3UY.9D[S&%!\V]9*M9S8V*@
M%)9XDXL;NGL/[82\BB^A.:]_T:ZUM0R4;+B@10N6$109:?[Q?2O$'D#R# .<
M%N \!HR> +@MP'VNAU$+&#W7@]<"O.<"_!;@U]HW8M5*AUC@8,;H#K'*6K)5
MC3I=-5H*G)&JLFX%DT\SB1.!S$B.[RC#39Y)BCYDB2P<0!<K!B!K2'#T#GW-
M>,8(1I_7P' )&Y$E_"VZ(LD9>AV"P%G.WTBS+[<A>OWJ#7J%,B)MZ89+1CXS
MA8RT\F<F;527353.$U&YZ",E8LU11%)(!_"A&N\K\*94J)/)>9#ITE$2?L3L
M#+GV6^18SF@@GL7SX>[0=%[F/7J9]U@-OX52PJTA>$]+MRLYM^9SCY?<5I89
M8YBLVD*[D/7WB9+D*0OT638YKA<ECKY_D,SH2D#!_QZJL2:,T7 8U9(]Y25.
M8&[(-9D#VX(1_/F'[5M_#258)UFHDRS2219K(NL5QJ@KC)&*/;B!+9 -#*6R
M ?HUL-HLMX$U,[?[^3FTL$>^XX_[9N&AF>MY=M\H.C1RK,G$=OMFL7(VOZF5
MUVGE*;4*80F,02IW]R=%:Q@\A6A*'Z<6]5%WD4YWL7>0I(GO=PY[HOJ=J+Y2
M5,4N]V^W!1[LCT/2*_V<NO3H) MUDD4ZR6)-9+W,C[O,C_\?>])89V'H) MU
MDD4ZR6)-9+W"F'2%,?G=/6ERL-[9UN,%=G*P2)T_M@F5 9PJO$ZR6!-93_CS
M3OASI? +^0'/Y%N%,.<@!L\0YT?W-Z6+4U^0H^XBG>YB360]\6WKU['0>O'W
M14NA^BI3>SDU \<=1EH=QKK8FB28>\?T MBJOE#A**$;(IKC4S?:7=I<U%<5
MC\8O[>G"'A@/[6G47,G\HF]NB.01<)7)[2F'I71EG8UE&;/FTJ7I"%K6EP1W
M5 A:U,TUX!1892"?+RD5#YW*07?U%?P'4$L#!!0    ( "F!J5A 4:*1X@8
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MDSS4YUH],ET+F:=UL&I!&F>;W]&/^D+L!"B./H#6 70_8' @P*D#G&,S#.J
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M"K8>6:ZU67@DRUSJ!3L95G@),Y#/U92KF=VQ9*0$*@BCB,-B9-VZU^-8QYN
M;P368FN,="9SQE[TY$LVLAPM" I(I6; ZK.",12%)E(R?K6<5G>D!FZ/-^SW
M)G>5RQP+&+/B.\ED/K*N+)3! M>%?&3KS]#F$VJ^E!7"_*)U&^M8**V%9&4+
M5@I*0ILO?FU]V *XP0& UP*\]P+\%N";1!ME)JT)EC@9<K9&7$<K-CTPWABT
MRH90?8LSR=4N43B9W.$"TQ30S)3,;9JRFDJ!+O20UY"A3Z^J8 0(=#8!B4DA
M/JK-Y]D$G9U\1">(4/24LUI@FHFA+94BS6NG[>EWS>G>@=._8GZ)?/<<>8X7
M],#'Q^$SJ!3<,7#_+=Q6/G1F>)T9GN'S#_ ]\"6FY _6!7:.QHP*5I ,-_5&
M,S3E((#*9H$MT#VARCR""S13BZ"*6UGWXW8N)%?E^;//CT9 T"] _V6O1853
M&%F5/HNOP$I./[B1<]/GSG\B>^.5WWGE'V-/-O7Q>(K+ZF:"H*V3OJ0;IL@P
MZ;:R2MP@"-2-K;:SZ8F*7"_LHM[(##J9P3_)O$$IN\A@I=I8I>^M3W;#'&X+
M\N/0W9&]'Q5>#0ZH#CO5X;M4I[@B4I6749T16?-^@\,]#;$7A3M"]X/<P F"
M?J51IS0ZJO1!YL#[)$7[IX6#:$?2?I ?#0;]BN).47Q4T1/3CN'6P?:^^Q3&
M>_7FQTZXZUI/U""._!V-]E8'UJ^?:FQ+0@4J8*%PSF6L<N3-B]),)*M,4YXS
MJ5J\&>;J$0:N ]3^@C&YF>@^WSWKR5]02P,$%     @ *8&I6,%L2(E8 P
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M$G\SNE4[QRB_E3LA_LM//B3G/2]O$4UIK',$,7_NZ25-TYQDVO&M@O;J.O/
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M >+]FA!^6$@#W;\S%O\"4$L#!!0    ( "F!J5B1<M3<= 0  *<4   9
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M4(K=Q,/>?N&.+5?:+OC9>$V7, /]97TKS<QOM12L JZ8X$C"8N)=X<LICJR
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MJ_D\:WAM#A>T72HJ-77ZP'O^I#PPGQ08J=34W $P^L0>F*^[6]K=T-@0-4Z
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MQ8]M(DX BF<<X+4 ;PB8O0#P6X#_6@^S%C![K8>@!9BCV\W93>)B+'&TXNR
MN+96;/K&9-^@5;X(U85R*[EZ2A1.1K^J6OS,A$!;X.@VQQS03^B*2I+5!=$:
MHO<Q2$P*\4$]$-I '"^$HJ\YJP6FF5C94D6C.>VT]7S=>/9>\.RC+XS*7*"$
M9I"-X./S^/ ,WE99Z%+A'5-Q[9TE_(+Y!?+='Y'G>+.1>#:OA_MCQ_E_WI/_
M[+V7#+^K"]_P^2_PF1(@16U*X!;2FJMJ4)HGCVE1JWRC'6<EVK"RJB4VKSS;
MH01S2NC^M)C^^JR(T2<)I?A[K$::*&;C4>@N>2DJG,+:4FU0 '\ *WKW@QLZ
M/X\)-"59/"59,A%93\I9)^7L''NT91*4FK@HOJ%.4O$D*?0D3?N2&H!Z!D=I
M*R6M>?_1>_7^-YW@PYBR35"!"4K_7#U$,_7CM;(?3A4;,?(#IV\4CQ@%BT7?
M*!ES%RX[HU[F@BYSP=G,_5;I-(SVMK/ [ZW;*<GB*<F2B<AZV0^[[(=OH@6%
M4THY)5D\)5DR$5E/RGDGY?PMMJ#YLYX0+(-!!WIN,P_G@P;TW"8,!C;)",_\
MA?:SZ+*V.)NU&Q"2DU2?7?T?F-ZCFA(YVHW.\GQO"4])%D])EDQ$UA-CV8FQ
M?!/=:#FEE%.2Q5.2)1.1]:1TG:>AQWF+_:B-ZK1)^#/7'72D,:M@X0]ZTIC5
MTA]P)6-6WM(9]"7[9'XL@>_-X"[4N6LJFY&AV^T^#ER9D7BP?^U>;MR1_5A_
M3##SZA-]\R5"S2U[0@4J8*=<.1=S%2IOAOMF(5EEIM<[)M4L;&YSP!EP;:">
M[YC2LEUH!]TGENA?4$L#!!0    ( "F!J5@@C8F\.0,  .P3   -    >&PO
M<W1Y;&5S+GAM;-U8;6_:,!#^*U&Z3JTT-4#6E*R M"%5FK1-E=H/^U89X@1+
MCITYIH/]^OGL$%[J0ZP?-EA0B>\>WW./?9?&[:#62TX?9I3J8%%R40_#F=;5
MARBJIS-:DOI*5E08))>J)-J8JHCJ2E&2U1!4\JC7Z21129@(1P,Q+^]*70=3
M.1=Z&":M*W"WS]DP[";OP\#1C65&A^'3Q=L?<ZEOWP3N?O;N[*SS='F[Z[^P
MP&48>4FO#R"]ZG1P8@ Q\N0P\GW<&/7--K6=?FZ(7. Y%M8_2-$>01AQZM%C
MY*\E@6&#HZ;:HT$NQ;KH<>@<AIV4-'@F?!B."6<3Q2 J)R7C2^?N@6,JN52!
M-MUFTG7!4_]R<-=9T(@-3\F$5#:WR^"^)\WT'6!E@4#&>2NP%SK':% 1K:D2
M=\:PDZWS!10TX\=E9106BBR[O>MP'6!O)LE$JHRJ-DTW7+E& TYSD*-8,8.[
MEE4$H-:R-(.,D4(*8C6L(IJ!H9U2SA_@*?V>;W$O\HVZ=:!JHAT:0<W0T3@#
M^#?9'/<F;?PJWJ!BSU)_FIOE"&M#H]%[17.VL/8B;P5@[%V<G5057W[DK! E
M=8L_..%H0%9QP4PJ]LMD@U:9&@=58?!,E6;33<]/1:I'NM"K=EKDN.;>"6K^
MN_M<4$$5X9NB3>\?\RZ_6G%\\Z\DV]\JNX*]&IM7[[&+O#X%D<DIB#R)GNR?
M@LCT^$7&QZDQ:@X9&R>9K7-,ZPW@O#@,O\'IDZ^3!I,YXYJ)QIJQ+*/BQ7'&
MT&LR,7_*;/&;^1G-R9SKQQ8<ANOQ5YJQ>9FVL^YA(YI9Z_$76%XW:0^K)A<3
M&5W0;-R8JIC886 &)FMS0< N<F<O/X+%.,R/ (;EP11@,2X*R_,_K:>/KL=A
MF+:^%^FC,7TTQD7YD+']8'G\,:FY_"M-TSA.$FQ'QV.O@C&V;TD"/WXV3!M$
M8'D@TY_M-5YMO$/V]P%6TWT=@JT4[T1LI?A> ^+?-XA(4W^UL3P0@54!ZQW(
M[\\#/>6/B6.H*J8->X)Q)$TQ!'K1WZ-)@NQ. A]_?;"G)([3U(\ YE<0QQ@"
M3R..8 I  X;$L7T/[KR/HM5[*EK_?V_T&U!+ P04    "  I@:E8EXJ[',
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M\]&YV0@;[R=<X*KJ[LT'*! I>RS#!GM5M7B4*-H9):MP]8I]YHKK4K VA X
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MBT:I\[#N5E\;7FT_J]M^$GCZ"U!+ P04    "  I@:E8]4F2S $"  !>)
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I+;J- %(7AK5@L(.7[
M(DDKSJ@GF4;9 '+*#\4VB**59/=M.0/GH![T)*HS0@7B\HO!)P0\/.=#-^W[
M4]GMA[+X.!Y.9=7LIFGXE5)9[_*Q*S?]D$_G(YM^/';3>3ENT]"MW[IM3KI<
MMFG\/J-Y?/@^<_'R.>3_F=AO-OMU_MVO_QSS:?K'X/3>CV]EE_/4+%ZZ<9NG
M59,^#M?=)5TV<G.>W"R>7E?-^/0J3:H=I!"D]8,,@JQ^D$.0UP\*"(KZ02T$
MM?6#;B'HMG[0'03=U0^ZAZ#[^D&R1!F7!$DSK FT%N1:"+P6!%L(Q!8D6PC,
M%D1;"-069%L(W!:$6PCD%J1;".P6Q%L(]%;46PGT5M1;"?36V<,V@=Z*>BN!
MWHIZ*X'>BGHK@=Z*>BN!WHIZ*X'>BGHK@=Z*>BN!WH9Z&X'>AGH;@=Z&>AN!
MWC9[64*@MZ'>1J"WH=Y&H+>AWD:@MZ'>1J"WH=Y&H+>AWD:@MZ/>3J"WH]Y.
MH+>CWDZ@MZ/>3J"WSUYV$^CMJ+<3Z.VHMQ/H[:BW$^CMJ+<3Z.VHMQ/H':AW
M$.@=J'<0Z!VH=Q#H':AW$.@=J'<0Z!VSCY4$>@?J'01Z!^H=!'H'ZAT$>@?J
M'01ZMZAW2Z!WBWJW/ZEWF3X/N5Q[OM9X_9^D>CJ?FZ^7ORR_=LYNP@7G!+\3
M/?X%4$L#!!0    ( "F!J5C63,"2X $  .,C   3    6T-O;G1E;G1?5'EP
M97-=+GAM;,W:RT[#,! %T%^)LD6-ZU=YB+(!MM %/V"2"8V:Q)9MH/P]3@J5
M0*6B*A)WTZBU/7?BD<ZJEP]OCD*V[MH^S/-EC.Z"L5 NJ3.AL([ZM%);WYF8
MOOHGYDRY,D_$Q'0Z8Z7M(_5Q$H<:^=7E#=7FN8W9[3K]'!K;SW-/;<BSZ\W&
M(6N>&^?:IC0QK;.7OOJ6,OE(*-+)<4]8-BZ<I TYVYDPK/P<\''N_H6\;RK*
M%L;'.].E76S=LA#?6@K%_A([>K1UW914V?*Y2T>*X#R9*BR)8M<6FZ(G^Y-C
MNF':?/*C\\<R^P+3SH6W+J2)>3H\[G,DP^F)2X7(QV;_*VX34^FCWX^&:5=4
M_3([7>^K]:MQ'H&-C^/O^.N,M_4/[$. ]"%!^E @?6B0/F8@?9R"]'$&TL<Y
M2!]\BM((BJ@<A52.8BI'096CJ,I16.4HKG(46#F*K )%5H$BJT"15:#(*E!D
M%2BR"A19!8JL D56@2*K1)%5HL@J4625*+)*%%DEBJP215:)(JM$D56BR*I0
M9%4HLBH4616*K I%5H4BJT*15:'(JE!D52BR:A19-8JL&D56C2*K1I%5H\BJ
M4635*+)J%%DUBJPS%%EG_RGKH[6K/XX?GT5GFOXSGXW_[;EZ!U!+ 0(4 Q0
M   ( "F!J5@'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ *8&I6.7"61?P    *P(  !$
M     ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ *8&I6)E<
MG",0!@  G"<  !,              ( !S@$  'AL+W1H96UE+W1H96UE,2YX
M;6Q02P$"% ,4    "  I@:E89%%&(N\%  ##'P  &               @($/
M"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ *8&I6*FR
MP&^N!@  UAL  !@              ("!- X  'AL+W=O<FMS:&5E=',O<VAE
M970R+GAM;%!+ 0(4 Q0    ( "F!J5C].,.,H (  &P'   8
M  " @1@5  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    "  I
M@:E8'3O/0ED'   ^)   &               @('N%P  >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&UL4$L! A0#%     @ *8&I6++F:(@@#0  I(<  !@
M         ("!?1\  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0
M   ( "F!J5CZ,B;RE0<  )L?   8              " @=,L  !X;"]W;W)K
M<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  I@:E8_8O0%'H/   A)@
M&               @(&>-   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L!
M A0#%     @ *8&I6'#0Y.U_#P  AR\  !@              ("!3D0  'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( "F!J5A6BK-!T 0
M /$*   8              " @0-4  !X;"]W;W)K<VAE971S+W-H965T.2YX
M;6Q02P$"% ,4    "  I@:E8,GO%(\$"  "!!@  &0              @($)
M60  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( "F!J5A9
M8!"ZD00  .\*   9              " @0%<  !X;"]W;W)K<VAE971S+W-H
M965T,3$N>&UL4$L! A0#%     @ *8&I6+]9#P7.!0  O@T  !D
M     ("!R6   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "F!J5BE1Y0ULP<  'P3   9              "
M@0R%  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ *8&I
M6'"5[8+T P  $ D  !D              ("!]HP  'AL+W=O<FMS:&5E=',O
M<VAE970Q."YX;6Q02P$"% ,4    "  I@:E8MIC(Q*<"  #R!P  &0
M        @($AD0  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0
M   ( "F!J5A*9%:LR@@  (I%   9              " @?^3  !X;"]W;W)K
M<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ *8&I6)?WO=%S P  9 <
M !D              ("! )T  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q0
M2P$"% ,4    "  I@:E8:.CF$4(#  !'!P  &0              @(&JH
M>&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( "F!J5BAM) #
M@0,  '((   9              " @2.D  !X;"]W;W)K<VAE971S+W-H965T
M,C,N>&UL4$L! A0#%     @ *8&I6$#I8OGH P  J0@  !D
M ("!VZ<  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    "  I
M@:E8?7[CUMP"  "\!@  &0              @('ZJP  >&PO=V]R:W-H965T
M<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( "F!J5C;?Z2UC ,  ,@(   9
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M970S,"YX;6Q02P$"% ,4    "  I@:E8[U8_Z;8"   R!@  &0
M    @(&>Q   >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    (
M "F!J5A[Q%O0'@0   (*   9              " @8O'  !X;"]W;W)K<VAE
M971S+W-H965T,S(N>&UL4$L! A0#%     @ *8&I6!-ZH=/\!0  72<  !D
M             ("!X,L  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"
M% ,4    "  I@:E8=ZPYKST$  #0&P  &0              @($3T@  >&PO
M=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( "F!J5C\\&W<B0(
M #,&   9              " @8?6  !X;"]W;W)K<VAE971S+W-H965T,S4N
M>&UL4$L! A0#%     @ *8&I6 0GI[Z%!0  9"T  !D              ("!
M1]D  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4    "  I@:E8
MT+_XD!$#  # "0  &0              @($#WP  >&PO=V]R:W-H965T<R]S
M:&5E=#,W+GAM;%!+ 0(4 Q0    ( "F!J5B/N[X&! 4   P@   9
M      " @4OB  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%
M  @ *8&I6*<BPVU$!0  B2@  !D              ("!AN<  'AL+W=O<FMS
M:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  I@:E8E9@>D;(#   &$P
M&0              @($![0  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+
M 0(4 Q0    ( "F!J5A 4:*1X@8  "5!   9              " @>KP  !X
M;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ *8&I6#[$T+WA
M @  X@<  !D              ("! _@  'AL+W=O<FMS:&5E=',O<VAE970T
M,BYX;6Q02P$"% ,4    "  I@:E8P6Q(B5@#   U#0  &0
M@($;^P  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( "F!
MJ5@N W6G?04  .LI   9              " @:K^  !X;"]W;W)K<VAE971S
M+W-H965T-#0N>&UL4$L! A0#%     @ *8&I6(:4D]72 @  F0D  !D
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M=#0Y+GAM;%!+ 0(4 Q0    ( "F!J5@C%5?0\0(  "@(   9
M  " @;(< 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @
M*8&I6*AT8:K: P  H0X  !D              ("!VA\! 'AL+W=O<FMS:&5E
M=',O<VAE970U,2YX;6Q02P$"% ,4    "  I@:E8PN)?=D\(   !5@  &0
M            @('K(P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4
M Q0    ( "F!J5@7.:$"$@4  +\D   9              " @7$L 0!X;"]W
M;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ *8&I6-W^U.VK P
MVA   !D              ("!NC$! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX
M;6Q02P$"% ,4    "  I@:E8D7+4W'0$  "G%   &0              @(&<
M-0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( "F!J5BC
M9O9]40,  ,X*   9              " @4<Z 0!X;"]W;W)K<VAE971S+W-H
M965T-38N>&UL4$L! A0#%     @ *8&I6.O%!6B5"@  2'$  !D
M     ("!SST! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "F!J5@@C8F\.0,  .P3   -              "
M 0U8 0!X;"]S='EL97,N>&UL4$L! A0#%     @ *8&I6)>*NQS     $P(
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9>&UL4$L%!@    !% $4 VA(  *]E 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>276</ContextCount>
  <ElementCount>284</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive (Loss) Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Balance Sheet Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccounts</Role>
      <ShortName>Balance Sheet Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Liability Related to the Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</Role>
      <ShortName>Liability Related to the Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Organization and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Balance Sheet Accounts (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables</Role>
      <ShortName>Balance Sheet Accounts (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/BalanceSheetAccounts</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Investments</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/IntangibleAssets</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockholdersEquity</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Leases</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables</Role>
      <ShortName>Liability Related to the Sale of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/NetLossPerShare</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Organization and Significant Accounting Policies - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail</Role>
      <ShortName>Organization and Significant Accounting Policies - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Collaboration and License Agreements - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails</Role>
      <ShortName>Collaboration and License Agreements - Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails</Role>
      <ShortName>Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails</Role>
      <ShortName>Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails</Role>
      <ShortName>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails</Role>
      <ShortName>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Collaboration and License Agreements - Amgen, Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Amgen, Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Collaboration and License Agreements - Visirna Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Visirna Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Balance Sheet Accounts - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail</Role>
      <ShortName>Balance Sheet Accounts - Summary of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails</Role>
      <ShortName>Balance Sheet Accounts - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails</Role>
      <ShortName>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Intangible Assets - Expected Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails</Role>
      <ShortName>Intangible Assets - Expected Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockholdersEquityTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Commitments and Contingencies - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail</Role>
      <ShortName>Commitments and Contingencies - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Components of Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails</Role>
      <ShortName>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Stock-Based Compensation - Expenses Included in Operating Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails</Role>
      <ShortName>Stock-Based Compensation - Expenses Included in Operating Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Summarize Information about Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of RSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Liability Related to the Sale of Future Royalties - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails</Role>
      <ShortName>Liability Related to the Sale of Future Royalties - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Liability Related to the Sale of Future Royalties - Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails</Role>
      <ShortName>Liability Related to the Sale of Future Royalties - Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="arwr-20240331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Net Loss Per Share - Antidulitive (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails</Role>
      <ShortName>Net Loss Per Share - Antidulitive (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 8 fact(s) appearing in ix:hidden were eligible for transformation: ecd:TrdArrDuration -  arwr-20240331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="arwr-20240331.htm">arwr-20240331.htm</File>
    <File>arwr-20240331.xsd</File>
    <File>arwr-20240331_cal.xml</File>
    <File>arwr-20240331_def.xml</File>
    <File>arwr-20240331_lab.xml</File>
    <File>arwr-20240331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="717">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="52">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>94
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "arwr-20240331.htm": {
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20240331",
   "dts": {
    "inline": {
     "local": [
      "arwr-20240331.htm"
     ]
    },
    "schema": {
     "local": [
      "arwr-20240331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "arwr-20240331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arwr-20240331_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20240331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20240331_pre.xml"
     ]
    }
   },
   "keyStandard": 236,
   "keyCustom": 48,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 30,
   "memberCustom": 41,
   "hidden": {
    "total": 13,
    "http://xbrl.sec.gov/dei/2023": 5,
    "http://xbrl.sec.gov/ecd/2023": 8
   },
   "contextCount": 276,
   "entityCount": 1,
   "segmentCount": 79,
   "elementCount": 547,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 717,
    "http://xbrl.sec.gov/ecd/2023": 52,
    "http://xbrl.sec.gov/dei/2023": 30
   },
   "report": {
    "R1": {
     "role": "http://www.arrowheadresearch.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
     "longName": "0000002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R4": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
     "longName": "0000004 - Statement - Consolidated Statements of Operations and Comprehensive (Loss) Income",
     "shortName": "Consolidated Statements of Operations and Comprehensive (Loss) Income",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "0000005 - Statement - Consolidated Statements of Stockholders\u2019 Equity",
     "shortName": "Consolidated Statements of Stockholders\u2019 Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-42",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000006 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies",
     "longName": "0000007 - Disclosure - Organization and Significant Accounting Policies",
     "shortName": "Organization and Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements",
     "longName": "0000008 - Disclosure - Collaboration and License Agreements",
     "shortName": "Collaboration and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccounts",
     "longName": "0000009 - Disclosure - Balance Sheet Accounts",
     "shortName": "Balance Sheet Accounts",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.arrowheadresearch.com/role/Investments",
     "longName": "0000010 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssets",
     "longName": "0000011 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquity",
     "longName": "0000012 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingencies",
     "longName": "0000013 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.arrowheadresearch.com/role/Leases",
     "longName": "0000014 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensation",
     "longName": "0000015 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurements",
     "longName": "0000016 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties",
     "longName": "0000017 - Disclosure - Liability Related to the Sale of Future Royalties",
     "shortName": "Liability Related to the Sale of Future Royalties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.arrowheadresearch.com/role/NetLossPerShare",
     "longName": "0000018 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R20": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Organization and Significant Accounting Policies (Tables)",
     "shortName": "Organization and Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables",
     "longName": "9954473 - Disclosure - Collaboration and License Agreements (Tables)",
     "shortName": "Collaboration and License Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables",
     "longName": "9954474 - Disclosure - Balance Sheet Accounts (Tables)",
     "shortName": "Balance Sheet Accounts (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.arrowheadresearch.com/role/InvestmentsTables",
     "longName": "9954475 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsTables",
     "longName": "9954476 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityTables",
     "longName": "9954477 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.arrowheadresearch.com/role/LeasesTables",
     "longName": "9954478 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationTables",
     "longName": "9954479 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables",
     "longName": "9954480 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables",
     "longName": "9954481 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)",
     "shortName": "Liability Related to the Sale of Future Royalties (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.arrowheadresearch.com/role/NetLossPerShareTables",
     "longName": "9954482 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail",
     "longName": "9954483 - Disclosure - Organization and Significant Accounting Policies - Narrative (Detail)",
     "shortName": "Organization and Significant Accounting Policies - Narrative (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:IncreaseDecreaseInCashAndInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
     "longName": "9954484 - Disclosure - Collaboration and License Agreements - Revenue (Details)",
     "shortName": "Collaboration and License Agreements - Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-67",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails",
     "longName": "9954485 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)",
     "shortName": "Collaboration and License Agreements - Receivables and Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
     "longName": "9954486 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)",
     "shortName": "Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-87",
      "name": "arwr:MilestonePaymentReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
     "longName": "9954487 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)",
     "shortName": "Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "arwr:NumberOfDistinctPerformanceObligations",
      "unitRef": "obligation",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-93",
      "name": "arwr:NumberOfDistinctPerformanceObligations",
      "unitRef": "obligation",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
     "longName": "9954488 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "shortName": "Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "arwr:DevelopmentRegulatoryAndSalesMilestonesPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-98",
      "name": "arwr:NumberOfDistinctPerformanceObligations",
      "unitRef": "obligation",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
     "longName": "9954489 - Disclosure - Collaboration and License Agreements - Amgen, Inc (Details)",
     "shortName": "Collaboration and License Agreements - Amgen, Inc (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-102",
      "name": "arwr:NumberOfAgreements",
      "unitRef": "agreement",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails",
     "longName": "9954490 - Disclosure - Collaboration and License Agreements - Visirna Therapeutics, Inc. (Details)",
     "shortName": "Collaboration and License Agreements - Visirna Therapeutics, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-109",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail",
     "longName": "9954491 - Disclosure - Balance Sheet Accounts - Summary of Property and Equipment (Detail)",
     "shortName": "Balance Sheet Accounts - Summary of Property and Equipment (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails",
     "longName": "9954492 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details)",
     "shortName": "Balance Sheet Accounts - Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "arwr:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "arwr:AccruedResearchAndDevelopmentExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
     "longName": "9954493 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)",
     "shortName": "Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
     "longName": "9954494 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails",
     "longName": "9954495 - Disclosure - Intangible Assets - Expected Future Amortization (Details)",
     "shortName": "Intangible Assets - Expected Future Amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityDetails",
     "longName": "9954496 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockByClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail",
     "longName": "9954497 - Disclosure - Commitments and Contingencies - Narrative (Detail)",
     "shortName": "Commitments and Contingencies - Narrative (Detail)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
     "longName": "9954498 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
     "longName": "9954499 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)",
     "shortName": "Leases - Components of Lease Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails",
     "longName": "9954500 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "shortName": "Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails",
     "longName": "9954501 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)",
     "shortName": "Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9954502 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-175",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
     "longName": "9954503 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)",
     "shortName": "Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-3",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-3",
      "name": "arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails",
     "longName": "9954504 - Disclosure - Stock-Based Compensation - Expenses Included in Operating Expenses (Details)",
     "shortName": "Stock-Based Compensation - Expenses Included in Operating Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-154",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails",
     "longName": "9954505 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)",
     "shortName": "Stock-Based Compensation - Summarize Information about Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails",
     "longName": "9954506 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of RSUs Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-184",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-185",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9954507 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-212",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-212",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
     "longName": "9954508 - Disclosure - Liability Related to the Sale of Future Royalties - Narrative (Details)",
     "shortName": "Liability Related to the Sale of Future Royalties - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-250",
      "name": "arwr:CashReceivedAsDueUnderCollaborationAgreement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-250",
      "name": "arwr:CashReceivedAsDueUnderCollaborationAgreement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails",
     "longName": "9954509 - Disclosure - Liability Related to the Sale of Future Royalties - Activity (Details)",
     "shortName": "Liability Related to the Sale of Future Royalties - Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "arwr:RoyaltiesLiabilityNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails",
     "longName": "9954510 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails",
     "longName": "9954511 - Disclosure - Net Loss Per Share - Antidulitive (Details)",
     "shortName": "Net Loss Per Share - Antidulitive (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240331.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r592"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables included in accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r499",
      "r549",
      "r597",
      "r763"
     ]
    },
    "arwr_AccruedCapitalExpenditureCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "AccruedCapitalExpenditureCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued capital expenditures",
        "label": "Accrued Capital Expenditure, Current",
        "documentation": "Accrued Capital Expenditure, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expense",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued R&amp;D expenses; co-development",
        "label": "Accrued Research And Development Co-Development Expense, Current",
        "documentation": "Accrued Research And Development Co-Development Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued R&amp;D expenses",
        "label": "Accrued Research And Development Expense, Current",
        "documentation": "Accrued Research And Development Expense, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r126",
      "r451"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r74",
      "r133",
      "r447",
      "r467",
      "r468"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r8",
      "r23",
      "r360",
      "r363",
      "r402",
      "r463",
      "r464",
      "r692",
      "r693",
      "r694",
      "r698",
      "r699",
      "r700"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r642"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r477",
      "r698",
      "r699",
      "r700",
      "r748",
      "r769"
     ]
    },
    "arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional remaining development regulatory and sales milestones payments",
        "label": "Additional Remaining Development Regulatory And Sales Milestones Payments",
        "documentation": "Additional remaining development regulatory and sales milestones payments."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "AdditionalTenantImprovementAllowanceInterestPerAnnum",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional tenant improvement allowance interest per annum",
        "label": "Additional Tenant Improvement Allowance, Interest Per Annum",
        "documentation": "Additional Tenant Improvement Allowance, Interest Per Annum"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AdditionalTenantImprovementAllowanceLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "AdditionalTenantImprovementAllowanceLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional tenant improvement allowance liability",
        "label": "Additional Tenant Improvement Allowance Liability",
        "documentation": "Additional Tenant Improvement Allowance Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r52",
      "r308"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash flow from operating activities",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r624",
      "r634",
      "r659"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r616",
      "r627",
      "r637",
      "r662"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r628",
      "r638",
      "r655",
      "r663",
      "r667",
      "r675"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r337",
      "r345"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AmgenIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "AmgenIncorporatedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amgen",
        "label": "Amgen Incorporated [Member]",
        "documentation": "Amgen Incorporated."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r32",
      "r35"
     ]
    },
    "arwr_AmountIntendsToInvestForBuildoutOfFacilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "AmountIntendsToInvestForBuildoutOfFacilities",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount intends to invest for buildout of the facilities",
        "label": "Amount Intends To Invest For Buildout Of Facilities",
        "documentation": "Amount intends to invest for buildout of facilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r178"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Planned area of the site (in sq ft)",
        "label": "Area of Land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r747"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r129",
      "r154",
      "r184",
      "r192",
      "r196",
      "r235",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r353",
      "r357",
      "r379",
      "r444",
      "r504",
      "r592",
      "r604",
      "r711",
      "r712",
      "r754"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Assets and Liabilities",
        "label": "Assets and Liabilities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r122",
      "r136",
      "r154",
      "r235",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r353",
      "r357",
      "r379",
      "r592",
      "r711",
      "r712",
      "r754"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "arwr_AtTheMarketAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "AtTheMarketAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At The Market Agreement",
        "label": "At The Market Agreement [Member]",
        "documentation": "At-the-market agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r243",
      "r439",
      "r702"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale securities, at fair value",
        "verboseLabel": "Current investments, Available-for-sale, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r243"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r670"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r671"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r669"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r668"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r667"
     ]
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital expenditures included in accrued expenses",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r29"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r124",
      "r563"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "periodStartLabel": "BEGINNING OF PERIOD",
        "periodEndLabel": "END OF PERIOD",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r85",
      "r152"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH:",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r85"
     ]
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of noncash investing activities:",
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "documentation": "Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CashReceivedAsDueUnderCollaborationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "CashReceivedAsDueUnderCollaborationAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "Cash Received As Due Under Collaboration Agreement",
        "documentation": "Cash received as due under collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r131",
      "r132",
      "r183",
      "r276",
      "r277",
      "r278",
      "r280",
      "r283",
      "r288",
      "r290",
      "r470",
      "r471",
      "r472",
      "r473",
      "r575",
      "r681",
      "r696"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "arwr_CollaborationAndLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration And License Agreements [Abstract]",
        "label": "Collaboration And License Agreements [Abstract]",
        "documentation": "Collaboration and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r115",
      "r117"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "arwr_ColoradoOwnerLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "ColoradoOwnerLLCMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Colorado Owner, LLC",
        "label": "Colorado Owner L L C [Member]",
        "documentation": "Colorado Owner, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CommercialMilestonePaymentsAtFirstCommercialSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "CommercialMilestonePaymentsAtFirstCommercialSale",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial milestone payments at first commercial sale",
        "label": "Commercial Milestone Payments At First Commercial Sale",
        "documentation": "Commercial milestone payments at first commercial sale."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CommercialNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "CommercialNotesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial notes",
        "label": "Commercial Notes [Member]",
        "documentation": "Commercial Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r61",
      "r445",
      "r490"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r94",
      "r256",
      "r257",
      "r550",
      "r710"
     ]
    },
    "arwr_CommitmentsCapitalExpendituresIncurredToDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "CommitmentsCapitalExpendituresIncurredToDate",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capital expenditures incurred",
        "label": "Commitments, Capital Expenditures Incurred To Date",
        "documentation": "Commitments, Capital Expenditures Incurred To Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserve for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "arwr_CommonStockCapitalSharesValueReservedForFutureIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "CommonStockCapitalSharesValueReservedForFutureIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares value reserved for future issuance",
        "label": "Common Stock Capital Shares Value Reserved For Future Issuance",
        "documentation": "Common stock, capital shares value reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r595",
      "r596",
      "r598",
      "r599",
      "r600",
      "r601",
      "r698",
      "r699",
      "r748",
      "r767",
      "r769"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r491"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r68",
      "r491",
      "r510",
      "r769",
      "r770"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 124,133 and 107,312 shares",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r446",
      "r592"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r652"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r651"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r650"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive (loss) income, net of tax:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive (loss) income",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r102",
      "r141",
      "r143",
      "r148",
      "r440",
      "r458"
     ]
    },
    "arwr_ComputerAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "ComputerAndSoftwareMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers and software",
        "label": "Computer And Software [Member]",
        "documentation": "Computer And Software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConstructionInProgressMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress [Member]",
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Receivables and Contract Liabilities",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r714"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r294",
      "r297"
     ]
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities included in deferred revenue",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r297"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Contract liabilities",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r297"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r583",
      "r585",
      "r766"
     ]
    },
    "arwr_CorporateHeadquartersInPasadenaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "CorporateHeadquartersInPasadenaMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Headquarters In Pasadena",
        "label": "Corporate Headquarters In Pasadena [Member]",
        "documentation": "Corporate Headquarters in Pasadena"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r272",
      "r278",
      "r403",
      "r565",
      "r567"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current investments, Available-for-sale, Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current",
        "documentation": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Current investments, Available-for-sale, Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current",
        "documentation": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Current investments, Available-for-sale, Adjusted Basis",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r243",
      "r703"
     ]
    },
    "us-gaap_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities",
        "label": "Debt Securities [Member]",
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r596",
      "r771"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r36"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense for property and equipment",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r188"
     ]
    },
    "arwr_DevelopmentAndSalesMilestonesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "DevelopmentAndSalesMilestonesPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development and sales milestone payments",
        "label": "Development And Sales Milestones Payments",
        "documentation": "Development And Sales Milestones Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DevelopmentRegulatoryAndSalesMilestonesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "DevelopmentRegulatoryAndSalesMilestonesPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development regulatory and sales milestones payments",
        "label": "Development Regulatory And Sales Milestones Payments",
        "documentation": "Development regulatory and sales milestones payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r296",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r310",
      "r338",
      "r339",
      "r341",
      "r587"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r608"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r641"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DrugManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "DrugManufacturingFacilityMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug Manufacturing Facility",
        "label": "Drug Manufacturing Facility [Member]",
        "documentation": "Drug manufacturing facility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net (loss) gain per share (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r171",
      "r173",
      "r175",
      "r176",
      "r177",
      "r181",
      "r368",
      "r369",
      "r441",
      "r459",
      "r569"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Diluted net (loss) gain per share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r173",
      "r175",
      "r176",
      "r177",
      "r181",
      "r368",
      "r369",
      "r441",
      "r459",
      "r569"
     ]
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (loss) income per share attributable to Arrowhead Pharmaceuticals, Inc.:",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r178",
      "r179",
      "r180"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r380"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period to recognize pre-tax compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized pre-tax compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized pre-tax compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r744"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r680"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r606"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r119",
      "r144",
      "r145",
      "r146",
      "r157",
      "r158",
      "r159",
      "r161",
      "r167",
      "r169",
      "r182",
      "r236",
      "r237",
      "r291",
      "r342",
      "r343",
      "r344",
      "r348",
      "r349",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r402",
      "r463",
      "r464",
      "r465",
      "r477",
      "r531"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r649"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r613",
      "r624",
      "r634",
      "r659"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r610",
      "r621",
      "r631",
      "r656"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "arwr_FacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "FacilitiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facilities",
        "label": "Facilities [Member]",
        "documentation": "Facilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372",
      "r375"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372",
      "r375"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r372",
      "r407",
      "r408",
      "r409",
      "r573",
      "r574",
      "r583",
      "r584",
      "r585"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r374",
      "r376"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r299",
      "r304",
      "r372",
      "r407",
      "r583",
      "r584",
      "r585"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r299",
      "r304",
      "r372",
      "r408",
      "r573",
      "r574",
      "r583",
      "r584",
      "r585"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r372",
      "r409",
      "r573",
      "r574",
      "r583",
      "r584",
      "r585"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r407",
      "r408",
      "r409",
      "r573",
      "r574",
      "r583",
      "r584",
      "r585"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r370",
      "r376"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r244",
      "r245",
      "r246",
      "r274",
      "r288",
      "r365",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r457",
      "r572",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r704",
      "r705",
      "r706",
      "r707"
     ]
    },
    "arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four",
        "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful Lives",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r127",
      "r252"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (remainder)",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r252",
      "r253",
      "r437",
      "r438"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r438"
     ]
    },
    "arwr_FiniteLivedIntangibleAssetsImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "FiniteLivedIntangibleAssetsImpairment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Finite-Lived Intangible Assets, Impairment",
        "documentation": "Finite-Lived Intangible Assets, Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r437"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r663"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r663"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r663"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r663"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r663"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_GSKHBVAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "GSKHBVAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK-HBV Agreement",
        "label": "GSK-HBV Agreement [Member]",
        "documentation": "GSK-HBV Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_GSKLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "GSKLicenseAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK License Agreement",
        "label": "GSK License Agreement [Member]",
        "documentation": "GSK License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r514"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "arwr_GlaxosmithklineIntellectualPropertyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "GlaxosmithklineIntellectualPropertyLimitedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK",
        "label": "Glaxosmithkline Intellectual Property Limited [Member]",
        "documentation": "Glaxosmithkline Intellectual Property Limited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Short-term and Long-term Investments and Marketable Securities",
        "label": "Held To Maturity Securities And Marketable Securities Table [Table Text Block]",
        "documentation": "Held to maturity securities and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_HorizonLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "HorizonLicenseAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Horizon License Agreement",
        "label": "Horizon License Agreement [Member]",
        "documentation": "Horizon License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_HorizonTherapeuticsIrelandDACMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "HorizonTherapeuticsIrelandDACMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Horizon",
        "label": "Horizon Therapeutics Ireland DAC [Member]",
        "documentation": "Horizon Therapeutics Ireland DAC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "(Loss) income before income tax (benefit) expense and noncontrolling interest",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r75",
      "r108",
      "r184",
      "r191",
      "r195",
      "r197",
      "r442",
      "r453",
      "r570"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r515"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r255",
      "r515"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax (benefit) expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r116",
      "r168",
      "r169",
      "r189",
      "r347",
      "r350",
      "r461"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes paid",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "arwr_IncreaseDecreaseInCashAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "IncreaseDecreaseInCashAndInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (decrease) in cash and investments",
        "label": "Increase (Decrease) In Cash And Investments",
        "documentation": "Increase decrease in cash and investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r695"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, net",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r683",
      "r695"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r620",
      "r628",
      "r638",
      "r655",
      "r663",
      "r667",
      "r675"
     ]
    },
    "arwr_InducementAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "InducementAwardsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Awards",
        "label": "Inducement Awards [Member]",
        "documentation": "Inducement Awards"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_InitialTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "InitialTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial transaction price",
        "label": "Initial Transaction Price",
        "documentation": "Initial transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r609",
      "r679"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r609",
      "r679"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r609",
      "r679"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r110",
      "r147",
      "r187",
      "r387",
      "r516",
      "r602",
      "r768"
     ]
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterestAndDividend",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest and Dividend",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization (accretion) of note premiums/discounts",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r111",
      "r112",
      "r118",
      "r202",
      "r204",
      "r377",
      "r378"
     ]
    },
    "arwr_JamesHamiltonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "JamesHamiltonMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "James Hamilton [Member]",
        "documentation": "James Hamilton"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_JanssenPharmaceuticalsIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "JanssenPharmaceuticalsIncorporationMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen",
        "label": "Janssen Pharmaceuticals Incorporation [Member]",
        "documentation": "Janssen Pharmaceuticals, Incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_KenMyszkowskiMarch12PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "KenMyszkowskiMarch12PlanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ken Myszkowski March 12 Plan [Member]",
        "documentation": "Ken Myszkowski March 12 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_KenMyszkowskiMarch28Plan1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "KenMyszkowskiMarch28Plan1Member",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ken Myszkowski March 28 Plan 1 [Member]",
        "documentation": "Ken Myszkowski March 28 Plan 1"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_KenMyszkowskiMarch28Plan2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "KenMyszkowskiMarch28Plan2Member",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ken Myszkowski March 28 Plan 2 [Member]",
        "documentation": "Ken Myszkowski March 28 Plan 2"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_KenMyszkowskiMarch28Plan3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "KenMyszkowskiMarch28Plan3Member",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ken Myszkowski March 28 Plan 3 [Member]",
        "documentation": "Ken Myszkowski March 28 Plan 3"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_KenMyszkowskiMarch28Plan4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "KenMyszkowskiMarch28Plan4Member",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ken Myszkowski March 28 Plan 4 [Member]",
        "documentation": "Ken Myszkowski March 28 Plan 4"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_KenMyszkowskiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "KenMyszkowskiMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ken Myszkowski [Member]",
        "documentation": "Ken Myszkowski"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LaboratoryAndOfficeFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "LaboratoryAndOfficeFacilityMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory and Office Facility",
        "label": "Laboratory And Office Facility [Member]",
        "documentation": "Laboratory and office facility."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandSubjectToGroundLeases",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office space leases (in sq ft)",
        "label": "Land Subject to Ground Leases",
        "documentation": "Area of land subject to a ground lease."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r591"
     ]
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Cost",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Assets and Liabilities and Lease Cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r752"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 and thereafter",
        "label": "Lessee Operating Lease Liability Payments Due Year Five And After Year Five",
        "documentation": "Lessee operating lease liability payments due year five and after year five."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024 (remainder of fiscal year)",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r753"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r401"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r751"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities, Noncontrolling Interest and Stockholders\u2019 Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r107",
      "r450",
      "r592",
      "r697",
      "r708",
      "r749"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r123",
      "r154",
      "r235",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r354",
      "r357",
      "r358",
      "r379",
      "r592",
      "r711",
      "r754",
      "r755"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r63",
      "r64",
      "r65",
      "r66",
      "r154",
      "r235",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r354",
      "r357",
      "r358",
      "r379",
      "r711",
      "r754",
      "r755"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Related To The Sale Of Future Royalties [Abstract]",
        "documentation": "Liability Related To The Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Related to the Sale of Future Royalties",
        "label": "Liability Related To The Sale Of Future Royalties [Text Block]",
        "documentation": "Liability Related To The Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilitySaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "LiabilitySaleOfFutureRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to the sale of future royalties",
        "label": "Liability, Sale of Future Royalties",
        "documentation": "Liability, Sale of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilitySaleOfFutureRoyaltiesInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "LiabilitySaleOfFutureRoyaltiesInterestRate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to the sale of future royalties, interest rate",
        "label": "Liability, Sale Of Future Royalties, Interest Rate",
        "documentation": "Liability, Sale Of Future Royalties, Interest Rate"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilitySaleOfFutureRoyaltiesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "LiabilitySaleOfFutureRoyaltiesRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability, Sale Of Future Royalties [Roll Forward]",
        "label": "Liability, Sale Of Future Royalties [Roll Forward]",
        "documentation": "Liability, Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LicenseAndCoFundingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "LicenseAndCoFundingAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Co-Funding Agreement",
        "label": "License And Co Funding Agreement [Member]",
        "documentation": "License and co-funding agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r346",
      "r746"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liabilities",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r682"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r578",
      "r715",
      "r764",
      "r765"
     ]
    },
    "arwr_MaximumAdditionalTenantImprovementAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "MaximumAdditionalTenantImprovementAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum additional tenant improvement allowance",
        "label": "Maximum Additional Tenant Improvement Allowance",
        "documentation": "Maximum Additional Tenant Improvement Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r305",
      "r434",
      "r462",
      "r482",
      "r483",
      "r536",
      "r538",
      "r540",
      "r541",
      "r543",
      "r560",
      "r561",
      "r571",
      "r575",
      "r586",
      "r593",
      "r713",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "arwr_MilestonePaymentEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "MilestonePaymentEarned",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "label": "Milestone Payment Earned",
        "documentation": "Milestone payment earned."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "MilestonePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable",
        "label": "Milestone Payment Receivable",
        "documentation": "Milestone Payment Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial",
        "label": "Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial",
        "documentation": "Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three",
        "label": "Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three",
        "documentation": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponFDAApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "MilestonePaymentReceivableUponFDAApproval",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon FDA approval",
        "label": "Milestone Payment Receivable, Upon FDA Approval",
        "documentation": "Milestone Payment Receivable, Upon FDA Approval"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "MilestonePaymentReceivableUponReceiptOfRoyaltyPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon receipt of royalty payments",
        "label": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments",
        "documentation": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "MilestonePaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "label": "Milestone Payment Received",
        "documentation": "Milestone payment received."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r305",
      "r434",
      "r462",
      "r482",
      "r483",
      "r536",
      "r538",
      "r540",
      "r541",
      "r543",
      "r560",
      "r561",
      "r571",
      "r575",
      "r586",
      "r593",
      "r713",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r106",
      "r154",
      "r235",
      "r263",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r379",
      "r449",
      "r493"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r666"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market instruments",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r717"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_MunicipalBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MunicipalBondsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Municipal securities",
        "label": "Municipal Bonds [Member]",
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments."
       }
      }
     },
     "auth_ref": []
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r201",
      "r578",
      "r715",
      "r764",
      "r765"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.",
        "terseLabel": "Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r87",
      "r109",
      "r121",
      "r140",
      "r142",
      "r146",
      "r154",
      "r160",
      "r162",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r174",
      "r184",
      "r191",
      "r195",
      "r197",
      "r235",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r369",
      "r379",
      "r456",
      "r512",
      "r529",
      "r530",
      "r570",
      "r602",
      "r711"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to noncontrolling interest, net of tax",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r103",
      "r140",
      "r142",
      "r168",
      "r169",
      "r455",
      "r694"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense on liability related to the sale of future royalties",
        "verboseLabel": "Non-cash interest expense recognized",
        "label": "Non-Cash Interest Expense, Liability Related to Sale of Future Royalties",
        "documentation": "Non-Cash Interest Expense, Liability Related to Sale of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r617",
      "r628",
      "r638",
      "r655",
      "r663"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- controlling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r291",
      "r698",
      "r699",
      "r700",
      "r769"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other expense",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NovartisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "NovartisMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis",
        "label": "Novartis [Member]",
        "documentation": "Novartis."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "NumberOfAgreements",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of agreements",
        "label": "Number Of Agreements",
        "documentation": "Number of agreements."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfDistinctBundle": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "NumberOfDistinctBundle",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of distinct bundle",
        "label": "Number Of Distinct Bundle",
        "documentation": "Number of distinct bundle."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfDistinctPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "NumberOfDistinctPerformanceObligations",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of distinct performance obligations",
        "label": "Number Of Distinct Performance Obligations",
        "documentation": "Number of distinct performance obligations."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfOptionsToRenew": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "NumberOfOptionsToRenew",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options to renew",
        "label": "Number Of Options To Renew",
        "documentation": "Number of options to renew."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_OlpasiranAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "OlpasiranAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Olpasiran Agreement",
        "label": "Olpasiran Agreement [Member]",
        "documentation": "Olpasiran agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating (loss) income",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r191",
      "r195",
      "r197",
      "r570"
     ]
    },
    "arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities",
        "documentation": "Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r394",
      "r591"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total operating lease liabilities (includes current portion)",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r390"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r391",
      "r397"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r389"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r591"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r399",
      "r591"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leased Assets [Line Items]",
        "label": "Operating Leased Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "OrganizationAndSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization And Significant Accounting Policies [Line Items]",
        "label": "Organization And Significant Accounting Policies [Line Items]",
        "documentation": "Organization and significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "OrganizationAndSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization And Significant Accounting Policies [Table]",
        "label": "Organization And Significant Accounting Policies [Table]",
        "documentation": "Organization and significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r88",
      "r89",
      "r101"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r592"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in unrealized losses on available-for-sale securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r138",
      "r139"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r592"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r615",
      "r626",
      "r636",
      "r661"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r629",
      "r639",
      "r664"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r618",
      "r629",
      "r639",
      "r664"
     ]
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "arwr_PatrickOBrienMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "PatrickOBrienMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patrick O'Brien [Member]",
        "documentation": "Patrick O'Brien"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r645"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r655"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r644"
     ]
    },
    "arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of commission to sales agent",
        "label": "Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock",
        "documentation": "Percentage of commission on aggregate gross proceeds from sale of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of eligible to receive tiered royalties on net sales",
        "label": "Percentage Of Eligible To Receive Tiered Royalties On Net Sales",
        "documentation": "Percentage of eligible to receive tiered royalties on net sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r276"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r491"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r276"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r491",
      "r510",
      "r769",
      "r770"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r247",
      "r248",
      "r564"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the issuance of common stock, net of offering costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales and maturities of investments",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "arwr_ProceedsFromSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "ProceedsFromSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the sale of future royalties",
        "label": "Proceeds from Sale of Future Royalties",
        "documentation": "Proceeds from Sale of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercises of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r12"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net (loss) income including noncontrolling interest",
        "verboseLabel": "Net income (loss)",
        "terseLabel": "Net (loss) income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r140",
      "r142",
      "r150",
      "r154",
      "r160",
      "r168",
      "r169",
      "r184",
      "r191",
      "r195",
      "r197",
      "r235",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r352",
      "r355",
      "r356",
      "r369",
      "r379",
      "r442",
      "r454",
      "r476",
      "r512",
      "r529",
      "r530",
      "r570",
      "r589",
      "r590",
      "r603",
      "r694",
      "r711"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, gross",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r125",
      "r452"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r443",
      "r452",
      "r592"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTransfersAndChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTransfersAndChanges",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, reclassification",
        "label": "Property, Plant and Equipment, Transfers and Changes",
        "documentation": "Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r643"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r298",
      "r305",
      "r333",
      "r334",
      "r335",
      "r410",
      "r434",
      "r462",
      "r482",
      "r483",
      "r536",
      "r538",
      "r540",
      "r541",
      "r543",
      "r560",
      "r561",
      "r571",
      "r575",
      "r586",
      "r593",
      "r596",
      "r709",
      "r713",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r259",
      "r260",
      "r261",
      "r262",
      "r298",
      "r305",
      "r333",
      "r334",
      "r335",
      "r410",
      "r434",
      "r462",
      "r482",
      "r483",
      "r536",
      "r538",
      "r540",
      "r541",
      "r543",
      "r560",
      "r561",
      "r571",
      "r575",
      "r586",
      "r593",
      "r596",
      "r709",
      "r713",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ]
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Realized gain on investments",
        "label": "Realized Investment Gains (Losses)",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r610",
      "r621",
      "r631",
      "r656"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r155",
      "r156",
      "r272",
      "r278",
      "r403",
      "r566",
      "r567"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "ResearchEquipmentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research equipment",
        "label": "Research Equipment [Member]",
        "documentation": "Research Equipment"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchFacilityInMadisonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "ResearchFacilityInMadisonMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Facility in Madison",
        "label": "Research Facility In Madison [Member]",
        "documentation": "Research facility in Madison."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchFacilityInSanDiegoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "ResearchFacilityInSanDiegoMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Facility in San Diego",
        "label": "Research Facility In San Diego [Member]",
        "documentation": "Research Facility in San Diego."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r611",
      "r622",
      "r632",
      "r657"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r612",
      "r623",
      "r633",
      "r658"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r619",
      "r630",
      "r640",
      "r665"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r124",
      "r152"
     ]
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted stock units",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r98",
      "r448",
      "r466",
      "r468",
      "r474",
      "r492",
      "r592"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r157",
      "r158",
      "r159",
      "r161",
      "r167",
      "r169",
      "r236",
      "r237",
      "r342",
      "r343",
      "r344",
      "r348",
      "r349",
      "r359",
      "r361",
      "r362",
      "r364",
      "r367",
      "r463",
      "r465",
      "r477",
      "r769"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186",
      "r190",
      "r193",
      "r194",
      "r198",
      "r199",
      "r201",
      "r295",
      "r296",
      "r436"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for amended operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r591"
     ]
    },
    "arwr_RoyaltiesLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "RoyaltiesLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to the sale of future royalties",
        "periodStartLabel": "Carrying value as of September 30, 2023",
        "periodEndLabel": "Carrying value as of March 31, 2024",
        "label": "Royalties, Liability, Noncurrent",
        "documentation": "Royalties, Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_RoyaltyPaymentThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "RoyaltyPaymentThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payment threshold",
        "label": "Royalty Payment Threshold",
        "documentation": "Royalty Payment Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_RoyaltyPharmaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "RoyaltyPharmaAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Pharma Agreement",
        "label": "Royalty Pharma Agreement [Member]",
        "documentation": "Royalty Pharma Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r674"
     ]
    },
    "arwr_SaleOfStockAggregatePurchasePrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "SaleOfStockAggregatePurchasePrice",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate purchase price paid by investors",
        "label": "Sale Of Stock, Aggregate Purchase Price",
        "documentation": "Sale Of Stock, Aggregate Purchase Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares of common stock issued (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock offering price (in dollars per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_SalesRelatedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "SalesRelatedMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-related milestone payments",
        "label": "Sales Related Milestone Payments",
        "documentation": "Sales-related milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareAntidulitiveDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "arwr_ScheduleOfCurrentProductsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "ScheduleOfCurrentProductsTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company's Current Pipeline",
        "label": "Schedule of Current Products [Table Text Block]",
        "documentation": "Schedule of Current Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Payment Arrangement, Expensed",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34",
      "r437"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r33",
      "r34"
     ]
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "documentation": "Schedule of held to maturity securities and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "documentation": "Schedule of held to maturity securities and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Liability Related to the Sale of Future Royalties",
        "label": "Schedule Of Liability Related To The Sale Of Future Royalties [Table Text Block]",
        "documentation": "Schedule Of Liability Related To The Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Leased Assets [Table]",
        "label": "Schedule of Operating Leased Assets [Table]",
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Awards Outstanding",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r49"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share Activity Related to RSUs",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summarized Information about Stock Options",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r48"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r96",
      "r97",
      "r98",
      "r130",
      "r131",
      "r132",
      "r183",
      "r276",
      "r277",
      "r278",
      "r280",
      "r283",
      "r288",
      "r290",
      "r470",
      "r471",
      "r472",
      "r473",
      "r575",
      "r681",
      "r696"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shares of Common Stock and Preferred Stock",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r39",
      "r41",
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r67",
      "r68",
      "r96",
      "r97",
      "r98"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r605"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r607"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r479",
      "r480",
      "r481",
      "r537",
      "r539",
      "r542",
      "r544",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r562",
      "r577",
      "r596",
      "r715",
      "r764"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r327"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award (in shares)",
        "periodStartLabel": "Beginning of period (in shares)",
        "periodEndLabel": "End of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r322",
      "r323"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Grant Date Fair Value Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r326"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r309",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r588"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, share reserve for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options Outstanding, Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r329"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r320"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r315"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r319"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r321"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r318"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Remaining Contractual Term (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r591"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r20",
      "r119",
      "r144",
      "r145",
      "r146",
      "r157",
      "r158",
      "r159",
      "r161",
      "r167",
      "r169",
      "r182",
      "r236",
      "r237",
      "r291",
      "r342",
      "r343",
      "r344",
      "r348",
      "r349",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r402",
      "r463",
      "r464",
      "r465",
      "r477",
      "r531"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r479",
      "r480",
      "r481",
      "r537",
      "r539",
      "r542",
      "r544",
      "r548",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r562",
      "r577",
      "r596",
      "r715",
      "r764"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r182",
      "r436",
      "r469",
      "r478",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r500",
      "r501",
      "r502",
      "r503",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r511",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r531",
      "r597"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r158",
      "r159",
      "r182",
      "r436",
      "r469",
      "r478",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r491",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r500",
      "r501",
      "r502",
      "r503",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r511",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r531",
      "r597"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r614",
      "r625",
      "r635",
      "r660"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued, net of offering costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r67",
      "r68",
      "r98",
      "r470",
      "r531",
      "r545"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock - restricted stock units vesting (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r98"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r67",
      "r68",
      "r98",
      "r319"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued, net of offering costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r67",
      "r68",
      "r98",
      "r477",
      "r531",
      "r545",
      "r603"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock - restricted stock units vesting",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r67",
      "r68",
      "r98"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r20",
      "r98"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Arrowhead Pharmaceuticals, Inc. stockholders\u2019 equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r71",
      "r72",
      "r90",
      "r493",
      "r510",
      "r532",
      "r533",
      "r592",
      "r604",
      "r697",
      "r708",
      "r749",
      "r769"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total noncontrolling interest and stockholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r119",
      "r120",
      "r145",
      "r157",
      "r158",
      "r159",
      "r161",
      "r167",
      "r236",
      "r237",
      "r291",
      "r342",
      "r343",
      "r344",
      "r348",
      "r349",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r367",
      "r381",
      "r382",
      "r386",
      "r402",
      "r464",
      "r465",
      "r475",
      "r493",
      "r510",
      "r532",
      "r533",
      "r546",
      "r603",
      "r697",
      "r708",
      "r749",
      "r769"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest and stockholders\u2019 equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r153",
      "r275",
      "r277",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r291",
      "r366",
      "r534",
      "r535",
      "r547"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/BalanceSheetAccounts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Accounts",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity."
       }
      }
     },
     "auth_ref": [
      "r691"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplementary disclosure of cash flows:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r654"
     ]
    },
    "arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda",
        "label": "Takeda Pharmaceuticals United States Of America Incorporated [Member]",
        "documentation": "Takeda Pharmaceuticals United States of America Incorporated."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r646"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r653"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r673"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r274",
      "r288",
      "r365",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r457",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r704",
      "r705",
      "r706",
      "r707"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r677"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r675"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r678"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r676"
     ]
    },
    "arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants",
        "label": "Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]",
        "documentation": "Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_TwoThousandTwentyOneIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "TwoThousandTwentyOneIncentivePlanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Incentive Plan",
        "label": "Two Thousand Twenty One Incentive Plan [Member]",
        "documentation": "Two thousand twenty one incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_TwoThousandsFourEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "TwoThousandsFourEquityIncentivePlanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2004 Equity Incentive Plan",
        "label": "Two Thousands Four Equity Incentive Plan [Member]",
        "documentation": "Two thousands four equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_TwoThousandsThirteenIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "TwoThousandsThirteenIncentivePlanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 Incentive Plan",
        "label": "Two Thousands Thirteen Incentive Plan [Member]",
        "documentation": "Two thousands thirteen incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r351"
     ]
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government bonds",
        "label": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USTreasurySecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Treasuries",
        "label": "US Treasury Securities [Member]",
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r583",
      "r585",
      "r762"
     ]
    },
    "arwr_UnderwritingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "UnderwritingAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underwriting Agreement",
        "label": "Underwriting Agreement [Member]",
        "documentation": "Underwriting Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r672"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r396",
      "r591"
     ]
    },
    "arwr_VisirnaESOPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "VisirnaESOPMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Visirna ESOP",
        "label": "Visirna ESOP [Member]",
        "documentation": "Visirna ESOP"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_VisirnaLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "VisirnaLicenseAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Visirna License Agreement",
        "label": "Visirna License Agreement [Member]",
        "documentation": "Visirna License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_VisirnaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "VisirnaTherapeuticsIncMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Visirna Therapeutics, Inc.",
        "label": "Visirna Therapeutics, Inc. [Member]",
        "documentation": "Visirna Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_WI": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "WI",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetail",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wisconsin",
        "label": "WISCONSIN"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r701"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average diluted shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r177"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average basic shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r177"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossIncome",
      "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in calculating",
        "verboseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_WilliamWaddillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20240331",
     "localname": "WilliamWaddillMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "William Waddill [Member]",
        "documentation": "William Waddill"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//210/tableOfContent"
  },
  "r692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>95
<FILENAME>0001628280-24-022215-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-24-022215-xbrl.zip
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M-Z(S(E^[!IDG6TPOFC(84'!)GZGM,AQ<O8ZQ?M&!MXQR*G-6XR[L5AB.Y52
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MQFTP[T3YK&_/9SU+/G,;)CQ9/JM*'O+,;=SM1/FL;<_G3.69VT#64?A\3_W
MLXR FHS3/QP+G/W^CQ-=H[F-#ITPK_-:I[F+_YP%KW-9J^O<QGM.F-<YK==U
M[B)'U# O>HYI/5MF2.R%R,4_R(CZOY&190>GZO76N0LIY<6- X6/ZMR%C]82
M^)_4^3[Q__KIOO@_K7VW-/ M#QXQ01MV/&_M6W 74]7N;'*J\L5=5.ELV'\H
M@>8N?L0=1[4F<O0 *5I<2#1W<:7SX?^A1)J[$!*G+#U >AL7(LU=6.E\^'\H
MD>8N>L0I2P^0&LB#2#>XBRB=#_\/)-*-X@2.\F5I]41%NCBAJI/C_Z%$NCC!
ML3N"(?J?MU\\BYYHK*I1G%C5@;EQ*+@7)W3TAV7;%AG]04P3_CI1O!<GDG-H
M=NP/^$_6ZX5'?3?T#.I''X>4F&P\,*'V+_ /([Q%::M6,U2MKJIZM:%66P,-
MW#5#(4:C:B@-];_1SIO?XP<3&Q@PLISRD%I/P^!"TRJU<?#YQ3*#X86J*/^[
MQ*YL_^*/B=/^Y='[!/='?T>/F3VL_4M 'FTZ?>:CZ\$ RX9KVV3LTXOI'Y]-
MRQ_;9 *3MRV'EME-GT?$>X)!/+I!X(XN< 3/U LL@]AE8EM/S@42(OXY'EQ+
MKV@:&U\ = C,Z8OCH5?@IT^KW[>:E9:2_)-24=GWG]CSO.F/,6'T<5!B]\!$
M</Z_EO32F[G&HX<K)=,-D1;_"0C^/$9@.4\7BJ3",Z8O^,0FGL2,B!2!.[ZH
M QW8Q",:&( RZI4B7DPOA^&XW@6^"-\U ,B4![B/-[GX^P. WY=NZ(MT[XZ(
M\W?9)XY?]@%D@^A"W_J+7J@:O(5]?(EFVH#G,-;$,U<9E7_<]!ZN+J7^0^?A
MJK\,@87!\S+:_E7WQWWOH7?5ESHWE]+5?W5_Z]Q\NY*ZM]^_]_K]WNT-]U/X
M@_A#@$W@.K)TV94TI59MY3AHY<V@JXF#_N]M_K=V%IQ"_^OM_7?I%U"ZCNO<
MA"-XB"'%NOF>#G"Y4TN20W I,ZEU<>D:K, 3GMLH,;4\@ O:JE+^%U/=\Z>T
MSXJ?!Y]",O<^X)E1Z=:A'U?&>?0E2ZLT6O6T2Y9>4936NRO6UHM?%=Z??,N;
MQ6_=2C==R[3Q*ZYFBR)JT\$J"=SQ]ES_ QZ,#_=WEE:UBK1-+:C_"L$FIIX]
MN:=CUPM*TL#U1B0 <^HUN!A8K]0L!UXXDV6MU'Y=*\B!F0?I,E5W__K1N7^X
MNK_^MW1_=7=[_R#=_;CO_^C</$@/MQ(LK ^P>DJJ+MW>2VKM@_E1NOTJ/?QV
M)2VLN;/UMM-]P)_5EEZ5EFC$F0VTG2KYZGI2,*32GU/ 2)'%+H&K1,T=EH@[
M=OM5Y&@MX\Z$;\HC>,00;RN;9%*>4.*5J3/%H5YJL\"4I*NRA,[%UJO+BEXN
M@N6N55JM]PWW%&JPJ6[E YR5&GSPX'46YMJNUX,#8OLS15@MM=U35H0/]YV;
M?H^I.Z$)DS5A,,/,5!4./'?T?_Y3K2N?=_LW</>YFQ_78CLZ8C5_R\< E32P
M0 4[(0M;;2^\5RSP]!7NO6&W3F6SAN$SM:PWE:IVUEX'-UYD6I[>TR?+1_D*
M;N"7*5_KI7;G_O[VC]^N.I?2W6^=^^^=[M6/AUZW<]V7I=Y-M\(QM]<X:%>O
MQ C8_"5W('FS>4O$E_PQ-3#@:TJ6(UF!+QE#9GM]E#B:5TXH+H+55FU6:NCR
MIC#;UG]?5=(]Z=U!-0]D $;L.885LU&\4AJ"D=[I.49<BQQ6I7X ;DC7#9W
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MQ*NE=EVKOYWVQQ34O79!R=X-7>>-[ZN"\ZLKU;)>Y4FB-NKLB*HQ6"3BF%)
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M:BC/M6T\L6G%6PBGFBIP1/=G?E9DVBG!<D*@R[Q7]Q?&H^BZ!_)*_:O7P".
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M^)E:&DE8J4&1F0!HI79-;N[?8"@C&<BR'Y=:Y7UI6VA=+@6NY%'@NF&!R^O
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MS]0)A?UZ"*W:A>?@&_ZP@F$W]&&ZU)MMA26)@PH&:WUU-TN8JX4&T.X:=@.
M4BI;UA5=5O4,>L<($S8-6FYGVZ,V\E7&4Z;G9<8>-(@[(^\U?MY=/K -O%Q5
M&YP$U(29FV?,("M055G+SX1^7<6/TNJ%J&;#$@]#/.V]G*BR^2S_%I;+'EU^
MN!.G@QC%P ',![OSW&?+I.:7R0\?\WEGTM69L2&U9.$VFZK(6H+"WK47'I^-
MJ 0@,S2R#PA([.ZL-&2UR34@XQ5@.H*8XJ#(2_EGUN5]?T:K(\]+XMN:?[V;
MWZ_ZF=3\VT:#Y7'_>67EWH6>,228/^0.I+&'!D\P8;E$],_0&N,AFO-R/;-,
M(+HC$W;L[\'M&$!-C][%!+ZS"3N[>36E<>K%HX&+AR8W=+'!<F*8VE1.[G"8
MPGWKNJQI^P3\./0["Z:$]STN?!Y!\K2:=WXF-+VAWBJUX1^YQ<-9>K'5DJ>N
MW0-%J@(K=DN3:]IJ7E"A]U,*H%X]%X9O^E%]3CPG'&7+ _="C_GN6>C=PEHG
M6:K=F-)?@=!X9/-[1.$)F"5=U[8I>X%_.]A'CK JM-*4ZRHO,7)A_AZUF/+!
M ::!HJZJ<JNU=VE1#HWA F["1(I9;,+DO0G3F_)A]YBWJJ/RKLI**P,C2&S"
M%!V0>V["9 %(W&]7ZW*CMD]*J=B$$9LPQ]R$^=J[Z=QTQ2;,:3JH6,R*OE+/
ML.*(H(\M""1WS&Q;X9MFX9LB16\C@E[%I#93KQTUS-5J)!Q&$'YHX<&4Q@_-
M!$R8#0)V\=ZUJ3CT.8NH@"W?#XECL(J"ACL:N4ZDAEDR-G[I#@;P*G!*#=<_
MMYV: VGE7DSSVT&749P)5FI!:I3:5:TE:]RTS=K'%@) L(#-66S='$@_;P&K
M]\IFZ6J3M[)9YVX=9UKJ]2S,F?=*O;Z-J6^HL_F^K+1X*YTLK.(CE7)-":/-
M*[F&I[UKV*!KM8Y[\8WB FW$C..XJ_0XD0:6 VNIV(PYL%F\)N+]=4K]W2/>
MF@KVL0ZN9F:=$\4^3,&QN,&6/B 6-=3PF80]Q!9,\;=@"N*/X+IHQ0> ,3\!
MUT@Y6BGQS,0S@-R):YIC37O/,K!+!?XNHD0[+H>H?_#_K^;TO9^1%G_H..;R
M%PM7WL'H7?/MD>VK5\,.D:+P!ZM,?T\">C484"-UXKRFE]JXAZSMO1/ 0<1)
M1)K2K8Z<0[/**F:IM;U=J&Q#5V(9/72C"-Y7T0C/&,6C,<HE#V".+9[$@GKP
M!36B_NU@4</<.GOILB3M@QVDLW(SQ:)8Q-2](P$-=\\3G,B\#M:\6=[4JEC?
MSB=33Y98OM[5OW[T?N]<7]T\]*7.S:5T?]5_N.]U'ZXNV>\B7Z^X.Y)?KK[U
M;FXP__+VJW1W==^[O11;C^M6BNH!_:?4[A"635 5N=E:+9L@MB>+#S6%)ZPU
ML41'4U9.LI@?_TKZ"M;<M>KY@%M!O-'A;P>:^\EH#9TGI8$]$[2&W%#.8G=6
MB*$0PZD8UGF20QVK=>A5N95P+I W.>0IYK P2QVF8KKAHTV7IYE7."+-T(X=
MJ3"MY^FSXT>4\?H+M1+MC!Q4=!N)HML/QV.;8@4%XDTDT_(-V_4QVQ8/1&!H
M?F"[+PN=NF$*YQ'+ %*,;3)!E4#7O^Z05V4:;-&Y738U!6#8<PQW1*6 O%)L
MGFB9^SA-O!L*;,;;&PI),^35'&!3.U0?'4#( P+D#O!Q0U-ODNMJJ:W+BKI/
M#VM^PD%"((HC$-FVI'A7#-X]MJ%KO!W;R,2HY=7"X&2W)8UY>FP;E(G'@@UJ
MOS%! :',"DTJ#K6/42KV3C=X)-KA'9)D7=DE8PMQP!J[FA8>+?(Q#]<.S:A.
M&%G7^74)!7OG;11W>4R:X<DLCQLSB!EZKA;  RMFB#TMOX3!C1O\FP:X;J:V
M'?52NW$BA\VW#,H*">%G:IDF,A](0K#$FB8W$SH5Y)B"_"G UN[3Q6%AM1L1
M[\ERHCBMMHQK PP1ZF7-:%69<IH]\0*98!E;\/YA2''-<T<PF@E:0(X;8&5C
M,) (5LT,Z),'Z^68>"S--AA2GP) 2 C<Q?Q9UV%!:((?XF.=<+D?P!>L<&IE
M>0%=H%$\C"KN (]=WT)F7GC4)F"!T<\OEAD,85H,GPMW11RX4.:WD$<801BL
MO^6(Q'^7U-4WML3"OSA:1+I%::M6,U2MKJIZM:%66P--J[<,A1B-JJ$TU/_&
MA(#XIJ$W-ZZ>:/G1H^1GF0Q@@A?$?B$3'W&Z"$I Y"+1W](KHDK[ET</\;TZ
MU%Q)FFS;=SS/?1E28DIW0P+ZQ* A$U=?ED#MK,<>+^._8<(6N%)W48Z^SN2H
M/Y,CB?NY?)AIA8^K8]T.W!A#VZA,\V+5[<.5I%:D>+&\"4?P'&/5?EQ>#V^]
M)^)8?Q'45',>PX>.8][!XHA>*7Z\'<R8/N?YY<Q9A:O[P&!K .!V@@[HZ]!!
M?_4.GF> L_H 0_ABLXHTTP6S%JW<E@/>3">(O\,!4EA<QX@;\'-*[=O[;YV;
MWO_K//1N;UB&:;_W[:;WM=?MW#Q(G6[W]L<-:]1U=WO=Z_:N^M/E-Y[_&T4!
MO\4O9;.:#P9?G# <K90/I]<NDLF\_T8=BJL@'AZYIRAETB5]IK8[7J[T_PYR
MZ\M6P/^$?F -)M%7EF/"8RZTQA' G;PT;="C;.(6*"$_?/0MTR(>MCOXX-$!
M1<L.%=B0>A2/L<;UTX$X$XGXK- .Q@0UY7,WLC'8)_7S1V9BC#VP]SR8CT2=
M)UC$F MN1J1%8V1$3<"W@SIR2 (I@"4.C\VR_N1H>F$\A[*>-X\3R;=L&E65
MP+<^T=EM!@G!:($O1Q7IA\_"/-*CY\)LQZX7#$"&7+1M[F\ZD@$76;C]'W=W
MH(,!"A@P?.2:42%-D]HP/6\BL]<LS$IM?&83]L &QE>#!?E$/785/AIM*0\(
M1K$@W(CB20;+'R'M@/^A@2>7QI8IP_/IF+W;##TVQY\."+;IOCC,  -(T2":
M767UN1]B8L,/UHS2%LQEX8WC2.\@J6$FK/H<M>V85I8SM!Z1U5$!4;S61TF&
M5Q/)'X.!#@1AKV?S]R@0GK#C&5/"CST7IA.LW@0_!("1BO200#<<</F18+7V
MB(0,@;XT(A/)!D!X@ [X!:;B8+5^9I(&0[!R\"4XG$7VNU,R(1G]88@;]4"^
MV4ABU)01&'A#3,T57;99S[.B-7U C1EBL9HN>CI.<!>1P'] _B7HYOI;+;Q)
M:>2O(9!G("FV^\(HS( 9 \E/% 0C(H4TML84'S>+IR:,GE*MH54/N'BOMYZ6
MJ8W; FQJ,V^#I7N@5B-CGUY,__@\W4VW'/8R=M/G^%FQBX(F]AOWD?$R^GEN
M?5>4R */X[+QF^.?*_#3I]7O-;6B-K3$GY2*FOC]ND?I6D5O5C-YE*95:GH]
MDT>IK4I-:;[[J$W![(AU4;QY.5=JZRPJ/N)1R9!^F&M)J0/KXC8G@4YAWC>@
M=\]EKN */*68K!?=>H)@CQ=4Z1Z_6RX5=N9JH$L\TW)'%%8@] 5SD8S#[^PF
MVR1CV_V+^)8'+_[0N;\M=^YNN_K'[?=M3X80=]CW4]+3SOP4],4&?S8C5;'E
M3GS1</.7:R[)S\VW%.)3(#A$\J$][KF4%FC&0@"V(I-KCR,!.%W4ZV<$^M$3
M=81QN(" T!ZY#O$FI^<PK4$ K&+WG6]79V4&1W*N?M*(,  +NO[E)"K??W1K
MG>X6PE*@>25(P^DO? +MVZ#]^UWC@%@_$?5?)*9F#/N"K7S)-M\U;DZ?B[WW
MK?_/<K6F:ZV6<BY3SBB6<1*T /878\7+:VT8D+\L3P0X3F7!>R _J4E85HLP
M^381ZQ\W_RCKK6;K%-T;[7PP7Q@=GY-7T]U&_Q5MW1(^C=#K[X'^[N;NNG/"
MP!>H%ZA/4/5?OYRB,2-BM7P%K?(JU/$]] V;IE5]Q8Y@H%A?_OBOZGE%KS*0
M^).@AECVMI*/[ZI8]LYYV8L/U"1K@*.MB6M/#.6P5'8IGH&TX6G>LQOZ4G_B
M!W0D?>C>]%/G/[]+W6+KU]^)9P%YMI>R$Z;%G4?+7?@:AY,10<YR85ZN^?+V
M-'P1#W\O',>5W#'%!HJ^9)-':4 ,RV;%\/"L<!<&/W ]QXHV(/ZP?"S^8CFR
M](+G@-GY<#P02CQC&)U?GA^17ZBK)\?EUJ;'A1>OB@YA6TLG@&4I(#^I-+:)
M09./#H\]>*(U9E7=J!'BX7-XTL RXCHVMFNPLAHPASOB$R WD1=FL[Y*2($X
M"&O @'@XQ8&%Q9,D3=&J2R?4)3 ZYB48\(QT3'G&*V(^$SP_CDR<GMAE/V#A
M'X=ZK%6F8[(")7Y%ZK,3V;;TDTZ YZP@P@(?9Q7U+K8]=SO5#=%J7JMNIG99
MU0]1UKRY8X4(=M:^/JM"=7P0+%-052H,C<A[FR+XJ>.YMCV*S_VS3.F9 ,7[
MJ-)M]ZIS\X%\E,J2&P91R6P/R]" 7,XRY>5I88.HCL+?4G5G6&[C55LZ1?_=
MLJD?N Z](Q,<)Q;:L)Y1V?X8NT['&%J ,/SA=G UFTS/88/7IRO; XYWN^)B
M]?EY_$:I75,JZ[H; Z]LG-EH.D 0"C9"5FA@+F&H""W0?2\D*C*.A,:?@Z'E
MF=*?(4@2]9"6"R+ZN6@"LJ5&XDX>D!)QP9VX4IDM@3(CTL!S1]%"Q'HYE!_A
M2694:83Q>,RZ:\>USU;6GG@[5NK_UND_=,H:3#(T64V*N*;L$RN$@^4JYH<5
M 1=C^)IIRA<K&$H^JE,J_3:!EZ%TV1,#WFK2$:Q.TCWU0QNNG WTS;O\H?L"
M4S(] I"W#)G59+/ 'W ".2J  >@@0!YL?!Q7YF +>F<,MMG8C<MR2-URK]>3
M/D2'*-F-BT.)RJ%8([@ZDD)\P@@&9H&"D0BNV"[H%,N0%I^)E3ML_W/AEH$B
MH[SC.&X(:[F)!?RN7F%,6-JV8X Y!'@%+@%0I ]7G;N/J+]&:%R]@U7R3"R;
ME<2 )<$'($1%78Q8W\8+!.A;5'!@4K$:@LOH9O/&JXSAQ'9'EN&!#@5H2_[$
M,3U<93Y\[?8_"I0<$R4]6*8M9A83:1Z/>LM7X'4<@9.E1XJLC<T\O ^K"HU=
MU#,6NV&J,1$, :@R295&$Q<63*RX,_$#SQT/)]('>-C'R#(=N7X VFHT@L65
MF*!+RJ"9: !JQ3="&\S9V5UBF3PB-+Z"G<.4!QF/P?J-*KDA4PT;G#OF)K"B
M51& ML%/]^N7E/@QF.'*/F(-, 94CSI1!7>LW?166WQZ4WKNO$N-UM:7&CUV
MU=#U)0&UQ)* ^KO5L(1\[R_?5PA,%@\!,2;H#%)F(D35#5GI7E.ZM@RL?R]U
MGCP:R2%;R[_U_RE+X]#S0Q+Y/Y'+ U^S. "($RXH+ZYGFP 4*DOTU;!#'T,R
M=OS$-Y$'U/_4P\*7,"EIFK0I?4 7CGKVA"F0W[[\_K$R_W&(I?L\^HS!7;CB
MD5)G^G@6V?@'T LL_37%#/N42EAX5=*V"OUP58ERJ88HH]\7,-187<+%<J*G
M$-*B465#:[1%<=PXWL2L"A)51V4TV:VNY<O0M>U)V7U!GVGI)Q8JDY[A S.)
MV0!!8B1<PX()6[DB@5@,O%E^7!<1:UTB6AV*127A;\!T?_'QK* F G@^[N\$
M%CS7B<8K2[];8)8[1'I8BI"RN4Q+/\:73*L_RLOIXE('^.P!RV'9AA%?!V9%
M^@K#7IHF>&ZKTP!R $T]G Y]A24Q$C4;O8I@" #!)6'J)E-0[&CI^\LA2% 1
MKF?ZD@-&GNW"C20 .^$QC&KNP=.P(0M  Z,[:"Q,Z<M&A'Q:*C<^+S+. E0L
M<LU\6XJNR#0X U_C4HSE(]\,#B>#//;\H35>>)='8W<97NJ'0(68NX\3=CM<
M-(Y*G+X=+L9*)R<13DXC>T,"E& J&%0RD" B'- %-3C2C2T</RK]"JNS"=C#
MTK#@CHZ9]S&K93R-X]LH@C&6OW4Z=U,@1\'_>8UY%KU9#LO,.[G$Y6@Q_#\K
M2UT!.6%78VW9N#PIT J0,8IB);8-GW':6.K71*;,T$6 UZ _;(1PZ+'8)ZM#
M2A>F/R(F _&TONJ 6+A^)86-YK.8VI8@"B#KGC&,8HXZ.%P8'XSB,!'J6!1H
M&>EL 9WUT8P\KPCSEFOZTY'@U#LP.<;3N-0_V-N $&+,G_-(;+3M%QE*;0O,
M/\(>4'Q8=ZF'@KU ?,N) L5(_ZCZK1_SV5[ $N+(<5"E)#4X6$(]HMDSF8L4
MF4N 7_!\PF#A\0'P\L_0PCN07U-!@Z>X7B0'H8?J%70G;MDP1H"Z"EC<<AH#
M7&K9,'W$QF8,C,_,[X$+6*,'#"\";+UHIRSTGB*MCK85$#T)NIV(%/=LN!(0
M#E:/$2C_\C]G\)N FRA%-F4?I7ST2+T8U@J#M<XN';GP2B/>H0";T#<\:SS'
M([;J"EGQ81CE;81YF.Q4$-9 W[=>X<%.,/3C$20*E4<9(QR*0;&H #7@D_FZ
MS[-U8OHFQCJL0_S(*B)3(XA9%S!]Q&+YTRGC")/G7"V>L7EM 4Y-5.$9";_:
MY&&3>W'CF%EDOAMZ1E3<.Y8:X.)<"P9#SPV?(F/()S;#!QHC*,5 &Q]7A'AK
M&^2&@CL;R2E>$WDE;*N,^3JV31Y=+[;>IZZ5/]/RT\<;4U45LC7&<R?$QC>P
MW8!-.^S1T&=*QI\W#@"!B=J?10%?=A\,SJ")DHX_C&=^!LK,#/V@(J:N>Z0N
MV+O>O ID<Z'-VG0W+)J2S(PEBX7YYI7B5Q@TW8G&LNM>^+2P!STSW=&H929$
MS#$W8*]E46]8]L#[C8+:]D3>1(H7"Q;)QP72;1K6B$P;R*$EC*8#*ENP-)?#
M8.\TP2G,XMEAXI&@3-\F&9CIMH3UY!WA>3\I?]AQ3/S/%3#E&>0#Y*43=(GG
MX=KW.[%#FGJ_MXG-I!J5QLJ&KS3=ZT4+%MXIQS">OSI>0K%% ),$]ON'+*=\
M/WOX82;?*K6UBO;NU-_,+]H-S'*.G>FN$A@/?1A@?Z9#+^EC,/\4U]-/.\>J
M4FKKK5IEM1?S\HZ^M;"_5897E)G^G2MTU&V#$.8^-[DKTF7H37.7MC$VDMM$
MI  74W0S)>5/[714SQYE#1/ ,4W%'/6=+(Q>_-1+&OVWY\0H[,V'D)H=*L@;
M5G1?#[J%S(E92Q S6ER0?!@P&'NN0:G)]%"ZK)/:^V!$ -X.^H%K_$1OUS)C
M7M_' <U;YV'N*Z6>NU9J5[561=\ Q9EE#W"CP BT]]%#'42)-H#4?Q PO,%:
M819L;!PC\\$">)'Q2MPZ RBXSI.+MTP[F,X,_N5LE1D4U^;LC:.]8C!KGA;Z
MWQ 37$)LD1+9RK.W1/;X:G?54_ <;Q>HG[3JT3<1]1D/F>&W'$'_!V4\A<%=
M7W=EZ8L[Z$C]!1,RBO,A-;ON"W7BO^($(W8+09Z-9]'>Y\AR9?HH3LN;O1\<
MNZ6<2?! ?<S^6RL^_A#L//]]">K=?'U'A&Y"='W@ WM2C[VOEUZ"E+D$Z: ]
M:O^?O7=M3AS)$D#_BL*Q<Z,J0F;T%JK>(()RN7H\6V77M5V],??+A@R)T;20
M:#WL\OSZ>TZFA 220 (! F?OK,L&/3)/GO=3-"U)A%,NLA"V9*HULU!RB,M
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MT)%;U5./XSE&S.AB:+2N0#7C=#!X2CLJ(YV>\)4-BI_Y 1&%<.K'+J.ZI<N
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M2A8@?KN@)#3O2!#9H-;=_S_V;/[;%P&.[@6^#L7DEE0)7K7K%H[Y5 (#U0)
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ML)G5V1?5U0L=GAFQ9CB&LC110IC:(:@X$0EF\)"Q$$WMB Z1L-<E%;'+7DE
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M Q[% >V\8(<I+LRR TWLVJS"*REB9XH"O2-IF0IX$L1)V],;;^T%3.U/[6!
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MP]"@H"@?"A_P>0  T/8IQUE9VD? -Y(AQY^$;C:>S=EB'"J?*)#\>>PFY@4
MDD1!^D?@/Z5L%182QB-8(=L&6\$<O7(B@@W!A/H+;H"1 ^X,8 DW33-HX8J
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MBXHA7V1?L1"PNQ=)H)9'-)+"H>? 9C.",^*3D (]EEI\I\/#S*DQBP'RHT2
M8U"85+1N<O1T8)]G)(:7'"RR'KQ4KJFF3VU]\ETX/?BT%]DP*;#\\4E/['^X
MUY#MQ6!/F1!AO<' MO@,&OV#^_#F#.3HTCP<P;3Q%-'/R,81G!0>,E2$G1@.
M0V,ZN@,=00IB*T2*=R#X*BQE_#L1%^#28HN##'*QJ\>^!#$4XK>OC8>TE\RZ
M!F:L%-L=.$1T-%+&. ;MO:[VZ'E]:>5Q_PDX*BUSQ$DRMH$7/WE8;&<VS&UR
M@D;\8(<@"=84;UJYO/D=3%@?*$), +6 TSL8P3YY.K2KF"7'(8,#,.&]9SP)
MD;<0!>7)1DNCST-F.\&BT]RCI!&A]#2%$J&-L5( 'JIY'R0-T.+#*C(AYI7X
MD\AE"Q1RV#C@'^(_/H+%,G;8Y /LW[A.>NBC'$PZH=#Q,N.Q)4:(KU.?3*4J
M_#(RVDV^67Y=@:_>SW]NMBN=1B?WJVK%R/U\T5!&K5*M-5<::O'GM4YC(Y-J
M5]JM_&_V-R=%J,)S,ENKC;2;.;VL+S+B=,;_;+0%*$S?M.$^-W-K5J[ T^([
M$(6BGMEXX/ B&+0?S.4:KK]RX5#?3]!M_DH?R"#_)BSI*[*DR0M.YG1L==8+
M!!Z\>)F:3ZAU@I;+1\'?8(LFDDG+A/Z^@&WV$0SN[1#NH.A32,)J2L+V)&&=
M(R/6=7PT.[N4KM-W>8D4L]N:F;>M%12\??[L]0GOY6;G7&16'@V6+O5TB2B"
M4[37Y1*5JF) I5&LA-J"%JC+%GF248U'5 "SI5?;J@KP\80>FN5B9@F""U45
M8 6"2YOW5*MK)DHK$"PA/]=MGJU 4('@R8*@"9;@FB5>% B6D)]U!8)'512D
MX$'^N^\-1!8&!J]C7+O=YTG,@PA3\<*IW(F3Z(3<U,V5V]WD\[_L>7:'QQMS
M'QVJ2P!(2C"6E@/LF&O6HU%*NVVEW4>+:J6TY1<,0Z\U]@'H2FFWX!X^$J4]
MB3N\-.DE3F\[K8+?AEXU]E'O4A4B+6#)G68=4B47RW765,6#R\D;I;-*+G+[
MR32*]Y-1NKH;GL@$WM/4V%T[]I,2.#LW\471[\>IC+_\?#8=_L L?,R5F\T_
M3J/\1-&>C3:%.K(;WM767FJE,>IZK5VN%H&JL=NKXI;*U;RS!#O![JJ\*A0\
M5!2LZIWZFFY0A8(E9&C)6A@K%%0H6'Z!J>GUVNLZO2@0+!4_RV77EP $3^+*
M;[[VXFNN_(Y)(<#,,YLJGOEX&%I?LR_L\2*<$J;UT<'0V\URI4HJ='B5*TRA
M@T*'C5UP&GJSNOHEIP*&4O*R7A9&E@ 43B(%ZL6ZS*>5]53?2VJ-BL0N$(E]
MFH'82BZ6:>S*E2B4QBJ-51J[1[E8LQ.O4MAM^P1.4V%W??%Q"-&0JT8\3A\$
M54?G[5"FU$IE-O1JL_,JKV)I.SIOUD]T AV=C>J:24JGVM)Y=P7'%#B?(CC7
M='/E A0*G!4X[U\2%#@K<#YN<#;T]LH!]@J;CQ.;#TD.2H#,Y+MY3^T 5;=!
MU41/$4IU&\P=274;/(5N@_?V+]5KL*R=X$Y#OE2GP7W)E^HT*(QDU6FPE.Q4
MG095IT'5:5#UERGN%:SIM95+-:C,BO(RU"P7,TO@O=O=O8I"P0-%P8YN&N5J
MS*1 <*==,!0(*A \=1"LZT9-]5L]'A"LEXN9)0#!D\BS5:T&%Q87::P<DJ:2
M@G9DL*W:U>!(LH*48"P]F=6J3:6TI>2-ZC6H!"-?,'2CLP] 5TJK=MJRY-_N
MQ?8_]5Z#IEZMJ[YEY>2-ZENFY&*!SJY<#DOIK-)9I;-[]*4IA2TI8TY3856K
M0=5J<%LWO*NMO=1*8S;U=KM<?9E4?YE7U5);LYC:\5[Q;D"8% H>.0I6]49=
M==DZ'A2LKWE!J%!0H>#)HF!3K]77O I2(%A"?JI6@R=YXZ=:#;Y@YG4:KRM!
MI^*9R\30E6WVHX]G5L*T/CJ8>GME[XE"A_(RM%&N_#V%#H<L3&>&WE&M!H^$
ME^VR\+$$F' 2&5"JTV#"_79MS>N^ _/D'!YG5-\R)1>Y&EM=M3BSTEBEL4IC
M]R@7J[:C4@I;SNCE(U%8U6E0=1K<WA7XR?1+J;?U9FO-! C5,.5UZE$Z85#-
MK';O?%;@K,!Y(3C7=7/ENB *G!4X[U\2%#@K<#YR<-;KS4/J,*>P>9O8?$""
M4 )H+MQJL#G-^']&06@/)N(CV^US-_Q@MJA+RT;79%0++2IN)Q'[7S1;]IGI
M:V_-BJ'!*QW;<W7-\[6Z^9NN#>"/<,CAOS[GVLBC]D><VA]1YR,A17%[+;K5
M?5N?':B1&2BP?RT?!N-FF0]?AIYXB(VX-H8E>WW-&U"GI8KV,$RGKSVS0.O[
M]A-WM=Z$GIGV+&68)0E21U_6V MLO'W^0&5YX/&T=^-O;Z:>DA)?31]A/9#O
M*%S\R%PSE3TQW6S,>-DR_SM,6@B-V2,_[P$U?YZS 4SV W.>V21 %,U*.HAY
MEH"S:Q<K_$2]G?+>NHK2[(E<('P]VQ51"B!LS'4CYH (@N9,$H$+2-13[1ER
MUK< +T/-Y_^*;"F[030>>WY(\GB!,NU._N-_M4VC]3'0 %Z?PV%EL9P>#*@4
MKVR;01TGZL,,'/Z(SUB>&T1."!N$KHU9".M)',2ZUHL">&40P%-!Y#/7XIDO
MQ;CS[PQ]]L0=\6Y@Z"AR85M) D]";@U=H,[C)!D*\<3.Q46C4I^",[.])BZ:
M%7-ZH/IN<''$;->9:/V(XW-$\H12&@L"#V-R8-!G.QQJ+LB$9 $;CQU)M5C<
M0^XXW I1(<:^!V\.)S!\"'"!? ZT9_@>_U^P99P1C.2-E<,7^/ER;HG<C'T;
ME@&O3&7<A]G"^BTO"(.,+@R20<[C0<1/8HF8!0S+\P%,X(<$-O^*F(]DA_=H
MWUG @"9,URZ 7O"\:[-C );Y))JTB :;*YZAD[#W2&FCL><2$9^8$R50'M!X
MWCB5:)\'H6];2'SQ)>!$B-C,W%"H&1^-'6_"YP"BSS, T9S2:Z.^'D#@2)VI
MD=I; XAX^CD $0ZSJYNBOA#06%SAMS TS&]$H,R>F=\/CD'N7@Q4G!'!>0E,
M(2!#J*D1@!,.4G?H.0"J(X#))SZ"-:^J^T< I0_I8H'2</:S<?,)D @@G/$5
M,O$@_P(9B0OF ]@.0GJ3G0\X@:H\ML<<7XM$MV <NT_CH_4E( "H_P@P((="
MAL'&-<01+'@.#Z-@3-C,@0T.H!:/L<1#>M7 (8:B83C&,2(?WN-JCY[7%X.G
MVRQ:';!6A\$9&13._\G#8JHB>WINESEY#1>%B  2H.#A@2<":?'Q5V\^W=(6
M=NT".G#M3#9T?7?XXBC69<MU21E[I]D+M!H-(MQ"XB>0R_*ABG8[:_+&^T6U
M4HM1/C8,V\D'T_L&R5 !X-=Q)QN#90:JX4STE_:!X 5+,5UD9B](]MEDM?&:
MY![KV*R'ILP4:<1;'=*[012B9OC>A#EH\*"1#VC(''B1-Q@$/,1#^Q#X  2;
MV-S!2;KPOB=XFP#&_K1V]]/)("KF[CIV__^\L3GO-!J6838-HU9O&?7.P#2;
M':O*K%;=JK:,_VF;;Y;H7WM:8G=TE,]O@?KU^N\_KB^O'_ZOUKVYU"ZZWZ\?
MNE^UNZO[VQ]W%U?WAZ^ V?T 0!B$ NPR'U$89&4 QW*P-/H$['CZD&<3T!4O
M>AQ.R1S^!$_B()4!MR+?%H+G\R>..\7 ]T;T&SCA@"QC,39Q5'0(H>76#QN#
MV)CU!,#C\2TX^X#9-"?;%>T.=BYJ"HZ/].%]CC<>T7D*U5,<&X9P.DT]!0$P
MPA[ (N%'%AO;>%Q(A1^^1O,JSRS +\:IE>*+;=&2*IC=%N6[9EX5FRZPI^$B
M6)#[EF0+C0>DG1(>I)?"?^$$"(_C=)(=- C9X]P.6M&Z<OM$=NK9E\GA)&_3
MLQ'NN?_@OH>'F[_L !T%MEBM(W" )2/./'4/PGMI\T=O^E1TQ8 SP#]A8-!;
M Q(BP'@XK0%Y8FB7N)A/=U@COA+D/8+7PO)C">KC))\X6 3 28&+-H\/&\2#
M8 F_C\NJ2TU8D#9=RAS0 0YF!.PSIS"YT<0H#XQX:YBM2BO=,,.E!Y^WAE%-
M#U+XQ#UH"1_UN"^?JNIR![P0KT/2TYZBL2=F.^CE/P>!.2=E3^&#]LBWM4XC
M]0@5FH_9,:=7L&@^,>=S>,:YV3+K6^39$9S;;D'CN46$U4PBJ3D#,F0T] 50
MX1>W '[(/[#& 3" V=T8\L%&B?P@0A6%WSX/;6LX-=2( 8#1+A+"$LCB@?_7
M05H<1XO&@N^-:J6:\!VD*Q@RU'\!/SF'O!'8>=(1$>]I?^.# :<KFZ]?+W3:
M0Q!I@F0S A5ZI-W%[;_WT.<&V@.'*$<<5U#<SN&GY^+(@>861ZP"**9YY-J2
MKA?/E/:I'@<BV7"Z0<<*G@&6D.X87  @2G\#;,>3G1F39:$DP?2(+L\($\B=
MF!+"I3K#PL_>H L(D-HD<(RJ" /CPGOFKOR+WJ-+KJ/3!4^8Z$I$&S^1H0#L
M"SPA)^]'MX"6M:(DXXR&WNI4=:!:1@JG)(ZA#"4"@H)DD:7SUFQ7&E4\/8@G
MQ?#L$1;YB!X)T!.+SLOBB3&S^VC."U3U?(F:]2E=B*VI>)(^J"TLJZ^Y($UP
M(K<X%P>5MW6SDSTNX<T4[-/]2.I!_\D./&#2@,M--IE_XM@_?&',LK,'IAA'
M 4 ["60(O<O2, 83"[=2#_B!Q$!K+QJ F6%S 6*#R%UH.@/ST: 25U4N+%L+
MG[GS%'LN*YJZ3\V4ZSW,^]0RB?, #EK>,^HIQ51H$MQ ;$%H1R/$77+8@7DV
M@!\&'U9PE8D1$SFCD!0ZV(T#_B'^XR,8ZF.'33[8+LV0'OHH!Y/"B0R9B4@A
M$HJO4UY5JH)?,KE'OEE^78&OWL]_WC(JG5K^5]6*D?OYHJ$,LU)MYS^R:*C%
MG]>KS<U-JO;B4$L2HEX,YNK,_2PGZDJ@Q"P+1W:_[_"-%T%8YK\19>'L7]HW
MX<N[2GUY&IA>JZ2*O4B93)A<T6BL<M,,C:\B8;)3D6DS"UY.BF*T7'?T0R%T
M;6-BV-F&&&ZI?DDAZIS9Z.WV(ABB'[S35B'4IE([@80[CX6DM9.;Y OLPW3B
M_;#IH/6]/K^ATCLBZK=68B;>"JL?3TV)(_HU.=AE3P.@1:]<0_H@POD%()E&
M53>-5O$R6N4I<*#D[(#DS*BV=*.]>SG;T*Y:?F2^)E?9R\B\2AK+0:6C2"RK
MUO5J9_62@ >68'2 G#&,IMYJ=';.F9.QR[X(Y^WKM?\0"P(1!>HU0Z^NV_6B
M!-;,<7/'; !W.FOV\BF)#5!,^3=?,:D8A6]XF,:;V.X*H1*O*I]TX&G>*]K=
MJZV]U!J)._+*U>T.H1:V$MSC%EP3#I+EZ_TB]YB9^^R:N$O<H'5PB,^?@F>[
M8%0B"S'^'J^E12#]:PY$QPE1AP-$!B!1J[IF%<$#V"B5K)5G:4:MKG<::YIK
M&]G;#K]NR:4(L"^:!ZNGD4-:)+*%XJ"W*3>+"$TTC6HV,U_$^BY,A_+<1R\;
M7SB;]#0;U>LO2@>AQ$,V$IM-@4Q'&:T>K\?.<1ICFFD49RZ_-:M3E5CRUL5"
MV.)ZD8B8PI01F8V0R0H189A&=2J$G8H!) DJ<02H^&G-R$1ZZID$KR2ND\*F
M9>QRG#XBYH^).YFL+XH^K;;3_&I) \R8M9'WO3@I:(8.%#E:,S(1IPLS<TE2
MDOA3$=&->7$!!G^+"-CI,-FTRD$VGQQ(QGW+1B*<W7.NW7@AUYH:B8'Y4:-4
M=LSWY7X@1>.%8/\-ZE-^'IFVFY?G*_.52,L"PB*1*)GHPG/)H">F?$FB6>]#
M^" 1A>_,#[5KG6AJ5C]>PU>:4<G]>85^8WQ\=PRQZ$O!3Y.X5\O@7B"  A1D
M,? 9U=8A %]^NBB^DM1V' IUS\:7DQIW1X\RFOX/S[?_G:#'BP@J"&,TTY3<
M?,),(<@\:.K:VV8S):Y $1>6AH'K(ADD3CQ_&4V-CEEI; Y-C;J9DFD5-#4;
M1KJ9+*8%<D7DO8@=.7Y@S":T.)KL'25+3K3O0^:/6!91<\ X'V0K6@*RAB%0
MUOBH?4TRD>^FIW0OLS:_B&S-NSA;<R<@-(= BX.Z-^^!?G6J/U %%%+4_+GM
M 3Z*S(&%L%H<1Q<08/6!]A# #D*$Z<F4&N5ZJ'0<4UPUT%SWD9SX^1E>*2V]
ME):QU<%"3$&UP"(3 $7"U8JSF;NB$-D=IY)BH Q?/!]DKWK^9U(T8 * *S>&
M),5P.K-PY?3X1H'T^#TEPU\_7'W3:A4!-//_^_<?W9N'ZX?NP_4_KBA='C[X
M&O_[\OK^XNOM_8^[JWNM^_GVQX/VK7OWY]6#=G=]_^>&3(:=D.:5$IIG!R[T
M#NYJ]E)M]FFCOF"C[YT\P3X)@U:.1X5N0D_6L=%\._CY,H9U7PMB<RG2*P-9
MN^1 5E\(9!>W-P]WMU_O"<2^W]U>7%TB;A7-B)K"I#JV\-G3,J^FBK%=VH'E
M"$DB$\-SA/WZ'>W:/MK0AW]R>YA*&+==K!@24(D(N7(KN_)QLO*I2A3<%>J&
MJF6[5&Z-:)@M--KC\:CR:$-EVE#'P+BPG:G$[:M?<@OH6B%6O?#1[ -MT\4$
M@@#_%$EXL-2^+B]#<#!9)%+N'93X'A<5PNI#]L 6KR>3^^I"\Z/X5(+33JJH
MP$*"R!I.K08FPBPK&D7";I^NVRE+<H18JLYECS)!7U18Q+,*?G,QM/D %L>M
MB$Z/MYCZ"DNF;&KZ+K71Y7>46,W&6,G2QQ*8.E5J<RC/ <$(UH='8%B8*!&"
M"<\^O3"A?<K+BG;M2K[%M4"X%'AY>%_.=SVS/N(+C/5OJH9&R=F3Q<^)'1Z3
MHX<P>SI.)3)$:='D!$!N6LR-3WR OW1Z8X'GD@>0!7&%52Q\:P'5GI+)PV@^
MU0.D&8#Y^D]1;DIR-3-QEZ,4B:/A,Z6NIX**-44GQ*]_1OU'^CG(RPRAL,P@
MB+3+!W8H#I=(_J$]ILLW+PALG.P"6AQ!OG<W0S,XD]^!%FE&C9T;C;/>NSCS
M/ZO&T[4)+.;[J(A>1!G]/(%=/8,"033&VG1![,ZE2@7X!?E:J R?!.HMJ)U<
M M9%(!FB\K[R0R&V&:&5T\@[3Q5 4I8,+"]O\4]90%&C2CV"R"$6]_R[^-R9
MY!@H?Z]HGZDFC:QZ!@C!R2&FYTYM#;K@&JAFK,3(-5?\C*9_0EI-#I31<I7)
MGV3RMPXSDW]/Y$JW!P?=N860-K5 =[N"?!/T@B"3ZH-=QS6\I/6IW0(69)12
M( #H]^'O)_/>@)?=5$EYLV2S1])DBXQ(TFC]]&IB=I 1;N+HRJ7Z) %6@8MA
ME]!M2(6'A5,";R()L-!  <N+K%*)5Q/-L7^B'19Z\[_/Q]["\Y^NE -X#M8G
MHK_<,N,J*XNV%C)[?N*OLC5\)5$S^]C</L<#O'&U@V%J4.6.+H![Q/MVIAT!
M6J2BJHM%%Q9T.3%B6!H&SL(P!6&&)ZRAXJ5DV+_"-"KFLLT;1HI_K5G4[WMZ
MNU![\2Y4W,'1,=Z4:^LJ5>'4[]V[!^WZ6E['WS[\<76G7=]\N;W[UGVXOKU9
MUZO4J9?<JV0L]"I]O?J]^U6XDZXNKV]^/X+BL5_FR_'-E.PCC'2?/.=)."I\
M."-A95/1%$->J0)L3G>SZ/,1%GV L[/#[%$,S:!5(<?S-9;X?)0'+('&</8-
MDMW511\'[D61'R2E:>.F)A7M:_(T'<U[\;TWV>ZBH*@?C<F4AU7)P9*>*&DI
MKXKV#4XDN-/I<M_ EBJ!*#8_MSIQRI/;'1:K=/BOO-_!E%P/#^-8H:DOHF'I
MJ$@'35$#-YS0/DHF1EPN,'OCD+G[3W;'N5?-'7FF'5KQM2NYDVNO]"8OJ+JY
MLO*WRJ[\W87:C]=<VI?NQ</MW185?^]7)1GS3MTF+;A-2L!$SV)&ID8@^6\3
MXQGL55%Q.2XQ2(Y Q*8G@#TO"N@Z2!2A!+RC?] OTVLA[@3\F0"#T&"9XT4&
MR&3!03%S$3-E<R';(5!-O'KW5Q=9SYTB90%2;F9W>7%KM*0_(@D[%5>IS*+"
MJ9G3G!+_7?)L78L CDPE-PG,A1;!CYN[J]^O[Q^N[JXNM?ONUZM[[?:+=O7W
M']AM N#CQ]WUP_65N(3^<7^%7\K#PVH&Q/Z/"3>>RU_!XEK)6;PX(NKRZDOW
MQ]>'>^W']]L;X.G-]>U=AK6'R,:U^[X8U6;)^;@X(.3;]<T5J.B7*]#,3"#;
MP?$OU+JBQ63/>14G.R7G9&,A)PLXHM:\$]K%7DRO^H"Q[[95@!9GUCOMO^Q?
M'US/O8E&,*I%SF]8R1T? $O.&V\TEXU@\MSJ?\!;;Z/::QA=WW_P1V[8_^*P
MQS>:"!D!P?@5?AC8OW@?I@_GB3<D+8/S=AWUNO!; $2R+^KV/; (BKZI]8HW
MK;2D-IQD?4:6^W>'8?#UU&L_+?]W5JI>FK*1G?*WT'<>N#\*;@</?A\G#3_\
M['C6SW1JG3=)6Z!^-Y2?X3!PVF-C]++[$7^S2)1KI?8G9A)OXJNK%U(.PZFR
MYGW;Y\**EUT)\(8_T,[(G0BG:6'33\5BB3B/)CLWS@;OWFE,R&+2:2J4$C!&
M": [+IH+MIF&@WHPB -%0,!@!.M=H9+I"['D((JH&V:ETUFMB/KV*Y^;[4JG
M6K9)=2JU1EW-2<UI@W-J;Z*Z_YYK?[<*67$WL"46*'I=L/K*02W]P0Z=4UT[
M68-X,7?)PE.E =J;F-/HAR=/A2LPY'9&@Q<+M.PRB*48@>ZIIUB17,Y]SO(?
M<;ZWVR_[5.^3>[72SY0[SOF#=U[V>5Y0%.!6KD[JE4:C2)KU?#@;GL'.S4J]
M/G]*ZK& BQ3L,V.FM?J)H2]U4J?H,PDS^.=GCII\[SE]^N=91F'PWQ?BU"S^
M3JZLIZM8KUO<;JV.-KNKN-6JS ICOGOC14>0V9QR!0G_S[7;1U,X\?XTJF\^
M_8WAG/[ &8:>N]#SM(=6,:?,)C+;4SX9&/J.22>727MJ=$L]^# QD5[%'.T;
M!GC!ZP^>ASM%L*UQ,3Y]H,F9<M)<;:@5G-ODJ$W>4WOSJ?;>;+X7W=<*NI>5
M@*PO(,9[(G9#$7,CQ#1:BIH;QJXO6+H&W2&1:PNX$9VDW\Q!D/F&LJ9'S G^
MSYOKFR_SX);VO^X^/G:?F.UT1^$T*KG1Z+SO45DB' GH#?2 0:HI2-7??&I2
M3^L8D>(I*DC:!-_=]^QU]G)^$XB#-K=J!:SBQIM/?W)7^S8)_OW3>PY^VAO9
M,#=<XOMXF3%C^S9CVW<NX?I V%)&:%B%,6O;H,OB*W(%(-]L;J,Y:YC;,V=/
M4PR:[PWC?=$&S8IF(MWSO=E>WS8]39K-6B**6ANUU^L[LM<[<#(S&LL-]AUU
M'2D%EQ9M;8WEAF:SNA5#<\.=MH^7&=.&9M/8KJ&Y?;:4&,L*,69=0[.YW*F:
M(P"YAF93^$W;I?>;'I@8E,$[>G D*X$/],!HMK+EU-R-Y006VJ<BAI/BKO)G
MKK:!M@J8F<J?N5=FS)B9RI^Y9\:L;68N]V?F"$"^F=G>MIEYFF+P*C/S5$GV
M&C/S-&FVLIG9WI&9V=FLF7F:W'VUF7F$#K3.<C.SI;R9>V7&M)G94M[,/3-F
M73.SM=R;F2, N69F2WDSRV=FGBK)E#=SVV8F[, [,3-;RIM9!C/S^!QHK0(Y
M2RWES=PK,V;,3.7-W#-CUC8SEWHS\P0@W\Q4WLSRF9FG2C+ES=RZF;FC]* 6
M>C/;>JNAO)G*F[G1#;1 $E"[^N;3=Q;"TS^UV__]V;=YJ7+CCY\;TW9F.W%G
MWHK&!N[C5$O&W[D+'V,SN,@-N',@K"HC7JS"K'5MS_92%V>>4.3:GFWAXC24
MB[-$MN>IDDRY.+=N>^XHU:6-J>DMO:%<G,K%N=D-M$!>4+OQYM-?MN/8;*3]
MA4MW-F/0*!]G06[,V)[--Y\^>\SO:]^HV<R!\**,@+ Z-_*-ON6^RXTD%K6%
M8[.E')L;MI3,]T93Y9VO3+2:2M97B>=ELL9WE#[5[KSYU-+KG4:!M//WU,0B
MJ;0Z@]$K=M& IV5W%-'A-^F:@AU2<OJFF)OF7*-BQIRC(?.Z]>3Q<G&IVG;1
M2K4S:]_PPMIK+>M%E@#QM0?L1@J3BT;PC=N'188\H-8NH0>OT$#6P(+#!JE"
MI+4G65+:=I&?+A>"3WTW^;\B.YQH[!E,OT#7L(\R]8.>'2+TL+]RX#E]:A:I
M@6A&>:]*?P?C.P[^@VD!2+P#/Y._1E;TL>_A\Q!FC@6/83T^SL2?[A4S9A-L
MR(S#LZ0)%\U[""^@MC?L%[P4, D&";#&<^B=4^U0C?D^-JVAALZ5>4;G=/*2
M7,\VF9\7L-FV\PDZBD8RU?01U@,J1.'B1W;?=GY!K9?.3.'FS/^NT.',,),.
M9T,_7L.8/?+SGL_9SW,V@"5^8,XSFP2XRV11"B J2_99B@FZ?*(ZR7ESS0P%
M1+#.@;"(G1^": 0 ./E8HC9KS85MUJ[^^X_KS]</A3KD&2:MXC#Z'\$7YJHM
M8+;=&J;=K!BMVA'TAFD7$KVK7T.[9X>D0#>1.-\O-1@/JTI[,4)<>E9$6\HE
M-?JF4W>>]VYF,^@(=<NWBY=6TBQ(P&7V=_'WK"^Z>;XM>..FF=4IM#'5*D8I
MVI@L7/Q@L*W%B^G!8<$3#>X_D(DC[-?_8KF;'1<Z_G'?\].&/IZ<AF$X#CZ\
M?__\_%R!:58>O:?W7=\:@A$5O.?]1^:_[[.0O6^W.O5JZSW,UC Z-<-L&,U&
MS:PUZ^_[1JM1,UI]_JM6JPQ#8$9W)-H)XF7X'=BT#%L/8A,%>T!&,!J*UR[,
M:2RGI9W9R3_AI[T)F)D#[G/7XJ*=N01&K5:IX<.9]N6RA7@@FG.WL3>W[0BS
MM3OV;4=K8D]%HPEG"39KE*P'))N%B^,%!5.!P@F!0M-LF^VJ6:L:]7:C^1Z.
M==[SD+/^&,Z;(V;QB!@4"("8P0+""]KNX5")NKTZ@. H\2NU[]/OU/&W6?7?
M@SI4EC4+4N*XVSVJ^(YCOKCC&-7SOZ=;SC<VT4QJXEM3&\ZN-YS:WC8<L6BU
MV^Q^MZF"8K>6[#;W\&[82'(WE<\3AST'R[>/BJZQ0&-RB+\Q-V(^J'I=Z/JF
MS%<%)JOJU381Q:A6C/_<8;.\/ J,['[?X0I<U@87.1VC:IPG*&&[_4B>5%]6
M>OB??F31Y82&;5M/60OWL:4;6054I\@#4SWF/_OG&"-2JQF_P/(VC-G3GSRY
MB62*JU_<BO#R+DFF&$=^$#%Q+,2P*<VHL7.C?L;>Q;MH>J,/CUM#O$G4NA;=
M1,()H$Z;M@RRTKYG1KN7=ZNU:F+=WS._QUP>G-_^<O@D'L6L5DVE];O6>E-I
M_?%HO?FBUL^EZBNM/TVM-V&O5VI_-&IOOF:S-]K:C\I]Y:*2J*Q1:U27ZG6G
MVE1Z73Z]-I5>'Y%>OV8[5WI]-'IM5(W*]<U]"31[#XN_IA ][;\_WWW5KMT@
M9.CI36*67AFHI.2OJ/S=7_RAY.^!_?)<;S0!DRKD;H!X>6\-^8@E JGD<4?R
M>-']JN0Q1QXOF&-%CK 4OMKN3TPL4-*Y:^G\VOVLI#-'.K^R'G>47.Y-+K_?
M72FYS)'+[SX/0 X5;.Y7/"^OOBCQS!'/2SZP75L)YQZ%LWZ:@HEYK2)Y%-,6
M1815B+FV?X^8'W+?F6AW?.SY(091)7%5NLSS1B>3[6I9Z<;P+2>BV+ @B=4"
MW7\W+\?3&=V;CTPJF OZ/[/_69B-*/EZCDS\4$N2RVVW#WKZX1P_V5,^ZW]N
M)1R[T,L_3E,%%>/3%PJ[&W*?8^)RY1 )6AJ*FD2$+Y'OVL'P<*EJF$!5C- T
MZQ^W0UJST!2TY#][8C#- CW^#) 3D15V_4"XY %VY8V%]@Q<UGS>9Y:,@AUQ
M)GXV8OY/+ ,01-8P?9X*&[  $-L.?@9:CULL B,"W?PVLMT>V#!.\G,&HY_9
M[ZCV > X/,4<"N8]L^'3T.<4? L(/O;M)TH2\;&,PD",!;^%&64B;Q?+XI3D
M91+1\Q+;]U&0(#=WOBQ5"FK5S50I:)2A2L%,08(]$#DO/?JE2\7[Z]]ON@\_
M[JZ*E"?(+S4SA;QF:V_;6?8F$/565AZA2B&%(X'$@X]V -H"0PT!'OH1&(@$
M-?T"9F-<*04()*+R[1"A:LB<00PH1'[Q WJASR,7GJ+WL"@<>CZLNE]97,ID
MOF+$/NB-5>WZ'S#K0!2ZZ%#J07V%61]$G8NZ6>ET\K]:M3K%YD9J5"LM\^6A
M"IY:<X]YS7(=\PH*9/?N[O:O/ZZZE]KW/[IWW[H75S\>KB^Z7^]U[?KFHE+
MR6#42^]E.(1C>4%^?9Y\6,$?<0@K>A^\U_[DKLO!4.U6IMI\S<O>;N1L>7F1
M0R!L/E'1(EO8P&M?!#\DLIY]]VT@VQCH-A^(A4>E2[1)NHE-$G]7Q-&U\V-.
M:4XTQN(3S?N>UY_ _PW#D?/I_P-02P,$%     @ *H&I6#+746-V$P  &=D
M !$   !A<G=R+3(P,C0P,S,Q+GAS9.U=;7/;-A+^WE_!T\W<I3.5;<E.8OOJ
MW,AVG+BU+8WMM+U/'9B$)(PI0 5 O^37WP)\$26^@*3D!'=T/S26A-T%\"R
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MA(.Z/LUFHZP:(P!O<V>DKM;DI%6U")(S1/AOR _P)3@C]$JSL"A?BQ&0=ZN
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M-%U4O&_+B^ERW6*<%@2ME,/IT>$$97 !8KWQC%NF4SV:',$SZ0*/EAL=FQ\
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MC%3@6U?.;X_NGON3#[*L^I+K.\T[C.S:6>6K^+ZM?](GP'UV"IG)% #KZB(
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M#3>NWN$*Y&Y(@+J'89D 4$EJCZC%H/2[ &9,L<*/P+Y=Y=@NZWICE]K+0]J
MK)>K19/(&U'UWIVH,_->!(889,$LR6]I7<!Q3XAC"C_V1,%]"'-?3N8*YI^F
M-(33%D0?T@'FHQDNRM7?]/(C[_N2QJYBKS$V\@9?3>?$W3?3X[HA?OFU-;\?
M@HB)&\&46)\5X87%(!(K+EKA9 S)M-Z7NQU17T5WR]-/-[T*E.)2\2R7VKE#
M)E,[PE#H[KVV2:IL9.M:BKLPC2D7VY O5]564]$TLXRWH+I@SR_UZS,A.T5^
M(BN!M*@N" R4D_2C312]9V]LZY/)]T<YJCW&AV%5"_FU\?]O ?GZ\#-,N_4^
MITTIE&QKX9"J?2"%8]X10FM< /(9-8BPE8>_U>ONZ4#]< 09:.(?QD&J:<-:
MH'Y:L'B1S0T=I+M?,JB#=,\Q[L=!PF) UCO&B2&.?.=(T1JQA=F2ZFE'2)JW
MWG89QD&Z8SEL)O_BM#\M*^S^AZ3V:G'434()!FP,+$55#Y1Z18:YWLD)(),0
M*:FK,W%O[70GB!_(4[H/<;9466UEM!</Z@+2LYV/BO4C\0,GWCG@16::G%I^
M)BV%P-$'I@H/7BF*@=4^W:A;H(XIW34 [?8IR =BW7L\A"E9B^YM>35=D@0K
M^@FH:$I4H;8#)?2%U]NA=&%%9VV]BD+)UB6$#6"/*?,U&C;V%_!#ZL,OBXDW
M6J48) -1X/2F\QBY9<JB#9"1T\0]O#;\LAC33OYHV+>+$!^(;[^1W_SQ"\Z.
M\=?%?'6PG$BGO#6VWH3GJO8NM;HW269X$#IQJX7<HX>[!>(Q-5X?#0-[B?4!
M5=_:;96HK.%.,0Y.,)V$9AY=W955106MT15X<-VW;?QA_]VHMY,8]Y-&67?M
M7M9+H!;STSO1UI^<#@7F%VO >N11=GA+TT1*WU$VRJ2L7UKW."?%\T3>E68&
ML-;1U5,CDN(#B\EREU/6KO6NTOG+^ZJPOT,WK7NKWT83><E>%\50J'I%HLO,
M*P]UPSZ EB80F,:C^0[$F!(?N\GYJH[I-\_MJJXO-?A?XT"IDLJ6@@;DI,8B
M3PQD)D6:L[#!FF)=ZVJX[U&,*>701N ]9WJ?!N.\M/.L\1TISD6Y_BJ(^JLY
MS'^?Y[/+1S _@^6TOSEIB&$ 8S/4##4S163[\(;+.S;-,U\<X:2H;#A8<HN=
M(T(;$5@TQC&7>.*."^^P]<FR;;'UU6S;ON<\=BT.DZBWT*6LF ZZ7I N<KU.
M0&>5L!YJ>*"IN$?J87]&< "&75690XJPF07=%N3W$:HOR8M:AU9[AFN;+ .@
MO[G, X4NM;=XZ_S_KEC'98U'Q+Q>0MTO!:_/$$<).@H#S(68R>DTGE9++,QX
MFZ,WR6;7NE77[FC'E/D?#PW["W;ONO \9<*SD1F+K_<]D<9656.C\,RDDA&<
M4=&U;H%]7XQC2OB/AW2["K%-/=F]($Z/ZX6OWPH%Z.=)3A[J93\LB:*9UK8P
M+]<'6%%R)8(R;KO#)'V1C"F9/RB[]B^W!]%JIQ4!Z)($%2+C2M?VN3XRKU)B
M'C!D UB;E3YD++%M4<>^<OFCTVOW%^./F9^97%DM#Y.A(12CSM%<G:5]9VDB
M&*ZD%XQ;72^/SH7%>D\9!13<RR@RE(?RDMKFG[]=,,NS0AFM9B%#O?:G-B#W
M-C"1 O# ):;8O-W'[O< CR[K<A_&W)ZHWDTD^[&]%]?KRZ^)OOKTL/XTT1A+
M*L6R(H0]5=Q1%LY4,@*B$ 54:_;L!/2'S*OTX=;PXMR/'5ZWNR4340^U'M8J
M@/6CSRW.WSJH@X!Y?GNT6J[H3QKLAP/H>NVS]W]I4RO;> YZ&M5U?+%^_'>0
MGG9=O::@$OC9R;>OG''ZZ1?H\EEG]+.VBZN3U_/EJCM:4W[=!>GC <S/OG-A
M-!/EO#2E&!8UL5,+BD0@H6,BN"S \QR5W"J,W#/POEJY+]P+4'X[.HS839(&
MX3G%=#%IP30$QT+QGD74)CHCM&M^94#S08S!4QC],KAJ$1Z62LW\E)V'<>=$
M_[98MU/"?#8\[H51V5L6K/!,.^L9!+#,@9;%!)IMV[I0>F^#&X,_].^S@@:E
MWG[\L%<P[?X.LR/\E3S)HVX]W.6U'Y9%=UU!X-E7,JS._]5B_KZV$.E(+GU+
M6?8)KZEO]V#SVJJ7\AK2^:M?4%PQ6U1 DUPOO)$1&=AZE+IP6FG:9Y:E,46+
M*""TKFZ[$<R^NAI-(C?%:^<82LA,8P$6G =F.!94C@MI6R>0ML4V!J>I+6MV
M;5=T+RDUO4*VWFM[^>:WZ^8@%%.4)9W/7>1,<R0/RSO"&% %$-G*W+I6;&MP
M8W <AF71,'+:CY7^#5>U ]P[[#:.R#21N7@QG1U5Y^+R;WN8VYW>T]1N]A]I
M(P/XCS73,3\]Q@X^X:D#][:< 3E-PUQT0#U(EWDDW]/&0M0$9#Z&Q!1ZB_5.
M6NU;MX6Z)\2^BN[:U]WTLJ?YGT>G+6PG%H CI_7JI(T43A9?5U)F&%"$E&P.
MLO7AK!VACLF4#LF_JZIQ'Y)M9F]OF)CO<*Y5QR0[F1SW@25(@G0Y3RQH7YC5
M1GKNI0R^=2'!O0".R>X^..6:2'%+BWSV>?U/I+C^+W_Z?U!+ P04    "  J
M@:E8EA$H".A4   -RP, %0   &%R=W(M,C R-# S,S%?9&5F+GAM;.R]67-;
M29(N^-Z_(J?NZWAE[$M9=U]C*E/5FE&F9)*R^LX3+18/$ETDCAH E<G^]>,!
M[@O( R . ()*2Y.X0">^</].A'N$+__ZO_\\/?GA&TZFHV[\;W_A?V5_^0''
MJ<NC\=&__>7W+V_!_>5___N__,N__E\ _^>G3^]_^+E+9Z<XGOWP9H)AAOF'
M/T:SXQ]FQ_C#?W:3?XZ^A1\^GH19Z2:G /\^_V=ONJ_GD]'1\>P'P82Z^MC5
M;R=_"\GG4'R$@D:#4JE 2%F"8(9;SKP5BO_?1W_3C*F2'((2RH#*QD%P3  6
ME9T,,M-SY@\]&8W_^;?Z1PQ3_(&F-Y[.O_VWOQS/9E__]N./?_SQQU__C).3
MOW:3HQ\%8_+'JT__Y?+C?S[X_!]R_FGNO?]Q_MOKCTY'CWV0'LM__#^_OO^<
MCO$TP&@\G85QNAF AL^SZW]X&XW^\>*7]-'IZ&_3^;]_WZ4PFROHV2G\L/ 3
M]3NX^AC4'P$7(/E?_YSFO_S[O_SPPX7DPB1-NA/\A.6'RR]___3N(=+1>/9C
M'IW^>/F9'\/)"2&>/V%V_A7_[2_3T>G7$[SZV?$$RT+T5U.NH'2%\[_JTWY<
M&],Q 9FDLXA /\5QI7A#C(\]?7W,U\^"C"6<G<P:(G[X[*9XN],P:BG@!X]N
M@';^(#C%TXB3EE#O//<6SBN0]Q'61X;)I/OC&$.>X!0)X?%?4W?ZXQSGFVX\
M[4Y&N:ZPGV?T9UURIUWY/.O2/X^[DTP+]B__?3::G3\_B3#Y8P)UZ67RXF7_
M7TL\_=94B#.C\:@N0^_IV\LA*MJA)X5_SG"<\6*1ND)STJ4['SJI2V1WK=.3
M$/%D_M/#LRD<A?#U\'I(@H_OZ,OIH?0\YVP]J"(<*"DUN) ,L,04QJ"TEN$A
M(Z97#"MA&N><N!R"N"'DCW@RFU[]I,I=SF6^&,6%C!O,ZTN()WCH%4JA@P'N
M7 +%HX080P&3(LM>A6A9&6I.<P1WYW/#FH/)U<PNW\:E-I4RZ4Z;ZG/6-1/C
MA:8(]%]^Z";$8K*CZ%?S)>)OZ:2;8OZWO\PF9WCSPVX\(U;_<C(?D%Y;/*I?
M-&/"Q5OTICO]VHWK.W;PYVAZR%1,69@,-ENRHD@PX).UP+AA6>2@E1Z,&(\!
M:LB3)S;Z)WBS@J(7<69M@3]&H379< _3S_,MJA>HPWNF1R,V/ JH(0L6FDY/
M<&!]Q75#27UCE$BJ\%(P 28C0?GL(0C."69F6:IHM; OEPIWK-+M,V$980_
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MYG$W.:]2(=33ZV.MZ>6YUO0P9^U+<@RB9C5;"S.$&GH8ZNV_##5KOI_5N^3
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MMYA<*D66LE & ^=,Z=3ZZ';WF?I,N.#.$W49I0Y T)\QSFYVCJO@B$*C6Y/
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MMH;P[ZMO#<D-\4Y>P7'(M*DYZDG6EO0V@$^:@RS.<>YD4;G76?2V%;C AAI
M?TL(K+'>?@U_CD[/3J\7]8A,I@"L%*P;A8=@8X08I#'2E&SO;Y K:>[.H)O;
M,=<2>]="9@.<G;SI3D^[\7Q;^!@F'R:?9S6@ZA_AY P_XN3S<9C@H:4=WSG#
MP21N:V95;113)%AN;1'<&]^\YE4/6)LWE=K?*;:6_K $F>.9'IS-CKM)K2US
M:'GAV8@:9*54[2@;P24L] 9((8ME(=O6#O$3</:,$&M)>X #D@?0WDVG9P0K
M"&ET0 OHK+Z(M_3>24C:NI*U*#5X8V 27$#92P*L(.4!SE0?P/IP-IO.PKBV
M&SXTQ<@8F 3&$A%3*,+&-*U02)2T@0?!6Y^R/X5G+VFPJKP'Z6B#!2<3S$_O
M6YD<2N29&!MM;9=B8HW#]N"1<Z4<;6O]G.ME[IY[(=L'?@R@@T%:UMQ&^6!#
M\R)HIVMH?JS90M4(CDE&^BJ+D!7+)*!!&;*/%D1#F0_0+?8Q=)<[G!/.HG .
M4-;ZU0)KH]*H"&A0JBC)<VYM3"Y&LZ],6$'6@W2&?8CL]@:'B05OB@ TBF9M
MZZQK*W/CHQ(Z%Z9=Z[+PST#:5SZL*O6'I+!K7\!60#^%::W4?/H5Q]-P(>!)
M/7*I-P<_G=]\Y&,XGQ>^_R-,\F]G59(DJHNU[E:5RGF0RF'0F"SY1L"UIB6O
MUL0/GB87<T*,*:C2/@!ZH+GL PUW0L\/^>M:!A#<07JQYKX;W[I8.\08I)8L
M@A8UE402:J<9 ^DS.?8YBY):.\W+X-L+G@VECX?<\0VY\W$R2C<&/+,BE!#)
M@%?"@$*6(!:=( FODV5%.#X@3^Y@V3-.K"[G1\[6U@LYN!U#<W0TP2-RY#Z>
M3=(QK8!SF(?1%"89(6-.B!K$',E>\PC$2RT%$EW%/1HL:E7WW% O6<L#"/,1
M7;>,-'O3C:<C>NQ\"_R$"6L"XH<[*Q,+3!D?%&@9:ZT$AD!<=)"U)>N,1YE8
MZ]HV2P%\R8097B./\&?EL]@YO6\=#+X)7T>S<'*QJ<W/?3[A%">$ETRBMV>S
MLPG6K2Z,B?..<YY5X!!=#>$QM-,YCQI28LFE$C&*?O%IJXW_DDFR*;$_0I65
MCVKGF&ESJ]'[X8BX7?&/IC4NX</X>EF<%V/Y..G(/,[3MR3"B_?@UEQI7TPA
M^N(!N;.@$BL032"NYU*TXTB_[)?MT0#,BR?1IA7R"*/6/M*]<XQ4NWZ)1&9R
M#"S4#@\UXUX9T"5Y9ZVLX;]#>-9[=$BWLCP?4>Z@3</GA+UN>4W;9 W<Q7$:
MX?0W^F>A9@E=)/#?1=BOY, 23V]9@V#5234J2O!A=HR36QAN*.6$#)[S $G5
M\C6"K VO8@&4S).;6M#HUI=G"\&LNV3<?_!%W*G Y'(@VTF&&LW =:2%#,D!
MS]XKGLCKPJ%GN-&"!&UT?7_Y6%^V.U..8-)]Q<GLO&8:S@[&N28@?KTX#JR-
M*>?!DMQY:7Q&2-)4<\I(6BG)!K?!<9%-\:$TKU+P/*QM174WT/V#&X*V.A@B
MP7T1Q KP,E^A#\2A2AP\#V]+=0]:J[8O==;4RY8H5!N $E8"R&PA'U^0399Y
M@A*P*&V5,K%]\,J6J/-<-84=8,XRZFC>-'-R=O1K&)^5D&J[O?'1VY!&)Z/9
M^64 =Y39A-K!,\O:YJYH!:ZP#-QP@BCK25&_L]EG!MI"G8+6FND&$FOK',#W
M(7:3^H%SFO6'4D8)[Z$S/ A3R.5S+M38?^;!<14(;+#<290FV5Y*?W:H/5-[
M6]$VK]]Z >6F07G"'+).$IQ"#2I46-I9<LN984X*'Z+KI>?[3]XSM:XEN(;Q
MRC6_9AX(.:]1@MW1)'P]'J5P<I&<SFE86PRX$ 0HC;4"M1/@@_&^^"AHOVJ0
MG[00P,OW%-K)M[72+[S0VY"NZDOT -4P+W0AD,UGB3925#>4E!OG(BX&AUFS
MY!RM:(G,"%4KS_M<+!A6.+$=3>J7HK);JG\BOW23FE]&N"TU/OLZ.?S/=X?<
M"!<=<^ \C4RN!Z>OO .?O"DL&56>K,P_Q?37H^[;C_5Q%[JM7]W2Z\4PF\TR
M;23L;G5)-;2H[^8[!Z6);F1A2%;[CF3:P#R3# 2*:NH1J-+KRFC72RZTW7)7
MD]^ Q1;ZP-B_8@M+"7]!LOXJDANPV(*@\5S@]<8R5C>;X 1T&D1.44@OE/"]
MPHNVK<!>Q19:Z&\9@;4NMD"2NBD<$!5BLK4S;1:T'P@3P1OI0'JO>3'&R'XE
MFY\KMG![T.T56UA*[%T+F37> N]6?; QQ"0) [>R'IBJ H&1>XQ<T]2R5):U
MV 9WI%+&RLI;668#7!N\[Z;3FPB!\X.4)F=D5,_>A,GDG'XX#P4C RT'EZT#
M4\B^4K4#C8LU4U_PDF6TF@71^.*@%[#-GS<-<^'=7@L#U,PXF&#X4-Z'<3X4
M%F70LA9 Y//$ @9>:Z*^S=9&ZPOM2(WY<#/ZOBA]17FV/AV^-:_+(-!?_OR*
MXSRJ,9_3=^-T5K/KOG0_D_--JY6QA70#.67::LB_HC4/!6@58\HZA.AE[XC;
MOJ.^=(4/*^:&1XX7Y0U/N[/Q[-VXQH)-OW3OQM]P.GO;37XZ&YWD[FSVH=P<
MBQ]:FU$[+B%Q6\OXF'D=>@U!^,(C#]X;UHL/RXRZ%WP83,P+_>-A(BC?8Y@^
MB"M<J4'3@B>UC(SL [91%.1[G$X1YP/^C-,T&7V]Q'U)G*!,(?4YVKW)<E?>
MUJ:UEK[BC#FAK,>H6IM43T-:VY1\]/$71T3!>*9T\) 2)RM7: ^AYK-*&:1U
M+KHL>]706WNV&XV.;,F!!R9C(VF_I$A)Q57Q5AE F^N\ZC%O*0XBHD<,NH@D
M&[-HAR,EFS%@A7C)932QI6"W/A"_QTNNJ=H5HMY6T<N6*$3+LF"UK9*I6=,J
MU0JVGI"G[%ERPN1TORO0RZ5.@WC)H9FSC#K:>\F3KS7$"_^##,O_/@N3&4[(
M:_L8IB'C.%P>YGE?4Z9L!('S8AW)@B?W '1.-BFOZ+]^ 72]AMO-:*NEM-0-
M*N+6$92?+AV*J]B^=^//8?SS"(^Z2W!:9&DM^>TZ8JY'PC7FC#-@.EEO7.;<
M]7.'GQMISU3?5+"M7_V'X'X->33MQE=!@63%)UTLH(^I5NB)$ Q:R#$Y[B5C
MQ? 5E7YGH+W7^>IBW5BLI8M,!U8D2*L9^6F)0Q19PSP()2:3G.E5P^VEQ5JV
M]C7:27EC$9=]0+VVB,NE%-4K[FX5*6\LXE)+Y5TM?)$*$Q<M@X*KO1%"P>R+
MXH&W""MY"1&7[36_C'!;1UR^.3AT196B(@,K3:U_0SM:=-R!RXFEJ'TQ[*EH
MVEX1EV\.=B7B<BEA=ZM+JF6XR67 I[))DBN9P3LF0>FD:M\N#YPK[@6Y 62.
M[$]H[,J*6E)2C=?0-_5R"R=?R8D[OVY:S7/(20H&I09H*\LLN"03).XYSR[0
M?RW"@QX;>Y_LIK5EVSJ"%K]>5J*[;H=W'^)5JG0/D"WC:_L"V[Q)M;X.NTTI
MH'68;F^PI3#G,$C0LB9U2%KU'+?D7FJF: ?2%F6+_)8ML^0)ZVM+)%E&[NV/
M64^Z2<C=AS_&.'G__LUU*_:$4M9.CK)FB43)P!,42-9KX25W_/[.L?!<];'G
M;SB&=!A-=&W%.%BN3$$1C;4*.#("4;/?YP>XRBIK!4,=2J^."+N>*S/$UK^:
M%!^J<N6">?=CH/O V+^,F:6$OR#C8A7)#9@Q$Y7*/N@,)AM:'U1!\-&QVH\O
MF(C:9FS1Y'(W,F9:Z&\9@;7.F+F30! ,LB Y!XV^%OFV#@*G:;%4$GHNN,N]
M LE>1M+%4F)?F'2QC,P&B*2O,=^?S^)_89I]Z?X^H<T_7T0F'B:ODF-> :9:
M'R8S#M'7ND.15X?=8A3-HP(7@=G\?=.@\7)-9-[Z1OFJA\.'^4RG7[I/.,8_
M#HL3:*)G(+PAPX^X3O8!"Y"MESY'5J+M%T?P^//W0[.M!#A$5M5\NA^^SBNN
MCX_F\YX#"R=?<')Z:(V512H)MDA-JYC+M/[$",&;R$T2U00<)!QV(:3]H,00
M\F]XP?@4O(JK%L4>SR8AS0ZQ&*XBTR!CJAWM2H @1(8BN2W<1UURZV9ASZ/:
M?Y*LH86&IZKSE>W28CG(>2[CRMQQ&,_>G7Z==-_FIP8')R?='_.*_,SF$FR]
MDM%"$DYAZNY%JU_6QF16 E.JUWZQQ*#[089!1=W0\;[(&>H!L&8437 Z^XB3
M@_'X[/2P1!%M(JR\H*L6LP%OE0)F.')BL(_W+ZT7I6BM,/H>D61PX3]DR\J-
M27L#?C\*<1Y]=2@$*F^, DU6+ZBH+"UU]7"*A<"*9DRS?DO(4L.^,GZL)NZ'
MQ%B[5^GGXVXRJYO=7!!ONNGL, G.E27/6M<>@THH#[%$#5KZ),G9-B:U=CT?
MHM@//C22\D.]V^$S.6O[RFY<DUR[,O_) <EGWDCBBKPCG*Z=Y;G4*.TS0%>?
M9*L>&7>LSGPQ_ WI1#&!\WHTY;2I7:SG^=\*#!+WR'WE:%HW2'P:T=KK33K&
M?%;;_CPZSE4=,69#O1!A*=7^S5Q!9!(A*VD==R+SV+SQ3@]<&^NET8X3#Q:B
MUN+?E:S1=V-ZL_$Z3/%]_0=5-?64GU;36&@YK366:UDD&\$7(\APUZ$@"F%%
MZZ(U3\#9UC5D>]5WPZA@@&.X!= N;]?[@!LH0?1)8-M)#6VFQG[T6$,'&R>*
M-,B,<05J-8]:XR-!L%F#)V-.25:#G5L7+]@"09Y) -T./Y81_0"\N,I1.ACG
MG_$;GG3S[*=YX9[I=1DX9@URAF"S9>2_90&><0NYZ+HUD^O 6[=OZ@%K\XY4
M0T5VPVIA@!O=O^.8-M<30GB03TG4T]E%A9F[(%66/HB@(;'@Z[4S^9)%>T@\
M<ZUJ*\32^E"_%[!](DM[30RPKES87@=WW,V+@XB#.+VX>I#2HBHE@Q:UJ#(!
M@Q!U '2L1,UX3O=3R=<OL?<LJBU4WAK.*6JLA %6E7L7F*.CX]F'\OOE:<5A
M4,J)1. ,%Y' R4Q+GK5@$BNR,",Y[Q5(N?(AP3U FR=':PW>;T/93/P#+"%W
MP5T?++^I903'LT,F:=.+PM%$=:P7#Q*\9!FB=1*Y#H;\ND')<1_1GK-C+04,
M$&*P -UOW46A20*8>)*Q) 1GDJW!X/25+0BH>$277?&IM3'R+*C70I(5U= P
MQ.#F^N/R9N)ZNM$0$FT*1):J:430R'SF0.L9L](K9TKKL^<'(/;*SEA/Q(-O
M'?-K*9D,3QD->?"FUC(7'*(,' R3$7U((;'61QP/46SC\F\MU3SYLB\MUP$T
M_8\P&=4#WAM &)++-8XILMJ'4+ $T<@"F45IM/2RZ-9VP0,0+UW/ZTEUD'C"
M*R"9N8Q!*]!>UC:319'!83UDSV@_45E'U=HGV!NUKB;%#9=;_CSKTC]_JEM4
MO</&\71^;M*B_'+/)[>\C%]E,HTNX#\?APD^&/J 1AX?X45=PYN/? SG\S">
M/\(DW]@$4M%KK;R#XE7MNR,->!<\\,@=8^0 .MO:@%X?=;N+_&>Q3!>!N;AS
M1.-$\58#=XG,ZN(C>%HM(;KD<V&Y9#7<;?^:X#<5$K!AEBX.&]BDLG<EMJ!6
MO;M.NS=6"*%%@>0C(W<>0W7GR0'@2E8++QC9FJVWQ]]^],!&&7"_..RJFABB
M;O EEJL.L3W0#%5E^@Z2+1647EDS"U2\AEB'5W:)3N64 ]0BLZ"XK0V8N".0
MT@94.I7F$46;4/)SI9\'TO$RTFQ=9^3+']V7X^ZL1GQ.WW9GDUK9M)8@3;1H
MD>59D5[>%!J-$F6@73,'22AS=?)\ABR"#<Q)EV-ZSK1>;L@MU'E=0S'=X%)M
MG7-[&^67X]%DACA^#*/0+@DF.617.PO7#+#@R)"RCFOM;49YOV=)#\T_,>!^
MZ+V51 =\X[_\0<C./Y"%_ C&%*QRA1$?>6W%9F($5SNSQ:"8R[8$AL^ZTLL,
MN!=:;R;1ULW,WHWS6<)K4W1Z546BN&PD33)'7ZM(:+)#/6?$2UFRE,KKW*^-
MW>//?[DZ;2"OUGFP_QA-1Y-Q^.7SAX]7I7-<S%X;!3F8"(I5-):H)6D5B8(5
M0A5[:>_!HU^NXM:34L-$U>N+U;GK=]4:)'-,SDH&/-7*8XY["$$7PI:E"YG(
M%5H'2=X!\+K]Y]5U,<!EQ>J"N)G&.-][;_K,:2 W?(CY;,>97X,F#Q(?=T3'
M YP)##.W'#3+3M4BZG5NF;[*A@QE9!9-$,&IU@5A7@YOGSF?V'7:+J': >CZ
MR^G7D^X<<7[7=E$EZ=) 0$Q9>Q$AVZ1I1R%@H=8Z82QX3K(RJ7D V$(PFS>\
MMJ_K;@A%#1"%_ FGL\DHS3#/H?U.FIE^^OS[E6N01 F6G/AD8XU?<P*",1;0
M>6:X)<.D^<KU)*#O3&JHL '6H]I%NQO/@5WV09_+9EJ3?";?,+_M)F_/:D_T
M=]/IV;SBCK7&>8<&A$56JR!C/3JP4 ME,"4T3:-U;-K2('>0=<->#0^KQ@%6
ML97E=55A\&)^!V>SXVXR^A_,]"(5X3@W8&O]4!6,A. 0P6BFA4G.Y^9%&II/
MXM7Q=KLTV(8[TG-"W\+HI!XTT(O[=_JWL\-D>&".S R31*U]EQ3X6K(<N8LY
M%6/IBQVE]_VY?&?Y-DBQC;.C1?.Z+ ]+\R@XJMM2;2R+DU&7#U4((D93[Z,T
MR=ER#BZ9 N0Y.AN%,RA:-Y4?8!K?*;YA*@R0B[/NE.:OZ/5L_C[IIK5\F2[,
MZT+.8DU>$IYF$XL%48RVP@4LN&OL?F0:W]F]82H,<"&T[I1^^1,G:32]>5V_
M=.1UO!N3JSN>CM(_PLD9'GJ7=#!<0C%(;C,O&9QV&B+98EY(QQGZ':-[GWE]
MY_^VR=*P..OUN?7)_#.8'Y_L9<&*0V^#11\*U+KUH)AB$$JDMUBH4+C)(JK0
MF-+]D+TZ4@Z@L %*NUZ?(^/DVRCAXUA_Z\;?<$I3N0CSF+\=MW]?TZ!^ZV;_
M'\X^8>J.QM73O74P/3UT)J%319/EST)-;$S@?!)0>$XF1IN-:6U7;&1BKX[4
MNT>7A65O=_"=N-A<R)>X_%']'#\4EO3AC*&-A9&EY9@%GVJL1F"\Q!!0QM9Q
MXIN=X?>W9'<(]/!U<3O[NMP\Z>(??9@=X^3+<1A?K1,\%E&4##334CM>DDD6
M4S @$E-2,%HGL'5Z^M8F^_TEVDE:/7R?_.83NC^?G9Z&R7E7YHX\YC#.'\YF
MTQG]/1H?79S.-L_U7F;0X=/ 5Q;![F2(LY0*D[9ZE [KH6)MW6L+<&:4R<G7
M1H:[<AKQ?O<RQ TZPPMG$$7M]6AKD<9:1\MBD=9(,AM-\XX4KS!#?!F6#I<A
MOHRR=S)#7#B',H5:^45G4+4[>[1: QEK2@LAL>36I5?V*T-\*08\E2&^C":&
M3QKN@^:U9(@OI9FGLX=7$>OPR@[<2YV(P]S48G$%R3Q&[2 43#FD0$OJ4&4B
M=B5#O*&.EY'F]C+$2XBU>88#EYD'Q6G"P7@.W!<1$C*2A=ZS#/&E%+-:AO@R
M4MU6AGA2F)*0&8SP9#F95,!I7\ DS]')K)U?7O.[G"'>1.^M)+JM#/$H;:P]
MZ,'ZDJJ]7+M=D$QDX"%HKY2_'S#TPC/$6VB]F40WE"$N2\&"9 *;:H>JX#U$
M*05X\HF81YF+"[V4O*,9XBOKM(&\!@B=NIL#EC*A8 0FQ=I2LPA%GH0)$+3-
MM'_XC-@Z8V#/LHW7\<56U\5+R3;N,Z?OV<9+91LO19--I&VNHN.7DFW,N,HF
MTI)O]+Q*+D9PH03(1EB1C3'R?DOP5\3;I;*-=XZVRZAVF(9I3Z0>.N^B,LJ#
MUS61%76U[J,':SAACI;VEM:G(Z\A5W0IG2^5*[J,PG8I9^_RWO?6?>%%8LNA
MXM(&43@XSPJHQ%+MNR$A*:DSS\4PL3,W<HLFL8.L'?B2::LTV"5>7QV7T3M[
M-E\M[D<Z7$=/7$Z47O^$V4D07C!RRQPM#2P&L-J@]A8]P];!PQN;W/?W8"=H
MT_H8;MVWG?;'9^=[:T6HK2!5]-X LGKDZ&IH:I::+#KF@H^9.]GOI&?#P%\-
M_7>>%0N/+389,7:9?3!]-TXG9QEI$M?MB*Y^U3Q@;(DQAX\76U4 C<+%>@4W
M7F:0T%<?ROT8X!K8>*OCF$Q6"50*.*VXU?0VX&+*4(*RP6J>DFU=,;'Q%-H%
MDK4!=G&R*8N)AF<!Q09.IE^I-]/S$CM6>2$2MZ)YAN 0$]E4@-DV>;TXVFQ;
MC-B5R+,%_;,O2O3+9'SM5XFQ!CL+H\EI+QZ$,.B$9[FDUC[N$W"V?Q>R-:YT
MP^AL@&.[I]NQ]P$WT'7'D\"V<V_13(W]Z+&&#C9.%"N%\+2(@W>$3S$=:O0.
M!^<<RS*DA+%UR: M$.29"X+M\&,9T0]S[C\WTLG-^AF_X4GWM6*\M+LO#Y.S
MS38*S&!+K(&!*8!7#"%X)3GW&DUHO2_U@+5Y-[JA(A\>YC?5P@!'GW_',3EE
M)X3P()^2J&O?SAH-=!>D**Y6.Z>-GC$2@I"2WA.,8*7B3$F5@FQ]0=D+V#Z1
MI;TF!EA7>I9<"$SY(NHY$J_%\7WF$*U+8$JQT1>%_M74R-@E?VT [2U<DK:2
MG?GI\^_3@T1OS6AV/EPZYF.C;##_\ME)[E#"I>4V)>)IM'Z^'M)7)7'(B6.-
M*#51Z,;KP#XE7'*!/#(6 9FC=SW4^$WG$PC.4$I;DG7-XX)>8\+E$BP=+N%R
M&67ORK'7W> K[0IRK@+0'I5 22O!F^#!82D\V*Q]:%TL8L_"?)?BP)-AOLOH
MXJ6$2?:9T_<PWZ7"?)>BR2;B)5?1\4OAKPF"923OL# 10"5!^XP(ELSL>68=
M\UZVOD)\.;Q=*LQWYVB[C&HW'N:KE96:E0Q&DQ>G4$EP2DK0)7N77,J<M4Z_
M>0UAODOI?*DPWV44]C+#(3]U)R=ONTG]1X=.&B9,S) LK\75HH; 3 9F5'2F
M%.W8QK,?FLYP!_D^L%.TNP1ZF:_+91BH9UJ)$ ID;\D]R)F!UUD!DVB\MLSE
MYGF4WZ.'M\+2K44:+T.Q7>J>\^Q$[U;@KX$CP;H@@(7:."4R\K21)[ Z&4P>
M$=7+>97NSNW[F[25-VD-@NU29YYGY_F/N3ZNYYE<D8ZI6D2Z]FCQT4/@,H H
MB@DN,R-K^,6\2'?G]OU%VLJ+M ;!=JD)T+/SO.QX=&NJQD5G \W264WZ8#9"
M#$&!,URASUXXW[S YN:F]_UUVLKKM![-=JGQT-+&;,@A6^$9.%<3L6LU@"@Q
M@O:QJ*RB=:R\F/?I27]I)[7PGS@Z.JZ5P[_A)!SAW$#Z.<SP;1A-YAU_;K\\
M01(/DZ9U7?H"RB@./@L/O%@F(LM&QIUIC#:,"%[0^OABCHD&H^"+\GW[BX-D
MH(T0G(.UAH'"2(NG0 99ZEI(A;8.U;I5RB[,^P6]>[M _AU\D9=B[HMZ>^\>
M+#POB!R]Y,YE\&S>VRDG$D1!X)9A$H*D$5Z.U;/DY+^_Q[OY'@_)X1=\>O:\
M('S1P@H;H-2U3"EEP4>G(7.&3DB'.KV<<^HE)__]9=[-EWE(#K_$$[S:L_QY
M*5BNC)9&0."U@HD-M:BR3Q "%Y89YWS8F5;(36?^_37>S==X,/:^S#/#YV7
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M&%)/FO0LQ#"-HQ0BC$7J"QJE.%T\[]F%\\"X3U4;S'>D+%^5GG@AR[4 I%(
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M;S'.OV)^TW^SJG+YY'U)N!SN2[',U8!?RH)],NADHS'*=%]I1QQTU$%/ODL
M+)C@ZU*X[IEN*+;5E;G.^+-=H1L(.[Q2-WEMYEHVAZZUKF1"X/N>S]7N17$@
MC_@T@80D!*(X"D1&,8I#H^0<YQQ.O 6V1-0M7\< N%W752W7DYS"'=_[&Q3
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M/V#5[(V1B#%#?@AQFDE[W\<)Q*IZ0N+YJ=0Q*(@\K22#X\-/;65TM(R-_"-
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MPN?4\R(:0H%( %$<QI"B3+6;4=5M$$HHQXM:I8#J+;Z=T8U6W8:&_G7WMIA
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M<<^4-+A+T+(%;F:#U*2LV.306A88&WRM5X!U&&M_MLZJC5T$SWC=,;NA9ZQ
M=I'LN[7(+AOJ@A#GJDT?7&#,HH#@#&:">Q#Y)(0DRSP8L,R/,Q2)*/+,BJ,/
MAS=9#U85T3OEDC?4+.*">QCT;#9;T<RT:$OEJLOE=1SINL>]RU#4?NCY8T7W
MA#H:S+G_S,5NM.M5VXSOL5C*]ZNVB\_FACJE'L%!&D O#1.(:"H/2<+SH8?D
MN%D4A"PP<FSK$I[ZN'1S_</-IYO[FP]?K\#GV\_O;C_?W]U^^G3S^4=P\_G^
MP]V'K_?@^O-[\/7^]MU__/OMI_<?[K[^TS^F@9_\,_CP?WZ^N?]/:^?<..":
MIZX)8#0\?PT: /55F>O7J?OR:@GKWM<W3O:M/(!:8(SX!?7>M_06YJN\%I]4
M<=(;:1NN'G*Z[%K0?,I7XJ863]6"IX3* U@,:2;DH4SNU?)XQGQ(/>PE4>8C
M+S6J=J9#=&KO8<,":'@ 6R;ZUEF_*CY PXBI'U$'4#WEX1HF,\714H<7(63N
M8300V96G48?DO!Y' Q ./(\F[[H(![Y^(?E2!:#)8\-7(FD]%66=_X]*9*GJ
M/KZ%9R&. B^$<99)ZR3!":0T]&$2DRQ)L$^"(# )_3%G8>+0H+[=?;Y)&)4&
M]88O*$_&L)*<R9_Q_UJKUHIME[U+0HZU@-=3--/"::9V]L*5]U'\VJ+8LP04
M3Q,$*-DC,DG LQ8#;Q@.;0+0>+"TT4AV^NM.KM R5RXL59I=&E?J/\JH>I'T
MY,(]_M.^W#/Q@S"B''JQCR'"*8,X2V,8,R]"# N,/*,<ZDN8F?JB6O464$>&
MYB\#ZN#7]\43R5>&EM%%N.LILKG0-+RFM@?26'&Y0,"1"KN(E5F5F0O0]M6:
MDS$OK2]3W:R4>I5T?B+EWT63*- >'P<:5S(AREI^AGWE_,9:W$:N;3W-(0U1
MA,,$,C^*(?+E89!&/H>)((PD.(Z16?;$5(Q.K!@';-M6L7$\,7K:\5N VTQS
M#CA6Q1H:VU ITBW7_7W6(,'MNT;5MJR#3=>-AOD_#T)D)PI F!IDYU5Z'+/Y
M1J5]I@'[=#V@B>C9*?QWQ:JY"_Q;7C^^D\?+XDF4_?WAZX((DD5I$$/L\4R5
M5X@A38(,DMAC'*'$1\PH4W>4VN3!$RWM8?:-RH9;KKD\#*KJ/2(3I>IQ7XH7
ML5H;EAD;!U)/RSJ#Q]#([)'Y3=(%/>$KL"'M3L5I2>A(3XW3FE79:(F]KS'T
M7G):OKMU/QXO,QU& :.>[T&"2:QB*9G\6T!@E"6(DIAX/'11OWN$A8D5Q,D"
MWA=T4C"'F>&(HC@BD'@>AXA1#"DG GHB2QE+/#]@P6(E'H@\'KPIT+@%>LB*
M,=1\5FCUE/"TWZ699G;99J)G=U"[;/)RZAJ@35M/?8R!;Z&@N@9 FA75=4:Z
MM&S7!U*J'D"5I-A7%,M94]!RN98ZH"D8LSU9ID$H!*84^I[:,*B0FBPD"/HT
M\RD/TS1+M.)Q+^1CXEUC4X!+[AH]7VIYM6ORJG'6L*Y":\.=;54M,_ U==WT
MD!HJ/%,TNW)88)(#^87P."]_9<;%&]6XLH+J="$KN^',,_.DMF1K50WKG31G
M'HKR]?KWO-+-S#OZ\O3F:DL3]$3_JI^/=US:<:7A1% S=7 H(_A54724[SHJ
MC54NWO$19\O%&Q5HF(LW_J!%SL[];\7]8[&NI&JN[A_SLA9B=2/Y72DB7^2D
M=LXX>90A0O@A#,(T@TB>&B%E&,$T#$@44'GH85I=64R(3KP0 \\/P88L4'0-
M\D-T@1M?FU/!8;9<)0-@PP'H6=C#YGP5N0N^+OVLF0G LDN34:#5&]#J'K1\
M ]JS?-Q5,HRAU*/9+[ICS9?N8BC=3GZ+Z;LSMQ-N'00WJZHNFV^L:NK#WC^2
M57?:^UPT#@;![XKE\F-1JI<6<9!D$?=BZ/D>@BA(0TC2D$(4^K$O AXR:G8$
MFY7]B?7VMA'QW=>?3;OTS3N/FJ>Y;W9V9K_UZER[ Y&&!94W=V(;N?K&J^IK
MZ!*U?E6R@DY8EX?*-YFEMV[7:L?\MU7+?Y*)<=;H]3(N[+:SAH3*#,U;SW9;
MMMU#(151&L,4TT1U7DP@1I1!$L>$^BR36Y*1U_@HE8DWAU9;#(C:%<4_#I">
M.K]8;#.M:RZQL>H;E<B1ACI.8U9%,BKF_GH??_B-.D-M?$5:K80X3@*/IQ$,
MPRB""*44IBGU8!)FW&<Q\B,4S=H<RHC]F;S*WTB'*+.9=61WOME\N;<[M?M$
M'7&W_I%:15E-R;?2+<J,^6_+R)QD8ISWC++CPN)>627R5'=BJ6),?LKEW^MB
M)3J&J@6)O(1%-( 1YM+2%#%5,4D4)BEF<G(R%"=:,4GG24WM15:T8=D2!T\]
M=?#<D3>X*QU'3.,:V1D.AMI7D04=7; AW"M8=Q 87!([@\+N:OC<5^'J5EA+
MS-&[X/$1YKL!UI)DY]Y7[XT+ZZG?K)[7=?5)O(BEW[DJ2$0CPGP"J=1ATFC&
M\I"<A2GT"$D]P@,/Z:DN#5H3ZZZ&%/ M:Z8?@4;/ZG0DL)F2VE9,5WU1%-TK
MT,D_07<D#1%=UTP_0NEM2J:?%OEDQ?215\SC02SJ,\]7E=FL^+)9R>59"BV[
MKZOLJIKRF]10/E,YV5V]Y"]RF]MF1OO8BPG*,HACGDKSF?HP%0&""?:%'U*2
MLL0H*7-G](F70$?+;-?9%5]OG[$6RFQ%=&0FV$6."N!HW]@=>]:=XJA8^WO#
M\8?,=X./DDMI%]X)5L@#[NO-BIML#,??_J;VB!,"GM\N+I?-T )KZ8&>H++#
M>/Z2\S59.MQ.QL6RVEE.##G;)C,NTG"_.?.DY=93%L^BK%]5+(U*?E7^RN>F
MY^PF:-T+(XRSC,(THP*B+$20I/)@E'&1(($2ZF5&W;S/DYSZ6F?]]$3*5Q55
MT/.RJ:38,&*X?9V'4'-/<PJ,X4;7T;YJH@'K73PF#>?7E]K5[GB>X+Q;IC8
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M5KUV(53[NNW2X2R[/S>ARDV61E^UO"5V4U5KY<L:./$7+(ICBE@"$Y0FJI!
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M"0&S.. 98ZGG1;2#_<-*LWSHS*#W?&E#_N'S^[<!6V\GG0T^PS-NHS;4GV!
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M&!6\+>[=Q!@,?Z_J!'PNZO\4M4K2?5CE_R-X&Q__L2B['ZGG_ 4A(LYX3&%
M4*CTOP=)D"EO;,J#@"'.A%''PGG9GWCOV.1#]_G^;<\GY;$M>\: /-G#FOS>
M7'QMTG3$[^KOAF&H,T^]H7'ZS4VHX>W_L4RI[6'I"FQDZ!.H%-/RIS5X%378
M\GW5)4J!K"C!@/<)C.99(7=MB<_#_-N8][-.S,DSP[Q<F'>J_XG\GC^MG[JS
M<$RS@*<1@K'P XAB%D'JTPR&?N*%?NJ%,=?N1K\S\L2;0$=+O[W\KMCC6O8B
M8<P48$?&X2'_)/,7-(#?'6^V)N]'Q1@V<C_^@'D\^?ONV' O7UUX$<4\\1!D
M/E8A"%D TT2=P&.?IY03)J'12RG9']KD,[*KN-,1 XJ:?NCXCOCC2^,2D<Q6
MAIXL1A'BQQBWB@S?&6BVB/!C[ \CP8_^WKQR]SVAZR4I/^55O1<)IUFN^^0
M$^\)'5V@"%^!AK1^2>[34H\O"&<"FZV.H:R3-#77DLNJOO;I46<KJGU6L&$E
M[?,/VY98*<KZ7I1/VYJ201CZ84A2N?4H:RQ4/<<C$L XQCXBL<<"%!I%OQV0
MF'@)-@2A?/')NM3F$5CTSL27"6MZ;E5R*F+3U-H\+8NS>AH'!&:N?'%*P,,:
M%2>?-#?T/JQJE>G-N9S;JOO/IWPE_(678!)Z3$"&4FGK13&&&&<)Y"0E7B($
M3A.MKGBC5"9>?2U=T%&\ZO\"%&UPNS*P"$_C=-X\="*]V7*T%MS(?#PKF)4M
M>7K4V0S+LX(-K<SS#[M;EL$B"A'/O"B (<M4LTH601P$ 61R@4;$"U#B:Y6X
M'Z7RELMRK-.B 4[VR])(>H?+TDF+22W!G"[+X.V796"R+ /+9;F)FI3C<E4A
M-'\17:IQ+BJ59/R^>"+Y:I%F:<9X%L'0EW\@C"-(XC2%1(01]E 44LZ,0JG/
M$)QXL0[)@RW]JR91'?S:\J"9@::-H9Z!ZQ(9LX5\(2CFP=":DKJ*?CY';MYP
M9TWA#^*;==^S"%Z2"J5Q/)#EG5!CJ;+!XD4LBZ;SXYUX4''51:EJ*"EO>[5Q
MRE>]5WXA@HAE"4NAB 2%*(DSF*( 0S],<<A)2*,4:8<S7<[/U&IDPR H>PX!
MW[(H?]KSV(1%M^7;-M$GU2;\Q"!HQ\$DC2NB-X#>4$]M4=\P!P;<@2U[0/+7
M1$55VQ"J:A-#-2_J!L%3\Z)O%T[E[-MW%6'E#K31F"L'9.:+PG*'R4Y<EL-A
M+;8I>::X?RS6E?RJ[G^3@[W*L_^-Q&*E]L0O\B/MW+\ICOQ$A 3BE*KXVDQ(
M<S4C,*(98HAY'O>T^J28$)UXPY&?HP\V9(&B:Z#$=('3V!\F@,/0-?*;JF'0
M<@!:%M0=T!XX-AW/=5$RT.<3H&6GM!5J=8]:W:*FPF#S#6K/\GE7&ME0[%&U
MJSO6?+K54+H=!6KZKMVI?IN%=)L- Y"ZTA#JEKTZJ/Q<;7VB)/&XB#,$A4^D
M,1^P &(A5#$PPF*2>5E"M"H%.>)G:J^6R@,Y4O?=[!;@4LSU+@EF1-+4938:
MZCE1<J,C.!Q=-%S*S:SW$(Z@V[^F<#6L95HVJ1[5_U0!^Q=I@,JA[Z0!6N9,
MT9:_D(;I[@\&3[:AF%(;E\H5^5ZT__WP.UNN52.EO@+CG93C0Y8)5B]8*(@?
M!CY,>)1!A$4(22PP#$1("67"]]/ I%[BO.P;J57S(HRJC$+><=,VZJL>KYH_
M@=ARW1P1RXU,S>\-4\;GG7,]/?WMSJ296G_73)KZ$PP8O );WD'[B)K&O1_N
MOM$%\/=2@>]ZN?Y\!3:B;0O'*N% *YW#7/@WF157Z?3S,C]O1OZ;3,Q!4O_;
M<#%S"Z\NW7[0(G"OE>"'WU5B726:?M-WQ7*9%:5Z<:&2TT0B.&2$)1#%G@JB
M\540=1RE'DO\&!D5')A?A(E/$IM>M9MFGCTC;1=XI03;]E$SM?JRGVN];>[;
MGD'[$XQE^Z]-@Z^!7%?@H,/KWD<Q11/7MYN8M^X(9B_ 'Z,WV,43Y*Q+V.6<
M6/@ _D.L?GJM_N?OQ6_5W_.?Y+N/0:KNS4+]*^PS0TRG821AL*4,&M(@2-L+
MZ]#FROH<&@97U0Y1L;NB'D?'T<VTII2C-]+GQICO)EI3FIT;:-UW+-;FCU__
MHZO_MBG_UGV'(1=I$GD"<I\0:2\R#U(<A3#S<12CS"-$:,5YCI.9V+J3= _K
MVQDLUM/P:"@M)T*;J:NC\MIHJ=."&^@G)P#8:2:SB3=32&?%&E5%I]^>3PF=
ME6!'_9Q_VO(XO"F$_C%?Y;7XI&H0W\B97CWD="G:GAS[#3&$GQ$O#&!$DQ@B
M/\4P3;$/ X(%2Z. 18E1$U$+'J9V;0V:8+0\P88IL.4*7%LTQ[%!6_-$.2V&
MAD=";?@F2=)T@(FKTY@%!_,>I^PA.C@/73"4G>YJZA5_VK:"[/LW"B\CTDQB
MD!">091&,<1IXD&,@B#$7DP0U6IY=X;.Q#JHK;AMW>GR%#AZZL2!R&8JHY5V
M0'&"_I5GA'*TYD]1F75=GQ%U?^V>>]QN?;;5P[]*J[&Q5_KKND66!9$($(9!
M%*N&6J$O3S5)"CDC<<Q80&EB5-C[!)V)UV=7_7Y#5N<^T@@FO97J0'BSE6HC
MM_%2/2.5HZ7Z_W/WKLUQX\B:\%]AQ&[L=D<($[R )'C.)]F6>[1K6PI;/2?.
MVQ\J<)4Y4R(U9)7=FE__ B2KBG4C 11(:39VSXS')I&9#PN)S$1>SE&9=:N.
MB'JX5<<>MW0#5"[7;5VO.?NPKO+BL;V6:P*8]1?^L_FG>N%'%'.!**!4M?X)
M& ,HY QPZE.495$2!5I]L<S(3KR154O,LO#JIKMTWC!SY17M,(M2"*[X:CHV
MU-XON7RN8>Y70\-?#U]-6]\Y:H;F?8-4RX#7<M"E*5RUMSRJ!([_;)]P,!S-
M3FY7)KP>T7FM=B,@C@QUL[=?YYK]8UD)GJOY:_5MT3*XP''$B#3@ ?-#KNQZ
M A#A"/@T8)%/$Q1&9E/0W/,XL:KZLE8A'Z686BVD^GHJ%N0^M%=-$WPI33WV
MNO@;*CV'U]P]QE6&7\OZV[G$'L#UC=Q2G^+PW^H:>@!BU_?,0Z3,>Y)LYJH'
M(7G(5ZK%/64I"2,,($\0@(120&B2 )I2E"0\HBS2<N9.+3ZQ-FUH*&4:A+^0
M7S<5_"_ZC4>.P!C6>Y>*:*:P3*4SZBYR3@RKIB)'B\W62^2<&/T6(F>?,>\A
M>=O.>WRHV'VYS&G.Z_NJI->L?)8G^,<E?M3M)3FZT.2QCX:^FC[:I!]ON&C2
MF14KG#6'6\>1?K_)<82&MYAS<$QC(T:X>'\H=ARUI=06VZH]Y?CJL[6IU!:T
MWZY2_R6'R57P\N0J^*K)5=!E<A5TEUQE@<H$R55PXN0JZ""Y"KZ9Y"IHD5QU
M^(Y]==MU<5AX\!'GU=_P<LUWI7<+@E(:9($/!!72HL4< I)$,?"%CX@?IBP-
MM?*MC"E/'>(\J!XSKQ33PT_/[Y\$%3.MUP"B#N7C@BO%A]<PTALRZK:6RDAX
MAV50>G1GKV R@N-4\9'9 A8'_-_R.J\*_/"=5_B9KU<YE;XT[<XS0E,(0T8!
M]5-?*HT4 BP8 H)' H4<1D&D=2DR2FEB)=&1]OJTKU3AX?GV%H9(:=A!KN0W
M4P?G1;<Q@ 8Q,+!^7&%A9_I8_!S,S!X=\09MGL$%YC-X=.38LW:T7K#04H<S
M_VYP57"VX+$0'&4(!(D*TP5"ZJ<DC$&2^=0G/HR%7E>2 1H3:Z;/A^,G#3;C
M&5 T5-'EHIHIH:.9I5Y+\7)A#73.Y4+;:9NC3^SQAK(K93,LUZ":.?/J? IF
MF/<]U3+RJ'G(\OKQ<7535>KJH1W!]H&K.1:Y7-5X H[.6A-K$LE"Q1^;'@E5
M)6$JU_7^;9Z:H2@Y\W:LZ0<OM; :CU^ZALE,"UD@Y+A)D2D&5O%,+0*SA31-
MQ.U'-8W>FSF10WECJY?;HEY5S7E0-TFF#]]QT5U,;L<^'I2__B:77GV0O\"M
M$[=@418)$G% ?!$ R!(!2"(2$">8)Q!SD:9LT0Z\_;;"U4HO.O,61#/9R(<"
M:N_I=_PQ+YI^LP3+?Z"\R19AY7*)JUH-"FXS1^9*'''YRP@C2&-*!( I57?0
M. -9@ 5(>9J*,)7&;1IWOXR;@OV__+O8B*?]J[AI:L__W_M)Z 4AWP*K;SI;
MJ973ZPGJM44:*RGJ+I=I*^V)AAV-Q)X2N1=5?0-Y3A-\PM=.C'(ITK]')M4$
M']%9ZM44O%U0(]?6WFTJP'SH(T0Y C#S8S5R(@4H\!'P,T0PA-3/N%:;[_,D
M)G;B6C5$6UH>MJC#/8&*WJEQF:QF.KP5LR4V537<25%<%L+M$YB_!NZD@"?+
MWTX_:7GCO)2_RCO19-I_DM[8[8H_U0O"XH1A/P01IP1 )+V8+((!0)!SZ*=!
M$ JC/G GJ4Q]DZQH>G?":XM _E!TO8:P8=7;:8@T+Y O%=SPLKB1N322V?Q>
M>$@F5W? )VG,>]\[).;1W>[@P^;!S(^2Z[+@7SDMY7'[\F'-'\J;/]7!SN_$
M32%*^?V;,_QII1O3-%ARXIW9<>)M6/'8FGNKTNNX4;_?'C]7WO53N=:]23$%
M;SS(.1%N9AO;,61&$4X+ *P"G29T9HMW6@C?#WO:O&YQGZH*0_-58[^_Q\_Y
M"B\;(FQ33-%8H.RA5/;Z(DO"***IM*I%D@&8Q(D\UQD'&0J2* O#S(=:32>,
M*4^>.M;0]WB/ =6?O.' X&K2"$R-V]FI(#(T#79<J';?+51]1KP-)]Y#V41"
MIH+,X(YW*NCL;GX=0FAV)6P#P^!%L=&"\UT?V\BY=ZELM<#$$WA(?PS&MF6&
M&KG#B)HI$:4!@ 2JSC\Q!&% Y;<B*8W38)(!/"?9F5@SM[%;<GYTC&4_D@N_
M@9X+-Q^R]H%S2U"GF\8SB,7<PWA.,_,V9_$, F<]BF=X5?/:VIMF6/D#_O.6
MR15SD=.&;EOTOZ 9C,)8")#B2%J9F&"0A3 &+(D8QB0D<:15FS!*:6*UU=+V
M)'%OG[K7DM<OOQW&:U@/.47!3,58 V!4H:LEG%6Y[O#*L]7N:@G8+^35>\'.
M;OFDAI8HS; (?9H$<1  CB/I![*4@LP/!>!I0H($1CC S&2VU79EHVUI/G;J
M0;UB9BCLA-8[\ZU$,=M;#0GI1D@B[L[G([X=';6[=6<]-8_$.3P CQ^P")[L
MVH'^E2^E<_ 9KYHR^JZ</N?U=<$^X^H??*5Z@N[^NFD1N@BC)*28,A#AF ,(
M*0<XQA#P6/I<(A404?VD]<MXF=J,WS3+O1.>8D]YN1L&O1TKS63V'8_]?VE[
MZ)I4J%SX<33",_-!;FC?__NA;1#9F0]UNUA/OS'T=X7^JO2>-NC7.XQ59>;3
M#OW=O[@J!W #U& TZ$(2\\6'W&"Q%S%RM*2E+29_/5VQ'8T21C@C((:JTVP8
M09#%(@*<<L@03WB0&?6KW"T]\:&@"!D:8SNI-:TQ*UD,S3&UD4<K*,T-LB/6
M75EDNX7G-<F.!#JRR8Z?,-L==;5:?%5AK.L_\WJ1!5C:4"( 098RZ:6@%!"?
M0<!P$&8)ITF((YV-L;?JU(:2.FSJE73;EMYG::*NJTU(3M+6/(_W41C>*-:R
M&5HD=F)I;YJ38@SM%_E";Z_(_[7;)_MKS;)%3K*_V1VG_]'NV/B8%[B@.5[N
MTC:;'PDA&888^2!- [E5TBP&6+GVC(4XR$C$"*$F9\@9.E-GAVRH]A*ZC7;.
M&$QZAXX#X<UVEXW<QN?1B%2.#J=S5&8]J49$/3RVQAZW#9+?%G(/8+K*?_ /
M>(4W2;QQD#(_Y@2@#%-YK*E)NVHR422/-1I'+&$^7_S@%2GUH^2G29G\8OL$
M3:/$/>KJ[AN/Y@&; :8;)+\<!*L8N;'T%B'R8=$NB)"?67CF /FP>,?Q\9'G
M+2*!=\MG7.<5+@ZGV"%*(Y;Z"'"?"@"3% $B?"Z=M0 %<4+#.(BU8WSGJ$Q\
MKF[)6HTV/ N-1H3-A<!FF_*$K#;M<<X*;1#H<B&\70AK!P+>D'85E!H3:C#<
M=/;E^0))8_SOA8A&'[9.(,)=!P/Y5>_$5_Z#%VO>1E(CCFDB+0$ *4ZE>4!\
M@)(D!=*$]WVJ#/G4*!PT1&QBO;-/6L53.^)F\6DMV/1,>U=@F.DD>QQLTG1&
M!727A'.>U-PI-J-"GTB@&7_'O'JCN:%N$F^^ETOYRM=585"H<?KMB7=I0]3K
M496_SM6Z*HR++\[(/KPSW8AMMA]M)3:JG1@6RJI,XLR2LU5$#(O4+WX8>=+6
MHVZG8#6E5NTDH+OUJE[AID?$(F!IEH5I"'RN\FI9R@!"(@89C8*4LC1$F9:E
MKD=NXDW9^9;=V*^&A<W<*J_'A:F'/0B@KI_M"A8K;]L:$0NO6T?0"WSOP>5G
M]L!U1#WVP[7>LNCGQO[^4-[S4B6V?BS,6[B=?GWB'2NIKNNF $&E:]S?W.WU
M-%'SE,I54>K6U@S!,'Z@.D# ;'/J"C]%%[9A6>T:KYU9<[Y>:\-"[;57&WG4
MOAW]QV7Y\XOD5?[QMND$(G?U=<&Z<+G\LPK -1D1NVST;86%'Q.(DPP!O\EJ
M(&$&5'=ZD$ &XY"FOO 3TR[UES T];WO^OEYV40(I&7)MM25KU>T''OYAF4/
M;_G\#_,F]Q=]%3TO>4ZLS?1,TPE?L=;T=&I@O=W!6C!ORY^W8[#7(G^2TAA7
M<#ELHG\1.[/WUG<!WJF6^T[6=3AJ)[Q\U$[XJJ-V0I>C=D+SB+I#5"88M1-.
M/&HG-(BTCZWQ^J-VPH&XN^X[EDDTF[9E[UZV?_QKSBM%Y^43_R&Q4,DBB(:A
M0# "?ARH.>(I!"0**> ,"I1D.(J9D06C1W;J%)O=X)@M[>;@_'+]-\,<&ST4
M]2P.]]B8:;TA6-QGXA@)ZRHQ1X_HO'DZ1D <I>V8O3US9^E/VW9AE'&?JT;0
M&:800!&E( L8 C2(*!<!A@$UNM"[G*6I?2%%W1OIZ_JNZ^OJG>CK>D''-@??
M2T]CS?L5S+39Q8UU)VH?YPZSU^YD^^EU&M.Y ]!9%]GCE1T,!?K**<]_J*O8
MWY\E%_1[+M6Y^H<[<?]=<O#PLVS\N*I>W4M&Y3]\*"5?MT7[K_+7P1=1G/(X
MQ1E@,0X E!:R--^""+ P8D'H9SSR4^N)0@X8G%@)'\^JJ;8\>VO)M(=W7*LP
MU;/BS%O]+!N[1RC6Y:L-[QY3S'MYL7E(\7_!Q!\7GU?#AW[ECV:FLX\'*^W8
M]12_7H]A51C:,.5)GILRT(9KKV/;:_CV;HO-0V_@>UTPWFGF[^9J-I3C_3;5
MD"F'Z!I-J')!]_7&6SE$;7 VEDLZ=A[05[[":E:/FM*5%X_U-97;8]UT&?K
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MN;G$PJA 8%16JX*!\ZO.5D P*EB_H&#\81<M +<9C LA*$DBB5J4)>KJSJ>
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MJ6CZ!][^]VUQ7_%GG+,/7/"JXJP[S:\+UDR2: ="+OP@"Z6.8\#'* ,P\1G
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M_R:74.6_][S*2_9?/'_\+HWL+NS?_*-RU[?#HA<1#1,,0P$"F H ">(@\[$
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M!$QD:08Q#WQMY3A.;V+5V#'0_(#?EZ#CP=LR893B.(J=AC9TBXB9+MR <=V
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MC0$,8Y2(*)(NI'[!M!;)B3?QE@>OSX0J#-ZP87#$ZF&H86HX1\9LMX^#8F.
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M+=6PY#4\&8PZM\5:STB;$$$S56<*GO='RY'+?#X[+%PE^1E2GS?SSPZ:HW1
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MWTPO8HL6Q&XZ#^]4"1>\JCAK0EZ-E5'?UO6:LP5-0@8CN;%)K-I'18R!#/$
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M:+QBMG\9SQ<WQ4JJAYLG7CWFQ>-O5?ES]5WEI>+B91$P#-,HXX"FB "8)C'
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MT&PE8*?8[U=]G?QWVS91UXS)KU/?E](36_Y_^7/SXPAYP'R4)=(9$HGJYR
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MD'51R_7]-2=ONGZ"J&-MUT\].EEQU8]Z)N+8([Z(<<8\CB,6YY@D483S@+"
MA)%0U09N2ZM^U(ZE5WXHB?/"*LE+O5N\<P[!1/Z2HJH?];.65&W9\GP%51*'
MEUY.M663A6*JP6(&9_]ZB@F@X_+P'=>G_&:$S?X$FRMPR^4=4C5.>D,J@<?[
M20*M]E,^1HS9H3Y<:+J3_ CZ.\?WL=\;A @_DI_EP^KAFK%2;0&1MG8E+[PW
M#X^+^GM[N5$M,7X0B?!,!$3D<13@T*<$1UZ1X,+/(IP2(E(:I$6BUU@("MCY
M%;?%!)$-*FC9XH+*+3*(K+$!A.,@S!T73Y<L@UZ(.VYML4 =&FB ![IVS"U
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MX93[\HSQJ8^S(/5P$G&21F%&0OW4@*,0')\&?85H#Q2U4)$$"RV$W>?+^=2
MBZF%*4LPH0;%L">(N: :=G_%B<MA3Q!T6 ][ZD$S _%#W32OZTH-*N<5?;JF
M=+$B\^OE:[)8/,D?=DTI0B\)XR0H<!;'(8X\P7!.PT0-2!:<B#C-O!QBWFE!
M=9Y)T,-?HOG6*H=967K<T[.1K/,$)K0*/!K 1ST"]BP0$(&6[ <]F).>_B V
M[)_=L)<-HS+=]$W.CAL*?0G0+.1A'GM)@#V>%5(GT!SG42+_H(4?$Y8D*=<Z
MCF%@'2N%=KXT+EK[G0[M?-Z!!X9/]#BI&1RQSA_S*]#8J&"+X0P0Q;:"%7I
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M\,7;GWUZERH#D__/[LG/64KCA*E$"LZ25-X=N, D3CWL^Y'47@GA.=5R+E^
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M7(0BP7[DJQ^++$Q!?F -F(Z/W8.63]">..>9IN=+L<P*F/0=<&&0P.XH?QU
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MXLCC!<XX#[&7A<P/DR3(6*K=%/P<--<2WH%?G^V=AZU# #)R]2S/QF7<.B>
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MYZE:H^L'U1_[7UTP4D@I_"].%N_DAS5+0^JG$8UQQ#C%4>Z'."-9A+.LB/S
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M/4PI8U%4Y'[(@UG%OQ)YNM_KWX!&@6I]K'GWL1Z UOYPURB@KQ(R:BM,UK@
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MK686-*^ES27A?*P>2V6!@0S@TRLXUBH=8-1"5B[W^_*A%8./MY]N!H8D8+K
M"#/.ZP@[?(!I ET6V#6FSU-J5C5^>MGI2LC/DK933W[^:5.CO*9_?JOG\HUF
M/5"$SE>JN.&3RINNJZ&[^;YN[\?54E(Y;Y,ZI33Q9KGQLZ=A'@=Y[.&<!AQ'
MU$]Q08,09S1._8*%)$]!D0N[Z#E6$[O I91TT%L_53,@Y'__KRSPT_^+>$L0
M,-IA><-T;QK/M0TP+=7AUD[@[K!#/7H'09.]O5JCZ"2*XH9[UNY%5I&;^$[E
M@K&']S$G4 P;RQY=O,]E2.*$$I+X."4BDMHWD8JW8 (+$:2^EP1$I%J9,#K
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MG%Q,Z$5VMAU ;JR]'3PZOOML)-:1P5&MWHLEA@W=3 :1E"J037*@>!80N0_
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MZ*37,2IR&Y&Q&G!DX@(UR)(C\SP57X:>@K4#D :K16P/I ;R[@ U]]]]7>P
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MHX.@ZW3$Y.K#:O99M+[8^0ZZ2.\$B@.[2.^BH=$/U=_^Y^W8ZIP+7F^>#-/
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MC[ST"O%$P;-W7*.((W4ZB#S8XYRSPW8%.X\4LNJ]]2GF6TLP,/G":>;M^+]
MQ5?).T.#8BA$EA"WWN?&_A9B<^VT3-827SJ#K@#9YY1/M@\*]PEGA]!P R?Z
M?BR_!\-R^6<<?X_ONLG\Z^R*1RJED12!B(%;#8QJEC1BTDMB8X@6GS!ZZ4'Q
M.7D$IX/R47H].Q3G?7KY9W<5K7326(%HS%=1-N6N3BJA)(WQ6EC#BX]O.(C0
MNE<^K6+V$"V>)U0!>_'*, .;SN>:?2D0=]H@)Q9CK9Q2&ISXX$YYW;V#U+H7
M2$W#=6]-GB5@7W<WTRO'L<WI0PA[RA 7S.>!LA2QA"G%SA,=2D<#AU%:]QJJ
M9;CNK<=VWVONXN?'G%XD^.P]GU8K'XR52 8*'@_E IE@&;(T<BQ4(,RMW5WM
M_8KS+!%U9TT,#\63*JEMT[F86D6=E-8$Q$0B>6M18,0F1$/"P9A(+.&G,Y%]
MGWX&FQS;A"G<5R_-=WO]/._\'WD(,Z!ZV=SQB&O1[8N5O?[L272A:\[E%^Z1
M%>&T$T9C%+7PB., 47"B&H"6O.)6)+'>?>3H;?F4@G)EK LY_G2[2*5<YK9A
M(T@(7"'&<=XVA")P.0V2&!.JDDJP=0HSMX.<NA>+1^A]>R7J<2)OX-#*LZ!R
MVNVB, "+1*V2# F+ ^*1$:2=C,A0EB@)R5%??";7H^^W4FIZI%+74]L/E7!#
MZ%@E96-'-2<<(ZJ,A#VC)'*&1O#/8-=$*[#%I6M)GU)0>4KTP9K< HD#Q%H[
MZ+K\L[O\VMWD/NC91U\:U3<3#^(#!RLS]N@G+K^.IO,8)\_\U)_PV[<?)G'#
MCRV\PW#CXW):MGU(Y5=1<!Y!]!"C:L1]B,C*Q)!17F%F/([KU[E;(KA6.&H#
MVX= LCMW?#1@:3_?N-DHC.ST-K< 6IU!"T,C#==667!4C,T)D* 4$P-!B=+$
M1;"V_$/[5F):J;HM>T*7D7T+('H@/^_E#VG13!B\W8?"=X]YDH12)#"6>7ZL
M1%I2E0><N$@BIL:4KJ-]GJK*CE\9]:^#JJPN:I_[O^74AS]S([)'975W5778
M8&FD0\%HX",Y@PRG"3:@-3AY*WA(O8[B'1^I#)'"RNP&D&QMA%S,+[_&99>\
M=3:2%D8*PL$Y3MDX!XZL4QXQ3TPR%DLG?2^ ;/]&Y9-I0'P4DFM%>,RF\ZM/
M>9#YPJAZ@XV7$HRJS(Y9I!YI%7SN/L!])%1JTBN(A%4?G3[P7P\GSY,/ME*(
M6L9G.5R6+0!@A5NO(Q8R=\OT+"(>E$7&"X)8TIH0S1(/O>Z9^D"@YO%QA++6
MU7V Y"HK_)W]:W1]<WUOJES$S%N$4XK9_!EDE7/(628EDRFH]2/@()4_^6AE
MI1^BLJZ$_!J(1!96;F7SWMX7V!!#+#..+OHM("Z,0S:)[,YP:J,3+MK2SQ$;
M":F;LS14&'N\S%L 3G=]W4T6/'RTTP_3Q=#/\+L=W\2/<?KY*TCX2H'SI+4D
M2'JB<@<WAAQ)#"FB5*+$2%-\Y$4/LNI&* 64OPZGPIIH"UP+^F<7-_.OW32W
MA+]2))$@::XSYAQQ8QW2/B8PTXRRI+ -JO3%R YRZH8S@X+I*,FW"*(WL]D-
ML&$ID\)&A:)68MGJP!C-D!=*IR!HRJD+ P-H24K=B.<$X#E XBT"Y\/-?#:W
MDS":?+F223)G,4-XD2M,.?""!5C2"/!7EEA*2M_R[Z*GKH=T @@=*OL&</3Q
M[KN[S^8 +F0D 7:'4QAQ)W,9L#?(1$(XUW!T][MGV>>QOA=E=5.PRV-K 'TT
MA[(?#FU#K= B=_)QN9->CDR=9PY^%:@-' <0Z*#H.LAC&BR;>FA4'27_1M&T
M.L4UU2I2K5%.\ 7K&WENC\&!,<MYX@SBX=*.]W9JZN9$GP9%!\B]400]/L2C
MQ];(1%&4'*2DLI2B54@:QZD("0M=>KSU,R3UPI(^;RP=JH$& +5@X"<[R\,W
MKW,5U$HUTWQWFQ_9?KI]^)&/]G8Q\_M/.PWO;_*-+(AV:9,?3>]:)"!=61&]
M@I@5$2' -.=QX-: ,%SP,3IO>2J?=#T0+[T@;,X'PDWHO 7L/WJO?L+9\FQX
M,WGT?GT5G66"88<$S5VK&'"I!<:(F<"-#8$F7_IB8Q_Z^MV[XC,"Z5#*:0MX
M'Z<C_Q =845ML@ZB(TXEXA%[Y)+PR%,CO,*):C(@R)[0T@]09W237T3HM=.+
M'N?F??DR70Q4_7@S]5_!5"^XNG(R88:!$:PIS1GY#N7B>P1[0# :86O0-0AM
MR3)Z]E/]$'(&U_,#2+8M(_.JF\Q&H(Z%<CY%'W,5Z(<G%A1;S*6Q' GF<N]L
M'!' 7J,@%+BOQ#&/2P_YV(O ?F [H^O\X=13VT8]NF5^9;^-YG:\/+@7%X&?
M0'%38 ]\QF5?OWR<VPEL+TT("=P2Y'1.#91PFFL3!?(>>^V3BX[VRY\][/O]
M '8&E_VGTD%MF,'YG4M@[!?81IG=T6R6.X%.[JWW8BC QVD'L4>8O0:)+[?<
M(]' T>^M,\F@2+1"W..$G+2PK4)*0I,(?]BO?*H ,?T > 8O E6TT\*!^_A>
M48)5IAY"$&>QS>/)<Q=E+I%(WFBE6"ZC&.+Z8Y\;7')&#P$'"_<,9K\O]L=\
M,:')3@)X [D((D[\*,[>PU^SN<QOV0OB*5/]^E?LL7K9AA:'LE6HP\6CSU^L
M?7Y3)VK 'N/!0N@7.#CWX&II"2>?35%$J4F*AA;>KWL1>*QQ^C#_&J>/OKA,
MM*31ZV#!F60V)QT1X<#"1H=$,(83#^%O+/TZOI&0REF#@R%EW8H=KX4&SCDX
MM+_%Z?PV5Q[/06"Y(/G;\MKX$I989/D3;9@T(2+/9'8D)0-;#9&+LIK0(),!
M:15_AWJ6K+HP*Z#\']ZBRFJB97!EAE9%9$R8S!,P@E5NU$O!$0C$HV1CXD)Q
M+EWYG)YGR:K<N: T%/I"[4"]U(X>?Y[>?'EG)S<)3/K-%.S]:^M'X]'\=E5I
MXEB0ULF  @L:\23 RB<<$)$$6&+Y+J;?->HS'VH4-8=JM1M(Q+7A BMTT_P#
MMR"E#RF-?%SC1A)+98+@1FN;"YRP09IP"\Q9132+3'K5"S#/?JIN5OR@D"DK
MYMJ@69$.;N1=$5P,-@C/D.;@,'*;V1!:0?"*)=:,&NMT+XRLKUPWUWU02!PE
MQ,K%GXL$V$5/GMA]F=IO7T?>CI<]-0B0J9)$VEJ*N(AY:*FFR%AI3#*.PIG<
MQX5YIA!T*P%U;4@Y3[B<E&M#)7Y99V&U<V(0V.L\D<+#"<GS?%L3DD(2)P*B
MB=+WJZAY#BK;"*A7/UQ(L5UI*=>$ROS;].K?;ZZ(I-IIK)$V0"FX\@1^930R
MWLB$O>1IYR#@6?3_\TOW_7_EY9:@R+]Z!(CE9RJJOHRBNL.EUD*CB 76+1<
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MK;.TRJ$V03(FE$3&!IS'?^2NWXJAB+DE7/)@::]H_;D#IB]!]2S1\3KOAE9
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M3!,&<$$7""]GT!0P@D^6JU8&=X@AW"2(AHSAY?1Z,B]K"Q\M6:WD[7!3^*-
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M41KY%?67]J^?XB2FT?SHEF '?;#>\V])./25:UN0 #,VMI,5P6^NO^4!]L"
M&XU'\]LROMMA7ZSWQ%P(%/M)MIT(K*2+MV/9>FVR"@1A;?IZ&P@L'$>O+]M+
MB4W==3TOHX9>!;HX@[CP4_S/S6AZ;U?*&.4]/M-+R4U=?>TOPU:S@#Y^'RH#
MZ.G*1;)_=A!;(//GH[W]/<^:A6CKVDY\+)WXTV?](_8U".?X7)_[1:H]N.ZA
MA<<[<IW[V@]"?T6_&'/\"LS$EVYZ>W3JR.85ZZEI7=Y=3^9K7R2/Q^ODC6*A
M))+M"]?+OMJIBFX_N516W<?8%=#3PRHU<TJ>EW6W@_'Z23Y TOLBZEA?JV;G
MJKV4LD4(_^0JGO*D^2<_\9_\Q/UT$_[[LEO$X\=NCZ<K54NCVK4[-C);6P'C
M\3U99;;&^G+UCO6-XN[Z\%Z[\TRT.< Z>D\\7J=:DMJN';&!T=I.[8K:,I=N
M/ZY6[]@^+HYO[?WB5?<YCJ.?Q[#"T-%/%YM7K'>0'*:OG7*I':< *>'>J?^0
MTLC#NJ\G9?;:\ZO7,X&'Z;*WO&K;S!BGOTZ[FV]O9K.;@AK=M6ZU[-Q#[>CS
M,JIM4;_FCI#AGM!26MRU;K6\W$.MZ_,RJKX7N\MN;L<EWH'7UZJ6;GOPGMLH
MB_H:NO!SB,3'MQ_M*!12U*8EJR76'JZO'9*I'2CG2!$HS%25,HW;UJR6+WN@
MXIZ136VW\^YF^.+[EV*V<>NB]5)=#_4RGQ%/0]I;4/;(0I14XJ:UZ^6I%M#E
M#F&U8$KO22UN4+>N7"_#]!B[^IR@:F=6_.=F-+_-DV"7HH3PYGK9V7&4@)@(
MW);2[IZ?JI=P>J"Z#Q-E[;!QS<S\/EL<(I^_@I2^=F.0\J=YJ4AROT_5RU4]
M^.[N$%$VI__W<?YFXKOK0G?HO3Y0+V6UF*ZWBZTY#?]PR3R4IG=\J)?&F[H[
M.D",M3M-_FA^,N>KRZ\R2N_[C5[Z;NGV:4_A-;?)/\R_QNG ^WOS-WJINJ6+
MJSV%5WM76W<SMM.WH]F\X%/W]E5[J;.EZZQG!51;@3]:EJ-[_VY>LE>V0DN7
M6;M%4_WF_\[XEU?@<VOWTF1+5UD]A551I3<S],7:;U?WCOO;;K8K7RO9F5L0
ML?J+*TV.Y[.[WWE0Z>:U>RFQE0NLG>*I[NVL>=[';K^-"_925TL74+O$4KO4
M.3M4F:-""MNT7B]]M71AM$,H+5SQ%VF/^7BA7@IJZ99GDQBJ.R'=T:F2=VOT
MTD=+=S!KS+>1YGVT.O;-5Z4M79,TF*;:37X%QV5%V,]QYJ>CQ3-,H3S5YY?O
MI<26+D#ZBZSZN11&F2X[YIA^?^"NU//S<ZOWTFQ+=R&]!=9J0XVG\X,^=N.1
M'\79QVGGGU)^9'>-'9\ITFJC+QL%^FYL_]0/2#FPD/7Y]8\JN5TM'QXO76I2
MZO.K5RP$[:VWIS6[/>55O91Z$YWON_F*U#(FO/]7JE5R%=7S#OD-;]%7?Y#_
MX>PL_N__\?\!4$L#!!0    ( "J!J5CB@&E!.P$  /D!   6    87)W<BTR
M,#(T,S,Q>&5X,S$Q+FAT;7516T^#,!1^WZ^H??"M0H?S 0J)ANE(IC.&:'PL
M<%;J6$M*E<U?;V%;8KP\->><?I=S/K;([Y?)A"WFUVG"S@A!J2[?MZ L$J#
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M7!5=&YUH_GZ&(,9<ALB_ %!+ P04    "  J@:E8KW$79CH!  #Y 0  %@
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M^=3XUG@]L0[R!.?8^7^R/%@ QJ;1-J>]\G7*P32A F>P%YV!$=:>( OIV(;
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MB!CF=/F!8F\A1 C'P[7QK0.81P88"D0PGKUXT!]U)L&P, HI\SY;\<&V15Y
M1A6"!"?55-OZ>?=\5Y_X(KL5-]N!Y)+FBA;EI775$6DW[I&>Q"[5=.5C\!O.
M9[XG(1)V7:]?(Z:75?5E!PA9X_Y<\7MBH47GAF:.'<W9B+,]FS(@=]$$>DKB
MO#>27]JC"/$HCR(>7T@6<MP&ZU%@!AD'H16G@+BQ)!(('7#E-EKP(0.[_EI)
MQDGP2@)2JGF3*@?)(].SW4H+!/9\71P\#%S'%>EO=\W\X^+DD'K=8Q-1;&]_
M="(M1/>>[IK3BU\69Z T/GY:G)SSW^=G9_.3GZD__OFH[:(Z256^'Y;/R/05
M&(-A'5>Z(MZVRD//Q&RG<2^MJD7DVELF53J!@,H%F]6W+5MW9*:3L=@$:TXG
M41GIN]Q/,1D(0$1Z?Y V429K G '1P(+)M%X C':]D(+#O," U%6PO5-KE4I
M]M>BTCMRL8KQ=DE2FY5$MGVH96 %8<DH5^L;RSOJD\\I]SQ2;0K QL(S*;.
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M+3(P,C0P,S,Q7W!R92YX;6Q02P$"% ,4    "  J@:E8XH!I03L!  #Y 0
M%@              @ $M,P, 87)W<BTR,#(T,S,Q>&5X,S$Q+FAT;5!+ 0(4
M Q0    ( "J!J5BO<1=F.@$  /D!   6              "  9PT P!A<G=R
M+3(P,C0S,S%X97@S,3(N:'1M4$L! A0#%     @ *H&I6#[#(TDZ 0  ^0$
M !8              ( !"C8# &%R=W(M,C R-#,S,7AE>#,R,2YH=&U02P$"
M% ,4    "  J@:E8<S)=;CH!  #Y 0  %@              @ %X-P, 87)W
M<BTR,#(T,S,Q>&5X,S(R+FAT;5!+ 0(4 Q0    ( "J!J5C[P:1<8R\  !6F
M   <              "  >8X P!E>&AI8FET,3 Q+6%R<F]W:&5A9&EN9'4N
9:'1M4$L%!@     +  L Y (  (-H P    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>arwr-20240331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arwr="http://www.arrowheadresearch.com/20240331"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arwr-20240331.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2024-05-01</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-02</startDate>
            <endDate>2024-01-02</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:UnderwritingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-02</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-11</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:GSKHBVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputerAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ComputerAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-02</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-02</startDate>
            <endDate>2022-12-02</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-25</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2023-10-01</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-10-01</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:VisirnaESOPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-01</startDate>
            <endDate>2022-11-30</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch12PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch12PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:KenMyszkowskiMarch28Plan4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="obligation">
        <measure>arwr:obligation</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="bundle">
        <measure>arwr:bundle</measure>
    </unit>
    <unit id="agreement">
        <measure>arwr:agreement</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="option">
        <measure>arwr:option</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-26">0000879407</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-27">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-28">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-29">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-30">false</dei:AmendmentFlag>
    <ecd:TrdArrDuration contextRef="c-261" id="f-890">P11D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-263" id="f-891">P262D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-265" id="f-892">P11D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-267" id="f-893">P11D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-269" id="f-894">P11D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-271" id="f-895">P11D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-273" id="f-896">P11D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-275" id="f-897">P15D</ecd:TrdArrDuration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-38042</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">ARROWHEAD PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-10">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-12">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">91105</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-14">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-15">304-3400</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-16">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-17">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-18">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-19">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-20">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-21">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-22">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-23">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-24">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-25" unitRef="shares">124200230</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-31" unitRef="usd">127704000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-32" unitRef="usd">110891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-33" unitRef="usd">395410000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-34" unitRef="usd">292735000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-3" decimals="-3" id="f-35" unitRef="usd">11022000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-4" decimals="-3" id="f-36" unitRef="usd">8813000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-3" decimals="-3" id="f-37" unitRef="usd">7514000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-4" decimals="-3" id="f-38" unitRef="usd">7082000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-3" decimals="-3" id="f-39" unitRef="usd">541650000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-4" decimals="-3" id="f-40" unitRef="usd">419521000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-41" unitRef="usd">359252000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-42" unitRef="usd">290262000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-43" unitRef="usd">9412000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-4" decimals="-3" id="f-44" unitRef="usd">10262000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-45" unitRef="usd">44626000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-46" unitRef="usd">45297000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-3" decimals="-3" id="f-47" unitRef="usd">210000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-4" decimals="-3" id="f-48" unitRef="usd">210000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-3" decimals="-3" id="f-49" unitRef="usd">955150000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-4" decimals="-3" id="f-50" unitRef="usd">765552000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-3" decimals="-3" id="f-51" unitRef="usd">8521000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">35866000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-53" unitRef="usd">37055000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-54" unitRef="usd">39763000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-55" unitRef="usd">13741000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-56" unitRef="usd">17963000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-57" unitRef="usd">5285000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">10563000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-3" decimals="-3" id="f-59" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-4" decimals="-3" id="f-60" unitRef="usd">866000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-61" unitRef="usd">573000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-62" unitRef="usd">435000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-63" unitRef="usd">65175000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">105456000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-65" unitRef="usd">113632000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-66" unitRef="usd">104608000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-67" unitRef="usd">280938000</arwr:RoyaltiesLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-68" unitRef="usd">268326000</arwr:RoyaltiesLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-3" decimals="-3" id="f-69" unitRef="usd">394570000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">372934000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="c-3" id="f-71" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-4" id="f-72" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-73"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-74"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-75" unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-76" unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-77" unitRef="shares">124133000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-78" unitRef="shares">124133000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-79" unitRef="shares">107312000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-80" unitRef="shares">107312000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-3" decimals="-3" id="f-81" unitRef="usd">217000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">200000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-3" decimals="-3" id="f-83" unitRef="usd">1768866000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-4" decimals="-3" id="f-84" unitRef="usd">1300395000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-3" decimals="-3" id="f-85" unitRef="usd">-1095000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-4" decimals="-3" id="f-86" unitRef="usd">-3222000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-3" decimals="-3" id="f-87" unitRef="usd">-1284194000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">-1026030000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-3" decimals="-3" id="f-89" unitRef="usd">483794000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-4" decimals="-3" id="f-90" unitRef="usd">271343000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-3" decimals="-3" id="f-91" unitRef="usd">11611000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-4" decimals="-3" id="f-92" unitRef="usd">15819000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-93" unitRef="usd">495405000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-94" unitRef="usd">287162000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-3" decimals="-3" id="f-95" unitRef="usd">955150000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-4" decimals="-3" id="f-96" unitRef="usd">765552000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-97" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-98" unitRef="usd">146267000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-99" unitRef="usd">3551000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-100" unitRef="usd">208813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-5" decimals="-3" id="f-101" unitRef="usd">101122000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-6" decimals="-3" id="f-102" unitRef="usd">74881000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-3" id="f-103" unitRef="usd">217613000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-7" decimals="-3" id="f-104" unitRef="usd">158576000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-105" unitRef="usd">25069000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-6" decimals="-3" id="f-106" unitRef="usd">23221000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-107" unitRef="usd">48674000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-3" id="f-108" unitRef="usd">44206000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">126191000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-6" decimals="-3" id="f-110" unitRef="usd">98102000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-111" unitRef="usd">266287000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-3" id="f-112" unitRef="usd">202782000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-113" unitRef="usd">-126191000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-6" decimals="-3" id="f-114" unitRef="usd">48165000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-115" unitRef="usd">-262736000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-3" id="f-116" unitRef="usd">6031000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-5" decimals="-3" id="f-117" unitRef="usd">6250000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-6" decimals="-3" id="f-118" unitRef="usd">4560000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">9052000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-7" decimals="-3" id="f-120" unitRef="usd">7242000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">7244000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-6" decimals="-3" id="f-122" unitRef="usd">5057000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-123" unitRef="usd">12611000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-7" decimals="-3" id="f-124" unitRef="usd">7906000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-125" unitRef="usd">189000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-126" unitRef="usd">8000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-127" unitRef="usd">610000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-128" unitRef="usd">515000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-5" decimals="-3" id="f-129" unitRef="usd">-805000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-6" decimals="-3" id="f-130" unitRef="usd">-489000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-131" unitRef="usd">-2949000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-3" id="f-132" unitRef="usd">-149000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-133" unitRef="usd">-126996000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-134" unitRef="usd">47676000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-135" unitRef="usd">-265685000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-136" unitRef="usd">5882000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-137" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-6" decimals="-3" id="f-138" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-139" unitRef="usd">-3313000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-3" id="f-140" unitRef="usd">17000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-141" unitRef="usd">-126996000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-6" decimals="-3" id="f-142" unitRef="usd">47676000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-143" unitRef="usd">-262372000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-3" id="f-144" unitRef="usd">5865000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-145" unitRef="usd">-1696000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-146" unitRef="usd">-999000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-147" unitRef="usd">-4208000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-148" unitRef="usd">-1485000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-149" unitRef="usd">-125300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-150" unitRef="usd">48675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-151" unitRef="usd">-258164000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-152" unitRef="usd">7350000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-153"
      unitRef="usdPerShare">-1.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-154"
      unitRef="usdPerShare">0.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-155"
      unitRef="usdPerShare">-2.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-156"
      unitRef="usdPerShare">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-157"
      unitRef="usdPerShare">-1.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-158"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-159"
      unitRef="usdPerShare">-2.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-160"
      unitRef="usdPerShare">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-161" unitRef="shares">123285000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-162" unitRef="shares">106757000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-163" unitRef="shares">115307000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-164" unitRef="shares">106394000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-165" unitRef="shares">123285000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-166" unitRef="shares">108143000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-167" unitRef="shares">115307000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-168" unitRef="shares">107893000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-169" unitRef="usd">216000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-170" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-171" unitRef="usd">2125000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-7" decimals="-3" id="f-172" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-173" unitRef="usd">-56000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-174" unitRef="usd">-74000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-175" unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-7" decimals="-3" id="f-176" unitRef="usd">-196000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-177" unitRef="usd">-126836000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-6" decimals="-3" id="f-178" unitRef="usd">47602000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">-260245000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-7" decimals="-3" id="f-180" unitRef="usd">5669000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c-8" decimals="-3" id="f-181" unitRef="shares">107312000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-8" decimals="-3" id="f-182" unitRef="usd">200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-9" decimals="-3" id="f-183" unitRef="usd">1300395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-10" decimals="-3" id="f-184" unitRef="usd">-3222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-11" decimals="-3" id="f-185" unitRef="usd">-1026030000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-12" decimals="-3" id="f-186" unitRef="usd">15819000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-187" unitRef="usd">287162000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-13" decimals="-3" id="f-188" unitRef="usd">19694000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-3" id="f-189" unitRef="usd">19694000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-15" decimals="-3" id="f-190" unitRef="shares">34000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-13" decimals="-3" id="f-191" unitRef="usd">267000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-14" decimals="-3" id="f-192" unitRef="usd">267000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-15" decimals="-3" id="f-193" unitRef="shares">154000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-16" decimals="-3" id="f-194" unitRef="usd">58000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-14" decimals="-3" id="f-195" unitRef="usd">58000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-16" decimals="-3" id="f-196" unitRef="usd">1909000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-14" decimals="-3" id="f-197" unitRef="usd">1909000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-17" decimals="-3" id="f-198" unitRef="usd">-132864000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-18" decimals="-3" id="f-199" unitRef="usd">-2512000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-14" decimals="-3" id="f-200" unitRef="usd">-135376000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c-19" decimals="-3" id="f-201" unitRef="shares">107500000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-19" decimals="-3" id="f-202" unitRef="usd">200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-20" decimals="-3" id="f-203" unitRef="usd">1320356000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-21" decimals="-3" id="f-204" unitRef="usd">-1255000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-3" id="f-205" unitRef="usd">-1158894000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-3" id="f-206" unitRef="usd">13307000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-24" decimals="-3" id="f-207" unitRef="usd">173714000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-25" decimals="-3" id="f-208" unitRef="usd">17750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-209" unitRef="usd">17750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-26" decimals="-3" id="f-210" unitRef="shares">120000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-25" decimals="-3" id="f-211" unitRef="usd">1512000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-3" id="f-212" unitRef="usd">1512000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-26" decimals="-3" id="f-213" unitRef="shares">723000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-26" decimals="-3" id="f-214" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-25" decimals="-3" id="f-215" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-5" decimals="-3" id="f-216" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-26" decimals="-3" id="f-217" unitRef="shares">15790000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-26" decimals="-3" id="f-218" unitRef="usd">16000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-25" decimals="-3" id="f-219" unitRef="usd">429249000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-5" decimals="-3" id="f-220" unitRef="usd">429265000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-27" decimals="-3" id="f-221" unitRef="usd">-56000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-222" unitRef="usd">-56000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-27" decimals="-3" id="f-223" unitRef="usd">216000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-5" decimals="-3" id="f-224" unitRef="usd">216000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-28" decimals="-3" id="f-225" unitRef="usd">-125300000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-29" decimals="-3" id="f-226" unitRef="usd">-1696000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-5" decimals="-3" id="f-227" unitRef="usd">-126996000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c-30" decimals="-3" id="f-228" unitRef="shares">124133000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-30" decimals="-3" id="f-229" unitRef="usd">217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-230" unitRef="usd">1768866000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-231" unitRef="usd">-1095000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-232" unitRef="usd">-1284194000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-3" id="f-233" unitRef="usd">11611000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-3" decimals="-3" id="f-234" unitRef="usd">495405000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c-35" decimals="-3" id="f-235" unitRef="shares">105960000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-236" unitRef="usd">198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-3" id="f-237" unitRef="usd">1219213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-37" decimals="-3" id="f-238" unitRef="usd">-136000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-38" decimals="-3" id="f-239" unitRef="usd">-820755000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-3" id="f-240" unitRef="usd">19819000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-3" id="f-241" unitRef="usd">418339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-41" decimals="-3" id="f-242" unitRef="usd">19390000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-42" decimals="-3" id="f-243" unitRef="usd">19390000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-43" decimals="-3" id="f-244" unitRef="shares">82000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-41" decimals="-3" id="f-245" unitRef="usd">576000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-42" decimals="-3" id="f-246" unitRef="usd">576000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-43" decimals="-3" id="f-247" unitRef="shares">98000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-43" decimals="-3" id="f-248" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-41" decimals="-3" id="f-249" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-42" decimals="-3" id="f-250" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-44" decimals="-3" id="f-251" unitRef="usd">-122000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-42" decimals="-3" id="f-252" unitRef="usd">-122000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-45" decimals="-3" id="f-253" unitRef="usd">-41325000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-46" decimals="-3" id="f-254" unitRef="usd">-486000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-42" decimals="-3" id="f-255" unitRef="usd">-41811000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c-47" decimals="-3" id="f-256" unitRef="shares">106140000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-257" unitRef="usd">199000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-258" unitRef="usd">1239178000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-259" unitRef="usd">-258000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-3" id="f-260" unitRef="usd">-862080000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-3" id="f-261" unitRef="usd">19333000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-3" id="f-262" unitRef="usd">396372000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-53" decimals="-3" id="f-263" unitRef="usd">20612000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-6" decimals="-3" id="f-264" unitRef="usd">20612000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-54" decimals="-3" id="f-265" unitRef="shares">64000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-53" decimals="-3" id="f-266" unitRef="usd">520000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-6" decimals="-3" id="f-267" unitRef="usd">520000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-54" decimals="-3" id="f-268" unitRef="shares">665000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-55" decimals="-3" id="f-269" unitRef="usd">-74000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-6" decimals="-3" id="f-270" unitRef="usd">-74000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-56" decimals="-3" id="f-271" unitRef="usd">48675000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-57" decimals="-3" id="f-272" unitRef="usd">-999000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-6" decimals="-3" id="f-273" unitRef="usd">47676000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c-58" decimals="-3" id="f-274" unitRef="shares">106869000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-275" unitRef="usd">199000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-276" unitRef="usd">1260310000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-277" unitRef="usd">-332000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-3" id="f-278" unitRef="usd">-813405000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-62" decimals="-3" id="f-279" unitRef="usd">18334000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-63" decimals="-3" id="f-280" unitRef="usd">465106000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">-262372000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-7" decimals="-3" id="f-282" unitRef="usd">5865000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">37444000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-3" id="f-284" unitRef="usd">40002000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-285" unitRef="usd">8788000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-7" decimals="-3" id="f-286" unitRef="usd">5358000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="-3" id="f-287" unitRef="usd">-896000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-7" decimals="-3" id="f-288" unitRef="usd">82000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">80000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-7" decimals="-3" id="f-290" unitRef="usd">0</us-gaap:RealizedInvestmentGainsLosses>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-291" unitRef="usd">12612000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-7" decimals="-3" id="f-292" unitRef="usd">7906000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-293" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-7" decimals="-3" id="f-294" unitRef="usd">68024000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-295" unitRef="usd">2643000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-3" id="f-296" unitRef="usd">-20309000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-297" unitRef="usd">-8402000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-7" decimals="-3" id="f-298" unitRef="usd">6688000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-299" unitRef="usd">-11000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-7" decimals="-3" id="f-300" unitRef="usd">-27279000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-301" unitRef="usd">-866000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-7" decimals="-3" id="f-302" unitRef="usd">-99135000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">4417000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-304" unitRef="usd">1205000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">-210217000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-3" id="f-306" unitRef="usd">-107187000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-307" unitRef="usd">102731000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-308" unitRef="usd">66225000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-1" decimals="-3" id="f-309" unitRef="usd">309982000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-7" decimals="-3" id="f-310" unitRef="usd">192528000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-1" decimals="-3" id="f-311" unitRef="usd">208615000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-7" decimals="-3" id="f-312" unitRef="usd">141994000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-313" unitRef="usd">-204098000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-3" id="f-314" unitRef="usd">-116759000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">1779000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-7" decimals="-3" id="f-316" unitRef="usd">1096000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">429265000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-7" decimals="-3" id="f-318" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:ProceedsFromSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-319" unitRef="usd">0</arwr:ProceedsFromSaleOfFutureRoyalties>
    <arwr:ProceedsFromSaleOfFutureRoyalties contextRef="c-7" decimals="-3" id="f-320" unitRef="usd">250000000</arwr:ProceedsFromSaleOfFutureRoyalties>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-321" unitRef="usd">431044000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-3" id="f-322" unitRef="usd">251096000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">16729000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-7" decimals="-3" id="f-324" unitRef="usd">27150000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-325" unitRef="usd">84000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-326" unitRef="usd">-196000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-327" unitRef="usd">110891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-40" decimals="-3" id="f-328" unitRef="usd">108005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-3" decimals="-3" id="f-329" unitRef="usd">127704000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-63" decimals="-3" id="f-330" unitRef="usd">134959000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-331" unitRef="usd">-3014000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-7" decimals="-3" id="f-332" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-3" id="f-333" unitRef="usd">7265000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-7" decimals="-3" id="f-334" unitRef="usd">12831000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-335">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General and Recent Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#x201c;Company&#x201d;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#x2019;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#x201c;RNAi&#x201d;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#x2019;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.508%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;plozasiran (ARO-APOC3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;zodasiran (ARO-ANG3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;olpasiran&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-MUC5AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-MMP7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK-4532990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;fazirsiran&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;JNJ-3989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-C3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-PNPLA3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-CFB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Muscle&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-DUX4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-DM1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Central Nervous System (CNS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#x2019;s principal executive offices are located in Pasadena, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Thus far in fiscal 2024, the Company has continued to develop and advance its pipeline and partnered candidates. Several key recent developments include: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.7pt"&gt;Completed enrollment in Amgen&#x2019;s Phase 3 OCEAN(a) - outcome trial of olpasiran, triggering a $50.0&#160;million milestone payment to the Company, which was paid in the third quarter of fiscal 2024;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Presented final data from the double-blind treatment period of the Company&#x2019;s Phase 2 SHASTA-2 study of investigational plozasiran in patients with severe Hypertriglyceridemia. Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Announced an Expanded Access Program (EAP) to make investigational plozasiran available outside of a clinical trial for qualifying patients with familial chylomicronemia syndrome (FCS); &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Initiated a Phase 1/2a clinical trial of ARO-DM1, being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, being developed as a potential treatment for complement mediated renal disease; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt"&gt;Entered into an Amended and Restated License Agreement with GSK, pursuant to which GSK received a worldwide, exclusive license to develop and commercialize JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen Pharmaceuticals, Inc. See Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company&#x2019;s financial position at March&#160;31, 2024 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company&#x2019;s Annual Report on Form 10-K for the year ended September&#160;30, 2023 for more complete descriptions and discussions. Operating results and cash flows for the six months ended March&#160;31, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending September&#160;30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s primary sources of financing have been through the sale of its equity securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#x2019;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#x2019;s pipeline of drug candidates and its headcount have both expanded. Additionally, significant capital investment will be required as the Company&#x2019;s pipeline matures into later stage clinical trials.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the Company had $127.7 million in cash, cash equivalents and restricted cash ($2.2 million in restricted cash) and $395.4&#160;million in available-for-sale securities to fund operations. During the six months ended March&#160;31, 2024, the Company&#x2019;s cash, cash equivalents and restricted cash and investments balance increased by $119.5 million which was primarily due to the net proceeds of $429.3&#160;million from the underwritten offering in January 2024 discussed below, offset by ongoing expenses related to the Company&#x2019;s research and development programs, general and administrative expenses and capital expenditures. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 2, 2024, the Company entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued 15,790,000 shares of common stock at a price of $28.50 per share. The aggregate purchase price paid by investors was $450.0&#160;million and the Company received net proceeds of $429.3&#160;million after deducting advisory fees and offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company is eligible to receive up to $2.8 billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no changes to the significant accounting policies disclosed in the Company&#x2019;s most recent Annual Report on Form 10-K for the fiscal year ended September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded an income tax benefit of $3.3 million and $0 for the six months ended March&#160;31, 2024 and 2023, respectively. The income tax benefit is primarily due to the discrete change in the Company&#x2019;s uncertain tax positions related to the statute of limitation expiration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to improve its income tax disclosure requirements. Under the ASU, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This ASU will become effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <arwr:ScheduleOfCurrentProductsTableTextBlock contextRef="c-1" id="f-336">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.172%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.508%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;plozasiran (ARO-APOC3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;zodasiran (ARO-ANG3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;olpasiran&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-MUC5AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-MMP7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK-4532990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;fazirsiran&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;JNJ-3989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-C3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-PNPLA3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-CFB&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Muscle&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-DUX4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;ARO-DM1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Central Nervous System (CNS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Various&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:ScheduleOfCurrentProductsTableTextBlock>
    <arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial contextRef="c-64" decimals="-5" id="f-337" unitRef="usd">50000000</arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-338" unitRef="usd">127700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-3" decimals="-5" id="f-339" unitRef="usd">2200000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-3" decimals="-5" id="f-340" unitRef="usd">395400000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <arwr:IncreaseDecreaseInCashAndInvestments contextRef="c-1" decimals="-5" id="f-341" unitRef="usd">119500000</arwr:IncreaseDecreaseInCashAndInvestments>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-65" decimals="-5" id="f-342" unitRef="usd">429300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-65"
      decimals="INF"
      id="f-343"
      unitRef="shares">15790000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-66"
      decimals="2"
      id="f-344"
      unitRef="usdPerShare">28.50</us-gaap:SaleOfStockPricePerShare>
    <arwr:SaleOfStockAggregatePurchasePrice contextRef="c-65" decimals="-5" id="f-345" unitRef="usd">450000000</arwr:SaleOfStockAggregatePurchasePrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-65" decimals="-5" id="f-346" unitRef="usd">429300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments contextRef="c-3" decimals="-8" id="f-347" unitRef="usd">2800000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-348" unitRef="usd">-3300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-349" unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-350">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to improve its income tax disclosure requirements. Under the ASU, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This ASU will become effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-351">COLLABORATION AND LICENSE AGREEMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of revenue recognized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;116,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;132,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;146,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;208,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance of receivables and contract liabilities related to the Company&#x2019;s collaboration and license agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.575%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.947%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.950%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Receivables included in accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contract liabilities included in deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Glaxosmithkline Intellectual Property (No. 3) Limited (&#x201c;GSK&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;GSK License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#x201c;GSK License Agreement&#x201d;). Under the GSK License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. GSK dosed the first patient in a Phase 2b trial in March 2023 and paid a $30.0&#160;million milestone payment to the Company in the third quarter of fiscal 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is eligible for an additional payment of $100.0 million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0 million at first commercial sale, and up to $590.0 million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"&gt;GSK-HBV Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 11, 2023, the Company entered into an Amended and Restated License Agreement with GSK (the &#x201c;GSK-HBV Agreement&#x201d;) pursuant to which GSK received a worldwide, exclusive license to develop and commercialize JNJ-3989 (formerly ARO-HBV), the Company&#x2019;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. JNJ-3989 had previously been licensed to Janssen in October 2018. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the GSK-HBV Agreement, the Company received $2.7&#160;million in December 2023, upon signing the amended GSK-HBV Agreement. The Company is eligible to receive up to $832.5&#160;million in development and sales milestone payments under the GSK-HBV Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no contract assets and liabilities recorded as of March&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Horizon Therapeutics Ireland DAC (&#x201c;Horizon&#x201d;) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, Horizon and the Company entered into a collaboration and license agreement (the &#x201c;Horizon License Agreement&#x201d;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services, including the Company&#x2019;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#x201c;Horizon R&amp;amp;D Services&#x201d;). The Company received a $40.0&#160;million upfront payment in July 2021. Revenue was recognized on a straight-line basis over the timeframe for completing the Horizon R&amp;amp;D Services, concluding in the first quarter of 2023. Further, the Company received an additional $15.0&#160;million upon Horizon&#x2019;s initiation of a Phase 1 clinical trial in January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 6, 2023, Amgen completed its acquisition of Horizon and subsequently notified the Company of Amgen&#x2019;s intent to terminate the HZN-457 license. Horizon exercised its right to terminate the Horizon License Agreement for convenience, which took effect on December 21, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#x201c;Takeda License Agreement&#x201d;). Under the Takeda License Agreement, Takeda and the Company will co-develop the Company&#x2019;s fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#x2019;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50/50 profit sharing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on net sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the &#x201c;Takeda R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Takeda R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Takeda License Agreement, the Company received $300.0&#160;million as an upfront payment in January 2021 and an additional $40.0&#160;million upon Takeda&#x2019;s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to $527.5&#160;million in additional potential development, regulatory and commercial milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has allocated the total $300.0&#160;million initial transaction price to its one distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;amp;D Services. Revenue was recognized using the input method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Phase 2 study visits for patients in the SEQUOIA and AROAAT2002 studies concluded by December 31, 2023, and the Company has substantially completed its performance obligation under the Takeda license agreement. As such, all revenue has been fully recognized as of December 31, 2023. There were no further deferred revenue and contract liabilities as of March 31, 2024&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has recorded $13.8&#160;million as accrued expenses as of March&#160;31, 2024 that was primarily driven by co-development and co-commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company and the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. ARO-PNPLA3 is in Phase 1 clinical trials, which are &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;now being developed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, on December 11, 2023, the Company entered into the GSK-HBV Agreement, as discussed above, pursuant to which GSK received an exclusive license for JNJ-3989 (formerly ARO-HBV). JNJ-3989 had previously been licensed to Janssen in October 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"&gt;Amgen Inc. (&#x201c;Amgen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#x201c;Olpasiran Agreement&#x201d;), Amgen received a worldwide, exclusive license to the Company&#x2019;s novel RNAi olpasiran (previously referred to as AMG- 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Olpasiran Agreement, the Company has received $35.0&#160;million in upfront payments and $21.5&#160;million in the form of an equity investment by Amgen in the Company&#x2019;s common stock. Further, the Company received additional an $55.0&#160;million in milestone payments; $10.0&#160;million upon Amgen&#x2019;s initiation of a Phase 1 study in September 2018,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$20.0&#160;million upon its initiation of a Phase 2 clinical study in July 2020, and $25.0&#160;million upon its first subject enrollment in a Phase 3 trial in December 2022. The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were no contract assets and liabilities recorded as of March&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, Royalty Pharma Investments 2019 ICAV (&#x201c;Royalty Pharma&#x201d;) and the Company entered into the Royalty Pharma Agreement. In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $535.0&#160;million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 11.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022, the Company and Visirna, its subsidiary, entered into a License Agreement (the &#x201c;Visirna License Agreement&#x201d;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#x2019;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#x2019;s Republic of China, Hong Kong, Macau and Taiwan). &lt;/span&gt;&lt;/div&gt;The Company also performs manufacturing and development work pursuant to a Clinical Supply Agreement between the parties contemplated by the Visirna License Agreement. The Company received $0.1&#160;million and $0.9&#160;million as consideration for this manufacturing and development work for the six months ended March&#160;31, 2024 and 2023, respectively. There were no contract assets and liabilities recorded as of March&#160;31, 2024.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-352">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of revenue recognized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.982%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.403%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.988%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,685&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;29,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;116,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;132,468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;146,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;208,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-67" decimals="-3" id="f-353" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-68" decimals="-3" id="f-354" unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-69" decimals="-3" id="f-355" unitRef="usd">2685000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-70" decimals="-3" id="f-356" unitRef="usd">29323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-71" decimals="-3" id="f-357" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-72" decimals="-3" id="f-358" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-73" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-74" decimals="-3" id="f-360" unitRef="usd">21667000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-75" decimals="-3" id="f-361" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-76" decimals="-3" id="f-362" unitRef="usd">116156000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-77" decimals="-3" id="f-363" unitRef="usd">866000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-78" decimals="-3" id="f-364" unitRef="usd">132468000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-79" decimals="-3" id="f-365" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="-3" id="f-366" unitRef="usd">111000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-81" decimals="-3" id="f-367" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="-3" id="f-368" unitRef="usd">355000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-83" decimals="-3" id="f-369" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-84" decimals="-3" id="f-370" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-85" decimals="-3" id="f-371" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-86" decimals="-3" id="f-372" unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-373" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-6" decimals="-3" id="f-374" unitRef="usd">146267000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-375" unitRef="usd">3551000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-7" decimals="-3" id="f-376" unitRef="usd">208813000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-377">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance of receivables and contract liabilities related to the Company&#x2019;s collaboration and license agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.636%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:59.575%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.947%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.414%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.950%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Receivables included in accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Contract liabilities included in deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNet contextRef="c-3" decimals="-3" id="f-378" unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-4" decimals="-3" id="f-379" unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:ContractWithCustomerLiability contextRef="c-3" decimals="-3" id="f-380" unitRef="usd">0</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-4" decimals="-3" id="f-381" unitRef="usd">866000</us-gaap:ContractWithCustomerLiability>
    <arwr:MilestonePaymentReceivable contextRef="c-87" decimals="-5" id="f-382" unitRef="usd">30000000</arwr:MilestonePaymentReceivable>
    <arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree contextRef="c-88" decimals="-5" id="f-383" unitRef="usd">100000000</arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree>
    <arwr:CommercialMilestonePaymentsAtFirstCommercialSale contextRef="c-89" decimals="-5" id="f-384" unitRef="usd">190000000</arwr:CommercialMilestonePaymentsAtFirstCommercialSale>
    <arwr:SalesRelatedMilestonePayments contextRef="c-89" decimals="-5" id="f-385" unitRef="usd">590000000</arwr:SalesRelatedMilestonePayments>
    <arwr:InitialTransactionPrice contextRef="c-90" decimals="-5" id="f-386" unitRef="usd">2700000</arwr:InitialTransactionPrice>
    <arwr:DevelopmentAndSalesMilestonesPayments contextRef="c-91" decimals="-5" id="f-387" unitRef="usd">832500000</arwr:DevelopmentAndSalesMilestonesPayments>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-92" decimals="INF" id="f-388" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-92" decimals="INF" id="f-389" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-93"
      decimals="INF"
      id="f-390"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice contextRef="c-94" decimals="-5" id="f-391" unitRef="usd">40000000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentEarned contextRef="c-95" decimals="-5" id="f-392" unitRef="usd">15000000</arwr:MilestonePaymentEarned>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales contextRef="c-96" decimals="2" id="f-393" unitRef="number">0.20</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales contextRef="c-97" decimals="2" id="f-394" unitRef="number">0.25</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-98"
      decimals="INF"
      id="f-395"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:NumberOfDistinctBundle
      contextRef="c-98"
      decimals="INF"
      id="f-396"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-98"
      decimals="INF"
      id="f-397"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice contextRef="c-98" decimals="-5" id="f-398" unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentEarned contextRef="c-99" decimals="-5" id="f-399" unitRef="usd">40000000</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments contextRef="c-100" decimals="-5" id="f-400" unitRef="usd">527500000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:InitialTransactionPrice contextRef="c-98" decimals="-5" id="f-401" unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-98"
      decimals="INF"
      id="f-402"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-101" decimals="-5" id="f-403" unitRef="usd">13800000</us-gaap:AccruedLiabilitiesCurrent>
    <arwr:NumberOfAgreements
      contextRef="c-102"
      decimals="INF"
      id="f-404"
      unitRef="agreement">2</arwr:NumberOfAgreements>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement contextRef="c-103" decimals="-5" id="f-405" unitRef="usd">35000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-103" decimals="-5" id="f-406" unitRef="usd">21500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentReceived contextRef="c-104" decimals="-5" id="f-407" unitRef="usd">55000000</arwr:MilestonePaymentReceived>
    <arwr:MilestonePaymentReceived contextRef="c-105" decimals="-5" id="f-408" unitRef="usd">10000000</arwr:MilestonePaymentReceived>
    <arwr:MilestonePaymentReceived contextRef="c-106" decimals="-5" id="f-409" unitRef="usd">20000000</arwr:MilestonePaymentReceived>
    <arwr:MilestonePaymentReceived contextRef="c-107" decimals="-5" id="f-410" unitRef="usd">25000000</arwr:MilestonePaymentReceived>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-104" decimals="INF" id="f-411" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-104" decimals="INF" id="f-412" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments contextRef="c-108" decimals="-5" id="f-413" unitRef="usd">535000000</arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-109" decimals="-5" id="f-414" unitRef="usd">100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-110" decimals="-5" id="f-415" unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-111" decimals="-5" id="f-416" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-111" decimals="-5" id="f-417" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock contextRef="c-1" id="f-418">BALANCE SHEET ACCOUNTS&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property, plant and equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;75,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;62,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;56,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;104,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;103,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;158,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;166,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;409,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;332,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(49,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(41,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;359,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;290,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for property, plant and equipment for the three months ended March&#160;31, 2024 and 2023 was $4.1&#160;million and $2.2&#160;million, respectively. Depreciation and amortization expense for property and equipment for the six months ended March&#160;31, 2024 and 2023 was $7.9&#160;million and $4.5&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of fiscal 2024, the Company completed the build out of one of its laboratory and office facilities in Verona, Wisconsin, which resulted in the reclassification of $75.3&#160;million from construction in progress to building as of March&#160;31, 2024. Further, the Company commenced depreciation on the newly completed facility over a 39-year period.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accrued R&amp;amp;D expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;14,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;16,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accrued R&amp;amp;D expenses; co-development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;13,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;7,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;14,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total accrued expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;37,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;39,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-419">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property, plant and equipment:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Building&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;75,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;62,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;56,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Furniture&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Computers and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;104,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;103,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;158,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;166,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;409,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;332,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(49,971)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(41,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;359,252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;290,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-112" decimals="-3" id="f-420" unitRef="usd">2996000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-113" decimals="-3" id="f-421" unitRef="usd">2996000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-114" decimals="-3" id="f-422" unitRef="usd">75262000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-115" decimals="-3" id="f-423" unitRef="usd">0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-116" decimals="-3" id="f-424" unitRef="usd">62926000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-117" decimals="-3" id="f-425" unitRef="usd">56509000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-118" decimals="-3" id="f-426" unitRef="usd">4150000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-119" decimals="-3" id="f-427" unitRef="usd">1540000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-120" decimals="-3" id="f-428" unitRef="usd">923000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-121" decimals="-3" id="f-429" unitRef="usd">700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-122" decimals="-3" id="f-430" unitRef="usd">104723000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-123" decimals="-3" id="f-431" unitRef="usd">103813000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-124" decimals="-3" id="f-432" unitRef="usd">158243000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-125" decimals="-3" id="f-433" unitRef="usd">166655000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-3" decimals="-3" id="f-434" unitRef="usd">409223000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-4" decimals="-3" id="f-435" unitRef="usd">332213000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-3" decimals="-3" id="f-436" unitRef="usd">49971000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-437" unitRef="usd">41951000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-3" decimals="-3" id="f-438" unitRef="usd">359252000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-4" decimals="-3" id="f-439" unitRef="usd">290262000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-5" decimals="-5" id="f-440" unitRef="usd">4100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-6" decimals="-5" id="f-441" unitRef="usd">2200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-442" unitRef="usd">7900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-7" decimals="-5" id="f-443" unitRef="usd">4500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-126" decimals="-5" id="f-444" unitRef="usd">-75300000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentTransfersAndChanges contextRef="c-127" decimals="-5" id="f-445" unitRef="usd">75300000</us-gaap:PropertyPlantAndEquipmentTransfersAndChanges>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-128" id="f-446">P39Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-447">&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expenses consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accrued R&amp;amp;D expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;14,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;16,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accrued R&amp;amp;D expenses; co-development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;13,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Accrued capital expenditures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;7,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;14,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total accrued expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;37,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;39,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <arwr:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-3" decimals="-3" id="f-448" unitRef="usd">14443000</arwr:AccruedResearchAndDevelopmentExpenseCurrent>
    <arwr:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-4" decimals="-3" id="f-449" unitRef="usd">16125000</arwr:AccruedResearchAndDevelopmentExpenseCurrent>
    <arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent contextRef="c-3" decimals="-3" id="f-450" unitRef="usd">13751000</arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent>
    <arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent contextRef="c-4" decimals="-3" id="f-451" unitRef="usd">5895000</arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent>
    <arwr:AccruedCapitalExpenditureCurrent contextRef="c-3" decimals="-3" id="f-452" unitRef="usd">7265000</arwr:AccruedCapitalExpenditureCurrent>
    <arwr:AccruedCapitalExpenditureCurrent contextRef="c-4" decimals="-3" id="f-453" unitRef="usd">14044000</arwr:AccruedCapitalExpenditureCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-454" unitRef="usd">1596000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-455" unitRef="usd">3699000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-3" decimals="-3" id="f-456" unitRef="usd">37055000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-4" decimals="-3" id="f-457" unitRef="usd">39763000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-458">INVESTMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.269%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;396,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;395,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;396,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;395,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;295,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;292,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;295,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;292,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company has determined that the available-for-sale securities that were in an unrealized loss position did not have any credit loss impairment as of March&#160;31, 2024 and 2023.</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock contextRef="c-1" id="f-459">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.265%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.269%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;396,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;395,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;396,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(850)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;395,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.596%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.323%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.185%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;295,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;292,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;295,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;292,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-129" decimals="-3" id="f-460" unitRef="usd">396249000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-129" decimals="-3" id="f-461" unitRef="usd">11000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-129" decimals="-3" id="f-462" unitRef="usd">850000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-129" decimals="-3" id="f-463" unitRef="usd">395410000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-3" decimals="-3" id="f-464" unitRef="usd">396249000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-3" decimals="-3" id="f-465" unitRef="usd">11000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-3" decimals="-3" id="f-466" unitRef="usd">850000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-3" decimals="-3" id="f-467" unitRef="usd">395410000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-130" decimals="-3" id="f-468" unitRef="usd">295699000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-130" decimals="-3" id="f-469" unitRef="usd">3000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-130" decimals="-3" id="f-470" unitRef="usd">2967000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-130" decimals="-3" id="f-471" unitRef="usd">292735000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-4" decimals="-3" id="f-472" unitRef="usd">295699000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-4" decimals="-3" id="f-473" unitRef="usd">3000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-4" decimals="-3" id="f-474" unitRef="usd">2967000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-4" decimals="-3" id="f-475" unitRef="usd">292735000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-476">INTANGIBLE ASSETS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the six months ended March&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense was $0.4 million for each of the three months ended March&#160;31, 2024 and 2023, and $0.9 million for each of six months ended March&#160;31, 2024 and 2023. None of the intangible assets with definite useful lives are anticipated to have a residual value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.099%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-477">The following table presents the components of intangible assets: &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.361%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,348&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;14,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-131" decimals="INF" id="f-478" unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-131" decimals="INF" id="f-479" unitRef="usd">14097000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-131" decimals="INF" id="f-480" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-131" decimals="INF" id="f-481" unitRef="usd">7631000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-131" id="f-482">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-132" decimals="INF" id="f-483" unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-132" decimals="INF" id="f-484" unitRef="usd">1348000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-132" decimals="INF" id="f-485" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-132" decimals="INF" id="f-486" unitRef="usd">1781000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-132" id="f-487">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-133" decimals="INF" id="f-488" unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-133" decimals="INF" id="f-489" unitRef="usd">15445000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-133" decimals="INF" id="f-490" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-133" decimals="INF" id="f-491" unitRef="usd">9412000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-134" decimals="INF" id="f-492" unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-134" decimals="INF" id="f-493" unitRef="usd">13321000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-134" decimals="INF" id="f-494" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-134" decimals="INF" id="f-495" unitRef="usd">8407000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-134" id="f-496">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-135" decimals="INF" id="f-497" unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-135" decimals="INF" id="f-498" unitRef="usd">1274000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-135" decimals="INF" id="f-499" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-135" decimals="INF" id="f-500" unitRef="usd">1855000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-135" id="f-501">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-136" decimals="INF" id="f-502" unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-136" decimals="INF" id="f-503" unitRef="usd">14595000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-136" decimals="INF" id="f-504" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-136" decimals="INF" id="f-505" unitRef="usd">10262000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-5" decimals="-5" id="f-506" unitRef="usd">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-6" decimals="-5" id="f-507" unitRef="usd">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-508" unitRef="usd">900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-7" decimals="-5" id="f-509" unitRef="usd">900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-510">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.099%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2024 (remainder)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;850&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-511" unitRef="usd">850000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-3" decimals="-3" id="f-512" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-3" decimals="-3" id="f-513" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-3" decimals="-3" id="f-514" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-3" decimals="-3" id="f-515" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <arwr:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour contextRef="c-3" decimals="-3" id="f-516" unitRef="usd">1762000</arwr:FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-3" decimals="-3" id="f-517" unitRef="usd">9412000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-518">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.310%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.049%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024 and September&#160;30, 2023, respectively, 11,723,683 and 12,709,837 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#x2019;s 2004 Equity Incentive Plan, 2013 Incentive Plan, 2021 Incentive Plan, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 2, 2024, the Company entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued 15,790,000 shares of common stock at an offering price of $28.50 per share. The aggregate purchase price paid by investors was $450.0&#160;million and the Company received net proceeds of $429.3&#160;million after deducting advisory fees and offering expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 2, 2022, the Company entered into an open market sale agreement (the &#x201c;Open Market Sale Agreement&#x201d;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#x2019;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#x201c;ATM Offering&#x201d;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of March&#160;31, 2024, no shares have been issued under the Open Market Sale Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-519">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.310%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.047%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.049%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;124,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-520"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-521" unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-3" decimals="-3" id="f-522" unitRef="shares">124133000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-523" unitRef="shares">124133000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-3"
      decimals="INF"
      id="f-524"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-3" decimals="INF" id="f-525" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-3" decimals="-3" id="f-526" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-3" decimals="-3" id="f-527" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-528"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-529" unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-4" decimals="-3" id="f-530" unitRef="shares">107312000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-531" unitRef="shares">107312000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-4"
      decimals="INF"
      id="f-532"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-4" decimals="INF" id="f-533" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-4" decimals="-3" id="f-534" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-4" decimals="-3" id="f-535" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-137"
      decimals="INF"
      id="f-536"
      unitRef="shares">11723683</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-138"
      decimals="INF"
      id="f-537"
      unitRef="shares">12709837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-65"
      decimals="INF"
      id="f-538"
      unitRef="shares">15790000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-66"
      decimals="2"
      id="f-539"
      unitRef="usdPerShare">28.50</us-gaap:SaleOfStockPricePerShare>
    <arwr:SaleOfStockAggregatePurchasePrice contextRef="c-65" decimals="-5" id="f-540" unitRef="usd">450000000</arwr:SaleOfStockAggregatePurchasePrice>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-65" decimals="-5" id="f-541" unitRef="usd">429300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <arwr:CommonStockCapitalSharesValueReservedForFutureIssuance contextRef="c-139" decimals="INF" id="f-542" unitRef="usd">250000000</arwr:CommonStockCapitalSharesValueReservedForFutureIssuance>
    <arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock contextRef="c-140" decimals="3" id="f-543" unitRef="number">0.030</arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="c-141"
      decimals="INF"
      id="f-544"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-545">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of March&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company owns land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#x2019;s manufacturing process development and analytical activities. During the first quarter of fiscal 2024, the Company completed the build out of one of its laboratory and office facilities.&lt;/span&gt;&lt;/div&gt;As of March&#160;31, 2024, the Company has incurred $247.0 million and intends to spend an additional $37.0 million to $51.0 million to complete the build out of the facilities.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-3" decimals="INF" id="f-546" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:AreaOfLand contextRef="c-142" decimals="-3" id="f-547" unitRef="sqft">160000</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand contextRef="c-143" decimals="-3" id="f-548" unitRef="sqft">140000</us-gaap:AreaOfLand>
    <arwr:CommitmentsCapitalExpendituresIncurredToDate contextRef="c-144" decimals="-5" id="f-549" unitRef="usd">247000000</arwr:CommitmentsCapitalExpendituresIncurredToDate>
    <arwr:AmountIntendsToInvestForBuildoutOfFacilities contextRef="c-145" decimals="-5" id="f-550" unitRef="usd">37000000</arwr:AmountIntendsToInvestForBuildoutOfFacilities>
    <arwr:AmountIntendsToInvestForBuildoutOfFacilities contextRef="c-146" decimals="-5" id="f-551" unitRef="usd">51000000</arwr:AmountIntendsToInvestForBuildoutOfFacilities>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-552">LEASES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Pasadena, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases 49,000 square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for one additional five-year term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;San Diego, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases 144,000 square feet of office and research and development laboratory space located at 10102 Hoyt Park, San Diego, California, which lease expires on April&#160;30, 2038. Pursuant to the lease, within &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease agreement grants the Company the right to receive an Additional Tenant Improvement Allowance (&#x201c;ATIA&#x201d;) funded by the lessor, with a maximum amount of $7.2 million, subject to a 7% interest per annum over the base term. Further, on September&#160;25, 2023, the Company executed the first amendment to the lease, which grants a second ATIA with a maximum amount of $23.6 million, bearing interest at a rate of 9% per annum over the base term. The Company received $30.8&#160;million&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ATIA from the lessor during the first quarter of fiscal 2024. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increased lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company previously subleased additional research and development space in San Diego, California, which subleases ended during the fiscal year of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;Madison, Wisconsin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases space for office and laboratory facilities, which expires on September&#160;30, 2031. The lease contains options to renew for two terms of five years. After accounting for additional rental square feet added pursuant to amendments to the lease agreement in 2019 and 2020, the Company currently leases a total of 115,000  square feet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;113,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.298%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Variable lease cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Variable lease cost is primarily related to operating expenses associated with the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was no short-term lease cost during the first half of fiscal 2024. There was $0.4&#160;million and $0.7&#160;million short-term lease cost during the three and six months ended March&#160;31, 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2024 (remainder of fiscal year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;6,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;14,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;13,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;128,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;194,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(75,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total operating lease liabilities (includes current portion)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;118,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash received for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchanged for amended operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-147" decimals="-3" id="f-553" unitRef="sqft">49000</us-gaap:LandSubjectToGroundLeases>
    <arwr:NumberOfOptionsToRenew
      contextRef="c-148"
      decimals="INF"
      id="f-554"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-148" id="f-555">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-149" decimals="-3" id="f-556" unitRef="sqft">144000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-149" id="f-557">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:NumberOfOptionsToRenew
      contextRef="c-150"
      decimals="INF"
      id="f-558"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-149" id="f-559">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <arwr:MaximumAdditionalTenantImprovementAllowance contextRef="c-149" decimals="-5" id="f-560" unitRef="usd">7200000</arwr:MaximumAdditionalTenantImprovementAllowance>
    <arwr:AdditionalTenantImprovementAllowanceInterestPerAnnum contextRef="c-149" decimals="2" id="f-561" unitRef="number">0.07</arwr:AdditionalTenantImprovementAllowanceInterestPerAnnum>
    <arwr:MaximumAdditionalTenantImprovementAllowance contextRef="c-151" decimals="-5" id="f-562" unitRef="usd">23600000</arwr:MaximumAdditionalTenantImprovementAllowance>
    <arwr:AdditionalTenantImprovementAllowanceInterestPerAnnum contextRef="c-151" decimals="2" id="f-563" unitRef="number">0.09</arwr:AdditionalTenantImprovementAllowanceInterestPerAnnum>
    <arwr:AdditionalTenantImprovementAllowanceLiability contextRef="c-152" decimals="-5" id="f-564" unitRef="usd">30800000</arwr:AdditionalTenantImprovementAllowanceLiability>
    <arwr:NumberOfOptionsToRenew
      contextRef="c-153"
      decimals="INF"
      id="f-565"
      unitRef="option">2</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-153" id="f-566">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-153" decimals="-3" id="f-567" unitRef="sqft">115000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-568">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.657%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.144%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;44,626&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;45,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;10,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;113,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;104,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.298%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Variable lease cost &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;370&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,003&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) Variable lease cost is primarily related to operating expenses associated with the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-3" decimals="-3" id="f-569" unitRef="usd">44626000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-4" decimals="-3" id="f-570" unitRef="usd">45297000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-3" decimals="-3" id="f-571" unitRef="usd">5285000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-4" decimals="-3" id="f-572" unitRef="usd">10563000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-573" unitRef="usd">113632000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-574" unitRef="usd">104608000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost contextRef="c-154" decimals="-3" id="f-575" unitRef="usd">2572000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-155" decimals="-3" id="f-576" unitRef="usd">2343000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-156" decimals="-3" id="f-577" unitRef="usd">5566000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-157" decimals="-3" id="f-578" unitRef="usd">4412000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-158" decimals="-3" id="f-579" unitRef="usd">491000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-159" decimals="-3" id="f-580" unitRef="usd">500000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-160" decimals="-3" id="f-581" unitRef="usd">967000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-161" decimals="-3" id="f-582" unitRef="usd">1033000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-154" decimals="-3" id="f-583" unitRef="usd">836000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-155" decimals="-3" id="f-584" unitRef="usd">160000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-156" decimals="-3" id="f-585" unitRef="usd">1615000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-157" decimals="-3" id="f-586" unitRef="usd">370000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-158" decimals="-3" id="f-587" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-159" decimals="-3" id="f-588" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-160" decimals="-3" id="f-589" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-161" decimals="-3" id="f-590" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-5" decimals="-3" id="f-591" unitRef="usd">3899000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-6" decimals="-3" id="f-592" unitRef="usd">3003000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-593" unitRef="usd">8148000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-7" decimals="-3" id="f-594" unitRef="usd">5815000</us-gaap:LeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-5" id="f-595" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-6" decimals="-5" id="f-596" unitRef="usd">400000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-7" decimals="-5" id="f-597" unitRef="usd">700000</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-598">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:83.996%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.804%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2024 (remainder of fiscal year)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;6,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;15,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;14,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;13,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;128,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;194,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(75,868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Total operating lease liabilities (includes current portion)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;118,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.284%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.162%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.166%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash received for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Right-of-use assets obtained in exchanged for amended operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;13.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;6.6&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="c-3" decimals="-3" id="f-599" unitRef="usd">6997000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-3" decimals="-3" id="f-600" unitRef="usd">15356000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-3" decimals="-3" id="f-601" unitRef="usd">15696000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-3" decimals="-3" id="f-602" unitRef="usd">14869000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-3" decimals="-3" id="f-603" unitRef="usd">13511000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive contextRef="c-3" decimals="-3" id="f-604" unitRef="usd">128356000</arwr:LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-3" decimals="-3" id="f-605" unitRef="usd">194785000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-3" decimals="-3" id="f-606" unitRef="usd">75868000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-3" decimals="-3" id="f-607" unitRef="usd">118917000</us-gaap:OperatingLeaseLiability>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-5" decimals="-3" id="f-608" unitRef="usd">0</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-6" decimals="-3" id="f-609" unitRef="usd">8918000</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-1" decimals="-3" id="f-610" unitRef="usd">3099000</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-7" decimals="-3" id="f-611" unitRef="usd">17929000</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-5" decimals="-3" id="f-612" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-613" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-614" unitRef="usd">64000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-7" decimals="-3" id="f-615" unitRef="usd">22582000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c-5" decimals="-3" id="f-616" unitRef="usd">2046000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-6" decimals="-3" id="f-617" unitRef="usd">1098000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-618" unitRef="usd">4016000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-7" decimals="-3" id="f-619" unitRef="usd">2196000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-3" id="f-620">P13Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-63" id="f-621">P6Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-3" decimals="3" id="f-622" unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-63" decimals="3" id="f-623" unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-624">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#x201c;2004 Plan&#x201d;) and the 2013 Incentive Plan (the &#x201c;2013 Plan&#x201d;), 0 and 2,967,887 shares, respectively, of the Company&#x2019;s common stock are reserved for grants of stock options and restricted stock awards to employees and directors as of March&#160;31, 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 18, 2021, the Company&#x2019;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#x201c;2021 Plan&#x201d;), which authorized 8,000,000 shares (subject to certain adjustments) available for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#x2019;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of March&#160;31, 2024, the total number of shares available for issuance was 4,553,827 shares, which includes 158,678 and 134,389 shares that were forfeited under the 2013 and 2021 Plans, respectively, and 3,689,089 shares have been granted under the 2021 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, there were 688,165 shares reserved for options and 637,563 shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#x2019;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.711%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2004 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,358,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;688,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,078,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,609,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,844,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;637,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,091,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,967,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,876,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,325,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,169,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expenses included in operating expenses:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the stock option activity for the six months ended March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,263,477&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;22.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(30,437)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;61.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(154,347)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;11.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,078,693&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;23.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;26,788,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercisable at March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,054,866&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;22.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;26,788,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the three months ended March&#160;31, 2024 &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and 2023 was $2.5 million and $1.4 million, respectively. The total intrinsic value of the options exercised during the six months ended March&#160;31, 2024 and 2023 was $3.1&#160;million and $3.6&#160;million, respectively&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to stock options outstanding for the three months ended March&#160;31, 2024 and 2023, was $0.6 million and $2.2 million, respectively. Stock-based compensation expense related to stock options outstanding for the six months ended March&#160;31, 2024 and 2023, was $2.1&#160;million and $4.6&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of March&#160;31, 2024, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $0.8&#160;million will be recognized in the Company&#x2019;s results of operations over a weighted average period of 4 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#x2019;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. No options were granted during the six months ended March&#160;31, 2024 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Visirna ESOP&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: On October 1, 2023, Visirna, a subsidiary of the Company, granted 7,500,000 stock options to its employees from the Employee Stock Option Plan (the &#x201c;Visirna ESOP&#x201d;), which authorizes 20,000,000 shares for issuance. The Visirna ESOP is independently managed by Visirna, including the valuation process. For the three and six months ended March&#160;31, 2024, stock-based compensation expense related to the Visirna ESOP was $1.2&#160;million and $3.2 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted Stock Units (&#x201c;RSUs&#x201d;), including market-based, time-based and performance-based awards, have been granted under the Company&#x2019;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#x2019;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#x2019;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,241,640&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;58.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,838,025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;30.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(876,352)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;53.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(112,150)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;44.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,091,163&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;49.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs was determined based on the closing price of the Company&#x2019;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March&#160;31, 2024 and 2023, the Company recorded $16.0 million and $18.4 million of expense related to RSUs, respectively. For the six months ended March&#160;31, 2024 and 2023, the Company recorded $32.2&#160;million and $35.4&#160;million of expense related to RSUs, respectively. As of March&#160;31, 2024, there was $112.0&#160;million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 1.7 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-162"
      decimals="INF"
      id="f-625"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-163"
      decimals="INF"
      id="f-626"
      unitRef="shares">2967887</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-163"
      decimals="INF"
      id="f-627"
      unitRef="shares">2967887</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-164"
      decimals="INF"
      id="f-628"
      unitRef="shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="c-3" decimals="INF" id="f-629" unitRef="shares">4553827</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-165"
      decimals="INF"
      id="f-630"
      unitRef="shares">158678</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-166"
      decimals="INF"
      id="f-631"
      unitRef="shares">134389</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-166"
      decimals="INF"
      id="f-632"
      unitRef="shares">3689089</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-167"
      decimals="INF"
      id="f-633"
      unitRef="shares">688165</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-168"
      decimals="INF"
      id="f-634"
      unitRef="shares">637563</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c-1" id="f-635">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.243%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.381%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.708%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.711%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;As of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2004 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,358,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;32,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;688,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,078,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,609,510&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,844,090&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;637,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;5,091,163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,967,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;2,876,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,325,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,169,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-162"
      decimals="INF"
      id="f-636"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-163"
      decimals="INF"
      id="f-637"
      unitRef="shares">1358377</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-169"
      decimals="INF"
      id="f-638"
      unitRef="shares">32151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-170"
      decimals="INF"
      id="f-639"
      unitRef="shares">688165</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-640" unitRef="shares">2078693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-171"
      decimals="INF"
      id="f-641"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-172"
      decimals="INF"
      id="f-642"
      unitRef="shares">1609510</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-173"
      decimals="INF"
      id="f-643"
      unitRef="shares">2844090</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-168"
      decimals="INF"
      id="f-644"
      unitRef="shares">637563</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-174"
      decimals="INF"
      id="f-645"
      unitRef="shares">5091163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-162"
      decimals="INF"
      id="f-646"
      unitRef="shares">0</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-163"
      decimals="INF"
      id="f-647"
      unitRef="shares">2967887</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-163"
      decimals="INF"
      id="f-648"
      unitRef="shares">2967887</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-169"
      decimals="INF"
      id="f-649"
      unitRef="shares">2876241</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-170"
      decimals="INF"
      id="f-650"
      unitRef="shares">1325728</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding contextRef="c-3" decimals="INF" id="f-651" unitRef="shares">7169856</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-652">&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock-based compensation expenses included in operating expenses:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.370%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;8,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;15,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;17,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;9,491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;11,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;18,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;16,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;20,613&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;34,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;40,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-154" decimals="-3" id="f-653" unitRef="usd">7097000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-155" decimals="-3" id="f-654" unitRef="usd">8745000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-156" decimals="-3" id="f-655" unitRef="usd">15413000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-157" decimals="-3" id="f-656" unitRef="usd">17147000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-158" decimals="-3" id="f-657" unitRef="usd">9491000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-159" decimals="-3" id="f-658" unitRef="usd">11868000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-160" decimals="-3" id="f-659" unitRef="usd">18860000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-161" decimals="-3" id="f-660" unitRef="usd">22855000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-661" unitRef="usd">16588000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-6" decimals="-3" id="f-662" unitRef="usd">20613000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-663" unitRef="usd">34273000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-3" id="f-664" unitRef="usd">40002000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-665">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the stock option activity for the six months ended March&#160;31, 2024:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:46.268%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.623%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,263,477&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;22.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(30,437)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;61.11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(154,347)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;11.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,078,693&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;23.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;26,788,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Exercisable at March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;2,054,866&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;22.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;3.9 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;26,788,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-4" decimals="INF" id="f-666" unitRef="shares">2263477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-4"
      decimals="2"
      id="f-667"
      unitRef="usdPerShare">22.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-668" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-669"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-670" unitRef="shares">30437</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-671"
      unitRef="usdPerShare">61.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-672" unitRef="shares">154347</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-673"
      unitRef="usdPerShare">11.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-3" decimals="INF" id="f-674" unitRef="shares">2078693</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-675"
      unitRef="usdPerShare">23.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-676">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-3" decimals="0" id="f-677" unitRef="usd">26788979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="c-3" decimals="INF" id="f-678" unitRef="shares">2054866</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-3"
      decimals="2"
      id="f-679"
      unitRef="usdPerShare">22.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-680">P3Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-3" decimals="0" id="f-681" unitRef="usd">26788746</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-175" decimals="-5" id="f-682" unitRef="usd">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-176" decimals="-5" id="f-683" unitRef="usd">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-177" decimals="-5" id="f-684" unitRef="usd">3100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-178" decimals="-5" id="f-685" unitRef="usd">3600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-175" decimals="-5" id="f-686" unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-176" decimals="-5" id="f-687" unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-177" decimals="-5" id="f-688" unitRef="usd">2100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-178" decimals="-5" id="f-689" unitRef="usd">4600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-179" decimals="-5" id="f-690" unitRef="usd">800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-177" id="f-691">P4M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-692" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-7" decimals="INF" id="f-693" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-180"
      decimals="INF"
      id="f-694"
      unitRef="shares">7500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-181"
      decimals="INF"
      id="f-695"
      unitRef="shares">20000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-182" decimals="-5" id="f-696" unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-183" decimals="-5" id="f-697" unitRef="usd">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-698">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:72.876%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.621%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at September&#160;30, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;4,241,640&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;58.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;1,838,025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;30.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(876,352)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;53.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;(112,150)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;44.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;Outstanding at March&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;5,091,163&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%"&gt;49.58&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-184"
      decimals="INF"
      id="f-699"
      unitRef="shares">4241640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-184"
      decimals="2"
      id="f-700"
      unitRef="usdPerShare">58.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-185"
      decimals="INF"
      id="f-701"
      unitRef="shares">1838025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-185"
      decimals="2"
      id="f-702"
      unitRef="usdPerShare">30.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-185"
      decimals="INF"
      id="f-703"
      unitRef="shares">876352</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-185"
      decimals="2"
      id="f-704"
      unitRef="usdPerShare">53.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-185"
      decimals="INF"
      id="f-705"
      unitRef="shares">112150</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-185"
      decimals="2"
      id="f-706"
      unitRef="usdPerShare">44.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-174"
      decimals="INF"
      id="f-707"
      unitRef="shares">5091163</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-174"
      decimals="2"
      id="f-708"
      unitRef="usdPerShare">49.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-186" decimals="-5" id="f-709" unitRef="usd">16000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-187" decimals="-5" id="f-710" unitRef="usd">18400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-185" decimals="-5" id="f-711" unitRef="usd">32200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-188" decimals="-5" id="f-712" unitRef="usd">35400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-174" decimals="-5" id="f-713" unitRef="usd">112000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-185" id="f-714">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-715">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The Company&#x2019;s valuation techniques and inputs used to measure fair value and the definition of the three levels (Level 1, Level 2, and Level 3) of the fair value hierarchy are disclosed in Note 10 - Fair Value Measurements of Notes to Consolidated Financial Statements of Part IV, &#x201c;Item 15. Exhibits and Financial Statement Schedules&#x201d; of its Annual Report on Form 10-K for the year ended September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At March&#160;31, 2024 and September&#160;30, 2023, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;217,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;217,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;390,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;395,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;77,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;77,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;87,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;87,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;395,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;482,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;231,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;231,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;261,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;292,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;261,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;293,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-716">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.466%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.449%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;120,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;217,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;217,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;390,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;395,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;77,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;77,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. Treasuries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;82,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;87,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;87,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;395,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;482,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;22,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;231,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;231,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total available-for-sale securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;261,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;292,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Money market instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Total financial assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;31,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;261,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;293,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-189" decimals="-3" id="f-717" unitRef="usd">4963000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-190" decimals="-3" id="f-718" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-191" decimals="-3" id="f-719" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-192" decimals="-3" id="f-720" unitRef="usd">4963000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-193" decimals="-3" id="f-721" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-194" decimals="-3" id="f-722" unitRef="usd">48637000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-195" decimals="-3" id="f-723" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-196" decimals="-3" id="f-724" unitRef="usd">48637000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-197" decimals="-3" id="f-725" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-198" decimals="-3" id="f-726" unitRef="usd">3949000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-199" decimals="-3" id="f-727" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-200" decimals="-3" id="f-728" unitRef="usd">3949000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-201" decimals="-3" id="f-729" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-202" decimals="-3" id="f-730" unitRef="usd">120710000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-203" decimals="-3" id="f-731" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-204" decimals="-3" id="f-732" unitRef="usd">120710000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-205" decimals="-3" id="f-733" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-206" decimals="-3" id="f-734" unitRef="usd">217151000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-207" decimals="-3" id="f-735" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-208" decimals="-3" id="f-736" unitRef="usd">217151000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-209" decimals="-3" id="f-737" unitRef="usd">4963000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-210" decimals="-3" id="f-738" unitRef="usd">390447000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-211" decimals="-3" id="f-739" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-212" decimals="-3" id="f-740" unitRef="usd">395410000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-213" decimals="-3" id="f-741" unitRef="usd">77080000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-214" decimals="-3" id="f-742" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-215" decimals="-3" id="f-743" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-216" decimals="-3" id="f-744" unitRef="usd">77080000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-217" decimals="-3" id="f-745" unitRef="usd">4993000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-218" decimals="-3" id="f-746" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-219" decimals="-3" id="f-747" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-220" decimals="-3" id="f-748" unitRef="usd">4993000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-221" decimals="-3" id="f-749" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-222" decimals="-3" id="f-750" unitRef="usd">4997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-223" decimals="-3" id="f-751" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-224" decimals="-3" id="f-752" unitRef="usd">4997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-209" decimals="-3" id="f-753" unitRef="usd">82073000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-210" decimals="-3" id="f-754" unitRef="usd">4997000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-211" decimals="-3" id="f-755" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-212" decimals="-3" id="f-756" unitRef="usd">87070000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-209" decimals="-3" id="f-757" unitRef="usd">87036000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-210" decimals="-3" id="f-758" unitRef="usd">395444000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-211" decimals="-3" id="f-759" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-212" decimals="-3" id="f-760" unitRef="usd">482480000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-225" decimals="-3" id="f-761" unitRef="usd">31553000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-226" decimals="-3" id="f-762" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-227" decimals="-3" id="f-763" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-228" decimals="-3" id="f-764" unitRef="usd">31553000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-229" decimals="-3" id="f-765" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-230" decimals="-3" id="f-766" unitRef="usd">7093000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-231" decimals="-3" id="f-767" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-232" decimals="-3" id="f-768" unitRef="usd">7093000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-233" decimals="-3" id="f-769" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-234" decimals="-3" id="f-770" unitRef="usd">22205000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-235" decimals="-3" id="f-771" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-236" decimals="-3" id="f-772" unitRef="usd">22205000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-237" decimals="-3" id="f-773" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-238" decimals="-3" id="f-774" unitRef="usd">231884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-239" decimals="-3" id="f-775" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-240" decimals="-3" id="f-776" unitRef="usd">231884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-241" decimals="-3" id="f-777" unitRef="usd">31553000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-242" decimals="-3" id="f-778" unitRef="usd">261182000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-243" decimals="-3" id="f-779" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-244" decimals="-3" id="f-780" unitRef="usd">292735000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-245" decimals="-3" id="f-781" unitRef="usd">347000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-246" decimals="-3" id="f-782" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-247" decimals="-3" id="f-783" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-248" decimals="-3" id="f-784" unitRef="usd">347000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-241" decimals="-3" id="f-785" unitRef="usd">347000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-242" decimals="-3" id="f-786" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-243" decimals="-3" id="f-787" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-244" decimals="-3" id="f-788" unitRef="usd">347000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-241" decimals="-3" id="f-789" unitRef="usd">31900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-242" decimals="-3" id="f-790" unitRef="usd">261182000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-243" decimals="-3" id="f-791" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-244" decimals="-3" id="f-792" unitRef="usd">293082000</us-gaap:AssetsFairValueDisclosure>
    <arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock contextRef="c-1" id="f-793">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0&#160;million in cash to the Company in consideration for the Company&#x2019;s future royalty interest in olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in September 2016 under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0 million upfront and agreed to pay up to an additional $160.0&#160;million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0&#160;million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $50.0&#160;million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0&#160;million upon Royalty Pharma&#x2019;s receipt of at least $70.0&#160;million of royalty payments under the Royalty Pharma Agreement in any single calendar year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $250.0&#160;million from Royalty Pharma was recorded as a liability related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay this upfront funding received under the  Royalty Pharma Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records the obligations at their carrying value using the effective interest method. In order to amortize the sale of future royalties, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods. The Company periodically assesses the amount and the timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success and sales price, among others. To the extent such payments are greater or less than the Company&#x2019;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. As of March&#160;31, 2024, the estimated effective interest rate was 9.3%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity with respect to the liability related to the sale of future royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Carrying value as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;268,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Carrying value as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;280,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock>
    <arwr:InitialTransactionPrice contextRef="c-249" decimals="-5" id="f-794" unitRef="usd">410000000</arwr:InitialTransactionPrice>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement contextRef="c-250" decimals="-5" id="f-795" unitRef="usd">250000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <arwr:MilestonePaymentReceivable contextRef="c-251" decimals="-5" id="f-796" unitRef="usd">160000000</arwr:MilestonePaymentReceivable>
    <arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial contextRef="c-64" decimals="-5" id="f-797" unitRef="usd">50000000</arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial>
    <arwr:MilestonePaymentReceivableUponFDAApproval contextRef="c-251" decimals="-5" id="f-798" unitRef="usd">50000000</arwr:MilestonePaymentReceivableUponFDAApproval>
    <arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments contextRef="c-251" decimals="-5" id="f-799" unitRef="usd">60000000</arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments>
    <arwr:RoyaltyPaymentThreshold contextRef="c-251" decimals="-5" id="f-800" unitRef="usd">70000000</arwr:RoyaltyPaymentThreshold>
    <arwr:LiabilitySaleOfFutureRoyalties contextRef="c-252" decimals="-5" id="f-801" unitRef="usd">250000000</arwr:LiabilitySaleOfFutureRoyalties>
    <arwr:LiabilitySaleOfFutureRoyaltiesInterestRate contextRef="c-252" decimals="3" id="f-802" unitRef="number">0.093</arwr:LiabilitySaleOfFutureRoyaltiesInterestRate>
    <arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock contextRef="c-1" id="f-803">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the activity with respect to the liability related to the sale of future royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:79.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.688%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Carrying value as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;268,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Non-cash interest expense recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;12,612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Carrying value as of March 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;280,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-4" decimals="-3" id="f-804" unitRef="usd">268326000</arwr:RoyaltiesLiabilityNoncurrent>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-5" decimals="-3" id="f-805" unitRef="usd">12612000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-3" decimals="-3" id="f-806" unitRef="usd">280938000</arwr:RoyaltiesLiabilityNoncurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-807">NET LOSS PER SHARE&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted net loss per share for the three and six months ended March&#160;31, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;                            &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.260%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(125,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(258,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;123,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average diluted shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;123,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;108,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net (loss) gain per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net (loss) gain per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.006%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-808">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted net loss per share for the three and six months ended March&#160;31, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;                            &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:43.057%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.260%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Net (loss) income attributable to Arrowhead Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(125,300)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;48,675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(258,164)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;7,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;123,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;106,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;1,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Weighted-average diluted shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;123,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;108,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;115,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;107,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Basic net (loss) gain per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Diluted net (loss) gain per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1.02)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2.24)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;0.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-809" unitRef="usd">-125300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-6" decimals="-3" id="f-810" unitRef="usd">48675000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-811" unitRef="usd">-258164000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-3" id="f-812" unitRef="usd">7350000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-813" unitRef="shares">123285000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-6" decimals="-3" id="f-814" unitRef="shares">106757000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-815" unitRef="shares">115307000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-3" id="f-816" unitRef="shares">106394000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-5" decimals="-3" id="f-817" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-6" decimals="-3" id="f-818" unitRef="shares">1386000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-3" id="f-819" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-7" decimals="-3" id="f-820" unitRef="shares">1499000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-821" unitRef="shares">123285000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-6" decimals="-3" id="f-822" unitRef="shares">108143000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-823" unitRef="shares">115307000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-3" id="f-824" unitRef="shares">107893000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-825"
      unitRef="usdPerShare">-1.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-6"
      decimals="2"
      id="f-826"
      unitRef="usdPerShare">0.46</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-827"
      unitRef="usdPerShare">-2.24</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-828"
      unitRef="usdPerShare">0.07</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-829"
      unitRef="usdPerShare">-1.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-6"
      decimals="2"
      id="f-830"
      unitRef="usdPerShare">0.45</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-831"
      unitRef="usdPerShare">-2.24</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-832"
      unitRef="usdPerShare">0.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-833">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.006%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Six Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;3,290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;4,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-253"
      decimals="-3"
      id="f-834"
      unitRef="shares">595000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-254"
      decimals="-3"
      id="f-835"
      unitRef="shares">767000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-255"
      decimals="-3"
      id="f-836"
      unitRef="shares">657000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-256"
      decimals="-3"
      id="f-837"
      unitRef="shares">779000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-257"
      decimals="-3"
      id="f-838"
      unitRef="shares">3411000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-258"
      decimals="-3"
      id="f-839"
      unitRef="shares">3583000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-259"
      decimals="-3"
      id="f-840"
      unitRef="shares">3931000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-260"
      decimals="-3"
      id="f-841"
      unitRef="shares">3290000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="-3" id="f-842" unitRef="shares">4006000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-6" decimals="-3" id="f-843" unitRef="shares">4350000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-844" unitRef="shares">4588000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="-3" id="f-845" unitRef="shares">4069000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-5" id="f-846">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-5" id="f-847">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-5" id="f-848">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-1" id="f-849">&lt;div style="margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the quarter ended March&#160;31, 2024, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.354%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.358%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Title&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Adoption Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Plan Start Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Plan End Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Vesting and&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Subject to&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Sell-To-&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Cover &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:4.55pt;font-weight:700;line-height:120%;position:relative;top:-2.44pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%"&gt;Other&lt;br/&gt;Shares&lt;br/&gt;Being Sold&lt;br/&gt;(Subject to&lt;br/&gt;Certain&lt;br/&gt;Conditions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;James Hamilton&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Chief Discovery and Translational Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;3/26/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1/6/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1/17/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;60,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ken Myszkowski&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Chief Financial Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;3/12/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;6/11/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;2/28/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;115,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ken Myszkowski&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Chief Financial Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;3/28/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1/6/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1/17/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;15,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ken Myszkowski&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Chief Financial Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;3/28/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1/6/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1/17/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;15,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ken Myszkowski&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Chief Financial Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;3/28/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1/6/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1/17/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;15,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Ken Myszkowski&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Chief Financial Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;3/28/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1/6/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1/17/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;18,750&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Patrick O'Brien&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Chief Operating Officer and General Counsel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;3/21/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1/6/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;1/17/2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;67,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;William Waddill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;3/27/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;12/16/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;12/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:120%"&gt;7,495&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt; This column indicates the total number of shares vesting in connection with equity awards, not the number of shares to be sold. The actual number of shares to be sold will be a smaller number based on whatever is required to satisfy payment of applicable withholding taxes under sell-to-cover arrangements.</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-261" id="f-850">James Hamilton</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-261" id="f-851">Chief Discovery and Translational Medicine</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-261" id="f-852">3/26/2024</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-261" id="f-853">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-262"
      decimals="INF"
      id="f-854"
      unitRef="shares">60000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-263" id="f-855">Ken Myszkowski</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-263" id="f-856">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-263" id="f-857">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-263" id="f-858">3/12/2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-264"
      decimals="INF"
      id="f-859"
      unitRef="shares">115000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-265" id="f-860">Ken Myszkowski</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-265" id="f-861">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-265" id="f-862">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-265" id="f-863">3/28/2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-266"
      decimals="INF"
      id="f-864"
      unitRef="shares">15000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-267" id="f-865">Ken Myszkowski</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-267" id="f-866">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-267" id="f-867">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-267" id="f-868">3/28/2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-268"
      decimals="INF"
      id="f-869"
      unitRef="shares">15000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-269" id="f-870">Ken Myszkowski</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-269" id="f-871">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-269" id="f-872">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-269" id="f-873">3/28/2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-270"
      decimals="INF"
      id="f-874"
      unitRef="shares">15000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-271" id="f-875">Ken Myszkowski</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-271" id="f-876">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-271" id="f-877">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-271" id="f-878">3/28/2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-272"
      decimals="INF"
      id="f-879"
      unitRef="shares">18750</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-273" id="f-880">Patrick O'Brien</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-273" id="f-881">Chief Operating Officer and General Counsel</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-273" id="f-882">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-273" id="f-883">3/21/2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-274"
      decimals="INF"
      id="f-884"
      unitRef="shares">67500</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-275" id="f-885">William Waddill</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-275" id="f-886">Board Member</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-275" id="f-887">3/27/2024</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-275" id="f-888">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c-276"
      decimals="INF"
      id="f-889"
      unitRef="shares">7495</ecd:TrdArrSecuritiesAggAvailAmt>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
